PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Michal, M; Berry, RS; Rubin, BP; Kilpatrick, SE; Agaimy, A; Kazakov, DV; Steiner, P; Ptakova, N; Martinek, P; Hadravsky, L; Michalova, K; Szep, Z; Michal, M				Michal, Michael; Berry, Ryan S.; Rubin, Brian P.; Kilpatrick, Scott E.; Agaimy, Abbas; Kazakov, Dmitry V.; Steiner, Petr; Ptakova, Nikola; Martinek, Petr; Hadravsky, Ladislav; Michalova, Kvetoslava; Szep, Zoltan; Michal, Michal			EWSR1-SMAD3-rearranged Fibroblastic Tumor An Emerging Entity in an Increasingly More Complex Group of Fibroblastic/Myofibroblastic Neoplasms	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						soft tissues; acral fibroblastic spindle cell neoplasm; EWSR1-SMAD3-rearranged fibroblastic tumor; ERG; lipofibromatosis; lipofibromatosis-like neural tumor; myofibroma; fibromatosis; calcifying aponeurotic fibroma	CALCIFYING APONEUROTIC FIBROMA; PHOSPHATURIC MESENCHYMAL TUMORS; NTRK1 GENE FUSIONS; SOFT-TISSUE TUMORS; TRANSCRIPTION FACTOR; SUBSET; RECURRENT; ERG; SARCOMAS; LIPOFIBROMATOSIS	Three cases of superficial acral fibroblastic spindle cell neoplasms with EWSR1-SMAD3 fusion have been recently reported. Their differential diagnosis is broad, primarily comprising rare tumors from the fibroblastic/myofibroblastic category. The aim of this report is to present 4 new cases of this entity and to discuss the appropriate differential diagnosis. Also, as the ERG antibody seems to be a characteristic marker for these tumors, we analyzed ERG immunostaining characteristics in potential mimics of this entity. All cases in our cohort occurred in women aged 5 to 68 years (mean, 36.5 y). Two were located on the hand, 1 on foot, and the last case arose on the calf. The tumor size ranged from 1 to 1.5 cm in the greatest dimension, with a mean size of 1.2 cm. Except for one recent case, follow-up was available, ranging from 7 to 18 years (mean, 11.7 y), with a recurrence noted in 1 case after 10 years. All tumors were subcutaneous and showed 2 main components. One consisted of bland, spindled cells with elongated nuclei which were round when observed on the cross-section. These cells mostly grew in relatively hypercellular, well-organized, and intersecting fascicles. The second component was prominently hyalinized and paucicellular, but lacked calcifications. Both components showed either a distinct zonation pattern, or they were randomly intermingled with each other. In all 3 analyzable tumors, next-generation sequencing showed EWSR1-SMAD3 gene fusion in each case. By fluorescence in situ hybridization, one tested case also revealed unbalanced rearrangement of the EWSR1 gene. All 4 cases showed strong, diffuse nuclear expression of ERG, whereas none of the mimics stained with this antibody except for weak to moderate staining in calcifying aponeurotic fibromas (9/10 cases). Two tumors showed focal weak to moderate expression of SAT-B2. The 4 herein presented cases further broaden the clinicopathologic spectrum of tumors with EWSR1-SMAD3 gene fusion. They also confirm that they represent a novel entity for which we propose the name EWSR1-SMAD3-rearranged fibroblastic Tumor. Our study also proves that in the context of fibroblastic/myofibroblastic tumors, ERG immunohistochemistry is a relatively specific marker for these neoplasms.	[Michal, Michael; Kazakov, Dmitry V.; Steiner, Petr; Ptakova, Nikola; Martinek, Petr; Michalova, Kvetoslava; Michal, Michal] Charles Univ Prague, Fac Med Pilsen, Dept Pathol, Plzen, Czech Republic; [Michal, Michael] Charles Univ Prague, Fac Med Pilsen, Biomed Ctr, Plzen, Czech Republic; [Michal, Michael; Kazakov, Dmitry V.; Steiner, Petr; Ptakova, Nikola; Martinek, Petr; Michalova, Kvetoslava; Michal, Michal] Biopt Lab Ltd, Plzen, Czech Republic; [Hadravsky, Ladislav] Charles Univ Prague, Fac Med 1, Dept Pathol, Prague, Czech Republic; [Berry, Ryan S.; Rubin, Brian P.; Kilpatrick, Scott E.] Cleveland Clin, Dept Pathol, Robert J Tomsich Pathol & Lab Med Inst, Cleveland, OH 44106 USA; [Agaimy, Abbas] Friedrich Alexander Univ Erlangen Nurnberg, Inst Pathol, Erlangen, Germany; [Szep, Zoltan] Cytopathos Ltd, Bratislava, Slovakia	Michal, M (reprint author), Charles Univ Prague, Dept Pathol, Med Fac, Alej Svobody 80, Plzen 32300, Czech Republic.; Michal, M (reprint author), Charles Univ Prague, Charles Univ Hosp Plzen, Alej Svobody 80, Plzen 32300, Czech Republic.	michael.michal@medima.cz	Michal, Michael/I-3497-2017	Michal, Michael/0000-0003-4403-7027	National Sustainability Program I (NPU I) [LO1503]; Ministry of Education Youth and Sports of the Czech RepublicMinistry of Education, Youth & Sports - Czech Republic [260 391]	Supported in parts by the National Sustainability Program I (NPU I) Nr. LO1503 and by the grant SVV-2017 No. 260 391 provided by the Ministry of Education Youth and Sports of the Czech Republic. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Agaimy A, 2017, AM J SURG PATHOL, V41, P195, DOI 10.1097/PAS.0000000000000752; Agaram NP, 2016, AM J SURG PATHOL, V40, P1407, DOI 10.1097/PAS.0000000000000675; Al-Ibraheemi A, 2018, MODERN PATHOL, V31, P18; Antonescu CR, 2017, AM J SURG PATHOL, V41, P677, DOI 10.1097/PAS.0000000000000811; Fetsch JF, 2000, AM J SURG PATHOL, V24, P1491, DOI 10.1097/00000478-200011000-00004; Fetsch JF, 1998, HUM PATHOL, V29, P1504, DOI 10.1016/S0046-8177(98)90022-3; Flucke U, 2011, MODERN PATHOL, V24, P1444, DOI 10.1038/modpathol.2011.108; Furusato B, 2010, PROSTATE CANCER P D, V13, P228, DOI 10.1038/pcan.2010.23; Haller F, 2016, J PATHOL, V238, P700, DOI 10.1002/path.4701; Hantschke M, 2010, AM J SURG PATHOL, V34, P216, DOI 10.1097/PAS.0b013e3181c7d8b2; Jo VY, 2013, AM J SURG PATHOL, V37, P710, DOI 10.1097/PAS.0b013e3182772bba; Kao YC, 2018, AM J SURG PATHOL, V42, P522, DOI 10.1097/PAS.0000000000001002; Kao YC, 2018, AM J SURG PATHOL, V42, P28, DOI 10.1097/PAS.0000000000000938; Laskin WB, 2009, AM J SURG PATHOL, V33, P1, DOI 10.1097/PAS.0b013e3181788533; Lee JC, 2016, MODERN PATHOL, V29, P1335, DOI 10.1038/modpathol.2016.137; Lee JC, 2015, J PATHOL, V235, P539, DOI 10.1002/path.4465; Linos K, 2014, AM J SURG PATHOL, V38, P1649, DOI 10.1097/PAS.0000000000000270; Michal M, 2006, AM J SURG PATHOL, V30, P721, DOI 10.1097/00000478-200606000-00007; Miettinen M, 2011, AM J SURG PATHOL, V35, P432, DOI 10.1097/PAS.0b013e318206b67b; Puls F, 2016, J PATHOL, V238, P502, DOI 10.1002/path.4683; Shon W, 2015, J CLIN PATHOL, V68, P125, DOI 10.1136/jclinpath-2014-202601; Skalova A, 2018, AM J SURG PATHOL, V42, P234, DOI 10.1097/PAS.0000000000000972; Tajima S, 2016, MED MOL MORPHOL, V49, P203, DOI 10.1007/s00795-015-0115-2; Wang WL, 2012, MODERN PATHOL, V25, P1378, DOI 10.1038/modpathol.2012.97	24	2	3	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	OCT	2018	42	10					1325	1333		10.1097/PAS.0000000000001109			9	Pathology; Surgery	Pathology; Surgery	GV1RN	WOS:000445858300006	29957732				2019-10-28	
J	Sigel, CS; Drill, E; Zhou, Y; Basturk, O; Askan, G; Pak, LM; Vakiani, E; Wang, T; Boerner, T; Do, RKG; Simpson, AL; Jarnagin, W; Klimstra, DS				Sigel, Carlie S.; Drill, Esther; Zhou, Yi; Basturk, Olca; Askan, Gokce; Pak, Linda M.; Vakiani, Efsevia; Wang, Tao; Boerner, Thomas; Do, Richard K. G.; Simpson, Amber L.; Jarnagin, William; Klimstra, David S.			Intrahepatic Cholangiocarcinomas Have Histologically and Immunophenotypically Distinct Small and Large Duct Patterns	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						intrahepatic cholangiocarcinoma; albumin; periductal infiltration	IN-SITU-HYBRIDIZATION; PERIPHERAL-TYPE; HEPATOCELLULAR DIFFERENTIATION; MOLECULAR-FEATURES; VIRUS-INFECTION; HEPATITIS; ALBUMIN; MARKER; CLASSIFICATION; ORIGIN	Intrahepatic cholangiocarcinomas are histologically heterogenous. Using a cohort of 184 clinically defined, resected intrahepatic cholangiocarcinomas, we retrospectively classified the histology into 4 subtypes: large duct (LD), small duct (SD) (predominantly tubular [SD1] or predominantly anastomosing/cholangiolar, [SD2]), or indeterminate. Then, we tested the 4 subtypes for associations with risk factors, patient outcomes, histology, and immunophenotypic characteristics. SD was the most common (84%; 24% SD1 and 60% SD2) with lower proportions of LD (8%), and indeterminate (8%). Primary sclerosing cholangitis was rare (2%), but correlated with LD (P = 0.005). Chronic hepatitis, frequent alcohol use, smoking, and steatosis had no histologic association. LD was associated with mucin production (P < 0.001), perineural invasion (P = 0.002), CA19-9 staining (P < 0.001), CK7(+), CK19(+), CD56(-) immunophenotype (P = 0.005), and negative albumin RNA in situ hybridization (P < 0.001). SD was histologically nodular (P = 0.019), sclerotic (P < 0.001), hepatoid (P = 0.042), and infiltrative at the interface with hepatocytes (P < 0.001). Albumin was positive in 71% of SD and 18% of LD (P = 0.0021). Most albumin positive tumors (85%) lacked extracellular mucin (P < 0.001). S100P expression did not associate with subtype (P > 0.05). There was no difference in disease-specific or recurrence-free survival among the subtypes. Periductal infiltration and American Joint Committee on Cancer eighth edition pT stage predicted survival by multivariable analysis accounting for gross configuration, pT stage, and histologic type. pT2 had worse outcome relative to other pT stages. Significant differences in histology and albumin expression distinguish LD from SD, but there is insufficient evidence to support further subclassification of SD.	[Sigel, Carlie S.; Basturk, Olca; Askan, Gokce; Vakiani, Efsevia; Wang, Tao; Klimstra, David S.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA; [Drill, Esther] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, 1275 York Ave, New York, NY 10021 USA; [Boerner, Thomas; Simpson, Amber L.; Jarnagin, William] Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10021 USA; [Do, Richard K. G.] Mem Sloan Kettering Canc Ctr, Dept Radiol, 1275 York Ave, New York, NY 10021 USA; [Zhou, Yi] Wake Forest Sch Med, Dept Pathol, Winston Salem, NC USA; [Pak, Linda M.] Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA	Sigel, CS (reprint author), 1275 York Ave, New York, NY 10065 USA.	sigelc@mskcc.org	Basturk, Olca/N-7214-2017	Basturk, Olca/0000-0003-2747-1366	Cancer Center Support Grant of the National Institutes of Health/National Cancer Institute [P30CA008748]; Cycle for Survival	Supported in part by the Cancer Center Support Grant of the National Institutes of Health/National Cancer Institute under award number P30CA008748 and Cycle for Survival. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Aishima S, 2007, AM J SURG PATHOL, V31, P1059, DOI 10.1097/PAS.0b013e31802b34b6; Aishima S, 2011, AM J SURG PATHOL, V35, P590, DOI 10.1097/PAS.0b013e31820ffdf1; Akita M, 2017, MODERN PATHOL, V30, P986, DOI 10.1038/modpathol.2017.22; Altekruse SF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120574; Amin MB, 2017, AJCC CANC STAGING MA; Bosman FT, 2010, WHO CLASSIFICATION T; Cardinale V, 2012, WORLD J GASTRO ONCOL, V4, P94, DOI 10.4251/wjgo.v4.i5.94; Choe JY, 2014, CLIN MOL HEPATOL, V20, P214, DOI 10.3350/cmh.2014.20.2.214; Coulouarn C, 2012, CARCINOGENESIS, V33, P1791, DOI 10.1093/carcin/bgs208; Denniston MM, 2014, ANN INTERN MED, V160, P293, DOI 10.7326/M13-1133; DeOliveira ML, 2011, HEPATOLOGY, V53, P1363, DOI 10.1002/hep.24227; Doussot A, 2016, J AM COLL SURGEONS, V223, P493, DOI 10.1016/j.jamcollsurg.2016.05.019; Edge SB, 2010, AJCC CANC STAGING MA; Ferrone CR, 2016, ANN SURG ONCOL, V23, P290, DOI 10.1245/s10434-014-4247-8; Hayashi A, 2016, AM J SURG PATHOL, V40, P1021, DOI 10.1097/PAS.0000000000000670; Khan SA, 2012, GUT, V61, P1657, DOI 10.1136/gutjnl-2011-301748; Komuta M, 2008, HEPATOLOGY, V47, P1544, DOI 10.1002/hep.22238; Komuta M, 2012, HEPATOLOGY, V55, P1876, DOI 10.1002/hep.25595; Krishna M, 1997, AM J SURG PATHOL, V21, P147, DOI 10.1097/00000478-199702000-00003; Liau JY, 2014, MODERN PATHOL, V27, P1163, DOI 10.1038/modpathol.2013.241; Maithel SK, 2013, CANCER-AM CANCER SOC, V119, P3929, DOI 10.1002/cncr.28312; Mosnier JF, 2009, MODERN PATHOL, V22, P182, DOI 10.1038/modpathol.2008.123; NAKAJIMA T, 1988, HUM PATHOL, V19, P1228, DOI 10.1016/S0046-8177(88)80156-4; Nakanuma Y, 2015, BEST PRACT RES CL GA, V29, P277, DOI 10.1016/j.bpg.2015.02.006; Nakanuma Y, 2010, WORLD J HEPATOL, V2, P419, DOI 10.4254/wjh.v2.i12.419; Ott JJ, 2012, VACCINE, V30, P2212, DOI 10.1016/j.vaccine.2011.12.116; Rhee H, 2018, LIVER INT, V38, P113, DOI 10.1111/liv.13492; Sempoux C, 2011, SEMIN LIVER DIS, V31, P49, DOI 10.1055/s-0031-1272839; Shahid M, 2015, AM J SURG PATHOL, V39, P25, DOI 10.1097/PAS.0000000000000343; Tickoo SK, 2002, AM J SURG PATHOL, V26, P989, DOI 10.1097/01.PAS.0000021226.30983.C7; Tsai JH, 2012, HISTOPATHOLOGY, V61, P1106, DOI 10.1111/j.1365-2559.2012.04316.x; Weber SM, 2015, HPB, V17, P669, DOI 10.1111/hpb.12441; Yeh YC, 2017, AM J SURG PATHOL, V41, P1630, DOI 10.1097/PAS.0000000000000957; Yu TH, 2011, MODERN PATHOL, V24, P810, DOI 10.1038/modpathol.2011.41	34	2	2	3	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	OCT	2018	42	10					1334	1345		10.1097/PAS.0000000000001118			12	Pathology; Surgery	Pathology; Surgery	GV1RN	WOS:000445858300007	30001234				2019-10-28	
J	Swanson, EA; March, JK; Clayton, F; Couturier, MR; Arcega, R; Smith, R; Evason, KJ				Swanson, Eric A.; March, Jordon K.; Clayton, Frederic; Couturier, Marc R.; Arcega, Ramir; Smith, Richard; Evason, Kimberley J.			Epithelial Inclusions in Gallbladder Specimens Mimic Parasite Infection Histologic and Molecular Examination of Reported Cystoisospora belli Infection in Gallbladders of Immunocompetent Patients	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						Cystoisospora belli; gallbladder; immunocompetent	ISOSPORA; PATIENT; CHOLECYSTECTOMY; TISSUE; AIDS	Recent publications have described epithelial cytoplasmic vacuoles and inclusions incidentally noted within gallbladder epithelium and concluded that they represent coccidian parasite infection, in particular, Cystoisospora belli. We identified 8 gallbladder specimens from our institution in the past 3 years in which this diagnosis was suggested or in which similar epithelial alterations were prominent. Molecular analysis was performed on the 8 gallbladder specimens and on 3 positive control specimens: small bowel biopsies from acquired immunodeficiency syndrome patients with diarrhea. Polymerase chain reaction using primers designed to amplify an internal transcribed spacer (ITS2) in the C. belli ribosomal gene cluster was performed on the DNA samples. All 8 gallbladder specimens were negative for amplification, while a product consistent with C. belli was amplified from all 3 positive controls. Histologically, the gallbladder cytoplasmic inclusions stained diffusely positive for Grocott-Gomori's methenamine silver and Periodic acid-Schiff with diastase. In contrast, sections from a positive control small bowel biopsy demonstrated organisms that were negative for Grocott-Gomori's methenamine silver and showed a distinct capsular and punctate internal staining on Periodic acid-Schiff with diastase in various parasite forms. Together, the lack of molecular evidence of C. belli and the distinct morphologic and special staining patterns in these gallbladders compared with positive control small bowel suggest that these epithelial changes do not represent true C. belli infection. Our results suggest that gallbladders of immunocompetent patients may occasionally show epithelial changes that can morphologically mimic C. belli infection. Pathologists should be aware of this histologic variant to minimize unnecessary treatment, testing, and patient anxiety.	[Swanson, Eric A.; March, Jordon K.; Clayton, Frederic; Couturier, Marc R.; Smith, Richard; Evason, Kimberley J.] Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA; [Evason, Kimberley J.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; [Arcega, Ramir] Cedar Sinai Med Ctr, Dept Pathol, Los Angeles, CA USA	Swanson, EA; Evason, KJ (reprint author), Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA.	eric.swanson@path.utah.edu; Kimberley.evason@hci.utah.edu			NIH/NCIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [K08CA172288, R01CA222570]; National Cancer Institute of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA042014]	K.J.E. is partially supported by NIH/NCI K08CA172288 and NIH/NCI R01CA222570. Research reported in this publication utilized the Biorepository and Molecular Pathology Shared Resource at Huntsman Cancer Institute at the University of Utah and was supported by the National Cancer Institute of the National Institutes of Health under Award Number P30CA042014. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Ash L, 1997, ATLAS HUMAN PARASITO; BENATOR DA, 1994, ANN INTERN MED, V121, P663, DOI 10.7326/0003-4819-121-9-199411010-00006; Binford CH, 1976, PATHOLOGY TROPICAL E, V1; Clayton F, 1997, GASTROENTEROL CLIN N, V26, P191, DOI 10.1016/S0889-8553(05)70293-4; FRENCH AL, 1995, CLIN INFECT DIS, V21, P852, DOI 10.1093/clinids/21.4.852; Lai KK, 2016, AM J SURG PATHOL, V40, P1070, DOI 10.1097/PAS.0000000000000660; Legua P, 2013, CURR OPIN INFECT DIS, V26, P479, DOI 10.1097/01.qco.0000433320.90241.60; Leiva JI, 1997, AM J SURG, V174, P414, DOI 10.1016/S0002-9610(97)00118-9; Lichtenberg FV, 1991, PATHOLOGY INFECT DIS; Lindsay DS, 1997, CLIN MICROBIOL REV, V10, P19, DOI 10.1128/CMR.10.1.19; Lindsay DS, 1997, J PARASITOL, V83, P620, DOI 10.2307/3284235; Martelli Matthew G, 2016, J Miss State Med Assoc, V57, P174; MICHIELS JF, 1994, PATHOL RES PRACT, V190, P1089, DOI 10.1016/S0344-0338(11)80908-8; Mubeen A, 2018, MODERN PATHOL, V31, P580; Murphy SC, 2011, J MOL DIAGN, V13, P359, DOI 10.1016/j.jmoldx.2011.01.007; Noor M, 2018, MODERN PATHOL, V31, P580; RESTREPO C, 1987, AM J CLIN PATHOL, V87, P536, DOI 10.1093/ajcp/87.4.536; Rose G, 2018, MODERN PATHOL, V31, P687; Takahashi H, 2015, BMJ CASE REPORTS, V2015, DOI 10. 1136/bcr-2015-209966; Tatum AL, 1916, J BIOL CHEM, V27, P243; Walther Z, 2009, HUM PATHOL, V40, P1342, DOI 10.1016/j.humpath.2009.01.020	21	4	4	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	OCT	2018	42	10					1346	1352		10.1097/PAS.0000000000001094			7	Pathology; Surgery	Pathology; Surgery	GV1RN	WOS:000445858300008	30020094				2019-10-28	
J	Mohammad, N; Haimes, JD; Mishkin, S; Kudlow, BA; Leong, MY; Chew, SH; Koay, E; Whitehouse, A; Cope, N; Ali, RH; Kobel, M; Stewart, CJR; McCluggage, WG; Lee, CH				Mohammad, Nissreen; Haimes, Josh D.; Mishkin, Skyler; Kudlow, Brian A.; Leong, May Ying; Chew, Sung Hock; Koay, Eleanor; Whitehouse, Ann; Cope, Nichola; Ali, Rola H.; Koebel, Martin; Stewart, Colin J. R.; McCluggage, W. Glenn; Lee, Cheng-Han			ALK Is a Specific Diagnostic Marker for Inflammatory Myofibroblastic Tumor of the Uterus	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						ALK; uterine sarcoma; inflammatory myofibroblastic tumor; genetic fusion	ANAPLASTIC LYMPHOMA KINASE; FEMALE GENITAL-TRACT; GENE REARRANGEMENTS; EXPRESSION; FUSION; DISTINCTION	Inflammatory myofibroblastic tumor (IMT) is a myofibroblastic/fibroblastic neoplasm of intermediate malignant potential. It is frequently characterized by genetic fusion of ALK with a variety of partner genes, which results in the activated ALK signaling pathway that can be targeted with kinase inhibitors. IMTs can occur in the gynecologic tract, with the uterus (corpus and cervix) being the most frequent site. Recent studies suggest that IMTs in the gynecologic tract are underrecognized, and a low-threshold for performing ALK immunohistochemistry has been proposed. The aim of this study was to evaluate the specificity of ALK immunohistochemistry for IMTs among uterine mesenchymal and mixed epithelial/mesenchymal tumors. We performed ALK immunohistochemistry on 14 molecularly confirmed uterine IMTs and 260 other uterine pure mesenchymal and mixed epithelial/mesenchymal tumors. Cases showing any positive cytoplasmic and/or membranous staining of the tumor cells were considered to be ALK positive. All 14 IMTs were confirmed to harbor ALK genetic fusion by RNA sequencing, and ALK immunostaining in the form of granular cytoplasmic positivity with paranuclear accentuation was observed in all 14 cases. ALK was negative (complete absence of staining) in all the other pure mesenchymal tumors and in all mixed epithelial/mesenchymal tumors examined. Our findings show that ALK is a highly specific diagnostic immunohistochemical marker for ALK fusion in uterine mesenchymal tumors. In the work-up of uterine mesenchymal tumors, particularly smooth muscle tumors showing myxoid stromal changes, a diagnosis of IMT should be strongly considered if ALK positivity is observed.	[Mohammad, Nissreen; Lee, Cheng-Han] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada; [Lee, Cheng-Han] BC Canc, Dept Pathol & Lab Med, Room 3225,600 W 10th Ave, Vancouver, BC V5Z 4E6, Canada; [Koebel, Martin] Calgary Lab Serv, Dept Pathol & Lab Med, Calgary, AB, Canada; [Koebel, Martin] Univ Calgary, Calgary, AB, Canada; [Haimes, Josh D.; Mishkin, Skyler; Kudlow, Brian A.] ArcherDX Inc, Boulder, CO USA; [Leong, May Ying; Chew, Sung Hock] KK Womens & Childrens Hosp, Dept Pathol & Lab Med, Singapore, Singapore; [Koay, Eleanor; Stewart, Colin J. R.] King Edward Mem Hosp, Dept Histopathol, Perth, WA, Australia; [Whitehouse, Ann] Sullivan Nicolaides Pathol, Brisbane, Qld, Australia; [Cope, Nichola] Royal Devon & Exeter Hosp, Dept Pathol, Exeter, Devon, England; [McCluggage, W. Glenn] Belfast Hlth & Social Care Trust, Dept Pathol, Belfast, Antrim, North Ireland; [Ali, Rola H.] Kuwait Univ, Dept Pathol, Kuwait, Kuwait	Lee, CH (reprint author), BC Canc, Dept Pathol & Lab Med, Room 3225,600 W 10th Ave, Vancouver, BC V5Z 4E6, Canada.	chenghanlee@gmail.com					Alassiri AH, 2016, AM J SURG PATHOL, V40, P1051, DOI 10.1097/PAS.0000000000000677; Azuno Y, 2003, AM J OBSTET GYNECOL, V189, P890, DOI 10.1067/S0002-9378(03)00208-4; Bennett JA, 2017, MODERN PATHOL, V30, P1489, DOI 10.1038/modpathol.2017.69; Bridge JA, 2001, AM J PATHOL, V159, P411, DOI 10.1016/S0002-9440(10)61711-7; Cessna MH, 2002, MODERN PATHOL, V15, P931, DOI 10.1097/01.MP.0000026615.04130.1F; Chiang S, 2018, AM J SURG PATHOL, V42, P791, DOI 10.1097/PAS.0000000000001055; Cook JR, 2001, AM J SURG PATHOL, V25, P1364, DOI 10.1097/00000478-200111000-00003; Fletcher C, 2013, WHO CLASSIFICATION T; Fraggetta F, 2015, J CLIN ONCOL, V33, pE7, DOI 10.1200/JCO.2013.48.8304; Fuehrer NE, 2012, ARCH PATHOL LAB MED, V136, P623, DOI 10.5858/arpa.2011-0341-OA; Haimes JD, 2017, AM J SURG PATHOL, V41, P773, DOI 10.1097/PAS.0000000000000801; Kushnir Christina L, 2013, Gynecol Oncol Case Rep, V6, P39, DOI 10.1016/j.gynor.2013.07.007; Lawrence B, 2000, AM J PATHOL, V157, P377, DOI 10.1016/S0002-9440(10)64550-6; Li XQ, 2004, HUM PATHOL, V35, P711, DOI 10.1016/j.humpath.2003.12.004; Ma ZG, 2003, GENE CHROMOSOME CANC, V37, P98, DOI 10.1002/gcc.10177; Olgan S, 2011, EUR J OBSTET GYN R B, V157, P234, DOI 10.1016/j.ejogrb.2011.02.016; Parra-Herran C, 2016, AM J SURG PATHOL, V40, P285, DOI 10.1097/PAS.0000000000000593; Parra-Herran C, 2015, AM J SURG PATHOL, V39, P157, DOI 10.1097/PAS.0000000000000330; Pickett JL, 2017, AM J SURG PATHOL, V41, P1433, DOI 10.1097/PAS.0000000000000909; Rabban JT, 2005, AM J SURG PATHOL, V29, P1348, DOI 10.1097/01.pas.0000172189.02424.91; Shintaku M, 2006, PATHOL INT, V56, P625, DOI 10.1111/j.1440-1827.2006.02018.x; Subbiah V, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0160-2; Yamamoto H, 2016, HISTOPATHOLOGY, V69, P72, DOI 10.1111/his.12910	23	1	1	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	OCT	2018	42	10					1353	1359		10.1097/PAS.0000000000001120			7	Pathology; Surgery	Pathology; Surgery	GV1RN	WOS:000445858300009	30015720				2019-10-28	
J	Mangray, S; Kelly, DR; LeGuellec, S; Fridman, E; Aggarwal, S; Shago, M; Matoso, A; Madison, R; Pramanik, S; Zhong, S; Li, R; Lombardo, KA; Cramer, S; Pressey, J; Ross, JS; Corona, RJ; Bratslavsky, G; Argani, P; Coindre, JM; Somers, GR; Ali, SM; Yakirevich, E				Mangray, Shamlal; Kelly, David R.; LeGuellec, Sophie; Fridman, Eddie; Aggarwal, Sangeeta; Shago, Mary; Matoso, Andres; Madison, Russell; Pramanik, Sharmila; Zhong, Shan; Li, Rong; Lombardo, Kara A.; Cramer, Stuart; Pressey, Joseph; Ross, Jeffrey S.; Corona, Robert J.; Bratslavsky, Gennady; Argani, Pedram; Coindre, Jean-Michel; Somers, Gino R.; Ali, Siraj M.; Yakirevich, Evgeny			Clinicopathologic Features of a Series of Primary Renal CIC-rearranged Sarcomas With Comprehensive Molecular Analysis	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						CIC; DUX4; kidney; NUTM1; sarcoma; undifferentiated	ROUND-CELL SARCOMAS; NUT MIDLINE CARCINOMA; MALIGNANT NEUROEPITHELIAL TUMORS; GENETICALLY-DISTINCT-VARIANT; CIC-FOXO4 GENE FUSION; NATIONAL-WILMS-TUMOR; EWING-LIKE-SARCOMA; PATHOLOGY-CENTER; KIDNEY; EXPRESSION	CIC-rearranged sarcomas rarely occur in visceral organs including the kidney. The most common fusion partner with CIC is the DUX4 gene, but variant fusion partners have also been reported. Herein, we describe the clinicopathologic features and comprehensive molecular profiling of 4 cases of primary renal CIC-rearranged sarcomas. All cases occurred in females, age range 13 to 82 years and included 3 resections and 1 needle biopsy specimen. There was a tendency for development of metastatic disease predominantly to the lungs and poor disease outcome despite different treatment strategies. Histologically, variable round cell (20% to 100%), spindle cell (0% to 80%), and rhabdoid morphologies (0% to 20%) were seen. By immunohistochemistry diffuse WT1 nuclear (2 to 3+, similar to 90%) labeling was present in 1 case, with cytoplasmic staining in the others (3+, 40% to 75%). CD99 was focally positive in all 4 cases (<= 10%); 1 case each was diffusely positive for c-myc (2 to 3+, similar to 90%) and ETV4 (3+, similar to 90%); 1 case was focally positive for c-myc (2+, similar to 5%) and calretinin (2+, similar to 5%); and all cases were negative for cytokeratin and NKX2.2. CIC rearrangement by fluorescence in situ hybridization was present in the 3 cases tested. Comprehensive genomic profiling (CGP) of 3 cases revealed a CIC-DUX4 fusion in 2 cases, and 1 CIC-NUTM1 fusion. All 4 CIC-rearranged renal sarcomas had low mutation burden, and except HLA-A and MLL mutations lacked genomic alterations in other oncogenic drivers. Material from the needle biopsy was insufficient for CGP but that case was positive with the DUX4 immunohistochemical stain as were the 2 CIC-DUX4 tumors. In conclusion, CIC-rearranged sarcomas rarely occur in the kidney with a tendency for poor outcome and in this series we illustrate an example with CIC-NUTM1 fusion, an emerging variant, at a visceral site. Testing by fluorescence in situ hybridization or CGP is optimal to avoid missing cases that harbor variant fusion partners.	[Mangray, Shamlal; Lombardo, Kara A.; Yakirevich, Evgeny] Brown Univ, Rhode Isl Hosp, Alpert Med Sch, Providence, RI 02903 USA; [Kelly, David R.; Li, Rong; Cramer, Stuart] Childrens Alabama, Birmingham, AL USA; [Kelly, David R.; Li, Rong; Cramer, Stuart] Univ Alabama Birmingham, Med Sch, Birmingham, AL USA; [LeGuellec, Sophie] Claudius Regaud Inst, IUCT Oncopole, Toulouse, France; [Coindre, Jean-Michel] Bergonie Inst, Bordeaux, France; [Fridman, Eddie] Sheba Med Ctr, Tel Aviv, Israel; [Aggarwal, Sangeeta; Pramanik, Sharmila] Santa Clara Valley Med Ctr, San Jose, CA 95128 USA; [Shago, Mary; Somers, Gino R.] Univ Toronto, Hosp Sick Children, Toronto, ON, Canada; [Matoso, Andres; Argani, Pedram] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Madison, Russell; Zhong, Shan; Ross, Jeffrey S.; Ali, Siraj M.] Fdn Med Inc, Cambridge, MA USA; [Pressey, Joseph] Childrens Hosp Cincinnati, Cincinnati, OH USA; [Ross, Jeffrey S.; Corona, Robert J.; Bratslavsky, Gennady] Upstate Med Univ, Syracuse, NY USA	Yakirevich, E (reprint author), Rhode Isl Hosp, APC 12,593 Eddy St, Providence, RI 02903 USA.	eyakirevich@lifespan.org					Antonescu CR, 2017, AM J SURG PATHOL, V41, P941, DOI 10.1097/PAS.0000000000000846; Argani P, 2000, AM J SURG PATHOL, V24, P1087, DOI 10.1097/00000478-200008000-00006; Argani P, 2016, WHO CLASSIFICATION T, P54; Argani P, 2017, AM J SURG PATHOL, V41, P1702, DOI 10.1097/PAS.0000000000000926; Argani P, 2015, AM J SURG PATHOL, V39, P365, DOI 10.1097/PAS.0000000000000338; Bauer DE, 2012, CLIN CANCER RES, V18, P5773, DOI 10.1158/1078-0432.CCR-12-1153; Bergerat S, 2017, PATHOL RES PRACT, V213, P154, DOI 10.1016/j.prp.2016.11.015; Bishop JA, 2016, CANCER CYTOPATHOL, V124, P901, DOI 10.1002/cncy.21761; Camille A, 2017, PEDIAT DEV PATHOL; Chalmers ZR, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0424-2; Chang KTE, 2018, J MOL DIAGN, V20, P63, DOI 10.1016/j.jmoldx.2017.09.007; Chau NG, 2016, CANCER-AM CANCER SOC, V122, P3632, DOI 10.1002/cncr.30242; Donahue JE, 2017, PEDIAT DEV PATHOL; Edge SB, 2010, KIDNEY AJCC CANC STA, P479; Ellison DA, 2007, HUM PATHOL, V38, P205, DOI 10.1016/j.humpath.2006.08.026; Fletcher CDM, 2013, WHO CLASSIFICATION T, P236; French CA, 2017, WHO CLASSIFICATION H, P20; Gambarotti M, 2016, HISTOPATHOLOGY, V69, P624, DOI 10.1111/his.12985; Graham C, 2012, HUM PATHOL, V43, P180, DOI 10.1016/j.humpath.2011.04.023; He J, 2016, BLOOD, V127, P3004, DOI 10.1182/blood-2015-08-664649; Hung YP, 2016, MODERN PATHOL, V29, P1324, DOI 10.1038/modpathol.2016.140; Hung YP, 2016, MODERN PATHOL, V29, P370, DOI 10.1038/modpathol.2016.31; Italiano A, 2012, GENE CHROMOSOME CANC, V51, P207, DOI 10.1002/gcc.20945; Jimenez RE, 2002, AM J SURG PATHOL, V26, P320, DOI 10.1097/00000478-200203000-00005; Kawamura-Saito M, 2006, HUM MOL GENET, V15, P2125, DOI 10.1093/hmg/ddl136; Le Guellec S, 2016, MODERN PATHOL, V29, P1523, DOI 10.1038/modpathol.2016.155; Lee CJ, 2005, J NEURO-ONCOL, V73, P101, DOI 10.1007/s11060-004-4598-2; Mangray S, 2016, AM J SURG PATHOL, V40, P1298, DOI 10.1097/PAS.0000000000000688; Martignoni G, 2016, MESENCHYMAL TUMORS O, P59; Oyama R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04967-0; Parham DM, 2001, AM J SURG PATHOL, V25, P133, DOI 10.1097/00000478-200102000-00001; PDQ Pediatric Treatment Editorial Board, 2002, WILMS TUM OTH CHILDH; Peifer M, 2012, NAT GENET, V44, P1104, DOI 10.1038/ng.2396; Shukla SA, 2015, NAT BIOTECHNOL, V33, P1152, DOI 10.1038/nbt.3344; Siegele B, 2017, AM J SURG PATHOL, V41, P423, DOI 10.1097/PAS.0000000000000772; Sirohi D, 2018, HISTOPATHOLOGY, V72, P528, DOI 10.1111/his.13368; Smith SC, 2015, MODERN PATHOL, V28, P57, DOI 10.1038/modpathol.2014.83; Solomon DA, 2014, AM J SURG PATHOL, V38, P1724, DOI 10.1097/PAS.0000000000000335; Specht K, 2014, GENE CHROMOSOME CANC, V53, P622, DOI 10.1002/gcc.22172; Sturm D, 2016, CELL, V164, P1060, DOI 10.1016/j.cell.2016.01.015; Sugita S, 2017, HUM PATHOL, V65, P225, DOI 10.1016/j.humpath.2017.01.012; Sugita S, 2014, AM J SURG PATHOL, V38, P1571, DOI 10.1097/PAS.0000000000000286; Vujanic GM, 2007, AM J SURG PATHOL, V31, P1459, DOI 10.1097/PAS.0b013e31804d43a4; Wang LL, 2007, AM J SURG PATHOL, V31, P576, DOI 10.1097/01.pas.0000213432.14740.14; Watson S, 2018, J PATHOL, V245, P29, DOI 10.1002/path.5053; Wu MK, 2018, MODERN PATHOL, V31, P169, DOI 10.1038/modpathol.2017.100; Yoshida A, 2017, HISTOPATHOLOGY, V71, P461, DOI 10.1111/his.13252; Yoshida A, 2016, AM J SURG PATHOL, V40, P313, DOI 10.1097/PAS.0000000000000570; Yoshimoto M, 2009, CANCER GENET CYTOGEN, V195, P1, DOI 10.1016/j.cancergencyto.2009.06.015	49	2	3	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	OCT	2018	42	10					1360	1369		10.1097/PAS.0000000000001098			10	Pathology; Surgery	Pathology; Surgery	GV1RN	WOS:000445858300010	29901569				2019-10-28	
J	Munari, E; Rossi, G; Zamboni, G; Lunardi, G; Marconi, M; Sommaggio, M; Netto, GJ; Hoque, MO; Brunelli, M; Martignoni, G; Haffner, MC; Moretta, F; Pegoraro, MC; Cavazza, A; Samogin, G; Furlan, V; Mariotti, FR; Vacca, P; Moretta, L; Bogina, G				Munari, Enrico; Rossi, Giulio; Zamboni, Giuseppe; Lunardi, Gianluigi; Marconi, Marcella; Sommaggio, Marco; Netto, George J.; Hoque, Mohammad O.; Brunelli, Matteo; Martignoni, Guido; Haffner, Michael C.; Moretta, Francesca; Pegoraro, Maria C.; Cavazza, Alberto; Samogin, Giuseppina; Furlan, Vanna; Mariotti, Francesca R.; Vacca, Paola; Moretta, Lorenzo; Bogina, Giuseppe			PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs An Interclone Evaluation by Differently Trained Pathologists	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						PD-L1; PD-1; SP263; 22C3; lung cancer	IMMUNE CHECKPOINT INHIBITORS; PULMONARY SQUAMOUS-CELL; SMALL BIOPSY; EXPRESSION; IMMUNOHISTOCHEMISTRY; DEATH; IMMUNOTHERAPY; PEMBROLIZUMAB; RELIABILITY	Pembrolizumab is the only programmed cell death 1/programmed death-ligand 1 inhibitor for treatment of patients with non-small cell lung cancer, with a companion diagnostic assay, the 22C3 PharmDx. Although in many studies 22C3 and Ventana's SP263 appear to yield overlapping results, they show discrepancies at clinically relevant cutoffs (1% and 50%). We provide a solid comparison between 22C3 and SP263 assays in a large cohort of non-small cell lung cancer cases taking into account interobserver variability between trained pathologists who are used to either clone in their clinical practice. Serial sections of tissue microarrays, built from 198 cases of resected lung cancer, were stained for 22C3 on the Dako Link-48 platform and for SP263 on the Ventana Benchmark Ultra, following manufacturer's instructions. A protocol was also developed to run the 22C3 antibody on the Ventana platform. The pathologist used to 22C3 scored consistently higher than the pathologist used to SP263 at both 1% and 50% cutoff for all assays. For 22C3 and SP263 on respective platforms, we found statistically significant differences in terms of proportion of positive cases at both cutoffs; at 50% cutoff, around half of the cases positive with SP263 would have been defined negative with 22C3 by both pathologists. Important differences were also observed, when comparing clone 22C3 and SP263, both run on the Ventana platform. The lowest differences were seen with 22C3 run on both platforms. Assays 22C3 and SP263 show important discrepancies in identifying programmed death-ligand 1-positive cases at clinically relevant cutoffs, with possible underestimation of patients suitable for pembrolizumab therapy.	[Munari, Enrico; Zamboni, Giuseppe; Marconi, Marcella; Sommaggio, Marco; Bogina, Giuseppe] Sacro Cuore Don Calabria Hosp, Dept Pathol, Via Sempreboni 5, I-37024 Negrar, VR, Italy; [Lunardi, Gianluigi] Sacro Cuore Don Calabria Hosp, Dept Oncol, Negrar, Italy; [Moretta, Francesca] Sacro Cuore Don Calabria Hosp, Dept Lab Med, Negrar, Italy; [Rossi, Giulio] AUSL Romagna, Dept Pathol, Ravenna, Italy; [Zamboni, Giuseppe; Brunelli, Matteo; Martignoni, Guido] Univ Verona, Dept Diagnost & Publ Hlth, Verona, Italy; [Martignoni, Guido] Pederzoli Hosp, Dept Pathol, Peschiera Del Garda, Italy; [Pegoraro, Maria C.] Pederzoli Hosp, Dept Oncol, Peschiera Del Garda, Italy; [Cavazza, Alberto] Arcispedale S Maria Nuova IRCCS, Dept Pathol, Reggio Emilia, Italy; [Samogin, Giuseppina; Furlan, Vanna] Conegliano Hosp, Dept Pathol, Conegliano, Italy; [Mariotti, Francesca R.; Vacca, Paola; Moretta, Lorenzo] IRCCS Bambino Gesu Pediat Hosp, Immunol Res Area, Rome, Italy; [Netto, George J.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; [Hoque, Mohammad O.] Johns Hopkins Univ, Sch Med, Dept Otolaringol, Baltimore, MD USA; [Haffner, Michael C.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA	Munari, E (reprint author), Sacro Cuore Don Calabria Hosp, Dept Pathol, Via Sempreboni 5, I-37024 Negrar, VR, Italy.	enrico.munari@sacrocuore.it	Mariotti, Francesca Romana/Z-2998-2019; Munari, Enrico/J-7516-2016; Giuseppe, Zamboni/L-6029-2019; Moretta, Francesca/Z-3169-2019; Brunelli, Matteo/AAA-7679-2019; Vacca, Paola/K-2603-2016	Mariotti, Francesca Romana/0000-0002-3421-6470; Munari, Enrico/0000-0002-3867-6685; Giuseppe, Zamboni/0000-0001-7428-4673; Moretta, Francesca/0000-0002-1150-8622; Hoque, Mohammad Obaidul/0000-0001-6701-9978; Vacca, Paola/0000-0002-0757-0108	Associazione Italiana Ricerca sul Cancro (AIRC)Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG 2014 15283]	Partially supported by Associazione Italiana Ricerca sul Cancro (AIRC) [IG 2014 15283 to L.M.]. The remaining authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Adam J, 2018, ANN ONCOL, V29, P953, DOI 10.1093/annonc/mdy014; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Brahmer JR, 2013, CANCER IMMUNOL RES, V1, P85, DOI 10.1158/2326-6066.CIR-13-0078; Brunnstrom H, 2017, MODERN PATHOL, V30, P1411, DOI 10.1038/modpathol.2017.59; Buttner R, 2017, J CLIN ONCOL, V35, P3867, DOI 10.1200/JCO.2017.74.7642; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Gniadek TJ, 2017, MODERN PATHOL, V30, P530, DOI 10.1038/modpathol.2016.213; Gridelli C, 2016, EXPERT OPIN BIOL TH, V16, P1479, DOI 10.1080/14712598.2016.1234602; Hendry S, 2018, J THORAC ONCOL, V13, P367, DOI 10.1016/j.jtho.2017.11.112; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Hirsch FR, 2017, J THORAC ONCOL, V12, P208, DOI 10.1016/j.jtho.2016.11.2228; Ilie M, 2016, ANN ONCOL, V27, P147, DOI 10.1093/annonc/mdv489; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; Kitazono S, 2015, CLIN LUNG CANCER, V16, P385, DOI 10.1016/j.cllc.2015.03.008; Marchetti A, 2017, J THORAC ONCOL, V12, P1654, DOI 10.1016/j.jtho.2017.07.031; Munari E, 2017, ONCOTARGET, V8, P90123, DOI 10.18632/oncotarget.21485; Munari EZG, 2018, J THORAC ONCOL; Neuman T, 2016, J THORAC ONCOL, V11, P1863, DOI 10.1016/j.jtho.2016.08.146; Nishimura H, 1999, IMMUNITY, V11, P141, DOI 10.1016/S1074-7613(00)80089-8; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Pesce S, 2017, J ALLERGY CLIN IMMUN, V139, P335, DOI 10.1016/j.jaci.2016.04.025; Ratcliffe MJ, 2017, CLIN CANCER RES, V23, P3585, DOI 10.1158/1078-0432.CCR-16-2375; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Scheel AH, 2016, MODERN PATHOL, V29, P1165, DOI 10.1038/modpathol.2016.117; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Yearley JH, 2017, CLIN CANCER RES, V23, P3158, DOI 10.1158/1078-0432.CCR-16-1761	26	16	16	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	OCT	2018	42	10					1384	1389		10.1097/PAS.0000000000001105			6	Pathology; Surgery	Pathology; Surgery	GV1RN	WOS:000445858300012	29901568				2019-10-28	
J	Johncilla, M; Jessurun, J; Brown, I; Hornick, JL; Bellizzi, AM; Shia, J; Yantiss, RK				Johncilla, Melanie; Jessurun, Jose; Brown, Ian; Hornick, Jason L.; Bellizzi, Andrew M.; Shia, Jinru; Yantiss, Rhonda K.			Are Enterocolic Mucosal Mast Cell Aggregates Clinically Relevant in Patients Without Suspected or Established Systemic Mastocytosis?	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						systemic mastocytosis; mast cells; incidental enterocolic mast cell aggregates	CLASSIFICATION	The World Health Organization considers enterocolic mast cell aggregates with atypical morphologic and/or immunohistochemical features diagnostic of systemic mastocytosis mostly because published data are heavily influenced by inclusion of symptomatic patients with systemic disease. We occasionally encounter atypical mast cells in gastrointestinal biopsy samples from patients in whom systemic mastocytosis is not suspected. The aim of this study was to describe the clinicopathologic features and implications of atypical enterocolic mast cell aggregates in 16 patients without suspected or established systemic mastocytosis. Mast cell infiltrates were assessed for morphology, distribution, associated inflammatory cells, and CD117 and CD25 immunoexpression. Most (63%) patients were women; 15 underwent endoscopic examination for screening (n = 7), abdominal pain (n = 3), diarrhea (n = 3), changing bowel habits (n = 1), and dysphagia (n = 1). Mast cell aggregates were detected in 1 colectomy specimen for cancer. Colonic involvement was most common (n = 14) and resulted in polypoid (n = 10), edematous (n = 2), or normal (n = 3) mucosae. All cases featured CD117/CD25(+), ovoid mast cells concentrated beneath the epithelium, or diffusely involving the entire mucosal thickness. Eosinophils were numerous and obscured mast cells in 63% of cases. Spontaneous resolution of symptoms occurred in all patients (mean follow-up: 54 mo), and asymptomatic patients remained symptom-free (mean follow-up: 17 mo). Of 4 patients evaluated for systemic mastocytosis, 3 had negative bone marrow biopsies and one lacked a KIT mutation in peripheral blood. We conclude that, although careful clinical assessment of patients with incidental enterocolic mast cell aggregates is reasonable, labeling them with a systemic hematologic disorder may not be justified.	[Johncilla, Melanie; Jessurun, Jose; Yantiss, Rhonda K.] Weill Cornell Med, Dept Pathol & Lab Med, 525 East 68th St,Starr 1031E, New York, NY 10065 USA; [Shia, Jinru] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA; [Brown, Ian] Envoi Pathol, Kelvin Grove, Qld, Australia; [Hornick, Jason L.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Hornick, Jason L.] Harvard Med Sch, Boston, MA USA; [Bellizzi, Andrew M.] Univ Iowa Hosp & Clin, Dept Pathol, Iowa City, IA 52242 USA	Johncilla, M (reprint author), Weill Cornell Med, Dept Pathol & Lab Med, 525 East 68th St,Starr 1031E, New York, NY 10065 USA.	mej9041@med.cornell.edu		Bellizzi, Andrew/0000-0002-8264-6379	Translational Research Program, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine	Supported by Translational Research Program, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	[Anonymous], 1869, Br Med J, V2, P323; Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Ayadi L, 2015, PATHOLOGICA, V107, P14; Castells MC, 2006, J ALLERGY CLIN IMMUN, V117, P1513, DOI 10.1016/j.jaci.2006.04.016; CHERNER JA, 1988, GASTROENTEROLOGY, V95, P657, DOI 10.1016/S0016-5085(88)80012-X; Doyle LA, 2014, AM J SURG PATHOL, V38, P832, DOI 10.1097/PAS.0000000000000190; ELLIS JM, 1949, ARCH PATHOL, V48, P426; Hahn HP, 2007, AM J SURG PATHOL, V31, P1669, DOI 10.1097/PAS.0b013e318078ce7a; Jensen RT, 2000, HEMATOL ONCOL CLIN N, V14, P579, DOI 10.1016/S0889-8588(05)70298-7; KETTELHUT BV, 1989, AM J CLIN PATHOL, V91, P558, DOI 10.1093/ajcp/91.5.558; Kochi S, 2014, ENDOSCOPY S1, V46; Komi DEA, 2018, CLIN REV ALLERG IMMU, V54, P397, DOI 10.1007/s12016-017-8619-2; Pardanani A, 2016, AM J HEMATOL, V91, P1147, DOI 10.1002/ajh.24553; Sangster A, 1878, T CLIN SOC LONDON, V11, P161; Schuch A, 2017, IMMUNOL ALLERGY CLIN, V37, P153, DOI 10.1016/j.iac.2016.08.017; Shih AR, 2016, HISTOPATHOLOGY, V69, P1021, DOI 10.1111/his.13033; Swerdlow SH, 2017, WHO CLASSIFICATION T; Valent P, 2017, BLOOD, V129, P1420, DOI 10.1182/blood-2016-09-731893; Valent P, 2017, CANCER RES, V77, P1261, DOI 10.1158/0008-5472.CAN-16-2234; Wood JD, 2004, GASTROENTEROLOGY, V127, P635, DOI 10.1053/j.gastro.2004.02.017; Yi C, 2015, AM J DIG DIS, V2, P100	21	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	OCT	2018	42	10					1390	1395		10.1097/PAS.0000000000001126			6	Pathology; Surgery	Pathology; Surgery	GV1RN	WOS:000445858300013	30001235				2019-10-28	
J	Sun, Y; Argani, P; Tickoo, SK; Epstein, JI				Sun, Yue; Argani, Pedram; Tickoo, Satish K.; Epstein, Jonathan I.			Acquired Cystic Disease-associated Renal Cell Carcinoma (ACKD-RCC)-like Cysts	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						end-stage renal disease; renal cell carcinoma; acquired cystic disease	NEOPLASIA; CLASSIFICATION; SPECTRUM; KIDNEYS	Acquired cystic disease-associated renal cell carcinoma (ACKD-RCC), originally described by Tickoo and colleagues, is found exclusively in patients with end-stage renal disease. Tickoo and colleagues noted: Many of the tumors (16 of 24 dominant tumors) appeared to arise in a cyst, most often completely filling the cystic space. The cells lining such cysts were morphologically similar to those in the rest of the tumor. Subsequent literature lacks analysis of cysts lined by cells identical to ACKD-RCC, yet lacking areas of solid growth. The current study evaluates 16 cases ACKD-RCC-like cysts. All specimens were nephrectomies and occurred in the setting of end-stage renal disease. Of the 16 cases, 9 were in men. Patient's ages ranged from 32 to 66 years (median: 57). The cysts ranged in size from 0.2 to 2.5 cm. Twelve cases had unilateral cysts with the remaining 4 seen in both kidneys. Nine cysts were multilocular, 6 unilocular, and 1 consisted of closely clustered cysts. The atypical cysts showed architectural variation. One cyst was lined by a single layer of atypical cells (1/16), whereas in the majority these were either focally lined by 2 to 4 cell layers of atypical cells (6/16 cases) or showed occasional short papillary formations (9/16). Calcium oxalate crystals were noted in cyst walls in 7/16 cases. A total of 12/16 cases had separate RCCs (2 cases with 2 RCCs each; 1 case with 3). Carcinoma ranged in size from 3 mm to 5 cm in the largest dimension: 4 were pT1 ACKD-RCC; 5 were pT1 papillary RCC; 5 were pT1 clear cell papillary RCC; 1 was pT3 clear cell RCC; and 1 pT1 unclassified. Our study formally analyzes for the first time in the literature atypical cysts lined with vacuolated cells with eosinophilic cytoplasm that are likely the earliest precursors of ACKD-RCC. When these cysts are encountered, especially ones that are multilocular or clustered, they may be misdiagnosed as ACKD-RCC. ACKD-RCC-like cysts should be recognized as a distinct entity from ACKD-RCC, defined by the lack of any solid nodular growth within the cyst.	[Sun, Yue; Argani, Pedram; Epstein, Jonathan I.] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; [Tickoo, Satish K.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA	Epstein, JI (reprint author), Johns Hopkins Univ Hosp, Weinberg Bldg,Rm 2242,401 N Broadway St, Baltimore, MD 21231 USA.	jepstein@jhmi.edu					Cheuk W, 2002, HUM PATHOL, V33, P761, DOI 10.1053/hupa.2002.125370; Hosseini M, 2014, HUM PATHOL, V45, P1406, DOI 10.1016/j.humpath.2014.02.014; Humphrey PA, 2016, EUR UROL, V70, P106, DOI 10.1016/j.eururo.2016.02.028; Kong MX, 2013, RARE TUMORS, V5, P185, DOI 10.4081/rt.2013.e57; Matoso A, 2016, AM J SURG PATHOL, V40, P202, DOI 10.1097/PAS.0000000000000557; Nouh MAAM, 2010, BJU INT, V105, P620, DOI 10.1111/j.1464-410X.2009.08817.x; Srigley JR, 2013, AM J SURG PATHOL, V37, P1469, DOI 10.1097/PAS.0b013e318299f2d1; Sule N, 2005, AM J SURG PATHOL, V29, P443, DOI 10.1097/01.pas.0000152131.58492.97; Tickoo SK, 2006, AM J SURG PATHOL, V30, P141, DOI 10.1097/01.pas.0000185382.80844.b1	9	0	0	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	OCT	2018	42	10					1396	1401		10.1097/PAS.0000000000001124			6	Pathology; Surgery	Pathology; Surgery	GV1RN	WOS:000445858300014	30001236				2019-10-28	
J	Balakrishna, JP; Bhavsar, T; Nicolae, A; Raffeld, M; Jaffe, ES; Pittaluga, S				Balakrishna, Jayalakshmi P.; Bhavsar, Tapan; Nicolae, Alina; Raffeld, Mark; Jaffe, Elaine S.; Pittaluga, Stefania			Human Herpes Virus 6 (HHV-6)-associated Lymphadenitis Pitfalls in Diagnosis in Benign and Malignant Settings	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						human herpes virus 6; acute lymphadenitis; lymphoproliferative disorder; viral inclusions; peripheral T-cell lymphoma	HUMAN HERPESVIRUS-6 INFECTION; HHV-6; PCR; HUMAN-HERPESVIRUS-6; IDENTIFICATION; IMMUNOGLOBULIN; POPULATION; SEQUENCES; VARIANT; ADULTS	Human herpes virus 6 (HHV-6) is a member of the beta-herpesvirinae subfamily. Most people acquire HHV-6 primary infection early in life and reactivation may occur, most often in immunocompromised individuals, leading to various clinical manifestations. HHV-6 infected cells may be identified in lymph nodes in both reactive and neoplastic conditions. Cases were retrieved from the hematopathology consultation service archives at National Institutes of Health from 2003 to 2017 in which infection by HHV-6 had been documented by immunohistochemical stains to HHV-6 gp60/110 envelope glycoprotein. Five cases of reactive lymphadenitis and 3 cases of lymphoma; 2 angioimmunoblastic T-cell lymphoma and 1 classic Hodgkin lymphoma, positive for HHV-6 were identified. The reactive lymph nodes showed marked paracortical hyperplasia and admixed large atypical lymphoid cells exhibiting pleomorphic nuclei, vesicular chromatin, and prominent eosinophilic intranuclear inclusions. Vascular proliferation and necrosis were also present, raising suspicion of peripheral T-cell lymphoma. The 3 cases of lymphoma showed similar viral inclusions, in addition to the characteristic features diagnostic of the lymphoma. Staining for HHV-6 was positive with a membranous and Golgi pattern and was restricted to cells with evident inclusions on hematoxylin and eosin. HHV-6 infected cells were positive for CD3 and CD4. HHV-6 lymphadenitis can present with morphologic atypia creating a diagnostic pitfall for lymphoma. In such cases, careful attention to the characteristic viral inclusions can lead to immunohistochemical analysis highlighting the replicating virus. In cases of lymphoma, identification of the inclusions is key in detecting the associated infection as well as in avoiding misinterpretation of the lymphoma subtype.	[Balakrishna, Jayalakshmi P.; Nicolae, Alina; Raffeld, Mark; Jaffe, Elaine S.; Pittaluga, Stefania] NCI, Lab Pathol, Ctr Canc Res, NIH, Bldg 10,10 Ctr Dr,Room 2S235, Bethesda, MD 20892 USA; [Bhavsar, Tapan] Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA	Pittaluga, S (reprint author), NCI, Lab Pathol, Ctr Canc Res, NIH, Bldg 10,10 Ctr Dr,Room 2S235, Bethesda, MD 20892 USA.	stefpitt@mail.nih.gov		Balakrishna, Jayalakshmi/0000-0002-8906-2704	Center for Cancer Research, National Cancer Institute, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)	Supported by funding from the intramural program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health.	Ablashi D, 2014, ARCH VIROL, V159, P863, DOI 10.1007/s00705-013-1902-5; ABLASHI DV, 1987, NATURE, V329, P207, DOI 10.1038/329207a0; AKASHI K, 1993, NEW ENGL J MED, V329, P168, DOI 10.1056/NEJM199307153290304; Bai YF, 2014, INT J CLIN EXP PATHO, V7, P3413; Bates M, 2009, J MED VIROL, V81, P779, DOI 10.1002/jmv.21455; CUENDE JI, 1994, J MED VIROL, V43, P115, DOI 10.1002/jmv.1890430203; DEWHURST S, 1993, J CLIN MICROBIOL, V31, P416; Dojcinov SD, 2011, BLOOD, V117, P4726, DOI 10.1182/blood-2010-12-323238; Forghieri F, 2016, BRIT J HAEMATOL, V172, P561, DOI 10.1111/bjh.13871; Grivel JC, 2003, J VIROL, V77, P8280, DOI 10.1128/JVI.77.15.8280-8289.2003; IRVING WL, 1990, BRIT MED J, V300, P156, DOI 10.1136/bmj.300.6718.156; Isegawa Y, 1999, J VIROL, V73, P8053; Lawnicki LC, 2003, J MOL DIAGN, V5, P82, DOI 10.1016/S1525-1578(10)60456-4; Luppi M, 1998, AM J PATHOL, V153, P815, DOI 10.1016/S0002-9440(10)65623-4; LUSSO P, 1991, J IMMUNOL, V147, P685; Maric I, 2004, MODERN PATHOL, V17, P1427, DOI 10.1038/modpathol.3800179; Merelli E, 1996, J NEUROL SCI, V137, P42, DOI 10.1016/0022-510X(95)00319-W; Mori Y, 2007, HUMAN HERPESVIRUSES: BIOLOGY, THERAPY, AND IMMUNOPROPHYLAXIS, P833; OKUNO T, 1989, J CLIN MICROBIOL, V27, P651; RAMASAMY I, 1992, J CLIN PATHOL, V45, P770, DOI 10.1136/jcp.45.9.770; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; Tang HM, 2013, P NATL ACAD SCI USA, V110, P9096, DOI 10.1073/pnas.1305187110; TORELLI G, 1991, BLOOD, V77, P2251; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202; YAMANISHI K, 1988, LANCET, V1, P1065; Zerr DM, 2005, NEW ENGL J MED, V352, P768, DOI 10.1056/NEJMoa042207; Zhou YP, 2007, BRIT J HAEMATOL, V138, P44, DOI 10.1111/j.1365-2141.2007.06620.x	27	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	OCT	2018	42	10					1402	1408		10.1097/PAS.0000000000001121			7	Pathology; Surgery	Pathology; Surgery	GV1RN	WOS:000445858300015	29975251				2019-10-28	
J	Ma, CQ; Olevian, DC; Lowenthal, BM; Jayachandran, P; Kozak, MM; Chang, DT; Pai, RK				Ma, Changqing; Olevian, Dane C.; Lowenthal, Brett M.; Jayachandran, Priya; Kozak, Margaret M.; Chang, Daniel T.; Pai, Reetesh K.			Loss of SATB2 Expression in Colorectal Carcinoma Is Associated With DNA Mismatch Repair Protein Deficiency and BRAF Mutation	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						colorectal carcinoma; SATB2; CDX2; DNA mismatch repair; BRAF; KRAS	ISLAND METHYLATOR PHENOTYPE; CANCER; TUMORS; DIFFERENTIATION; ADENOCARCINOMA; CYTOKERATIN-20; PROGNOSIS; INTESTINE; SURVIVAL; FEATURES	The special AT-rich sequence binding protein (SATB2) has been reported to be a specific immunohistochemical marker for colorectal carcinoma; however, correlation of SATB2 expression with molecular alterations commonly assessed in colorectal carcinoma has not been performed. We examined the immunohistochemical expression of SATB2 in 586 adenocarcinomas of the gastrointestinal (GI) tract and pancreas to assess its utility in diagnosis and analyze the clinicopathologic and molecular characteristics of colorectal carcinoma stratified by SATB2 expression. SATB2 and CDX2 expression were evaluated in 266 adenocarcinomas of lower GI tract origin (246 colorectal and 20 appendiceal mucinous), 208 adenocarcinomas of upper GI tract and small intestinal origin (74 esophagus/esophagogastric junction, 103 stomach, 20 duodenal, and 11 jejunoileal), and 112 pancreatic ductal adenocarcinomas. SATB2 expression was more frequently identified in adenocarcinomas of lower GI tract origin (222/266, 83%) compared with upper GI tract, small intestinal, or pancreatic origin (26/320, 8%) (P < 0.001). Compared with CDX2 alone, dual positive expression for SATB2 and CDX2 (SATB2(+)/CDX2(+)) has a significantly higher specificity for adenocarcinoma of lower GI tract origin (94% vs. 57%, P < 0.001). In colorectal carcinoma, loss of SATB2 expression was more frequently observed in DNA mismatch repair (MMR) protein deficient tumors (31%) compared with MMR protein proficient tumors (13%) (P < 0.01). A BRAF V600E mutation was more frequently identified in colorectal carcinomas with loss of SATB2 expression compared with those with positive SATB2 expression (29% vs. 3%) (P < 0.001). In summary, SATB2 expression is a relatively specific marker of lower GI tract origin; however, loss of SATB2 expression is more commonly seen in colorectal carcinoma with MMR protein deficiency and BRAF mutation.	[Ma, Changqing; Olevian, Dane C.; Lowenthal, Brett M.; Pai, Reetesh K.] Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA USA; [Jayachandran, Priya; Kozak, Margaret M.; Chang, Daniel T.] Stanford Univ, Dept Radiat Oncol, Stanford, CA 94305 USA	Pai, RK (reprint author), Univ Pittsburgh, Presbyterian Hosp, Dept Pathol, 200 Lothrop St,Room A-610, Pittsburgh, PA 15213 USA.	pair@upmc.edu					[Anonymous], 2018, MEDCALC STAT SOFTWAR; Baba Y, 2009, CLIN CANCER RES, V15, P4665, DOI 10.1158/1078-0432.CCR-09-0401; Britanova O, 2005, EUR J NEUROSCI, V21, P658, DOI 10.1111/j.1460-9568.2005.03897.x; Chen ZME, 2004, AM J SURG PATHOL, V28, P1352, DOI 10.1097/01.pas.0000135520.72965.50; Dobreva G, 2003, GENE DEV, V17, P3048, DOI 10.1101/gad.1153003; Dobreva G, 2006, CELL, V125, P971, DOI 10.1016/j.cell.2006.05.012; Dragomir A, 2014, AM J CLIN PATHOL, V141, P630, DOI 10.1309/AJCPWW2URZ9JKQJU; Eberhard J, 2012, BRIT J CANCER, V106, P931, DOI 10.1038/bjc.2012.34; FitzPatrick DR, 2003, HUM MOL GENET, V12, P2491, DOI 10.1093/hmg/ddg248; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Gurzu S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057699; Gurzu S, 2012, PATHOL RES PRACT, V208, P163, DOI 10.1016/j.prp.2012.01.003; Kim JH, 2013, AM J SURG PATHOL, V37, P1532, DOI 10.1097/PAS.0b013e31829ab1c1; Lin F, 2014, ARCH PATHOL LAB MED, V138, P1015, DOI 10.5858/arpa.2013-0452-OA; Liu CL, 2002, AM J PATHOL, V161, P1557, DOI 10.1016/S0002-9440(10)64434-3; Lugli A, 2008, MODERN PATHOL, V21, P1403, DOI 10.1038/modpathol.2008.117; Magnusson K, 2011, AM J SURG PATHOL, V35, P937, DOI 10.1097/PAS.0b013e31821c3dae; McGregor DK, 2004, AM J SURG PATHOL, V28, P712, DOI 10.1097/01.pas.0000126757.58474.12; Moh M, 2016, AM J SURG PATHOL, V40, P419, DOI 10.1097/PAS.0000000000000553; Pai RK, 2012, AM J SURG PATHOL, V36, P744, DOI 10.1097/PAS.0b013e31824430d7; Montiel DP, 2015, ANN DIAGN PATHOL, V19, P249, DOI 10.1016/j.anndiagpath.2015.05.004; Salari K, 2012, P NATL ACAD SCI USA, V109, pE3196, DOI 10.1073/pnas.1206004109; Walsh MD, 2013, MODERN PATHOL, V26, P1642, DOI 10.1038/modpathol.2013.101; Zlobec I, 2011, J PATHOL, V225, P336, DOI 10.1002/path.2879	24	6	6	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	OCT	2018	42	10					1409	1417		10.1097/PAS.0000000000001116			9	Pathology; Surgery	Pathology; Surgery	GV1RN	WOS:000445858300016	30001238				2019-10-28	
J	Kenwright, D; Charlton, A; Grainger, R				Kenwright, Diane; Charlton, Amanda; Grainger, Rebecca			Teaching twenty-first century trainees	PATHOLOGY			English	Editorial Material							MEDICAL-EDUCATION; MILLENNIALS		[Kenwright, Diane; Grainger, Rebecca] Univ Otago, Dept Pathol & Mol Med, Wellington, New Zealand; [Charlton, Amanda] LabPlus, Auckland, New Zealand	Kenwright, D (reprint author), Univ Otago, Dept Pathol & Mol Med, Wellington Sch Med & Hlth Sci, POB 7343, Wellington, New Zealand.	diane.kenwright@otago.ac.nz					Algiraigri AH, 2014, MED EDUC ONLINE, V19, DOI 10.3402/meo.v19.25141; Cantillon P, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1961; Cateten O, 2009, MED TEACH, V29, P591; Cirillo F., 2006, AGILE PROCESS SOFTWA, P54; Desy JR, 2017, MAYO CLIN PROC, V92, P243, DOI 10.1016/j.mayocp.2016.10.026; Friedlander MJ, 2011, ACAD MED, V86, P415, DOI 10.1097/ACM.0b013e31820dc197; Gradl-Dietsch G, 2016, BMC MED EDUC, V16, DOI 10.1186/s12909-016-0804-0; Harden RM, 2000, MED TEACH, V22, P334; Kenwright D, 2017, MED SCI ED, V35, P1; Kost A, 2015, ACAD MED, V90, P20, DOI 10.1097/ACM.0000000000000446; Naritoku WY, 2016, ACAD PATHOL, V3, DOI 10.1177/2374289516667746; Oh RC, 2005, FAM MED, V37, P537; Pendelton D, 2003, THE NEW CONSULTATION; Roberts DH, 2012, MED TEACH, V34, P274, DOI 10.3109/0142159X.2011.613498; Royal College of Pathologists of Australasia (RCPA), 2018, AN PATH HDB 2018; Rudland J, 2013, CLIN TEACH, V10, P99, DOI 10.1111/j.1743-498X.2012.00634.x; Sargeant JM, 2009, ADV HEALTH SCI EDUC, V14, P399, DOI 10.1007/s10459-008-9124-4; Thistlethwaite J, 2010, MED TEACH, V32, P880, DOI 10.3109/0142159X.2010.519068; Tucker CR, 2017, MED TEACH, V39, P783, DOI 10.1080/0142159X.2016.1270435; Waljee JF, 2018, JAMA-J AM MED ASSOC, V319, P1547, DOI 10.1001/jama.2018.3804; Young JQ, 2014, MED TEACH, V36, P371, DOI 10.3109/0142159X.2014.889290	21	0	0	1	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	OCT	2018	50	6					591	592		10.1016/j.pathol.2018.07.001			2	Pathology	Pathology	GU7XB	WOS:000445543400001	30170701				2019-10-28	
J	Miller, GC; Campbell, CM; Manoharan, B; Bryant, R; Cavallucci, D; O'Rourke, N; Clouston, AD				Miller, Gregory C.; Campbell, Catherine M.; Manoharan, Bavahuna; Bryant, Richard; Cavallucci, David; O'Rourke, Nicholas; Clouston, Andrew D.			Subclassification of hepatocellular adenomas: practical considerations in the implementation of the Bordeaux criteria	PATHOLOGY			English	Article						Liver neoplasms; adenoma; liver cell; hepatocellular adenoma; immunohistochemistry	FOCAL NODULAR HYPERPLASIA; MALIGNANT-TRANSFORMATION; GLUTAMINE-SYNTHETASE; CLASSIFICATION; DISTINCTION; MUTATIONS; CARCINOMA; RISK	Hepatocellular adenomas are benign liver lesions with a risk of rupture and malignant transformation. Various molecular subgroups have been identified which appear to have characteristic morphological and immunohistochemical features. We examined the morphology and immunohistochemical profile of a series of 121 HCA from 97 patients to identify the HCA subtypes present and determine the number at risk for malignant transformation according to the World Health Organization (WHO) criteria for hepatocellular adenomas. There were 34 HNF1 alpha inactivated HCA (28%), 61 inflammatory HCA (50%), 15 beta-catenin activated HCA (12%) and 11 unclassified adenomas (9%). This proportion of cases was similar to that seen in other series utilising molecular classification. The morphological features of the adenomas were suggestive but not definite indicators of the subtypes present. Morphological features that showed overlap between the subtypes included steatosis within the lesion, a ductular reaction and focal atypia, so that immunohistochemical typing was required for accurate classification. In conclusion, immunohistochemistry is a clinically useful surrogate for identifying underlying molecular changes in the HCA subtypes.	[Miller, Gregory C.; Manoharan, Bavahuna; Bryant, Richard; Cavallucci, David; O'Rourke, Nicholas; Clouston, Andrew D.] Univ Queensland, Fac Med, Brisbane, Qld, Australia; [Bryant, Richard; Cavallucci, David; O'Rourke, Nicholas] Royal Brisbane & Womens Hosp, Dept Surg, Brisbane, Qld, Australia	Miller, GC (reprint author), Unit 5-38 Bishop St, Kelvin Grove, Qld 4059, Australia.	gregorymiller@envoi.com.au	Cavallucci, David/K-6382-2012	Cavallucci, David/0000-0003-2112-6465			[Anonymous], 1994, HEPATOLOGY, V20, P15; Balabaud C, 2014, VIRCHOWS ARCH, V465, P495, DOI 10.1007/s00428-014-1649-8; Bellamy COC, 2013, HISTOPATHOLOGY, V62, P431, DOI 10.1111/his.12011; Bioulac-Sage P, 2010, FOCAL NODULAR HYPERP, P417; Bioulac-Sage P, 2007, HEPATOLOGY, V46, P740, DOI 10.1002/hep.21743; Bioulac-Sage P, 2017, SEMIN DIAGN PATHOL, V34, P112, DOI 10.1053/j.semdp.2016.12.007; Bioulac-Sage P, 2014, CLIN RES HEPATOL GAS, V38, P245, DOI 10.1016/j.clinre.2014.01.001; Bioulac-Sage P, 2012, LIVER INT, V32, P1217, DOI 10.1111/j.1478-3231.2012.02786.x; Dokmak S, 2009, GASTROENTEROLOGY, V137, P1698, DOI 10.1053/j.gastro.2009.07.061; Farges O, 2011, GUT, V60, P85, DOI 10.1136/gut.2010.222109; Hale G, 2016, MODERN PATHOL, V29, P1370, DOI 10.1038/modpathol.2016.122; Henriet E, 2017, HEPATOLOGY, V66, P2016, DOI 10.1002/hep.29336; Joseph NM, 2014, MODERN PATHOL, V27, P62, DOI 10.1038/modpathol.2013.114; Lagana SM, 2013, APPL IMMUNOHISTO M M, V21, P170, DOI 10.1097/PAI.0b013e31825d527f; Laumonier H, 2008, HEPATOLOGY, V48, P808, DOI 10.1002/hep.22417; Micchelli STL, 2008, MODERN PATHOL, V21, P491, DOI 10.1038/modpathol.2008.8; Nault JC, 2017, GASTROENTEROLOGY, V152, P880, DOI 10.1053/j.gastro.2016.11.042; Nguyen TB, 2016, MODERN PATHOL, V29, P283, DOI 10.1038/modpathol.2015.162; Pilati C, 2014, CANCER CELL, V25, P428, DOI 10.1016/j.ccr.2014.03.005; Rebouissou S, 2016, HEPATOLOGY, V64, P2047, DOI 10.1002/hep.28638; Ronald M, 2004, HPB (Oxford), V6, P25, DOI 10.1080/13651820310020846; ROOKS JB, 1979, JAMA-J AM MED ASSOC, V242, P644, DOI 10.1001/jama.242.7.644; Sakellariou S, 2012, HISTOPATHOLOGY, V60, pE58, DOI 10.1111/j.1365-2559.2011.04153.x; Saldarriaga J, 2017, HISTOPATHOLOGY, V71, P989, DOI 10.1111/his.13283; Sasaki M, 2011, HEPATOL RES, V41, P982, DOI 10.1111/j.1872-034X.2011.00851.x; Sempoux C, 2017, HUM PATHOL, V62, P122, DOI 10.1016/j.humpath.2016.10.004; Shafizadeh N, 2014, HUM PATHOL, V45, P976, DOI 10.1016/j.humpath.2013.12.011; van Aalten SM, 2011, J HEPATOL, V55, P120, DOI 10.1016/j.jhep.2010.10.030; Zucman-Rossi J, 2006, HEPATOLOGY, V43, P515, DOI 10.1002/hep.21068	29	2	2	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	OCT	2018	50	6					593	599		10.1016/j.pathol.2018.05.003			7	Pathology	Pathology	GU7XB	WOS:000445543400002	30149989				2019-10-28	
J	Newland, RC; Chan, C; Chapuis, PH; Keshava, A; Rickard, MJFX; Young, CJ; Dent, OF				Newland, Ronald C.; Chan, Charles; Chapuis, Pierre H.; Keshava, Anil; Rickard, Matthew J. F. X.; Young, Christopher J.; Dent, Owen F.			Competing risks analysis of the effect of local residual tumour on recurrence and cancer-specific death after resection of colorectal cancer: implications for staging	PATHOLOGY			English	Article						Colorectal cancer; staging; local residual tumour; recurrence; prognosis	COLON-CANCER; SURVIVAL; CARCINOMA; SYSTEM; CLASSIFICATION; TERMINOLOGY; PROGNOSIS; PATHOLOGY; OUTCOMES; SURFACE	The pTNM staging system for colorectal cancer (CRC) is not entirely effective in discriminating between potentially curative and non-curative resections because it does not account for local residual tumour in patients with stages I, II or III. This study aimed to evaluate the prognostic importance of histologically verified tumour in any line of resection of the bowel resection specimen (TLR) in relation to pTNM stages and to demonstrate how TLR may be integrated into pTNM staging. Information on patients in the period 1995 to 2010 with complete follow-up to the end of 2015 was extracted from a prospective database of CRC resections. The outcome variables were the competing risks incidence of CRC recurrence and CRC-specific death. After exclusions, 2220 patients remained. In 1930 patients with pTNM stages I-III tumour, recurrence was markedly higher in those with TLR than in those without (HR 6.0, 95% CI 4.2-8.5, p < 0.001) and this persisted after adjustment for covariates associated with recurrence. CRC-specific death was markedly higher in the presence of TLR (HR 7.7, CI 5.3-11.2, p < 0.001), which persisted after adjustment for relevant covariates. These results justify removing patients with TLR from pTNM stages I to III and placing them in stage IV, thereby allowing the categorisation of all patients with any known residual tumour into three prognostically distinct groups. This study demonstrates how TLR may be integrated into pTNM staging, thus improving the definition of the three stages which are considered potentially curable (I, II and III).	[Newland, Ronald C.; Chan, Charles] Concord Hosp, Div Anat Pathol, Sydney, NSW, Australia; [Chan, Charles] Sydney Med Sch, Discipline Pathol, Sydney, NSW, Australia; [Chapuis, Pierre H.; Keshava, Anil; Rickard, Matthew J. F. X.; Young, Christopher J.; Dent, Owen F.] Concord Hosp, Colorectal Surg Unit, Sydney, NSW, Australia; [Chapuis, Pierre H.; Dent, Owen F.] Sydney Med Sch, Discipline Surg, Sydney, NSW, Australia	Dent, OF (reprint author), Concord Hosp, Colorectal Surg Unit, Concord, NSW 2139, Australia.	Owen.Dent@netspeed.com.au		Keshava, Anil/0000-0002-1340-7817			American Joint Committee for Cancer, 1977, MAN STAG CANC 1977; [Anonymous], 2017, AJCC CANC STAGING MA; Bateman AC, 2005, J CLIN PATHOL, V58, P426, DOI 10.1136/jcp.2004.019802; Beahrs OH, 1988, AJCC MANUAL FOR STAG; Bokey EL, 1999, BRIT J SURG, V86, P1164, DOI 10.1046/j.1365-2168.1999.01216.x; Bokey EL, 2003, DIS COLON RECTUM, V46, P860, DOI 10.1097/01.DCR.0000074731.78773.BB; Compton CC, 2000, ARCH PATHOL LAB MED, V124, P979; Darakhshan A, 2008, ANN SURG, V247, P650, DOI 10.1097/SLA.0b013e318163d264; DAVIS NC, 1983, AUST NZ J SURG, V53, P211, DOI 10.1111/j.1445-2197.1983.tb02430.x; Dent OF, 2017, ANZ J SURG, V87, P34, DOI 10.1111/ans.13758; Dukes CE, 1932, J PATHOL BACTERIOL, V35, P323, DOI 10.1002/path.1700350303; Edge SB, 2009, AM JOINT COMMITTEE C; FIELDING LP, 1991, J GASTROEN HEPATOL, V6, P325, DOI 10.1111/j.1440-1746.1991.tb00867.x; GABRIEL WB, 1951, BRIT J SURG, V38, P401, DOI 10.1002/bjs.18003815202; Gibson KM, 2014, DIS COLON RECTUM, V57, P916, DOI 10.1097/DCR.0000000000000162; Gooley TA, 1999, STAT MED, V18, P695, DOI 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.3.CO;2-F; HERMANEK P, 1980, J CANCER RES CLIN, V98, P185, DOI 10.1007/BF00405962; HERMANEK P, 1995, WORLD J SURG, V19, P184, DOI 10.1007/BF00308624; Hermanek P, 1987, TNM CLASSIFICATION O, DOI [10.1007%2F978-3-642-8298-6, DOI 10.1007/2F978-3-642-8298-6]; Keshava A, 2007, COLORECTAL DIS, V9, P609, DOI 10.1111/j.1463-1318.2006.01136.x; NEWLAND RC, 1993, CANCER, V72, P1536, DOI 10.1002/1097-0142(19930901)72:5<1536::AID-CNCR2820720508>3.0.CO;2-U; NEWLAND RC, 1981, CANCER, V47, P1424, DOI 10.1002/1097-0142(19810315)47:6<1424::AID-CNCR2820470630>3.0.CO;2-O; NEWLAND RC, 1987, CANCER, V60, P852, DOI 10.1002/1097-0142(19870815)60:4<852::AID-CNCR2820600422>3.0.CO;2-5; Peduzzi P, 1995, J CLIN EPIDEMIOL, V48, P1503, DOI 10.1016/0895-4356(95)00048-8; Petersen VC, 2002, GUT, V51, P65, DOI 10.1136/gut.51.1.65; PHEILS MT, 1976, MED J AUSTRALIA, V1, P17, DOI 10.5694/j.1326-5377.1976.tb76694.x; Punt CJA, 2007, JNCI-J NATL CANCER I, V99, P998, DOI 10.1093/jnci/djm024; Putter H, 2007, STAT MED, V26, P2389, DOI 10.1002/sim.2712; Quirke P, 2007, LANCET ONCOL, V8, P651, DOI 10.1016/S1470-2045(07)70205-X; Satagopan JM, 2004, BRIT J CANCER, V91, P1229, DOI 10.1038/sj.bjc.6602102; The Royal College of Pathologists, 2014, STAND DAT REP CANC D; TURNBULL RB, 1967, ANN SURG, V166, P420	32	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	OCT	2018	50	6					600	606		10.1016/j.pathol.2018.07.003			7	Pathology	Pathology	GU7XB	WOS:000445543400003	30149993	Bronze			2019-10-28	
J	Eyraud, D; Granger, B; Bardier, A; Loncar, Y; Gottrand, G; Le Naour, G; Siksik, JM; Vaillant, JC; Klatzmann, D; Puybasset, L; Charlotte, F; Augustin, J				Eyraud, Daniel; Granger, Benjamin; Bardier, Armelle; Loncar, Yann; Gottrand, Gaelle; Le Naour, Gilles; Siksik, Jean-Michel; Vaillant, Jean-Christophe; Klatzmann, David; Puybasset, Louis; Charlotte, Frederic; Augustin, Jeremy			Immunological environment in colorectal cancer: a computer-aided morphometric study of whole slide digital images derived from tissue microarray	PATHOLOGY			English	Article						Digital imaging; colorectal cancer; microenvironment; regulatory T cells; tissue microarray; FOXP3; IDO	REGULATORY T-CELLS; INDOLEAMINE 2,3-DIOXYGENASE; PROGNOSTIC VALUE; COLON-CANCER; EXPRESSION; METASTASIS; TRYPTOPHAN; MICROENVIRONMENT; FOXP3; RISK	Cancer research has moved from investigating tumour cells to including analysis of the tumour microenvironment as well. The aim of this study was to assess the cellular infiltrate of colorectal cancer (CRC) using computer-aided analysis of whole slide digital image derived from tissue microarray (TMA). TMA slides from 31 CRC patients were immunostained for forkhead box protein 3 (FOXP3) and immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO) at four sites: centre (C) and invasive front (F) of the tumour, proximal non-metastatic draining lymph node (N-), tumour-draining lymph node with metastasis (N+) and healthy mucosa at 10 cm from the cancer (M). We analysed the proportion of IDO+ tissue areas in the lamina propria or in the non-epithelial area of the lymph node and in epithelial cells in each site. The normal mucosa of patients operated on for benign disease was also analysed. The proportion (%) of FOXP3+ tissue area in C, F, N-, N+ and M were 2.3 +/- 1.8, 2.6 +/- 2.9, 6.0 +/- 2.9, 14.2 +/- 5.8 and 1.2 +/- 0.8 (p < 0.001). The proportion (%) of IDO+ tissue area in the lamina propria of C, F, N-, N+ and M were 1.6 +/- 3.1, 1.1 +/- 1.3, 3.4 +/- 2.5, 9.1 +/- 8.5 and 6.7 +/- 5.4 (p < 0.001). IDO+ tissue area in the lamina propria was not significantly different between healthy mucosa of patients with cancer than without (1.8 +/- 3 vs 1.1 +/- 0.95). The proportion of IDO positive tissue area in the epithelium was significantly higher in healthy mucosa of patients with cancer than without (5.4 +/- 13.8 vs 2.1 +/- 2.4). The FOXP3+ tissue area was increased in healthy mucosa of CRC patients in comparison with healthy mucosa of patients with colorectal resection for disease other than cancer: 1.20 +/- 1.81 versus 0.81 +/- 0.51 (p < 0.05). The proportion of IDO+ tissue area in lymph node (N-) was correlated with the proportion of FOXP3+ tissue area in tumour area (r = 0.44, p < 0.01). TMA technique permits simultaneous analysis of FOXP3+ and IDO+ cells at different sites including tumour, draining non-metastatic lymph node, metastatic lymph node and normal mucosa.	[Eyraud, Daniel; Loncar, Yann; Puybasset, Louis] Hop La Pitie Salpetriere, Dept Anesthesie Reanimat, Paris, France; [Eyraud, Daniel; Bardier, Armelle; Le Naour, Gilles; Charlotte, Frederic; Augustin, Jeremy] Hop La Pitie Salpetriere, UIMAP, Serv Anat Pathol, Paris, France; [Eyraud, Daniel; Gottrand, Gaelle; Klatzmann, David] UPMC, Hop Pitie Salpetriere, Serv Biotherapies, CNRS 7211,INSERM 959, Paris, France; [Granger, Benjamin] Hop La Pitie Salpetriere, Dept Biostat Sante Publ & Informat Med, Paris, France; [Siksik, Jean-Michel; Vaillant, Jean-Christophe] Hop La Pitie Salpetriere, Serv Chirurg Digest & Transplantat Hepat, Paris, France	Eyraud, D (reprint author), Hop La Pitie Salpetriere, Serv Anat Pathol, 47-83 Blvd Hop, F-75013 Paris, France.	daniel.eyraud@aphp.fr					Brandacher G, 2006, CLIN CANCER RES, V12, P1144, DOI 10.1158/1078-0432.CCR-05-1966; Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9; Camp RL, 2008, J CLIN ONCOL, V26, P5630, DOI 10.1200/JCO.2008.17.3567; Chaput N, 2009, GUT, V58, P520, DOI 10.1136/gut.2008.158824; Chiba T, 2004, BRIT J CANCER, V91, P1711, DOI 10.1038/sj.bjc.6602201; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Gao YF, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-71; Glimelius I, 2012, HISTOPATHOLOGY, V61, P26, DOI 10.1111/j.1365-2559.2012.04185.x; Hanna E, 2009, ORAL DIS, V15, P8, DOI 10.1111/j.1601-0825.2008.01471.x; Hedvat CV, 2002, HUM PATHOL, V33, P968, DOI 10.1053/hupa.2002.127438; Kolodziej LR, 2011, AMINO ACIDS, V41, P1173, DOI 10.1007/s00726-010-0787-9; Laghi L, 2009, LANCET ONCOL, V10, P877, DOI 10.1016/S1470-2045(09)70186-X; Matera L, 2010, GUT, V59, P419, DOI 10.1136/gut.2009.203422; Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457; Menon AG, 2004, LAB INVEST, V84, P493, DOI 10.1038/labinvest.3700055; Miller TJ, 2017, PATHOLOGY, V49, P721, DOI 10.1016/j.pathol.2017.08.007; Mougiakakos D, 2010, ADV CANCER RES, V107, P57, DOI 10.1016/S0065-230X(10)07003-X; Munn DH, 2007, J CLIN INVEST, V117, P1147, DOI 10.1172/JCI31178; Pages F, 2005, NEW ENGL J MED, V353, P2654, DOI 10.1056/NEJMoa051424; Poitrasson-Riviere M, 2008, J IMMUNOL, V180, P7294, DOI 10.4049/jimmunol.180.11.7294; Salama P, 2009, J CLIN ONCOL, V27, P186, DOI 10.1200/JCO.2008.18.7229; Sinicrope FA, 2009, GASTROENTEROLOGY, V137, P1270, DOI 10.1053/j.gastro.2009.06.053; Sobhani I, 2009, GUT, V58, P743, DOI 10.1136/gut.2008.175521; Suzuki Y, 2012, LUNG CANCER, V67, P361; Uyttenhove C, 2003, NAT MED, V9, P1269, DOI 10.1038/nm934; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; Yamada K, 2008, J CHROMATOGR B, V867, P57, DOI 10.1016/j.jchromb.2008.03.010; Zlobec I, 2008, CLIN CANCER RES, V14, P143, DOI 10.1158/1078-0432.CCR-07-1380	28	0	0	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	OCT	2018	50	6					607	612		10.1016/j.pathol.2018.04.006			6	Pathology	Pathology	GU7XB	WOS:000445543400004	30166125	Green Published			2019-10-28	
J	Tang, F; Chen, JN; Zhang, NN; Gong, LP; Jiang, Y; Feng, ZY; Xiao, L; Li, HG; Du, H; Wu, B; Shao, CK				Tang, Fang; Chen, Jian-ning; Zhang, Na-na; Gong, Li-ping; Jiang, Ye; Feng, Zhi-ying; Xiao, Lin; Li, Hai-gang; Du, Hong; Wu, Bin; Shao, Chun-kui			Expression of CCL21 by EBV-associated gastric carcinoma cells protects CD8(+)CCR7(+) T lymphocytes from apoptosis via the mitochondria-mediated pathway	PATHOLOGY			English	Article						Epstein-Barr virus; EBV; gastric carcinoma; apoptosis; CCL21; CCR7	EPSTEIN-BARR-VIRUS; LYMPHOID STROMA; SOUTHERN CHINA; RECEPTOR-7; GUANGZHOU	About 10% of gastric carcinomas are associated with Epstein-Barr virus (EBV), which are defined as EBV-associated gastric carcinomas (EBVaGCs). EBVaGCs are usually accompanied by massive lymphocytes infiltration, among which CD8(+) T cells are predominant. To date, the apoptosis of the infiltrating CD8(+) T cells in EBVaGC has not been investigated. In the present study, we assessed the immunophenotype and apoptosis of tumour infiltrating lymphocytes (TILs) in both EBVaGC and EBV-negative gastric carcinoma (EBVnGC). We found that CD8(+) CCR7(+) T lymphocytes were increased in EBVaGC compared to EBVnGC [60.53 +/- 28.41/high power fields (HPF) vs 19.63 +/- 15.97/HPF; p < 0.001]. Moreover, the apoptosis index of TILs was lower in EBVaGC than that in EBVnGC (1.34 +/- 0.90 vs 5.94 +/- 3.77; p < 0.001). Given that the CCL21-CCR7 axis is reported to be potentially involved in apoptosis, we examined the expression of CCL21 in both EBVaGC and EBVnGC. We found that CCL21 expression was higher in EBVaGC than in EBVnGC (p < 0.001). We also showed that the expression of CCL21 by EBVaGC cells protected CD8(+) CCR7(+) T lymphocytes from apoptosis. Furthermore, the up-regulation of Bcl-2 contributed to the inhibition of apoptosis in CD8(+) CCR7(+) T cells. Collectively, these findings suggest that expression of CCL21 by EBVaGC cells protects CD8(+) CCR7(+) T lymphocytes from apoptosis via the mitochondria-mediated pathway. To our best knowledge, this is the first study to investigate the apoptosis of CD8(+) T cells in EBVaGC.	[Tang, Fang; Chen, Jian-ning; Zhang, Na-na; Gong, Li-ping; Jiang, Ye; Feng, Zhi-ying; Xiao, Lin; Shao, Chun-kui] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Pathol, 600 Tianhe Rd, Guangzhou 510630, Guangdong, Peoples R China; [Tang, Fang] Guilin Med Univ, Affiliated Hosp, Dept Pathol, Guilin, Peoples R China; [Xiao, Lin] Zhengzhou Univ, Affiliated Hosp 1, Dept Pathol, Henan Key Lab Tumour Pathol, Zhengzhou, Henan, Peoples R China; [Li, Hai-gang] Sun Yat Sen Univ, Dept Pathol, Affiliated Hosp 2, Guangzhou, Guangdong, Peoples R China; [Du, Hong] Guangzhou First Municipal Peoples Hosp, Dept Pathol, Guangzhou, Guangdong, Peoples R China; [Wu, Bin] Sun Yat Sen Univ, Affiliated Hosp 2, Dept Gastroenterol, Guangzhou, Guangdong, Peoples R China	Shao, CK (reprint author), Sun Yat Sen Univ, Affiliated Hosp 3, Dept Pathol, 600 Tianhe Rd, Guangzhou 510630, Guangdong, Peoples R China.	shaochk@mail.sysu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81572309, 81301694, 81272553]; Guangdong Natural Science FoundationNational Natural Science Foundation of Guangdong Province [2014A030313034, S2012020010898]; Guangzhou Science and Technology Project, Guangdong Province, China [201707010119]	This work was supported by the National Natural Science Foundation of China (grant numbers 81572309, 81301694 and 81272553), the Guangdong Natural Science Foundation (grant numbers 2014A030313034 and S2012020010898) and the Guangzhou Science and Technology Project (grant number 201707010119), Guangdong Province, China. The authors state that there are no conflicts of interest to disclose.	Akiba S, 2008, CANCER SCI, V99, P195, DOI 10.1111/j.1349-7006.2007.00674.x; American Joint Committee on Cancer, 2010, AJCC CANC STAGING MA, P117, DOI DOI 10.1007/978-0-387-88441-7; Bonecchi R, 2009, FRONT BIOSCI-LANDMRK, V14, P540, DOI 10.2741/3261; Chen JN, 2012, J CLIN GASTROENTEROL, V46, P262, DOI 10.1097/MCG.0b013e318249c4b8; Chen JN, 2011, VIRUS RES, V160, P191, DOI 10.1016/j.virusres.2011.06.011; Chen JN, 2010, J MED VIROL, V82, P658, DOI 10.1002/jmv.21731; Ding YZ, 2003, CLIN CANCER RES, V9, P3406; Dong M, 2016, HUM PATHOL, V53, P25, DOI 10.1016/j.humpath.2016.02.007; EPSTEIN M. A., 1965, WISTAR INST SYMP MONOGR, V4, P69; International Agency for Research on Cancer, 1997, IARC MON EV CARC RIS, V70, P255; Kijima Y, 2003, CANCER LETT, V200, P33, DOI 10.1016/S0304-3835(03)00410-5; Kim JW, 2005, CLIN CANCER RES, V11, P7901, DOI 10.1158/1078-0432.CCR-05-1346; Kuzushima K, 1999, J CLIN INVEST, V104, P163, DOI 10.1172/JCI6062; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Lee JH, 2009, J GASTROEN HEPATOL, V24, P354, DOI 10.1111/j.1440-1746.2009.05775.x; NAKAMURA S, 1994, CANCER, V73, P2239, DOI 10.1002/1097-0142(19940501)73:9<2239::AID-CNCR2820730902>3.0.CO;2-#; ODA K, 1993, AM J PATHOL, V143, P1063; Saiki Y, 1996, LAB INVEST, V75, P67; Sallusto F, 2000, IMMUNOL REV, V177, P134, DOI 10.1034/j.1600-065X.2000.17717.x; SHIBATA D, 1992, AM J PATHOL, V140, P769; Shinozaki-Ushiku A, 2015, INT J ONCOL, V46, P1421, DOI 10.3892/ijo.2015.2856; Taylor GS, 2015, ANNU REV IMMUNOL, V33, P787, DOI 10.1146/annurev-immunol-032414-112326; TOKUNAGA M, 1993, AM J PATHOL, V143, P1250; Uozaki H, 2008, INT J CLIN EXP PATHO, V1, P198; van Beek J, 2006, AM J SURG PATHOL, V30, P59, DOI 10.1097/01.pas.0000176428.06629.1e; Wakiguchi H, 2002, CRIT REV ONCOL HEMAT, V44, P193, DOI 10.1016/S1040-8428(02)00111-7; Wang Y, 2005, WORLD J GASTROENTERO, V11, P3234, DOI 10.3748/wjg.v11.i21.3234	27	0	1	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	OCT	2018	50	6					613	621		10.1016/j.pathol.2018.05.004			9	Pathology	Pathology	GU7XB	WOS:000445543400005	30149990				2019-10-28	
J	De Paoli-Iseppi, R; Prentice, L; Marthick, JR; Thomson, R; Holloway, AF; Dickinson, JL; Burgess, J				De Paoli-Iseppi, Ricardo; Prentice, Louise; Marthick, James R.; Thomson, Russell; Holloway, Adele F.; Dickinson, Joanne L.; Burgess, John			Multiple endocrine neoplasia type 1: clinical correlates of MEN1 gene methylation	PATHOLOGY			English	Article						Methylation; MEN 1; parathyroid; familial	TUMOR-SUPPRESSOR; TRANSCRIPTION; CANCER; EXPRESSION; METHYLOME; VARIANTS; PROMO	Multiple endocrine neoplasia type 1 (MEN 1) has marked severity variation between individuals with the same mutation. To investigate any relationship between promoter methylation and clinical features, blood and tissue samples were collected from 16 members of the Tasman 1 MEN 1 kindred carrying a common splice site mutation and 7 patients with sporadic MEN 1. Methylation at 39 CpGs in the MEN1 promoter were assessed in formalin fixed, paraffin embedded parathyroid tissue. Clinical disease severity markers included age at first parathyroid operation, parathyroid hormone level and corrected serum calcium levels. Six patients with sporadic hyperparathyroidism were used for comparison. Minimal methylation was observed in all patients across CpG sites 1-23. In contrast, hypermethylation was observed at CpG sites 24-31 in MEN 1 patients, a pattern not observed in patients with non-MEN 1 parathyroid disease. Mean methylation at sites 24-31 was significantly correlated with age at first parathyroid operation (r = 0.652, p = 0.041). A permutation test, utilising the mean correlation coefficient (r = -0.401) revealed a possible association between relative PHPT severity and methylation score for each significant CpG site (p < 0.103). This novel study reveals evidence supporting a possible association between altered MEN1 promoter methylation and clinical severity of disease.	[De Paoli-Iseppi, Ricardo; Marthick, James R.; Thomson, Russell; Dickinson, Joanne L.] Univ Tasmania, Menzies Inst Med Res, Canc Genet & Immunol, Hobart, Tas, Australia; [Prentice, Louise; Holloway, Adele F.; Burgess, John] Univ Tasmania, Sch Med, Hobart, Tas, Australia; [Prentice, Louise; Burgess, John] Royal Hobart Hosp, Hobart, Tas, Australia	Dickinson, JL (reprint author), Univ Tasmania, Menzies Inst Med Res, 17 Liverpool St, Hobart, Tas 7000, Australia.	Jo.Dickinson@utas.edu.au	Thomson, Russell/H-5653-2012	Thomson, Russell/0000-0003-4949-4120; De Paoli-Iseppi, Ricardo/0000-0001-7724-9144	Royal Hobart Hospital Research Foundation; Australian Cancer Research Foundation; Australian Research Council Future FellowshipAustralian Research Council; Hobart Cancer Auxiliary Scholarship	This work was supported by the Royal Hobart Hospital Research Foundation and the Australian Cancer Research Foundation. JD is supported by an Australian Research Council Future Fellowship. RDP was supported by a Hobart Cancer Auxiliary Scholarship. The authors state that there are no conflicts of interest to disclose.	Agarwal SK, 1999, CELL, V96, P143, DOI 10.1016/S0092-8674(00)80967-8; Almeida MQ, 2010, CANCER GENET CYTOGEN, V203, P30, DOI 10.1016/j.cancergencyto.2010.09.006; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BENSON L, 1987, AM J MED, V82, P731, DOI 10.1016/0002-9343(87)90008-8; Bock C, 2005, BIOINFORMATICS, V21, P4067, DOI 10.1093/bioinformatics/bti652; Burgess J, 2010, CLIN ENDOCRINOL, V72, P13, DOI 10.1111/j.1365-2265.2009.03662.x; Burgess JR, 1998, J INTERN MED, V243, P465; Burgess JR, 2000, CLIN ENDOCRINOL, V53, P205, DOI 10.1046/j.1365-2265.2000.01032.x; Cavallari I, 2009, GENE CHROMOSOME CANC, V48, P383, DOI 10.1002/gcc.20650; Chan AOO, 2003, ONCOGENE, V22, P924, DOI 10.1038/sj.onc.1206123; Chandrasekharappa SC, 2003, J INTERN MED, V253, P606, DOI 10.1046/j.1365-2796.2003.01165.x; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; Farre D, 2003, NUCLEIC ACIDS RES, V31, P3651, DOI 10.1093/nar/gkg605; Fromaget M, 2003, J MOL BIOL, V333, P87, DOI 10.1016/j.jmb.2003.08.001; Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298; Jeschke J, 2012, EPIGENETICS-US, V7, P701, DOI 10.4161/epi.20445; Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Khodaei-O'Brien S, 2000, BIOCHEM BIOPH RES CO, V276, P508, DOI 10.1006/bbrc.2000.3471; Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Lamberts SWJ, 2001, FRONT NEUROENDOCRIN, V22, P309, DOI 10.1006/frne.2001.0218; Landrum MJ, 2016, NUCLEIC ACIDS RES, V44, pD862, DOI 10.1093/nar/gkv1222; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Nicolia V, 2017, J NEUROPATH EXP NEUR, V76, P27, DOI 10.1093/jnen/nlw099; Pannett AAJ, 2001, J CLIN ENDOCR METAB, V86, P4371, DOI 10.1210/jc.86.9.4371; SHEPHERD JJ, 1985, MED J AUSTRALIA, V142, P395, DOI 10.5694/j.1326-5377.1985.tb133152.x; Starker LF, 2011, GENE CHROMOSOME CANC, V50, P735, DOI 10.1002/gcc.20895; Swarts DR, 2013, J CLIN ENDOCR METAB, V99, pE374; Trump D, 1996, QJM-INT J MED, V89, P653; Valdes N, 1998, ANTICANCER RES, V18, P2685; Wilson HE, 1998, TRENDS ENDOCRIN MET, V9, P396, DOI 10.1016/S1043-2760(98)00098-8; Zablewska B, 2003, J CLIN ENDOCR METAB, V88, P3845, DOI 10.1210/jc.2003-030288	34	1	1	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	OCT	2018	50	6					622	628		10.1016/j.pathol.2018.05.006			7	Pathology	Pathology	GU7XB	WOS:000445543400006	30149991				2019-10-28	
J	Klebe, S; Prabhakaran, S; Hocking, A; Pulford, E; Moore, S; Nicola, M; Allen, PW; Henderson, DW				Klebe, Sonja; Prabhakaran, Sarita; Hocking, Ashleigh; Pulford, Emily; Moore, Sarah; Nicola, Mario; Allen, Philip W.; Henderson, Douglas W.			Pleural malignant mesothelioma versus pleuropulmonary synovial sarcoma: a clinicopathological study of 22 cases with molecular analysis and survival data	PATHOLOGY			English	Article						Pleura; mesothelioma; sarcomatoid; biphasic; monophasic; synovial; sarcoma; TLE1; t(X; 18); FISH; RT-PCR; age; survival	SYT-SSX FUSION; TLE1 EXPRESSION; DIFFERENTIAL-DIAGNOSIS; LUNG; TRANSCRIPTS; NEOPLASMS; PROTEINS; EMPHASIS; FEATURES; TUMORS	The aim of this study was to carry out a comparative analysis by transducin-like enhancer of split 1 (TLE1) immunohistochemistry and molecular analysis of SYT-SSX, for 16 pleural predominantly sarcomatoid mesotheliomas and six cases of pleuropulmonary synovial sarcoma (five pleural in distribution only, with one case of a predominantly subpleural upper lobe synovial sarcoma), all of which were solely or predominantly monophasic. Our comparison included survival and some clinical data. We consider that the following points emerged from this study: Clear discrimination between pleural sarcomatoid mesothelioma and synovial sarcoma can be impossible from H& E-stained sections and conventional immunohistochemical markers for mesothelioma, and on TLE1 immunolabelling. In line with current approaches to diagnosis, we defined the mesotheliomas according to their negative SYT-SSX status, versus a positive result by fluorescence in situ hybridisation (FISH) or by reverse transcriptase PCR (RT-PCR) for synovial sarcoma. In this series, predominantly sarcomatoid mesotheliomas out-numbered the synovial sarcomas in a ratio of similar to 3: 1. The synovial sarcomas were diagnosed in patients significantly younger on average than the sarcomatoid mesotheliomas. The synovial sarcoma patients had significantly longer survivals than the predominantly sarcomatoid mesotheliomas.	[Klebe, Sonja; Prabhakaran, Sarita; Hocking, Ashleigh; Pulford, Emily; Henderson, Douglas W.] Flinders Univ S Australia, Dept Anat Pathol, Adelaide, SA, Australia; [Klebe, Sonja; Allen, Philip W.] Flinders Med Ctr, SA Pathol Dept Surg Pathol, Bedford Pk, SA, Australia; [Moore, Sarah; Nicola, Mario] SA Pathol Dept Mol Pathol, Adelaide, SA, Australia	Klebe, S (reprint author), Flinders Univ S Australia, Dept Anat Pathol, Bedford Pk, SA 5042, Australia.; Klebe, S (reprint author), Flinders Med Ctr, SA Dept Surg Pathol, Bedford Pk, SA, Australia.	sonja.klebe@sa.gov.au		Prabhakaran, Sarita/0000-0003-3252-2519	Flinders University	SK and DWH have provided medicolegal reports on diagnosis for lawyers representing both plaintiffs and defendants irrespective of any past history of causal factors such as asbestos exposure and tobacco smoking, as stated explicitly in their reports. This study was supported by Flinders University. The authors state that there are no conflicts of interest to disclose.	ABENOZA P, 1986, HUM PATHOL, V17, P1107, DOI 10.1016/S0046-8177(86)80415-4; Addis B, 2009, HISTOPATHOLOGY, V54, P55, DOI 10.1111/j.1365-2559.2008.03178.x; Aiyappan V, 2014, CHEST, V145, DOI 10.1378/chest.1779773; Al-Rajhi N, 1999, J SURG ONCOL, V70, P194, DOI 10.1002/(SICI)1096-9098(199903)70:3<194::AID-JSO10>3.0.CO;2-8; Allen TC, 2005, AM J SURG PATHOL, V29, P866, DOI 10.1097/01.pas.0000165529.78945.dc; Amary MFC, 2007, MODERN PATHOL, V20, P482, DOI 10.1038/modpathol.3800761; Attanoos RL, 2000, HISTOPATHOLOGY, V37, P224, DOI 10.1046/j.1365-2559.2000.00981.x; Aubry MC, 2001, AM J SURG PATHOL, V25, P776, DOI 10.1097/00000478-200106000-00009; Begueret H, 2005, AM J SURG PATHOL, V29, P339; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; Caliandro R, 2000, REV MAL RESPIR, V17, P498; Cappello F, 2001, PATHOLOGY, V33, P142, DOI 10.1080/00313020120038728; Carbone M, 2002, ANTICANCER RES, V22, P3443; Chan JA, 2003, HISTOPATHOLOGY, V43, P72, DOI 10.1046/j.1365-2559.2003.01643.x; Chuang HC, 2013, PATHOL INT, V63, P573, DOI 10.1111/pin.12113; Colwell AS, 2002, J THORAC CARDIOV SUR, V124, P828, DOI 10.1067/mtc.2002.124242; CORSON JM, 1984, HUM PATHOL, V15, P615, DOI 10.1016/S0046-8177(84)80284-1; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; Davis SR, 2007, CANCER CELL, V11, P305, DOI 10.1016/j.ccr.2007.03.016; DELEEUW B, 1995, HUM MOL GENET, V4, P1097, DOI 10.1093/hmg/4.6.1097; DICKERSIN GR, 1991, ULTRASTRUCT PATHOL, V15, P379, DOI 10.3109/01913129109016247; dosSantos NR, 1997, HUM MOL GENET, V6, P1549, DOI 10.1093/hmg/6.9.1549; Egger JF, 2002, MODERN PATHOL, V15, P998, DOI 10.1097/01.MP.0000026616.41545.FF; Essary LR, 2002, CANCER, V94, P459, DOI 10.1002/cncr.10188; Fisher C, 1998, Ann Diagn Pathol, V2, P401, DOI 10.1016/S1092-9134(98)80042-7; FISHER C, 1986, HUM PATHOL, V17, P996, DOI 10.1016/S0046-8177(86)80083-1; Gaertner E, 1996, AM J SURG PATHOL, V20, P36, DOI 10.1097/00000478-199601000-00004; Galateau-Salle F, 2016, J THORAC ONCOL, V11, P142, DOI 10.1016/j.jtho.2015.11.005; Haldar M, 2008, CLIN ORTHOP RELAT R, V466, P2156, DOI 10.1007/s11999-008-0340-2; Haldar M, 2007, CANCER CELL, V11, P375, DOI 10.1016/j.ccr.2007.01.016; Hammar SP, 2008, DAIL HAMMARS PULMONA, P558; Henderson DW, 2013, J CLIN PATHOL, V66, P854, DOI 10.1136/jclinpath-2013-201609; Hinterberger M, 2007, MODERN PATHOL, V20, P248, DOI 10.1038/modpathol.3800736; Hirano Hiroshi, 2002, Medical Electron Microscopy, V35, P102, DOI 10.1007/s007950200013; Hisaoka M, 1999, HISTOPATHOLOGY, V34, P205; Husain AN, 2018, ARCH PATHOL LAB MED, V142, P89, DOI 10.5858/arpa.2017-0124-RA; Jawahar DA, 1997, RESP MED, V91, P568, DOI 10.1016/S0954-6111(97)90093-7; Kao YC, 2017, GENE CHROMOSOME CANC, V56, P296, DOI 10.1002/gcc.22435; Klebe S, 2016, J CLIN PATHOL, V69, P136, DOI 10.1136/jclinpath-2015-203184; Klebe S, 2010, MODERN PATHOL, V23, P470, DOI 10.1038/modpathol.2009.180; Knosel T, 2010, EUR J CANCER, V46, P1170, DOI 10.1016/j.ejca.2010.01.032; Kosemehmetoglu K, 2009, MODERN PATHOL, V22, P872, DOI 10.1038/modpathol.2009.47; Kubouchi Y, 2013, ANN THORAC CARDIOVAS, V19, P144, DOI 10.5761/atcs.cr.12.01908; Langner K, 1998, PATHOLOGE, V19, P442, DOI 10.1007/s002920050310; Marchevsky AM, 2017, HUM PATHOL, V67, P160, DOI 10.1016/j.humpath.2017.07.015; Matsuyama A, 2010, VIRCHOWS ARCH, V457, P577, DOI 10.1007/s00428-010-0975-8; Miettinen M, 2001, AM J SURG PATHOL, V25, P610, DOI 10.1097/00000478-200105000-00007; NAKAMURA T, 1984, AM J SURG PATHOL, V8, P429, DOI 10.1097/00000478-198406000-00003; Ng SB, 2003, ARCH PATHOL LAB MED, V127, P85; Nicholson AG, 1998, HISTOPATHOLOGY, V33, P508; Nicholson AG, 1997, HISTOPATHOLOGY, V30, P349, DOI 10.1046/j.1365-2559.1997.d01-616.x; O'Kane SL, 2006, ACTA ONCOL, V45, P449, DOI 10.1080/02841860500468927; ORDONEZ NG, 1990, HUM PATHOL, V21, P733, DOI 10.1016/0046-8177(90)90034-3; Powers A, 2005, MALIGNANT MESOTHELIO, P543; Rekhi B, 2012, INDIAN J MED RES, V136, P766; Stimmler LM, 2010, PATHOLOGY, V42, pS84; Suster S, 2005, AM J SURG PATHOL, V29, P569, DOI 10.1097/01.pas.0000157934.50936.3e; Terry J, 2007, AM J SURG PATHOL, V31, P240, DOI 10.1097/01.pas.0000213330.71745.39; Tezcan Y, 2012, ARCH IRAN MED, V15, P331, DOI 012155/AIM.0018; Valente AL, 2013, APPL IMMUNOHISTO M M, V21, P408, DOI 10.1097/PAI.0b013e318279f9ee; Vander Salm T J, 2000, Semin Thorac Cardiovasc Surg, V12, P89; Vohra H. A., 2004, EUR J INTERN MED, V15, P465, DOI [10.1016/j.ejim.2004.08.004, DOI 10.1016/J.EJIM.2004.08.004]; Vora A, 2013, THYROID, V23, P371, DOI 10.1089/thy.2012.0472; Weinbreck N, 2007, MODERN PATHOL, V20, P617, DOI 10.1038/modpathol.3800775; WITKIN GB, 1989, AM J SURG PATHOL, V13, P490, DOI 10.1097/00000478-198906000-00005; Zaccarini DJ, 2018, APPL IMMUNOHISTO M M, V26, P368, DOI 10.1097/PAI.0000000000000436	66	1	1	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	OCT	2018	50	6					629	634		10.1016/j.pathol.2018.06.001			6	Pathology	Pathology	GU7XB	WOS:000445543400007	30170702				2019-10-28	
J	Forest, F; Patoir, A; Dal Col, P; Sulaiman, A; Camy, F; Laville, D; Bayle-Bleuez, S; Fournel, P; Habougit, C				Forest, Fabien; Patoir, Arnaud; Dal Col, Pierre; Sulaiman, Abdulrazzaq; Camy, Florian; Laville, David; Bayle-Bleuez, Sophie; Fournel, Pierre; Habougit, Cyril			Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications	PATHOLOGY			English	Article						BRCA1-associated protein1; BAP1; mesothelin; PD-L1; mesothelioma; overall survival	BRCA1-ASSOCIATED PROTEIN-1; EFFUSION CYTOLOGY; SURVIVAL; DIAGNOSIS; IMMUNOHISTOCHEMISTRY; PROLIFERATIONS; FISH; RARE	For malignant pleural mesothelioma (MPM), histopathological subtype is one of the most important prognostic factors. Several immunohistochemical stains whose expressions have possible therapeutic implications have been identified in MPM such as BAP1, mesothelin and PDL1. The aim of our work was to evaluate the clinical significance and prognostic implications of BAP1, mesothelin and PD-L1 expression in 117 patients with a diagnosis of MPM who were diagnosed in our institution between 2002 and 2017. We also correlated this immunohistochemical profile to a recently described nuclear grading and to histopathological subtype. Mesothelin expression, BAP1 loss and PD-L1 expression were associated with histopathological subtype (p < 0.0001), BAP1 loss was more frequent in epithelioid subtype whereas PD-L1 expression was more frequent in non-epithelioid subtype. For epithelioid MPM, BAP1 expression was associated with overall survival (p = 0.034), with a longer survival when BAP1 expression is lost. Necrosis and nuclear grading are associated with overall survival (p = 0.0048 and < 0.0001, respectively), with longer survival when necrosis was absent and for grade I. For nonepithelioid MPM, overall survival was not related to clinical, histopathological or immunohistochemical expression of BAP1, mesothelin or PD-L1. In multivariate analysis, grade I for nuclear grading was an independent prognostic factor associated with overall survival (p < 0.0001). In epithelioid and non-epithelioid MPM, we analysed overall survival in subgroups with combined mesothelin, BAP1 and PD-L1 expression. In epithelioid MPM, BAP1 retained/mesothelin negativity/PD-L1 > 1%, and BAP1 retained/mesothelin positivity/PD-L1 > 1% profiles, are associated with shorter overall survival. In non-epithelioid MPM, BAP1 loss/mesothelin negativity/PD-L1 > 1% is associated with shorter overall survival. Our work confirms that nuclear grading in epithelioid MPM is a strong and independent prognosis factor. Moreover, this study on several promising immunohistochemical stains whose expressions have possible therapeutic implications identifies subgroups with a poor prognosis.	[Forest, Fabien; Dal Col, Pierre; Camy, Florian; Laville, David; Habougit, Cyril] Univ Hosp St Etienne, North Hosp, Dept Pathol, St Etienne, France; [Patoir, Arnaud; Sulaiman, Abdulrazzaq] Univ Hosp St Etienne, North Hosp, Dept Thorac Surg, St Etienne, France; [Bayle-Bleuez, Sophie] Univ Hosp St Etienne, North Hosp, Dept Pneumol, St Etienne, France; [Fournel, Pierre] Lucien Neuwirth Canc Inst, Dept Oncol, St Priest En Jarez, France	Forest, F (reprint author), CHU St Etienne, Hop Nord, Serv Anat & Cytol Pathol, Ave Albert Raimond, F-42055 St Etienne 2, France.	fabien.forest@chu-st-etienne.fr	Forest, Fabien/O-7054-2019	Forest, Fabien/0000-0001-7582-3923; Fournel, Pierre/0000-0002-3884-6816			Alfaleh MA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186137; Alley EW, 2017, LANCET ONCOL, V18, P623, DOI 10.1016/S1470-2045(17)30169-9; Andrici J, 2016, PATHOLOGY, V48, P336, DOI 10.1016/j.pathol.2016.03.005; Andrici J, 2015, MODERN PATHOL, V28, P1360, DOI 10.1038/modpathol.2015.87; Arzt L, 2014, PATHOL ONCOL RES, V20, P145, DOI 10.1007/s12253-013-9677-2; Bott M, 2011, NAT GENET, V43, P668, DOI 10.1038/ng.855; Cedres S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121071; Chou A, 2018, HISTOPATHOLOGY, V72, P509, DOI 10.1111/his.13392; Cigognetti M, 2015, MODERN PATHOL, V28, P1043, DOI 10.1038/modpathol.2015.65; Combaz-Lair C, 2016, HUM PATHOL, V52, P9, DOI 10.1016/j.humpath.2016.01.010; De Rienzo A, 2016, CANCER RES, V76, P319, DOI 10.1158/0008-5472.CAN-15-0751; Farzin M, 2015, PATHOLOGY, V47, P302, DOI 10.1097/PAT.0000000000000250; Galateau-Salle F, 2014, ANN PATHOL, V34, P51, DOI 10.1016/j.annpat.2014.01.009; Habougit C, 2017, VIRCHOWS ARCH, V470, P639, DOI 10.1007/s00428-017-2109-z; Husain AN, 2018, ARCH PATHOL LAB MED, V142, P89, DOI 10.5858/arpa.2017-0124-RA; Hwang HC, 2016, AM J SURG PATHOL, V40, P120, DOI 10.1097/PAS.0000000000000529; Inaguma S, 2017, ONCOTARGET, V8, P26744, DOI 10.18632/oncotarget.15814; Jaouen A, 2016, ANN PATHOL, V36, P111, DOI 10.1016/j.annpat.2016.01.005; Kadota K, 2012, MODERN PATHOL, V25, P260, DOI 10.1038/modpathol.2011.146; Kao SC, 2017, J THORAC ONCOL, V12, P1421, DOI 10.1016/j.jtho.2017.05.024; LaFave LM, 2015, NAT MED, V21, P1344, DOI 10.1038/nm.3947; Leblay N, 2017, J THORAC ONCOL, V12, P724, DOI 10.1016/j.jtho.2016.12.019; Mancuso MR, 2017, TRANSL LUNG CANCER R, V6, P295, DOI 10.21037/tlcr.2017.06.01; Mansfield AS, 2014, J THORAC ONCOL, V9, P1036, DOI 10.1097/JTO.0000000000000177; McGregor SM, 2015, HUM PATHOL, V46, P1670, DOI 10.1016/j.humpath.2015.06.024; Nasu M, 2015, J THORAC ONCOL, V10, P565, DOI 10.1097/JTO.0000000000000471; Owen D, 2017, HUM PATHOL, V60, P82, DOI 10.1016/j.humpath.2016.10.005; Parrotta R, 2017, J THORAC ONCOL, V12, P1309, DOI 10.1016/j.jtho.2017.03.023; Pulford E, 2017, DIS MARKERS, DOI 10.1155/2017/1310478; Righi L, 2016, J THORAC ONCOL, V11, P2006, DOI 10.1016/j.jtho.2016.06.020; Rosen LE, 2018, MODERN PATHOL, V31, P598, DOI 10.1038/modpathol.2017.170; Servais EL, 2012, CLIN CANCER RES, V18, P2478, DOI 10.1158/1078-0432.CCR-11-2614; Sheffield BS, 2015, AM J SURG PATHOL, V39, P977, DOI 10.1097/PAS.0000000000000394; Thapa B, 2017, J THORAC ONCOL, V12, P850, DOI 10.1016/j.jtho.2017.02.013; Zhang YF, 2015, SCI REP-UK, V5, DOI 10.1038/srep09928	35	4	4	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	OCT	2018	50	6					635	641		10.1016/j.pathol.2018.05.002			7	Pathology	Pathology	GU7XB	WOS:000445543400008	30145072				2019-10-28	
J	Shimomura, H; Sasahira, T; Nakashima, C; Shimomura-Kurihara, M; Kirita, T				Shimomura, Hiroyuki; Sasahira, Tomonori; Nakashima, Chie; Shimomura-Kurihara, Miyako; Kirita, Tadaaki			Downregulation of DHRS9 is associated with poor prognosis in oral squamous cell carcinoma	PATHOLOGY			English	Article						DHRS9; tumour suppressor; prognosis; oral cancer	ADENOMATOUS POLYPOSIS-COLI; COLORECTAL-CANCER; EXPRESSION; RETINOL; GENES; HEAD; NECK; CHEMORADIOTHERAPY; METASTASIS; METABOLISM	Oral squamous cell carcinoma (OSCC) has a high potential for local invasion and nodal metastasis. Therefore, early detection and elucidation of the detailed molecular mechanisms underlying OSCC are essential. Dehydrogenase/reductase member 9 (DHRS9) is downregulated in recurrent OSCC. Although DHRS9 is reported to act as a tumour suppressor in several malignancies, its expression in OSCC cells is unknown. In this study, we examined DHRS9 expression immunohistochemically in specimens from a sample of 98 OSCC patients. Reduced DHRS9 expression was observed in 68 of 98 patients (69.4%) with OSCC. A significant association was found between low DHRS9 expression and local progression (T factor) (p = 0.0135). Furthermore, patients with low DHRS9 expression had a significantly poorer prognosis than those with high DHRS9 expression (p = 0.0443). In multivariate analysis using the Cox proportional hazards model, decreased DHRS9 expression strongly correlated with worse prognosis. The study findings suggest that DHRS9 might be a useful diagnostic and prognostic marker for OSCC.	[Shimomura, Hiroyuki; Nakashima, Chie; Shimomura-Kurihara, Miyako; Kirita, Tadaaki] Nara Med Univ, Dept Oral & Maxillofacial Surg, Kashihara, Nara, Japan; [Sasahira, Tomonori] Nara Med Univ, Dept Mol Pathol, 840 Shijo Cho, Kashihara, Nara 6348521, Japan	Sasahira, T (reprint author), Nara Med Univ, Dept Mol Pathol, 840 Shijo Cho, Kashihara, Nara 6348521, Japan.	sasa@naramed-u.ac.jp			Japan Society for the Promotion of Science, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science	This work was supported in part by Grant-in-Aid for Scientific Research from Japan Society for the Promotion of Science, Japan. The authors state that there are no conflicts of interest to disclose.	Chansri N, 2008, PHARM RES-DORD, V25, P428, DOI 10.1007/s11095-007-9398-x; Fabricius EM, 2011, INT J ONCOL, V39, P1083, DOI 10.3892/ijo.2011.1139; Ferris RL, 2016, NEW ENGL J MED, V375, P1856, DOI 10.1056/NEJMoa1602252; Hijiya N, 2017, PATHOL INT, V67, P83, DOI 10.1111/pin.12495; Hu L, 2016, TUMOR BIOL, V37, P837, DOI 10.1007/s13277-015-3880-6; Jette C, 2004, J BIOL CHEM, V279, P34397, DOI 10.1074/jbc.M314021200; Jones RJ, 2007, J BIOL CHEM, V282, P8317, DOI 10.1074/jbc.M608667200; Kropotova ES, 2014, PATHOL ONCOL RES, V20, P707, DOI 10.1007/s12253-014-9751-4; Limongi ZM, 2005, CANCER GENET CYTOGEN, V161, P181, DOI 10.1016/j.cancergencyto.2005.01.018; Liu N, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0360-3; Miyawaki A, 2010, ONCOL REP, V23, P1205, DOI 10.3892/or_00000751; Pares X, 2008, CELL MOL LIFE SCI, V65, P3936, DOI 10.1007/s00018-008-8591-3; Perez-Sayans M, 2012, ORAL ONCOL, V48, P56, DOI 10.1016/j.oraloncology.2011.09.001; Reuter CWM, 2007, BRIT J CANCER, V96, P408, DOI 10.1038/sj.bjc.6603566; Sasahira T, 2016, VIRCHOWS ARCH, V469, P163, DOI 10.1007/s00428-016-1955-4; Sasahira T, 2016, BRIT J CANCER, V115, P52, DOI 10.1038/bjc.2016.167; Sasahira T, 2014, INT J CLIN ONCOL, V19, P431, DOI 10.1007/s10147-014-0684-4; Shield KD, 2017, CA-CANCER J CLIN, V67, P51, DOI 10.3322/caac.21384; Shimomura H, 2015, INT J CLIN ONCOL, V20, P308, DOI 10.1007/s10147-014-0711-5; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Soref CM, 2001, J BIOL CHEM, V276, P24194, DOI 10.1074/jbc.M100332200; Supic G, 2009, ORAL ONCOL, V45, P1051, DOI 10.1016/j.oraloncology.2009.07.007; Suzuki H, 2009, ORAL ONCOL, V45, P569, DOI 10.1016/j.oraloncology.2008.07.009; Tan J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.283; Wang JD, 2006, GASTROENTEROLOGY, V130, P747, DOI 10.1053/j.gastro.2005.12.017; Woo YJ, 2012, BIOCHEM BIOPH RES CO, V425, P944, DOI 10.1016/j.bbrc.2012.08.038; Xu Q, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-159	27	2	2	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	OCT	2018	50	6					642	647		10.1016/j.pathol.2018.06.002			6	Pathology	Pathology	GU7XB	WOS:000445543400009	30149992				2019-10-28	
J	Ravindran, P; Wiltshire, S; Das, K; Wilson, RB				Ravindran, Praveen; Wiltshire, Stephanie; Das, Kamalakanta; Wilson, Robert B.			Vitamin C deficiency in an Australian cohort of metropolitan surgical patients	PATHOLOGY			English	Article						Vitamin C; nutrition; scurvy	ASCORBIC-ACID DEFICIENCY; SCURVY; SUPPLEMENTATION; POPULATION; PREVALENCE; DIALYSIS; PEOPLE	Vitamin C is an essential micronutrient in the human diet. While large population studies measuring vitamin C have been performed in other countries, there are few studies of deficiency in the Australian population. This study aimed to quantify vitamin C deficiency, identify scorbutic symptoms and examine dietary associations in a cohort of preoperative general surgical patients. Vitamin C levels were determined in a cohort of patients referred to a single surgeon between January 2011 and December 2013. Baseline data were collected along with data on fruit consumption, weekly citrus fruit intake and presence of scorbutic symptoms. A total of 309 patients were included in the study and 21.4% of our cohort showed a vitamin C level <= 11.4 mu mol/L (deficient). Mean citrus fruit intake was significantly higher in the normal vitamin C groups (>28.4 mu mol/L) and patients with vitamin C levels <= 28.4 were more likely to consume no fruit (p=0.0004) which was also significant on multivariate analysis. Neither age nor gender appeared predictive of suboptimal vitamin C levels. No symptoms were significantly related to vitamin C levels on multivariate analysis. Vitamin C deficiency was common in Australian adults attending a surgical practice within south western Sydney. Review of the Australian recommended daily allowance for vitamin C is suggested, not only in clinically well patients but particularly in ICU and hospital inpatients. Larger studies examining the prevalence and impact of vitamin C deficiency in the Australian population are required to further investigate these findings.	[Ravindran, Praveen; Wiltshire, Stephanie; Das, Kamalakanta; Wilson, Robert B.] Liverpool Hosp, Dept Surg, Sydney, NSW, Australia; [Ravindran, Praveen] Western Sydney Univ, Sydney, NSW, Australia; [Ravindran, Praveen] MARCS Inst Brain Behav & Dev, Sydney, NSW, Australia; [Das, Kamalakanta; Wilson, Robert B.] Univ New South Wales, Fac Med, Dept Surg, Sydney, NSW, Australia	Ravindran, P (reprint author), Liverpool Hosp, Dept Surg, Liverpool, NSW 2170, Australia.	praveen_6309@hotmail.com		Ravindran, Praveen/0000-0001-9405-877X			Akbarshahi H, 2008, DIGEST SURG, V25, P165, DOI 10.1159/000136478; Australian Bureau of Statistics, 1998, NAT NUTR SURV NUTR I; Benzie IFF, 1999, P NUTR SOC, V58, P469, DOI 10.1017/S0029665199000610; Bikker A, 2016, INT J SURG OPEN, V2, P15, DOI 10.1016/j.ijso.2016.02.009; Blee TH, 2002, SURGERY, V131, P408, DOI 10.1067/msy.2002.122373; Cahill L, 2009, AM J EPIDEMIOL, V170, P464, DOI 10.1093/aje/kwp156; Carr AC, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1891-y; Carr AC, 2016, NUTRIENTS, V8, DOI 10.3390/nu8060341; Cevikel MH, 2008, EUR SURG RES, V40, P29, DOI 10.1159/000108622; CHATTERJEE I, 1961, ANN NY ACAD SCI, V92, P36, DOI 10.1111/j.1749-6632.1961.tb46105.x; Christie-David DJ, 2017, DIABETIC MED, V34, P294, DOI 10.1111/dme.13287; Clase CM, 2013, SEMIN DIALYSIS, V26, P546, DOI 10.1111/sdi.12099; Delanghe JR, 2007, CLIN CHEM, V53, P1397, DOI 10.1373/clinchem.2007.088658; Delanghe JR, 2011, GENES NUTR, V6, P341, DOI 10.1007/s12263-011-0237-7; Elia M, 2005, NUTRITION, V21, P1100, DOI 10.1016/j.nut.2005.03.005; Ellinger S, 2009, CURR OPIN CLIN NUTR, V12, P588, DOI 10.1097/MCO.0b013e328331a5b5; Fukushima R, 2010, CURR OPIN CLIN NUTR, V13, P669, DOI 10.1097/MCO.0b013e32833e05bc; Gabb G, 2015, AUST FAM PHYSICIAN, V44, P438; Giladi AM, 2011, INJURY, V42, P78, DOI 10.1016/j.injury.2010.01.104; GLUECKSOHNWAELS.S, 1963, SCIENCE, V142, P1269, DOI 10.1126/science.142.3597.1269; Golriz F, 2017, PEDIATR RADIOL, V47, P214, DOI 10.1007/s00247-016-3726-4; Hagel AF, 2018, J INT MED RES, V46, P168, DOI 10.1177/0300060517714387; Hansen Esben P K, 2012, J Clin Med Res, V4, P135, DOI 10.4021/jocmr726w; Hasselholt S, 2015, BRIT J NUTR, V113, P1539, DOI 10.1017/S0007114515000690; He EYJ, 2010, MED J AUSTRALIA, V193, P555, DOI 10.5694/j.1326-5377.2010.tb04051.x; HODGES RE, 1969, AM J CLIN NUTR, V22, P535; Huang A, 2000, J BIOL CHEM, V275, P17399, DOI 10.1074/jbc.M002248200; HUGHES RE, 1980, BRIT J NUTR, V43, P385, DOI 10.1079/BJN19800102; Kotze V., 2011, S AFR J CLIN NUTR, V24, P19; Langlois K, 2016, HEALTH REP, V27, P3; Leger D, 2008, CAN FAM PHYSICIAN, V54, P1403; Lykkesfeldt J, 2000, AM J CLIN NUTR, V71, P530; Lykkesfeldt J, 2010, BRIT J NUTR, V103, P1251, DOI 10.1017/S0007114509993229; Mapp SJ, 2006, MED J AUSTRALIA, V185, P331, DOI 10.5694/j.1326-5377.2006.tb00589.x; Mayberry J., 2004, 3 YEAR FOOD DRUG LAW; Mosdol A, 2008, J PUBLIC HEALTH-UK, V30, P456, DOI 10.1093/pubmed/fdn076; Nathens AB, 2002, ANN SURG, V236, P814, DOI 10.1097/00000658-200212000-00014; Olmedo JM, 2006, INT J DERMATOL, V45, P909, DOI 10.1111/j.1365-4632.2006.02844.x; Oudemans-van Straaten HM, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0460-x; Perret JL, 2004, PRESSE MED, V33, P170, DOI 10.1016/S0755-4982(04)98515-6; Raynaud-Simon A, 2010, J NUTR HEALTH AGING, V14, P407; Riess KP, 2009, SURG OBES RELAT DIS, V5, P81, DOI 10.1016/j.soard.2008.06.007; Robitaille L, 2016, NUTR J, V15, DOI 10.1186/s12937-016-0158-9; Ruston D, 2004, NATL DIET NUTR SURVE, V4; Schleicher RL, 2009, AM J CLIN NUTR, V90, P1252, DOI 10.3945/ajcn.2008.27016; Singer R, 2008, NEPHROLOGY, V13, P17, DOI 10.1111/j.1440-1797.2007.00857.x; Smith A, 2011, CAN MED ASSOC J, V183, pE752, DOI 10.1503/cmaj.091938; Taylor CA, 2000, EUR J CLIN NUTR, V54, P573, DOI 10.1038/sj.ejcn.1601059; Wrieden WL, 2000, J EPIDEMIOL COMMUN H, V54, P355, DOI 10.1136/jech.54.5.355	49	4	4	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	OCT	2018	50	6					654	658		10.1016/j.pathol.2018.07.004			5	Pathology	Pathology	GU7XB	WOS:000445543400011	30177219				2019-10-28	
J	Costa, AMG; Escott, R; Garland, SM; Byers, D; Tabrizi, SN				Costa, Anna-Maria G.; Escott, Ros; Garland, Suzanne M.; Byers, Deane; Tabrizi, Sepehr N.			Development of a pilot proficiency program for human papillomavirus DNA detection	PATHOLOGY			English	Article						Human papillomavirus; HPV DNA; external quality assurance	QUALITY-ASSURANCE; GLOBAL PROFICIENCY	Human papillomavirus (HPV) DNA testing has become routine in many diagnostic laboratories, particularly with changes from cervical cytology to HPV DNA as primary screening as of 1 December 2017 in Australia. External quality assurance (EQA) is essential for assessment of laboratory performance once HPV testing is implemented. The aim of this study was to develop a pilot program to evaluate and determine stability of material that could be utilised in an ongoing external quality assurance program (EQAP). Two sample types were evaluated: cells in PreservCyt solution (ThinPrep) from stored clinical specimens and HPV-seeded swabs. Two panels sent 5 months apart were distributed to 18 Australian and two New Zealand laboratories (participants) for testing by Hybrid Capture 2 (HC2) or alternative molecular methods. Participants were given 1 month to test specimens. Eight ThinPrep specimens in Panel 1 were reported correctly by 73% (11/15) of HC2 participants and 40% (2/5) of participants performing alternative methods. Of eight dry swab specimens, 58% (23/40) and 78% (25/32) were correctly identified by HC2 and alternative methods, respectively. Panel 2 included four ThinPrep and two swab specimens. ThinPrep specimens were reported correctly by 100% (60/60) of participants utilising HC2 and 95% (19/20) utilising alternative methods. Dry swab specimens were reported correctly by 89% (25/28) of participants utilising HC2 and 100% (10/10) of participants utilising alternative methods. These results indicate that both specimen types are suitable for utilisation in an EQAP and outline some issues of EQAP for ongoing assessment of HPV molecular methods in diagnostic molecular laboratories.	[Costa, Anna-Maria G.; Garland, Suzanne M.; Tabrizi, Sepehr N.] Royal Womens Hosp, Dept Microbiol & Infect Dis, Parkville, Vic, Australia; [Costa, Anna-Maria G.; Garland, Suzanne M.; Tabrizi, Sepehr N.] Royal Childrens Hosp, Dept Microbiol, Parkville, Vic, Australia; [Escott, Ros; Byers, Deane] RCPA Quality Assurance Programs Pty Ltd Serology, Parkville, Vic, Australia; [Garland, Suzanne M.; Tabrizi, Sepehr N.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Garland, Suzanne M.; Tabrizi, Sepehr N.] Univ Melbourne, Dept Obstet & Gynaecol, Melbourne, Vic, Australia	Costa, AMG (reprint author), Royal Womens Hosp, Dept Microbiol & Infect Dis, Parkville, Vic, Australia.; Costa, AMG (reprint author), Royal Childrens Hosp, Dept Microbiol, Parkville, Vic, Australia.	annamaria.costa@rch.org.au			Quality Use of Pathology Program (QUPP) of Australian Government's Department of Health and Ageing	This pilot project was conducted by the RCPA Quality Assurance Programs Pty Ltd (Serology) through a grant provided by Quality Use of Pathology Program (QUPP) of Australian Government's Department of Health and Ageing. The focus group included Deane Byers, Ros Escott, Ian Frazer, Suzanne Garland, William Rawlinson, Marion Saville, Sepehr Tabrizi and Mark Van Asten. With thanks to Symbion Laverty Pathology, North Ryde, NSW, for pre-issue testing for Panel 1, and for providing specimens used for Panel 2. We thank the molecular microbiology laboratory at The Royal Women's Hospital, Melbourne, including Andrew Daley from The Royal Children's Hospital, Melbourne. We also thank the laboratories who participated in testing the panels provided by the pilot program.	Castle PE, 2008, J CLIN MICROBIOL, V46, P3437, DOI 10.1128/JCM.00620-08; Cubie HA, 2005, J CLIN VIROL, V33, P287, DOI 10.1016/j.jcv.2004.12.011; Dalstein V, 2009, J VIROL METHODS, V156, P77, DOI 10.1016/j.jviromet.2008.11.002; Dillner Lena, 2008, Central European Journal of Public Health, V16, pS18; Eklund C, 2012, J CLIN MICROBIOL, V50, P2289, DOI 10.1128/JCM.00840-12; Eklund C, 2010, J CLIN MICROBIOL, V48, P4147, DOI 10.1128/JCM.00918-10; Engesaeter B, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-2028-7; Fagan EJ, 2010, J CLIN VIROL, V48, P251, DOI 10.1016/j.jcv.2010.05.006; Gravitt PE, 2000, J CLIN MICROBIOL, V38, P357; Moriarty AT, 2013, ARCH PATHOL LAB MED, V137, P606, DOI 10.5858/arpa.2012-0149-CP; National Pathology Accreditation Advisory Council (NPAAC), 2017, REQ LAB REP TESTS NA; Quint WGV, 2006, J CLIN MICROBIOL, V44, P571, DOI 10.1128/JCM.44.2.571-579.2006; Stevens MP, 2008, J CLIN MICROBIOL, V46, P3813, DOI 10.1128/JCM.01169-08; Stevens MP, 2006, J CLIN MICROBIOL, V44, P2428, DOI 10.1128/JCM.02608-05; Tabrizi SN, 2010, SEX HEALTH, V7, P335, DOI 10.1071/SH09152; Tachezy R, 2007, COLLEGIUM ANTROPOL, V31, P61; vdVeen N, 2017, FRAMEWORK EXECUTION	17	0	0	1	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	OCT	2018	50	6					659	664		10.1016/j.pathol.2018.05.005			6	Pathology	Pathology	GU7XB	WOS:000445543400012	30139535				2019-10-28	
J	Sachdev, R; Goel, S; Gautam, D; Sood, N				Sachdev, Ritesh; Goel, Shalini; Gautam, Dheeraj; Sood, Nitin			Angioimmunoblastic T-cell lymphoma presenting with extensive marrow plasmacytosis and hypergammaglobulinaemia: a diagnostic challenge	PATHOLOGY			English	Letter							BONE-MARROW; PERIPHERAL-BLOOD		[Sachdev, Ritesh; Goel, Shalini; Gautam, Dheeraj] Medanta, Dept Pathol Lab Med & Transfus Med, Gurgaon, India; [Sood, Nitin] Medanta, Dept Med Oncol & Hematol, Gurgaon, India	Sachdev, R (reprint author), Medanta, Dept Pathol Lab Med & Transfus Med, Gurgaon, India.	sachdev05@gmail.com		Goel, Shalini/0000-0003-2866-790X			Ahsanuddin AN, 2011, INT J CLIN EXP PATHO, V4, P416; Cho YU, 2009, AM J CLIN PATHOL, V131, P640, DOI 10.1309/AJCPQXKCHQH4VAJ5; Dogan A, 2003, BRIT J HAEMATOL, V121, P681, DOI 10.1046/j.1365-2141.2003.04335.x; Dogan A, 2017, WHO CLASSIFICATION T, P407; Garicochea B, 2014, J ANAL ONCOL, V3, P191; Grogg KL, 2007, BRIT J HAEMATOL, V137, P416, DOI 10.1111/j.1365-2141.2007.06577.x; Nagoshi H, 2013, INT J HEMATOL, V98, P366, DOI 10.1007/s12185-013-1411-z; Sakai H, 2007, INTERNAL MED, V46, P419, DOI 10.2169/internalmedicine.46.6121; Yamane A, 2007, ACTA HAEMATOL-BASEL, V117, P74, DOI 10.1159/000096894	9	0	0	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	OCT	2018	50	6					665	668		10.1016/j.pathol.2018.03.014			4	Pathology	Pathology	GU7XB	WOS:000445543400013	30143343				2019-10-28	
J	Chang, ST; Hsieh, YC; Kuo, CC; Chuang, SS				Chang, Sheng-Tsung; Hsieh, Yen-Chuan; Kuo, Chun-Chi; Chuang, Shih-Sung			Colonic CD30 positive plasmablastic plasmacytoma masquerading as anaplastic large cell lymphoma	PATHOLOGY			English	Letter							MYELOMA		[Chang, Sheng-Tsung; Hsieh, Yen-Chuan; Kuo, Chun-Chi; Chuang, Shih-Sung] Chi Mei Med Ctr, Dept Pathol, Tainan, Taiwan; [Chang, Sheng-Tsung] Natl Tainan Inst Nursing, Dept Nursing, Tainan, Taiwan; [Chuang, Shih-Sung] Taipei Med Univ, Sch Med, Dept Pathol, Taipei, Taiwan; [Chuang, Shih-Sung] Natl Taiwan Univ, Taipei, Taiwan	Chuang, SS (reprint author), Chi Mei Med Ctr, Dept Pathol, Tainan, Taiwan.	cmh5301@mail.chimei.org.tw					Ahn JS, 2017, J CLIN PATHOL, V70, P775, DOI 10.1136/jclinpath-2016-204294; Avet-Loiseau H, 2001, BLOOD, V98, P3082, DOI 10.1182/blood.V98.10.3082; Campo E, 2017, WHO CLASSIFICATION T, P321; Chang ST, 2007, AM J CLIN PATHOL, V128, P339, DOI 10.1309/27H8XJH31F3GUNAT; Greipp PR, 1998, BLOOD, V91, P2501, DOI 10.1182/blood.V91.7.2501.2501_2501_2507; Lee YY, 2017, PATHOLOGY, V49, P479, DOI 10.1016/j.pathol.2017.05.007; McKenna RW, 2017, HEMATOPATHOLOGY, P473; McKenna RW, 2017, WHO CLASSIFICATION T, P241; Otsuki T, 2001, LEUKEMIA LYMPHOMA, V42, P761, DOI 10.3109/10428190109099339; Valera A, 2010, AM J SURG PATHOL, V34, P1686, DOI 10.1097/PAS.0b013e3181f3e29f	10	0	0	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	OCT	2018	50	6					668	670		10.1016/j.pathol.2018.03.011			4	Pathology	Pathology	GU7XB	WOS:000445543400014	30098797				2019-10-28	
J	Tang, C; Kumar, P; Mackinlay, N				Tang, Catherine; Kumar, Poomahal; Mackinlay, Naomi			Cryoglobulin crystals in a patient with chronic lymphocytic leukaemia	PATHOLOGY			English	Letter									[Tang, Catherine; Kumar, Poomahal; Mackinlay, Naomi] Royal North Shore Hosp, Dept Haematol, St Leonards, NSW, Australia; [Tang, Catherine] Princess Margaret Hosp, Dept Med Oncol & Haematol, Toronto, ON, Canada	Tang, C (reprint author), Royal North Shore Hosp, Dept Haematol, St Leonards, NSW, Australia.; Tang, C (reprint author), Princess Margaret Hosp, Dept Med Oncol & Haematol, Toronto, ON, Canada.	catherine.tang@uhn.ca					Arora S, 2016, BLOOD CELL MOL DIS, V60, P7, DOI 10.1016/j.bcmd.2016.05.009; Fohlen-Walter A, 2002, AM J CLIN PATHOL, V117, P606; Ghetie D, 2015, RHEUM DIS CLIN N AM, V41, P93, DOI 10.1016/j.rdc.2014.09.008; Ibbottson R, 2014, LEUKEMIA, V26, P170; Neel A, 2014, AM J HEMATOL, V89, P156, DOI 10.1002/ajh.23608	5	0	0	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	OCT	2018	50	6					670	671		10.1016/j.pathol.2018.03.012			2	Pathology	Pathology	GU7XB	WOS:000445543400015	30082080				2019-10-28	
J	Chua, CC; Omerod, A; Wight, J; Juneja, S; Zantomio, D				Chua, Chong Chyn; Omerod, Amanda; Wight, Joel; Juneja, Surender; Zantomio, Daniela			Correlation of mutation status and morphological changes in essential thrombocythaemia and myelofibrosis	PATHOLOGY			English	Letter							MYELOPROLIFERATIVE NEOPLASMS; CALRETICULIN MUTATIONS; POLYCYTHEMIA-VERA; DIAGNOSIS; CRITERIA; SUBTYPES; UTILITY; JAK2		[Chua, Chong Chyn; Zantomio, Daniela] Austin Pathol, Dept Lab Haematol, Heidelberg, Vic, Australia; [Omerod, Amanda; Juneja, Surender] Royal Melbourne Hosp, Dept Lab Haematol, Melbourne, Vic, Australia; [Wight, Joel; Zantomio, Daniela] Austin Hlth, Clin Haematol, Heidelberg, Vic, Australia	Chua, CC (reprint author), Austin Pathol, Dept Lab Haematol, Heidelberg, Vic, Australia.	cchyn.chua@gmail.com	Juneja, Surender K/H-9017-2019	Chua, Chong Chyn/0000-0002-2162-3288			Alvarez-Larran A, 2014, BRIT J HAEMATOL, V166, P911, DOI 10.1111/bjh.12990; Boyd EM, 2010, BRIT J HAEMATOL, V149, P250, DOI 10.1111/j.1365-2141.2010.08083.x; Kim SY, 2015, AM J CLIN PATHOL, V143, P635, DOI 10.1309/AJCPUAAC16LIWZMM; Loghavi S, 2016, AM J CLIN PATHOL, V145, P418, DOI [10.1093/AJCP/AQW005, 10.1093/ajcp/aqw005]; Michiels JJ, 2002, INT J HEMATOL, V76, P133, DOI 10.1007/BF02982575; Mondet J, 2015, HAEMATOLOGICA, V100, DOI 10.3324/haematol.2014.118927; Rapado I, 2009, J MOL DIAGN, V11, P155, DOI 10.2353/jmoldx.2009.080110; Rumi E, 2017, BLOOD, V129, P680, DOI 10.1182/blood-2016-10-695957; Tefferi A, 2014, AM J HEMATOL, V89, pE121, DOI 10.1002/ajh.23743; Thiele J, 2005, HAEMATOL-HEMATOL J, V90, P1128; Wilkins BS, 2008, BLOOD, V111, P60, DOI 10.1182/blood-2007-05-091850	11	0	0	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	OCT	2018	50	6					671	674		10.1016/j.pathol.2018.02.005			4	Pathology	Pathology	GU7XB	WOS:000445543400016	30097170				2019-10-28	
J	Jang, HSI; Parratt, JDE; Tsang, VHM; Coyle, LA; Fernando, SL				Jang, Helena Sung-In; Parratt, John Douglas Edward; Tsang, Venessa Hin Man; Coyle, Luke Anthony; Fernando, Suran Loshana			Serum vascular endothelial growth factor (VEGF) level can be used as a diagnostic marker in POEMS syndrome	PATHOLOGY			English	Letter									[Jang, Helena Sung-In; Fernando, Suran Loshana] Royal North Shore Hosp, Dept Clin Immunol & Allergy, Sydney, NSW, Australia; [Jang, Helena Sung-In; Fernando, Suran Loshana] New South Wales Hlth Pathol, Immunorheumatol Lab, Sydney, NSW, Australia; [Parratt, John Douglas Edward] Royal North Shore Hosp, Dept Neurol, Sydney, NSW, Australia; [Parratt, John Douglas Edward; Tsang, Venessa Hin Man; Coyle, Luke Anthony; Fernando, Suran Loshana] Univ Sydney, Sydney, NSW, Australia; [Tsang, Venessa Hin Man] Royal North Shore Hosp, Dept Endocrinol, Sydney, NSW, Australia; [Coyle, Luke Anthony] Royal North Shore Hosp, Dept Haematol, Sydney, NSW, Australia	Jang, HSI (reprint author), Royal North Shore Hosp, Dept Clin Immunol & Allergy, Sydney, NSW, Australia.; Jang, HSI (reprint author), New South Wales Hlth Pathol, Immunorheumatol Lab, Sydney, NSW, Australia.	helena.s.jang@gmail.com					Dispenzieri A, 2017, AM J HEMATOL, V92, P814, DOI 10.1002/ajh.24802; Heer K, 2015, CLIN CANCER RES, V7, P3291; Misawa S, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009157; Rajkumar SV, 2014, LANCET ONCOL, V15, pE538, DOI 10.1016/S1470-2045(14)70442-5; Salven P, 2015, BLOOD, V96, P3713; Smets P, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1184-x	6	0	0	1	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	OCT	2018	50	6					674	676		10.1016/j.pathol.2018.03.010			4	Pathology	Pathology	GU7XB	WOS:000445543400017	30082079				2019-10-28	
J	McIver, CJ; Er, N; Mukerjee, C; Tokis, S; Taylor, P				McIver, Christopher J.; Er, Noel; Mukerjee, Chinmoy; Tokis, Sophie; Taylor, Peter			A simplified and rapid method for the direct identification of microorganisms in positive BacT/ALERT blood culture bottles using MALDI-TOF MS	PATHOLOGY			English	Letter							DESORPTION IONIZATION-TIME; FLIGHT MASS-SPECTROMETRY		[McIver, Christopher J.; Er, Noel; Mukerjee, Chinmoy; Tokis, Sophie; Taylor, Peter] St George Hosp, Microbiol Dept NSWHP, Kogarah, NSW, Australia; [McIver, Christopher J.; Taylor, Peter] Univ New South Wales, Sch Med Sci, Sydney, NSW, Australia	McIver, CJ (reprint author), St George Hosp, Microbiol Dept NSWHP, Kogarah, NSW, Australia.; McIver, CJ (reprint author), Univ New South Wales, Sch Med Sci, Sydney, NSW, Australia.	christopher.mciver@health.nsw.gov.au					Bhatti MM, 2014, J CLIN MICROBIOL, V52, P4334, DOI 10.1128/JCM.01788-14; French K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0169332; Jakovljev A, 2015, BMC MICROBIOL, V15, DOI 10.1186/s12866-015-0594-2; KALDOR J, 1977, AM J CLIN PATHOL, V68, P284, DOI 10.1093/ajcp/68.2.284; La Scola B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008041; McIver CJ, 2017, PATHOLOGY, V49, P656, DOI 10.1016/j.pathol.2017.05.012; Prete PSC, 2011, BBA-BIOMEMBRANES, V1808, P164, DOI 10.1016/j.bbamem.2010.10.016; Qian Q, 2007, J CLIN MICROBIOL, V45, P2267, DOI 10.1128/JCM.00369-07; Schubert S, 2011, J MOL DIAGN, V13, P701, DOI 10.1016/j.jmoldx.2011.07.004; Valentine N, 2005, APPL ENVIRON MICROB, V71, P58, DOI 10.1128/AEM.71.1.58-64.2005	10	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	OCT	2018	50	6					676	679		10.1016/j.pathol.2018.03.016			5	Pathology	Pathology	GU7XB	WOS:000445543400018	30145071				2019-10-28	
J	Caridi, G; de Abreu, IBR; Alves, JA; Lugani, F; Campagnoli, M; Galliano, M; Minchiotti, L				Caridi, Gianluca; de Abreu, Ilidio B. R.; Alves, Jose A.; Lugani, Francesca; Campagnoli, Monica; Galliano, Monica; Minchiotti, Lorenzo			A novel splicing mutation in the ALB gene causing analbuminaemia in a Portuguese woman	PATHOLOGY			English	Letter							CONGENITAL ANALBUMINEMIA; ALBUMIN GENE		[Caridi, Gianluca; Lugani, Francesca] Ist Giannina Gaslini, IRCCS, Lab Mol Nephrol, Genoa, Italy; [de Abreu, Ilidio B. R.; Alves, Jose A.] Hosp Dr Nelio Mendonca, Dept Clin Pathol, Serv Saude Regiao Autonoma Madeira EPE, Funchal, Portugal; [Campagnoli, Monica; Galliano, Monica; Minchiotti, Lorenzo] Univ Pavia, Dept Mol Med, Pavia, Italy	Minchiotti, L (reprint author), Univ Pavia, Dept Mol Med, Pavia, Italy.	loremin@unipv.it	Alves, Jose/AAB-2894-2019; Caridi, Gianluca/F-7052-2010	Caridi, Gianluca/0000-0001-6700-3001			Afshinnia F, 2016, J CLIN ENDOCR METAB, V101, P2468, DOI 10.1210/jc.2016-1099; [Anonymous], EXAC BROWS BET; Caridi G, 2018, ANN LAB MED, V38, P185, DOI 10.3343/alm.2018.38.2.185; Ha C.E., 2007, HAWAII MED J, V66, P150; Kim S, 2017, AM SURGEON, V83, P1220; Levitt DG, 2016, INT J GEN MED, V9, P229, DOI 10.2147/IJGM.S102819; Lyon AW, 1998, CLIN CHEM, V44, P2365; Minchiotti L, 2013, BBA-GEN SUBJECTS, V1830, P5494, DOI 10.1016/j.bbagen.2013.04.019; MINGHETTI PP, 1986, J BIOL CHEM, V261, P6747; Toye JM, 2012, PAED CHILD HEALT-CAN, V17, pE20, DOI 10.1093/pch/17.6.e20; Ward AJ, 2010, J PATHOL, V220, P152, DOI 10.1002/path.2649; WATKINS S, 1994, P NATL ACAD SCI USA, V91, P2275, DOI 10.1073/pnas.91.6.2275	12	1	1	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	OCT	2018	50	6					679	682		10.1016/j.pathol.2018.03.015			5	Pathology	Pathology	GU7XB	WOS:000445543400019	30143345				2019-10-28	
J	Ching, D; de Boer, B; Kumarasinghe, MP				Ching, Daniel; de Boer, Bastiaan; Kumarasinghe, M. Priyanthi			HPV positive oesophageal squamous cell carcinoma presenting as a metastasis to the thyroid masquerading as a primary malignancy, diagnosed by cytology	PATHOLOGY			English	Letter							GLAND; MANAGEMENT; DISEASE		[Ching, Daniel; de Boer, Bastiaan; Kumarasinghe, M. Priyanthi] PathWest QEII Med Ctr, Dept Anat Pathol, Perth, WA, Australia; [de Boer, Bastiaan] Fiona Stanley Hosp, Dept Anat Pathol, Perth, WA, Australia; [Kumarasinghe, M. Priyanthi] UWA, Sch Pathol & Lab Med, Perth, WA, Australia	Ching, D (reprint author), PathWest QEII Med Ctr, Dept Anat Pathol, Perth, WA, Australia.	danielching.lh@gmail.com					Chen ED, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-106; Chen H, 1999, WORLD J SURG, V23, P177, DOI 10.1007/PL00013162; De Santis S, 2017, J STOMATOL ORAL MAXI, V118, P103, DOI 10.1016/j.jormas.2017.02.004; Dustin SM, 2012, DIAGN CYTOPATHOL, V40, P416, DOI 10.1002/dc.21802; KIERNEY PC, 1994, ANN SURG ONCOL, V1, P345, DOI 10.1007/BF02303572; Lam KY, 1998, ARCH PATHOL LAB MED, V122, P37; Lin JD, 1998, THYROID, V8, P149, DOI 10.1089/thy.1998.8.149; Ludmir EB, 2015, J GASTROINTEST ONCOL, V6, P287, DOI 10.3978/j.issn.2078-6891.2015.001; MCCABE DP, 1985, AM J SURG, V150, P519, DOI 10.1016/0002-9610(85)90167-9; Nakhjavani MK, 1997, CANCER-AM CANCER SOC, V79, P574, DOI 10.1002/(SICI)1097-0142(19970201)79:3<574::AID-CNCR21>3.0.CO;2-#; Nixon IJ, 2017, ANN SURG ONCOL, V24, P1533, DOI 10.1245/s10434-016-5683-4; Rahman M, 2017, CYTOJOURNAL, V14, DOI 10.4103/cytojournal.cytojournal_50_16	12	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	OCT	2018	50	6					682	684		10.1016/j.pathol.2018.03.017			4	Pathology	Pathology	GU7XB	WOS:000445543400020	30143344				2019-10-28	
J	Thomson, SE; Millar, S; Twoon, M; Dundas, S; Tadros, A				Thomson, S. E.; Millar, S.; Twoon, M.; Dundas, S.; Tadros, A.			Primary cutaneous osteosarcoma: a lesion arising de novo in the posterior triangle of the neck	PATHOLOGY			English	Letter							EXTRASKELETAL OSTEOSARCOMA; OSTEOGENIC-SARCOMA; SCALP; SKIN		[Thomson, S. E.; Millar, S.; Tadros, A.] Aberdeen Royal Infirm, Plast & Reconstruct Surg Unit, Aberdeen, Scotland; [Twoon, M.] Univ Aberdeen, Aberdeen, Scotland; [Dundas, S.] Univ Aberdeen, Pathol Dept, Aberdeen, Scotland	Thomson, SE (reprint author), Aberdeen Royal Infirm, Plast & Reconstruct Surg Unit, Aberdeen, Scotland.	suzanne.thomson@doctors.org.uk					BINKHUYSEN FHB, 1986, DIAGN IMAG CLIN MED, V55, P384; Choi Lisa E, 2014, J Bone Joint Surg Am, V96, pe2, DOI 10.2106/JBJS.M.00339; Covello SP, 2003, J AM ACAD DERMATOL, V49, P124, DOI 10.1067/mjd.2003.297; KIRCIK L, 1995, INT J DERMATOL, V34, P861, DOI 10.1111/j.1365-4362.1995.tb04424.x; Kuo TT, 1996, AM J DERMATOPATH, V18, P109, DOI 10.1097/00000372-199602000-00022; Llamas-Velasco M, 2013, AM J DERMATOPATH, V35, pE106, DOI 10.1097/DAD.0b013e31827f0a6f; Massi D, 2007, J CUTAN PATHOL, V34, P61, DOI 10.1111/j.1600-0560.2006.00562.x; Park SG, 2011, ANN DERMATOL, V23, pS160, DOI 10.5021/ad.2011.23.S2.S160; REYES CV, 1989, INT J DERMATOL, V28, P38, DOI 10.1111/j.1365-4362.1989.tb01308.x; Riddle ND, 2009, CLIN EXP DERMATOL, V34, pE879, DOI 10.1111/j.1365-2230.2009.03637.x; Santos-Juanes J, 2004, J AM ACAD DERMATOL, V51, pS94, DOI 10.1016/j.jaad.2004.04.021; Singh R, 2006, J Orthop Surg (Hong Kong), V14, P192; Sio TT, 2016, AM J CLIN ONCOL-CANC, V39, P32, DOI 10.1097/COC.0000000000000005	13	0	0	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	OCT	2018	50	6					684	688		10.1016/j.pathol.2018.04.003			6	Pathology	Pathology	GU7XB	WOS:000445543400021	30145068				2019-10-28	
J	Li, JJ; Kim, L; Henderson, C				Li, Jing Jing; Kim, Lauren; Henderson, Christopher			A case of intrathoracic symplastic haemangioma could have been misdiagnosed as angiosarcoma	PATHOLOGY			English	Letter							HYALINIZING ANGIECTATIC TUMOR		[Li, Jing Jing; Kim, Lauren; Henderson, Christopher] Liverpool Hosp, Dept Anat Pathol, Liverpool, NSW, Australia	Li, JJ (reprint author), Liverpool Hosp, Dept Anat Pathol, Liverpool, NSW, Australia.	jingjingli2001@gmail.com					CARLA T G, 1991, Pathologica (Genoa), V83, P237; Folpe AL, 2004, AM J SURG PATHOL, V28, P1417, DOI 10.1097/01.pas.0000141406.02581.fb; Goh SGN, 2006, J CUTAN PATHOL, V33, P735, DOI 10.1111/j.1600-0560.2006.00552.x; Kutzner H, 2000, HAUTARZT, V51, P327, DOI 10.1007/s001050051126; LACH B, 1994, CANCER, V74, P1915, DOI 10.1002/1097-0142(19941001)74:7<1915::AID-CNCR2820740715>3.0.CO;2-1; Meis-Kindblom JM, 1998, AM J SURG PATHOL, V22, P683, DOI 10.1097/00000478-199806000-00005; Samardzija G, 2016, PEDIATR DEVEL PATHOL, V19, P249, DOI 10.2350/14-09-1547-CR.1; Smith MEF, 1996, AM J SURG PATHOL, V20, P21, DOI 10.1097/00000478-199601000-00002; Tsang WYW, 1994, INT J SURG PATHOL, V1, pS202; Wassef M, 2015, PEDIATRICS, V136, pE203, DOI 10.1542/peds.2014-3673	10	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	OCT	2018	50	6					688	691		10.1016/j.pathol.2018.03.013			5	Pathology	Pathology	GU7XB	WOS:000445543400022	30143342				2019-10-28	
J	Cellier, L; Jacquemus, J; Youssef-Provencal, N; Houlier, A; de la Fouchardiere, A				Cellier, Lucie; Jacquemus, Julien; Youssef-Provencal, Nelly; Houlier, Aurelie; de la Fouchardiere, Arnaud			Tri-phenotypic naevus: a case report	PATHOLOGY			English	Letter							BAP1 EXPRESSION; MELANOMA		[Cellier, Lucie; Jacquemus, Julien; Houlier, Aurelie; de la Fouchardiere, Arnaud] Ctr Leon Berard, Dept Biopathol, Lyon, France; [Youssef-Provencal, Nelly] CYPATH Pathol Lab, Lyon, France	de la Fouchardiere, A (reprint author), Ctr Leon Berard, Dept Biopathol, Lyon, France.	arnaud.delafouchardiere@lyon.unicancer.fr	de la Fouchardiere, Arnaud/I-2807-2019	de la Fouchardiere, Arnaud/0000-0003-2251-8241			Blokx WAM, 2015, VIRCHOWS ARCH, V466, P117, DOI 10.1007/s00428-014-1674-7; Cabaret O, 2017, GENE CHROMOSOME CANC, V56, P691, DOI 10.1002/gcc.22473; Murali R, 2013, PATHOLOGY, V45, P606, DOI 10.1097/PAT.0b013e3283653818; Scolyer RA, 2004, PATHOLOGY, V36, P419, DOI 10.1080/00313020412331283879; Wiesner T, 2012, AM J SURG PATHOL, V36, P818, DOI 10.1097/PAS.0b013e3182498be5; Yeh I, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00758-3	6	0	0	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	OCT	2018	50	6					691	693		10.1016/j.pathol.2018.04.004			4	Pathology	Pathology	GU7XB	WOS:000445543400023	30122258				2019-10-28	
J	Mochel, MC; Garcia, P; Memari, P; Domson, G; Smith, SC				Mochel, Mark Cameron; Garcia, Paulo; Memari, Patrick; Domson, Gregory; Smith, Steven Christopher			The Morel-Lavallee lesion: a report of two cases	PATHOLOGY			English	Letter									[Mochel, Mark Cameron; Garcia, Paulo; Memari, Patrick; Smith, Steven Christopher] Virginia Commonwealth Univ, Dept Pathol, Sch Med, Richmond, VA 23284 USA; [Domson, Gregory] Virginia Commonwealth Univ, Dept Orthoped Surg, Sch Med, Richmond, VA USA; [Smith, Steven Christopher] Virginia Commonwealth Univ, Dept Surg, Sch Med, Richmond, VA USA	Mochel, MC (reprint author), Virginia Commonwealth Univ, Dept Pathol, Sch Med, Richmond, VA 23284 USA.	mark.mochel@vcuhealth.org					Kalaci A, 2007, CLIN IMAG, V31, P287, DOI 10.1016/j.clinimag.2007.01.012; Kumar S, 2015, J CLIN DIAGN RES, V9; Lee YJ, 2017, INT WOUND J, V14, P1258, DOI 10.1111/iwj.12793; McLean K, 2017, RADIOGRAPHICS, V37, P190, DOI 10.1148/rg.2017160169; Mellado Jose M, 2005, Magn Reson Imaging Clin N Am, V13, P775, DOI 10.1016/j.mric.2005.08.006; Scolaro JA, 2016, J AM ACAD ORTHOP SUR, V24, P667, DOI 10.5435/JAAOS-D-15-00181	6	0	0	1	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	OCT	2018	50	6					693	694		10.1016/j.pathol.2018.03.018			3	Pathology	Pathology	GU7XB	WOS:000445543400024	30145069				2019-10-28	
J	Chang, C; Lin, SH; Medeiros, LJ; Chang, KC				Chang, Chen; Lin, Sheng-Hsiang; Medeiros, L. Jeffrey; Chang, Kung-Chao			Kikuchi disease: an unusual case with features suggesting an infectious aetiology	PATHOLOGY			English	Letter							PAROTID-GLAND; LYMPHADENITIS; CYST		[Chang, Chen; Chang, Kung-Chao] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Dept Pathol, Coll Med, Tainan, Taiwan; [Lin, Sheng-Hsiang] Natl Cheng Kung Univ, Inst Clin Med, Coll Med, Tainan, Taiwan; [Medeiros, L. Jeffrey] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA	Chang, KC (reprint author), Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Dept Pathol, Coll Med, Tainan, Taiwan.	changkc@mail.ncku.edu.tw	Medeiros, L. Jeffrey/AAB-1018-2019				Dave SP, 2007, LARYNGOSCOPE, V117, P106, DOI 10.1097/01.mlg.0000246196.35413.35; Fisman D, 2012, CLIN MICROBIOL INFEC, V18, P946, DOI 10.1111/j.1469-0691.2012.03968.x; Kikuchi M., 1972, NIPPON KETSUEKI GAKK, V35, P379; KUO TT, 1995, AM J SURG PATHOL, V19, P798, DOI 10.1097/00000478-199507000-00008; Onciu M, 2003, ADV ANAT PATHOL, V10, P204, DOI 10.1097/00125480-200307000-00003; SUSTER S, 1991, AM J SURG PATHOL, V15, P388, DOI 10.1097/00000478-199104000-00008; TERRY JH, 1991, AM J SURG, V162, P324, DOI 10.1016/0002-9610(91)90141-Y; Yen TL, 2004, LARYNGOSCOPE, V114, P1500, DOI 10.1097/00005537-200408000-00034	8	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	OCT	2018	50	6					694	697		10.1016/j.pathol.2018.04.005			5	Pathology	Pathology	GU7XB	WOS:000445543400025	30145070				2019-10-28	
J	Sng, LH; Peh, JWL; Kee, MTL; Ya'akob, NBM; Ong, RTH; Wong, CW; Chee, CBE; Wang, YT				Sng, L-H; Peh, J. W. L.; Kee, M. T. L.; Ya'akob, N. B. M.; Ong, R. T-H; Wong, C. W.; Chee, C. B. E.; Wang, Y. T.			Clofazimine drug susceptibility testing for Mycobacterium tuberculosis: the case of using the right diluent (vol 50, pg 549, 2018)	PATHOLOGY			English	Correction																Sng LH, 2018, PATHOLOGY, V50, P549, DOI 10.1016/j.pathol.2018.01.006	1	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	OCT	2018	50	6					698	698		10.1016/j.pathol.2018.08.001			1	Pathology	Pathology	GU7XB	WOS:000445543400026					2019-10-28	
J	Ravella, L; Lopez, J; Descotes, F; Lifante, JC; David, C; Decaussin-Petrucci, M				Ravella, Lucie; Lopez, Jonathan; Descotes, Francoise; Lifante, Jean-Christophe; David, Catherine; Decaussin-Petrucci, Myriam			DICER1 mutated, solid/trabecular thyroid papillary carcinoma in an 11-year-old child	ANNALES DE PATHOLOGIE			French	Article						Papillary thyroid carcinoma; Solid variant; Post radiation; Poorly differentiated thyroid carcinoma; DICER1	PAPILLARY THYROID-CARCINOMA; NEEDLE-ASPIRATION-CYTOLOGY; SOLID VARIANT; MUTATIONS	We report the case of an 11-year-old patient diagnosed with a solid variant of papillary thyroid carcinoma. Papillary thyroid carcinoma (PTC) is the most common thyroid cancer, representing 80-90% of all newly diagnosed thyroid cancers. Among the many variants described, solid/trabecular variant of papillary thyroid carcinoma is a rare entity and account for 3% of thyroid cancers. It is more common in children and young adults, and it is seen in higher proportion in post radiation papillary thyroid carcinoma cases. Histologically, solid variant papillary carcinoma is characterized by a predominantly solid, trabecular or insular growth pattern, and the presence of cytological features typical of PTC. Its main differential diagnosis is poorly differentiated thyroid carcinoma. It has a less favorable prognosis than the classical papillary type, with a higher risk of distant metastasis, extrathyroidal extension and lympho-vascular invasion. It is associated with a slightly lower long-term survival in adult cases, but not in children. The management of solid variant PTC includes surgery, associated or not with postoperative radioiodine ablation, according to the aggressiveness criteria. Our patient had a DICER1 somatic mutation. Carriers of germline DICER1 mutations are predisposed to a rare cancer syndrome, the DICER1 syndrome, with a higher risk of numerous tumors and infrequently differentiated thyroid carcinomas. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Ravella, Lucie; David, Catherine; Decaussin-Petrucci, Myriam] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Serv Anat & Cytol Pathol, 165 Chemin Grand Revoyet, F-69310 Pierre Benite, France; [Lopez, Jonathan; Descotes, Francoise] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Serv Biochim & Biol Mol, 165 Chemin Grand Revoyet, F-69310 Pierre Benite, France; [Lifante, Jean-Christophe] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Serv Chirurg Endocrinienne, 165 Chemin Grand Revoyet, F-69310 Pierre Benite, France	Ravella, L (reprint author), Hosp Civils Lyon, Ctr Hosp Lyon Sud, Serv Anat & Cytol Pathol, 165 Chemin Grand Revoyet, F-69310 Pierre Benite, France.	lucieravelta@gmail.com					Abdul Rahman Wan, 2013, CASE REP, V2013; CARCANGIU ML, 1985, CANCER, V55, P805, DOI 10.1002/1097-0142(19850215)55:4<805::AID-CNCR2820550419>3.0.CO;2-Z; Durieux E, 2016, VIRCHOWS ARCH, V468, P631, DOI 10.1007/s00428-016-1922-0; Frio TR, 2011, JAMA-J AM MED ASSOC, V305, P68, DOI 10.1001/jama.2010.1910; Giorgadze TA, 2015, CANCER CYTOPATHOL, V123, P71, DOI 10.1002/cncy.21504; Higuchi M, 2017, CYTOPATHOLOGY, V28, P268, DOI 10.1111/cyt.12399; Lloyd RV, 2017, IARC WHO CLASSIFICAT, V10; NIKIFOROV Y, 1994, CANCER-AM CANCER SOC, V74, P748, DOI 10.1002/1097-0142(19940715)74:2<748::AID-CNCR2820740231>3.0.CO;2-H; Nikiforov YE, 1997, CANCER RES, V57, P1690; Nikiforov YE, 2001, AM J SURG PATHOL, V25, P1478, DOI 10.1097/00000478-200112000-00002; Nikiforov YE, 2016, JAMA ONCOL, V2, P1023, DOI 10.1001/jamaoncol.2016.0386; Ohashi R, 2017, HISTOPATHOLOGY, V70, P775, DOI 10.1111/his.13132; Rutter MM, 2016, J CLIN ENDOCR METAB, V101, P1, DOI 10.1210/jc.2015-2169; Sak Serpil Dizbay, 2015, Turk Patoloji Derg, V31 Suppl 1, P34, DOI 10.5146/tjpath.2015.01313; Solarski M, 2018, ENDOCR-RELAT CANCER, V25, pR197, DOI 10.1530/ERC-17-0509; Volante M, 2007, AM J SURG PATHOL, V31, P1256, DOI 10.1097/PAS.0b013e3180309e6a; 2009, SCIENCE, V325, P965, DOI DOI 10.1126/SCIENCE.1174334	17	1	1	0	3	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	OCT	2018	38	5					316	320		10.1016/j.annpat.2018.04.003			5	Pathology	Pathology	HU8CP	WOS:000465510300012	29884466				2019-10-28	
J	Kroft, SH				Kroft, Steven H.			The Evolution of the Clinical Pathologist	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Editorial Material									[Kroft, Steven H.] Med Coll Wisconsin, Dept Pathol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA	Kroft, SH (reprint author), Med Coll Wisconsin, Dept Pathol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	skroft@mcw.edu					Black JH, 1931, AM J CLIN PATHOL, V1, P1; Rodriguez FH, 2007, LABMEDICINE, V38, P595, DOI 10.1309/RTKE4EKQ61HMN37U	2	1	1	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	OCT	2018	150	4					283	284		10.1093/AJCP/AQY119			2	Pathology	Pathology	GS3SN	WOS:000443541200001	30165557				2019-10-28	
J	Bagnasco, M; Saverino, D; Pupo, F; Marchiano, M; Alessio, MG; Schlumberger, W; Antico, A; Pesce, G; Bizzaro, N				Bagnasco, Marcello; Saverino, Daniele; Pupo, Francesca; Marchiano, Manuela; Alessio, Maria Grazia; Schlumberger, Wolfgang; Antico, Antonio; Pesce, Giampaola; Bizzaro, Nicola			Estimate of the Prevalence of Anti-Gastric Parietal Cell Autoantibodies in Healthy Individuals Is Method Dependent	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Autoimmune gastritis; Anti-gastric parietal cell autoantibodies; Healthy individuals; Immunofluorescence; ELISA	HELICOBACTER-PYLORI INFECTION; ATROPHIC BODY GASTRITIS; AUTOIMMUNE GASTRITIS; PERNICIOUS-ANEMIA; INTRINSIC-FACTOR; DIAGNOSIS; DISEASE; CLASSIFICATION; POPULATION; ANTIBODIES	Objectives: Anti-parietal cell antibodies (APCA) are a serologic marker of autoimmune gastritis. Their prevalence in healthy individuals is not well defined. Methods: We evaluated APCA prevalence in 515 healthy blood-donors by rat/primate tissue indirect immunofluorescence (IIF), enzyme-linked immunosorbent assay (ELISA), and immunoblot. Results: Fifty-three of 515 (10.3%) subjects were positive for APCA by at least one method: 18 only by ELISA, 10 by rodent tissue IIF, and one by primate tissue IIF; 18 were positive by ELISA and primate tissue IIF, and one by ELISA and rodent tissue IIF. Two were positive by both IIF methods, and three were triple positive. APCA positivity was confirmed by immunoblot in 100% of ELISA positive, in 95.8% of positive primate tissue IIF, and in 50% of positive rat tissue IIF. Conclusions: A great discrepancy in APCA prevalence detected by different methods in this cohort was apparent. Thus, the results on APCA prevalence in healthy individuals are likely method-dependent.	[Bagnasco, Marcello; Pupo, Francesca; Marchiano, Manuela; Pesce, Giampaola] Univ Genoa, Dipartimento Med Interna, Genoa, Italy; [Saverino, Daniele] Univ Genoa, Dipartimento Med Sperimentale, Genoa, Italy; [Bagnasco, Marcello; Saverino, Daniele; Pupo, Francesca; Marchiano, Manuela; Pesce, Giampaola] Osped Policlin San Martino, Lab Autoimmunol, Genoa, Italy; [Alessio, Maria Grazia] Papa Giovanni Hosp XXIII, Clin Chem Lab, Bergamo, Italy; [Schlumberger, Wolfgang] Euroimmun, Inst Expt Immunol, Lubeck, Germany; [Antico, Antonio] Civ Hosp, Clin Pathol Lab, Santorso, Italy; [Bizzaro, Nicola] San Antonio Hosp, Clin Pathol Lab, Tolmezzo, Italy	Bagnasco, M (reprint author), Univ Genoa, DIMI, Viale Benedetto 15,6, I-16132 Genoa, Italy.	Bagnasco@unige.it	Saverino, Daniele/I-4741-2014				Alonso N, 2005, J CLIN ENDOCR METAB, V90, P5254, DOI 10.1210/jc.2005-0580; Annibale B, 2001, HELICOBACTER, V6, P225, DOI 10.1046/j.1083-4389.2001.00032.x; Antico A, 2008, IT J LAB MED, V4, P125; Antico A, 2010, RIV ITALIANA MED LAB, V6, P198; Antico A, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/520970; Betterle C, 2002, ENDOCR REV, V23, P327, DOI 10.1210/er.23.3.327; Bettington M, 2013, PATHOLOGY, V45, P145, DOI 10.1097/PAT.0b013e32835cc22c; Bizzaro N, 2014, AUTOIMMUN REV, V13, P565, DOI 10.1016/j.autrev.2014.01.042; de Leon AC, 2012, IMMUNOL LETT, V147, P63, DOI 10.1016/j.imlet.2012.06.004; Cockburn AN, 2013, ADV ANAT PATHOL, V20, P148, DOI 10.1097/PAP.0b013e31828d185d; De Block CEM, 2003, DIABETES CARE, V26, P82, DOI 10.2337/diacare.26.1.82; De Block CEM, 2001, CLIN EXP IMMUNOL, V126, P236, DOI 10.1046/j.1365-2249.2001.01668.x; Dixon MF, 1996, AM J SURG PATHOL, V20, P1161, DOI 10.1097/00000478-199610000-00001; ELISEI R, 1990, AUTOIMMUNITY, V8, P65, DOI 10.3109/08916939008998434; GOLDKORN I, 1989, J BIOL CHEM, V264, P18768; Guariso G, 2009, CLIN CHIM ACTA, V402, P54, DOI 10.1016/j.cca.2008.12.014; Hershko C, 2006, BLOOD, V107, P1673, DOI 10.1182/blood-2005-09-3534; Jevremovic D, 2006, AM J SURG PATHOL, V30, P1412, DOI 10.1097/01.pas.0000213337.25111.37; KARLSSON FA, 1988, J CLIN INVEST, V81, P475, DOI 10.1172/JCI113344; Kokkola A, 1998, SCAND J GASTROENTERO, V33, P88; Lahner E, 2009, AM J GASTROENTEROL, V104, P2071, DOI 10.1038/ajg.2009.231; Lam-Tse Wai-Kwan, 2003, Pediatr Endocrinol Rev, V1, P22; Liaskos C, 2010, CLIN CHIM ACTA, V411, P411, DOI 10.1016/j.cca.2009.12.012; Marignani M, 1999, AM J GASTROENTEROL, V94, P766; Neumann WL, 2013, NAT REV GASTRO HEPAT, V10, P529, DOI 10.1038/nrgastro.2013.101; Ohkusa T, 2001, ANN INTERN MED, V134, P380, DOI 10.7326/0003-4819-134-5-200103060-00010; Pan XF, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001440; Rugge M, 2010, ALIMENT PHARM THER, V31, P1104, DOI 10.1111/j.1365-2036.2010.04277.x; Sterzl I, 2008, PHYSIOL RES, V57, pS135; Sugiu K, 2006, HEPATO-GASTROENTEROL, V53, P11; Toh BH, 2014, AUTOIMMUN REV, V13, P459, DOI 10.1016/j.autrev.2014.01.048; Toh BH, 2012, AUTOIMMUNITY, V45, P527, DOI 10.3109/08916934.2012.702813; Toh BH, 1997, NEW ENGL J MED, V337, P1441, DOI 10.1056/NEJM199711133372007; Toh BH, 2000, IMMUNOL TODAY, V21, P348, DOI 10.1016/S0167-5699(00)01653-4; TOH BH, 1990, P NATL ACAD SCI USA, V87, P6418, DOI 10.1073/pnas.87.16.6418; Torbenson M, 2002, MODERN PATHOL, V15, P102, DOI 10.1038/modpathol.3880499; Tozzoli R, 2010, AUTOIMMUN REV, V10, P80, DOI 10.1016/j.autrev.2010.08.006; Van den Driessche A, 2009, NETH J MED, V67, P376; Vannella L, 2013, ALIMENT PHARM THER, V37, P375, DOI 10.1111/apt.12177; Vannella L, 2012, WORLD J GASTROENTERO, V18, P1279, DOI 10.3748/wjg.v18.i12.1279; Varbanova M, 2014, BEST PRACT RES CL GA, V28, P1031, DOI 10.1016/j.bpg.2014.10.005; Veijola LI, 2010, WORLD J GASTROENTERO, V16, P83, DOI 10.3748/wjg.v16.i1.83; Weetman AP, 2005, BEST PRACT RES CL EN, V19, P17, DOI 10.1016/j.beem.2004.11.004; Zhang Y, 2013, CANCER EPIDEM BIOMAR, V22, P821, DOI 10.1158/1055-9965.EPI-12-1343	44	0	0	1	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	OCT	2018	150	4					285	292		10.1093/AJCP/AQY061			8	Pathology	Pathology	GS3SN	WOS:000443541200002	30007281				2019-10-28	
J	Hudson, CA; Burack, WR; Leary, PC; Bennett, JM				Hudson, Chad A.; Burack, W. Richard; Leary, Patricia C.; Bennett, John M.			Clinical Utility of Classical and Nonclassical Monocyte Percentage in the Diagnosis of Chronic Myelomonocytic Leukemia	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Chronic myelomonocytic leukemia; Monocyte subsets; Nonclassical monocytes; Flow cytometry	DIFFERENTIATION; CMML; MDS	Objectives: To determine if a clinically applicable flow cytometry methodology could identify chronic myelomonocytic leukemia (CMML) cases. Methods: Monocyte subset screening (CD14/CD16 expression) was performed on 68 blood and 25 bone marrow specimens with a monocytosis and/or flagged as possible CMML. Fifty thousand total events were obtained per case. Cases were categorized as CMML, atypical chronic myeloid leukemia (aCML), or non-CMML + non-aCML by clinicopathologic diagnosis. Results: The methodology differentiated blood and bone marrow CMML cases from non-CMML + non-aCML but not three aCML cases in the clinical setting. Furthermore, a decreased percentage of nonclassical monocytes (CD14(dim)CD16(+)) showed better sensitivity than the previously described approach that relied on increased percentage of classical monocytes (CD14(bright)CD16(-)). Conclusions: Quantification of monocyte subsets is useful in clinical practice as a diagnostic marker of CMML in blood and bone marrow specimens. The percentage of nonclassical monocytes should be included in analysis of monocyte subsets.	[Hudson, Chad A.; Burack, W. Richard; Leary, Patricia C.; Bennett, John M.] Univ Rochester, Dept Pathol & Lab Med, James P Wilmot Canc Inst, 601 Elmwood Ave, Rochester, NY 14642 USA; [Bennett, John M.] Univ Rochester, Dept Med, James P Wilmot Canc Inst, Rochester, NY USA	Hudson, CA (reprint author), Univ Rochester, Dept Pathol & Lab Med, Med Ctr, Box 628,601 Elmwood Ave, Rochester, NY 14642 USA.	chad_hudson@urmc.rochester.edu		Hudson, Chad/0000-0003-1112-6760			BENNETT JM, 1994, BRIT J HAEMATOL, V87, P746, DOI 10.1111/j.1365-2141.1994.tb06734.x; Droin N, 2010, BLOOD, V115, P78, DOI 10.1182/blood-2009-05-224352; Lalkhen AG, 2008, BJA EDUC, V8, P221, DOI 10.1093/bjaceaccp/mkn041; Patnaik MM, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2017.66; Selimoglu-Buet D, 2017, BLOOD, V130, P832, DOI 10.1182/blood-2017-04-779579; Selimoglu-Buet D, 2015, BLOOD, V125, P3618, DOI 10.1182/blood-2015-01-620781; Swerdlow SH, 2017, WHO CLASSIFICATION T; Talati C, 2017, BLOOD, V129, P1881, DOI 10.1182/blood-2016-12-753210; van Lochem EG, 2004, CYTOM PART B-CLIN CY, V60B, P1, DOI 10.1002/cyto.b.20008	9	4	4	2	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	OCT	2018	150	4					293	302		10.1093/AJCP/AQY054			10	Pathology	Pathology	GS3SN	WOS:000443541200003	29982327				2019-10-28	
J	Girma, M; Desale, A; Hassen, F; Sisay, A; Tsegaye, A				Girma, Mekonnen; Desale, Adinew; Hassen, Fatuma; Sisay, Abay; Tsegaye, Aster			Survey-Defined and Interview-Elicited Challenges That Faced Ethiopian Government Hospital Laboratories as They Applied ISO 15189 Accreditation Standards in Resource-Constrained Settings in 2017	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						LQMS; Accreditation; Challenge; ISO 15189; SLMTA/SLIPTA; Medical laboratory	HEALTH; SYSTEMS; QUALITY; CARE	Objectives: The World Health Organization African Regional Office recommends ISO 15189 standards to improve performance quality in sub-Saharan African laboratories. We specify challenges Ethiopian laboratorians encountered applying ISO 15189 standards. Methods: From a structured survey at 12 Ethiopian government hospitals, 175 laboratory staff replied; all were aware of the ISO standards and 138 had been involved in the ISO 15189 inspection process. In addition, 11 laboratory heads, 10 quality officers, and three medical directors were interviewed in depth. Results: Half or more respondents identified six challenges obstructing accreditation to a "large" or "very large" degree: (1) low management support, (2) inadequate training, (3) insufficient infrastructure, (4) excessive documentation, (5) little mentorship, and (6) increased accreditation-related workload. Interviewees added (7) poor equipment, (8) unavailable/poor-quality reagents, and (9) high staff turnover. Conclusions: The survey and interviews specified nine major challenges for Ethiopian government hospital laboratories that seriously obstruct meeting ISO 15189 demands.	[Girma, Mekonnen] Univ Gondar, Sch Biomed & Lab Sci, Coll Med & Hlth Sci, Gondar, Ethiopia; [Girma, Mekonnen; Hassen, Fatuma; Sisay, Abay; Tsegaye, Aster] Univ Addis Ababa, Dept Med Lab Sci, Coll Hlth Sci, Addis Ababa, Ethiopia; [Desale, Adinew] Ethiopian Publ Hlth Inst, Addis Ababa, Ethiopia	Girma, M (reprint author), Univ Gondar, Sch Biomed & Lab Sci, Coll Med & Hlth Sci, Gondar, Ethiopia.; Girma, M (reprint author), Univ Addis Ababa, Dept Med Lab Sci, Coll Hlth Sci, Addis Ababa, Ethiopia.	mekon-nen2302@gmail.com		Tsegaye, Aster/0000-0002-9026-4629			Alemnji GA, 2014, TROP MED INT HEALTH, V19, P450, DOI 10.1111/tmi.12269; Alkhenizan A, 2012, J FAM COMMUNITY MED, V19, P74, DOI 10.4103/2230-8229.98281; [Anonymous], 151892012 ISO; Cohen S, 2014, AFR J HOSPITALITY TO, V3, P1; El-Jardali F, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-86; Gachuki T, 2014, AFR J LAB MED, V3, DOI 10.4102/ajlm.v3i2.216; Gershy-Damet GM, 2010, AM J CLIN PATHOL, V134, P393, DOI [10.1309/AJCPTUUC2V1WJOBM, 10.1309/AJCPTUUC2V1WJQBM]; Guevara G, 2014, AFR J LAB MED, V3, DOI 10.4102/ajlm.v3i2.199; Hiwotu TM, 2014, AFR J LAB MED, V3, DOI 10.4102/ajlm.v3i2.228; Ho B, 2012, BIOCHEM MEDICA, V22, P247; Masanza MM, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-S1-S8; McGrowder D, 2010, ACCREDIT QUAL ASSUR, V15, P569, DOI 10.1007/s00769-010-0686-5; Mesfin EA, 2015, PAN AFR MED J, V22, DOI 10.11604/pamj.2015.22.136.7187; Mothabeng D, 2012, AFR J LAB MED, V1, DOI 10.4102/ajlm.v1i1.9; Ndihokubwayo JB, 2016, AFR J LAB MED, V5, DOI 10.4102/ajlm.v5i1.280; Nicklin W, 2008, VALUE IMPACT ACCREDI; Nkengasong JN, 2010, AM J CLIN PATHOL, V134, P368, DOI [10.1309/AJCPMPSINO9BRMU6, 10.1309/AJCPMPSINQ9BRMU6]; Peter TF, 2010, AM J CLIN PATHOL, V134, P550, DOI 10.1309/AJCPH1SKQ1HNWGHF; Ravaghi Hamid, 2015, Glob J Health Sci, V7, P358, DOI 10.5539/gjhs.v7n4p358; Ravaghi H, 2014, ACCREDIT QUAL ASSUR, V19, P301, DOI 10.1007/s00769-014-1060-9; Sisay Abay, 2015, Pan Afr Med J, V20, P314, DOI 10.11604/pamj.2015.20.314.5375; World Health Organization, 2007, EV BUS STRENGTH HLTH	22	0	0	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	OCT	2018	150	4					303	309		10.1093/AJCP/AQY049			7	Pathology	Pathology	GS3SN	WOS:000443541200004	29992301	Bronze			2019-10-28	
J	Siliezar, MM; Munoz, CC; Solano-Iturri, JD; Ortega-Comunian, L; Mollejo, M; Montes-Moreno, S; Piris, MA				Siliezar, Marcos M.; Celerio Munoz, Catuxa; Danel Solano-Iturri, Jon; Ortega-Comunian, Laura; Mollejo, Manuela; Montes-Moreno, Santiago; Piris, Miguel A.			Spontaneously Ruptured Spleen Samples in Patients With Infectious Mononucleosis Analysis of Histology and Lymphoid Subpopulations	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Infectious mononucleosis; Epstein-Barr virus; Splenic spontaneous rupture	CONCERTED ACTION BHM4-CT98-3936	Objectives: Spontaneous rupture of the spleen is occasionally seen as the presenting event in infectious mononucleosis (IM). Diagnosis of these cases can be very challenging. Methods: We describe the morphologic and immunohistochemical findings in a series of seven splenectomy specimens removed after spontaneous rupture in patients with IM. Most cases were submitted for a second opinion since the histology of the cases suggested malignant lymphoma. Results: All the cases showed similar findings, with red pulp expansion occupied by activated T and B cells, including scattered large lymphocytes with both T- and B-cell markers, together with a polymorphic background rich in cytotoxic T cells. Clonality analysis revealed T-cell receptor clonal patterns in four of the six cases evaluated. Conclusions: IM should be considered a possible diagnosis in any case of splenic rupture whose histology suggests possible aggressive lymphoma.	[Siliezar, Marcos M.; Celerio Munoz, Catuxa; Montes-Moreno, Santiago] Hosp Univ Marques Valdecilla, IDIVAL, Pathol Serv, Santander, Spain; [Danel Solano-Iturri, Jon; Ortega-Comunian, Laura] Hosp Univ Basurto, Pathol Serv, Bilbao, Spain; [Mollejo, Manuela] Hosp Virgen de la Salud, Pathol Serv, Toledo, Spain; [Piris, Miguel A.] Fdn Jimenez Diaz, CIBERONC, Pathol Serv, Madrid, Spain	Piris, MA (reprint author), Hosp Univ Fdn Jimenez Diaz, Dept Pathol, Avd ReyesCatolicos 2, Madrid 28040, Spain.	miguel.piris@quironsalud.es		Mollejo, Manuela/0000-0001-5658-0532	Asociacion Espanola contra el Cancer (AECC); Ministerio de Economia y Competitividad (MINECO) [SAF2013-47416-R]; Instituto Salud Carlos III (ISCIII)-Fondo de Investigacion Sanitaria [RD012/0036/0060, PI16/01294, CIBERONC, PIE15/00076]; Madrid Autonomous Community	This work was supported by grants from the Asociacion Espanola contra el Cancer (AECC), the Ministerio de Economia y Competitividad (MINECO) (SAF2013-47416-R), the Instituto Salud Carlos III (ISCIII)-Fondo de Investigacion Sanitaria (RD012/0036/0060, PI16/01294, CIBERONC, PIE15/00076), and the Madrid Autonomous Community.	Aubrey-Bassler FK, 2012, BMC EMERG MED, V12, DOI 10.1186/1471-227X-12-11; Bartlett A, 2016, INJURY, V47, P531, DOI 10.1016/j.injury.2015.10.071; Evans PAS, 2007, LEUKEMIA, V21, P207, DOI 10.1038/sj.leu.2404479; Heo DH, 2017, J MED VIROL, V89, P332, DOI 10.1002/jmv.24618; Langerak AW, 2012, LEUKEMIA, V26, P2159, DOI 10.1038/leu.2012.246; Louissaint A, 2012, MODERN PATHOL, V25, P1149, DOI 10.1038/modpathol.2012.70; O'Malley DP GT, 2009, ATLAS NONTUMOR PATHO, P283; RUTKOW IM, 1978, ARCH SURG-CHICAGO, V113, P718; SMITH EB, 1946, BLOOD, V1, P317, DOI 10.1182/blood.V1.4.317.317; van Krieken JHJM, 2007, LEUKEMIA, V21, P201, DOI 10.1038/sj.leu.2404467	10	0	0	0	7	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	OCT	2018	150	4					310	317		10.1093/AJCP/AQY056			8	Pathology	Pathology	GS3SN	WOS:000443541200005	30007337				2019-10-28	
J	Arbefeville, S; Nelson, K; Thonen-Kerr, E; Ferrieri, P				Arbefeville, Sophie; Nelson, Kari; Thonen-Kerr, Elizabeth; Ferrieri, Patricia			Prospective Postimplementation Study of Solana Group A Streptococcal Nucleic Acid Amplification Test vs Conventional Throat Culture	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Pharyngitis; Group A Streptococcus; Rapid antigen detection test; Throat culture; Nucleic acid amplification test	MULTICENTER CLINICAL-EVALUATION; ANTIGEN-DETECTION; RHEUMATIC-FEVER; PHARYNGITIS; ASSAY; DIAGNOSIS; PREVENTION; PYOGENES; STREP	Objectives: We evaluated the Solana Group A Streptococcus Assay (Quidel, San Diego, CA), a nucleic acid amplification test (NAAT), as a substitute for backup culture on throat specimens with a negative rapid group A Streptococcus (GAS) antigen assay. Methods: During October 2016, all throat swabs from patients with a negative GAS antigen assay from local urgent care centers were processed by NAAT and conventional culture in real time. Results: The overall agreement of the 2,090 tested throat swab specimens of the NAAT with the culture was 2,050 (98%) of 2,090. Sensitivity, specificity, positive predictive value, and negative predictive value were 91.4%, 98.5%, 78.0%, and 99.5%, respectively. Conclusions: In summary, this postimplementation study supported high sensitivity and specificity of the GAS NAAT as a backup test for negative rapid GAS antigen tests.	[Arbefeville, Sophie; Nelson, Kari; Thonen-Kerr, Elizabeth; Ferrieri, Patricia] Univ Minnesota, Med Ctr, Infect Dis Diagnost Lab, Minneapolis, MN 55455 USA; [Arbefeville, Sophie; Nelson, Kari; Thonen-Kerr, Elizabeth; Ferrieri, Patricia] Fairview Hlth Syst, Minneapolis, MN USA; [Arbefeville, Sophie; Ferrieri, Patricia] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA	Arbefeville, S (reprint author), Univ Minnesota, Sch Med, Dept Lab Med & Pathol, MMC 609 Mayo,420 Delaware St SE, Minneapolis, MN 55455 USA.	sarbefev@umn.edu					Alcaide ML, 2007, INFECT DIS CLIN N AM, V21, P449, DOI 10.1016/j.idc.2007.03.001; Anderson NW, 2013, J CLIN MICROBIOL, V51, P1474, DOI 10.1128/JCM.00176-13; Boyanton BL, 2016, J CLIN MICROBIOL, V54, P175, DOI 10.1128/JCM.02405-15; Cohen DM, 2015, J CLIN MICROBIOL, V53, P2258, DOI 10.1128/JCM.00490-15; Dingle TC, 2014, CLIN INFECT DIS, V59, P643, DOI 10.1093/cid/ciu400; Fox JW, 2006, J CLIN MICROBIOL, V44, P3918, DOI 10.1128/JCM.01399-06; Gerber MA, 2004, CLIN MICROBIOL REV, V17, P571, DOI 10.1128/CMR.17.3.571-580.2004; GERBER MA, 1986, J PEDIATR-US, V108, P654, DOI 10.1016/S0022-3476(86)81036-8; Gerber MA, 2009, CIRCULATION, V119, P1541, DOI 10.1161/CIRCULATIONAHA.109.191959; Gurol Y, 2010, INT J PEDIATR OTORHI, V74, P591, DOI 10.1016/j.ijporl.2010.02.020; Henson AM, 2013, J CLIN MICROBIOL, V51, P4207, DOI [10.1128/JCM.01892-13, 10.1]; Kalra MG, 2016, AM FAM PHYSICIAN, V94, P24; Kolukirik M, 2016, ANN CLIN MICROB ANTI, V15, DOI 10.1186/s12941-016-0162-0; Lean WL, 2014, PEDIATRICS, V134, P771, DOI 10.1542/peds.2014-1094; Leber A., 2016, RESP TRACT CULTURES; Pritt BS, 2016, J CLIN MICROBIOL, V54, P2413, DOI 10.1128/JCM.01472-16; Shulman ST, 2012, CLIN INFECT DIS, V55, pE86, DOI [10.1093/cid/cis847, 10.1093/cid/cis629]; Spellerberg B., 2015, MANUAL CLIN MICROBIO, P383; Stewart EH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111727; Uphoff TS, 2016, J CLIN MICROBIOL, V54, P2388, DOI 10.1128/JCM.01268-16; Upton A, 2016, J CLIN MICROBIOL, V54, P153, DOI 10.1128/JCM.02440-15	21	2	2	1	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	OCT	2018	150	4					333	337		10.1093/AJCP/AQY051			5	Pathology	Pathology	GS3SN	WOS:000443541200007	29982326				2019-10-28	
J	Titus, LJ; Reisch, LM; Tosteson, ANA; Nelson, HD; Frederick, PD; Carney, PA; Barnhill, RL; Elder, DE; Weinstock, MA; Piepkorn, MW; Elmore, JG				Titus, Linda J.; Reisch, Lisa M.; Tosteson, Anna N. A.; Nelson, Heidi D.; Frederick, Paul D.; Carney, Patricia A.; Barnhill, Raymond L.; Elder, David E.; Weinstock, Martin A.; Piepkorn, Michael W.; Elmore, Joann G.			Malpractice Concerns, Defensive Medicine, and the Histopathology Diagnosis of Melanocytic Skin Lesions	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Medical malpractice; Defensive medicine; Assurance behaviors; Skin pathology; Diagnosis; Melanoma; Melanocytic skin lesions	PHYSICIANS; PATHOLOGY; TRENDS; EXPERIENCES; MELANOMA; CLAIMS; ERROR; RATES	Objectives: The impact of malpractice concerns on pathologists' use of defensive medicine and interpretations of melanocytic skin lesions (MSLs) is unknown. Methods: A total of 207 pathologists interpreting MSLs responded to a survey about past involvement in malpractice litigation, influence of malpractice concerns on diagnosis, and use of assurance behaviors (defensive medicine) to alleviate malpractice concerns. Assurance behaviors included requesting second opinions, additional slides, additional sampling, and ordering specialized tests. Results: Of the pathologists, 27.5% reported that malpractice concerns influenced them toward a more severe MSL diagnosis. Nearly all (95.2%) pathologists reported practicing at least one assurance behavior due to malpractice concerns, and this practice was associated with being influenced toward a more severe MSL diagnosis (odds ratio, 2.72; 95% confidence interval, 1.41-5.26). Conclusions: One of four US skin pathologists upgrade MSL diagnosis due to malpractice concerns, and nearly all practice assurance behaviors. Assurance behaviors are associated with rendering a more severe MSL diagnosis.	[Titus, Linda J.] Geisel Sch Med Dartmouth, Norris Cotton Canc Ctr, Dartmouth Inst Hlth Policy & Clin Practice, Dept Epidemiol, Hanover, NH USA; [Titus, Linda J.] Geisel Sch Med Dartmouth, Norris Cotton Canc Ctr, Dartmouth Inst Hlth Policy & Clin Practice, Dept Pediat, Hanover, NH USA; [Reisch, Lisa M.; Tosteson, Anna N. A.; Frederick, Paul D.] Geisel Sch Med Dartmouth, Norris Cotton Canc Ctr, Dartmouth Inst Hlth Policy & Clin Practice, Dept Med, Hanover, NH USA; [Tosteson, Anna N. A.] Geisel Sch Med Dartmouth, Norris Cotton Canc Ctr, Dartmouth Inst Hlth Policy & Clin Practice, Dept Community & Family Med, Hanover, NH USA; [Nelson, Heidi D.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA; [Nelson, Heidi D.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA; [Carney, Patricia A.] Oregon Hlth & Sci Univ, Dept Family Med, Portland, OR 97201 USA; [Barnhill, Raymond L.] Univ Paris 05, Paris Sci & Letters Res Univ, Inst Curie, Dept Pathol, Paris, France; [Elder, David E.] Hosp Univ Penn, Dept Pathol & Lab Med, 3400 Spruce St, Philadelphia, PA 19104 USA; [Weinstock, Martin A.] Rhode Isl Hosp, Providence Dept Dermatol, VA Med Ctr, Ctr Dermatoepidemiol, Providence, RI USA; [Weinstock, Martin A.] Brown Univ, Dept Dermatol, Providence, RI 02912 USA; [Weinstock, Martin A.] Brown Univ, Dept Epidemiol, Providence, RI 02912 USA; [Piepkorn, Michael W.] Univ Washington, Sch Med, Dept Med, Div Dermatol, Seattle, WA 98195 USA; [Piepkorn, Michael W.] Dermatopathol Northwest, Bellevue, WA USA; [Elmore, Joann G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA	Elmore, JG (reprint author), Univ Calif Los Angeles, 10940 Wilshire Blvd,Suite 710, Los Angeles, CA 90024 USA.	jelmore@uw.edu			National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01 CA151306, R01 CA201376]	This work was supported by the National Cancer Institute (R01 CA151306 and R01 CA201376). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	American Cancer Society, 2017, KEY STAT MEL SKIN CA; Bishop TF, 2010, ARCH INTERN MED, V170, P1081, DOI 10.1001/archinternmed.2010.155; Carney PA, 2016, J AM ACAD DERMATOL, V74, P317, DOI 10.1016/j.jaad.2015.09.037; Carrier ER, 2010, HEALTH AFFAIR, V29, P1585, DOI 10.1377/hlthaff.2010.0135; Elmore JG, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j2813; FIRTH D, 1993, BIOMETRIKA, V80, P27, DOI 10.2307/2336755; Hermer LD, 2010, J GEN INTERN MED, V25, P470, DOI 10.1007/s11606-010-1259-3; Kornstein MJ, 2007, ARCH PATHOL LAB MED, V131, P615; Krader CG, 2012, DERMATOLOGY TIMES; Lott JP, 2018, JAMA DERMATOL, V154, P24, DOI 10.1001/jamadermatol.2017.4060; Marsch A, 2012, DERMATOL CLIN, V30, P593, DOI 10.1016/j.det.2012.06.011; O'Leary KJ, 2012, ACAD MED, V87, P142, DOI 10.1097/ACM.0b013e31823f2c86; Paik M, 2013, J EMPIR LEGAL STUD, V10, P612, DOI 10.1111/jels.12021; Reisch LM, 2015, AM J CLIN PATHOL, V144, P916, DOI 10.1309/AJCP80LYIMOOUJIF; Schaffer AC, 2017, JAMA INTERN MED, V177, P710, DOI 10.1001/jamainternmed.2017.0311; Studdert DM, 2005, JAMA-J AM MED ASSOC, V293, P2609, DOI 10.1001/jama.293.21.2609; Summerton N, 2000, BRIT J GEN PRACT, V50, P565; Troxel DB, 2012, AM J SURG PATHOL, V36, pE1, DOI 10.1097/PAS.0b013e31823836bb; Troxel DB, 2006, ARCH PATHOL LAB MED, V130, P617; Welch HG, 2005, BRIT MED J, V331, P481, DOI 10.1136/bmj.38516.649537.E0	20	0	0	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	OCT	2018	150	4					338	345		10.1093/AJCP/AQY057			8	Pathology	Pathology	GS3SN	WOS:000443541200008	30007278	Green Published			2019-10-28	
J	Young, S; Griego-Fullbright, C; Wagner, A; Chargin, A; Patterson, BK; Chabot-Richards, D				Young, Stephen; Griego-Fullbright, Christen; Wagner, Aaron; Chargin, Amanda; Patterson, Bruce K.; Chabot-Richards, Devon			Concordance of PD-L1 Expression Detection in Non-Small Cell Lung Cancer (NSCLC) Tissue Biopsy Specimens Between OncoTect iO Lung Assay and Immunohistochemistry (IHC)	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						PD-L1 quantification; TIL quantification; Aneuploidy; NSCLC; Flow cytometry; Single cells	TUMOR-INFILTRATING LYMPHOCYTES; QUANTIFICATION; BIOMARKER	Objectives: We report on the validity of a fully quantitative technology to determine tumor cells' PD-L1 expression compared with a standard immunohistochemical (IHC) assay in non-small cell lung cancer. Methods: Nineteen fresh tissue specimens were processed into single-cell suspensions using the IncellPREP Kit. Cells were treated with the OncoTect iO Lung Assay, which quantitatively assessed tumor-infiltrating lymphocytes (TILs), DNA content, and PD-L1 expression on diploid and aneuploid tumor populations. Results: Comparison of the OncoTect iO Lung Assay with IHC revealed a concordance of 95% overall (negative percent agreement, 97%; positive percent agreement, 89%). PD-L1 expression varied depending on the DNA content. The number of TILs and antigen-presenting cells (APCs) was significantly decreased in tumor compared with normal lung tissue. Conclusions: The nonsubjective OncoTect iO Lung Assay has been shown to be at least as accurate and sensitive as IHC for the detection of PD-L1 expression while providing additional information to guide treatment.	[Young, Stephen; Griego-Fullbright, Christen; Wagner, Aaron; Chabot-Richards, Devon] TriCore Reference Labs, Albuquerque, NM USA; [Chargin, Amanda; Patterson, Bruce K.] IncellDx, 1700 El Camino, Menlo Pk, CA 94027 USA	Patterson, BK (reprint author), IncellDx, 1700 El Camino, Menlo Pk, CA 94027 USA.	brucep@incelldx.com					Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Chargin A, 2016, CANCER IMMUNOL IMMUN, V65, P1317, DOI 10.1007/s00262-016-1889-3; Chen F, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0278-7; Choma D, 2001, BRIT J CANCER, V85, P14, DOI 10.1054/bjoc.2001.1892; Curiel TJ, 2003, NAT MED, V9, P562, DOI 10.1038/nm863; Djenidi F, 2015, J IMMUNOL, V194, P3475, DOI 10.4049/jimmunol.1402711; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Francisco LM, 2009, J EXP MED, V206, P3015, DOI 10.1084/jem.20090847; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Geng YT, 2015, CELL PHYSIOL BIOCHEM, V37, P1560, DOI 10.1159/000438523; Gettinger SN, 2012, J CLIN ONCOL, V30; Grigg C, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0153-x; Hussong JW, 2010, ARCH PATHOL LAB MED, V134, pE40, DOI 10.1043/1543-2165-134.6.e40; Kasprzyk M, 2006, LUNG CANCER, V51, P201, DOI 10.1016/j.lungcan.2005.10.014; Mu CY, 2011, MED ONCOL, V28, P682, DOI 10.1007/s12032-010-9515-2; NICOLSON GL, 1987, CANCER RES, V47, P1473; Obeid JM, 2017, CANCER IMMUNOL IMMUN, V66, P33, DOI 10.1007/s00262-016-1908-4; Patel SP, 2015, MOL CANCER THER, V14, P847, DOI 10.1158/1535-7163.MCT-14-0983; Sharpe AH, 2007, NAT IMMUNOL, V8, P239, DOI 10.1038/ni1443; Suzuki S, 2016, JPN J CLIN ONCOL, V46, P191, DOI 10.1093/jjco/hyv201; Velcheti V, 2014, LAB INVEST, V94, P107, DOI 10.1038/labinvest.2013.130	21	0	0	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	OCT	2018	150	4					346	352		10.1093/AJCP/AQY063			7	Pathology	Pathology	GS3SN	WOS:000443541200009	30052717				2019-10-28	
J	Celli, R; Barbieri, AL; Colunga, M; Sinard, J; Gibson, JA				Celli, Romulo; Barbieri, Andrea L.; Colunga, Monica; Sinard, John; Gibson, Joanna A.			Optimal Intraoperative Assessment of Gastric Margins	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Intraoperative consultation; Frozen section; Gastric margin; Gastrectomy; Adenocarcinoma	RESECTION-LINE INVOLVEMENT; ESOPHAGOGASTRIC JUNCTION; CANCER SURGERY; FROZEN-SECTION; SURGICAL-MANAGEMENT; PROGNOSTIC IMPACT; ADENOCARCINOMA; ESOPHAGEAL; GASTRECTOMY; SURVIVAL	Objectives: Intraoperative pathology consultation (IOC) to assess margins is frequently requested during surgery of the stomach and gastroesophageal junction. Methods: We studied 110 consecutive patients undergoing gastrectomy with IOC margin assessment. Results: Gastric margins at IOC utilized the most blocks but were least often positive. In 64% of patients, the entire gastric margin was examined using average six blocks; representative sections were examined in 25% of patients using two blocks. There was no difference in patient outcome between those who had entire vs representative sections of margin examined. Gross variables showing strongest associations with positive margins were tumor size and tumor distance to margin. Tumors sized greater than 2.3 cm had significantly increased risk of positive margin, and tumor distance greater than 4.5 cm to margin was associated with negative margins. Conclusions: We conclude representative sections of the closest gastric margin are sufficient to ensure R0 resection in the majority of cases.	[Celli, Romulo; Barbieri, Andrea L.; Sinard, John; Gibson, Joanna A.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; [Colunga, Monica] Yale Univ, Sch Publ Hlth, New Haven, CT USA	Gibson, JA (reprint author), Yale Univ, Sch Med, Yale New Haven Hosp, Dept Pathol, 20 York St,EP2-610, New Haven, CT 06510 USA.	joanna.gibson@yale.edu		Gibson, Joanna/0000-0003-0406-4872			Ajani JA, 2016, J NATL COMPR CANC NE, V14, P1286, DOI 10.6004/jnccn.2016.0137; Ajani JA, 2011, J NATL COMPR CANC NE, V9, P830, DOI 10.6004/jnccn.2011.0072; Allum WH, 2011, GUT, V60, P1449, DOI 10.1136/gut.2010.228254; Aurello P, 2014, ANTICANCER RES, V34, P6283; Barbour AP, 2007, ANN SURG, V246, P1, DOI 10.1097/01.sla.0000255563.65157.d2; Bickenbach KA, 2013, ANN SURG ONCOL, V20, P2663, DOI 10.1245/s10434-013-2950-5; Bissolati M, 2017, GASTRIC CANCER, V20, P70, DOI 10.1007/s10120-015-0589-6; Bosman FT, 2010, WHO CLASSIFICATION T; BOZZETTI F, 1982, ANN SURG, V196, P685, DOI 10.1097/00000658-198212001-00012; Cascinu S, 1999, JPN J CLIN ONCOL, V29, P291, DOI 10.1093/jjco/29.6.291; Chen JD, 2013, EJSO-EUR J SURG ONC, V39, P229, DOI 10.1016/j.ejso.2012.08.004; Cho BC, 2007, J SURG ONCOL, V95, P461, DOI 10.1002/jso.20731; Edge SB, 2010, AJCC CANC STAGING MA; FERREIRO JA, 1995, MAYO CLIN PROC, V70, P1137, DOI 10.4065/70.12.1137; Gunderson LL, 2002, SEMIN RADIAT ONCOL, V12, P150, DOI 10.1053/srao.2002.30817; Japanese Gastric Canc Assoc, 2017, GASTRIC CANCER, V20, P1, DOI 10.1007/s10120-016-0622-4; Japanese Gastric Cancer Association, 2011, Gastric Cancer, V14, P113, DOI 10.1007/s10120-011-0042-4; Kim SY, 2012, J GASTRIC CANCER, V12, P113, DOI 10.5230/jgc.2012.12.2.113; Kim SH, 1999, J GASTROINTEST SURG, V3, P24, DOI 10.1016/S1091-255X(99)80004-3; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Lester SC., 2010, MANUAL SURG PATHOLOG; Makris EA, 2017, SURG CLIN N AM, V97, P295, DOI 10.1016/j.suc.2016.11.006; Marchevsky AM, 2015, INTRAOPERATIVE CONSU; Mariette C, 2002, BRIT J SURG, V89, P1156, DOI 10.1046/j.1365-2168.2002.02185.x; Morgagni P, 2008, WORLD J SURG, V32, P2661, DOI 10.1007/s00268-008-9747-x; Nagata T, 2011, J SURG ONCOL, V104, P592, DOI 10.1002/jso.22022; NAKAMURA K, 1992, CANCER, V70, P1030, DOI 10.1002/1097-0142(19920901)70:5<1030::AID-CNCR2820700504>3.0.CO;2-C; Novis DA, 1997, ARCH PATHOL LAB MED, V121, P559; PAPACHRISTOU DN, 1980, AM J SURG, V139, P711, DOI 10.1016/0002-9610(80)90369-4; Postlewait LM, 2016, J SURG ONCOL, V113, P277, DOI 10.1002/jso.24110; Postlewait LM, 2015, J SURG ONCOL, V112, P203, DOI 10.1002/jso.23971; Raziee HR, 2012, GASTRIC CANCER, V15, pS116, DOI 10.1007/s10120-011-0112-7; Samson PS, 2002, WORLD J SURG, V26, P428, DOI 10.1007/s00268-001-0243-9; SCHROCK TR, 1978, AM J SURG, V135, P348, DOI 10.1016/0002-9610(78)90064-8; Shen JG, 2006, HEPATO-GASTROENTEROL, V53, P976; Shen JG, 2006, WORLD J GASTROENTERO, V12, P3883, DOI 10.3748/wjg.v12.i24.3883; Shin D, 2013, WORLD J GASTRO ONCOL, V5, P4, DOI 10.4251/wjgo.v5.i1.4; Siewert JR, 2000, ANN SURG, V232, P353; Siewert JR, 1998, ANN SURG, V228, P449, DOI 10.1097/00000658-199810000-00002; Spicer J, 2014, ANN SURG ONCOL, V21, P2580, DOI 10.1245/s10434-014-3669-7; Wang SY, 2009, ANN SURG ONCOL, V16, P2738, DOI 10.1245/s10434-009-0616-0; YOKOTA T, 1993, J SURG ONCOL, V53, P60, DOI 10.1002/jso.2930530115; Zheng HC, 2008, VIRCHOWS ARCH, V452, P525, DOI 10.1007/s00428-007-0572-7	43	0	0	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	OCT	2018	150	4					353	363		10.1093/AJCP/AQY062			11	Pathology	Pathology	GS3SN	WOS:000443541200010	30020407				2019-10-28	
J	Speck, O; Appelman, HD; Owens, SR				Speck, Olga; Appelman, Henry D.; Owens, Scott R.			Mid- and Deep-Zone Gastritis A Histologic Pattern Associated With Autoimmune Disease but Distinct From Autoimmune Atrophic Gastritis	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Gastritis; Autoimmune; Helicobacter pylori	HELICOBACTER-PYLORI INFECTION; NEGATIVE GASTRITIS; FOLLOW-UP; MUCOSA; MANIFESTATIONS; AUTOANTIBODIES; ERADICATION; PREVALENCE; DYSPEPSIA; THERAPY	Objectives: We sought to characterize a histologic pattern of mid- and deep-zone gastritis, distinct from the typical pattern of Helicobacter pylori or autoimmune gastritis and to see if it had any clinicopathologic association(s). Methods: We analyzed inflammatory patterns and composition, excluded autoimmune gastritis using immunohistochemistry, and reviewed the medical record for demographics, medical/surgical history, presenting symptoms, endoscopic findings, and medications for 28 cases. Results: All cases had inflammation in the middle and/or deep mucosal zones with sparing of the superficial/pit compartment. Subfeatures included corpus or antral predominance, pangastric involvement, prominence of a subset(s) of inflammatory cells, and degree of epithelial injury. Of 28 patients, 13 had autoimmune disease(s), autoantibodies, or both. There was no other unifying clinical feature. Conclusions: This unique pattern of gastritis should be distinguished from other entities such as H pylori and autoimmune gastritis. At least a subset may be an autoimmune condition different from classic autoimmune gastritis.	[Speck, Olga; Appelman, Henry D.; Owens, Scott R.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA	Owens, SR (reprint author), Univ Michigan, Dept Pathol, Med Sci 1 M5224, 1301 Catherine St, Ann Arbor, MI 48109 USA.	srowens@med.umich.edu					Annibale B, 2001, HELICOBACTER, V6, P225, DOI 10.1046/j.1083-4389.2001.00032.x; BLACK DD, 1988, J PEDIATR GASTR NUTR, V7, P353, DOI 10.1097/00005176-198805000-00007; Bordi C, 1997, J PATHOL, V182, P339, DOI 10.1002/(SICI)1096-9896(199707)182:3<339::AID-PATH854>3.0.CO;2-V; BURMAN P, 1992, GASTROENTEROLOGY, V103, P934, DOI 10.1016/0016-5085(92)90027-V; De Block CEM, 1999, J CLIN ENDOCR METAB, V84, P4062, DOI 10.1210/jc.84.11.4062; Ebert EC, 2012, J CLIN GASTROENTEROL, V46, P25, DOI 10.1097/MCG.0b013e3182329d9c; Elitsur Y, 2013, AM J GASTROENTEROL, V108, P1182, DOI 10.1038/ajg.2013.153; ELTA GH, 1987, AM J GASTROENTEROL, V82, P749; GENTA RM, 1993, MODERN PATHOL, V6, P281; Genta RM, 2010, AM J SURG PATHOL, V34, pE25, DOI 10.1097/PAS.0b013e3181e51067; Haber MM, 2010, ALIMENT PHARM THER, V32, P83, DOI 10.1111/j.1365-2036.2010.04310.x; Jevremovic D, 2006, AM J SURG PATHOL, V30, P1412, DOI 10.1097/01.pas.0000213337.25111.37; JONSSON KA, 1989, SCAND J GASTROENTERO, V24, P385, DOI 10.3109/00365528909093064; Kyzekova J, 1999, HEPATO-GASTROENTEROL, V46, P2048; Lin JM, 2010, AM J SURG PATHOL, V34, P1672, DOI 10.1097/PAS.0b013e3181f3de93; McKenna BJ, 2006, NAT CLIN PRACT GASTR, V3, P165, DOI 10.1038/ncpgasthep0420; Muller H, 2001, DIGESTION, V64, P30, DOI 10.1159/000048836; Nordenstedt H, 2013, AM J GASTROENTEROL, V108, P65, DOI 10.1038/ajg.2012.372; Picceli VF, 2013, LUPUS, V22, P1150, DOI 10.1177/0961203313503911; Presotto F, 2003, HELICOBACTER, V8, P578, DOI 10.1111/j.1523-5378.2003.00187.x; Rindi G, 2005, EUR J GASTROEN HEPAT, V17, P559, DOI 10.1097/00042737-200505000-00013; STOLTE M, 1992, Z GASTROENTEROL, V30, P729; Teufel A, 2010, J CLIN GASTROENTEROL, V44, P208, DOI 10.1097/MCG.0b013e3181c74e0d; Torbenson M, 2002, MODERN PATHOL, V15, P102, DOI 10.1038/modpathol.3880499; Veijola LI, 2010, WORLD J GASTROENTERO, V16, P83, DOI 10.3748/wjg.v16.i1.83; Visser WE, 2013, ENDOCRIN METAB CLIN, V42, P287, DOI 10.1016/j.ecl.2013.02.008; Vorobjova T, 2000, VIRCHOWS ARCH, V437, P37, DOI 10.1007/s004280000202	27	0	0	0	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	OCT	2018	150	4					364	374		10.1093/AJCP/AQY065			11	Pathology	Pathology	GS3SN	WOS:000443541200011	30032289				2019-10-28	
J	Bharani, V; Kakkar, N; Mahajan, V; Azad, C				Bharani, Vani; Kakkar, Nandita; Mahajan, Vidushi; Azad, Chandrika			Subcutaneous Fat Necrosis of Newborn: Unfamiliar Histomorphology of a Familiar Lesion	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Editorial Material									[Bharani, Vani; Kakkar, Nandita] Postgrad Inst Med Educ & Res, Chandigarh, India; [Mahajan, Vidushi; Azad, Chandrika] Govt Med Coll & Hosp, Chandigarh, Punjab, India	Kakkar, N (reprint author), Postgrad Inst Med Educ & Res, Dept Histopathol, Chandigarh 160012, India.	nandita_kakkar@yahoo.com					Grewal SK, 2016, SUBCUTANEOUS FAT NEC; James WD, 2016, DIS SUBCUTANEOUS FAT, P484; Mahe E, 2007, BRIT J DERMATOL, V156, P709, DOI 10.1111/j.1365-2133.2007.07782.x; Pai SA, 2007, INDIAN J DERMATOL VE, V73, P357, DOI 10.4103/0378-6323.35747	4	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	OCT	2018	26	7					621	622		10.1177/1066896917751052			2	Pathology; Surgery	Pathology; Surgery	GS5TF	WOS:000443733000006	29336186				2019-10-28	
J	Mundi, I; Pankaj, R; Grover, G; Chhabra, M				Mundi, Irneet; Pankaj, Ritu; Grover, Geetanjali; Chhabra, Mohinish			Blue Beads on the Duodenal Surface: Cause of Diarrhea in a Renal Transplant Recipient	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Editorial Material							CRYPTOSPORIDIOSIS		[Mundi, Irneet; Pankaj, Ritu; Grover, Geetanjali; Chhabra, Mohinish] Fortis Hosp Mohali, Mohali, India	Mundi, I (reprint author), Fortis Hosp, Dept Lab Med, Phase 8, Mohali 160062, India.	irneet04@yahoo.co.in		Mundi, Irneet/0000-0003-0983-6771			Florescu Diana F, 2016, World J Transplant, V6, P460, DOI 10.5500/wjt.v6.i3.460; Ogata S, 2009, ACTA MED OKAYAMA, V63, P287; Shirley DAT, 2012, CURR OPIN INFECT DIS, V25, P555, DOI 10.1097/QCO.0b013e328357e569; Tran MQ, 2005, CLIN NEPHROL, V63, P305	4	0	0	1	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	OCT	2018	26	7					623	624		10.1177/1066896918755918			2	Pathology; Surgery	Pathology; Surgery	GS5TF	WOS:000443733000007	29390930				2019-10-28	
J	Mengoli, MC; Zanelli, M; Zizzo, M; Giunta, A; Cerami, LB; Cavazza, A; Mengoli, MC; De Marco, L				Mengoli, Maria Cecilia; Zanelli, Magda; Zizzo, Maurizio; Giunta, Alessandro; Cerami, Lillo Bruno; Cavazza, Alberto; Mengoli, Maria Chiara; De Marco, Loredana			Placental Tissue in Colon and Liver	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Editorial Material							AMNIOTIC-FLUID EMBOLISM		[Mengoli, Maria Cecilia; Zanelli, Magda; Zizzo, Maurizio; Giunta, Alessandro; Cerami, Lillo Bruno; Cavazza, Alberto; De Marco, Loredana] IRCCS, Azienda Unita Sanit Locale, Reggio Emilia, Italy; [Zizzo, Maurizio] Univ Modena & Reggio Emilia, Clin & Expt Med PhD Program, Modena, Italy; [Mengoli, Maria Chiara] Univ Modena & Reggio Emilia, Sch Med, Modena, Italy	Mengoli, MC (reprint author), IRCCS, Azienda Unita Sanit Locale, Pathol Unit, Viale Risorgimento 80, I-42123 Reggio Emilia, Italy.	cecilia.mengoli@gmail.com	Cavazza, Alberto/K-2531-2018	Cavazza, Alberto/0000-0003-3590-319X; zanelli, Magda/0000-0002-8733-9933; Zizzo, Maurizio/0000-0001-9841-7856; Mengoli, Maria Cecilia/0000-0002-1437-8747			Balazic J, 2003, INT J LEGAL MED, V117, P165, DOI 10.1007/s00414-003-0368-5; Benson MD, 2014, OBSTET MED, V7, P17, DOI 10.1177/1753495X13513578; CLARK SL, 1995, AM J OBSTET GYNECOL, V172, P1158, DOI 10.1016/0002-9378(95)91474-9; Kamoi S, 2003, INT J GYNECOL PATHOL, V22, P303, DOI 10.1097/01.PGP.0000054822.24312.59; Sinicina I, 2010, INT J LEGAL MED, V124, P55, DOI 10.1007/s00414-009-0351-x	5	0	0	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	OCT	2018	26	7					625	626		10.1177/1066896918757913			2	Pathology; Surgery	Pathology; Surgery	GS5TF	WOS:000443733000008	29444594				2019-10-28	
J	Podoll, MB; Singh, K; Quddus, MR				Podoll, Mirna B.; Singh, Kamaljeet; Quddus, M. Ruhul			Endometrial Pneumatosis	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Editorial Material							PNEUMOPOLYCYSTIC ENDOMETRITIS		[Podoll, Mirna B.; Singh, Kamaljeet; Quddus, M. Ruhul] Brown Univ, Women & Infants Hosp Rhode Isl, Alpert Med Sch, Providence, RI 02912 USA	Singh, K (reprint author), Brown Univ, Women & Infants Hosp Rhode Isl, Alpert Med Sch, Dept Pathol, 101 Dudley St, Providence, RI 02905 USA.	ksingh@wihri.com		Singh, Kamaljeet/0000-0002-2506-5703			Chua YJ, 2014, INT J GYNECOL PATHOL, V33, P511, DOI 10.1097/PGP.0000000000000090; DYLEWSKI J, 1989, REV INFECT DIS, V11, P470; MURAM D, 1990, AM J OBSTET GYNECOL, V162, P1282, DOI 10.1016/0002-9378(90)90037-8; PERKINS MB, 1960, AM J OBSTET GYNECOL, V80, P332; Val-Bernal JF, 2006, AM J SURG PATHOL, V30, P258, DOI 10.1097/01.pas.0000179236.91515.c8	5	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	OCT	2018	26	7					627	628		10.1177/1066896918760193			2	Pathology; Surgery	Pathology; Surgery	GS5TF	WOS:000443733000009	29529911				2019-10-28	
J	Dennis, K; O'Neil, M; Harrington, A				Dennis, Katie; O'Neil, Maura; Harrington, Anthony			Not all neck mass fine-needle aspirations with squamous cells are squamous cell carcinoma; report of a case of recurrent thyroid carcinoma with papillary and squamous components	CYTOJOURNAL			English	Article						Fine-needle aspiration; neck mass; papillary thyroid carcinoma; squamous cell carcinoma		We report a case of a 65-year-old female who had a total thyroidectomy 12 years ago for papillary thyroid carcinoma (PTC) who presented with a recurrent thyroid bed mass. Fine-needle aspiration biopsy yielded malignant cells, consistent with squamous cell carcinoma (SCCa). Surgical resection was performed, and histologic evaluation of the mass showed mixed PTC and SCCa. The tumor cells were positive for BRAF V600E mutation. Thyroid carcinomas with admixed papillary carcinoma and SCCa are rare and are associated with aggressive behavior, high rates of metastasis, and poor outcomes. Although SCCa presenting as a neck mass is relatively common, clinical history and appropriate workup are essential for accurate diagnosis and determination of origin.	[Dennis, Katie; O'Neil, Maura; Harrington, Anthony] Univ Kansas, Sch Med, Dept Pathol & Lab Med, 3901 Rainbow Blvd, Kansas City, KS 66160 USA	Dennis, K (reprint author), Univ Kansas, Sch Med, Dept Pathol & Lab Med, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.	kdennis2@kumc.edu; maurafoneil@gmail.com; aharrington2@kumc.edu					BRONNER MP, 1991, MODERN PATHOL, V4, P637; Ito Y, 2012, J THROID RES, DOI 10.1155/2012/230283; Kitahara S, 2006, SURG TODAY, V36, P171, DOI 10.1007/s00595-005-3107-3; Kleer CG, 2000, MODERN PATHOL, V13, P742, DOI 10.1038/modpathol.3880129; Lee JI, 2013, INTERNAL MED, V52, P1593, DOI 10.2169/internalmedicine.52.9310; MIYAUCHI A, 1985, WORLD J SURG, V9, P128, DOI 10.1007/BF01656263; Rausch T, 2010, PATHOL RES PRACT, V206, P263, DOI 10.1016/j.prp.2009.05.003; Syed MI, 2011, J LARYNGOL OTOL, V125, P3, DOI 10.1017/S0022215110002070	8	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0974-5963	1742-6413		CYTOJOURNAL	CytoJournal	SEP 21	2018	15								23	10.4103/cytojournal.cytojournal_19_17			5	Pathology	Pathology	HI1AD	WOS:000456175200002	30294355	DOAJ Gold, Green Published			2019-10-28	
J	Layfield, LJ; Esebua, M; Dodd, L; Giorgadze, T; Schmidt, RL				Layfield, Lester J.; Esebua, Magda; Dodd, Leslie; Giorgadze, Tamar; Schmidt, Robert L.			The Papanicolaou Society of Cytopathology guidelines for respiratory cytology: Reproducibility of categories among observers	CYTOJOURNAL			English	Article						Endobronchial ultrasound guided; fine needle aspirates; lung; Papanicolaou Society of Cytopathology guidelines; reproducibility; respiratory cytology	INTEROBSERVER REPRODUCIBILITY; STANDARDIZED TERMINOLOGY; THYROID CYTOPATHOLOGY; DIAGNOSTIC-ACCURACY; BETHESDA SYSTEM; AGREEMENT; NOMENCLATURE; MALIGNANCY; LESIONS	Introduction: The Papanicolaou Society of Cytopathology (PSC) has developed a set of guidelines for reporting respiratory cytology. While the malignancy risk for each category is known, the interobserver reproducibility of these diagnostic categories has not been well described. Methods: Fifty-five cytologic specimens obtained by fine needle aspiration from the pulmonary nodules were independently reviewed by four board-certified cytopathologists and assigned to the diagnostic categories described by the PSC guidelines for respiratory specimens. Statistical analysis for diagnostic accuracy was performed for absolute agreement and chance-corrected agreement (kappa). Differences in frequency of distribution of diagnoses between raters were assessed using the Kruskal-Wallis test. Results: No significant differences in distribution of scores by raters were observed. On average, the absolute agreement was 49.5% and the chance-corrected agreement (kappa) was 20%. 34.5% of interrater comparisons were in full agreement, and total lack of agreement between the four categories was found in 3% of cases. Combining the "suspicious for malignancy" category with the "malignant" category did not significantly alter interrater agreement statistics. Conclusions: The PSC categories showed only fair reproducibility among four cytopathologists. Agreement between raters was at best fair and did not improve significantly when the categories "suspicious for malignancy" and "malignant" were combined. The most common source of disagreement appeared to be between the categories "suspicious" and "malignant."	[Layfield, Lester J.; Esebua, Magda] Univ Missouri, Dept Pathol & Anat Sci, Columbia, MO 65212 USA; [Dodd, Leslie] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; [Giorgadze, Tamar] Med Coll Wisconsin, Dept Pathol & Lab Med, Milwaukee, WI 53226 USA; [Schmidt, Robert L.] Univ Utah, Dept Pathol & Arup Labs, Salt Lake City, UT 84112 USA	Layfield, LJ (reprint author), Univ Missouri, Dept Pathol & Anat Sci, Columbia, MO 65212 USA.	layfieldl@health.missouri.edu; esebuam@health.missouri.edu; leslie.dodd@unchealth.unc.edu; tgiorgadze@mcw.edu; robert.schmidt@hsc.utah.edu					Ahmed S, 2013, J PAK MED ASSOC, V63, P1252; Baloch ZW, 2008, DIAGN CYTOPATHOL, V36, P425, DOI 10.1002/dc.20830; Bhasin TS, 2013, J CLIN DIAGN RES, V7, P1051, DOI 10.7860/JCDR/2013/5754.3087; Bossuyt PM, 2003, CLIN CHEM, V49, P7, DOI 10.1373/49.1.7; Bossuyt PM, 2003, CLIN CHEM, V49, P1, DOI 10.1373/49.1.1; Clary KM, 2005, ACTA CYTOL, V49, P378, DOI 10.1159/000326169; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Crippa S, 2012, AM J CLIN PATHOL, V137, P833, DOI 10.1309/AJCP5AKCU3VHVXCL; Crippa S, 2010, AM J CLIN PATHOL, V134, P343, DOI 10.1309/AJCPXM9WIRQ8JZBJ; FDA, 2007, STAT GUID REP RES ST; Gerhard R, 2007, CYTOPATHOLOGY, V18, P105, DOI 10.1111/j.1365-2303.2006.00430.x; Kottner J, 2011, J CLIN EPIDEMIOL, V64, P96, DOI 10.1016/j.jclinepi.2010.03.002; Layfield LJ, 2016, DIAGN CYTOPATHOL, V44, P399, DOI 10.1002/dc.23457; Layfield LJ, 2015, DIAGN CYTOPATHOL, V43, P892, DOI 10.1002/dc.23326; Layfield LJ, 2015, DIAGN CYTOPATHOL, V43, P797, DOI 10.1002/dc.23305; Pitman MB, 2014, DIAGN CYTOPATHOL, V42, P338, DOI 10.1002/dc.23092; Schmidt RL, 2013, ARCH PATHOL LAB MED, V137, P558, DOI 10.5858/arpa.2012-0198-RA; Shinkins B, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2778	18	1	1	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0974-5963	1742-6413		CYTOJOURNAL	CytoJournal	SEP 21	2018	15								22	10.4103/cytojournal.cytojournal_4_18			9	Pathology	Pathology	HI1AD	WOS:000456175200001	30294354	DOAJ Gold, Green Published			2019-10-28	
J	Homeyer, A; Hammad, S; Schwen, LO; Dahmen, U; Hofener, H; Gao, Y; Dooley, S; Schenk, A				Homeyer, Andre; Hammad, Seddik; Schwen, Lars Ole; Dahmen, Uta; Hoefener, Henning; Gao, Yan; Dooley, Steven; Schenk, Andrea			Focused scores enable reliable discrimination of small differences in steatosis	DIAGNOSTIC PATHOLOGY			English	Article						Automated image analysis; Fatty liver; Heterogeneity; Histology; Hotspot analysis; Steatosis; Tile-based analysis	FATTY LIVER-DISEASE; IMAGE-ANALYSIS; HEPATIC STEATOSIS; HETEROGENEITY; QUANTIFICATION; CHALLENGES; PATHOLOGY; PATTERNS	Background: Automated image analysis enables quantitative measurement of steatosis in histological images. However, spatial heterogeneity of steatosis can make quantitative steatosis scores unreliable. To improve the reliability, we have developed novel scores that are "focused" on steatotic tissue areas. Methods: Focused scores use concepts of tile-based hotspot analysis in order to compute statistics about steatotic tissue areas in an objective way. We evaluated focused scores on three data sets of images of rodent liver sections exhibiting different amounts of dietary-induced steatosis. The same evaluation was conducted with the standard steatosis score computed by most image analysis methods. Results: The standard score reliably discriminated large differences in steatosis (intraclass correlation coefficient ICC = 0.86), but failed to discriminate small (ICC = 0.54) and very small (ICC = 0.14) differences. With an appropriate tile size, mean-based focused scores reliably discriminated large (ICC = 0.92), small (ICC = 0.86) and very small (ICC = 0.83) differences. Focused scores based on high percentiles showed promise in further improving the discrimination of very small differences (ICC = 0.93). Conclusions: Focused scores enable reliable discrimination of small differences in steatosis in histological images. They are conceptually simple and straightforward to use in research studies.	[Homeyer, Andre; Schwen, Lars Ole; Hoefener, Henning; Schenk, Andrea] Fraunhofer MEVIS, Fallturm 1, D-28359 Bremen, Germany; [Hammad, Seddik; Gao, Yan; Dooley, Steven] Heidelberg Univ, Med Fac Mannheim, Dept Med 2, Sect Mol Hepatol, D-68167 Mannheim, Germany; [Hammad, Seddik] South Valley Univ, Fac Vet Med, Dept Forens Med & Toxicol, Qena 83523, Egypt; [Dahmen, Uta] Jena Univ Hosp, Dept Gen Visceral & Vasc Surg, Drackendorfer Str 1, D-07747 Jena, Germany	Homeyer, A (reprint author), Fraunhofer MEVIS, Fallturm 1, D-28359 Bremen, Germany.	andre.homeyer@mevis.fraunhofer.de		Homeyer, Andre/0000-0002-9910-7136; Schwen, Lars Ole/0000-0003-0195-9603; Hofener, Henning/0000-0002-6375-0234	German Federal Ministry of Education and Research (BMBF) via the LiSyM network [031L0040, 031L0043]; Fraunhofer Society via the QuantMed project	This work was funded by the German Federal Ministry of Education and Research (BMBF) via the LiSyM network (grant numbers 031L0040 and 031L0043) and by the Fraunhofer Society via the QuantMed project.	Batool N, 2016, 2016 6 INT C IM PROC, P1; Brunt EM, 2007, MODERN PATHOL, V20, pS40, DOI 10.1038/modpathol.3800680; Catta-Preta M, 2011, VIRCHOWS ARCH, V459, P477, DOI 10.1007/s00428-011-1147-1; Christgen M, 2015, HUM PATHOL, V46, P1341, DOI 10.1016/j.humpath.2015.05.016; de Vet HCW, 2003, J CLIN EPIDEMIOL, V56, P1137, DOI 10.1016/j.jclinepi.2003.08.012; Decarie PO, 2011, INSIGHTS IMAGING, V2, P533, DOI 10.1007/s13244-011-0112-5; Fava GA, 2012, INT J CLIN PRACT, V66, P11, DOI 10.1111/j.1742-1241.2011.02825.x; Fox SB, 2004, APMIS, V112, P413, DOI 10.1111/j.1600-0463.2004.apm11207-0803.x; Fujii M, 2013, MED MOL MORPHOL, V46, P141, DOI 10.1007/s00795-013-0016-1; Homeyer A, 2017, DIAGN PATHOL, V12, DOI 10.1186/s13000-017-0671-y; Kendall MG, 1945, BIOMETRIKA, V33, P239, DOI 10.1093/biomet/33.3.239; Kleiner DE, 2012, SEMIN LIVER DIS, V32, P3, DOI 10.1055/s-0032-1306421; Kong J, 2011, IEEE INT C BIOINFORM, P333, DOI 10.1109/BIBM.2011.37; Lee MJ, 2013, PATHOL RES PRACT, V209, P371, DOI 10.1016/j.prp.2013.04.001; Li M, 2011, HUM PATHOL, V42, P356, DOI 10.1016/j.humpath.2010.07.013; Li M, 2018, BMC CANCER, V18, DOI 10.1186/s12885-017-3916-y; Miele L, 2017, EUR REV MED PHARMACO, V21, P86; Nawaz S, 2015, MODERN PATHOL, V28, P766, DOI 10.1038/modpathol.2015.37; Norman GR, 2008, HEALTH QUAL LIFE OUT, V6, DOI 10.1186/1477-7525-6-81; O'Connor JPB, 2015, CLIN CANCER RES, V21, P249, DOI 10.1158/1078-0432.CCR-14-0990; Plancoulaine B, 2015, VIRCHOWS ARCH, V467, P711, DOI 10.1007/s00428-015-1865-x; Ramachandran R, 2009, J CLIN PATHOL, V62, P481, DOI 10.1136/jcp.2008.058248; Schwen LO, 2016, COMPUT BIOL MED, V73, P108, DOI 10.1016/j.compbiomed.2016.04.004; Shaker M, 2014, WORLD J GASTROENTERO, V20, P5320, DOI 10.3748/wjg.v20.i18.5320; Volzke H, 2012, WORLD J GASTROENTERO, V18, P3492, DOI 10.3748/wjg.v18.i27.3492; Yersiz H, 2013, LIVER TRANSPLANT, V19, P437, DOI 10.1002/lt.23615	26	0	0	0	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	SEP 20	2018	13								76	10.1186/s13000-018-0753-5			9	Pathology	Pathology	GU4YB	WOS:000445290200001	30231920	DOAJ Gold, Green Published			2019-10-28	
J	Gagne, A; Tetu, B; Orain, M; Turcotte, S; Plante, M; Gregoire, J; Renaud, MC; Bairati, I; Trudel, D				Gagne, Andreanne; Tetu, Bernard; Orain, Michele; Turcotte, Stephane; Plante, Marie; Gregoire, Jean; Renaud, Marie-Claude; Bairati, Isabelle; Trudel, Dominique			HtrA1 expression and the prognosis of high-grade serous ovarian carcinoma: a cohort study using digital analysis (vol 13, 57, 2018)	DIAGNOSTIC PATHOLOGY			English	Correction									[Gagne, Andreanne; Tetu, Bernard; Orain, Michele; Turcotte, Stephane; Plante, Marie; Gregoire, Jean; Renaud, Marie-Claude; Bairati, Isabelle; Trudel, Dominique] Laval Univ, CHU Quebec, Hotel Dieu De Quebec, Canc Res Ctr, 11 Cote Palais, Quebec City, PQ G1R 2J6, Canada; [Tetu, Bernard; Orain, Michele] Laval Univ, CHU Quebec, Hop St Sacrement, Anat Pathol & Cytol Dept, 1050 Chemin Ste Foy, Quebec City, PQ G1S 4L8, Canada; [Plante, Marie; Gregoire, Jean; Renaud, Marie-Claude] CHU Quebec, Hotel Dieu De Quebec, Gynecol Oncol Div, 11 Cote Palais, Quebec City, PQ G1R 2J6, Canada; [Trudel, Dominique] CHU Montreal, Hop St Luc, Dept Pathol, 058 Rue St Denis, Montreal, PQ H2X 3J4, Canada; [Trudel, Dominique] Univ Montreal, Teaching Hosp CR CHUM, Montreal Canc Inst, Res Ctr, 900 Rue St Denis, Montreal, PQ H2X 0A9, Canada; [Trudel, Dominique] Univ Montreal, Dept Pathol & Cellular Biol, 2900 Blvd Edouard Montpetit, Montreal, PQ H3T 1J4, Canada; [Tetu, Bernard] CHU Quebec, Hop St Sacrement, Dept Pathol, 1050 Chemin Ste Foy, Quebec City, PQ G1S 4L8, Canada	Tetu, B (reprint author), Laval Univ, CHU Quebec, Hotel Dieu De Quebec, Canc Res Ctr, 11 Cote Palais, Quebec City, PQ G1R 2J6, Canada.; Tetu, B (reprint author), Laval Univ, CHU Quebec, Hop St Sacrement, Anat Pathol & Cytol Dept, 1050 Chemin Ste Foy, Quebec City, PQ G1S 4L8, Canada.	bernard.tetu@fmed.ulaval.ca		Gagne, Andreanne/0000-0002-3833-4159			Gagne A, 2018, DIAGN PATHOL, V13, DOI 10.1186/s13000-018-0736-6	1	0	0	0	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	SEP 17	2018	13									10.1186/s13000-018-0748-2			1	Pathology	Pathology	GU4XT	WOS:000445289400001	30223832	DOAJ Gold, Green Published			2019-10-28	
J	Segawa, K; Sugita, S; Aoyama, T; Kubo, T; Asanuma, H; Sugawara, T; Ito, Y; Tsujiwaki, M; Fujita, H; Emori, M; Hasegawa, T				Segawa, Keiko; Sugita, Shintaro; Aoyama, Tomoyuki; Kubo, Terufumi; Asanuma, Hiroko; Sugawara, Taro; Ito, Yumika; Tsujiwaki, Mitsuhiro; Fujita, Hiromi; Emori, Makoto; Hasegawa, Tadashi			Detection of specific gene rearrangements by fluorescence in situ hybridization in 16 cases of clear cell sarcoma of soft tissue and 6 cases of clear cell sarcoma-like gastrointestinal tumor	DIAGNOSTIC PATHOLOGY			English	Article						Clear cell sarcoma of soft tissue (CCSST); Clear cell sarcoma-like gastrointestinal tumor (CCSLGT); EWSR1-ATF1; EWSR1-CREB1; EWSR1-CREM	OSTEOCLAST-RICH TUMOR; MOLECULAR ANALYSIS; TRACT; PARTS; TRANSCRIPTS; LOCATION; MELANOMA; VARIANT; FUSIONS; ENTITY	Background: Clear cell sarcoma of soft tissue (CCSST) and clear cell sarcoma-like gastrointestinal tumor (CCSLGT) are malignant mesenchymal tumors that share some pathological features, but they also have several different characteristics. They are well known to express chimeric fusions of Ewing sarcoma breakpoint region 1 (EWSR1) and cAMP response element-binding protein (CREB) family members; namely, EWSR1-activating transcription factor 1 (ATF1) and EWSR1-CREB1. In addition, recent studies have suggested the presence of other fusions. Methods: We used fluorescence in situ hybridization to detect specific rearrangements including EWSR1, ATF1, CREB1, and cAMP response element modulator (CREM) in 16 CCSST and 6 CCSLGT cases. We also used reverse transcription polymerase chain reaction (RT-PCR) to detect specific chimeric fusions of EWSR1-ATF1 and EWSR1-CREB1 using fresh tumor samples in available cases. Results: A total of 15 of 16 CCSST cases (93.8%) had EWSR1 rearrangement, of which 11 (68.8%) also had ATF1 rearrangement, suggestive of the presence of EWSR1-ATF1 fusions. One CCSST case (6.3%) was found to have EWSR1 and CREM rearrangements, and 4 of 6 CCSLGT cases (66.7%) had EWSR1 rearrangement, of which 2 (33. 3%) showed ATF1 rearrangement and the other 2 cases (33.3%) showed CREB1 rearrangement. These cases most likely had EWSR1-ATF1 and EWSR1-CREB1 fusions, respectively. RT-PCR was performed in 8 available cases, including 6 CCSSTs and 2 CCSLGTs. All CCSSTs showed EWSR1-ATF1 fusions. Among the 2 CCSLGT cases, one had EWSR1-ATF1 fusion and the other had EWSR1-CREB1 fusion. Conclusions: Rearrangements of EWSR1 and ATF1 or EWSR1-ATF1 fusion were predominantly found in CCSST, whereas those of EWSR1 and CREB1 or EWSR1-CREB1 tended to be detected in CCSLGT. A novel CREM fusion was also detected in a few cases of CCSST and CCSLGT. The cases in which EWSR1 rearrangement was detected without definitive partner genes should be considered for the presence of CREM rearrangement.	[Segawa, Keiko; Sugita, Shintaro; Aoyama, Tomoyuki; Asanuma, Hiroko; Sugawara, Taro; Ito, Yumika; Tsujiwaki, Mitsuhiro; Fujita, Hiromi; Hasegawa, Tadashi] Sapporo Med Univ, Sch Med, Dept Surg Pathol, Sapporo, Hokkaido 0608543, Japan; [Kubo, Terufumi] Sapporo Med Univ, Sch Med, Dept Pathol, Sapporo, Hokkaido 0608556, Japan; [Emori, Makoto] Sapporo Med Univ, Sch Med, Dept Orthoped Surg, Sapporo, Hokkaido 0608543, Japan	Sugita, S (reprint author), Sapporo Med Univ, Sch Med, Dept Surg Pathol, Sapporo, Hokkaido 0608543, Japan.	ssugita@sapmed.ac.jp					ALPERS CE, 1985, AM J SURG PATHOL, V9, P57, DOI 10.1097/00000478-198501000-00010; Antonescu CR, 2002, J MOL DIAGN, V4, P44, DOI 10.1016/S1525-1578(10)60679-4; Antonescu CR, 2006, CLIN CANCER RES, V12, P5356, DOI 10.1158/1078-0432.CCR-05-2811; Bale TA, 2018, BRAIN PATHOL, V28, P183, DOI 10.1111/bpa.12504; Giacomini CP, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003464; Green C, 2018, PATHOLOGY, V50, P490, DOI 10.1016/j.pathol.2018.05.001; Hantschke M, 2010, AM J SURG PATHOL, V34, P216, DOI 10.1097/PAS.0b013e3181c7d8b2; Kao YC, 2017, AM J SURG PATHOL, V41, P482, DOI 10.1097/PAS.0000000000000788; Kato T, 2017, DIAGN CYTOPATHOL, V45, P1137, DOI 10.1002/dc.23786; Klijn C, 2015, NAT BIOTECHNOL, V33, P306, DOI 10.1038/nbt.3080; Kosemehmetoglu K, 2010, J CLIN PATHOL, V63, P416, DOI 10.1136/jcp.2008.057471; Miura Y, 2012, PATHOL INT, V62, P16, DOI 10.1111/j.1440-1827.2011.02739.x; Stockman DL, 2012, AM J SURG PATHOL, V36, P857, DOI 10.1097/PAS.0b013e31824644ac; Sugita S, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0486-2; Wang J, 2015, ARCH PATHOL LAB MED, V139, P407, DOI 10.5858/arpa.2013-0547-RS; Wang WL, 2009, MODERN PATHOL, V22, P1201, DOI 10.1038/modpathol.2009.85; Washimi K, 2017, PATHOL INT, V67, P534, DOI 10.1111/pin.12573; Zambrano E, 2003, INT J SURG PATHOL, V11, P75, DOI 10.1177/106689690301100202	18	0	0	0	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	SEP 15	2018	13								73	10.1186/s13000-018-0752-6			8	Pathology	Pathology	GT5EO	WOS:000444528900002	30219084	DOAJ Gold, Green Published			2019-10-28	
J	Sun, LM; Feng, LS; Cui, JW				Sun, Lemeng; Feng, Liangshu; Cui, Jiuwei			Increased expression of claudin-17 promotes a malignant phenotype in hepatocyte via Tyk2/Stat3 signaling and is associated with poor prognosis in patients with hepatocellular carcinoma	DIAGNOSTIC PATHOLOGY			English	Article						Hepatocytes; Tight junction; Migration; CLDN17; Tyrosine kinase 2; Signal transducer and activator of transcription 3	JUNCTION BARRIER FUNCTION; OVARIAN-CANCER CELLS; TIGHT JUNCTIONS; BIOMARKER; PHOSPHORYLATION; PROLIFERATION	Background: Hepatocellular carcinoma (HCC) is the second leading cause of cancer death in Asia; however, the molecular mechanism in its tumorigenesis remains unclear. Abnormal expression of claudins (CLDNs), a family of tight junction (TJ) proteins, plays an important role in the metastatic phenotype of epithelial-derived tumors by affecting tight junction structure, function and related cellular signaling pathways. In a previous study, we used a tissue chip assay to identify CLDN17 as an upregulated gene in HCC. Here we aimed to use molecular biology technology to explore the effect of CLDN17 on the malignant phenotype of HCC and the underlying molecular mechanism, with the objective of identifying a new target for HCC treatment and the control of HCC metastasis. Method: The expression levels of CLDN17 in HCC tissues and histologically non-neoplastic hepatic tissues were explored by immunohistochemistry. Stable transfection of the hepatocyte line HL7702 with CLDN17 was detected by real-time polymerase chain reaction (PCR), western blotting and immunofluorescence. The impact of CLDN17 on the malignant phenotype of HL7702 cells in vitro was assessed by a Cell Counting Kit-8 (CCK8) assay, a Transwell assay and a wound-healing experiment. Western blotting was utilized to detect the activation state of Tyrosine kinase 2 (Tyk2) / signal transducer and activator of transcription3 (Stat3) pathway. A Tyk2 RNA interference (RNAi) was utilized to determine the impact of the Tyk2/Stat3 signaling pathway on the malignant phenotype of hepatocytes. Results: In this work, our research group first found that CLDN17 was highly expressed in HCC tissues and was associated with poor prognosis. In addition, we demonstrated that CLDN17 affected the Stat3 signaling pathway via Tyk2 and ultimately enhanced the migration ability of hepatocytes. Conclusion: In conclusion, we confirmed that the upregulated expression of CLDN17 significantly enhances the migration ability of hepatocytes in vitro and we found that the activation of the Stat3 pathway by Tyk2 may an important mechanism by which CLDN17 promotes aggressiveness in hepatocytes.	[Sun, Lemeng; Cui, Jiuwei] Jilin Univ, Bethune Hosp 1, Stem Cell & Canc Ctr, Changchun 130021, Jilin, Peoples R China; [Feng, Liangshu] Jilin Univ, Hosp 1, Dept Neurol, Changchun, Jilin, Peoples R China; [Feng, Liangshu] Jilin Univ, Hosp 1, Neurosci Ctr, Changchun, Jilin, Peoples R China	Cui, JW (reprint author), Jilin Univ, Bethune Hosp 1, Stem Cell & Canc Ctr, Changchun 130021, Jilin, Peoples R China.	cjwjlu@126.com					Ahmad R, 2017, ONCOGENE, V36, P6592, DOI 10.1038/onc.2017.259; Cherradi S, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0558-5; Cunniffe C, 2014, ANTICANCER RES, V34, P2851; D'Souza T, 2005, J BIOL CHEM, V280, P26233, DOI 10.1074/jbc.M502003200; D'Souza T, 2007, EXP CELL RES, V313, P3364, DOI 10.1016/j.yexcr.2007.06.026; Dahiya N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022119; de la Fuente LM, 2018, INT J GYNECOL PATHOL, V37, P101, DOI 10.1097/PGP.0000000000000394; Zavala-Zendejas VE, 2011, CANCER INVEST, V29, P1, DOI 10.3109/07357907.2010.512594; Escudero-Esparza A, 2011, FRONT BIOSCI-LANDMRK, V16, P1069, DOI 10.2741/3736; Gao M, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-205; Gonzalez-Mariscal L, 2008, BBA-BIOMEMBRANES, V1778, P729, DOI 10.1016/j.bbamem.2007.08.018; Jiang L, 2014, ONCOTARGET, V5, P7663, DOI 10.18632/oncotarget.2288; Koval M, 2013, ANNU REV PHYSIOL, V75, P551, DOI 10.1146/annurev-physiol-030212-183809; Li CP, 2016, CARCINOGENESIS, V37, P557, DOI 10.1093/carcin/bgw036; Li XC, 2013, ONCOL LETT, V6, P101, DOI 10.3892/ol.2013.1330; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu Z, 2012, FUNCTIONS CLAUDIN 7; Micke P, 2014, INT J CANCER, V135, P2206, DOI 10.1002/ijc.28857; Ouban A, 2018, HISTOL HISTOPATHOL, V33, P1013, DOI 10.14670/HH-11-980; Ouban A, 2010, HISTOL HISTOPATHOL, V25, P83, DOI 10.14670/HH-25.83; Philip R, 2015, ONCOTARGET, V6, P2046, DOI 10.18632/oncotarget.2858; Suh Y, 2017, ONCOGENE, V36, P1167, DOI 10.1038/onc.2016.294; Suh Y, 2013, ONCOGENE, V32, P4873, DOI 10.1038/onc.2012.505; Szasz Marcell A, 2012, Magy Onkol, V56, P209, DOI MagyOnkol.2012.56.3.209; Takasawa K, 2017, CANCER LETT, V403, P66, DOI 10.1016/j.canlet.2017.05.033; Tsukita S, 1999, CURR OPIN CELL BIOL, V11, P628, DOI 10.1016/S0955-0674(99)00016-2; Turksen K, 2011, BBA-REV CANCER, V1816, P73, DOI 10.1016/j.bbcan.2011.04.001; Worst TS, 2017, MOL CELL PROTEOMICS, V16, P998, DOI 10.1074/mcp.M117.068577; Yoshida T, 2011, ANTICANCER RES, V31, P2517; Zhang XW, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0600-4	30	1	1	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	SEP 15	2018	13								72	10.1186/s13000-018-0749-1			10	Pathology	Pathology	GT5EO	WOS:000444528900001	30219077	DOAJ Gold, Green Published			2019-10-28	
J	Wickenden, K; Nawaz, N; Mamand, S; Kotecha, D; Wilson, AL; Wagner, SD; Ahearne, MJ				Wickenden, Katherine; Nawaz, Nadia; Mamand, Sami; Kotecha, Deevia; Wilson, Amy L.; Wagner, Simon D.; Ahearne, Matthew J.			PD1(hi) cells associate with clusters of proliferating B-cells in marginal zone lymphoma	DIAGNOSTIC PATHOLOGY			English	Article						Marginal zone lymphoma; Follicular helper T-cells; Spatial characteristics	REGULATORY T-CELLS; FOLLICULAR LYMPHOMA; BREAST-CANCER; EXPRESSION; SURVIVAL; NUMBERS; SUBSET	Background: Abnormally sustained immune reactions drive B-cell proliferation in some cases of marginal zone lymphoma but the CD4(+) T-cell subsets, which are likely to contribute to the B-cell responses in the tumour microenvironment, are not well characterised and neither has the spatial distribution of the different subsets in involved lymph nodes been investigated. Methods: Employing a workflow of multiplex semi-automated immunohistochemistry combined with image processing we investigated association between infiltrating T-cells and proliferating lymphoma B-cells. Results: Both total numbers of activating follicular helper (Tfh) cells (defined by high expression of PD1) and suppressive regulatory (Treg) T-cells (defined by FOXP3(+) expression) and the Tfh:Treg ratio, assessed over relatively large areas of tissue, varied among cases of marginal zone lymphoma. We determined spatial distribution and demonstrated that PD1(hi) cells showed significantly more clustering than did FOXP3(+). To investigate the association of infiltrating T-cells with lymphoma B-cells we employed Pearson correlation and Morisita-Horn index, statistical measures of interaction. We demonstrated that PD1(hi) cells were associated with proliferating B-cells and confirmed this by nearest neighbour analysis. Conclusions: The unexpected architectural complexity of T-cell infiltration in marginal zone lymphoma, revealed in this study, further supports a key role for Tfh cells in driving proliferation of lymphoma B-cells. We demonstrate the feasibility of digital analysis of spatial architecture of T-cells within marginal zone lymphoma and future studies will be needed to determine the clinical importance of these observations.	[Wagner, Simon D.] Univ Leicester, Leicester Canc Res Ctr, Lancaster Rd, Leicester LE1 7HB, Leics, England; Univ Leicester, Ernest & Helen Scott Haematol Res Inst, Lancaster Rd, Leicester LE1 7HB, Leics, England	Wagner, SD (reprint author), Univ Leicester, Leicester Canc Res Ctr, Lancaster Rd, Leicester LE1 7HB, Leics, England.	sw227@le.ac.uk		Wagner, Simon/0000-0002-8914-0370	Leicester Haematology Research Fund; Hope Fund for Cancer Research; Government of Iraq	NN and ALW were supported by the Leicester Haematology Research Fund and the Hope Fund for Cancer Research. SM was supported by a PhD studentship from the Government of Iraq.	Ahearne MJ, 2014, VIRCHOWS ARCH, V465, P351, DOI 10.1007/s00428-014-1615-5; Ahearne MJ, 2013, BRIT J HAEMATOL, V162, P360, DOI 10.1111/bjh.12401; Ame-Thomas P, 2012, LEUKEMIA, V26, P1053, DOI 10.1038/leu.2011.301; Arcaini L, 2016, BLOOD, V127, P2072, DOI 10.1182/blood-2015-11-624312; Arribas Alberto J, 2012, Blood, V119, pe9, DOI 10.1182/blood-2011-02-339556; Baddeley A, 2015, SPATIAL POINT PATTER; Carreras J, 2006, BLOOD, V108, P2957, DOI 10.1182/blood-2006-04-018218; Clipson A, 2015, LEUKEMIA, V29, P1177, DOI 10.1038/leu.2014.330; Craig VJ, 2010, LEUKEMIA, V24, P1186, DOI 10.1038/leu.2010.76; Du MQ, 2017, BEST PRACT RES CL HA, V30, P13, DOI 10.1016/j.beha.2016.09.002; Fang DF, 2017, J EXP MED, V214, P1861, DOI 10.1084/jem.20170494; Glass G, 2009, J HISTOCHEM CYTOCHEM, V57, P899, DOI 10.1369/jhc.2009.953612; Gu-Trantien C, 2013, J CLIN INVEST, V123, P2873, DOI 10.1172/JCI67428; Lee AM, 2006, J CLIN ONCOL, V24, P5052, DOI 10.1200/JCO.2006.06.4642; Linterman MA, 2011, NAT MED, V17, P975, DOI 10.1038/nm.2425; Linterman MA, 2010, SEMIN IMMUNOPATHOL, V32, P183, DOI 10.1007/s00281-009-0194-z; Linterman MA, 2010, J EXP MED, V207, P353, DOI 10.1084/jem.20091738; Maley CC, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0638-4; Nawaz S, 2016, CANCER LETT, V380, P296, DOI 10.1016/j.canlet.2015.11.018; Pangault C, 2010, LEUKEMIA, V24, P2080, DOI 10.1038/leu.2010.223; Parry M, 2015, CLIN CANCER RES, V21, P4174, DOI 10.1158/1078-0432.CCR-14-2759; Pirici D, 2009, J HISTOCHEM CYTOCHEM, V57, P567, DOI 10.1369/jhc.2009.953240; Rao DA, 2017, NATURE, V542, P110, DOI 10.1038/nature20810; Rinaldi A, 2011, BLOOD, V117, P1595, DOI 10.1182/blood-2010-01-264275; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Vinuesa CG, 2016, ANNU REV IMMUNOL, V34, P335, DOI 10.1146/annurev-immunol-041015-055605; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Yang ZZ, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.1; Zinzani PL, 2012, HEMATOL-AM SOC HEMAT, P426, DOI 10.1182/asheducation-2012.1.426; Zucca E, 2014, CLIN CANCER RES, V20, P5207, DOI 10.1158/1078-0432.CCR-14-0496	31	0	0	1	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	SEP 15	2018	13								74	10.1186/s13000-018-0750-8			10	Pathology	Pathology	GT5EO	WOS:000444528900003	30219078	DOAJ Gold, Green Published			2019-10-28	
J	Segura, SE; Ramos-Rivera, G; Suhrland, M				Segura, Sheila E.; Ramos-Rivera, Gloria; Suhrland, Mark			Educational Case: Infectious Diseases: Pathogenesis, Diagnosis, Treatment, and Prevention	ACADEMIC PATHOLOGY			English	Article						pathology competencies; diagnostic medicine; cytopathology; cytologic diagnosis; infectious diseases; cervix disease; herpes infection; trichomoniasis; candidiasis		The following fictional case is intended as a learning tool within the Pathology Competencies for Medical Education (PCME), a set of national standards for teaching pathology. These are divided into three basic competencies: Disease Mechanisms and Processes, Organ System Pathology, and Diagnostic Medicine and Therapeutic Pathology. For additional information, and a full list of learning objectives for all three competencies.	[Segura, Sheila E.; Ramos-Rivera, Gloria; Suhrland, Mark] Montefiore Hosp & Med Ctr, 111 East 210th St, Bronx, NY 10467 USA	Segura, SE (reprint author), Montefiore Hosp & Med Ctr, 111 East 210th St, Bronx, NY 10467 USA.	sesd05@hotmail.com					Aliye UC, 2000, J PEDIAT GASTROENTER, V31, P572; Centers for disease control and prevention, FUNG DIS TYP FUNG DI; Centers for Disease Control and Prevention, 2015, 2015 STD TREATM GUID; Centers for Disease Control & Prevention, 2015, SEX TRANSM DIS TREAT; Edmund C, 2014, CYTOLOGY DIAGNOSTIC; Khalbuss WE, 2013, QUICK COMPENDIUM CYT, P25; Van der Pol B, 2007, CLIN INFECT DIS, V44, P23, DOI 10.1086/509934; World Health Organization, 2017, HERP SIMPL VIR	8	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	SEP 14	2018	5								UNSP 2374289518794191	10.1177/2374289518794191			6	Pathology	Pathology	GT5VI	WOS:000444577700001	30246142	DOAJ Gold, Green Published			2019-10-28	
J	Tan, J; Hu, JP; He, YH; Cui, FL				Tan, Jian; Hu, Jianpeng; He, Yonghui; Cui, Feilun			RETRACTION: Protective role of silymarin in a mouse model of renal Ischemia-Reperfusion injury (Retraction of Vol 10, art no 198, 2015)	DIAGNOSTIC PATHOLOGY			English	Retraction									[Tan, Jian; Hu, Jianpeng; He, Yonghui; Cui, Feilun] Jiangsu Univ, Affiliated Peoples Hosp, Dept Urol, Zhenjiang 212013, Peoples R China	Cui, FL (reprint author), Jiangsu Univ, Affiliated Peoples Hosp, Dept Urol, Zhenjiang 212013, Peoples R China.	pdcuifeilun@163.com					Tan J, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0436-4	1	0	0	0	4	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	SEP 12	2018	13								71	10.1186/s13000-018-0746-4			1	Pathology	Pathology	GT5EN	WOS:000444528800002	30208935	DOAJ Gold, Green Published			2019-10-28	
J	Yang, XY; Wang, HC; Zhang, MM; Liu, J; Lv, B; Chen, FP				Yang, Xinyu; Wang, Haichao; Zhang, Menmen; Liu, Jin; Lv, Ben; Chen, Fangping			RETRACTION: HMGB1: a novel protein that induced platelets active and aggregation via Toll-like receptor-4, NF-kappa B and cGMP dependent mechanisms (Retraction of Vol 10, art no 134, 2015)	DIAGNOSTIC PATHOLOGY			English	Retraction									[Yang, Xinyu; Liu, Jin; Lv, Ben; Chen, Fangping] Cent S Univ, Xiangya Hosp 3, Dept Haematol, Changsha, Hunan, Peoples R China; [Wang, Haichao; Lv, Ben] North Shore LIJ Hlth Syst, Feinstein Inst Med Res, Lab Emergency Med, Manhasset, NY 11030 USA; [Zhang, Menmen; Chen, Fangping] Cent S Univ, Xiangya Hosp, Dept Hemotol, Changsha 410078, Hunan, Peoples R China	Chen, FP (reprint author), Cent S Univ, Xiangya Hosp 3, Dept Haematol, Changsha, Hunan, Peoples R China.; Chen, FP (reprint author), Cent S Univ, Xiangya Hosp, Dept Hemotol, Changsha 410078, Hunan, Peoples R China.	hope058@163.com					Yang XY, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0348-3; YANG XY, 2015, BMC DIAGNOSTIC PATHO, V10	2	0	0	0	4	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	SEP 12	2018	13								70	10.1186/s13000-018-0747-3			1	Pathology	Pathology	GT5EN	WOS:000444528800001	30208922	DOAJ Gold, Green Published			2019-10-28	
J	Zhou, MF; Tong, XZ				Zhou, Meifeng; Tong, Xiuzhen			RETRACTION: Downregulated poly-C binding protein-1 is a novel predictor associated with poor prognosis in acute myeloid leukemia (Retraction of Vol 10, art no 147, 2015)	DIAGNOSTIC PATHOLOGY			English	Retraction									[Zhou, Meifeng; Tong, Xiuzhen] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Hematol, Guangzhou 510080, Guangdong, Peoples R China	Tong, XZ (reprint author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Hematol, Guangzhou 510080, Guangdong, Peoples R China.	tongxz05@163.com					Zhou MF, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0377-y	1	0	0	0	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	SEP 12	2018	13								69	10.1186/s13000-018-0745-5			1	Pathology	Pathology	GT5CO	WOS:000444523700001	30208907	DOAJ Gold, Green Published			2019-10-28	
J	Kriegsmann, M; Kriegsmann, K; Harms, A; Longuespee, R; Zgorzelski, C; Leichsenring, J; Muley, T; Winter, H; Kazdal, D; Goeppert, B; Warth, A				Kriegsmann, Mark; Kriegsmann, Katharina; Harms, Alexander; Longuespee, Remi; Zgorzelski, Christiane; Leichsenring, Jonas; Muley, Thomas; Winter, Hauke; Kazdal, Daniel; Goeppert, Benjamin; Warth, Arne			Expression of HMB45, MelanA and SOX10 is rare in non-small cell lung cancer	DIAGNOSTIC PATHOLOGY			English	Article						NSCLC; Lung cancer; SOX10; HMB45; MelanA; Immunohistochemistry	MALIGNANT-MELANOMA; LARGE-SCALE; TUMORS; CARCINOMA; PULMONARY; DIAGNOSIS; IMMUNOMARKERS; MORPHOLOGY; EMPHASIS; SPECTRUM	Background: Non-small cell lung cancer (NSCLC) and melanoma are frequent entities in routine diagnostics. Whereas the differential diagnosis is usually straight forward based on histomorphology, it can be challenging in poorly differentiated tumors as melanoma may mimic various histological patterns. Distinction of the two entities is of outmost importance as both are treated differently. HMB45 and MelanA are recommended immunohistological markers for melanoma in this scenario. SOX10 has been described as an additional marker for melanoma. However, comprehensive large-scale data about the expression of melanoma markers in NSCLC tumor tissue specimen are lacking so far. Methods: Therefore, we analyzed the expression of these markers in 1085 NSCLC tumor tissue samples. Tissue microarrays of NSCLC cases were immunohistochemically stained for HMB45, MelanA, and SOX10. Positivity of a marker was defined as >= 1% positive tumor cells. Results: In 1027 NSCLC tumor tissue samples all melanoma as well as conventional immunohistochemical markers for NSCLC could be evaluated. HMB45, MelanA, and SOX10 were positive in 1 (< 1%), 0 (0%) and 5 (< 1%) cases. The HMB45 positive case showed co-expression of SOX10 and was classified as large cell carcinoma. Three out of five SOX10 positive cases were SqCC and one case was an adenosquamous carcinoma. Conclusions: Expression of HMB45, MelanA and SOX10 is evident but exceedingly rare in NSCLC cases. Together with conventional immunomarkers a respective marker panel allows a clear-cut differential diagnosis even in poorly differentiated tumors.	[Kriegsmann, Mark; Harms, Alexander; Longuespee, Remi; Zgorzelski, Christiane; Leichsenring, Jonas; Kazdal, Daniel; Goeppert, Benjamin; Warth, Arne] Univ Hosp Heidelberg, Inst Pathol, Neuenheimer Feld 224, Heidelberg, Germany; [Kriegsmann, Katharina] Univ Hosp Heidelberg, Dept Internal Med Hematol Oncol & Rheumatol 5, Heidelberg, Germany; [Harms, Alexander; Muley, Thomas; Winter, Hauke; Kazdal, Daniel] Translat Lung Res Ctr Heidelberg, Heidelberg, Germany; [Harms, Alexander; Muley, Thomas; Winter, Hauke; Kazdal, Daniel] German Ctr Lung Res, Heidelberg, Germany; [Muley, Thomas] Heidelberg Univ, Thoraxklin, Translat Res Unit, Heidelberg, Germany; [Winter, Hauke] Heidelberg Univ, Thoraxklin, Dept Thorac Surg, Heidelberg, Germany; [Warth, Arne] UEGP, Inst Pathol Cytopathol & Mol Pathol, Wetzlar, Limburg, Germany	Kriegsmann, M (reprint author), Univ Hosp Heidelberg, Inst Pathol, Neuenheimer Feld 224, Heidelberg, Germany.	mark.kriegsmann@med.uni-heidelberg.de			Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG); Baden-Wurttemberg Ministry of Science, Research and the Arts; RuprechtKarls-Universitat Heidelberg	We acknowledge financial support by Deutsche Forschungsgemeinschaft within the funding programme Open Access Publishing, by the Baden-Wurttemberg Ministry of Science, Research and the Arts and by RuprechtKarls-Universitat Heidelberg.	Adler NR, 2017, BRIT J CANCER, V117, P1026, DOI 10.1038/bjc.2017.254; Albores-Saavedra J, 2014, AM J CLIN PATHOL, V141, P850, DOI 10.1309/AJCPS88CMJRXZBWA; Brenn T, 2015, PATHOLOGE, V36, P53, DOI 10.1007/s00292-014-2001-4; Burke AP, 2015, IARC PUBLICATION, V7, P1; Deavers MT, 2003, INT J GYNECOL PATHOL, V22, P162, DOI 10.1097/01.PGP.0000040032.16722.D8; Dimitriou F, 2018, CURR OPIN ONCOL, V30, P118, DOI 10.1097/CCO.0000000000000432; Gambichler T, 2016, CLIN EXP DERMATOL, V41, P709, DOI 10.1111/ced.12928; Goh GH, 2016, VIRCHOWS ARCH, V469, P111, DOI 10.1007/s00428-016-1943-8; GOWN AM, 1986, AM J PATHOL, V123, P195; Grzegorek I, 2015, ANTICANCER RES, V35, P3353; Hsieh MS, 2016, HUM PATHOL, V56, P134, DOI 10.1016/j.humpath.2016.05.021; Ivanov SV, 2013, BRIT J CANCER, V109, P444, DOI 10.1038/bjc.2013.326; Jassem E, 2006, BIOMARKERS, V11, P262, DOI 10.1080/13547500600652277; Jungbluth AA, 1998, AM J SURG PATHOL, V22, P595, DOI 10.1097/00000478-199805000-00011; Kato M, 2017, MED ONCOL, V34, DOI 10.1007/s12032-016-0865-2; Kriegsmann M, 2018, HISTOPATHOLOGY, V72, P997, DOI 10.1111/his.13455; Kriegsmann M, 2016, MOL CELL PROTEOMICS, V15, P3081, DOI 10.1074/mcp.M115.057513; Kriegsmann M, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0441-7; Kwon AY, 2016, VIRCHOWS ARCH, V468, P597, DOI 10.1007/s00428-016-1918-9; Lezcano C, 2017, AM J DERMATOPATH, V39, P896, DOI 10.1097/DAD.0000000000000872; Lisenko K, 2017, APPL IMMUNOHISTOCHEM; Mezencev R, 2017, J NEUROPATH EXP NEUR, V76, P155, DOI 10.1093/jnen/nlw113; Miettinen M, 2015, AM J SURG PATHOL, V39, P826, DOI 10.1097/PAS.0000000000000398; Mohamed A, 2013, APPL IMMUNOHISTO M M, V21, P506, DOI 10.1097/PAI.0b013e318279bc0a; Motoi T, 2005, HUM PATHOL, V36, P871, DOI 10.1016/j.humpath.2005.05.018; Nelson ER, 2017, HUM PATHOL, V67, P205, DOI 10.1016/j.humpath.2017.08.011; Parra-Medina R, 2017, ANN DIAGN PATHOL, V26, P70, DOI 10.1016/j.anndiagpath.2016.07.010; Peng J, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008772; Petersson F, 2012, HUM PATHOL, V43, P726, DOI 10.1016/j.humpath.2011.07.001; Pfarr N, 2016, GENE CHROMOSOME CANC, V55, P821, DOI 10.1002/gcc.22378; Plaza JA, 2016, J CUTAN PATHOL, V43, P313, DOI 10.1111/cup.12654; Plaza JA, 2010, AM J DERMATOPATH, V32, P129, DOI 10.1097/DAD.0b013e3181b34a19; Tsilimigras DI, 2018, RESPIR MED CASE REP, V23, P52, DOI 10.1016/j.rmcr.2017.12.001; Tudrej KB, 2017, ARCH MED SCI, V13, P1493, DOI 10.5114/aoms.2016.60655; Warth A, 2015, PATHOLOGE, V36, P194, DOI 10.1007/s00292-015-0085-0; Warth A, 2016, ONCOTARGET, V7, P29761, DOI 10.18632/oncotarget.8858; Warth A, 2014, EUR RESPIR J, V43, P872, DOI 10.1183/09031936.00018013; Warth A, 2012, HISTOPATHOLOGY, V61, P1017, DOI 10.1111/j.1365-2559.2012.04308.x; Waxman Elizabeth S, 2016, J Adv Pract Oncol, V7, P514; Wick MR, 2016, SEMIN DIAGN PATHOL, V33, P204, DOI 10.1053/j.semdp.2016.04.005; Wilson RW, 1997, AM J SURG PATHOL, V21, P1196, DOI 10.1097/00000478-199710000-00010; Yamamoto Y, 2017, MOL CLIN ONCOL, V7, P39, DOI 10.3892/mco.2017.1256; Yin H, 2017, CLIN TRANSL ONCOL, V19, P1035, DOI 10.1007/s12094-017-1641-2; Zhao Y, 2016, ONCOTARGETS THER, V9, P1671, DOI 10.2147/OTT.S101344; Zhong WD, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-248; Zhou DJ, 2014, TUMOR BIOL, V35, P9935, DOI 10.1007/s13277-014-1893-1	46	0	0	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	SEP 11	2018	13								68	10.1186/s13000-018-0751-7			6	Pathology	Pathology	GT5CM	WOS:000444523500001	30205833	DOAJ Gold, Green Published			2019-10-28	
J	Theparee, T; Shanes, E; Maurer, D; Palma, E; Lee, HK; Benirschke, R; Dohnal, J; Pease, G; Walls, T; Thomson, R; Kaul, K				Theparee, Talent; Shanes, Elisheva; Maurer, Darryck; Palma, Emmanuel; Lee, Hong-Kee; Benirschke, Robert; Dohnal, James; Pease, Garrison; Walls, Timothy; Thomson, Richard, Jr.; Kaul, Karen			A New Era in Pathology Consultation: The MyPathologist Electronic Consultation Tool	ACADEMIC PATHOLOGY			English	Article						consultation; clinical pathology; electronic medical record; communication; laboratory; residency training	ACADEMIC-MEDICAL-CENTER; CLINICAL PATHOLOGY; RESIDENT EDUCATION; REQUESTS; IMPACT	Pathologists and laboratory scientists provide valuable guidance on laboratory utilization, test ordering, interpretation, and quality control provided that clinical staff can easily access the laboratory team. To encourage consultation between clinicians with laboratory scientists and pathologists, we developed an easily accessible electronic tool termed "MyPathologist," placed on the homepage of our electronic health record system. Over its 2-year pilot, utilization of this consultation tool climbed as we continued to publicize it and incorporated education into housestaff onboarding and electronic health record training. Physician satisfaction with the tool was high. Additionally, this became the primary source of consults to our residency call service. Evaluation of MyPathologist questions received during its pilot period showed that more than half the questions were of significant educational value to the residents, often focusing on results interpretation, appropriate test ordering, and quality control. MyPathologist is a novel electronic tool for pathology consultation within our electronic health record and also represents an avenue for educating residents, improving utilization of the laboratory, and improving patient care.	[Theparee, Talent; Shanes, Elisheva; Lee, Hong-Kee; Benirschke, Robert; Dohnal, James; Pease, Garrison; Thomson, Richard, Jr.; Kaul, Karen] NorthShore Univ HealthSyst, Dept Pathol & Lab Med, 2650 Ridge Ave, Evanston, IL 60091 USA; [Maurer, Darryck; Palma, Emmanuel] NorthShore Univ HealthSyst, Hlth Informat Technol, Evanston, IL USA; [Walls, Timothy] Sentara Reference Labs, Norfolk, VA USA	Kaul, K (reprint author), NorthShore Univ HealthSyst, Dept Pathol & Lab Med, 2650 Ridge Ave, Evanston, IL 60091 USA.	kkaul@northshore.org	Lee, Hong-Kee/Y-1148-2019		NorthShore University HealthSystem Department of Pathology	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was funded by the NorthShore University HealthSystem Department of Pathology.	[Anonymous], 2014, J Grad Med Educ, V6, P182, DOI 10.4300/JGME-06-01s1-09; Balogh E, 2015, IMPR DIAGN HLTH CAR, DOI [10.17226/21794, DOI 10.17226/21794]; Do MC, 2008, ARCH PATHOL LAB MED, V132, P1317, DOI 10.1043/1543-2165(2008)132[1317:CSPAOC]2.0.CO;2; Hickner J, 2014, J AM BOARD FAM MED, V27, P268, DOI 10.3122/jabfm.2014.02.130104; Hoofnagle AN, 2007, CLIN CHEM, V53, P134, DOI 10.1373/clinchem.2006.078550; Krasowski MD, 2015, BMC MED INFORM DECIS, V15, DOI 10.1186/s12911-015-0137-7; Laposata M, 2016, ARCH PATHOL LAB MED, V140, P505, DOI 10.5858/arpa.2015-0499-ED; Rinder H, 2007, CLIN CHEM, V53, P3, DOI 10.1373/clinchem.2006.080218; Schmidt RL, 2016, AM J CLIN PATHOL, V145, P666, DOI [10.1093/ajcp/aqw020, 10.1093/AJCP/AQW020]; Schmidt RL, 2014, AM J CLIN PATHOL, V142, P286, DOI 10.1309/AJCP88PPUTFDRACC; Warren JS, 2013, AM J CLIN PATHOL, V139, P289, DOI 10.1309/AJCP4G6UAUXCFTQF	11	1	1	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	SEP 10	2018	5								UNSP 2374289518798820	10.1177/2374289518798820			7	Pathology	Pathology	GT3IR	WOS:000444395800001	30214917	DOAJ Gold, Green Published			2019-10-28	
J	Hu, SM; Panarelli, NC				Hu, Shaomin; Panarelli, Nicole C.			Educational Case: Immune-Related Disorders of the Bowel: Celiac Disease	ACADEMIC PATHOLOGY			English	Article						pathology competencies; organ system pathology; gastrointestinal tract; immune-related disorders of the bowel; celiac disease; collagenous sprue; villous blunting; serologic studies	GLUTEN-FREE DIET; T-CELL LYMPHOMA; GASTROINTESTINAL SYMPTOMS; ENTEROPATHY; DIAGNOSIS; ENTITY; RISKS	The following fictional case is intended as a learning tool within the Pathology Competencies for Medical Education (PCME), a set of national standards for teaching pathology. These are divided into three basic competencies: Disease Mechanisms and Processes, Organ System Pathology, and Diagnostic Medicine and Therapeutic Pathology. For additional information, and a full list of learning objectives for all three competencies, see http://journals.sagepub.com/doi/10.1177/2374289517715040.	[Hu, Shaomin; Panarelli, Nicole C.] Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10467 USA	Panarelli, NC (reprint author), Albert Einstein Coll Med, Montefiore Med Ctr, 111 East 210th St,Cent 428, Bronx, NY 10467 USA.	npanarel@montefiore.org					Brown IS, 2014, AM J SURG PATHOL, V38, P666, DOI 10.1097/PAS.0000000000000153; Collin P, 2017, ANN MED, V49, P23, DOI 10.1080/07853890.2016.1222450; de Roest RH, 2013, INT J CLIN PRACT, V67, P895, DOI 10.1111/ijcp.12128; Elitsur Y, 2017, DIGEST DIS SCI, V62, P175, DOI 10.1007/s10620-016-4354-4; Freeman HJ, 2015, WORLD J GASTROENTERO, V21, P9233, DOI 10.3748/wjg.v21.i31.9233; Hall NJ, 2009, ALIMENT PHARM THER, V30, P315, DOI 10.1111/j.1365-2036.2009.04053.x; Husby S, 2012, J PEDIATR GASTR NUTR, V54, P136, DOI 10.1097/MPG.0b013e31821a23d0; Ilus T, 2014, AM J GASTROENTEROL, V109, P1471, DOI 10.1038/ajg.2014.194; Lau MSY, 2017, CURR OPIN GASTROEN, V33, P173, DOI 10.1097/MOG.0000000000000343; Malamut G, 2012, SEMIN IMMUNOPATHOL, V34, P601, DOI 10.1007/s00281-012-0322-z; Niland Benjamin, 2018, Gastroenterol Hepatol (N Y), V14, P82; Ondrejka S, 2016, CURR HEMATOL MALIG R, V11, P504, DOI 10.1007/s11899-016-0357-7; Pagliari D, 2015, J IMMUNOL RES, DOI 10.1155/2015/123653; Pai RK, 2014, SEMIN DIAGN PATHOL, V31, P124, DOI 10.1053/j.semdp.2014.02.006; Panarelli NC, 2018, MODERN PATHOL, V31, P844, DOI 10.1038/s41379-018-0015-9; Potter MDE, 2018, J GASTROEN HEPATOL, V33, P781, DOI 10.1111/jgh.14039; Rostami K, 1999, AM J GASTROENTEROL, V94, P888; Rubio-Tapia A, 2012, AM J GASTROENTEROL, V107, P1538, DOI 10.1038/ajg.2012.219; Samasca G, 2017, EUR J CLIN INVEST, V47, P394, DOI 10.1111/eci.12755; Shenoy S, 2016, WORLD J GASTRO ONCOL, V8, P509, DOI 10.4251/wjgo.v8.i6.509; Singhi AD, 2014, MODERN PATHOL, V27, P543, DOI 10.1038/modpathol.2013.150; Smedby KE, 2005, GUT, V54, P54, DOI 10.1136/gut.2003.032094; Smyrk Thomas C, 2017, Surg Pathol Clin, V10, P823, DOI 10.1016/j.path.2017.07.004; Stamnaes J, 2015, SEMIN IMMUNOL, V27, P343, DOI 10.1016/j.smim.2015.11.001; Staudacher HM, 2012, J NUTR, V142, P1510, DOI 10.3945/jn.112.159285; Uenishi RH, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/1471-230X-14-36; Volta U, 2016, DIGEST LIVER DIS, V48, P1018, DOI 10.1016/j.dld.2016.05.024	27	0	0	1	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	SEP 10	2018	5								UNSP 2374289518799253	10.1177/2374289518799253			7	Pathology	Pathology	GT3JS	WOS:000444399600001	30214918	DOAJ Gold, Green Published			2019-10-28	
J	Miura, K; Yamashita, K				Miura, Katsutoshi; Yamashita, Kanna			Evaluation of aging, diabetes mellitus, and skin wounds by scanning acoustic microscopy with protease digestion	PATHOBIOLOGY OF AGING AND AGE-RELATED DISEASES			English	Article						Scanning acoustic microscopy; skin; aging; diabetes mellitus; wound; elasticity; protease	MAILLARD REACTION; CROSS-LINKING; MECHANISM	Scanning acoustic microscopy (SAM) can assess tissue stiffness by calculating the speed of sound (SOS) through tissues. SOS increases as tissue stiffness increases. Sensitivity to protease digestion depends on protein type, concentration, and modification. We analyzed the SOS images of formalin-fixed paraffin-embedded skin sections from elderly, young, diabetic, and nondiabetic subjects, as well as chronic and acute wounds. SAM provided high-resolution histology similar to LM and revealed characteristic SOS alteration following pepsin treatment. SOS values of dermis samples from elderly subjects (especially females) were lower than those of younger adults, which was indicative of age-related dermal softening and loosening. SOS values of elderly females were lower than those of younger females and elderly males. Dermal SOS showed a positive correlation with epidermal thickness. SOS values of epidermis of elderly subjects were higher than those of younger adults and showed a rapid decline 0.5h after protease digestion. Reticular dermis of diabetic patients exhibited greater pepsin resistance than that of nondiabetic patients. Chronic wounds exhibited greater SOS values and pepsin resistance than acute wounds. SOS variation with aging, diabetes mellitus, and wound fibrosis reflected histological and mechanical changes associated with senescence and disease duration. Epidermal thickness reflects age-related changes in dermal stiffness.	[Miura, Katsutoshi; Yamashita, Kanna] Hamamatsu Univ Sch Med, Dept Hlth Sci Pathol & Anat, Hamamatsu, Shizuoka, Japan	Miura, K (reprint author), 1-20-1 Handa Yama,Higashiku, Hamamatsu, Shizuoka 4313192, Japan.	kmiura@hama-med.ac.jp			JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JP15K08375, JP17K1088901]	This work was supported by JSPS KAKENHI Grant Numbers JP15K08375, JP17K1088901.	Akhtar R, 2011, MATER TODAY, V14, P96, DOI 10.1016/S1369-7021(11)70059-1; Argyropoulos AJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153806; BOSS GR, 1981, WESTERN J MED, V135, P434; BRAVERMAN IM, 1982, J INVEST DERMATOL, V78, P434, DOI 10.1111/1523-1747.ep12507866; Bucala R, 2014, J CLIN INVEST, V124, P1887, DOI 10.1172/JCI75224; Dong CB, 2016, INT J NANOMED, V11, P2107, DOI 10.2147/IJN.S103501; FENSKE NA, 1986, J AM ACAD DERMATOL, V15, P571, DOI 10.1016/S0190-9622(86)70208-9; Gkogkolou P, 2012, DERM-ENDOCRINOL, V4, DOI 10.4161/derm.22028; HARVELL JD, 1994, J AM ACAD DERMATOL, V31, P1015, DOI 10.1016/S0190-9622(94)70273-X; International Diabetes Federation, 2017, IDF DIAB ATL 2017 GL; Jensen AS, 2006, ULTRASOUND MED BIOL, V32, P1943, DOI 10.1016/j.ultrasmedbio.2006.06.011; KURBAN RS, 1990, J DERMATOL SURG ONC, V16, P908, DOI 10.1111/j.1524-4725.1990.tb01554.x; Langton A. K., 2010, International Journal of Cosmetic Science, V32, P330, DOI 10.1111/j.1468-2494.2010.00574.x; Miura K., 2016, MICROSCOPY ANAL, P381; Miura K, 2012, LAB INVESTIG, V92; Miura K, 2016, BIOMED RES INT, DOI 10.1155/2016/6125204; Miura K, 2015, PATHOL INT, V65, P355, DOI 10.1111/pin.12288; Miyata T, 2003, CLIN CHEM LAB MED, V41, P1150, DOI 10.1515/CCLM.2003.178; Monnier VM, 2005, ANN NY ACAD SCI, V1043, P533, DOI 10.1196/annals.1333.061; Monnier VM, 1996, DIABETES, V45, pS67, DOI 10.2337/diab.45.3.S67; MONNIER VM, 1990, J GERONTOL, V45, pB105, DOI 10.1093/geronj/45.4.B105; MONTAGNA W, 1990, BRIT J DERMATOL, V122, P61, DOI 10.1111/j.1365-2133.1990.tb16127.x; Naylor EC, 2011, MATURITAS, V69, P249, DOI 10.1016/j.maturitas.2011.04.011; Ritz-Timme S, 2003, BRIT J DERMATOL, V149, P951, DOI 10.1111/j.1365-2133.2003.05618.x; ROSENBERG CS, 1990, NURS CLIN N AM, V25, P247; Saijo Y., 2009, IMAGING MED, V1, P47, DOI DOI 10.2217/IIM.09.8; SIBBALD RG, 1984, INT J DERMATOL, V23, P567, DOI 10.1111/j.1365-4362.1984.tb05694.x; Singh VP, 2014, KOREAN J PHYSIOL PHA, V18, P1, DOI 10.4196/kjpp.2014.18.1.1; Verzijl N, 2000, J BIOL CHEM, V275, P39027, DOI 10.1074/jbc.M006700200; Yaar M, 2007, BRIT J DERMATOL, V157, P874, DOI 10.1111/j.1365-2133.2007.08108.x	30	0	0	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	2001-0001			PATHOBIOL AGING AGE	Pathobiol. Aging Age-relat. Dis.	SEP 6	2018	8								1516072	10.1080/20010001.2018.1516072			12	Pathology	Pathology	GU0TE	WOS:000444964400001	30220987	DOAJ Gold, Green Published			2019-10-28	
J	Cachin, F				Cachin, F.			Editorial	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Editorial Material									[Cachin, F.] Ctr Lutte Canc, Serv Med Nucl, 58 Rue Montalembert, F-63100 Clermont Ferrand, France	Cachin, F (reprint author), Ctr Lutte Canc, Serv Med Nucl, 58 Rue Montalembert, F-63100 Clermont Ferrand, France.	florent.cachin@clermont.unicancer.fr	cachin, florent/X-8220-2019	cachin, florent/0000-0003-2171-1496				0	0	0	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	SEP-OCT	2018	42	5					293	294		10.1016/j.mednuc.2018.07.002			2	Pathology	Pathology	HO3XT	WOS:000460857000001					2019-10-28	
J	Bonardel, G; Barrau, C; Soussan, M; D'Estanque, E; Erra, B; Etard, C; Fayard, N; Haber, MO; Hapdey, S; Hindle, E; Hyafil, F; Vaylet, CL; Lairez, O; Leroux, PY; Olivier, P; Queneau, M; Rust, E; Seban, R; Sibille, L; Soret, M; Wartski, M				Bonardel, G.; Barrau, C.; Soussan, M.; D'Estanque, E.; Erra, B.; Etard, C.; Fayard, N.; Haber, M. O.; Hapdey, S.; Hindle, E.; Hyafil, F.; Vaylet, C. Labriolle; Lairez, O.; Leroux, P. Y.; Olivier, P.; Queneau, M.; Rust, E.; Seban, R.; Sibille, L.; Soret, M.; Wartski, M.		Grp Travail Radioprotection SFMN	CT good practices for hybrid nuclear medicine (SPECT/CT and PET/CT): Introduction	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Article								Nuclear medicine hybrid imaging is a technological evolution of gamma camera scintigraphy or positron emission tomography imaging methods that are now often coupled with an anatomical imaging device, essentially a CT scanner. Following a large demand from the nuclear physicians themselves, but also from the French Nuclear Safety Authority, this guide is intended for the entire nuclear medicine community to integrate both the aspects of radiation protection related to coupled CT and those related to the quality of the CT images according to the clinical context. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Bonardel, G.; Queneau, M.] Ctr Cardiol Nord, Med Nucl, 32-36 Rue Moulins Gemeaux, F-93200 St Denis, Reunion, France; [Barrau, C.; D'Estanque, E.; Sibille, L.] Hop Caremeau, Med Nucl, Pl Pr Debre, F-30029 Nimes, France; [Soussan, M.] CHU Avicenne, Med Nucl, 125 Rue Stalingrad, F-93000 Bobigny, France; [Erra, B.] CHU Bretonneau, Med Nucl, 2 Blvd Tonnele, F-37044 Tours 9, France; [Etard, C.] IRSN, 31 Ave Div Leclerc, F-92260 Fontenay Aux Roses, France; [Fayard, N.] ASN, 15 Rue Louis Lejeune, F-92120 Montrouge, France; [Haber, M. O.; Soret, M.] Grp Hosp Pitie Salpetriere, Med Nucl, 47-83 Blvd Hop, F-75651 Paris 13, France; [Hapdey, S.] Ctr Henri Becquerel, Med Nucl, I Rue Amiens, F-76038 Rouen, France; [Hindle, E.] Hop Pellegrin Tripode, Med Nucl, Pl Amelie Raba Leon, F-33076 Bordeaux, France; [Hyafil, F.] Hop Bichat Claude Bernard, Med Nucl, 46 Rue H Huchard, F-75018 Paris, France; [Vaylet, C. Labriolle] Hop Enfants A Trousseau, Med Nucl, 26 Ave Dr A Netter, F-75571 Paris 12, France; [Lairez, O.] Hop Rangueil, Med Nucl, 1 Ave J Poulhes TSA50032, F-31059 Toulouse, France; [Leroux, P. Y.] Hop Augustin Morvan, Med Nucl, 3 Ave Foch, F-29269 Brest, France; [Olivier, P.] CHU Nancy, Med Nucl, Rue Morvan, F-54511 Nancy, France; [Rust, E.] Clin Diaconat, Med Nucl, 1 Blvd Pr Roosevelt, F-68200 Mulhouse, France; [Seban, R.] Inst Gustave Roussy, Med Nucl, 114 Rue E Vaillant, F-94805 Villejuif, France; [Wartski, M.] Grp Hosp Cochin, Med Nucl, 27 Rue Faubourg St Jacques, F-75014 Paris, France	Bonardel, G (reprint author), Ctr Cardiol Nord, Med Nucl, 32-36 Rue Moulins Gemeaux, F-93200 St Denis, Reunion, France.	gerald.bonardel@gmail.com	SALAUN, Pierre-Yves/X-6701-2019	SALAUN, Pierre-Yves/0000-0002-3899-2135			Bonardel G, 2014, MED NUCL, V38, P188, DOI 10.1016/j.mednuc.2014.03.002; Celier D., MISE JOUR NRD PEDIAT, DOI [10.1016/j.mednuc.2017.02.084, DOI 10.1016/J.MEDNUC.2017.02.084]	2	1	1	0	2	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	SEP-OCT	2018	42	5					295	297		10.1016/j.mednuc.2018.07.003			3	Pathology	Pathology	HO3XT	WOS:000460857000002					2019-10-28	
J	Bonardel, G; Barrau, C; Soussan, M; D'Estanque, E; Erra, B; Etard, C; Fayard, N; Haber, MO; Hapdey, S; Hindie, E; Hyafil, F; Vaylet, CL; Lairez, O; Leroux, PY; Olivier, P; Queneau, M; Rust, E; Seban, R; Sibille, L; Soret, M; Wartski, M				Bonardel, G.; Barrau, C.; Soussan, M.; D'Estanque, E.; Erra, B.; Etard, C.; Fayard, N.; Haber, M. O.; Hapdey, S.; Hindie, E.; Hyafil, F.; Vaylet, C. Labriolle; Lairez, O.; Leroux, P. Y.; Olivier, P.; Queneau, M.; Rust, E.; Seban, R.; Sibille, L.; Soret, M.; Wartski, M.		Grp Travail Radioprotection SFMN	Physical recalls and optimization tools for the image quality and the dose delivered to the patient	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Article								Many parameters can affect the patient's dose and the CT image quality. It is therefore essential, in order to optimize the patient's dosimetry, to know the influence of these parameters as well as their link with the dose modulation tools. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Bonardel, G.; Queneau, M.] Ctr Cardiol Nord, Med Nucl, 32-36 Rue Moulins Gemeaux, F-93200 St Denis, Reunion, France; [Barrau, C.; D'Estanque, E.; Sibille, L.] Hop Caremeau, Med Nucl, Pl Pr Debre, F-30029 Nimes, France; [Soussan, M.] CHU Avicenne, Med Nucl, 125 Rue Stalingrad, F-93000 Bobigny, France; [Erra, B.] CHU Bretonneau, Med Nucl, 2 Blvd Tonnele, F-37044 Tours 9, France; [Etard, C.] IRSN, 31 Ave Div Leclerc, F-92260 Fontenay Aux Roses, France; [Fayard, N.] ASN, 15 Rue Louis Lejeune, F-92120 Montrouge, France; [Haber, M. O.; Soret, M.] Grp Hosp Pitie Salpetriere, Med Nucl, 47-83 Blvd Hop, F-75651 Paris 13, France; [Hapdey, S.] Ctr Henri Becquerel, Med Nucl, I Rue Amiens, F-76038 Rouen, France; [Hindie, E.] Hop Pellegrin Tripode, Med Nucl, Pl Amelie Raba Leon, F-33076 Bordeaux, France; [Hyafil, F.] Hop Bichat Claude Bernard, Med Nucl, 46 Rue H Huchard, F-75018 Paris, France; [Vaylet, C. Labriolle] Hop Enfants A Trousseau, Med Nucl, 26 Ave Dr A Netter, F-75571 Paris 12, France; [Lairez, O.] Hop Rangueil, Med Nucl, 1 Ave J Poulhes TSA50032, F-31059 Toulouse, France; [Leroux, P. Y.] Hop Augustin Morvan, Med Nucl, 3 Ave Foch, F-29269 Brest, France; [Olivier, P.] CHU Nancy, Med Nucl, Rue Morvan, F-54511 Nancy, France; [Rust, E.] Clin Diaconat, Med Nucl, 1 Blvd Pr Roosevelt, F-68200 Mulhouse, France; [Seban, R.] Inst Gustave Roussy, Med Nucl, 114 Rue E Vaillant, F-94805 Villejuif, France; [Wartski, M.] Grp Hosp Cochin, Med Nucl, 27 Rue Faubourg St Jacques, F-75014 Paris, France	Bonardel, G (reprint author), Ctr Cardiol Nord, Med Nucl, 32-36 Rue Moulins Gemeaux, F-93200 St Denis, Reunion, France.	gerald.bonardel@gmail.com	SALAUN, Pierre-Yves/X-6701-2019	SALAUN, Pierre-Yves/0000-0002-3899-2135				0	0	0	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	SEP-OCT	2018	42	5					298	313		10.1016/j.mednuc.2018.07.004			16	Pathology	Pathology	HO3XT	WOS:000460857000003					2019-10-28	
J	Bonardel, G; Barrau, C; Soussan, M; D'Estanque, E; Erra, B; Etard, C; Fayard, N; Haber, MO; Hapdey, S; Hindle, E; Hyafil, F; Vaylet, CL; Lairez, O; Leroux, PY; Olivier, P; Queneau, M; Rust, E; Seban, R; Sibille, L; Soret, M; Wartski, M				Bonardel, G.; Barrau, C.; Soussan, M.; D'Estanque, E.; Erra, B.; Etard, C.; Fayard, N.; Haber, M. O.; Hapdey, S.; Hindle, E.; Hyafil, F.; Vaylet, C. Labriolle; Lairez, O.; Leroux, P. Y.; Olivier, P.; Queneau, M.; Rust, E.; Seban, R.; Sibille, L.; Soret, M.; Wartski, M.		Grp Travail Radioprotection SFMN	Consideration of clinical context	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Article								Once the imaging examination is justified by the clinical context, given the low doses of ionizing radiation delivered by nuclear imaging, the quality of the medical diagnosis always takes precedence over dosimetric considerations. Corollary to this assertion, the voluntary alteration of the image quality and therefore of the quality of the diagnosis on the basis of radiation protection considerations alone constitutes medical malpractice. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Bonardel, G.; Queneau, M.] Ctr Cardiol Nord, Med Nucl, 32-36 Rue Moulins Gemeaux, F-93200 St Denis, Reunion, France; [Barrau, C.; D'Estanque, E.; Sibille, L.] Hop Caremeau, Med Nucl, Pl Pr Debre, F-30029 Nimes, France; [Soussan, M.] CHU Avicenne, Med Nucl, 125 Rue Stalingrad, F-93000 Bobigny, France; [Erra, B.] CHU Bretonneau, Med Nucl, 2 Blvd Tonnele, F-37044 Tours 9, France; [Etard, C.] IRSN, 31 Ave Div Leclerc, F-92260 Fontenay Aux Roses, France; [Fayard, N.] ASN, 15 Rue Louis Lejeune, F-92120 Montrouge, France; [Haber, M. O.; Soret, M.] Grp Hosp Pitie Salpetriere, Med Nucl, 47-83 Blvd Hop, F-75651 Paris 13, France; [Hapdey, S.] Ctr Henri Becquerel, Med Nucl, I Rue Amiens, F-76038 Rouen, France; [Hindle, E.] Hop Pellegrin Tripode, Med Nucl, Pl Amelie Raba Leon, F-33076 Bordeaux, France; [Hyafil, F.] Hop Bichat Claude Bernard, Med Nucl, 46 Rue H Huchard, F-75018 Paris, France; [Vaylet, C. Labriolle] Hop Enfants A Trousseau, Med Nucl, 26 Ave Dr A Netter, F-75571 Paris 12, France; [Lairez, O.] Hop Rangueil, Med Nucl, 1 Ave J Poulhes TSA50032, F-31059 Toulouse, France; [Leroux, P. Y.] Hop Augustin Morvan, Med Nucl, 3 Ave Foch, F-29269 Brest, France; [Olivier, P.] CHU Nancy, Med Nucl, Rue Morvan, F-54511 Nancy, France; [Rust, E.] Clin Diaconat, Med Nucl, 1 Blvd Pr Roosevelt, F-68200 Mulhouse, France; [Seban, R.] Inst Gustave Roussy, Med Nucl, 114 Rue E Vaillant, F-94805 Villejuif, France; [Wartski, M.] Grp Hosp Cochin, Med Nucl, 27 Rue Faubourg St Jacques, F-75014 Paris, France	Bonardel, G (reprint author), Ctr Cardiol Nord, Med Nucl, 32-36 Rue Moulins Gemeaux, F-93200 St Denis, Reunion, France.	gerald.bonardel@gmail.com	SALAUN, Pierre-Yves/X-6701-2019	SALAUN, Pierre-Yves/0000-0002-3899-2135				0	0	0	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	SEP-OCT	2018	42	5					314	317		10.1016/j.mednuc.2018.07.005			4	Pathology	Pathology	HO3XT	WOS:000460857000004					2019-10-28	
J	Bonardel, G; Barrau, C; Soussan, M; D'Estanque, E; Erra, B; Etard, C; Fayard, N; Haber, MO; Hapdey, S; Hindle, E; Hyafil, F; Vaylet, CL; Lairez, O; Leroux, PY; Olivier, P; Queneau, M; Rust, E; Seban, R; Sibille, L; Soret, M; Wartski, M				Bonardel, G.; Barrau, C.; Soussan, M.; D'Estanque, E.; Erra, B.; Etard, C.; Fayard, N.; Haber, M. O.; Hapdey, S.; Hindle, E.; Hyafil, F.; Vaylet, C. Labriolle; Lairez, O.; Leroux, P. Y.; Olivier, P.; Queneau, M.; Rust, E.; Seban, R.; Sibille, L.; Soret, M.; Wartski, M.		Grp Travail Radioprotection SFMN	Clinical illustrations in oncology	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Article							PET/CT	The examples and clinical cases presented in this section are not intended to be considered as absolute models in terms of image quality or device parameter settings. They must initiate an individual analysis according to CT parameters and image quality. Nevertheless, they present practically different CT levels, which can be used according to the clinical context and the type of device. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Bonardel, G.; Queneau, M.] Ctr Cardiol Nord, Med Nucl, 32-36 Rue Moulins Gemeaux, F-93200 St Denis, Reunion, France; [Barrau, C.; D'Estanque, E.; Sibille, L.] Hop Caremeau, Med Nucl, Pl Pr Debre, F-30029 Nimes, France; [Soussan, M.] CHU Avicenne, Med Nucl, 125 Rue Stalingrad, F-93000 Bobigny, France; [Erra, B.] CHU Bretonneau, Med Nucl, 2 Blvd Tonnele, F-37044 Tours 9, France; [Etard, C.] IRSN, 31 Ave Div Leclerc, F-92260 Fontenay Aux Roses, France; [Fayard, N.] ASN, 15 Rue Louis Lejeune, F-92120 Montrouge, France; [Haber, M. O.; Soret, M.] Grp Hosp Pitie Salpetriere, Med Nucl, 47-83 Blvd Hop, F-75651 Paris 13, France; [Hapdey, S.] Ctr Henri Becquerel, Med Nucl, I Rue Amiens, F-76038 Rouen, France; [Hindle, E.] Hop Pellegrin Tripode, Med Nucl, Pl Amelie Raba Leon, F-33076 Bordeaux, France; [Hyafil, F.] Hop Bichat Claude Bernard, Med Nucl, 46 Rue H Huchard, F-75018 Paris, France; [Vaylet, C. Labriolle] Hop Enfants A Trousseau, Med Nucl, 26 Ave Dr A Netter, F-75571 Paris 12, France; [Lairez, O.] Hop Rangueil, Med Nucl, 1 Ave J Poulhes TSA50032, F-31059 Toulouse, France; [Leroux, P. Y.] Hop Augustin Morvan, Med Nucl, 3 Ave Foch, F-29269 Brest, France; [Olivier, P.] CHU Nancy, Med Nucl, Rue Morvan, F-54511 Nancy, France; [Rust, E.] Clin Diaconat, Med Nucl, 1 Blvd Pr Roosevelt, F-68200 Mulhouse, France; [Seban, R.] Inst Gustave Roussy, Med Nucl, 114 Rue E Vaillant, F-94805 Villejuif, France; [Wartski, M.] Grp Hosp Cochin, Grp Travail Radioprotect SFMN, Med Nucl, 27 Rue Faubourg St Jacques, F-75014 Paris, France	Bonardel, G (reprint author), Ctr cardiol Nord, Serv Scintig, 32-36 Rue Moulins Gemaux, F-93200 St Denis, Reunion, France.	gerald.bonardel@gmail.com	SALAUN, Pierre-Yves/X-6701-2019	SALAUN, Pierre-Yves/0000-0002-3899-2135			Boellaard R, 2015, EUR J NUCL MED MOL I, V42, P328, DOI 10.1007/s00259-014-2961-x; De Wever W, 2009, JBR-BTR, V92, P13; Deroose CM, 2016, J NUCL MED, V57, P1949, DOI 10.2967/jnumed.116.179234; Houzard C, 2010, MED NUCL, V34, P439, DOI 10.1016/j.mednuc.2010.06.005; Kim Suk Chul, 2005, World J Surg Oncol, V3, P64, DOI 10.1186/1477-7819-3-64; Kuehl H, 2005, NUKLEARMED-NUCL MED, V44, pS24; Vercellino L, 2014, CLIN NUCL MED, V39, P431, DOI 10.1097/RLU.0b013e31829af8c0	7	0	0	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	SEP-OCT	2018	42	5					318	341		10.1016/j.mednuc.2018.07.006			24	Pathology	Pathology	HO3XT	WOS:000460857000005					2019-10-28	
J	Bonardel, G; Barrau, C; Soussan, M; D'Estanque, E; Erra, B; Etard, C; Fayard, N; Haber, MO; Hapdey, S; Hindle, E; Hyafil, F; Vaylet, CL; Lairez, O; Leroux, PY; Olivier, P; Queneau, M; Rust, E; Seban, R; Sibille, L; Soret, M; Wartski, M				Bonardel, G.; Barrau, C.; Soussan, M.; D'Estanque, E.; Erra, B.; Etard, C.; Fayard, N.; Haber, M. O.; Hapdey, S.; Hindle, E.; Hyafil, F.; Vaylet, C. Labriolle; Lairez, O.; Leroux, P. Y.; Olivier, P.; Queneau, M.; Rust, E.; Seban, R.; Sibille, L.; Soret, M.; Wartski, M.		Grp Travail Radioprotection SFMN	Clinical illustrations in osteoarticular	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Article						scinti; bone scan		The examples and clinical cases presented in this section are not intended to be considered as absolute models in terms of image quality or device parameter settings. They must initiate an individual analysis according to CT parameters and image quality. Nevertheless, they present practically different CT levels, which can be used according to the clinical context and the type of device. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Bonardel, G.; Queneau, M.] Ctr Cardiol Nord, Med Nucl, 32-36 Rue Moulins Gemeaux, F-93200 St Denis, Reunion, France; [Barrau, C.; D'Estanque, E.; Sibille, L.] Hop Caremeau, Med Nucl, Pl Pr Debre, F-30029 Nimes, France; [Soussan, M.] CHU Avicenne, Med Nucl, 125 Rue Stalingrad, F-93000 Bobigny, France; [Erra, B.] CHU Bretonneau, Med Nucl, 2 Blvd Tonnele, F-37044 Tours 9, France; [Etard, C.] IRSN, 31 Ave Div Leclerc, F-92260 Fontenay Aux Roses, France; [Fayard, N.] ASN, 15 Rue Louis Lejeune, F-92120 Montrouge, France; [Haber, M. O.; Soret, M.] Grp Hosp Pitie Salpetriere, Med Nucl, 47-83 Blvd Hop, F-75651 Paris 13, France; [Hapdey, S.] Ctr Henri Becquerel, Med Nucl, I Rue Amiens, F-76038 Rouen, France; [Hindle, E.] Hop Pellegrin Tripode, Med Nucl, Pl Amelie Raba Leon, F-33076 Bordeaux, France; [Hyafil, F.] Hop Bichat Claude Bernard, Med Nucl, 46 Rue H Huchard, F-75018 Paris, France; [Vaylet, C. Labriolle] Hop Enfants A Trousseau, Med Nucl, 26 Ave Dr A Netter, F-75571 Paris 12, France; [Lairez, O.] Hop Rangueil, Med Nucl, 1 Ave J Poulhes TSA50032, F-31059 Toulouse, France; [Leroux, P. Y.] Hop Augustin Morvan, Med Nucl, 3 Ave Foch, F-29269 Brest, France; [Olivier, P.] CHU Nancy, Med Nucl, Rue Morvan, F-54511 Nancy, France; [Rust, E.] Clin Diaconat, Med Nucl, 1 Blvd Pr Roosevelt, F-68200 Mulhouse, France; [Seban, R.] Inst Gustave Roussy, Med Nucl, 114 Rue E Vaillant, F-94805 Villejuif, France; [Wartski, M.] Grp Hosp Cochin, Med Nucl, 27 Rue Faubourg St Jacques, F-75014 Paris, France	Bonardel, G (reprint author), Ctr Cardiol Nord, Serv Scintig, 32-36 Rue Moulins Gemaux, F-93200 St Denis, Reunion, France.	gerald.bonardel@gmail.com	SALAUN, Pierre-Yves/X-6701-2019	SALAUN, Pierre-Yves/0000-0002-3899-2135			Agrawal K, 2015, SEMIN NUCL MED, V45, P347, DOI 10.1053/j.semnuclmed.2015.02.002; Guezennec C, 2017, CANCER IMAGING, V17, DOI 10.1186/s40644-017-0118-4; Huellner MW, 2014, EUR J NUCL MED MOL I, V41, pS50, DOI 10.1007/s00259-013-2533-5; Muller N, 2016, MED NUCL, V40, P315, DOI 10.1016/j.mednuc.2016.05.001; Palmedo H, 2014, EUR J NUCL MED MOL I, V41, P59, DOI 10.1007/s00259-013-2532-6; Schleich FS, 2012, EJNMMI RES, V2, DOI 10.1186/2191-219X-2-53; Schweizer T, 2018, EUR J NUCL MED MOL I, V45, P283, DOI 10.1007/s00259-017-3827-9; Yuan HF, 2015, INT ORTHOP, V39, P1417, DOI 10.1007/s00264-015-2709-7	8	0	0	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	SEP-OCT	2018	42	5					342	353		10.1016/j.mednuc.2018.07.007			12	Pathology	Pathology	HO3XT	WOS:000460857000006					2019-10-28	
J	Bonardel, G; Barrau, C; Soussan, M; D'Estanque, E; Erra, B; Etard, C; Fayard, N; Haber, MO; Hapdey, S; Hindle, E; Hyafil, F; Vaylet, CL; Lairez, O; Leroux, PY; Olivier, P; Queneau, M; Rust, E; Seban, R; Sibille, L; Soret, M; Wartski, M				Bonardel, G.; Barrau, C.; Soussan, M.; D'Estanque, E.; Erra, B.; Etard, C.; Fayard, N.; Haber, M. O.; Hapdey, S.; Hindle, E.; Hyafil, F.; Vaylet, C. Labriolle; Lairez, O.; Leroux, P. Y.; Olivier, P.; Queneau, M.; Rust, E.; Seban, R.; Sibille, L.; Soret, M.; Wartski, M.		Grp Travail Radioprotection SFMN	Clinical illustrations in pneumology (pulmonary embolism)	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Article						Pulmonary embolism; V/Q SPECT	TOMOGRAPHY; SPECT	The examples and clinical cases presented in this section are not intended to be considered as absolute models in terms of image quality or device parameter settings. They must initiate an individual analysis according to CT parameters and image quality. Nevertheless, they present practically different CT levels, which can be used according to the clinical context and the type of device. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Bonardel, G.; Queneau, M.] Ctr Cardiol Nord, Med Nucl, 32-36 Rue Moulins Gemeaux, F-93200 St Denis, Reunion, France; [Barrau, C.; D'Estanque, E.; Sibille, L.] Hop Caremeau, Med Nucl, Pl Pr Debre, F-30029 Nimes, France; [Soussan, M.] CHU Avicenne, Med Nucl, 125 Rue Stalingrad, F-93000 Bobigny, France; [Erra, B.] CHU Bretonneau, Med Nucl, 2 Blvd Tonnele, F-37044 Tours 9, France; [Etard, C.] IRSN, 31 Ave Div Leclerc, F-92260 Fontenay Aux Roses, France; [Fayard, N.] ASN, 15 Rue Louis Lejeune, F-92120 Montrouge, France; [Haber, M. O.; Soret, M.] Grp Hosp Pitie Salpetriere, Med Nucl, 47-83 Blvd Hop, F-75651 Paris 13, France; [Hapdey, S.] Ctr Henri Becquerel, Med Nucl, I Rue Amiens, F-76038 Rouen, France; [Hindle, E.] Hop Pellegrin Tripode, Med Nucl, Pl Amelie Raba Leon, F-33076 Bordeaux, France; [Hyafil, F.] Hop Bichat Claude Bernard, Med Nucl, 46 Rue H Huchard, F-75018 Paris, France; [Vaylet, C. Labriolle] Hop Enfants A Trousseau, Med Nucl, 26 Ave Dr A Netter, F-75571 Paris 12, France; [Lairez, O.] Hop Rangueil, Med Nucl, 1 Ave J Poulhes TSA50032, F-31059 Toulouse, France; [Leroux, P. Y.] Hop Augustin Morvan, Med Nucl, 3 Ave Foch, F-29269 Brest, France; [Olivier, P.] CHU Nancy, Med Nucl, Rue Morvan, F-54511 Nancy, France; [Rust, E.] Clin Diaconat, Med Nucl, 1 Blvd Pr Roosevelt, F-68200 Mulhouse, France; [Seban, R.] Inst Gustave Roussy, Med Nucl, 114 Rue E Vaillant, F-94805 Villejuif, France; [Wartski, M.] Grp Hosp Cochin, Grp Travail Radioprotect SFMN, Med Nucl, 27 Rue Faubourg St Jacques, F-75014 Paris, France	Bonardel, G (reprint author), Ctr Cardiol Nord, Serv Scintig, 32-36 Rue Moulins Gemaux, F-93200 St Denis, Reunion, France.	gerald.bonardel@gmail.com	SALAUN, Pierre-Yves/X-6701-2019	SALAUN, Pierre-Yves/0000-0002-3899-2135			Le Duc-Pennec A, 2012, CHEST, V141, P381, DOI 10.1378/chest.11-0090; Le Roux PY, 2015, NUCL MED COMMUN, V36, P922, DOI 10.1097/MNM.0000000000000351; Mazurek A, 2015, RESPIRATION; Roach PJ, 2013, J NUCL MED, V54, P1588, DOI 10.2967/jnumed.113.124602; Roach PJ, 2010, SEMIN NUCL MED, V40, P455, DOI 10.1053/j.semnuclmed.2010.07.005; Viau P, 2011, MED NUCL, V35, P117, DOI 10.1016/j.mednuc.2010.10.003; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753	7	0	0	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	SEP-OCT	2018	42	5					354	358		10.1016/j.mednuc.2018.07.008			5	Pathology	Pathology	HO3XT	WOS:000460857000007					2019-10-28	
J	Bonardel, G; Barrau, C; Soussan, M; D'Estanque, E; Erra, B; Etard, C; Fayard, N; Haber, MO; Hapdey, S; Hindle, E; Hyafil, F; Vaylet, CL; Lairez, O; Leroux, PY; Olivier, P; Queneau, M; Rust, E; Seban, R; Sibille, L; Soret, M; Wartski, M				Bonardel, G.; Barrau, C.; Soussan, M.; D'Estanque, E.; Erra, B.; Etard, C.; Fayard, N.; Haber, M. O.; Hapdey, S.; Hindle, E.; Hyafil, F.; Vaylet, C. Labriolle; Lairez, O.; Leroux, P. Y.; Olivier, P.; Queneau, M.; Rust, E.; Seban, R.; Sibille, L.; Soret, M.; Wartski, M.		Grp Travail Radioprotection SFMN	Clinical illustrations in endocrinology	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Article							SCINTIGRAPHY; GUIDELINES; SPECT/CT; SURGERY; NECK	The examples and clinical cases presented in this section are not intended to be considered as absolute models in terms of image quality or device parameter settings. They must initiate an individual analysis according to CT parameters and image quality. Nevertheless, they present practically different CT levels, which can be used according to the clinical context and the type of device. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Bonardel, G.; Queneau, M.] Ctr Cardiol Nord, Med Nucl, 32-36 Rue Moulins Gemeaux, F-93200 St Denis, Reunion, France; [Barrau, C.; D'Estanque, E.; Sibille, L.] Hop Caremeau, Med Nucl, Pl Pr Debre, F-30029 Nimes, France; [Soussan, M.] CHU Avicenne, Med Nucl, 125 Rue Stalingrad, F-93000 Bobigny, France; [Erra, B.] CHU Bretonneau, Med Nucl, 2 Blvd Tonnele, F-37044 Tours 9, France; [Etard, C.] IRSN, 31 Ave Div Leclerc, F-92260 Fontenay Aux Roses, France; [Fayard, N.] ASN, 15 Rue Louis Lejeune, F-92120 Montrouge, France; [Haber, M. O.; Soret, M.] Grp Hosp Pitie Salpetriere, Med Nucl, 47-83 Blvd Hop, F-75651 Paris 13, France; [Hapdey, S.] Ctr Henri Becquerel, Med Nucl, I Rue Amiens, F-76038 Rouen, France; [Hindle, E.] Hop Pellegrin Tripode, Med Nucl, Pl Amelie Raba Leon, F-33076 Bordeaux, France; [Hyafil, F.] Hop Bichat Claude Bernard, Med Nucl, 46 Rue H Huchard, F-75018 Paris, France; [Vaylet, C. Labriolle] Hop Enfants A Trousseau, Med Nucl, 26 Ave Dr A Netter, F-75571 Paris 12, France; [Lairez, O.] Hop Rangueil, Med Nucl, 1 Ave J Poulhes TSA50032, F-31059 Toulouse, France; [Leroux, P. Y.] Hop Augustin Morvan, Med Nucl, 3 Ave Foch, F-29269 Brest, France; [Olivier, P.] CHU Nancy, Med Nucl, Rue Morvan, F-54511 Nancy, France; [Rust, E.] Clin Diaconat, Med Nucl, 1 Blvd Pr Roosevelt, F-68200 Mulhouse, France; [Seban, R.] Inst Gustave Roussy, Med Nucl, 114 Rue E Vaillant, F-94805 Villejuif, France; [Wartski, M.] Grp Hosp Cochin, Grp Travail Radioprotect SFMN, Med Nucl, 27 Rue Faubourg St Jacques, F-75014 Paris, France	Bonardel, G (reprint author), Ctr Cardiol Nord, Med Nucl, 32-36 Rue Moulins Gemeaux, F-93200 St Denis, Reunion, France.	gerald.bonardel@gmail.com	SALAUN, Pierre-Yves/X-6701-2019	SALAUN, Pierre-Yves/0000-0002-3899-2135			Aide N, 2009, J CLIN ENDOCR METAB, V94, P2075, DOI 10.1210/jc.2008-2313; Bardet S, 2010, MED NUCL, V34, P457, DOI 10.1016/j.mednuc.2010.05.001; Giraudet AL, 2017, MED NUCL, V41, pS23, DOI 10.1016/j.mednuc.2017.03.002; Glazer DI, 2013, RADIOGRAPHICS, V33, P397, DOI 10.1148/rg.332125051; Hindie E, 2015, J NUCL MED, V56, P737, DOI 10.2967/jnumed.115.156018; Quak E, 2018, EUR J NUCL MED MOL I, V45, P658, DOI 10.1007/s00259-017-3911-1; Taieb D, 2012, EUR J NUCL MED MOL I, V39, P1977, DOI 10.1007/s00259-012-2215-8; Wong KK, 2010, CLIN NUCL MED, V35, P865, DOI 10.1097/RLU.0b013e3181f4a16d; Wong KK, 2016, WORLD J RADIOL, V8, P635, DOI 10.4329/wjr.v8.i6.635	9	0	0	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	SEP-OCT	2018	42	5					359	366		10.1016/j.mednuc.2018.07.009			8	Pathology	Pathology	HO3XT	WOS:000460857000008					2019-10-28	
J	Bonardel, G; Barrau, C; Soussan, M; D'Estanque, E; Erra, B; Etard, C; Fayard, N; Haber, MO; Hapdey, S; Hindle, E; Hyafil, F; Vaylet, CL; Lairez, O; Leroux, PY; Olivier, P; Queneau, M; Rust, E; Seban, R; Sibille, L; Soret, M; Wartski, M				Bonardel, G.; Barrau, C.; Soussan, M.; D'Estanque, E.; Erra, B.; Etard, C.; Fayard, N.; Haber, M. O.; Hapdey, S.; Hindle, E.; Hyafil, F.; Vaylet, C. Labriolle; Lairez, O.; Leroux, P. Y.; Olivier, P.; Queneau, M.; Rust, E.; Seban, R.; Sibille, L.; Soret, M.; Wartski, M.		Grp Travail Radioprotection SFMN	Clinical illustrations in neurology	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Article						Brain perfusion spect; Brain FDG PET; Brain FDOPA-PET; Amyloide PET		The examples and clinical cases presented in this section are not intended to be considered as absolute models in terms of image quality or device parameter settings. They must initiate an individual analysis according to CT parameters and image quality. Nevertheless, they present practically different CT levels, which can be used according to the clinical context and the type of device. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Bonardel, G.; Queneau, M.] Ctr Cardiol Nord, Med Nucl, 32-36 Rue Moulins Gemeaux, F-93200 St Denis, Reunion, France; [Barrau, C.; D'Estanque, E.; Sibille, L.] Hop Caremeau, Med Nucl, Pl Pr Debre, F-30029 Nimes, France; [Soussan, M.] CHU Avicenne, Med Nucl, 125 Rue Stalingrad, F-93000 Bobigny, France; [Erra, B.] CHU Bretonneau, Med Nucl, 2 Blvd Tonnele, F-37044 Tours 9, France; [Etard, C.] IRSN, 31 Ave Div Leclerc, F-92260 Fontenay Aux Roses, France; [Fayard, N.] ASN, 15 Rue Louis Lejeune, F-92120 Montrouge, France; [Haber, M. O.; Soret, M.] Grp Hosp Pitie Salpetriere, Med Nucl, 47-83 Blvd Hop, F-75651 Paris 13, France; [Hapdey, S.] Ctr Henri Becquerel, Med Nucl, I Rue Amiens, F-76038 Rouen, France; [Hindle, E.] Hop Pellegrin Tripode, Med Nucl, Pl Amelie Raba Leon, F-33076 Bordeaux, France; [Hyafil, F.] Hop Bichat Claude Bernard, Med Nucl, 46 Rue H Huchard, F-75018 Paris, France; [Vaylet, C. Labriolle] Hop Enfants A Trousseau, Med Nucl, 26 Ave Dr A Netter, F-75571 Paris 12, France; [Lairez, O.] Hop Rangueil, Med Nucl, 1 Ave J Poulhes TSA50032, F-31059 Toulouse, France; [Leroux, P. Y.] Hop Augustin Morvan, Med Nucl, 3 Ave Foch, F-29269 Brest, France; [Olivier, P.] CHU Nancy, Med Nucl, Rue Morvan, F-54511 Nancy, France; [Rust, E.] Clin Diaconat, Med Nucl, 1 Blvd Pr Roosevelt, F-68200 Mulhouse, France; [Seban, R.] Inst Gustave Roussy, Med Nucl, 114 Rue E Vaillant, F-94805 Villejuif, France; [Wartski, M.] Grp Hosp Cochin, Grp Travail Radioprotect SFMN, Med Nucl, 27 Rue Faubourg St Jacques, F-75014 Paris, France	Bonardel, G (reprint author), Ctr Cardiol Nord, Serv Scintig, 32-36 Rue Moulins Gemaux, F-93200 St Denis, Reunion, France.	gerald.bonardel@gmail.com	SALAUN, Pierre-Yves/X-6701-2019	SALAUN, Pierre-Yves/0000-0002-3899-2135				0	0	0	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	SEP-OCT	2018	42	5					367	369		10.1016/j.mednuc.2018.07.010			3	Pathology	Pathology	HO3XT	WOS:000460857000009					2019-10-28	
J	Bonardel, G; Barrau, C; Soussan, M; D'Estanque, E; Erra, B; Etard, C; Fayard, N; Haber, MO; Hapdey, S; Hindle, E; Hyafil, F; Vaylet, CL; Lairez, O; Leroux, PY; Olivier, P; Queneau, M; Rust, E; Seban, R; Sibille, L; Soret, M; Wartski, M				Bonardel, G.; Barrau, C.; Soussan, M.; D'Estanque, E.; Erra, B.; Etard, C.; Fayard, N.; Haber, M. O.; Hapdey, S.; Hindle, E.; Hyafil, F.; Vaylet, C. Labriolle; Lairez, O.; Leroux, P. Y.; Olivier, P.; Queneau, M.; Rust, E.; Seban, R.; Sibille, L.; Soret, M.; Wartski, M.		Grp Travail Radioprotection SFMN	Clinical illustrations in cardiology	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Article						myocardial perfusion scintigraphy; Radionuclide ventriculography; White blood cells scintigraphy; Myocardial scintigraphy with bone tracers; FDG-PET; Myocardial perfusion PET	CORONARY CT ANGIOGRAPHY; COMPUTED TOMOGRAPHY/COMPUTED TOMOGRAPHY; STATISTICAL ITERATIVE RECONSTRUCTION; ATTENUATION CORRECTION; MYOCARDIAL-PERFUSION; 1ST EXPERIENCE; IMAGE QUALITY; SPECT; MISREGISTRATION; PET	The examples and clinical cases presented in this section are not intended to be considered as absolute models in terms of image quality or device parameter settings. They must initiate an individual analysis according to CT parameters and image quality. Nevertheless, they present practically different CT levels which can be used according to the clinical context and the type of device. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Bonardel, G.; Queneau, M.] Ctr Cardiol Nord, Med Nucl, 32-36 Rue Moulins Gemeaux, F-93200 St Denis, Reunion, France; [Barrau, C.; D'Estanque, E.; Sibille, L.] Hop Caremeau, Med Nucl, Pl Pr Debre, F-30029 Nimes, France; [Soussan, M.] CHU Avicenne, Med Nucl, 125 Rue Stalingrad, F-93000 Bobigny, France; [Erra, B.] CHU Bretonneau, Med Nucl, 2 Blvd Tonnele, F-37044 Tours 9, France; [Etard, C.] IRSN, 31 Ave Div Leclerc, F-92260 Fontenay Aux Roses, France; [Fayard, N.] ASN, 15 Rue Louis Lejeune, F-92120 Montrouge, France; [Haber, M. O.; Soret, M.] Grp Hosp Pitie Salpetriere, Med Nucl, 47-83 Blvd Hop, F-75651 Paris 13, France; [Hapdey, S.] Ctr Henri Becquerel, Med Nucl, I Rue Amiens, F-76038 Rouen, France; [Hindle, E.] Hop Pellegrin Tripode, Med Nucl, Pl Amelie Raba Leon, F-33076 Bordeaux, France; [Hyafil, F.] Hop Bichat Claude Bernard, Med Nucl, 46 Rue H Huchard, F-75018 Paris, France; [Vaylet, C. Labriolle] Hop Enfants A Trousseau, Med Nucl, 26 Ave Dr A Netter, F-75571 Paris 12, France; [Lairez, O.] Hop Rangueil, Med Nucl, 1 Ave J Poulhes TSA50032, F-31059 Toulouse, France; [Leroux, P. Y.] Hop Augustin Morvan, Med Nucl, 3 Ave Foch, F-29269 Brest, France; [Olivier, P.] CHU Nancy, Med Nucl, Rue Morvan, F-54511 Nancy, France; [Rust, E.] Clin Diaconat, Med Nucl, 1 Blvd Pr Roosevelt, F-68200 Mulhouse, France; [Seban, R.] Inst Gustave Roussy, Med Nucl, 114 Rue E Vaillant, F-94805 Villejuif, France; [Wartski, M.] Grp Hosp Cochin, Med Nucl, 27 Rue Faubourg St Jacques, F-75014 Paris, France	Bonardel, G (reprint author), Ctr Cardiol Nord, Med Nucl, 32-36 Rue Moulins Gemeaux, F-93200 St Denis, Reunion, France.	gerald.bonardel@gmail.com	SALAUN, Pierre-Yves/X-6701-2019	SALAUN, Pierre-Yves/0000-0002-3899-2135			Abbara Suhny, 2009, J Cardiovasc Comput Tomogr, V3, P190, DOI 10.1016/j.jcct.2009.03.004; Achenbach S, 2010, EUR HEART J, V31, P340, DOI 10.1093/eurheartj/ehp470; Danad I, 2017, JAMA CARDIOL, V2, P1100, DOI 10.1001/jamacardio.2017.2471; Einstein AJ, 2010, J AM COLL CARDIOL, V56, P1914, DOI 10.1016/j.jacc.2010.05.057; Goetze S, 2007, J NUCL MED, V48, P1090, DOI 10.2967/jnumed.107.040535; Husmann L, 2008, EUR HEART J, V29, P191, DOI 10.1093/eurheartj/ehm613; Husmann L, 2009, EUR HEART J, V30, P600, DOI [10.1093/eurheartj/ehn490, 10.1093/eurheartj/ehn536]; Jacobs Jill E, 2006, J Am Coll Radiol, V3, P677, DOI 10.1016/j.jacr.2006.06.006; Javadi M, 2008, J NUCL CARDIOL, V15, P783, DOI [10.1016/j.nuclcard.2008.07.007, 10.1007/BF03007359]; Kajander S, 2010, CIRCULATION, V122, P603, DOI 10.1161/CIRCULATIONAHA.109.915009; Kennedy JA, 2009, J NUCL MED, V50, P1471, DOI 10.2967/jnumed.109.062141; LaBounty TM, 2010, AM J ROENTGENOL, V194, P933, DOI 10.2214/AJR.09.3371; Leipsic J, 2010, AM J ROENTGENOL, V195, P655, DOI 10.2214/AJR.10.4288; Leipsic J, 2010, AM J ROENTGENOL, V195, P649, DOI 10.2214/AJR.10.4285; Madsen MT, 2007, J NUCL MED, V48, P661, DOI 10.2967/jnumed.106.032680; Mark DB, 2010, J AM COLL CARDIOL, V55, P1029, DOI [10.1016/j.jacc.2009.11.048, 10.1016/j.jacc.2009.11.013]; Masood Y, 2005, J NUCL CARDIOL, V12, P676, DOI 10.1016/j.nuclcard.2005.08.006; O'Connor MK, 2006, SEMIN NUCL MED, V36, P258, DOI 10.1053/j.semnuclmed.2006.05.005; Scheffel H, 2008, HEART, V94, P1132, DOI 10.1136/hrt.2008.149971; Shaw LJ, 2009, J NUCL MED, V50, P1296, DOI 10.2967/jnumed.108.059592; Weigold WG, 2011, J CARDIOVASC COMPUT, V5, P136, DOI 10.1016/j.jcct.2011.04.004	21	0	0	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	SEP-OCT	2018	42	5					370	378		10.1016/j.mednuc.2018.07.011			9	Pathology	Pathology	HO3XT	WOS:000460857000010					2019-10-28	
J	Bonardel, G; Barrau, C; Soussan, M; D'Estanque, E; Erra, B; Etard, C; Fayard, N; Haber, MO; Hapdey, S; Hindle, E; Hyafil, F; Vaylet, CL; Lairez, O; Leroux, PY; Olivier, P; Queneau, M; Rust, E; Seban, R; Sibille, L; Soret, M; Wartski, M				Bonardel, G.; Barrau, C.; Soussan, M.; D'Estanque, E.; Erra, B.; Etard, C.; Fayard, N.; Haber, M. O.; Hapdey, S.; Hindle, E.; Hyafil, F.; Vaylet, C. Labriolle; Lairez, O.; Leroux, P. Y.; Olivier, P.; Queneau, M.; Rust, E.; Seban, R.; Sibille, L.; Soret, M.; Wartski, M.		Grp Travail Radioprotection SFMN	Pediatric clinical illustrations	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Article							FDG-PET; CT; NEUROBLASTOMA; SCINTIGRAPHY; SPECT/CT	The examples and clinical cases presented in this section are not intended to be considered as absolute models in terms of image quality or device parameter settings. They must initiate an individual analysis according to CT parameters and image quality. Nevertheless, they present practically different CT levels which can be used according to the clinical context and the type of device. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Bonardel, G.; Queneau, M.] Ctr Cardiol Nord, Med Nucl, 32-36 Rue Moulins Gemeaux, F-93200 St Denis, Reunion, France; [Barrau, C.; D'Estanque, E.; Sibille, L.] Hop Caremeau, Med Nucl, Pl Pr Debre, F-30029 Nimes, France; [Soussan, M.] CHU Avicenne, Med Nucl, 125 Rue Stalingrad, F-93000 Bobigny, France; [Erra, B.] CHU Bretonneau, Med Nucl, 2 Blvd Tonnele, F-37044 Tours 9, France; [Etard, C.] IRSN, 31 Ave Div Leclerc, F-92260 Fontenay Aux Roses, France; [Fayard, N.] ASN, 15 Rue Louis Lejeune, F-92120 Montrouge, France; [Haber, M. O.; Soret, M.] Grp Hosp Pitie Salpetriere, Med Nucl, 47-83 Blvd Hop, F-75651 Paris 13, France; [Hapdey, S.] Ctr Henri Becquerel, Med Nucl, I Rue Amiens, F-76038 Rouen, France; [Hindle, E.] Hop Pellegrin Tripode, Med Nucl, Pl Amelie Raba Leon, F-33076 Bordeaux, France; [Hyafil, F.] Hop Bichat Claude Bernard, Med Nucl, 46 Rue H Huchard, F-75018 Paris, France; [Vaylet, C. Labriolle] Hop Enfants A Trousseau, Med Nucl, 26 Ave Dr A Netter, F-75571 Paris 12, France; [Lairez, O.] Hop Rangueil, Med Nucl, 1 Ave J Poulhes TSA50032, F-31059 Toulouse, France; [Leroux, P. Y.] Hop Augustin Morvan, Med Nucl, 3 Ave Foch, F-29269 Brest, France; [Olivier, P.] CHU Nancy, Med Nucl, Rue Morvan, F-54511 Nancy, France; [Rust, E.] Clin Diaconat, Med Nucl, 1 Blvd Pr Roosevelt, F-68200 Mulhouse, France; [Seban, R.] Inst Gustave Roussy, Med Nucl, 114 Rue E Vaillant, F-94805 Villejuif, France; [Wartski, M.] Grp Hosp Cochin, Med Nucl, 27 Rue Faubourg St Jacques, F-75014 Paris, France	Bonardel, G (reprint author), Ctr Cardiol Nord, Med Nucl, 32-36 Rue Moulins Gemeaux, F-93200 St Denis, Reunion, France.	gerald.bonardel@gmail.com	SALAUN, Pierre-Yves/X-6701-2019	SALAUN, Pierre-Yves/0000-0002-3899-2135			Biermann M, 2013, ACTA RADIOL, V54, P1037, DOI 10.1258/ar.2012.120616; Binkovitz LA, 2003, PEDIATR RADIOL, V33, P598, DOI 10.1007/s00247-003-0943-4; Colleran GC, 2017, CANCER IMAGING, V17, DOI 10.1186/s40644-017-0130-8; De Palma D, 2016, CLIN TRANSL IMAGING, V4, P191, DOI 10.1007/s40336-016-0169-8; Fahey FH, 2007, RADIOLOGY, V243, P96, DOI 10.1148/radiol.2431060696; Fahey FH, 2017, J NUCL MED, V58, P1360, DOI 10.2967/jnumed.116.182899; Fahey FH, 2017, SEMIN NUCL MED, V47, P118, DOI 10.1053/j.semnuclmed.2016.10.006; IRSN, 2012, PRPHOM201212 IRSN; Nadel HR, 2014, EUR J NUCL MED MOL I, V41, pS104, DOI 10.1007/s00259-014-2697-7; Parisi MT, 2018, SEMIN NUCL MED, V48, P148, DOI 10.1053/j.semnuclmed.2017.11.002; Parisi MT, 2018, SEMIN MUSCULOSKEL R, V22, P25, DOI 10.1055/s-0037-1615782; Parisi MT, 2017, SEMIN NUCL MED, V47, P258, DOI 10.1053/j.semnuclmed.2017.01.002; Phillips M, 2009, PEDIATR BLOOD CANCER, V52, P97, DOI 10.1002/pbc.21782; Rozovsky K, 2008, AM J ROENTGENOL, V190, P1085, DOI 10.2214/AJR.07.2107; Sharp SE, 2013, Q J NUCL MED MOL IM, V57, P6; Sharp SE, 2009, J NUCL MED, V50, P1237, DOI 10.2967/jnumed.108.060467; Shulkin BL, 1996, RADIOLOGY, V199, P743, DOI 10.1148/radiology.199.3.8637999; Treves S T, 2014, PEDIAT NUCL MED MOL	18	0	0	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	SEP-OCT	2018	42	5					379	390		10.1016/j.mednuc.2018.07.012			12	Pathology	Pathology	HO3XT	WOS:000460857000011					2019-10-28	
J	Bonardel, G; Barrau, C; Soussan, M; D'Estanque, E; Erra, B; Etard, C; Fayard, N; Habert, MO; Hapdey, S; Hindie, E; Hyafil, F; Vaylet, CL; Lairez, O; Leroux, PY; Olivier, P; Queneau, M; Rust, E; Seban, R; Sibille, L; Soret, M; Wartski, M				Bonardel, G.; Barrau, C.; Soussan, M.; D'Estanque, E.; Erra, B.; Etard, C.; Fayard, N.; Habert, M. O.; Hapdey, S.; Hindie, E.; Hyafil, F.; Vaylet, C. Labriolle; Lairez, O.; Leroux, P. Y.; Olivier, P.; Queneau, M.; Rust, E.; Seban, R.; Sibille, L.; Soret, M.; Wartski, M.			Iodinated Contrast Agent (ICA)	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Article							ATTENUATION CORRECTION; CT	Iodinated Contrast Agent (ICA) may be used in nuclear medicine for level 3 and 4 CT level. The use of ICA in SPECT/CT or PET/CT is driven, for each patient, by the clinical context, the benefit/risk ratio and the availability and the date of the previous injected CT. The improvement in diagnostic performance of the exam is the main goal of the ICA injection during a hybrid NM procedure. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Bonardel, G.; Queneau, M.] Ctr Cardiol Nord, Med Nucl, 32-36 Rue Moulins Gemeaux, F-93200 St Denis, France; [Barrau, C.; D'Estanque, E.; Sibille, L.] Hop Caremeau, Med Nucl, Pl Pr Debre, F-30029 Nimes, France; [Soussan, M.] CHU Avicenne, Med Nucl, 125 Rue Stalingrad, F-93000 Bobigny, France; [Erra, B.] CHU Bretonneau, Med Nucl, 2 Blvd Tonnele, F-37044 Tours 9, France; [Etard, C.] IRSN, 31 Ave Div Leclerc, F-92260 Fontenay Aux Roses, France; [Fayard, N.] ASN, 15 Rue Louis Lejeune, F-92120 Montrouge, France; [Habert, M. O.; Soret, M.] Grp Hosp Pitie Salpetriere, Med Nucl, 47-83 Blvd Hop, F-75651 Paris 13, France; [Hapdey, S.] Ctr Henri Becquerel, Med Nucl, 1 Rue Amiens, F-76038 Rouen, France; [Hindie, E.] Hop Pellegrin Tripode, Med Nucl, Pl Amelie Raba Leon, F-33076 Bordeaux, France; [Hyafil, F.] Hop Bichat Claude Bernard, Med Nucl, 46 Rue H Huchard, F-75018 Paris, France; [Vaylet, C. Labriolle] Hop Enfants A Trousseau, Med Nucl, 26 Ave Dr A Netter, F-75571 Paris 12, France; [Lairez, O.] Hop Rangueil, Med Nucl, 1 Ave J Poulhes,TSA50032, F-31059 Toulouse, France; [Leroux, P. Y.] Hop Augustin Morvan, Med Nucl, 3 Ave Foch, F-29269 Brest, France; [Olivier, P.] CHU, Med Nucl, Rue Morvan, F-54511 Nancy, France; [Rust, E.] Clin Diaconat, Med Nucl, 1 Blvd Pr Roosevelt, F-68200 Mulhouse, France; [Seban, R.] Inst Gustave Roussy, Med Nucl, 114 Rue E Vaillant, F-94805 Villejuif, France; [Wartski, M.] Grp Hosp Cochin, Med Nucl, Grp Travail Radioprotect SFMN, 27 rue Faubourg St Jacques, F-75014 Paris, France	Bonardel, G (reprint author), Ctr Cardiol Nord, Med Nucl, 32-36 Rue Moulins Gemeaux, F-93200 St Denis, France.	gerald.bonardel@gmail.com	SALAUN, Pierre-Yves/X-6701-2019	SALAUN, Pierre-Yves/0000-0002-3899-2135			Ahmet A, 2009, ACTA PAEDIATR, V98, P1568, DOI 10.1111/j.1651-2227.2009.01412.x; Aschoff P, 2012, EUR J NUCL MED MOL I, V39, P316, DOI 10.1007/s00259-011-1919-5; Dizendorf E, 2003, J NUCL MED, V44, P732; Gloaguen A, 2017, REV FR ALLERGOL, V57, P595, DOI 10.1016/j.reval.2017.10.004; Williams FLR, 2017, J PERINAT MED, V45, P135, DOI 10.1515/jpm-2016-0141	5	0	0	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	SEP-OCT	2018	42	5					391	399		10.1016/j.mednuc.2018.07.013			9	Pathology	Pathology	HO3XT	WOS:000460857000012					2019-10-28	
J	Bonardel, G; Barrau, C; Soussan, M; D'Estanque, E; Erra, B; Etard, C; Fayard, N; Habert, MO; Hapdey, S; Hindie, E; Hyafil, F; Vaylet, CL; Lairez, O; Leroux, PY; Olivier, P; Queneau, M; Rust, E; Seban, R; Sibille, L; Soret, M; Wartski, M				Bonardel, G.; Barrau, C.; Soussan, M.; D'Estanque, E.; Erra, B.; Etard, C.; Fayard, N.; Habert, M. O.; Hapdey, S.; Hindie, E.; Hyafil, F.; Vaylet, C. Labriolle; Lairez, O.; Leroux, P. Y.; Olivier, P.; Queneau, M.; Rust, E.; Seban, R.; Sibille, L.; Soret, M.; Wartski, M.			Artifacts and Fitfalls/Tricks	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Article								Artifacts result from discrepancy between the estimated density values coming from the reconstructed CT image and the real value. They may come from many reasons (patient, device, algorithm, RX physical) and lead to deterioration of image quality and bad attenuation correction for SPECT or PET. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Bonardel, G.; Queneau, M.] Ctr Cardiol Nord, Med Nucl, 32-36 Rue Moulins Gemeaux, F-93200 St Denis, France; [Barrau, C.; D'Estanque, E.; Sibille, L.] Hop Caremeau, Med Nucl, Pl Pr Debre, F-30029 Nimes, France; [Soussan, M.] CHU Avicenne, Med Nucl, 125 Rue Stalingrad, F-93000 Bobigny, France; [Erra, B.] CHU Bretonneau, Med Nucl, 2 Blvd Tonnele, F-37044 Tours 9, France; [Etard, C.] IRSN, 31 Ave Div Leclerc, F-92260 Fontenay Aux Roses, France; [Fayard, N.] ASN, 15 Rue Louis Lejeune, F-92120 Montrouge, France; [Habert, M. O.; Soret, M.] Grp Hosp Pitie Salpetriere, Med Nucl, 47-83 Blvd Hop, F-75651 Paris 13, France; [Hapdey, S.] Ctr Henri Becquerel, Med Nucl, 1 Rue Amiens, F-76038 Rouen, France; [Hindie, E.] Hop Pellegrin Tripode, Med Nucl, Pl Amelie Raba Leon, F-33076 Bordeaux, France; [Hyafil, F.] Hop Bichat Claude Bernard, Med Nucl, 46 Rue H Huchard, F-75018 Paris, France; [Vaylet, C. Labriolle] Hop Enfants A Trousseau, Med Nucl, 26 Ave Dr A Netter, F-75571 Paris 12, France; [Lairez, O.] Hop Rangueil, Med Nucl, 1 Ave J Poulhes,TSA50032, F-31059 Toulouse, France; [Leroux, P. Y.] Hop Augustin Morvan, Med Nucl, 3 Ave Foch, F-29269 Brest, France; [Olivier, P.] CHU, Med Nucl, Rue Morvan, F-54511 Nancy, France; [Rust, E.] Clin Diaconat, Med Nucl, 1 Blvd Pr Roosevelt, F-68200 Mulhouse, France; [Seban, R.] Inst Gustave Roussy, Med Nucl, 114 Rue E Vaillant, F-94805 Villejuif, France; [Wartski, M.] Grp Hosp Cochin, Med Nucl, Grp Travail Radioprotect SFMN, 27 Rue Faubourg St Jacques, F-75014 Paris, France	Bonardel, G (reprint author), Ctr Cardiol Nord, Med Nucl, 32-36 Rue Moulins Gemeaux, F-93200 St Denis, France.	gerald.bonardel@gmail.com	SALAUN, Pierre-Yves/X-6701-2019	SALAUN, Pierre-Yves/0000-0002-3899-2135			Barrett JF, 2004, RADIOGRAPHICS, V24, P1679, DOI 10.1148/rg.246045065; F Edward Boas & Dominik Fleischmann, 2012, IMAGING MED, V4, P229, DOI DOI 10.2217/IIM.12.13; Modica MJ, 2011, RADIOGRAPHICS, V31, P811, DOI 10.1148/rg.313105138	3	0	0	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	SEP-OCT	2018	42	5					400	407		10.1016/j.mednuc.2018.07.014			8	Pathology	Pathology	HO3XT	WOS:000460857000013					2019-10-28	
J	Bonardel, G; Barrau, C; Soussan, M; D'Estanque, E; Erra, B; Etard, C; Fayard, N; Habert, MO; Hapdey, S; Hindie, E; Hyafil, F; Vaylet, CL; Lairez, O; Leroux, PY; Olivier, P; Queneau, M; Rust, E; Seban, R; Sibille, L; Soret, M; Wartski, M				Bonardel, G.; Barrau, C.; Soussan, M.; D'Estanque, E.; Erra, B.; Etard, C.; Fayard, N.; Habert, M. O.; Hapdey, S.; Hindie, E.; Hyafil, F.; Vaylet, C. Labriolle; Lairez, O.; Leroux, P. Y.; Olivier, P.; Queneau, M.; Rust, E.; Seban, R.; Sibille, L.; Soret, M.; Wartski, M.			Regulatory and practical aspects	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Article						Quality and regulatory controls; Installations constraints; Diagnostic Reference values; Medical reports		Quality and regulatory controls in hybrid nuclear medicine, layout and installations constraints, Diagnostic Reference values and regulatory and mandatory information in the medical report are presented in that part. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Bonardel, G.; Queneau, M.] Ctr Cardiol Nord, Med Nucl, 32-36 Rue Moulins Gemeaux, F-93200 St Denis, France; [Barrau, C.; D'Estanque, E.; Sibille, L.] Hop Caremeau, Med Nucl, Pl Pr Debre, F-30029 Nimes, France; [Soussan, M.] CHU Avicenne, Med Nucl, 125 Rue Stalingrad, F-93000 Bobigny, France; [Erra, B.] CHU Bretonneau, Med Nucl, 2 Blvd Tonnele, F-37044 Tours 9, France; [Etard, C.] IRSN, 31 Ave Div Leclerc, F-92260 Fontenay Aux Roses, France; [Fayard, N.] ASN, 15 Rue Louis Lejeune, F-92120 Montrouge, France; [Habert, M. O.; Soret, M.] Grp Hosp Pitie Salpetriere, Med Nucl, 47-83 Blvd Hop, F-75651 Paris 13, France; [Hapdey, S.] Ctr Henri Becquerel, Med Nucl, 1 Rue Amiens, F-76038 Rouen, France; [Hindie, E.] Hop Pellegrin Tripode, Med Nucl, Pl Amelie Raba Leon, F-33076 Bordeaux, France; [Hyafil, F.] Hop Bichat Claude Bernard, Med Nucl, 46 Rue H Huchard, F-75018 Paris, France; [Vaylet, C. Labriolle] Hop Enfants A Trousseau, Med Nucl, 26 Ave Dr A Netter, F-75571 Paris 12, France; [Lairez, O.] Hop Rangueil, Med Nucl, 1 Ave J Poulhes,TSA50032, F-31059 Toulouse, France; [Leroux, P. Y.] Hop Augustin Morvan, Med Nucl, 3 Ave Foch, F-29269 Brest, France; [Olivier, P.] CHU, Med Nucl, Rue Morvan, F-54511 Nancy, France; [Rust, E.] Clin Diaconat, Med Nucl, 1 Blvd Pr Roosevelt, F-68200 Mulhouse, France; [Seban, R.] Inst Gustave Roussy, Med Nucl, 114 Rue E Vaillant, F-94805 Villejuif, France; [Wartski, M.] Grp Hosp Cochin, Med Nucl, Grp Travail Radioprotect SFMN, 27 Rue Faubourg St Jacques, F-75014 Paris, France	Bonardel, G (reprint author), Ctr Cardiol Nord, Serv Scintig, 32-36 Rue Moulins Gemaux, F-93200 St Denis, France.	gerald.bonardel@gmail.com	SALAUN, Pierre-Yves/X-6701-2019	SALAUN, Pierre-Yves/0000-0002-3899-2135			[Anonymous], 2011, 15160 NFC; [Anonymous], 2012, 28 SOC FRANC PHYS ME; [Anonymous], 2008, 24 SOC FRANC PHYS ME	3	0	0	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	SEP-OCT	2018	42	5					408	413		10.1016/j.mednuc.2018.07.015			6	Pathology	Pathology	HO3XT	WOS:000460857000014					2019-10-28	
J	Bonardel, G; Barrau, C; Soussan, M; D'Estanque, E; Erra, B; Etard, C; Fayard, N; Habert, MO; Hapdey, S; Hindie, E; Hyafil, F; Vaylet, CL; Lairez, O; Leroux, PY; Olivier, P; Queneau, M; Rust, E; Seban, R; Sibille, L; Soret, M; Wartski, M				Bonardel, G.; Barrau, C.; Soussan, M.; D'Estanque, E.; Erra, B.; Etard, C.; Fayard, N.; Habert, M. O.; Hapdey, S.; Hindie, E.; Hyafil, F.; Vaylet, C. Labriolle; Lairez, O.; Leroux, P. Y.; Olivier, P.; Queneau, M.; Rust, E.; Seban, R.; Sibille, L.; Soret, M.; Wartski, M.			CT good practices for hybrid nuclear medicine (SPECT/CT and PET/CT): Conclusion	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Article									[Bonardel, G.; Queneau, M.] Ctr Cardiol Nord, Med Nucl, 32-36 Rue Moulins Gemeaux, F-93200 St Denis, France; [Barrau, C.; D'Estanque, E.; Sibille, L.] Hop Caremeau, Med Nucl, Pl Pr Debre, F-30029 Nimes, France; [Soussan, M.] CHU Avicenne, Med Nucl, 125 Rue Stalingrad, F-93000 Bobigny, France; [Erra, B.] CHU Bretonneau, Med Nucl, 2 Blvd Tonnele, F-37044 Tours 9, France; [Etard, C.] IRSN, 31 Ave Div Leclerc, F-92260 Fontenay Aux Roses, France; [Fayard, N.] ASN, 15 Rue Louis Lejeune, F-92120 Montrouge, France; [Habert, M. O.; Soret, M.] Grp Hosp Pitie Salpetriere, Med Nucl, 47-83 Blvd Hop, F-75651 Paris 13, France; [Hapdey, S.] Ctr Henri Becquerel, Med Nucl, 1 Rue Amiens, F-76038 Rouen, France; [Hindie, E.] Hop Pellegrin Tripode, Med Nucl, Pl Amelie Raba Leon, F-33076 Bordeaux, France; [Hyafil, F.] Hop Bichat Claude Bernard, Med Nucl, 46 Rue H Huchard, F-75018 Paris, France; [Vaylet, C. Labriolle] Hop Enfants A Trousseau, Med Nucl, 26 Ave Dr A Netter, F-75571 Paris 12, France; [Lairez, O.] Hop Rangueil, Med Nucl, 1 Ave J Poulhes,TSA50032, F-31059 Toulouse, France; [Leroux, P. Y.] Hop Augustin Morvan, Med Nucl, 3 Ave Foch, F-29269 Brest, France; [Olivier, P.] CHU, Med Nucl, Rue Morvan, F-54511 Nancy, France; [Rust, E.] Clin Diaconat, Med Nucl, 1 Blvd Pr Roosevelt, F-68200 Mulhouse, France; [Seban, R.] Inst Gustave Roussy, Med Nucl, 114 Rue E Vaillant, F-94805 Villejuif, France; [Wartski, M.] Grp Hosp Cochin, Med Nucl, Grp Travail Radioprotect SFMN, 27 Rue Faubourg St Jacques, F-75014 Paris, France	Bonardel, G (reprint author), Ctr Cardiol Nord, Med Nucl, 32-36 Rue Moulins Gemeaux, F-93200 St Denis, France.	gerald.bonardel@gmail.com						0	0	0	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	SEP-OCT	2018	42	5					414	416		10.1016/j.mednuc.2018.07.016			3	Pathology	Pathology	HO3XT	WOS:000460857000015					2019-10-28	
J	Reznikov, OH; Sachynska, OV; Poliakova, LI; Faliush, OA; Yanishevskyi, OV				Reznikov, O. H.; Sachynska, O., V; Poliakova, L., I; Faliush, O. A.; Yanishevskyi, O., V			The state of reproductive organs of young and aged male rats with the prolonged administration of letrozole and after its withdrawal	PATHOLOGIA			Ukrainian	Article						letrozole; male reproductive system; rats	NORMALIZES SERUM TESTOSTERONE; AROMATASE INHIBITOR; AZOOSPERMIC MEN; THERAPY; DEFICIENCY	Aim. Study of the reproductive organs after long-term administration of letrozole, the steroid aromatase inhibitor, followed by its withdrawal in young male rats and ones with age-related involution of reproductive organs. Material and methods. The experiments were carried out on Wistar rats with an initial age of 5 months and 15 months, which were gavaged with letrozole every other day at a dose of 1 mg/kg bw for 3 months and then 2 months following its discontinuation. The blood plasma testosterone and estradiol levels were measured by immunoassays. The spermatozoa contents in epididymis were calculated. The testicles and accessory sexual glands were weighed, and morphology of gonads and ventral prostate was studied. The results of the study were compared with those of control animals of corresponding age. Results. As the result of letrozole treatment, the ratio of testosterone and estradiol levels in blood plasma of aged rats increased. The spermatozoa content in epididymis rose up by on the average 28 %. The histological study revealed functional activation of Leydig cells, a significant retardation of involutive changes of their number and morphology. Some Leydig cells demonstrated the signs of functional exhaustion. Letrozole exerted an increase of relative weight of the coagulation gland by an average of 40 %, seminal vesicles by 31 %, and ventral prostate by 33 % compared with those of control animals. Two months after letrozole withdrawal, there were no signs of difference between letrozole-treated and control animals. In young rats, the effects of letrozole were almost not detectable. Conclusions. Letrozole administration to male rats with age-related involution of the reproductive system increases testosterone/estradiol ratio in blood plasma, the spermatozoa contents in epididymises and the weights of androgen-dependent accessory sexual glands. This is accompanied by slowing down of age-related changes of the gonad morphology and prostate gland. Letrozole-induced reproductive effects are reversible.	[Reznikov, O. H.] Acad NAMS Ukraine, Kiev, Ukraine; [Reznikov, O. H.] NAMS Ukraine, Dept Endocrinol Reprod & Adaptat, VP Komisarenko Inst Endocrinol & Metab, Kiev, Ukraine; [Sachynska, O., V; Poliakova, L., I; Faliush, O. A.; Yanishevskyi, O., V] NAMS Ukraine, VP Komisarenko Inst Endocrinol & Metab, Kiev, Ukraine	Reznikov, OH (reprint author), NAS Ukraine, Kiev, Ukraine.	reznikov39@gmail.com					Ahmed K, 2017, EUR UROL FOCUS, V3, P514, DOI 10.1016/j.euf.2017.12.004; Bhasin S, 2006, J CLIN ENDOCR METAB, V91, P1995, DOI 10.1210/jc.2005-2847; BHATNAGAR AS, 1992, J STEROID BIOCHEM, V41, P437, DOI 10.1016/0960-0760(92)90369-T; Bibancos M, 2015, J BRAS REPROD ASSIST, V19, P230, DOI 10.5935/1518-0557.20150045; Blaya R, 2017, CURR PHARM DESIGN, V23, P4470, DOI 10.2174/1381612823666170503150955; Burnett-Bowie SAM, 2009, CLIN ENDOCRINOL, V70, P116, DOI 10.1111/j.1365-2265.2008.03327.x; de Boer H, 2005, DIABETES OBES METAB, V7, P211, DOI 10.1111/j.1463-1326.2004.00397.x; de Ronde W, 2011, REPROD BIOL ENDOCRIN, V9, DOI 10.1186/1477-7827-9-93; Decaroli MC, 2017, VIRULENCE, V8, P545, DOI 10.1080/21505594.2016.1259053; Gelashvily O.A., 2008, SARATOVSKIJ NAUCHNO, V4, P125; Gregoriou O, 2012, FERTIL STERIL, V98, DOI 10.1016/j.fertnstert.2012.04.005; Haynes BP, 2003, J STEROID BIOCHEM, V87, P35, DOI 10.1016/S0960-0760(03)00384-4; Leder BZ, 2004, J CLIN ENDOCR METAB, V89, P1174, DOI 10.1210/jc.2003-031467; Loves S, 2008, EUR J ENDOCRINOL, V158, P741, DOI 10.1530/EJE-07-0663; Luchytskyy Ye.V, 2012, ENDOKRYNOLOHIA, V4, P56; Pouliot L, 2013, BIRTH DEFECTS RES B, V98, P374, DOI 10.1002/bdrb.21080; Pye SR, 2014, J CLIN ENDOCR METAB, V99, P1357, DOI 10.1210/jc.2013-2052; Rastrelli G, 2018, EXPERT REV CLIN PHAR, V11, P439, DOI 10.1080/17512433.2018.1445969; Reznikov A.G, 2014, MIZHNARODNYI ENDOKRY, V6, P11; Reznikov O.G, 2015, ENDOKRYNOLOHIA, V20, P425; Rhoden EL, 2004, NEW ENGL J MED, V350, P482, DOI 10.1056/NEJMra022251; Ribeiro MA, 2016, J BRAS REPROD ASSIST, V20, P82, DOI 10.5935/1518-0557.20160019; Schlegel PN, 2012, FERTIL STERIL, V98, P1359, DOI 10.1016/j.fertnstert.2012.10.023; Selim ME, 2013, ULTRASTRUCT PATHOL, V37, P204, DOI 10.3109/01913123.2013.772269; Solov'ev A.I, 2006, ZH AMN UKRAINY, V12, P781; Tan Ronny B W, 2014, Sex Med Rev, V2, P79, DOI 10.1002/smrj.23; Tarasenko L V, 2007, Fiziol Zh, V53, P11; Turner KJ, 2000, J ENDOCRINOL, V164, P225, DOI 10.1677/joe.0.1640225; Vanderschueren D, 2000, BONE, V27, P611, DOI 10.1016/S8756-3282(00)00363-X; Zapadnyuk I.P, 1974, LAB ZHYVOTNYE; Zhao D, 2014, ANDROLOGIA, V46, P456, DOI 10.1111/and.12122	31	0	0	2	2	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	SEP-DEC	2018		3					268	277		10.14739/2310-1237.2018.3.151647			10	Pathology	Pathology	HF9JB	WOS:000454557200001		DOAJ Gold			2019-10-28	
J	Kolesnyk, YM; Isachenko, MI; Melnikova, OV; Hrekova, TA				Kolesnyk, Yu M.; Isachenko, M. I.; Melnikova, O., V; Hrekova, T. A.			Characteristics of the nitric oxide system indicators in the left ventricle myocardium in SHR	PATHOLOGIA			English	Article						NOS isoforms; nitric oxide synthase; ventricular remodeling; left ventricle; heart; essential hypertension; rats; SHR	SYNTHASE; EXPRESSION; PRESSURE; MICE	The aim was to determine the morpho-functional parameters of the left ventricular myocardium NO system in the rats with essential hypertension (SHR line). Material and methods. We used a combination of modem highly informative methods, namely: research of NOS isoform profile (nNOS, iNOS eNOS) in the myocardial slices along with an assessment of their synthesis and expression of the corresponding mRNA; NO derived nitrites level determination directly in the myocardium homogenates and concentration of nitrotyrosine in blood plasma of rats. The results of the performed studies have shown that high blood pressure in the SHR was accompanied by a significant increase in the concentrations of all three NOS isoforms in the myocardium and increased expression of their mRNA. Higher concentration of nitrites by 18.8 % was detected in the SHR group compared with the control animals. The concentration of nitrotyrosine in blood plasma of rats with essential hypertension was also increased by 25 %. Conclusions. The predominance of IRM to constitutive isoforms of NOS with low IRM content to iNOS was noted in the myocardium of the control group rats while in SHR rats higher IRM values were marked for all NOS isoforms. The formation of hypertension is accompanied by high content of NO end metabolites and the development of systemic nitroso-oxidative stress with the increase of nitrotyrosine concentration.	[Kolesnyk, Yu M.] Zaporizhzhia State Med Univ, Zaporizhia, Ukraine; [Isachenko, M. I.; Melnikova, O., V; Hrekova, T. A.] Zaporizhzhia State Med Univ, Dept Pathophysiol, Zaporizhia, Ukraine	Kolesnyk, YM (reprint author), Zaporizhzhia State Med Univ, Zaporizhia, Ukraine.	fedotova@zsmu.pp.ua	Isachenko, Mariia/Y-1361-2019; Olha, Melnikova/AAC-6123-2019	Isachenko, Mariia/0000-0002-3026-1012; Olha, Melnikova/0000-0002-6807-8440			Antonio EL, 2015, REV BRAS CIR CARDIOV, V30, P70, DOI 10.5935/1678-741.20140093; Buchwalow IB, 2001, MOL CELL BIOCHEM, V217, P73, DOI 10.1023/A:1007286602865; Camici GG, 2015, EUR HEART J, V36, P3392, DOI 10.1093/eurheartj/ehv587; Alvarez MC, 2008, HYPERTENS RES, V31, P1465, DOI 10.1291/hypres.31.1465; Champion HC, 2004, CIRC RES, V94, P657, DOI 10.1161/01.RES.0000119323.79644.20; Dokken BB, 2015, ACAD EMERG MED, V22, P197, DOI 10.1111/acem.12575; Drummond GR, 2000, CIRC RES, V86, P347, DOI 10.1161/01.RES.86.3.347; Fedotova M. I, 2017, VISNYK UKRAINSKOI ME, V17, P91; Gorbunov N. V., 1995, B EKSPERIMENTALNOJ B, V7, P40; Jang JH, 2015, BASIC RES CARDIOL, V110, DOI 10.1007/s00395-015-0477-6; Kravchenko N. A, 2008, CITOLOGIYA GENETIKA, V4, P69; Manukhina EB, 2003, VESTN VITEBSK GOS ME, V2, P5; Ruetten H, 2005, CARDIOVASC RES, V66, P444, DOI 10.1016/j.cardiores.2005.01.021; Shabeeh H, 2017, HYPERTENSION, V69, P970, DOI 10.1161/HYPERTENSIONAHA.116.08792; Shimokawa H, 2010, PFLUG ARCH EUR J PHY, V459, P959, DOI 10.1007/s00424-010-0796-2; Tsutsui M, 2010, PHARMACOL THERAPEUT, V128, P499, DOI 10.1016/j.pharmthera.2010.08.010; Viaro F, 2000, Arq Bras Cardiol, V74, P380; Yuyun MF, 2018, MICROVASC RES, V119, P7, DOI 10.1016/j.mvr.2018.03.012; Zajcev V, 2003, PRIKLADNAYA MED STAT; Zherebiatiev A, 2016, IRAN J ALLERGY ASTHM, V15, P39	20	0	0	1	2	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	SEP-DEC	2018		3					278	283		10.14739/2310-1237.2018.3.151670			6	Pathology	Pathology	HF9JB	WOS:000454557200002		DOAJ Gold			2019-10-28	
J	Shelest, BO				Shelest, B. O.			Clinical and anamnestic features and their prognostic value in assessment of treatment efficiency of arterial hypertension with comorbidity	PATHOLOGIA			Ukrainian	Article						hypertension; obesity; telmisartan; prognosis; treatment	OBESITY	Antihypertensive treatment leads to regression of left ventricular hypertrophy, reduces the incidence of cardiovascular complications and improves survival rates, and this occurs regardless of the degree of lowering of blood pressure (BP). The aim of the study was to determinate the prognostic significance of clinical and anamnestic factors in the evaluation of effectiveness of therapeutic correction of arterial hypertension (AH) associated with obesity and diabetes mellitus by angiotensin II receptors blocker, telmisartan. Material and methods. 135 patients were examined, diagnosed with AH stage I-II associated with obesity of 1-2 degrees (mean age 61.6 +/- 6.7 years). Duration of study was 3 month. Chronic heart failure was no worse than II functional class by NYHA. Evaluation of prognostic properties of the studied factors was carried out using sequential hypothesis by Wald-Genkin, according to which all the indices were ranged with the subsequent determination of the prognostic coefficient (PC) and the general informativeness of the index (I). The groups were matched by sex, age, severity of the clinical condition, concomitant pathology. The control group consisted of 20 practically healthy persons of similar age and sex without signs of disease. Results. In the study, the predictive value of clinical and anamnestic parameters of the effectiveness of antihypertensive treatment was analyzed. The results show that some clinical and anamnesis factors of the disease can be used to determine the telmisartan effectiveness in the treatment of hypertension with obesity. The most informative criteria (I > 1.0) are the duration (more than 11 years) of arterial hypertension, as well as the age of the patient and the presence of concomitant pathology, in particular type 2 diabetes and obesity. Conclusions. Based on the obtained data about the value of clinical and anamnestic factors' significance in assessing of the antihypertensive therapy in patients with co-morbid pathology, it is assumed that patients with hypertension duration of more than 11 years with concomitant obesity and type 2 diabetes and those older than 71 years require special tactics in the selection of antihypertensive therapy. And, most likely, such patients need more frequent adjustment of the doses of the drug.	[Shelest, B. O.] Kharkiv Natl Med Univ, Dept Internal & Occupat Dis, Kharkov, Ukraine	Shelest, BO (reprint author), Kharkiv Natl Med Univ, Dept Internal & Occupat Dis, Kharkov, Ukraine.	shelestb@ua.fm					Cortez DN, 2015, ACTA PAUL ENFERM, V28, P250, DOI 10.1590/1982-0194201500042; Fuchs FD, 2015, OPEN HEART, V2, DOI 10.1136/openhrt-2014-000236; Gubler E. V., 1987, VYICHISLITELNYE METO; Haass M, 2011, CIRC-HEART FAIL, V4, P324, DOI 10.1161/CIRCHEARTFAILURE.110.959890; Jin CN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114958; Katayama S, 2018, HYPERTENS RES, V41, P213, DOI 10.1038/s41440-017-0001-5; Kenchaiah S, 2002, NEW ENGL J MED, V347, P305, DOI 10.1056/NEJMoa020245; Lifshits G. I., 2015, NAUCHNYY ALMANAKH, V11-4, P92, DOI [10.17117/na.2015.11.04.092, DOI 10.17117/NA.2015.11.04.092]; Machilskaya O. V, 2016, KARDIOLOGIYA SERDECH, V3, P55, DOI [10.17116/kardio20169355-65, DOI 10.17116/KARDIO20169355-65]; Malek F, 2013, COR VASA, V55, pE259, DOI 10.1016/j.crvasa.2013.04.002; Nagarajan V, 2016, ESC HEART FAIL, V3, P227, DOI 10.1002/ehf2.12120; Nicoll R, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091481; Paz MA, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004071; Ruschitzka F, 2012, EUR HEART J, V33, P1996, DOI 10.1093/eurheartj/ehs108; Shelest A, 2016, Georgian Med News, P81; Soldatenko I. V, 2010, VISNYK HNU VN KARA M; Tashchuk V. K, 2014, BUKOVYNSKYI MEDYCHNY, V18, P105; Tomina O. Ye, 2010, VISNYK HNU VN KARA M, V918, P77; Yang H, 2016, OPEN HEART, V3, DOI 10.1136/openhrt-2015-000339	19	0	0	0	0	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	SEP-DEC	2018		3					284	289		10.14739/2310-1237.2018.3.151678			6	Pathology	Pathology	HF9JB	WOS:000454557200003		DOAJ Gold			2019-10-28	
J	Kozlov, SV; Suloiev, KM; Koldunov, VV; Kozlova, YV; Mamedov, SM				Kozlov, S., V; Suloiev, K. M.; Koldunov, V. V.; Kozlova, Yu, V; Mamedov, Sh M.			Pathological changes in the heart under the use of psychostimulants	PATHOLOGIA			Ukrainian	Article						amphetamine; methamphetamine; heart; forensic pathology; human	DEATH	The aim of the work is to study pathomorphological changes in the heart in cases of death under the use of phenylalkylamine derivatives. Materials and methods. 58 forensic studies of people who died of poisoning with drugs during the period 2015-2017 in the Dnipropetrovsk region were done. All the deceased were men aged 28.8 +/- 6.7 years. As a control, the hearts of 15 people aged 21-36 years who died due to external causes not related to the effects of narcotics were examined. All the deceased were men aged 28.1 +/- 6.2 years. In all cases, the analysis of the circumstances, results of autopsy, forensic-histological, forensic toxicological and flame photometric studies was carried out. Results. Morphometric analysis revealed no significant changes in linear-weight characteristics of hearts in the deceased group compared to the control group. Mean K and Na levels in the samples corresponded to 172.4 +/- 15.6 and 125.5 +/- 9.4 mg % respectively. K/Na ratio of the myocardium ranged from 0.94 to 1.85. In each investigated heart of the deceased due to amphetamine and methamphetamine use, significant changes in K/Na balance were detected, and the number of heart divisions, where the K/Na ratio was less than 2, ranged from 1 to 6. From data of analysis of microscopic changes of myocardium of the deceased, who used the derivatives of phenylalkylamine (amphetamine, metamphetamine) during of life, the complex of microscopic signs was set as intracellular changes (vacuolisation) from the side of cardiomyocytes, diffuse focal areas of perivascular and interstitial cardiosclerosis, in combination with focal myocytolisis and hypertrophy of cardiomyocytes without the signs of injury of coronal vessels. Conclusions. The study of the hearts of the deceased who used phenylalkylamine derivatives, characteristic pathological changes at the tissue (a complex of characteristic microscopic signs) and molecular (violation of potassium-sodium equilibrium) levels were detected, indicating the development of acute cardiac dysfunction.	[Kozlov, S., V; Suloiev, K. M.] Hlth Minist Ukraine, Dept Pathol Anat & Forens Med, SI Dnipropetrovsk Med Acad, Dnipro, Ukraine; [Koldunov, V. V.; Kozlova, Yu, V] Hlth Minist Ukraine, Dept Pathol Physiol, SI Dnipropetrovsk Med Acad, Dnipro, Ukraine; [Mamedov, Sh M.] Hlth Minist Ukraine, SI Dnipropetrovsk Med Acad, Dnipro, Ukraine	Kozlov, SV (reprint author), Hlth Minist Ukraine, Dept Pathol Anat & Forens Med, SI Dnipropetrovsk Med Acad, Dnipro, Ukraine.	tanatholog@i.ua	kozlov, sergii/Y-8735-2019	kozlov, sergii/0000-0002-7619-4302; Kozlova, Yuliiya/0000-0002-1918-2946			Darke S, 2018, J FORENSIC SCI, V63, P1466, DOI 10.1111/1556-4029.13710; Drozdov A. L, 2016, KARDIOTOKSICHESKIE S; Herbeck DM, 2015, J ADDICT DIS, V34, P88, DOI 10.1080/10550887.2014.975610; Kula K, 2014, Arch Med Sadowej Kryminol, V64, P76; Rodinskij A.G, 2014, PATHOLOGIA, V3, P39, DOI [10.14739/2310-1237.2014.3.36636, DOI 10.14739/2310-1237.2014.3.36636]; Shintani-Ishida K, 2014, BBA-MOL BASIS DIS, V1842, P691, DOI 10.1016/j.bbadis.2014.01.013; Sokolova O. V., 2016, Sudebno-Meditsinskaya Ekspertiza, V59, P3, DOI 10.17116/sudmed20165913-6; Voskoboinik A, 2016, INTERN MED J, V46, P723, DOI 10.1111/imj.13050; Zhu R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151034	9	0	0	0	0	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	SEP-DEC	2018		3					290	295		10.14739/2310-1237.2018.3.151697			6	Pathology	Pathology	HF9JB	WOS:000454557200004		DOAJ Gold			2019-10-28	
J	Herasymova, OV; Protsiuk, TL; Protsiuk, LO; Dudarenko, OB; Kuleshov, OV				Herasymova, O., V; Protsiuk, T. L.; Protsiuk, L. O.; Dudarenko, O. B.; Kuleshov, O., V			Metabolic myocardial disorders in children with bronchial asthma	PATHOLOGIA			English	Article						bronchial asthma; child; biomarkers; cardiovascular system	SALBUTAMOL	Objective. To study specific features of potassium metabolism and myocardial damage markers in the children with bronchial asthma, depending on the level of BA control. Materials and methods. Comprehensive examination was carried out in 189 children with persistent BA aged 6-17 years: group 1 consisted of 124 with uncontrolled course of the disease, group 2 - 30 patients with partially controlled BA and 35 patients with controlled BA. The comparison group consisted of 30 patients with controlled asthma without changes from the cardiovascular system. The unified flame photometry method with fluid analyzer FFA-1 was used to determine the erythrocyte potassium level. Total creatine phosphokinase level was estimated by UV-test. Creatine phosphokinase-MB level was determined by M-subunit immunoinhibition. Total lactic dehydrogenase-1 level was calculated by modified colorimetric method using an assay kit for colorimetric determination of total LDH. Serum LDH1 level was estimated by UV-method with the kit for determination of isoenzyme LDH1 activity. Results. In the children with UC BA serum K' and erythrocyte K+ level was significantly lower compared to the children with PC BA, C BA, C BA with no changes in CVS and the control group. Total CPK and CPK-MB isoenzyme level in the children with UC BA, was significantly higher compared to those with PC BA, C BA, C BA without CVS changes and the control group. In the children with PC BA, total serum CPK level was also significantly higher compared to C BA (P = 0.007), C BA without CVS (P = 0.0002) changes and the control group (P = 0.001). Conclusion. Thus, the study demonstrated significant decrease of potassium level in blood serum and erythrocytes, twofold increase of total creatine phosphokinase and lactic dehydrogenase-1 isoenzyme levels, threefold increase in creatine phosphokinase-MB isoenzyme level, and one and a half time increase of total lactic dehydrogenase in the children with uncontrolled course of bronchial asthma.	[Herasymova, O., V; Protsiuk, T. L.] Natl Pirogov Mem Med Univ, Dept Pediat 1, Vinnytsia, Ukraine; [Protsiuk, L. O.; Dudarenko, O. B.] Natl Pirogov Mem Med Univ, Dept Hyg & Ecol, Vinnytsia, Ukraine; [Kuleshov, O., V] Natl Pirogov Mem Med Univ, Dept Propedeut Pediat Dis Patient Care, Vinnytsia, Ukraine	Herasymova, OV (reprint author), Natl Pirogov Mem Med Univ, Dept Pediat 1, Vinnytsia, Ukraine.	rossata@ukr.net					Andrzejowski P, 2016, ARCH DIS CHILDHOOD-E, V101, P194, DOI 10.1136/archdischild-2014-307285; Edgell H, 2016, RESP PHYSIOL NEUROBI, V231, P14, DOI 10.1016/j.resp.2016.05.014; Faruqi S, 2012, CLIN RESPIR J, V6, P81, DOI 10.1111/j.1752-699X.2011.00250.x; Farzan Sherry, 2013, J Allergy (Cairo), V2013, P602908, DOI 10.1155/2013/602908; Healy F, 2010, EUR J PEDIATR, V169, P1, DOI 10.1007/s00431-009-1027-8; Karmali SN, 2017, INTENS CARE MED EXP, V5, DOI 10.1186/s40635-017-0146-1; Lutfi M. F, 2013, ASIAN J BIOMEDICAL P, V3, P1; Mohammad HA, 2014, EGYPT J CHEST DIS TU, V63, P529, DOI 10.1016/j.ejcdt.2014.03.010; Oliveira NS, 2008, PEDIATR CRIT CARE ME, V9, P414, DOI 10.1097/PCC.0b013e31817e2b33; Padmanabhan R, 2016, INT J SCI RES, V5, P198; Patel Bh, 2015, EJPMR, V2, P562; Paulin R, 2014, CIRC RES, V115, P148, DOI 10.1161/CIRCRESAHA.115.301130; Rachaiah J, 2013, INT J MED SCI PUBLIC, V2, P1114, DOI [10.5455/ijmsph.2013.030720132, DOI 10.5455/IJMSPH.2013.030720132]; Rowan SC, 2016, LANCET RESP MED, V4, P225, DOI 10.1016/S2213-2600(15)00517-2; Sahan M, 2013, REV PORT PNEUMOL, V19, P200, DOI 10.1016/j.rppneu.2012.12.003; Schatz M, 2014, J ALLER CL IMM-PRACT, V2, P645, DOI 10.1016/j.jaip.2014.09.004; Suryanarayana H . V, 2013, INT J BIOL MED RES, V4, P3479; Umalakshmi V, 2015, J PHARM BIOL SCI, V10, P53, DOI [10.9790/3008-10335356, DOI 10.9790/3008-10335356]; Wahjudi M, 2016, INT J PHARM CLIN RES, V8, P221	19	0	0	0	0	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	SEP-DEC	2018		3					296	301		10.14739/2310-1237.2018.3.151707			6	Pathology	Pathology	HF9JB	WOS:000454557200005		DOAJ Gold			2019-10-28	
J	Barkovskyi, DY				Barkovskyi, D. Ye			Neuroimmunoendocrinal markers of prediction of preeclampsia	PATHOLOGIA			Ukrainian	Article						pregnancy; pre-eclampsia; homeostasis; neuroendocrine system; insulin resistance; immune system; cytokines	HYPERTENSIVE DISORDERS; PREGNANCY; STRESS; DEATH	Objective: to establish the features of neuroendocrine regulation of homeostasis and the immune system of a woman in the 1st trimester of pregnancy complicated by preeclampsia, and to establish prognostic criteria for the occurrence of this obstetric complication. Materials and methods. A dynamic observation of the course of pregnancy, childbirth and the postpartum period was carried out in women pregnant for the first time from the early stages of gestation (7-8 weeks); of these, 46 women were selected for whom the pregnancy was complicated by preeclampsia and who formed the following clinical groups: the 1st group -32 pregnant women with mild preeclampsia; the 2nd group -14 pregnant women with severe preeclampsia. The control group -48 somatically healthy pregnant women with the physiological course of pregnancy. In the serum of pregnant clinical observation groups in the 1st (10-14 weeks), in the 2nd (23-26 weeks) and in the 3rd trimesters (32-35 weeks), the concentration of adrenocorticotropic hormone, beta-endorphin was determined by ELISA, cortisol, insulin, placental lactogen, human chorionic gonadotropin, alpha-fetoprotein, the concentration of lymphocytes and markers of their activation (CD3, CD4, CD8, CD14, CD16, CD19, CD25, CD71, CD95, HLA DR) was determined by the immunofluorescence method using monoclonal antibodies. Results. For the women with the preeclampsia of the 1st degree the neuroendocrinal regulation of homeostasis is broken in the 1st trimester of pregnancy with creation of primary placental insufficiency, oppression of the stress-realizing function of the hypothalamo-pituitary system, development of insulin resistance, that as a whole testifies about dysadaptation of an organism of the women in the 1st trimester of pregnancy. In the 1st trimester the state of the fetoplacental complex for the pregnant women with preeclampsia, regardless of the degree of severity, is characterized by the dysbalance of hormones production, which testifies to development of primary placental insufficiency. Conclusions. For the women with preeclampsia of mild degree dysbalance of the immune system develops already in the 1st trimester of pregnancy as relative augmentation of total of T-lymphocytes with simultaneous decrease of their functional activity, particularly T-helpers of the 2nd type, which is accompanied by the decrease of anti-inflammatory cytokines production. For the women with preeclampsia of serious degree the quantitative parameters of non-specific and cellular immunity (CD3, CD4, CD8, CD16, HLA-DR) are reduced already in 1st trimester of pregnancy with simultaneous rising of the value of immunoregulatory index (CD4/CD8) and functional activity of T-helpers of the 1st type on the background of the activity oppression of the 2nd type T-helpers.	[Barkovskyi, D. Ye] Zaporizhzhia State Med Univ, Dept Obstet Gynecol & Reprod Med, FPE, Zaporizhzhia, Ukraine	Barkovskyi, DY (reprint author), Zaporizhzhia State Med Univ, Dept Obstet Gynecol & Reprod Med, FPE, Zaporizhzhia, Ukraine.	dmitro.barkovsky@gmail.com					Ader R., 2006, PSYCHONEUROIMMUNOLOG, VI, P39; Ahmad AS, 2012, BJOG-INT J OBSTET GY, V119, P1521, DOI 10.1111/j.1471-0528.2012.03460.x; Ayansina D, 2016, PREGNANCY HYPERTENS, V6, P344, DOI 10.1016/j.preghy.2016.08.231; Basbug D, 2017, GINEKOL POL, V88, P325, DOI 10.5603/GP.a2017.0061; Begum Z, 2015, J DHAKA MED COLL, V23, P89, DOI [10.3329/jdmc.v23i1.22701, DOI 10.3329/JDMC.V23I1.22701]; Bhattacharjee A, 2016, NEW INDIAN J OBGYN, V3, P20, DOI [10.21276/obgyn.2016.3.1.4, DOI 10.21276/OBGYN.2016.3.1.4]; Boeldt DS, 2017, J ENDOCRINOL, V232, pR27, DOI 10.1530/JOE-16-0340; Chaiworapongsa T, 2014, NAT REV NEPHROL, V10, P466, DOI 10.1038/nrneph.2014.102; Chiarello DI, 2018, PLACENTA, V69, P134, DOI 10.1016/j.placenta.2018.04.011; Christian LM, 2012, PROG NEUROBIOL, V99, P106, DOI 10.1016/j.pneurobio.2012.07.003; Christian LM, 2012, NEUROSCI BIOBEHAV R, V36, P350, DOI 10.1016/j.neubiorev.2011.07.005; Christian LM, 2010, BRAIN BEHAV IMMUN, V24, P49, DOI 10.1016/j.bbi.2009.05.055; Dhariwal Nerlyne K, 2017, Anesthesiol Clin, V35, P95, DOI 10.1016/j.anclin.2016.09.009; Folic M, 2008, ACTA MED MEDIANAE, V47, P65; Gathiram P, 2016, CARDIOVASC J AFR, V27, P71, DOI 10.5830/CVJA-2016-009; Goulopoulou S, 2017, HYPERTENSION, V70, P1066, DOI 10.1161/HYPERTENSIONAHA.117.08821; Harmon AC, 2016, CLIN SCI, V130, P409, DOI 10.1042/CS20150702; Kuklina EV, 2009, OBSTET GYNECOL, V113, P1299, DOI 10.1097/AOG.0b013e3181a45b25; Lindheimer MD, 2010, J AM SOC HYPERTENS, V4, P68, DOI 10.1016/j.jash.2010.03.002; Malik R, 2017, ADV EXP MED BIOL, V956, P375, DOI 10.1007/5584_2016_150; Mallick M, 2015, BANGLADESH MED RES C, V40, P97, DOI [10.3329/bmrcb.v40i3.25230, DOI 10.3329/BMRCB.V40I3.25230]; Matthiesen L, 2005, CHEM IMMUNOL ALLERGY, V89, P49, DOI 10.1159/000087912; Meher S, 2017, AM J OBSTET GYNECOL, V216, P121, DOI 10.1016/j.ajog.2016.10.016; Mikhailova VA, 2014, B EXP BIOL MED+, V157, P751, DOI 10.1007/s10517-014-2659-x; Moffett A, 2014, J CLIN INVEST, V124, P1872, DOI 10.1172/JCI68107; Moussa HN, 2014, WOMENS HEALTH, V10, P385, DOI [10.2217/WHE.14.32, 10.2217/whe.14.32]; Nguyen TA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188250; Roiz-Hernandez J, 2006, INT J GYNECOL OBSTET, V92, P101, DOI 10.1016/j.ijgo.2005.10.002; Say L, 2014, LANCET GLOB HEALTH, V2, pE323, DOI 10.1016/S2214-109X(14)70227-X; Szarka A, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-59; van Rijn BB, 2014, J HYPERTENS, V32, P408, DOI 10.1097/HJH.0000000000000027	31	0	0	0	0	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	SEP-DEC	2018		3					302	308		10.14739/2310-1237.2018.3.151718			7	Pathology	Pathology	HF9JB	WOS:000454557200006		DOAJ Gold			2019-10-28	
J	Liubomyrska, KS				Liubomyrska, K. S.			Immunogenetic factors for the development of premature rupture of membranes in preterm labour in Zaporizhzhia region	PATHOLOGIA			Ukrainian	Article						preterm labor; preterm premature rupture of fetal membranes; single nucleotide polymorphism; trans-activation genetic	NECROSIS-FACTOR-ALPHA; POLYMORPHISMS; RISK	Aim. To study single nucleotide polymorphism of proinflammatory cytokine genes IL1 beta (rs1143627) and TNF alpha (rs1800629) and determine mRNA level of IL1 beta IL17A genes at the local level in PROM during 26-34 weeks of pregnancy in the population of Zaporizhzhia region. Materials and methods. Cytokine gene markers were studied in 50 women with PROM in gestational age of 26-34 weeks and 50 pregnant women with physiological pregnancy and term labor without complications. Genotyping with TaqMan samples was performed on CFX96 (TM) Real-Time PCR Detection Systems amplifier (Bio-RadLaboratories, Inc, USA). For determination of mRNA level of proinflammatory cytokine genes IL1 beta (NM_000576.2) and IL17A (NM_002190.2) PCR in real time and the Luminaris HiGreen Fluorescein qPCR MasterMix reagent kit (ThermoScientific, USA) were used. Results. We were unable to identify statistically significant differences for each of the rs1143627 polymorphism genotypes (GG, GA and AA) of the IL1 beta gene between the main study group and the control group (chi(2) = 0.18, OR (GG) = 1.13; 95 % CI: 0.65-1.98; OR (GA) =1.54; 95 % CI: 0.68-3.49; and OR (AA) = 0.89; 95 % CI: 0.50-1.55, respectively, P > 0.05). Between the main and control groups, including all alleles of the rs1800629 polymorphism (AA, GG and AG) of the TNF alpha gene there was a tendency that didn't become of statistical significance - chi(2=) 0.44, OR (M)= 0.8; 95 % CI: 0.42-1.54; OR (GG) =1.25; 95 % CI: 0.65-2.39; and OR (AG) = 0.67; 95 % CI: 0.28-1.62, respectively, P < 0.05. The range of all obtained values of the relative normalized expression of IL1 beta gene mRNA in placenta was 1.43-227.93 (mean - 25.08), in fetal membranes - 1.23-139.24 (mean - 23.83). The range of relative normalized expression of mRNA of the IL-17A gene in placenta was 1.15-62.76 (mean -5.69), in fetal membranes -1.63-130.67 (mean - 19.31). Conclusions. In the population of Zaporizhzhia region, there is no reliable clinical association between the IL1 beta(rs1143627) and TNF alpha (rs1800629) genes and a high risk of developing premature rupture of the membranes in preterm pregnancy. PCR in real time allowed to identify the immune-mediated level of the development of PROM at the local level in the gestation period of 26-34 weeks as great increased genes transcriptional activity of pro-inflammatory cytokines IL1 beta and IL17A.	[Liubomyrska, K. S.] Zaporizhzhia State Med Univ, Dept Obstet & Gynecol, Zaporizhia, Ukraine	Liubomyrska, KS (reprint author), Zaporizhzhia State Med Univ, Dept Obstet & Gynecol, Zaporizhia, Ukraine.	lubomirskaae@gmail.com					Bitner A, 2010, ARCH MED SCI, V6, P552, DOI 10.5114/aoms.2010.14467; Bukowski R, 2017, PEERJ, V5, DOI 10.7717/peerj.3685; Ramos BRD, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0823-1; Hollegaard MV, 2008, ACTA OBSTET GYN SCAN, V87, P1285, DOI 10.1080/00016340802468340; Jafarzadeh L, 2013, INT J PREVENTIVE MED, V4, P896; Jones NM, 2010, J REPROD IMMUNOL, V87, P82, DOI 10.1016/j.jri.2010.06.158; Moura E, 2009, J REPROD IMMUNOL, V80, P115, DOI 10.1016/j.jri.2008.11.007; Musilova I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133929; Sata F, 2009, MOL HUM REPROD, V15, P121, DOI 10.1093/molehr/gan078; Sheikh IA, 2015, BMC GENOMICS, V17, DOI 10.1186/s12864-016-3089-0; Tchirikov M, 2018, J PERINAT MED, V46, P465, DOI 10.1515/jpm-2017-0027; Zare-Bidaki Majid, 2017, J Reprod Infertil, V18, P218	12	0	0	0	0	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	SEP-DEC	2018		3					309	318		10.14739/2310-1237.2018.3.151725			10	Pathology	Pathology	HF9JB	WOS:000454557200007		DOAJ Gold			2019-10-28	
J	Stepanchenko, KA				Stepanchenko, K. A.			Analysis of heart rate variability in patients with primary and secondary invasion with pinworms before and after a course of specific therapy	PATHOLOGIA			Ukrainian	Article						enterobiasis; adults; heart rate	ENTEROBIUS-VERMICULARIS	Objective: to study the state of the autonomic nervous system and adaptation-compensatory mechanisms in adult patients with enterobiasis with different duration of pinworm invasion before and after the course of anthelmintic therapy with the help of the heart rate variability method. Materials and methods. We examined 60 military cadets (men aged 19-24 years) with enterobiasis (the main group), among whom two groups of patients with different duration of enterobiasis invasion were formed. The 1st group included 35 military cadets with a primary enterobiasis invasion. The 2nd group with re-invasion -25 military cadets, control group - 30 practically healthy military cadets. The course of specific therapy was carried out with mebendazole. To assess the state of autonomic nervous system, the method of mathematical analysis of the heart rate was used based on the results of heart rate variability. Results. Patients with primary enterobiotic invasion had heart rate variability data characterized by high absolute and relative values of high-frequency H F-component of heart rate variability (2314.9 +/- 314.7 ms(2) and 55.6 +/- 3.1 %), and patients with re-invasion - high absolute and relative values of the very low-frequency VLF component of heart rate variability (1918.4 +/- 205.9 ms(2) and 49.7 +/- 2.9 %). We observed normalization of heart rate variability indicators up to the control group level in patients with primary enterobiasis invasion after the course of anthelmintic therapy. Whereas, high absolute and relative values of very low-frequency VLF-component of heart rate variability indicators in patients with re-invasion were preserved. Conclusions. Patients with primary pinworm infestation have predominant parasympathetic regulation in cardiac rhythm modulation. Patients with re-invasion have excessive centralization of cardiac rhythm control due to a disruption in the interaction between suprasegmental and segmental parts of the central autonomic nervous system, which persists after the course of anthelmintic therapy.	[Stepanchenko, K. A.] Kharkiv Med Acad Postgrad Educ, Dept Neurol & Child Neurol, Kharkov, Ukraine	Stepanchenko, KA (reprint author), Kharkiv Med Acad Postgrad Educ, Dept Neurol & Child Neurol, Kharkov, Ukraine.	kosty0516@gmail.com					Altun E, 2017, SAUDI MED J, V38, P314, DOI 10.15537/smj.2017.3.18061; Astaf'ev B. A, 1981, KLIN DIAGNOSTIKA LEC; Boas H, 2014, EPIDEMIOL INFECT, V142, P2114, DOI 10.1017/S0950268813003154; Choudhury Sunirmal, 2017, Trop Parasitol, V7, P119, DOI 10.4103/tp.TP_22_17; Devera R, 2001, ENFERM INFEC MICR CL, V19, P411, DOI 10.1016/S0213-005X(01)72679-1; Dezsenyi B, 2018, ACTA MICROBIOL IMM H, V65, P459, DOI 10.1556/030.65.2018.020; Ginetcinskaya T. A, 1978, CHASTNAYA PARAZITOLO; Herzig D, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00756; Carod-Artal FJ, 2018, CLIN AUTON RES, V28, P67, DOI 10.1007/s10286-017-0452-4; Kornyanskij G. P, 1968, PARAZITARNYE ZABOLEV; Lee MR, 2017, KOREAN J PARASITOL, V55, P579, DOI 10.3347/kjp.2017.55.5.579; Patsantara GG, 2016, J HELMINTHOL, V90, P337, DOI 10.1017/S0022149X15000334; Rainova I, 2018, BALK MED J, V35, P61, DOI 10.4274/balkanmedj.2017.0167; Rizvi Ghazala, 2015, Trop Parasitol, V5, P123, DOI 10.4103/2229-5070.162526; Savchenko L. P, 1962, MED PARAZITOLOGIYA P, V5, P557; Scheff JD, 2014, MATH BIOSCI, V252, P36, DOI 10.1016/j.mbs.2014.03.010; Shaffer F, 2017, FRONT PUBLIC HEALTH, V5, DOI 10.3389/fpubh.2017.00258; Sklyarova Valentyna О, 2018, Wiad Lek, V71, P674; Talyzin F. F, 1962, MED PARAZITOLOGIYA P, V5, P551; Taylor Aree, 2018, BMC Res Notes, V11, P603, DOI 10.1186/s13104-018-3708-8; Vozianova Zh. I, 2000, INFEKTSIINI PARAZYTA; Wang S, 2016, PARASITE, V23, DOI 10.1051/parasite/2016030	22	0	0	0	1	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	SEP-DEC	2018		3					319	324		10.14739/2310-1237.2018.3.151804			6	Pathology	Pathology	HF9JB	WOS:000454557200008		DOAJ Gold			2019-10-28	
J	Onishchenko, NV; Riabokon, YY; Riabokon, OV				Onishchenko, N., V; Riabokon, Yu Yu; Riabokon, O., V			The role of interleukin-10 gene polymorphism (rs 1800872) in the course of herpes zoster in adults	PATHOLOGIA			English	Article						herpes zoster; interleukin-10; gene polymorphism	IL-10 GENE; SUSCEPTIBILITY; RISK; EPIDEMIOLOGY; SERUM	Aim. The aim of the work was to determine the role of polymorphism of the interleukin-10 gene (rs 1800872) in the course of herpes zoster in adults. Materials and methods. 50 adult patients with herpes zoster were included into the study. The clinical course of the disease and development of the certain nature of complications were analyzed depending on the genetic polymorphism of the interleukin-10 gene. Statistical data processing was performed with using the formed patient database in the program STATISTICA for Windows 13 (StatSoft Inc., No JPZ8041382130ARCN10-J). Results. It was established that genotype TT of the IL-10 gene (rs 1800872) was recorded in 30 (60.0 %) patients with herpes zoster versus 14 (35.0 %) healthy people from the control group (P = 0.02), which confirmed the significance of the gene polymorphism IL-10 in reactivation of the varicella zoster virus and the manifestation of shingles. Analysis of the polymorphism of the IL-10 gene depending on the clinical form and the severity of shingle showed that genotype TT was significantly more frequently recorded in patients with severe course disease (86.7 % vs. 48.6 %, P = 0.01), however, did not influenced on the formation of certain clinical forms of the disease (P > 0.05). In patients with herpes zoster polymorphism of the IL-10 gene (rs 1800872) influenced the severity of the course of the disease, namely, the TT - genotype was associated with a severe course of the disease (P =0.01) and the development of neurological complications (P = 0.03), which were represented by meningitis (6), Ramsey-Hunt syndrome (3) and the subsequent formation of postherpetic neuralgia (3), as well as of ophthalmic nature (P = 0.0001), which were represented by herpetic blepharoconjunctivitis (16), keratouveitis (3), iridocyclitis (1), subconjunctival hemorrhages (1). Unlike the TT genotype, genotype TG of the IL-10 gene (rs 1800872) was associated with the development of complications with the addition of secondary bacterial microflora (x(2) = 4.5, P = 0.03), the incidence of which did not depend on the severity of herpes zoster (P > 0.05). Conclusions. In patients with herpes zoster, the TT-genotype of the IL-10 gene (rs 1800872) was associated with reactivation of the varicella zoster virus and development of a severe disease course, with formation of neurological (chi(2) = 4.75, P = 0.03) and ophthalmic (chi(2) = 14.75, P = 0.0001) complications. The TG genotype of the IL-10 gene (rs 1800872) is associated with the development of complications associated with the addition of secondary bacterial microflora (chi(2) = 4.5, P = 0.03).	[Onishchenko, N., V; Riabokon, O., V] Zaporizhzhia State Med Univ, Dept Infect Dis, Zaporizhzhia, Ukraine; [Riabokon, Yu Yu] Zaporizhzhia State Med Univ, Dept Children Infect Dis, Zaporizhzhia, Ukraine	Onishchenko, NV (reprint author), Zaporizhzhia State Med Univ, Dept Infect Dis, Zaporizhzhia, Ukraine.	helicobacter1403@gmail.com	Riabokon, Yurii/Z-3191-2019; Onishchenko, Nelli/J-7546-2017	Riabokon, Yurii/0000-0002-2273-8511; Onishchenko, Nelli/0000-0001-7775-7296; Riabokon, Olena/0000-0002-7394-4649			Borbinha C, 2016, CASE REP NEUROL, V8, P145, DOI 10.1159/000447296; Cho JW, 2007, J DERMATOL SCI, V45, P213, DOI 10.1016/j.jdermsci.2006.11.004; Crosslin DR, 2015, GENES IMMUN, V16, P1, DOI 10.1038/gene.2014.51; Forbes HJ, 2016, PAIN, V157, P30, DOI 10.1097/j.pain.0000000000000307; Grahn A, 2016, J INFECTION, V73, P254, DOI 10.1016/j.jinf.2016.04.035; Haanpaa M, 2002, SCAND J INFECT DIS, V34, P112, DOI 10.1080/00365540110077218; Hao MJ, 2015, J INFECT DEV COUNTR, V9, P190, DOI 10.3855/jidc.5255; Hoppe FM, 2018, J CLIN EPIDEMIOL, V97, P123, DOI 10.1016/j.jclinepi.2017.10.009; Hurme M, 2003, J MED VIROL, V70, P48; Johnson Robert W, 2015, Ther Adv Vaccines, V3, P109, DOI 10.1177/2051013615599151; Jones D, 2017, NEUROL-NEUROIMMUNOL, V4, DOI 10.1212/NXI.0000000000000382; Karpova M. I, 2011, CITOKINY VOSPALENIE, V10, P32; Kawai K, 2017, OPEN FORUM INFECT DI, V4, P313, DOI [10.1093/ofid/ofx163.733, DOI 10.1093/OFID/OFX163.733]; Kawai K, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-004833; Koshy E, 2018, INDIAN J DERMATOL VE, V84, P251, DOI 10.4103/ijdvl.IJDVL_1021_16; Lee CY, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0760-z; Marin M, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw119; Moraru M, 2012, J IMMUNOL, V188, P4412, DOI [10.4049/j.immunol.1103434, 10.4049/jimmunol.1103434]; Puzyryova LV, 2016, INFEKTSIYA IMMUN, V6, P103, DOI 10.15789/2220-7619-2016-2-103-108; Rojas JM, 2017, J IMMUNOL RES, DOI 10.1155/2017/6104054; Serebrennikova S, 2012, SIBIRSKIJ MED ZH IRK, V115, P5; Serinken M, 2016, ANN EMERG MED, V67, P141, DOI 10.1016/j.annemergmed.2015.04.010; Shi HJ, 2017, J HAINAN MED U, V23, P97; Tran KD, 2016, OPHTHALMOLOGY, V123, P1469, DOI 10.1016/j.ophtha.2016.03.005; Trifunovic J, 2015, BIOCHEM MEDICA, V25, P36, DOI 10.11613/BM.2015.004; Tseng HF, 2018, INT J INFECT DIS, V66, P99, DOI 10.1016/j.ijid.2017.11.016; Werner RN, 2017, J EUR ACAD DERMATOL, V31, P20, DOI 10.1111/jdv.13957; Zheleznikova GF, 2015, INFEKTSIYA IMMUN, V5, P79, DOI 10.15789/2220-7619-2015-1-79-84; [Железникова Г.Ф. Zheleznikova G.F.], 2013, [Российский иммунологический журнал, Russian Journal of Immunology, Rossiiskii immunologicheskii zhurnal], V7, P35	29	0	0	0	0	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	SEP-DEC	2018		3					325	329		10.14739/2310-1237.2018.3.151810			5	Pathology	Pathology	HF9JB	WOS:000454557200009		DOAJ Gold			2019-10-28	
J	Berezenko, VS; Zadorozhna, TD; Mykhailiuk, KZ; Tarasiuk, BA; Korobko, VF; Kelykhevych, SM				Berezenko, V. S.; Zadorozhna, T. D.; Mykhailiuk, Kh Z.; Tarasiuk, B. A.; Korobko, V. F.; Kelykhevych, S. M.			Morphological and ultrasound features of liver fibrosis in children with autoimmune hepatitis	PATHOLOGIA			Ukrainian	Article						autoimmune hepatitis; children; fibrosis; elastography	TRANSIENT ELASTOGRAPHY; NONINVASIVE ASSESSMENT; IMPULSE ELASTOGRAPHY	Aim. To study the ultrasound peculiarities of the liver parenchyma stiffness in children with autoimmune hepatitis by shear wave elastography comparing with the results of liver biopsy morphological investigation. Materials and methods. 40 children with autoimmune hepatitis were examined during the period of 2015-2018. All children were provided with a complex of laboratory tests according to the protocol, shear wave elastography of the liver and a puncture biopsy of the liver. The disease activity was ranged with the histological index of activity (IHA) according to Knodell by the results of a morphological study of liver biopsy and biochemical parameters (alanine aminotransferase, total bilirubin, gamma globulin, immunoglobulin G). The stage of the disease was estimated by the METAVIR histological index (HIS) and semi-quantitative elastography of the parenchyma shift wave. A comparison of the relationship between the histological activity of hepatitis and the parameters of the liver stiffness has been made. The changes in 23 children with hypertension were investigated in dynamics of liver stiffness (after 6 and 12 months of treatment). Result. A progressive fibrosis was diagnosed in 72.5 % (n = 29) (METAVIR F2) (chi(2) = 16.2; P < 0.001 between the group of children with F1-2 and F3-4 METAVIR). The ROC analysis showed that, the optimal "cut-off point" for the diagnosis of F3 METAVIR fibrosis was the stiffness index of 9.4 kPa, and for F4 METAVIR -13.0 kPa. Hepatitis activity influenced the stiffness of the liver parenchyma - with a decrease in the activity of the inflammatory process decreased and the rigidity of the liver parenchyma (P > 0.05). Conclusions. In 50 % of children with autoimmune hepatitis, the stage of fibrosis, which was determined by the method of elastography before treatment, corresponded to the data of the morphological study of liver biopsy. The activity of hepatitis affects the liver parenchyma stiffness, with the decrease of inflammatory process activity this index also decreases. The conducted research showed that in the process of treatment (anti-fibrotic and immunosuppressive therapy), after 6 and 12 months, the parameters of liver parenchyma severity decrease significantly (P < 0.05).	[Berezenko, V. S.; Mykhailiuk, Kh Z.] NAMS Ukraine, SI Inst Pediat Obstet & Gynaecol, Dept Pediat Hepatol, Kiev, Ukraine; [Berezenko, V. S.; Mykhailiuk, Kh Z.] Bogomolets Natl Med Univ, Dept Pediat 1, Kiev, Ukraine; [Zadorozhna, T. D.] NAMS Ukraine, Kiev, Ukraine; [Zadorozhna, T. D.; Kelykhevych, S. M.] NAMS Ukraine, SI Inst Pediat Obstet & Gynaecol, Lab Pathomorphol, Kiev, Ukraine; [Tarasiuk, B. A.] NAMS Ukraine, SI Inst Nucl Med & Diagnost Radiol, Sci Work, Kiev, Ukraine; [Korobko, V. F.] NAMS Ukraine, SI Inst Nucl Med & Diagnost Radiol, Kiev, Ukraine	Berezenko, VS (reprint author), NAMS Ukraine, SI Inst Pediat Obstet & Gynaecol, Dept Pediat Hepatol, Kiev, Ukraine.; Berezenko, VS (reprint author), Bogomolets Natl Med Univ, Dept Pediat 1, Kiev, Ukraine.	x_volocuga@ukr.net	Mykhailiuk, Hrystyna/V-8900-2019				[Anonymous], 2015, J HEPATOL, V63, P237, DOI 10.1016/j.jhep.2015.04.006; Bamber J, 2013, ULTRASCHALL MED, V34, P169, DOI 10.1055/s-0033-1335205; Berzigotti A, 2013, J HEPATOL, V59, P180, DOI 10.1016/j.jhep.2012.12.028; Bjornsson E, 2011, CLIN GASTROENTEROL H, V9, P57, DOI 10.1016/j.cgh.2010.07.016; Cassinotto C, 2016, HEPATOLOGY, V63, P1817, DOI 10.1002/hep.28394; Cassinotto C, 2014, J HEPATOL, V61, P550, DOI 10.1016/j.jhep.2014.04.044; Castera L, 2015, DIGEST DIS, V33, P498, DOI 10.1159/000374097; Chung JH, 2013, CLIN MOL HEPATOL, V19, P156, DOI 10.3350/cmh.2013.19.2.156; Guo LW, 2017, MED SCI MONITOR, V23, P5106, DOI 10.12659/MSM.907300; Hartl J, 2016, J HEPATOL, V65, P769, DOI 10.1016/j.jhep.2016.05.023; Lohse AW, 2015, J HEPATOL, V63, P971, DOI 10.1016/j.jhep.2015.06.030; Thiele M, 2016, GASTROENTEROLOGY, V150, P123, DOI 10.1053/j.gastro.2015.09.040; Tsochatzis EA, 2011, J HEPATOL, V54, P650, DOI 10.1016/j.jhep.2010.07.033; Zeng J, 2014, EUR RADIOL, V24, P2572, DOI 10.1007/s00330-014-3292-9	14	0	0	1	1	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	SEP-DEC	2018		3					330	336		10.14739/2310-1237.2018.3.151815			7	Pathology	Pathology	HF9JB	WOS:000454557200010		DOAJ Gold			2019-10-28	
J	Chornyi, VM; Polishchuck, NM; Kamyshnyi, OM; Holovakha, ML				Chornyi, V. M.; Polishchuck, N. M.; Kamyshnyi, O. M.; Holovakha, M. L.			Results of the in vitro study of the antibacterial activity of modified magnesium alloy in experiments with E. coil and P. aeruginosa test-strains	PATHOLOGIA			Ukrainian	Article						magnesium; alloys; prostheses and implants; bacteriocides; Escherichia coil; Pseudomonas aeruginosa		The aim. To study the sensitivity of gram-negative microorganisms (the main pathogens of implant-associated infections) to the products of biodegradation of magnesium alloy ML-10, with subsequent justification for its use in traumatologic practice as artificial implants with antibacterial activity. Methods. Magnesium alloy extract was prepared on the basis of Mueller-Hinton broth (pH 7.4). In sensitivity testing the reference test strains of Escherichia coll ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were used. The bacteriostatic activity of the alloy extract was estimated by the presence or absence of the visual growth in test-tubes with microorganisms; bactericidal activity - by presence or absence of the growth of microorganisms colonies on cups with Mueller-Hinton agar after sowing from test tubes. The results of the study showed that the studied extract of magnesium alloy ML-10 shows high bacteriostatic and bactericidal activity with reference strains of E. coil and P aeruginosa. The growth of this microorganisms on agar was observed only in test tubes, to which microorganisms at a concentration of 10(9), 10(8), 10(7) CFU/ml were added the day before. The maximum growth of colonies on agar after sowing from these containers was recorded only after the first day of incubation. During the incubation (37 degrees C) the number of colonies that grew in agar medium after the second and third sowing significantly decreased. Thus, the total number of E. coil colonies that grew after sowing on agar from tubes with the largest number of bacteria (10(9) CFU/ml) decreased from 220 (after the first day of incubation in extract) to 2 colonies after 72 hours of incubation of fluid in the thermostat, and from 192 to 1 colonies in experiments with P. aeruginosa. Similar results were obtained in experiments with lower microbial concentrations, which indicates high sensitivity of gram-negative microorganisms to ML-10 magnesium alloy extract. Conclusions. Magnesium alloy ML-10 in a liquid medium shows high bactericidal activity against gram-negative microorganisms, effectively suppressing the growth of reference strains of E. coil ATCC 25922 and P. aeruginosa ATCC 27853 during 72 hours.	[Chornyi, V. M.; Holovakha, M. L.] Zaporizhzhia State Med Univ, Dept Traumatol & Orthoped, Zaporizhia, Ukraine; [Polishchuck, N. M.; Kamyshnyi, O. M.] Zaporizhzhia State Med Univ, Dept Microbiol Virol & Immunol, Zaporizhzhia, Ukraine	Chornyi, VM (reprint author), Zaporizhzhia State Med Univ, Dept Traumatol & Orthoped, Zaporizhia, Ukraine.	chorniy.vadim.doc@gmail.com					Al-Mulhim FA, 2014, INT SURG, V99, P264, DOI 10.9738/INTSURG-D-13-00251.1; Brady R. A, 2009, SPRINGER SERIES BIOF; Busscher HJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004528; He GP, 2015, J MATER CHEM B, V3, P6676, DOI 10.1039/c5tb01319d; Martinez-Pastor JC, 2009, ANTIMICROB AGENTS CH, V53, P4772, DOI 10.1128/AAC.00188-09; Robinson DA, 2010, ACTA BIOMATER, V6, P1869, DOI 10.1016/j.actbio.2009.10.007; Scheffer D, 2008, ORTHOPADE, V37, P709, DOI 10.1007/s00132-008-1301-x; Stewart PS, 2001, LANCET, V358, P135, DOI 10.1016/S0140-6736(01)05321-1; Thakore Rachel V, 2015, J Clin Orthop Trauma, V6, P220, DOI 10.1016/j.jcot.2015.04.004	9	0	0	0	0	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	SEP-DEC	2018		3					337	340		10.14739/2310-1237.2018.3.151854			4	Pathology	Pathology	HF9JB	WOS:000454557200011		DOAJ Gold			2019-10-28	
J	Kryvenko, VI; Borodavko, OI				Kryvenko, V., I; Borodavko, O., I			The state of bone metabolism in patients with type 2 diabetes mellitus	PATHOLOGIA			Ukrainian	Article						type 2 diabetes mellitus; bone metabolism; osteoporosis	GLYCEMIC CONTROL; MARKERS	The aim of this work is to investigate the state of bone metabolism status and its relationship with carbohydrate metabolism in patients with type 2 diabetes. Materials and methods. 94 patients were studied, among whom the 1st group -22 patients with osteoporosis (OP), the 2nd group -22 patients with type 2 diabetes mellitus (DM), the a d group -50 patients with combined course of these diseases. An ultrasound densitometry using the Omnisense 7000 ultrasound densitometer (BeamMed Ltd, Israel) was performed for all the patients. The state of bone tissue was determined by criteria of the WHO. The levels of osteocalcin (OC), parathyroid hormone (PTH), calcitonin in blood serum, the level of deoxypyridinoline (DPD) were determined in morning urine for all patients. In patients with type 2 DM the levels of C-peptide, insulin, glucose, HbA1c and HOMA index were studied. Results. It was revealed that patients of the 3rd group had significant decrease in OC level by 44 %, DPD by 24 %, PHT by 28 % (P < 0.05) in comparison to the patients of the 1st group. In 53 % of patients of the 3rd group the development of OP was characterized by decreased bone formation and increased bone resorption. The patients of the 3rd group had significantly higher levels of Hblc by 11.5 %, glucose by 25 %, HOMA index by 7.2 % (P < 0.05), while the level of OC and DPD were lower by 8.5 % and 17 %, (P < 0.05) respectively in comparison with patients of group 2. The levels of OC and DPD were significantly lower in patients with decompensation of type 2 diabetes, in comparison with compensated diabetes by -12 % and -17 %, respectively (P < 0.05). The level of HbA1c significantly influences the state of bone metabolism. With an increase in HbA1c of more than 7.5 %, the level of OC decreases by 12 %, and DPD by 17 % (P < 0.05). Conclusions. The results suggest that type 2 DM leads to slowdown of bone metabolism, as the 3rd group patients had significantly reduced levels of OK and DPD as compared to the patients of the 1st group. Poor glycemic control can be one of the factors that reduce the level of bone markers.	[Kryvenko, V., I; Borodavko, O., I] Zaporizhzhia State Med Univ, Dept Family Med Therapy Cardiol & Neurol, Fac Postgrad Educ, Zaporizhzhia, Ukraine	Kryvenko, VI (reprint author), Zaporizhzhia State Med Univ, Dept Family Med Therapy Cardiol & Neurol, Fac Postgrad Educ, Zaporizhzhia, Ukraine.	oleo1714@gmail.com					[Anonymous], 2015, OFFICIAL POSITIONS I; Cho NH, 2015, IDF DIABETES ATLAS; Ferreira MT, 2015, DIABETES CARE, V38, P897, DOI 10.2337/dc14-2791; Kanazawa I, 2017, ENDOCR J, V64, P1043, DOI 10.1507/endocrj.EJ17-0323; Kanazawa I, 2009, J CLIN ENDOCR METAB, V94, P3031, DOI 10.1210/jc.2008-2187; Manulenko V. V, 2010, MEZHDUNARODNYJ NDOKR, V3; Mitchenko O. I, 2013, UKRAINSKYI MED CHASO, V2, P107; Miyake H, 2018, CALCIFIED TISSUE INT, V102, P1, DOI 10.1007/s00223-017-0324-x; Sanches CP, 2017, DIABETOL METAB SYNDR, V9, DOI 10.1186/s13098-017-0278-1; Starup-Linde Jakob, 2013, Front Endocrinol (Lausanne), V4, P21, DOI 10.3389/fendo.2013.00021; Verroken C, 2017, J CLIN ENDOCR METAB, V102, P1807, DOI 10.1210/jc.2016-3609; Wei JW, 2014, J CLIN INVEST, V124, P1781, DOI 10.1172/JCI72323	12	0	0	0	1	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	SEP-DEC	2018		3					341	345		10.14739/2310-1237.2018.3.151855			5	Pathology	Pathology	HF9JB	WOS:000454557200012		DOAJ Gold			2019-10-28	
J	Stepanov, YM; Simonova, OV; Mosiichuk, LM; Petishko, OP				Stepanov, Yu M.; Simonova, O., V; Mosiichuk, L. M.; Petishko, O. P.			Modern endoscopic criteria for stratification of patients with atrophic gastritis in the development of precancerous changes of the stomach	PATHOLOGIA			Ukrainian	Article						gastritis; stomach diseases; precancerous conditions; metaplasia; diagnosis; endosonography		Purpose: to identify the most significant endoscopic diagnostic criteria for the development of precancerous changes of the of the stomach mucosa (SM). Material and methods. 80 patients with atrophic gastritis were examined (34 (42.5 %) men and 46 (57.5 %) women, the average age (57.7 +/- 2.1) years. The diagnosis was set during endoscopic examinations and was morphologically confirmed in all cases. Esophagogastroduodenoscopy was performed using EVIS EXERA III video endoscopic system with Olympus 190 gastroscope (Japan). Examination of the stomach was carried out in white light regimen, magnification (near focus) and NBI regimen. All examined patients were divided into groups according to the presence and prevalence of intestinal metaplasia (IM) and the presence of SM dysplasia: group I - SM atrophy without IM (10 patients), II - SM atrophy with IM, limited of the antral part (20 patients), III - SM atrophy with diffuse (multifocal) IM (39 patients), IV - SM dysplasia (11 patients). Results. For the formation of group of patients with high risk of developing gastric cancer, diagnostic criteria of structural changes of gastric mucosa with pre-cancerous potential were identified. In white light upper endoscopy, the knotted / tuberous relief of the stomach mucosa can be considered as a diagnostic criterion for sensitivity (81.4 %) and specificity (60.0 %) indicators. The xanthomatosis of the stomach mucosa increases by 5 times the risk of IM or dysplasia in patients with atrophic gastritis (sensitivity - 47.1 %, specificity -90.0 %). Magnification endoscopy and endoscopy with narrow-band imaging allowed us to establish another diagnostic criterion for the formation of the group with high risk of developing gastric cancer: pyloric metaplasia (pseudopylorisation) of the gastric corpus. Pyloric metaplasia increases the frequency of detection of structural precancerous changes in a patient with atrophic gastritis by almost 7 times (sensitivity - 71.4 %, specificity - 70.0 %). Conclusion. The established endoscopic criteria (nodular relief of the stomach (OR = 4.96), xanthomatosis of the stomach (OR = 4.94), pyloric metaplasia of the stomach body (OR = 6.72)) can be applied in the formation of a group of patients with atrophic gastritis who have high potential for the development of gastric cancer and require careful examination using modern endoscopic equipment and dynamic surveillance.	[Stepanov, Yu M.] Natl Acad Med Sci Ukraine, State Inst, Inst Gastroenterol, Dnipro, Ukraine; [Simonova, O., V] Natl Acad Med Sci Ukraine, Dept Minimally Invas Endoscop Intervent & Instrum, Inst Gastroenterol, State Inst, Dnipro, Ukraine; [Mosiichuk, L. M.] Natl Acad Med Sci Ukraine, Dept Dis Stomach & Duodenum Dietet & Clin Nutr, State Inst, Inst Gastroenterol, Dnipro, Ukraine; [Petishko, O. P.] Natl Acad Med Sci Ukraine, Dept Sci Org Methodol Work & Informat Technol, State Inst, Inst Gastroenterol, Dnipro, Ukraine	Stepanov, YM (reprint author), Natl Acad Med Sci Ukraine, State Inst, Inst Gastroenterol, Dnipro, Ukraine.	gastrodnepr@i.ua					Cohen J, 2012, ATLAS NDOSKOPII PISC; Dinis-Ribeiro M, 2012, ENDOSCOPY, V44, P74, DOI 10.1055/s-0031-1291491; Halafyan A. A, 2014, SOVREMENNYE STAT MET; Hun H, 2013, KOREAN J HELICOBACTE, V13, P6, DOI [10.7704/kjhugr.2013.13.1.6, DOI 10.7704/KJHUGR.2013.13.1.6]; Nikishaev V. I, 2013, UKRAINSKYI ZH MALOIN, V17, P25; Olmez S, 2015, GASTROENT RES PRACT, DOI 10.1155/2015/434039; Pimentel-Nunes P, 2012, ENDOSCOPY, V44, P236, DOI 10.1055/s-0031-1291537; Simonova O. V, 2016, P 4 INT MED C KYIV, P59; Stepanov Yu. M, 2013, HASTROENTEROLOHIIA, V4, P23; Stepanov Yu. M, 2017, HASTROENTEROLOHIIA, V1, P85, DOI [10.22141/2308-2097.51.1.2017.97873., DOI 10.22141/2308-2097.51.1.2017.97873]; Sugano K, 2015, GUT, V64, P1353, DOI 10.1136/gutjnl-2015-309252; Tkach S. M, 2016, SUCHASNA HASTROENTER, V1, P110; Yakovenko V. O, 2013, ENDOSCOPICHNA MORFOL; Yao K, 2008, NEW CHALLENGES IN GASTROINTESTINAL ENDOSCOPY, P169, DOI 10.1007/978-4-431-78889-8_16	14	0	0	1	1	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	SEP-DEC	2018		3					346	353		10.14739/2310-1237.2018.3.151857			8	Pathology	Pathology	HF9JB	WOS:000454557200013		DOAJ Gold			2019-10-28	
J	Koziolkin, OA; Kuznietsov, AA; Novikova, LV				Koziolkin, O. A.; Kuznietsov, A. A.; Novikova, L., V			Prediction of the functional outcome of acute recurrent cerebral ischemic hemispheric stroke	PATHOLOGIA			English	Article						acute stroke; prognosis	NIH STROKE; MORTALITY	The aim of the work is to develop criteria for predicting the functional outcome of the acute period of recurrent cerebral ischemic hemispheric stroke (RCIHS) based on a comprehensive clinical and paraclinical examinations. Materials and methods. An open, comparative, prospective, cohort study of 111 patients (49 (44.1 %) women and 62 (55.9 %) men, age 72.0 (64.0; 77.0) years) with acute RCIHS was performed. All patients underwent a detailed clinical and neurological examination using National Institutes of Health Stroke Scale, mRS (modified Rankin scale), computed tomography of the brain, hematological and biochemical investigation. Results. Based on a univariate logistic regression analysis, it was found that the functional outcome of the acute RCIHS is influenced by the following parameters: age of patient (OR 1.06, 95 % CI 1.00-1.11, P = 0.0284), contralateral localization of RCIHS (OR 2.86 95 % CI 1.05-7.79, P = 0.0391), the baseline NIHSS score (OR 1.76. 95 % CI 1.38-2.26; P < 0. 0001), the infarct volume (OR 1.03, 95 % CI 1.00-1.05, P = 0.0221). It was determined that localization of RCIHS in the contralateral hemisphere was associated with the unfavorable functional outcome on the 21(st) day of the disease (x(2) = 4.44, P = 0.0352). The independent influence of the initial level of glycemia on the functional outcome of the acute period of RCIHS in patients without diabetes (OR 2.39 95 % CI 1.32-4.33, P = 0.0042) was revealed. Conclusions. The independent predictor of the unfavorable functional outcome of the acute period of the RCIHS (mRS >= 3 at 21st day of disease) was score by NIHSS >10 at baseline (sensitivity 73.3 %, specificity 90.5 %). The mathematical model, which included the baseline levels of neurological deficit was developed and it could determine the prognosis of the functional outcome of the acute period of RCIHS with an accuracy of 87.5 % (AUC = 0.92, P < 0.05).	[Koziolkin, O. A.; Kuznietsov, A. A.; Novikova, L., V] Zaporizhzhia State Med Univ, Dept Nervous Dis, Zaporizhia, Ukraine	Novikova, LV (reprint author), Zaporizhzhia State Med Univ, Dept Nervous Dis, Zaporizhia, Ukraine.	l.novikova.med@gmail.com	Koziolkin, Oleksandr/AAA-5382-2019; Novikova, Liubov/AAA-5632-2019; Kuznietsov, Anton/AAA-5158-2019	Koziolkin, Oleksandr/0000-0001-9878-5798; Novikova, Liubov/0000-0001-5853-2438; Kuznietsov, Anton/0000-0002-6118-9682			Alonso A, 2015, CEREBROVASC DIS, V40, P10, DOI 10.1159/000430871; Antono I. P., 2003, MED NOVOSTI, V11, P3; Bruno A, 2013, J STROKE CEREBROVASC, V22, P781, DOI 10.1016/j.jstrokecerebrovasdis.2012.03.011; Chin Y Y, 2018, Med J Malaysia, V73, P90; Fan CY, 2017, J STROKE CEREBROVASC, V26, P2915, DOI 10.1016/j.jstrokecerebrovasdis.2017.07.035; Fuentes B, 2009, STROKE, V40, P562, DOI 10.1161/STROKEAHA.108.519926; Hedna VS, 2013, J CLIN NEUROL, V9, P97, DOI 10.3988/jcn.2013.9.2.97; Inoa V, 2014, CEREBROVASC DIS, V37, P251, DOI 10.1159/000358869; Jorgensen H S, 1996, J Stroke Cerebrovasc Dis, V6, P5, DOI 10.1016/S1052-3057(96)80020-6; Klochikhina O. A., 2018, KARDIOVASKULIARNA TE, V17, P33; Kruetzelmann A, 2011, STROKE, V42, P1251, DOI 10.1161/STROKEAHA.110.600148; Laredo C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27883-3; Lee SJ, 2017, BMC NEUROL, V17, DOI 10.1186/s12883-017-0865-7; Markkula R. L., 2014, INT J NEUROREHABILIT, V1, P103, DOI [10.4172/2376-0281.1000103, DOI 10.4172/2376-0281.1000103]; Mozharovskaya M. A., 2012, CONSILIUM MED, V9, P44; Nardi K, 2012, J DIABETES COMPLICAT, V26, P70, DOI 10.1016/j.jdiacomp.2012.03.001; Rakhmanova Sh. P., 2011, MEZHDUNARODNYJ NEVRO, V1, P59; Raza SA, 2017, CEREBROVASC DIS EXTR, V7, P120, DOI 10.1159/000479933; Reznik ME, 2018, INT J STROKE, V13, P806, DOI 10.1177/1747493018783759; Soriano-Tarraga C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22579-0; Sung JY, 2017, PEERJ, V5, DOI 10.7717/peerj.2948; Swarowska M, 2016, J STROKE CEREBROVASC, V25, P2752, DOI 10.1016/j.jstrokecerebrovasdis.2016.07.029; Yaghi S, 2016, NEUROHOSPITALIST, V6, P102, DOI 10.1177/1941874416641466; Zhang J, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008624	24	0	0	0	0	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	SEP-DEC	2018		3					354	359		10.14739/2310-1237.2018.3.151859			6	Pathology	Pathology	HF9JB	WOS:000454557200014		DOAJ Gold			2019-10-28	
J	Abramov, AV; Shamenko, VO; Kolesnyk, YM				Abramov, A., V; Shamenko, V. O.; Kolesnyk, Yu M.			Comparative characteristics of vasopressinergic neurons of the supraoptic and paraventricular nuclei of hypothalamus response in the intermittent hypoxic hypoxia	PATHOLOGIA			Ukrainian	Article						Arg-vasopressin; cFos protein; hypoxia-inducible factor; hypothalamus; hypoxia	PITUITARY-ADRENAL AXIS; STRESS; PHYSIOLOGY; ALTITUDE; SYSTEM	The vasopressinergic system of the hypothalamus occupies an important place in the neuroendocrine mechanisms of maintaining homeostasis, controlling autonomic reactions and the processes of adaptation of the organism to the acute and chronic stressors. The main portion of the magnocellular vasopressin-synthesizing neurons is localized in the supraoptic nucleus (SON) and in the lateral part of the posterior magnocellular subnuclei of the paraventricular nucleus (PVNpmI). The aim of study was to establish the features of the vasopressinergic neurons of the hypothalamus magnocellular nuclei functional state under the influence of prolonged intermittent hypoxic hypoxia and in the post-hypoxic period. Materials and methods. The research was carried out on 30 male Wistar rats. Intermittent hypoxia was modeled by daily 6 hour stay of rats at the simulated altitude of 6000 m (pO(2) = 9.8 %) for 15 days, the post-hypoxic period lasted 10 days. The distribution of [Arg(8)]-vasopressin (AVP), cFos, HIF-1 alpha, and HIF-3 alpha proteins was investigated by quantitative immunofluorescence methods in serial frontal sections of hypothalamus. Results. The hypoxic hypoxia action led to SON neurons degeneration, inhibition ofAVP synthesis in SON by 40%, decrease of cFos protein content by 56 %, and the failure of reaction to hypoxia from the HIF-proteins family. In PVNpmI neurons, intermittent hypoxia stimulated 6-fold increase in the AVP content along with cFos-protein increase by 80%. The response of PVNpmI neurons to hypoxia was accompanied by 3-times increase of the HIF family proteins content. In the post-hypoxic period the AVP content was partially restored in SON neurons, but decrease of cFos-protein synthesis indicated inhibition of secretory activity in SON. In the post-hypoxic period the content of the AVP and the HIF-proteins decreased significantly in PVNpmI neurons, but the level of all proteins remained higher than in the control group. At the same time, the level of cFos secretory activity did not change significantly as compared with the hypoxic period. These data indicate the stability of the high level of functional activity of the PVNpmI vasopressinergic neurons during the 10-day post-hypoxic period. Conclusions. Intermittent hypoxia stimulates the functional activity of the PVNpmI that manifests as an increase of vasopressin, cFos, HIF-1 alpha, and HIF-3 alpha proteins synthesis in magnocellular neurons. In the post-hypoxic period, a slight decrease in the synthesis of vasopressin, HIF-1 alpha and HIF-3 alpha proteins is observed without a decrease in the cFos protein content in PVNpmI. Intermittent hypoxia inhibits the functional activity of SON neurons, which is partially restored in the post hypoxic period.	[Abramov, A., V] Zaporizhzhia State Med Univ, Dept Pathol Physiol, Zaporizhzhia, Ukraine; [Abramov, A., V] ZSMU, Sci Med Lab Ctr, Zaporizhzhia, Ukraine; [Shamenko, V. O.] Zaporizhzhia State Med Univ, Dept Children Dis, Fac Postgrad Educ, Zaporizhzhia, Ukraine; [Kolesnyk, Yu M.] Zaporizhzhia State Med Univ, Zaporizhzhia, Ukraine	Abramov, AV (reprint author), Zaporizhzhia State Med Univ, Dept Pathol Physiol, Zaporizhzhia, Ukraine.; Abramov, AV (reprint author), ZSMU, Sci Med Lab Ctr, Zaporizhzhia, Ukraine.	abramov@zsmu.pp.ua	Andrii, Abramov/AAC-5575-2019	Andrii, Abramov/0000-0001-8520-2258			Abramov A V, 1998, Ross Fiziol Zh Im I M Sechenova, V84, P173; Aguilera G, 2000, REGUL PEPTIDES, V96, P23, DOI 10.1016/S0167-0115(00)00196-8; Bankir L, 2017, J INTERN MED, V282, P284, DOI 10.1111/joim.12645; Berezovskij V.A, 2012, PRIRODNAYA INSTRUMEN; Coldren KM, 2017, AM J PHYSIOL-REG I, V312, pR982, DOI 10.1152/ajpregu.00543.2016; Gajdyshev I.P, 2004, RESHENIE NAUCHNYKH I; Han F, 2005, NEUROSCI RES, V51, P371, DOI 10.1016/j.neures.2004.12.013; Bonfiglio JJ, 2011, NEUROENDOCRINOLOGY, V94, P12, DOI 10.1159/000328226; KARASH YM, 1988, NORMOBARICHESKAYA GI; Keller-Wood M, 2015, COMPR PHYSIOL, V5, P1161, DOI 10.1002/cphy.c140065; Kolesnik Yu.M, 1993, ROSSIJSKIJ FIZIOLOGI, V79, P34; McEwen BS, 2007, PHYSIOL REV, V87, P873, DOI 10.1152/physrev.00041.2006; Myers B, 2014, FRONT NEUROENDOCRIN, V35, P180, DOI 10.1016/j.yfrne.2013.12.003; Myers DA, 2014, ADV EXP MED BIOL, V814, P147, DOI 10.1007/978-1-4939-1031-1_13; Nicolaides NC, 2015, NEUROIMMUNOMODULAT, V22, P6, DOI 10.1159/000362736; Ostergaard L, 2014, HYPOXIA, V2, P143, DOI 10.2147/HP.S57894; PIRS E, 1962, GISTOKHIMIYA; RAMIREZ G, 1992, AVIAT SPACE ENVIR MD, V63, P891; Ramirez JM, 2007, ANNU REV PHYSIOL, V69, P113, DOI 10.1146/annurev.physiol.69.031905.163111; Robach P, 2002, PFLUG ARCH EUR J PHY, V444, P821, DOI 10.1007/s00424-002-0894-x; Rostrup M, 1998, ACTA PHYSIOL SCAND, V162, P389, DOI 10.1046/j.1365-201X.1998.00335.x; Rotondo F, 2016, PITUITARY, V19, P345, DOI 10.1007/s11102-015-0703-0; Shell B, 2016, CURR HYPERTENS REP, V18, DOI 10.1007/s11906-016-0627-8; SILVERMAN AJ, 1983, ANNU REV NEUROSCI, V6, P357, DOI 10.1146/annurev.ne.06.030183.002041; Sivukhina EV, 2016, STEROIDS, V111, P21, DOI 10.1016/j.steroids.2016.01.008; Sivukhina EV, 2014, STEROIDS, V81, P70, DOI 10.1016/j.steroids.2013.11.001; Summanen M, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00002; SWANSON LW, 1983, ANNU REV NEUROSCI, V6, P269, DOI 10.1146/annurev.ne.06.030183.001413; Szczepanska-Sadowska E, 2018, CURR HYPERTENS REP, V20, DOI 10.1007/s11906-018-0823-9; Volpi S, 2004, STRESS, V7, P75, DOI 10.1080/10253890410001733535	30	0	0	2	2	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	SEP-DEC	2018		3					360	366		10.14739/2310-1237.2018.3.151862			7	Pathology	Pathology	HF9JB	WOS:000454557200015		DOAJ Gold			2019-10-28	
J	Tishchenko, SV				Tishchenko, S., V			Features of angiotensin II expression in the arcuate nucleus of the hypothalamus of experimental rats with arterial hypertension of various etiology	PATHOLOGIA			Ukrainian	Article						hypothalamus; arcuate nucleus; angiotensin II; arterial hypertension; rats	RECEPTORS; SYSTEM	It is proved that the effectiveness of blood pressure regulation mainly depends on those neuromodulators and neurohormones that are formed in or enter the hypothalamus. The important role of the arcuate nucleus (ArC) both as the intrahypothalamic regulator of the functional activity of its nuclear structures, and the coordinator over the suprasegmental and segmental centers of blood pressure regulation is proved. There are data that blood pressure is dependent on the content of the pressor neurohormone angiotensin II in the ArC of hypothalamus. The aim of the study was to determine the specific properties of angiotensin II content in the ArC of hypothalamus in the rats of Wistar and SHR lines with etiologically different arterial hypertension: endocrine-salt and essential. Materials and methods. The study was carried out on 24 mature male rats 250-270 g weight at the age of 13-14 months, which were divided into three experimental groups each consisting of 8 animals. First group of the Wistar rats with normal BP parameters (Ps/Pd = 110/75 +/- 5 mm)was a control one. The second was the group of Wistar rats with the endocrine-salt model of arterial hypertension (Ps/Pd 145/110 +/- 10 mm). The third group was presented by the SHR rats with spontaneous arterial hypertension (Ps/Pd = 150/110 +/- 10 mm). An immunohistochemical method was used to study the content of angiotensin II in the ArC, which was followed by digital processing of the data by Image J and EXCEL-7.0. Results. Reduction in the content and concentration of angiotensin II is observed in the rats with arterial hypertension independently of its etiology and pathogenesis. Peculiarities of angiotensin II content in ArC of hypothalamus are dependent from the etiology and pathogenesis of arterial hypertension. In essential hypertension (SHR) lower levels of angiotensin II expression in the ArC structure of the hypothalamus are observed than in secondary endocrine associated arterial hypertension.			gancheva@zsmu.pp.ua	Hancheva, Olha/X-9959-2019				Arakawa H, 2011, AM J PHYSIOL-HEART C, V300, pH951, DOI 10.1152/ajpheart.01144.2010; CHRONWALL BM, 1985, PEPTIDES, V6, P1, DOI 10.1016/0196-9781(85)90128-7; Eudy RJ, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-180; Gerasimova A. S, 2008, MED NAUKI, V3; GUNTHER S, 1980, NATURE, V287, P230, DOI 10.1038/287230a0; Iellamo F, 2001, AUTON NEUROSCI-BASIC, V90, P66, DOI 10.1016/S1566-0702(01)00269-7; Kawabe T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045180; McKinley MJ, 2003, INT J BIOCHEM CELL B, V35, P901, DOI 10.1016/S1357-2725(02)00306-0; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152; NAZARALI AJ, 1990, AM J HYPERTENS, V3, P59, DOI 10.1093/ajh/3.1.59; NORSTROM A, 1971, Z ZELLFORSCH MIK ANA, V113, P271, DOI 10.1007/BF00339421; Paxinos G, 2007, RAT BRAIN STEREOTAXI; Peruzzo B, 2004, CELL TISSUE RES, V317, P147, DOI 10.1007/s00441-004-0899-1; Zajcev V, 2003, PRIKLADNAYA MED STAT	14	0	0	0	0	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	SEP-DEC	2018		3					367	371		10.14739/2310-1237.2018.3.151864			5	Pathology	Pathology	HF9JB	WOS:000454557200016		DOAJ Gold			2019-10-28	
J	Buchakchyiska, NM; Polkovnikova, KY				Buchakchyiska, N. M.; Polkovnikova, K. Yu			Prognostic value of serum copeptin level in patients with subarachnoid haemorrhage	PATHOLOGIA			Ukrainian	Article						subarachnoid hemorrhage; prognosis		Subarachnoid haemorrhage (SAH) is one of the most common forms of intracranial vascular pathology and one of the severest types of cerebral circulation disorders. According to epidemiology, up to 5000 cases of SAH of an aneurysmal genesis occur annually in Ukraine with an average incidence of 12 cases / 100.000 / year per 45 million people. Purpose of the study. Evaluation of diagnostic informativeness of copeptin serum values in determining the risk of complications in patients with subarachnoid hemorrhage. Materials and methods. A prospective, cohort study of 82 patients (40 men and 42 women, mean age 49.6 +/- 1.3 years) was conducted. The diagnosis was made on the basis of clinical neuroimaging criteria. Aneurysmal genesis of SAH according to cerebral angiography was verified in 58 (71.9 %). Serum copeptin level was determined on the 3rd day of the disease by ELISA. The development of a complex of SAH complications in the form of secondary ischemia and cerebral angiospasm was considered as the primary end point. The threshold value of serum concentration of copeptin in the assessment of the risk of the development of SAH complications was determined by the results of ROC analysis. Results. The combination of SAH complications was diagnosed in 27 (32.9 %) patients, while the serum level of copeptin in this subcohort was significantly higher than that in the group of patients without complications by 44.2 % 0.738 (0.667-0.800) ng / ml versus 0.419 (0.347-0.549), P < 0.01). The serum level of copeptin >= 0.605 ng / ml was found to be associated with an increase in the cumulative risk of SAH complications by 9.5 times (95 % CI 3.6-24.8, P < 0.0001; AUC = 0.95 +/- 0.02 95 % CI 0.90-0.99, P = 0.001; diagnostic accuracy is 85.4 %; sensitivity - 85.2 %, specificity - 85.5 %). Conclusion. The serum level of copeptin is a highly informative marker for the detection of individual cumulative risk of complications in patients with SAH.	[Buchakchyiska, N. M.] Minist Hlth Ukraine, SI Zaporizhzhia Med Acad Postgrad Educ, Dept Nervous Dis, Kiev, Ukraine; [Polkovnikova, K. Yu] Zaporizhzhia Reg Council, Zaporizhzhia Reg Clin Hosp, Communal Inst, Neurol Dept, Zaporizhia, Ukraine	Buchakchyiska, NM (reprint author), Minist Hlth Ukraine, SI Zaporizhzhia Med Acad Postgrad Educ, Dept Nervous Dis, Kiev, Ukraine.	kuzya.cat01121981@gmail.com					Aksu F, 2016, CLIN LAB, V62, P2387, DOI 10.7754/Clin.Lab.2016.160532; Cusack TJ, 2018, CURR TREAT OPTION NE, V20, DOI 10.1007/s11940-018-0486-5; De Marchis GM, 2018, EUR J NEUROL, V25, P562, DOI 10.1111/ene.13554; Fernandez SJ, 2019, J NEUROSURG, V130, P1446, DOI 10.3171/2017.10.JNS17795; Fung C, 2016, J NEUROSURG, V124, P299, DOI 10.3171/2015.2.JNS14614; Kingwell Katie, 2014, Nat Rev Neurol, V10, P1, DOI 10.1038/nrneurol.2013.257; Li MH, 2013, ANN INTERN MED, V159, P514, DOI 10.7326/0003-4819-159-8-201310150-00004; Naval NS, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2012.03.006; Neidert MC, 2018, NEUROSURGERY, V83, P1286, DOI 10.1093/neuros/nyx609; Niesten JM, 2013, NEURORADIOLOGY, V55, P1071, DOI 10.1007/s00234-013-1217-y; Pedachenko E. G, 2017, UKRAINSKYI NEIROKHIR, V1, P33; Schmidt JM, 2014, NEUROCRIT CARE, V20, P390, DOI 10.1007/s12028-013-9909-z; Sugimoto K, 2013, NEUROSURG REV, V36, P259, DOI 10.1007/s10143-012-0424-z; Tamargo RJ, 2012, CRIT CARE, V16, DOI 10.1186/cc10594; Voloshyn P. V., 2017, UKRAYINSKYI VISNYK P, V25, P10; Yoneda H, 2013, STROKE, V44, P2155, DOI 10.1161/STROKEAHA.113.001015; Ziai W, 2017, SEMIN NEUROL, V37, P103, DOI 10.1055/s-0037-1598083; Zozulya I. S, 2015, UKRAINSKYI MEDYCHNYI, V5, P34	18	0	0	0	0	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	SEP-DEC	2018		3					372	377		10.14739/2310-1237.2018.3.151867			6	Pathology	Pathology	HF9JB	WOS:000454557200017		DOAJ Gold			2019-10-28	
J	Kuznietsov, AA				Kuznietsov, A. A.			Diagnostic value of the integral assessment of electroencephalographic pattern in patients in the acute period of spontaneous supratentorial intracerebral hemorrhage	PATHOLOGIA			English	Article						cerebral hemorrhage; electroencephalography; X-Ray tomography	QUANTITATIVE EEG; CEREBRAL-ISCHEMIA; BRAIN-FUNCTION; PROGNOSIS	The main purpose of the study was to verify the diagnostic informative value of the integral evaluation of the electroencephalographic pattern in patients with spontaneous supratentorial intracerebral hemorrhage (SSICH) on the basis of the comparison of brain activity changes with clinical and neuroimaging data. Material and methods. Prospective cohort study of 46 patients in acute period of SSICH was conducted. It included complex clinical (using Glasgow Coma Scale, Full Outline of UnResponsiveness (FOUR) score, National Institute of Health Stroke Scale, Intracerebral hemorrhage score) and neuroimaging estimation of cerebral injury severity in the onset of the disease. Investigation of brain bioelectrical activity was made during first 24-48 hours from the onset with determination of average absolute spectral rhythm power (AASRP), relative spectral rhythm power (RSRP), fronto-occipital rhythm gradient (FORG) in the affected hemisphere (AH) and intact hemisphere (IH), interhemispheric rhythm asymmetry values. Results. On the basis of cluster analysis 2types of the brain bioelectric activity changes were identified in patients with SSICH. Type I of EEG pattern was registered in 56.5 % patients, it was characterized by ipsilateral increase of RSRP of delta-range with the dominance of theta-range rhythms in slow-wave activity structure in combination with smoothing of zonal differences of alpha-range rhythms in AH, whereas type II was characterized by bilateral domination of the RSRP delta-range with an accent in IH in combination with FORG inversion of a-range due to elevation of the alpha 2-subrange in the anterior areas of IH. The patients with type II of EEG pattern were characterized by ipsilateral increase of RSRP delta-range with the dominance of theta-range rhythms in slow-wave activity structure in combination with smoothing of zonal differences of a-range rhythms in AH. The patients with type II of EEG pattern were characterized by more severe brain impairment (ICH score 3 (2; 4) versus 0 (0; 1), P <0.0001). Type II of EEG pattern was revealed in 94.7 % of patients with medium/severe dysfunction of subtentorial structures (FOUR score <= 14), type I - in 92.6 % of patients with low dysfunction or without any dysfunction (FOUR score >14). Conclusions. Complex analysis of bioelectric activity of the brain in patients with SSICH allows to identify the integral types of EEG pattern, which represent the functional state of cerebral structures and are associated with the clinical and neuroimaging criteria of midline shift severity.	[Kuznietsov, A. A.] Zaporizhzhia State Med Univ, Dept Nervous Dis, Zaporizhia, Ukraine	Kuznietsov, AA (reprint author), Zaporizhzhia State Med Univ, Dept Nervous Dis, Zaporizhia, Ukraine.	titus3.05@gmail.com	Kuznietsov, Anton/AAA-5158-2019	Kuznietsov, Anton/0000-0002-6118-9682	scientific research work in Zaporizhzhia state medical university "Optimization of the diagnostic, treatment and rehabilitation approaches in patients with acute and chronic cerebral bloodflow violations" [0113U000798]	Investigation is funded as a part of scientific research work in Zaporizhzhia state medical university "Optimization of the diagnostic, treatment and rehabilitation approaches in patients with acute and chronic cerebral bloodflow violations", number of state registration 0113U000798 (2013-2017).	Anastasi AA, 2017, STROKE RES TREAT, DOI 10.1155/2017/8276136; Assenza G, 2013, RESTOR NEUROL NEUROS, V31, P177, DOI 10.3233/RNN-120244; Bentes C, 2018, CLIN NEUROPHYSIOL, V129, P1680, DOI 10.1016/j.clinph.2018.05.021; Chen Y, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-1951-y; Chernii T. V, 2014, ZH NEVROLOH B M MANK, V3, P81; Cherniy V. I, 2016, MIZHNARODNYI NEVROLO, V5, P41, DOI [10.22141/2224-0713.5.83.2016.78470, DOI 10.22141/2224-0713.5.83.2016.78470]; Diedler J, 2009, NEUROCRIT CARE, V11, P210, DOI 10.1007/s12028-009-9236-6; Finnigan SP, 2007, CLIN NEUROPHYSIOL, V118, P2525, DOI 10.1016/j.clinph.2007.07.021; Fiorella D, 2015, WORLD NEUROSURG, V84, P1136, DOI 10.1016/j.wneu.2015.05.063; Kirkman MA, 2013, J NEUROSURG ANESTH, V25, P228, DOI 10.1097/ANA.0b013e3182836059; Li J, 2017, J BIOMED RES, V31, P11, DOI 10.7555/JBR.31.20150171; Purandare M, 2018, SEIZURE-EUR J EPILEP, V61, P122, DOI 10.1016/j.seizure.2018.08.014; Schreuder FHBM, 2017, J NEUROL NEUROSUR PS, V88, P76, DOI 10.1136/jnnp-2016-314386; Sheorajpanday RVA, 2011, CLIN NEUROPHYSIOL, V122, P874, DOI 10.1016/j.clinph.2010.07.028; Sheorajpanday RVA, 2010, CLIN NEUROPHYSIOL, V121, P1719, DOI 10.1016/j.clinph.2009.10.037; van Putten MJAM, 2016, J CLIN NEUROPHYSIOL, V33, P203, DOI 10.1097/WNP.0000000000000272; Wolf ME, 2017, INT J NEUROSCI, V127, P421, DOI 10.1080/00207454.2016.1189913; Wu J, 2016, J NEUROPHYSIOL, V115, P2399, DOI 10.1152/jn.00978.2015; Xin XY, 2017, J CLIN NEUROPHYSIOL, V34, P162, DOI 10.1097/WNP.0000000000000341; Xu P, 2008, IEEE ENG MED BIO, P2924, DOI 10.1109/IEMBS.2008.4649815	20	0	0	1	1	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	SEP-DEC	2018		3					378	385		10.14739/2310-1237.2018.3.151869			8	Pathology	Pathology	HF9JB	WOS:000454557200018		DOAJ Gold			2019-10-28	
J	Voitsenko, KI				Voitsenko, K., I			Early morphological changes in the knee joint of rats after opioid exposure	PATHOLOGIA			Ukrainian	Article						analgesics; cartilage articular; knee joint; rat		The objective is to study early morphological changes of rats' knee joint after experimental opioid exposure. Materials and methods. Research material is mature, non-breeding male rats 4.5 months old (n = 16) with body weight 80 g. Animals were divided into 2 groups: experimental and control. The experimental group of rats (n = 10) got the injection of nalbuphine hydrochloride intramuscularly, one time per day during 7 days; initial dose - 8 mg/kg. The condition of chronic opioid exposure has been modeled. The rats of control group (n = 6) got the injection of physiological solution intramuscularly during 7 days. The distal epiphysis of rat thigh and proximal epiphysis of rat tibia taking into account the preservation of topographical correlation of the knee joint structural components have been used for histological analysis. Following decalcination, the histologic specimens have been stained with hematoxylin, eosin, azure and azan by Heidenhain. The thickness of the cover synovial layer of articular cartilage has been measured. Results. The architectonics of articular cartilage distorts, the cover synovial layer of articular cartilage gets thinner due to experimental action of opiates. There is also tendency towards volume decrease of chondrocytes in proliferation zone and thickness loss of the cartilage. Conclusions. At the early stage of opioid exposure the structure abnormality of laboratory rats' knee joint can be seen in the synovial layer and in the zone of chondrocytes proliferation. These research data can be a prerequisite for opioid chondropathy.	[Voitsenko, K., I] Danylo Halytsky Lviv Natl Med Univ, Dept Normal Anat, Lvov, Ukraine	Voitsenko, KI (reprint author), Danylo Halytsky Lviv Natl Med Univ, Dept Normal Anat, Lvov, Ukraine.	kostya_89@ukr.net					Adrashkin A. P, 2003, ROL SERDECHNO SOSUDI; Bekesevych A. M., 2016, KLIN ANATOMIIA TA OP, V15, P24; Bohm M, 2012, ENDOCR REV, V33, P623, DOI 10.1210/er.2011-1016; Dudina O. O, 2014, VISNIK SOCIALNOI GIG, V2, P49; Ezzatabadipour M, 2011, IRAN J BASIC MED SCI, V14, P514; Grygoryeva E. A, 2010, UKRAINSKYI MORFOLOHI, V8, P40; Kryvko Yu. Ya, 2017, KLIN ANATOMIA TA OPE, V16, P111, DOI [10.24061/1727-0847.16.1.2017.24, DOI 10.24061/1727-0847.16.1.2017.24]; Makar B. H, 2015, NAUKOVYI VISNYK UZ M, V2, P20; Onysko R, 2013, Deklaratsiinyi patent Ukrainy na vynakhid, Patent No. 76564; Paltov Y, 2016, NATURAL SCI READINGS, P25; Paltov Y. V, 2016, DTSCH WISSENSCHAFTSH, V2, P30; Pokotylo P. B, 2015, HALYTSKYI LIKARSKYI, V22, P50; Raietska L. V., 2008, BOROTBA ORHANIZOVANO, V18, P67; Romejs B., 1953, MIKROSKOPICHESKAYA T; Zelzer E, 2004, DEVELOPMENT, V131, P2161, DOI 10.1242/dev.01053; Zinko A. V, 2016, VISNYK PROBLEM BIOLO, V2, P117	16	0	0	0	0	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	SEP-DEC	2018		3					386	389		10.14739/2310-1237.2018.3.151871			4	Pathology	Pathology	HF9JB	WOS:000454557200019		DOAJ Gold			2019-10-28	
J	Stefanchuk, RO; Yanchuk, AO; Stefanchuk, MM; Stefanchuk, MO; Blazhivska, NY				Stefanchuk, R. O.; Yanchuk, A. O.; Stefanchuk, M. M.; Stefanchuk, M. O.; Blazhivska, N. Ye.			The right to euthanasia: for or against?	PATHOLOGIA			Ukrainian	Review						euthanasia; right to die; legal status		The purpose of the research is to determine the feasibility of introducing euthanasia in Ukraine based on the analysis of world experience. Euthanasia is the most controversial and ambiguous topic of scientific research, which is on the brink of medicine and law. Euthanasia is the type of behavior of the medical officer (action, inaction or decision) committed consciously and intentionally, and also aimed at ending the unbearable suffering (physical, mental, moral and other characters), carried out on a repeated and unambiguous request of the patient (and his legal representative), subject to his complete, timely and objective awareness of the consequences of such interference resulting from the death of the patient. In the world there is no single approach to the issues of legalization of euthanasia. Today, the tendency towards legalization of passive euthanasia in the legal order of some economically developed countries is developing. However, this was preceded by a serious social controversy on this issue with the widest possible involvement of it, in the law, medicine, bioethics, philosophy, sociology and other sciences. However, in spite of the established trends, euthanasia in none of its forms can be considered as a sufficient legal basis for depriving a person of his life and the corresponding termination of his right to life. The priority direction of development should be not the legalization of euthanasia, but the development of palliative care, which aims to eliminate pain and provide comprehensive support to patients, members of their families, and others.	[Stefanchuk, R. O.] Natl Acad Legal Sci, Kharkov, Ukraine; [Stefanchuk, R. O.] Kharkov Natl Univ, Dept Civil Law Disciplines, Kharkov, Ukraine; [Yanchuk, A. O.] Minist Hlth Ukraine, State Secretary, Kiev, Ukraine; [Stefanchuk, M. M.] Kyiv Natl Econ Univ, State Higher Educ Estab, Dept Legal Regulat Econ, Kiev, Ukraine; [Stefanchuk, M. O.] Taras Shevchenko Natl Univ Kyiv, Kiev, Ukraine; [Blazhivska, N. Ye.] Higher Adm Court Ukraine, Kiev, Ukraine	Stefanchuk, RO (reprint author), Natl Acad Legal Sci, Kharkov, Ukraine.; Stefanchuk, RO (reprint author), Kharkov Natl Univ, Dept Civil Law Disciplines, Kharkov, Ukraine.						Alfonsa H, 2002, EUTHANASIE PROCES RE; Bacon F, 1977, SOCHINENIYA, V1; Brzhezinski T, 2012, ETYKA LEKARSKA; Erimia C.-L, 2016, J LAW ADM, V5, P49; Griffiths J, 1998, EUTHANASIA LAW NETHE; Ivanyushkin A. Ya, 1990, PROFESSIONALNAYA ETI; Leone S, 2000, SMERTELNNIE CHORY; Murphy W. F, 1977, COMP CONSTITUTIONAL; Onwuteaka-Philipsen BD, 2012, LANCET, V380, P908, DOI 10.1016/S0140-6736(12)61034-4; Slavakina N. A, 1999, EVTANAZIYA PROTIV PR; Soloviov A. V, 2005, PRAVO ZHYTTIA TSYVIL; Sudo Z, 1987, NON TRADITIONAL REF	12	0	0	1	1	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	SEP-DEC	2018		3					390	395		10.14739/2310-1237.2018.3.151873			6	Pathology	Pathology	HF9JB	WOS:000454557200020		DOAJ Gold			2019-10-28	
J	Scherbynina, MB; Shevchenko, TM; Hladun, VM				Scherbynina, M. B.; Shevchenko, T. M.; Hladun, V. M.			Modern diagnostics of gastroesophageal reflux disease: actual progress and prospects	PATHOLOGIA			Ukrainian	Review						gastroesophageal reflux disease; gastroinstestional; esophageal pH monitoring; high-resolution manometry; acoustic myography	ESOPHAGEAL MOTILITY DISORDERS; RESOLUTION MANOMETRY	According to modern concepts, gastroesophageal reflux disease (GERD) is referred to quasi-endogenous diseases. It is recognized that the underlying cause of the disease is the discoordination of the motor and evacuation function of the upper digestive tract, primarily the oesophagogastric transition as an antireflux barrier. The decrease in clearance of the oesophagus with time leads to a change in the structure of its mucosa in the form of Barrett's oesophagus and cancer. From this perspective adequate treatment of GERD requires early detection. It is important to understand the possibilities of modern clinical and instrumental methods of diagnosing GERD in the everyday practice of gastroenterologists. The review presents the findings of the American and Lyon consensus about GERD. It is shown that the criteria for GERD determining are specific for each method of its diagnosics, so additional research may not always confirm the diagnosis. The main methods of diagnosing GERD are the upper endoscopy, the 24-hour pH-metry monitoring. The latter is the gold standard for assessing the presence of gastro-oesophageal reflux. To make a decision before invasive antireflux procedures and surgery, high-resolution manometry (HRM) is recommended. Further studies are related to the use of three-dimensional high-resolution manometry (3D-HRM). HRM and 3D-HRM of the esophagus are high-tech methods for diagnosing the oesophageal motor function, with an encouraging prospect. However, consensus on GERD confirmed there are no current limitations of available studies of the oesophagus and offer to look for new directions in diagnosis and treatment approaches. In this connection, it is interesting to analyze the sound signals of muscle fibers. The review presents data on the possibilities of modern clinical and instrumental methods for diagnosing GERD in the everyday practice of gastroenterologists and discussing a number of promising initiatives in this direction.	[Scherbynina, M. B.] Oles Honchar Dniprovsky Natl Univ, Fac Med Technol Diagnost & Rehabil, Dnipro, Ukraine; [Shevchenko, T. M.; Hladun, V. M.] Oles Honchar Dniprovsky Natl Univ, Fac Med Technol Diagnost & Rehabil, Dept Modern Technol Diagnost & Treatment Proc, Dnipro, Ukraine	Scherbynina, MB (reprint author), Oles Honchar Dniprovsky Natl Univ, Fac Med Technol Diagnost & Rehabil, Dnipro, Ukraine.						Ates F, 2015, GASTROENTEROLOGY, V148, P334, DOI 10.1053/j.gastro.2014.10.010; Aziz Q, 2016, GASTROENTEROLOGY, V150, P1368, DOI 10.1053/j.gastro.2016.02.012; Bartels E. M, 2017, ANN SPORTS MED RES, V4, P1101; Bytzer P, 2012, CLIN GASTROENTEROL H, V10, P1360, DOI 10.1016/j.cgh.2012.06.030; Claudel CG, 2018, PHYSIOL REP, V6, DOI 10.14814/phy2.13580; Dent J, 1999, GUT, V44, pS1, DOI 10.1136/gut.44.2008.S1; Drossman DA, 2016, GASTROENTEROLOGY, V150, P1257, DOI 10.1053/j.gastro.2016.03.035; El-Serag HB, 2014, GUT, V63, P871, DOI 10.1136/gutjnl-2012-304269; Frazzoni M, 2016, CLIN GASTROENTEROL H, V14, P40, DOI 10.1016/j.cgh.2015.06.026; Gyawali CP, 2018, GUT, V67, P1351, DOI 10.1136/gutjnl-2017-314722; Harrison AP, 2013, PHYSIOL REP, V1, DOI 10.1002/phy2.29; Herregods TVK, 2017, NEUROGASTROENT MOTIL, V29, DOI 10.1111/nmo.13129; Jobe BA, 2013, J AM COLL SURGEONS, V217, P586, DOI 10.1016/j.jamcollsurg.2013.05.023; Kahrilas PJ, 2015, NEUROGASTROENT MOTIL, V27, P160, DOI 10.1111/nmo.12477; Kandulski A, 2013, ALIMENT PHARM THER, V38, P643, DOI 10.1111/apt.12428; Kwiatek MA, 2011, NEUROGASTROENT MOTIL, V23, pE461, DOI 10.1111/j.1365-2982.2011.01733.x; Lin ZY, 2017, NEUROGASTROENT MOTIL, V29, DOI 10.1111/nmo.13054; Moayyedi P, 2008, DIGESTION, V78, P61, DOI 10.1159/000151257; Nicodeme F, 2015, DIS ESOPHAGUS, V28, P684, DOI 10.1111/dote.12262; Penagini R, 2015, J NEUROGASTROENTEROL, V21, P265, DOI 10.5056/jnm14075; Perederii V. H, 2012, PRAKTYCHNA HASTROENT; Roman S, 2017, NEUROGASTROENT MOTIL, V29, DOI 10.1111/nmo.13067; Roman S, 2017, NEUROGASTROENT MOTIL, V29, DOI 10.1111/nmo.12920; Roman S, 2016, AM J GASTROENTEROL, V111, P372, DOI 10.1038/ajg.2016.1; Savarino E, 2017, NAT REV GASTRO HEPAT, V14, P665, DOI 10.1038/nrgastro.2017.130; Savarino E, 2016, DIGEST LIVER DIS, V48, P1124, DOI 10.1016/j.dld.2016.06.021; Savarino E, 2013, NAT REV GASTRO HEPAT, V10, P371, DOI 10.1038/nrgastro.2013.50; Takashima T, 2012, DIGESTION, V86, P55, DOI 10.1159/000338849; Turco R, 2017, ESOPHAGEAL GASTRIC D, P925, DOI [10.1007/978-3-642-11202-7_80, DOI 10.1007/978-3-642-11202-7_80]; Wang Z, 2018, AM J GASTROENTEROL, V113, P1148, DOI 10.1038/s41395-018-0070-3; Xie CX, 2017, BMC GASTROENTEROL, V17, DOI 10.1186/s12876-017-0693-7; Xie CX, 2017, J NEUROGASTROENTEROL, V23, P27, DOI 10.5056/jnm16008	32	0	0	0	0	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	SEP-DEC	2018		3					396	404		10.14739/2310-1237.2018.3.151877			9	Pathology	Pathology	HF9JB	WOS:000454557200021		DOAJ Gold			2019-10-28	
J	Mostovoy, YM; Demchuk, AV; Konstantynovych, TV; Pentiuk, NO; Blazhevska, LV				Mostovoy, Yu M.; Demchuk, A., V; Konstantynovych, T., V; Pentiuk, N. O.; Blazhevska, L., V			Clinic morphological features of Goodpasture's syndrome manifested with respiratory disorders	PATHOLOGIA			English	Article						Goodpasture's syndrome; respiratory failure; hemoptysis	DISEASE	Goodpasture's syndrome is one of rare pathological conditions. It stipulates problem of timely diagnostics and prescription of early pathogenic therapy for cessation of progressive autoimmune inflammation and safe of patient's life. Presented clinical case demonstrates difficulties of recognizing Goodpasture's syndrome in case of its debut with dominating symptoms and signs of bacterial affection of the lungs and severe respiratory failure. Case presentation. We described case of Goodpasture's syndrome in the middle-aged woman (54 years old) which began from symptoms of community-acquired pneumonia, hemoptysis and finished tragically with developing severe respiratory and renal failures. Conclusions. Management of community-acquired pneumonia patient, who has recurrent hemoptysis, minimal changes of the urinary system, who does not give adequate answer to the antibiotic treatment, must include additional investigation for revealing immunological systemic genesis of pulmonary tissue injury. It improves prognosis by virtue of early use adequate pathogenic therapy.	[Mostovoy, Yu M.; Demchuk, A., V; Konstantynovych, T., V; Pentiuk, N. O.] Natl Pirogov Mem Med Univ, Dept Propedeut Internal Med, Vinnytsia, Ukraine; [Blazhevska, L., V] Vinnytsia City Clin Hosp 1, Pulmonol Dept, Vinnytsia, Ukraine	Demchuk, AV (reprint author), Natl Pirogov Mem Med Univ, Dept Propedeut Internal Med, Vinnytsia, Ukraine.	anna.demchuk@i.ua	Konstantynovych, Tetyana/W-2030-2019; Demchuk, Anna/D-4712-2019	Konstantynovych, Tetyana/0000-0002-3180-6942; Demchuk, Anna/0000-0003-0509-6948			Dammacco F, 2013, AUTOIMMUN REV, V12, P1101, DOI 10.1016/j.autrev.2013.06.014; Fisher M, 1997, KIDNEY INT, V51, P222, DOI 10.1038/ki.1997.27; Greco A, 2015, AUTOIMMUN REV, V14, P246, DOI 10.1016/j.autrev.2014.11.006; Huart A, 2016, J AUTOIMMUN, V73, P24, DOI 10.1016/j.jaut.2016.05.015; Iaremenko O. B, 2018, UKRAINSKYI PULMONOLO, V2, P39, DOI [10.31215/2306-4927-2018-100-2-39-46, DOI 10.31215/2306-4927-2018-100-2-39-46]; Kathuria P, 2017, GOODPASTURE SYNDROME; Kitagawa W, 2008, NEPHROL DIAL TRANSPL, V23, P3126, DOI 10.1093/ndt/gfn179; Lahmer T, 2012, AUTOIMMUN REV, V12, P169, DOI 10.1016/j.autrev.2012.04.002; Mostovoj Y. M, 2008, ZDOROVIA UKRAINY, V3, P56; Pedchenko V, 2010, NEW ENGL J MED, V363, P343, DOI 10.1056/NEJMoa0910500; Scollo V, 2017, CLIN MED INSIGHT-CAS, V10, DOI 10.1177/1179547617726077; STANTON M. C., 1958, AUSTRALASEAN ANN MED, V7, P132; Stojkovikj Jagoda, 2016, Open Access Maced J Med Sci, V4, P683, DOI 10.3889/oamjms.2016.127; van Daalen EE, 2018, CLIN J AM SOC NEPHRO, V13, P63, DOI 10.2215/CJN.04290417; Yang R, 2009, CLIN IMMUNOL, V133, P245, DOI 10.1016/j.clim.2009.07.005	15	0	0	0	0	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	SEP-DEC	2018		3					405	410		10.14739/2310-1237.2018.3.151882			6	Pathology	Pathology	HF9JB	WOS:000454557200022		DOAJ Gold			2019-10-28	
J	Wright, Jr; Abrams, J				Wright, James R., Jr.; Abrams, Jeanne			Martha Wollstein of Babies Hospital in New York City (1868-1939)-The First North American Pediatric Pathologist	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						history of pathology; Martha Wollstein; Babies Hospital of New York City; Rockefeller Institute for Medical Research; Women's Medical College; Judaism	YOUNG-CHILDREN; TUBERCULOUS LESIONS; RESPIRATORY-TRACT; INFANTS; INFLUENZA; BACILLUS; INFLAMMATIONS; PROVISION		[Wright, James R., Jr.] Univ Calgary, Calgary Lab Serv, Alberta Childrens Hosp, Dept Pathol & Lab Med, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada; [Wright, James R., Jr.] Univ Calgary, Dept Paediat, Alberta Childrens Hosp, Calgary, AB, Canada; [Abrams, Jeanne] Univ Denver, Univ Lib, Rocky Mt Jewish Hist Soc, Denver, CO USA; [Abrams, Jeanne] Univ Denver, Ctr Juda Studies, Rocky Mt Jewish Hist Soc, Denver, CO USA	Wright, Jr (reprint author), Univ Calgary, Calgary Lab Serv, Alberta Childrens Hosp, Dept Pathol & Lab Med, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada.	jim.wright@cls.ab.ca			Ohio State University Medical Heritage Center	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Dr Wright's historical research is supported, in part, by a Scholar in Residence Award from The Ohio State University Medical Heritage Center.	Abrams J, J MED BIOGR; Adami JG, 1908, PRINCIPLES PATHOLOGY, V1; Adami JG, 1912, TXB PATHOLOGY STUDEN; Amoss HL, 1916, J EXP MED, V23, P403, DOI 10.1084/jem.23.3.403; [Anonymous], 1939, NY TIMES, V113, P2075; [Anonymous], 1939, NEW YORK HERALD TRIB, P40; Arthur F H, 1974, J Am Med Womens Assoc (1972), V29, P508; Baker R., 1944, 1 WOMAN DOCTOR STORY; Brooks HT, 1915, TXB GEN SPECIAL PATH; Bugbee HG, 1924, J AMER MED ASSOC, V83, P1887, DOI 10.1001/jama.1924.02660240001001; Clague S, 2014, LANCET RESP MED, V2, P184, DOI 10.1016/S2213-2600(14)70057-8; D'Cruz C, 2015, PEDIATR DEVEL PATHOL, V18, P522, DOI 10.2350/15-10-1718-OA.1; DAMROSCH DS, 1964, J PEDIATR-US, V65, P477, DOI 10.1016/S0022-3476(64)80283-3; Dawson P., 2016, DOROTHY MANS WORLD V, P115; Delafield F., 2001, HDB POSTMORTEM EXAMI; DISANTAGNESE PA, 1950, PEDIATRICS, V6, P402; Dunn PM, 2007, ARCH DIS CHILD-FETAL, V92, P419, DOI 10.1136/fnn.2005.091397; Harvey JD, 2000, BIOGRAPHICAL DICT WO; Hoffman N Y, 1982, JAMA, V248, P1551, DOI 10.1001/jama.248.13.1551; HUFF DS, 1983, J PEDIATR-US, V102, P165, DOI 10.1016/S0022-3476(83)80330-8; Kozakewich H., 2016, BRIEF HIST BOSTON CH; Luft E, 1999, Watermark (Arch Libr Hist Health Sci), V22, P73; MacDermot HE, 1941, MAUDE ABBOTT MEMOIR; Marcus JR, 1981, AM JEWISH WOMAN 1654, P72; McConnell G., 1911, MANUAL PATHOLOGY; McLean S, 1923, AM J DIS CHILD, V26, P69; MELTZER A, 1990, AM JEWISH ARCH, V42, P49; RADBILL SX, 1955, AMA AM J DIS CHILD, V90, P411, DOI 10.1001/archpedi.1955.04030010413005; Tebbe- Grossman J., 2009, M WOLLSTEIN 1868 193; Vawter G F, 1988, Perspect Pediatr Pathol, V12, P1; Wagner E, 1879, MANUAL GEN PATHOLOGY; Waugh D., 2000, MAUDIE MCGILL M ABBO; Welsh L., 1925, REMINISCENCES 30 YEA, P44; WIGLESWORTH FW, 1984, PERSPECT PEDIAT PATH, V8, P291; Wilson DC, 1970, LONE WOMAN STORY E B; Wollstein M, 1916, J EXP MED, V23, P353, DOI 10.1084/jem.23.3.353; Wollstein M, 1919, J EXP MED, V30, P555, DOI 10.1084/jem.30.6.555; Wollstein M, 1905, J Exp Med, V6, P391, DOI 10.1084/jem.6.4-6.391; Wollstein M, 1922, AM J DIS CHILD, V23, P511; Wollstein M, 1936, AM J DIS CHILD, V51, P765; Wollstein M, 1921, AM J DIS CHILD, V21, P48; Wollstein M, 1918, J AMER MED ASSOC, V71, P639, DOI 10.1001/jama.1918.02600340031009; Wollstein M, 1918, J EXP MED, V28, P377, DOI 10.1084/jem.28.4.377; Wollstein M, 1920, AM J DIS CHILD, V19, P459; Wollstein M, 1923, AM J DIS CHILD, V25, P310; Wollstein M, 1919, AM J DIS CHILD, V17, P165; Wollstein M, 1912, AM J DIS CHILD, V4, P197; Wollstein M, 1909, ARCH INTERN MED, V3, P221; Wollstein M, 1914, AM J DIS CHILD, V8, P362; Wollstein M, 1906, J EXP MED, V8, P681, DOI 10.1084/jem.8.6.681; Wollstein M, 1904, J MED RES, V10, P11; Wollstein M, 1928, AM J DIS CHILD, V36, P998; Wollstein M, 1923, AM J DIS CHILD, V25, P257; Wollstein M, 1916, AM J DIS CHILD, V12, P254; Wollstein M, 1927, ARCH PATHOL LAB MED, V3, P1; Wollstein M., 1908, WOMANS MED J, V18, P65; Wollstein M., 1928, SURG GYNECOL OBSTET, V46, P774; Wollstein M., 1903, REPORT PATHOLOGICAL, P26; Wollstein M, 1930, AM J DIS CHILD, V39, P115; Wright JR, 2017, ARCH PATHOL LAB MED, V141, P704, DOI 10.5858/arpa.2016-0348-HP; Wright James R Jr, 2017, CMAJ, V189, pE281, DOI 10.1503/cmaj.160976; Wright JR, 2016, PEDIATR DEVEL PATHOL, V19, P493, DOI [10.2350/16-03-1786-OA.1, 10.2350/16-03-1786-OA.1.1]; Wright JR, 2016, ARCH PATHOL LAB MED, V140, P983, DOI 10.5858/arpa.2016-0113-HP; Wright JR, 2015, ARCH PATHOL LAB MED, V139, P1161, DOI 10.5858/arpa.2014-0528-HP; Wright JR, 2016, CAN J PATHOL, V8, P77; Ziegler E, 1883, TXB GEN PATHOLOGICAL	66	1	1	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	SEP-OCT	2018	21	5					437	443		10.1177/1093526617738853			7	Pathology; Pediatrics	Pathology; Pediatrics	HF4VA	WOS:000454230700002	29216802				2019-10-28	
J	Sekar, T; Mushtaq, J; AlBadry, W; Soole, F; Nagy, A; Powell, B; Chong, H				Sekar, Thivya; Mushtaq, Jameel; AlBadry, Waleed; Soole, Frederick; Nagy, Anita; Powell, Barry; Chong, Heung			Plaque-like Myofibroblastic Tumor: 2 Cases of This Unusual Dermal Tumor Which Occurs in Infancy and Early Childhood	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						plaque-like myofibroblastic tumor; smooth muscle actin; dermatofibroma; infancy	MULTIPLE CLUSTERED DERMATOFIBROMA; ATYPICAL CLINICAL VARIANT; FIBROUS HISTIOCYTOMAS; PROTUBERANS; CHAIN; DERMATOMYOFIBROMA; DIAGNOSIS; RARE	Plaque-like myofibroblastic tumor (PLMT) is a rare dermal spindle cell tumor which occurs in infancy or childhood within the first 4 years of life. The tumor is often pruritic and mostly presents on the lower back. We describe 2 cases with characteristic clinical and histological features of this entity, thus adding to the 10 cases which have so far been reported. Histologically, the lesion resembles a dermatofibroma. However, diffuse and uniform immunohistochemical staining with smooth muscle actin favors a myofibroblastic lineage. PLMT should be considered in the differential diagnosis of a dermal spindle cell tumor in the pediatric age-group.	[Sekar, Thivya; Nagy, Anita; Chong, Heung] St George Hosp, Dept Cellular Pathol, London, England; [Mushtaq, Jameel; AlBadry, Waleed; Powell, Barry] St George Hosp, Dept Plast Surg, London, England; [AlBadry, Waleed] Cairo Univ, Fac Med, Plast Surg Dept, Cairo, Egypt; [Soole, Frederick] Royal Marsden Hosp, Paediat Oncol Dept, London, England	Sekar, T (reprint author), St Georges Univ Hosp NHS Fdn Trust, Blackshaw Rd, London SW17 0QT, England.	tssekar@gmail.com					Alesini F, 2017, PEDIATR DERMATOL, V34, P176, DOI 10.1111/pde.13034; Bhabha FK, 2016, AUSTRALAS J DERMATOL, V57, pE20, DOI 10.1111/ajd.12257; Bruecks AK, 2002, ARCH PATHOL LAB MED, V126, P1179; Campagnolo OA, 2017, AN BRAS DERMATOL, V92, P101, DOI 10.1590/abd1806-4841.20175189; Castellanos-Gonzalez M, 2011, ACTAS DERMO-SIFILOGR, V102, P467, DOI 10.1016/j.ad.2010.12.003; Clarke JT, 2007, PEDIATR DERMATOL, V24, pE83, DOI 10.1111/j.1525-1470.2007.00449.x; Coffin CM, 2012, PEDIATR DEVEL PATHOL, V15, P127, DOI 10.2350/10-12-0944-PB.1; De Unamuno P, 2000, BRIT J DERMATOL, V142, P1040, DOI 10.1046/j.1365-2133.2000.03494.x; Gershtenson PC, 2010, J CUTAN PATHOL, V37, pE42, DOI 10.1111/j.1600-0560.2009.01325.x; Espineira-Carmona MJ, 2013, EUR J DERMATOL, V23, P270, DOI 10.1684/ejd.2013.1951; Kim TI, 2016, J DERMATOL, V43, P582, DOI 10.1111/1346-8138.13241; Linos K, 2014, AM J SURG PATHOL, V38, P1649, DOI 10.1097/PAS.0000000000000270; Marqueling AL, 2013, PEDIATR DERMATOL, V30, P600, DOI 10.1111/pde.12185; McGee JS, 2014, PEDIATR DERMATOL, V31, P105, DOI [10.1111/j.1525-1470.2012.01801.x, 10.1111/j.1525-1470.2011.01681.x]; Mentzel T, 2009, AM J DERMATOPATH, V31, P44, DOI 10.1097/DAD.0b013e3181914e6f; Moreno de Vega Haro MJ, 1999, ACTA DERMOSIFILIOGR, V90, P318; Moulonguet I, 2017, AM J DERMATOPATH, V39, P767, DOI 10.1097/DAD.0000000000000869; Panicker Vinitha Varghese, 2017, J Cutan Aesthet Surg, V10, P51, DOI 10.4103/JCAS.JCAS_117_16; Pinto-Almeida T, 2013, AN BRAS DERMATOL, V88, P63, DOI 10.1590/abd1806-4841.20132647; Pusztaszeri M, 2011, CASE REP DERMATOL, V3, P32, DOI 10.1159/000324721; Rognstad OB, 2009, J DTSCH DERMATOL GES, V7, P962, DOI 10.1111/j.1610-0387.2009.07103.x; Rose C, 1999, PEDIATR DERMATOL, V16, P456, DOI 10.1046/j.1525-1470.1999.00117.x; Salgado R, 2011, GENE CHROMOSOME CANC, V50, P510, DOI 10.1002/gcc.20874; Shaheen B, 2014, CLIN EXP DERMATOL, V39, P88, DOI 10.1111/ced.12200; Simon MP, 1997, NAT GENET, V15, P95, DOI 10.1038/ng0197-95; Soon SL, 2003, J CUTAN MED SURG, V7, P455, DOI 10.1007/s10227-002-0155-9; Tardio JC, 2011, J CUTAN PATHOL, V38, P967, DOI 10.1111/j.1600-0560.2011.01739.x; Wollina U, 2013, J DERMATOL CASE REP, V7, P121, DOI 10.3315/jdcr.2013.1160	28	1	1	1	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	SEP-OCT	2018	21	5					444	448		10.1177/1093526617746807			5	Pathology; Pediatrics	Pathology; Pediatrics	HF4VA	WOS:000454230700003	29224420				2019-10-28	
J	Huang, HY; Gheorghe, G; North, PE; Suchi, M				Huang, Huiya; Gheorghe, Gabriela; North, Paula E.; Suchi, Mariko			Expanding the Phenotype of ALK-positive Histiocytosis: A Report of 2 Cases	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						ALK; histiocytosis; infant; hepatomegaly; thrombocytopenia; Rosai-Dorfman disease; kidney	ROSAI-DORFMAN-DISEASE; JUVENILE XANTHOGRANULOMA; LYMPHADENOPATHY	ALK-positive histiocytosis is a recently described rare histiocytic proliferative disorder of early infancy. When infants present with anemia, thrombocytopenia, and hepatosplenomegaly, this entity should be included in the differential diagnosis along with hemophagocytic lymphohistiocytosis, metabolic/storage diseases, hematopoietic malignancies, and autoimmune thrombocytopenia. We report 2 new cases of ALK-positive histiocytosis, one with kidney involvement and the other with extensive bone marrow involvement in addition to an overt liver disease. Renal involvement by ALK-positive histiocytosis has not been reported. The infiltrating histiocytes in this case showed Rosai-Dorfman disease-like morphology including emperipolesis. The histiocytes in the second case with extensive bone marrow involvement had foamy cytoplasm initially suggesting storage disease. Our 2 cases highlight previously unrecognized diversity of ALK-positive histiocytosis in clinical manifestation, organ involvement, and cytomorphologic features and further elucidate the diagnostic challenges of this rare entity.	[Huang, Huiya; Gheorghe, Gabriela; North, Paula E.; Suchi, Mariko] Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA; [Gheorghe, Gabriela; North, Paula E.; Suchi, Mariko] Childrens Hosp Wisconsin, Dept Pathol & Lab Med, 9000 W Wisconsin Ave, Milwaukee, WI 53226 USA; [Gheorghe, Gabriela] Childrens Minnesota, Minneapolis, MN USA	Suchi, M (reprint author), Childrens Hosp Wisconsin, Dept Pathol & Lab Med, 9000 W Wisconsin Ave, Milwaukee, WI 53226 USA.	msuchi@mcw.edu					Chan JKC, 2008, BLOOD, V112, P2965, DOI 10.1182/blood-2008-03-147017; Chow CP, 2009, PEDIATR BLOOD CANCER, V52, P415, DOI 10.1002/pbc.21880; Dehner LP, 2003, AM J SURG PATHOL, V27, P579, DOI 10.1097/00000478-200305000-00003; Ferguson SD, 2015, CHILD NERV SYST, V31, P777, DOI 10.1007/s00381-014-2604-3; Janssen D, 2005, AM J SURG PATHOL, V29, P21, DOI 10.1097/01.pas.0000147395.01229.06; Lauwers GY, 2000, HUM PATHOL, V31, P380, DOI 10.1016/S0046-8177(00)80254-3; Rossbach HC, 2006, PEDIATR BLOOD CANCER, V47, P629, DOI 10.1002/pbc.20605	7	2	2	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	SEP-OCT	2018	21	5					449	455		10.1177/1093526617740784			7	Pathology; Pediatrics	Pathology; Pediatrics	HF4VA	WOS:000454230700004	29224419				2019-10-28	
J	Ferro, E; Capra, AP; Zirilli, G; Meduri, A; Urso, M; Briuglia, S; La Rosa, MA				Ferro, Elisa; Capra, Anna Paola; Zirilli, Giuseppina; Meduri, Alessandro; Urso, Mario; Briuglia, Silvana; La Rosa, Maria Angela			FTL c.-168G > C Mutation in Hereditary Hyperferritinemia Cataract Syndrome: A New Italian Family	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						hyperferritinemia; hereditary cataract; genetic autosomal dominant disease; c.-168G > C mutation; hereditary hyperferritinemia cataract syndrome; ferritin light chain gene	IRON-RESPONSIVE ELEMENT; FERRITIN LIGHT-CHAIN; GLYCOSYLATED FERRITIN; SERUM; GENE	We describe a new Italian family with 7 members affected by hereditary hyperferritinemia cataract syndrome (HHCS), an uncommon autosomal dominant disease caused by mutations of the iron-responsive element of the ferritin light chain (FTL) gene determining its overexpression. The family diagnosis of HHCS took place after finding high ferritin levels in a 6-year-old girl. Seven members of the family had bilateral and symmetrical cataracts, normal iron, and hematological parameters except for high serum ferritin levels. About 160 families/unrelated cases with HHCS are known worldwide. This report documents a second Italian family, with a c.-168G>C mutation that is located in the highly conserved 3-nucleotide bulge structure of the FTL in the 5' untranslated region. This case shows how important the family history is in reaching a correct diagnosis and avoiding unnecessary and invasive analysis. HHCS should be considered in the differential diagnosis of childhood hyperferritinemia, especially in the presence of normal transferrin saturation.	[Ferro, Elisa; Capra, Anna Paola; Zirilli, Giuseppina; Briuglia, Silvana; La Rosa, Maria Angela] Univ Hosp Messina, Dept Human Pathol Adult & Dev Age Gaetano Barresi, Via C Valeria 1, I-98100 Messina, Italy; [Meduri, Alessandro; Urso, Mario] Univ Hosp Messina, Dept Biomed & Dent Sci & Morphofunct Imaging, Messina, Italy	Ferro, E (reprint author), Univ Hosp Messina, Dept Human Pathol Adult & Dev Age Gaetano Barresi, Via C Valeria 1, I-98100 Messina, Italy.	ferro_elisa@alice.it		Ferro, Elisa/0000-0001-9645-4530			BEAUMONT C, 1995, NAT GENET, V11, P444, DOI 10.1038/ng1295-444; Bennett TM, 2013, MOL VIS, V19, P835; Bowes O, 2014, LANCET, V383, P1520, DOI 10.1016/S0140-6736(14)60484-0; Brooks DG, 2002, INVEST OPHTH VIS SCI, V43, P1121; Campagnoli MF, 2002, EUR J PEDIATR, V161, P499, DOI 10.1007/s00431-002-1019-4; Cazzola M, 1997, BLOOD, V90, P814, DOI 10.1182/blood.V90.2.814.814_814_821; Cosentino I, 2016, OPHTHALMIC GENET, V37, P318, DOI 10.3109/13816810.2015.1059460; Craig JE, 2003, ARCH OPHTHALMOL-CHIC, V121, P1753, DOI 10.1001/archopht.121.12.1753; Santotoribio JD, 2014, MED CLIN-BARCELONA, V142, P93, DOI 10.1016/j.medcli.2013.07.007; Giansily-Blaizot M, 2013, HAEMATOLOGICA, V98, pE42, DOI 10.3324/haematol.2012.077198; GIRELLI D, 1995, BRIT J HAEMATOL, V90, P931, DOI 10.1111/j.1365-2141.1995.tb05218.x; GIRELLI D, 1995, BLOOD, V86, P4050, DOI 10.1182/blood.V86.11.4050.bloodjournal86114050; Girelli D, 2001, BRIT J HAEMATOL, V115, P334, DOI 10.1046/j.1365-2141.2001.03116.x; Hetet G, 2003, BLOOD, V102, P1904, DOI 10.1182/blood-2003-02-0439; Kannengiesser C, 2009, HAEMATOL-HEMATOL J, V94, P335, DOI 10.3324/haematol.2008.000125; Lachlan KL, 2004, EUR J HUM GENET, V12, P790, DOI 10.1038/sj.ejhg.5201252; Lenzhofer M, 2015, OPTOMETRY VISION SCI, V92, P40; Luscieti S, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-30; Perruccio K, 2013, CASE REP PEDIAT, DOI 10.1155/2013/806034; Rank CU, 2015, EUR ONCOL HAEMATOL, V11, P147; Thurlow V, 2012, ANN CLIN BIOCHEM, V49, P302, DOI 10.1258/acb.2011.011229; Tsantoula F, 2014, J PEDIAT HEMATOL ONC, V36, P304; Tuysuz G, 2013, GENET COUNSEL, V24, P393; Yin D, 2014, HEPATOLOGY, V59, P1204, DOI 10.1002/hep.26681	24	0	0	2	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	SEP-OCT	2018	21	5					456	460		10.1177/1093526618755200			5	Pathology; Pediatrics	Pathology; Pediatrics	HF4VA	WOS:000454230700005	29426274				2019-10-28	
J	Matsuno, R; Gifford, AJ; Fang, JM; Warren, M; Lukeis, RE; Trahair, T; Sugimoto, T; Marachelian, A; Asgharzadeh, S; Maris, JM; Ikegaki, N; Shimada, H				Matsuno, Ryosuke; Gifford, Andrew J.; Fang, Junming; Warren, Mikako; Lukeis, Robyn E.; Trahair, Toby; Sugimoto, Tohru; Marachelian, Araz; Asgharzadeh, Shahab; Maris, John M.; Ikegaki, Naohiko; Shimada, Hiroyuki			Rare MYC-amplified Neuroblastoma With Large Cell Histology	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						MYC amplification; unfavorable histology; large cell; MYC protein overexpression; neuroblastoma; no MYCN amplification	CHILDRENS ONCOLOGY GROUP; N-MYC; PHENOTYPE	Background: Although MYCN (aka N-myc) amplification is reported in similar to 20% of neuroblastomas, MYC (aka C-myc) amplification appears to be a rare event in this disease. As of today, only 2 MYC-amplified neuroblastomas have been briefly mentioned in the literature. Methods: We studied here the clinicopathological features of 3 MYC-amplified neuroblastomas. Results: All 3 patients (2 females and 1 male) had stage 4 disease. One female is currently alive and well 52 months after the diagnosis, while the other female and male patients died of disease 24 and 20 months after the diagnosis, respectively. Further analysis on 2 tumors revealed unfavorable histology with MYC protein overexpression but with neither MYCN amplification nor MYCN protein overexpression. Both of these tumors exhibited "large cell neuroblastoma" histology with enlarged, uniquely open nuclei and nucleolar hypertrophy, along with "aberrant" desmin expression. Conclusions: MYC-amplified neuroblastomas are extremely rare and seem to present with distinct clinicopathological features.	[Matsuno, Ryosuke; Warren, Mikako; Asgharzadeh, Shahab; Shimada, Hiroyuki] Childrens Hosp Los Angeles, Dept Pathol & Lab Med, MS 43,4650 Sunset Blvd, Los Angeles, CA 90027 USA; [Gifford, Andrew J.] Prince Wales Hosp, Dept Anat Pathol, Randwick, NSW, Australia; [Gifford, Andrew J.] Univ New South Wales, Sch Womens & Childrens Hlth, Sydney, NSW, Australia; [Fang, Junming] Kaiser Permanente Med Ctr, Dept Pathol, San Francisco, CA USA; [Lukeis, Robyn E.] St Vincents Hosp, SydPath, Cytogenet Lab, Darlinghurst, NSW, Australia; [Trahair, Toby] Sydney Childrens Hosp, Kids Canc Ctr, Randwick, NSW, Australia; [Sugimoto, Tohru] Saiseikai Shiga Hosp, Ritto, Shiga, Japan; [Marachelian, Araz; Asgharzadeh, Shahab] Childrens Hosp Los Angeles, Div Hematol Oncol, Los Angeles, CA 90027 USA; [Maris, John M.] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Div Oncol, Philadelphia, PA 19104 USA; [Maris, John M.] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; [Ikegaki, Naohiko] Univ Illinois, Dept Anat & Cell Biol, Chicago, IL USA	Shimada, H (reprint author), Childrens Hosp Los Angeles, Dept Pathol & Lab Med, MS 43,4650 Sunset Blvd, Los Angeles, CA 90027 USA.	hshimada@chla.usc.edu		Trahair, Toby/0000-0002-3295-228X; Gifford, Andrew/0000-0002-4092-2347	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U10CA098543/U10CA180886]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was partly supported by the fund from NIH Grant, U10CA098543/U10CA180886.	Ambros PF, 2009, BRIT J CANCER, V100, P1471, DOI 10.1038/sj.bjc.6605014; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Gabay M, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014241; Gurney JG, 1997, J PEDIAT HEMATOL ONC, V19, P428, DOI 10.1097/00043426-199709000-00004; Ikegaki N, 2013, P NATL ACAD SCI USA, V110, P6097, DOI 10.1073/pnas.1118262110; Kalkat M, 2017, GENES-BASEL, V8, DOI 10.3390/genes8060151; Khudyakov J, 2009, DEV DYNAM, V238, P716, DOI 10.1002/dvdy.21881; Knoepfler PS, 2006, EMBO J, V25, P2723, DOI 10.1038/sj.emboj.7601152; Maris JM, 2010, NEW ENGL J MED, V362, P2202, DOI 10.1056/NEJMra0804577; Molenaar JJ, 2012, NATURE, V483, P589, DOI 10.1038/nature10910; Saito-Ohara F, 2003, CANCER RES, V63, P1876; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Shimada H, 1999, CANCER, V86, P364, DOI 10.1002/(SICI)1097-0142(19990715)86:2<364::AID-CNCR21>3.3.CO;2-Z; Stine ZE, 2015, CANCER DISCOV, V5, P1024, DOI 10.1158/2159-8290.CD-15-0507; Suganuma R, 2013, PEDIATR BLOOD CANCER, V60, P363, DOI 10.1002/pbc.24238; Sugimoto T, 2001, JPN J CANCER RES, V92, P152, DOI 10.1111/j.1349-7006.2001.tb01077.x; Tornoczky T, 2004, CANCER-AM CANCER SOC, V100, P390, DOI 10.1002/cncr.20005; Valentijn LJ, 2012, P NATL ACAD SCI USA, V109, P19190, DOI 10.1073/pnas.1208215109; van Riggelen J, 2010, NAT REV CANCER, V10, P301, DOI 10.1038/nrc2819; Wang LL, 2015, BRIT J CANCER, V113, P57, DOI 10.1038/bjc.2015.188; Wang LL, 2013, CANCER-AM CANCER SOC, V119, P3718, DOI 10.1002/cncr.28251	22	1	1	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	SEP-OCT	2018	21	5					461	466		10.1177/1093526617749670			6	Pathology; Pediatrics	Pathology; Pediatrics	HF4VA	WOS:000454230700006	29426276				2019-10-28	
J	Olaya, M; Gil, F; Salcedo, JD; Salazar, AJ; Silva, JL; Bernal, JE				Olaya-C, Mercedes; Gil, Fabian; Salcedo, Juan D.; Salazar, Ana J.; Silva, Jaime L.; Bernal, Jaime E.			Anatomical Pathology of the Umbilical Cord and Its Maternal and Fetal Clinical Associations in 434 Newborns	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						umbilical cord; cord accident; coiling index; placenta; single umbilical artery; stillbirth	COILING INDEX; PLACENTAL PATHOLOGY; PERINATAL OUTCOMES; RISK-FACTORS; MALFORMATIONS; ABNORMALITIES; LESIONS; LENGTH; ARTERY; SEX	Introduction: Umbilical cord (UC) abnormalities and their clinical relations in 434 newborns were analyzed. We had previously reported on clinical associations of long and short UCs with any kind of malformation. This study focuses on other UC features (insertion, vessels, entanglements, coiling, and knots) and their associations with clinical characteristics and neonatal prognosis. Methods: An observational analytic study was performed on placentas from consecutive deliveries. Ordered logistic regression with bivariate and multivariate analysis was performed to evaluate the relationship between variables of interest concerning UC abnormalities. Results: A total of 434 placentas made up the study. UC abnormalities were abnormal insertion, 82 (18.86%); coiling (hypo and hypercoiled), 177 (40.78%); single umbilical artery (SUA), 4 (0.92%); entanglements, 8 (1.84%); true knots, 3 (0.69%); webs in UC base, 9 (2.07%); and right twist, 68 (15.67%). After analyzing maternal and fetal complications during pregnancy, multivariate analysis confirmed the recognized association between malformations and SUA and male gender; further confirmation was also made between hypertensive disorders of pregnancy and true knots. Discussion: UC abnormalities associated with undesirable outcomes are varied and should be recognized and described. Clinical factors associated with anatomical UC abnormalities are not completely understood and justify forthcoming studies.	[Olaya-C, Mercedes] Pontificia Univ Javeriana, Hosp Univ San Ignacio, Med Sch, Dept Pathol, Bogota, Colombia; [Gil, Fabian] Pontificia Univ Javeriana, Dept Clin Epidemiol & Biostat, Bogota, Colombia; [Salcedo, Juan D.] Pontificia Univ Javeriana, Hosp Univ San Ignacio, Sch Med, Bogota, Colombia; [Salazar, Ana J.] Pontificia Univ Javeriana, Hosp Univ San Ignacio, Dept Pathol, Bogota, Colombia; [Silva, Jaime L.] Pontificia Univ Javeriana, Hosp Univ San Ignacio, Dept Obstet & Gynecol, Bogota, Colombia; [Bernal, Jaime E.] Pontificia Univ Javeriana, Med Sch, Inst Human Genet, Bogota, Colombia; [Bernal, Jaime E.] Univ Tecnol Bolivar, Cartagena De Indias, Colombia	Olaya, M (reprint author), Pontificia Univ Javeriana, Dept Patol, Fac Med, Carrera 7 40-62, Bogota, Colombia.	olaya.m@javeriana.edu.co		Bernal Villegas, Jaime Eduardo/0000-0002-9733-5143; SILVA HERRERA, JAIME LUIS/0000-0001-6822-0374	Pontificia Universidad Javeriana and its Hospital Universitario San Ignacio, Bogota, Colombia [PPTA 00005140]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study makes up part of the research project entitled, "Factors that determine umbilical cord length,'' (ID PPTA 00005140) financed by the Pontificia Universidad Javeriana and its Hospital Universitario San Ignacio, Bogota, Colombia.	ALESSANDRI LM, 1992, BRIT J OBSTET GYNAEC, V99, P711, DOI 10.1111/j.1471-0528.1992.tb13868.x; Avagliano L, 2010, HUM PATHOL, V41, P971, DOI 10.1016/j.humpath.2009.07.026; Baergen RN, 2007, SEMIN DIAGN PATHOL, V24, P23, DOI 10.1053/j.semdp.2007.02.004; Baergen RN, 2001, PEDIATR DEVEL PATHOL, V4, P144, DOI 10.1007/s100240010135; Baergen RN, 2005, MANUAL KAUFMANNS PAT, P249; Blackburn W., 2006, HUMAN MALFORMATIONS, P1413; Castilla E, 2002, ECLAMC MANUAL OPERAC; Chan JSY, 2012, PEDIATR DEVEL PATHOL, V15, P487, DOI 10.2350/12-06-1211-OA.1; Chitra T, 2012, OBSTET GYNECOL INT, DOI 10.1155/2012/213689; Clapp JF, 2003, AM J OBSTET GYNECOL, V189, P488, DOI 10.1067/S0002-9378(03)00371-5; Collins JH, 2011, SILENT RISK ISSUES H; de Laat MWM, 2007, EUR J OBSTET GYN R B, V130, P66, DOI 10.1016/j.ejogrb.2006.01.018; Di Naro E, 2012, DJUOG, V6, P66; Ezimokhai M, 2000, AM J PERINAT, V17, P441, DOI 10.1055/s-2000-13452; FLETCHER S, 1993, BRIT J OBSTET GYNAEC, V100, P234, DOI 10.1111/j.1471-0528.1993.tb15236.x; Gilbert-Barness E, 1993, Birth Defects Orig Artic Ser, V29, P113; GRAFE MR, 1994, J NEUROPATH EXP NEUR, V53, P407, DOI 10.1097/00005072-199407000-00013; Grange D K, 1987, Birth Defects Orig Artic Ser, V23, P191; Hasegawa Junichi, 2006, Taiwan J Obstet Gynecol, V45, P21; Horn LC, 2004, EUR J OBSTET GYN R B, V113, P134, DOI 10.1016/S0301-2115(03)00371-3; Kalish RB, 2003, AM J OBSTET GYNECOL, V189, P736, DOI 10.1067/S0002-9378(03)00715-4; KAPLAN C, 1993, PATHOL ANNU, V28, P15; Kaplan C., 2007, COLOR ATLAS GROSS PL, P25; Kashanian M, 2006, INT J GYNECOL OBSTET, V95, P8, DOI 10.1016/j.ijgo.2006.05.029; Khong TY, 2010, PATHOLOGY, V42, P618, DOI 10.3109/00313025.2010.520309; Lisi A, 2005, AM J MED GENET A, V134A, P49, DOI 10.1002/ajmg.a.30514; Machin GA, 2000, PEDIATR DEVEL PATHOL, V3, P462, DOI 10.1007/s100240010103; Mu Shu-Chi, 2008, Pediatrics and Neonatology, V49, P230, DOI 10.1016/S1875-9572(09)60016-4; Ohno Y, 2016, J OBSTET GYNAECOL RE, V42, P1457, DOI 10.1111/jog.13092; Olaya-C M, 2015, J Neonatal Perinatal Med, V8, P251, DOI 10.3233/NPM-15915056; Olaya-C M, 2016, J Neonatal Perinatal Med, V9, P49, DOI 10.3233/NPM-16814108; Olaya-C M, 2014, APM, V20, P22; Ovalle S. Alfredo, 2005, Rev. chil. obstet. ginecol., V70, P303, DOI 10.4067/S0717-75262005000500005; Peres LC, 2012, PEDIATR DEVEL PATHOL, V15, P303, DOI 10.2350/12-03-1172-OA.1; Petersson K, 2002, ACTA OBSTET GYN SCAN, V81, P284; Pinar H, 2014, OBSTET GYNECOL, V123, P325, DOI 10.1097/AOG.0000000000000100; Pinar H, 2010, CLIN OBSTET GYNECOL, V53, P656, DOI 10.1097/GRF.0b013e3181eb68fe; Predanic M, 2005, AM J OBSTET GYNECOL, V193, P387, DOI 10.1016/j.ajog.2004.12.092; Predanic M, 2005, J ULTRAS MED, V24, P185, DOI 10.7863/jum.2005.24.2.185; Predanic M, 2005, J ULTRAS MED, V24, P192; RANA J, 1995, OBSTET GYNECOL, V85, P573, DOI 10.1016/0029-7844(94)00435-G; Rittler M, 2004, BIRTH DEFECTS RES A, V70, P13, DOI 10.1002/bdra.10131; Rittler M, 2010, PEDIATR DEVEL PATHOL, V13, P465, DOI 10.2350/10-01-0788-OA.1; Roberts JM, 2013, OBSTET GYNECOL, V122, P1122, DOI 10.1097/01.AOG.0000437382.03963.88; Silver RM, 2007, AM J OBSTET GYNECOL, V196, P433, DOI 10.1016/j.ajog.2006.11.041; Stefos T, 2003, EUR J OBSTET GYN R B, V107, P41, DOI 10.1016/S0301-2115(02)00307-X; Tantbirojn P, 2009, PLACENTA, V30, P1083, DOI 10.1016/j.placenta.2009.09.005	47	1	2	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	SEP-OCT	2018	21	5					467	474		10.1177/1093526618758204			8	Pathology; Pediatrics	Pathology; Pediatrics	HF4VA	WOS:000454230700007	29460686				2019-10-28	
J	Hallett, JM; Bryant, V; Drake, D; George, S; Upadhyaya, M				Hallett, John M.; Bryant, Victoria; Drake, David; George, Simi; Upadhyaya, Manasvi			Aborted Tracheo-esophageal Fistula in a Neonate	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						pediatric surgery; esophageal atresia; tracheoesophageal fistula; thoracic; gastroenterology	ESOPHAGEAL ATRESIA; EMBRYOLOGY	Esophageal atresia (EA) is an uncommon congenital anomaly which is often associated with a tracheoesophageal fistula. An isolated EA is a rarer anomaly and its diagnosis has implications for the ongoing treatment and outcome of the infant. For the first time, we report a case of a premature newborn with a pure EA and a tracheal diverticulum, containing both respiratory and esophageal mucosa. We have termed this an aborted trachea-esophageal fistula. Recognition of these very rare variations of foregut anomalies may contribute to our understanding of their pathogenesis.	[Hallett, John M.; Drake, David; Upadhyaya, Manasvi] St Thomas Hosp, Dept Paediat Surg, London, England; [Bryant, Victoria; George, Simi] St Thomas Hosp, Dept Pathol, London, England	Hallett, JM (reprint author), Scottish Ctr Regenerat Med, 5 Little France Dr, Edinburgh EH16 4UU, Midlothian, Scotland.	John.hallett@ed.ac.uk					Crisera CA, 1999, J PEDIATR SURG, V34, P204, DOI 10.1016/S0022-3468(99)90258-0; GOH DW, 1991, J PEDIATR SURG, V26, P160, DOI 10.1016/0022-3468(91)90898-4; Gross RE, 1953, SURG INFANCY CHILDHO, P76; HAIGHT C, 1957, J THORAC SURG, V34, P141; Ioannides AS, 2009, SEMIN PEDIATR SURG, V18, P2, DOI 10.1053/j.sempedsurg.2008.10.002; Keith A, 1910, Br Med J, V1, P376; KLUTH D, 1976, J PEDIATR SURG, V11, P901, DOI 10.1016/S0022-3468(76)80066-8; Kluth D, 2003, PEDIAT SURG, V12, P3; KOOP CE, 1954, SURG GYNECOL OBSTET, V98, P687; Ladd WE, 1944, NEW ENGL J MED, V230, P625, DOI 10.1056/NEJM194405252302101; MATHEY J, 1954, THORAX, V9, P106, DOI 10.1136/thx.9.2.106; Pansky B., 1982, REV MED EMBRYOLOGY; Possogel AK, 1998, J PEDIATR SURG, V33, P606, DOI 10.1016/S0022-3468(98)90326-8; Sasaki T, 2001, SURG TODAY, V31, P133, DOI 10.1007/s005950170197; SWENSON O, 1948, PEDIATRICS, V1, P195; Vogt EC, 1929, AM J ROENTGENOL RADI, V22, P463; WATERSON DJ, 1962, LANCET, V1, P819; WATERSTON DJ, 1963, LANCET, V2, P55; Williams AK, 2003, J PEDIATR SURG, V38, P173, DOI 10.1053/jpsu.2003.50037	19	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	SEP-OCT	2018	21	5					475	479		10.1177/1093526617708858			5	Pathology; Pediatrics	Pathology; Pediatrics	HF4VA	WOS:000454230700008	28492107				2019-10-28	
J	Szymanski, LJ; Molas-Torreblanca, K; Bawab, R; Kim, E; Don, D; Mascarenhas, L; Stanley, P; Zhou, S; Shillingford, N				Szymanski, Linda J.; Molas-Torreblanca, Kira; Bawab, Ramzi; Kim, Eugene; Don, Debra; Mascarenhas, Leo; Stanley, Phillip; Zhou, Shengmei; Shillingford, Nick			Bronchial Mucoepidermoid Carcinoma With the Classic MAML2 Gene Rearrangement in a 2-year-old Boy	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						pediatric; pulmonary mucoepidermoid carcinoma; bronchial; MAML2; lung tumor	TUMOR; LUNG; TRANSLOCATION; TRACHEAL; EGFR	Pulmonary mucoepidermoid carcinoma (PMEC) is rare. To date, primary PMEC has not been reported in a child younger than 3 years of age. We report a case of a 2-year-old boy who presented with 3 episodes of wheezing, cough, and fever over a period of I month. Radiologic findings were consistent with foreign body aspiration with consequent bronchial obstruction. Bronchoscopy was performed and attempts to retrieve the foreign body resulted in a biopsy of a fleshy lesion. By histology, the lesion was an epithelial neoplasm comprising cells arranged in a nested pattern. The neoplastic cells were round with round nuclei and amphophilic, vacuolated cytoplasm. Our diagnosis was low-grade salivary gland-type carcinoma of the bronchus. The pneumonectomy specimen showed a well-circumscribed, polypoid intrabronchial mass measuring 2.1 cm in greatest dimension. Histologic examination of the tumor showed an admixture of intermediate cells which were predominant, a small number of mucus cells and rare foci of squamous cells. The final diagnosis rendered was a low-grade mucoepidermoid carcinoma of the bronchus. Accurate diagnosis of PMEC can be challenging on limited biopsy material as seen in the case reported here. The use of molecular studies such as MAML2 gene rearrangement may facilitate diagnosis in difficult cases. Increased awareness of this entity and further molecular studies are needed for a better understanding of the pathogenesis of PMEC. To date, the reported age range for primary bronchial mucoepidermoid carcinoma is between 3 years and 78 years. This case represents the youngest patient reported in the English literature.	[Szymanski, Linda J.; Bawab, Ramzi; Zhou, Shengmei; Shillingford, Nick] Childrens Hosp Los Angeles, Dept Pathol & Lab Med, MS 43,4650 Sunset Blvd, Los Angeles, CA 90027 USA; [Molas-Torreblanca, Kira; Kim, Eugene; Don, Debra; Mascarenhas, Leo; Stanley, Phillip; Zhou, Shengmei; Shillingford, Nick] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA; [Molas-Torreblanca, Kira] Childrens Hosp Los Angeles, Dept Hosp Med, Los Angeles, CA 90027 USA; [Kim, Eugene] Childrens Hosp Los Angeles, Gen Pediat Surg, Los Angeles, CA 90027 USA; [Don, Debra] Childrens Hosp Los Angeles, Dept Surg, Div Otolaryngol, Los Angeles, CA 90027 USA; [Mascarenhas, Leo] Childrens Hosp Los Angeles, Dept Pediat, Div Hematol Oncol, Los Angeles, CA 90027 USA; [Stanley, Phillip] Childrens Hosp Los Angeles, Dept Radiol, Los Angeles, CA 90027 USA	Shillingford, N (reprint author), Childrens Hosp Los Angeles, Dept Pathol & Lab Med, MS 43,4650 Sunset Blvd, Los Angeles, CA 90027 USA.	nshillingford@chla.usc.edu	Mascarenhas, Leo/M-1801-2019	Mascarenhas, Leo/0000-0001-7790-0777			Anton-Pacheco J, 1998, PEDIATR SURG INT, V13, P524, DOI 10.1007/s003830050390; Brassesco MS, 2011, PEDIATR BLOOD CANCER, V56, P311, DOI 10.1002/pbc.22872; Desai DP, 1998, ANN OTO RHINOL LARYN, V107, P790, DOI 10.1177/000348949810700910; Dinopoulos A, 2000, PEDIATR HEMAT ONCOL, V17, P401, DOI 10.1080/08880010050034346; GREEN LK, 1991, THORAX, V46, P65, DOI 10.1136/thx.46.1.65; Han SW, 2008, LUNG CANCER, V61, P30, DOI 10.1016/j.lungcan.2007.11.014; HANCOCK BJ, 1993, J PEDIATR SURG, V28, P1133, DOI 10.1016/0022-3468(93)90147-D; Ishikawa Y, 2015, WHO CLASSIFICATION T, P99; Liu XL, 2007, ARCH PATHOL LAB MED, V131, P1400; Martins C, 2004, J MOL DIAGN, V6, P205, DOI 10.1016/S1525-1578(10)60511-9; Roby BB, 2011, ARCH OTOLARYNGOL, V137, P925, DOI 10.1001/archoto.2011.153; Rossi G, 2009, LUNG CANCER, V63, P159, DOI 10.1016/j.lungcan.2008.09.007; Saade RE, 2016, JAMA OTOLARYNGOL, V142, P234, DOI 10.1001/jamaoto.2015.3270; Seethala RR, 2010, AM J SURG PATHOL, V34, P1106, DOI 10.1097/PAS.0b013e3181de3021; SMETANA H F, 1952, Mil Surg, V111, P335; Zhu F, 2014, PLOS ONE	16	0	0	2	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	SEP-OCT	2018	21	5					480	485		10.1177/1093526617707855			6	Pathology; Pediatrics	Pathology; Pediatrics	HF4VA	WOS:000454230700009	28492094				2019-10-28	
J	Saluja, R; Faye-Petersen, O; Heller, DS				Saluja, Rasleen; Faye-Petersen, Ona; Heller, Debra S.			Ectopic Liver Within the Placental Parenchyma of a Stillborn Fetus	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						ectopic liver; placenta; placental neoplasm; hepatic adenoma; monodermal teratoma	HEPATOCELLULAR ADENOMA; TISSUE; TUMOR	Rarely, liver tissue can be seen in the umbilical cord, where it is thought to result from ectopic localization during embryogenesis. The placental parenchyma is also a rare site for this occurrence. The exact pathophysiology of ectopic liver in the placenta is unknown. It has been considered that aberrant migration or displacement of cells from the developing hepatic buds leads to ectopic liver formation, including groups of liver cells that become entrapped in the foregut as the diaphragm closes. Additional hypotheses put forward have included monodermal teratoma and hepatocellular adenoma. While the lesions may not actually be adenomas, this term has been most utilized in the literature. Hepatocellular adenomas of the placenta are extremely rare; only 9 cases have been reported thus far. We report an additional occurrence of ectopic liver in the placenta, which is the only one reported in a stillborn, and review the literature.	[Saluja, Rasleen] Univ Hawaii, Honolulu, HI 96822 USA; [Faye-Petersen, Ona] Univ Alabama Birmingham, Birmingham, AL USA; [Heller, Debra S.] Rutgers State Univ, New Jersey Sch Med, Newark, NJ 07103 USA	Heller, DS (reprint author), Rutgers State Univ, New Jersey Sch Med, Newark, NJ 07103 USA.	hellerds@njms.rutgers.edu					CHEN KTK, 1986, AM J SURG PATHOL, V10, P436, DOI 10.1097/00000478-198606000-00009; Dargent JL, 2000, HISTOPATHOLOGY, V37, P287, DOI 10.1046/j.1365-2559.2000.01020-5.x; DeNapoli TS, 2015, PEDIATR DEVEL PATHOL, V18, P422, DOI 10.2350/14-12-1592-CR.1; Dimmick JE, 1992, DEV PATHOLOGY EMBRYO, P545; FOX H, 1964, J PATHOL BACTERIOL, V88, P137, DOI 10.1002/path.1700880118; Lara-Diaz VJ, 2011, PEDIATR DEVEL PATHOL, V14, P422, DOI 10.2350/11-01-0955-CR.1; Khalifa MA, 1998, INT J GYNECOL PATHOL, V17, P241, DOI 10.1097/00004347-199807000-00008; Matsuyama T, 2004, INT J GYNECOL PATHOL, V23, P398, DOI 10.1097/01.pgp.0000139662.05916.70; Preminger A, 2001, J PEDIATR SURG, V36, P1085, DOI 10.1053/jpsu.2001.24761; QURESHI F, 1995, PEDIATR PATHOL LAB M, V15, P51, DOI 10.3109/15513819509026939; Vaideeswar P, 2011, J POSTGRAD MED, V57, P229, DOI 10.4103/0022-3859.85220; Vesoulis Z, 1998, AM J SURG PATHOL, V22, P355, DOI 10.1097/00000478-199803000-00011; Yee EU, 2016, INT J SURG PATHOL, V24, P640, DOI 10.1177/1066896916645186	13	2	2	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	SEP-OCT	2018	21	5					486	488		10.1177/1093526617712640			3	Pathology; Pediatrics	Pathology; Pediatrics	HF4VA	WOS:000454230700010	28593805				2019-10-28	
J	Cheon, E; Yang, S; Han, JH; Lee, KC; Park, JE				Cheon, Eunjae; Yang, Saemi; Han, Jae Ho; Lee, Kwang Chul; Park, Jun Eun			Systemic Juvenile Xanthogranuloma Involving the Bone Marrow, Multiple Bones, and the Skin That Developed During Treatment of Acute Lymphoblastic Leukemia in Remission State	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						juvenile xanthogranuloma; systemic; bone marrow; lymphoblastic leukemia	NEUROFIBROMATOSIS; ASSOCIATION; LIVER	Juvenile xanthogranuloma (JXG) is a rare benign disorder classified as non-Langerhans cell histiocytosis, with unclear etiology and pathogenesis. JXG is generally characterized by solitary or multiple cutaneous nodules that resolve spontaneously over a few years. JXG rarely presents as extracutaneous lesions that progress to a symptomatic systemic disorder through multiple organ involvement. We encountered a systemic JXG case involving the bone marrow, multiple bones, and the skin during acute lymphoblastic leukemia (ALL) treatment. A 16-year-old boy undergoing ALL treatment experienced unexplained prolonged fever and scalp, hip joint, and right knee joint pain for 2 weeks during interim maintenance chemotherapy. Bone marrow pathologic findings revealed no evidence of leukemia relapse but showed diffuse infiltration of histiocytes with several Touton-type giant cells; the stains were positive for CD68 and negative for CD1a and S100 protein. Bone and skin biopsies confirmed the findings. Symptoms have resolved since maintenance chemotherapy, which included vincristine, dexamethasone, 6-mercaptopurine, and methotrexate. Bone marrow involvement of JXG is very rare, occurring only in patients less than 1 year of age; however, this case was reported in an adolescent during ALL treatment.	[Cheon, Eunjae; Yang, Saemi; Han, Jae Ho; Park, Jun Eun] Ajou Univ, Sch Med, Dept Pediat, 164 Worldcup Ro, Suwon 16499, South Korea; [Lee, Kwang Chul] Korea Univ, Coll Med, Dept Pediat, Seoul, South Korea	Park, JE (reprint author), Ajou Univ, Sch Med, Dept Pediat, 164 Worldcup Ro, Suwon 16499, South Korea.	pedpje@ajou.ac.kr		Park, Jun Eun/0000-0003-4292-3500			Azorin D, 2009, PEDIATR DERMATOL, V26, P709, DOI 10.1111/j.1525-1470.2009.01018.x; Cambiaghi S, 2004, PEDIATR DERMATOL, V21, P97, DOI 10.1111/j.0736-8046.2004.21201.x; Chantranuwat C, 2004, PEDIATR DEVEL PATHOL, V7, P646, DOI 10.1007/s10024-004-1012-1; Chiou CC, 2007, J EUR ACAD DERMATOL, V21, P532, DOI 10.1111/j.1468-3083.2006.02013.x; Dehner LP, 2003, AM J SURG PATHOL, V27, P579, DOI 10.1097/00000478-200305000-00003; Fenot M, 2014, J AM ACAD DERMATOL, V71, P389, DOI 10.1016/j.jaad.2014.02.049; Ferrari F, 2014, JAMA DERMATOL, V150, P42, DOI 10.1001/jamadermatol.2013.6434; Freyer DR, 1996, J PEDIATR-US, V129, P227, DOI 10.1016/S0022-3476(96)70247-0; Hara T, 2006, PEDIATR BLOOD CANCER, V47, P103, DOI 10.1002/pbc.20514; HernandezMartin A, 1997, J AM ACAD DERMATOL, V36, P355, DOI 10.1016/S0190-9622(97)80207-1; Hu WK, 2004, PEDIATR DEVEL PATHOL, V7, P71, DOI 10.1007/s10024-003-4040-3; Janssen D, 2005, AM J SURG PATHOL, V29, P21, DOI 10.1097/01.pas.0000147395.01229.06; Kesserwan C, 2007, PEDIATR DEVEL PATHOL, V10, P161, DOI 10.2350/06-06-0106.1; Maly E, 2012, J PEDIAT HEMATOL ONC, V34, P222, DOI 10.1097/MPH.0b013e31823321ca; Nakatani T, 2004, J PEDIAT HEMATOL ONC, V26, P371, DOI 10.1097/00043426-200406000-00007; Perez-Becker R, 2011, PEDIATR BLOOD CANCER, V56, P859, DOI 10.1002/pbc.22756; Shin HT, 2004, J PEDIAT HEMATOL ONC, V26, P591, DOI 10.1097/01.mph.0000135282.39550.99; Shoo BA, 2008, J AM ACAD DERMATOL, V59, P488, DOI 10.1016/j.jaad.2008.03.046; Stover DG, 2008, PEDIATR BLOOD CANCER, V51, P130, DOI 10.1002/pbc.21523; Weitzman S, 2005, PEDIATR BLOOD CANCER, V45, P256, DOI 10.1002/pbc.20246	20	1	2	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	SEP-OCT	2018	21	5					489	493		10.1177/1093526617721775			5	Pathology; Pediatrics	Pathology; Pediatrics	HF4VA	WOS:000454230700011	28836893				2019-10-28	
J	Pilson, K; Farrell, M; Lynch, B; Devaney, D				Pilson, Keith; Farrell, Michael; Lynch, Beyan; Devaney, Deirdre			A Case of Juvenile Onset Neuronal Intranuclear Inclusion Disease With a Negative Antemortem Skin Biopsy	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						neurodegenerative; intranuclear; inclusions; hyaline inclusion; neuronal inclusions; ubiquitination		Neuronal intranuclear (hyaline) inclusion disease (NIID) is a rare neurodegenerative disorder with a variable clinical presentation and multiple subtypes. We present the clinicopathologic details of a patient with juvenile-onset NIID and discuss the pathogenesis. We also discuss the utility of antemortem skin biopsy which was negative in our case.	[Pilson, Keith; Devaney, Deirdre] Temple St Childrens Univ Hosp, Dept Histopathol, Dublin, Ireland; [Farrell, Michael] Beaumont Hosp, Dept Neuropathol, Dublin, Ireland; [Lynch, Beyan] Temple St Childrens Univ Hosp, Dept Paediat, Dublin, Ireland	Pilson, K (reprint author), Childrens Univ Hosp, Dept Histopathol, Dublin, Ireland.	keithpilson@gmail.com					DYKEN P, 1983, ANN NEUROL, V13, P351, DOI 10.1002/ana.410130402; Love S, 2004, HISTOPATHOLOGY, V44, P309, DOI 10.1111/j.1365-2559.2004.01794.x; McFadden K, 2005, J NEUROPATH EXP NEUR, V64, P545, DOI 10.1093/jnen/64.6.545; Sone J, 2011, NEUROLOGY, V76, P1372, DOI 10.1212/WNL.0b013e3182166e13; Sone Jun, 2017, Brain Nerve, V69, P5, DOI 10.11477/mf.1416200628; Sone J, 2016, BRAIN, V139, P3170, DOI 10.1093/brain/aww249; Takahashi-Fujigasaki Junko, 2015, Brain Nerve, V67, P199, DOI 10.11477/mf.1416200112	7	0	1	1	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	SEP-OCT	2018	21	5					494	496		10.1177/1093526617724293			3	Pathology; Pediatrics	Pathology; Pediatrics	HF4VA	WOS:000454230700012	28853324				2019-10-28	
J	Terry, J; Brown, K; Hiebert, J; Al-Rawahi, GN; Moxham, JP; Krajden, M; Jassem, AN; Tucker, L				Terry, Jefferson; Brown, Kelly; Hiebert, Joanne; Al-Rawahi, Ghada N.; Moxham, J. Paul; Krajden, Mel; Jassem, Agatha N.; Tucker, Lori			Measles Lymphadenopathy in a Child With PFAPA Syndrome	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						PFAPA; periodic fever; measles; lymphadenopathy; tonsillectomy; tonsil	CERVICAL ADENITIS SYNDROME; PERIODIC FEVER; APHTHOUS STOMATITIS; APHTOUS STOMATITIS; PHARYNGITIS; TONSILS; VIRUS; TONSILLECTOMY; NEUTROPHILS; CELLS	Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome is a common cause of periodic fever in children. The pathogenesis of PFAPA is unknown but likely involves immune system dysregulation and may be initiated by an environmental trigger. Tonsillectomy resolves or improves symptoms in some patients, but the reason for this is unknown; moreover, specific abnormalities in tonsillectomy specimens from PFAPA patients have not been described. Here, we report measles virus in tonsil from a child with PFAPA. Measles-type viral cytopathic effect was discovered on histological examination of tonsillar tissue after therapeutic tonsillectomy for PFAPA. Molecular testing showed the left tonsil was positive for measles RNA by reverse transcription polymerase chain reaction (RT-PCR) while the right tonsil was inconclusive (weakly positive). Real-time RT-PCR specific for measles vaccine strain RNA (genotype A) was weakly reactive in the left tonsil tissue when tested in 3 independent replicates, but this result could not be confirmed with conventional genotyping by sequencing. The relationship and clinical significance between measles virus and PFAPA in this case is unclear but may be related to PFAPA-associated immune dysregulation. Additional investigation of measles virus in PFAPA patients would be helpful in further exploring this potential association.	[Terry, Jefferson; Al-Rawahi, Ghada N.; Krajden, Mel; Jassem, Agatha N.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada; [Terry, Jefferson; Brown, Kelly; Al-Rawahi, Ghada N.; Moxham, J. Paul; Krajden, Mel; Jassem, Agatha N.; Tucker, Lori] British Columbia Childrens Hosp, Vancouver, BC, Canada; [Brown, Kelly; Tucker, Lori] Univ British Columbia, Dept Pediat, Div Pediat Rheumatol, Vancouver, BC, Canada; [Hiebert, Joanne] Publ Hlth Agcy Canada, Natl Microbiol Lab, Winnipeg, MB, Canada; [Moxham, J. Paul] Univ British Columbia, Dept Surg, Vancouver, BC, Canada	Terry, J (reprint author), BC Childrens Hosp, Dept Pathol, Room 2H53,4480 Oak St, Vancouver, BC V6H 3V4, Canada.	jefferson.terry@cw.bc.ca		Brown, Kelly/0000-0001-5385-3582; Terry, Jefferson/0000-0001-5464-8679; Hiebert, Joanne/0000-0003-3238-1859			Anlar B, 2002, J PAEDIATR CHILD H, V38, P424, DOI 10.1046/j.1440-1754.2002.t01-1-00029.x; Brown KL, 2010, BMC PEDIATR, V10, DOI 10.1186/1471-2431-10-65; Burton MJ, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008669.pub2; Di Gioia SA, 2015, SCI REP-UK, V5, DOI 10.1038/srep10200; Dytrych P, 2015, MOL IMMUNOL, V65, P139, DOI 10.1016/j.molimm.2015.01.004; Federici S, 2015, ANN RHEUM DIS, V74, P799, DOI 10.1136/annrheumdis-2014-206580; Forsvoll J, 2015, SCAND J IMMUNOL, V82, P76, DOI 10.1111/sji.12303; GAULIER A, 1991, VIRCHOWS ARCH A, V419, P245, DOI 10.1007/BF01626355; Hofer M, 2014, RHEUMATOLOGY, V53, P1125, DOI 10.1093/rheumatology/ket460; Hummel KB, 2006, J VIROL METHODS, V132, P166, DOI 10.1016/j.jviromet.2005.10.006; Kolly L, 2013, J ALLERGY CLIN IMMUN, V131, P1635, DOI 10.1016/j.jaci.2012.07.043; Lantto U, 2015, APMIS, V123, P523, DOI 10.1111/apm.12383; LekstromHimes JA, 1996, CLIN INFECT DIS, V22, P22; Long SS, 1999, J PEDIATR-US, V135, P1, DOI 10.1016/S0022-3476(99)70316-1; MARSHALL GS, 1987, J PEDIATR-US, V110, P43, DOI 10.1016/S0022-3476(87)80285-8; Padeh S, 1999, J PEDIATR-US, V135, P98, DOI 10.1016/S0022-3476(99)70335-5; Peridis S, 2010, AM J OTOLARYNG, V31, P472, DOI 10.1016/j.amjoto.2009.06.005; Pignataro L, 2009, ARCH OTOLARYNGOL, V135, P548, DOI 10.1001/archoto.2009.56; Ryan ME, 1996, PEDIATR INFECT DIS J, V15, P270, DOI 10.1097/00006454-199603000-00022; Stojanov S, 2011, P NATL ACAD SCI USA, V108, P7148, DOI 10.1073/pnas.1103681108; Sundqvist M, 2013, ARTHRITIS RHEUM-US, V65, P2971, DOI 10.1002/art.38134; Tejesvi MV, 2016, EUR J CLIN MICROBIOL, V35, P963, DOI 10.1007/s10096-016-2623-y; Thomas KT, 1999, J PEDIATR-US, V135, P15, DOI 10.1016/S0022-3476(99)70321-5; Valenzuela PM, 2009, CLIN RHEUMATOL, V28, P1235, DOI 10.1007/s10067-009-1222-z; Yamazaki T, 2014, CLIN RHEUMATOL, V33, P677, DOI 10.1007/s10067-014-2542-1; Yim D, 2013, J PAEDIATR CHILD H, V49, P704, DOI 10.1111/jpc.12172	26	0	0	1	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	SEP-OCT	2018	21	5					497	501		10.1177/1093526617727970			5	Pathology; Pediatrics	Pathology; Pediatrics	HF4VA	WOS:000454230700013	28882091				2019-10-28	
J	Khedr, S; Piskorski, A; Bingham, AR; Goldstein, J; Laptook, AR; De Paepe, ME				Khedr, Salwa; Piskorski, Anna; Bingham, Adrienne R.; Goldstein, Justin; Laptook, Abbot R.; De Paepe, Monique E.			Occult Massive Visceral Fat Necrosis Following Therapeutic Hypothermia for Neonatal Encephalopathy	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						adipose tissue; whole-body cooling; apparent stillbirth	SUBCUTANEOUS FAT; NEWBORN; HYPERCALCEMIA; COMPLICATIONS; CRYSTALS; INFANTS	Therapeutic hypothermia (head or whole-body cooling) improves survival and neurodevelopmental outcome in term newborns with moderate-to-severe encephalopathy. Hypothermia treatment is well tolerated; the most common side effect is thrombocytopenia. In about 1% of infants, focal subcutaneous fat necrosis has been reported. We describe a case of clinically unsuspected massive visceral fat necrosis in a term infant with Apgar score 0 at 1 min ("resuscitated apparently stillborn" infant) who was treated with therapeutic hypothermia for 72 h and expired on the 25th day of life following a neonatal course complicated by severe encephalopathy, pulmonary artery hypertension, persistent thrombocytopenia, hypoglycemia, and severe basal ganglia-thalamic abnormalities on magnetic resonance imaging. Postmortem examination revealed extensive visceral (brown) fat necrosis, involving thoracic, abdominal, and retroperitoneal adipose tissue, with distinctive sparing of the subcutaneous (white) fat. The fulminant-yet clinically occult-visceral fat necrosis seen in this case suggests that (lesser degrees of) fat necrosis may go unrecognized in hypoxic-ischemic newborns, especially in those treated with hypothermia, and underscores the importance of close monitoring of encephalopathic newborns both in the short and long terms for complications of fat necrosis (hypercalcemia and nephrocalcinosis).	[Khedr, Salwa; Piskorski, Anna; De Paepe, Monique E.] Women & Infants Hosp Rhode Isl, Dept Pathol, 101 Dudley St, Providence, RI 02905 USA; [Khedr, Salwa; Piskorski, Anna; De Paepe, Monique E.] Brown Univ, Alpert Med Sch, Dept Pathol & Lab Med, Providence, RI 02912 USA; [Bingham, Adrienne R.; Goldstein, Justin; Laptook, Abbot R.] Women & Infants Hosp Rhode Isl, Dept Pediat, Providence, RI USA; [Bingham, Adrienne R.; Goldstein, Justin; Laptook, Abbot R.] Brown Univ, Dept Pediat, Alpert Med Sch, Providence, RI 02912 USA	De Paepe, ME (reprint author), Women & Infants Hosp Rhode Isl, Dept Pathol, 101 Dudley St, Providence, RI 02905 USA.	mdepaepe@wihri.org					Akcay A, 2013, PEDIATR DERMATOL, V30, P120, DOI 10.1111/j.1525-1470.2011.01716.x; [Anonymous], 2014, Obstet Gynecol, V123, P896, DOI 10.1097/01.AOG.0000445580.65983.d2; Battin MR, 2001, PEDIATRICS, V107, P480, DOI 10.1542/peds.107.3.480; Borgia F, 2006, J PAEDIATR CHILD H, V42, P316, DOI 10.1111/j.1440-1754.2006.00862.x; Burden AD, 1999, PEDIATR DERMATOL, V16, P384, DOI 10.1046/j.1525-1470.1999.00101.x; Channon HJ, 1926, BIOCHEM J, V20, P84, DOI 10.1042/bj0200084; COOK JS, 1992, PEDIATRICS, V90, P93; Del Pozzo-Magana BR, 2016, PEDIATR DERMATOL, V33, pE353, DOI 10.1111/pde.12973; Dodson MV, 2014, ADIPOCYTE, V3, P236, DOI 10.4161/adip.28321; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; HICKS MJ, 1993, PEDIATR DERMATOL, V10, P271, DOI 10.1111/j.1525-1470.1993.tb00375.x; Hogeling M, 2012, PEDIATR DERMATOL, V29, P59, DOI 10.1111/j.1525-1470.2011.01374.x; Jacobs SE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003311.pub3; KRUSE K, 1993, J PEDIATR-US, V122, P460, DOI 10.1016/S0022-3476(05)83441-9; Llamas-Velasco M, 2015, J CUTAN PATHOL, V42, P413, DOI 10.1111/cup.12478; Mahe E, 2007, BRIT J DERMATOL, V156, P709, DOI 10.1111/j.1365-2133.2007.07782.x; Oza V, 2010, ARCH DERMATOL, V146, P882, DOI 10.1001/archdermatol.2010.176; PROKS C, 1966, J CLIN PATHOL, V19, P193, DOI 10.1136/jcp.19.2.193; Sahin S, 2015, J PEDIATR-US, V166, P1545, DOI 10.1016/j.jpeds.2015.02.066; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Strohm B, 2011, PEDIATRICS, V128, pE450, DOI 10.1542/peds.2010-3508; Tran JT, 2003, PEDIATR DERMATOL, V20, P257, DOI 10.1046/j.1525-1470.2003.20315.x; Vasireddy S, 2009, PEDIATR RADIOL, V39, P73, DOI 10.1007/s00247-008-1019-2; Zifman E, 2010, J PEDIATR ENDOCR MET, V23, P1185, DOI 10.1515/jpem.2010.186	24	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	SEP-OCT	2018	21	5					502	506		10.1177/1093526617737881			5	Pathology; Pediatrics	Pathology; Pediatrics	HF4VA	WOS:000454230700014	29108501				2019-10-28	
J	Finsterer, J; Zarrouk-Mahjoub, S				Finsterer, Josef; Zarrouk-Mahjoub, Sinda			TK2-related Myopathic Mitochondrial Depletion Syndrome	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Letter							MUTATIONS		[Finsterer, Josef] Krankenanstalt Rudolfstiftung Wien, Vienna, Austria; [Zarrouk-Mahjoub, Sinda] Univ Tunis El Manar, Pasteur Inst Tunis, Tunis, Tunisia; [Zarrouk-Mahjoub, Sinda] Genom Platform, Tunis, Tunisia	Finsterer, J (reprint author), Postfach 20, A-1180 Vienna, Austria.	fifigs1@yahoo.de					Alston CL, 2013, NEUROLOGY, V81, P2051, DOI 10.1212/01.wnl.0000436931.94291.e6; Knierim E, 2015, MITOCHONDRION, V20, P1, DOI 10.1016/j.mito.2014.10.007; Martin-Hernandez E, 2017, PEDIATR DEVEL PATHOL, V20, P416, DOI 10.1177/1093526616686439; Roos S, 2014, NEUROMUSCULAR DISORD, V24, P713, DOI 10.1016/j.nmd.2014.05.009; Termglinchan T, 2016, NEUROL-GENET, V2, DOI 10.1212/NXG.0000000000000095; Tyynismaa H, 2012, HUM MOL GENET, V21, P66, DOI 10.1093/hmg/ddr438	6	2	3	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	SEP-OCT	2018	21	5					507	508		10.1177/1093526617743906			2	Pathology; Pediatrics	Pathology; Pediatrics	HF4VA	WOS:000454230700015	29173062				2019-10-28	
J	Martin-Hernandez, E; Martinez-Azorin, F				Martin-Hernandez, Elena; Martinez-Azorin, Francisco			Author's Reply: TK2-related Myopathic Mitochondrial Depletion Syndrome	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Letter							DNA DEPLETION; MUTATION; PATIENT; FORM		[Martin-Hernandez, Elena] Hosp Univ 12 Octubre, Serv Pediat, Unidad Enfermedades Mitocondriales Metab Heredita, Madrid, Spain; [Martinez-Azorin, Francisco] Inst Invest Hosp, Lab Enfermedades Mitocondriales, Madrid, Spain	Martin-Hernandez, E (reprint author), Hosp Univ 12 Octubre, Serv Pediat, Unidad Enfermedades Mitocondriales Metab Heredita, Madrid, Spain.	emartinhernandez@salud.madrid.org		Martinez-Azorin, Francisco/0000-0001-6250-7745			Behin A, 2012, NEUROLOGY, V78, P644, DOI 10.1212/WNL.0b013e318248df2b; Camara Y, 2015, NEUROLOGY, V84, P2286, DOI 10.1212/WNL.0000000000001644; Chanprasert S, 2013, MOL GENET METAB, V110, P153, DOI 10.1016/j.ymgme.2013.07.009; Finsterer J, 2018, PEDIATR DEVEL PATHOL, V21, P507, DOI 10.1177/1093526617743906; Garone C, 2014, EMBO MOL MED, V6, P1016, DOI 10.15252/emmm.201404092; He J, 2012, NUCLEIC ACIDS RES, V40, P6109, DOI 10.1093/nar/gks266; Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1007, DOI 10.1001/archneur.60.7.1007; Marti R, 2010, PEDIATR RES, V68, P151, DOI 10.1203/00006450-201011001-00294; Martin-Hernandez E, 2005, PEDIATR NEPHROL, V20, P1299, DOI 10.1007/s00467-005-1948-z; Martin-Hernandez E, 2017, PEDIATR DEVEL PATHOL, V20, P416, DOI 10.1177/1093526616686439; Paradas C, 2013, NEUROLOGY, V80, P504, DOI 10.1212/WNL.0b013e31827f0ff7; Roos S, 2014, NEUROMUSCULAR DISORD, V24, P713, DOI 10.1016/j.nmd.2014.05.009	12	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	SEP-OCT	2018	21	5					509	510		10.1177/1093526617743907			2	Pathology; Pediatrics	Pathology; Pediatrics	HF4VA	WOS:000454230700016	29173060				2019-10-28	
J	[Anonymous]				[Anonymous]			Abstracts from the meeting of the Paediatric Pathology Society, Lisbon, Portugal , September 7-9, 2017 Abstracts	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article																	0	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	SEP-OCT	2018	21	5					NP1	NP13		10.1177/1093526618777181			13	Pathology; Pediatrics	Pathology; Pediatrics	HF4VA	WOS:000454230700001	29923794				2019-10-28	
J	Chun, TT; Chung, CS; Fallon, EA; Hutchins, NA; Clarke, E; Rossi, AL; Cioffi, WG; Heffernan, DS; Ayala, A				Chun, Tristen T.; Chung, Chun-Shiang; Fallon, Eleanor A.; Hutchins, Noelle A.; Clarke, Erlyana; Rossi, Anne-Lise; Cioffi, William G.; Heffernan, Daithi S.; Ayala, Alfred			Group 2 Innate Lymphoid Cells (ILC2s) Are Key Mediators of the Inflammatory Response in Polymicrobial Sepsis	AMERICAN JOURNAL OF PATHOLOGY			English	Article							SEPTIC SHOCK; CECAL LIGATION; NKT CELLS; MORTALITY; TISSUE; MOUSE; IL-33; INTERLEUKIN-33; ANTAGONIST; MECHANISMS	Sepsis remains a major public health concern, characterized by marked immune dysfunction. Innate lymphoid cells develop from a common lymphoid precursor but have a role in orchestrating inflammation during innate response to infection. Here, we investigate the pathologic contribution of the group 2 innate lymphoid cells (ILC2s) in a murine model of acute septic shock (cecal ligation and puncture). Flow cytometric data revealed that ILC2s increase in number and percentage in the small intestine and in the peritoneal cells and inversely decline in the liver at 24 hours after septic insult. Sepsis also resulted in changes in ILC2 effector cytokine (IL-13) and activating cytokine (IL-33) in the plasma of mice and human patients in septic shock. Of interest, the sepsis-induced changes in cytokines were abrogated in mice deficient in functionally invariant natural killer T cells. Mice deficient in IL-13 producing cells, including ILC2s, had a survival advantage after sepsis along with decreased morphologic evidence of tissue injury and reduced IL-10 levels in the peritoneal fluid. Administration of a suppressor of tumorigenicity 2 (IL-33R) receptor blocking antibody led to a transient survival advantage. Taken together, these findings suggest that ILC2s may play an unappreciated role in mediating the inflammatory response in both mice and humans; further, modulating ILC2 response in vivo may allow development of immunomodulatory strategies directed against sepsis.	[Chun, Tristen T.; Chung, Chun-Shiang; Fallon, Eleanor A.; Hutchins, Noelle A.; Clarke, Erlyana; Rossi, Anne-Lise; Cioffi, William G.; Heffernan, Daithi S.; Ayala, Alfred] Brown Univ, Rhode Isl Hosp, Alpert Med Sch, Div Surg Res, Providence, RI 02903 USA; [Heffernan, Daithi S.] Brown Univ, Rhode Isl Hosp, Alpert Med Sch, Dept Surg, Providence, RI 02903 USA; [Heffernan, Daithi S.] Brown Univ, Rhode Isl Hosp, Alpert Med Sch, Div Trauma & Surg Crit Care, Providence, RI 02903 USA	Ayala, A (reprint author), Rhode Isl Hosp, 593 Eddy St,Aldrich 227, Providence, RI 02903 USA.	aayala@lifespan.org		Rossi, Anne-Lise/0000-0001-9991-2445	NIH/National Institute of General Medical SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01 GM046354-20, R35 GM118097, T32 GM065085, K08-GM110495]; Armand D. Versaci Research Scholar in Surgical Sciences Fellowship	Supported by NIH/National Institute of General Medical Sciences grants R01 GM046354-20 (A.A.), R35 GM118097 (A.A.), T32 GM065085 (N.A.H.), and K08-GM110495 (D.S.H.), and Armand D. Versaci Research Scholar in Surgical Sciences Fellowship awards (T.T.C. and E.A.F.).	Alves JC, 2010, NAT MED, V16, P708, DOI 10.1038/nm.2156; Angus DC, 2011, JAMA-J AM MED ASSOC, V306, P2614, DOI 10.1001/jama.2011.1853; AYALA A, 1992, CIRC SHOCK, V36, P191; AYALA A, 1994, J SURG RES, V56, P579, DOI 10.1006/jsre.1994.1092; BAKER CC, 1983, SURGERY, V94, P331; Bernard GR, 2014, CRIT CARE MED, V42, P504, DOI 10.1097/CCM.0000000000000043; Blackwell TS, 1996, BRIT J ANAESTH, V77, P110; Boomer JS, 2011, JAMA-J AM MED ASSOC, V306, P2594, DOI 10.1001/jama.2011.1829; Chang Di, 2015, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, V27, P138, DOI 10.3760/cma.j.issn.2095-4352.2015.02.012; Committee for the Update of the Guide for the Care and Use of Laboratory Animals; National Research Council, 2011, GUIDE CARE USE LAB A; Cui JQ, 1997, SCIENCE, V278, P1623, DOI 10.1126/science.278.5343.1623; Eberl G, 2015, SCIENCE, V348, DOI 10.1126/science.aaa6566; Gronke K, 2017, METHODS MOL BIOL, V1559, P255, DOI 10.1007/978-1-4939-6786-5_17; Halim TYF, 2014, CURR PROTOC IMMUNOL, V106; Hams E, 2014, P NATL ACAD SCI USA, V111, P367, DOI 10.1073/pnas.1315854111; Hashiguchi M, 2015, EUR J IMMUNOL, V45, P876, DOI 10.1002/eji.201444969; Heffernan DS, 2013, SHOCK, V40, P122, DOI 10.1097/SHK.0b013e31829ca519; Ho J, 2015, CLIN EXP ALLERGY, V45, P394, DOI 10.1111/cea.12462; Hu CK, 2009, J IMMUNOL, V182, P2467, DOI 10.4049/jimmunol.0801463; Klose CSN, 2016, NAT IMMUNOL, V17, P765, DOI 10.1038/ni.3489; Kuethe JW, 2014, J SURG RES, V191, P19, DOI 10.1016/j.jss.2014.05.024; Lee WY, 2010, NAT IMMUNOL, V11, P295, DOI 10.1038/ni.1855; Levy Mitchell M, 2003, Intensive Care Med, V29, P530; Li S, 2016, IMMUNOL LETT, V169, P1, DOI 10.1016/j.imlet.2015.11.009; Matsukawa A, 2000, J IMMUNOL, V164, P2738, DOI 10.4049/jimmunol.164.5.2738; MELDRUM DR, 1991, J SURG RES, V51, P158, DOI 10.1016/0022-4804(91)90088-4; Monneret G, 2008, MOL MED, V14, P64, DOI 10.2119/2007-00102.Monneret; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Munford RS, 2001, AM J RESP CRIT CARE, V163, P316, DOI 10.1164/ajrccm.163.2.2007102; Novotny AR, 2012, IMMUNOBIOLOGY, V217, P616, DOI 10.1016/j.imbio.2011.10.019; Oboki K, 2010, P NATL ACAD SCI USA, V107, P18581, DOI 10.1073/pnas.1003059107; Opal SM, 2013, JAMA-J AM MED ASSOC, V309, P1154, DOI 10.1001/jama.2013.2194; Otto GP, 2011, CRIT CARE, V15, DOI 10.1186/cc10332; Pichery M, 2012, J IMMUNOL, V188, P3488, DOI 10.4049/jimmunol.1101977; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Rankin L, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00022; Rittirsch D, 2008, NAT REV IMMUNOL, V8, P776, DOI 10.1038/nri2402; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Scanlon ST, 2012, CURR OPIN IMMUNOL, V24, P707, DOI 10.1016/j.coi.2012.08.009; SILVA AT, 1992, J INFECT DIS, V166, P331, DOI 10.1093/infdis/166.2.331; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; SPOONER CE, 1992, CLIN IMMUNOL IMMUNOP, V62, pS11, DOI 10.1016/0090-1229(92)90036-N; Tsiotou AG, 2005, MED SCI MONITOR, V11, pRA76; Venet F, 2008, J LEUKOCYTE BIOL, V83, P523, DOI 10.1189/jlb.0607371; Walker JA, 2013, CURR OPIN IMMUNOL, V25, P148, DOI 10.1016/j.coi.2013.02.010; Wang P, 1996, AM J PHYSIOL-REG I, V270, pR927; Wesche-Soldato DE, 2007, AM J PATHOL, V171, P87, DOI 10.2353/ajpath.2007.061099; Xu Jiaquan, 2010, Natl Vital Stat Rep, V58, P1; Young JS, 2016, SHOCK, V45, P534, DOI 10.1097/SHK.0000000000000553; Zhu JF, 2015, CYTOKINE, V75, P14, DOI 10.1016/j.cyto.2015.05.010	50	2	2	5	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	SEP	2018	188	9					2097	2108		10.1016/j.ajpath.2018.05.009			12	Pathology	Pathology	GR5XP	WOS:000442715500015	29935165	Green Published			2019-10-28	
J	Cohen, JN; Yeh, I; Jordan, RC; Wolsky, RJ; Horvai, AE; McCalmont, TH; LeBoit, PE				Cohen, Jarish N.; Yeh, Iwei; Jordan, Richard C.; Wolsky, Rebecca J.; Horvai, Andrew E.; McCalmont, Timothy H.; LeBoit, Philip E.			Cutaneous Non-Neural Granular Cell Tumors Harbor Recurrent ALK Gene Fusions	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						non-neural; granular cell tumor; Schwannian; ALK; gene fusion	OF-THE-LITERATURE; INFLAMMATORY MYOFIBROBLASTIC TUMORS; INTEGRATIVE GENOMICS VIEWER; BURROWS-WHEELER TRANSFORM; NOONAN-SYNDROME; ORAL-CAVITY; CLINICOPATHOLOGICAL ANALYSIS; ATYPICAL FIBROXANTHOMA; FIBROUS HISTIOCYTOMA; READ ALIGNMENT	Non-neural granular cell tumor (NNGCT; also known as primitive polypoid granular cell tumor) is a rare neoplasm composed of large ovoid cells with abundant granular cytoplasm, variable nuclear pleomorphism, and the potential for regional lymph node spread. In contrast to conventional granular cell tumor (GCT), NNGCT lacks S100 expression and can exhibit greater nuclear atypia and mitotic activity. Therefore, we investigated clinicopathologic features of 12 NNGCT, and also used next-generation sequencing to identify potential driver events in a subset of NNGCT and 6 GCT. NNGCT demonstrated mild-to-moderate nuclear pleomorphism, variable mitotic activity (0 to 10/10 high-power fields), and were S100(-). Genetic analysis of 5 cutaneous NNGCT revealed gene fusions involving the anaplastic lymphoma kinase gene (ALK) in 3 cases (60%). Specifically, an interstitial deletion of chromosome 2 resulting in an in-frame fusion of dyanactin 1 (DCTN1) to ALK was identified in 2 cases, and a translocation resulting in a fusion between sequestosome 1 (SQSTM1) on chromosome 5 and ALK was identified in one case. Two of 6 GCT (33%) showed gains of chromosome 7. No other molecular or chromosomal alterations were detected in NNGCT and GCT. ALK immunohistochemistry revealed weak-to-moderate positivity in 4/9 cutaneous NNCGT (44%) including all 3 tumors with ALK fusions. Three oral NNGCT lacked ALK expression. NNGCT with ALK immunostaining did not have morphologic features distinguishing them from those without ALK staining. Our results demonstrate that a subset of NNGCT harbor ALK fusions, suggest that NNGCT are molecularly diverse, and further substantiate NNGCT as distinct from GCT.	[Cohen, Jarish N.; Wolsky, Rebecca J.; Horvai, Andrew E.; McCalmont, Timothy H.; LeBoit, Philip E.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA; [Cohen, Jarish N.; Yeh, Iwei; Jordan, Richard C.; McCalmont, Timothy H.; LeBoit, Philip E.] Univ Calif San Francisco, Dept Dermatopathol, San Francisco, CA 94143 USA; [Jordan, Richard C.] Univ Calif San Francisco, Dept Orofacial Sci, San Francisco, CA 94143 USA; [Jordan, Richard C.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; [Jordan, Richard C.] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA; [Yeh, Iwei] Univ Calif San Francisco, Clin Canc Genom Lab, San Francisco, CA 94143 USA; [Yeh, Iwei; Jordan, Richard C.; McCalmont, Timothy H.; LeBoit, Philip E.] Univ Calif San Francisco, Helen Diller Canc Ctr, San Francisco, CA 94143 USA; [Wolsky, Rebecca J.] Zuckerberg San Francisco Gen Hosp, Dept Pathol, San Francisco, CA USA	LeBoit, PE (reprint author), 1701 Div St,Suit 280, San Francisco, CA 94115 USA.	philip.leboit@ucsf.edu		Yeh, Iwei/0000-0002-3941-3561			Agusti J, 2014, AM J DERMATOPATH, V36, pE84, DOI 10.1097/DAD.0b013e318296fe84; Al Habeeb A, 2009, J CLIN PATHOL, V62, P847, DOI 10.1136/jcp.2008.063453; Al Habeeb A, 2008, AM J DERMATOPATH, V30, P156, DOI 10.1097/DAD.0b013e318164101c; BARNHILL RL, 1990, AM J SURG PATHOL, V14, P113, DOI 10.1097/00000478-199002000-00002; Basile JR, 2003, ORAL SURG ORAL MED O, V96, P70, DOI 10.1016/S1079-2104(03)00097-0; Busam KJ, 2014, AM J SURG PATHOL, V38, P925, DOI 10.1097/PAS.0000000000000187; Chaudhry IH, 2005, HISTOPATHOLOGY, V47, P179, DOI 10.1111/j.1365-2559.2005.02192.x; Childers ELB, 2011, ANN DIAGN PATHOL, V15, P157, DOI 10.1016/j.anndiagpath.2010.10.003; d'Amore ESG, 2013, AM J SURG PATHOL, V37, P780, DOI 10.1097/PAS.0b013e318287791f; Deguchi Y, 2017, MOL CLIN ONCOL, V7, P351, DOI 10.3892/mco.2017.1324; Dickson BC, 2018, MODERN PATHOL, V31, P23; Doyle LA, 2015, MODERN PATHOL, V28, P904, DOI 10.1038/modpathol.2015.49; Epstein DS, 2007, J CUTAN PATHOL, V34, P405, DOI 10.1111/j.1600-0560.2006.00632.x; Fanburg-Smith JC, 1998, AM J SURG PATHOL, V22, P779, DOI 10.1097/00000478-199807000-00001; Feci Luca, 2014, Dermatol Pract Concept, V4, P59, DOI 10.5826/dpc.0402a12; FISHER ER, 1962, CANCER, V15, P936, DOI 10.1002/1097-0142(196209/10)15:5<936::AID-CNCR2820150509>3.0.CO;2-F; GOMEZ CS, 1994, HISTOPATHOLOGY, V24, P123, DOI 10.1111/j.1365-2559.1994.tb01290.x; Griewank KG, 2018, MODERN PATHOL, V31, P418, DOI 10.1038/modpathol.2017.146; Griewank KG, 2014, MODERN PATHOL, V27, P502, DOI 10.1038/modpathol.2013.168; Griffin CA, 1999, CANCER RES, V59, P2776; Jedrych J, 2015, BRIT J DERMATOL, V172, P1427, DOI 10.1111/bjd.13548; JONES EW, 1989, BRIT J DERMATOL, V120, P185; Kazakov DV, 2018, AM J DERMATOPATH, V40, P805, DOI 10.1097/DAD.0000000000001085; Lai K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188272; Lawrence B, 2000, AM J PATHOL, V157, P377, DOI 10.1016/S0002-9440(10)64550-6; Lazar AJF, 2005, AM J SURG PATHOL, V29, P927, DOI 10.1097/01.pas.0000157294.55796.d3; LEBOIT PE, 1991, AM J SURG PATHOL, V15, P48, DOI 10.1097/00000478-199101000-00006; Lerman M, 2007, ORAL SURG ORAL MED O, V103, P382, DOI 10.1016/j.tripleo.2006.06.052; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Lopez-Villaescusa MT, 2014, ACTAS DERMO-SIFILOGR, V105, P878, DOI 10.1016/j.ad.2014.03.001; MARTIN RW, 1990, ARCH DERMATOL, V126, P1051, DOI 10.1001/archderm.126.8.1051; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Mihic-Probst D, 2004, ANTICANCER RES, V24, P19; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Newton P, 2014, J CUTAN PATHOL, V41, P536, DOI 10.1111/cup.12336; Park SH, 2017, J DERMATOL, V44, pE280, DOI 10.1111/1346-8138.13960; Rabkin MS, 2012, AM J DERMATOPATH, V34, P766, DOI 10.1097/DAD.0b013e31825aa415; Ramaswamy PV, 2010, PEDIATR DERMATOL, V27, P209, DOI 10.1111/j.1525-1470.2010.01111.x; Rausch T, 2012, BIOINFORMATICS, V28, pI333, DOI 10.1093/bioinformatics/bts378; Rawal YB, 2017, HEAD NECK PATHOL, V11, P404, DOI 10.1007/s12105-016-0760-3; Ricci F, 2012, EUR J DERMATOL, V22, P574, DOI 10.1684/ejd.2012.1768; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Schrader KA, 2009, CLIN GENET, V75, P185, DOI 10.1111/j.1399-0004.2008.01100.x; Sheth S, 2011, MODERN PATHOL, V24, P343, DOI 10.1038/modpathol.2010.203; Sidwell RU, 2008, PEDIATR DERMATOL, V25, P341, DOI 10.1111/j.1525-1470.2008.00678.x; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Solomon LW, 2016, HEAD NECK PATHOL, V10, P367, DOI 10.1007/s12105-015-0673-6; Takeuchi K, 2011, HAEMATOL-HEMATOL J, V96, P464, DOI 10.3324/haematol.2010.033514; Talevich E, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004873; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Van der Auwera Geraldine A, 2013, Curr Protoc Bioinformatics, V43, DOI 10.1002/0471250953.bi1110s43; Wang AR, 1999, AM J SURG PATHOL, V23, P1401, DOI 10.1097/00000478-199911000-00011; Wang GY, 2017, PATHOLOGY, V49, P44, DOI 10.1016/j.pathol.2016.09.061; Wiesner T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4116; Wright NA, 2010, J CUTAN PATHOL, V37, P380, DOI 10.1111/j.1600-0560.2009.01297.x; Yang H, 2015, NAT PROTOC, V10, P1556, DOI 10.1038/nprot.2015.105; Ye K, 2009, BIOINFORMATICS, V25, P2865, DOI 10.1093/bioinformatics/btp394; Yeh I, 2015, AM J SURG PATHOL, V39, P581, DOI 10.1097/PAS.0000000000000387; Yeh I, 2009, J CUTAN PATHOL, V36, P46, DOI 10.1111/j.1600-0560.2008.01214.x	60	0	0	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	SEP	2018	42	9					1133	1142		10.1097/PAS.0000000000001122			10	Pathology; Surgery	Pathology; Surgery	GR3QM	WOS:000442509200002	30001233				2019-10-28	
J	Vos, S; Elias, SG; van der Groep, P; Smolders, YH; van Gils, CH; van Diest, PJ				Vos, Shoko; Elias, Sjoerd G.; van der Groep, Petra; Smolders, Yvonne H.; van Gils, Carla H.; van Diest, Paul J.			Comprehensive Proteomic Profiling-derived Immunohistochemistry-based Prediction Models for BRCA1 and BRCA2 Germline Mutation-related Breast Carcinomas	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						breast cancer; hereditary; BRCA1; BRCA2; immunohistochemistry	SPORADIC BREAST; ESTROGEN-RECEPTOR; OVARIAN-CANCER; INDIVIDUAL PROGNOSIS; DIAGNOSIS TRIPOD; RISK-ASSESSMENT; FAMILY-HISTORY; EXPRESSION; PATHOLOGY; PROMOTER	Heredity, mostly due to BRCA germline mutations, is involved in 5% to 10% of all breast cancer cases. Potential BRCA germline mutation carriers may be missed following the current eligibility criteria for BRCA genetic testing. The purpose of this study was to, therefore, develop an immunohistochemistry-based model to predict likelihood of underlying BRCA1 and BRCA2 germline mutations in unselected female breast cancer patients. The study group consisted of 100 BRCA1-related, 46 BRCA2-related, and 94 sporadic breast carcinomas. Tumor expression of 44 proteins involved in (BRCA-related) breast carcinogenesis was assessed by immunohistochemistry. A prediction model for BRCA-related versus non-BRCA-related breast cancer was developed using Lasso logistic regression analysis with cross-validation. The model was assessed for its discriminative value and clinical usefulness. The optimal prediction model included 14 predictors (age, cyclinD1, ER alpha, ER beta, FGFR2, FGFR3, FGFR4, GLUT1, IGFR, Ki67, mitotic activity index, MLH1, p120, and TOP2A), showed excellent discriminative performance (area under the receiving operating characteristic curve=0.943; 95% confidence interval=0.909-0.978), and reasonable calibration. To enhance possible implementation, we developed an alternative model only considering more widely available immunostains. This model included 15 predictors (age, BCL2, CK5/6, CK8/18, cyclinD1, E-cadherin, ER alpha, HER2, Ki67, mitotic activity index , MLH1, p16, PMS2, PR, and vimentin), and still showed very good discriminative performance (area under the receiving operating characteristic curve=0.853; 95% confidence interval=0.795-0.911). We present a well-applicable and accurate tool to predict which breast cancer patients may have an underlying BRCA germline mutation, largely consisting of immunohistochemical markers independent of clinical characteristics. This may improve identification of potential BRCA germline mutation carriers and optimize referral for germline mutation testing.	[Vos, Shoko; van der Groep, Petra; Smolders, Yvonne H.; van Diest, Paul J.] Univ Med Ctr Utrecht, Dept Pathol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands; [Elias, Sjoerd G.; van Gils, Carla H.] Univ Utrecht, Univ Med Ctr Utrecht, Dept Epidemiol, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands	Vos, S (reprint author), Univ Med Ctr Utrecht, Dept Pathol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	s.vos-4@umcutrecht.nl	Elias, Sjoerd G/E-6057-2011	Elias, Sjoerd G/0000-0003-3903-4024	Pink Ribbon Breast Cancer Foundation	Supported by an unrestricted educational grant from the Pink Ribbon Breast Cancer Foundation. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033; Armes JE, 1998, CANCER-AM CANCER SOC, V83, P2335, DOI 10.1002/(SICI)1097-0142(19981201)83:11<2335::AID-CNCR13>3.0.CO;2-N; Armes JE, 1999, CANCER RES, V59, P2011; Bane AL, 2009, BREAST CANCER RES TR, V117, P183, DOI 10.1007/s10549-008-0087-1; Biswas S, 2016, BREAST CANCER RES TR, V155, P375, DOI 10.1007/s10549-016-3686-2; Brohet RM, 2014, J MED GENET, V51, P98, DOI 10.1136/jmedgenet-2013-101974; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; Chen SN, 2007, J CLIN ONCOL, V25, P1329, DOI 10.1200/JCO.2006.09.1066; Cheon JY, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0121-3; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Collins GS, 2015, ANN INTERN MED, V162, P55, DOI 10.7326/M14-0697; Da Silva L, 2010, MODERN PATHOL, V23, pS46, DOI 10.1038/modpathol.2010.37; Daidone MG, 2002, J CLIN ONCOL, V20, P3752, DOI 10.1200/JCO.2002.99.116; Davies H, 2017, NAT MED, V23, P517, DOI 10.1038/nm.4292; Donders ART, 2006, J CLIN EPIDEMIOL, V59, P1087, DOI 10.1016/j.jclinepi.2006.01.014; Dworkin AM, 2009, FAM CANCER, V8, P339, DOI 10.1007/s10689-009-9240-1; Eccles DM, 2015, ANN ONCOL, V26, P2057, DOI 10.1093/annonc/mdv278; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050; Freneaux P, 2000, BRIT J CANCER, V83, P1318, DOI 10.1054/bjoc.2000.1438; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Hassanein M, 2013, PATHOBIOLOGY, V80, P219, DOI 10.1159/000339432; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Honrado E, 2005, J CLIN ONCOL, V23, P7503, DOI 10.1200/JCO.2005.01.3698; Honrado E, 2006, CRIT REV ONCOL HEMAT, V59, P27, DOI 10.1016/j.critrevonc.2006.01.006; Huang YQ, 2016, J CLIN ONCOL, V34, P2157, DOI 10.1200/JCO.2015.65.9128; Hudelist G, 2007, ENDOCR-RELAT CANCER, V14, P1053, DOI 10.1677/ERC-06-0075; JAAKKOLA S, 1993, INT J CANCER, V54, P378, DOI 10.1002/ijc.2910540305; Janssen KJM, 2010, J CLIN EPIDEMIOL, V63, P721, DOI 10.1016/j.jclinepi.2009.12.008; Kang E, 2012, BREAST CANCER RES TR, V134, P1189, DOI 10.1007/s10549-012-2022-8; Kang HH, 2006, BRIT J CANCER, V95, P914, DOI 10.1038/sj.bjc.6603358; Kleibl Z, 2016, BREAST, V28, P136, DOI 10.1016/j.breast.2016.05.006; Kuroso K, 2010, PATHOBIOLOGY, V77, P231, DOI 10.1159/000314346; Lakhani SR, 2005, CLIN CANCER RES, V11, P5175, DOI 10.1158/1078-0432.CCR-04-2424; Lakhani SR, 2002, J CLIN ONCOL, V20, P2310, DOI 10.1200/JCO.2002.09.023; Lakhani SR, 1998, JNCI-J NATL CANCER I, V90, P1138, DOI 10.1093/jnci/90.15.1138; Lakhani SR, 1997, LANCET, V349, P1505; Lancaster JM, 1996, NAT GENET, V13, P238, DOI 10.1038/ng0696-238; Li MX, 2016, GENE, V584, P26, DOI 10.1016/j.gene.2016.03.004; Lips EH, 2011, ANN ONCOL, V22, P870, DOI 10.1093/annonc/mdq468; Litwiniuk MM, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-100; Lynch BJ, 1998, HUM PATHOL, V29, P1140, DOI 10.1016/S0046-8177(98)90427-0; Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8; Mavaddat N, 2013, JNCI-J NATL CANCER I, V105, P812, DOI 10.1093/jnci/djt095; Mavaddat N, 2012, CANCER EPIDEM BIOMAR, V21, P134, DOI 10.1158/1055-9965.EPI-11-0775; Meijer D, 2008, ENDOCR-RELAT CANCER, V15, P101, DOI 10.1677/ERC-07-0080; Meinshausen N, 2007, COMPUT STAT DATA AN, V52, P374, DOI 10.1016/j.csda.2006.12.019; Miolo G, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-360; Moelans CB, 2010, MODERN PATHOL, V23, P1029, DOI 10.1038/modpathol.2010.84; Moons KGM, 2015, ANN INTERN MED, V162, pW1, DOI 10.7326/M14-0698; Osin P, 1998, EUR J CANCER, V34, P1683, DOI 10.1016/S0959-8049(98)00248-2; Osin P P, 1999, Breast Cancer Res, V1, P36, DOI 10.1186/bcr11; Palacios J, 2003, CLIN CANCER RES, V9, P3606; Palacios J, 2008, PATHOBIOLOGY, V75, P85, DOI 10.1159/000123846; Pavlou M, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h3868; Peng M, 2014, EMBO J, V33, P1698, DOI 10.15252/embj.201387530; Rezvan PH, 2015, BMC MED RES METHODOL, V15, DOI 10.1186/s12874-015-0074-2; Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761; Roy R, 2012, NAT REV CANCER, V12, P68, DOI 10.1038/nrc3181; Schmidt MK, 2009, EUR J CANCER, V45, P2376, DOI 10.1016/j.ejca.2009.03.008; Schwartz MD, 2004, J CLIN ONCOL, V22, P1823, DOI 10.1200/JCO.2004.04.086; Spurdle AB, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0474-y; Stuckey AR, 2015, AM J OBSTET GYNECOL, V213, P161, DOI 10.1016/j.ajog.2015.03.003; Tenhagen M, 2016, J MAMMARY GLAND BIOL, V21, P81, DOI 10.1007/s10911-016-9358-3; Tomlinson DC, 2012, INT J CANCER, V130, P2857, DOI 10.1002/ijc.26304; Turner NC, 2007, ONCOGENE, V26, P2126, DOI 10.1038/sj.onc.1210014; van Buuren S, 2011, J STAT SOFTW, V45, P1; van de Ven RAH, 2015, DIS MODEL MECH, V8, P373, DOI 10.1242/dmm.018648; van der Groep P, 2008, BREAST CANCER RES TR, V111, P475, DOI 10.1007/s10549-007-9817-z; van der Groep P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056055; van Roosmalen MS, 2004, AM J MED GENET A, V124A, P346, DOI 10.1002/ajmg.a.20374; VANDIEST PJ, 1992, HUM PATHOL, V23, P603, DOI 10.1016/0046-8177(92)90313-R; Varesco L, 2013, BREAST, V22, P1130, DOI 10.1016/j.breast.2013.07.053; Vleugel MM, 2005, J CLIN PATHOL, V58, P172, DOI 10.1136/jcp.2004.019885; Werner H, 2012, LANCET ONCOL, V13, pE537, DOI 10.1016/S1470-2045(12)70362-5; Wessels LFA, 2002, CANCER RES, V62, P7110; Winter C, 2016, ANN ONCOL, V27, P1532, DOI 10.1093/annonc/mdw209; Wozniak MB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125026; Zhang JX, 2013, LANCET ONCOL, V14, P1295, DOI 10.1016/S1470-2045(13)70491-1	80	0	0	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	SEP	2018	42	9					1262	1272		10.1097/PAS.0000000000001115			11	Pathology; Surgery	Pathology; Surgery	GR3QM	WOS:000442509200015	29979200				2019-10-28	
J	Allanson, BM; Low, TH; Clark, JR; Gupta, R				Allanson, Benjamin M.; Low, Tsu-Hui; Clark, Jonathan R.; Gupta, Ruta			Squamous Cell Carcinoma of the External Auditory Canal and Temporal Bone: An Update	HEAD & NECK PATHOLOGY			English	Article						External auditory canal; Middle ear; Macroscopic examination; Squamous cell carcinoma; Staging systems; Temporal bone	MIDDLE-EAR; CANCER; MEATUS; TUMORS; CT	Squamous cell carcinoma (SCC) is the most common primary malignancy to affect the temporal bone, including primary cutaneous SCC of the pinna, external auditory canal, middle and inner ear. This anatomically complex region generates complicated three-dimensional specimens that can be a challenge for macroscopic and microscopic pathologic assessment. A universally accepted staging classification for these malignancies is still to be established. A brief summary of the regional anatomy, etiology and epidemiology, presentation and diagnosis, radiologic assessment and treatment follows with a review of the pathologic assessment of the different types of specimens generated and an update on staging for SCC of the temporal bone.	[Allanson, Benjamin M.; Gupta, Ruta] Royal Prince Alfred Hosp, Dept Tissue Pathol & Diagnost Oncol, Bldg 94,Missenden Rd,Via John Hopkins Dr, Camperdown, NSW 2050, Australia; [Low, Tsu-Hui; Clark, Jonathan R.] Chris OBrien Lifehouse, Sydney Head & Neck Canc Inst, Head & Neck Surg, Sydney, NSW, Australia; [Clark, Jonathan R.; Gupta, Ruta] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia	Gupta, R (reprint author), Royal Prince Alfred Hosp, Dept Tissue Pathol & Diagnost Oncol, Bldg 94,Missenden Rd,Via John Hopkins Dr, Camperdown, NSW 2050, Australia.; Gupta, R (reprint author), Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia.	Ruta.Gupta@health.nsw.gov.au		Gupta, Ruta/0000-0003-2940-313X; Low, Tsu-Hui (Hubert)/0000-0001-8958-736X; Clark, Jonathan/0000-0003-1209-772X			Ahn JY, 2008, CLIN EXP OTORHINOLAR, V1, P139, DOI 10.3342/ceo.2008.1.3.139; ARRIAGA M, 1990, ANN OTO RHINOL LARYN, V99, P714, DOI 10.1177/000348949009900909; Brant JA, 2017, OTOL NEUROTOL, V38, P1153, DOI 10.1097/MAO.0000000000001491; Breau Randall L, 2002, Curr Oncol Rep, V4, P76, DOI 10.1007/s11912-002-0051-x; Califano JA, 2017, AJCC CANC STAGING MA, P171; Chao YK, 2014, ANN NY ACAD SCI, V1325, P1, DOI 10.1111/nyas.12516; El-Naggar A, 2017, WHO CLASSIFICATION H, P263; Fletcher C, 2013, DIAGNOSTIC HISTOPATH, P2127; Gillespie MB, 2001, ARCH OTOLARYNGOL, V127, P803; GOLDINGWOOD DG, 1989, J LARYNGOL OTOL, V103, P653, DOI 10.1017/S0022215100109624; Higgins TS, 2010, OTOL NEUROTOL, V31, P1473, DOI 10.1097/MAO.0b013e3181f7ab85; HIRAIDE F, 1983, ANN OTO RHINOL LARYN, V92, P290, DOI 10.1177/000348948309200315; Lo WC, 2008, LARYNGOSCOPE, V118, P2151, DOI 10.1097/MLG.0b013e3181839b8c; Mazzoni A, 2014, ACTA OTORHINOLARYNGO, V34, P129; McMonagle BA, 2006, OTOL NEUROTOL, V27, P903, DOI 10.1097/01.mao.0000224079.77849.5b; MICHAELS L, 1980, CLIN OTOLARYNGOL, V5, P235, DOI 10.1111/j.1365-2273.1980.tb01653.x; MICHAELS L, 1993, CLIN OTOLARYNGOL, V18, P257, DOI 10.1111/j.1365-2273.1993.tb00843.x; Moffat DA, 2005, LARYNGOSCOPE, V115, P341, DOI 10.1097/01.mlg.0000154744.71184.c7; Moody SA, 2000, AM J OTOL, V21, P582; Ong CK, 2008, CANCER IMAGING, V8, DOI 10.1102/1470-7330.2008.0031; Ouaz K, 2013, EUR ANN OTORHINOLARY, V130, P175, DOI 10.1016/j.anorl.2012.08.003; Rinaldo A, 2005, ACTA OTO-LARYNGOL, V125, P5, DOI 10.1080/00016480410018287; Shu MT, 2011, OTOL NEUROTOL, V32, pE24, DOI 10.1097/MAO.0b013e3181e711a0; Snell R., 2012, CLIN ANATOMY REGIONS; STELL PM, 1985, J LARYNGOL OTOL, V99, P847, DOI 10.1017/S0022215100097796; Thompson LDR, 2017, HEAD NECK PATHOL, V11, P78, DOI 10.1007/s12105-017-0790-5; Tsai ST, 1997, INT J CANCER, V71, P208; Ussmuller J, 2000, LARYNGO RHINO OTOL, V79, P21; Wang ZY, 2016, CLIN IMAG, V40, P1262, DOI 10.1016/j.clinimag.2016.08.020; Zanoletti E, 2010, ACTA OTO-LARYNGOL, V130, P913, DOI 10.3109/00016480903390152; Zhang T, 2013, EUR ARCH OTO-RHINO-L, V270, P1607, DOI 10.1007/s00405-012-2159-4	31	1	2	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	SEP	2018	12	3			SI		407	418		10.1007/s12105-018-0908-4			12	Pathology	Pathology	GP7WG	WOS:000441120700010	30069837	Green Published			2019-10-28	
J	Zhang, XF; Ko, HM; Torres, J; Panchal, HJ; Cai, ZJ; Wagner, M; Sands, BE; Colombel, JF; Cho, J; Taouli, B; Harpaz, N				Zhang, Xiaofei; Ko, Huaibin Mabel; Torres, Joana; Panchal, Hinaben J.; Cai, Zhenjian; Wagner, Mathilde; Sands, Bruce E.; Colombel, Jean-Frederic; Cho, Judy; Taouli, Bachir; Harpaz, Noam			Luminally polarized mural and vascular remodeling in ileal strictures of Crohn's disease	HUMAN PATHOLOGY			English	Article						Crohn's disease; Stricture; Vasculopathy; Muscularis mucosae; Digital morphometry; Type V collagen	INFLAMMATORY BOWEL DISEASES; INTESTINAL-FIBROSIS; NATURAL-HISTORY; STEM-CELLS; PATHOGENESIS; COLLAGEN; MECHANISM; COHORT	Intestinal stricture, a major complication of Crohn's disease (CD), results from fibromuscular remodeling and expansion of the intestinal wall. The corresponding microanatomical alterations have not been fully described, hindering progress toward understanding their pathogenesis and devising appropriate treatments. We used tissue-specific staining and quantitative digital histomorphometry for this purpose. Serial histologic sections from 37 surgically resected ileal strictures and adjacent nonstrictured controls from patients with CD were evaluated after staining for smooth muscle actin, collagen (Sirius red), and collagen types I, III, and V. Overall mural thickening in strictures was increased 2.2 +/- 0.2-fold compared with nonstrictured regions of the same specimens. The muscular layer most altered was the muscularis mucosae (MM). Compared with the internal and external layers of the muscularis propria, (MP) which were expanded 1.9 +/- 0.2- and 1.3 +/- 0.1-fold, respectively, the MM was expanded 17.7 +/- 2.6-fold, reflecting the combined effects of architectural disarray, an 11.6 +/- 1.4-fold increase smooth muscle content, and elaboration of pericellular type V collagen. In contrast, the architecture of the MP was preserved and pericellular collagen was virtually absent; rather, fibrosis in this layer was limited to expansion of the intramuscular septa by collagen types I and III. The muscular arteries and veins within the strictured submucosa frequently exhibited eccentric, luminally oriented adventitial mantles comprising hyperplastic myocytes and extracellular type V collagen. We conclude that the fibromuscular remodeling which results in CD-associated ileal strictures predominantly involves the MM and submucosal vasculature in a luminally polarized fashion and suggests that mucosal-based factors may contribute to stricture pathogenesis. (C) 2018 Elsevier Inc. All rights reserved.	[Zhang, Xiaofei; Ko, Huaibin Mabel; Cai, Zhenjian; Harpaz, Noam] Icahn Sch Med Mt Sinai, Dept Pathol, 1468 Madison Ave, New York, NY 10029 USA; [Ko, Huaibin Mabel; Torres, Joana; Sands, Bruce E.; Colombel, Jean-Frederic; Cho, Judy; Harpaz, Noam] Icahn Sch Med Mt Sinai, Dr Henry D Janowitz Div Gastroenterol, New York, NY 10029 USA; [Torres, Joana] Hosp Beatriz Angelo, Gastroenterol Div, Dept Surg, Loures, Portugal; [Panchal, Hinaben J.] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10065 USA; [Wagner, Mathilde] UPMC, Sorbonne Univ, Hop Pitie Salpetriere, AP HP,Dept Radiol, Paris, France; [Cho, Judy] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA; [Taouli, Bachir] Icahn Sch Med Mt Sinai, Dept Radiol, New York, NY 10029 USA	Harpaz, N (reprint author), Icahn Sch Med Mt Sinai, Dept Pathol, 1468 Madison Ave, New York, NY 10029 USA.	noam.harpaz@mountsinai.org	Sands, Bruce/R-7887-2019; Harpaz, Noam/L-3411-2017	Sands, Bruce/0000-0001-5762-5042; Ko, Huaibin Mabel/0000-0003-1062-2383; Harpaz, Noam/0000-0003-4923-2200; Panchal, Hina/0000-0001-6366-1672	Dr Sanford J. Grossman Trust for Integrative Studies in IBD; International Organization for the Study of IBD	This work was supported by the Dr Sanford J. Grossman Trust for Integrative Studies in IBD and by a grant from the International Organization for the Study of IBD.	Bettenworth D, 2017, DIGEST DIS, V35, P25, DOI 10.1159/000449079; Bettenworth D, 2016, INFLAMM BOWEL DIS, V22, P241, DOI 10.1097/MIB.0000000000000598; Buisson A, 2012, ALIMENT PHARM THER, V35, P625, DOI 10.1111/j.1365-2036.2012.05002.x; Burke JP, 2007, AM J GASTROENTEROL, V102, P439, DOI 10.1111/j.1572-0241.2006.01010.x; Chen WQ, 2017, J CROHNS COLITIS, V11, P92, DOI 10.1093/ecco-jcc/jjw126; Cosnes J, 2011, GASTROENTEROLOGY, V140, P1785, DOI 10.1053/j.gastro.2011.01.055; Funayama Y, 1999, DIGEST DIS SCI, V44, P2319, DOI 10.1023/A:1026677325411; Graham M F, 1995, Inflamm Bowel Dis, V1, P220, DOI 10.1002/ibd.3780010309; GRAHAM MF, 1988, GASTROENTEROLOGY, V94, P257, DOI 10.1016/0016-5085(88)90411-8; GRAHAM MF, 1987, GASTROENTEROLOGY, V92, P400, DOI 10.1016/0016-5085(87)90134-X; Hatoum OA, 2005, INFLAMM BOWEL DIS, V11, P304, DOI 10.1097/01.MIB.0000160772.78951.61; Koukoulis G, 2001, ARCH PATHOL LAB MED, V125, P1331; Kugathasan S, 2017, LANCET, V389, P1710, DOI 10.1016/S0140-6736(17)30317-3; LEE EY, 1991, MODERN PATHOL, V4, P87; Mak KM, 2016, ANAT REC, V299, P613, DOI 10.1002/ar.23330; Patil DT, 2016, AM J SURG PATHOL, V40, P1316, DOI 10.1097/PAS.0000000000000710; Peyrin-Biroulet L, 2012, AM J GASTROENTEROL, V107, P1693, DOI 10.1038/ajg.2012.298; Randolph GJ, 2016, AM J PATHOL, V186, P3066, DOI 10.1016/j.ajpath.2016.07.026; Rieder F, 2017, GASTROENTEROLOGY, V152, P340, DOI 10.1053/j.gastro.2016.09.047; Rieder F, 2013, GUT, V62, P1072, DOI 10.1136/gutjnl-2012-304353; Rieder F, 2011, AM J PATHOL, V179, P2660, DOI 10.1016/j.ajpath.2011.07.042; Severi C, 2014, EUR J HISTOCHEM, V58, P307, DOI 10.4081/ejh.2014.2457; van Haaften WT, 2017, ALIMENT PHARM THER, V46, P26, DOI 10.1111/apt.14092; WAKEFIELD AJ, 1989, LANCET, V2, P1057; WAKEFIELD AJ, 1991, GASTROENTEROLOGY, V100, P1279; Worsdorfer P, 2017, PHARMACOL THERAPEUT, V171, P13, DOI 10.1016/j.pharmthera.2016.07.017; Wong SP, 2015, PHARMACOL THERAPEUT, V151, P107, DOI 10.1016/j.pharmthera.2015.03.006; Yamamoto T, 2005, WORLD J GASTROENTERO, V11, P3971, DOI 10.3748/wjg.v11.i26.3971	28	0	0	1	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	SEP	2018	79						42	49		10.1016/j.humpath.2018.03.004			8	Pathology	Pathology	GU3HT	WOS:000445167900004	29555578				2019-10-28	
J	Chen, T; Li, Q; Zhang, XY; Long, R; Wu, YX; Wu, J; Fu, XS				Chen, Ting; Li, Qing; Zhang, Xiaoyan; Long, Ran; Wu, Yaxin; Wu, Jiao; Fu, Xiangsheng			TOX expression decreases with progression of colorectal cancers and is associated with CD4 T-cell density and Fusobacterium nucleatum infection	HUMAN PATHOLOGY			English	Article						Antitumor; Colorectal cancer; Fusobacterium nucleatum; T cells; TOX	COLON SERRATED POLYPS; GENE; MICROBIOTA; CARCINOMA; LYMPHOMA; THERAPY; PATHWAY; SYSTEM; TUMORS; RISK	Fusobacterium nucleatum in the tumor microenvironment plays an important role in the development of colorectal cancer. The underlying mechanism of action, however, remains to be elucidated. We evaluated the relation of F nucleatum amount to thymocyte selection-associated high-mobility group box (TOX) protein expression and CD4(+) T-cell density in 138 human colorectal tissues. TOX expression and CD4(+) T-cell density in F nucleatum-negative tissues were significantly higher compared to those in F nucleatum-positive tissues (P < .001 and P = .002, respectively). We found a negative correlation between F nucleatum abundance and TOX expression (P < .001) and CD4(+) T-cell density (P < .001). TOX expression in normal mucosa, hyperplastic polyps, and adenomas was significantly higher than in sessile serrated adenomas and different stages of carcinomas (P < .05). Moreover, CD4(+) T-cell density in high-TOX expression tissues was significantly higher than in low-TOX expression tissues (P = .003). A positive correlation was found between TOX expression and CD4(+) T-cell density in colorectal tissues (Spearman correlation coefficient: 0.362, 95% confidence interval: 0.051-0.641, P = .022). Our findings suggest that F nucleatum may suppress antitumor immune responses by decreasing CD4(+) T-cell density and TOX expression in the progression of colorectal cancer. (C) 2018 Elsevier Inc. All rights reserved.	[Chen, Ting; Li, Qing; Wu, Yaxin; Wu, Jiao; Fu, Xiangsheng] Southwest Med Univ, Affiliated Hosp, Dept Gastroenterol, Luzhou 646000, Sichuan, Peoples R China; [Zhang, Xiaoyan] Southwest Med Univ, Affiliated Hosp, Dept Dermatol, Luzhou 646000, Sichuan, Peoples R China; [Long, Ran] Southwest Med Univ, Affiliated Hosp, Dept Med Imaging, Luzhou 646000, Sichuan, Peoples R China; [Fu, Xiangsheng] North Sichuan Med Coll, Affiliated Hosp, Dept Gastroenterol, Rd Wenhua 63, Nanchong City 637000, Sichuan, Peoples R China	Fu, XS (reprint author), North Sichuan Med Coll, Affiliated Hosp, Dept Gastroenterol, Rd Wenhua 63, Nanchong City 637000, Sichuan, Peoples R China.	drfuxs@gmail.com	Fu, Xiangsheng/H-9411-2019		Natural Science Foundation of Sichuan Science and Technology Agency, Chengdu City, China [201565]	This work was supported by Natural Science Foundation of Sichuan Science and Technology Agency, Chengdu City, China, under Award No. 201565.	Aliahmad P, 2008, J EXP MED, V205, P245, DOI 10.1084/jem.20071944; Aliahmad P, 2012, CURR OPIN IMMUNOL, V24, P173, DOI 10.1016/j.coi.2011.12.001; Aliahmad P, 2011, J IMMUNOL, V187, P5931, DOI 10.4049/jimmunol.1101474; Braggio E, 2011, CLIN CANCER RES, V17, P4245, DOI 10.1158/1078-0432.CCR-11-0395; Carter JH, 2004, CLIN CANCER RES, V10, P3448, DOI 10.1158/1078-0432.CCR-03-0210; Chen YY, 2017, ONCOTARGET, V8, P31705, DOI 10.18632/oncotarget.15992; Cowper-Sal-lari R, 2012, NAT GENET, V44, P1191, DOI 10.1038/ng.2416; Fu XS, 2014, INT J CLIN EXP PATHO, V7, P7319; Galon J, 2014, J PATHOL, V232, P199, DOI 10.1002/path.4287; Gur C, 2015, IMMUNITY, V42, P344, DOI 10.1016/j.immuni.2015.01.010; Huang YS, 2015, BLOOD, V125, P1435, DOI 10.1182/blood-2014-05-571778; Jobin C, 2013, CANCER DISCOV, V3, P384, DOI 10.1158/2159-8290.CD-13-0042; Kaplan CW, 2010, INFECT IMMUN, V78, P4773, DOI 10.1128/IAI.00567-10; Kostic AD, 2013, CELL HOST MICROBE, V14, P207, DOI 10.1016/j.chom.2013.07.007; Kostic AD, 2012, GENOME RES, V22, P292, DOI 10.1101/gr.126573.111; Li L, 2013, HUM PATHOL, V44, P1079, DOI 10.1016/j.humpath.2012.09.013; Louis P, 2014, NAT REV MICROBIOL, V12, P661, DOI 10.1038/nrmicro3344; Loy A, 2008, ENVIRON MICROBIOL, V10, P2894, DOI 10.1111/j.1462-2920.2008.01706.x; Lu FI, 2010, AM J SURG PATHOL, V34, P927, DOI 10.1097/PAS.0b013e3181e4f256; Mima K, 2016, GUT, V65, P1973, DOI 10.1136/gutjnl-2015-310101; Mima K, 2015, JAMA ONCOL, V1, P653, DOI 10.1001/jamaoncol.2015.1377; Morimura S, 2014, ARCH DERMATOL RES, V306, P843, DOI 10.1007/s00403-014-1501-7; Safavi S, 2015, HAEMATOLOGICA, V100, P55, DOI 10.3324/haematol.2014.112912; Sears CL, 2014, CELL HOST MICROBE, V15, P317, DOI 10.1016/j.chom.2014.02.007; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Tahara T, 2014, CANCER RES, V74, P1311, DOI 10.1158/0008-5472.CAN-13-1865; Tessema M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034850; Vong QP, 2014, BLOOD, V124, P3905, DOI 10.1182/blood-2014-06-582965; Yu JH, 2016, INT J CANCER, V139, P1318, DOI 10.1002/ijc.30168; Yu X, 2015, AM J CANCER RES, V5, P3516	30	6	6	2	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	SEP	2018	79						93	101		10.1016/j.humpath.2018.05.008			9	Pathology	Pathology	GU3HT	WOS:000445167900010	29792893				2019-10-28	
J	Lang-Schwarz, C; Melcher, B; Haumaier, F; Lang-Schwarz, K; Rupprecht, T; Vieth, M; Sterlacci, W				Lang-Schwarz, Corinna; Melcher, Balint; Haumaier, Franziska; Lang-Schwarz, Klaus; Rupprecht, Thomas; Vieth, Michael; Sterlacci, William			Budding and tumor-infiltrating lymphocytes - combination of both parameters predicts survival in colorectal cancer and leads to new prognostic subgroups	HUMAN PATHOLOGY			English	Article						Budding; Tumor-infiltrating lymphocytes (TILs); Colorectal cancer; Prognosis; Subgroups	PEMBROLIZUMAB; INFLAMMATION; METASTASIS; RECURRENCE; CARCINOMA; RESECTION; MELANOMA; IMPACT; INDEX	Tumor budding is an independent prognostic factor in colorectal cancer (CRC) and has recently been well defined by the International Concensus Conference on Tumor Budding (ITBCC). Tumor-infiltrating lymphocytes (TILs) are also an issue in different human cancers and correlate with prognosis in CRC. Here we evaluate the combination of budding and TILs in CRC with regard to prognosis. Hematoxylin and eosin (H&E)-stained slides of 501 CRC patients, diagnosed between 2005 and 2010, were reevaluated for tumor budding according to the ITBCC criteria. Low (n = 331) was compared to intermediate/high budding (n = 170). The percentage of TILs was also assessed, and the following four groups were established: low budding + TILs <= 5% (n = 162), low budding + TILS <= 5% (n = 169), high budding + TILS >5% (n = 68), high budding + TILs <= 5% (n = 93). The combination of both markers revealed highly significant differences in overall survival (OS) between the four groups (P = .001). The low budding/>5% TILs group showed longest OS, followed by high budding/>5% TILs cases, followed by tumors with low budding/<= 5% TILs. OS was worst for the high budding/<= 5% TILs group. The combined score also correlated with T, N, M, L, V staging, development of disease relapse and distant metastasis. Our study shows that - even in the age of molecular pathology - it is still important to pay special attention to tumor morphology for additional information on tumor behavior and prognosis. Combining different morphological parameters of tumor and tumor environment can help to further subdivide CRC into new prognostic groups. (C) 2018 Elsevier Inc. All rights reserved.	[Lang-Schwarz, Corinna; Melcher, Balint; Haumaier, Franziska; Vieth, Michael; Sterlacci, William] Klinikum Bayreuth, Inst Pathol, D-95445 Bayreuth, Germany; [Lang-Schwarz, Klaus] Klinikum Bayreuth, Dept Anesthesiol, D-95445 Bayreuth, Germany; [Rupprecht, Thomas] Klinikum Bayreuth, Childrens Clin, D-95445 Bayreuth, Germany	Lang-Schwarz, C (reprint author), Klinikum Bayreuth, Inst Pathol, D-95445 Bayreuth, Germany.	Corinna.Lang-Schwarz@klinikum-bayreuth.de					Ali AA, 2004, EJSO-EUR J SURG ONC, V30, P292, DOI 10.1016/j.ejso.2003.11.018; Compton CC, 2012, PATHOLOGY PROGNOSTIC; Eriksen AC, 2017, DIAGN PATHOL, V12, DOI 10.1186/s13000-017-0653-0; Hamilton SR, 2010, WHO CLASSIFICATION T, P138; HASE K, 1993, DIS COLON RECTUM, V36, P627, DOI 10.1007/BF02238588; Hendry S, 2017, ADV ANAT PATHOL, V24, P311, DOI 10.1097/PAP.0000000000000161; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Huh JW, 2012, ARCH SURG-CHICAGO, V147, P366, DOI 10.1001/archsurg.2012.35; JASS JR, 1986, HISTOPATHOLOGY, V10, P437, DOI 10.1111/j.1365-2559.1986.tb02497.x; Kanazawa H, 2008, COLORECTAL DIS, V10, P41, DOI 10.1111/j.1463-1318.2007.01240.x; Kazama S, 2006, BRIT J CANCER, V94, P293, DOI 10.1038/sj.bjc.6602927; Klintrup K, 2005, EUR J CANCER, V41, P2645, DOI 10.1016/j.ejca.2005.07.017; Lee WS, 2010, CANCER-AM CANCER SOC, V116, P5188, DOI 10.1002/cncr.25293; Lugli A, 2012, BRIT J CANCER, V106, P1713, DOI 10.1038/bjc.2012.127; Lugli A, 2009, BRIT J CANCER, V101, P1382, DOI 10.1038/sj.bjc.6605318; Lugli A, 2017, MODERN PATHOL, V30, P1299, DOI 10.1038/modpathol.2017.46; Mei Z, 2014, BRIT J CANCER, V110, P1595, DOI 10.1038/bjc.2014.46; Mitrovic B, 2012, MODERN PATHOL, V25, P1315, DOI 10.1038/modpathol.2012.94; Nagtegaal ID, 2015, CURR COLORECT CANC R, V11, P259, DOI 10.1007/s11888-015-0280-7; Neumann JHL, 2015, PATHOLOGE, V36, P137, DOI 10.1007/s00292-015-0005-3; Ogino S, 2009, CLIN CANCER RES, V15, P6412, DOI 10.1158/1078-0432.CCR-09-1438; Pages F, 2005, NEW ENGL J MED, V353, P2654, DOI 10.1056/NEJMoa051424; Pox CP, 2013, DEUT MED WOCHENSCHR, V138, P2545, DOI 10.1055/s-0033-1353953; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Rogers AC, 2016, BRIT J CANCER, V115, P831, DOI 10.1038/bjc.2016.274; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; Schachter J, 2017, LANCET, V390, P1853, DOI 10.1016/S0140-6736(17)31601-X; Tzankov A, 2010, LEUKEMIA LYMPHOMA, V51, P199, DOI 10.3109/10428190903370338; Ueno H, 2004, GASTROENTEROLOGY, V127, P385, DOI 10.1053/S0016-5085(04)00717-6; Ueno H, 2002, HISTOPATHOLOGY, V40, P127, DOI 10.1046/j.1365-2559.2002.01324.x; Ueno H, 2004, BRIT J SURG, V91, P327, DOI 10.1002/bjs.4429; van Wyk HC, 2015, CANCER TREAT REV, V41, P151, DOI 10.1016/j.ctrv.2014.12.007; Wang LM, 2009, AM J SURG PATHOL, V33, P134, DOI 10.1097/PAS.0b013e318184cd55	33	4	5	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	SEP	2018	79						160	167		10.1016/j.humpath.2018.05.010			8	Pathology	Pathology	GU3HT	WOS:000445167900019	29787819				2019-10-28	
J	Rakaee, M; Kilvaer, TK; Dalen, SM; Richardsen, E; Paulsen, EE; Hald, SM; Al-Saad, S; Andersen, S; Donnem, T; Bremnes, RM; Busund, LT				Rakaee, Mehrdad; Kilvaer, Thomas K.; Dalen, Stig Manfred; Richardsen, Elin; Paulsen, Erna-Elise; Hald, Sigurd M.; Al-Saad, Samer; Andersen, Sigve; Donnem, Tom; Bremnes, Roy M.; Busund, Lill-Tove			Evaluation of tumor-infiltrating lymphocytes using routine H&E slides predicts patient survival in resected non-small cell lung cancer	HUMAN PATHOLOGY			English	Article						TILs; Tumor-infiltrating lymphocytes; NSCLC; Prognosis; Lung cancer; Immunoscore	TNM STAGE GROUPINGS; CLASSIFICATION; RECOMMENDATIONS; IMMUNOSCORE; DENSITY; RECURRENCE; PROPOSALS; PROGNOSIS; REVISION; EDITION	The presence of tumor-infiltrating lymphocytes (TILs) positively impacts the outcome of non- small cell lung cancer (NSCLC) patients. Most previous studies have assessed TILs using different immunohistochemical assays. The purpose of this study was to develop and validate a histopathological scoring model for the assessment of TILs in whole-tissue hematoxylin and eosin (H&E)-stained section slides of NSCLC patients and to evaluate the model in an immunoscore setting. Therefore, TIL was evaluated manually on H&E slides from 537 surgical specimens of primary resected stage I-III NSCLC patients. Using stromal TIL score as a stepwise discrete variable, increasing survival was seen with rising TIL level: disease-specific survival (DSS; P = .008), overall survival (P = .036) and disease-free survival (P = .006). Subgroup analysis revealed that high stromal TILs level was associated with superior DSS (P = .047) in patients with squamous cell carcinoma, but not in patients with adenocarcinoma. Multivariable analysis confirmed that high TIL levels independently predict improved prognosis for all endpoints in the overall cohort. In conclusion, high stromal TIL level is an independent favorable prognostic factor in stage NSCLC patients. The comprehensive histological evaluation conducted in this study may be helpful in streamlining TIL quantification for routine clinical use in a future NSCLC immunoscore setting. (C) 2018 Elsevier Inc. All rights reserved.	[Rakaee, Mehrdad; Richardsen, Elin; Al-Saad, Samer; Busund, Lill-Tove] UiT Arctic Univ Norway, Dept Med Biol, N-9019 Tromso, Norway; [Kilvaer, Thomas K.; Paulsen, Erna-Elise; Andersen, Sigve; Donnem, Tom; Bremnes, Roy M.] Univ Hosp North Norway, Dept Oncol, N-9019 Tromso, Norway; [Kilvaer, Thomas K.; Paulsen, Erna-Elise; Hald, Sigurd M.; Andersen, Sigve; Donnem, Tom; Bremnes, Roy M.] UiT Arctic Univ Norway, Dept Clin Med, N-9019 Tromso, Norway; [Dalen, Stig Manfred; Richardsen, Elin; Al-Saad, Samer; Busund, Lill-Tove] Univ Hosp North Norway, Dept Clin Pathol, N-9019 Tromso, Norway	Rakaee, M (reprint author), UiT Arctic Univ Norway, Dept Med Biol, Translat Canc Res Grp, N-9019 Tromso, Norway.	Mehrdad.r.khanehkenari@uit.no; kilvaer@gmail.com; Stig.Manfred.dalen@unn.no; elin.richardsen@unn.no; epa014@post.uit.no; sigurd.hald@uit.no; samer.al-saad@unn.no; sigve.andersen@uit.no; tom.donnem@uit.no; roy.bremnes@uit.no; lill.tove.busund@unn.no			North Norwegian Health Authority; Norwegian Cancer SocietyNorwegian Cancer Society	The authors would like to thank the North Norwegian Health Authority and the Norwegian Cancer Society for supporting the research.	Al-Shibli KI, 2008, CLIN CANCER RES, V14, P5220, DOI 10.1158/1078-0432.CCR-08-0133; Brambilla E, 2016, J CLIN ONCOL, V34, P1223, DOI 10.1200/JCO.2015.63.0970; Bremnes RM, 2016, J THORAC ONCOL, V11, P789, DOI 10.1016/j.jtho.2016.01.015; Denkert C, 2010, J CLIN ONCOL, V28, P105, DOI 10.1200/JCO.2009.23.7370; Dieci MV, 2018, SEMIN CANCER BIOL, V52, P16, DOI 10.1016/j.semcancer.2017.10.003; Dieu-Nosjean MC, 2008, J CLIN ONCOL, V26, P4410, DOI 10.1200/JCO.2007.15.0284; Dieu-Nosjean MC, 2014, TRENDS IMMUNOL, V35, P571, DOI 10.1016/j.it.2014.09.006; Donnem T, 2016, ANN ONCOL, V27, P226, DOI 10.1093/annonc/mdv560; Donnem T, 2015, CLIN CANCER RES, V21, P2635, DOI 10.1158/1078-0432.CCR-14-1905; Eerola AK, 2000, CLIN CANCER RES, V6, P1875; Feng W, 2016, ONCOTARGET, V7, P7227, DOI 10.18632/oncotarget.6979; Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245; Galon J, 2014, J PATHOL, V232, P199, DOI 10.1002/path.4287; Goldstraw P, 2007, J THORAC ONCOL, V2, P706, DOI 10.1097/JTO.0b013e31812f3c1a; Goldstraw P, 2016, J THORAC ONCOL, V11, P39, DOI 10.1016/j.jtho.2015.09.009; Halama N, 2011, CANCER RES, V71, P5670, DOI 10.1158/0008-5472.CAN-11-0268; Hald SM, 2017, CLIN LUNG CANCER, DOI [10.1016/j.clIc.2017.12.001, DOI 10.1016/J.CLIC.2017.12.001]; Horne ZD, 2011, J SURG RES, V171, P1, DOI 10.1016/j.jss.2011.03.068; Huh JW, 2012, ARCH SURG-CHICAGO, V147, P366, DOI 10.1001/archsurg.2012.35; Jiang DX, 2017, SCI REP-UK, V7, DOI 10.1038/srep44823; Kilic A, 2011, J SURG RES, V167, P207, DOI 10.1016/j.jss.2009.08.029; McShane LM, 2006, BREAST CANCER RES TR, V100, P229, DOI 10.1007/s10549-006-9242-8; Pages F, 2009, J CLIN ONCOL, V27, P5944, DOI 10.1200/JCO.2008.19.6147; Park HS, 2016, J SURG ONCOL, V114, P17, DOI 10.1002/jso.24275; Paulsen EE, 2017, CANCER IMMUNOL IMMUN, V66, P1449, DOI 10.1007/s00262-017-2039-2; Paulsen EE, 2017, CLIN LUNG CANCER, V18, P220, DOI 10.1016/j.cllc.2016.09.009; Paulsen EE, 2015, NEOPLASIA, V17, P839, DOI 10.1016/j.neo.2015.11.004; Rakaee M, 2016, ONCOTARGET, V7, P72184, DOI 10.18632/oncotarget.12360; Ruffini E, 2009, ANN THORAC SURG, V87, P365, DOI 10.1016/j.athoracsur.2008.10.067; Saied A, 2014, J SURG RES, V187, P525, DOI 10.1016/j.jss.2013.12.018; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; Savas P, 2016, NAT REV CLIN ONCOL, V13, P228, DOI 10.1038/nrclinonc.2015.215; Schalper KA, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju435; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630	34	5	5	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	SEP	2018	79						188	198		10.1016/j.humpath.2018.05.017			11	Pathology	Pathology	GU3HT	WOS:000445167900023	29885403				2019-10-28	
J	Fujiki, R; Ikeda, M; Yoshida, A; Akiko, M; Yao, Y; Nishimura, M; Matsushita, K; Ichikawa, T; Tanaka, T; Morisaki, H; Morisaki, T; Ohara, O				Fujiki, Ryoji; Ikeda, Makoto; Yoshida, Akiko; Akiko, Maeda; Yao, Yue; Nishimura, Motio; Matsushita, Kazuyuki; Ichikawa, Tomohiko; Tanaka, Tomoaki; Morisaki, Hiroko; Morisaki, Takayuki; Ohara, Osamu			Assessing the Accuracy of Variant Detection in Cost-Effective Gene Panel Testing by Next-Generation Sequencing	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							LABORATORY STANDARDS; EXOME; COLLEGE; DNA	There is significant debate within the diagnostics community regarding the accuracy of variant identification by next-generation sequencing and the necessity of confirmatory testing of detected variants. Because the quality threshold to discriminate fake positives depends on the workflow, no regulatory standard regarding this matter has yet been published. The goal of this study was to empirically determine the threshold to perform additional Sanger sequencing and to reduce the experimental cost to a practical level. Using 278 model genes, a hybridization capture based protocol was examined to meet the clinical requirements of Low cost, high efficiency, and high-quality data. To reduce excessive false-positive detection, filtering processes were introduced to remove mismapped reads and strand biased detection to a published best-practices pipeline. With seven samples from the 1000 Genomes Project, 2750 single-nucleotide polymorphisms and 142 insertions/deletions were identified by our designed workflow. Compared with variants registered in the single nucleotide polymorphism database (dbSNP), a zero false-positive threshold value was determined (quality score > 1000). The variants satisfying these criteria accounted for 95.6% of single-nucleotide polymorphisms and 50.7% of insertions/deletions. Except for deletions located within the highly repeated sequences, the workflow achieved 100% sensitivity. The established threshold allowed us to discriminate between convincing variants and those requiring validation, a design that reconciles the competing objectives of cost minimization and quality maximization of clinical gene panel testing.	[Fujiki, Ryoji; Ohara, Osamu] Kazusa DNA Res Inst, Dev Technol Dept, Chiba, Japan; [Ikeda, Makoto] Percipere LLC, Tokyo, Japan; [Yoshida, Akiko; Akiko, Maeda] RIKEN, Ctr Dev Biol, Retinal Regenerat Lab, Kobe, Hyogo, Japan; [Yoshida, Akiko; Akiko, Maeda] Inst Biomed Res & Innovat Hosp, Dept Ophthalmol, Kobe, Hyogo, Japan; [Akiko, Maeda] Case Western Reserve Univ, Dept Ophthalmol & Visual Sci, Cleveland, OH 44106 USA; [Yao, Yue; Tanaka, Tomoaki] Chiba Univ, Grad Sch Med, Dept Mol Diag, Chiba, Japan; [Nishimura, Motio; Matsushita, Kazuyuki; Ichikawa, Tomohiko; Tanaka, Tomoaki] Chiba Univ Hosp, Div Clin Genet, Chiba, Japan; [Morisaki, Hiroko] Sakakibara Heart Inst, Dept Med Genet, Tokyo, Japan; [Morisaki, Takayuki] Tokyo Univ Technol, Sch Hlth Sci, Tokyo, Japan	Fujiki, R (reprint author), Kazusa DNA Res Inst, 2-6-7 Kazusa Kamatari, Kisarazu City, Chiba 2920818, Japan.	fujiki@kazusa.or.jp	Ohara, Osamu/G-5448-2015	Ohara, Osamu/0000-0002-3328-9571; Matsushita, Kazuyuki/0000-0001-6742-0761; Tanaka, Tomoaki/0000-0002-9761-1750	Kazusa DNA Research Institute Foundation; Japan Agency for Medical Research and Development (AMED)Japan Agency for Medical Research and Development (AMED) [JP17ek0109276]	Supported by The Kazusa DNA Research Institute Foundation and the Japan Agency for Medical Research and Development (AMED) JP17ek0109276 (Toshiyuki Fukao, principal investigator).	Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; Aziz N, 2015, ARCH PATHOL LAB MED, V139, P481, DOI 10.5858/arpa.2014-0250-CP; Bamshad MJ, 2011, NAT REV GENET, V12, P745, DOI 10.1038/nrg3031; Baudhuin LM, 2015, J MOL DIAGN, V17, P456, DOI 10.1016/j.jmoldx.2015.03.004; Browne S, 2003, MOL VIS, V9, P129; Chung J, 2016, SCI REP-UK, V6, DOI 10.1038/srep26732; Consugar MB, 2015, GENET MED, V17, P253, DOI 10.1038/gim.2014.172; Gonzaga-Jauregui C, 2012, ANNU REV MED, V63, P35, DOI 10.1146/annurev-med-051010-162644; Gullapalli Rama R, 2012, J Pathol Inform, V3, P40, DOI 10.4103/2153-3539.103013; Jamuar SS, 2015, HUM GENOMICS, V9, DOI 10.1186/s40246-015-0031-5; Kalia SS, 2017, GENET MED, V19, P249, DOI 10.1038/gim.2016.190; Knierim E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028240; Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111; Koboldt DC, 2013, CURR PROTOC BIOINFOR, V44; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Matthijs G, 2016, EUR J HUM GENET, V24, P2, DOI 10.1038/ejhg.2015.226; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Metzker ML, 2010, NAT REV, V11, P31, DOI [DOI 10.1038/NRG2626, 10.1038/nrg2626]; Meyts I, 2016, J ALLERGY CLIN IMMUN, V138, P957, DOI 10.1016/j.jaci.2016.08.003; Mu WB, 2016, J MOL DIAGN, V18, P923, DOI 10.1016/j.jmoldx.2016.07.006; Rehm HL, 2013, GENET MED, V15, P733, DOI 10.1038/gim.2013.92; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Strom SP, 2014, GENET MED, V16, P510, DOI 10.1038/gim.2013.183; Van der Auwera GA, 2013, CURR PROTOC BIOINFOR, V43; Wang J, 2014, INVEST OPHTH VIS SCI, V55, P6213, DOI 10.1167/iovs.14-14936; Yubero D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156359	27	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	SEP	2018	20	5					572	582		10.1016/j.jmoldx.2018.04.004			11	Pathology	Pathology	GS8AR	WOS:000443929200002	29953964				2019-10-28	
J	de Jonge, MM; Ruano, D; van Eijk, R; van der Stoep, N; Nielsen, M; Wijnen, JT; ter Haar, NT; Baalbergen, A; Bos, MEMM; Kagie, MJ; Vreeswijk, MPG; Gaarenstroom, KN; Kroep, JR; Smit, VTHBM; Bosse, T; van Wezel, T; van Asperen, CJ				de Jonge, Marthe M.; Ruano, Dina; van Eijk, Ronald; van der Stoep, Nienke; Nielsen, Maartje; Wijnen, Juul T.; ter Haar, Natalja T.; Baalbergen, Astrid; Bos, Monique E. M. M.; Kagie, Marjolein J.; Vreeswijk, Maaike P. G.; Gaarenstroom, Katja N.; Kroep, Judith R.; Smit, Vincent T. H. B. M.; Bosse, Tjalling; van Wezel, Tom; van Asperen, Christi J.			Validation and Implementation of BRCA1/2 Variant Screening in Ovarian Tumor Tissue	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							MAINTENANCE THERAPY; PHASE-2 TRIAL; INHERITED MUTATIONS; FOUNDER MUTATIONS; SOMATIC MUTATION; CANCER PATIENTS; DOUBLE-BLIND; BREAST; HYPERMETHYLATION; PERFORMANCE	BRCA1/2 variant analysis in tumor tissue could streamline the referral of patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer to genetic counselors and select patients who benefit most from targeted treatment. We investigated the sensitivity of BRCA1/2 variant analysis in formalin-fixed, paraffin-embedded tumor tissue using a combination of next-generation sequencing and copy number variant multiplex ligation-dependent probe amplification. After optimization using a training cohort of known BRCA1/2 mutation carriers, validation was performed in a prospective cohort in which screening of BRCA1/2 tumor DNA and leukocyte germline DNA was performed in parallel. BRCA1 promoter hypermethylation and pedigree analysis were also performed. In the training cohort, 45 of 46 germline BRCA1/2 variants were detected (sensitivity, 98%). In the prospective cohort (n = 62), all six germline variants were identified (sensitivity, 100%), together with five somatic BRCA1/2 variants and eight cases with BRCA1 promoter hypermethylation. In four BRCA1/2 variant negative patients, surveillance or prophylactic management options were offered on the basis of positive family histories. We conclude that BRCA1/2 formalin-fixed, paraffin-embedded tumor tissue analysis reliably detects BRCA1/2 variants. When taking family history of BRCA1/2 variant negative patients into account, tumor BRCA1/2 variant screening allows more efficient selection of epithelial ovarian cancer patients for genetic counseling and simultaneously selects patients who benefit most from targeted treatment.	[de Jonge, Marthe M.; Ruano, Dina; van Eijk, Ronald; ter Haar, Natalja T.; Smit, Vincent T. H. B. M.; Bosse, Tjalling; van Wezel, Tom] Leiden Univ, Med Ctr, Dept Pathol, Leiden, Netherlands; [van der Stoep, Nienke; Nielsen, Maartje; Wijnen, Juul T.; van Asperen, Christi J.] Leiden Univ, Med Ctr, Dept Clin Genet, Leiden, Netherlands; [Vreeswijk, Maaike P. G.] Leiden Univ, Med Ctr, Dept Human Genet, Leiden, Netherlands; [Gaarenstroom, Katja N.] Leiden Univ, Med Ctr, Dept Gynecol, Leiden, Netherlands; [Kroep, Judith R.] Leiden Univ, Med Ctr, Dept Med Oncol, Leiden, Netherlands; [Baalbergen, Astrid] Reinier de Graaf Hosp, Dept Gynaecol, Delft, Netherlands; [Bos, Monique E. M. M.] Erasmus MC, Dept Med Oncol, Rotterdam, Netherlands; [Kagie, Marjolein J.] Haaglanden Med Ctr, Dept Gynecol, The Hague, Netherlands	van Wezel, T (reprint author), Leiden Univ, Med Ctr, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.	t.van_wezel@lumc.nl	van Wezel, Tom/Z-3092-2019	van Wezel, Tom/0000-0001-5773-7730; van Eijk, Ronald/0000-0001-7955-6295; Nielsen, Maartje/0000-0002-5351-1870	AstraZenecaAstraZeneca	Supported by AstraZeneca (financial support for next-generation sequencing).	Alsop K, 2012, J CLIN ONCOL, V30, P2654, DOI 10.1200/JCO.2011.39.8545; Baldwin RL, 2000, CANCER RES, V60, P5329; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Berchuck A, 1998, CLIN CANCER RES, V4, P2433; Buzolin AL, 2017, HUM GENOMICS, V11, DOI 10.1186/s40246-017-0110-x; Coyne GO, 2017, DRUGS, V77, P113, DOI 10.1007/s40265-016-0688-7; Davies H, 2017, NAT MED, V23, P517, DOI 10.1038/nm.4292; Davila RE, 2006, GASTROINTEST ENDOSC, V63, P546, DOI 10.1016/j.gie.2006.02.002; Do HD, 2015, CLIN CHEM, V61, P64, DOI 10.1373/clinchem.2014.223040; Drew Y, 2011, JNCI-J NATL CANCER I, V103, P334, DOI 10.1093/jnci/djq509; Ellison G, 2018, HUM MUTAT, V39, P394, DOI 10.1002/humu.23375; Ellison G, 2015, BMC CLIN PATHOL, V15, DOI 10.1186/s12907-015-0004-6; Endris V, 2016, VIRCHOWS ARCH, V468, P697, DOI 10.1007/s00428-016-1919-8; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Ewald IP, 2009, GENET MOL BIOL, V32, P437, DOI 10.1590/S1415-47572009005000049; Ferla R, 2007, ANN ONCOL, V18, P93, DOI 10.1093/annonc/mdm234; Fokkema IFAC, 2011, HUM MUTAT, V32, P557, DOI 10.1002/humu.21438; Goodwin S, 2016, NAT REV GENET, V17, P333, DOI 10.1038/nrg.2016.49; Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167; King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759; Konstantinopoulos PA, 2015, CANCER DISCOV, V5, P1137, DOI 10.1158/2159-8290.CD-15-0714; Lancaster JM, 2015, GYNECOL ONCOL, V136, P3, DOI 10.1016/j.ygyno.2014.09.009; Ledermann J, 2014, LANCET ONCOL, V15, P852, DOI 10.1016/S1470-2045(14)70228-1; Ledermann JA, 2016, LANCET ONCOL, V17, P1579, DOI 10.1016/S1470-2045(16)30376-X; Lheureux S, 2017, CLIN CANCER RES, V23, P4086, DOI 10.1158/1078-0432.CCR-16-2615; Lindor NM, 2013, ONCOLOGIST, V18, P518, DOI 10.1634/theoncologist.2012-0452; Loman NJ, 2012, NAT BIOTECHNOL, V30, P434, DOI 10.1038/nbt.2198; Lord CJ, 2016, NAT REV CANCER, V16, P110, DOI 10.1038/nrc.2015.21; Mafficini A, 2016, ONCOTARGET, V7, P1076, DOI 10.18632/oncotarget.6834; Marquard AM, 2015, BIOMARK RES, V3, DOI 10.1186/s40364-015-0033-4; Martincorena I, 2015, SCIENCE, V349, P1483, DOI 10.1126/science.aab4082; Mirza MR, 2016, NEW ENGL J MED, V375, P2154, DOI 10.1056/NEJMoa1611310; Naipal KAT, 2014, CLIN CANCER RES, V20, P4816, DOI 10.1158/1078-0432.CCR-14-0571; Norquist BM, 2016, JAMA ONCOL, V2, P482, DOI 10.1001/jamaoncol.2015.5495; PetrijBosch A, 1997, NAT GENET, V17, P341, DOI 10.1038/ng1197-341; Plon SE, 2008, HUM MUTAT, V29, P1282, DOI 10.1002/humu.20880; Pujade-Lauraine E, 2017, LANCET ONCOL, V18, P1274, DOI 10.1016/S1470-2045(17)30469-2; Roy R, 2012, NAT REV CANCER, V12, P68, DOI 10.1038/nrc3181; Rubenstein JH, 2015, GASTROENTEROLOGY, V149, P777, DOI 10.1053/j.gastro.2015.07.036; Shin S, 2017, ONCOTARGET, V8, P34858, DOI 10.18632/oncotarget.16799; Shirts BH, 2016, GENET MED, V18, P974, DOI 10.1038/gim.2015.212; Sutcliffe S, 2000, INT J CANCER, V87, P110, DOI 10.1002/1097-0215(20000701)87:1<110::AID-IJC16>3.0.CO;2-6; Swisher EM, 2017, LANCET ONCOL, V18, P75, DOI [10.1016/S1470-2045(16)30559-9, 10.1016/s1470-2045(16)30559-9]; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Trujillano D, 2015, J MOL DIAGN, V17, P162, DOI 10.1016/j.jmoldx.2014.11.004; van Eijk R, 2013, EXP MOL PATHOL, V94, P121, DOI 10.1016/j.yexmp.2012.06.004; Veeck J, 2010, J CLIN ONCOL, V28, pE563, DOI 10.1200/JCO.2010.30.1010; Vergote I, 2016, EUR J CANCER, V69, P127, DOI 10.1016/j.ejca.2016.10.006; Wallace AJ, 2016, EUR J HUM GENET, V24, pS10, DOI 10.1038/ejhg.2016.94; Weren RDA, 2017, HUM MUTAT, V38, P226, DOI 10.1002/humu.23137; Williams C, 1999, AM J PATHOL, V155, P1467, DOI 10.1016/S0002-9440(10)65461-2	51	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	SEP	2018	20	5					600	611		10.1016/j.jmoldx.2018.05.005			12	Pathology	Pathology	GS8AR	WOS:000443929200005	29936257	Green Published, Other Gold			2019-10-28	
J	Hsieh, AYY; Budd, M; Deng, D; Gadawska, I; Cote, HCF				Hsieh, Anthony Y. Y.; Budd, Matthew; Deng, David; Gadawska, Izabella; Cote, Helene C. F.			A Monochrome Multiplex Real-Time Quantitative PCR Assay for the Measurement of Mitochondrial DNA Content	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							HIV-INFECTED PATIENTS; COPY NUMBER; TRANSCRIPTION FACTOR; OXIDATIVE STRESS; GASTRIC-CANCER; BLOOD-CELLS; BIOGENESIS; DEPLETION; DECREASE; NUCLEAR	Mitochondrial DNA copies per cell (mtDNA content) can fluctuate with cellular aging, oxidative stress, and mitochondrial dysfunction, and has been investigated in cancer, diabetes, HIV, and metabolic disease. mtDNA content testing in both clinical and basic settings is expected to increase as research uncovers its biological relevance. Herein, we present a novel mtDNA content assay developed on monochrome multiplex real-time quantitative PCR (MMqPCR) principles. This assay offers a greater than twofold improvement on time effectiveness and cost-effectiveness over conventional (monoplex) qPCR, as well as improved reproducibility given the reduced effects of human pipetting errors. The new MMqPCR method was compared with the gold standard monoplex qPCR assay on DNA from a variety of sources, including human whole blood, skeletal muscle, and commercial cell lines. The MMqPCR assay is reproducible (n = 98, r = 0.99, P < 0.0001) and highly correlated to the monoplex qPCR assay (n = 160, r > 0.98, P < 0.0001). Intra-assay and interassay variabilities, as established independently by multiple operators, range between 4.3% and 7.9% and between 2.9% and 9.2%, respectively. This robust assay can quantify >82 pg of template DNA per reaction, with a minimum mtDNA/nuclear DNA ratio of 20, and is especially suitable for studies that require high throughput.	[Hsieh, Anthony Y. Y.; Budd, Matthew; Deng, David; Gadawska, Izabella; Cote, Helene C. F.] Univ British Columbia, Dept Pathol & Lab Med, G227,2211 Wesbrook Mall, Vancouver, BC V6T 2B5, Canada; [Hsieh, Anthony Y. Y.; Cote, Helene C. F.] Univ British Columbia, Ctr Blood Res, Vancouver, BC, Canada; [Cote, Helene C. F.] Womens Hlth Res Inst, Vancouver, BC, Canada	Cote, HCF (reprint author), Univ British Columbia, Dept Pathol & Lab Med, G227,2211 Wesbrook Mall, Vancouver, BC V6T 2B5, Canada.	helene.cote@ubc.ca			Canadian Institutes of Health Research (CIHR) Emerging Team grant on Cellular Aging and HIV Comorbidities in Women and Children [TCO-125269]; University of British Columbia (UBC); UBC Centre for Blood Research; CIHRCanadian Institutes of Health Research (CIHR)	Supported by a Canadian Institutes of Health Research (CIHR) Emerging Team grant on Cellular Aging and HIV Comorbidities in Women and Children TCO-125269 (H.C.F.C.), the University of British Columbia (UBC) (A.Y.Y.H), the UBC Centre for Blood Research (A.Y.Y.H), and CIHR (A.Y.Y.H.).	Ajaykumar A, 2017, 26 ANN CAN C HIV AID; Amaudo E, 1991, LANCET, V337, P508; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Barrientos A, 1997, MOL BRAIN RES, V52, P284, DOI 10.1016/S0169-328X(97)00278-7; Casula M, 2005, J INFECT DIS, V191, P1468, DOI 10.1086/429412; Cawthon RM, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkn1027; Cote HCF, 2002, NEW ENGL J MED, V346, P811, DOI 10.1056/NEJMoa012035; Cote HCF, 2006, AIDS, V20, P1343, DOI 10.1097/01.aids.0000232250.89404.00; Cote HC, 2007, CRIT CARE, V11, DOI 10.1186/cc6096; Cui HH, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-110; Dalakas MC, 2001, LAB INVEST, V81, P1537, DOI 10.1038/labinvest.3780367; Dimmock D, 2010, CLIN CHEM, V56, P1119, DOI 10.1373/clinchem.2009.141549; Fernandes J, 2014, CANCER EPIDEM BIOMAR, V23, P2430, DOI 10.1158/1055-9965.EPI-14-0471; FISHER RP, 1985, J BIOL CHEM, V260, P1330; FUKUHARA H, 1969, EUR J BIOCHEM, V11, P135, DOI 10.1111/j.1432-1033.1969.tb00750.x; Goto M, 2003, J MED VIROL, V70, P497, DOI 10.1002/jmv.10423; He X, 2014, ONCOTARGET, V7, P22834; Hsieh AYY, 2016, J MOL DIAGN, V18, P425, DOI 10.1016/j.jmoldx.2016.01.004; Kim MY, 2011, ARCH GERONTOL GERIAT, V53, pE218, DOI 10.1016/j.archger.2010.11.019; Kogelnik AM, 1996, NUCLEIC ACIDS RES, V24, P177, DOI 10.1093/nar/24.1.177; Lee HC, 1998, FEBS LETT, V441, P292, DOI 10.1016/S0014-5793(98)01564-6; Lee HC, 2000, BIOCHEM J, V348, P425, DOI 10.1042/0264-6021:3480425; Lee HC, 2005, INT J BIOCHEM CELL B, V37, P822, DOI 10.1016/j.biocel.2004.09.010; Lee HK, 1998, DIABETES RES CLIN PR, V42, P161, DOI 10.1016/S0168-8227(98)00110-7; LIN LI, 1989, BIOMETRICS, V45, P255, DOI 10.2307/2532051; Malik AN, 2015, DIABETES RES CLIN PR, V110, P257, DOI 10.1016/j.diabres.2015.10.006; Meierhofer D, 2004, CARCINOGENESIS, V25, P1005, DOI 10.1093/carcin/bgh104; Memon Ashfaque A, 2017, Biomol Detect Quantif, V13, P32, DOI 10.1016/j.bdq.2017.08.001; Mengel-From J, 2014, HUM GENET, V133, P1149, DOI 10.1007/s00439-014-1458-9; Miro O, 2003, AIDS RES HUM RETROV, V19, P1027, DOI 10.1089/088922203322588387; Miro O, 2004, CLIN INFECT DIS, V39, P710, DOI 10.1086/423176; Moraes CT, 1999, MOL BIOL CELL, V10, P3345, DOI 10.1091/mbc.10.10.3345; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; Pisano A, 2016, CARDIOVASC PATHOL, V25, P103, DOI 10.1016/j.carpath.2015.09.009; Ruijter JM, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp045; Schick BA, 2007, CLIN PHARMACOL THER, V81, P650, DOI 10.1038/sj.clpt.6100124; Serth J, 2000, AM J PATHOL, V156, P1189, DOI 10.1016/S0002-9440(10)64989-9; Shikuma CM, 2001, AIDS, V15, P1801, DOI 10.1097/00002030-200109280-00009; Song J, 2001, DIABETES CARE, V24, P865, DOI 10.2337/diacare.24.5.865; Spinazzola A, 2007, BIOSCIENCE REP, V27, P39, DOI 10.1007/s10540-007-9036-1; Stringer HAJ, 2013, J NEUROL SCI, V325, P142, DOI 10.1016/j.jns.2012.12.023; TRITSCHLER HJ, 1992, NEUROLOGY, V42, P209, DOI 10.1212/WNL.42.1.209; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; Wang Y, 2006, BRIT J CANCER, V95, P1087, DOI 10.1038/sj.bjc.6603377; Wen SL, 2013, ONCOL LETT, V6, P1098, DOI 10.3892/ol.2013.1492; Yen MY, 2002, BRIT J OPHTHALMOL, V86, P1027, DOI 10.1136/bjo.86.9.1027; Yu M, 2011, LIFE SCI, V89, P65, DOI 10.1016/j.lfs.2011.05.010; Zanet DL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057787	48	0	0	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	SEP	2018	20	5					612	620		10.1016/j.jmoldx.2018.05.001			9	Pathology	Pathology	GS8AR	WOS:000443929200006	29936256				2019-10-28	
J	Lamoury, FMJ; Hajarizadeh, B; Soker, A; Martinez, D; Quek, C; Cunningham, P; Catlett, B; Cloherty, G; Marks, P; Amin, J; Grebely, J; Dore, GJ; Applegate, TL				Lamoury, Francois M. J.; Hajarizadeh, Behzad; Soker, Angelica; Martinez, Danica; Quek, Camelia; Cunningham, Philip; Catlett, Beth; Cloherty, Gavin; Marks, Philippa; Amin, Janaki; Grebely, Jason; Dore, Gregory J.; Applegate, Tanya L.			Evaluation of a Hepatitis C Virus Core Antigen Assay in Plasma and Dried Blood Spot Samples	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							DIAGNOSIS; RNA	Simplified, affordable tools to diagnose active hepatitis C virus (HCV) infection are needed to scale up treatment. This study evaluated the analytical performance of HCV core antigen (HCVcAg) detection in samples of plasma and dried venous blood spots (DBSs). Paired plasma and DBS samples were prepared from remnant diagnostic samples, and plasma HCV RNA and HCVcAg were quantified. Sensitivity and specificity for HCVcAg (>3 fmol/L) at two HCV RNA thresholds (>= 15 and >= 3000 IU/mL) were calculated. Of 120 paired samples tested, 25 had nonquantifiable HCV RNA and 95 had quantifiable HCV RNA. The median HCV RNA level in plasma was 5.6 log(10) IU/mL (interquartile range: 5.2 to 6.2). The median HCVcAg levels in plasma and DBS samples were 2.3 log(10) fmol/L (interquartile range: 0.1 to 3.1) and 1.1 log(10) fmol/L (interquartile range: 0.0 to 1.9), respectively. For diagnosing HCV RNA >= 3000 IU/mL, the sensitivity and specificity of HCVcAg in plasma were 97.7% (95% CI, 91%-100%) and 100% (95% CI, 87%-100%), respectively. The sensitivity and specificity of HCVcAg in DBS were 88.6% (95% CI, 80%-94%) and 97% (95% CI, 82%-100%), respectively. The data from this study demonstrate good sensitivity and specificity of HCVcAg in plasma at an HCV RNA threshold of >= 3000 IU/mL. The level of HCVcAg quantified in plasma was higher than that in DBS.	[Lamoury, Francois M. J.; Hajarizadeh, Behzad; Soker, Angelica; Martinez, Danica; Quek, Camelia; Marks, Philippa; Amin, Janaki; Grebely, Jason; Dore, Gregory J.; Applegate, Tanya L.] Univ New South Wales, Kirby Inst, Sydney, NSW, Australia; [Cunningham, Philip; Catlett, Beth] St Vincents Appl Med Res, Sydney, NSW, Australia; [Cloherty, Gavin] Abbott Diagnost, Abbott Pk, IL USA; [Amin, Janaki] Macquarie Univ, Fac Med & Hlth Sci, Sydney, NSW, Australia	Applegate, TL (reprint author), UNSW Sydney, Kirby Inst, Viral Hepatitis Clin Res Program, Wallace Wurth Bldg, Sydney, NSW 2052, Australia.	tapplegate@kirby.unsw.edu.au		Cunningham, Philip/0000-0003-2613-6910; Hajarizadeh, Behzad/0000-0003-2212-2028; Lamoury, Francois/0000-0003-3060-9506; Applegate, Tanya/0000-0002-8657-4261; Amin, Janaki/0000-0003-2161-9366	Australian Government Department of Health and AgeingAustralian GovernmentDepartment of Health & Ageing; National Health and Medical Research Program [1053206]; National Health and Medical Research Council Career Development fellowship; National Health and Medical Research Council Practitioner Research fellowshipNational Health and Medical Research Council of Australia; National Health and Medical Research Council Early Career fellowshipNational Health and Medical Research Council of Australia	Supported by Australian Government Department of Health and Ageing and the National Health and Medical Research Program grant 1053206 (G.J.D.), a National Health and Medical Research Council Career Development fellowship (J.G.), a National Health and Medical Research Council Practitioner Research fellowship (G.J.D.), and a National Health and Medical Research Council Early Career fellowship (B.H.). The Kirby Institute is funded by Australian Government Department of Health and Ageing and the National Health and Medical Research Program grant 1053206.	[Anonymous], 2017, WHO GUID HEP B C TES; Blach S, 2017, LANCET GASTROENTEROL, V2, P161, DOI 10.1016/S2468-1253(16)30181-9; Coats JT, 2015, INT J DRUG POLICY, V26, P1050, DOI 10.1016/j.drugpo.2015.05.001; Cohn J, 2015, CURR OPIN HIV AIDS, V10, P369, DOI 10.1097/COH.0000000000000180; Freiman JM, 2016, ANN INTERN MED, V165, P345, DOI 10.7326/M16-0065; Grebely J, 2017, LANCET GASTROENTEROL, V2, P514, DOI 10.1016/S2468-1253(17)30075-4; Hajarizadeh B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122232; Lamoury FMJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131437; Nguyen LT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163900; Loggi E, 2013, J CLIN VIROL, V56, P207, DOI 10.1016/j.jcv.2012.11.012; Martinello M, 2016, HEPATOLOGY, V64, P1911, DOI 10.1002/hep.28844; McLeod A, 2014, J EPIDEMIOL COMMUN H, V68, P1182, DOI 10.1136/jech-2014-204451; Medici MC, 2011, J CLIN VIROL, V51, P260, DOI 10.1016/j.jcv.2011.05.003; Murayama A, 2012, J CLIN MICROBIOL, V50, P1943, DOI 10.1128/JCM.00487-12; Ottiger C, 2013, J CLIN VIROL, V58, P535, DOI 10.1016/j.jcv.2013.08.028; R Development Core Team, 2011, R LANG ENV STAT COMP; Roblin DW, 2011, AM J MANAG CARE, V17, P548; Ross RS, 2010, J CLIN MICROBIOL, V48, P1161, DOI 10.1128/JCM.01640-09; Soulier A, 2016, J INFECT DIS, V213, P1087, DOI 10.1093/infdis/jiv423; Southern WN, 2011, J VIRAL HEPATITIS, V18, P474, DOI 10.1111/j.1365-2893.2010.01327.x; TAKAHASHI K, 1992, J GEN VIROL, V73, P667, DOI 10.1099/0022-1317-73-3-667; Tokita H, 2000, J CLIN MICROBIOL, V38, P3450; Volk ML, 2009, HEPATOLOGY, V50, P1750, DOI 10.1002/hep.23220; World Health Organization, 2016, WHO HIGHL HEP TEST I; YOUDEN WJ, 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3	25	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	SEP	2018	20	5					621	627		10.1016/j.jmoldx.2018.05.010			7	Pathology	Pathology	GS8AR	WOS:000443929200007	29959023				2019-10-28	
J	Pengelly, RJ; Rowaiye, B; Pickard, K; Moran, B; Dayal, S; Tapper, W; Mirnezami, A; Cecil, T; Mohamed, F; Carr, N; Ennis, S				Pengelly, Reuben J.; Rowaiye, Babatunde; Pickard, Karen; Moran, Brendan; Dayal, Sanjeev; Tapper, William; Mirnezami, Alex; Cecil, Tom; Mohamed, Faheez; Carr, Norman; Ennis, Sarah			Analysis of Mutation and Loss of Heterozygosity by Whole-Exome Sequencing Yields Insights into Pseudomyxoma Peritonei	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							APPENDICEAL MUCINOUS NEOPLASMS; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; LOW-GRADE; PROPOSED CLASSIFICATION; CYTOREDUCTIVE SURGERY; GENETIC-VARIATION; KRAS MUTATIONS; CANCER; SURVIVAL; TUMORS	Pseudomyxoma peritonei (PMP) is a clinical syndrome characterized by gross mucinous ascites originating from a disseminated intraperitoneal neoplasm. Although typically confined to the abdomen, mortality is high if untreated. Biomarkers, including genetic mutation profiles, may aid treatment selection and decision making. We applied whole-exome sequencing to five patients diagnosed with low-grade appendiceal mucinous neoplasms, using paired tumor and germline samples identify biomarkers. Multiple bioinformatic approaches were applied to these data to assess both somatic mutation profiles and Loss of heterozygosity events. Mutation profiles of the tumors were consistent with deamination of methylcytosine being the prevailing mechanism. Pathogenic mutations were identified in both KRAS and GNAS in all samples, and further mutations in genes implicated in PMP, namely FGFR2, APC, SMAD2, and FAT4. No TP53 somatic mutations were identified, matching expectations for low-grade tumors. Four of five samples exhibited clonal loss of heterozygosity; these regions were further examined and found to contain genes harboring pathogenic somatic mutations in some samples. RNF43 was hereby implicated in the pathogenesis of PMP of appendiceal origin, having previously been found to increase sensitivity to Wnt signaling and to have involvement in similar mucinous tumors. In conclusion, we have investigated the mutation profile of PMP of appendiceal origin and provided the first report of RNF43 involvement in its progression.	[Pengelly, Reuben J.; Tapper, William; Ennis, Sarah] Univ Southampton, Dept Human Genet & Genom Med, Fac Med, Southampton, Hants, England; [Pickard, Karen; Mirnezami, Alex] Univ Southampton, Canc Sci Unit, Fac Med, Southampton, Hants, England; [Rowaiye, Babatunde; Moran, Brendan; Dayal, Sanjeev; Cecil, Tom; Mohamed, Faheez; Carr, Norman] Basingstoke & North Hampshire Hosp, Peritoneal Malignancy Inst, Aldermaston Rd, Basingstoke RG24 9NA, Hants, England	Carr, N (reprint author), Basingstoke & North Hampshire Hosp, Peritoneal Malignancy Inst, Aldermaston Rd, Basingstoke RG24 9NA, Hants, England.	n.j.carr@soton.co.uk		Carr, Norman/0000-0002-5087-6874; Pengelly, Reuben/0000-0001-7022-645X	Pelican Cancer Foundation; Cancer Research UKCancer Research UK	Supported by the Pelican Cancer Foundation (B.R. and N.C.) and Cancer Research UK (R.J.P., K.P., and S.E.).	Alakus H, 2014, GENOME MED, V6, DOI 10.1186/gm559; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; Amini A, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/1750-1172-9-71; Carr NJ, 2016, AM J SURG PATHOL, V40, P14, DOI 10.1097/PAS.0000000000000535; Carr NJ, 2012, J CLIN PATHOL, V65, P919, DOI 10.1136/jclinpath-2012-200843; Chu PG, 2011, AM J SURG PATHOL, V35, P1830, DOI 10.1097/PAS.0b013e3182299c25; Chua TC, 2012, J CLIN ONCOL, V30, P2449, DOI 10.1200/JCO.2011.39.7166; Davison JM, 2014, MODERN PATHOL, V27, P1521, DOI 10.1038/modpathol.2014.37; Elias D, 2010, EJSO-EUR J SURG ONC, V36, P456, DOI 10.1016/j.ejso.2010.01.006; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121; Gleeson EM, 2018, AM J CLIN ONCOL-CANC, V41, P777, DOI 10.1097/COC.0000000000000376; Hara K, 2015, PATHOL RES PRACT, V211, P657, DOI 10.1016/j.prp.2015.06.004; Hidalgo I, 2012, CELL STEM CELL, V11, P649, DOI 10.1016/j.stem.2012.08.001; Hosoda W, 2015, VIRCHOWS ARCH, V466, P665, DOI 10.1007/s00428-015-1751-6; King RJ, 2017, ONCOTARGET, V8, P67152, DOI 10.18632/oncotarget.17934; Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111; Komatsu H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087875; Lee JH, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-2847-4; Levine EA, 2012, J AM COLL SURGEONS, V214, P599, DOI 10.1016/j.jamcollsurg.2011.12.028; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Liu X, 2014, CLIN CHEM, V60, P1004, DOI 10.1373/clinchem.2014.225565; Min BH, 2016, J PATHOL, V240, P304, DOI 10.1002/path.4777; Misdraji J, 2004, MODERN PATHOL, V17, P1447, DOI 10.1038/modpathol.3800212; Misdraji J, 2003, AM J SURG PATHOL, V27, P1089, DOI 10.1097/00000478-200308000-00006; Moran B, 2015, COLORECTAL DIS, V17, P772, DOI 10.1111/codi.12975; Nishikawa G, 2013, BRIT J CANCER, V108, P951, DOI 10.1038/bjc.2013.47; Noguchi R, 2015, CANCER MED-US, V4, P1809, DOI 10.1002/cam4.542; Nummela P, 2015, INT J CANCER, V136, pE282, DOI 10.1002/ijc.29245; Pai RK, 2014, HUM PATHOL, V45, P227, DOI 10.1016/j.humpath.2013.10.021; Pai RK, 2005, ADV ANAT PATHOL, V12, P291, DOI 10.1097/01.pap.0000194625.05137.51; Pietrantonio F, 2016, ANN ONCOL, V27, P2097, DOI 10.1093/annonc/mdw314; Ryland GL, 2013, J PATHOL, V229, P469, DOI 10.1002/path.4134; Serra S, 2018, J CLIN PATHOL, V71, P1, DOI 10.1136/jclinpath-2017-204763; Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308; Shetty S, 2013, AM SURGEON, V79, P1171; Shetty S, 2013, J SURG RES, V180, P97, DOI 10.1016/j.jss.2012.10.053; Singhi AD, 2014, HUM PATHOL, V45, P1737, DOI 10.1016/j.humpath.2014.04.018; Sio TT, 2014, J HUM GENET, V59, P124, DOI 10.1038/jhg.2013.132; Smeenk RM, 2008, EJSO-EUR J SURG ONC, V34, P196, DOI 10.1016/j.ejso.2007.04.002; Staaf J, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r136; Taggart MW, 2013, AM J SURG PATHOL, V37, P1192, DOI 10.1097/PAS.0b013e318282649b; Van Allen EM, 2014, NAT MED, V20, P682, DOI 10.1038/nm.3559; Yamada N, 2011, CLIN EPIGENETICS, V2, P85, DOI 10.1007/s13148-011-0037-3; Zauber P, 2011, SCAND J GASTROENTERO, V46, P869, DOI 10.3109/00365521.2011.565070	46	1	2	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	SEP	2018	20	5					635	642		10.1016/j.jmoldx.2018.05.002			8	Pathology	Pathology	GS8AR	WOS:000443929200009	29936255				2019-10-28	
J	Lam, SW; Cleton-Jansen, AM; Cleven, AHG; Ruano, D; van Wezel, T; Szuhai, K; Bovee, JVMG				Lam, Suk Wai; Cleton-Jansen, Anne-Marie; Cleven, Arjen H. G.; Ruano, Dina; van Wezel, Tom; Szuhai, Karoly; Bovee, Judith V. M. G.			Molecular Analysis of Gene Fusions in Bone and Soft Tissue Tumors by Anchored Multiplex PCR-Based Targeted Next-Generation Sequencing	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							NODULAR FASCIITIS; DERMATOFIBROSARCOMA PROTUBERANS; SIGNAL PATTERNS; EWING SARCOMA; TRANSLOCATION; NEOPLASMS; SPECTRUM; FISH; CYST	Molecular assays for translocation detection in bone and soft tissue tumors have gradually been incorporated into routine diagnostics. However, conventional methods such as fluorescence in situ hybridization (FISH) and reverse transcriptase-PCR come with several drawbacks. In this study, the applicability of a novel technique termed anchored multiplex PCR (AMP) for next-generation sequencing (NGS), using the Archer FusionPlex Sarcoma kit, aimed at 26 genes, was evaluated and compared with FISH and reverse transcriptase-PCR. In case of discrepant results, further analysis occurred with a third independent technique. Eighty-one samples were subjected to AMP-based targeted NGS, and 86% (n = 70) were successfully conducted and were either fusion positive (n = 48) or fusion negative, but met all criteria for good quality (n = 22). A concordance of 90% was found between NGS and conventional techniques. AMP-based targeted NGS showed superior results, as in four cases reverse transcriptase-PCR and FISH were false negative. Moreover, because the assay targets one partner of a gene fusion, novel or rare fusion partners can be identified. Indeed, it revealed COL1A1 and SEC31A as novel fusion partners for USP6 in nodular fasciitis. Despite the fact that fusions involving genes outside the selectively captured region cannot be detected and false-negative results due to poor quality samples can be encountered, this method has demonstrated excellent diagnostic utility for translocation detection in sarcomas.	[Lam, Suk Wai; Cleton-Jansen, Anne-Marie; Cleven, Arjen H. G.; Ruano, Dina; van Wezel, Tom; Bovee, Judith V. M. G.] Leiden Univ, Med Ctr, Dept Pathol, POB 9600,L1-Q, NL-2300 RC Leiden, Netherlands; [Szuhai, Karoly] Leiden Univ, Med Ctr, Dept Cell & Chem Biol, Leiden, Netherlands	Bovee, JVMG (reprint author), Leiden Univ, Med Ctr, Dept Pathol, POB 9600,L1-Q, NL-2300 RC Leiden, Netherlands.	j.v.m.g.bovee@lumc.nl	van Wezel, Tom/Z-3092-2019; Szuhai, Karoly/A-1100-2008	van Wezel, Tom/0000-0001-5773-7730; Szuhai, Karoly/0000-0002-1228-4245; Cleton-Jansen, Anne-Marie/0000-0002-9048-4867; Lam, Suk Wai/0000-0001-9782-5938	Leiden University Medical Center	Supported by Leiden University Medical Center.	Brandal P, 2008, GENE CHROMOSOME CANC, V47, P558, DOI 10.1002/gcc.20559; Chen S, 2016, GENE CHROMOSOME CANC, V55, P340, DOI 10.1002/gcc.22336; Cui CH, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00089; Ducimetiere F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020294; Erickson-Johnson MR, 2011, LAB INVEST, V91, P1427, DOI 10.1038/labinvest.2011.118; Guseva NV, 2017, GENE CHROMOSOME CANC, V56, P266, DOI 10.1002/gcc.22432; Janknecht R, 2005, GENE, V363, P1, DOI 10.1016/j.gene.2005.08.007; Labropoulos SV, 2007, BIOL-TARGETS THER, V1, P347; Mitelman F, 2007, NAT REV CANCER, V7, P233, DOI 10.1038/nrc2091; Noujaim J, 2017, BRIT J CANCER, V116, P669, DOI 10.1038/bjc.2017.4; Noujaim J, 2015, CANCER BIOL MED, V12, P375, DOI 10.7497/j.issn.2095-3941.2015.0067; Oliveira AM, 2014, HUM PATHOL, V45, P1, DOI 10.1016/j.humpath.2013.03.005; Papp G, 2017, PATHOL ONCOL RES, V23, P863, DOI 10.1007/s12253-017-0200-z; Patel NR, 2017, MODERN PATHOL, V30, P1577, DOI 10.1038/modpathol.2017.78; Rossi S, 2007, CLIN CANCER RES, V13, P7322, DOI 10.1158/1078-0432.CCR-07-1744; Sankar S, 2011, CANCER GENET-NY, V204, P351, DOI 10.1016/j.cancergen.2011.07.008; Shin C, 2016, HISTOPATHOLOGY, V69, P784, DOI 10.1111/his.13011; Shing DC, 2003, CANCER RES, V63, P4568; Simon MP, 1997, NAT GENET, V15, P95, DOI 10.1038/ng0197-95; Sorensen PHB, 2002, J CLIN ONCOL, V20, P2672, DOI 10.1200/JCO.2002.03.137; Srinivasan M, 2002, AM J PATHOL, V161, P1961, DOI 10.1016/S0002-9440(10)64472-0; van Eijk R, 2013, EXP MOL PATHOL, V94, P121, DOI 10.1016/j.yexmp.2012.06.004; van IJzendoorn DGP, 2015, GENE CHROMOSOME CANC, V54, P565, DOI 10.1002/gcc.22269; Vargas AC, 2016, HISTOPATHOLOGY, V69, P1000, DOI 10.1111/his.13031; Zheng ZL, 2014, NAT MED, V20, P1479, DOI 10.1038/nm.3729	25	6	7	2	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	SEP	2018	20	5					653	663		10.1016/j.jmoldx.2018.05.007			11	Pathology	Pathology	GS8AR	WOS:000443929200011	30139549				2019-10-28	
J	Dupuy, A; Lemonnier, F; Fataccioli, V; Martin-Garcia, N; Robe, C; Pelletier, R; Poullot, E; Moktefi, A; Mokhtari, K; Rousselet, MC; Traverse-Glehen, A; Delarue, R; Tournilhac, O; Delfau-Larue, MH; Haioun, C; Ortonne, N; Copie-Bergman, C; de Leval, L; Pujals, A; Gaulard, P				Dupuy, Aurelie; Lemonnier, Francois; Fataccioli, Virginie; Martin-Garcia, Nadine; Robe, Cyrielle; Pelletier, Romain; Poullot, Elsa; Moktefi, Anissa; Mokhtari, Karima; Rousselet, Marie C.; Traverse-Glehen, Alexandra; Delarue, Richard; Tournilhac, Olivier; Delfau-Larue, Marie H.; Haioun, Corinne; Ortonne, Nicolas; Copie-Bergman, Christiane; de Leval, Laurence; Pujals, Anais; Gaulard, Philippe			Multiple Ways to Detect IDH2 Mutations in Angioimmunoblastic T-Cell Lymphoma from Immunohistochemistry to Next-Generation Sequencing	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							ACUTE MYELOID-LEUKEMIA; ISOCITRATE DEHYDROGENASE MUTATIONS; MELTING-CURVE-ANALYSIS; CLINICAL-RESPONSE; CANCER; RHOA; DIFFERENTIATION; CLASSIFICATION; ENASIDENIB; GUIDELINE	Angioimmunoblastic T-cell lymphoma (AITL) is a peripheral T-cell Lymphoma associated with chemoresistance and a poor prognosis. Various nonsynonymous mutations in the R172 residue of IDH2 are present in 20% to 30% of AITL patients. In addition to their diagnostic value, these mutations are potentially targetabLe, especially by isocitrate dehydrogenase (IDH) 2 inhibitor, and therefore their identification in a routine setting is clinically relevant. However, in AITL, the neoplastic cells may be scarce, making the identification of molecular anomalies difficult. We evaluated the diagnostic value of different methods to detect IDH2 mutations in formalin-fixed, paraffin-embedded tumor samples. Immunohistochemistry with an anti-IDH2 R172K antibody, Sanger sequencing, high-resolution melting PCR, allele-specific real-time quantitative PCR, and next-generation sequencing (NGS) were applied to biopsy specimens from 42 AITL patients. We demonstrate that the IDH2 R172K antibody is specific to this amino acid substitution and highly sensitive for the detection of the IDH2(R172K) variant, the most frequent substitution in this disease. In our study, NGS and allele-specific real-time quantitative PCR displayed a good sensitivity, detecting 96% and 92% of IDH2 mutations, respectively, in contrast to Sanger sequencing and high-resolution melting PCR, which showed a significantly Lower detection rate (58% and 42%, respectively). These results suggest that a combination of immunohistochemistry and AS-PCR or NGS should be considered for the identification of IDH2 mutations in AITL in a routine setting.	[Dupuy, Aurelie; Lemonnier, Francois; Fataccioli, Virginie; Martin-Garcia, Nadine; Robe, Cyrielle; Delfau-Larue, Marie H.; Haioun, Corinne; Ortonne, Nicolas; Copie-Bergman, Christiane; Pujals, Anais; Gaulard, Philippe] Inst Mondor Rech Biomed, INSERM, U955, Equipe 9, Creteil, France; [Dupuy, Aurelie; Lemonnier, Francois; Fataccioli, Virginie; Martin-Garcia, Nadine; Robe, Cyrielle; Moktefi, Anissa; Delfau-Larue, Marie H.; Haioun, Corinne; Ortonne, Nicolas; Copie-Bergman, Christiane; Pujals, Anais; Gaulard, Philippe] Univ Paris Est, Creteil, France; [Lemonnier, Francois; Haioun, Corinne] Hop Henri Mondor, AP HP, Unite Hemopathies Lymphoides, Creteil, France; [Lemonnier, Francois; Pelletier, Romain; Poullot, Elsa; Moktefi, Anissa; Ortonne, Nicolas; Copie-Bergman, Christiane; Pujals, Anais; Gaulard, Philippe] Hop Henri Mondor, AP HP, Dept Pathol, Creteil, France; [Delfau-Larue, Marie H.] Hop Henri Mondor, AP HP, Serv Immunol Biol, Creteil, France; [Mokhtari, Karima] Hop La Pitie Salpetriere, AP HP, Dept Neuropathol, Paris, France; [Rousselet, Marie C.] Hop Angers, Dept Pathol, Angers, France; [Traverse-Glehen, Alexandra] Hop Lyon Sud, Dept Pathol, Lyon, France; [Delarue, Richard] Necker Enfants Malad, AP HP, Dept Hematol, Paris, France; [Tournilhac, Olivier] Ctr Hosp Univ Clermont Ferrand, Hop Estaing, Serv Therapie Cellulaire & Hematol Clin Adulte, Clermont Ferrand, France; [de Leval, Laurence] Lausanne Univ Hosp, Dept Pathol, Lausanne, Switzerland	Pujals, A (reprint author), Hop Henri Mondor, Dept Pathol, 51 Ave Marechal de Lattre de Tassigny, F-94010 Creteil, France.	anais.pujals@aphp.fr	de Leval, Laurence/M-4889-2017	de Leval, Laurence/0000-0003-3994-516X; Pujals, Anais/0000-0002-3452-7420; Ortonne, Nicolas/0000-0003-0111-7422; copie bergman, christiane/0000-0001-5408-894X; Haioun, Corinne/0000-0003-0095-5379; gaulard, philippe/0000-0002-4243-905X; Lemonnier, Francois/0000-0001-6205-5419	Fondation pour la Recherche MedicaleFondation pour la Recherche Medicale [DEQ20160334875]; Association pour la Recherche contre le CancerFondation ARC pour la Recherche sur le Cancer [PJA 20151203507]; Association pour la Recherche Therapeutique, Genetique et Immunologique dans les Lymphomes grant; Leukemia and Lymphoma Society (LLS) grant [LLS SCOR 7013-17]	Supported in part by the Fondation pour la Recherche Medicale grant N.DEQ20160334875, Association pour la Recherche contre le Cancer grant N. PJA 20151203507, Association pour la Recherche Therapeutique, Genetique et Immunologique dans les Lymphomes grant, and Leukemia and Lymphoma Society (LLS) grant LLS SCOR 7013-17 (P.G.).	Amary MF, 2011, J PATHOL, V224, P334, DOI 10.1002/path.2913; Amatangelo MD, 2017, BLOOD, V130, P732, DOI 10.1182/blood-2017-04-779447; Attygalle A, 2002, BLOOD, V99, P627, DOI 10.1182/blood.V99.2.627; Boutzen H, 2016, J EXP MED, V213, P483, DOI 10.1084/jem.20150736; Cairns RA, 2013, CANCER DISCOV, V3, P730, DOI 10.1158/2159-8290.CD-13-0083; Cairns RA, 2012, BLOOD, V119, P1901, DOI 10.1182/blood-2011-11-391748; Catteau A, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-58; Chan SM, 2015, NAT MED, V21, P178, DOI 10.1038/nm.3788; Dang L, 2016, ANN ONCOL, V27, P599, DOI 10.1093/annonc/mdw013; de Leval L, 2015, HAEMATOLOGICA, V100, pE361, DOI 10.3324/haematol.2015.126300; de Leval L, 2011, HISTOPATHOLOGY, V58, P49, DOI 10.1111/j.1365-2559.2010.03704.x; de Leval L, 2010, BRIT J HAEMATOL, V148, P673, DOI 10.1111/j.1365-2141.2009.08003.x; Dobay MP, 2017, HAEMATOLOGICA, V102, pE148, DOI 10.3324/haematol.2016.158428; Dupuis J, 2006, AM J SURG PATHOL, V30, P490, DOI 10.1097/00000478-200604000-00009; Emadi A, 2015, AM J HEMATOL, V90, pE77, DOI 10.1002/ajh.23965; Federico M, 2013, J CLIN ONCOL, V31, P240, DOI 10.1200/JCO.2011.37.3647; Fujii T, 2016, DISCOV MED, V21, P373; Grassian AR, 2014, CURR OPIN GASTROEN, V30, P295, DOI 10.1097/MOG.0000000000000050; Janin M, 2014, J CLIN ONCOL, V32, P297, DOI 10.1200/JCO.2013.50.2047; Laurent C, 2017, J CLIN ONCOL, V35, P2008, DOI 10.1200/JCO.2016.71.2083; Lemonnier F, 2016, P NATL ACAD SCI USA, V113, P15084, DOI 10.1073/pnas.1617929114; Lindeman NI, 2013, J MOL DIAGN, V15, P415, DOI 10.1016/j.jmoldx.2013.03.001; Marafioti T, 2010, HAEMATOL-HEMATOL J, V95, P432, DOI 10.3324/haematol.2009.010991; Rodriguez-Pinilla SM, 2008, AM J SURG PATHOL, V32, P1787, DOI 10.1097/PAS.0b013e31817f123e; Medeiros BC, 2017, LEUKEMIA, V31, P272, DOI 10.1038/leu.2016.275; Nakamoto-Matsubara R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109714; Nguyen TB, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2016.122; Odejide O, 2014, BLOOD, V123, P1293, DOI 10.1182/blood-2013-10-531509; Palomero T, 2014, NAT GENET, V46, P166, DOI 10.1038/ng.2873; Patel KP, 2011, J MOL DIAGN, V13, P678, DOI 10.1016/j.jmoldx.2011.06.004; Piccaluga PP, 2013, J CLIN ONCOL, V31, P3019, DOI 10.1200/JCO.2012.42.5611; Preusser M, 2011, CLIN NEUROPATHOL, V30, P217, DOI 10.5414/NP300422; Quivoron C, 2011, CANCER CELL, V20, P25, DOI 10.1016/j.ccr.2011.06.003; Sakata-Yanagimoto M, 2015, CURR HEMATOL MALIG R, V10, P429, DOI 10.1007/s11899-015-0289-7; Sakata-Yanagimoto M, 2015, INT J HEMATOL, V102, P523, DOI 10.1007/s12185-015-1738-8; Sakata-Yanagimoto M, 2014, NAT GENET, V46, P171, DOI 10.1038/ng.2872; Schwartz FH, 2017, J PATHOL, V242, P129, DOI 10.1002/path.4898; Stein EM, 2017, BLOOD, V130, P722, DOI 10.1182/blood-2017-04-779405; Stein EM, 2015, HEMATOL-AM SOC HEMAT, P579, DOI 10.1182/asheducation-2015.1.579; Stein EM, 2015, BEST PRACT RES CL HA, V28, P112, DOI 10.1016/j.beha.2015.10.016; Swerdlow SH, 2017, WHO CLASSIFICATION T, P585; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Tsiatis AC, 2010, J MOL DIAGN, V12, P425, DOI 10.2353/jmoldx.2010.090188; Vallois D, 2016, BLOOD, V128, P1490, DOI 10.1182/blood-2016-02-698977; van den Bent MJ, 2013, J NEURO-ONCOL, V112, P173, DOI 10.1007/s11060-013-1056-z; Wang C, 2015, BLOOD, V126, P1741, DOI 10.1182/blood-2015-05-644591; Wang HY, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0362-7; Yen K, 2017, CANCER DISCOV, V7, P478, DOI 10.1158/2159-8290.CD-16-1034; Yoo HY, 2014, NAT GENET, V46, P371, DOI 10.1038/ng.2916	49	1	1	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	SEP	2018	20	5					677	685		10.1016/j.jmoldx.2018.05.012			9	Pathology	Pathology	GS8AR	WOS:000443929200013	29981867				2019-10-28	
J	Jang, BG; Kim, HS; Chang, WY; Bae, JM; Kang, GH				Jang, Bo Gun; Kim, Hye Sung; Chang, Weon Young; Bae, Jeong Mo; Kang, Gyeong Hoon			Prognostic Significance of EPHB2 Expression in Colorectal Cancer Progression	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						EPHB2; Colorectal neoplasms; Immunohistochemistry; Prognosis	RECEPTOR TYROSINE KINASE; EPHRIN LIGANDS; GENE-EXPRESSION; CELLS; SURVIVAL; PROFILE; TUMORS	Background: A receptor tyrosine kinase for ephrin ligands, EPHB2, is expressed in normal colorectal tissues and colorectal cancers (CRCs). The aim of this study was to investigate EPHB2 expression over CRC progression and determine its prognostic significance in CRC. Methods: To measure EPHB2 mRNA and protein expression, real-time polymerase chain reaction and immunohistochemistry were performed in 32 fresh-frozen and 567 formalin-fixed paraffin-embedded CRC samples, respectively. We further investigated clinicopathological features and overall and recurrence-free survival according to EPHB2 protein expression. Results: The EPHB2 level was upregulated in CRC samples compared to non-cancerous tissue in most samples and showed a strong positive correlation with AXIN2. Notably, CD44 had a positive association with both mRNA and protein levels of EPHB2. Immunohistochemical analysis revealed no difference in EPHB2 expression between adenoma and carcinoma areas. Although EPHB2 expression was slightly lower in invasive fronts compared to surface area (p < .05), there was no difference between superficial and metastatic areas. EPHB2 positivity was associated with lymphatic (p < .001) and venous (p = .001) invasion, TNM stage (p < .001), and microsatellite instability (p = .036). Kaplan-Meier analysis demonstrated that CRC patients with EPHB2 positivity showed better clinical outcomes in both overall (p = .049) and recurrence-free survival (p = .015). However, multivariate analysis failed to show that EPHB2 is an independent prognostic marker in CRCs (hazard ratio, 0.692; p = .692). Conclusions: Our results suggest that EPHB2 is overexpressed in a subset of CRCs and is a significant prognostic marker.	[Jang, Bo Gun; Kim, Hye Sung] Jeju Natl Univ, Sch Med, Jeju Natl Univ Hosp, Dept Pathol, Jeju, South Korea; [Chang, Weon Young] Jeju Natl Univ, Sch Med, Jeju Natl Univ Hosp, Dept Gen Surg, Jeju, South Korea; [Bae, Jeong Mo; Kang, Gyeong Hoon] Seoul Natl Univ, Coll Med, Dept Pathol, 103 Daehak Ro, Seoul 03080, South Korea; [Bae, Jeong Mo; Kang, Gyeong Hoon] Seoul Natl Univ, Coll Med, Canc Res Inst, Lab Epigenet, Seoul, South Korea	Kang, GH (reprint author), Seoul Natl Univ, Coll Med, Dept Pathol, 103 Daehak Ro, Seoul 03080, South Korea.	ghkang@snu.ac.kr	Kang, Gyeong Hoon/F-1051-2010	Kang, Gyeong Hoon/0000-0003-2380-6675	Korean Society of Pathologists in 2015	This work was supported by a grant from the Korean Society of Pathologists in 2015.	Alazzouzi H, 2005, CANCER RES, V65, P10170, DOI 10.1158/0008-5472.CAN-05-2580; Bae JM, 2013, BRIT J CANCER, V109, P1004, DOI 10.1038/bjc.2013.430; Batlle E, 2005, NATURE, V435, P1126, DOI 10.1038/nature03626; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Boyd AW, 2014, NAT REV DRUG DISCOV, V13, P39, DOI 10.1038/nrd4175; Cortina C, 2007, NAT GENET, V39, P1376, DOI 10.1038/ng.2007.11; Fox BP, 2004, BIOCHEM BIOPH RES CO, V318, P882, DOI 10.1016/j.bbrc.2004.04.102; Guan M, 2009, INT J CANCER, V124, P88, DOI 10.1002/ijc.23890; Guo DL, 2006, CARCINOGENESIS, V27, P454, DOI 10.1093/carcin/bgi259; Hafner C, 2004, CLIN CHEM, V50, P490, DOI 10.1373/clinchem.2003.026849; Hafner C, 2006, MODERN PATHOL, V19, P1369, DOI 10.1038/modpathol.3800660; Herath NI, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-144; Herath NI, 2010, INT J CANCER, V126, P2003, DOI 10.1002/ijc.25147; Janes PW, 2008, CURR CANCER DRUG TAR, V8, P473, DOI 10.2174/156800908785699315; Jubb AM, 2005, CLIN CANCER RES, V11, P5181, DOI 10.1158/1078-0432.CCR-05-0143; Kim JH, 2014, MODERN PATHOL, V27, P443, DOI 10.1038/modpathol.2013.160; Kinch MS, 2003, CLIN CANCER RES, V9, P613; Kumar SR, 2009, CANCER RES, V69, P3736, DOI 10.1158/0008-5472.CAN-08-3232; Lackmann M, 2008, SCI SIGNAL, V1, DOI 10.1126/stke.115re2; Lugli A, 2005, CLIN CANCER RES, V11, P6450, DOI 10.1158/1078-0432.CCR-04-2458; Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020; Nakamura R, 2005, CANCER SCI, V96, P42, DOI 10.1111/j.1349-7006.2005.00007.x; Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806; Tang XX, 2000, P NATL ACAD SCI USA, V97, P10936, DOI 10.1073/pnas.190123297	24	0	0	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	SEP	2018	52	5					298	306		10.4132/jptm.2018.06.29			9	Pathology	Pathology	GT3KB	WOS:000444400600005	30016858	DOAJ Gold, Green Published			2019-10-28	
J	Chan, AWH; Tong, JHM; Kwan, JSH; Chow, C; Chung, LY; Chau, SL; Lung, RWM; Ng, CSH; Wan, IYP; Mok, TSK; To, KF				Chan, Anthony W. H.; Tong, Joanna H. M.; Kwan, Johnny S. H.; Chow, Chit; Chung, Lau Y.; Chau, Shuk L.; Lung, Raymond W. M.; Ng, Calvin S. H.; Wan, Innes Y. P.; Mok, Tony S. K.; To, Ka F.			Assessment of programmed cell death ligand-1 expression by 4 diagnostic assays and its clinicopathological correlation in a large cohort of surgical resected non-small cell lung carcinoma	MODERN PATHOLOGY			English	Article							PD-L1 EXPRESSION; POOR-PROGNOSIS; CHECKPOINT INHIBITORS; CANCER; ADENOCARCINOMA; PEMBROLIZUMAB; SURVIVAL; MUTATION; IMMUNOHISTOCHEMISTRY; CHEMOTHERAPY	Immune checkpoint blockade targeting the PD-1/PD-L1 axis has recently demonstrated efficacy and promise in cancer treatment. Appropriate biomarker selection is therefore essential for improving treatment efficacy. However, the establishment of PD-L1 assay in pathology laboratories is complicated by the presence of multiple testing platforms using different scoring systems. Here we assessed the PD-L1 expression in 713 consecutive non-small cell lung carcinomas by four commercially available PD-L1 immunohistochemical assays, namely, 22C3, 28-8, SP142 and SP263. The analytical performances of the four assays and diagnostic performances across clinically relevant cutoffs were evaluated. The prevalence of PD-L1 (22C3) expression was 21% with a = 50% cutoff and 56% with a >= 1% cutoff. High PD-L1 expression (using a = 50% cutoff) was significantly associated with male sex (P = 0.001), ever smoking history (P < 0.001), squamous cell carcinoma (P = 0.001), large cell carcinoma (P < 0.001), lymphoepithelioma-like carcinoma (P = 0.006), sarcomatoid carcinoma (P < 0.001), mutant KRAS (P = 0.005) and wild-type EGFR (P = 0.003). Elevated PD-L1 expression was also significantly associated with shorter survival in patients with adenocarcinoma (log-rank P = 0.026) and remained an independent prognostic factor by multivariable analysis. Among the four assays, 22C3, 28-8 and SP263 were highly concordant for tumor cell scoring. With a cutoff of = 50% (i. e., the threshold for first-line patient selection), inter-rater agreement was high among the three assays with percentage agreement > 97%. In conclusion, three PD-L1 assays showed good analytical performance and a high agreement with each other, but not all cases were correctly classified using the same clinical cutoff. Further studies comparing the predictive value of these assays are required to address the interchangeability of these assays for clinical use.	[Chan, Anthony W. H.; Tong, Joanna H. M.; Kwan, Johnny S. H.; Chow, Chit; Chung, Lau Y.; Chau, Shuk L.; Lung, Raymond W. M.; To, Ka F.] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China; [Chan, Anthony W. H.; Tong, Joanna H. M.; Kwan, Johnny S. H.; Chow, Chit; Chung, Lau Y.; Chau, Shuk L.; Lung, Raymond W. M.; Mok, Tony S. K.; To, Ka F.] Chinese Univ Hong Kong, State Key Lab Oncol South China, Hong Kong, Hong Kong, Peoples R China; [Chan, Anthony W. H.; Tong, Joanna H. M.; Kwan, Johnny S. H.; Chow, Chit; Chung, Lau Y.; Chau, Shuk L.; Lung, Raymond W. M.; To, Ka F.] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China; [Ng, Calvin S. H.; Wan, Innes Y. P.] Chinese Univ Hong Kong, Dept Surg, Div Cardiothorac Surg, Hong Kong, Hong Kong, Peoples R China; [Mok, Tony S. K.] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China	To, KF (reprint author), Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China.; To, KF (reprint author), Chinese Univ Hong Kong, State Key Lab Oncol South China, Hong Kong, Hong Kong, Peoples R China.; To, KF (reprint author), Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China.	kfto@cuhk.edu.hk	Lung Wai Ming, Raymond/D-1274-2014; Ng, Calvin S. H./L-4429-2016; Mok, Tony Shu Kam/B-2310-2019; Chan, Anthony/N-6719-2016	Ng, Calvin S. H./0000-0002-8074-0900; Mok, Tony Shu Kam/0000-0002-8251-0551; Chan, Anthony/0000-0002-1771-163X	AstraZenecaAstraZeneca; BI; PfizerPfizer; NovartisNovartis; SFJ; RocheRoche Holding; MSD; Clovis Oncology; BMSBristol-Myers Squibb; EisaiEisai Inc; Taiho; Roche/GenentechRoche HoldingGenentech; Eli LillyEli Lilly; Ariad/Takeda; AmgenAmgen	Professor T.M. received grant or research support from AstraZeneca, BI, Pfizer, Novartis, SFJ, Roche, MSD, Clovis Oncology, BMS, Eisai, Taiho; Speaker's fee from AstraZeneca, Roche/Genentech, Pfizer, Eli Lilly, BI, MSD, Novartis, BMS, Taiho, Ariad/Takeda, Amgen; honoraria from AstraZeneca, Roche/Genentech, Pfizer, Eli Lilly, BI, Merck Serono, MSD, Novartis, SFJ Pharmaceutical, ACEA Biosciences, Inc., Vertex Pharmaceuticals, BMS, OncoGenex Pharmaceuticals, Inc., Celgene, Ignyta, Inc., Fishawack Facilitate Ltd. He is a major stock shareholder on Sanomics Ltd. He serves as advisory board for AstraZeneca, Roche/Genentech, Pfizer, Eli Lilly, BI, Clovis Oncology, Merck Serono, MSD, Novartis, SFJ Pharmaceutical, ACEA Biosciences, Inc., Vertex Pharmaceuticals, BMS, geneDecode Co., OncoGenex Technologies Inc., Celgene, Ignyta, Inc., Cirina, Fishawack Facilitate Ltd and board director for IASLC, Chinese Lung Cancer Research Foundation Ltd., Chinese Society of Clinical Oncology (CSCO), Hong Kong Cancer Therapy Society (HKCTS). Professor A.W.H.C. serves as an advisor for Novartis. Professor C.S.H.N. serves as an advisor/consultant for Janssen Pharmaceutical, Inc. The remaining authors declare that they have no conflict of interest.	Aggarwal C, 2016, ANN ONCOL, V27, DOI 10.1093/annonc/mdw378.14; Boussiotis VA, 2016, NEW ENGL J MED, V375, P1767, DOI 10.1056/NEJMra1514296; Chen N, 2017, CANCER IMMUNOL IMMUN, V66, P1175, DOI 10.1007/s00262-017-2005-z; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Hanna N, 2017, J CLIN ONCOL, V35, P3484, DOI 10.1200/JCO.2017.74.6065; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Hirsch FR, 2017, J THORAC ONCOL, V12, P208, DOI 10.1016/j.jtho.2016.11.2228; Inman BA, 2017, CLIN CANCER RES, V23, P1886, DOI 10.1158/1078-0432.CCR-16-1417; Lee CK, 2017, J THORAC ONCOL, V12, P403, DOI 10.1016/j.jtho.2016.10.007; Marchetti A, 2017, J THORAC ONCOL, V12, P1654, DOI 10.1016/j.jtho.2017.07.031; Massi D, 2014, ANN ONCOL, V25, P2433, DOI 10.1093/annonc/mdu452; Muenst S, 2014, BREAST CANCER RES TR, V146, P15, DOI 10.1007/s10549-014-2988-5; Munari E, 2017, ONCOTARGET, V8, P90123, DOI 10.18632/oncotarget.21485; Pai-Scherf L, 2017, ONCOLOGIST, V22, P1392, DOI 10.1634/theoncologist.2017-0078; Postow MA, 2015, J CLIN ONCOL, V33, P1974, DOI 10.1200/JCO.2014.59.4358; Rangachari D, 2017, J THORAC ONCOL, V12, P878, DOI 10.1016/j.jtho.2016.12.026; Ratcliffe MJ, 2017, CLIN CANCER RES, V23, P3585, DOI 10.1158/1078-0432.CCR-16-2375; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Rimm DL, 2017, JAMA ONCOL, V3, P1051, DOI 10.1001/jamaoncol.2017.0013; Scheel AH, 2016, MODERN PATHOL, V29, P1165, DOI 10.1038/modpathol.2016.117; Shimoji M, 2016, LUNG CANCER, V98, P69, DOI 10.1016/j.lungcan.2016.04.021; Sorensen SF, 2016, TRANSL ONCOL, V9, P64, DOI 10.1016/j.tranon.2016.01.003; Sun JM, 2016, J THORAC ONCOL, V11, P1003, DOI 10.1016/j.jtho.2016.04.007; Tong JH, 2016, CLIN CANCER RES, V22, P3048, DOI 10.1158/1078-0432.CCR-15-2061; Velcheti V, 2014, LAB INVEST, V94, P107, DOI 10.1038/labinvest.2013.130; Wang A, 2015, EJSO-EUR J SURG ONC, V41, P450, DOI 10.1016/j.ejso.2015.01.020; Yang CY, 2014, EUR J CANCER, V50, P1361, DOI 10.1016/j.ejca.2014.01.018; Yeung SF, 2015, J THORAC ONCOL, V10, P1292, DOI 10.1097/JTO.0000000000000620; Zhang MH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10925-7; Zhang Y, 2014, ONCOTARGETS THER, V7, P567, DOI 10.2147/OTT.S59959; Zhang YX, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000515; Zhou Wei, 2011, Chin J Cancer, V30, P287; Zhou ZJ, 2015, TRANSL LUNG CANCER R, V4, P203, DOI 10.3978/j.issn.2218-6751.2015.03.02	33	12	12	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	SEP	2018	31	9					1381	1390		10.1038/s41379-018-0053-3			10	Pathology	Pathology	GT5SG	WOS:000444569400004	29713040	Bronze			2019-10-28	
J	Saeger, W; Schmid, KW				Saeger, W.; Schmid, K. W.			Ectopic Tissue	PATHOLOGE			German	Editorial Material							DIAGNOSIS		[Saeger, W.] Univ Hamburg, UKE, Inst Neuropathol, Martinistr 52, D-20246 Hamburg, Germany; [Schmid, K. W.] Univ Duisburg Essen, Univ Klinikum Essen, Inst Pathol, Hufelandstr 55, D-45147 Essen, Germany	Saeger, W (reprint author), Univ Hamburg, UKE, Inst Neuropathol, Martinistr 52, D-20246 Hamburg, Germany.; Schmid, KW (reprint author), Univ Duisburg Essen, Univ Klinikum Essen, Inst Pathol, Hufelandstr 55, D-45147 Essen, Germany.	w.saeger@uke.de; kw.schmid@uk-essen.de					Guth U, 2007, PATHOLOGE, V28, P291, DOI 10.1007/s00292-006-0874-6; Kuhn W, 2011, PATHOLOGE, V32, P497, DOI 10.1007/s00292-011-1480-9; Reis H, 2011, PATHOLOGE, V32, P521, DOI 10.1007/s00292-011-1461-z; SAEGER W, 1993, PATHOLOGE, V14, P371	4	0	0	0	2	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	SEP	2018	39	5					371	372		10.1007/s00292-018-0476-0			2	Pathology	Pathology	GS5HA	WOS:000443687300001	30135975	Bronze			2019-10-28	
J	Saeger, W				Saeger, W.			Ectopia of the pituitary	PATHOLOGE			German	Article						Anterior pituitary gland; Adenoma; Choristoma; Pituitary neoplasms; Posterior pituitary gland	GROWTH-HORMONE DEFICIENCY; OPTIC-NERVE HYPOPLASIA; OF-THE-LITERATURE; POSTERIOR PITUITARY; SPHENOID SINUS; CONGENITAL HYPOPITUITARISM; EMPTY SELLA; CLINICORADIOLOGICAL CORRELATION; ADRENOCORTICAL-CELLS; CUSHINGS-DISEASE	The adenohypophysis has a large intrasellar part and two small parts at the pituitary stalk and the pharynx. Near this extrasellar pituitary tissue, and also in sinus sphenoidalis and sinus cavernosus, ectopic pituitary adenomas can develop. They are indistinguishable in structure and function from usual intrasellar adenomas. The neurohypophysis can show dystopias within complex malformations. In so-called pituitary stalk interruption syndrome, a real ectopia of the neurohypophysis is found at the eminentia mediana of the hypothalamus. Ectopic tissue in the pituitary is extremely rare: foci of ganglionic cells were found in the neurohypophysis and adrenocortical tissue in the adenohypophysis. Focal squamous epithelia in the anterior pituitary are a common finding but they are rather metaplastic from parenchymal cells than ectopic tissue. Small foci of ectopic salivary gland tissue are not rare in the intermediate zone.	[Saeger, W.] Univ Hamburg, UKE, Inst Neuropathol, Martinistr 52, D-20246 Hamburg, Germany	Saeger, W (reprint author), Univ Hamburg, UKE, Inst Neuropathol, Martinistr 52, D-20246 Hamburg, Germany.	w.saeger@uke.de					Ahmed S, 2013, JAMA OTOLARYNGOL, V139, P91, DOI 10.1001/jamaoto.2013.1190a; Ali R, 2010, IRISH J MED SCI, V179, P593, DOI 10.1007/s11845-008-0236-x; Asa SL, 2011, TUMORS OF THE PITUIT, P1; Bas F, 2006, J PEDIATR ENDOCR MET, V19, P535; Binder G, 2002, EUR J ENDOCRINOL, V147, P755, DOI 10.1530/eje.0.1470755; Bozzola M, 2000, EUR J ENDOCRINOL, V143, P493, DOI 10.1530/eje.0.1430493; Brodsky MC, 2004, ARCH OPHTHALMOL-CHIC, V122, P125, DOI 10.1001/archopht.122.1.125; Brodsky MC, 1999, AM J OPHTHALMOL, V127, P238, DOI 10.1016/S0002-9394(98)00338-9; Carmichael HT, 1931, ARCH NEURO PSYCHIATR, V26, P966, DOI 10.1001/archneurpsyc.1931.02230110064002; Choh NA, 2009, J PEDIATR ENDOCR MET, V22, P407; Coire CI, 1998, NEUROSURGERY, V42, P650, DOI 10.1097/00006123-199803000-00039; Collie RB, 2005, OTOLARYNG HEAD NECK, V133, P453, DOI 10.1016/j.otohns.2004.10.015; Brito LBD, 2014, BRAZ J OTORHINOLAR, V80, P451, DOI 10.1016/j.bjorl.2014.05.022; de Graaff LCG, 2008, CLIN ENDOCRINOL, V69, P112, DOI 10.1111/j.1365-2265.2007.03167.x; Dutta P, 2010, INDIAN PEDIATR, V47, P615, DOI 10.1007/s13312-010-0135-x; Dutta P, 2009, J PEDIATR ENDOCR MET, V22, P921; ERDHEIM J, 1904, SITZUNGSBERICHTE K 3, V113, P537; Flitsch J, 2015, PITUITARY, V18, P279, DOI 10.1007/s11102-014-0591-8; Gondim JA, 2004, ACTA RADIOL, V45, P689, DOI 10.1080/02841850410008405; Guerrero CA, 2007, NEUROSURGERY, V61, P879, DOI 10.1227/01.NEU.0000280059.90596.85; Gurazada K, 2014, PITUITARY, V17, P423, DOI 10.1007/s11102-013-0520-2; Hartill V, 2017, FRONT PEDIATR, V5, DOI 10.3389/fped.2017.00244; Hochstetter F, 1924, ENTWICKLUNG HIRNANHA, P1; HOLM R, 1989, J PATHOL, V158, P213, DOI 10.1002/path.1711580307; Horvath E, 2000, ACTA NEUROPATHOL, V100, P106, DOI 10.1007/s004010051200; Hosaka N, 2002, AM J SURG PATHOL, V26, P1078, DOI 10.1097/01.PAS.0000020160.04273.19; Hou L, 2002, NEUROSURGERY, V50, P618, DOI 10.1097/00006123-200203000-00035; Johnston PC, 2014, ENDOCRINE, V47, P717, DOI 10.1007/s12020-014-0313-z; Kaushik C, 2010, J COMPUT ASSIST TOMO, V34, P612, DOI 10.1097/RCT.0b013e3181dbe5d1; Kim SS, 2003, HORM RES, V60, P277, DOI 10.1159/000074245; Kjaer KW, 1999, APMIS, V107, P937; Knappe UJ, 2017, NEUROSURGERY, V80, P525, DOI 10.1227/NEU.0000000000001319; Kusano Y, 2013, J NEUROIMAGING, V23, P135, DOI 10.1111/j.1552-6569.2011.00620.x; Liang JC, 2014, CLIN NEUROPATHOL, V33, P197, DOI 10.5414/NP300702; Lo FS, 2004, J PEDIATR ENDOCR MET, V17, P1519; Lukezic M, 2000, CLIN ENDOCRINOL, V53, P77, DOI 10.1046/j.1365-2265.2000.01030.x; Maghnie M, 2001, J CLIN ENDOCR METAB, V86, P1574, DOI 10.1210/jc.86.4.1574; Maintz D, 2000, AM J NEURORADIOL, V21, P1116; Mizutani A, 2009, BRIT J NEUROSURG, V23, P321, DOI 10.1080/02688690902842767; Mudd PA, 2012, CLIN NEUROPATHOL, V31, P24, DOI 10.5414/NP300421; Nishiike S, 2014, AURIS NASUS LARYNX, V41, P586, DOI 10.1016/j.anl.2014.07.004; Oka H, 1996, VIRCHOWS ARCH, V427, P613; Osamura R, 2017, WHO CLASSIFICATION T, P11; Pasquini E, 2003, EUR J ENDOCRINOL, V148, P253, DOI 10.1530/eje.0.1480253; Phillips PH, 2001, J AAPOS, V5, P275, DOI 10.1067/mpa.2001.118220; Pojskic M, 2017, WORLD NEUROSURG, V104, DOI 10.1016/j.wneu.2017.05.070; Priesel A, 1927, VIRCHOWS ARCH A, V266, P407, DOI 10.1007/BF02126281; Rocque BG, 2009, ENDOCR PRACT, V15, P143, DOI 10.4158/EP.15.2.143; Rotondo F, 2012, APPL IMMUNOHISTO M M, V20, P77, DOI 10.1097/PAI.0b013e3182247506; SAEGER W, 1994, VIRCHOWS ARCH, V425, P93; Saeger W, 1981, PATHOLOGIE ENDOKRINE, P1; SCHOCHET SS, 1974, ARCH PATHOL, V98, P193; Seltzer J, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2014.10.FOCUS14685; Simon D, 2006, CLIN ENDOCRINOL, V64, P416, DOI 10.1111/j.1365-2265.2006.02484.x; Sindoni A, 2018, CLIN NUCL MED, V43, pE25, DOI 10.1097/RLU.0000000000001889; Sioshansi PC, 2015, JAMA OTOLARYNGOL, V141, P649, DOI 10.1001/jamaoto.2015.0706; Spatz H, 1953, VERH ANAT GES MAIN S, V100, P46; Stanek J, 2001, PEDIATR DEVEL PATHOL, V4, P192, DOI 10.1007/s100240010131; SUMI T, 1993, ENDOCR PATHOL, V4, P155, DOI 10.1007/BF02915304; Suzuki J, 2004, ENDOCR J, V51, P97, DOI 10.1507/endocrj.51.97; Veit JA, 2013, LARYNGOSCOPE, V123, P1132, DOI 10.1002/lary.23867; Wang CZ, 2017, J NEUROENDOCRINOL, V29, DOI 10.1111/jne.12451; Wang H, 2010, J NEURO-OPHTHALMOL, V30, P135, DOI 10.1097/WNO.0b013e3181c5d1a2; Wang Q, 2016, WORLD NEUROSURG, V95, DOI 10.1016/j.wneu.2016.08.062; WORSTER-DROUGHT C, 1956, J Laryngol Otol, V70, P453, DOI 10.1017/S0022215100053184; Yang J, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008912; Zerikly RK, 2009, NAT CLIN PRACT ENDOC, V5, P174, DOI 10.1038/ncpendmet1039; Zhou HJ, 2017, PITUITARY, V20, P477, DOI 10.1007/s11102-017-0807-9; Zucchini S, 1998, J PEDIATR ENDOCR MET, V11, P35; Zucchini S, 1995, HORM RES, V44, P8, DOI 10.1159/000184666	70	0	0	1	4	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	SEP	2018	39	5					373	378		10.1007/s00292-018-0473-3			6	Pathology	Pathology	GS5HA	WOS:000443687300002	30120512				2019-10-28	
J	Theurer, S; Siebolts, U; Lorenz, K; Dralle, H; Schmid, KW				Theurer, S.; Siebolts, U.; Lorenz, K.; Dralle, H.; Schmid, K. W.			Ectopic tissue of the thyroid gland and the parathyroid glands	PATHOLOGE			German	Article						Thyroid gland; Thyroid dysgenesis; Parasitic nodule; Parathyroid glands; Parathyromatosis	PRIMARY HYPERPARATHYROIDISM; SURGICAL IMPLICATIONS; LYMPH-NODE; CARCINOMA; ANATOMY; CANCER; METASTASES; EXPERIENCE; LOCATION; PATIENT	Ectopic thyroid tissue results from developmental defects of the early stages of thyroid embryogenesis, in which the median thyroid anlage descends from the floor of the mouth to its final pre-tracheal position. The most common sites of ectopic thyroid tissue are accordingly in the area of the floor of the mouth and in the course of the thyroglossal duct. Rare localizations are intrathoracic (mediastinal, cardiac, pulmonary) and subdiaphragmatic (including the adrenals, liver, gall bladder, and gastrointestinal tract). The most important differential diagnosis of ectopic thyroid is metastasis of differentiated thyroid carcinoma. By contrast, the term parathyroidectopy is not uniformly defined. Usually, the cervicalcentral localizations are referred to as " positional variants" (with the exception of the maxillary sinus and high parapharyngeal), whereas the cervical-lateral localizations (carotid sheath, vagus nerve) and those below the brachiocephalic andmediastinal positions (extraligamentary, aortopulmonary window, paravagal) and other rare localizations are classified as " ectopic parathyroid tissue". Parathyroidectomy is very common (in autopsy studies in 28 to 42.8% of all humans). In the context of primary hyperparathyroidism (pHPT), there is a prevalence of 6.3 to 16% of ectopic hyperfunctional parathyroid tissue (predominantly adenomas), which play an important role in the surgical treatment of pHPT.	[Theurer, S.; Schmid, K. W.] Univ Duisburg Essen, Univ Klinikum Essen, Inst Pathol, Hufelandstr 55, D-45147 Essen, Germany; [Siebolts, U.] Martin Luther Univ Halle Wittenberg, Univ Klinikum Halle, Inst Pathol, Halle, Germany; [Lorenz, K.] Martin Luther Univ Halle Wittenberg, Univ Klinikum Halle, Klin & Poliklin Viszeral Gefass & Endokrine Chiru, Halle, Germany; [Dralle, H.] Univ Duisburg Essen, Univ Klinikum Essen, Klin Allgemeinchirurg Viszeral & Transplantat Chi, Essen, Germany	Schmid, KW (reprint author), Univ Duisburg Essen, Univ Klinikum Essen, Inst Pathol, Hufelandstr 55, D-45147 Essen, Germany.	kw.schmid@uk-essen.de					Abdallah-Matta MP, 2002, J ENDOCRINOL INVEST, V25, P264, DOI 10.1007/BF03344002; AKERSTROM G, 1988, ACTA CHIR SCAND, V154, P549; AKERSTROM G, 1984, SURGERY, V95, P14; Baker LJ, 2014, ENDOCRINOL DIAB META, DOI 10.1530/EDM-14-0027; BARNES BA, 1961, JAMA-J AM MED ASSOC, V178, P556, DOI 10.1001/jama.1961.03040450020004; Basaria S, 2001, J CLIN ENDOCR METAB, V86, P392, DOI 10.1210/jc.86.1.392; Camargo RY, 2018, INT J ENDOCRINOL, DOI 10.1155/2018/4682876; Chen CL, 2014, J CHIN MED ASSOC, V77, P492, DOI 10.1016/j.jcma.2013.03.015; de Oliveira Filho Jose Rildo Fernandes, 2014, J Med Case Rep, V8, P66, DOI 10.1186/1752-1947-8-66; Di Mari N, 2010, PATHOLOGICA, V102, P102; DOMINGUEZMALAGON H, 1995, AM J CLIN PATHOL, V104, P408; Fernandez-Ranvier GG, 2007, CANCER-AM CANCER SOC, V110, P255, DOI 10.1002/cncr.22790; Foroulis CN, 2009, THYROID, V19, P213, DOI 10.1089/thy.2008.0222; Giordano TJ, 2018, SURG PATHOLOGY, P355; Gonzalez-Gonzalez Abel, 2008, Endocrinol Nutr, V55, P301, DOI 10.1016/S1575-0922(08)72185-5; Gopal RA, 2009, ENDOCR PRACT, V15, P322, DOI 10.4158/EP08362.ORR1; Goswamy J, 2016, CURR OPIN OTOLARYNGO, V24, P155, DOI 10.1097/MOO.0000000000000234; Hamidi S, 2006, MED SCI MONITOR, V12, pCR86; HARACH HR, 1993, PEDIATR PATHOL, V13, P71, DOI 10.3109/15513819309048194; Hickman W, 1869, T PATHOL SOC LOND, V20, P160; Hojaij F, 2011, ANAT SCI INT, V86, P204, DOI 10.1007/s12565-011-0111-0; King WLM, 1942, SURG GYNECOL OBSTET, V74, P991; Koea JB, 1999, SURG ONCOL, V8, P155, DOI 10.1016/S0960-7404(99)00037-7; Kuffner HA, 2005, THYROID, V15, P1095, DOI 10.1089/thy.2005.15.1095; LACK EE, 1988, ARCH PATHOL LAB MED, V112, P304; Lappas D, 2012, ANAT SCI INT, V87, P160, DOI 10.1007/s12565-012-0142-1; Lorenz K, 2003, Chirurg, V74, P593, DOI 10.1007/s00104-003-0683-x; Magne F, 2015, HORM RES PAEDIAT, V83, P79, DOI 10.1159/000365393; Marx A, 2018, PATHOLOGE; Meister P, 2016, PATHOLOGE, V37, P473, DOI 10.1007/s00292-016-0181-9; MICHAL M, 1993, HISTOPATHOLOGY, V22, P85; MISHRIKI YY, 1983, ACTA CYTOL, V27, P188; Mohebati A, 2012, CLIN ANAT, V25, P19, DOI 10.1002/ca.21220; Nakai K, 2014, CLIN NEPHROL, V81, P52, DOI 10.5414/CN107533; Nanka O, 2006, Rozhl Chir, V85, P618; Nilsson M, 2017, DEVELOPMENT, V144, P2123, DOI 10.1242/dev.145615; Nilsson M, 2016, EUR THYROID J, V5, P79, DOI 10.1159/000447333; Noussios G, 2012, EXP CLIN ENDOCR DIAB, V120, P604, DOI 10.1055/s-0032-1327628; Noussios G, 2011, EUR J ENDOCRINOL, V165, P375, DOI 10.1530/EJE-11-0461; PALMER JA, 1975, ARCH SURG-CHICAGO, V110, P1004; Phitayakorn R, 2006, AM J SURG, V191, P418, DOI 10.1016/j.amjsurg.2005.10.049; Policeni BA, 2012, SEMIN ULTRASOUND CT, V33, P104, DOI 10.1053/j.sult.2011.12.005; Postiglione MP, 2002, P NATL ACAD SCI USA, V99, P15462, DOI 10.1073/pnas.242328999; Quiros RN, 2004, ARCH SURG-CHICAGO, V139, P501, DOI 10.1001/archsurg.139.5.501; REDDICK RL, 1977, LANCET, V1, P549; RICHMOND I, 1990, THORAX, V45, P293, DOI 10.1136/thx.45.4.293; Ruda JM, 2005, OTOLARYNG HEAD NECK, V132, P359, DOI 10.1016/j.otohns.2004.10.005; RUSSELL CF, 1982, BRIT J SURG, V69, P244, DOI 10.1002/bjs.1800690503; Ryu HS, 2012, THYROID, V22, P755, DOI 10.1089/thy.2012.0014; Saeger W, 2018, PATHOLOGE; SAUK JJ, 1970, J PATHOL, V102, P239, DOI 10.1002/path.1711020408; SAWADY J, 1989, MODERN PATHOL, V2, P652; Schmid KW, 2015, PATHOLOGE, V36, P171, DOI 10.1007/s00292-015-0071-6; Shah Bhavin C, 2007, Ann Thorac Cardiovasc Surg, V13, P122; Sheu-Grabellus SY, 2015, PATHOLOGE, V36, P229, DOI 10.1007/s00292-015-0016-0; Sheu-Grabellus S-Y, 2015, PATHOLOGIE UROGENITA, P714; Stein T, 2018, HEAD NECK PATHOL, V12, P71, DOI 10.1007/s12105-017-0826-x; Synoracki S, 2015, PATHOLOGE, V36, P254, DOI 10.1007/s00292-015-0017-z; THOMPSON NW, 1982, SURGERY, V92, P814; Togashi S, 2004, AURIS NASUS LARYNX, V31, P287, DOI 10.1016/j.anl.2004.03.006; Tucci G, 1999, G Chir, V20, P97; Tzankov A, 2016, PATHOLOGE, V37, P400, DOI 10.1007/s00292-016-0197-1; VELLAR ID, 1973, AUST NZ J SURG, V42, P257, DOI 10.1111/j.1445-2197.1973.tb06791.x; Wang Shu-Chi, 2017, J Endourol Case Rep, V3, P149, DOI 10.1089/cren.2017.0080	64	1	1	0	4	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	SEP	2018	39	5					379	389		10.1007/s00292-018-0467-1			11	Pathology	Pathology	GS5HA	WOS:000443687300003	30105609				2019-10-28	
J	Saeger, W				Saeger, W.			Ectopia of the adrenal	PATHOLOGE			German	Article						Ectopia; Adrenal rest tumor; Ectopic ACTH syndrome; Adrenal cortex; Adrenal medulla; Pheochromocytoma	ACTH-SECRETING PHEOCHROMOCYTOMA; STEROID CELL TUMOR; OF-THE-LITERATURE; CUSHINGS-SYNDROME; THYROID-TISSUE; CORTICAL ADENOMA; SPERMATIC CORD; HYPERPLASIA; GLAND; CARCINOMA	Ectopia of nodular adrenocortical tissue is very frequently found in the periadrenal region. It corresponds to accessory adrenal tissue and is a normal variant. Ectopia in more distant regions are found in inner male or female genitalia. Strong long- lasting hyperstimultions induce hyperplasia and simulate true tumors (" adrenal rest tumors"). Real autonomic tumors from ectopic adrenal tissue with or without hyperfunction are rare. Ectopia of adrenomedullary tissue are nearly exclusively found in the surroundings of normal medulla. Ectopia in the adrenals corresponds almost exclusively with thyroid tissue. Ectopic secretion of hormones, mostly ACTH, can be found in pheochromocytomas and induces hyperfunction ( Cushing's syndrome).	[Saeger, W.] Univ Klinikum Hamburg Eppendorf, Inst Pathol, Martinistr 52, D-20246 Hamburg, Germany	Saeger, W (reprint author), Univ Klinikum Hamburg Eppendorf, Inst Pathol, Martinistr 52, D-20246 Hamburg, Germany.	w.saeger@uke.de					Abdelhamid S, 1996, ARCH INTERN MED, V156, P1190, DOI 10.1001/archinte.156.11.1190; Al-Arfaj AL, 1998, EUR J SURG, V164, P275, DOI 10.1080/110241598750004508; Amos AM, 1998, UROLOGY, V52, P331, DOI 10.1016/S0090-4295(98)00192-7; ANDERSON JR, 1980, POSTGRAD MED J, V56, P806, DOI 10.1136/pgmj.56.661.806; ARNOLD J, 1989, POSTGRAD MED J, V65, P847, DOI 10.1136/pgmj.65.769.847; Ayala AR, 2000, J CLIN ENDOCR METAB, V85, P2903, DOI 10.1210/jc.85.8.2903; Bas F, 2000, J PEDIATR ENDOCR MET, V13, P663; Bayraktar F, 2006, EXP CLIN ENDOCR DIAB, V114, P444, DOI 10.1055/s-2006-924154; BENVENUTI S, 1991, J UROLOGIE, V97, P107; Bohinc BN, 2011, THYROID, V21, P1033, DOI 10.1089/thy.2010.0390; Brenner N, 2008, CAN J UROL, V15, P3924; BUSUTTIL A, 1974, J PATHOL, V113, P231, DOI 10.1002/path.1711130406; Teijeiro JMC, 2013, VIRCHOWS ARCH, V463, P149; Cariou J, 2008, PROG UROL, V18, P68, DOI 10.1016/j.purol.2007.12.004; CASELITZ J, 1979, ENDOKRINOLOGIE, V74, P163; Chen HD, 2017, ENDOCR PATHOL, V28, P146, DOI 10.1007/s12022-016-9461-4; Chew KT, 2017, HORM MOL BIOL CLIN I; CINA SJ, 1995, ARCH PATHOL LAB MED, V119, P561; Claahsen-van der Grinten HL, 2006, J PEDIATR ENDOCR MET, V19, P177; Cohade C, 2009, GYNECOL ENDOCRINOL, V25, P624, DOI 10.1080/09513590903015411; Ruiz MD, 2009, HORM RES, V72, P504; de Miguel V, 2010, MEDICINA-BUENOS AIRE, V70, P254; DELMAS V, 1986, ANN UROL, V20, P261; Dhom G, 1981, PATHOLOGIE ENDOKRINE, P729; Ekinci N, 2017, TURK J GASTROENTEROL, V28, P401, DOI 10.5152/tjg.2017.17208; Erem C, 2005, J ENDOCRINOL INVEST, V28, P561, DOI 10.1007/BF03347247; Falhammar H, 2017, ENDOCRINE, V55, P305, DOI 10.1007/s12020-016-1127-y; GAFFEY MJ, 1990, AM J CLIN PATHOL, V94, P706, DOI 10.1093/ajcp/94.6.706; Giner J, 2017, CHILD NERV SYST, V33, P1009, DOI 10.1007/s00381-017-3397-y; GUTOWSKI WT, 1979, J UROLOGY, V121, P353, DOI 10.1016/S0022-5347(17)56783-X; HARRISON LA, 1990, AM J NEURORADIOL, V11, P1185; Hirai H, 2016, INTERNAL MED, V55, P2985, DOI 10.2169/internalmedicine.55.7071; Kiepe D, 2008, HORM RES, V70, P139; Kirkby-Bott J, 2012, WORLD J SURG, V36, P1382, DOI 10.1007/s00268-012-1488-1; Lamas C, 2009, EXP CLIN ENDOCR DIAB, V117, P440, DOI 10.1055/s-0029-1202274; LANDRY GS, 1982, MIL MED, V147, P666; Leibowitz J, 1998, J CLIN ENDOCR METAB, V83, P3786, DOI 10.1210/jc.83.11.3786; Li XG, 2012, CHINESE MED J-PEKING, V125, P1193, DOI 10.3760/cma.j.issn.0366-6999.2012.06.042; Linder B, 2009, INT J UROL, V16, P912, DOI 10.1111/j.1442-2042.2009.02372.x; LIVNE PM, 1987, J UROLOGY, V137, pA344, DOI 10.1016/S0022-5347(17)76112-5; Lois KB, 2016, CLIN ENDOCRINOL, V84, P177, DOI 10.1111/cen.12960; Louiset E, 2008, J ENDOCRINOL, V196, P1, DOI 10.1677/JOE-07-0413; Mari M, 2004, UROL INT, V73, P191, DOI 10.1159/000079705; Mitschke H, 1981, PATHOLOGIE ENDOKRINE, P971; Nelson AA, 1939, ARCH PATHOL, V27, P955; Neto LV, 2007, ENDOCR PATHOL, V18, P46, DOI 10.1007/s12022-007-0006-8; Niedziela M, 2012, GINEKOL POL, V83, P700; Oh HC, 2003, ENDOCR J, V50, P739, DOI 10.1507/endocrj.50.739; Pang SY, 1997, BAILLIERE CLIN OB GY, V11, P281, DOI 10.1016/S0950-3552(97)80038-7; Pfister C, 1995, ANN CHIR, V49, P963; Puar T, 2017, J CLIN ENDOCR METAB, V102, P339, DOI 10.1210/jc.2016-2702; Bermudez RP, 2011, CIR ESPAN, V89, P688, DOI 10.1016/j.ciresp.2010.05.020; Ren PT, 2013, WORLD J GASTROENTERO, V19, P778, DOI 10.3748/wjg.v19.i5.778; Romero-Rojas A, 2013, THYROID, V23, P1644, DOI 10.1089/thy.2013.0063; Sa DJ, 1997, POTTERS PATHOLOGY FE, P1151; Saeger W, 2016, PATHOLOGE, V37, P238, DOI 10.1007/s00292-016-0163-y; Saeger W, 1998, ENDOCR PATHOL, V9, P241, DOI 10.1007/BF02739964; Sahnoun L, 2006, ARCH PEDIATRIE, V13, P1316, DOI 10.1016/j.arcped.2006.06.027; Sakuma I, 2016, J CLIN ENDOCR METAB, V101, P841, DOI 10.1210/jc.2015-2855; Sato M, 1998, INTERNAL MED, V37, P403, DOI 10.2169/internalmedicine.37.403; Shigematsu K, 2007, PATHOL RES PRACT, V203, P543, DOI 10.1016/j.prp.2007.03.006; Shiraishi T, 1999, HUM PATHOL, V30, P105, DOI 10.1016/S0046-8177(99)90309-X; Souverijns G, 2000, EUR RADIOL, V10, P1165, DOI 10.1007/s003309900263; Sturm N, 2004, ANN PATHOL, V24, P183, DOI 10.1016/S0242-6498(04)93944-2; Surrey LF, 2012, CASE REP PATHOL, DOI 10.1155/2012/326418; Thomas TT, 2013, J PEDIATR SURG, V48, pE23, DOI 10.1016/j.jpedsurg.2013.04.006; Tingi E, 2018, J OBSTET GYNAECOL, V38, P1174, DOI 10.1080/01443615.2017.1410535; Tong AL, 2014, INT J CLIN EXP PATHO, V7, P4415; TSUCHIDA Y, 1984, CANCER, V53, P1609, DOI 10.1002/1097-0142(19840401)53:7<1609::AID-CNCR2820530732>3.0.CO;2-8; Tsujimura A, 1996, BRIT J UROL, V77, P605, DOI 10.1046/j.1464-410X.1996.99026.x; VERDONK C, 1982, AM J MED, V73, P455, DOI 10.1016/0002-9343(82)90753-7; Wang XL, 2012, NEUROENDOCRINOL LETT, V33, P265; White A, 2000, J CLIN ENDOCR METAB, V85, P4771, DOI 10.1210/jc.85.12.4771; Wright JP, 2018, FAM CANCER, V17, P381, DOI 10.1007/s10689-017-0042-6; Zaarour MG, 2014, ENDOCR PRACT, V20, pE69, DOI 10.4158/EP13092.CR; Zhao Y, 2018, ANN ENDOCRINOL-PARIS, V79, P75, DOI 10.1016/j.ando.2017.03.003	76	0	0	0	3	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	SEP	2018	39	5					409	414		10.1007/s00292-018-0459-1			6	Pathology	Pathology	GS5HA	WOS:000443687300007	30054734				2019-10-28	
J	Song, B; Lee, K; Lee, C; Moon, KC				Song, Boram; Lee, Kyoungbun; Lee, Cheol; Moon, Kyung Chul			Prognostic significance of microscopic tumor extension in local recurrence of myxofibrosarcoma and undifferentiated pleomorphic sarcoma	PATHOLOGY INTERNATIONAL			English	Article						local recurrence; microscopic extension; Myxofibrosarcoma; undifferentiated pleomorphic sarcoma	SOFT-TISSUE SARCOMAS; MALIGNANT FIBROUS HISTIOCYTOMA; INFILTRATIVE GROWTH; SINGLE INSTITUTION; TAIL SIGN; EXTREMITIES; SURVIVAL; SYSTEMS; PATTERN; SERIES	Myxofibrosarcoma (MFS) and undifferentiated pleomorphic sarcoma (UPS) frequently display infiltrative growth into the adjacent normal soft tissue. In this study, we aimed to determine whether the microscopic extension into surrounding normal tissue can influence the local recurrence of MFS and UPS. A total of 42 cases (22 MFS and 20 UPS) were examined. The length of the microscopic extension was measured from the edge of the main tumor mass to the end of infiltration. The length of 5.5mm was selected as the optimal cut-off value that could predict local recurrence using the receiver operating characteristic (ROC) curve and Youden index. Longer length of microscopic extension was significantly correlated with the status of resection margin (P=0.032). The group with longer length of microscopic extension (>5.5mm) had significantly worse recurrence-free survival than the group with shorter length of microscopic extension (5.5mm) (P=0.000). Multivariate analysis revealed that the length of microscopic extension was independent predictors of recurrence-free survival (P=0.018). In conclusion, microscopic extensions at the edge of the main mass into the surrounding normal tissue were observed in most MFS and UPS patients, and the length of microscopic extension was associated with local recurrence.	[Song, Boram; Lee, Kyoungbun; Lee, Cheol; Moon, Kyung Chul] Seoul Natl Univ, Coll Med, Dept Pathol, Seoul, South Korea	Moon, KC (reprint author), Univ Coll Med, Dept Pathol, 103 Daehak Ro, Seoul 110799, South Korea.	blue7270@snu.ac.kr	Lee, Kyoung-Bun/J-2571-2016	Lee, Kyoung-Bun/0000-0001-8427-3003	Seoul National University Hospital Research Fund [03-2015-0230]	This work was supported by grant 03-2015-0230 from the Seoul National University Hospital Research Fund.	Alamanda VK, 2013, ACTA ONCOL, V52, P793, DOI 10.3109/0284186X.2012.711953; Biau DJ, 2012, CANCER-AM CANCER SOC, V118, P5867, DOI 10.1002/cncr.27639; Cany L, 1999, J SURG ONCOL, V71, P4, DOI 10.1002/(SICI)1096-9098(199905)71:1<4::AID-JSO2>3.0.CO;2-W; Fanburg-Smith J C, 1999, Ann Diagn Pathol, V3, P1, DOI 10.1016/S1092-9134(99)80003-3; Fletcher C, 2013, WHO CLASSIFICATION T; Fletcher CDM, 2002, WHO CLASSIFICATION T; Hajian-Tilaki K, 2013, CASP J INTERN MED, V4, P627; Hong NJL, 2013, ANN SURG ONCOL, V20, P80, DOI 10.1245/s10434-012-2572-3; Huang HY, 2004, HUM PATHOL, V35, P612, DOI 10.1016/j.humpath.2004.01.016; Iwata S, 2014, J SURG ONCOL, V110, P707, DOI 10.1002/jso.23708; Kang S, 2014, EJSO-EUR J SURG ONC, V40, P406, DOI 10.1016/j.ejso.2013.12.010; Kaya M, 2008, SKELETAL RADIOL, V37, P1085, DOI 10.1007/s00256-008-0542-4; Kaya M, 2011, J ORTHOP SCI, V16, P413, DOI 10.1007/s00776-011-0100-0; Kikuta K, 2015, SKELETAL RADIOL, V44, P55, DOI 10.1007/s00256-014-1992-5; Kikuta K, 2013, JPN J CLIN ONCOL, V43, P1093, DOI 10.1093/jjco/hyt119; Lefkowitz RA, 2013, SKELETAL RADIOL, V42, P809, DOI 10.1007/s00256-012-1563-6; Lehnhardt M, 2009, LANGENBECK ARCH SURG, V394, P313, DOI 10.1007/s00423-008-0368-5; Pisters PWT, 1996, J CLIN ONCOL, V14, P1679, DOI 10.1200/JCO.1996.14.5.1679; Potter BK, 2008, CLIN ORTHOP RELAT R, V466, P3093, DOI 10.1007/s11999-008-0529-4; Ramanathan RC, 2001, ANN SURG ONCOL, V8, P278, DOI 10.1245/aso.2001.8.4.278; Sanfilippo R, 2011, ANN SURG ONCOL, V18, P720, DOI 10.1245/s10434-010-1341-4; SINGER S, 1994, ANN SURG, V219, P165, DOI 10.1097/00000658-199402000-00008; Stojadinovic A, 2002, ANN SURG, V235, P424, DOI 10.1097/00000658-200203000-00015; SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615; TROJANI M, 1984, INT J CANCER, V33, P37, DOI 10.1002/ijc.2910330108; WEISS SW, 1978, CANCER-AM CANCER SOC, V41, P2250, DOI 10.1002/1097-0142(197806)41:6<2250::AID-CNCR2820410626>3.0.CO;2-W; WEISS SW, 1977, CANCER, V39, P1672, DOI 10.1002/1097-0142(197704)39:4<1672::AID-CNCR2820390442>3.0.CO;2-C; Weiss SW, 2014, ENZINGER WEISSS SOFT; Yoo HJ, 2014, EUR RADIOL, V24, P1749, DOI 10.1007/s00330-014-3181-2; Zagars GK, 2003, CANCER, V97, P2530, DOI 10.1002/cncr.11365	30	1	1	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	SEP	2018	68	9					509	516		10.1111/pin.12709			8	Pathology	Pathology	GS8GQ	WOS:000443947100002	30094896				2019-10-28	
J	Ibis, K; Saglam, S; Saglam, EK; Firat, P; Yilmazbayhan, D; Toker, A; Ozkan, B; Hancer, VS; Buyukdogan, M; Disci, R; Pilanci, KN				Ibis, Kamuran; Saglam, Sezer; Saglam, Esra Kaytan; Firat, Pinar; Yilmazbayhan, Dilek; Toker, Alper; Ozkan, Berker; Hancer, Veysel S.; Buyukdogan, Murat; Disci, Rian; Pilanci, Kezban Nur			Prognostic significance of carbonic anhydrase IX overexpression in stage III non-small cell lung cancer patients after neoadjuvant treatment	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Non-small cell lung cancer (NSCLC); Carbonic anhydrase IX (CA DC); Neoadjuvant treatment; Prognosis; Overall survival; Disease free survival	POOR-PROGNOSIS; GENE-EXPRESSION; CA-IX; HYPOXIA; RADIOTHERAPY; CARCINOMA; PLASMA	Background: To assess the prognostic importance of carbonic anhydrase IX (CA IX), a hypoxic biomarker, after neoadjuvant treatment in Stage III non-small cell lung cancer (NSCLC) patients. Methods: Tissue CA IX expression was examined after surgical resection in 77 patients who had undergone neoadjuvant treatment. The effects of CA IX overexpression and other clinical factors on disease-free survival and overall survival were investigated. Results: In multivariate analysis, number of neoadjuvant chemotherapy (CT) courses and gender emerged as significant independent predictors for disease-free survival, where administration of 2-3 courses of neoadjuvant chemotherapy (CT) (HR, 3.2 [95% CI 1.3-7.6], p = 0.009) and female gender were associated with poor survival (HR, 3.2 [95% CI 1.3-7.7], p = 0.009). The only significant independent predictor for overall survival was recurrence (HR, 5.6 [95% CI 2.4-12.8], p < 0.001). On the other hand, CA IX overexpression was not associated with disease free survival (p = 0.560) or overall survival (p = 0.799). Discussion: Our results do not suggest a prognostic role for CA IX overexpression in stage III NSCLC patients who received neoadjuvant treatment.	[Ibis, Kamuran; Saglam, Esra Kaytan] Istanbul Univ, Dept Radiat Oncol, Med Fac, Istanbul, Turkey; [Saglam, Sezer] Istanbul Bilim Univ, Dept Med Oncol, Istanbul, Turkey; [Firat, Pinar] Koc Univ, Dept Pathol, Sch Med, Istanbul, Turkey; [Toker, Alper; Ozkan, Berker] Istanbul Univ, Dept Thorac Surg, Med Fac, Istanbul, Turkey; [Hancer, Veysel S.] Istinye Univ, Dept Med Genet, Istanbul, Turkey; [Buyukdogan, Murat] Goztepe Med Pk Hosp, Istanbul, Turkey; [Disci, Rian] Istanbul Univ, Med Fac, Dept Biostat, Basic Med Sci, Istanbul, Turkey; [Pilanci, Kezban Nur] Istanbul Haseki Egit Arastirma Hosp, Dept Med Oncol, Istanbul, Turkey; [Yilmazbayhan, Dilek] Istanbul Univ, Med Fac, Dept Pathol, Istanbul, Turkey	Saglam, S (reprint author), Gayrettepe Florence Nightingale Hastanesi, Cemil Arslan Guder Sok 8, TR-34349 Istanbul, Turkey.	saglam@istanbul.edu.tr	DISCI, RIAN/L-3788-2018; hancer, veysel sabri/X-8971-2018; Buyukdogan, Murat/Y-2855-2018	DISCI, RIAN/0000-0002-5569-0913; hancer, veysel sabri/0000-0003-2994-1077; Buyukdogan, Murat/0000-0001-7948-0235; Ibis, Kamuran/0000-0001-7928-6264; YILMAZBAYHAN, EMINE DILEK/0000-0002-4836-567X	Turkish Medical Oncology Society [P-TFOD-2015-17]	This study was funded by Turkish Medical Oncology Society(P-TFOD-2015-17)	Andersen S, 2011, LUNG CANCER, V72, P294, DOI 10.1016/j.lungcan.2010.10.006; Brahimi-Horn MC, 2007, J MOL MED-JMM, V85, P1301, DOI 10.1007/s00109-007-0281-3; Chamie K, 2017, JAMA ONCOL, V3, P913, DOI 10.1001/jamaoncol.2016.4419; Dehing-Oberije C, 2011, INT J RADIAT ONCOL, V81, P360, DOI 10.1016/j.ijrobp.2010.06.011; Dorai T, 2005, EUR J CANCER, V41, P2935, DOI 10.1016/j.ejca.2005.09.011; Eriksen JG, 2007, RADIOTHER ONCOL, V83, P383, DOI 10.1016/j.radonc.2007.05.009; Giatromanolaki A, 2001, CANCER RES, V61, P7992; Goldstraw P, 2009, J THORAC ONCOL, V4, P671, DOI 10.1097/JTO.0b013e31819e7814; Ilie M, 2010, BRIT J CANCER, V102, P1627, DOI 10.1038/sj.bjc.6605690; Kim SJ, 2005, LUNG CANCER, V49, P325, DOI 10.1016/j.lungcan.2005.03.036; Kim SJ, 2004, CLIN CANCER RES, V10, P7925, DOI 10.1158/1078-0432.CCR-04-0636; Kon-No H, 2006, LUNG CANCER, V54, P409, DOI 10.1016/j.lungcan.2006.08.017; Le QT, 2006, CLIN CANCER RES, V12, P1507, DOI 10.1158/1078-0432.CCR-05-2049; Lindskog S, 1997, PHARMACOL THERAPEUT, V74, P1, DOI 10.1016/S0163-7258(96)00198-2; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Malentacchi F, 2009, LUNG CANCER, V64, P271, DOI 10.1016/j.lungcan.2008.10.001; Ostheimer C, 2014, STRAHLENTHER ONKOL, V190, P276, DOI 10.1007/s00066-013-0484-1; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Simi L, 2006, LUNG CANCER, V52, P59, DOI 10.1016/j.lungcan.2005.11.017; Stewart DJ, 2014, J THORAC ONCOL, V9, P675, DOI 10.1097/JTO.0000000000000148; Stinchcombe Thomas E, 2009, Proc Am Thorac Soc, V6, P233, DOI 10.1513/pats.200809-110LC; Swinson DEB, 2004, BRIT J CANCER, V91, P1301, DOI 10.1038/sj.bjc.6602149; Swinson DEB, 2003, J CLIN ONCOL, V21, P473, DOI 10.1200/JCO.2003.11.132; Tafreshi NK, 2014, SUBCELL BIOCHEM, V75, P221, DOI 10.1007/978-94-007-7359-2_12; Vermylen P, 1999, EUR RESPIR J, V14, P806, DOI 10.1034/j.1399-3003.1999.14d14.x; Wykoff CC, 2000, CANCER RES, V60, P7075	26	0	0	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	SEP	2018	214	9					1291	1296		10.1016/j.prp.2018.07.010			6	Pathology	Pathology	GV3DC	WOS:000445973500008	30029935				2019-10-28	
J	Vastrad, C; Vastrad, B				Vastrad, Chanabasayya; Vastrad, Basavaraj			Bioinformatics analysis of gene expression profiles to diagnose crucial and novel genes in glioblastoma multiform	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Glioblastoma multiform; Molecular markers; Modules; Pathway enrichment analysis; PPI; Network	STEM-LIKE CELLS; MINICHROMOSOME MAINTENANCE PROTEIN-7; ACTIVATING TRANSCRIPTION FACTOR-3; SPINDLE-ASSOCIATED PROTEIN-1; TOPOISOMERASE-II-ALPHA; TUMOR-SUPPRESSOR GENE; PRIMARY BRAIN-TUMORS; GROWTH IN-VIVO; GLIOMA-CELL; SIGNALING PATHWAY	Therefore, the current study aimed to diagnose the genes associated in the pathogenesis of GBM. The differentially expressed genes (DEGs) were diagnosed using the limma software package. The ToppFun was used to perform pathway and Gene Ontology (GO) enrichment analysis of the DEGs. Protein-protein interaction (PPI) networks, extracted modules, miRNA-target genes regulatory network and miRNA-target genes regulatory network were used to obtain insight into the actions of DEGs. Survival analysis for DEGs carried out. A total of 701 DEGs, including 413 upregulated and 288 downregulated genes, were diagnosed between U1118MG cell line (PK 11195 treated with 1 h exposure) and U1118MG cell line (PK 11195 treated with 24 h exposure). The up-regulated genes were enriched in superpathway of pyrimidine deoxyribonucleotides de novo biosynthesis, cell cycle, cell cycle process and chromosome. The down-regulated genes were enriched in folate transformations I, biosynthesis of amino acids, cellular amino acid metabolic process and vacuolar membrane. The current study screened the genes in PPI network, extracted modules, miRNA-target genes regulatory network and miRNA-target genes regulatory network with higher degrees as hub genes, which included MYC, TERF2IP, CDK1, EEF1G, TXNIP, SLC1A5, RGS4 and IER5L Survival suggested that low expressed NR4A2, SLC7 A5, CYR61 and ID1 in patients with GBM was linked with a positive prognosis for overall survival. In conclusion, the current study could improve our understanding of the molecular mechanisms in the progression of GBM, and these crucial as well as new molecular markers might be used as therapeutic targets for GBM.	[Vastrad, Chanabasayya] Biostat & Bioinformat, Dharwad 580001, Karnataka, India; [Vastrad, Basavaraj] SETS Coll Pharm, Dept Pharmaceut, Dharwad 580002, Karnataka, India	Vastrad, C (reprint author), Biostat & Bioinformat, Dharwad 580001, Karnataka, India.	channu.vastrad@gmail.com					Abeysinghe HR, 1999, CANCER GENET CYTOGEN, V114, P136, DOI 10.1016/S0165-4608(99)00064-3; Adams S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112945; Aguirre-Gamboa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074250; Akimitsu N, 2003, BIOCHEM BIOPH RES CO, V307, P301, DOI 10.1016/S0006-291X(03)01169-0; Alarcon C, 2009, CELL, V139, P757, DOI 10.1016/j.cell.2009.09.035; Albulescu R, 2013, MEDIAT INFLAMM, DOI 10.1155/2013/979748; Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Ando K, 2010, CANCER SCI, V101, P639, DOI 10.1111/j.1349-7006.2009.01457.x; Arai Y, 1998, ACTA NEUROCHIR, V140, P377, DOI 10.1007/s007010050112; ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Ayllon V, 2007, ONCOGENE, V26, P3451, DOI 10.1038/sj.onc.1210142; Balci T, 2016, GENE, V590, P120, DOI 10.1016/j.gene.2016.06.024; Barth RF, 2008, P NATL ACAD SCI USA, V105, P17493, DOI 10.1073/pnas.0809569105; Basso K, 2010, ADV IMMUNOL, V105, P193, DOI 10.1016/S0065-2776(10)05007-8; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Berlingieri MT, 2007, ONCOGENE, V26, P2136, DOI 10.1038/sj.onc.1210010; Bernstein SL, 2006, MOL VIS, V12, P147; Bhowmick DA, 2004, CANCER RES, V64, P1220, DOI 10.1158/0008-5472.CAN-03-3137; Bigey P, 2000, GENE, V242, P407, DOI 10.1016/S0378-1119(99)00501-6; Bin OY, 1998, CELL GROWTH DIFFER, V9, P877; Buczkowicz P, 2013, BRAIN PATHOL, V23, P244, DOI 10.1111/j.1750-3639.2012.00633.x; Cahill DP, 2007, CLIN CANCER RES, V13, P2038, DOI 10.1158/1078-0432.CCR-06-2149; Calogero A, 2004, CANCER CELL INT, V4, DOI 10.1186/1475-2867-4-1; Cappelli E, 2012, J CANCER RES CLIN, V138, P897, DOI 10.1007/s00432-012-1217-z; Cascon A, 2012, CANCER RES, V72, P3119, DOI 10.1158/0008-5472.CAN-11-3891; Caspi R, 2016, NUCLEIC ACIDS RES, V44, pD471, DOI 10.1093/nar/gkv1164; Caunt CJ, 2013, FEBS J, V280, P489, DOI 10.1111/j.1742-4658.2012.08716.x; Chang AL, 2016, CANCER RES, V76, P5671, DOI 10.1158/0008-5472.CAN-16-0144; Chatr-aryamontri A, 2017, NUCLEIC ACIDS RES, V45, pD369, DOI 10.1093/nar/gkw1102; Chen J, 2009, NUCLEIC ACIDS RES, V37, pW305, DOI 10.1093/nar/gkp427; Chen YL, 2007, J PHARMACOL EXP THER, V323, P746, DOI 10.1124/jpet.107.126193; Chen Y, 2007, J CELL BIOCHEM, V100, P1337, DOI 10.1002/jcb.21194; Cheng G, 2015, TUMOR BIOL, V36, P2869, DOI 10.1007/s13277-014-2915-8; Chilosi M, 1998, AM J PATHOL, V152, P209; Cho HR, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17062-1; Chou CH, 2018, NUCLEIC ACIDS RES, V46, pD296, DOI 10.1093/nar/gkx1067; Chung WJ, 2005, J NEUROSCI, V25, P7101, DOI 10.1523/JNEUROSCI.5258-04.2005; Cotton M, 2009, CELL SIGNAL, V21, P1045, DOI 10.1016/j.cellsig.2009.02.008; Dahlquist KD, 2002, NAT GENET, V31, P19, DOI 10.1038/ng0502-19; Dammann R, 2000, NAT GENET, V25, P315; Day BW, 2011, NEURO-ONCOLOGY, V13, P1202, DOI 10.1093/neuonc/nor119; Dong P, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0185637; Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224; Duncan CG, 2010, ONCOTARGET, V1, P265, DOI 10.18632/oncotarget.137; Erkan EP, 2014, ONCOGENE, V33, P4778, DOI 10.1038/onc.2013.423; Ernst A, 2010, ONCOGENE, V29, P3411, DOI 10.1038/onc.2010.83; Facoetti A, 2006, ANTICANCER RES, V26, P3513; Facoetti A, 2006, ANTICANCER RES, V26, P1071; Fang L, 2016, ONCOL REP, V36, P1506, DOI 10.3892/or.2016.4955; Felsberg J, 2011, INT J CANCER, V129, P659, DOI 10.1002/ijc.26083; Fortin SP, 2012, MOL CANCER RES, V10, P958, DOI 10.1158/1541-7786.MCR-11-0616; Fulda S, 2012, NAT REV DRUG DISCOV, V11, P109, DOI 10.1038/nrd3627; Ghosh Debashis, 2003, Functional & Integrative Genomics, V3, P180; Gioutlakis A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186039; Gomori E, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-8; Goto M, 2005, J BIOL CHEM, V280, P37246, DOI 10.1074/jbc.M506486200; Gratas C, 1997, BRAIN PATHOL, V7, P863, DOI 10.1111/j.1750-3639.1997.tb00889.x; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Grunnet ML, 2000, CLIN NEUROPATHOL, V19, P230; Guastella AR, 2016, MOL IMAGING, V15, P1, DOI 10.1177/1536012116644881; Guo DL, 2011, CANCER DISCOV, V1, P442, DOI 10.1158/2159-8290.CD-11-0102; Guo L, 2017, CELL CYCLE, V16, P1705, DOI 10.1080/15384101.2017.1356507; Guo QH, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0325-6; HALL CL, 1995, CELL, V82, P19, DOI 10.1016/0092-8674(95)90048-9; Hansberg-Pastor V, 2017, MOL CELL ENDOCRINOL, V439, P317, DOI 10.1016/j.mce.2016.09.018; Hara T, 2006, ONCOGENE, V25, P566, DOI 10.1038/sj.onc.1209078; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Herquel B, 2011, P NATL ACAD SCI USA, V108, P8212, DOI 10.1073/pnas.1101544108; Hong SW, 2012, J BIOL CHEM, V287, P24017, DOI 10.1074/jbc.M111.319822; Hong Y, 2012, NEUROSCI LETT, V518, P138, DOI 10.1016/j.neulet.2012.04.071; Hsu YC, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.22; Hu F, 2013, LEUKEMIA RES, V37, P447, DOI 10.1016/j.leukres.2012.11.010; Ilencikova D, 2011, PEDIATR BLOOD CANCER, V57, P1067, DOI 10.1002/pbc.23217; Iurlaro R, 2014, METHOD ENZYMOL, V542, P59, DOI 10.1016/B978-0-12-416618-9.00003-0; Jain M, 2012, SCIENCE, V336, P1040, DOI 10.1126/science.1218595; Jair KW, 2006, CANCER RES, V66, P682, DOI 10.1158/0008-5472.CAN-05-1980; Jewison T, 2014, NUCLEIC ACIDS RES, V42, pD478, DOI 10.1093/nar/gkt1067; Jiang L, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.8; Jin X, 2011, CANCER RES, V71, P7125, DOI 10.1158/0008-5472.CAN-11-1330; Joel M, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0398-x; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Joshi K, 2013, STEM CELLS, V31, P1051, DOI 10.1002/stem.1358; Kadowaki M, 2012, INT J CANCER, V130, P267, DOI 10.1002/ijc.26082; Kalluri HSG, 2016, EUR J PHARMACOL, V791, P510, DOI 10.1016/j.ejphar.2016.09.026; Kim D, 2015, NATURE, V520, P363, DOI 10.1038/nature14363; Kim W, 2018, EXP MOL MED, V50, DOI 10.1038/emm.2017.247; Kirkegaard LJ, 1998, AM J CLIN PATHOL, V109, P69; Koul D, 2008, CANCER BIOL THER, V7, P1321, DOI 10.4161/cbt.7.9.6954; KRETH FW, 1993, J NEUROSURG, V78, P762, DOI 10.3171/jns.1993.78.5.0762; Kulkarni S, 2018, MOL CANCER RES, V16, P103, DOI 10.1158/1541-7786.MCR-17-0146; Kull F J, 2000, Essays Biochem, V35, P61; Lachmann A, 2010, BIOINFORMATICS, V26, P2438, DOI 10.1093/bioinformatics/btq466; Lam PYP, 2000, BRIT J NEUROSURG, V14, P28; Lan Q, 2016, ONCOTARGET, V7, P9680, DOI 10.18632/oncotarget.7109; LANDAU BJ, 1994, CANCER RES, V54, P1105; Lang F, 2006, PHYSIOL REV, V86, P1151, DOI 10.1152/physrev.00050.2005; Lasorella A, 2005, MOL CELL BIOL, V25, P3563, DOI 10.1128/MCB.25.9.3563-3574.2005; Lee Y, 2016, LAB INVEST, V96, P137, DOI 10.1038/labinvest.2015.140; Li DW, 2013, CLIN CANCER RES, V19, P62, DOI 10.1158/1078-0432.CCR-12-1588; Li M, 2011, J EXP MED, V208, P2657, DOI 10.1084/jem.20111102; Li Q, 2016, TUMOR BIOL, V37, P14537, DOI 10.1007/s13277-016-5299-0; Li SZ, 2014, SCI REP-UK, V4, DOI 10.1038/srep06910; Lin RP, 2015, GENET MOL RES, V14, P3142, DOI 10.4238/2015.April.10.25; Lin XC, 2009, INT J CANCER, V124, P1020, DOI 10.1002/ijc.23767; Liu MY, 2012, INT IMMUNOPHARMACOL, V14, P283, DOI 10.1016/j.intimp.2012.07.015; Liu YS, 2017, ONCOGENE, V36, P5006, DOI 10.1038/onc.2017.129; Liu YJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep20642; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Lyons SA, 2007, CANCER RES, V67, P9463, DOI 10.1158/0008-5472.CAN-07-2034; Ma SQ, 2015, INT J MOL MED, V35, P1561, DOI 10.3892/ijmm.2015.2173; Martinez-Garay I, 2006, GENOMICS, V87, P243, DOI 10.1016/j.ygeno.2005.11.006; McCall TD, 2007, CANCER RES, V67, P5179, DOI 10.1158/0008-5472.CAN-06-4177; MEERSCHAERT J, 1995, J IMMUNOL, V154, P4099; Meng QM, 2014, J MOL NEUROSCI, V53, P262, DOI 10.1007/s12031-013-0215-1; Mercurio S, 2004, DEVELOPMENT, V131, P2137, DOI 10.1242/dev.01045; Mi HY, 2017, NUCLEIC ACIDS RES, V45, pD183, DOI 10.1093/nar/gkw1138; Mir SE, 2010, CANCER CELL, V18, P244, DOI 10.1016/j.ccr.2010.08.011; Mohapatra S, 1996, J EXP MED, V183, P1663, DOI 10.1084/jem.183.4.1663; Morales AG, 2013, CHILD NERV SYST, V29, P2241, DOI 10.1007/s00381-013-2175-8; Murphy AC, 2014, APOPTOSIS, V19, P629, DOI 10.1007/s10495-013-0935-2; Nakahata AM, 2014, ONCOL LETT, V8, P1487, DOI 10.3892/ol.2014.2369; Nakano I, 2008, J NEUROSCI RES, V86, P48, DOI 10.1002/jnr.21471; Nettersheim D, 2016, ONCOTARGET, V7, P74931, DOI 10.18632/oncotarget.11647; Nijaguna MB, 2015, J BIOL CHEM, V290, P23401, DOI 10.1074/jbc.M115.664037; Norton JD, 2000, J CELL SCI, V113, P3897; Oelmann E, 1997, INT J CANCER, V71, P1066, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1066::AID-IJC25>3.0.CO;2-A; Orchard S, 2014, NUCLEIC ACIDS RES, V42, pD358, DOI 10.1093/nar/gkt1115; Palanichamy K, 2016, CLIN CANCER RES, V22, P3513, DOI 10.1158/1078-0432.CCR-15-2308; Panicker SP, 2010, ONCOTARGET, V1, P289; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pelloski CE, 2006, CLIN CANCER RES, V12, P3935, DOI 10.1158/1078-0432.CCR-05-2202; Pelzer AE, 2006, J UROLOGY, V175, P1517, DOI 10.1016/S0022-5347(05)00651-8; Pena-Altamira E, 2014, EUR J NEUROSCI, V39, P176, DOI 10.1111/ejn.12407; Peset I, 2008, TRENDS CELL BIOL, V18, P379, DOI 10.1016/j.tcb.2008.06.005; Petri V, 2014, J BIOMED SEMANT, V5, DOI 10.1186/2041-1480-5-7; Phan RT, 2004, NATURE, V432, P635, DOI 10.1038/nature03147; Polewski MD, 2017, STEM CELLS DEV, V26, P1236, DOI 10.1089/scd.2017.0123; Polzin RG, 2004, GENE, V341, P209, DOI 10.1016/j.gene.2004.06.052; Prabhakar S, 2014, CELL BIOL INT, V38, P145, DOI 10.1002/cbin.10201; Prasad TSK, 2009, NUCLEIC ACIDS RES, V37, pD767, DOI 10.1093/nar/gkn892; Priller M, 2011, CLIN CANCER RES, V17, P6791, DOI 10.1158/1078-0432.CCR-11-1214; Reifenberger G, 2012, INT J CANCER, V131, P1342, DOI 10.1002/ijc.27385; Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rollbrocker B, 1996, ACTA NEUROPATHOL, V92, P70, DOI 10.1007/s004010050491; Rong Y, 2006, CANCER RES, V66, P7067, DOI 10.1158/0008-5472.CAN-06-0346; Ruano Y, 2008, CANCER-AM CANCER SOC, V112, P1575, DOI 10.1002/cncr.23338; Rulseh AM, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-220; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; Salhia B, 2008, AM J PATHOL, V173, P1828, DOI 10.2353/ajpath.2008.080043; Salwinski L, 2004, NUCLEIC ACIDS RES, V32, pD449, DOI 10.1093/nar/gkh086; Sayers EW, 2010, NUCLEIC ACIDS RES, V38, pD5, DOI [10.1093/nar/gkp967, 10.1093/nar/gkq1184]; Schaefer CF, 2009, NUCLEIC ACIDS RES, V37, pD674, DOI 10.1093/nar/gkn653; Schlenska-Lange A, 2008, ANTICANCER RES, V28, P1055; Seng S, 2009, ONCOGENE, V28, P378, DOI 10.1038/onc.2008.396; Sethupathy P, 2006, RNA, V12, P192, DOI 10.1261/rna.2239606; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Sharma V, 2008, INT J CANCER, V123, P2204, DOI 10.1002/ijc.23771; Sheleg SV, 2002, J NEURO-ONCOL, V60, P53, DOI 10.1023/A:1020288015457; Sidiropoulos K, 2017, BIOINFORMATICS, V33, P3461, DOI 10.1093/bioinformatics/btx441; Singh D, 2012, SCIENCE, V337, P1231, DOI 10.1126/science.1220834; Stiles CD, 2008, NEURON, V58, P832, DOI 10.1016/j.neuron.2008.05.031; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sur S, 2016, MOL CELL BIOCHEM, V416, P33, DOI 10.1007/s11010-016-2693-2; Tamura RE, 2012, CURR MOL MED, V12, P634; Tanabe Mao, 2012, Curr Protoc Bioinformatics, VChapter 1, DOI 10.1002/0471250953.bi0112s38; Taniguchi T, 2003, NAT MED, V9, P568, DOI 10.1038/nm852; Tatenhorst L, 2004, J NEUROPATH EXP NEUR, V63, P210, DOI 10.1093/jnen/63.3.210; Thakkar JP, 2014, CANCER EPIDEM BIOMAR, V23, P1985, DOI 10.1158/1055-9965.EPI-14-0275; Tilghman J, 2014, CANCER RES, V74, P3168, DOI 10.1158/0008-5472.CAN-13-2103; Tonjes M, 2013, NAT MED, V19, P901, DOI 10.1038/nm.3217; Toledo CM, 2015, CELL REP, V13, P2425, DOI 10.1016/j.celrep.2015.11.021; Tsai SF, 2017, ONCOTARGET, V8, P4051, DOI 10.18632/oncotarget.13266; Vakilian A, 2017, NEUROCHEM INT, V103, P1, DOI 10.1016/j.neuint.2016.12.013; Valensin S, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-196; Valter MM, 1999, CANCER RES, V59, P5608; Vanden Bosch A, 2010, J CELL SCI, V123, P3244, DOI 10.1242/jcs.063875; Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101; Wang DP, 2016, SCI REP-UK, V6, DOI 10.1038/srep21710; Wang GZ, 2016, J CANCER, V7, P1431, DOI 10.7150/jca.15497; Wang H, 2003, CANCER RES, V63, P4315; Wang R, 2011, J CELL BIOCHEM, V112, P3621, DOI 10.1002/jcb.23293; Wang ZY, 2015, CURR PHARM DESIGN, V21, P1268, DOI 10.2174/1381612821666141211115949; Weiler M, 2013, ONCOGENE, V32, P1099, DOI 10.1038/onc.2012.137; WERNERT N, 1992, AM J PATHOL, V140, P119; Wolfgang CD, 1997, MOL CELL BIOL, V17, P6700, DOI 10.1128/MCB.17.11.6700; Wu N, 2012, FEBS LETT, V586, P3831, DOI 10.1016/j.febslet.2012.08.023; Xia JG, 2015, NAT PROTOC, V10, P823, DOI 10.1038/nprot.2015.052; Xing CY, 2013, MOL CANCER THER, V12, P94, DOI 10.1158/1535-7163.MCT-12-0672; Xu L, 2017, P NATL ACAD SCI USA, V114, P3981, DOI 10.1073/pnas.1609758114; Yamada M, 2006, J BIOL CHEM, V281, P20749, DOI 10.1074/jbc.M602089200; Yamashita Y, 2010, J NEURO-ONCOL, V100, P43, DOI 10.1007/s11060-010-0147-3; Yin D, 2010, INT J CANCER, V127, P2257, DOI 10.1002/ijc.25257; Yip S, 2009, CLIN CANCER RES, V15, P4622, DOI 10.1158/1078-0432.CCR-08-3012; Yokota Y, 2002, J CELL PHYSIOL, V190, P21, DOI 10.1002/jcp.10042; Zaki N, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-163; Zarnescu O, 2011, MICRON, V42, P793, DOI 10.1016/j.micron.2011.04.005; Zeng WFF, 2007, J CLIN PATHOL, V60, P218, DOI 10.1136/jcp.2006.036806; Zhang B, 2013, BIOMATERIALS, V34, P9171, DOI 10.1016/j.biomaterials.2013.08.039; Zhang J, 2012, CARCINOGENESIS, V33, P312, DOI 10.1093/carcin/bgr289; Zhang LH, 2015, ONCOGENE, V34, P600, DOI 10.1038/onc.2013.593; Zhang R, 2008, CANCER CHEMOTH PHARM, V62, P407, DOI 10.1007/s00280-007-0619-0; Zhang YW, 2007, ONCOGENE, V26, P269, DOI 10.1038/sj.onc.1209790; Zhang ZG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096283; Zhao ZY, 2015, TUMOR BIOL, V36, P4189, DOI 10.1007/s13277-015-3055-5; Zhou B, 2012, ONCOL REP, V28, P1263, DOI 10.3892/or.2012.1929; Zhou XP, 2013, J MOL NEUROSCI, V50, P78, DOI 10.1007/s12031-012-9864-8; Zhu HF, 2018, ONCOL LETT, V15, P2700, DOI 10.3892/ol.2017.7573; Zhu T, 2018, CNS NEUROSCI THER, V24, P178, DOI 10.1111/cns.12803; Zinn PO, 2013, INT J ONCOL, V42, P929, DOI 10.3892/ijo.2013.1770; Zohrabian VM, 2009, ANTICANCER RES, V29, P119	212	2	2	8	19	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	SEP	2018	214	9					1395	1461		10.1016/j.prp.2018.07.015			67	Pathology	Pathology	GV3DC	WOS:000445973500024	30097214				2019-10-28	
J	Moghaddam, Y; Andalib, A; Mohammad-Ganji, M; Homayouni, V; Sharifi, M; Ganjalikhani-Hakemi, M				Moghaddam, Yaser; Andalib, Alireza; Mohammad-Ganji, Maryam; Homayouni, Vida; Sharifi, Mohammadreza; Ganjalikhani-Hakemi, Mazdak			Evaluation of the effect of TIM-3 suppression by miR-498 and its effect on apoptosis and proliferation rate of HL-60 cell line	PATHOLOGY RESEARCH AND PRACTICE			English	Article						AML; HL-60; miR-498; miRNA; TIM-3	IMMUNE RECEPTOR TIM-3; MYELOID-LEUKEMIA; DOWN-REGULATION; STEM-CELLS; OLDER PATIENTS; CANCER GROWTH; EXPRESSION; MIR-125A-3P; INDUCTION	Background: Acute Myeloid Leukemia (AML) is a Cancer of hematopoietic stem cells with a rapid progression. TIM-3 is expressed on leukemic stem cells (LSCs) in most types of AML and might have a positive effect on maintenance of malignant phenotype. MicroRNAs play important roles in either cancer progression or suppression. In this study were evaluated, the inhibitory effect of miR-498 on TIM-3 expression and its impact on proliferation and survival of HL-60 cell line. Methods: Firstly, the probable inhibitory effect of miR-498 on TIM-3 expression was predicted. HL-60 cells were cultured and expression of TIM-3 was induced on the cells using phorbol miristate acetate. The cells were transfected with miR-498 and expression level of TIM-3 were measured using with q-RT-PCR and flow cytometry methods. In addition, the effect of suppression of TIM-3 expression in HL-60 cell line was analyzed with apoptosis and cell proliferation assays. Results: Bioinformatics analyses predicted that miR-498 has high ability to silence TIM-3 gene expression. Our experiments confirmed that miR-498 was able to strongly silence TIM-3 expression (68% silencing) in HL-60 cell line (P < 0.002). Also, the cells with suppressed expression of TIM-3 had a lower proliferation and higher apoptosis rates. Conclusion: Based on our results, the miR-498 can effectively suppress TIM-3 expression in the AML cell line. TIM-3 suppression, in turn, inhibits malignant cell proliferation and induces its apoptosis. Collectively, suppression of TIM-3 by miR-498 can be considered as a potential powerful way for treatment of AML.	[Moghaddam, Yaser; Andalib, Alireza; Mohammad-Ganji, Maryam; Ganjalikhani-Hakemi, Mazdak] Isfahan Univ Med Sci, Dept Immunol, Fac Med, Esfahan, Iran; [Homayouni, Vida; Ganjalikhani-Hakemi, Mazdak] Isfahan Univ Med Sci, Acqured Immunodeficiency Res Ctr, Esfahan, Iran; [Sharifi, Mohammadreza] Isfahan Univ Med Sci, Sch Med, Dept Genet & Mol Biol, Esfahan, Iran	Ganjalikhani-Hakemi, M (reprint author), Isfahan Univ Med Sci, Dept Immunol, Fac Med, Esfahan, Iran.	mghakemi@med.mui.ac.ir	Hakemi, Mazdak Ganjalikhani/V-7950-2017; Sharifi, Mohammadreza/H-1017-2016	Hakemi, Mazdak Ganjalikhani/0000-0002-4764-7616; Sharifi, Mohammadreza/0000-0002-1538-9034	Isfahan University of Medical Sciences [394953]	This work was financially supported by Isfahan University of Medical Sciences (Grant number: 394953).	Akashi K., 2015, TIM 3 IS NOVEL THERA, P307; Bret C, 2016, EXPERT REV HEMATOL, V9, P351, DOI 10.1586/17474086.2016.1141673; Emamdoost F, 2017, INDIAN J HEMATOL BLO, V33, P342, DOI 10.1007/s12288-016-0733-4; Fooladinezhad H, 2016, BRIT J BIOMED SCI, V73, P129, DOI 10.1080/09674845.2016.1194564; Gopalan V, 2015, EXP CELL RES, V330, P423, DOI 10.1016/j.yexcr.2014.08.006; Hashiguchi Y, 2012, INT J ONCOL, V40, P1477, DOI 10.3892/ijo.2012.1363; Islam F, 2017, HUM PATHOL, V62, P141, DOI 10.1016/j.humpath.2017.01.014; Jiang F, 2004, J BIOL CHEM, V279, P53213, DOI 10.1074/jbc.M410395200; Jongen-Lavrencic M, 2008, BLOOD, V111, P5078, DOI 10.1182/blood-2008-01-133355; Kasiappan R, 2014, CANCER RES, V74, P6194, DOI 10.1158/0008-5472.CAN-14-1702; Kasiappan R, 2012, J BIOL CHEM, V287, P41297, DOI 10.1074/jbc.M112.407189; Kikushige Y, 2016, EXP HEMATOL, V44, pS36, DOI 10.1016/j.exphem.2016.06.033; Kikushige Y, 2015, ONCOLOGY-BASEL, V89, P28, DOI 10.1159/000431062; Kikushige Y, 2012, ANN NY ACAD SCI, V1266, P118, DOI 10.1111/j.1749-6632.2012.06550.x; Kluiver J, 2006, LEUKEMIA, V20, P1931, DOI 10.1038/sj.leu.2404387; Koguchi K, 2006, J EXP MED, V203, P1413, DOI 10.1084/jem.20060210; Li CX, 2014, INT J CLIN EXP PATHO, V7, P6880; Lin Y, 2015, J BIOL CHEM, V290, P1818, DOI 10.1074/jbc.M114.599191; Liu RN, 2015, BIOMED PHARMACOTHER, V72, P52, DOI 10.1016/j.biopha.2015.04.005; Lowenberg B, 2009, NEW ENGL J MED, V361, P1235, DOI 10.1056/NEJMoa0901409; Prokhorov A, 2015, INT J BIOCHEM CELL B, V59, P11, DOI 10.1016/j.biocel.2014.11.017; Reddy KB, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0185-1; Sabatos CA, 2003, NAT IMMUNOL, V4, P1102, DOI 10.1038/ni988; Sanz MA, 2016, ANN HEMATOL, V95, P1583, DOI 10.1007/s00277-016-2666-2; Saultz JN, 2016, J CLIN MED, V5, DOI 10.3390/jcm5030033; Schaar DG, 2009, EXP HEMATOL, V37, P245, DOI 10.1016/j.exphem.2008.10.002; Shima T, 2012, BLOOD, V120, DOI 10.1182/blood.V120.21.859.859; Silva IG, 2015, ONCOTARGET, V6, P33823, DOI 10.18632/oncotarget.5257; Tao JL, 2014, LEUKEMIA RES, V38, P714, DOI 10.1016/j.leukres.2014.03.018; Ufkin ML, 2014, LEUKEMIA RES, V38, P402, DOI 10.1016/j.leukres.2013.12.021; Wang HW, 2015, CELL IMMUNOL, V293, P49, DOI 10.1016/j.cellimm.2014.12.005; Wang MX, 2015, J CANCER RES THER, V11, pC107, DOI 10.4103/0973-1482.163859; Wouters BJ, 2016, BLOOD, V127, P42, DOI 10.1182/blood-2015-07-604512; Yan Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055832	34	1	1	0	3	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	SEP	2018	214	9					1482	1488		10.1016/j.prp.2018.07.019			7	Pathology	Pathology	GV3DC	WOS:000445973500028	30107988				2019-10-28	
J	Caswell, JL; Bassel, LL; Rothenburger, JL; Grone, A; Sargeant, JM; Beck, AP; Ekman, S; Gibson-Corley, KN; Kuiken, T; LaDouceur, EEB; Meyerholz, DK; Origgi, FC; Posthaus, H; Priestnall, SL; Ressel, L; Sharkey, L; Teixeira, LBC; Uchida, K; Ward, JM; Webster, JD; Yamate, J				Caswell, Jeff L.; Bassel, Laura L.; Rothenburger, Jamie L.; Grone, Andrea; Sargeant, Jan M.; Beck, Amanda P.; Ekman, Stina; Gibson-Corley, Katherine N.; Kuiken, Thijs; LaDouceur, Elise E. B.; Meyerholz, David K.; Origgi, Francesco C.; Posthaus, Horst; Priestnall, Simon L.; Ressel, Lorenzo; Sharkey, Leslie; Teixeira, Leandro B. C.; Uchida, Kazuyuki; Ward, Jerrold M.; Webster, Joshua D.; Yamate, Jyoji			Observational Study Design in Veterinary Pathology, Part 1: Study Design	VETERINARY PATHOLOGY			English	Editorial Material						reproducibility of results; research design; epidemiology; pathology; descriptive studies; observational studies; study design; case control; cohort; hypothesis; bias; laboratory medicine	STROBE-VET STATEMENT; PULMONARY-FIBROSIS; CLINICAL PATHOLOGY; DOGS; CATS; DISEASE; EPIDEMIOLOGY; LESIONS; HERPESVIRUS; EXPRESSION	Observational studies are the basis for much of our knowledge of veterinary pathology and are highly relevant to the daily practice of pathology. However, recommendations for conducting pathology-based observational studies are not readily available. In part 1 of this series, we offer advice on planning and conducting an observational study with examples from the veterinary pathology literature. Investigators should recognize the importance of creativity, insight, and innovation in devising studies that solve problems and fill important gaps in knowledge. Studies should focus on specific and testable hypotheses, questions, or objectives. The methodology is developed to support these goals. We consider the merits and limitations of different types of analytic and descriptive studies, as well as of prospective vs retrospective enrollment. Investigators should define clear inclusion and exclusion criteria and select adequate numbers of study subjects, including careful selection of the most appropriate controls. Studies of causality must consider the temporal relationships between variables and the advantages of measuring incident cases rather than prevalent cases. Investigators must consider unique aspects of studies based on archived laboratory case material and take particular care to consider and mitigate the potential for selection bias and information bias. We close by discussing approaches to adding value and impact to observational studies. Part 2 of the series focuses on methodology and validation of methods.	[Caswell, Jeff L.; Bassel, Laura L.] Univ Guelph, Dept Pathobiol, Guelph, ON N1G 2W1, Canada; [Rothenburger, Jamie L.] Univ Calgary, Fac Vet Med, Canadian Wildlife Hlth Cooperat, Dept Ecosyst & Publ Hlth, Calgary, AB, Canada; [Grone, Andrea] Univ Utrecht, Fac Vet Med, Dept Pathobiol, Utrecht, Netherlands; [Sargeant, Jan M.] Univ Guelph, Dept Populat Med, Guelph, ON, Canada; [Sargeant, Jan M.] Univ Guelph, Ctr Publ Hlth & Zoonoses, Guelph, ON, Canada; [Beck, Amanda P.] Albert Einstein Coll Med, Bronx, NY 10467 USA; [Ekman, Stina] Swedish Univ Agr Sci, Dept Biomed & Vet Publ Hlth, Uppsala, Sweden; [Gibson-Corley, Katherine N.] Univ Iowa, Dept Pathol, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA; [Kuiken, Thijs] Erasmus Univ, Med Ctr, Dept Virosci, Rotterdam, Netherlands; [LaDouceur, Elise E. B.] Joint Pathol Ctr, Silver Spring, MD USA; [Meyerholz, David K.] Univ Iowa, Carver Coll Med, Iowa City, IA USA; [Origgi, Francesco C.] Univ Bern, Vetsuisse Fac, Ctr Fish & Wildlife Hlth, Bern, Switzerland; [Posthaus, Horst] Univ Bern, Vetsuisse Fac, Inst Anim Pathol, Bern, Switzerland; [Priestnall, Simon L.] Royal Vet Coll, Deparment Pathobiol & Populat Sci, Hatfield, Herts, England; [Ressel, Lorenzo] Univ Liverpool, Inst Vet Sci, Dept Vet Pathol & Publ Hlth, Liverpool, Merseyside, England; [Sharkey, Leslie] Tufts Univ, Cummings Sch Vet Med, Dept Clin Sci, North Grafton, MA USA; [Teixeira, Leandro B. C.] Univ Wisconsin, Dept Pathobiol Sci, Madison, WI 53706 USA; [Uchida, Kazuyuki] Univ Tokyo, Dept Vet Pathol, Tokyo, Japan; [Ward, Jerrold M.] GlobalVetPathol, Montgomery, MD USA; [Webster, Joshua D.] Genentech Inc, San Francisco, CA USA; [Yamate, Jyoji] Osaka Prefecture Univ, Grad Sch Life & Environm Sci, Lab Vet Pathol, Izumisano City, Osaka, Japan	Caswell, JL (reprint author), Univ Guelph, Dept Pathobiol, Guelph, ON N1G 2W1, Canada.	jcaswell@uoguelph.ca	Meyerholz, David/J-8131-2019; Caswell, Jeff/B-9279-2018	Meyerholz, David/0000-0003-1552-3253; Rothenburger, Jamie/0000-0003-1634-9154; Gibson-Corley, Katherine/0000-0002-1846-1580; Caswell, Jeff/0000-0002-1991-3219	Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada [RGPIN-2017-03872]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Aspects of this article were supported by a grant from the Natural Sciences and Engineering Research Council of Canada (RGPIN-2017-03872, J. Caswell).	Avallone G, 2017, VET PATHOL, V54, P212, DOI 10.1177/0300985816671379; Barnes J, 2016, VET PATHOL, V53, P447, DOI 10.1177/0300985815610390; Bauer BS, 2016, VET PATHOL, V53, P1197, DOI 10.1177/0300985816642276; Beck J, 2017, VET PATHOL, V54, P767, DOI 10.1177/0300985817712559; Beckwith-Cohen B, 2017, VET PATHOL, V54, P141, DOI 10.1177/0300985816653793; Benali SL, 2016, VET PATHOL, V53, P803, DOI 10.1177/0300985815624494; Camus MS, 2016, VET PATHOL, V53, P1117, DOI 10.1177/0300985816638721; Caswell JL, 2018, VET PATHOL, V55; Chakrabarti S, 2013, VET PATHOL, V50, P147, DOI 10.1177/0300985812453176; Chilton J, 2016, VET PATHOL, V53, P417, DOI 10.1177/0300985815618435; Concato John, 2004, NeuroRx, V1, P341, DOI 10.1602/neurorx.1.3.341; Cooper TK, 2016, VET PATHOL, V53, P504, DOI 10.1177/0300985815594853; Cooper TK, 2017, VET PATHOL, V54, P851, DOI 10.1177/0300985817709886; Dohoo I. R., 2009, VET EPIDEMIOLOGIC RE; Finno CJ, 2016, VET PATHOL, V53, P77, DOI 10.1177/0300985815598787; Ford J, 2017, VET PATHOL, V54, P964, DOI 10.1177/0300985817725387; Gaffney PM, 2016, VET PATHOL, V53, P637, DOI 10.1177/0300985815604725; Robles TG, 2017, VET PATHOL, V54, P328, DOI 10.1177/0300985816660748; Gaynor AM, 2016, VET PATHOL, V53, P567, DOI 10.1177/0300985815594852; Guy MK, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0230; Harbison CE, 2016, VET PATHOL, V53, P468, DOI 10.1177/0300985815612152; Hill AB, 2015, J ROY SOC MED, V108, P32, DOI 10.1177/0141076814562718; Kamiie J, 2017, VET PATHOL, V54, P111, DOI 10.1177/0300985816653792; Kohnken R, 2017, VET PATHOL, V54, P475, DOI 10.1177/0300985816685137; LaDouceur EEB, 2016, VET PATHOL, V53, P648, DOI 10.1177/0300985815603431; Lair S, 2016, VET PATHOL, V53, P22, DOI 10.1177/0300985815604726; Levi M, 2017, VET PATHOL, V54, P437, DOI 10.1177/0300985816684915; Maeda S, 2016, VET PATHOL, V53, P102, DOI 10.1177/0300985815591081; Marchevsky AM, 2010, AM J CLIN PATHOL, V133, P366, DOI [10.1309/AJCPC2O7YSWKCTGS, 10.1309/AJCPC2Q7YSWKCTGS]; McEndaffer L, 2017, VET PATHOL, V54, P669, DOI 10.1177/0300985817695516; Mitchell EP, 2017, VET PATHOL, V54, P977, DOI 10.1177/0300985817728556; O'Connor AM, 2016, J VET INTERN MED, V30, P1896, DOI 10.1111/jvim.14592; Radaelli E, 2016, VET PATHOL, V53, P477, DOI 10.1177/0300985815608673; Rasotto R, 2017, VET PATHOL, V54, P571, DOI 10.1177/0300985817698208; Roels E, 2016, VET PATHOL, V53, P1210, DOI 10.1177/0300985816641991; Rothenburger JL, 2015, VET PATHOL, V52, P201, DOI 10.1177/0300985814528220; Sargeant JM, 2017, J VET INTERN MED, V31, P1035, DOI 10.1111/jvim.14741; Sargeant JM, 2016, PREV VET MED, V134, P188, DOI 10.1016/j.prevetmed.2016.09.005; Sargeant JM, 2014, ZOONOSES PUBLIC HLTH, V61, P10, DOI 10.1111/zph.12127; Sihvo HK, 2017, VET PATHOL, V54, P119, DOI 10.1177/0300985816658099; Taha-Abdelaziz K, 2016, J VET DIAGN INVEST, V28, P369, DOI 10.1177/1040638716646806; Thompson JJ, 2016, VET PATHOL, V53, P545, DOI 10.1177/0300985815610388; van Elk CE, 2009, J WILDLIFE DIS, V45, P895, DOI 10.7589/0090-3558-45.4.895; Vitiello V, 2017, VET PATHOL, V54, P775, DOI 10.1177/0300985817705171; Williams KJ, 2007, VET PATHOL, V44, P849, DOI 10.1354/vp.44-6-849; Williams KJ, 2014, VET PATHOL, V51, P372, DOI 10.1177/0300985814521838; Williams KJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077754; Zini E, 2016, VET PATHOL, V53, P136, DOI 10.1177/0300985815591078	48	3	3	1	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	SEP	2018	55	5					607	621		10.1177/0300985818785705			15	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GR5JY	WOS:000442667700003	30071806	Green Accepted			2019-10-28	
J	Wormstrand, B; Ostevik, L; Ekman, S; Olstad, K				Wormstrand, Bjorn; Ostevik, Liv; Ekman, Stina; Olstad, Kristin			Septic Arthritis/Osteomyelitis May Lead to Osteochondrosis-Like Lesions in Foals	VETERINARY PATHOLOGY			English	Article						bacteria; cartilage canals; foal; growth cartilage; histology; osteochondral lesions; septic arthritis	ACUTE HEMATOGENOUS OSTEOMYELITIS; EPIPHYSEAL CARTILAGE COMPLEX; STANDARD-BRED TROTTERS; STAPHYLOCOCCUS-AUREUS; METAPHYSEAL VESSELS; TIBIOTARSAL JOINT; BLOOD-VESSELS; GROWTH PLATE; DISTAL FEMUR; YOUNG FOALS	Failure of the cartilage canal blood supply leads to ischemic chondronecrosis which causes osteochondrosis, and osteochondral lesions. Osteochondrosis is a disease with a heritable component and usually occurs under aseptic conditions. Because bacteria can bind to growth cartilage and disrupt the blood supply in pigs and chickens, we considered whether this might play a role in development of equine osteochondrosis. The aim of this study was to examine whether bacteria are present in canals in the growth cartilage of foals with septic arthritis/osteomyelitis, and whether this is associated with osteochondrosis. The material consisted of 7 foals aged 9-117 days euthanized because of septic arthritis/osteomyelitis. The 7 cases had 16 lesions in growth cartilage that were evaluated histologically. Bacteria were present in cartilage canals in foals with septic arthritis/osteomyelitis. Portions of necrotic canals adjacent to bacteria frequently contained neutrophils, termed acute septic canals; or granulation tissue with neutrophils, termed chronic septic canals. Acute and chronic septic canals were associated with ischemic chondronecrosis in the articular-epiphyseal cartilage complex (AECC) of 5 cases and in the physis of 2 cases, and ossification was focally delayed in 5 of those 7 cases. Lesions occurred with and without adjacent osteomyelitis. Bacteria were present in cartilage canals and were associated with focal chondronecrosis in both the AECC and the physis. This establishes sepsis as a plausible cause of some osteochondral lesions in horses. It is recommended that horses with sepsis-related osteochondral lesions may be used for breeding without increasing the prevalence of OCD-predisposing genes in the population.	[Wormstrand, Bjorn; Ostevik, Liv; Olstad, Kristin] Norwegian Univ Life Sci, Oslo, Norway; [Ekman, Stina] Swedish Univ Agr Sci, Uppsala, Sweden	Wormstrand, B (reprint author), Norwegian Univ Life Sci, Fac Vet Med, Dept Compan Anim Clin Sci, Equine Sect, Post Box 8146 Dept, N-0033 Oslo, Norway.	bjorn.wormstrand@nmbu.no			Swedish-Norwegian Foundation for Equine Research/Research Council of Norway [H1147117/218962]	The study was funded by grant H1147117/218962 from the Swedish-Norwegian Foundation for Equine Research/Research Council of Norway, with contributions from Norsk Rikstoto and Jordbruksavtalen.	Aasmundstad T, 2014, ANIMAL, V8, P1045, DOI 10.1017/S1751731114001074; ALDERSON M, 1986, J BONE JOINT SURG BR, V68, P268; CARLSON CS, 1995, VET PATHOL, V32, P641, DOI 10.1177/030098589503200605; CARLSON CS, 1991, J ORTHOP RES, V9, P317, DOI 10.1002/jor.1100090303; CARLSON CS, 1989, VET PATHOL, V26, P47, DOI 10.1177/030098588902600108; DENECKE R, 1986, RHEUMATOL INT, V6, P239, DOI 10.1007/BF00541313; Dik K J, 1999, Equine Vet J Suppl, P9; Edmonds EW, 2013, CLIN ORTHOP RELAT R, V471, P1118, DOI 10.1007/s11999-012-2290-y; EMSLIE KR, 1983, AM J PATHOL, V110, P333; Etterlin PE, 2015, ACTA VET SCAND, V57, DOI 10.1186/s13028-015-0154-7; Finnoy A, 2017, BMC VET RES, V13, DOI 10.1186/s12917-017-1197-y; FIRTH EC, 1993, NEW ZEAL VET J, V41, P73, DOI 10.1080/00480169.1993.35738; FIRTH EC, 1982, RES VET SCI, V33, P159, DOI 10.1016/S0034-5288(18)32329-4; FIRTH EC, 1983, RES VET SCI, V34, P231, DOI 10.1016/S0034-5288(18)32265-3; FIRTH EC, 1988, VET QUART, V10, P99, DOI 10.1080/01652176.1988.9694156; GRONDAHL AM, 1993, J AM VET MED ASSOC, V203, P101; Hackett ES, 2015, EQUINE VET J, V47, P405, DOI 10.1111/evj.12307; Haggett EF, 2012, EQUINE VET J, V44, P91, DOI 10.1111/j.2042-3306.2011.00498.x; HAM KN, 1965, AUST J EXP BIOL MED, V43, P625, DOI 10.1038/icb.1965.47; HANCE SR, 1993, J AM VET MED ASSOC, V202, P637; Heinonen M, 2007, VET REC, V160, P573, DOI 10.1136/vr.160.17.573; Hellings IR, 2016, J ANAT, V228, P162, DOI 10.1111/joa.12391; HOWLETT CR, 1980, J ANAT, V130, P745; Jensen HE, 2010, IN VIVO, V24, P257; Johansen LK, 2011, APMIS, V119, P111, DOI 10.1111/j.1600-0463.2010.02700.x; LUFTI AM, 1970, J ANAT, V106, P135; Lykkjen S, 2014, EQUINE VET J, V46, P32, DOI 10.1111/evj.12058; Lykkjen S, 2010, ANIM GENET, V41, P111, DOI 10.1111/j.1365-2052.2010.02117.x; Mackie EJ, 2008, INT J BIOCHEM CELL B, V40, P46, DOI 10.1016/j.biocel.2007.06.009; OGDEN JA, 1979, YALE J BIOL MED, V52, P423; OLSSON S, 1973, J AM VET RADIOL SOC, V14, P4; Olsson S E, 1978, Acta Radiol Suppl, V358, P299; Olstad K, 2008, EQUINE VET J, V40, P433, DOI 10.2746/042516408X300269; Olstad K, 2008, EQUINE VET J, V40, P30, DOI 10.2746/042516407X239836; Olstad K, 2015, VET PATHOL, V52, P785, DOI 10.1177/0300985815588778; Olstad K, 2013, OSTEOARTHR CARTILAGE, V21, P730, DOI 10.1016/j.joca.2013.02.005; Olstad K, 2011, VET PATHOL, V48, P1165, DOI 10.1177/0300985811398250; Olstad K, 2007, J ORTHOP RES, V25, P1094, DOI 10.1002/jor.20375; Olstad K, 2013, CARTILAGE, V4, P239, DOI 10.1177/1947603513480024; Razakandrainibe R, 2013, INT J BIOCHEM CELL B, V45, P1165, DOI 10.1016/j.biocel.2013.03.010; Reiland S, 1978, Acta Radiol Suppl, V358, P123; REILAND S, 1978, ACTA RADIOL DIAGN, P45; Rejno S, 1978, Acta Radiol Suppl, V358, P153; ROBINSON JA, 1993, EQUINE VET J, V25, P214, DOI 10.1111/j.2042-3306.1993.tb02946.x; Russell CM, 2008, AUST VET J, V86, P266, DOI 10.1111/j.1751-0813.2008.00311.x; SPEERS DJ, 1985, INFECT IMMUN, V49, P443; Tiemann A, 2014, GMS Interdiscip Plast Reconstr Surg DGPW, V3, pDoc08, DOI 10.3205/iprs000049; Toth F, 2015, OSTEOARTHR CARTILAGE, V23, P300, DOI 10.1016/j.joca.2014.11.009; van Grevenhof EM, 2009, EQUINE VET J, V41, P11, DOI 10.2746/042516408X334794; Weiss DJ, 1998, J VET INTERN MED, V12, P317, DOI 10.1111/j.1939-1676.1998.tb02129.x; Ytrehus B, 2004, BONE, V35, P1294, DOI 10.1016/j.bone.2004.08.016; Ytrehus B, 2004, J ORTHOP RES, V22, P1201, DOI 10.1016/j.orthres.2004.03.006; Ytrehus B, 2004, J VET MED A, V51, P188, DOI 10.1111/j.1439-0442.2004.00621.x	53	3	3	3	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	SEP	2018	55	5					693	702		10.1177/0300985818777786			10	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GR5JY	WOS:000442667700012	29807507				2019-10-28	
J	Diaz-Delgado, J; Whitley, DB; Storts, RW; Heatley, JJ; Hoppes, S; Porter, BF				Diaz-Delgado, Josue; Whitley, Derick B.; Storts, Ralph W.; Heatley, Jill J.; Hoppes, Sharman; Porter, Brian F.			The Pathology of Wobbly Hedgehog Syndrome	VETERINARY PATHOLOGY			English	Article						atelerix albiventris; erinaceus europaeus; hedgehog; myelin; myelinopathy; neuronal/axonal degeneration; status spongiosus	CENTRAL-NERVOUS-SYSTEM; SPONGY DEGENERATION; SPONGIFORM LEUKOENCEPHALOMYELOPATHY; ATELERIX-ALBIVENTRIS; HEREFORD CALVES; DISEASE; BRAINS; EDEMA	Wobbly hedgehog syndrome (WHS) is a leading cause of neurologic disease in African pygmy hedgehogs (APHs; Atelerix albiventris). This study describes the signalment, clinical signs, gross, microscopic, and ultrastructural lesions of WHS in a cohort of 12 pet APHs. Microscopically, lesions consisted of status spongiosus of the white matter, typically bilateral and symmetrical, with myelin degeneration and loss that was accompanied by neuronal/axonal degeneration plus reactive microgliosis and mild, focal astrocytosis and astrogliosis. Lesions were most severe in the cerebellum and medulla oblongata, as well as cervical and thoracic spinal cord. Less affected areas were the corona radiata, corpus callosum, corpus striatum, internal capsule, and the mesencephalon. Ultrastructurally, the lesions consisted of splitting of the myelin sheath at the intraperiod line with subsequent focal expansion, resulting in status spongiosus, disruption, dilatation, rhexis, and phagocytosis. Based on these results, WHS is best described as a "spongy myelinopathy" with widespread central nervous system involvement.	[Diaz-Delgado, Josue; Whitley, Derick B.; Storts, Ralph W.; Porter, Brian F.] Texas A&M Univ, Dept Vet Pathobiol, Coll Vet Med & Biomed Sci, College Stn, TX 77843 USA; [Whitley, Derick B.] Texas A&M Univ, Antech Diagnost DBW, Coll Vet Med & Biomed Sci, College Stn, TX 77843 USA; [Heatley, Jill J.; Hoppes, Sharman] Texas A&M Univ, Dept Vet Small Anim Clin Sci, Coll Vet Med & Biomed Sci, College Stn, TX 77843 USA	Diaz-Delgado, J (reprint author), Texas A&M Univ, Dept Vet Pathobiol, Coll Vet Med & Biomed Sci, College Stn, TX 77843 USA.	josue.diaz101@alu.ulpgc.es					ADACHI M, 1973, HUM PATHOL, V4, P331, DOI 10.1016/S0046-8177(73)80098-X; Cantile C, 2016, JUBB KENNEDY PALMERS, P342; CORDY DR, 1969, PATHOL VET, V6, P487, DOI 10.1177/030098586900600602; Gavier-Widen D, 2001, J COMP PATHOL, V124, P52, DOI 10.1053/jcpa.2000.0428; Gerhauser I, 2013, EXP TOXICOL PATHOL, V65, P375, DOI 10.1016/j.etp.2011.12.001; Graesser D, 2006, J EXOT PET MED, V15, P59, DOI 10.1053/j.jepm.2005.11.010; HAGEN G, 1990, VET PATHOL, V27, P187, DOI 10.1177/030098589002700306; HARPER P, 1989, AUST VET J, V66, P46, DOI 10.1111/j.1751-0813.1989.tb03014.x; Heatley JF, 2005, SEMIN AVIAN EXOT PET, V14, P182, DOI 10.1016/j.saep.2005.07.002; Jepson L, 2016, EXOTIC ANIMAL MED QU, P223; JOLLY RD, 1974, J PATHOL, V114, P199, DOI 10.1002/path.1711140404; Karkamo V, 2013, J COMP PATHOL, V148, P96, DOI 10.1016/j.jcpa.2012.11.203; KELLY DF, 1976, ACTA NEUROPATHOL, V35, P151, DOI 10.1007/BF00690561; Li FY, 2006, NEUROBIOL DIS, V21, P35, DOI 10.1016/j.nbd.2005.06.009; Madarame H, 2015, J COMP PATHOL, V152, P88; Martin-Vaquero P, 2012, J VET INTERN MED, V26, P402, DOI 10.1111/j.1939-1676.2011.00873.x; Palmer AC, 1998, VET REC, V143, P550, DOI 10.1136/vr.143.20.550; Pei-Chi H, 2015, J EXOT PET MED, V24, P105, DOI 10.1053/j.jepm.2014.11.003; RICHARDS RB, 1978, J COMP PATHOL, V88, P317, DOI 10.1016/0021-9975(78)90034-8; Stephan H, 1991, INSECTIVORA STEREOTA; Storts RW, 2001, THOMSONS SPECIAL VET, P381; Struys-Ponsar C, 1994, J Neural Transm Suppl, V44, P111; Thomas NJ, 1998, VET PATHOL, V35, P479, DOI 10.1177/030098589803500602; VIZOSO AD, 1981, BRIT J EXP PATHOL, V62, P79; ZACHARY JF, 1985, VET PATHOL, V22, P561, DOI 10.1177/030098588502200609	25	1	1	2	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	SEP	2018	55	5					711	718		10.1177/0300985818768033			8	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GR5JY	WOS:000442667700014	29673307				2019-10-28	
J	Mangosing, S; Perminov, E; Gonzalez, O; Barkei, EK; Corbin, EM; Kumar, S; Dick, EJ				Mangosing, Sara; Perminov, Ekaterina; Gonzalez, Olga; Barkei, Erica K.; Corbin, Emily M.; Kumar, Shyamesh; Dick, Edward J., Jr.			Uterine Tumors Resembling Ovarian Sex Cord Tumors in Four Baboons (Papio spp.)	VETERINARY PATHOLOGY			English	Article						sex cord-gonadal stromal tumors; endometrial stromal tumors; uterus; neoplasia; ovarian neoplasms; primates	STROMAL TUMORS; UTROSCT	Uterine tumors resembling ovarian sex cord tumors (UTROSCTs) are rare uterine neoplasms that exhibit prominent sex cordlike differentiation. The authors describe 4 cases of UTROSCTs that were identified as incidental lesions in female baboons. All baboons were in good body condition. One animal had a 2-mm-diameter yellow-tan mass in the uterine body along the attachment of the left broad ligament; the other 3 did not have any gross lesions in the uterus. Histologically, the myometrium contained multifocal well-demarcated neoplasms composed of cuboidal to columnar cells arranged in variable arrangements of sheets, nests, cords, trabecular, and retiform patterns that occasionally formed Call-Exner-like bodies. In all cases, the neoplastic cells were diffusely positive for WT-1 and negative for calretinin, CD99, and desmin. One case was positive for inhibin and CD10. To the best of the authors' knowledge, this is the first report of UTROSCTs in nonhuman primates and in the veterinary literature.	[Mangosing, Sara; Perminov, Ekaterina; Gonzalez, Olga; Kumar, Shyamesh; Dick, Edward J., Jr.] Texas Biomed Res Inst, Southwest Natl Primate Res Ctr, POB 760549, San Antonio, TX 78245 USA; [Mangosing, Sara; Perminov, Ekaterina] Western Univ Hlth Sci, Coll Vet Med, Pomona, CA USA; [Barkei, Erica K.; Corbin, Emily M.] Joint Pathol Ctr, Silver Spring, MD USA	Kumar, S (reprint author), Texas Biomed Res Inst, Southwest Natl Primate Res Ctr, POB 760549, San Antonio, TX 78245 USA.	shykumar@txbiomed.org			Southwest National Primate Research Center Grant from the National Center for Research Resources, National Institutes of Health [P51 RR013986]; Office of Research Infrastructure Programs [P51 OD011133]; Office of Research Infrastructure Programs (ORIP) of the National Institutes of Health [1 C06 RR016228]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This investigation used resources that were supported by the Southwest National Primate Research Center Grant P51 RR013986 from the National Center for Research Resources, National Institutes of Health and are currently supported by the Office of Research Infrastructure Programs through P51 OD011133. This investigation was conducted in facilities constructed with support from the Office of Research Infrastructure Programs (ORIP) of the National Institutes of Health through Grant 1 C06 RR016228. The views expressed in this article are those of the author and do not reflect the official policy of the Department of the Army/Navy/Air Force, Department of Defense, or the US Government.	Abdullazade S, 2010, ANN DIAGN PATHOL, V14, P432, DOI 10.1016/j.anndiagpath.2010.07.001; Blake EA, 2014, EUR J OBSTET GYN R B, V181, P163, DOI 10.1016/j.ejogrb.2014.07.050; CLEMENT PB, 1976, AM J CLIN PATHOL, V66, P512; Czernobilsky B, 2008, INT J GYNECOL PATHOL, V27, P229, DOI 10.1097/PGP.0b013e3181569a21; de Leval L, 2010, AM J SURG PATHOL, V34, P1749, DOI 10.1097/PAS.0b013e3181f8120c; Gupta M, 2010, ULTRASTRUCT PATHOL, V34, P16, DOI 10.3109/01913120903506603; Hendrickx A, 1971, EMBRYOLOGY BABOON, P3; Hurrell DP, 2007, J CLIN PATHOL, V60, P1148, DOI 10.1136/jcp.2006.044842; Irving JA, 2006, MODERN PATHOL, V19, P17, DOI 10.1038/modpathol.3800475; Kurman RJ, 2014, WHO CLASSIFICATION T; Liu CY, 2015, INT J CLIN EXP PATHO, V8, P4158; Martin LJ, 2003, MECH AGEING DEV, V124, P865, DOI 10.1016/S0047-6374(03)00134-9; MOREHEAD RP, 1945, AM J PATHOL, V21, P53; O'Meara AC, 2009, GYNECOL ONCOL, V114, P140, DOI 10.1016/j.ygyno.2009.03.021; Pradhan D, 2013, ARCH PATHOL LAB MED, V137, P1832, DOI 10.5858/arpa.2012-0634-RS; Schraag SM, 2017, GYNECOL ONCOL REP, V19, P53, DOI 10.1016/j.gore.2017.01.004; Staats PN, 2009, AM J SURG PATHOL, V33, P1206, DOI 10.1097/PAS.0b013e3181a7b9cf; Umeda S, 2014, INT J CLIN EXP PATHO, V7, P1051; Walker ML, 2008, BIOL REPROD, V79, P398, DOI 10.1095/biolreprod.108.068536; Zamecnik M, 2006, Cesk Patol, V42, P145	20	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	SEP	2018	55	5					753	758		10.1177/0300985818766208			6	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GR5JY	WOS:000442667700019	29661120	Green Accepted			2019-10-28	
J	Araujo, ALD; Amaral-Silva, GK; Fonseca, FP; Palmier, NR; Lopes, MA; Speight, PM; de Almeida, OP; Vargas, PA; Santos-Silva, AR				Damaceno Araujo, Anna Luiza; Amaral-Silva, Gleyson Kleber; Fonseca, Felipe Paiva; Palmier, Natalia Rangel; Lopes, Marcio Ajudarte; Speight, Paul M.; de Almeida, Oslei Paes; Vargas, Pablo Agustin; Santos-Silva, Alan Roger			Validation of digital microscopy in the histopathological diagnoses of oral diseases	VIRCHOWS ARCHIV			English	Article						Validation; Whole slide imaging; Digital pathology; Intraobserver agreement	FROZEN-SECTION DIAGNOSIS; AMERICAN-PATHOLOGISTS PATHOLOGY; LABORATORY QUALITY CENTER; SURGICAL PATHOLOGY; VIRTUAL SLIDE; LIGHT-MICROSCOPY; NEEDLE BIOPSIES; SALIVARY-GLAND; WHOLE; TELEPATHOLOGY	Whole slide imaging (WSI) systems are being increasingly used in educational and professional settings, highlighting the value of digital microscopy and favouring its acceptance for use in primary diagnosis. There has been a reluctance to introduce diagnostic applications due to a lack of validation and regulation of these devices. This study aims to provide information regarding the performance of WSI and to validate it for use in the diagnosis of oral diseases, using the intraobserver variability as the primary form of analysis. Seventy (n = 70) H&E-stained glass slides of oral biopsies were scanned using the Aperio Digital Pathology System at a magnification of x 20. Two experienced oral pathologists blindly analysed all H&E-stained sections with a conventional light microscope (CLM) and, after 3-month washout, with WSI. Clinical information was provided along with the cases in both analyses. The intraobserver agreement between CLM and WSI was 97% (kappa = 0.9) for both pathologists. The majority of preferred diagnoses were by CLM. Both pathologists had the same discordances in different cases. Challenging cases and cases with insufficient quantity of tissue for analyses were considered the main reasons for disagreement rather than the diagnostic methods. Median time taken to make a diagnosis was higher only in CLM for one pathologist. Time outliers occurred in discordant cases and in other difficult cases. This study provides evidence of a high performance of WSI for diagnostic purposes in clinical practice, routine pathology and primary diagnosis in the field of oral pathology.	[Damaceno Araujo, Anna Luiza; Amaral-Silva, Gleyson Kleber; Palmier, Natalia Rangel; Lopes, Marcio Ajudarte; de Almeida, Oslei Paes; Vargas, Pablo Agustin; Santos-Silva, Alan Roger] Univ Campinas UNICAMP, Piracicaba Dent Sch, Semiol & Oral Pathol Areas, Oral Diag Dept, Av Limeira 901, BR-13414903 Piracicaba, SP, Brazil; [Fonseca, Felipe Paiva] Fed Univ Minas Gerais UFMG, Sch Dent, Dept Oral Surg & Pathol, Belo Horizonte, MG, Brazil; [Speight, Paul M.] Univ Sheffield, Sch Clin Dent, Unit Oral & Maxillofacial Pathol, Sheffield, S Yorkshire, England	Santos-Silva, AR (reprint author), Univ Campinas UNICAMP, Piracicaba Dent Sch, Semiol & Oral Pathol Areas, Oral Diag Dept, Av Limeira 901, BR-13414903 Piracicaba, SP, Brazil.	alan@unicamp.br	Santos-Silva, Alan Roger/B-6121-2008; Damaceno Araujo, Anna Luiza/A-9812-2019; Vargas, Pablo Agustin/C-5208-2012; Fonseca, Felipe/C-4158-2012	Santos-Silva, Alan Roger/0000-0003-2040-6617; Damaceno Araujo, Anna Luiza/0000-0002-3725-8051; Vargas, Pablo Agustin/0000-0003-1840-4911; do Amaral Silva, Gleyson Kleber/0000-0002-6644-3264; Fonseca, Felipe/0000-0002-6657-4547	Coordination for the Improvement of Higher Education Personnel (CAPES/PROEX, Brazil); National Council for Scientific and Technological Development (CNPq, Brazil)National Council for Scientific and Technological Development (CNPq); Sao Paulo Research Foundation (FAPESP, Brazil)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2009/53839-2]	This study was funded by the Coordination for the Improvement of Higher Education Personnel (CAPES/PROEX, Brazil), the National Council for Scientific and Technological Development (CNPq, Brazil) and the grants from Sao Paulo Research Foundation (FAPESP, Brazil) process number: 2009/53839-2, which supported the acquisition of the equipment used.	Al-Janabi S, 2012, J CLIN PATHOL, V65, P152, DOI 10.1136/jclinpath-2011-200277; Bauer TW, 2013, ARCH PATHOL LAB MED, V137, P518, DOI 10.5858/arpa.2011-0678-OA; Boyce BF, 2015, BIOTECH HISTOCHEM, V90, P321, DOI 10.3109/10520295.2015.1033463; Brunelli M, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-S1-S12; Campbell WS, 2014, HUM PATHOL, V45, P1713, DOI 10.1016/j.humpath.2014.04.007; Canadian Association of Pathologists Telepathology Guidelines Committee, 2014, J Pathol Inform, V5, P15, DOI 10.4103/2153-3539.129455; Cornish TC, 2012, ADV ANAT PATHOL, V19, P152, DOI 10.1097/PAP.0b013e318253459e; Evans AJ, 2009, SEMIN DIAGN PATHOL, V26, P165, DOI 10.1053/j.semdp.2009.09.006; Fallon MA, 2010, ARCH PATHOL LAB MED, V134, P1020, DOI 10.1043/2009-0320-OA.1; Farahani N, 2015, PATHOL LAB MED INT, V7, P23, DOI 10.2147/PLMI.S59826; Fine JL, 2008, HUM PATHOL, V39, P564, DOI 10.1016/j.humpath.2007.08.007; Fonseca FP, 2015, MED ORAL PATOL ORAL, V20, pE17, DOI 10.4317/medoral.19863; Fonyad L, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-35; Food and Drug Administration, FDA ALL MARK 1 WHOL; Frierson HF, 2007, HUM PATHOL, V38, P1330, DOI 10.1016/j.humpath.2007.02.006; Houghton JP, 2014, J CLIN PATHOL, V67, P1052, DOI 10.1136/jclinpath-2014-202491; Jukic DM, 2011, ARCH PATHOL LAB MED, V135, P372, DOI 10.1043/2009-0678-OA.1; Khurram SA, 2017, DIAGN HISTOPATHOL, V23, P250, DOI DOI 10.1016/J.MPDHP.2017.04.008; Krishnamurthy S, 2013, ARCH PATHOL LAB MED, V137, P1733, DOI 10.5858/arpa.2012-0437-OA; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lange H, 2011, LABMEDICINE, V42, P587, DOI 10.1309/LMA2M9NQQFOZCVHC; Li XX, 2007, HUM PATHOL, V38, P1842, DOI 10.1016/j.humpath.2007.04.019; Loughrey MB, 2015, VIRCHOWS ARCH, V467, P137, DOI 10.1007/s00428-015-1780-1; Lowry R, VASSARSTATS WEB SITE; Nielsen PS, 2010, HUM PATHOL, V41, P1770, DOI 10.1016/j.humpath.2010.05.015; Ordi J, 2015, J CLIN PATHOL, V68, P33, DOI 10.1136/jclinpath-2014-202524; Pantanowitz L, 2013, ARCH PATHOL LAB MED, V137, P1710, DOI 10.5858/arpa.2013-0093-CP; Pantanowitz Liron, 2011, J Pathol Inform, V2, P36, DOI 10.4103/2153-3539.83746; Parwani Anil V, 2014, J Pathol Inform, V5, P38, DOI 10.4103/2153-3539.143325; Randell R, 2013, HISTOPATHOLOGY, V62, P351, DOI 10.1111/j.1365-2559.2012.04323.x; Saco A, 2017, DIGEST LIVER DIS, V49, P1240, DOI 10.1016/j.dld.2017.07.002; Saco A, 2016, PATHOBIOLOGY, V83, P89, DOI 10.1159/000442823; Speight PM, 2007, HEAD NECK PATHOL, V1, P61, DOI 10.1007/s12105-007-0014-5; Stathonikos Nikolas, 2013, J Pathol Inform, V4, P15, DOI 10.4103/2153-3539.114206; Tabata K, 2017, PATHOL INT, V67, P547, DOI 10.1111/pin.12590; TAKEUCHI J, 1976, CANCER, V38, P2349, DOI 10.1002/1097-0142(197612)38:6<2349::AID-CNCR2820380622>3.0.CO;2-8; TAKEUCHI J, 1975, CANCER, V36, P1771, DOI 10.1002/1097-0142(197511)36:5<1771::AID-CNCR2820360532>3.0.CO;2-Z; Thorstenson S, 2010, ADV ADM LAB, V19, P69; Thrall MJ, 2015, ARCH PATHOL LAB MED, V139, P656, DOI 10.5858/arpa.2014-0073-OA; van der Post RS, 2013, HISTOPATHOLOGY, V63, P114, DOI 10.1111/his.12131; Vodovnik Aleksandar, 2016, J Pathol Inform, V7, P4, DOI 10.4103/2153-3539.175377; Weinstein RS, 2004, HUM PATHOL, V35, P1303, DOI 10.1016/j.humpath.2004.09.002; Wilbur DC, 2009, ARCH PATHOL LAB MED, V133, P1949, DOI 10.1043/1543-2165-133.12.1949; Yagi Y, 2005, VIRTUAL MICROSCOPY V	44	2	2	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	SEP	2018	473	3					321	327		10.1007/s00428-018-2382-5			7	Pathology	Pathology	GS2RQ	WOS:000443403100007	29858684				2019-10-28	
J	Saleh, J				Saleh, Jasmine			Murine models of melanoma	PATHOLOGY RESEARCH AND PRACTICE			English	Review						Melanoma; Metastatic; Skin cancer; Mouse; Murine melanoma models	ULTRAVIOLET-RADIATION; MOUSE MODELS; TRANSGENIC MICE; GROWTH; VACCINE; EXPRESSION; METASTASES; GENETICS; LESSONS	Melanoma is an aggressive and highly metastatic skin cancer, carrying a poor prognosis with a median survival time of 5.3-10 months depending on the stage of disease. Research has advanced our understanding of the underlying pathology of melanoma and strategies to prevent and treat melanoma. Mouse models have been developed to elucidate the molecular, immunological, and cellular mechanisms contributing to proliferation and metastasis of melanoma. This review article aims to provide an overview of various types of murine melanoma models, including xenograft and syngeneic transplantation models, genetically modified models, ultraviolent radiation models, and chemically induced models, and discuss the advantages and limitations of each model.	[Saleh, Jasmine] Univ Michigan, Dept Otolaryngol Head & Neck Surg, 1150 West Med Ctr Dr, Ann Arbor, MI 48109 USA	Saleh, J (reprint author), Univ Michigan, Dept Otolaryngol Head & Neck Surg, 1150 West Med Ctr Dr, Ann Arbor, MI 48109 USA.	salehjas@med.umich.edu		Saleh, Jasmine/0000-0003-2896-6299			Ackermann J, 2005, CANCER RES, V65, P4005, DOI 10.1158/0008-5472.CAN-04-2970; Bald T, 2014, NATURE, V507, P109, DOI 10.1038/nature13111; Basel MT, 2018, CANCER LETT, V412, P256, DOI 10.1016/j.canlet.2017.10.009; Beaumont KA, 2014, HEALTHCARE-BASEL, V2, P27, DOI 10.3390/healthcare2010027; Becker JC, 2010, EXP DERMATOL, V19, P157, DOI 10.1111/j.1600-0625.2009.00986.x; Bertolotto C., 1998, B16 MELANOMA CELLS I; Chawla R, 2010, CELL CYCLE, V9, P3305, DOI 10.4161/cc.9.16.12632; Chin L, 2003, NAT REV CANCER, V3, P559, DOI 10.1038/nrc1145; Day CP, 2017, LAB INVEST, V97, P698, DOI 10.1038/labinvest.2016.155; Florell SR, 2007, J CUTAN PATHOL, V34, P667, DOI 10.1111/j.1600-0560.2006.00679.x; Herlyn M, 2010, J INVEST DERMATOL, V130, P911, DOI 10.1038/jid.2009.441; Janssen LME, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0283-9; Kuzu OF, 2015, CANCER GROWTH METAST, P81, DOI 10.4137/CGM.S21214; Lee H, 2014, BIOMOL THER, V22, P267, DOI 10.4062/biomolther.2014.074; Leonard MK, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081647; Liu Q, 2018, CANCER IMMUNOL IMMUN, V67, P299, DOI 10.1007/s00262-017-2079-7; McKinney Andrea J, 2011, Chin J Cancer, V30, P153; Noonan FP, 2003, PIGM CELL RES, V16, P16, DOI 10.1034/j.1600-0749.2003.00014.x; Overwijk WW, 2001, CURR PROTOC IMMUNOL, DOI [10.1002/0471142735.im2001s39, DOI /10.1002/0471142735.IM2001S39]; Parkin DM, 2011, BRIT J CANCER, V105, pS66, DOI 10.1038/bjc.2011.486; Powell MB, 1999, CARCINOGENESIS, V20, P1747, DOI 10.1093/carcin/20.9.1747; Recio JA, 2002, CANCER RES, V62, P6724; Richmond A, 2008, DIS MODEL MECH, V1, P78, DOI 10.1242/dmm.000976; Robinson JP, 2017, MELANOMA RES, V27, P545, DOI 10.1097/CMR.0000000000000403; SABZEVARI H, 1993, CANCER RES, V53, P4933; Sandru A, 2014, J Med Life, V7, P572; Sanmamed MF, 2016, ANN ONCOL, V27, P1190, DOI 10.1093/annonc/mdw041; Tas F, 2012, J ONCOL, DOI 10.1155/2012/647684; Tormo D, 2006, AM J PATHOL, V169, P665, DOI 10.2353/ajpath.2006.060017; Vasievich EA, 2012, MOL PHARMACEUT, V9, P261, DOI 10.1021/mp200350n; Walker GJ, 2002, J INVEST DERMATOL, V119, P783, DOI 10.1046/j.1523-1747.2002.00217.x; Zaidi MR, 2008, J INVEST DERMATOL, V128, P2381, DOI 10.1038/jid.2008.177; Zaidi MR, 2011, NATURE, V469, P548, DOI 10.1038/nature09666; Zhao FS, 2017, INT IMMUNOPHARMACOL, V52, P238, DOI 10.1016/j.intimp.2017.09.019; Zhao XM, 2012, NEURO-ONCOLOGY, V14, P574, DOI 10.1093/neuonc/nos061	35	1	1	1	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	SEP	2018	214	9					1235	1238		10.1016/j.prp.2018.07.008			4	Pathology	Pathology	GV3DC	WOS:000445973500001	30037646				2019-10-28	
J	Virgilio, E; Giarnieri, E; Giovagnoli, MR; Montagnini, M; Proietti, A; D'Urso, R; Mercantini, P; Balducci, G; Cavallini, M				Virgilio, Edoardo; Giarnieri, Enrico; Giovagnoli, Maria Rosaria; Montagnini, Monica; Proietti, Antonella; D'Urso, Rosaria; Mercantini, Paolo; Balducci, Genoveffa; Cavallini, Marco			Long non-coding RNAs in the gastric juice of gastric cancer patients	PATHOLOGY RESEARCH AND PRACTICE			English	Review						Long non coding RNA; lncRNAs; Gastric juice; GJ; Gastric cancer	UP-REGULATED EXPRESSION; CELL-PROLIFERATION; CLINICAL-SIGNIFICANCE; TUMOR-MARKERS; BIOMARKER; LAVAGE; UCA1; IDENTIFICATION; RELEVANCE; CARCINOMA	Differently from other digestive malignancies, gastric cancer (GC) carcinogenesis seems more heterogeneous and unclear. This entails failing in identification of reliable serum tumor markers for screening early GC (EGC) as well as persisting ominous prognosis of this disease. Recently, investigation of human noncoding genome, especially long noncoding molecules (lncRNAs), has provided promising data. As for GC, however, since the current information on GC-specific lncRNAs is still scarce and comes largely from analyses performed on tissue or serum of affected patients, we decided to review the current literature dealing with expression of such molecules in the gastric juice (GJ) of GC patients. In the case of GC, in fact, several cytological and molecular works have already demonstrated GJ to be an interesting biological material for improving clinicopathologic and prognostic knowledge of this cancer. For this review, we burrowed into the literature on lncRNAs expressed in GJ of GC patients. PubMed, Science Direct, Scopus, Web of Science, Google Scholar and ResearchGate were the search engines entertained. As of 2018, only seven studies have been reported. LINC00152, AA174084, UCA1, RMRP, ABHD11-AS1, LINC00982 and H19 were the GJ lncRNAs examined. Following our review, we can conclude that, due to their high specificity and reliability, GJ lncRNAs should deserve a prominent role in the field of GC research: importantly, they could be used for screening EGC, ameliorating the existing methods of staging (which are still far from being completely accurate), improving the prognostic capacity of the current diagnostic armamentarium and, finally, providing new and valuable therapeutic targets.	[Virgilio, Edoardo; Mercantini, Paolo; Balducci, Genoveffa; Cavallini, Marco] Sapienza Univ, St Andrea Hosp, Fac Med & Psychol, Dept Med & Surg Sci, Rome, Italy; [Virgilio, Edoardo; Mercantini, Paolo; Balducci, Genoveffa; Cavallini, Marco] Sapienza Univ, St Andrea Hosp, Fac Med & Psychol, Dept Translat Med, Rome, Italy; [Giarnieri, Enrico; Giovagnoli, Maria Rosaria; Montagnini, Monica; Proietti, Antonella; D'Urso, Rosaria] Sapienza Univ, St Andrea Hosp, Fac Med & Psychol, Dept Clin, Rome, Italy; [Giarnieri, Enrico; Giovagnoli, Maria Rosaria; Montagnini, Monica; Proietti, Antonella; D'Urso, Rosaria] Sapienza Univ, St Andrea Hosp, Fac Med & Psychol, Dept Mol Med, Rome, Italy	Virgilio, E (reprint author), Univ Sapienza, Fac Med & Psychol, Div Emergency Surg, Dept Med & Surg Sci & Translat Med,St Andrea Hosp, Via Grottarossa 1035-39, I-00189 Rome, Italy.	aresedo1992@yahoo.it		PROIETTI, Antonella/0000-0002-8863-8863; D'URSO, Rosaria/0000-0002-5477-1834			Chen JS, 2016, NEOPLASMA, V63, P223, DOI 10.4149/207_150821N454; Chen SX, 2016, TUMOR BIOL, V37, P6801, DOI 10.1007/s13277-015-4404-0; Chen WM, 2016, ONCOTARGET, V7, P9773, DOI 10.18632/oncotarget.6949; Duraes C, 2014, VIRCHOWS ARCH, V464, P367, DOI 10.1007/s00428-013-1533-y; Fei ZH, 2016, TUMOR BIOL, V37, P1983, DOI 10.1007/s13277-015-3979-9; Ferri M, 2013, INT J SURG, V11, P1016, DOI 10.1016/j.ijsu.2013.05.031; Gezer U, 2014, CELL BIOL INT, V38, P1076, DOI 10.1002/cbin.10301; Hamashima C, 2014, WORLD J GASTROENTERO, V20, P13767, DOI 10.3748/wjg.v20.i38.13767; Han Y, 2014, PATHOLOGY, V46, P396, DOI 10.1097/PAT.0000000000000125; Hewson Chris, 2016, Noncoding RNA Res, V1, P3, DOI 10.1016/j.ncrna.2016.06.001; Jamali L, 2018, J CELL PHYSIOL, V233, P8538, DOI 10.1002/jcp.26850; Li PF, 2014, WORLD J GASTROENTERO, V20, P5411, DOI 10.3748/wjg.v20.i18.5411; Li PF, 2015, CLIN CHIM ACTA, V444, P132, DOI 10.1016/j.cca.2015.02.018; Liu HS, 2014, WORLD J GASTROENTERO, V20, P12007, DOI 10.3748/wjg.v20.i34.12007; Pang QQ, 2014, TUMOR BIOL, V35, P5441, DOI 10.1007/s13277-014-1709-3; Pilozzi E, 2011, AM SURGEON, V77, P38; Shao YF, 2016, ONCOTARGET, V7, P37812, DOI 10.18632/oncotarget.9336; Shao YF, 2014, TUMOR BIOL, V35, P9591, DOI 10.1007/s13277-014-2243-z; Shao YF, 2014, CANCER-AM CANCER SOC, V120, P3320, DOI 10.1002/cncr.28882; Shi T, 2016, DIS MARKERS, DOI 10.1155/2016/9085195; Sun WL, 2016, J CANCER RES CLIN, V142, P2231, DOI 10.1007/s00432-016-2183-7; van der Pol E, 2012, PHARMACOL REV, V64, P676, DOI 10.1124/pr.112.005983; Virgilio E, 2018, CYTOPATHOLOGY, V29, P41, DOI 10.1111/cyt.12484; Virgilio E, 2018, MED HYPOTHESES, V114, P30, DOI 10.1016/j.mehy.2018.02.023; Virgilio E, 2018, ANTICANCER RES, V38, P1911, DOI 10.21873/anticanres.12428; Virgilio E, 2018, ANTICANCER RES, V38, P613, DOI 10.21873/anticanres.12265; Virgilio E, 2017, ANTICANCER RES, V37, P5595, DOI 10.21873/anticanres.11993; Virgilio E, 2017, ANTICANCER RES, V37, P4199, DOI 10.21873/anticanres.11810; Virgilio E, 2017, ANTICANCER RES, V37, P2817, DOI 10.21873/anticanres.11632; Virgilio E, 2016, MED HYPOTHESES, V94, P1, DOI 10.1016/j.mehy.2016.06.010; Virgilio E, 2016, ACTA CYTOL, V60, P161, DOI 10.1159/000445765; Virgilio E, 2014, MED HYPOTHESES, V82, P403, DOI 10.1016/j.mehy.2014.01.005; Wang XS, 2006, CLIN CANCER RES, V12, P4851, DOI 10.1158/1078-0432.CCR-06-0134; Wu DD, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0709-5; Yang YB, 2016, TUMOR BIOL, V37, P1183, DOI 10.1007/s13277-015-3903-3; Yu Y, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12349; Zhang L, 2013, CANCER LETT, V332, P94, DOI 10.1016/j.canlet.2013.01.023; Zhao J, 2015, AM J CANCER RES, V5, P907; Zheng Q, 2015, CLIN TRANSL ONCOL, V17, P640, DOI 10.1007/s12094-015-1290-2; Zhou XY, 2015, SCI REP-UK, V5, DOI 10.1038/srep11516	40	8	8	1	7	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	SEP	2018	214	9					1239	1246		10.1016/j.prp.2018.07.023			8	Pathology	Pathology	GV3DC	WOS:000445973500002	30078471				2019-10-28	
J	Huang, LN; Jiang, XM; Wang, ZD; Zhong, XY; Tai, S; Cui, YF				Huang, Lining; Jiang, Xingming; Wang, Zhidong; Zhong, Xiangyu; Tai, Sheng; Cui, Yunfu			Small nucleolar RNA host gene 1: A new biomarker and therapeutic target for cancers	PATHOLOGY RESEARCH AND PRACTICE			English	Review						lncRNA; SNHG1; Biomarker; Cancer; Therapy	LONG NONCODING RNA; CELL LUNG-CANCER; GASTRIC-CANCER; HEPATOCELLULAR-CARCINOMA; LNCRNA SNHG1; LIVER-CANCER; COLORECTAL-CANCER; ESOPHAGEAL CANCER; POOR-PROGNOSIS; UP-REGULATION	Objectives: Long non-coding RNAs (lncRNAs), a group of transcripts with length greater than 200 nucleotides, have been involved in multiple pathophysiological processes of the human body, especially in tumorigenesis and progression of cancers. The aberrant expression of lncRNAs processes crucial functions involved in proliferation, apoptosis and metastatic capacity of cancers. Recent studies have revealed that small nucleolar RNA host gene 1 (SNHG1), a long non-coding RNA transcribed from UHG, was located in chromosome 11. Aberrant expression of SNHG1 has been demonstrated to be associated with various sites of cancers such as glioma, esophageal cancer, gastric cancer and many others, and its deregulation could be related to survival and prognosis of cancer patients. Pertinent to clinical practice, SNHG1 might act as a prognostic biomarker for tumors and might even serve as potential target for therapy. In this review, we summarized current researches concerning the role of SNHG1 in tumor progression and discussed its mechanisms involved. Materials and methods: In this review, we summarized and figured out recent studies concerning the expression and biological mechanisms of SNHG1 in tumor development. The related studies were obtained through a systematic search of PubMed, Embase and Cochrane Library. Results: SNHG1 was a valuable cancer-related lncRNA that the expression level was up-regulation in a variety of malignancies, including glioma, esophageal cancer, lung cancer, gastric cancer, hepatocellular carcinoma, colorectal carcinoma, prostate cancer, cervical cancer, osteosarcoma, neuroblastoma, nasopharyngeal carcinoma. The aberrant expressions of SNHG1 have shown to contribute to proliferation, migration, and invasion of cancer cells. Conclusions: SNHG1 represents promising novel biomarkers for various cancer types and have a great potential to be effectively used in clinical practice in the near future.	[Huang, Lining; Jiang, Xingming; Wang, Zhidong; Zhong, Xiangyu; Tai, Sheng; Cui, Yunfu] Harbin Med Univ, Affiliated Hosp 2, Dept Hepatopancreatobiliary Surg, Harbin 150086, Heilongjiang, Peoples R China	Cui, YF (reprint author), Harbin Med Univ, Affiliated Hosp 2, Dept Hepatopancreatobiliary Surg, Harbin 150086, Heilongjiang, Peoples R China.	yfcui777@hotmail.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81602088]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2017M621305]; Heilongjiang Postdoctoral Science Foundation [LBH-Z16096]; Health and Family Planning Commission Research Project of Heilongjiang Province [2016-049]; Innovative Science Foundation of Harbin Medical University [2016LCZX09]	This study was funded by National Natural Science Foundation of China (81602088), China Postdoctoral Science Foundation (2017M621305), Heilongjiang Postdoctoral Science Foundation (LBH-Z16096), Health and Family Planning Commission Research Project of Heilongjiang Province (2016-049) and Innovative Science Foundation of Harbin Medical University (2016LCZX09).	Akerley W, 2017, J NATL COMPR CANC NE, V15, P689, DOI 10.6004/jnccn.2017.0074; Ali A, 2017, CURR OPIN UROL, V27, P217, DOI 10.1097/MOU.0000000000000385; Arun G, 2016, GENE DEV, V30, P34, DOI 10.1101/gad.270959.115; Attard G, 2016, LANCET, V387, P70, DOI 10.1016/S0140-6736(14)61947-4; Barney C, 2017, CHIN CLIN ONCOL, V6, DOI 10.21037/cco.2017.06.18; Bertuccio P, 2009, INT J CANCER, V125, P666, DOI 10.1002/ijc.24290; Bronner C, 2017, GENOME RES, V27, P1174, DOI 10.1101/gr.216986.116; Bruix J, 1998, HEPATOLOGY, V27, P1578, DOI 10.1002/hep.510270617; Burk RD, 2017, NATURE, V543, P378, DOI 10.1038/nature21386; Chen R, 2001, GENOME RES, V11, P1807, DOI 10.1101/gr.203601; Chuang SC, 2009, CANCER LETT, V286, P9, DOI 10.1016/j.canlet.2008.10.040; Cui Y, 2017, ONCOTARGET, V8, P17785, DOI 10.18632/oncotarget.14854; Dela Cruz CS, 2011, CLIN CHEST MED, V32, P605, DOI 10.1016/j.ccm.2011.09.001; DeSantis CE, 2014, CA-CANCER J CLIN, V64, P252, DOI 10.3322/caac.21235; Dhir A, 2015, NAT STRUCT MOL BIOL, V22, P319, DOI 10.1038/nsmb.2982; Eltawansy S, 2015, AM J CASE REP, V16, P31, DOI 10.12659/AJCR.892370; Essadi I, 2015, NEW ENGL J MED, V372, P1470, DOI 10.1056/NEJMc1500692; Frenel JS, 2017, J CLIN ONCOL, V35, P4035, DOI 10.1200/JCO.2017.74.5471; Frey MR, 1997, HISTOCHEM CELL BIOL, V108, P365, DOI 10.1007/s004180050177; Furuse J, 2008, BIOL-TARGETS THER, V2, P779; Gibb EA, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-38; Goyal A, 2017, NUCLEIC ACIDS RES, V45, DOI 10.1093/nar/gkw883; Guichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256; Guo FJ, 2015, BIOCHEM BIOPH RES CO, V465, P293, DOI 10.1016/j.bbrc.2015.08.027; Han P, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0583-1; Hessels D, 2003, EUR UROL, V44, P8, DOI 10.1016/S0302-2838(03)00201-X; Hu YB, 2017, BIOCHEM BIOPH RES CO, V491, P926, DOI 10.1016/j.bbrc.2017.07.137; Iyer MK, 2015, NAT GENET, V47, P199, DOI 10.1038/ng.3192; Jiang Z, 2018, BIOCHEM BIOPH RES CO, V495, P238, DOI 10.1016/j.bbrc.2017.11.012; Kalantari E, 2017, CANCER BIOMARK, V20, P563, DOI 10.3233/CBM-170383; Kamijo T, 2012, INT J CLIN ONCOL, V17, P190, DOI 10.1007/s10147-012-0415-7; Kim TW, 2016, ONCOTARGET, V7, P4195, DOI 10.18632/oncotarget.6549; Kunej T, 2014, CRIT REV CL LAB SCI, V51, P344, DOI 10.3109/10408363.2014.944299; Lan X., 2018, J CELL MOL MED; Lau E, 2014, NAT REV GENET, V15, DOI 10.1038/nrg3795; Li JP, 2017, BIOCHEM BIOPH RES CO, V487, P146, DOI 10.1016/j.bbrc.2017.03.169; Li J, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12312; Lin YS, 2013, J EPIDEMIOL, V23, P233, DOI 10.2188/jea.JE20120162; LINK MP, 1986, NEW ENGL J MED, V314, P1600, DOI 10.1056/NEJM198606193142502; Liu Y, 2018, BIOCHEM CELL BIOL, V96, P38, DOI 10.1139/bcb-2017-0188; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Lu Q., 2018, FASEB J; Luo S, 2016, CELL STEM CELL, V18, P637, DOI 10.1016/j.stem.2016.01.024; Marquardt JU, 2014, J HEPATOL, V60, P346, DOI 10.1016/j.jhep.2013.10.014; Mirabello L, 2009, CANCER-AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121; Panzitt K, 2007, GASTROENTEROLOGY, V132, P330, DOI 10.1053/j.gastro.2006.08.026; Ponjavic J, 2007, GENOME RES, V17, P556, DOI 10.1101/gr.6036807; Reck M, 2014, ANN ONCOL, V25, P27, DOI 10.1093/annonc/mdu199; Roberts LR, 2008, NEW ENGL J MED, V359, P420, DOI 10.1056/NEJMe0802241; Rosell R, 2013, LANCET, V382, P720, DOI 10.1016/S0140-6736(13)61715-8; Sahu D, 2016, ONCOTARGET, V7, P58022, DOI 10.18632/oncotarget.11158; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Shen Y, 2017, EMBO REP, V18, P536, DOI 10.15252/embr.201643139; Shi SM, 2017, ONCOTARGET, V8, P79366, DOI 10.18632/oncotarget.18121; Shi T, 2016, DIS MARKERS, DOI 10.1155/2016/9085195; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395; Song Y, 2015, CANCER BIOMARK, V15, P591, DOI 10.3233/CBM-150499; Song YM, 2014, NATURE, V509, P91, DOI 10.1038/nature13176; Sun XT, 2017, CANCER BIOMARK, V20, P67, DOI 10.3233/CBM-170112; Sun Y, 2017, ONCOGENE, V36, P6774, DOI 10.1038/onc.2017.286; Thin KZ, 2018, PATHOL RES PRACT, V214, P801, DOI 10.1016/j.prp.2018.04.003; Tian T, 2018, ONCOTARGET, V9, P2128, DOI 10.18632/oncotarget.23255; TYCOWSKI KT, 1994, SCIENCE, V266, P1558, DOI 10.1126/science.7985025; Underwood JG, 2010, NAT METHODS, V7, P995, DOI 10.1038/NMETH.1529; Wang H, 2018, PHARMAZIE, V73, P150, DOI 10.1691/ph.2018.7877; Wang HY, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0169-y; Wang JD, 2018, INT J ONCOL, V52, P77, DOI 10.3892/ijo.2017.4187; Wang Q, 2017, BIOMED PHARMACOTHER, V91, P906, DOI 10.1016/j.biopha.2017.05.014; Westermann F, 2002, CANCER LETT, V184, P127, DOI 10.1016/S0304-3835(02)00199-4; Wu HK, 2017, CANCER BIOMARK, V20, P191, DOI 10.3233/CBM-170204; Xu CH, 2017, ONCOTARGET, V8, P12041, DOI 10.18632/oncotarget.14510; Xu YT, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.503; Yan Y, 2017, ONCOTARGET, V8, P35750, DOI 10.18632/oncotarget.16189; Yang H, 2018, ONCOL REP, V40, P261, DOI 10.3892/or.2018.6412; Yu R, 2010, PROG BRAIN RES, V182, P207, DOI 10.1016/S0079-6123(10)82009-6; Zeng ZY, 2011, SCI CHINA LIFE SCI, V54, P966, DOI 10.1007/s11427-011-4223-5; Zhang AL, 2016, CANCER LETT, V375, P323, DOI 10.1016/j.canlet.2016.03.003; Zhang HY, 2017, BIOMED PHARMACOTHER, V90, P650, DOI 10.1016/j.biopha.2017.03.104; Zhang H, 2016, MED SCI MONITOR, V22, P4820, DOI 10.12659/MSM.898574; Zhang YM, 2017, SCI REP-UK, V7, DOI 10.1038/srep40786; Zhang ZY, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12505; Zhao Y, 2018, EUR REV MED PHARMACO, V22, P976, DOI 10.26355/eurrev_201802_14379; Zhu HX, 2015, BIOCHEM BIOPH RES CO, V467, P223, DOI 10.1016/j.bbrc.2015.10.002; Zugazagoitia J, 2016, CLIN THER, V38, P1551, DOI 10.1016/j.clinthera.2016.03.026	85	4	4	2	9	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	SEP	2018	214	9					1247	1252		10.1016/j.prp.2018.07.033			6	Pathology	Pathology	GV3DC	WOS:000445973500003	30107989				2019-10-28	
J	Sui, F; Sun, WJ; Su, X; Chen, P; Hou, P; Shi, BY; Yang, Q				Sui, Fang; Sun, Wanjing; Su, Xi; Chen, Pu; Hou, Peng; Shi, Bingyin; Yang, Qi			Gender-related differences in the association between concomitant amplification of AIB1 and HER2 and clinical outcomes in glioma patients	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Glioma; Gender; AIB1 copy number alteration; HER2 copy number alteration; Clinicopathological characteristics	CENTRAL-NERVOUS-SYSTEM; STEROID-RECEPTOR COACTIVATOR-3; NUMBER VARIATION ANALYSIS; BREAST-CANCER; MAGNETIC NANOPARTICLES; BRAIN-TUMORS; COPY NUMBER; GENETIC ALTERATIONS; GASTRIC-CANCER; GLIOBLASTOMA	Background Previous studies demonstrated that AIB1 or HER2 copy number gain (CNG), respectively, were independent predictors for poor prognosis of glioma patients, especially in females. We hypothesize that there are some connections between the two genes and sex-specific characteristics, thus this study aimed to analyze gender-related differences in the prognosis of glioma patients. Methods: Using Real-Time Quantitative Reverse Transcription PCR (RT-qPCR) method, we examined AIB1 and HER2 CNG in gliomas samples (n = 114), and inspected the correlation of various genotypes with patients outcomes. Results: Concomitant AIB1 and HER2 amplification were closely related to shorter survival time and radio-therapy resistance in female gliomas patients (P < 0.01), which also served as an independent risk factor. No significant prognostic value was found with AIB1 and HER2 CNG in male patients. However, linear regression analysis showed a positive relationship between the copy number of AIB1 and HER2 (P < 0.01) in male patients, rather than female patients. Conclusion: In this study, we reveal a gender difference in the prognostic value of concomitant AIB1 and HER2 CNG in glioma patients which were barely noticed before. These observations indicated that genetic alterations synergistic with essential respects of sex determination influence glioma biology and patients outcomes.	[Sui, Fang; Su, Xi; Chen, Pu; Hou, Peng; Shi, Bingyin; Yang, Qi] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Endocrinol, Xian 710061, Shaanxi, Peoples R China; [Sun, Wanjing] Dezhou Peoples Hosp, Dept Pharm, Dezhou 253014, Peoples R China; [Hou, Peng; Shi, Bingyin; Yang, Qi] Xi An Jiao Tong Univ, Affiliated Hosp 1, Key Lab Tumor Precis Med Shaanxi Prov, Xian 710061, Shaanxi, Peoples R China	Yang, Q (reprint author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Endocrinol, Xian 710061, Shaanxi, Peoples R China.; Yang, Q (reprint author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Key Lab Tumor Precis Med Shaanxi Prov, Xian 710061, Shaanxi, Peoples R China.	yangqi2015@xjtu.edu.cn		Su, Xi/0000-0001-7469-666X	Natural Science Basic Research Plan in Shaanxi Province of China [2015JM8390]	This study was supported by the Natural Science Basic Research Plan in Shaanxi Province of China (Program No. 2015JM8390).	Afyounian E, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1626-8; Aiello KA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164546; Alkner S, 2013, ANN ONCOL, V24, P1244, DOI 10.1093/annonc/mds613; Anic GM, 2014, J NEURO-ONCOL, V118, P297, DOI 10.1007/s11060-014-1427-0; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Buczkowicz P, 2014, NAT GENET, V46, P451, DOI 10.1038/ng.2936; Chang AK, 2012, ONCOL LETT, V4, P588, DOI 10.3892/ol.2012.803; Chen LH, 2016, J CANCER, V7, P2052, DOI 10.7150/jca.16069; Chien LN, 2016, FRONT PUBLIC HEALTH, V4, DOI 10.3389/fpubh.2016.00151; Claus EB, 2006, CANCER, V106, P1358, DOI 10.1002/cncr.21733; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Franceschi E, 2016, FUTUR NEUROL, V11, P197, DOI 10.2217/fnl-2016-0014; Garee JP, 2014, MOL ENDOCRINOL, V28, P846, DOI 10.1210/me.2013-1379; Hirose Y, 2013, BRAIN TUMOR PATHOL, V30, P203, DOI 10.1007/s10014-013-0148-y; Hou P, 2007, CLIN CANCER RES, V13, P1161, DOI 10.1158/1078-0432.CCR-06-1125; Iqbal Nida, 2014, Mol Biol Int, V2014, P852748, DOI 10.1155/2014/852748; Ji MJ, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-147; Lahusen T, 2007, CANCER RES, V67, P7256, DOI 10.1158/0008-5472.CAN-07-1013; List HJ, 2001, BREAST CANCER RES TR, V68, P21, DOI 10.1023/A:1017910924390; Liu M, 2015, THERANOSTICS, V5, P71, DOI 10.7150/thno.10117; Liu R, 2017, ONCOTARGET, V8, P92275, DOI 10.18632/oncotarget.21228; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Mazor T, 2017, P NATL ACAD SCI USA, V114, P10743, DOI 10.1073/pnas.1708914114; Mehta A, 2014, BREAST, V23, P2, DOI 10.1016/j.breast.2013.09.006; Molitoris JK, 2017, J NEURO-ONCOL, V134, P331, DOI 10.1007/s11060-017-2529-2; Ostrom Q, 2013, EPILEPSIA, V54, P25, DOI 10.1111/epi.12439; Ostrom QT, 2016, NEURO-ONCOLOGY, V18, pv1, DOI 10.1093/neuonc/now207; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Pollo B, 2011, NEUROL SCI, V32, pS209, DOI 10.1007/s10072-011-0802-2; Qaddoumi I, 2016, ACTA NEUROPATHOL, V131, P833, DOI 10.1007/s00401-016-1539-z; Shen J, 2016, MOL CARCINOGEN, V55, P2089, DOI 10.1002/mc.22453; Shi J, 2015, ONCOTARGET, V6, P14344, DOI 10.18632/oncotarget.3852; Shi J, 2012, INT J MOL SCI, V13, P4714, DOI 10.3390/ijms13044714; Shi J, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-50; Shinojima N, 2004, J NEUROSURG, V101, P219, DOI 10.3171/jns.2004.101.2.0219; Song XZ, 2016, P NATL ACAD SCI USA, V113, P4970, DOI 10.1073/pnas.1604274113; Sun T, 2012, BIOL SEX DIFFER, V3, DOI 10.1186/2042-6410-3-3; Suzuki H, 2015, NAT GENET, V47, P458, DOI 10.1038/ng.3273; Tabori U, 2006, INT J RADIAT ONCOL, V64, P402, DOI 10.1016/j.ijrobp.2005.07.962; Tien JCY, 2012, EXPERT OPIN THER TAR, V16, P1085, DOI 10.1517/14728222.2012.718330; Trifiletti DM, 2017, WORLD NEUROSURG, V103, P330, DOI 10.1016/j.wneu.2017.04.035; Tseng MY, 2006, J NEUROSURG, V105, P297, DOI 10.3171/ped.2006.105.4.297; Vareslija D, 2016, CLIN CANCER RES, V22, P2765, DOI 10.1158/1078-0432.CCR-15-1583; VERTOSICK FT, 1991, NEUROSURGERY, V28, P496, DOI 10.1227/00006123-199104000-00002; Vigneswaran K, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.03.57; Wu GJ, 2005, J CLIN ENDOCR METAB, V90, P4688, DOI 10.1210/jc.2004-2281; Yang HW, 2017, J BIOMED NANOTECHNOL, V13, P655, DOI 10.1166/jbn.2017.2386; Yang HW, 2016, J NANOSCI NANOTECHNO, V16, P6505, DOI 10.1166/jnn.2016.10841; Yang W., 2017, BIORXIV; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yarden Y, 2012, NAT REV CANCER, V12, P553, DOI 10.1038/nrc3309	52	0	0	1	3	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	SEP	2018	214	9					1253	1259		10.1016/j.prp.2018.06.013			7	Pathology	Pathology	GV3DC	WOS:000445973500004	30153912				2019-10-28	
J	Qin, LT; Tang, RX; Lin, P; Li, Q; Yang, H; Luo, DZ; Chen, G; He, Y; Li, P				Qin, Li-ting; Tang, Rui-xue; Lin, Peng; Li, Qing; Yang, Hong; Luo, Dian-zhong; Chen, Gang; He, Yun; Li, Ping			Biological function of UCA1 in hepatocellular carcinoma and its clinical significance: Investigation with in vitro and meta-analysis	PATHOLOGY RESEARCH AND PRACTICE			English	Article						UCA1; Hepatocellular carcinoma; Proliferation; Apoptosis; Meta-analysis	LONG NONCODING RNA; CELL LUNG-CANCER; BLADDER-CANCER; QRT-PCR; PROMOTES; EXPRESSION; LNCRNA; PROGRESSION; BIOMARKERS; GROWTH	Urothelial cancer associated 1 (UCA1) was upregulated in hepatocellular carcinoma (HCC) tissues and cell lines, and the expression of UCA1 was associated with several clinical features and malignant behaviours in HCC. However, none of these findings completely interpreted the role of UCA1 in HCC. We conducted this investigation to validate the expression of UCA1 and its relationship with Tumor Node Metastasis (TNM) stage in 41 HCC tissues and their paired noncancerous adjacent tissues by real-time qPCR. Furthermore, we also explored the biological functions of UCA1 in vitro with HCC cell lines. Most importantly, we conducted a comprehensive meta-analysis and bioinformatics investigation based on peer-reviewed literature and in silico approaches to further summarise the clinical value and functions of UCA1 in HCC. UCA1 expression was remarkably upregulated in HCC tissues, and its expression was profoundly higher in advanced stages than in early stages. Reducing the expression levels of UCA1 suppressed the proliferation and induced apoptosis of HCC cells. Furthermore, the present meta-analysis validated that up-regulated UCA1 was closely related to larger tumour size and advanced TNM stages, and the overexpression of UCA1 was significantly correlated with a shorter OS. Additionally, according to GO analysis, the target genes were found concentrated in the following biological processes: extracellular matrix organisation, cilium assembly and cilium morphogenesis. KEGG pathway analysis showed that the UCA1-related genes were significantly enriched in the following pathways: hippo signalling pathway, bile secretion and gastric acid secretion. This evidence hinted that UCA1 could play an indispensable proliferation-related key role in HCC via the hippo signalling pathway. However, the exact molecular mechanism needs to be verified with future functional experiments.	[Qin, Li-ting; Tang, Rui-xue; Luo, Dian-zhong; Li, Ping] Guangxi Med Univ, Affiliated Hosp 1, Dept Pathol, Nanning, Guangxi Zhuang, Peoples R China; [Lin, Peng; Li, Qing; Yang, Hong; Chen, Gang; He, Yun] Guangxi Med Univ, Affiliated Hosp 1, Dept Med Ultrason, Nanning, Guangxi Zhuang, Peoples R China	Li, P (reprint author), Guangxi Med Univ, Affiliated Hosp 1, Dept Pathol, Nanning, Guangxi Zhuang, Peoples R China.; He, Y (reprint author), Guangxi Med Univ, Affiliated Hosp 1, Dept Med Ultrason, Nanning, Guangxi Zhuang, Peoples R China.	228388072@qq.com; liping@gxmu.edu.cn		Chen, Gang/0000-0002-4864-1451	Innovation Project of Guangxi Graduate Education [YCBZ2017040]	The study was supported by Innovation Project of Guangxi Graduate Education (YCBZ2017040).	Burra P, 2018, CANCERS, V10, DOI 10.3390/cancers10020046; Chen G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060317; El-Tawdi AHF, 2016, EXPERT REV GASTROENT, V10, P869, DOI 10.1080/17474124.2016.1193003; Gao X, 2018, FEBS OPEN BIO, V8, P94, DOI 10.1002/2211-5463.12354; Guo S, 2015, INT J CLIN EXP PATHO, V8, P5395; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He RQ, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3646-1; He RQ, 2017, AM J TRANSL RES, V9, P1561; He RQ, 2015, INT J CLIN EXP PATHO, V8, P15632; Hu JJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep23521; Huang ZL, 2015, ONCOL REP, V34, P2403, DOI 10.3892/or.2015.4259; Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161; Kamel MM, 2016, TRANSL RES, V168, P134, DOI 10.1016/j.trsl.2015.10.002; Klingenberg M, 2017, J HEPATOL, V67, P603, DOI 10.1016/j.jhep.2017.04.009; Li HJ, 2017, CELL PHYSIOL BIOCHEM, V43, P2548, DOI 10.1159/000484507; Li JJ, 2016, CANCER CELL INT, V16, DOI 10.1186/s12935-016-0352-z; Li JJ, 2016, ONCOTARGETS THER, V9, P1721, DOI 10.2147/OTT.S100040; Li TF, 2018, ONCOL REP, V39, P1072, DOI 10.3892/or.2018.6182; Li W, 2018, CLIN TRANSPLANT, V32, DOI 10.1111/ctr.13193; Li XC, 2016, TUMOR BIOL, V37, P7599, DOI 10.1007/s13277-015-4655-9; Li ZH, 2017, CELL PHYSIOL BIOCHEM, V42, P1407, DOI 10.1159/000479205; Liang CJ, 2018, ONCOTARGETS THER, V11, P47, DOI 10.2147/OTT.S151390; Liang L, 2017, PATHOL RES PRACT, V213, P1494, DOI 10.1016/j.prp.2017.10.001; Luo JH, 2017, ONCOL LETT, V14, P5556, DOI 10.3892/ol.2017.6886; Ma WJ, 2017, CELL PHYSIOL BIOCHEM, V41, P609, DOI 10.1159/000457883; Marcellin P, 2018, LIVER INT, V38, P2, DOI 10.1111/liv.13682; Najjar M, 2018, J HEPATOCELL CARCINO, V5, P17, DOI 10.2147/JHC.S86792; Nie W, 2016, CANCER LETT, V371, P99, DOI 10.1016/j.canlet.2015.11.024; Pan Y, 2016, CELL PHYSIOL BIOCHEM, V40, P219, DOI 10.1159/000452539; Qiu LP, 2017, LIFE SCI, V191, P273, DOI 10.1016/j.lfs.2017.10.007; Ren FH, 2018, BMC CANCER, V18, DOI 10.1186/s12885-017-3941-x; Roche B, 2018, LIVER INT, V38, P139, DOI 10.1111/liv.13659; Shen J, 2015, CANCERS, V7, P1847, DOI 10.3390/cancers7030865; Shi X, 2017, CANCER LETT, V400, P175, DOI 10.1016/j.canlet.2017.04.032; Song W, 2017, PANMINERVA MED, V59, P278, DOI [10.23736/S00310808.17.03238-4, 10.23736/S0031-0808.17.03238-4]; Srivastava AK, 2014, TUMOR BIOL, V35, P11435, DOI 10.1007/s13277-014-2474-z; Sun T, 2017, CELL PHYSIOL BIOCHEM, V44, P716, DOI 10.1159/000485285; Tang A, 2018, ABDOM RADIOL, V43, P13, DOI 10.1007/s00261-017-1209-1; Tao K, 2015, INT J CLIN EXP MED, V8, P21854; Wang F, 2015, ONCOTARGET, V6, P1; Wang ZQ, 2017, CANCER LETT, V408, P10, DOI 10.1016/j.canlet.2017.08.013; Wang ZQ, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.143; Xiao JN, 2017, J CANCER RES CLIN, V143, P981, DOI 10.1007/s00432-017-2370-1; Xie ZY, 2017, MED SCI MONITOR, V23, DOI 10.12659/MSM.904675; Yang X, 2018, FEBS OPEN BIO, V8, P64, DOI 10.1002/2211-5463.12349; Yang ZG, 2015, DIS MARKERS, DOI 10.1155/2015/191029; Yoneda M, 2018, J GASTROENTEROL, V53, P181, DOI 10.1007/s00535-017-1414-2; Zhang SL, 2017, AM J TRANSL RES, V9, P366; Zhang Y, 2017, INT J ONCOL, V51, P1705, DOI 10.3892/ijo.2017.4164; Zhang Y, 2017, AM J TRANSL RES, V9, P3904; Zheng ZK, 2018, J INT MED RES, V46, P348, DOI 10.1177/0300060517726441; Zhong DN, 2018, MOL MED REP, V17, P1148, DOI 10.3892/mmr.2017.7999	52	2	2	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	SEP	2018	214	9					1260	1272		10.1016/j.prp.2018.03.025			13	Pathology	Pathology	GV3DC	WOS:000445973500005	30017333				2019-10-28	
J	Jepsen, RK; Klarskov, LL; Lippert, MF; Novotny, GW; Hansen, TP; Christensen, IJ; Hogdall, E; Riis, LB				Jepsen, Rikke Karlin; Klarskov, Louise Laurberg; Lippert, Michael Friis; Novotny, Guy Wayne; Hansen, Tine Plato; Christensen, Ib Jade; Hogdall, Estrid; Riis, Lene Buhl			Digital image analysis of pan-cytokeratin stained tumor slides for evaluation of tumor budding in pT1/pT2 colorectal cancer: Results of a feasibility study	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Colorectal cancer; Tumor budding; Digital image analysis; Immunohistochemistry; Pan-cytokeratin; Interobserver agreement	LYMPH-NODE METASTASIS; RECTAL-CANCER; DISTANT METASTASES; CARCINOMA; BIOPSIES; RISK; INTEROBSERVER; METAANALYSIS; MULTICENTER; PREDICTS	Tumor budding is an independent prognostic factor in colorectal cancer. However, varying degrees of interobserver agreement and reproducibility challenges the use of tumor budding in diagnostics. Immunohistochemical staining of tumor slides with pan-cytokeratin visualizes the budding tumor cells and has been suggested to improve reproducibility. Here we demonstrate the methodology of tumor budding assessment using digital image analysis based on tumor slides stained for pan-cytokeratin, and investigate interobserver agreement, agreement between manual and digital assessment methods and digital reproducibility between users. Tumor slides from 126 patients with pT1/pT2 colorectal cancer were stained with pan-cytokeratin and tumor budding at the invasive tumor front was assessed by conventional manual microscopy. A digital image analysis algorithm for identification and quantification of budding tumor cells was developed and tested on the pan-cytokeratin stained slides. Manual assessment of tumor budding using pan-cytokeratin stained tumor slides exhibited high correlations (Spearman Rank 0.84-0.89, p < 0.001),excellent agreement between observers (Intra-class correlation coefficient (ICC): 0.86 -0.87) and 2.20 higher odds for regional metastases with increasing budding counts (p = 0.017). Digital image analysis correlated well to manual assessment (Spearman Rank 0.71-0.88) and agreement between the two methods was good (ICC 0.62-0.82). However, only a trend towards increased odds for metastatic progression was found for the adjusted digital estimates (p = 0.076). Digital estimates were higher than manual estimates, demonstrated by a systematic median difference of 3-4.5 buds. Image analysis was highly reproducible between users of the algorithm (ICC 0.98). In conclusion, assessment of tumor budding using pan-cytokeratin stained tumor slides is a method with high correlation and agreement between observers. Digital image analysis quantifies budding tumor cells in high agreement with manual estimates, but approval of the digital slides by a pathologist is mandatory. The method qualifies for further investigation.	[Jepsen, Rikke Karlin; Klarskov, Louise Laurberg; Novotny, Guy Wayne; Hansen, Tine Plato; Christensen, Ib Jade; Hogdall, Estrid; Riis, Lene Buhl] Univ Copenhagen, Herlev & Gentofte Hosp, Dept Pathol, Herlev Ringvej 75, DK-2730 Herlev, Denmark; [Jepsen, Rikke Karlin; Klarskov, Louise Laurberg; Novotny, Guy Wayne; Hansen, Tine Plato; Christensen, Ib Jade; Hogdall, Estrid; Riis, Lene Buhl] Univ Copenhagen, Herlev & Gentofte Hosp, Mol Unit, Herlev Ringvej 75, DK-2730 Herlev, Denmark; [Lippert, Michael Friis] Visiopharm AS, Res & Regulatory Dev, Agern Alle 24, DK-2970 Horsholm, Denmark; [Jepsen, Rikke Karlin] Univ Copenhagen, Dept Pathol, Rigshosp, Blegdamsvej 9, DK-2100 Copenhagen O, Denmark	Jepsen, RK (reprint author), Univ Copenhagen, Dept Pathol, Rigshosp, Blegdamsvej 9, DK-2100 Copenhagen O, Denmark.	rikke.karlin.jepsen@regionh.dk; louise.laurberg.klarskov@regionh.dk; mfl@visiopharm.com; guy.wayne.novotny@regionh.dk; tine.plato.hansen.01@regionh.dk; Ib.Jarle.Christensen@regionh.dk; Estrid.Hoegdall@regionh.dk; Lene.Buhl.Riis@regionh.dk		Hogdall, Estrid/0000-0003-4689-5658	Beckett Foundation [38069/38079]; A.P. Moller Foundation for the Advancement of Medical Science [14-187]; Krista and Viggo Petersens Foundation [5793/44]; Fabrikant Einer Willumsen Foundation [6000073]; Vald Foersom and Thyra Foersoms Foundation [41452-001]	The work was supported by Beckett Foundation (38069/38079), The A.P. Moller Foundation for the Advancement of Medical Science (14-187), Krista and Viggo Petersens Foundation (5793/44), Fabrikant Einer Willumsen Foundation (6000073) and Vald Foersom and Thyra Foersoms Foundation (41452-001). Funding sources had no influence in any part of the study.	Beaton C, 2013, COLORECTAL DIS, V15, P788, DOI 10.1111/codi.12129; Bosch SL, 2013, ENDOSCOPY, V45, P827, DOI 10.1055/s-0033-1344238; Brierley J. D., 2016, TNM CLASSIFICATION M; Caie PD, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-156; Danish Colorectal Cancer Group, 2015, ANN AUD DAN COL CANC; Dawson H, 2015, FRONT MED-LAUSANNE, V2, DOI 10.3389/fmed.2015.00011; De Smedt L, 2016, VIRCHOWS ARCH, V468, P397, DOI 10.1007/s00428-015-1886-5; Ferlay J, GLOBOCAN 2012 V1 0; Gill MD, 2012, BRIT J CANCER, V107, P417, DOI 10.1038/bjc.2012.305; Holten-Rossing H, 2017, HISTOPATHOLOGY, V71, P866, DOI 10.1111/his.13305; Ishikawa Y, 2008, CANCER, V112, P924, DOI 10.1002/cncr.23248; Kai K, 2016, PATHOL INT, V66, P75, DOI 10.1111/pin.12374; Karamitopoulou E, 2013, MODERN PATHOL, V26, P295, DOI 10.1038/modpathol.2012.155; Kawachi H, 2015, MODERN PATHOL, V28, P872, DOI 10.1038/modpathol.2015.36; Koelzer VH, 2017, J PATHOL CLIN RES, V3, P171, DOI 10.1002/cjp2.73; Koelzer VH, 2016, HUM PATHOL, V47, P4, DOI 10.1016/j.humpath.2015.08.007; Koelzer VH, 2015, VIRCHOWS ARCH, V466, P485, DOI 10.1007/s00428-015-1740-9; Lugli A, 2017, MODERN PATHOL, V30, P1299, DOI 10.1038/modpathol.2017.46; Mitrovic B, 2012, MODERN PATHOL, V25, P1315, DOI 10.1038/modpathol.2012.94; Nordi Q.C., 2017, NORDIC IMMUNOHISTOCH; Okamura T, 2016, DIS COLON RECTUM, V59, P396, DOI 10.1097/DCR.0000000000000567; Pedersen NJ, 2017, ONCOTARGET, V8, P18227, DOI 10.18632/oncotarget.15314; Prall F, 2007, HISTOPATHOLOGY, V50, P151, DOI 10.1111/j.1365-2559.2006.02551.x; Puppa G, 2012, HISTOPATHOLOGY, V61, P562, DOI 10.1111/j.1365-2559.2012.04270.x; Rogers AC, 2016, BRIT J CANCER, V115, P831, DOI 10.1038/bjc.2016.274; Rogers AC, 2014, MODERN PATHOL, V27, P156, DOI 10.1038/modpathol.2013.124; Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395; Suzuki A, 2009, AM J SURG PATHOL, V33, P1601, DOI 10.1097/PAS.0b013e3181ae29d6; Syk E, 2011, COLORECTAL DIS, V13, P255, DOI 10.1111/j.1463-1318.2009.02119.x; Thiery JP, 2009, B ACAD NAT MED PARIS, V193, P1969, DOI 10.1016/S0001-4079(19)32372-6; Thiery JP, 2009, B ACAD NATL MED, V193, P1978; van Wyk HC, 2015, CANCER TREAT REV, V41, P151, DOI 10.1016/j.ctrv.2014.12.007; Wang LM, 2009, AM J SURG PATHOL, V33, P134, DOI 10.1097/PAS.0b013e318184cd55; Zlobec I, 2014, BRIT J CANCER, V110, P1008, DOI 10.1038/bjc.2013.797	34	2	2	0	4	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	SEP	2018	214	9					1273	1281		10.1016/j.prp.2018.07.002			9	Pathology	Pathology	GV3DC	WOS:000445973500006	30017334				2019-10-28	
J	Law, S; Sanyal, S; Chatterjee, R; Law, A; Law, A; Chattopadhyay, S				Law, Sujata; Sanyal, Shalini; Chatterjee, Ritam; Law, Atrayo; Law, Aditya; Chattopadhyay, Sukalpa			Therapeutic management of peritoneal ascitic sarcomatosis by Ruta graveolens: A study in experimental mice	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Peritoneal sarcomatosis; Chemotherapy; c-Myc; Chk2; CD 95	NEUTRAL RED; MOUSE MODEL; CELL-DEATH; C-MYC; APOPTOSIS; L.; CYTOTOXICITY; METABOLISM; EXPRESSION; KINASE	Relevance: Malignant peritoneal sarcomatosis related ascitic formation often leads to grave consequences but the therapeutic management of the fatal pathophysiological condition remains a rarely discussed issue. The present study investigates the anti-neoplastic activity of the plant alkaloid from Ruta graveolens on ascitic Sarcoma-180 bearing mice as a model of human malignant peritoneal ascites. Materials and Methods: The efficacy of the loco-regional administration of Ruta graveolens on tumour cells was explored with cytopathological and cytotoxicological studies, along with the expressional modulation vital regulatory molecules viz. Chk2, c-Myc, CD95 and Aurora kinase. Results: The study revealed a series of anti-neoplastic events exerted by Ruta graveolens that included the boosting of anti-tumour immunity, generation of tumour cell cytotoxicity and disruption of cellular energetics which lead to the induction of apoptosis and simultaneous impairment of cell division in tumour cells. Expressional decline of c-Myc oncoproteins and mitosis promoter Aurora kinase A together with up regulation of vital tumour suppressor Chk-2 and apoptosis inducer CD 95 in ascitic tumour cells was also found to be associated with Ruta administration. Conclusion: Our observations revealed that loco-regional Ruta administration resulted in the anti-neoplastic effect on peritoneal sarcoma related ascites and the alteration of vital regulatory molecules which depicted the therapeutic utility of Ruta in the management of peritoneal malignant ascites.	[Law, Sujata; Sanyal, Shalini; Chatterjee, Ritam; Law, Atrayo; Law, Aditya; Chattopadhyay, Sukalpa] Calcutta Sch Trop Med, Dept Biochem & Med Biotechnol, Stem Cell Res & Applicat Unit, 108 CR Ave, Kolkata 700073, W Bengal, India	Law, S (reprint author), Calcutta Sch Trop Med, Dept Biochem & Med Biotechnol, Stem Cell Res & Applicat Unit, 108 CR Ave, Kolkata 700073, W Bengal, India.	msuj2002@yahoo.co.in		Sanyal, Shalini/0000-0001-8796-1362; Law, Sujata/0000-0002-2115-7440			Alzoreky NS, 2003, INT J FOOD MICROBIOL, V80, P223, DOI 10.1016/S0168-1605(02)00169-1; Banerji P, 2001, IN VIVO, V15, P181; BELETTI M.E., 2005, BRAZ J MORPHOL SCI, V22, P85; Boericke W., 2002, POCKET MANUAL HOMOEO; BORENFREUND E, 1985, TOXICOL LETT, V24, P119, DOI 10.1016/0378-4274(85)90046-3; Borra Ricardo Carneiro, 2009, Braz. oral res., V23, P255, DOI 10.1590/S1806-83242009000300006; Chaklader M., 2011, Experimental Oncology, V33, P83; Chaklader M, 2013, MOL CELL BIOCHEM, V382, P293, DOI 10.1007/s11010-013-1750-3; Chaklader M, 2012, ARH HIG RADA TOKSIKO, V63, P271, DOI 10.2478/10004-1254-63-2012-2255; Chatterjee Ritam, 2016, Proceedings of the Zoological Society (Calcutta), V69, P114, DOI 10.1007/s12595-014-0132-5; Chattopadhyay S, 2016, EXP CELL RES, V340, P91, DOI 10.1016/j.yexcr.2015.11.027; Ciapetti G, 1996, BIOMATERIALS, V17, P1259, DOI 10.1016/0142-9612(96)88670-4; Cowperthwaite Allen Corson, 2003, TXB MATERIA MED CHAR; Dang CV, 1999, MOL CELL BIOL, V19, P1; Das P., 2009, J STEM CELLS, V5, P65; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Ivanova A, 2005, FITOTERAPIA, V76, P344, DOI 10.1016/j.fitote.2005.02.008; Katayama H, 2001, J BIOL CHEM, V276, P46219, DOI 10.1074/jbc.M107540200; Kent J. T., 1980, LECT HOMOEOPATHIC MA; Kim Hee-Sun, 2013, Clin Exp Reprod Med, V40, P23, DOI 10.5653/cerm.2013.40.1.23; Kostova I, 1999, MONATSH CHEM, V130, P703, DOI 10.1007/s007060050230; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Mejri J, 2010, IND CROP PROD, V32, P671, DOI 10.1016/j.indcrop.2010.05.002; Miller DM, 2012, CLIN CANCER RES, V18, P5546, DOI 10.1158/1078-0432.CCR-12-0977; O'Brien J, 2000, EUR J BIOCHEM, V267, P5421, DOI 10.1046/j.1432-1327.2000.01606.x; Oliva A, 2003, J AGR FOOD CHEM, V51, P890, DOI 10.1021/jf0259361; Oliva A., 2000, CURR TOP PHYTOCHEM, V3, P167; Pathak S, 2003, INT J ONCOL, V23, P975; Preethi K C, 2006, Asian Pac J Cancer Prev, V7, P439; Raghav SK, 2006, J ETHNOPHARMACOL, V104, P234, DOI 10.1016/j.jep.2005.09.008; Repetto G, 2008, NAT PROTOC, V3, P1125, DOI 10.1038/nprot.2008.75; Ribble D, 2005, BMC BIOTECHNOL, V5, DOI 10.1186/1472-6750-5-12; San Miguel E, 2003, ECON BOT, V57, P231, DOI 10.1663/0013-0001(2003)057[0231:RRLRIT]2.0.CO;2; Sanyal S, 2016, CELL BIOL TOXICOL, V32, P7, DOI 10.1007/s10565-016-9314-4; Sohaebuddin SK, 2010, PART FIBRE TOXICOL, V7, DOI 10.1186/1743-8977-7-22; Sridharan Gokul, 2012, J Oral Maxillofac Pathol, V16, P251, DOI 10.4103/0973-029X.99081; Sugimoto K, 2002, CELL STRUCT FUNCT, V27, P457, DOI 10.1247/csf.27.457; Tondon K. P., 1970, J AM I HOMOEOPATHY J, V63, P109; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847	39	1	1	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	SEP	2018	214	9					1282	1290		10.1016/j.prp.2018.07.006			9	Pathology	Pathology	GV3DC	WOS:000445973500007	30025594				2019-10-28	
J	Ishida, Y; Kido, A; Akahane, M; Kishi, S; Tsukamoto, S; Fujii, H; Honoki, K; Tanaka, Y				Ishida, Yukako; Kido, Akira; Akahane, Manabu; Kishi, Shingo; Tsukamoto, Shinji; Fujii, Hiromasa; Honoki, Kanya; Tanaka, Yasuhito			Mesenchymal stem cells up-regulate the invasive potential of prostate cancer cells via the eotaxin-3/CCR3 axis	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Mesenchymal stem cells; Cancer microenvironment; Eotaxin-3; CCR3; Homing chemokines	SYSTEMIC-LUPUS-ERYTHEMATOSUS; CHEMOKINE RECEPTORS; BONE-MARROW; EOSINOPHILS; ENGRAFTMENT; MIGRATION; EXPRESS; TRANSPLANTATION; PROGRESSION; ADHESION	This study aimed to clarify the role of mesenchymal stem cells (MSCs) as a component of the cancer micro-environment. We investigated the homing-related chemokine expression levels of MSCs treated with a prostate cancer cell line (PC-3) -conditioned medium. Among several homing chemokines, an antibody array revealed that expression of eotaxin-3 (but not eotxin-1 and -2) was highly enhanced in MSCs treated with PC-3-conditioned medium. A gene expression array showed significantly increased expression of CCR3, a receptor of eotaxin-3, in PC-3. In a matrigel invasion assay, interferon-gamma, a specific inhibitor of eotaxin-related homing, significantly reduced the transmigration of PC-3 cells, under co-cultured condition with MSCs, in a dose-dependent manner (P < 0.05). Consistent with these results, anti-CCR3 antibody successfully reduced PC-3 migration under the co-cultured condition. These findings suggest that MSCs to modulation of the invasive potential of prostate cancer cells via the eotaxin-3/CCR3 axis.	[Ishida, Yukako; Kido, Akira; Tsukamoto, Shinji] Nara Med Univ, Dept Rehabil Med, 840 Shijo Cho, Kashihara, Nara 6348522, Japan; [Akahane, Manabu] Nara Med Univ, Dept Publ Hlth Hlth Management & Policy, Nara, Japan; [Kishi, Shingo; Tsukamoto, Shinji; Fujii, Hiromasa; Honoki, Kanya; Tanaka, Yasuhito] Nara Med Univ, Dept Orthoped Surg, Nara, Japan	Kido, A (reprint author), Nara Med Univ, Dept Rehabil Med, 840 Shijo Cho, Kashihara, Nara 6348522, Japan.	akirakid@naramed-u.ac.jp	Tsukamoto, Shinji/L-6013-2019		JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JP24592241, JP15K01381]	This work was supported by JSPS KAKENHI Grant Numbers JP24592241, JP15K01381.	Agarwal M, 2013, PROSTATE, V73, P573, DOI 10.1002/pros.22597; Bergfeld SA, 2010, CANCER METAST REV, V29, P249, DOI 10.1007/s10555-010-9222-7; Campbell EM, 1998, J IMMUNOL, V161, P7047; Carrion F, 2010, LUPUS, V19, P317, DOI 10.1177/0961203309348983; Croitoru-Lamoury J, 2007, J INTERF CYTOK RES, V27, P53, DOI 10.1089/jir.2007.0037; Ellyard JI, 2007, TISSUE ANTIGENS, V70, P1, DOI 10.1111/j.1399-0039.2007.00869.x; Fouillard L, 2003, LEUKEMIA, V17, P474, DOI 10.1038/sj.leu.2402786; Furbert-Harris P, 2003, PROSTATE, V57, P165, DOI 10.1002/pros.10286; Gatault S, 2012, CANCER IMMUNOL IMMUN, V61, P1527, DOI 10.1007/s00262-012-1288-3; Heidegger I, 2015, PROSTATE, V75, P1904, DOI 10.1002/pros.23086; Honczarenko M, 2006, STEM CELLS, V24, P1030, DOI 10.1634/stemcells.2005-0319; IUIS/WHO, 2003, CYTOKINE, V21, P48; Ji JF, 2004, STEM CELLS, V22, P415, DOI 10.1634/stemcells.22-3-415; Kido A, 2012, ONCOL LETT, V4, P745, DOI 10.3892/ol.2012.813; Laurent V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10230; Le Blanc K, 2007, LEUKEMIA, V21, P1733, DOI 10.1038/sj.leu.2404777; Lin ZY, 2012, BIOMED PHARMACOTHER, V66, P525, DOI 10.1016/j.biopha.2012.02.001; Ponte AL, 2007, STEM CELLS, V25, P1737, DOI 10.1634/stemcells.2007-0054; Marx J, 2008, SCIENCE, V320, P38, DOI 10.1126/science.320.5872.38; McNeel DG, 2014, CANCER IMMUNOL RES, V2, P988, DOI 10.1158/2326-6066.CIR-14-0073; Ruster B, 2006, BLOOD, V108, P3938, DOI 10.1182/blood-2006-05-025098; Sakkal S, 2016, CURR MED CHEM, V23, P650, DOI 10.2174/0929867323666160119094313; Segers VFM, 2006, AM J PHYSIOL-HEART C, V290, pH1370, DOI 10.1152/ajpheart.00523.2005; Sordi V, 2005, BLOOD, V106, P419, DOI 10.1182/blood-2004-09-3507; Stich S, 2009, CELL TISSUE RES, V336, P225, DOI 10.1007/s00441-009-0768-z; Sun LY, 2010, ARTHRITIS RHEUM-US, V62, P2467, DOI 10.1002/art.27548; Tsukamoto S, 2012, INT J ONCOL, V40, P163, DOI 10.3892/ijo.2011.1220; Zhu F, 2014, ONCOL REP, V31, P2049, DOI 10.3892/or.2014.3060	28	0	0	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	SEP	2018	214	9					1297	1302		10.1016/j.prp.2018.06.012			6	Pathology	Pathology	GV3DC	WOS:000445973500009	30029937				2019-10-28	
J	Sun, SG; Zhang, Q; Wang, QY; Wu, Q; Xu, GL; Chang, P; Hu, H; Bai, F				Sun, Shougang; Zhang, Quan; Wang, Qiongying; Wu, Qiang; Xu, Guangli; Chang, Peng; Hu, Hao; Bai, Feng			Local delivery of thalidomide to inhibit neointima formation in rat model with artery injury	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Thalidomide; Vascular endothelial growth factor; Neointimal hyperplasia; Restenosis	IN-STENT RESTENOSIS; PACLITAXEL-ELUTING STENT; BALLOON ANGIOPLASTY; MUSCLE; PROLIFERATION; IMPLANTATION; HYPERPLASIA	Objective: To observe the effect of local administration of thalidomide on neointimal formation after balloon-induced carotid artery injury in rats. Methods: Forty-eight male Sprague-Dawley rats were randomly divided into 3 groups (n = 16): Sham operation group (group A), alone operation group (group B) and Thalidomide group (group C). The carotid arteries of group B and group C were injured by a conventional percutaneous transluminal coronary angioplasty (PTCA) balloon catheter. Group C was treated by local delivery of thalidomide, and group B did not receive thalidomide. The arteries of group A were not injured. Seven and 14 days after balloon injury, rats were sacrificed. Serum concentrations of vascular endothelial growth factor (VEGF) and tumor necrosis factor-alpha (TNF-alpha) were measured using enzyme-linked immunosorbent assay (ELISA). Neointima area, lumen area, macrophage infiltration and local expression of VEGF were measured using morphometric and immunohistochemical analyses. Real-time reverse transcriptase polymerase chain reaction (RT-PCR) was used to examine VEGF mRNA expression. Results: The VEGF levels were significantly increased in group B than in group C at 7 days (4.82 +/- 0.17 pg/mL vs 0.98 +/- 0.1 pg/mL, P < 0.01) and 14 days (6.3 +/- 0.16 pg/mL vs 1.03 +/- 0.09 pg/mL, P < 0.01). The TNF-alpha levels were also significantly increased in group B than in group C at 7 days (83 +/- 1.01 pg/mL vs 76.37 +/- 0.75 pg/mL, P < 0.01) and 14 days (84.06 +/- 1.11 pg/mL vs 78.46 +/- 0.94 pg/mL, P < 0.01). However, the area of neointimal formation was significantly reduced in group C than in group B at 14 days (0.07 +/- 0.01 mm(2) vs 0.12 +/- 0.04 mm(2), P < 0.01). Macrophage infiltration and local expression of VEGF in the injured arteries were significantly reduced in group C than in group B at 14 days. VEGF mRNA expression was significantly reduced in Group C than in group B at 14 days (6.3 +/- 0.16 vs 1.02 +/- 0.1, P < 0.01). Conclusions: Thalidomide, which is a specific VEGF inhibitor, significantly inhibited neointimal hyperplasia and vascular restenosis after balloon injury to the carotid artery in rats, thus potentially providing a novel method for the prevention and treatment of restenosis, especially in-stent restenosis.	[Sun, Shougang; Wang, Qiongying; Wu, Qiang; Xu, Guangli; Chang, Peng; Hu, Hao; Bai, Feng] Lanzhou Univ, Dept Cardiol, Hosp 2, Lanzhou 730030, Gansu, Peoples R China; [Zhang, Quan] Pingliang Peoples Hosp, Dept Cardiol, Pingliang 744000, Peoples R China	Bai, F (reprint author), Lanzhou Univ, Dept Cardiol, Hosp 2, Lanzhou 730030, Gansu, Peoples R China.	baifeng@medmail.com			Gansu province Natural Science Foundation [1506RJZA226, 1506RJZA249]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [NSFC-81270332]; Gansu Administration of Traditional Medicine Foundation [GZK-2010-Z-1]	This study was supported by the Gansu province Natural Science Foundation (1506RJZA226 and 1506RJZA249), the National Natural Science Foundation of China (NSFC-81270332), Gansu Administration of Traditional Medicine Foundation (GZK-2010-Z-1), The authors thank Dr. Wei Zhu for Pathological analysis of this study.	Ahmed K, 2014, J CARDIOL, V64, P273, DOI 10.1016/j.jjcc.2014.02.002; Andhavarapu S, 2013, EXPERT REV HEMATOL, V6, P69, DOI [10.1586/ehm.12.62, 10.1586/EHM.12.62]; Bus P., 2017, DIABETOLOGIA, P1; Byrne RA, 2013, LANCET, V381, P461, DOI 10.1016/S0140-6736(12)61964-3; Cook KM, 2010, CA-CANCER J CLIN, V60, P222, DOI 10.3322/caac.20075; Curcio A, 2011, CIRC J, V75, P1287, DOI 10.1253/circj.CJ-11-0366; Kastrati A, 2005, JAMA-J AM MED ASSOC, V293, P165, DOI 10.1001/jama.293.2.165; Katsaros KM, 2014, EUROINTERVENTION, V10, P224, DOI 10.4244/EIJV10I2A36; Kim YG, 2013, CIRC J, V77, P2928, DOI 10.1253/circj.CJ-12-1259; Lee SP, 2011, CIRC J, V75, P2581, DOI 10.1253/circj.CJ-11-0113; Pallero MA, 2010, J VASC RES, V47, P309, DOI 10.1159/000265565; Rissanen TT, 2003, CIRC RES, V92, P1098, DOI 10.1161/01.RES.0000073584.46059.E3; Scheller B, 2003, EUR HEART J, V24, P1462, DOI 10.1016/S0195-668X(03)00317-8; Scheller B, 2006, NEW ENGL J MED, V355, P2113, DOI 10.1056/NEJMoa061254; Scheller B, 2012, JACC-CARDIOVASC INTE, V5, P323, DOI 10.1016/j.jcin.2012.01.008; Shishido K, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.002949; Stefanadis C, 2007, ATHEROSCLEROSIS, V195, P269, DOI 10.1016/j.atherosclerosis.2006.12.034; Stone GW, 2004, NEW ENGL J MED, V350, P221, DOI 10.1056/NEJMoa032441; Usui M, 2002, FASEB J, V16, P1838, DOI 10.1096/fj.02-0094fje; Yoshitomi Y, 2001, AM HEART J, V142, P445, DOI 10.1067/mhj.2001.117321	20	0	0	0	5	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	SEP	2018	214	9					1303	1308		10.1016/j.prp.2018.02.019			6	Pathology	Pathology	GV3DC	WOS:000445973500010	30029933				2019-10-28	
J	Wang, LC; Ma, QY; Li, DY; Mu, SM; Li, Y; Wang, YF; Shi, PF; Yu, HB; Gao, CH; Guo, K; Zhang, ZL				Wang, Liancai; Ma, Qingyong; Li, Deyu; Mu, Senmao; Li, Yong; Wang, Yafeng; Shi, Pengfei; Yu, Haibo; Gao, Chunhui; Guo, Kun; Zhang, Zhuoli			Indoleamine 2, 3-dioxygenase and B7-H1 expressions as prognostic and follow-up markers in human pancreatic carcinoma	PATHOLOGY RESEARCH AND PRACTICE			English	Article						IDO; B7-H1; Pancreatic carcinoma; Prognosis; Human	T-CELLS; COLORECTAL-CANCER; IMMUNE EVASION; 2,3-DIOXYGENASE; IDO; MECHANISM; SUPPRESSION; INDUCE; GROWTH; TUMORS	This study was to test hypotheses that indoleamine 2, 3-dioxygenase and B7-H1 expressions can be used as prognostic markers in human pancreatic carcinoma (PC). Ninety-five patients were recruited who had undergone radical surgical resection for PC. IDO and B7-H1 expressions in PC tissue specimens were evaluated by immunohistochemistry (IHC) techniques. The clinical and pathological features of these specimens were analyzed. IDO positive, B7-H1 positive, and combined IDO/B7-H1 positive tumors exhibited significant correlations with lymphocytic infiltration, perineural invasion, TNM status, and pathologic grade (p < .05), which tended to show strong correlations with malignant progression of PC. Also, IDO correlated with diabetes mellitus (DM) and HAD scale and B7-H1 correlated with smoke (p < .05). In addition, the correlation analysis indicated that IDO had a positive correlation with B7-H1 (p < .05). Moreover, the results showed that a combination of IDO and B7-H1 expressions could serve as independent prognostic marker after adjusting by Cox proportional hazards regression models (p < .05). IDO and B7-H1 expressions were observed in patient with PC tissues and are important markers for PC malignant progression. A combination of IDO and B7-H1 expression can be served as an independent prognostic marker for PC.	[Wang, Liancai; Li, Deyu; Mu, Senmao; Li, Yong; Wang, Yafeng; Shi, Pengfei; Yu, Haibo; Gao, Chunhui] Henan Prov Peoples Hosp, Dept Hepatobiliary Surg, 7 Weiwu Rd, Zhengzhou 450003, Henan, Peoples R China; [Ma, Qingyong; Guo, Kun] Xi An Jiao Tong Univ, Hosp 1, Dept Hepatobiliary Surg, Xian 710061, Shaanxi, Peoples R China; [Zhang, Zhuoli] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA	Li, DY (reprint author), Henan Prov Peoples Hosp, Dept Hepatobiliary Surg, 7 Weiwu Rd, Zhengzhou 450003, Henan, Peoples R China.	lidy0408@henu.edu.cn					[Anonymous], 2009, ENCY BRITANNICA ENCY; Bennaceur K., 2008, BIOCH BIOPHYS ACTA; Brandacher G, 2006, CLIN CANCER RES, V12, P1144, DOI 10.1158/1078-0432.CCR-05-1966; DeSantis C, 2014, CA-CANCER J CLIN, V64, P52, DOI 10.3322/caac.21203; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Fallarino F, 2006, J IMMUNOL, V176, P6752, DOI 10.4049/jimmunol.176.11.6752; Geng L, 2008, J CANCER RES CLIN, V134, P1021, DOI 10.1007/s00432-008-0364-8; Han SJ, 2009, NEUROREPORT, V20, P1597, DOI 10.1097/WNR.0b013e32833188f7; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Hirano F, 2005, CANCER RES, V65, P1089; Hong Soon-Pyo, 2007, J Cardiol, V50, P351; Kallberg E, 2010, PROSTATE, V70, P1461, DOI 10.1002/pros.21181; Koblish HK, 2010, MOL CANCER THER, V9, P489, DOI 10.1158/1535-7163.MCT-09-0628; Kunk PR, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0119-z; Lee SK, 2005, J DERMATOL SCI, V40, P95, DOI 10.1016/j.jdermsci.2005.06.008; Manuel ER, 2015, CANCER IMMUNOL RES, V3, P1096, DOI 10.1158/2326-6066.CIR-14-0214; Muller AJ, 2005, NAT MED, V11, P312, DOI 10.1038/nm1196; Ohigashi Y, 2005, CLIN CANCER RES, V11, P2947, DOI 10.1158/1078-0432.CCR-04-1469; Prendergast GC, 2008, ONCOGENE, V27, P3889, DOI 10.1038/onc.2008.35; Reiche EMV, 2006, INT REV PSYCHIATR, V17, P515, DOI 10.1080/02646830500382102; Reiche EMV, 2004, LANCET ONCOL, V5, P617, DOI 10.1016/S1470-2045(04)01597-9; Sarkhosh K, 2004, J CELL PHYSIOL, V201, P146, DOI 10.1002/jcp.20043; Stewart R, 2015, CANCER IMMUNOL RES, V3, P1052, DOI 10.1158/2326-6066.CIR-14-0191; Uyttenhove C, 2003, NAT MED, V9, P1269, DOI 10.1038/nm934; von Winterfeld M, 2014, EUR J CANCER, V50, P2958, DOI 10.1016/j.ejca.2014.09.002; Williams CA, 2008, IMMUNOLOGY, V124, P89, DOI 10.1111/j.1365-2567.2007.02743.x; Witkiewicz A, 2008, J AM COLL SURGEONS, V206, P849, DOI 10.1016/j.jamcollsurg.2007.12.014; Yasunari K, 2006, AM J HYPERTENS, V19, P573, DOI 10.1016/j.amjhyper.2005.10.027; Zou WP, 2005, NAT REV CANCER, V5, P263, DOI 10.1038/nrc1586	29	2	2	0	3	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	SEP	2018	214	9					1309	1314		10.1016/j.prp.2018.02.016			6	Pathology	Pathology	GV3DC	WOS:000445973500011	30029936				2019-10-28	
J	Zhao, SL; Xiao, XF; Sun, S; Li, D; Wang, W; Fu, Y; Fan, FY				Zhao, Silin; Xiao, Xuefei; Sun, Shuang; Li, Da; Wang, Wei; Fu, Yan; Fan, Fuyuan			MicroRNA-30d/JAG1 axis modulates pulmonary fibrosis through Notch signaling pathway	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Pulmonary fibrosis (PF); JAG1; Notch signaling; miR-30d; Primary normal human lung fibroblast (NHLF)	TO-MESENCHYMAL TRANSITION; EPITHELIAL-CELLS; MICRORNA TARGETS; RENAL FIBROSIS; LUNG FIBROSIS; EXPRESSION; ACTIVATION; PROLIFERATION; BIOGENESIS; BINDING	Pulmonary fibrosis (PF) is a fibroproliferative disease which can finally end up fatal lung failure. PF is characterized by abnormal proliferation of fibroblast, dysregulated fibroblast differentiation to myofibroblast and disorganized collagen and extracellular matrix (ECM) production, deposition and degradation. JAG1/Notch signaling has been reported to play a key role in tissue fibrosis including PF. Herein, we confirmed the abnormal upregulation of JAG1 mRNA expression and protein levels in PF tissue specimens; JAG1 knockdown reduced TGF-beta 1-induced alpha-SMA and Collagen I protein levels. From the aspect of miRNA regulation, we searched for candidate miRNAs which might target JAG1 to inhibit its expression. Among the selected miRNAs, miR-30d expression was downregulated in PF tissues; miR-30d overexpression attenuated TGF-beta 1-induced primary normal human lung fibroblast (NHLF) proliferation, as well as alpha-SMA and Collagen I protein levels. Through directly binding to the 3'-UTR of JAG1, miR-30d significantly inhibited JAG1 mRNA expression and protein level. Furthermore, JAG1 overexpression partially reversed the effect of miR-30d on NHLF proliferation and alpha-SMA and Collagen I proteins upon TGF-beta 1 stimulation; miR-30d could suppress TGF-beta 1 function on NHLFs through blocking JAG1/Notch signaling. Rescuing miR-30d expression to suppress TGF-beta 1-induced activation of JAG1/Notch signaling may present a promising strategy for PF treatment.	[Zhao, Silin; Xiao, Xuefei; Sun, Shuang; Li, Da; Wang, Wei; Fu, Yan; Fan, Fuyuan] Hunan Univ Chinese Med, Affiliated Hosp 1, Dept Resp Med, Hunan Hosp, 95 Middle Shaoshan Rd, Changsha 410000, Hunan, Peoples R China	Fan, FY (reprint author), Hunan Univ Chinese Med, Affiliated Hosp 1, Dept Resp Med, Hunan Hosp, 95 Middle Shaoshan Rd, Changsha 410000, Hunan, Peoples R China.	ffy023@163.com					Aoyagi-Ikeda K, 2011, AM J RESP CELL MOL, V45, P136, DOI 10.1165/rcmb.2010-0140OC; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ASTON C, 1995, AM J RESP CRIT CARE, V151, P1597, DOI 10.1164/ajrccm.151.5.7537587; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995; Brennan EP, 2013, J AM SOC NEPHROL, V24, P627, DOI 10.1681/ASN.2012060550; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Cao ZW, 2016, NAT MED, V22, P154, DOI 10.1038/nm.4035; Chen YX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046512; Chillakuri CR, 2012, SEMIN CELL DEV BIOL, V23, P421, DOI 10.1016/j.semcdb.2012.01.009; Chuang PY, 2013, J MOL MED, V91, P549, DOI 10.1007/s00109-012-0983-z; Cushing L, 2011, AM J RESP CELL MOL, V45, P287, DOI 10.1165/rcmb.2010-0323OC; Datta A, 2011, BRIT J PHARMACOL, V163, P141, DOI 10.1111/j.1476-5381.2011.01247.x; Dweep H, 2015, NAT METHODS, V12, P697, DOI 10.1038/nmeth.3485; Dweep H, 2011, J BIOMED INFORM, V44, P839, DOI 10.1016/j.jbi.2011.05.002; Foshay Kara M, 2007, Curr Stem Cell Res Ther, V2, P264, DOI 10.2174/157488807782793781; Geng J, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0286-3; Gorka J, 2015, POL ARCH MED WEWN, V125, P685, DOI 10.20452/pamw.3055; Guan SH, 2017, MOL BIOSYST, V13, P2116, DOI 10.1039/c7mb00247e; Hamada N, 2008, AM J RESP CELL MOL, V39, P440, DOI 10.1165/rcmb.2007-0330OC; Inman CK, 2003, J BIOL CHEM, V278, P48684, DOI 10.1074/jbc.M308001200; Inui M, 2010, NAT REV MOL CELL BIO, V11, P252, DOI 10.1038/nrm2868; John Bino, 2006, V342, P101, DOI 10.1385/1-59745-123-1:101; Bueno MJ, 2008, CELL CYCLE, V7, P3143, DOI 10.4161/cc.7.20.6833; Jung YS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038773; Kim VN, 2005, MOL CELLS, V19, P1; Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644; Kim YK, 2007, EMBO J, V26, P775, DOI 10.1038/sj.emboj.7601512; Komori T, 2005, J CELL BIOCHEM, V95, P445, DOI 10.1002/jcb.20420; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lai EC, 2004, DEVELOPMENT, V131, P965, DOI 10.1242/dev.01074; Leask A, 2010, J CELL COMMUN SIGNAL, V4, P197, DOI 10.1007/s12079-010-0101-3; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Liang HH, 2012, INT J BIOCHEM CELL B, V44, P2152, DOI 10.1016/j.biocel.2012.08.019; Lin LX, 2015, INT J CLIN EXP MED, V8, P13227; Liu YJ, 2017, EXP THER MED, V14, P561, DOI 10.3892/etm.2017.4573; Ma XY, 2015, MOL MED REP, V12, P2784, DOI 10.3892/mmr.2015.3719; MacKenzie B, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0242-2; Milosevic J, 2012, AM J RESP CELL MOL, V47, P879, DOI 10.1165/rcmb.2011-0377OC; Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031; Morrissey J, 2002, J AM SOC NEPHROL, V13, pS14; Nyhan KC, 2010, BBA-MOL CELL RES, V1803, P1386, DOI 10.1016/j.bbamcr.2010.09.001; Pottier N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006718; Rajasekaran S, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00254; Sassoli C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063896; Tsukui T, 2015, AM J PATHOL, V185, P2939, DOI 10.1016/j.ajpath.2015.07.022; Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069; Zeng Y, 2003, P NATL ACAD SCI USA, V100, P9779, DOI 10.1073/pnas.1630797100; Zhang K, 2015, WORLD J GASTROENTERO, V21, P878, DOI 10.3748/wjg.v21.i3.878; Zhang L, 2015, TOXICOL APPL PHARM, V283, P50, DOI 10.1016/j.taap.2015.01.001; Zhou Y, 2016, J PHARM PHARMACOL, V68, P389, DOI 10.1111/jphp.12518	53	1	1	0	10	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	SEP	2018	214	9					1315	1323		10.1016/j.prp.2018.02.014			9	Pathology	Pathology	GV3DC	WOS:000445973500012	30029934				2019-10-28	
J	Zhang, RJ; Hao, HY; Liu, QJ; Zuo, HY; Chang, YN; Zhi, ZJ; Guo, PP; Hao, YM				Zhang, Rong-Jin; Hao, Hui-Yao; Liu, Qing-Juan; Zuo, Hong-Ye; Chang, Ying-Na; Zhi, Zhong-Ji; Guo, Peng-Peng; Hao, Yong-Mei			Protective effects of Schisandrin on high glucose-induced changes of RhoA and eNOS activity in human umbilical vein endothelial cells	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Human umbilical vein endothelial cells; Schisandrin; RhoA; eNOS; NO; p-MYPT1	NITRIC-OXIDE; VASCULAR DYSFUNCTION; OXIDATIVE STRESS; KINASE; ATHEROSCLEROSIS; CHINENSIS; PATHWAY; ACTIVATION; MECHANISMS; STATINS	Schisandrin, derived from the Chinese medicinal herb Schisandra chinensis, has been found to confer protective effects on circulation systems. But the underlying molecular mechanisms remain unclear. The aim of this study was to investigate the effects of a high level of glucose on RhoA and eNOS activity in human umbilical vein endothelial cells(HUVECs) and how Schisandrin plays a role in mediating these effects. To find the optimal treatment time, HUVECs were cultured at a high glucose concentration (30 mM) for different lengths of time (0, 12, 24, and 48 h). Subsequently, the cells were randomized into five groups: a normal group, a high glucose group, and three high glucose groups that were given different doses (5, 10, and 20 mu M) of Schisandrin. The cells were pretreated with Schisandrin for 24 h before stimulation with high glucose. The morphology of HUVECs in the various groups was assessed under a light microscope. Immunocytochemical staining was used to detect the level of p-MYPT1 expression. The levels of RhoA activity were determined using the RhoA Activation Assay Biochem Kit. The levels of eNOS activity were examined using a nitrate reduction test. The results showed that in the high glucose group, the activity of RhoA was increased and the activity of eNOS was reduced, thus decreasing the secretion of NO. However, after pretreatment with Schisandrin (10, 20 mu M), the activity of RhoA was inhibited and the activity of eNOS increased, which led to an increase in NO production compared with the high glucose group. There was no evident difference between the 5 mu M Schisandrin group and the high glucose group. Taken together, these findings indicate that Schisandrin can improve the function of endothelial cells by lowering the activity of RhoA/Rho kinase and raising both the activity of eNOS and the production of NO.	[Zhang, Rong-Jin; Hao, Hui-Yao; Zuo, Hong-Ye; Guo, Peng-Peng; Hao, Yong-Mei] Hebei Med Univ, Hosp 2, Dept Endocrinol, 215 West Heping Rd, Shijiazhuang 053000, Hebei, Peoples R China; [Liu, Qing-Juan] Hebei Med Univ, Dept Pathol, Shijiazhuang, Hebei, Peoples R China; [Chang, Ying-Na] China Elect Technol Grp Corp, Res Inst 54, Affiliated Hosp, Dept Internal Med, Beijing, Peoples R China; [Zhi, Zhong-Ji] Hebei Med Univ, Hosp 3, Dept Endocrinol, Shijiazhuang, Hebei, Peoples R China	Hao, YM (reprint author), Hebei Med Univ, Hosp 2, Dept Endocrinol, 215 West Heping Rd, Shijiazhuang 053000, Hebei, Peoples R China.	hym8601@126.com			Natural Fund of Hebei Province [H2015206506]	This work was supported by the Natural Fund of Hebei Province (no.H2015206506). Moreover, we thank editors at Nature Research Editing Service for language editing.	Beckman JA, 2002, JAMA-J AM MED ASSOC, V287, P2570, DOI 10.1001/jama.287.19.2570; Birukova AA, 2004, J CELL PHYSIOL, V201, P55, DOI 10.1002/jcp.20055; Cao YF, 2010, XENOBIOTICA, V40, P38, DOI 10.3109/00498250903366052; Faria A, 2017, PHARMACOL THERAPEUT, V172, P50, DOI 10.1016/j.pharmthera.2016.11.013; Forstermann U, 2017, CIRC RES, V120, P713, DOI 10.1161/CIRCRESAHA.116.309326; Forte M, 2016, OXID MED CELL LONGEV, DOI 10.1155/2016/7364138; Guo LY, 2008, EUR J PHARMACOL, V591, P293, DOI 10.1016/j.ejphar.2008.06.074; Han NR, 2017, AM J CHINESE MED, V45, P159, DOI 10.1142/S0192415X17500112; Kim HK, 2011, PHYTOTHER RES, V25, P1776, DOI 10.1002/ptr.3486; Li F, 2015, ACTA PHARMACOL SIN, V36, P1337, DOI 10.1038/aps.2015.70; Li F, 2015, J PHARMACOL SCI, V129, P1, DOI 10.1016/j.jphs.2015.02.003; Park JH, 2015, INT IMMUNOPHARMACOL, V25, P276, DOI 10.1016/j.intimp.2015.02.014; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Rikitake Y, 2005, CIRC RES, V97, P1232, DOI 10.1161/01.RES.0000196564.18314.23; Sawada N, 2014, ANTIOXID REDOX SIGN, V20, P1251, DOI 10.1089/ars.2013.5524; Seo J, 2016, FREE RADICAL BIO MED, V90, P133, DOI 10.1016/j.freeradbiomed.2015.11.020; Shen K, 2015, REJUV RES, V18, P517, DOI 10.1089/rej.2015.1697; Shimokawa H, 2016, CIRC RES, V118, P352, DOI 10.1161/CIRCRESAHA.115.306532; Song FJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149991; Srinivasan S, 2004, DIABETOLOGIA, V47, P1727, DOI 10.1007/s00125-004-1525-1; Su XY, 2017, DRUG DELIV, V24, P10, DOI 10.1080/10717544.2016.1225854; Szopa A, 2017, PHYTOCHEM REV, V16, P195, DOI 10.1007/s11101-016-9470-4; Vanhoutte PM, 2013, CURR OPIN PHARMACOL, V13, P265, DOI 10.1016/j.coph.2012.12.002; Wang JP, 2012, CARDIOVASC DIABETOL, V11, DOI 10.1186/1475-2840-11-7; Wang Y, 2016, OXID MED CELL LONGEV, DOI 10.1155/2016/4206392; Yamamoto E, 2010, BIOCHEM BIOPH RES CO, V403, P258, DOI 10.1016/j.bbrc.2010.11.008; Yao L, 2013, CARDIOVASC RES, V97, P509, DOI 10.1093/cvr/cvs371; Yu JS, 2017, SCI REP-UK, V7, DOI 10.1038/srep45171; Zhou QA, 2011, TRENDS PHARMACOL SCI, V32, P167, DOI 10.1016/j.tips.2010.12.006; Zhou Q, 2009, CURR PHARM DESIGN, V15, P3108, DOI 10.2174/138161209789057986	30	1	1	1	4	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	SEP	2018	214	9					1324	1329		10.1016/j.prp.2018.02.010			6	Pathology	Pathology	GV3DC	WOS:000445973500013	30031586				2019-10-28	
J	Ding, QP; Shen, L; Nie, XH; Lu, B; Pan, XY; Su, ZZ; Yan, A; Yan, RF; Zhou, Y; Li, LQ; Xu, J				Ding, Qiuping; Shen, Liang; Nie, Xiaohu; Lu, Bin; Pan, Xuyan; Su, Zhongzhou; Yan, Ai; Yan, Renfu; Zhou, Yue; Li, Liqin; Xu, Jie			MiR-223-3p overexpression inhibits cell proliferation and migration by regulating inflammation-associated cytokines in glioblastomas	PATHOLOGY RESEARCH AND PRACTICE			English	Article						MiR-223-3p; NLRP3; GBM; Inflammation	NLRP3; INFLAMMASOMES; EXPRESSION; MICRORNA-223; ACTIVATION; CARCINOMA; INVASION; PLATFORM; DISEASE	Glioblastoma(GBM) is most common brain tumor in adults. Currently standard treatments have limited effect to increase the survival, because there are still largely unclear mechanisms in glioblastoma development. miR-223 was involved in various types of cancer, however, the function of miR-223-3p in GBM was still unclear. In our study, real-time PCR was performed to exam the expression level of miR-223-3p and NLRP3 (Nucleotide-binding oligomerization domain(NOD)-like receptor family PYRIN domain containing-3) in GBM tissues. Following that, mimic or inhibitor of miR-223-3p were used to modulate miR-223-3p expression in GBM cell lines respectively. Then, we analyzed cell proliferation and migration by cell counting kit and transwell assay. Further, western blot was performed to detect several inflammation-associated cytokines level in GBM cell lines. We found that miR223-3p was decreased but NLRP3 was increased in GBM tissues. Treatment with miR-223-3p mimic inhibits cell proliferation and migration via decreasing several inflammation-associated cytokines, including interleukin-1 beta (IL-1 beta), monocyte chemoattractant protein-1 (MCP-1), IL-8 and IL-18. Importantly, these effects induced by miR-223-3p could be attenuated by NLRP3 overexpression, which was considered as one of target genes of miR-223-3p. In conclusion, these results indicated that miR-223-3p might act as a suppressor and a potential therapy target of GBM.	[Ding, Qiuping] Huzhou Cent Hosp, Dept Surg, Hongqi Rd 198, Huzhou 313000, Zhejiang, Peoples R China; [Shen, Liang; Nie, Xiaohu; Lu, Bin; Pan, Xuyan; Su, Zhongzhou; Yan, Ai; Yan, Renfu; Zhou, Yue; Xu, Jie] Huzhou Cent Hosp, Dept Neurosurg, Hongqi Rd 198, Huzhou 313000, Zhejiang, Peoples R China; [Li, Liqin] Huzhou Cent Hosp, Huzhou Key Lab Mol Med, Huzhou, Zhejiang, Peoples R China	Xu, J (reprint author), Huzhou Cent Hosp, Dept Neurosurg, Hongqi Rd 198, Huzhou 313000, Zhejiang, Peoples R China.	chzxujie@sina.com			Huzhou General Science and Social Development Project Foundation [2016GYB38]	Huzhou General Science and Social Development Project Foundation (2016GYB38).	Abais JM, 2015, ANTIOXID REDOX SIGN, V22, P1111, DOI 10.1089/ars.2014.5994; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Charles NA, 2011, GLIA, V59, P1169, DOI 10.1002/glia.21136; Chen K, 2007, NAT REV GENET, V8, P93, DOI 10.1038/nrg1990; Chuang SY, 2013, P NATL ACAD SCI USA, V110, P16079, DOI 10.1073/pnas.1306556110; Cuddapah VA, 2014, NAT REV NEUROSCI, V15, P455, DOI 10.1038/nrn3765; Feng ZY, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.549; Franchi L, 2009, NAT IMMUNOL, V10, P241, DOI 10.1038/ni.1703; Glasgow SM, 2013, J NEUROSCI, V33, P13560, DOI 10.1523/JNEUROSCI.0321-13.2013; Han L, 2012, CNS NEUROSCI THER, V18, P573, DOI 10.1111/j.1755-5949.2012.00344.x; Harris J, 2011, J BIOL CHEM, V286, P9587, DOI 10.1074/jbc.M110.202911; Heneka MT, 2013, NATURE, V493, P674, DOI 10.1038/nature11729; Hornung V, 2010, EUR J IMMUNOL, V40, P620, DOI 10.1002/eji.200940185; Jia CY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027008; Johnson LA, 2010, CURR NEUROL NEUROSCI, V10, P259, DOI 10.1007/s11910-010-0111-9; Kang W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033919; Kanneganti TD, 2010, NAT REV IMMUNOL, V10, P688, DOI 10.1038/nri2851; Kefas B, 2009, J NEUROSCI, V29, P15161, DOI 10.1523/JNEUROSCI.4966-09.2009; Koizumi Y, 2012, CELL MICROBIOL, V14, P149, DOI 10.1111/j.1462-5822.2011.01707.x; Kurozumi A, 2016, CANCER SCI, V107, P84, DOI 10.1111/cas.12842; Lamkanfi M, 2009, IMMUNOL REV, V227, P95, DOI 10.1111/j.1600-065X.2008.00730.x; Li G, 2017, FORESTS, V8, DOI 10.3390/f8030056; Li LL, 2015, AM J CANCER RES, V5, P442; Liu LW, 2017, ONCOTARGET, V8, P63764, DOI 10.18632/oncotarget.19541; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Lu W, 2016, ONCOTARGET, V7, P62364, DOI 10.18632/oncotarget.11634; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Mitchell DA, 2009, NEUROTHERAPEUTICS, V6, P527, DOI 10.1016/j.nurt.2009.04.003; Mizutani K, 2009, NEOPLASIA, V11, P1235, DOI 10.1593/neo.09988; Neudecker V, 2017, J EXP MED, V214, P1737, DOI 10.1084/jem.20160462; Sathornsumetee S, 2006, EXPERT REV ANTICANC, V6, P1087, DOI 10.1586/14737140.6.7.1087; Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Tarassishin L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103432; Tarassishin L, 2014, J PROTEOMICS, V99, P152, DOI 10.1016/j.jprot.2014.01.024; Vandanmagsar B, 2011, NAT MED, V17, P179, DOI 10.1038/nm.2279; Wang XF, 2012, J CANCER RES CLIN, V138, P573, DOI 10.1007/s00432-011-1114-x; Wong QWL, 2008, GASTROENTEROLOGY, V135, P257, DOI 10.1053/j.gastro.2008.04.003; Xie XJ, 2017, MOL PAIN, V13, DOI 10.1177/1744806917706582; Yang WY, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1464-x; Zhang CZ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-229; Zhang H, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20160608; Zhou KR, 2016, J IMMUNOL RES, DOI 10.1155/2016/9238290; Zhu XM, 2011, J NEURO-ONCOL, V104, P83, DOI 10.1007/s11060-010-0473-5	46	8	8	0	2	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	SEP	2018	214	9					1330	1339		10.1016/j.prp.2018.05.012			10	Pathology	Pathology	GV3DC	WOS:000445973500014	30033329				2019-10-28	
J	Wang, YP; Li, DM; Liu, YD; Tian, SY; Chen, XW				Wang, Yuping; Li, Dongmei; Liu, Yunduo; Tian, Songyu; Chen, Xiuwei			Expression and clinicopathological significance of hematopoietic pre-B cell leukemia transcription factor-interacting protein in cervical carcinoma	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Hematopoietic pre-B-cell leukemia transcription factor-interacting protein; Hpip; Cervical cancer; Metastasis; Prognosis	EPITHELIAL-MESENCHYMAL TRANSITION; CLINICAL-PRACTICE GUIDELINES; PI3K/AKT SIGNALING PATHWAY; OVARIAN-CANCER CELLS; HPIP; ACTIVATION; PROLIFERATION; CLASSIFICATION; MIGRATION; INVASION	Hematopoietic pre-B-cell leukemia transcription factor(PBX)-interacting protein (HPIP) is overexpressed in various malignancies, but its role in cervical cancer (CC) remains unknown. This study investigated the correlations of HPIP expression with clinicopathological factors and prognosis of cervical carcinoma patients. Expression of HPIP was detected in CC from 167 patients along with 45 corresponding normal cervical specimens by immunohistochemistry. HPIP immunoreactivity was overexpressed in CC cases compared with that in normal endometrium (P < 0.05). High HPIP expression was positively correlated with FIGO stage, histological grade, lymph node metastasis and recurrence (P < 0.05). Patients with high HPIP expression exhibited significantly poorer overall survival (OS) and disease-free survival (DFS) than patients with low HPIP expression (both P < 0.001). Cox multivariate analysis showed that high HPIP expression was an independent prognostic factor for both OS [hazard ratio (HR) = 8.791, 95% confidence interval (CI) = 2.098-36.826; P = 0.003 and DFS of patients with CC (HR = 10.485, 95% CI = 2.512-36.826; P = 0.001)]. We identified HPIP protein expression as a novel independent poor prognostic indicator in CC.	[Wang, Yuping] Second Hosp Yulin City, Dept Gynecol & Obstet, Yulin City, Shanxi, Peoples R China; [Li, Dongmei] Peoples Hosp Yuyang Dist, Dept Gynecol & Obstet, Yulin City, Shanxi, Peoples R China; [Liu, Yunduo; Tian, Songyu; Chen, Xiuwei] Harbin Med Univ Canc Hosp, Dept Gynecol, Harbin, Heilongjiang, Peoples R China	Chen, XW (reprint author), Harbin Med Univ Canc Hosp, Dept Gynecol, Harbin, Heilongjiang, Peoples R China.	doctorchenxiuwei@126.com			Harbin Science and technology innovation talents special fund project [2015RAXYJO54]; Haiyan Foundation of the Harbin Medical University Cancer Hospital/the Foundation of the Harbin Medical University Cancer Hospital [JJZD2017-04]	This work was supported by grants of the Harbin Science and technology innovation talents special fund project (2015RAXYJO54), Haiyan Foundation of the Harbin Medical University Cancer Hospital/the Foundation of the Harbin Medical University Cancer Hospital (JJZD2017-04). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abramovich C, 2002, ONCOGENE, V21, P6766, DOI 10.1038/sj.onc.1205784; Benedet JL, 2000, INT J GYNECOL OBSTET, V70, P209; Bugide S, 2015, ONCOGENE, V34, P4601, DOI 10.1038/onc.2014.389; Bugide S, 2017, CELL ONCOL, V40, P133, DOI 10.1007/s13402-016-0308-2; Chen B, 2016, ONCOL REP, V36, P3664, DOI 10.3892/or.2016.5157; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Chen YJ, 2016, ONCOL RES, V24, P153, DOI 10.3727/096504016X14612603423476; Colombo N, 2012, ANN ONCOL, V23, P27, DOI 10.1093/annonc/mds268; Feng YY, 2015, SCI REP-UK, V5, DOI 10.1038/srep09429; Mai H, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.44; Manavathi B, 2012, J BIOL CHEM, V287, P5600, DOI 10.1074/jbc.M111.289843; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; Pan J, 2016, BIOMED PHARMACOTHER, V77, P176, DOI 10.1016/j.biopha.2015.12.012; Penzel R, 2003, INT J CANCER, V105, P494, DOI 10.1002/ijc.11101; Shi SM, 2017, INT J MOL MED, V39, P479, DOI 10.3892/ijmm.2017.2851; Shostak K, 2014, CELL DEATH DIFFER, V21, P811, DOI 10.1038/cdd.2014.2; Wang SC, 2015, BIOMED PHARMACOTHER, V75, P33, DOI 10.1016/j.biopha.2015.08.027; Wang XH, 2008, BBA-MOL CELL RES, V1783, P1220, DOI 10.1016/j.bbamcr.2008.01.026; Xu XJ, 2013, IUBMB LIFE, V65, P873, DOI 10.1002/iub.1202; Zhang GY, 2016, ONCOL RES, V24, P33, DOI 10.3727/096504016X14575597858654	20	0	0	3	4	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	SEP	2018	214	9					1340	1344		10.1016/j.prp.2017.07.031			5	Pathology	Pathology	GV3DC	WOS:000445973500015	30033330				2019-10-28	
J	Hong, L; Wang, ST; Li, W; Wu, DC; Chen, WS				Hong, Lan; Wang, Shengtan; Li, Wei; Wu, Dongcai; Chen, Wangsheng			Tumor-associated macrophages promote the metastasis of ovarian carcinoma cells by enhancing CXCL16/CXCR6 expression	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Ovarian carcinoma; Tumor-associated macrophage; Chemokines; Cell migration; Cell invasion	CANCER METASTASIS; PI3K/AKT PATHWAY; HEPATOCELLULAR-CARCINOMA; UP-REGULATION; INVASION; ACTIVATION; MIGRATION; CXCR6; OSTEOSARCOMA; GROWTH	This study investigated the underlying mechanism by which C-X-C motif chemokine ligand 16 (CXCL16)/C-X-C motif chemokine receptor 6 (CXCR6) signaling is activated by tumor-associated macrophages and assists in regulating the metastasis of ovarian carcinoma. Specimens of ovarian carcinoma tissue and adjacent tissue were collected from 20 ovarian carcinoma patients. Human THP-1 cells were induced to differentiate into macrophages, which were then co-cultured with SKOV3 cells and low concentrations of tumor necrosis factor-alpha (TNF-alpha) to simulate the inflammatory microenvironment of ovarian carcinoma. Additionally, small interfering RNA (siRNA) targeting CXCR6 was transfected into SKOV3 cells; after which, the levels of nuclear factor kappa B p65 (NF-kappa B p65) protein and phosphorylated PI3K and Akt were measured. The migration and invasion abilities of the SKOV3 cells were also tested. The levels of TNF-alpha, interluekin-6 (IL-6), NF-kappa B p65, CXCL16, and CXCR6 expression in the ovarian carcinoma tissues were higher than those in the precancerous tissues. CXCR6 expression was positively correlated with TNF-alpha, IL-6, and CXCL16 expression. Co-culture of SKOV3 cells with macrophages significantly promoted CXCL16, CXCR6, NF-kappa B, and p65 expression by the SKOV3 cells, increased their levels of phosphorylated PI3K and Akt, and increased the migration and invasion abilities of SKOV3 cells. Silencing of CXCR6 or blocking the PI3K/Akt signal pathway markedly attenuated the expression of NF-kappa B p65 and phosphorylation of PI3K and Akt, as well as the migration and invasion abilities of SKOV3 cells. These findings demonstrate that macrophages can promote the migration and invasion of ovarian carcinoma cells by affecting the CXCL16/CXCR6 pathway.	[Hong, Lan; Wang, Shengtan; Li, Wei] Hainan Gen Hosp, Dept Gynecol, Haikou 570311, Hainan, Peoples R China; [Wu, Dongcai] Hainan Gen Hosp, Dept Obstet, Haikou 570311, Hainan, Peoples R China; [Chen, Wangsheng] Hainan Gen Hosp, Dept Radiol, 19 Xiuhua Rd, Haikou 570311, Hainan, Peoples R China; [Hong, Lan] Southern Med Univ, Guangzhou 510515, Guangdong, Peoples R China	Chen, WS (reprint author), Hainan Gen Hosp, Dept Radiol, 19 Xiuhua Rd, Haikou 570311, Hainan, Peoples R China.	wschen_ok@126.com			Hainan Key Science and Technology Project [ZDXM2015069]; Hainan Natural Science Foundation [813209]	This study was supported by grants from the Hainan Key Science and Technology Project (ZDXM2015069) and the Hainan Natural Science Foundation-funded Project (813209).	Armaiz-Pena GN, 2015, ONCOTARGET, V6, P4266, DOI 10.18632/oncotarget.2887; Ben-Baruch A, 2006, CANCER METAST REV, V25, P357, DOI 10.1007/s10555-006-9003-5; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Darash-Yahana M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006695; Deng L, 2010, BBA-REV CANCER, V1806, P42, DOI 10.1016/j.bbcan.2010.01.004; Dong YQ, 2015, TUMOR BIOL, V36, P1477, DOI 10.1007/s13277-014-2631-4; Gao Q, 2012, CANCER RES, V72, P3546, DOI 10.1158/0008-5472.CAN-11-4032; Gooden MJM, 2014, BRIT J CANCER, V110, P1535, DOI 10.1038/bjc.2014.55; Griesmann H., 2016, GUT, V66; Guo Li, 2011, Chin J Cancer, V30, P336; Hao NB, 2015, CANCER LETT, V361, P57, DOI 10.1016/j.canlet.2015.02.043; Hattermann K, 2008, MOL CELL NEUROSCI, V39, P133, DOI 10.1016/j.mcn.2008.03.009; Hershberger P. M., 2014, PROBING CXCR6 CXCL16; Hu ZB, 2016, INT J MED SCI, V13, P858, DOI 10.7150/ijms.16724; Jimenez-Sanchez A, 2017, CELL, V170, P927, DOI 10.1016/j.cell.2017.07.025; Jin YF, 2016, EXP MOL PATHOL, V101, P50, DOI 10.1016/j.yexmp.2016.06.002; Ke TW, 2015, ANN SURG ONCOL, V22, P2649, DOI 10.1245/s10434-014-4305-2; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mitra AK, 2015, ONCOGENE, V34, P5923, DOI 10.1038/onc.2015.43; Porta C, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00064; Qiu B, 2016, INT J CLIN EXP PATHO, V9, P5368; Robinson-Smith TM, 2007, CANCER RES, V67, P5708, DOI 10.1158/0008-5472.CAN-06-4375; Ryan AE, 2015, ONCOGENE, V34, P1563, DOI 10.1038/onc.2014.86; Segaliny AI, 2015, INT J CANCER, V137, P73, DOI 10.1002/ijc.29376; Shimaoka T, 2004, J LEUKOCYTE BIOL, V75, P267, DOI 10.1189/jlb.1003465; Singh R, 2016, ONCOTARGET, V7, P7343, DOI 10.18632/oncotarget.6944; Strissel PL, 2017, CANCER IMMUNOL RES, V5, DOI 10.1158/2326-6074.TUMIMM16-A55; Takiguchi G, 2016, CANCER SCI, V107, P290, DOI 10.1111/cas.12871; Toy EP, 2001, GYNECOL ONCOL, V80, P194, DOI 10.1006/gyno.2000.6070; Vermorken JB, 2001, INT J GYNECOL CANCER, V11, P73, DOI 10.1046/j.1525-1438.2001.11(suppl.1)sup1073.x; Wenes M, 2016, CELL METAB, V24, P701, DOI 10.1016/j.cmet.2016.09.008; Xiao G, 2015, ONCOTARGET, V6, P14165, DOI 10.18632/oncotarget.3690; Xu JM, 2014, INT J IMMUNOPATH PH, V27, P553, DOI 10.1177/039463201402700411; Yousif NG, 2014, CELL BIOL INT, V38, P85, DOI 10.1002/cbin.10184; Zhang AL, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935-017-0396-8; Zhang J, 2014, ONCOTARGET, V5, P9664, DOI 10.18632/oncotarget.1856; Zhou ZN, 2014, ONCOGENE, V33, P3784, DOI 10.1038/onc.2013.363; Zonta YR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040763	38	4	4	1	5	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	SEP	2018	214	9					1345	1351		10.1016/j.prp.2018.07.009			7	Pathology	Pathology	GV3DC	WOS:000445973500016	30049511				2019-10-28	
J	Liv, JL; Han, S; Hu, RH; Huang, J; Zhang, RY; Li, KZ; Li, L; Zhang, GA; Zhaog, HL				Liv, Jianli; Han, Sha; Hu, Ronghang; Huang, Jian; Zhang, Renya; Li, Kaizhi; Li, Lu; Zhang, Guoan; Zhaog, Hongli			CD51 is an independent unfavorable prognostic factor in esophageal squamous cell carcinoma	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Esophageal squamous cell carcinoma; CD51; Prognosis	INTEGRIN ALPHA-V; TGF-BETA; OVEREXPRESSION; PROLIFERATION; EXPRESSION; OSTEOPONTIN; PROGRESSION; APOPTOSIS; LARYNGEAL	Background: Esophageal squamous cell carcinoma (ESCC) is a common cancer in East Asia and some other parts of the world with a dismal prognosis. CD51 (integrin alpha v),a transmembrane glycoprotein responsible for cell-to-matrix binding has been found to enhance tumor progression. However, its expression and clinicopathological significance in ESCC tumors are not fully understood. The purpose of this study was to investigate the expression level of CD51 and to explore its clinicopathological significance in ESCC. Methods: The expression of CD51 in 122 ESCC samples was examined by immunohistochemistry and its clinicopathological significance was evaluated. Results: The expression of CD51 was observed in tumor cell membrane and/or cytoplasm, with a positive rate of 48.36% (59/122). High expression of CD51 was significantly associated with lymph node metastasis (P = 0.031), tumor size (P = 0.028) and invasive depth (P = 0.027). Kaplan-Meier analysis revealed that positive expression of CD51 was correlated with poor overall survival of ESCC patients (P = 0.015). Multivariate analysis suggested that CD51 was an independent prognositic factor for ESCC (hazard ration = 1.604; 95% CI, 1.086-2.368; P = 0.017). Conclusion These data suggested CD51 was a predictor for the prognosis of ESCC patients.	[Liv, Jianli; Zhang, Renya; Li, Kaizhi; Li, Lu] Jining Med Univ, Affiliated Hosp, Dept Pathol, Jining 272000, Shandong, Peoples R China; [Han, Sha] Jining Med Univ, Life Sci Expt Ctr, Jining 272000, Shandong, Peoples R China; [Hu, Ronghang] Jining Med Univ, Affiliated Hosp, Dept Thorac Surg, Jining 272000, Shandong, Peoples R China; [Huang, Jian] Jining Med Univ, Affiliated Hosp, Cent Lab, Jining 272029, Shandong, Peoples R China; [Zhang, Guoan] Jining Med Univ, Forens Sci Ctr, 16 Taibaihu Rd, Jining 272067, Shandong, Peoples R China; [Zhang, Guoan] Jining Med Univ, Canc Pathol Inst, Jining 272000, Shandong, Peoples R China; [Zhaog, Hongli] Shandong Control Ctr Digest Dis, Dept Gastroenterol, 11 Taibai Rd, Jining 272067, Shandong, Peoples R China	Zhang, GA (reprint author), Jining Med Univ, Forens Sci Ctr, 16 Taibaihu Rd, Jining 272067, Shandong, Peoples R China.; Zhaog, HL (reprint author), Shandong Control Ctr Digest Dis, Dept Gastroenterol, 11 Taibai Rd, Jining 272067, Shandong, Peoples R China.	zga2007@126.com; xushulinfeng@163.com		Huang, Jian/0000-0003-0149-1799	Natural Science Foundation of Shandong provinceNatural Science Foundation of Shandong Province [2013ZRC03007, ZR2016HL25]; Jining Medical University [JY2017KJ040]; Science and Technology Development Project of Jining Science and Technology Bureau [2014jnjc17]; Jining science and technology boost the old and new kinetic energy conversion project [2017SMNS001]	This study is supported by Natural Science Foundation of Shandong province (2013ZRC03007, ZR2016HL25), Supporting Fund of Jining Medical University (JY2017KJ040), Science and Technology Development Project of Jining Science and Technology Bureau (2014jnjc17) and Jining science and technology boost the old and new kinetic energy conversion project (2017SMNS001).	Allum WH, 2009, J CLIN ONCOL, V27, P5062, DOI 10.1200/JCO.2009.22.2083; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Ha SY, 2014, J CLIN PATHOL, V67, P576, DOI 10.1136/jclinpath-2013-202163; Horioka K, 2016, INT J ONCOL, V48, P1499, DOI 10.3892/ijo.2016.3374; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI 10.3322/caac.20115; Jemal A, 2010, CANCER EPIDEM BIOMAR, V19, P1893, DOI 10.1158/1055-9965.EPI-10-0437; Lu JG, 2011, J CANCER RES CLIN, V137, P1613, DOI 10.1007/s00432-011-1024-y; Lu JG, 2009, EUR ARCH OTO-RHINO-L, V266, P89, DOI 10.1007/s00405-008-0675-z; Luo ZP, 2016, CANCER BIOTHER RADIO, V31, P153, DOI 10.1089/cbr.2016.1995; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Rustgi AK, 2014, NEW ENGL J MED, V371, P2499, DOI 10.1056/NEJMra1314530; Saleh S, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2396-9; Seguin L, 2015, TRENDS CELL BIOL, V25, P234, DOI 10.1016/j.tcb.2014.12.006; Sui X, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0541-x; Vogetseder A, 2013, INT J CANCER, V133, P2362, DOI 10.1002/ijc.28267; Waisberg J, 2014, ANTICANCER RES, V34, P5599; Wang J, 2017, ONCOGENE, V36, P1351, DOI 10.1038/onc.2016.299; Weis S., 2011, COLD SPRING HARB PER, V1, P6478, DOI DOI 10.1101/CSHPERSPECT.A006478; Wipff PJ, 2008, EUR J CELL BIOL, V87, P601, DOI 10.1016/j.ejcb.2008.01.012; Xie JJ, 2016, HUM PATHOL, V48, P69, DOI 10.1016/j.humpath.2015.09.029; Zhang GA, 2013, ONCOL LETT, V5, P797, DOI 10.3892/ol.2013.1125	23	0	0	0	1	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	SEP	2018	214	9					1352	1355		10.1016/j.prp.2018.07.005			4	Pathology	Pathology	GV3DC	WOS:000445973500017	30049512				2019-10-28	
J	Lv, JL; Liu, JX; Xiao, MB; Xu, H; Xu, CZ; Zhang, XN; Tang, L; Jiang, F; Zhou, YF; Zhang, ZJ; Qu, LS; Lu, CH				Lv, Jiale; Liu, Jinxia; Xiao, Mingbin; Xu, Hui; Xu, Chenzhou; Zhang, Xuening; Tang, Lei; Jiang, Feng; Zhou, Yifan; Zhang, Zijuan; Qu, Lishuai; Lu, Cuihua			ARP3 promotes tumor metastasis and predicts a poor prognosis in hepatocellular carcinoma	PATHOLOGY RESEARCH AND PRACTICE			English	Article						ARP3; Hepatocellular carcinoma; Prognosis; Metastasis	RISK-FACTORS; PREVENTION; PERSPECTIVES; MANAGEMENT; MOTILITY; INVASION; CELLS	Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide. Therefore, the study of the precise molecular mechanism underlying hepatocarcinogenesis has profound significance. In this study, we found that the expression of ARP3 was significantly up-regulated in HCC tissues and cell lines. Studies in liver cancer specimens showed that the expression of ARP3 is closely related to the pathological grade, distant metastasis and vascular invasion of HCC. According to the results of multivariate analysis, ARP3 is an independent prognostic factor for HCC patients. In vitro, knockdown of ARP3 expression significantly inhibited the invasion and migration of HCC cells and altered the expression of EMT markers. Based on the above conclusions, we conclude that ARP3 may be a potential prognostic indicator and therapeutic target for HCC patients.	[Lv, Jiale; Liu, Jinxia; Xiao, Mingbin; Xu, Hui; Xu, Chenzhou; Zhang, Xuening; Tang, Lei; Jiang, Feng; Zhang, Zijuan; Qu, Lishuai; Lu, Cuihua] Nantong Univ, Affiliated Hosp, Dept Gastroenterol, Nantong 226001, Jiangsu, Peoples R China; [Xiao, Mingbin; Jiang, Feng] Nantong Univ, Affiliated Hosp, Res Ctr Clin Med, Nantong 226001, Jiangsu, Peoples R China; [Zhou, Yifan] Nantong Univ, Med Coll, Clin Med, Class 4,Grade 14, Nantong 226001, Jiangsu, Peoples R China	Qu, LS; Lu, CH (reprint author), Nantong Univ, Affiliated Hosp, Dept Gastroenterol, Nantong 226001, Jiangsu, Peoples R China.	qulishuai1121@163.com; Lch670608@sina.com			Natural Science Foundation of Jiangsu ProvinceJiangsu Planned Projects for Postdoctoral Research FundsNatural Science Foundation of Jiangsu Province [BK20161286]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81401985, 81472272]	This work was supported by Natural Science Foundation of Jiangsu Province (BK20161286) and the National Natural Science Foundation of China (81401985, 81472272).	Bruix J, 2014, GUT, V63, P844, DOI 10.1136/gutjnl-2013-306627; Colas E, 2012, CLIN TRANSL ONCOL, V14, P715, DOI 10.1007/s12094-012-0866-3; Dutta R, 2017, PHARMACOL THERAPEUT, V173, P106, DOI 10.1016/j.pharmthera.2017.02.010; Fujiwara N, 2018, J HEPATOL, V68, P526, DOI 10.1016/j.jhep.2017.09.016; GAMUNDI SS, 1989, COMP BIOCHEM PHYS C, V92, P167, DOI 10.1016/0742-8413(89)90034-0; Giannelli G, 2016, J HEPATOL, V65, P798, DOI 10.1016/j.jhep.2016.05.007; Gross SR, 2013, CELL ADHES MIGR, V7, P199, DOI 10.4161/cam.23176; Jayachandran A, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0307-9; Liu Y, 2017, MED SCI MONITOR, V23, P695, DOI 10.12659/MSM.903261; Machesky LM, 2008, FEBS LETT, V582, P2102, DOI 10.1016/j.febslet.2008.03.039; Marquardt JU, 2014, CANCER CELL, V25, P550, DOI 10.1016/j.ccr.2014.04.002; Olson MF, 2009, CLIN EXP METASTAS, V26, P273, DOI 10.1007/s10585-008-9174-2; Otsubo T, 2004, MODERN PATHOL, V17, P461, DOI 10.1038/modpathol.3800062; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Poon RTP, 2000, ANN SURG, V232, P10, DOI 10.1097/00000658-200007000-00003; Rahbari NN, 2011, ANN SURG, V253, P453, DOI 10.1097/SLA.0b013e31820d944f; Rinninella E, 2017, J CLIN TRANSL HEPATO, V5, P235, DOI 10.14218/JCTH.2017.00002; van Zijl F, 2009, FUTURE ONCOL, V5, P1169, DOI [10.2217/fon.09.91, 10.2217/FON.09.91]; Vartiainen MK, 2004, CURR OPIN CELL BIOL, V16, P174, DOI 10.1016/j.ceb.2004.02.004; Vineis P, 2014, LANCET, V383, P549, DOI 10.1016/S0140-6736(13)62224-2; Yamazaki D, 2005, CANCER SCI, V96, P379, DOI 10.1111/j.1349-7006.2005.00062.x; Yang ZL, 2013, CANCER INVEST, V31, P132, DOI 10.3109/07357907.2012.756113; Yilmaz M, 2010, MOL CANCER RES, V8, P629, DOI 10.1158/1541-7786.MCR-10-0139; Yin XF, 2015, SCI REP-UK, V5, DOI 10.1038/srep12120; Zheng HC, 2008, ANTICANCER RES, V28, P2225	25	0	0	0	4	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	SEP	2018	214	9					1356	1361		10.1016/j.prp.2018.05.028			6	Pathology	Pathology	GV3DC	WOS:000445973500018	30049513				2019-10-28	
J	Wang, GH; Gu, YH; Lu, WQ; Liu, XR; Fu, H				Wang, Guohui; Gu, Yonghong; Lu, Weiqian; Liu, Xinrong; Fu, Hua			Fascin1 promotes gastric cancer progression by facilitatingcell migrationand epithelial-mesenchymal transition	PATHOLOGY RESEARCH AND PRACTICE			English	Article						fascin1; Cell migration; EMT markers; Gastric carcinoma; Clinicopathologic parameters	NEGATIVE BREAST-CANCER; ACTIN-BUNDLING PROTEIN; CELL MOTILITY; EXPRESSION; PROLIFERATION; CARCINOMA; PROGNOSIS; INVASION; ROLES	Background: Fascin1 regulates cell motility, migration and invasion. Abnormal fascin1 expression has been implicated in a variety of cancers. In this study, we measured fascin1 expression in gastric cancer tissues from 80 gastric cancer patients, and assessed the correlation of fascin1 expression with a series of clinicopathologic gastric cancer parameters.We also verified the results with 4 gastric cancer cell lines in subsequent in vitro studies. Methods: We measured mRNA expression of fascin1 with RT-qPCR, and measured protein expressions of fascin1 and EMT markers with western blot in gastric cancer cells. Additionally, we used RT-qPCR to assess fascin1 expression in gastric cancer tissues and adjacent normal tissue.Transwell assay was used for cell migration. Xenograft was established by subcutaneous injection of Fascin1 knockdown gastric cancer cells. Results: Fascin1 expression was greater in gastric cancer cell lines compared to normal cells and the expression increased with decreasing cell differentiation. In addition, fascin1 expression was significantly different between gastric cancer tissue and adjacent normal tissue. Fascin1 positivity was higher in poorly differentiated carcinomas compared to moderately and highly differentiated carcinomas. The fascin1 expression was associated with differentiation, tumor size, lymph node status, distant metastasis and TNM stage, but not patient age and sex. Fascin1 expression in gastric carcinoma cells and tissues is significantly higher than in normal gastric mucosa and adjacent tissue to cancerous tissues, and it increases as cancer cell differentiation decreases. Furthermore, fascin1 expression regulates gastric cancer cell migration, expressions of EMT markers and transcription factors as well as xenograft tumor formation. Conclusion: Fascin1 is related with clinicopathologic parameters of gastric cancer and overexpressed both in gastric cell lines and gastric tumor tissue. Knockdown of Fascin1 inhibited gastric cancer cell migration and EMT markers expression.	[Wang, Guohui] Cent S Univ, Xiangya Hosp 3, Med Lab Ctr, Changsha 410013, Hunan, Peoples R China; [Gu, Yonghong; Lu, Weiqian; Liu, Xinrong; Fu, Hua] Cent S Univ, Xiangya Hosp 3, Dept Pathol, 138 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China	Fu, H (reprint author), Cent S Univ, Xiangya Hosp 3, Dept Pathol, 138 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China.	fuhua78965@163.com			Science and Technology Planning Project of Hunan Province [2015SK20214]; Natural Science Funds For Youth Fund of Hunan Province [2018JJ3781]; National Natural Science Funds of ChinaNational Natural Science Foundation of China [51305464]	This study was supported by the Science and Technology Planning Project of Hunan Province (2015SK20214), Natural Science Funds For Youth Fund of Hunan Province (2018JJ3781) and the National Natural Science Funds of China (51305464).	Adams JC, 1999, MOL BIOL CELL, V10, P4177, DOI 10.1091/mbc.10.12.4177; Adams JC, 2004, CURR OPIN CELL BIOL, V16, P590, DOI 10.1016/j.ceb.2004.07.009; [Anonymous], 2014, WORLD CANC REPORT; Boer EF, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004946; Chan C, 2010, AM J SURG PATHOL, V34, P656, DOI 10.1097/PAS.0b013e3181db36c0; Davis PA, 2001, CRIT REV ONCOL HEMAT, V40, P77, DOI 10.1016/S1040-8428(00)00131-1; Fu H, 2009, PATHOLOGY, V41, P655, DOI 10.3109/00313020903273100; Gross SR, 2013, CELL ADHES MIGR, V7, P199, DOI 10.4161/cam.23176; Grothey A, 2000, BRIT J CANCER, V83, P870, DOI 10.1054/bjoc.2000.1395; Hashimoto Y, 2005, INT J BIOCHEM CELL B, V37, P1787, DOI 10.1016/j.biocel.2005.05.004; Jawhari A.U., 2003, WORLD J GASTROENTERO, V162, P69; Kefeli M, 2009, INT J GYNECOL PATHOL, V28, P328, DOI 10.1097/PGP.0b013e318195da9f; Kim SJ, 2012, PATHOL INT, V62, P777, DOI 10.1111/pin.12012; Kuzet SE, 2016, CELL TISSUE RES, V365, P607, DOI 10.1007/s00441-016-2467-x; [李建川 Li Jianchuan], 2017, [热固性树脂, Thermosetting Resin], V32, P1; National Cancer Institute, 2016, SEER STAT FACT SHEET; NCI, NON TRADITIONAL REF; Ono S, 1997, J BIOL CHEM, V272, P2527; Pan Y, 2017, ONCOTARGET, V8, P33144, DOI 10.18632/oncotarget.16562; Saika Kumiko, 2013, Gan To Kagaku Ryoho, V40, P2475; Savitskaya MA, 2016, BIOCHEMISTRY-MOSCOW+, V81, P806, DOI 10.1134/S0006297916080034; Tan VY, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-52; Tu L, 2016, TUMOR BIOL, V37, P8775, DOI 10.1007/s13277-015-4368-0; Vignjevic D, 2007, CANCER RES, V67, P6844, DOI 10.1158/0008-5472.CAN-07-0929; Wang L, 2017, CELL BIOL INT, V41, P833, DOI 10.1002/cbin.10786; Wang Y.L.Z., 2007, SHANGDONG MED J, V47, P52; Wu D, 2010, ANN ONCOL, V21, P589, DOI 10.1093/annonc/mdp333; Yamashiro S, 1998, MOL BIOL CELL, V9, P993, DOI 10.1091/mbc.9.5.993; Yan M, 2016, CHIN J CANCER, V35, DOI 10.1186/s40880-015-0059-x; Yang XC, 2016, ONCOL LETT, V12, P3619, DOI 10.3892/ol.2016.5044; Yang YS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125132; Yoder BJ, 2005, CLIN CANCER RES, V11, P186; Zhang NW, 2016, ONCOL REP, V36, P977, DOI 10.3892/or.2016.4889; Zhao JB, 2010, CANCER LETT, V290, P238, DOI 10.1016/j.canlet.2009.09.013	34	0	0	1	3	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	SEP	2018	214	9					1362	1369		10.1016/j.prp.2018.06.018			8	Pathology	Pathology	GV3DC	WOS:000445973500019	30060981				2019-10-28	
J	Zhang, XB; Shen, DH; Wang, Y				Zhang, Xiaobo; Shen, Danhua; Wang, Ying			Detection of the DICER1 hotspot mutation alongside immunohistochemical analysis may provide a better diagnostic measure for ovarian Sertoli-Leydig cell tumors	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Sertoli-Leydig cell tumors; SLCTs; alpha-Inhibin; Calretinin; FOXL2; DICER1	CORD-STROMAL TUMORS; CLINICOPATHOLOGICAL ANALYSIS; CARCINOMA; NEOPLASMS	Background: To evaluate the clinicopathological and histopathological characteristics of ovarian Sertoli-Leydig cell tumors (SLCTs) in relation to differential diagnosis, and patient prognosis. Methods: A review of clinical data, pathological morphology and immunohistochemical analysis of SLCTs were performed in 18 SLCTs patients. The DICER1 gene mutation was assessed in eight cases that were obtained from in-house surgical resections. Results: Among 18 SLCTs patients, three cases had well-differentiated tumors, 8 cases had moderately-differentiated tumors, and the remaining 7 cases had poorly-differentiated tumors. Among the moderately-differentiated tumors, three cases occurred coincidently with other diseases - one case occurred with endometrial carcinoma (grade I), and two cases with endometrial carcinoma of the ovary (grade 2 and grade 3). Immunohistochemical staining for alpha-inhibin, calretinin, and FOXL2 was positive in all the biopsies tested. The intensity of staining varied depending on the percentage of Sertoli cells and the primitive gonad interstitial composition. DICER1 mutations were detected in three of eight cases that were evaluated and were significantly more in low age range patients (P < 0.05). The initial symptoms of these three cases were sexual changes and elevation of androgen levels. The follow-up time in this study ranged from 3 to 87 months with the mean followup time of 29.1 months. Prognosis was generally favorable. There was no recurrence or metastasis in any patient, except for one case with recurrence of endometrial carcinoma. Conclusion: The clinical presentation of SLCTs can be both varied and complex. Pathological examination is imperative for both diagnostic and prognostic grading. Immunohistochemical stain of alpha-inhibin, FOXL2, and calretinin and genetic testing for DICER1 mutations will be more potent for differential diagnosis.	[Zhang, Xiaobo; Shen, Danhua; Wang, Ying] Peking Univ, Peoples Hosp, Dept Pathol, 11 Xizhimen South St, Beijing 100044, Peoples R China	Shen, DH (reprint author), Peking Univ, Peoples Hosp, Dept Pathol, 11 Xizhimen South St, Beijing 100044, Peoples R China.	shenpath_people@126.com					Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Chen LW, 2014, INT J CLIN EXP PATHO, V7, P1176; Conlon N, 2015, MODERN PATHOL, V28, P1603, DOI 10.1038/modpathol.2015.115; Di Giacinto P, 2012, CLIN MED INSIGHT-CAS, V5, P149, DOI 10.4137/CCRep.S10555; Fuller P. J., 2016, CLINICALGENETICS; Goulvent T, 2016, HISTOPATHOLOGY, V68, P279, DOI 10.1111/his.12747; Gui T, 2012, GYNECOL ONCOL, V127, P384, DOI 10.1016/j.ygyno.2012.07.114; Juan Rosai o.v.J. Z., 2007, APPL LIMITATION IMMU, P1598; Kato N, 2017, HUM PATHOL, V59, P41, DOI 10.1016/j.humpath.2016.09.005; Kommoss S, 2013, MODERN PATHOL, V26, P860, DOI 10.1038/modpathol.2012.226; Liu Ai-jun, 2010, Chinese Journal of Pathology, V39, P62, DOI 10.3760/cma.j.issn.0529-5807.2010.01.018; Movahedi-Lankarani S, 2002, AM J SURG PATHOL, V26, P1477, DOI 10.1097/00000478-200211000-00010; Oliva E, 2014, WHO CLASSIFICATION T; Oost EE, 2015, INT J GYNECOL PATHOL, V34, P266, DOI 10.1097/PGP.0000000000000150; Schleiermacher G, 2011, BRIT J CANCER, V105, P1940, DOI 10.1038/bjc.2011.472; Shanbhogue AKP, 2010, RADIOGRAPHICS, V30, P903, DOI 10.1148/rg.304095745; Shirley S, 2010, J CANCER RES THER, V6, P304, DOI 10.4103/0973-1482.73322; Tomlinson MW, 1997, EUR J GYNAECOL ONCOL, V18, P44; Wenxin Zheng D. S., 2013, SCIENCE, P671; Witkowski L, 2013, BRIT J CANCER, V109, P2744, DOI 10.1038/bjc.2013.637; YOUNG RH, 1985, AM J SURG PATHOL, V9, P543, DOI 10.1097/00000478-198508000-00001; Zhang HY, 2014, INT J CLIN EXP PATHO, V7, P6956; Zhao CQ, 2007, AM J SURG PATHOL, V31, P1378, DOI 10.1097/PAS.0b013e3180339961	23	0	0	0	3	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	SEP	2018	214	9					1370	1375		10.1016/j.prp.2018.02.018			6	Pathology	Pathology	GV3DC	WOS:000445973500020	30072170				2019-10-28	
J	Yin, S; Chen, FF; Yang, GF				Yin, Shuai; Chen, Fang-fang; Yang, Gui-fang			Vimentin immunohistochemical expression as a prognostic factor in gastric cancer: A meta-analysis	PATHOLOGY RESEARCH AND PRACTICE			English	Review						Vimentin; Gastric cancer; Prognosis; Clinicopathological; Features	EPITHELIAL-MESENCHYMAL TRANSITION; CLINICAL-SIGNIFICANCE; MIGRATION; STATISTICS; RESISTANCE; INVASION; EMT	Objective: The prognostic value of vimentin expression in Gastric Cancer (GC) has been assessed for years while the results are still in dispute. Thus, we performed a meta-analysis to determine the effect of vimentin immunohistochemical (IHC) expression on the prognosis of GC. Methods: Literature searches were performed in PubMed and Embase. The meta-analysis examined the association of vimentin IHC expression with prognosis and clinicopathological characteristics of GC patients. Results: In total, ten studies involving 1598 cases were enrolled in this meta-analysis. Vimentin positive expression was significantly correlated with poor overall survival (OS) in GC patients (HR = 2.05, 95% CI: 1.29-3.24) but there was a significant degree of heterogeneity (I-2 = 77%, P = 0.0006). Subgroup analysis indicated that vimentin expression had an unfavorable impact on OS in Chinese patients (HR = 2.43, 95% CI: 1.30-4.55). Moreover, vimentin positive expression rates was significantly associated with age, tumor location, TNM stage and lymph node metastasis. However, vimentin positive expression rates did not correlate with gender, grade of differentiation, vascular invasion, the depth of invasion, hepatic metastasis or peritoneal metastasis. Conclusions: Positive vimentin expression could serve as a poor prognostic marker in GC.	[Yin, Shuai; Yang, Gui-fang] Wuhan Univ, Zhongnan Hosp, Dept Pathol, Wuhan 430071, Hubei, Peoples R China; [Chen, Fang-fang] Wuhan Univ, Renmin Hosp, Dept Pathol, Wuhan, Hubei, Peoples R China	Yang, GF (reprint author), Wuhan Univ, Zhongnan Hosp, Dept Pathol, Wuhan 430071, Hubei, Peoples R China.	15927234022@163.com					Brzozowa M, 2015, PRZ GASTROENTEROL, V10, P7, DOI 10.5114/pg.2014.47502; Chen J, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756-9966-33-38; Ebert AD, 2000, EXP CELL RES, V257, P223, DOI 10.1006/excr.2000.4881; Fuyuhiro Y, 2010, ANTICANCER RES, V30, P5239; Gurzu S, 2015, APMIS, V123, P223, DOI 10.1111/apm.12347; Hou FT, 2012, MED ONCOL, V29, P2691, DOI 10.1007/s12032-011-0127-2; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Ivaska J, 2007, EXP CELL RES, V313, P2050, DOI 10.1016/j.yexcr.2007.03.040; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI 10.3322/caac.20115; Kidd ME, 2014, AM J RESP CELL MOL, V50, P1, DOI 10.1165/rcmb.2013-0314TR; Kim HP, 2014, ONCOGENE, V33, P3334, DOI 10.1038/onc.2013.285; Kim MA, 2009, HISTOPATHOLOGY, V54, P442, DOI 10.1111/j.1365-2559.2009.03247.x; Kokkinos MI, 2007, CELLS TISSUES ORGANS, V185, P191, DOI 10.1159/000101320; Lazarova DL, 2016, J CELL MOL MED, V20, P989, DOI 10.1111/jcmm.12850; Liu WF, 2012, INT J MOL SCI, V13, P6399, DOI 10.3390/ijms13056399; Liu ZF, 2014, J CELL MOL MED, V18, P610, DOI 10.1111/jcmm.12209; Mendez MG, 2010, FASEB J, V24, P1838, DOI 10.1096/fj.09-151639; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; Ryu HS, 2012, HUM PATHOL, V43, P520, DOI 10.1016/j.humpath.2011.07.003; Santos MI, 2008, BIOMATERIALS, V29, P4306, DOI 10.1016/j.biomaterials.2008.07.033; Satelli A, 2011, CELL MOL LIFE SCI, V68, P3033, DOI 10.1007/s00018-011-0735-1; Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z; TAKEMURA K, 1994, PATHOBIOLOGY, V62, P149, DOI 10.1159/000163895; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Wang YR, 2014, INT J MOL MED, V33, P1514, DOI 10.3892/ijmm.2014.1707; Xie RX, 2016, TUMOR BIOL, V37, P12049, DOI 10.1007/s13277-016-5070-6; Zhang H, 2013, J CANCER RES CLIN, V139, P1033, DOI 10.1007/s00432-012-1363-3; Zhao WW, 2013, CTS-CLIN TRANSL SCI, V6, P184, DOI 10.1111/cts.12043	29	4	4	1	5	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	SEP	2018	214	9					1376	1380		10.1016/j.prp.2018.07.014			5	Pathology	Pathology	GV3DC	WOS:000445973500021	30078472				2019-10-28	
J	Yin, YC; Xu, ML; Gao, J; Li, MJ				Yin, Yancun; Xu, Maolei; Gao, Ju; Li, Minjing			Alkaline ceramidase 3 promotes growth of hepatocellular carcinoma cells via regulating S1P/S1PR2/PI3K/AKT signaling	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Hepatocellular carcinoma; Ceramidase; S1P; Apoptosis	ACUTE MYELOID-LEUKEMIA; LONG-CHAIN CERAMIDES; SPHINGOSINE 1-PHOSPHATE; SUPPORTS DEVELOPMENT; CANCER; SPHINGOSINE-1-PHOSPHATE; METABOLISM; CLONING; ENZYME	Objective: Hepatocellular carcinoma (HCC) is one of the cancer types with poor prognosis. To effectively treat HCC, new molecular targets and therapeutic approaches must be identified. Alkaline ceramidase 3 (Acer3) hydrolyzed long-chain unsaturated ceramide to produce free fatty acids and sphingosine. However, whether and how Acer3 modulates progression of HCC remains largely unknown. Methods: Acer3 mRNA levels in different types of human HCC samples or normal tissues were determined from Gene Expression across Normal and Tumor tissue (GENT) database. The expression level of Acer3 in human HCC cell lines were examined by western blot. Overall survival and disease-free survival of HCC patients were determined by Kaplan-Meier analysis. Effects of Acer3 knockdown by lentivirus infection were evaluated on cell growth and apoptosis. The mechanisms involved in HCC cells growth and apoptosis were analyzed by western blot. Results: In silico analysis of TCGA databases of HCC patients showed that the expression of Acer3 significantly inversely correlates with the overall and disease-free survival of HCC patients. Knockdown expression of Acer3 resulted in decreased cell growth and increased apoptosis. Notably, inhibition of Acer3 resulted in intracellular exhaustion of Sphingosine-l-phosphate (S1P) and inhibited activation of S1PR2/PI3K/AKT signaling. Finally, knockdown of Acer3 induced up-regulation of Bax and down-regulation of Bcl-2. Conclusions: Our study suggests that Acer3 contributes to HCC propagation, and suggests that inhibition of Acer3 may be novel strategy for treating human HCC.	[Yin, Yancun] Binzhou Med Univ, Sch Basic Med Sci, Taishan Scholar Immunol Program, Yantai 264003, Shandong, Peoples R China; [Li, Minjing] Binzhou Med Univ, Med & Pharm Res Ctr, Yantai 264003, Shandong, Peoples R China; [Xu, Maolei] Binzhou Med Univ, Key Lab Tradit Chinese Med Prescript Effect & Cli, State Adm Tradit Chinese Med, Sch Pharm, Yantai 264003, Shandong, Peoples R China; [Gao, Ju] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA	Li, MJ (reprint author), 346 Guanhai Rd, Yantai 264003, Shandong, Peoples R China.	yinyc1985@126.com; xumaolei1234@163.com; jxg712@case.edu; liminjing512@126.com		Yin, Yancun/0000-0003-2755-9595; Li, Minjing/0000-0001-9276-4654	National Natural Science Foundation of ChinaNational Natural Science Foundation of China [31501146, 81600128]; Natural Science Foundation of Shandong ProvinceNatural Science Foundation of Shandong Province [BS2015SW024, BS20151YY013]; Taishan Scholar Program	This work was supported by the National Natural Science Foundation of China [grant numbers 31501146, 81600128]; the Natural Science Foundation of Shandong Province [grant numbers BS2015SW024, BS20151YY013]; and the Taishan Scholar Program.	Allemani C, 2018, LANCET, V391, P1023, DOI 10.1016/S0140-6736(17)33326-3; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen C, 2016, BIOCHEM BIOPH RES CO, V478, P33, DOI 10.1016/j.bbrc.2016.07.099; Cheng JC, 2018, MOL CANCER RES, V16, P1543, DOI 10.1158/1541-7786.MCR-17-0681; Forner A, 2018, LANCET, V391, P1301, DOI 10.1016/S0140-6736(18)30010-2; Hu W, 2010, J BIOL CHEM, V285, P7964, DOI 10.1074/jbc.M109.063586; Ikeda H, 2003, GASTROENTEROLOGY, V124, P459, DOI 10.1053/gast.2003.50049; Ksiazek M, 2015, J LIPID RES, V56, P1271, DOI 10.1194/jlr.R059543; Li CL, 2015, BIOCHEM BIOPH RES CO, V465, P47, DOI 10.1016/j.bbrc.2015.07.123; Li F, 2018, FASEB J, V32, P3058, DOI 10.1096/fj.201700445RR; Li MJ, 2017, CELL COMMUN SIGNAL, V15, DOI 10.1186/s12964-017-0208-8; Mao CG, 2001, J BIOL CHEM, V276, P26577, DOI 10.1074/jbc.M102818200; Mao CG, 2003, J BIOL CHEM, V278, P31184, DOI 10.1074/jbc.M303875200; Miller E, 2012, CHEM BIOL, V19, P955, DOI 10.1016/j.chembiol.2012.07.005; Nault JC, 2018, J HEPATOL, V69, P237, DOI 10.1016/j.jhep.2018.02.016; Patmanathan SN, 2017, CELL SIGNAL, V34, P66, DOI 10.1016/j.cellsig.2017.03.002; Shin G, 2011, CANCER INFORM, V10, P149, DOI 10.4137/CIN.S7226; Spiegel S, 2011, NAT REV IMMUNOL, V11, P403, DOI 10.1038/nri2974; Wan DF, 2004, P NATL ACAD SCI USA, V101, P15724, DOI 10.1073/pnas.0404089101; Wang K, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.36; Wang K, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005591	21	1	1	0	3	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	SEP	2018	214	9					1381	1387		10.1016/j.prp.2018.07.029			7	Pathology	Pathology	GV3DC	WOS:000445973500022	30097213				2019-10-28	
J	Jia, CM; Tian, YY; Quan, LN; Jiang, L; Liu, AC				Jia, Chui-Ming; Tian, Yu-Yang; Quan, Li-Na; Jiang, Li; Liu, Ai-Chun			miR-26b-5p suppresses proliferation and promotes apoptosis in multiple myeloma cells by targeting JAG1	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Multiple myeloma; miR-26b-5p; JAG1; Proliferation	PATHOGENESIS; SENSITIVITY; EXPRESSION; THERAPY; JAGGED1; DISEASE; CANCER; HES1	Background: Though the levels of diagnosis and treatment of multiple myeloma (MM) have been largely improved recent years, the prognosis of these patients remain unacceptable. It is urgent for us to discover the exact mechanism and determine some new indicators for MM. MiRNAs play a critical role in the occurrence and progression of cancers, including MM. MiR-26b-5p has been reported to be closely related to cells proliferation in human pulmonary cancer, hepatocellular carcinoma and so on. Material and methods: Here, we measured the expression of miR-26b-5p in MM samples and cell lines by real- time PCR. Then, Kaplan-Meier Curves were applied to assess the effect of miR-26b-5p expression on MM patients prognosis. Functionally, MU assay and Flow cytometry were conducted to explore the functions of miR-26b-5p in cells proliferation and apoptosis. Furthermore, bioinformatics tools, Pearson's correlation coefficient analysis, gain-and loss of-function experiments and rescue experiment were used to determine the relationship between JAG1 and miR-26b-5p in MM cells. In addition, we also confirmed the role of JAG1 in MM cells proliferation and apoptosis by gain-and loss of-function experiments. Results: Here, we reported for the first time that miR-26b-5p was under-expressed in MM by real-time PCR. Clinically, Kaplan-Meier Curves showed that MM patients with lower miR-26b-5p expression had worse prognosis. Functionally, MIT assay revealed that miR-26b-5p inhibited cells proliferation. Flow cytometry indicated that miR-26b-5p accelerated tumor cells apoptosis. Furthermore, bioinformatics tools, Pearson's correlation coefficient analysis gain-and loss of-function experiments showed that JAG1 was the target of miR-26b-5p in MM cells. And, gain-and loss of-function experiments for JAG1 confirmed that JAG1 was an oncogene in MM cells. What's more, rescue experiment showed that JAG1 mediated the function of miR-26b-5p in MM cells. Conclusion: MiR-26b-5p acts as a tumor suppressor through suppressing cells proliferation and inducing cells apoptosis via directly targeting JAG1 in MM. MiR-26b-5p could be a potential and ponderable tumor target for MM in future.	[Jia, Chui-Ming; Tian, Yu-Yang; Quan, Li-Na; Jiang, Li; Liu, Ai-Chun] Harbin Med Univ, Canc Hosp, Hematol Dept, Harbin 150081, Heilongjiang, Peoples R China	Liu, AC (reprint author), Harbin Med Univ, Canc Hosp, Hematol Dept, Harbin 150081, Heilongjiang, Peoples R China.	liuaichun_vip0@yeah.net			Science and Technology Research Project of Education Department of Heilongjiang Province [12541527]	The present study was supported by the Science and Technology Research Project of Education Department of Heilongjiang Province (12541527).	Colombo M, 2014, ONCOTARGET, V5, P10393, DOI 10.18632/oncotarget.2084; Grochowski CM, 2016, GENE, V576, P381, DOI 10.1016/j.gene.2015.10.065; Guo JF, 2016, EXPERT OPIN THER TAR, V20, P107, DOI 10.1517/14728222.2015.1071355; Ikeda S, 2017, CANCER SCI, V108, P641, DOI 10.1111/cas.13183; Jundt F, 2004, BLOOD, V103, P3511, DOI 10.1182/blood-2003-07-2254; Liu ZY, 2016, BIOCHEM BIOPH RES CO, V469, P692, DOI [10.1016/j.bbrc.2015.11.36, 10.1016/j.bbrc.2015.11.136]; Ludwig H, 2017, HEMATOL-AM SOC HEMAT, P212, DOI 10.1182/asheducation-2017.1.212; Mateosi MV, 2017, HEMATOL-AM SOC HEMAT, P498, DOI 10.1182/asheducation-2017.1.498; Nahi H, 2016, EUR J HAEMATOL, V96, P46, DOI 10.1111/ejh.12546; Nefedova Y, 2008, BLOOD, V111, P2220, DOI 10.1182/blood-2007-07-102632; Ramakrishnan V, 2012, LEUKEMIA, V26, P340, DOI 10.1038/leu.2011.192; Rohena-Rivera K, 2018, J BIOL CHEM, V293, P8295, DOI 10.1074/jbc.H118.002880; Rossi M, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.12.13; Schwarzer R, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.37; Stamato MA, 2017, ONCOTARGET, V8, P106527, DOI 10.18632/oncotarget.22507; Tang B, 2018, INT J CANCER, V142, P109, DOI 10.1002/ijc.31041; Terpos E, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408-017-0037-4; Wang T, 2017, ONCOTARGETS THER, V10, P4465, DOI 10.2147/OTT.S143612; Wang Y, 2016, TUMOR BIOL, V37, P10965, DOI 10.1007/s13277-016-4964-7; Wilke CM, 2018, INT J CANCER, V142, P573, DOI 10.1002/ijc.31072; Wu TW, 2014, FEBS LETT, V588, P2107, DOI 10.1016/j.febslet.2014.04.044; Zhang Z, 2014, BRAIN RES, V1583, P65, DOI 10.1016/j.brainres.2014.07.037	22	3	3	1	4	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	SEP	2018	214	9					1388	1394		10.1016/j.prp.2018.07.025			7	Pathology	Pathology	GV3DC	WOS:000445973500023	30098829				2019-10-28	
J	Dousti, F; Shahrisa, A; Ansari, H; Hajjari, M; Birgani, YT; Mohammadiasl, J; Birgani, MT				Dousti, Fatemeh; Shahrisa, Arman; Ansari, Hossein; Hajjari, Mohammadreza; Birgani, Yaser Tahmasebi; Mohammadiasl, Javad; Birgani, Maryam Tahmasebi			Long non-coding RNAs expression levels in diffuse large B-cell lymphoma: An in silico analysis	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Diffuse large-B-cell lymphoma; Long noncoding RNA; GAS5; Biomarker; Bioinformatics analysis	LNCRNA GAS5; TRANSCRIPTOME; CANCER; BIOMARKERS	Long non-coding RNAs (lncRNAs), are lengthy noncoding transcripts with pivotal roles in biological pathways including cell cycle, apoptosis and chromatin remodeling. Aberrant expression of lncRNAs has been strongly connected with tumor progression and metastasis. However, the prognostic significance of lncRNAs in diffuse large-B-cell lymphoma (DLBCL) remains unclear. In this study, the expression levels of 189 approved lncRNAs were considered in DLBCL patients using several different genomic and transcriptome datasets. The analyses showed that the lncRNA GAS5 allocated the maximum score of RNA dysregulation and can be considered as good choice in DLBCLs' researches.	[Dousti, Fatemeh] Ahvaz Jundishapur Univ Med Sci, Sch Med, Dept Immunol, Ahwaz, Iran; [Shahrisa, Arman] Tarbiat Modares Univ, Fac Biosci, Dept Mol Genet, Tehran, Iran; [Ansari, Hossein] Islamic Azad Univ, Dept Biotechnol, Ahvaz Branch, Ahwaz, Iran; [Hajjari, Mohammadreza] Shahid Chamran Univ Ahvaz, Fac Sci, Dept Genet, Ahwaz, Iran; [Birgani, Yaser Tahmasebi] Ahvaz Jundishapur Univ Med Sci, Sch Publ Hlth, Dept Environm Hlth Engn, Ahwaz, Iran; [Birgani, Yaser Tahmasebi] Ahvaz Jundishapur Univ Med Sci, Environm Technol Res Ctr, Ahwaz, Iran; [Mohammadiasl, Javad; Birgani, Maryam Tahmasebi] Ahvaz Jundishapur Univ Med Sci, Sch Med, Dept Med Genet, Ahwaz, Iran; [Birgani, Maryam Tahmasebi] Ahvaz Jundishapur Univ Med Sci, Cellular & Mol Res Ctr, Ahwaz, Iran	Ansari, H (reprint author), Islamic Azad Univ, Dept Biotechnol, Ahvaz Branch, Ahwaz, Iran.; Birgani, MT (reprint author), Ahvaz Jundishapur Univ Med Sci, Sch Med, Dept Med Genet, Ahwaz, Iran.	hosseinasari62@gmail.com; tahmasebi-ma@ajums.ac.ir					Alhourani E., 2015, LEUK RES TREATMENT, V2015, P6; Ansari H., 2018, PATHOL ONCOL RES, P1; Arshi A., 2016, ARMAGHANE DANESH BIM, V21, P278; Artero-Castro A, 2009, EXP CELL RES, V315, P1372, DOI 10.1016/j.yexcr.2009.02.007; Birgani M. T., 2017, PATHOL ONCOL RES, V24, P1; Birgani M. T., 2017, CBAF MULTIPLE AUTOMA; Birgani MT, 2018, PATHOL ONCOL RES, V24, P329, DOI 10.1007/s12253-017-0241-3; Cerami E., 2012, CBIO CANC GENOMICS P; Chan WC, 1997, BLOOD, V89, P3909; Christensen MV, 2018, INT J ONCOL, V52, P5, DOI 10.3892/ijo.2017.4197; Clark MB, 2012, GENOME RES, V22, P885, DOI 10.1101/gr.131037.111; Cline MS, 2013, SCI REP-UK, V3, DOI 10.1038/srep02652; Eyre TA, 2006, NUCLEIC ACIDS RES, V34, pD319, DOI 10.1093/nar/gkj147; Fernandez-Mercado M, 2015, J CELL MOL MED, V19, P2307, DOI 10.1111/jcmm.12625; Forootan Amin, 2017, Biomol Detect Quantif, V12, P1, DOI 10.1016/j.bdq.2017.04.001; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Hagner PR, 2011, ONCOGENE, V30, P1531, DOI 10.1038/onc.2010.533; Jiang CJ, 2016, ONCOTARGET, V7, P7120, DOI 10.18632/oncotarget.6859; Lokman NA, 2011, CANCER MICROENVIRON, V4, P199, DOI 10.1007/s12307-011-0064-9; Lossos IS, 2006, J CLIN ONCOL, V24, P995, DOI 10.1200/JCO.2005.02.4786; MacPhee DJ, 2010, J PHARMACOL TOXICOL, V61, P171, DOI 10.1016/j.vascn.2009.12.001; Mao Y, 2017, CANCER GENE THER, V24, P267, DOI 10.1038/cgt.2017.14; Moran VA, 2012, NUCLEIC ACIDS RES, V40, P6391, DOI 10.1093/nar/gks296; Mori J, 2017, BIOL BLOOD MARROW TR, V23, P1398, DOI 10.1016/j.bbmt.2017.04.020; Nakamura Y, 2008, CANCER GENET CYTOGEN, V182, P144, DOI 10.1016/j.cancergencyto.2008.01.013; Peng W, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0346-4; Renganathan A, 2017, ADV EXP MED BIOL, V1008, P199, DOI 10.1007/978-981-10-5203-3_7; Rotaru I, 2014, ROM J MORPHOL EMBRYO, V55, P15; Stower H, 2012, NAT REV GENET, V13, DOI 10.1038/nrg3225; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tao RY, 2015, CARCINOGENESIS, V36, P1136, DOI 10.1093/carcin/bgv099; Tayari MM, 2016, AM J PATHOL, V186, P2462, DOI 10.1016/j.ajpath.2016.05.011; Tilly H, 2015, ANN ONCOL, V26, pV116, DOI 10.1093/annonc/mdv304; Verma A, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0230-7; Wen QR, 2017, INT J GYNECOL CANCER, V27, P1096, DOI 10.1097/IGC.0000000000001028; Winkle M, 2017, CRIT REV ONCOL HEMAT, V120, P77, DOI 10.1016/j.critrevonc.2017.08.011; Yang L, 2014, TRENDS BIOCHEM SCI, V39, P35, DOI 10.1016/j.tibs.2013.10.002; Yin Q, 2017, MED SCI MONITOR, V23, P6042, DOI 10.12659/MSM.907118; Younes A, 2015, J CLIN ONCOL, V33, P2835, DOI 10.1200/JCO.2015.61.9288; Yuan J, 2014, NUCLEIC ACIDS RES, V42, pD104, DOI 10.1093/nar/gkt1057; Zhu DX, 2017, ONCOTARGET, V8, P23228, DOI 10.18632/oncotarget.15571	41	1	1	0	0	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	SEP	2018	214	9					1462	1466		10.1016/j.prp.2018.08.006			5	Pathology	Pathology	GV3DC	WOS:000445973500025	30104077				2019-10-28	
J	Wang, L; Liu, L; Chen, YT; Du, Y; Wang, J; Liu, JH				Wang, Lei; Liu, Liang; Chen, Yuetong; Du, Yu; Wang, Jing; Liu, Jianghui			Correlation between adenosine triphosphate (ATP)-binding cassette transporter G2 (ABCG2) and drug resistance of esophageal cancer and reversal of drug resistance by artesunate	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Esophageal cancer; Artesunate; Multidrug resistance; Adenosine triphosphate (ATP)-binding cassette transporter G2 (ABCG2); Animal experiment	MULTIDRUG-RESISTANCE; PROSTATE-CANCER; CELL-LINE; IN-VITRO; EXPRESSION; MALARIA; APOPTOSIS; CHILDREN; RECEPTOR; THERAPY	The present study investigated the correlation between the abnormal expression of adenosine triphosphate (ATP)-binding cassette transporter G2 (ABCG2) in esophageal cancer and the drug resistance of esophageal cancer, the reversal effect in drug resistance of artesunate (Art), and the mechanism underlying esophageal cancer using nude mice with subcutaneous xenograft as an animal model. The gene and protein expression of ABCG2 was detected in 80 cases of esophageal cancer, atypical dysplasia, and normal mucosa. A subcutaneous xenograft tumor mouse model was established by subcutaneous inoculation of esophageal cancer cell line Eca109/ABCG2 into BALB/c nu/nu nude mice. The reversal of drug resistance by Art in esophageal cancer was studied in vivo. The mice model was injected intraperitoneally with Art and/or doxorubicin (ADM). The animals were divided into six groups: high dose Art (50 mg/kg), low dose Art (25 mg/kg), ADM (1 mg/kg), ADM and high-dose Art, ADM and low-dose Art, and physiological saline as a control. ABCG2 protein expression and cellular ADM concentration were detected by flow cytometry. The mRNA and protein expressions of ABCG2 in esophageal cancer were significantly higher than that in the normal esophagus (P < 0.01). The volume and mass of the subcutaneously implanted tumors in the ADM +Art high- and low-dose groups were significantly decreased than that in the control group (P < 0.05), while the apoptosis rate of tumor cells and the cellular concentration of ADM were increased significantly (P < 0.05), and the ABCG2 protein expression in the tumor cells decreased significantly (P < 0.05). Abnormally high expression of ABCG2 in esophageal cancer tissues is involved in the multidrug resistance of esophageal cancer. In vivo studies showed that Art could reverse the esophageal cancer drug resistance by regulating the ABCG2 expression in tumor cells.	[Wang, Lei] Hebei Med Univ, Dept Thorac Surg, Hosp 4, Shijiashuang 050011, Hebei, Peoples R China; [Liu, Liang; Chen, Yuetong; Wang, Jing; Liu, Jianghui] Hebei Med Univ, Tumor Inst, Hosp 4, Shijiashuang 050011, Hebei, Peoples R China; [Du, Yu] Hebei Med Univ, Dept CT, Hosp 4, Shijiashuang 050011, Hebei, Peoples R China	Liu, L (reprint author), Hebei Med Univ, Tumor Inst, Hosp 4, Shijiashuang 050011, Hebei, Peoples R China.	aliangdaziran@163.com			Natural Science Foundation of Hebei ProvinceNatural Science Foundation of Hebei Province [H2017206174]; Excellent talent project in clinical medicine - Hebei provincial government [Jicaishe [2017]46]; Key Medical Science Project of Hebei Province [20170149]	This study was supported by the Natural Science Foundation of Hebei Province (No. H2017206174), Excellent talent project in clinical medicine funded by Hebei provincial government in 2017 (No. Jicaishe [2017]46) and the Key Medical Science Project of Hebei Province (No. 20170149).	Abuaku BK, 2017, AM J TROP MED HYG, V97, P690, DOI 10.4269/ajtmh.15-0826; Bates SE, 2001, J BIOENERG BIOMEMBR, V33, P503, DOI 10.1023/A:1012879205914; Chen P, 2017, CELL PHYSIOL BIOCHEM, V43, P1939, DOI 10.1159/000484118; Eltahir HG, 2017, J TROP PEDIATRICS, V63, P18, DOI 10.1093/tropej/fmw041; Gupta P, 2017, PAEDIATR INT CHILD H, V37, P139, DOI 10.1080/20469047.2016.1209883; Kathawala RJ, 2017, J CELL BIOCHEM, V118, P2420, DOI 10.1002/jcb.25908; Kawabata S, 2003, CLIN CANCER RES, V9, P3052; Liu L, 2015, MOL MED REP, V12, P1465, DOI 10.3892/mmr.2015.3517; Liu L, 2014, MOL MED REP, V9, P1299, DOI 10.3892/mmr.2014.1949; Liu L, 2013, ONCOL LETT, V6, P1475, DOI 10.3892/ol.2013.1545; Lombard AP, 2017, MOL CANCER THER, V16, P2257, DOI 10.1158/1535-7163.MCT-17-0179; Napoletano C, 2016, ANTICANCER RES, V36, P5109, DOI 10.21873/anticanres.11080; Nunes JJ, 2017, NEOPLASIA, V19, P333, DOI 10.1016/j.neo.2017.02.002; Steinbach D, 2002, LEUKEMIA, V16, P1443, DOI 10.1038/sj.leu.2402541; Sun Y, 2017, TRANSL ONCOL, V10, P976, DOI 10.1016/j.tranon.2017.07.007; van den Heuvel-Eibrink MM, 2002, LEUKEMIA, V16, P833, DOI 10.1038/sj/leu/2402496; Wagner W, 2017, J PHYSIOL PHARMACOL, V68, P555; Wang ZZ, 2017, BIOL PHARM BULL, V40, P479, DOI 10.1248/bpb.b16-00908; Wei CM, 2018, J CELL PHYSIOL, V233, P476, DOI 10.1002/jcp.25907; Zhao WS, 2016, AM J CANCER RES, V6, P1026; Zhou Y, 2017, ONCOTARGET, V8, P18260, DOI 10.18632/oncotarget.15353	21	1	1	1	8	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	SEP	2018	214	9					1467	1473		10.1016/j.prp.2018.08.001			7	Pathology	Pathology	GV3DC	WOS:000445973500026	30104076				2019-10-28	
J	Liang, C; Yang, Y; Guan, JH; Lv, T; Qu, ST; Fu, Q; Zhao, HY				Liang, Chao; Yang, Yang; Guan, Junhong; Lv, Tao; Qu, Shengtao; Fu, Qiang; Zhao, Hongyu			LncRNA UCA1 sponges miR-204-5p to promote migration, invasion and epithelial-mesenchymal transition of glioma cells via upregulation of ZEB1	PATHOLOGY RESEARCH AND PRACTICE			English	Article						UCA1; miR-204-5p; ZEB1; Metastasis; Glioma	LONG NONCODING RNA; PROSTATE-CANCER; PROLIFERATION; EXPRESSION; CARCINOMA; RESISTANCE; MARKER	Long non-coding RNA urothelial carcinoma associated 1 (lncRNA UCA1) promotes cancer progression and enhances chemoresistance through miR-204-5p in a few cancers. However, no studies have investigated whether UCA1 regulates glioma metastasis through miR-204-5p and its target. In the present study, cell migration, invasion and epithelial-mesenchymal transition (EMT) were evaluated in glioma cells overexpressing UCA1. The relationships among UCA1, miR-204-5p and ZEB1 were examined by real-time PCR, western blotting and dual-luciferase reporter assays. The effect of UCA1 knockdown on xenograft tumor growth was investigated. The levels of miR-204-5p, fibronectin, COL5 A1 and ZEB1 in tumor tissues were also determined. The results showed that UCA1 overexpression promoted cell migration, invasion and EMT. UCA1 interacted with miR-204-5p and decreased its level. ZEB1 was identified as a direct target of miR-204-5p and miR-204-5p negatively regulated ZEB1 expression. Moreover, UCA1 sponged miR-204-5p and partially rescued the inhibitory effect of miR-204-5p on ZEB1. In our in vivo studies, UCA1 knockdown reduced tumor volume and tumor weight. In addition, the levels of fibronectin, COL5 A1 and ZEB1 were decreased, while miR-204-5p level was increased. The present study provides the first evidence that UCA1 promotes glioma metastasis through the miR-204-5p/ZEB1 axis, contributing to the understanding of the pathogenesis of glioma.	[Liang, Chao; Guan, Junhong; Lv, Tao; Qu, Shengtao; Fu, Qiang; Zhao, Hongyu] China Med Univ, Shengjing Hosp, Dept Neurosurg, 36 Sanhao St, Shenyang 110004, Liaoning, Peoples R China; [Liang, Chao] Jinzhou Med Univ, Affiliated Hosp 1, Dept Neurosurg, Jinzhou 121001, Liaoning, Peoples R China; [Yang, Yang] Jinzhou Cent Hosp, Dept Neurosurg, Jinzhou 121001, Liaoning, Peoples R China	Zhao, HY (reprint author), China Med Univ, Shengjing Hosp, Dept Neurosurg, 36 Sanhao St, Shenyang 110004, Liaoning, Peoples R China.	zhaocmu1974@yeah.net					Bexell D, 2013, CANCER TREAT REV, V39, P358, DOI 10.1016/j.ctrv.2012.06.006; Bian ZH, 2016, SCI REP-UK, V6, DOI 10.1038/srep23892; Caramel J, 2018, CANCER RES, V78, P30, DOI 10.1158/0008-5472.CAN-17-2476; Ewald JA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055414; Fang Z, 2017, CANCER MED-US, V6, P2897, DOI 10.1002/cam4.1253; Guo C, 2017, J CANCER, V8, P3555, DOI 10.7150/jca.20952; He ZZ, 2017, ARCH BIOCHEM BIOPHYS, V623, P1, DOI 10.1016/j.abb.2017.01.013; Jiao CJ, 2016, ONCOL REP, V36, P2960, DOI 10.3892/or.2016.5121; Jie XX, 2017, ONCOTARGET, V8, P81558, DOI 10.18632/oncotarget.18277; Jing FY, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317703650; Kaufhold S, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0062-0; Kondo Y, 2017, CANCER SCI, V108, P1927, DOI 10.1111/cas.13342; Kros JM, 2015, NEURO-ONCOLOGY, V17, P343, DOI 10.1093/neuonc/nou207; Li C, 2017, 2017 2ND INTERNATIONAL CONFERENCE ON IMAGE, VISION AND COMPUTING (ICIVC 2017), P8, DOI 10.1109/ICIVC.2017.7984449; Li DG, 2018, ONCOL RES, V26, P537, DOI 10.3727/096504017X15009792179602; Li Z, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12404; Liu HY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168406; Lu YY, 2016, TUMOR BIOL, V37, P11733, DOI 10.1007/s13277-015-4773-4; Lu YC, 2017, INT CONF AWARE SCI, P1, DOI 10.1109/ICAwST.2017.8256425; Ma PJ, 2017, CLIN CHIM ACTA, V475, P172, DOI 10.1016/j.cca.2017.10.020; Ordys BB, 2010, MOL NEUROBIOL, V42, P64, DOI 10.1007/s12035-010-8133-5; Orellana-Serradell O, 2017, ASIAN J ANDROL; Qian Y, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0635-6; Quezada C, 2018, MOL ASPECTS MED, V60, P38, DOI 10.1016/j.mam.2017.12.003; Sanchez-Tillo E, 2010, ONCOGENE, V29, P3490, DOI 10.1038/onc.2010.102; Shi J, 2017, ONCOTARGET, V8, P27582, DOI 10.18632/oncotarget.15175; Siebzehnrubl FA, 2013, EMBO MOL MED, V5, P1196, DOI 10.1002/emmm.201302827; Sun Y, 2018, ONCOL RES, V26, P103, DOI 10.3727/096504017X14934860122864; Vu T, 2017, CANCERS, V9, DOI 10.3390/cancers9120171; Wang X., 2016, CANC CHEMOTHER PHARM, V78; Wang XS, 2006, CLIN CANCER RES, V12, P4851, DOI 10.1158/1078-0432.CCR-06-0134; Wang XX, 2017, ONCOTARGET, V8, P28373, DOI 10.18632/oncotarget.16059; Wang ZQ, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.143; Wu GL, 2017, AM J TRANSL RES, V9, P3599; Xia ZQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132399; Yang GD, 2014, BBA-GENE REGUL MECH, V1839, P1097, DOI 10.1016/j.bbagrm.2014.08.012; Ying Z, 2013, CANCER RES, V73, P990, DOI 10.1158/0008-5472.CAN-12-2895; Zhang SL, 2017, AM J TRANSL RES, V9, P366; Zhang X, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0087-3; Zhao W, 2017, CLIN TRANSL ONCOL, V19, P735, DOI 10.1007/s12094-016-1597-7	40	14	15	2	9	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	SEP	2018	214	9					1474	1481		10.1016/j.prp.2018.07.036			8	Pathology	Pathology	GV3DC	WOS:000445973500027	30107990				2019-10-28	
J	Tsai, MJ; Chang, WA; Jian, SF; Chang, KF; Sheu, CC; Kuo, PL				Tsai, Ming-Ju; Chang, Wei-An; Jian, Shu-Fang; Chang, Kuo-Feng; Sheu, Chau-Chyun; Kuo, Po-Lin			Possible mechanisms mediating apoptosis of bronchial epithelial cells in chronic obstructive pulmonary disease - A next-generation sequencing approach	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Bioinformatics; COPD; Epithelium; Apoptosis; Next-generation sequencing	SIGNALING PATHWAY; CANCER CELLS; LUNG-CANCER; COPD; EXPRESSION; CIGARETTE; MICRORNA; RESPONSES; BIOINFORMATICS; INTERLEUKIN-6	Purpose: Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory airway disease characterized by persistent airflow limitation. Apoptosis of pulmonary structural cells contributes to pulmonary destruction and dysfunction. This study aimed to explore the possible mechanisms underlying decreased cell proliferation and increased apoptosis of bronchial epithelial cells of COPD. Materials and methods: The expression profiles of mRNAs and microRNAs in bronchial epithelial cells from a COPD patient and a normal subject were identified using next-generation sequencing (NGS) and analyzed using bioinformatic tools. Results: We identified 233 significantly upregulated and 204 significantly downregulated genes in COPD bronchial epithelial cells. The PI3K-Akt pathway was one of the most important dysregulated pathways in bronchial epithelial cells. We further identified that 3 genes involved in the PI3K-Akt signaling pathway, including IL6, F2R, and FGFR3, might be associated with inhibition of cell proliferation in bronchial epithelial cells, while S genes involved in the PI3K-Akt signaling pathway, including TLR4, IL6, F2R, FGFR3, and FGFR1, might be associated with apoptosis of bronchial epithelial cells. FGFR1 was also a predicted target for some upregulated miRNAs in COPD bronchial epithelial cells, including hsa-miR-195-5p, hsa-miR-424-5p, and hsa-miR-6724-5p. Conclusion: Our findings suggest PI3K-Akt signaling pathway plays an important role in COPD. We observed altered expression of apoptosis and cell proliferation-related genes that might contribute to the pathogenesis of COPD.	[Tsai, Ming-Ju; Chang, Wei-An; Jian, Shu-Fang; Sheu, Chau-Chyun; Kuo, Po-Lin] Kaohsiung Med Univ, Coll Med, Grad Inst Clin Med, 100,Shih Chuan 1st Rd, Kaohsiung 807, Taiwan; [Tsai, Ming-Ju; Chang, Wei-An; Sheu, Chau-Chyun] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Div Pulm & Crit Care Med, 100,TzYou 1st Rd, Kaohsiung 807, Taiwan; [Tsai, Ming-Ju; Sheu, Chau-Chyun] Kaohsiung Med Univ, Coll Med, Sch Med, Dept Internal Med, 100,Shih Chuan 1st Rd, Kaohsiung 807, Taiwan; [Tsai, Ming-Ju; Sheu, Chau-Chyun] Kaohsiung Med Univ, Coll Med, Sch Med, Dept Resp Therapy, 100,Shih Chuan 1st Rd, Kaohsiung 807, Taiwan; [Chang, Kuo-Feng] Welgene Biotech Inc, Taipei, Taiwan	Sheu, CC (reprint author), Kaohsiung Med Univ Hosp, Div Pulm & Crit Care Med, 100,Tz You 1st Rd, Kaohsiung 807, Taiwan.	SiegfriedTsai@gmail.com; 960215kmuh@gmail.com; chienfang1216@gmail.com; nickchang@welgene.com.tw; sheucc@gmail.com; kuopolin@seed.net.tw	Tsai, Ming-Ju/D-5566-2011	Sheu, Chau-Chyun/0000-0002-7979-3749; Chang, Wei An/0000-0002-0049-5758	National Science CouncilNational Science Council of Taiwan [NSC 102-2220-E-037-001]; Ministry of Science and TechnologyMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [MOST 104-2314-B-037-034-MY3, MOST 107-2320-B-037-011-MY3]; Kaohsiung Medical University Hospital [KMUHS10601, KMUH106-6R12, KMUH106-6T05]; Kaohsiung Medical University [KMU-DK 108003]	The authors gratefully acknowledge the support of research grants from National Science Council (NSC 102-2220-E-037-001), Ministry of Science and Technology (MOST 104-2314-B-037-034-MY3; MOST 107-2320-B-037-011-MY3), Kaohsiung Medical University Hospital (KMUHS10601; KMUH106-6R12; KMUH106-6T05), and Kaohsiung Medical University (KMU-DK 108003). The authors thank the Center for Research Resources and Development of Kaohsiung Medical University.	Bondi ML, 2014, J NANOBIOTECHNOL, V12, DOI 10.1186/s12951-014-0046-4; Chang WA, 2018, INT J CHRONIC OBSTR, V13, P2387, DOI 10.2147/COPD.S173206; Chen SC, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122657; Chien CM, 2010, EUR J PHARMACOL, V636, P52, DOI 10.1016/j.ejphar.2010.03.030; Comer DM, 2013, EUR RESPIR J, V41, P1058, DOI 10.1183/09031936.00063112; Cucak H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090685; Duan J, 2017, EXP THER MED, V13, P3203, DOI 10.3892/etm.2017.4430; El Agha E, 2018, AM J PHYSIOL-LUNG C, V315, pL248, DOI 10.1152/ajplung.00140.2018; Erdem ZN, 2017, TRANSL ONCOL, V10, P332, DOI 10.1016/j.tranon.2017.02.004; Erturk K, 2016, EUR REV MED PHARMACO, V20, P243; Ezzie ME, 2012, THORAX, V67, P122, DOI 10.1136/thoraxjnl-2011-200089; Galipon J, 2017, GENES-BASEL, V8, DOI 10.3390/genes8020068; Gogebakan B, 2014, MOL BIOL REP, V41, P5321, DOI 10.1007/s11033-014-3403-3; Guan YJ, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-016-3385-8; Harkness LM, 2014, PULM PHARMACOL THER, V29, P144, DOI 10.1016/j.pupt.2014.09.003; He Y, 2016, NEOPLASMA, V63, P523, DOI 10.4149/neo_2016_405; Higham A, 2018, INT J CHRONIC OBSTR, V13, P989, DOI 10.2147/COPD.S157728; Hogg JC, 2013, CHEST, V143, P1436, DOI 10.1378/chest.12-1766; Hou HH, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0106-1; Hua L, 2018, TECHNOL HEALTH CARE, V26, pS121, DOI 10.3233/THC-174257; Kelleher FC, 2013, CARCINOGENESIS, V34, P2198, DOI 10.1093/carcin/bgt254; Kesimer M, 2017, NEW ENGL J MED, V377, P911, DOI 10.1056/NEJMoa1701632; Kim V, 2011, CHEST, V140, P626, DOI 10.1378/chest.10-2948; Kode A, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-132; Kranenburg AR, 2005, J PATHOL, V206, P28, DOI 10.1002/path.1748; Lin C, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3081-3; Liu LM, 2018, ENVIRON TOXICOL, V33, P743, DOI 10.1002/tox.22561; Liu X, 2018, INT J CHRONIC OBSTR, V13, P1217, DOI 10.2147/COPD.S163459; Min T, 2011, J MOL MED, V89, P577, DOI 10.1007/s00109-011-0732-8; Molina-Pinelo S, 2014, EUR RESPIR J, V43, P1740, DOI 10.1183/09031936.00091513; Moodley YP, 2003, AM J RESP CELL MOL, V29, P490, DOI 10.1165/rcmb.2002-0262OC; Musri M. M., 2018, AM J RESP CELL MOL B, DOI [10.1165/rcmb.2017-00400C, DOI 10.1165/RCMB.2017-00400C]; Oh YS, 2011, DIABETES-METAB RES, V27, P813, DOI 10.1002/dmrr.1233; Osei ET, 2015, EUR RESPIR J, V46, P807, DOI 10.1183/13993003.02139-2014; Othumpangat S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030030; Othumpangat S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006444; Pace E, 2013, TOXICOL LETT, V223, P198, DOI 10.1016/j.toxlet.2013.09.013; Rossi A, 2017, INT J CHRONIC OBSTR, V12, P2593, DOI 10.2147/COPD.S132236; Salimian J, 2018, J RES MED SCI, V23, DOI 10.4103/jrms.JRMS_1054_17; Savale L, 2009, AM J RESP CRIT CARE, V179, P566, DOI 10.1164/rccm.200809-1398OC; Sheu CC, 2017, ONCOTARGET, V8, P82674, DOI 10.18632/oncotarget.19752; Smith SMG, 2005, PLATELETS, V16, P340, DOI 10.1080/00207230500120294; Starska K, 2018, CELL ONCOL, V41, P253, DOI 10.1007/s13402-017-0367-z; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Vejnar CE, 2012, NUCLEIC ACIDS RES, V40, P11673, DOI 10.1093/nar/gks901; Wang Y, 2018, J IMMUNOL, V200, P2571, DOI 10.4049/jimmunol.1701681; Xie ZX, 2018, J ENZYM INHIB MED CH, V33, P905, DOI 10.1080/14756366.2018.1460824; Xu Z., 2015, BIOMED RES INT, V2015; Zeng ZP, 2018, EXP LUNG RES, V44, P89, DOI 10.1080/01902148.2018.1439548; Zhang S, 2017, MOL MED REP, V15, P2595, DOI 10.3892/mmr.2017.6303; Zhang X., 2015, BIOMED RES INT, V2015	51	5	5	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	SEP	2018	214	9					1489	1496		10.1016/j.prp.2018.08.002			8	Pathology	Pathology	GV3DC	WOS:000445973500029	30115538				2019-10-28	
J	Zhu, YF; Dong, M				Zhu, Yu Feng; Dong, Ming			Expression of TUSC3 and its prognostic significance in colorectal cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Article						TUSC3; Colorectal cancer; Immunohistochemistry; Clinical significance; Prognosis	MESENCHYMAL TRANSITION; HYPOTHESIS; GSEA	Background: Colorectal cancer (CRC) is one of the most common cancers worldwide. Tumor suppressor candidate 3 (TUSC3) has been reported be associated with embryogenesis and metabolism. The aim of this study is to investigate the expression of TUSC3 in CRC tissues, and to evaluate the clinical pathological characters and prognostic significance. Method: First, we performed a bioinformatics analysis by using Oncomine and COEXPEDIA databases. Gene Set Enrichment Analysis (GSEA) was performed using TCGA data set. Then, the protein expression level of TUSC3 was detected by immunohistochemistry in 230 pairs of primary colorectal cancer and corresponding non-tumor tissues. Result: We investigated Oncomine databases and found that TUSC3 mRNA expression was significantly higher in CRC tissues compared with normal tissues. The immunohistochemistry results demonstrated that TUSC3 was overexpressed in the CRC tissues. Furthermore, TUSC3 overexpression was associated with T stage, lymph node metastasis, and distant metastasis. TUSC3 overexpression was associated with worse overall survival for CRC, and retained significance as an independent prognostic factor for CRC. Bioinformatics analysis indicated that TUSC3 expression was associated with epithelial-mesenchymal transition signaling pathway and TUSC3 co-expression genes were obtained from COEXPEDIA. Conclusion: TUSC3 may act as an oncogene in the progression of colorectal cancer. Moreover, TUSC3 has potential to be used as prognostic markers or therapeutic targets in CRC.	[Zhu, Yu Feng] China Med Univ, Shenyang, Liaoning, Peoples R China; [Dong, Ming] China Med Univ, Dept Gastrointestinal Surg, Affiliate Hosp 1, 92 Beima Rd,Postal Code 110001, Shenyang, Liaoning, Peoples R China	Dong, M (reprint author), China Med Univ, Dept Gastrointestinal Surg, Affiliate Hosp 1, 92 Beima Rd,Postal Code 110001, Shenyang, Liaoning, Peoples R China.	JinZhouzhuyufeng@163.com; dongming@cmu.edu.cn		Zhu, YuFeng/0000-0002-4211-8352	Liaoning Provincial Department of Education [2012(512)]	The study was supported by Special Fund for Special Professor of Liaoning Provincial Department of Education (Project Number 2012(512)) DuHongyu is the pathologist in First Affiliated Hospital of Jinzhou Medical University. SunCuicui is the pathologist in JinZhou central hospital. Thanks for their work in reading pathological sections.	Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036; Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9; Cao H, 2015, PATHOL RES PRACT, V211, P557, DOI 10.1016/j.prp.2015.05.010; Debrabant B, 2017, BIOINFORMATICS, V33, P1271, DOI 10.1093/bioinformatics/btw803; Gaspar C, 2008, AM J PATHOL, V172, P1363, DOI 10.2353/ajpath.2008.070851; Graudens E, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-3-r19; Kaiser S, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-7-r131; Khalid AM, 2013, BIOSCI BIOTECH BIOCH, V77, P2019, DOI 10.1271/bbb.130327; Kratochvilova K, 2015, INT J CANCER, V137, P1330, DOI 10.1002/ijc.29502; Li Y. G., 2016, TUMOR BIOL, V11, P1; Lin VC, 2017, ONCOTARGET, V8, P74119, DOI 10.18632/oncotarget.18271; Liu KC, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0632-9; Peng Y, 2017, ONCOTARGET, V8, P52960, DOI 10.18632/oncotarget.17674; Remotti Helen, 2013, Methods Mol Biol, V980, P13, DOI 10.1007/978-1-62703-287-2_2; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Sakai E., 2017, CANCER RES; Subramanian A, 2007, BIOINFORMATICS, V23, P3251, DOI 10.1093/bioinformatics/btm369; Taieb J., 2016, JNCI-J NATL CANCER I, V109, P270; Torre LA, 2016, CANCER EPIDEM BIOMAR, V25, P16, DOI 10.1158/1055-9965.EPI-15-0578; Usadel B, 2009, PLANT CELL ENVIRON, V32, P1633, DOI 10.1111/j.1365-3040.2009.02040.x; Vasickova K., 2017, CELL MOL LIFE SCI CM, V1, P1; Vasickova K., 2017, CELL MOL LIFE SCI CM; Whitlock EP, 2008, ANN INTERN MED, V149, P638, DOI 10.7326/0003-4819-149-9-200811040-00245; Yang S, 2017, NUCLEIC ACIDS RES, V45, pD389, DOI 10.1093/nar/gkw868; Yin DD, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0253-8; Zhou H, 2009, P NATL ACAD SCI USA, V106, P15750, DOI 10.1073/pnas.0908332106; Zou TT, 2002, ONCOGENE, V21, P4855, DOI 10.1038/sj.onc.1205613	27	4	4	1	3	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	SEP	2018	214	9					1497	1503		10.1016/j.prp.2018.07.004			7	Pathology	Pathology	GV3DC	WOS:000445973500030	30115537				2019-10-28	
J	Tsukamoto, Y; Futani, H; Kihara, T; Watanabe, T; Kumanishi, S; Matsuo, S; Hirota, S; Ueda, T; Yamamoto, H; Yoshiya, S				Tsukamoto, Yoshitane; Futani, Hiroyuki; Kihara, Takako; Watanabe, Takahiro; Kumanishi, Shunsuke; Matsuo, Shohei; Hirota, Seiichi; Ueda, Takafumi; Yamamoto, Hidetaka; Yoshiya, Shinichi			An extremely rare case of primary malignancy in giant cell tumor of bone, arising in the right femur and harboring H3F3A mutation	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Primary malignancy in giant cell tumor of bone; Undifferentiated round cell sarcoma; H3F3A mutation; Proximal femur	SOFT-TISSUE; H3F3A MUTATIONS; GENE FUSION; CHONDROBLASTOMA; COUNTERPART; DISTINCT; SARCOMA	We experienced a case of primary malignancy in giant cell tumor of bone (GCTB), arising in the right femur and harboring H3F3A mutation. A 27-year-old Japanese male without any prior disease history complained of pain in his right hip joint and right lower limb. Radiological images revealed an osteolytic and multicystic lesion existing mainly at the proximal epiphysis of the right femur. Preoperatiye clinical diagnosis was GCTB, although irregular marginal sclerosis was an atypical radiographic finding for conventional GCTBs. Biopsy sample from the lesion revealed the coexistence of typical GCTB and undifferentiated high-grade round cell sarcoma. Despite of the wide local resection of the tumor with preoperative and postoperative chemotherapy, the patient died of multiple distant metastases of the tumor 9 months after the surgery. Since heterozygous H3F3A c. 103G > T (p. Gly34Trp) mutation was detected not only in the biopsy sample from the primary site with typical GCTB and high-grade sarcoma components but also in the resected material from the metastatic site with only pure high-grade sarcoma component, the tumor was considered originally derived from conventional GCTB and acquire malignant transformation to high-grade sarcoma. Thus, this is an extremely rare case of primary malignancy in GCTB and the first case report of primary malignancy in GCTB proved the presence of H3F3A mutation even in the sarcoma component.	[Tsukamoto, Yoshitane; Kihara, Takako; Watanabe, Takahiro; Hirota, Seiichi] Hyogo Coll Med, Dept Surg Pathol, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan; [Futani, Hiroyuki; Kumanishi, Shunsuke; Yoshiya, Shinichi] Hyogo Coll Med, Dept Orthopaed Surg, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan; [Tsukamoto, Yoshitane; Matsuo, Shohei] Takarazuka City Hosp, Dept Pathol & Lab Med, 4-5-1 Kohama, Takarazuka, Hyogo 6650827, Japan; [Ueda, Takafumi] Osaka Natl Hosp, Dept Orthopaed Surg, Chuo Ku, 2-1-14 Hoenzaka, Osaka 5400006, Japan; [Yamamoto, Hidetaka] Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Higashi Ku, 3-1-1 Maidashi, Fukuoka, Fukuoka 8128582, Japan	Tsukamoto, Y (reprint author), Hyogo Coll Med, Dept Surg Pathol, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan.	tsuka-y@hyo-med.ac.jp		Matsuo, Shohei/0000-0002-2033-3908			Amary F, 2017, AM J SURG PATHOL, V41, P1059, DOI 10.1097/PAS.0000000000000859; Athanasou NA, 2013, WHO CLASSIFICATION T, P321; Behjati S, 2013, NAT GENET, V45, P1479, DOI 10.1038/ng.2814; Bertoni F, 2003, CANCER, V97, P2520, DOI 10.1002/cncr.11359; Branstetter DG, 2012, CLIN CANCER RES, V18, P4415, DOI 10.1158/1078-0432.CCR-12-0578; Cleven AHG, 2015, AM J SURG PATHOL, V39, P1576, DOI 10.1097/PAS.0000000000000512; Cupp JS, 2007, AM J SURG PATHOL, V31, P970, DOI 10.1097/PAS.0b013e31802b86f8; de saint Aubain Somerhausen N, 2013, WHO CLASSIFICATION T, P100; Folpe AL, 1999, MODERN PATHOL, V12, P894; Kaneko MK, 2014, CANCER SCI, V105, P744, DOI 10.1111/cas.12413; Lee JC, 2017, MODERN PATHOL, V30, P728, DOI 10.1038/modpathol.2016.236; Mancini I, 2017, HISTOPATHOLOGY, V71, P453, DOI 10.1111/his.13249; O'Connell JX, 2000, AM J SURG PATHOL, V24, P386, DOI 10.1097/00000478-200003000-00007; Ogura K, 2017, GENE CHROMOSOME CANC, V56, P711, DOI 10.1002/gcc.22469; Oliveira A. M., 2013, WHO CLASSIFICATION T, P106; Pierron G, 2012, NAT GENET, V44, P461, DOI 10.1038/ng.1107; Presneau N, 2015, J PATHOL CLIN RES, V1, P113, DOI 10.1002/cjp2.13; Righi A, 2017, HUM PATHOL, V68, P128, DOI 10.1016/j.humpath.2017.08.033; Tsukamoto Y., 2016, HUM PATHOL CASE REP, V6, P13; Tsukamoto Y, 2017, PATHOL RES PRACT, V213, P1315, DOI 10.1016/j.prp.2017.06.008; Wojcik J, 2016, AM J SURG PATHOL, V40, P72, DOI 10.1097/PAS.0000000000000506; Yamamoto H, 2018, HUM PATHOL, V73, P41, DOI 10.1016/j.humpath.2017.11.020	22	0	0	0	3	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	SEP	2018	214	9					1504	1509		10.1016/j.prp.2018.06.015			6	Pathology	Pathology	GV3DC	WOS:000445973500031	29970305				2019-10-28	
J	Fasciano, D; Wei, S; Li, R; Siegal, GP				Fasciano, Danielle; Wei, Shi; Li, Rong; Siegal, Gene P.			Chondroblastoma-like tumor of the skull in a patient with cardio-facio-cutaneous syndrome	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Cardio-facio-cutaneous syndrome; Chondroblastoma; Giant cell-rich lesion	GIANT-CELL LESIONS; MUTATIONS; BONE; NOONAN	Cardio-facio-cutaneous syndrome (CFCS) is a rare genetic disorder characterized by craniofacial deformities and heterogeneous cardiac and cutaneous manifestations. The condition is caused by de novo activating mutations in one of four genes encoding proteins involved in the RAS-MAPK signaling pathway; specifically BRAF, MEK1, MEK2, or KRAS. Variable malignancies have been reported in patients with CFCS. Herein we report a chondroblastoma-like lesion of the skull in a 20-year-old man with a clinical diagnosis of CFCS and a long-standing history of medically intractable epilepsy. Patients with CFCS have previously been noted to have poorly-defined giant cell lesions and this may be one such example.	[Fasciano, Danielle; Wei, Shi; Siegal, Gene P.] Univ Alabama Birmingham, Dept Pathol, NP 3545A,619 19th St South, Birmingham, AL 35249 USA; [Li, Rong] Childrens Hosp Alabama, Dept Pathol, Birmingham, AL 35233 USA	Wei, S (reprint author), Univ Alabama Birmingham, Dept Pathol, NP 3545A,619 19th St South, Birmingham, AL 35249 USA.	swei@uabmc.edu		Fasciano, Danielle/0000-0002-8843-9856			Armour CM, 2008, J MED GENET, V45, P249, DOI 10.1136/jmg.2007.054460; Cleven AHG, 2015, AM J SURG PATHOL, V39, P1576, DOI 10.1097/PAS.0000000000000512; Flanagan AM, 2014, HEAD NECK PATHOL, V8, P445, DOI 10.1007/s12105-014-0589-6; Kratz CP, 2015, BRIT J CANCER, V112, P1392, DOI 10.1038/bjc.2015.75; Neumann TE, 2009, EUR J HUM GENET, V17, P420, DOI 10.1038/ejhg.2008.188; Niihori T, 2006, NAT GENET, V38, P294, DOI 10.1038/ng1749; Pan ZG, 2012, HUM PATHOL, V43, P952, DOI 10.1016/j.humpath.2011.10.003; Park SW, 2017, HEAD NECK-J SCI SPEC, V39, P2171, DOI 10.1002/hed.24880; Rauen KA, 2013, ANNU REV GENOM HUM G, V14, P355, DOI 10.1146/annurev-genom-091212-153523; Reid Luke B, 2011, Skull Base Rep, V1, P71, DOI 10.1055/s-0031-1284217; Rodriguez-Viciana P, 2006, SCIENCE, V311, P1287, DOI 10.1126/science.1124642	11	0	0	0	0	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	SEP	2018	214	9					1510	1513		10.1016/j.prp.2018.08.003			4	Pathology	Pathology	GV3DC	WOS:000445973500032	30100356				2019-10-28	
J	Choi, EJ; Kim, MS; Yoo, NJ; Lee, SH				Choi, Eun Ji; Kim, Min Sung; Yoo, Nam Jin; Lee, Sug Hyung			Intratumoral heterogeneity for frameshift mutations of TP53BP1 and MFN1 genes in colorectal cancers	PATHOLOGY RESEARCH AND PRACTICE			English	Letter							APOPTOSIS; 53BP1		[Choi, Eun Ji; Kim, Min Sung; Yoo, Nam Jin; Lee, Sug Hyung] Catholic Univ Korea, Coll Med, Dept Pathol, 505 Banpo Dong, Seoul 137701, South Korea	Lee, SH (reprint author), Catholic Univ Korea, Coll Med, Dept Pathol, 505 Banpo Dong, Seoul 137701, South Korea.	suhulee@catholic.ac.kr			National Research Foundation of KoreaNational Research Foundation of Korea [2012R1A5A2047939]	This work was supported by a grant from National Research Foundation of Korea (2012R1A5A2047939).	Bi JP, 2015, INT J CLIN EXP PATHO, V8, P6070; Cuella-Martin R, 2016, MOL CELL, V64, P51, DOI 10.1016/j.molcel.2016.08.002; Huang QC, 2016, AUTOPHAGY, V12, P999, DOI 10.1080/15548627.2016.1166318; Imai K, 2008, CARCINOGENESIS, V29, P673, DOI 10.1093/carcin/bgm228; Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261; Oh HR, 2015, PATHOL ONCOL RES, V21, P713, DOI 10.1007/s12253-014-9878-3; Panier S, 2014, NAT REV MOL CELL BIO, V15, P7, DOI 10.1038/nrm3719; Pyakurel A, 2015, MOL CELL, V58, P244, DOI 10.1016/j.molcel.2015.02.021	8	0	0	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	SEP	2018	214	9					1514	1515		10.1016/j.prp.2018.07.024			2	Pathology	Pathology	GV3DC	WOS:000445973500033	30082159				2019-10-28	
J	Sasaki, K; Sugai, T; Ishida, K; Osakabe, M; Amano, H; Kimura, H; Sakuraba, M; Kashiwa, K; Kobayashi, S				Sasaki, Kousuke; Sugai, Tamotsu; Ishida, Kazuyuki; Osakabe, Mitsumasa; Amano, Hiroo; Kimura, Hiroaki; Sakuraba, Minoru; Kashiwa, Katsuhiko; Kobayashi, Seiichiro			Analysis of cancer-associated fibroblasts and the epithelial-mesenchymal transition in cutaneous basal cell carcinoma, squamous cell carcinoma, and malignant melanoma	HUMAN PATHOLOGY			English	Article						Cancer-associated fibroblast (CAF); CAF phenotype; Cutaneous cancer; Epithelial-mesenchymal transition; Immunohistochemistry	TUMOR MICROENVIRONMENT; HEAD; METASTASIS; NECK; SIGNATURE; SURVIVAL; GROWTH; SYSTEM; ROLES	Activated cancer-associated fibroblasts (CAFs) and fibroblasts that have undergone the epithelial-mesenchymal transition (EMT) in cancer stroma contribute to tumor progression and metastasis. However, no reports have investigated the CAF phenotype and its clinicopathological relevance in cutaneous malignant tumors, including basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and malignant melanoma (MM). Here, we investigated the CAF phenotype in cutaneous malignant tumors based on their histology and immunohistochemical expression of CAF-related markers, including adipocyte enhancer-binding protein 1 (AEBP1), podoplanin, platelet-derived growth factor receptor alpha (PDGFR alpha), PDGFR beta, fibroblast activating protein (FAP), CD10, S100A4, alpha-smooth muscle actin (alpha-SMA), and EMT-related markers (Zebl, Slug, and Twist). In addition, we assessed the role of the CAF phenotype in cutaneous malignant cancers using hierarchical cluster analysis. Consequently, 3 subgroups were stratified based on the expression pattern of CAF and EMT-related markers. Subgroup 1 was characterized by low expression of AEBP1, PDGFR alpha, PDGFR beta, FAP and Slug, whereas subgroup 2 was closely associated with high expression of PDGFR beta, S100A4 and Twist. In addition, high expression levels of podoplanin, PDGFR beta, CD10, S100A4, alpha-SMA, Zebl , Slug and Twist were observed in subgroup 3. High expression of CD10 was commonly found in all 3 subgroups. These subgroups were correlated with histologic subtypes, that is, subgroup 1, MM; subgroup 2, BCC; and subgroup 3, SCC. We suggest that the expression pattern of CAF- and EMT-related proteins plays crucial roles in the progression of BCC, SCC, and MM. (C) 2018 The Authors. Published by Elsevier Inc.	[Sasaki, Kousuke; Sugai, Tamotsu; Ishida, Kazuyuki; Osakabe, Mitsumasa] Iwate Med Univ, Sch Med, Dept Mol Diagnost Pathol, Morioka, Iwate 0208505, Japan; [Sasaki, Kousuke; Kimura, Hiroaki; Sakuraba, Minoru; Kashiwa, Katsuhiko; Kobayashi, Seiichiro] Iwate Med Univ, Sch Med, Dept Plast Surg, Morioka, Iwate 0208505, Japan; [Amano, Hiroo] Iwate Med Univ, Sch Med, Dept Dermatol, Morioka, Iwate 0208505, Japan	Sugai, T (reprint author), Iwate Med Univ, Dept Mol Diagnost Pathol, Morioka, Iwate 0208505, Japan.	tsugai@iwate-med.ac.jp					Augsten M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00062; Boswell J Scott, 2006, Dermatol Online J, V12, P9; Bussard KM, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0740-2; Cheon DJ, 2014, CLIN CANCER RES, V20, P711, DOI 10.1158/1078-0432.CCR-13-1256; El Khoury J, 2014, ARCH DERMATOL RES, V306, P359, DOI 10.1007/s00403-014-1456-8; Feller L, 2016, HEAD FACE MED, V12, DOI 10.1186/s13005-016-0106-0; Groessl M, 2014, J PROTEOME RES, V13, P4773, DOI 10.1021/pr500727h; Ha SY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099955; Hutchin ME, 2005, GENE DEV, V19, P214, DOI 10.1101/gad.1258705; Inamdar GS, 2010, BIOCHEM PHARMACOL, V80, P624, DOI 10.1016/j.bcp.2010.04.029; Karlsson MC, 2017, MOL ONCOL, V11, P781, DOI 10.1002/1878-0261.12092; Kartha VK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154645; Kim HS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174565; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lee SY, 2017, MOL CANCER, V16, DOI 10.1186/s12943-016-0577-4; Li HC, 2007, J CELL BIOCHEM, V101, P805, DOI 10.1002/jcb.21159; Li YY, 2015, CLIN CANCER RES, V21, P1447, DOI 10.1158/1078-0432.CCR-14-1773; Moore BA, 2005, LARYNGOSCOPE, V115, P1561, DOI 10.1097/01.mlg.0000173202.56739.9f; Omland SH, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3663-0; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Rangwala S, 2011, BRIT J DERMATOL, V165, P953, DOI 10.1111/j.1365-2133.2011.10507.x; Rasanen K, 2013, MOL CELL PROTEOMICS, V12, P3778, DOI 10.1074/mcp.M113.029587; Serrano-Gomez SJ, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0502-x; Shiga K, 2015, CANCERS, V7, P2443, DOI 10.3390/cancers7040902; Sugai T, 2017, GASTRIC CANCER, V20, P286, DOI 10.1007/s10120-016-0616-2; Ugorski M, 2016, AM J CANCER RES, V6, P370; Watts TL, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1091-6; Wojciechowska-Zdrojowy M, 2016, ANTICANCER RES, V36, P1591; Xing F, 2010, FRONT BIOSCI-LANDMRK, V15, P166, DOI 10.2741/3613; Yada K, 2004, AM J DERMATOPATH, V26, P463, DOI 10.1097/00000372-200412000-00004; Yamada N, 2017, HUM PATHOL, V60, P151, DOI 10.1016/j.humpath.2016.10.007; Yang XG, 2016, CANCER RES, V76, P4124, DOI 10.1158/0008-5472.CAN-15-2973; Zbytek Blazej, 2008, Expert Rev Dermatol, V3, P569, DOI 10.1586/17469872.3.5.569; Zhou B, 2014, J ORAL PATHOL MED, V43, P585, DOI 10.1111/jop.12172	34	4	4	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	SEP	2018	79						1	8		10.1016/j.humpath.2018.03.006			8	Pathology	Pathology	GU3HT	WOS:000445167900001	29555579	Other Gold			2019-10-28	
J	Luo, JD; Feng, J; Wen, QY; Qoyawayma, C; Wang, WY; Chen, LJ; Lu, JM; Zhan, YT; Xu, L; Zang, HJ; Fan, SQ; Chu, SZ				Luo, Jiadi; Feng, Juan; Wen, Qiuyuan; Qoyawayma, Christopher; Wang, Weiyuan; Chen, Lingjiao; Lu, Junmi; Zhan, Yuting; Xu, Lina; Zang, Hongjing; Fan, Songqing; Chu, Shuzhou			Elevated expression of IRS-1 associates with phosphorylated Akt expression and predicts poor prognosis of breast invasive ductal carcinoma	HUMAN PATHOLOGY			English	Article						Breast invasive ductal carcinoma (BIDC); Insulin receptor substrate 1 (IRS-1); p-Akt; Prognosis; Biomarker	INSULIN-RECEPTOR SUBSTRATE-1; TISSUE MICROARRAY ANALYSIS; NASOPHARYNGEAL CARCINOMA; PI3K/AKT/MTOR PATHWAY; CANCER; PROTEIN; TRANSCRIPTION; METASTASIS; ACTIVATION; THERAPY	Overexpression of insulin receptor substrate 1 (IRS-1) has been reported to promote cell growth, atypical hyperplasia, and carcinogenesis, and phosphorylated Akt (p-Akt) is certified to be involved in many types of cancers such as breast invasive ductal carcinoma (BIDC). However, the relationship between IRS-1 and Akt, as well as the role of expression of IRS-1 in BIDC, has never been reported. The purpose of this research is to investigate the association between expression of IRS-1 and p-Akt proteins and clinicopathological features of BIDC by immunohistochemistry, as well as the survival status. The results showed that the percentage of either elevated expression of IRS-1 or positive p-Akt expression in BIDC was significantly higher than that in control breast tissue from noncancer patients (P < .001 and P = .001, respectively). Overexpression of IRS-1 was evidently associated with positive expression of p-Akt = 0.337, P < .001). Also, positive percentage of p-Akt expression was statistically different among different molecular subtypes of BIDC (highest in luminal B BIDC, P = .009). Furthermore, significantly worse overall survival was found in BIDC patients with high expression of IRS-1 and p-Akt than in patients with low expression (P = .006 and P = .004, respectively). The multivariate Cox proportional hazard regression analysis showed that high expression of IRS-1 and positive expression of p-Akt protein were independent poor prognostic factors for patients with BIDC (P = .022 and P = .046, respectively). In conclusion, we report for the first time that overexpression of IRS-1 protein is associated with expression of p-Akt, and overexpression of 1RS-1 and positive expression of p-Akt might be independent biomarkers for poor prognosis in BIDC. (C) 2018 Elsevier Inc. All rights reserved.	[Luo, Jiadi; Feng, Juan; Wen, Qiuyuan; Wang, Weiyuan; Chen, Lingjiao; Lu, Junmi; Zhan, Yuting; Xu, Lina; Zang, Hongjing; Fan, Songqing; Chu, Shuzhou] Cent S Univ, Xiangya Hosp 2, Dept Pathol, Changsha 410011, Hunan, Peoples R China; [Qoyawayma, Christopher] Univ Pittsburgh, UPMC, Childrens Hosp Pittsburgh, Div Pediat, Pittsburgh, PA 15224 USA	Fan, SQ; Chu, SZ (reprint author), Cent S Univ, Xiangya Hosp 2, Dept Pathol, Changsha 410011, Hunan, Peoples R China.	songqingfan@csu.edu.cn; shuzhouchu@csu.edu.cn			National Natural Sciences Foundations of ChinaNational Natural Science Foundation of China [81472773, 81773218, 81272566]	This work was supported by grants from the National Natural Sciences Foundations of China (Nos. 81472773, 81773218, and 81272566).	Aleskandarany MA, 2011, BREAST CANCER RES TR, V127, P407, DOI 10.1007/s10549-010-1012-y; Andre F, 2008, ANN ONCOL, V19, P315, DOI 10.1093/annonc/mdm429; Bartlett JMS, 2013, BREAST CANCER RES TR, V138, P773, DOI 10.1007/s10549-013-2489-y; Bommer GT, 2010, J BIOL CHEM, V285, P1928, DOI 10.1074/jbc.M109.060319; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Bruna A, 2016, CELL, V167, P260, DOI 10.1016/j.cell.2016.08.041; Chan SH, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-64; Chu SZ, 2017, HUM PATHOL, V61, P173, DOI 10.1016/j.humpath.2016.09.039; Cicenas J, 2005, BREAST CANCER RES, V7, pR394, DOI 10.1186/bcr1015; Dearth RK, 2007, CELL CYCLE, V6, P705, DOI 10.4161/cc.6.6.4035; Elloul S, 2014, MOL CANCER RES, V12, P464, DOI 10.1158/1541-7786.MCR-13-0398; Escarcega RO, 2007, CLIN ONCOL-UK, V19, P154, DOI 10.1016/j.clon.2006.11.013; Esposito DL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036190; Fan SQ, 2006, HUM PATHOL, V37, P593, DOI 10.1016/j.humpath.2006.01.010; Gao J, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-471; Hu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072104; Huang J, 2011, GENE CHROMOSOME CANC, V50, P606, DOI 10.1002/gcc.20883; [IARC International Agency for Research on Cancer], 2014, WHO REPORT; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Koda M, 2005, J CLIN PATHOL, V58, P645, DOI 10.1136/jcp.2004.022590; Leen S, 2014, PATHOLOG RES INT, V2014; Li YZ, 2013, OR SURG OR MED OR PA, V116, P591, DOI 10.1016/j.oooo.2013.06.031; Luo JD, 2014, INT J CLIN EXP PATHO, V7, P6117; Marcotte R, 2016, CELL, V164, P293, DOI 10.1016/j.cell.2015.11.062; Mardilovich K, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-14; Porter HA, 2013, CANCER LETT, V338, P239, DOI 10.1016/j.canlet.2013.03.030; Shaw PE, 2001, HEREDITY, V87, P609; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Tanaka S, 1996, CANCER RES, V56, P3391; Tapia O, 2014, VIRCHOWS ARCH, V465, P25, DOI 10.1007/s00428-014-1588-4; Toska E, 2017, SCIENCE, V355, P1324, DOI 10.1126/science.aah6893; Xu ZZ, 2013, ANN HEMATOL, V92, P1351, DOI 10.1007/s00277-013-1770-9; Yang SX, 2016, CANCER TREAT REV, V45, P87, DOI 10.1016/j.ctrv.2016.03.004; Zhang Y, 2013, CANCER BIOMARK, V13, P299, DOI 10.3233/CBM-130352; Zheng HY, 2016, ONCOTARGET, V7, P4647, DOI 10.18632/oncotarget.6615	35	2	2	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	SEP	2018	79						9	17		10.1016/j.humpath.2018.03.003			9	Pathology	Pathology	GU3HT	WOS:000445167900002	29551677				2019-10-28	
J	Rezk, SA; Zhao, XH; Weiss, LM				Rezk, Sherif A.; Zhao, Xiaohui; Weiss, Lawrence M.			Epstein-Barr virus (EBV)-associated lymphoid proliferations, a 2018 update	HUMAN PATHOLOGY			English	Article						Epstein-Barr virus; B-cell lymphoproliferative disorders; T-cell lymphoproliferative disorders; Immunodeficiency-related lymphoproliferative disorders; Reactive lymphoid proliferations	NATURAL-KILLER-CELL; PRIMARY EFFUSION LYMPHOMA; PERIPHERAL T-CELL; REED-STERNBERG-CELLS; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS; SARCOMA-ASSOCIATED HERPESVIRUS; POSITIVE MUCOCUTANEOUS ULCER; IN-SITU HYBRIDIZATION; ACTIVE EBV INFECTION; MEMBRANE-PROTEIN 1	Epstein-Barr virus (EBV) has been linked to many human neoplasms including hematopoietic, epithelial, and mesenchymal tumors. Since our original review of EBV-associated lymphoproliferative disorders in 2007, many advances and developments have been reported. In this review, we will examine the recent advances in EBV-associated lymphoid/histiocytic proliferations, dividing them into reactive, B cell, T/NK cell, immunodeficiency-related, and histiocytic/dendritic cell proliferations. (C) 2018 Elsevier Inc. All rights reserved.	[Rezk, Sherif A.; Zhao, Xiaohui; Weiss, Lawrence M.] UCI, Med Ctr, Dept Pathol & Lab Med, Orange, CA 92868 USA; [Weiss, Lawrence M.] NeoGen Labs, Aliso Viejo, CA 92656 USA	Rezk, SA (reprint author), Univ Calif Irvine, Dept Pathol & Lab Med, 101 City Dr, Orange, CA 92868 USA.	srezk@uci.edu					Abate F, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005158; Aguilar C, 2015, CARDIOVASC PATHOL, V24, P60, DOI 10.1016/j.carpath.2014.08.007; AGUILERA NS, 1995, MODERN PATHOL, V8, P503; Anastasiadou E, 2009, CANCER LETT, V284, P165, DOI 10.1016/j.canlet.2009.04.025; Aozasa K, 2006, J CLIN EXP HEMATOP, V46, P5, DOI 10.3960/jslrt.46.5; Asada H, 2005, J INVEST DERMATOL, V125, P956, DOI 10.1111/j.0022-202X.2005.23915.x; Asada H, 2003, ARCH DERMATOL, V139, P1601, DOI 10.1001/archderm.139.12.1601; Au WY, 2004, BLOOD, V104, P243, DOI 10.1182/blood-2003-12-4197; Baecklund E, 2014, SEMIN CANCER BIOL, V24, P61, DOI 10.1016/j.semcancer.2013.12.001; Banks PM, 2004, WHO CLASSIFICATION T, P137; Bartoloni Giovanni, 2013, Cardiovasc Pathol, V22, pe5, DOI 10.1016/j.carpath.2012.08.002; Bhavsar T, 2017, AM J SURG PATHOL, V41, P795, DOI 10.1097/PAS.0000000000000823; Boroumand N, 2012, AM J SURG PATHOL, V36, P1074, DOI 10.1097/PAS.0b013e3182515fb5; Boyer DF, 2017, AM J SURG PATHOL, V41, P299, DOI 10.1097/PAS.0000000000000775; Brauninger A, 2001, J EXP MED, V194, P927, DOI 10.1084/jem.194.7.927; Brink AATP, 1997, J CLIN PATHOL, V50, P911, DOI 10.1136/jcp.50.11.911; Caldwell RG, 1998, IMMUNITY, V9, P405, DOI 10.1016/S1074-7613(00)80623-8; Campo E, 2017, WHO CLASSIFICATION T, P321; Capello D, 2005, HEMATOL ONCOL, V23, P61, DOI 10.1002/hon.751; Carbone A, 2005, BRIT J HAEMATOL, V130, P662, DOI 10.1111/j.1365-2141.2005.05613.x; Carbone A, 2003, LANCET ONCOL, V4, P22, DOI 10.1016/S1470-2045(03)00957-4; Carbone A, 2008, ONCOLOGIST, V13, P577, DOI 10.1634/theoncologist.2008-0036; Carbone A, 2009, BLOOD, V113, P1213, DOI 10.1182/blood-2008-09-180315; Castillo JJ, 2015, BLOOD, V125, P2323, DOI 10.1182/blood-2014-10-567479; Chan J K, 1998, Anat Pathol, V3, P77; Chan JK, 2017, WHO CLASSIFICATION T, P353; Chan JK, 2008, WHO CLASSIFICATION T, P245; Chan JKC, 2017, WHO CLASSIFICATION T, P368; Chan JKC, 2017, WHO CLASSIFICATION T, P309; Chang JL, 2017, INT SYM COMPUT INTEL, P476, DOI 10.1109/ISCID.2017.147; Chang KC, 2017, HISTOPATHOLOGY, V70, P442, DOI 10.1111/his.13085; Chang ST, 2007, AM J CLIN PATHOL, V128, P339, DOI 10.1309/27H8XJH31F3GUNAT; Chene A, 2009, SEMIN CANCER BIOL, V19, P411, DOI 10.1016/j.semcancer.2009.10.002; Cheuk W, 2005, AM J SURG PATHOL, V29, P832, DOI 10.1097/01.pas.0000157747.10967.f4; Cheuk W, 2001, AM J SURG PATHOL, V25, P721, DOI 10.1097/00000478-200106000-00003; Cheung MMC, 2003, SEMIN HEMATOL, V40, P221, DOI 10.1016/S0037-1963(03)00136-7; Cobo F, 1999, J PATHOL, V189, P288, DOI 10.1002/(SICI)1096-9896(199910)189:2<288::AID-PATH419>3.0.CO;2-F; Cohen JI, 2009, ANN ONCOL, V20, P1472, DOI 10.1093/annonc/mdp064; Cohen JI, 2011, BLOOD, V117, P5835, DOI 10.1182/blood-2010-11-316745; CopieBergman C, 1997, J PATHOL, V183, P287, DOI 10.1002/(SICI)1096-9896(199711)183:3<287::AID-PATH932>3.0.CO;2-Q; Mackey AC, 2007, J PEDIATR GASTR NUTR, V44, P265, DOI 10.1097/MPG.0b013e31802f6424; Crane GM, 2014, AM J SURG PATHOL, V38, P426, DOI 10.1097/PAS.0000000000000128; Deepak P, 2013, AM J GASTROENTEROL, V108, P99, DOI 10.1038/ajg.2012.334; Diepstra A, 2009, J CLIN ONCOL, V27, P3815, DOI 10.1200/JCO.2008.20.5138; Dittmer DP, 2014, BLOOD, V123, P460, DOI 10.1182/blood-2013-11-537076; Dogan A, 2017, WHO CLASSIFICATION T, P407; Dojcinov SD, 2011, BLOOD, V117, P4726, DOI 10.1182/blood-2010-12-323238; Dojcinov SD, 2010, AM J SURG PATHOL, V34, P405, DOI 10.1097/PAS.0b013e3181cf8622; Dong HY, 2005, AM J SURG PATHOL, V29, P1633, DOI 10.1097/01.pas.0000173023.02724.1f; Du MQ, 2002, BLOOD, V100, P3415, DOI 10.1182/blood-2002-02-0487; Dunmire SK, 2015, CURR TOP MICROBIOL, V390, P211, DOI 10.1007/978-3-319-22822-8_9; Dupuis J, 2006, BLOOD, V108, P4163, DOI 10.1182/blood-2006-04-017632; Elenitoba-Johnson KS, 2017, WHO CLASSIFICATION T, P444; Engels EA, 2013, AM J TRANSPLANT, V13, P1523, DOI 10.1111/ajt.12234; EPSTEIN MA, 1964, LANCET, V1, P702; Fan W, 2005, J VIROL, V79, P1244, DOI 10.1128/JVI.79.2.1244-1251.2005; Ferry JA, 2009, MODERN PATHOL, V22, P618, DOI 10.1038/modpathol.2009.36; Flavell KJ, 2000, J CLIN PATHOL-MOL PA, V53, P262, DOI 10.1136/mp.53.5.262; Gao JH, 2017, MODERN PATHOL, V30, P1100, DOI 10.1038/modpathol.2017.37; Gaulard P, 2017, WHO CLASSIFICATION T, P462; Gaulard P, 2017, WHO CLASSIFICATION T, P307; Ge R, 2014, INT J CLIN EXP PATHO, V7, P2421; Gibson SE, 2011, AM J SURG PATHOL, V35, P807, DOI 10.1097/PAS.0b013e3182190999; Gilmour KC, 2003, EXPERT REV MOL DIAGN, V3, P549, DOI 10.1586/14737159.3.5.549; Goedert JJ, 2000, SEMIN ONCOL, V27, P390; Gonzalez-Farre B, 2017, MODERN PATHOL, V30, P745, DOI 10.1038/modpathol.2016.233; Gonzalez-Farre B, 2014, MODERN PATHOL, V27, P1599, DOI 10.1038/modpathol.2014.68; Gottschalk S, 2005, ANNU REV MED, V56, P29, DOI 10.1146/annurev.med.56.082103.104727; Gratzinger D, 2017, AM J CLIN PATHOL, V147, P188, DOI 10.1093/ajcp/aqw213; Gru AA, 2015, CURR HEMATOL MALIG R, V10, P456, DOI 10.1007/s11899-015-0292-z; Gruver AM, 2012, AM J SURG PATHOL, V36, P1527, DOI 10.1097/PAS.0b013e31825d53b5; Grywalska E, 2015, SEMIN ONCOL, V42, P291, DOI 10.1053/j.seminoncol.2014.12.030; Gulley ML, 2002, AM J CLIN PATHOL, V117, P259; Gupta G, 2000, J AM ACAD DERMATOL, V42, P208, DOI 10.1016/S0190-9622(00)90127-0; Hart M, 2014, AM J SURG PATHOL, V38, P1522, DOI 10.1097/PAS.0000000000000282; Hasserjian RP, 2007, AM J CLIN PATHOL, V127, P860, DOI 10.1309/2F39NX1AL3L54WU8; Hawley RC, 2006, ARCH PATHOL LAB MED, V130, P1707; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HENLE G, 1968, P NATL ACAD SCI USA, V59, P94, DOI 10.1073/pnas.59.1.94; Henter JI, 2007, PEDIATR BLOOD CANCER, V48, P124, DOI 10.1002/pbc.21039; HO FCS, 1990, HEMATOL ONCOL, V8, P271, DOI 10.1002/hon.2900080505; Hochberg D, 2004, P NATL ACAD SCI USA, V101, P239, DOI 10.1073/pnas.2237267100; Hoshida Y, 2007, J RHEUMATOL, V34, P322; Hsi ED, 2017, INT J LAB HEMATOL, V39, P14, DOI 10.1111/ijlh.12650; Huang YL, 2009, AM J SURG PATHOL, V33, P682, DOI 10.1097/PAS.0b013e3181971591; Hudnall SD, 2005, MODERN PATHOL, V18, P519, DOI 10.1038/modpathol.3800369; Huppmann AR, 2014, AM J SURG PATHOL, V38, P316, DOI 10.1097/PAS.0000000000000107; IUCHI K, 1987, CANCER, V60, P1771, DOI 10.1002/1097-0142(19871015)60:8<1771::AID-CNCR2820600817>3.0.CO;2-2; Iwata S, 2010, J GEN VIROL, V91, P42, DOI 10.1099/vir.0.013482-0; Iwatsuki K, 2006, ARCH DERMATOL, V142, P587, DOI 10.1001/archderm.142.5.587; Iwatsuki K, 1999, BRIT J DERMATOL, V140, P715; Jaffe ES, 2017, WHO CLASSIFICATION T, P342; JONES JF, 1988, NEW ENGL J MED, V318, P733, DOI 10.1056/NEJM198803243181203; Kang MS, 2015, EXP MOL MED E, V131, P47; Kanno Hiroyuki, 1997, Leukemia (Basingstoke), V11, P525; Kanzler H, 1996, J EXP MED, V184, P1495, DOI 10.1084/jem.184.4.1495; Katzenstein ALA, 2010, AM J SURG PATHOL, V34, pE35, DOI 10.1097/PAS.0b013e3181fd8781; Kelly GL, 2006, P NATL ACAD SCI USA, V103, P14935, DOI 10.1073/pnas.0509988103; Khoddami M, 2015, JUNDISHAPUR J MICROB, V8, DOI 10.5812/jjm.27219; Kilger E, 1998, EMBO J, V17, P1700, DOI 10.1093/emboj/17.6.1700; Kim SH, 2000, BLOOD, V95, P294; Kimura H, 2001, BLOOD, V98, P280, DOI 10.1182/blood.V98.2.280; Kimura H, 2005, J INFECT DIS, V191, P531, DOI 10.1086/427239; Kitagawa N, 2000, EMBO J, V19, P6742, DOI 10.1093/emboj/19.24.6742; Ko Y-H, 2017, WHO CLASSIFICATION T, P355; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; Krause J, 2005, MICROSC RES TECHNIQ, V68, P168, DOI 10.1002/jemt.20230; Kuppers R, 2003, ANN NY ACAD SCI, V987, P173; Kuppers R, 2003, NAT REV IMMUNOL, V3, P801, DOI 10.1038/nri1201; Kuppers R, 2002, ANN ONCOL, V13, P11, DOI 10.1093/annonc/mdf601; Laichalk LL, 2005, J VIROL, V79, P1296, DOI 10.1128/JVI.79.2.1296-1307.2005; Lee YM, 2017, J PATHOL TRANSL MED, V51, P99, DOI 10.4132/jptm.2016.09.30; Leoncini L, 2017, WHO CLASSIFICATION T, P262; Leoncini L, 2017, WHO CLASSIFICATION T, P334; LEVINE PH, 1971, CANCER-AM CANCER SOC, V27, P416, DOI 10.1002/1097-0142(197102)27:2<416::AID-CNCR2820270227>3.0.CO;2-W; LIEBOW AA, 1972, HUM PATHOL, V3, P457, DOI 10.1016/S0046-8177(72)80005-4; Liebowitz D, 1998, NEW ENGL J MED, V338, P1413, DOI 10.1056/NEJM199805143382003; Lima M, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-95; Linke-Serinsoz E, 2017, SEMIN DIAGN PATHOL, V34, P352, DOI 10.1053/j.semdp.2017.04.003; LIPFORD EH, 1988, BLOOD, V72, P1674; Love C, 2012, NAT GENET, V44, P1321, DOI 10.1038/ng.2468; Luppi M, 2000, BLOOD, V96, P3279; Mack AA, 2008, CANCER RES, V68, P6963, DOI 10.1158/0008-5472.CAN-08-0627; Martinez D, 2013, AM J SURG PATHOL, V37, P272, DOI 10.1097/PAS.0b013e31826cb1d1; Matthews GV, 2000, BLOOD, V96, P2730; McGinness JL, 2012, J CUTAN PATHOL, V39, P377, DOI 10.1111/j.1600-0560.2011.01829.x; McKenna RW, 2017, WHO CLASSIFICATION T, P241; Miller DV, 2010, AM J SURG PATHOL, V34, P377, DOI 10.1097/PAS.0b013e3181ce9128; Mitarnun W, 2002, AM J HEMATOL, V70, P31, DOI 10.1002/ajh.10094; Mori A, 2003, LEUKEMIA RES, V27, P493, DOI 10.1016/S0145-2126(02)00266-7; Morscio Julie, 2016, World J Transplant, V6, P505, DOI 10.5500/wjt.v6.i3.505; Nakamura S, 2017, WHO CLASSIFICATION T, P304; Nakamura SJE, 2008, WHO CLASSIFICATION T; Nakanishi R, 2014, INT J CLIN EXP PATHO, V7, P1748; Nakashima Y, 2005, GENE CHROMOSOME CANC, V44, P247, DOI 10.1002/gcc.20245; Natkunam Y, 2017, AM J CLIN PATHOL, V147, P129, DOI 10.1093/ajcp/aqw214; Nava VE, 2005, ADV ANAT PATHOL, V12, P27, DOI 10.1097/01.pap.0000151318.34752.80; Navari M, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00728; Nelson BP, 2012, AM J CLIN PATHOL, V138, P568, DOI 10.1309/AJCPQYYE04AVGVYI; Nicolae A, 2015, BLOOD, V126, P863, DOI 10.1182/blood-2015-02-630632; NIEDOBITEK G, 1992, BLOOD, V79, P2520; Noguchi T, 2001, BRIT J HAEMATOL, V114, P84, DOI 10.1046/j.1365-2141.2001.02887.x; Ohshima K, 2008, PATHOL INT, V58, P209, DOI 10.1111/j.1440-1827.2008.02213.x; Ouedraogo DE, 2013, BLOOD, V122, P3030, DOI 10.1182/blood-2012-12-470393; Oyama T, 2003, AM J SURG PATHOL, V27, P16, DOI 10.1097/00000478-200301000-00003; Pan Shien-Tung, 2014, Korean J Pathol, V48, P140, DOI 10.4132/KoreanJPathol.2014.48.2.140; Petterson TE, 2008, PEDIATR BLOOD CANCER, V50, P654, DOI 10.1002/pbc.21358; Pileri SA, 2017, WHO CLASSIFICATION T, P403; Pittaluga S, 2017, WHO CLASSIFICATION T, P312; Pittaluga S, 2013, SEMIN DIAGN PATHOL, V30, P130, DOI 10.1053/j.semdp.2012.08.009; Quintanilla-Martinez L, 2000, BLOOD, V96, P443; Quintanilla-Martinez L, 2008, WHO CLASSIFICATION T, P278; Rezk S, 2017, HEMATOPATHOLOGY, P957; Rezk SA, 2007, HUM PATHOL, V38, P1293, DOI 10.1016/j.humpath.2007.05.020; Rezk SA, 2013, HUM PATHOL, V44, P937, DOI 10.1016/j.humpath.2012.10.005; Rezk SA, 2011, INT J CLIN EXP PATHO, V4, P713; Rickinson A, 2002, VIRUS RES, V82, P109; ROCHFORD R, 1993, P NATL ACAD SCI USA, V90, P352, DOI 10.1073/pnas.90.1.352; ROTH J, 1994, LEUKEMIA LYMPHOMA, V13, P137, DOI 10.3109/10428199409051664; Roughan JE, 2009, J VIROL, V83, P3968, DOI 10.1128/JVI.02609-08; Sadasivam Nandini, 2014, Br J Haematol, V165, P584, DOI 10.1111/bjh.12743; Said J, 2017, WHO CLASSIFICATION T, P449; Said J, 2017, WHO CLASSIFICATION T, P323; Said J, 2015, BLOOD, V126, P827, DOI 10.1182/blood-2015-06-648097; Salaverria I, 2014, BLOOD, V123, P1187, DOI 10.1182/blood-2013-06-507996; Salloum E, 1996, J CLIN ONCOL, V14, P1943, DOI 10.1200/JCO.1996.14.6.1943; Scarberry K, 2014, UROL ANNALS, V6, P242, DOI 10.4103/0974-7796.134286; Schmitz R, 2012, NATURE, V490, P116, DOI 10.1038/nature11378; Shannon-Lowe C, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0271; Shimoyama Y, 2006, J CLIN EXP HEMATOP, V46, P1, DOI 10.3960/jslrt.46.1; Song JY, 2015, AM J SURG PATHOL, V39, P141, DOI 10.1097/PAS.0000000000000328; Song JY, 2013, BLOOD, V122, P3712, DOI 10.1182/blood-2013-07-515882; Stein H, 2017, WHO CLASSIFICATION T, P424; Streubel B, 2006, LEUKEMIA, V20, P313, DOI 10.1038/sj.leu.2404045; Sugita Y, 2016, NEUROPATHOLOGY, V36, P313, DOI 10.1111/neup.12276; Sun L, 2015, ONCOL REP, V34, P3264, DOI 10.3892/or.2015.4305; Suzuki K, 2004, INT J ONCOL, V24, P1165; Swerdlow SH, 2017, WHO CLASSIFICATION T, P453; Szekely L, 1998, J GEN VIROL, V79, P1445, DOI 10.1099/0022-1317-79-6-1445; Takada H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174136; Takahara M, 2006, INT J CANCER, V119, P2775, DOI 10.1002/ijc.22139; Taniere P, 1998, EUR RESPIR J, V12, P102, DOI 10.1183/09031936.98.12010102; Thompson MP, 2004, CLIN CANCER RES, V10, P803, DOI 10.1158/1078-0432.CCR-0670-3; Thorley-Lawson DA, 2001, NAT REV IMMUNOL, V1, P75, DOI 10.1038/35095584; Timms JM, 2003, LANCET, V361, P217, DOI 10.1016/S0140-6736(03)12271-4; Tomita Y, 1998, ONCOLOGY-BASEL, V55, P27, DOI 10.1159/000011831; Trempat P, 2002, J VIROL, V76, P11139, DOI 10.1128/JVI.76.21.11139-11142.2002; Trivedi P, 2004, BLOOD, V103, P313, DOI 10.1182/blood-2003-05-1710; UCCINI S, 1990, INT J CANCER, V46, P581, DOI 10.1002/ijc.2910460405; Valera A, 2010, AM J SURG PATHOL, V34, P1686, DOI 10.1097/PAS.0b013e3181f3e29f; van Krieken Joannes H, 2004, Am J Clin Pathol, V122 Suppl, pS122; Wang W, 2018, HISTOPATHOLOGY, V72, P855, DOI 10.1111/his.13428; Weisenburger DD, 2011, BLOOD, V117, P3402, DOI 10.1182/blood-2010-09-310342; Weiss L, 2008, LYMPH NODES, P39; WEISS LM, 1987, AM J PATHOL, V129, P86; WEISS LM, 1989, NEW ENGL J MED, V320, P502, DOI 10.1056/NEJM198902233200806; WEISS LM, 1986, AM J PATHOL, V122, P392; WEISS LM, 1992, BLOOD, V79, P1789; Wick MJ, 2002, AM J CLIN PATHOL, V117, P582, DOI 10.1309/B3WH-QWBY-YV61-CE46; Williams H, 2006, BLOOD, V107, P862, DOI 10.1182/blood-2005-07-2702; Wilson WH, 1996, BLOOD, V87, P4531, DOI 10.1182/blood.V87.11.4531.bloodjournal87114531; Wolfe F, 2007, ARTHRITIS RHEUM, V56, P1433, DOI 10.1002/art.22579; Wondergem MJ, 2008, BLOOD, V111, P1739, DOI 10.1182/blood-2007-09-111534; Wu W, 2013, AM J CLIN PATHOL, V140, P258, DOI 10.1309/AJCPHZ3CHO4HUWET; Xu DS, 2007, J VIROL, V81, P6068, DOI 10.1128/JVI.02743-06; Yamada K, 2015, HISTOPATHOLOGY, V67, P70, DOI 10.1111/his.12627; Yamakawa N, 2014, J RHEUMATOL, V41, P293, DOI 10.3899/jrheum.130270; Yan JQ, 2017, ANN DIAGN PATHOL, V27, P1, DOI 10.1016/j.anndiagpath.2016.09.002; Yang LX, 2004, CANCER RES, V64, P5332, DOI 10.1158/0008-5472.CAN-04-0733; Yoshii M, 2012, ONCOL LETT, V4, P381, DOI 10.3892/ol.2012.754; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452; Young LS, 2003, ONCOGENE, V22, P5108, DOI 10.1038/sj.onc.1206556; Zhang QG, 2014, INT J CLIN EXP PATHO, V7, P3423	213	5	5	2	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	SEP	2018	79						18	41		10.1016/j.humpath.2018.05.020			24	Pathology	Pathology	GU3HT	WOS:000445167900003	29885408				2019-10-28	
J	Pyo, JS; Park, MJ; Kim, CN				Pyo, Jung-Soo; Park, Mee Ja; Kim, Chang-Nam			TPL2 expression is correlated with distant metastasis and poor prognosis in colorectal cancer	HUMAN PATHOLOGY			English	Article						Colorectal cancer; TPL2; Immunoscore; Prognosis; Immunohistochemistry	ACTIVATE ERK; TUMOR-GROWTH; MAP KINASE; KAPPA-B; PROGRESSION; INFLAMMATION; TRANSCRIPTION; INDUCTION; TPL-2/COT; ONCOGENE	Tumor progression locus 2 (TPL2) is a mitogen-activated protein kinase (MAPK) kinase kinase (MAP3K). The present study aimed to elucidate the clinicopathological significance and prognostic role of TPL2 expression in colorectal cancer (CRC) through immunohistochemistry. In the present study, the correlations between TPL2 expression and clinicopathological parameters, including survival rate, were investigated using 262 archival paraffin-embedded CRC tissue samples. In addition, the correlation between TPL2 expression and tumor-infiltrating lymphocytes was evaluated using immunoscore. High TPL2 expression was found in 40.1% of the 262 CRCs analyzed. Patients with high TPL2 expression had frequent distant metastasis compared to patients with low TPL2 expression. However, there was no significant correlation between high TPL2 expression and other clinicopathological parameters. High TPL2 expression was significantly correlated with low immunoscore. In subgroup analysis based on distant metastasis, there was a significant correlation between high TPL2 expression and low immunoscore in only CRCs without distant metastasis. High TPL2 expression significantly correlated with poor overall survival. In both CRCs with and without distant metastasis, CRCs with high TPL2 expression showed worse prognosis compared to CRCs with low TPL2 expression (P = .034 and P = .010, respectively). Taken together, our results showed that high TPL2 expression was significantly correlated with distant metastasis and low immunoscore. In addition, TPL2 expression can be useful for predicting the prognosis of patients with CRC. (C) 2018 Elsevier Inc. All rights reserved.	[Pyo, Jung-Soo; Park, Mee Ja] Eulji Univ, Eulji Univ Hosp, Dept Pathol, Sch Med, Daejeon 35233, South Korea; [Kim, Chang-Nam] Eulji Univ, Eulji Univ Hosp, Dept Surg, Sch Med, Daejeon, South Korea	Park, MJ (reprint author), Eulji Univ, Dept Pathol, Sch Med, 95 Dunsanseo Ro, Daejeon 35233, South Korea.; Kim, CN (reprint author), Eulji Univ, Dept Surg, Sch Med, 95 Dunsanseo Ro, Daejeon 35233, South Korea.	pmj@eulji.ac.kr; kimcn@eulji.ac.kr	Kim, Chang-Nam/W-2424-2019				Amin MB, 2016, AJCC CANC STAGING MA; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Boldrini L, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935-017-0474-y; Ceci JD, 1997, GENE DEV, V11, P688, DOI 10.1101/gad.11.6.688; Das S, 2005, J BIOL CHEM, V280, P23748, DOI 10.1074/jbc.M412837200; DeCicco-Skinner KL, 2011, ONCOGENE, V30, P389, DOI 10.1038/onc.2010.447; DeCicco-Skinner KL, 2013, CARCINOGENESIS, V34, P2789, DOI 10.1093/carcin/bgt319; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Eliopoulos AG, 2003, EMBO J, V22, P3855, DOI 10.1093/emboj/cdg386; Erny KM, 1996, ONCOGENE, V13, P2015; Galon J, 2014, J PATHOL, V232, P199, DOI 10.1002/path.4287; Gantke T, 2011, CELL RES, V21, P131, DOI 10.1038/cr.2010.173; Gkirtzimanaki K, 2013, P NATL ACAD SCI USA, V110, pE1470, DOI 10.1073/pnas.1215938110; Hayes DN, 2012, CLIN CANCER RES, V18, P2056, DOI 10.1158/1078-0432.CCR-11-0563; Jeong JK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020400; Khanal P, 2009, CARCINOGENESIS, V30, P682, DOI 10.1093/carcin/bgp040; Kim G, 2013, CARCINOGENESIS, V34, P341, DOI 10.1093/carcin/bgs342; Krcova Z, 2008, BIOMED PAP, V152, P21, DOI 10.5507/bp.2008.003; Lee HW, 2015, INT J MOL SCI, V16, P4471, DOI 10.3390/ijms16034471; Lee HW, 2013, MOL CANCER RES, V11, P1375, DOI 10.1158/1541-7786.MCR-13-0101-T; Lee J, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000548; Lee JH, 2016, CANCER RES, V76, P6712, DOI 10.1158/0008-5472.CAN-15-3274; Lee WJ, 2013, NEOPLASIA, V15, P1036, DOI 10.1593/neo.121914; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Montero-Conde C, 2013, CANCER DISCOV, V3, P520, DOI 10.1158/2159-8290.CD-12-0531; Pan HC, 2013, CARCINOGENESIS, V34, P2568, DOI 10.1093/carcin/bgt243; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; Pyo JS, 2016, PATHOL ONCOL RES, V22, P831, DOI 10.1007/s12253-016-0077-2; Pyo JS, 2015, J CANCER RES CLIN, V141, P1181, DOI 10.1007/s00432-014-1890-1; REMMELE W, 1987, PATHOLOGE, V8, P138; Shen CT, 2014, ENDOCR-RELAT CANCER, V21, P253, DOI 10.1530/ERC-13-0438; Sourvinos G, 1999, ONCOGENE, V18, P4968, DOI 10.1038/sj.onc.1202891; Stafford MJ, 2006, FEBS LETT, V580, P4010, DOI 10.1016/j.febslet.2006.06.004; Vougioukalaki M, 2011, CANCER LETT, V304, P80, DOI 10.1016/j.canlet.2011.02.004; Whitmarsh AJ, 2007, BBA-MOL CELL RES, V1773, P1285, DOI 10.1016/j.bbamcr.2006.11.011; Yang SH, 2003, GENE, V320, P3, DOI 10.1016/S0378-1119(03)00816-3	36	3	3	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	SEP	2018	79						50	56		10.1016/j.humpath.2018.05.003			7	Pathology	Pathology	GU3HT	WOS:000445167900005	29763718				2019-10-28	
J	Wang, G; Xiao, L; Zhang, M; Kamat, AM; Siefker-Radtke, A; Dinney, CP; Czerniak, B; Guo, CC				Wang, Gang; Xiao, Li; Zhang, Miao; Kamat, Ashish M.; Siefker-Radtke, Arlene; Dinney, Colin P.; Czerniak, Bogdan; Guo, Charles C.			Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases	HUMAN PATHOLOGY			English	Article						Bladder cancer; Small cell carcinoma; Urothelial carcinoma; Neuroendocrine differentiation; Immunohistochemistry; Retinoblastoma gene	UROTHELIAL CARCINOMA; NEOADJUVANT CHEMOTHERAPY; CANCER; VARIANTS; EXPRESSION; IDENTIFICATION; SIGNATURE; CISPLATIN; SUBTYPES; OUTCOMES	Small cell carcinoma (SmCC) of the bladder is a rare disease. We retrospectively studied a large series of bladder SmCC from a single institution. The patients included 69 men and 12 women with a mean age of 68 years. Most bladder SmCCs were presented at advanced stage, with tumors invading the musculads propria and beyond (n = 77). SmCC was pure in 27 cases and mixed with other histologic types in 54 cases, including urothelial carcinoma (UC) (n = 32), UC in situ (n = 26), glandular (n = 14), micropapillary (n = 4), sarcomatoid (n = 4), squamous (n = 3), and plasmacytoid (n = 1) features. Most SmCCs expressed neuroendocrine markers synaptophysin (41/56), chromogranin (26/55), and CD56 (39/41); however, they did not express UC luminal markers CK20 (0/17), GATA3 (1/30), and uroplakin II (1/22). Some SmCCs showed focal expression of CK5/6 (9/25), a marker for the basal molecular subtype. Furthermore, expression of the retinoblastoma 1 (RB1) gene protein was lost in most of the bladder SmCCs (2/23). The patients' survival was significantly associated with cancer stage but did not show a significant difference between mixed and pure SmCCs. Compared with conventional UC at similar stages, SmCC had a worse prognosis only when patients developed metastatic diseases. In conclusion, bladder SmCC is an aggressive disease that is frequently present at an advanced stage. A fraction of SmCCs show a basal molecular subtype, which may underlie its good response to chemotherapy. Inactivation of the RB1 gene may be implicated in the oncogenesis of bladder SmCC. (C) 2018 Elsevier Inc. All rights reserved.	[Wang, Gang; Xiao, Li; Zhang, Miao; Czerniak, Bogdan; Guo, Charles C.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Unit 85,1515 Holcombe Blvd, Houston, TX 77030 USA; [Kamat, Ashish M.; Dinney, Colin P.] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA; [Siefker-Radtke, Arlene] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA	Guo, CC (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, Unit 85,1515 Holcombe Blvd, Houston, TX 77030 USA.	ccguo@mdanderson.org			National Institutes of Health/National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P50CA91846]	The project is supported in part by the National Institutes of Health/National Cancer Institute under award number P50CA91846 (Project 1 and Core C) to B.C.	Al-Ahmadie H, 2016, WHO CLASSIFICATION T, P117; Amin MB, 2009, MODERN PATHOL, V22, pS96, DOI 10.1038/modpathol.2009.26; Antoni S, 2017, EUR UROL, V71, P96, DOI 10.1016/j.eururo.2016.06.010; BLOMJOUS CEM, 1989, CANCER, V64, P1347, DOI 10.1002/1097-0142(19890915)64:6<1347::AID-CNCR2820640629>3.0.CO;2-Q; Bryant CM, 2016, AM J CLIN ONCOL-CANC, V39, P69, DOI 10.1097/COC.0000000000000027; Camp RL, 2000, LAB INVEST, V80, P1943, DOI 10.1038/labinvest.3780204; Cheng L, 2005, AM J PATHOL, V166, P1533, DOI 10.1016/S0002-9440(10)62369-3; Cheng L, 2004, CANCER, V101, P957, DOI 10.1002/cncr.20456; Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009; CRAMER SF, 1981, CANCER-AM CANCER SOC, V47, P724, DOI 10.1002/1097-0142(19810215)47:4<724::AID-CNCR2820470417>3.0.CO;2-2; Dadhania V, 2016, EBIOMEDICINE, V12, P105, DOI 10.1016/j.ebiom.2016.08.036; DAVIS BH, 1983, ULTRASTRUCT PATHOL, V4, P197, DOI 10.3109/01913128309140790; Di Fiore R, 2013, J CELL PHYSIOL, V228, P1676, DOI 10.1002/jcp.24329; Edge SB, 2010, AJCC CANC STAGING MA, P497; Fujii T, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1846-0; George J, 2015, NATURE, V524, P47, DOI 10.1038/nature14664; Guo CC, 2011, HUM PATHOL, V42, P11, DOI 10.1016/j.humpath.2010.05.026; Kamat AM, 2016, LANCET, V388, P2796, DOI 10.1016/S0140-6736(16)30512-8; Liang Y, 2014, HUM PATHOL, V45, P1466, DOI 10.1016/j.humpath.2014.02.023; LOGOTHETIS CJ, 1992, J NATL CANCER I, V84, P1256, DOI 10.1093/jnci/84.16.1256; Lynch SP, 2013, EUR UROL, V64, P307, DOI 10.1016/j.eururo.2012.04.020; McConkey DJ, 2016, EUR UROL, V69, P855, DOI 10.1016/j.eururo.2015.08.034; MIYAMOTO H, 1995, BRIT J CANCER, V71, P831, DOI 10.1038/bjc.1995.160; Moch H, 2016, WHO CLASSIFICATION T, P77; Paner GP, 2014, HUM PATHOL, V45, P1473, DOI 10.1016/j.humpath.2014.02.024; Pasquier D, 2015, INT J RADIAT ONCOL, V92, P904, DOI 10.1016/j.ijrobp.2015.03.019; Pirollo KF, 2008, CLIN CANCER RES, V14, P2190, DOI 10.1158/1078-0432.CCR-07-1951; Pons F, 2011, CURR ONCOL REP, V13, P216, DOI 10.1007/s11912-011-0161-4; Seiler R, 2017, EUR UROL, V72, P142, DOI [10.1016/j.eururo.2017.03.021, 10.1016/j.eururo.2017.03.030]; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Torhorst J, 2001, AM J PATHOL, V159, P2249, DOI 10.1016/S0002-9440(10)63075-1; Willis DL, 2013, CURR OPIN UROL, V23, P435, DOI 10.1097/MOU.0b013e328363e415; Zheng XY, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0047-7	33	3	3	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	SEP	2018	79						57	65		10.1016/j.humpath.2018.05.005			9	Pathology	Pathology	GU3HT	WOS:000445167900006	29763719	Green Accepted			2019-10-28	
J	Uccella, S; La Rosa, S; Scaldaferri, D; Monti, L; Maragliano, R; Sorrenti, E; Gariboldi, M; Taramelli, R; Sessa, F; Acquati, F				Uccella, Silvia; La Rosa, Stefano; Scaldaferri, Debora; Monti, Laura; Maragliano, Roberta; Sorrenti, Elisa; Gariboldi, Marzia; Taramelli, Roberto; Sessa, Fausto; Acquati, Francesco			New insights into hypoxia-related mechanisms involved in different microvascular patterns of bronchopulmonary carcinoids and poorly differentiated neuroendocrine carcinomas. Role of ribonuclease T2 (RNASET2) and HIF-1 alpha	HUMAN PATHOLOGY			English	Article						RNASET2; Neuroendocrine Neoplasms; Lung; HIF-1 alpha; Alarmin; Microvascular Density	ENDOTHELIAL GROWTH-FACTOR; TUMOR; EXPRESSION; ANGIOGENESIS; PULMONARY; LUNG; IDENTIFICATION; DENSITY	Ribonuclease T2 (RNASET2) is a pleiotropic and polyfunctional protein, which exerts several different activities in neoplastic cells since the early steps of tumor development. Besides having an antitumorigenic activity, RNASET2 inhibits both bFGF-induced and VEGF-induced angiogenesis and has a role as a stress-response, alarmin-like, protein. In this study, we investigated RNASET2 expression in well differentiated and poorly differentiated neuroendocrine neoplasms of the lung (Lu-NENs), which are known to show clear-cut differences in morphology, biology and clinical behavior. In addition, we explored possible relationships between RNASET2 expression and a series of immunohistochemical markers related to hypoxic stress, apoptosis, proliferation and angiogenesis. Our results showed a significantly higher expression of RNASET2, HIF-1 alpha, and its target CA IX in poorly differentiated than in well-differentiated LuNENs, the former also showing higher proliferation and apoptotic rates, as well as a lower microvessel density (MVD) than the latter. Moreover, we were able to demonstrate in vitro an overexpression of RNASET2 in consequence of the activation of HIF-1 alpha. In conclusion, we suggest that in poorly differentiated LuNENs, RNASET2 expression may be induced by HIF-1 alpha, behaving as an alarmin-like molecule. In this aggressive group of cancers, which have highly deregulated proliferation pathways, RNASET2 fails to exert the growth-inhibiting effects described in other types of neoplasms. Its increased expression, however, may contribute to the typical phenotypic alterations seen in poorly differentiated Lu-NENs, such as the high apoptotic rate and the extensive necrosis, and may also enhance the low MVD observed in these neoplasms. (C) 2018 Elsevier Inc. All rights reserved.	[Uccella, Silvia; Maragliano, Roberta; Sessa, Fausto] Univ Insubria, Dept Med & Surg, Unit Pathol, I-21100 Varese, Italy; [La Rosa, Stefano] Lausanne Univ Hosp, Inst Pathol, Serv Clin Pathol, CH-1011 Lausanne, Switzerland; [Scaldaferri, Debora; Monti, Laura; Sorrenti, Elisa; Gariboldi, Marzia; Taramelli, Roberto; Acquati, Francesco] Univ Insubria, Dept Biotechnol & Life Sci, I-21100 Varese, Italy; [Acquati, Francesco] Prot Factory Politecn Milan, Interuniv Res Ctr Prot Biotechnol, I-21100 Varese, Italy; [Acquati, Francesco] Univ Insubria, I-21100 Varese, Italy	Uccella, S (reprint author), Univ Insubria, Dept Med & Surg, via O Rossi 9, I-21100 Varese, Italy.	silvia.uccella@uninsubria.it		uccella, silvia/0000-0002-5714-7295	University of Insubria (FAR 2017); Federico Ghidoni memorial funds	SU and FA were supported by funds from University of Insubria (FAR 2017); FA was supported from Federico Ghidoni memorial funds.	Acquati F, 2005, INT J ONCOL, V26, P1159; Acquati F, 2001, ONCOGENE, V20, P980, DOI 10.1038/sj.onc.1204178; Acquati F, 2013, P NATL ACAD SCI USA, V110, P8140, DOI 10.1073/pnas.1222079110; Acquati F, 2011, P NATL ACAD SCI USA, V108, P1104, DOI 10.1073/pnas.1013746108; Coffelt SB, 2008, CANCER RES, V68, P6482, DOI 10.1158/0008-5472.CAN-08-0044; Faggiano A, 2007, CANCER, V110, P265, DOI 10.1002/cncr.22791; Furlan D, 2008, HUM PATHOL, V39, P1483, DOI 10.1016/j.humpath.2008.02.013; Giatromanolaki A, 2001, ANTICANCER RES, V21, P4317; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; La Rosa S, 2003, HUM PATHOL, V34, P18, DOI 10.1053/hupa.2003.56; LeCouter J, 2001, NATURE, V412, P877, DOI 10.1038/35091000; Loureiro RMB, 2005, CYTOKINE GROWTH F R, V16, P77, DOI 10.1016/j.cytogfr.2005.01.005; Lualdi M, 2015, ONCOTARGET, V6, P7851, DOI 10.18632/oncotarget.3490; Luhtala N, 2010, TRENDS BIOCHEM SCI, V35, P253, DOI 10.1016/j.tibs.2010.02.002; Mairinger FD, 2014, J CANCER, V5, P465, DOI 10.7150/jca.9235; Marchio C, 2017, VIRCHOWS ARCH, V471, P713, DOI 10.1007/s00428-017-2177-0; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Panisova E, 2017, ONCOTARGET, V8, P77819, DOI 10.18632/oncotarget.20836; Pelosi G, 2018, VIRCHOWS ARCH, V472, P567, DOI 10.1007/s00428-018-2307-3; Pelosi G, 2017, TRANSL LUNG CANCER R, V6, P513, DOI 10.21037/tlcr.2017.09.04; Pinato DJ, 2014, BRIT J CANCER, V110, P115, DOI 10.1038/bjc.2013.682; Quinn AM, 2017, AM J SURG PATHOL, V41, P263, DOI 10.1097/PAS.0000000000000767; Roiz Levava, 2016, Oncoscience, V3, P71; Schwartz B, 2007, CANCER RES, V67, P5258, DOI 10.1158/0008-5472.CAN-07-0129; Smirnoff P, 2006, CANCER, V107, P2760, DOI 10.1002/cncr.22327; Steinemann D, 2003, GENE CHROMOSOME CANC, V37, P421, DOI 10.1002/gcc.10231; Takahashi Y, 2007, CLIN CANCER RES, V13, P187, DOI 10.1158/1078-0432.CCR-06-1408; Tan GM, 2004, APPL IMMUNOHISTO M M, V12, P31; Travis WD, 2015, WHO CLASSIFICATION T; Wang Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.539; Yazdani S, 2014, HUM PATHOL, V45, P866, DOI 10.1016/j.humpath.2013.09.024	31	2	2	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	SEP	2018	79						66	76		10.1016/j.humpath.2018.04.028			11	Pathology	Pathology	GU3HT	WOS:000445167900007	29763721				2019-10-28	
J	Ren, M; Lu, YW; Lv, JJ; Shen, XX; Kong, JC; Dai, B; Kong, YY				Ren, Min; Lu, Yawen; Lv, Jiaojie; Shen, Xuxia; Kong, Jincheng; Dai, Bo; Kong, Yunyi			Prognostic factors in primary anorectal melanoma: a clinicopathological study of 60 cases in China	HUMAN PATHOLOGY			English	Article						Anorectal melanoma; Immunohistochemistry; Prognostic factor; Clinicopathological feature; Disease-specific survival	MALIGNANT-MELANOMA; SURGICAL-TREATMENT; RECTAL MELANOMA; EXPERIENCE; RESECTION	To investigate the clinicopathological features and prognostic factors of primary anorectal melanoma, we described the clinical presentations, histopathology, and prognosis of 60 cases in China. Patients' age ranged from 17 to 86 years, with a female-to-male ratio of 2.33:1. The prevalent anatomic site of tumor was the anorectum. The mean tumor thickness was 11.5 mm, and mean tumor size was 2.9 cm. Abdomino-perineal resection was performed on 38 (63.3%) patients, whereas wide local excision was performed on 22 (36.7%) patients. Thirty-three (55.0%) patients were pathologically confirmed to have lymph node metastasis, and 9 (15%) patients had clinically distant metastasis at diagnosis. Histologically, epithelioid cell (91.7%) was the predominant cell type, followed by spindle (31.7%), pleomorphic (25.0%), and small round cell (5.0%). Solid sheet, nest, pseudopapillary, and pseudoalveolar growth patterns were noted in 45 (75.0%), 22 (36.7%), 13 (21.7%), and 6 (10.0%) cases, respectively. After a median follow-up of 44 months, the 5-year disease-specific survival rate was 33.3%. Age, tumor size, depth of invasion, tumor thickness, lymphatic metastasis, and lymphovascular and perineural invasion were significantly correlated with survival in univariate analysis. Multivariate analysis revealed that age greater than 70 years and tumor invasion beyond deep muscular layer/sphincter ani externus were independent poor prognostic factors. As the largest single-institution study of anorectal melanoma in an Asian population, we concluded that anorectal melanoma is a rare and lethal malignant neoplasm with morphologic diversity. Large population-based studies are still needed to establish an efficient staging system in evaluation of prognosis and facilitation of treatment for anorectal melanoma patients. (C) 2018 Elsevier Inc. All rights reserved.	[Ren, Min; Lu, Yawen; Lv, Jiaojie; Shen, Xuxia; Kong, Yunyi] Fudan Univ, Dept Pathol, Shanghai Canc Ctr, 270 Dongan Rd, Shanghai 200032, Peoples R China; [Ren, Min; Lu, Yawen; Lv, Jiaojie; Shen, Xuxia; Dai, Bo; Kong, Yunyi] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China; [Kong, Jincheng] Shanghai Jiao Tong Univ, Peoples Hosp 1, Dept Pathol, Shanghai 200032, Peoples R China; [Dai, Bo] Fudan Univ, Dept Urol, Shanghai Canc Ctr, 270 Dongan Rd, Shanghai 200032, Peoples R China	Kong, YY (reprint author), Fudan Univ, Dept Pathol, Shanghai Canc Ctr, 270 Dongan Rd, Shanghai 200032, Peoples R China.; Dai, B (reprint author), Fudan Univ, Dept Urol, Shanghai Canc Ctr, 270 Dongan Rd, Shanghai 200032, Peoples R China.	bodai1978@126.com; kyunyidb@126.com			Research Project of the Science and Technology Commission of Shanghai Municipality [16411967800]	This study was supported in part by the grant from the Research Project of the Science and Technology Commission of Shanghai Municipality (16411967800).	Aytac B, 2010, KAOHSIUNG J MED SCI, V26, P658, DOI 10.1016/S1607-551X(10)70100-5; Balch CM, 2009, J CLIN ONCOL, V27, P6199, DOI 10.1200/JCO.2009.23.4799; Ballo MT, 2002, J CLIN ONCOL, V20, P4555, DOI 10.1200/JCO.2002.03.002; Belli F, 2009, EJSO-EUR J SURG ONC, V35, P757, DOI 10.1016/j.ejso.2008.05.001; Bello DM, 2013, DIS COLON RECTUM, V56, P150, DOI 10.1097/DCR.0b013e31827901dd; Ben-Izhak O, 2002, HISTOPATHOLOGY, V41, P519, DOI 10.1046/j.1365-2559.2002.01444.x; BenIzhak O, 1997, CANCER, V79, P18, DOI 10.1002/(SICI)1097-0142(19970101)79:1<18::AID-CNCR4>3.0.CO;2-I; Bosman FT, 2010, WHO CLASSIFICATION T; BRADY MS, 1995, DIS COLON RECTUM, V38, P146, DOI 10.1007/BF02052442; Cagir B, 1999, DIS COLON RECTUM, V42, P1203, DOI 10.1007/BF02238576; Chae WY, 2016, CANCER RES TREAT, V48, P240, DOI 10.4143/crt.2014.305; Chang AE, 1998, CANCER, V83, P1664, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G; Chen HY, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002770; Cheung MC, 2008, J GASTROINTEST SURG, V12, P731, DOI 10.1007/s11605-007-0417-3; Chi ZH, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-85; CHIU YS, 1980, DIS COLON RECTUM, V23, P122, DOI 10.1007/BF02587610; Cote TR, 2009, MELANOMA RES, V19, P58, DOI 10.1097/CMR.0b013e32831ef262; Ercelep O, 2016, TUMOR BIOL, V37, P12033, DOI 10.1007/s13277-016-5076-0; GOLDMAN S, 1990, DIS COLON RECTUM, V33, P874, DOI 10.1007/BF02051925; Iddings DM, 2010, ANN SURG ONCOL, V17, P40, DOI 10.1245/s10434-009-0705-0; Ishizone S, 2008, INT J COLORECTAL DIS, V23, P1257, DOI 10.1007/s00384-008-0529-6; McLaughlin CC, 2005, CANCER-AM CANCER SOC, V103, P1000, DOI 10.1002/cncr.20866; Mikkelsen LH, 2016, APMIS, V124, P475, DOI 10.1111/apm.12529; Mills S. E., 2012, HISTOLOGY PATHOLOGIS; Pessaux P, 2004, BRIT J SURG, V91, P1183, DOI 10.1002/bjs.4592; Quan S H, 1966, CA Cancer J Clin, V16, P111, DOI 10.3322/canjclin.16.3.111; Ramakrishnan A. S., 2008, Indian Journal of Cancer, V45, P13; Roumen RMH, 1996, EUR J SURG ONCOL, V22, P598, DOI 10.1016/S0748-7983(96)92346-X; Santi R, 2015, J CLIN PATHOL, V68, P130, DOI 10.1136/jclinpath-2014-202572; Thibault C, 1997, DIS COLON RECTUM, V40, P661, DOI 10.1007/BF02140894; WANEBO HJ, 1981, CANCER, V47, P1891, DOI 10.1002/1097-0142(19810401)47:7<1891::AID-CNCR2820470730>3.0.CO;2-K; Wang M, 2013, COLORECTAL DIS, V15, P1086, DOI 10.1111/codi.12250; WARD MWN, 1986, BRIT J SURG, V73, P68, DOI 10.1002/bjs.1800730127; Yeh JJ, 2006, ANN SURG, V244, P1012, DOI 10.1097/01.sla.0000225114.56565.f9	34	1	1	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	SEP	2018	79						77	85		10.1016/j.humpath.2018.05.004			9	Pathology	Pathology	GU3HT	WOS:000445167900008	29763716				2019-10-28	
J	Yanagida, E; Miyoshi, H; Kawamoto, K; Nakashima, K; Matsuda, K; Yamada, K; Muto, R; Nagafuji, K; Seto, M; Ohshima, K				Yanagida, Eriko; Miyoshi, Hiroaki; Kawamoto, Keisuke; Nakashima, Kazutaka; Matsuda, Kotaro; Yamada, Kyohei; Muto, Reiji; Nagafuji, Koji; Seto, Masao; Ohshima, Koichi			Clinicopathological analysis of immunohistochemical expression of retinoic acid-related orphan receptor-gamma t in peripheral T-cell lymphoma, not otherwise specified	HUMAN PATHOLOGY			English	Article						ROR gamma t; PTCL-NOS; Pathology; Prognosis	ROR-GAMMA; DIFFERENTIATION; PTCL; LYMPHOCYTES; PROGRESSION; DISORDERS; LIGAND; MICE; NOS	Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is cytologically and phenotypically heterogeneous. Retinoic acid-related orphan receptor-gamma t (ROR gamma t) is a transcription factor that regulates the differentiation of naive CD4(+) helper T cells to Th17 cells. In the present study, we immunohistochemically confirmed the expression of ROR gamma t in PTCL-NOS. Pathological and clinical investigations were performed for 170 cases of PTCL-NOS. ROR gamma t-positive cases accounted for 17.6% (30/170) of the total cases, and they showed a significantly higher frequency of CD8 positivity (P = .033), lower counts of white blood cells (P = .030) and neutrophils (P = .039) in the peripheral blood, higher levels of hypergammaglobulinemia (P = .031), a higher frequency of a complete response (P = .009), and a tendency for a lower International Prognostic Index (P = .061) and better overall survival (P = .0806). These results suggest that ROR gamma t-positive PTCL-NOS could be a subpopulation of PTCL-NOS. Further research associated with this genomic abnormality at the transcriptional level is needed to confirm the results of this study. (C) 2018 Elsevier Inc. All rights reserved.	[Yanagida, Eriko; Miyoshi, Hiroaki; Kawamoto, Keisuke; Nakashima, Kazutaka; Matsuda, Kotaro; Yamada, Kyohei; Muto, Reiji; Seto, Masao; Ohshima, Koichi] Kurume Univ, Sch Med, Dept Pathol, Asahimachi 67, Kurume, Fukuoka 8300011, Japan; [Nagafuji, Koji] Kurume Univ Hosp, Dept Hematol, Kurume, Fukuoka 8300011, Japan	Miyoshi, H (reprint author), Kurume Univ, Sch Med, Dept Pathol, Asahimachi 67, Kurume, Fukuoka 8300011, Japan.	miyoshi_hiroaki@med.kurume-u.ac.jp					Akobeng AK, 2007, ACTA PAEDIATR, V96, P644, DOI 10.1111/j.1651-2227.2006.00178.x; ANDERSON P, 1990, J IMMUNOL, V144, P574; Brozyna AA, 2016, ONCOTARGET, V7, P63261, DOI 10.18632/oncotarget.11211; Gallamini A, 2004, BLOOD, V103, P2474, DOI 10.1182/blood-2003-09-3080; Huh JR, 2011, NATURE, V472, P486, DOI 10.1038/nature09978; Inghirami G, 2015, IMMUNOL REV, V263, P124, DOI 10.1111/imr.12248; Iqbal J, 2014, BLOOD, V123, P2915, DOI 10.1182/blood-2013-11-536359; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Karube K, 2008, MODERN PATHOL, V21, P617, DOI 10.1038/modpathol.2008.25; Kato T, 2017, VIRCHOWS ARCH, V471, P659, DOI 10.1007/s00428-017-2233-9; Kawamoto K, 2017, EUR J HAEMATOL, V98, P459, DOI 10.1111/ejh.12856; Kishimoto T, 2005, ANNU REV IMMUNOL, V23, P1, DOI 10.1146/annurev.immunol.23.021704.115806; Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018; Matsumoto Y, 2010, AM J CLIN PATHOL, V133, P281, DOI 10.1309/AJCP0SBHYVLY5EML; Miyoshi H, 2012, AM J CLIN PATHOL, V137, P879, DOI 10.1309/AJCPBPNV86VZENGV; Pileri SA, 2017, WHO CLASSIFICATION T, P403; Pileri SA, 2008, WHO CLASSIFICATION T, P306; Savage KJ, 2004, ANN ONCOL, V15, P1467, DOI 10.1093/annonc/mdh392; Slominski AT, 2014, FASEB J, V28, P2775, DOI 10.1096/fj.13-242040; Solt LA, 2011, NATURE, V472, P491, DOI 10.1038/nature10075; Ueda E, 2002, CANCER RES, V62, P901; Vose JM, 2008, J CLIN ONCOL, V26, P4124, DOI 10.1200/JCO.2008.16.4558; Wang TJ, 2014, BLOOD, V123, P3007, DOI 10.1182/blood-2013-12-544809; Yoh K, 2012, EUR J IMMUNOL, V42, P1999, DOI 10.1002/eji.201142250; Yokoyama S, 2016, CLIN CANCER RES, V22, P4727, DOI 10.1158/1078-0432.CCR-16-0434; Yoshida N, 2016, ANN SURG ONCOL, V23, P919, DOI 10.1245/s10434-015-4923-3; Zhan HQ, 2011, J CLIN PATHOL, V64, P319, DOI 10.1136/jcp.2010.084459; Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488	28	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	SEP	2018	79						86	92		10.1016/j.humpath.2018.05.002			7	Pathology	Pathology	GU3HT	WOS:000445167900009	29775622				2019-10-28	
J	Nakanishi, H; Miyata, Y; Mochizuki, Y; Yasuda, T; Nakamura, Y; Araki, K; Sagara, Y; Matsuo, T; Ohba, K; Sakai, H				Nakanishi, Hiromi; Miyata, Yasuyoshi; Mochizuki, Yasushi; Yasuda, Takuji; Nakamura, Yuichiro; Araki, Kyohei; Sagara, Yuji; Matsuo, Tomohiro; Ohba, Kojiro; Sakai, Hideki			Pathological significance and prognostic roles of densities of CD57+cells, CD68+cells, and mast cells, and their ratios in clear cell renal cell carcinoma	HUMAN PATHOLOGY			English	Article						CD57+cell; CD68+cell; Mast cell; Prognosis; Renal cell carcinoma	MICROVESSEL DENSITY; MACROPHAGES; EXPRESSION; PARAMETERS; SURVIVAL; IMPACT	The immune system is closely associated with malignant behavior in renal cell carcinoma (RCC). Therefore, understanding the pathological roles of immune cells in tumor stroma is essential to discuss the pathological characteristics of RCC. In this study, the clinical significance of densities of CD57+ cells, CD68+ cells, and mast cells, and their ratios were investigated in patients with clear cell RCC. The densities of CD57+, CD68+, and mast cells were evaluated by immunohistochemical techniques in 179 patients. Proliferation index, apoptotic index, and microvessel density were evaluated by using anti-Ki-67, anti-cleaved caspase-3, and anti-CD31 antibodies, respectively. The density of CD57+ cell was negatively correlated with grade, pT stage, and metastasis, although densities of CD68+ cell and mast cell were positively correlated. Ratios of CD68+ cell/CD57+ cell and mast cell/CD57+ cell were significantly correlated with grade, pT stage, and metastasis. Survival analyses showed that the CD68+ cell/CD57+ cell ratio was a significant predictor for cause-specific survival by multivariate analyses (hazard ratio = 1.41, 95% confidence interval = 1.03-1.93, P = .031) and was significantly correlated with proliferation index, apoptotic index, and microvessel density (r = .47, P < .001; r = -.31, P < .001; and r = .40, P < .001, respectively). In conclusion, CD57+ cells, CD68+ cells, and mast cells played important roles in malignancy in clear cell RCC. The CD68+ cell/CD57+ cell ratio was strongly correlated with pathological features and prognosis in these patients because this ratio reflected the status of cancer cell proliferation, apoptosis, and angiogenesis. (C) 2018 The Authors. Published by Elsevier Inc.	[Nakanishi, Hiromi; Miyata, Yasuyoshi; Mochizuki, Yasushi; Yasuda, Takuji; Nakamura, Yuichiro; Araki, Kyohei; Sagara, Yuji; Matsuo, Tomohiro; Ohba, Kojiro; Sakai, Hideki] Nagasaki Univ, Dept Nephrourol, Grad Sch Biomed Sci, 1-7-1 Sakamoto, Nagasaki 8528501, Japan	Miyata, Y (reprint author), Nagasaki Univ, Dept Nephrourol, Grad Sch Biomed Sci, 1-7-1 Sakamoto, Nagasaki 8528501, Japan.	int.doc.miya@m3.dion.ne.jp			JSPS KAKENHI grant from the Japanese Government, Tokyo, Japan [16K15690]	This study was supported by JSPS KAKENHI grant from the Japanese Government, Tokyo, Japan (16K15690).	Chaput N, 2013, BRIT J CANCER, V109, P1013, DOI 10.1038/bjc.2013.362; Chew V, 2010, J HEPATOL, V52, P370, DOI 10.1016/j.jhep.2009.07.013; Cros J, 2016, VIRCHOWS ARCH, V469, P331, DOI 10.1007/s00428-016-1973-2; Daurkin I, 2011, CANCER RES, V71, P6400, DOI 10.1158/0008-5472.CAN-11-1261; Donskov F, 2006, J CLIN ONCOL, V24, P1997, DOI 10.1200/JCO.2005.03.9594; Eiro N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052796; Fu HC, 2017, ANN SURG ONCOL, V24, P1435, DOI 10.1245/s10434-016-5702-5; FUHRMAN SA, 1982, AM J SURG PATHOL, V6, P655, DOI 10.1097/00000478-198210000-00007; Garcia JA, 2009, CURR OPIN ONCOL, V21, P266, DOI 10.1097/CCO.0b013e32832a05c8; Geissler K, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.985082; Guldur ME, 2014, J PAK MED ASSOC, V64, P300; Guo J, 2017, ONCOL REP, V38, P2003, DOI 10.3892/or.2017.5877; Hu GM, 2018, INT J CANCER, V142, P813, DOI 10.1002/ijc.31099; Ko EA, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1360457; Komohara Y, 2011, CANCER SCI, V102, P1424, DOI 10.1111/j.1349-7006.2011.01945.x; Kovaleva OV, 2016, ANAL CELL PATHOL, DOI 10.1155/2016/9307549; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Lindsten T, 2017, INT J ONCOL, V51, P104, DOI 10.3892/ijo.2017.3996; Mileshkin L, 2007, HAEMATOL-HEMATOL J, V92, P1075, DOI 10.3324/haematol.11208; Mitsunari K, 2017, ONCOL LETT, V13, P834, DOI 10.3892/ol.2016.5481; Miyata Y, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-372; Mohseni MG, 2010, INT UROL NEPHROL, V42, P109, DOI 10.1007/s11255-009-9577-2; Morita Y, 2017, ONCOL LETT, V14, P2111, DOI 10.3892/ol.2017.6466; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Motzer RJ, 2009, J NATL COMPR CANC NE, V7, P618, DOI 10.6004/jnccn.2009.0043; Ohnishi K, 2016, CANCER SCI, V107, P846, DOI 10.1111/cas.12929; Ohno S, 2005, ANTICANCER RES, V25, P463; Shieh YS, 2009, ANN SURG ONCOL, V16, P751, DOI 10.1245/s10434-008-0259-6; STEIN M, 1992, J EXP MED, V176, P287, DOI 10.1084/jem.176.1.287; Tuna B, 2006, EUR UROL, V50, P530, DOI 10.1016/j.eururo.2005.12.040; Watanabe S, 2012, HUM PATHOL, V43, P888, DOI 10.1016/j.humpath.2011.07.019; Yang JC, 2006, J CLIN ONCOL, V24, P5576, DOI 10.1200/JCO.2006.08.3774; Yin-Xu Zhang, 2011, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V33, P71, DOI 10.3881/j.issn.1000-503X.2011.01.015; Zinovkin D, 2016, INT J GYNECOL CANCER, V26, P1207, DOI 10.1097/IGC.0000000000000758	34	1	1	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	SEP	2018	79						102	108		10.1016/j.humpath.2018.05.007			7	Pathology	Pathology	GU3HT	WOS:000445167900011	29787818	Other Gold, Green Published			2019-10-28	
J	Gibson, WE; Gonzalez, RS; Cates, JMM; Liu, E; Shi, CJ				Gibson, William E.; Gonzalez, Raul S.; Cates, Justin M. M.; Liu, Eric; Shi, Chanjuan			Hepatic micrometastases are associated with poor prognosis in patients with liver metastases from neuroendocrine tumors of the digestive tract	HUMAN PATHOLOGY			English	Article						Micrometastases; Liver metastasis; Small intestine; Pancreas; Neuroendocrine tumor	EPIDEMIOLOGY; DEPOSITS; DISEASE	Pathologic examination of hepatic metastasectomies from patients with metastatic small intestinal or pancreatic neuroendocrine tumor frequently reveals micrometastases undetectable by radiologic or macroscopic gross examination. This finding raises the possibility that undetectable micrometastases remain in these patients after metastasectomy. Here we examined liver resections for micrometastases and assessed their impact on prognosis. Hepatic metastasectomies from 65 patients with neuroendocrine tumor of the small intestine (N = 43) or pancreas (N = 22) were reviewed for the presence of micrometastases, which were defined as microscopic tumor foci <= 1 mm in greatest dimension. Medical records were also reviewed for patient demographics, clinical history, and follow-up data. Micrometastasis was identified in 36 (55%) of 65 hepatic resection specimens. More hepatic micrometastases were seen in small intestinal cases than in pancreatic cases (29/43, 67%, versus 7/22, 32%; P < .01). They were typically present within portal tracts, sometimes with extension into the periportal region or sinusoidal spaces away from the portal tracts. Patients without hepatic micrometastases had fewer macrometastases or more RO hepatic resections than those with micrometastases. The presence of hepatic micrometastases was associated with poor overall survival both before (hazard ratio [HR] 3.43; 95% CI 1.14-10.30; P = .03) and after accounting for confounding variables in stratified Cox regression (HR 4.82; 95% CI 1.06 - 21.79; P = .04). In conclusion, hepatic micrometastases are common in patients with metastatic small intestinal or pancreatic neuroendocrine tumor and are independently associated with poor prognosis. These data suggest that surgical resection of hepatic metastases is likely not curative in these patients. (C) 2018 Elsevier Inc. All rights reserved.	[Gibson, William E.; Cates, Justin M. M.; Shi, Chanjuan] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37027 USA; [Gonzalez, Raul S.] Univ Rochester, Dept Pathol & Lab Med, Med Ctr, Rochester, NY 14642 USA; [Liu, Eric] Rocky Mt Canc Ctr, Dept Surg, Denver, CO 80218 USA	Shi, CJ (reprint author), Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, 1161 21st Ave South,C-3321 MCN, Nashville, TN 37232 USA.	Chanjuan.Shi@vanderbilt.edu	Cates, Justin/D-5927-2014	Cates, Justin/0000-0002-7336-5196	NIH/NIDDKUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [5P30 DK058404-13]; NIH/NCIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [5P50 CA095103-13]	This study is supported by NIH/NIDDK 5P30 DK058404-13 (CS) and NIH/NCI 5P50 CA095103-13 (CS).	Amin MB, 2017, AJCC CANC STAGING MA; Auernhammer CJ, 2011, GUT, V60, P1009, DOI 10.1136/gut.2009.204453; Bosman FT, 2010, WHO CLASSIFICATION T; Chan JA, 2016, HEMATOL ONCOL CLIN N, V30, pXIII, DOI 10.1016/j.hoc.2015.09.012; Charoenpitakchai M, 2017, VIRCHOWS ARCH, V470, P545, DOI 10.1007/s00428-017-2093-3; Elias D, 2010, ANN SURG, V251, P307, DOI 10.1097/SLA.0b013e3181bdf8cf; Estrella JS, 2013, AM J SURG PATHOL, V37, P1571, DOI 10.1097/PAS.0b013e318293ddf1; Farley HA, 2016, SURG ONCOL CLIN N AM, V25, P217, DOI 10.1016/j.soc.2015.08.010; Fata CR, 2017, AM J SURG PATHOL, V41, P128, DOI 10.1097/PAS.0000000000000751; Fraenkel M, 2012, BEST PRACT RES CL GA, V26, P691, DOI 10.1016/j.bpg.2013.01.006; Frilling A, 2015, CANCER-AM CANCER SOC, V121, P1172, DOI 10.1002/cncr.28760; Gonzalez RS, 2014, MODERN PATHOL, V27, P1288, DOI 10.1038/modpathol.2013.232; John BJ, 2012, EXPERT REV GASTROENT, V6, P357, DOI [10.1586/egh.11.60, 10.1586/EGH.11.60]; Lee SY, 2012, INT J HEPATOL, DOI 10.1155/2012/146590; Mocellin S, 2013, ANN ONCOL, V24, P3040, DOI 10.1093/annonc/mdt377; Modlin IM, 2003, CANCER-AM CANCER SOC, V97, P934, DOI 10.1002/cncr.11105; Modlin IM, 2007, AM J GASTROENTEROL, V102, P1464, DOI 10.1111/j.1572-0241.2007.01185.x; Pavel M, 2016, NEUROENDOCRINOLOGY, V103, P172, DOI [10.1159/000446025, 10.1159/000443167]; Phan AT, 2015, LANCET ONCOL, V16, P695, DOI 10.1016/S1470-2045(15)70136-1; Strosberg JR, 2013, J CLIN ONCOL, V31, P420, DOI 10.1200/JCO.2012.44.5924; Viudez A, 2016, CRIT REV ONCOL HEMAT, V101, P193, DOI 10.1016/j.critrevonc.2016.03.013; Viudez A, 2016, ONCOTARGET, V7, P24950, DOI 10.18632/oncotarget.7436; Yao JC, 2008, J CLIN ONCOL, V26, P3063, DOI 10.1200/JCO.2007.15.4377; Zappa M, 2012, TARGET ONCOL, V7, P107, DOI 10.1007/s11523-012-0219-8	24	3	3	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	SEP	2018	79						109	115		10.1016/j.humpath.2018.05.006			7	Pathology	Pathology	GU3HT	WOS:000445167900012	29763717	Green Accepted			2019-10-28	
J	Prathibha, S; Goyal, KG; Zynger, DL				Prathibha, Saranya; Goyal, Kashika G.; Zynger, Debra L.			Initial diagnosis of insignificant cancer, high-grade prostatic intraepithelial neoplasia, atypical small acinar proliferation, and negative have the same rate of upgrade to a Gleason score of 7 or higher on repeat prostate biopsy	HUMAN PATHOLOGY			English	Article						Prostate; Needle core biopsy; Repeat; Upgrade; Carcinoma	ACTIVE SURVEILLANCE; PROGNOSTIC-SIGNIFICANCE; FOLLOW-UP; RISK; MEN; RECLASSIFICATION; DISEASE; TIME	Extended prostate needle core biopsies are standard of care for the diagnosis of prostatic carcinoma. Subsequent biopsies may be performed for a variety of indications. Knowledge of biopsy characteristics indicating risk for progression may have utility to guide therapeutic management. Prostate needle core biopsies performed between 2008 and 2014 were reviewed. Patients with at least 1 subsequent biopsy were identified. Cases were categorized by worst initial diagnosis. Gleason <= 6 carcinoma was further classified as significant or insignificant with insignificant defined as follows: <= 2 cores with carcinoma, sites with <= 50% carcinoma, and unilateral carcinoma. A total of 329 men underwent repeat biopsies. Gleason 56 insignificant carcinoma, high-grade prostatic intraepithelial neoplasia (HGPIN) and/or atypical small acinar proliferation, and negative biopsies had a similar rate of Gleason >= 7 upon repeat biopsy (16%, 17%, 14%; P = .91). Initial biopsy diagnoses of Gleason <= 6 significant carcinoma had a higher rate of Gleason >= 7 on repeat biopsy compared with initial biopsies of Gleason <= 6 insignificant carcinoma (39%, 16%; P = .003). Within initial diagnoses of Gleason <= 6, 1 core compared with more than 1 core positive had a lower rate of Gleason >= 7 on repeat biopsy (17%, 30%), although this difference was not significant (P = .08). An initial biopsy diagnosed as Gleason >= 6 insignificant carcinoma, HGPIN and/or atypical small acinar proliferation, or negative had a similar substantial risk of Gleason >= 7 carcinoma upon subsequent biopsy. Our findings support the continued stratification of Gleason >= 6 and thus the diagnostic workup of all atypical foci to provide an accurate, thorough number of involved cores. (C) 2018 Elsevier Inc. All rights reserved.	[Prathibha, Saranya; Zynger, Debra L.] Ohio State Univ, Dept Pathol, Med Ctr, Columbus, OH 43210 USA; [Goyal, Kashika G.] Beth Israel Deaconess Med Ctr, Dept Internal Med, Boston, MA 02215 USA	Zynger, DL (reprint author), Ohio State Univ, Dept Pathol, Med Ctr, Columbus, OH 43210 USA.						American Cancer Society, 2018, CANC FACTS FIG 2018; Ankerst DP, 2015, EUR UROL, V68, P1083, DOI 10.1016/j.eururo.2015.03.023; [Anonymous], 2016, CLIN PRACT GUID ONC; Bul M, 2013, EUR UROL, V63, P597, DOI 10.1016/j.eururo.2012.11.005; Bul M, 2012, EUR UROL, V61, P370, DOI 10.1016/j.eururo.2011.06.027; Capitanio U, 2015, EUR UROL FOCUS, V1, P127, DOI 10.1016/j.euf.2015.05.002; Davis JW, 2016, BJU INT, V118, P68, DOI 10.1111/bju.13193; EPSTEIN JI, 1994, JAMA-J AM MED ASSOC, V271, P368, DOI 10.1001/jama.271.5.368; Freedland SJ, 2007, UROLOGY, V69, P495, DOI 10.1016/j.urology.2006.10.036; Gallo F, 2008, UROLOGY, V72, P628, DOI 10.1016/j.urology.2007.11.115; Iremashvili V, 2013, BJU INT, V111, P574, DOI 10.1111/j.1464-410X.2012.11127.x; Jain S, 2015, J UROLOGY, V194, P79, DOI 10.1016/j.juro.2015.01.102; Kattan MW, 2003, J UROLOGY, V170, P1792, DOI 10.1097/01.ju.0000091806.70171.41; Koca O, 2011, KOREAN J UROL, V52, P736, DOI 10.4111/kju.2011.52.11.736; Komisarenko M, 2016, J UROLOGY, V195, P307, DOI 10.1016/j.juro.2015.09.081; Leone L, 2014, ARCH ITAL UROL ANDRO, V86, P332, DOI 10.4081/aiua.2014.4.332; Loeb S, 2013, EUR UROL, V64, P876, DOI 10.1016/j.eururo.2013.05.049; Marenghi C, 2017, TUMORI, V103, P464, DOI 10.5301/tj.5000649; Merrimen JL, 2009, J UROLOGY, V182, P485, DOI 10.1016/j.juro.2009.04.016; Moore CK, 2005, J UROLOGY, V173, P70, DOI 10.1097/01.ju.0000148260.69779.c5; Patel P, 2015, CAN J UROL, V22, P8056; Peyromaure M, 2002, J UROLOGY, V167, P218, DOI 10.1016/S0022-5347(05)65416-X; Shah MD, 2017, AM J CLIN PATHOL, V148, P494, DOI [10.1093/AJCP/AQX103, 10.1093/ajcp/aqx103]; Sheridan TB, 2008, J UROLOGY, V179, P901, DOI 10.1016/j.juro.2007.10.062; Tseng KS, 2010, J UROLOGY, V183, P1779, DOI 10.1016/j.juro.2010.01.001; Wiener S, 2017, UROLOGY, V110, P161, DOI 10.1016/j.urology.2017.08.040	26	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	SEP	2018	79						116	121		10.1016/j.humpath.2018.05.011			6	Pathology	Pathology	GU3HT	WOS:000445167900013	29803813				2019-10-28	
J	Davidson, B; Totsch, M; Wohlschlaeger, J; Hager, T; Pinamonti, M				Davidson, Ben; Totsch, Martin; Wohlschlaeger, Jeremias; Hager, Thomas; Pinamonti, Maurizio			The diagnostic role of BAP1 in serous effusions	HUMAN PATHOLOGY			English	Article						BAP1; Malignant mesothelioma; Carcinoma; Effusions; Immunohistochemistry; Diagnosis	MALIGNANT MESOTHELIAL CELLS; CARCINOMA; PERITONEAL; CLAUDIN-4; CYTOLOGY; MARKER; IMMUNOHISTOCHEMISTRY; EXPRESSION; PAX2; FISH	The aim of this study was to analyze the diagnostic role of BAP1 in effusion cytology. Effusions (n = 258), consisting of 53 malignant mesotheliomas and 205 other cancers, the majority carcinomas (62 breast, 60 ovarian, 31 lung, 51 carcinomas of other origin, 1 melanoma), were analyzed for BAP1 expression using immunohistochemistry. BAP1 was lost in 46 (87%) mesotheliomas compared with 4 (2%) of 205 other cancers (P < .001), resulting in sensitivity and specificity of 87% and 98%, respectively. There was no significant difference between peritoneal (n = 14) and pleural (n = 39) mesotheliomas. The 4 carcinomas with loss of BAP1 included 1 ovarian, 1 breast, 1 uterine cervical, and 1 gastric carcinoma. The present study supports the role of BAP1 as a highly sensitive and specific marker for malignant mesothelioma in serous effusions and argues for inclusion of this test in all specimens in which this diagnosis is considered. (C) 2018 Elsevier Inc. All rights reserved.	[Davidson, Ben] Oslo Univ Hosp, Dept Pathol, Norwegian Radium Hosp, N-0310 Oslo, Norway; [Davidson, Ben] Univ Oslo, Fac Med, Inst Clin Med, N-0316 Oslo, Norway; [Totsch, Martin] Med Univ Graz, Inst Cytol, A-8036 Graz, Austria; [Wohlschlaeger, Jeremias; Hager, Thomas] Univ Hosp Essen, Dept Pathol, Essen, Germany; [Pinamonti, Maurizio] Univ Trieste, Unit Pathol, Dept Med Surg & Hlth Sci, I-34151 Trieste, Italy	Davidson, B (reprint author), Oslo Univ Hosp, Dept Pathol, Norwegian Radium Hosp, N-0310 Oslo, Norway.	bend@medisin.uio.no			Research Foundation at the Norwegian Radium Hospital	This work was supported by The Research Foundation at the Norwegian Radium Hospital.	Andrici J, 2016, HUM PATHOL, V51, P9, DOI 10.1016/j.humpath.2015.12.012; Andrici J, 2015, MODERN PATHOL, V28, P1360, DOI 10.1038/modpathol.2015.87; Cheung M, 2017, TRANSL LUNG CANCER R, V6, P270, DOI 10.21037/tlcr.2017.05.03; Cozzi I, 2018, DIAGN CYTOPATHOL, V46, P9, DOI 10.1002/dc.23837; Davidson B, 2007, DIAGN CYTOPATHOL, V35, P756, DOI 10.1002/dc.20771; Davidson B, 2016, HUM PATHOL, V58, P123, DOI 10.1016/j.humpath.2016.08.005; Davidson B, 2016, HUM PATHOL, V47, P104, DOI 10.1016/j.humpath.2015.08.020; Facchetti F, 2007, VIRCHOWS ARCH, V451, P669, DOI 10.1007/s00428-007-0448-x; Gao FF, 2012, APPL IMMUNOHISTO M M, V20, P272, DOI 10.1097/PAI.0b013e3182366531; Hwang HC, 2016, AM J SURG PATHOL, V40, P120, DOI 10.1097/PAS.0000000000000529; Jo VY, 2014, CANCER CYTOPATHOL, V122, P299, DOI 10.1002/cncy.21392; Kawai T, 2016, J CLIN PATHOL, V69, P706, DOI 10.1136/jclinpath-2015-203211; Kinoshita Y, 2018, CANCER CYTOPATHOL, V126, P54, DOI 10.1002/cncy.21928; Kleinberg L, 2007, AM J CLIN PATHOL, V127, P928, DOI 10.1309/V025QRN3R9CJGNPX; Laury AR, 2010, AM J SURG PATHOL, V34, P627, DOI 10.1097/PAS.0b013e3181da7687; Ordonez NG, 2013, MODERN PATHOL, V26, P1132, DOI 10.1038/modpathol.2013.34; Ordonez NG, 2013, MODERN PATHOL, V26, P553, DOI 10.1038/modpathol.2012.200; Walts AE, 2016, DIAGN CYTOPATHOL, V44, P599, DOI 10.1002/dc.23491; Yuan Y, 2009, AM J SURG PATHOL, V33, P1673, DOI 10.1097/PAS.0b013e3181b6bde3	19	4	4	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	SEP	2018	79						122	126		10.1016/j.humpath.2018.05.012			5	Pathology	Pathology	GU3HT	WOS:000445167900014	29802871				2019-10-28	
J	Iida, Y; Masuda, S; Nakanishi, Y; Shimizu, T; Nishimaki, H; Takahashi, M; Hikichi, M; Maruoka, S; Gon, Y; Takahashi, N; Hashimoto, S				Iida, Yuko; Masuda, Shinobu; Nakanishi, Yoko; Shimizu, Tetsuo; Nishimaki, Haruna; Takahashi, Mai; Hikichi, Mari; Maruoka, Shuichiro; Gon, Yasuhiro; Takahashi, Noriaki; Hashimoto, Shu			Clinicopathological characteristics of thyroid transcription factor 1-negative small cell lung cancers	HUMAN PATHOLOGY			English	Article						SCLC, small cell lung cancer; TTF-1, thyroid transcription factor 1; ASCL1, achaete-scute homolog like 1; NF1B, nuclear factor 1B; neuroendocrine differentiation; FFPE, formalin-fixed paraffin-embedded section	PROGASTRIN-RELEASING PEPTIDE; PULMONARY NEUROENDOCRINE TUMORS; TTF-1 EXPRESSION; CHROMOGRANIN-A; MARKER; DIFFERENTIATION; PROGRESSION; BIOMARKER; GROWTH; DRIVER	Limitations in obtaining surgically resected or biopsy samples of small cell lung cancer (SCLC) tumors make comprehensive biological analyses difficult. The loss of thyroid transcription factor 1 (TTF-1) has been associated with the aggressive behavior of non-small cell lung cancer; however, clinicopathological features of TTF-1-negative SCLC remain unclear. This study aimed to elucidate the characteristics of TTF-1-negative SCLC. We studied the associations between the expression of TTF-1 and the clinicopathological factors associated with SCLC, including survival and expression of neuroendocrine markers (synaptophysin, chromogranin A, and CD56), neuroendocrine cell-specific transcription factors (ASCL1, BRN2), a proliferation marker (Ki-67 labeling index), and an oncogene (NF1B). Formalin-fixed and paraffin-embedded sections of SCLC tumors were subjected to immunohistochemistry and quantitative reverse-transcription polymerase chain reaction analyses. In a case-control cohort matched for basic clinical factors, expression of ProGRP, synaptophysin, chromogranin A, and ASCL1 was significantly decreased in TTF-1-negative SCLC samples. In contrast, there was no significant correlation between Ki-67 labeling index and TTF-1. In a larger serial case cohort, TTF-1-negative SCLC cases were older at diagnosis, but there was no significant difference in the overall survival of patients with TTF-1-negative and TTF-1-positive SCLC. In conclusion, TTF-1-negative SCLC showed decreased neuroendocrine differentiation, and significantly worse clinical outcomes were not observed. (C) 2018 Elsevier Inc. All rights reserved.	[Iida, Yuko; Shimizu, Tetsuo; Takahashi, Mai; Hikichi, Mari; Maruoka, Shuichiro; Gon, Yasuhiro; Takahashi, Noriaki; Hashimoto, Shu] Nihon Univ, Sch Med, Dept Internal Med, Div Resp Med, Tokyo 1738610, Japan; [Masuda, Shinobu; Nakanishi, Yoko; Nishimaki, Haruna] Nihon Univ, Sch Med, Dept Pathol & Microbiol, Div Oncol Pathol, Tokyo, Japan	Masuda, S (reprint author), Nihon Univ, Sch Med, Dept Pathol & Microbiol, Div Oncol Pathol,Itabashi Ku, 30-1 Ohyaguchi Kamimachi, Tokyo 1738610, Japan.	masuda.shinobu@nihon-u.ac.jp					Battafarano RJ, 2005, J THORAC CARDIOV SUR, V130, P166, DOI 10.1016/j.jtcvs.2005.02.064; Berghmans T, 2006, ANN ONCOL, V17, P1673, DOI 10.1093/annonc/mdl287; Borromeo MD, 2016, CELL REP, V16, P1259, DOI 10.1016/j.celrep.2016.06.081; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Folpe AL, 1999, MODERN PATHOL, V12, P5; Gong ZY, 2016, BIOCHEM BIOPH RES CO, V479, P312, DOI 10.1016/j.bbrc.2016.09.066; Ishii J, 2014, PATHOL INT, V64, P415, DOI 10.1111/pin.12198; Ishii J, 2013, PATHOL INT, V63, P158, DOI 10.1111/pin.12042; Jiang TY, 2009, CANCER RES, V69, P845, DOI 10.1158/0008-5472.CAN-08-2762; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Kashiwagi K, 2012, PATHOL INT, V62, P232, DOI 10.1111/j.1440-1827.2011.02781.x; Kitamura H, 2009, ENDOCR PATHOL, V20, P101, DOI 10.1007/s12022-009-9072-4; Korse CM, 2012, EUR J CANCER, V48, P662, DOI 10.1016/j.ejca.2011.08.012; Kudo K, 2011, LUNG CANCER, V74, P401, DOI 10.1016/j.lungcan.2011.03.019; Macabeo-Ong M, 2002, MODERN PATHOL, V15, P979, DOI 10.1097/01.MP.0000026054.62220.FC; Misch D, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0250-z; Molina R, 2004, CLIN BIOCHEM, V37, P505, DOI 10.1016/j.clinbiochem.2004.05.007; Oh HJ, 2016, J THORAC DIS, V8, P2530, DOI 10.21037/jtd.2016.08.72; Osada H, 2005, CANCER RES, V65, P10680, DOI 10.1158/0008-5472.CAN-05-1404; Osada H, 2008, CANCER RES, V68, P1647, DOI 10.1158/0008-5472.CAN-07-5039; Oze I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007835; Pao W, 2011, LANCET ONCOL, V12, P175, DOI 10.1016/S1470-2045(10)70087-5; Qian HH, 2015, CLIN CHIM ACTA, V451, P208, DOI 10.1016/j.cca.2015.01.023; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Sakaeda M, 2013, LAB INVEST, V93, P408, DOI 10.1038/labinvest.2013.2; SEIGNEURIN D, 1991, PATHOL BIOL, V39, P1020; Semenova EA, 2016, CELL REP, V16, P631, DOI 10.1016/j.celrep.2016.06.020; Steele-Perkins G, 2005, MOL CELL BIOL, V25, P685, DOI 10.1128/MCB.25.2.685-698.2005; Tartarone A, 2017, MED ONCOL, V34, DOI 10.1007/s12032-017-0966-6; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; van Meerbeeck JP, 2011, LANCET, V378, P1741, DOI 10.1016/S0140-6736(11)60165-7; Wang Xin, 2017, Zhongguo Fei Ai Za Zhi, V20, P522, DOI 10.3779/j.issn.1009-3419.2017.08.04; Wu N, 2016, ONCOTARGET, V7, P57514, DOI 10.18632/oncotarget.11583; Yatabe Y, 2002, AM J SURG PATHOL, V26, P767, DOI 10.1097/00000478-200206000-00010; Yazawa T, 2015, PATHOL INT, V65, P277, DOI 10.1111/pin.12267	35	1	1	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	SEP	2018	79						127	134		10.1016/j.humpath.2018.05.009			8	Pathology	Pathology	GU3HT	WOS:000445167900015	29787820				2019-10-28	
J	Zhang, ZM; Ren, H; Yang, L; Zhang, XH; Liang, W; Wu, H; Huang, LL; Kang, JH; Xu, JB; Zhai, ET; Cai, SR; He, YT				Zhang, Zhimei; Ren, Hui; Yang, Liang; Zhang, Xinhua; Liang, Wei; Wu, Hui; Huang, Leilei; Kang, Jihui; Xu, Jianbo; Zhai, Ertao; Cai, Shirong; He, Yutong			Aberrant expression of stress-induced phosphoprotein 1 in colorectal cancer and its clinicopathologic significance	HUMAN PATHOLOGY			English	Article						STIP1; Oncogene; Colorectal cancer; Overall survival; Disease-free survival	OVARIAN-CANCER; OLIGONUCLEOTIDE ARRAYS; CELL-PROLIFERATION; PROTEIN; STATISTICS; CHAPERONE; PATHWAYS; TUMOR; STIP1; CARCINOMA	Stress-induced phosphoprotein 1 (STIP1) is an adaptor protein that bridges HSP70 and HSP90 folding and a secretory protein that regulates malignant tumor progression. The aim of the present study was to demonstrate the clinicopathological significance and prognostic role of STIP1 in colorectal cancer (CRC). We used data from The Cancer Genome Atlas (TCGA) to analyze STIP1 expression in CRC and utilized 8 pairs of fresh-frozen tissue samples to investigate STIP1 expression in CRC tissues and adjacent normal tissues using quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot assays. We also used immunohistochemical staining to detect STIP1 expression in 144 formalin-fixed, paraffin-embedded (FFPE) CRC tissue samples and determine the clinical significance of STIP1 expression in CRC. The results of bioinformatics analysis, qRT-PCR, and Western blot showed that STIP1 expression was higher in CRC tissues than in adjacent normal tissues. High STIP1 expression was significantly correlated with advanced T stage (P = .01), N stage (P = .001), M stage (P < .001), and TNM stage (P < .001). Moreover, Kaplan-Meier analyses indicated that higher STIP1 expression predicted a worse prognosis in patients with CRC, and Cox regression analysis revealed that STIP1 was an independent prognostic factor for overall survival and disease-free survival in patients with CRC. In conclusion, our results suggest that STIP1 acts as an oncogene in CRC and can therefore serve as a biomarker for the prognosis of patients with CRC. (C) 2018 Elsevier Inc. All rights reserved.	[Zhang, Zhimei; Huang, Leilei; Kang, Jihui] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pathol, Guangzhou 510080, Guangdong, Peoples R China; [Ren, Hui; Yang, Liang; Zhang, Xinhua; Wu, Hui; Xu, Jianbo; Zhai, Ertao; Cai, Shirong; He, Yutong] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, 58 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China; [Liang, Wei] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Guangzhou 510080, Guangdong, Peoples R China; [Zhai, Ertao] Sun Yat Sen Univ, Affiliated Hosp 1, Gen Surg Lab, Guangzhou 510080, Guangdong, Peoples R China	Zhai, ET; He, YT (reprint author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, 58 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China.	zhaiert@mail2.sysu.edu.cn; heyulong001@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81772579, 81372341, 81472260]; Natural Science Foundation of Guangdong ProvinceNational Natural Science Foundation of Guangdong Province [2017A030313513, 2017A030313861, 2015A030313053]; Postdoctoral Science Foundation of ChinaChina Postdoctoral Science Foundation [2017 M622878]; Science and Technology Foundation of Guangzhou [201707010125, 201607010050]; Medical Science and Technology Research Foundation of Guangdong Province [A2017058]; "3 and 3"Project of The First Affiliated Hospital of Sun Yat-sen University; Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities [15ykpy17]	This study was supported by grants from the National Natural Science Foundation of China (81772579, 81372341 and 81472260), the Natural Science Foundation of Guangdong Province (2017A030313513, 2017A030313861 and 2015A030313053), Postdoctoral Science Foundation of China (2017 M622878), the Science and Technology Foundation of Guangzhou (201707010125 and 201607010050), the Medical Science and Technology Research Foundation of Guangdong Province (A2017058), "3 and 3"Project of The First Affiliated Hospital of Sun Yat-sen University (Yulong He), and the Fundamental Research Funds for the Central Universities (15ykpy17).	Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Chao A, 2013, TAIWAN J OBSTET GYNE, V52, P185, DOI 10.1016/j.tjog.2013.04.006; Chao A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057084; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Chen ZB, 2017, BIOCHEM BIOPH RES CO, V493, P365, DOI 10.1016/j.bbrc.2017.09.016; Cho H, 2014, GENE CHROMOSOME CANC, V53, P277, DOI 10.1002/gcc.22136; Erlich RB, 2007, GLIA, V55, P1690, DOI 10.1002/glia.20579; Gaedcke J, 2010, GENE CHROMOSOME CANC, V49, P1024, DOI 10.1002/gcc.20811; Gaspar C, 2008, AM J PATHOL, V172, P1363, DOI 10.2353/ajpath.2008.070851; Graudens E, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-3-r19; Hong Y, 2010, CLIN EXP METASTAS, V27, P83, DOI 10.1007/s10585-010-9305-4; Huang LL, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0676-8; Kaiser S, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-7-r131; Ki DH, 2007, INT J CANCER, V121, P2005, DOI 10.1002/ijc.22975; Kubota H, 2010, CELL STRESS CHAPERON, V15, P1003, DOI 10.1007/s12192-010-0211-0; Linden R, 2008, PHYSIOL REV, V88, P673, DOI 10.1152/physrev.00007.2007; Notterman DA, 2001, CANCER RES, V61, P3124; Odunuga OO, 2004, BIOESSAYS, V26, P1058, DOI 10.1002/bies.20107; Picard D, 2002, CELL MOL LIFE SCI, V59, P1640, DOI 10.1007/PL00012491; Sabates-Beliver J, 2007, MOL CANCER RES, V5, P1263, DOI 10.1158/1541-7786.MCR-07-0267; Schmid AB, 2012, EMBO J, V31, P1506, DOI 10.1038/emboj.2011.472; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Skrzypczak M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013091; Taipale M, 2010, NAT REV MOL CELL BIO, V11, P515, DOI 10.1038/nrm2918; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tsai CL, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0040-z; Tsai CL, 2016, ONCOTARGET, V7, P50548, DOI 10.18632/oncotarget.10500; Tsai CL, 2012, CELL REP, V2, P283, DOI 10.1016/j.celrep.2012.07.002; Walsh N, 2011, CANCER LETT, V306, P180, DOI 10.1016/j.canlet.2011.03.004; Wang HS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190573; Wang J, 2017, ONCOTARGET, V8, P17012, DOI 10.18632/oncotarget.15222; Wang TH, 2010, MOL CELL PROTEOMICS, V9, P1873, DOI 10.1074/mcp.M110.000802; Young JC, 2004, NAT REV MOL CELL BIO, V5, P781, DOI 10.1038/nrm1492; Yuan MH, 2014, TUMOR BIOL, V35, P2391, DOI 10.1007/s13277-013-1316-8; Zhai ET, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0336-9	36	2	2	1	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	SEP	2018	79						135	143		10.1016/j.humpath.2018.05.016			9	Pathology	Pathology	GU3HT	WOS:000445167900016	29879402				2019-10-28	
J	Czapiewski, P; Kunc, M; Gorczynski, A; Haybaeck, J; Okon, K; Reszec, J; Lewczuk, A; Dzierzanowski, J; Karczewska, J; Biernat, W; Tuni-Zanoni, M; Castelnuovo, P; Taverna, C; Franchi, A; La Rosa, S; Sessa, F; Kloppel, G				Czapiewski, Piotr; Kunc, Michal; Gorczynski, Adam; Haybaeck, Johannes; Okon, Krzysztof; Reszec, Joanna; Lewczuk, Anna; Dzierzanowski, Jaroslaw; Karczewska, Joanna; Biernat, Wojciech; Tuni-Zanoni, Mario; Castelnuovo, Paolo; Taverna, Cecilia; Franchi, Alessandro; La Rosa, Stefano; Sessa, Fausto; Kloeppel, Guenter			Frequent expression of somatostatin receptor 2a in olfactory neuroblastomas: a new and distinctive feature	HUMAN PATHOLOGY			English	Article						Olfactory neuroblastoma; Neuroendocrine neoplasm; Somatostatin receptors; Immunohistochemistry; SSTR2A; SSTR5	NEUROENDOCRINE NEOPLASMS; TUMORS; ESTHESIONEUROBLASTOMA; OCTREOTIDE; SURVIVAL; SUBTYPES; IMMUNOHISTOCHEMISTRY; SCINTIGRAPHY; THERAPY; ANALOGS	Olfactory neuroblastoma (ONB) is a malignant neuroendocrine neoplasm with a usually slow course, but with considerable recurrence rate. Many neuroendocrine tumors have shown good response to the treatment with somatostatin analogs and somatostatin radioreceptor therapy. In ONBs, there are scarce data on somatostatin-based treatment and the cellular expression of somatostatin receptors (SSTR), the prerequisite for binding and effect of somatostatin on normal and tumor cells. The aim of our study was to investigate the immunohistochemical expression of SSTR2A and SSTR5 in a cohort of 40 ONBs. In addition, tissue microarrays containing 40 high-grade sinonasal carcinomas as well as 6 sinonasal lymphomas, 3 rhab-domyosarcomas, and 3 Ewing sarcomas were evaluated. Volante system was applied for staining evaluation. Thirty cases (75%) were immunopositive for SSTR2A and 3 (7.5%) for SSTR5. Among the 30 SSTR2A-positive ONBs, 19 tumors (63.3%) scored 2+ and 11 (36.7%) scored 3+. All SSTR5-positive ONBs scored 2+. Neither sinonasal carcinomas nor sinonasal small round blue cell neoplasms expressed SSTR2A or SSTR5. The frequent expression of SSTR2A provides a rationale for radioreceptor diagnosis and therapy with SST analogs in ONBs. SSTR2A expression in ONBs is a helpful adjunct in the differential diagnosis of ONBs. (C) 2018 Elsevier Inc. All rights reserved.	[Czapiewski, Piotr; Kunc, Michal; Gorczynski, Adam; Karczewska, Joanna; Biernat, Wojciech] Med Univ Gdansk, Dept Pathomorphol, Gdansk, Poland; [Czapiewski, Piotr; Haybaeck, Johannes] Otto von Guericke Univ, Dept Pathol, Magdeburg, Germany; [Haybaeck, Johannes] Med Univ Graz, Inst Pathol, Dept Neuropathol, Graz, Austria; [Okon, Krzysztof] Jagiellonian Univ, Dept Pathomorphol, Coll Med, Krakow, Poland; [Reszec, Joanna] Med Univ Bialystok, Dept Med Pathomorphol, Bialystok, Poland; [Lewczuk, Anna] Med Univ Gdansk, Dept Endocrinol & Internal Med, Gdansk, Poland; [Dzierzanowski, Jaroslaw] Med Univ Gdansk, Dept Neurosurg, Gdansk, Poland; [Tuni-Zanoni, Mario; Castelnuovo, Paolo] Univ Insubria, Dept Biotechnol & Life Sci DBSV, Div Otorhinolaryngol, Varese, Italy; [Taverna, Cecilia] Univ Florence, Dept Surg & Translat Med, Sect Anat Pathol, Florence, Italy; [Franchi, Alessandro] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy; [La Rosa, Stefano] Lausanne Univ Hosp, Inst Pathol, Serv Clin Pathol, Lausanne, Switzerland; [Sessa, Fausto] Univ Insubria, Dept Med & Surg, Varese, Italy; [Kloeppel, Guenter] Tech Univ Munich, Dept Pathol, Munich, Germany	Czapiewski, P (reprint author), Otto von Guericke Univ, Dept Pathol, Magdeburg, Germany.	czapiewskipiotr@gumed.edu.pl	Turri-Zanoni, Mario/H-9837-2019; Reszec, Joanna/T-7207-2018; Okon, Krzysztof/D-1345-2011; Kunc, Michal/N-6163-2018	Turri-Zanoni, Mario/0000-0002-3678-9088; Reszec, Joanna/0000-0002-0169-0897; Okon, Krzysztof/0000-0002-1921-5007; Gorczynski, Adam/0000-0002-1950-452X; Kunc, Michal/0000-0001-9529-2381	Medical University of GdanskUniversity of California System [ST-95]	This study was supported by the Medical University of Gdansk (Grant No. ST-95, to P. C., A. G., W. B.).	Broich G, 1997, ANTICANCER RES, V17, P2683; Brunner P, 2017, EUR J NUCL MED MOL I, V44, P468, DOI 10.1007/s00259-016-3486-2; Czapiewski P, 2016, ONCOTARGET, V7, P52584, DOI 10.18632/oncotarget.9683; Diakatou E, 2015, CLIN ENDOCRINOL, V83, P420, DOI 10.1111/cen.12775; Dinca Eduard B, 2012, J Med Case Rep, V6, P240; Dunbar EM, 2012, RARE TUMORS, V4, P101, DOI 10.4081/rt.2012.e33; El-Naggar A, 2017, WHO CLASSIFICATION H; Gonzalez B, 2014, ENDOCRINOL NUTR, V61, P523, DOI 10.1016/j.endonu.2014.05.006; Hankus J, 2016, NUCL MED REV, V19, P111, DOI 10.5603/NMR.2016.0022; Hofman MS, 2012, J MED IMAG RADIAT ON, V56, P40, DOI 10.1111/j.1754-9485.2011.02327.x; Hyams VJ, 1988, ATLAS TUMOR PATHOL, P240; Kaemmerer D, 2015, PANCREAS, V44, P648, DOI 10.1097/MPA.0000000000000316; Kane AJ, 2010, J NEUROSURG, V113, P340, DOI 10.3171/2010.2.JNS091897; Kasajima A, 2018, HUM PATHOL, V72, P144, DOI 10.1016/j.humpath.2017.11.008; Kasuki L, 2013, EUR J ENDOCRINOL, V169, P217, DOI 10.1530/EJE-13-0349; Konig MS, 2014, NEUROCHIRURGIE, V60, P151, DOI 10.1016/j.neuchi.2014.03.007; Konukiewitz B, 2017, MODERN PATHOL, V30, P587, DOI 10.1038/modpathol.2016.217; Kumar U, 2010, RESULTS PROBL CELL D, V50, P137, DOI 10.1007/400_2009_29; Lamberts SWJ, 1996, NEW ENGL J MED, V334, P246, DOI 10.1056/NEJM199601253340408; Liu Y, 2013, ONCOL LETT, V6, P821, DOI 10.3892/ol.2013.1435; Makis W, 2015, CLIN NUCL MED, V40, P317, DOI 10.1097/RLU.0000000000000705; Mehta S, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001281; Mukherji A, 2014, Gulf J Oncolog, V1, P89; Myssiorek D, 2005, LARYNGOSCOPE, V115, P1707, DOI 10.1097/01.mlg.0000172200.90129.9b; Nakamura A, 2016, ENDOCR J, V63, P135, DOI 10.1507/endocrj.EJ15-0371; Papotti M, 2002, VIRCHOWS ARCH, V440, P461, DOI 10.1007/s00428-002-0609-x; Patel YC, 1999, FRONT NEUROENDOCRIN, V20, P157, DOI 10.1006/frne.1999.0183; Petruzzelli GJ, 2015, AM J OTOLARYNG, V36, P547, DOI 10.1016/j.amjoto.2015.02.008; Preusser M, 2010, J NEURO-ONCOL, V97, P305, DOI 10.1007/s11060-009-0027-x; Rai U, 2015, PHARMACOL THERAPEUT, V152, P98, DOI 10.1016/j.pharmthera.2015.05.007; Rao AJ, 2011, J NEUROSURG-SPINE, V15, P571, DOI 10.3171/2011.6.SPINE11157; REUBI JC, 1990, J STEROID BIOCHEM, V37, P1073, DOI 10.1016/0960-0760(90)90468-Z; Reubi JC, 2003, ENDOCR REV, V24, P389, DOI 10.1210/er.2002-0007; Reubi JC, 2007, VIRCHOWS ARCH, V451, pS47, DOI 10.1007/s00428-007-0443-2; Rostomily RC, 2006, HEAD NECK-J SCI SPEC, V28, P305, DOI 10.1002/hed.20356; Savelli G, 2016, J NEURO-ONCOL, V127, P617, DOI 10.1007/s11060-016-2067-3; Sundin A, 2007, BEST PRACT RES CL EN, V21, P69, DOI 10.1016/j.beem.2006.12.003; Tajudeen BA, 2015, J NEUROL SURG PART B, V76, P43, DOI 10.1055/s-0034-1390011; Taniyama Y, 2005, ENDOCR J, V52, P605, DOI 10.1507/endocrj.52.605; Turner JH, 2012, HEAD NECK-J SCI SPEC, V34, P877, DOI 10.1002/hed.21830; Turri-Zanoni M, 2017, ORAL ONCOL, V74, P21, DOI 10.1016/j.oraloncology.2017.09.010; Van Gompel JJ, 2013, NEUROSURGERY, V72, P332, DOI 10.1227/NEU.0b013e31827fcdc2; Vezzosi D, 2005, EUR J ENDOCRINOL, V152, P757, DOI 10.1530/eje.1.01901; Volante M, 2007, MODERN PATHOL, V20, P1172, DOI 10.1038/modpathol.3800954; Wang YH, 2017, ONCOL LETT, V13, P1165, DOI 10.3892/ol.2017.5591; Watanabe N, 2014, ACTA HISTOCHEM CYTOC, V47, P219, DOI 10.1267/ahc.14024; Wick W, 2004, J NEURO-ONCOL, V70, P73, DOI 10.1023/B:NEON.0000040826.30636.4a; Wildemberg LEA, 2013, J ENDOCRINOL INVEST, V36, P38, DOI 10.3275/8305; Wildemberg LEA, 2012, J ENDOCRINOL INVEST, V35, P580, DOI 10.3275/7906; Zhang LB, 2017, CONTRAST MEDIA MOL I, DOI 10.1155/2017/9481276	50	1	1	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	SEP	2018	79						144	150		10.1016/j.humpath.2018.05.013			7	Pathology	Pathology	GU3HT	WOS:000445167900017	29807052				2019-10-28	
J	Xin, ZX; Zhang, Y; Jiang, Z; Zhao, L; Fan, LC; Wang, YQ; Xie, SW; Xun, SG; Zhu, YJ; Pan, JH; Liu, Q; Huang, YR; Dong, BJ; Xue, W				Xin, Zhixiang; Zhang, Yong; Jiang, Zhou; Zhao, Ling; Fan, Liancheng; Wang, Yanqing; Xie, Shaowei; Xun Shangguan; Zhu, Yinjie; Pan, Jiahua; Liu, Qiang; Huang, Yiran; Dong, Baijun; Xue, Wei			Insulinoma-associated protein 1 is a novel sensitive and specific marker for small cell carcinoma of the prostate	HUMAN PATHOLOGY			English	Article						Prostate cancer; Neuroendocrine tumors; Small cell carcinoma; Immunohistochemistry; Surgical pathology	NEUROENDOCRINE DIFFERENTIATION; CANCER; INSM1; TUMORS; EXPRESSION; NEOPLASMS; LUNG; ADENOCARCINOMA; PERSPECTIVES	The correct diagnosis of small cell carcinoma (SCC) of the prostate is critical because of its aggressive behavior and poor prognosis. The histopathologic diagnosis could be challenging without neuroendocrine markers, which currently has limitations. Insulinoma-associated protein 1 (INSM1), a zinc-finger transcription factor, is considered to play an important role in the development of several neuroendocrine precursor cells. Its diagnosis value has only recently been evaluated. In this study, we analyzed the expression of INSM in three high-throughput RNA sequencing data sets and performed INSM1 immunohistochemistry on a large series of prostatic SCCs and non-neuroendocrine prostate tissues. To validate its possible utility as a diagnostic marker, the performance of chromogranin and synaptophysin was used for comparison. We found INSM1 mRNA is up-regulated in neuroendocrine prostate carcinoma samples from the published data sets. The results were verified by the immunohistochemistry performance. INSM1 was positive in 92.3% of prostatic SCCs, compared with 53.8% positive for chromogranin, and 84.6% positive for synaptophysin. INSM1 was also stained all of the mixed SCC-acinar adenocarcinomas and metastatic SCCs progression from acinar adenocarcinoma. Only 3.4% of benign prostate tissues and 4.0% of prostate adenocarcinomas were INSM1 positive. Our data suggest that INSM1 is a novel sensitive and specific marker for detection of SCC of the prostate. Application of INSM1 in clinical pathologic diagnosis will be valuable. (C) 2018 Elsevier Inc. All rights reserved.	[Xin, Zhixiang; Zhang, Yong; Fan, Liancheng; Wang, Yanqing; Xun Shangguan; Zhu, Yinjie; Pan, Jiahua; Huang, Yiran; Dong, Baijun; Xue, Wei] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Urol, Shanghai 200127, Peoples R China; [Jiang, Zhou; Zhao, Ling; Liu, Qiang] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Pathol, Shanghai 200127, Peoples R China; [Xie, Shaowei] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Ultrasound, Shanghai 200127, Peoples R China	Dong, BJ; Xue, W (reprint author), 160 Pujian Rd, Shanghai, Peoples R China.	dongbaijun@hotmail.com; uroxuewei@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81 572 536, 81 672 850, 81 772 742, 81 702 840, 81 702 542]; Science and Technology Commission of Shanghai MunicipalityScience & Technology Commission of Shanghai Municipality (STCSM) [14 140 901 700, 16 411 969 800]; Shanghai Shenkang Hospital Development Center [SHDC12015125, 16CR3049A]; Shanghai Municipal Education CommissionShanghai Municipal Education Commission (SHMEC) [15ZZ058]; Shanghai Municipal Commission of Health and Family Planning [201640247]; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support [20152215]; Shanghai Jiao Tong University [YG2016ZD08, YG2017MS47, YG2017MS52]; Innovation Fund for Translational Research of Shanghai Jiao Tong University School of Medicine [15ZH4002]; Incubating Program for clinical Research and Innovation of Renji Hospital Shanghai Jiao Tong University School of Medicine [PYZY16-008, PYXJS16-015]	This work was supported by National Natural Science Foundation of China (81 572 536, 81 672 850, 81 772 742, 81 702 840, 81 702 542), Science and Technology Commission of Shanghai Municipality (14 140 901 700, 16 411 969 800), Shanghai Shenkang Hospital Development Center (SHDC12015125, 16CR3049A), Shanghai Municipal Education Commission (15ZZ058), Shanghai Municipal Commission of Health and Family Planning (201640247), Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (20152215), Shanghai Jiao Tong University (YG2016ZD08, YG2017MS47, YG2017MS52); Innovation Fund for Translational Research of Shanghai Jiao Tong University School of Medicine (15ZH4002), and Incubating Program for clinical Research and Innovation of Renji Hospital Shanghai Jiao Tong University School of Medicine (PYZY16-008, PYXJS16-015).	ABRAHAMSSON PA, 1993, J ANDROL, V14, P307; Akamatsu S, 2015, CELL REP, V12, P922, DOI 10.1016/j.celrep.2015.07.012; Ames HM, 2018, J NEUROPATH EXP NEUR, V77, P374, DOI 10.1093/jnen/nly014; Ather M Hammad, 2008, BMC Urol, V8, P21, DOI 10.1186/1471-2490-8-21; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Dermawan JK, 2018, HISTOPATHOLOGY, V72, P1067, DOI 10.1111/his.13458; DISANTAGNESE PA, 1992, CANCER-AM CANCER SOC, V70, P254, DOI 10.1002/1097-0142(19920701)70:1+<254::AID-CNCR2820701312>3.0.CO;2-E; Doxtader EE, 2018, CANCER CYTOPATHOL, V126, P243, DOI 10.1002/cncy.21972; Erasmus CE, 2002, CAN J NEUROL SCI, V29, P375, DOI 10.1017/S0317167100002250; Erickson LA, 2004, ADV ANAT PATHOL, V11, P175, DOI 10.1097/01.pap.0000131824.77317.a7; Fine SW, 2018, MODERN PATHOL, V31, pS122, DOI 10.1038/modpathol.2017.164; Fujino K, 2015, AM J PATHOL, V185, P3164, DOI 10.1016/j.ajpath.2015.08.018; GOTO Y, 1992, J BIOL CHEM, V267, P15252; Hansel DE, 2009, PROSTATE, V69, P603, DOI 10.1002/pros.20910; Helpap B, 1999, UROL INT, V62, P133, DOI 10.1159/000030376; La Rosa S, 2013, HUM PATHOL, V44, P1391, DOI 10.1016/j.humpath.2012.11.013; Lan MS, 2009, FASEB J, V23, P2024, DOI 10.1096/fj.08-125971; McColl K, 2017, ONCOTARGET, V8, P73745, DOI 10.18632/oncotarget.20572; Miyoshi Y, 2001, BJU INT, V88, P982, DOI 10.1046/j.1464-4096.2001.00936.x; Park JW, 2017, MODERN PATHOL, V30, P1262, DOI 10.1038/modpathol.2017.44; PEARSE AGE, 1969, J HISTOCHEM CYTOCHEM, V17, P303, DOI 10.1177/17.5.303; Priemer DS, 2016, ENDOCR PATHOL, V27, P123, DOI 10.1007/s12022-016-9421-z; Robinson D, 2016, NAT MED, V22, P298; Rooper LM, 2018, AM J SURG PATHOL, V42, P665, DOI 10.1097/PAS.0000000000001037; Rooper LM, 2017, AM J SURG PATHOL, V41, P1561, DOI 10.1097/PAS.0000000000000916; Rosenbaum JN, 2015, AM J CLIN PATHOL, V144, P579, DOI 10.1309/AJCPGZWXXBSNL4VD; Rush PS, 2018, J CUTAN PATHOL, V45, P129, DOI 10.1111/cup.13079; Sun Y, 2009, AM J TRANSL RES, V1, P148; Tan HL, 2014, CLIN CANCER RES, V20, P890, DOI 10.1158/1078-0432.CCR-13-1982; Tanigawa M, 2018, MED MOL MORPHOL, V51, P32, DOI 10.1007/s00795-017-0167-6; Theodoropoulos VE, 2005, UROLOGY, V66, P897, DOI 10.1016/j.urology.2005.04.064; Vlachostergios PJ, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00006; Wang W, 2008, AM J SURG PATHOL, V32, P65, DOI 10.1097/PAS.0b013e318058a96b; Yao JL, 2006, AM J SURG PATHOL, V30, P705, DOI 10.1097/00000478-200606000-00005; Yashi M, 2002, UROL INT, V69, P166, DOI 10.1159/000065572; Yoshida A, 2018, MODERN PATHOL, V31, P744, DOI 10.1038/modpathol.2017.189	36	9	8	3	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	SEP	2018	79						151	159		10.1016/j.humpath.2018.05.014			9	Pathology	Pathology	GU3HT	WOS:000445167900018	29885405				2019-10-28	
J	Lee, HE; Molina, JR; Sukov, WR; Roden, AC; Yi, ES				Lee, Hee Eun; Molina, Julian R.; Sukov, William R.; Roden, Anja C.; Yi, Eunhee S.			BAP1 loss is unusual in well-differentiated papillary mesothelioma and may predict A development of malignant mesothelioma	HUMAN PATHOLOGY			English	Article						Well-differentiated papillary mesothelioma; BAP1; p16; CDKN2A; Single-nucleotide polymorphism genomic microarray; Malignant mesothelioma	P16 FISH; PERITONEAL MESOTHELIOMA; P16/CDKN2A DELETION; GENE-EXPRESSION; PROLIFERATIONS; TUMORS; IMMUNOHISTOCHEMISTRY; OVEREXPRESSION; CANCER	Literature on BRCA1-associated protein 1 (BAP1) expression status in well-differentiated papillary mesothelioma (WDPM) is limited. In the present study, we examined the prevalence of BAP1 loss in WDPM by immunohistochemistry with clinical correlation, along with CDKN2A deletion status by fluorescence in situ hybridization (FISH). Eight patients diagnosed as having WDPM were identified from the surgical pathology file. Adenomatoid tumors (n = 8) and malignant mesothelioma (MM) (n = 39) were included for comparison. BAP1 immunohistochemistry was performed on representative block(s) from each case. CDKN2A FISH was also performed in the WDPMs and adenomatoid tumors. Clinical information was obtained from the medical records. Three of 8 WDPM patients showed synchronous or metachronous MM. All 3 cases showed BAP1 loss in both WDPM and the matched MM. Single-nucleotide polymorphism genomic microarray (n = 3) demonstrated a similar genetic profile in the WDPM and MM components, which supports their clonal relationship. The remaining 5 WDPM cases had intact BAP1 expression and had no evidence of disease on follow-up imaging studies at 1 to 71 months (median, 35 months). All 8 adenomatoid tumors had intact BAP1 expression, whereas 17 of 39 MM had BAP1 loss. CDKN2A FISH was negative for deletion in 4 WDPMs tested (including the case that developed MM) and all 8 adenomatoid tumors. In our study, WDPM did not show CDKN2A deletion in any case. BAP1 loss was also absent in all pure WDPM cases but was identified in all WDPM with synchronous or metachronous MM. Similar genetic landscape in WDPM and MM components suggested their clonal relationship. (C) 2018 Elsevier Inc. All rights reserved.	[Lee, Hee Eun; Sukov, William R.; Roden, Anja C.; Yi, Eunhee S.] Mayo Clin, Div Anat Pathol, Rochester, MN 55905 USA; [Molina, Julian R.] Mayo Clin, Div Med Oncol, Rochester, MN 55905 USA; [Sukov, William R.] Mayo Clin, Div Mol Genet, Rochester, MN 55905 USA	Yi, ES (reprint author), Mayo Clin, Div Anat Pathol, Rochester, MN 55905 USA.	Yi.Joanne@mayo.edu					CHENG JQ, 1994, CANCER RES, V54, P5547; Chiosea S, 2008, MODERN PATHOL, V21, P742, DOI 10.1038/modpathol.2008.45; Chung CTS, 2010, J CLIN PATHOL, V63, P630, DOI 10.1136/jcp.2010.076794; Churg A, 2014, AM J SURG PATHOL, V38, P990, DOI 10.1097/PAS.0000000000000200; Cigognetti M, 2015, MODERN PATHOL, V28, P1043, DOI 10.1038/modpathol.2015.65; Farzin M, 2015, PATHOLOGY, V47, P302, DOI 10.1097/PAT.0000000000000250; Galateau-Salle F, 2016, J THORAC ONCOL, V11, P142, DOI 10.1016/j.jtho.2015.11.005; Hwang H, 2014, AM J SURG PATHOL, V38, P681, DOI 10.1097/PAS.0000000000000176; Hwang HC, 2016, AM J SURG PATHOL, V40, P714, DOI 10.1097/PAS.0000000000000616; Ito T, 2015, AM J CLIN PATHOL, V143, P830, DOI 10.1309/AJCPOATJ9L4GCGDA; Joseph NM, 2017, MODERN PATHOL, V30, P246, DOI 10.1038/modpathol.2016.188; Lopez-Rios F, 2006, CANCER RES, V66, P2970, DOI 10.1158/0008-5472.CAN-05-3907; McGregor SM, 2015, HUM PATHOL, V46, P1670, DOI 10.1016/j.humpath.2015.06.024; Musti M, 2006, CANCER GENET CYTOGEN, V170, P9, DOI 10.1016/j.cancergencyto.2006.04.011; Prins JB, 1998, INT J CANCER, V75, P649, DOI 10.1002/(SICI)1097-0215(19980209)75:4<649::AID-IJC25>3.0.CO;2-2; Rai K, 2016, CLIN GENET, V89, P285, DOI 10.1111/cge.12630; Ribeiro C, 2013, ANN ONCOL, V24, P2147, DOI 10.1093/annonc/mdt135; Roggli V, 2015, WHO CLASSIFICATION T, P170; Romagosa C, 2011, ONCOGENE, V30, P2087, DOI 10.1038/onc.2010.614; Sheffield BS, 2015, AM J SURG PATHOL, V39, P977, DOI 10.1097/PAS.0000000000000394; Shinozaki-Ushiku A, 2017, HISTOPATHOLOGY, V70, P722, DOI 10.1111/his.13123; Testa JR, 2011, NAT GENET, V43, P1022, DOI 10.1038/ng.912; Wang A, 2016, J CLIN PATHOL, V69, P750, DOI 10.1136/jclinpath-2016-203866; Witkiewicz AK, 2011, CELL CYCLE, V10, P2497, DOI 10.4161/cc.10.15.16776; XIAO S, 1995, ONCOGENE, V11, P511; Yu H, 2010, MOL CELL BIOL, V30, P5071, DOI 10.1128/MCB.00396-10	26	4	4	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	SEP	2018	79						168	176		10.1016/j.humpath.2018.05.001			9	Pathology	Pathology	GU3HT	WOS:000445167900020	29763720				2019-10-28	
J	Oster, C; Stein, T; Kitahara, S; Alkan, S; Huang, Q				Oster, Cyrus; Stein, Theodore; Kitahara, Sumire; Alkan, Serhan; Huang, Qin			Kaposi sarcoma-associated herpesvirus/human herpesvirus 8-associated extracavitary primary effusion lymphoma presenting as multiple lymphomatous polyposis	HUMAN PATHOLOGY			English	Article						KSHV/HHV8-associated lymphoma; Primary effusion lymphoma; Multiple lymphomatous polyposis; HIV infection; Esophagogastroduodenoscopy; Colonoscopy	MANTLE-CELL LYMPHOMA; VARIANT; BOWEL	Primary effusion lymphoma (PEL) is a distinct clinicopathological entity usually characterized by presentation as a lymphomatous body cavity effusion in the absence of solid tumor mass or dissemination during its clinical course. PEL can also rarely occur as a solid lymphoma involving nodal and extra-nodal sites and is referred to as extracavitary PEL. Here we report a unique case of extracavitary PEL in a 49-year-old HIV-seropositive patient who presented with vague abdominal pain and 20-lb weight loss. Esophagogastroduodenoscopy and colonoscopy revealed more than 100 broad-based intestinal polyps ranging from 2 mm to 3 cm in size, spreading from the duodenum to the rectum as a typical impression of "intestinal polyposis syndrome." Multiple biopsies demonstrated sheets of large lymphoid cells with characteristic features of extracavitary PEL with strong Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 virus positivity by immunohistochemistry. Extracavitary PEL presenting as distinctive multiple lymphomatous polyposis as manifested in the case has not been described previously. (C) 2018 Elsevier Inc. All rights reserved.	[Oster, Cyrus; Kitahara, Sumire; Alkan, Serhan; Huang, Qin] Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USA; [Stein, Theodore] Cedars Sinai Med Ctr, Dept Gastroenterol, Los Angeles, CA 90048 USA	Huang, Q (reprint author), Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USA.	Qin.Huang@cshs.org					Cesarman E, 1996, AM J PATHOL, V149, P53; Cesarman E, 1999, SEMIN CANCER BIOL, V9, P165, DOI 10.1006/scbi.1998.0118; Cesarman E, 1997, SEMIN DIAGN PATHOL, V14, P54; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; Chadburn A, 2004, AM J SURG PATHOL, V28, P1401, DOI 10.1097/01.pas.0000138177.10829.5c; CORNES JS, 1961, CANCER, V14, P249, DOI 10.1002/1097-0142(196103/04)14:2<249::AID-CNCR2820140205>3.0.CO;2-8; DePond W, 1997, AM J SURG PATHOL, V21, P719, DOI 10.1097/00000478-199706000-00013; Fu K, 2005, BLOOD, V106, P4315, DOI 10.1182/blood-2005-04-1753; Guillet S, 2016, AM J HEMATOL, V91, P233, DOI 10.1002/ajh.24251; Huang Q, 2002, AM J SURG PATHOL, V26, P1363, DOI 10.1097/01.PAS.0000027302.89469.AB; Juskevicius D, 2014, HISTOPATHOLOGY, V65, P693, DOI 10.1111/his.12478; Liao GH, 2015, EXP MOL PATHOL, V99, P445, DOI 10.1016/j.yexmp.2015.09.010; Michopoulos S, 2008, J CLIN ONCOL, V26, P1555, DOI 10.1200/JCO.2007.14.9856; Nazarullah A, 2016, HUM PATHOL CASE REP, V4, P32, DOI [10.1016/j.ehpc.2015.08.001, DOI 10.1016/J.EHPC.2015.08.001]; Okazaki K, 2004, J GASTROENTEROL, V39, P1023, DOI 10.1007/s00535-004-1459-x; Oksenhendler E, 2002, BLOOD, V99, P2331, DOI 10.1182/blood.V99.7.2331; Ota Y., 2012, J CLIN EXP PATHOL, V2, P132; Pan ZG, 2012, AM J SURG PATHOL, V36, P1129, DOI 10.1097/PAS.0b013e31825b38ec; Said J, 2017, WHO CLASSIFICATION T, P325; Said J, 2017, WHO CLASSIFICATION T, P323; Swerdlow S, 2017, WHO CLASSIFICATION T, P285	21	0	0	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	SEP	2018	79						177	183		10.1016/j.humpath.2018.02.020			7	Pathology	Pathology	GU3HT	WOS:000445167900021	29505765				2019-10-28	
J	German, MN; Matkowskyj, KA; Hoffman, RJ; Agarwal, PD				German, Margarita N.; Matkowskyj, Kristina A.; Hoffman, Robert J.; Agarwal, Parul D.			A case of syphilitic hepatitis in an HIV-infected patient	HUMAN PATHOLOGY			English	Article						Syphilitic hepatitis; HIV; Cholestatic hepatitis		While the incidence of syphilis has been persistently on the rise in the United States, hepatitis as a complication of early syphilis is relatively uncommon. We present a case of a 51-year-old homosexual, HIV-positive man who presented with acute cholestatic hepatitis with a predominantly elevated alkaline phosphatase. After laboratory studies and imaging were unrevealing, a liver biopsy was performed that showed expanded portal tracts with a predominantly lymphoplas-macytic infiltrate and prominent bile ductular proliferation with periductal neutrophils. Testing revealed a positive rapid plasma reagin, and a subsequent Warthin-Starry stain of the liver tissue demonstrated the presence of scattered spirochetes, confirmed as Treponema pallidum spirochetes on immunohistochemistry testing. These findings confirmed a diagnosis of syphilitic hepatitis. With therapy, symptoms and liver enzymes rapidly normalized. Given the persistent rise in syphilis incidence along with the morbidity and mortality associated with a missed diagnosis, keen suspicion, early identification, and treatment are crucial. (C) 2018 Elsevier Inc. All rights reserved.	[German, Margarita N.; Agarwal, Parul D.] Univ Wisconsin, Sch Med & Publ Hlth, Div Gastroenterol & Hepatol, Madison, WI 53792 USA; [Matkowskyj, Kristina A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI 53792 USA; [Hoffman, Robert J.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI 53792 USA	German, MN (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Gastroenterol & Hepatol, 1685 Highland Ave,4240-4th Floor, Madison, WI 53705 USA.	mgerman@uwhealth.org					Adachi E, 2013, J INFECT CHEMOTHER, V19, P180, DOI 10.1007/s10156-012-0440-5; Bork JT, 2014, SEX TRANSM DIS, V41, P507, DOI 10.1097/OLQ.0000000000000143; Byard RW, 2018, J FORENSIC SCI, V63, P1312, DOI 10.1111/1556-4029.13709; Centers for Disease Control and Prevention, 2017, 2016 SEX TRANSM DIS; FEHER J, 1975, LANCET, V2, P896; Mullick CJ, 2004, CLIN INFECT DIS, V39, pE100, DOI 10.1086/425501; YOUNG MF, 1992, J CLIN GASTROENTEROL, V15, P174	7	1	1	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	SEP	2018	79						184	187		10.1016/j.humpath.2018.02.017			4	Pathology	Pathology	GU3HT	WOS:000445167900022	29505766				2019-10-28	
J	Krencz, I; Sebestyen, A; Papay, J; Jeney, A; Hujber, Z; Burger, CD; Keller, CA; Khoor, A				Krencz, Ildiko; Sebestyen, Anna; Papay, Judit; Jeney, Andras; Hujber, Zoltan; Burger, Charles D.; Keller, Cesar A.; Khoor, Andras			In situ analysis of mTORC1/2 and cellular metabolism-related proteins in human Lymphangioleiomyomatosis	HUMAN PATHOLOGY			English	Article						Lymphangioleiomyomatosis; mTORC1; mTORC2; Cellular metabolism; Immunohistochemistry	GLUTAMINE-METABOLISM; DIAGNOSIS; PROLIFERATION; GUIDELINES; SIROLIMUS; RAPAMYCIN; EFFICACY; THERAPY; TARGET; SAFETY	Lymphangioleiomyomatosis (LAM) is a rare progressive cystic lung disease with features of a low-grade neoplasm. It is primarily caused by mutations in TSC1 or TSC2 genes. Sirolimus, an inhibitor of mTOR complex 1 (mTORC1), slows down disease progression in some, but not all patients. Hitherto, other potential therapeutic targets such as mTOR complex 2 (mTORC2) and various metabolic pathways have not been investigated in human LAM tissues. The aim of this study was to assess activities of mTORC1, mTORC2 and various metabolic pathways in human LAM tissues through analysis of protein expression. Immunohistochemical analysis of p-S6 (mTORC1 downstream protein), Rictor (mTORC2 scaffold protein) as well as GLUT1, GAPDH, ATPB, GLS, MCT1, ACSS2 and CPT1A (metabolic pathway markers) were performed on lung tissue from 11 patients with sporadic LAM. Immunoreactivity was assessed in LAM cells with bronchial smooth muscle cells as controls. Expression of p-S6, Rictor, GAPDH, GLS, MCT1, ACSS2 and CPT1A was significantly higher in LAM cells than in bronchial smooth muscle cells (P < .01). No significant differences were found between LAM cells and normal bronchial smooth muscle cells in GLUT1 and ATPB expression. The results are uniquely derived from human tissue and indicate that, in addition to mTORC1, mTORC2 may also play an important role in the pathobiology of LAM. Furthermore, glutaminolysis, acetate utilization and fatty acid beta-oxidation appear to be the preferred bioenergetic pathways in LAM cells. mTORC2 and these preferred bioenergetic pathways appear worthy of further study as they may represent possible therapeutic targets in the treatment of LAM. (C) 2018 Elsevier Inc. All rights reserved.	[Krencz, Ildiko; Sebestyen, Anna; Papay, Judit; Jeney, Andras; Hujber, Zoltan] Semmelweis Univ, Dept Pathol & Expt Canc Res 1, H-1085 Budapest, Hungary; [Burger, Charles D.; Keller, Cesar A.] Mayo Clin, Div Pulm Allergy & Sleep Med, Jacksonville, FL 32224 USA; [Keller, Cesar A.] Mayo Clin, Div Transplant Med, Jacksonville, FL 32224 USA; [Khoor, Andras] Mayo Clin, Dept Lab Med & Pathol, 4500 San Pablo Rd, Jacksonville, FL 32224 USA	Khoor, A (reprint author), Mayo Clin, Dept Lab Med & Pathol, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.	khoor.andras@mayo.edu	Krencz, Ildiko/O-6434-2015		New National Excellence Program of The Ministry of Human Capacities [UNKP-17-3]; scientific grant of the Hungarian Respiratory Foundation; Bolyai Fellowship of Hungarian Academy of Sciences; Semmelweis University Innovation Found [STIA-KF-17]	This work was supported by the UNKP-17-3 New National Excellence Program of The Ministry of Human Capacities (I. K.), scientific grant of the Hungarian Respiratory Foundation (I. K.), Bolyai Fellowship of Hungarian Academy of Sciences (A. S.), and Semmelweis University Innovation Found STIA-KF-17 (A. S.).	Adachi K, 2015, HUM PATHOL, V46, P1685, DOI 10.1016/j.humpath.2015.02.019; Bee J, 2018, THORAX, V73, P369, DOI 10.1136/thoraxjnl-2017-210872; Beloribi-Djefaflia S, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.49; Calvo MB, 2010, INT J ENDOCRINOL, DOI 10.1155/2010/205357; Comerford SA, 2014, CELL, V159, P1591, DOI 10.1016/j.cell.2014.11.020; Csibi A, 2013, CELL, V153, P840, DOI 10.1016/j.cell.2013.04.023; Csibi A, 2014, CURR BIOL, V24, P2274, DOI 10.1016/j.cub.2014.08.007; DeBerardinis RJ, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600200; El-Chemaly S, 2014, EUR RESPIR REV, V23, P30, DOI 10.1183/09059180.00008813; Flavin RJ, 2011, AM J CLIN PATHOL, V135, P776, DOI 10.1309/AJCPPC9EX1ZHMRMA; Girones R, 2014, GEN MED LOS ANGEL, V03, P167; Glasgow CG, 2010, RESP MED, V104, pS45, DOI 10.1016/j.rmed.2010.03.017; Hamanaka RB, 2012, J EXP MED, V209, P211, DOI 10.1084/jem.20120162; Hayashi T, 2016, HUM PATHOL, V50, P34, DOI 10.1016/j.humpath.2015.11.002; Johnson SR, 2010, EUR RESPIR J, V35, P14, DOI 10.1183/09031936.00076209; Kennedy BK, 2016, CELL METAB, V23, P990, DOI 10.1016/j.cmet.2016.05.009; Li J, 2016, CANCER RES, V76, P4816, DOI 10.1158/0008-5472.CAN-15-2629; Li J, 2015, P NATL ACAD SCI USA, V112, pE21, DOI 10.1073/pnas.1417015112; Long NM, 2011, INSIGHTS IMAGING, V2, P679, DOI 10.1007/s13244-010-0062-3; Lu C, 2017, ANN AM THORAC SOC, V14, P919, DOI 10.1513/AnnalsATS.201610-824OC; Matsumoto Y, 1999, AM J RESP CELL MOL, V21, P327, DOI 10.1165/ajrcmb.21.3.3693; McCormack FX, 2016, AM J RESP CRIT CARE, V194, P748, DOI 10.1164/rccm.201607-1384ST; McCormack FX, 2011, NEW ENGL J MED, V364, P1595, DOI 10.1056/NEJMoa1100391; Medvetz D, 2015, MOL CANCER RES, V13, P3, DOI 10.1158/1541-7786.MCR-14-0343; Rahman MT, 2013, ONCOLOGY-BASEL, V84, P166, DOI 10.1159/000342967; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]; Shimobayashi M, 2014, NAT REV MOL CELL BIO, V15, P155, DOI 10.1038/nrm3757; Smolarek TA, 1998, AM J HUM GENET, V62, P810, DOI 10.1086/301804; Steagall WK, 2018, AM J RESP CELL MOL, V58, P678, DOI 10.1165/rcmb.2017-0403TR; Takada T, 2016, ANN AM THORAC SOC, V13, P1912, DOI 10.1513/AnnalsATS.201605-335OC; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Young LR, 2009, CHEST, V136, P926, DOI 10.1378/chest.09-0336; Zhang XC, 2010, ARCH PATHOL LAB MED, V134, P1823, DOI 10.1043/2009-0576-RS.1; Zhe XN, 2004, J HISTOCHEM CYTOCHEM, V52, P1537, DOI 10.1369/jhc.4A6438.2004; Zhou ZQ, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.011056	35	0	0	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	SEP	2018	79						199	207		10.1016/j.humpath.2018.05.018			9	Pathology	Pathology	GU3HT	WOS:000445167900024	29885404	Green Accepted			2019-10-28	
J	Zhang, YT; Wan, D; Gao, FP				Zhang, Yutao; Wan, Dan; Gao, Fuping			Primary low-grade fibromyxoid sarcoma of the breast: a rare case report with immunohistochemical and fluorescence in situ hybridization detection	HUMAN PATHOLOGY			English	Article						Low-grade fibromyxoid sarcoma; Breast; Differential diagnosis; Immunohistochemistry; Fluorescence in situ hybridization	EPITHELIOID FIBROSARCOMA SEF; TUMOR	Low-grade fibromyxoid sarcoma (LGFMS) is a rare tumor with a bland histologic appearance but malignant biological behavior. Primary LGFMS of the breast has not been described in the English-language literature. Here, we report a 58-year-old Chinese female patient who presented with a painless mass in the right breast for more than 30 years. The tumor consists of spindle cells resembling fibroblasts and includes 2 kinds of morphologic change, which are alternating collagenized hypocellular zone and cell-rich myxoid area. There are more arcades of curvilinear blood vessels. The spindle cells are not heteromorphic, and mitotic figures are scarce. Immunostaining shows that tumor cells are positive for vimentin, mucin4, CD99, and Bcl-2, but negative for smooth muscle actin, desmin, S100, CD34, ALK, and myogenin. FUS gene rearrangement is positively detected by fluorescence in situ hybridization. The patient has been followed up for 59 months and is in a favorable condition. This rare location of LGFMS should be noted. (C) 2018 Elsevier Inc. All rights reserved.	[Zhang, Yutao; Wan, Dan] First Peoples Hosp Zigong, Dept Pathol, Zigong 643000, Sichuan, Peoples R China; [Gao, Fuping] Peoples Hosp Gaochun, Dept Pathol, Nanjing 211300, Jiangsu, Peoples R China	Zhang, YT (reprint author), First Peoples Hosp Zigong, Dept Pathol, Zigong 643000, Sichuan, Peoples R China.	bondyzyt1999@163.com					Chatterjee J, 2016, J OBSTET GYNAECOL, V36, P852, DOI 10.1080/01443615.2016.1174819; Chaudhuri Kanad, 2016, J Oral Maxillofac Pathol, V20, P334, DOI 10.4103/0973-029X.185914; Doyle LA, 2011, AM J SURG PATHOL, V35, P733, DOI 10.1097/PAS.0b013e318210c268; EVANS HL, 1987, AM J CLIN PATHOL, V88, P615, DOI 10.1093/ajcp/88.5.615; EVANS HL, 1993, AM J SURG PATHOL, V17, P595, DOI 10.1097/00000478-199306000-00007; Hwang S, 2012, SKELETAL RADIOL, V41, P1263, DOI 10.1007/s00256-012-1417-2; Kesrouani C, 2016, ANN PATHOL, V36, P351, DOI 10.1016/j.annpat.2016.07.002; Konecna J, 2015, INT J SURG CASE REP, V14, P40, DOI 10.1016/j.ijscr.2015.06.022; Kurisaki-Arakawa A, 2014, INT J SURG CASE REP, V5, P1123, DOI 10.1016/j.ijscr.2014.09.034; Papp S, 2015, VIRCHOWS ARCH, V466, P223, DOI 10.1007/s00428-014-1684-5; Prieto-Granada C, 2015, GENE CHROMOSOME CANC, V54, P28, DOI 10.1002/gcc.22215; Reid R, 2003, AM J SURG PATHOL, V27, P1229, DOI 10.1097/00000478-200309000-00006; Shibata S, 2016, ONCOL LETT, V11, P2520, DOI 10.3892/ol.2016.4221; Thway K, 2015, INT J SURG PATHOL, V23, P454, DOI 10.1177/1066896915593801; Yoshida A, 2014, AM J SURG PATHOL, V38, P552, DOI 10.1097/PAS.0000000000000137	15	1	1	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	SEP	2018	79						208	211		10.1016/j.humpath.2018.02.013			4	Pathology	Pathology	GU3HT	WOS:000445167900025	29486291				2019-10-28	
J	Shabani, N; Razaviyan, J; Paryan, M; Tavangar, SM; Azizi, F; Mohammadi-Yeganeh, S; Hedayati, M				Shabani, Noushin; Razaviyan, Javad; Paryan, Mandi; Tavangar, Seyed Mohammad; Azizi, Fereidoun; Mohammadi-Yeganeh, Samira; Hedayati, Mehdi			Evaluation of miRNAs expression in medullary thyroid carcinoma tissue samples: miR-34a and miR-144 as promising overexpressed markers in MTC	HUMAN PATHOLOGY			English	Article						MTC; AXL; mTOR; miR-144; miR-34a	CELL-PROLIFERATION; AXL; ACTIVATION; APOPTOSIS; PATHWAY; MTOR; PROFILES; INVASION; KINASE; TARGET	Medullary thyroid carcinoma (MTC) is a rare neoplasia derived from neural parafollicular C cells. MicroRNAs (miRNAs) are small regulatory RNAs with essential roles in the biology of cancers such as MTC and can be applied as diagnostic markers. According to previous studies, miR-144 and miR-34 and their two oncogenes target, mammalian target of rapamycin (mTOR) and AXL receptor tyrosine kinase (AXL), were selected for further investigations in our study. Thirty MTC samples as well as thirty adjacent normal thyroid tissues were applied in this study including 28 formalin-fixed, paraffin-embedded (FFPE) and 2 fresh-frozen MTC samples. RNA extraction and complementary DNA (cDNA) synthesis were performed for all samples. After primer pairs and probes were designed, real-time polymerase chain reaction (real-time PCR) method was used, and the results were analyzed using 2(-Delta Delta Ct) method. Receiver operating characteristic (ROC) curve analysis was applied to assess the diagnostic value of the two miRNAs. AXL protein level was measured in all clinical samples using enzyme-linked immunosorbent assay (ELISA) method. Both miRNAs were up-regulated in all clinical samples compared to the normal tissues. AXL was up-regulated in most clinical samples while mTOR was down-regulated in most samples. Furthermore, the level of AXL protein increased. ROC curve analysis demonstrated that increased expression of miR-34a and miR-144 in MTC patients had significant predictive value. The results demonstrated that high expression of miR-144 and miR-34a can be considered as biomarkers of MTC. However, there was no statistically significant correlation between the expression of these miRNAs and target genes in MTC clinical samples. (C) 2018 Elsevier Inc. All rights reserved.	[Shabani, Noushin; Mohammadi-Yeganeh, Samira] Shahid Beheshti Univ Med Sci, Dept Biotechnol, Sch Adv Technol Med, Tehran, Iran; [Razaviyan, Javad] Shahid Beheshti Univ Med Sci, Sch Med, Dept Biochem, Tehran, Iran; [Paryan, Mandi] Pasteur Inst Iran, Dept Res & Dev, Prod & Res Complex, Tehran, Iran; [Tavangar, Seyed Mohammad] Univ Tehran Med Sci, Shariati Hosp, Dept Pathol, Tehran, Iran; [Azizi, Fereidoun] Shahid Beheshti Univ Med Sci, Endocrine Res Ctr, Res Inst Endocrine Sci, Tehran, Iran; [Hedayati, Mehdi] Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, CMERC, Tehran 193954795, Iran	Hedayati, M (reprint author), Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, CMERC, Tehran 193954795, Iran.; Mohammadi-Yeganeh, S (reprint author), Taleghani Hosp, Sch Adv Technol Med, Shahid Chamran Freeway, Tehran 1985717443, Iran.	n_shabani@ymail.com; javadrazaviyan@gmail.com; mpayan@gmail.com; tavangar@ams.ac.ir; aziz@endocrine.ac.ir; s.mohammadiyeganeh@sbmu.ac.ir; hedayati@endocrine.ac.ir	azizi, Fereidoun/K-1572-2017	azizi, Fereidoun/0000-0002-6470-2517	Endocrine Sciences Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran [877]; School of Advanced Technologies, Shahid Beheshti University of Medical Sciences [7456]	This work was funded by Endocrine Sciences Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran [grant number 877] and School of Advanced Technologies, Shahid Beheshti University of Medical Sciences [grant number 7456]. The authors should thank cellular and Molecular Biology Center, Shahid Beheshti University of Medical Sciences and also Pasteur Institute of Iran, Tehran, Iran for providing technical support.	Abraham D, 2011, CLIN CANCER RES, V17, P4772, DOI 10.1158/1078-0432.CCR-11-0242; Avilla E, 2011, CANCER RES, V71, P1792, DOI 10.1158/0008-5472.CAN-10-2186; Cargnello M, 2015, MUTAGENESIS, V30, P169, DOI 10.1093/mutage/geu045; Cho CY, 2016, RNA, V22, P303, DOI 10.1261/rna.052571.115; Chu YH, 2017, EXP MOL PATHOL, V103, P229, DOI 10.1016/j.yexmp.2017.10.002; Chu YH, 2016, ENDOCR PATHOL, V27, P312, DOI 10.1007/s12022-016-9449-0; El Bezawy R, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-016-0387-6; Esquinas C, 2017, INT J CHRONIC OBSTR, V12, P3381, DOI 10.2147/COPD.S145445; Fritz HK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135991; Galuppini F, 2017, VIRCHOWS ARCH, V471, P651, DOI 10.1007/s00428-017-2227-7; Gild ML, 2013, ENDOCR-RELAT CANCER, V20, P659, DOI 10.1530/ERC-13-0085; Hedayati M, 2006, IRAN J ENDOCRINOL ME, V8, P25; Hedayati M, 2011, J THROID RES, DOI 10.4061/2011/264248; Karami F, 2016, CHEM BIOL DRUG DES, V87, P317, DOI 10.1111/cbdd.12671; Kurowska-Stolarska M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15877; Li YY, 2014, IUBMB LIFE, V66, P507, DOI 10.1002/iub.1285; Lyra J, 2014, EUR J ENDOCRINOL, V171, P633, DOI 10.1530/EJE-14-0389; Ma YF, 2013, BIOCHEM BIOPH RES CO, V441, P958, DOI 10.1016/j.bbrc.2013.11.010; Mian C, 2012, THYROID, V22, P890, DOI 10.1089/thy.2012.0045; Mohammadi M, 2017, CELL J, V18, P485; Mohammadi-Yeganeh S, 2015, CHEM BIOL DRUG DES, V86, P1185, DOI 10.1111/cbdd.12584; Mudduluru G, 2011, ONCOGENE, V30, P2888, DOI 10.1038/onc.2011.13; Pennelli G, 2015, HUM PATHOL, V46, P50, DOI 10.1016/j.humpath.2014.09.006; Pishkari S, 2018, J ENDOCRINOL INVEST, V41, P269, DOI 10.1007/s40618-017-0735-6; Plaisier CL, 2011, NUCLEIC ACIDS RES, V39, pW125, DOI 10.1093/nar/gkr374; Rapa I, 2011, J CLIN ENDOCR METAB, V96, P2146, DOI 10.1210/jc.2010-2655; Santarpia L, 2013, ENDOCR-RELAT CANCER, V20, P809, DOI 10.1530/ERC-13-0357; Schneider TC, 2015, INT J ENDOCRINOL, DOI 10.1155/2015/348124; Vitale G, 2017, MOL ONCOL, V11, P1007, DOI 10.1002/1878-0261.12070; Wu XL, 2014, ONCOTARGET, V5, P9546, DOI 10.18632/oncotarget.2542; Xiang C, 2016, J HUAZHONG U SCI-MED, V36, P186, DOI 10.1007/s11596-016-1564-0; Yeganeh Marjan Zarif, 2015, Asian Pac J Cancer Prev, V16, P2107; Zhang LY, 2013, CARCINOGENESIS, V34, P454, DOI 10.1093/carcin/bgs346; Zhou FZ, 2017, INT J CLIN EXP PATHO, V10, P5612	34	3	3	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	SEP	2018	79						212	221		10.1016/j.humpath.2018.05.019			10	Pathology	Pathology	GU3HT	WOS:000445167900026	29885402				2019-10-28	
J	Liu, C				Liu, Cheng			The phrase NIFTP accentuates, rather than resolves, the current issues with thyroid neoplasia classification	HUMAN PATHOLOGY			English	Letter							ENCAPSULATED FOLLICULAR VARIANT; CARCINOMA		[Liu, Cheng] QIMR Berghofer Med Res Inst, Herston, Qld 4006, Australia	Liu, C (reprint author), QIMR Berghofer Med Res Inst, Herston, Qld 4006, Australia.	john.liu@qimrberghofer.edu.au					Kim TH, 2018, HISTOPATHOLOGY, V72, P648, DOI 10.1111/his.13401; Lee SE, 2017, THYROID, V27, P802, DOI 10.1089/thy.2016.0547; Lloyd RV, 2018, HUM PATHOL, V74, P1, DOI 10.1016/j.humpath.2017.12.027; Nikiforov YE, 2016, JAMA ONCOL, V2, P1023, DOI 10.1001/jamaoncol.2016.0386; Parente DN, 2018, WORLD J SURG, V42, P321, DOI 10.1007/s00268-017-4182-5	5	1	1	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	SEP	2018	79						222	222		10.1016/j.humpath.2018.02.030			1	Pathology	Pathology	GU3HT	WOS:000445167900027	29879400				2019-10-28	
J	Lloyd, RV				Lloyd, Ricardo V.			The phrase NIFTP accentuates, rather than resolves, the current issues with thyroid neoplasia classification-Reply	HUMAN PATHOLOGY			English	Letter							FOLLICULAR VARIANT; RISK STRATIFICATION; CARCINOMA		[Lloyd, Ricardo V.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI 53792 USA	Lloyd, RV (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI 53792 USA.	rvlloyd@wisc.edu					Liu J, 2006, CANCER-AM CANCER SOC, V107, P1255, DOI 10.1002/cncr.22138; Lloyd RV, 2018, HUM PATHOL, V74, P1, DOI 10.1016/j.humpath.2017.12.027; Nicholson KJ, 2018, CURR OPIN ONCOL, V30, P8, DOI 10.1097/CCO.0000000000000414; Nikiforov YE, 2016, JAMA ONCOL, V2, P1023, DOI 10.1001/jamaoncol.2016.0386; Nishino M, 2018, ARCH PATHOL LAB MED, V142, P446, DOI 10.5858/arpa.2017-0174-RA; Vivero M, 2013, THYROID, V23, P273, DOI 10.1089/thy.2012.0369	6	1	1	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	SEP	2018	79						223	223		10.1016/j.humpath.2018.02.029			1	Pathology	Pathology	GU3HT	WOS:000445167900028	29879401				2019-10-28	
J	Wang, XT; Xia, QY; Ye, SB; Wang, X; Li, R; Fang, R; Shi, SS; Zhang, RS; Tan, X; Chen, JY; Sun, K; Teng, XD; Ma, HH; Lu, ZF; Zhou, XJ; Rao, Q				Wang, Xiao-tong; Xia, Qiu-yuan; Ye, Sheng-bing; Wang, Xuan; Li, Rui; Fang, Ru; Shi, Shan-shan; Zhang, Ru-song; Tan, Xiao; Chen, Jie-yu; Sun, Ke; Teng, Xiao-dong; Ma, Heng-hui; Lu, Zhen-feng; Zhou, Xiao-jun; Rao, Qiu			RNA sequencing of Xp11 translocation-associated cancers reveals novel gene fusions and distinctive clinicopathologic correlations	MODERN PATHOLOGY			English	Article							RENAL-CELL CARCINOMA; BREAK-APART FISH; TFE3 GENE; CATHEPSIN-K; TUMOR PECOMA; TRANSCRIPT LANDSCAPE; URINARY-BLADDER; NEOPLASM PECOMA; C-MYC; REARRANGEMENT	Both Xp11 translocation renal cell carcinomas and the corresponding mesenchymal neoplasms are characterized by a variety of gene fusions involving TFE3. It has been known that tumors with different gene fusions may have different clinicopathologic features; however, further in-depth investigations of subtyping Xp11 translocation-associated cancers are needed in order to explore more meaningful clinicopathologic correlations. A total of 22 unusual cases of Xp11 translocation-associated cancers were selected for the current study; 20 cases were further analyzed by RNA sequencing to explore their TFE3 gene fusion partners. RNA sequencing identified 17 of 20 cases (85%) with TFE3-associated gene fusions, including 4 ASPSCR1/ASPL-TFE3, 3 PRCC-TFE3, 3 SFPQ/PSF-TFE3, 1 NONO-TFE3, 4 MED15-TFE3, 1 MATR3-TFE3, and 1 FUBP1-TFE3. The results have been verified by fusion fluorescence in situ hybridization (FISH) assays or reverse transcriptase polymerase chain reaction (RT-PCR). The remaining 2 cases with specific pathologic features highly suggestive of MED15-TFE3 renal cell carcinoma were identified by fusion FISH assay. We provide the detailed morphologic and immunophenotypic description of the MED15-TFE3 renal cell carcinomas, which frequently demonstrate extensively cystic architecture, similar to multilocular cystic renal neoplasm of low malignant potential, and expressed cathepsin K and melanotic biomarker Melan A. This is the first time to correlate the MED15-TFE3 renal cell carcinoma with specific clinicopathologic features. We also report the first case of the corresponding mesenchymal neoplasm with MED15-TFE3 gene fusion. Additional novel TFE3 gene fusion partners, MATR3 and FUBP1, were identified. Cases with ASPSCR1-TFE3, SFPQ-TFE3, PRCC-TFE3, and NONO-TFE3 gene fusion showed a wide variability in morphologic features, including invasive tubulopapillary pattern simulating collecting duct carcinoma, extensive calcification and ossification, and overlapping and high columnar cells with nuclear grooves mimicking tall cell variant of papillary thyroid carcinoma. Furthermore, we respectively evaluated the ability of TFE3 immunohistochemistry, TFE3 FISH, RT-PCR, and RNA sequencing to subclassify Xp11 translocation-associated cancers. In summary, our study expands the list of TFE3 gene fusion partners and the clinicopathologic features of Xp11 translocation-associated cancers, and highlights the importance of subtyping Xp11 translocation-associated cancers combining morphology, immunohistochemistry, and multiple molecular techniques.	[Wang, Xiao-tong; Xia, Qiu-yuan; Ye, Sheng-bing; Wang, Xuan; Li, Rui; Fang, Ru; Shi, Shan-shan; Zhang, Ru-song; Ma, Heng-hui; Lu, Zhen-feng; Zhou, Xiao-jun; Rao, Qiu] Nanjing Univ, Sch Med, Nanjing Jinling Hosp, Dept Pathol, Nanjing, Jiangsu, Peoples R China; [Tan, Xiao] Linyi Peoples Hosp, Dept Pathol, Linyi, Shandong, Peoples R China; [Chen, Jie-yu] Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Pathol, Nanjing, Jiangsu, Peoples R China; [Sun, Ke; Teng, Xiao-dong] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Pathol, Hangzhou, Zhejiang, Peoples R China	Rao, Q (reprint author), Nanjing Univ, Sch Med, Nanjing Jinling Hosp, Dept Pathol, Nanjing, Jiangsu, Peoples R China.	raoqiu1103@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81472391, 81372743]	The authors thank Nanjing Geneseeq Technology Inc., Nanjing, China, for the NGS service. This work was supported by grants from the National Natural Science Foundation of China (81472391 to Qiu Rao and 81372743 to Xiao-jun Zhou).	Agaram NP, 2015, AM J SURG PATHOL, V39, P813, DOI 10.1097/PAS.0000000000000389; Antic T, 2017, AM J SURG PATHOL, V41, P1576, DOI 10.1097/PAS.0000000000000927; Argani P, 2002, AM J SURG PATHOL, V26, P1553, DOI 10.1097/00000478-200212000-00003; Argani P, 2003, ONCOGENE, V22, P5374, DOI 10.1038/sj.onc.1206686; Argani P, 2003, AM J SURG PATHOL, V27, P750, DOI 10.1097/00000478-200306000-00005; Argani P, 2001, AM J PATHOL, V159, P179, DOI 10.1016/S0002-9440(10)61684-7; Argani P, 2001, AM J PATHOL, V158, P2089, DOI 10.1016/S0002-9440(10)64680-9; Argani P, 2017, AM J SURG PATHOL, V41, P655, DOI 10.1097/PAS.0000000000000835; Argani P, 2016, AM J SURG PATHOL, V40, P723, DOI 10.1097/PAS.0000000000000631; Argani P, 2015, SEMIN DIAGN PATHOL, V32, P103, DOI 10.1053/j.semdp.2015.02.003; Argani P, 2010, AM J SURG PATHOL, V34, P1395, DOI 10.1097/PAS.0b013e3181f17ac0; Argani P, 2009, AM J SURG PATHOL, V33, P609, DOI 10.1097/PAS.0b013e31818fbdff; BAZAR L, 1995, ONCOGENE, V10, P2229; BELGRADER P, 1991, J BIOL CHEM, V266, P9893; Bouchireb N, 1999, CHROMOSOME RES, V7, P577, DOI 10.1023/A:1009201914881; Calio A, 2017, MODERN PATHOL, V30, P407, DOI 10.1038/modpathol.2016.200; Camparo P, 2008, AM J SURG PATHOL, V32, P656, DOI 10.1097/PAS.0b013e3181609914; Chang IW, 2009, AM J SURG PATHOL, V33, P1894, DOI 10.1097/PAS.0b013e3181ba7a5f; Clark J, 1997, ONCOGENE, V15, P2233, DOI 10.1038/sj.onc.1201394; Classe M, 2017, HISTOPATHOLOGY, V70, P1089, DOI 10.1111/his.13167; de Nigris F, 2003, CELL CYCLE, V2, P325, DOI 10.4161/cc.2.4.414; Duan J, 2017, PLOS ONE, V12; Duncan R, 1996, MOL CELL BIOL, V16, P2274; Ellis CL, 2014, MODERN PATHOL, V27, P875, DOI 10.1038/modpathol.2013.208; Erazo A, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0182-4; Green WM, 2013, AM J SURG PATHOL, V37, P1150, DOI 10.1097/PAS.0b013e31828a69ae; Huang WH, 2015, GENE CHROMOSOME CANC, V54, P500, DOI 10.1002/gcc.22261; Johnson JO, 2014, NAT NEUROSCI, V17, P664, DOI 10.1038/nn.3688; Just PA, 2016, GENE CHROMOSOME CANC, V55, P541, DOI 10.1002/gcc.22356; Kim SH, 2011, VIRCHOWS ARCH, V459, P299, DOI 10.1007/s00428-011-1127-5; Klatte T, 2012, AM J CLIN PATHOL, V137, P761, DOI 10.1309/AJCPQ6LLFMC4OXGC; Lee SE, 2012, HUM PATHOL, V43, P1126, DOI 10.1016/j.humpath.2011.10.008; LeGallo RD, 2012, AM J SURG PATHOL, V36, P1410, DOI 10.1097/PAS.0b013e31826277a9; Liu FF, 2014, INT J CLIN EXP PATHO, V7, P6409; Macher-Goeppinger S, 2012, MODERN PATHOL, V25, P308, DOI 10.1038/modpathol.2011.169; Malouf GG, 2014, CLIN CANCER RES, V20, P4129, DOI 10.1158/1078-0432.CCR-13-3036; Martignoni G, 2009, MODERN PATHOL, V22, P1016, DOI 10.1038/modpathol.2009.58; Martignoni G, 2011, MODERN PATHOL, V24, P1313, DOI 10.1038/modpathol.2011.93; Mosquera JM, 2011, DIAGN MOL PATHOL, V20, P129, DOI 10.1097/PDM.0b013e31820e9c67; Ohe C, 2012, MED MOL MORPHOL, V45, P234, DOI 10.1007/s00795-012-0584-5; Pivovarcikova K, 2017, AM J SURG PATHOL, V41, P138, DOI 10.1097/PAS.0000000000000730; Rao Q, 2015, AM J SURG PATHOL, V39, P1181, DOI 10.1097/PAS.0000000000000502; Rao Q, 2013, AM J SURG PATHOL, V37, P804, DOI 10.1097/PAS.0b013e31827e17cb; Rao Q, 2013, HISTOPATHOLOGY, V62, P642, DOI 10.1111/his.12059; Ritterhouse LL, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-81; Russell CM, 2014, ANN CLIN LAB SCI, V44, P91; Schoolmeester JK, 2015, AM J SURG PATHOL, V39, P394, DOI 10.1097/PAS.0000000000000349; Shen Q, 2014, VIRCHOWS ARCH, V465, P607, DOI 10.1007/s00428-014-1655-x; Suzigan S, 2007, INT J SURG PATHOL, V15, P199, DOI 10.1177/1066896906295891; Tanaka M, 2009, AM J SURG PATHOL, V33, P1416, DOI 10.1097/PAS.0b013e3181a9cd6c; Varinot J, 2011, INT J SURG PATHOL, V19, P285, DOI 10.1177/1066896911400736; Wang XT, 2017, HISTOPATHOLOGY, V71, P835, DOI 10.1111/his.13256; Wang XT, 2017, HUM PATHOL, V63, P190, DOI 10.1016/j.humpath.2017.02.022; Wang XT, 2016, HISTOPATHOLOGY, V69, P450, DOI 10.1111/his.12949; Wang ZY, 2016, INT J CLIN EXP PATHO, V9, P11890; Williamson SR, 2013, AM J SURG PATHOL, V37, P1619, DOI 10.1097/PAS.0b013e318293729d; Xia QY, 2018, HISTOPATHOLOGY, V72, P786, DOI 10.1111/his.13439; Xia QY, 2017, AM J SURG PATHOL, V41, P663, DOI 10.1097/PAS.0000000000000837; Xia QY, 2017, MODERN PATHOL, V30, P416, DOI 10.1038/modpathol.2016.204; Zeitz MJ, 2009, J CELL BIOCHEM, V108, P125, DOI 10.1002/jcb.22234; Zhang J, 2013, ONCOGENE, V32, P2907, DOI 10.1038/onc.2012.350; Zhong MH, 2010, AM J SURG PATHOL, V34, P757, DOI 10.1097/PAS.0b013e3181dd577e	62	9	10	2	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	SEP	2018	31	9					1346	1360		10.1038/s41379-018-0051-5			15	Pathology	Pathology	GT5SG	WOS:000444569400001	29713041				2019-10-28	
J	De Pascalis, I; Morgante, L; Pacioni, S; D'Alessandris, QG; Giannetti, S; Martini, M; Ricci-Vitiani, L; Malinverno, M; Dejana, E; Larocca, LM; Pallini, R				De Pascalis, Ivana; Morgante, Liliana; Pacioni, Simone; D'Alessandris, Quintino Giorgio; Giannetti, Stefano; Martini, Maurizio; Ricci-Vitiani, Lucia; Malinverno, Matteo; Dejana, Elisabetta; Larocca, Luigi M.; Pallini, Roberto			Endothelial trans-differentiation in glioblastoma recurring after radiotherapy	MODERN PATHOLOGY			English	Article							STEM-LIKE CELLS; EXPRESSION; PERICYTES; PROLIFERATION; ANGIOGENESIS; PROTEINS; GROWTH; BRAIN; MICE	We hypothesized that in glioblastoma recurring after radiotherapy, a condition whereby the brain endothelium undergoes radiation-induced senescence, tumor cells with endothelial phenotype may be relevant for tumor neovascularization. Matched glioblastoma samples obtained at primary surgery and at surgery for tumor recurrence after radiotherapy, all expressing epidermal growth factor receptor variant III (EGFRvIII), were assessed by a technique that combines fluorescent in situ hybridization (FISH) for the EGFR/CEP7 chromosomal probe with immunostaining for endothelial cells (CD31) and activated pericytes (alpha Smooth Muscle Actin). Five EGFRvIII-expressing paired primary/recurrent glioblastoma samples, in which the tumor cells showed EGFR/CEP7 amplification, were then assessed by CD31 and a Smooth Muscle Actin immunofluorescence. In glomeruloid bodies, the ratio between CD31+ cells with amplified EGFR/CEP7 signal and the total CD31+ cells was 0.23 +/- 0.09 (mean +/- sem) and 0.63 +/- 0.07 in primary tumors and in recurrent ones, respectively (p < 0.002, Student-t test). In capillaries, the ratio of CD31+ cells with amplified EGFR/CEP7 over the total CD31+ cells lining the capillary lumen was 0.21 +/- 0.06 (mean +/- sem) and 0.42 +/- 0.07 at primary surgery and at recurrence, respectively (p < 0.005, Student-t test). Expression of a Smooth Muscle Actin by cells with EGFR/CEP7 amplification was not observed. Then, in glioblastoma recurring after radiotherapy, where the brain endothelium suffers from radiation-induced cell senescence, tumor-derived endothelium plays a role in neo-vascularization.	[De Pascalis, Ivana; Pacioni, Simone; D'Alessandris, Quintino Giorgio; Pallini, Roberto] Univ Cattolica Sacro Cuore, Inst Neurosurg, Rome, Italy; [Morgante, Liliana; Giannetti, Stefano] Univ Cattolica Sacro Cuore, Inst Human Anat, Rome, Italy; [Martini, Maurizio; Larocca, Luigi M.] Univ Cattolica Sacro Cuore, Inst Pathol, Rome, Italy; [Ricci-Vitiani, Lucia] Ist Super Sanita, Dept Oncol & Mol Med, Rome, Italy; [Malinverno, Matteo; Dejana, Elisabetta] Inst Mol Oncol Fdn, Fdn Italiana Ric Canc, New Strategies Inhibit Tumor Angiogenesis Program, Milan, Italy	Pallini, R (reprint author), Univ Cattolica Sacro Cuore, Inst Neurosurg, Rome, Italy.	roberto.pallini@unicatt.it	D'Alessandris, Quintino Giorgio/J-8827-2018; PALLINI, Roberto/AAA-3747-2019; Martini, Maurizio/AAB-1564-2019; Malinverno, Matteo/AAB-3239-2019; Larocca, Luigi Maria/M-9590-2019; Pallini, Roberto/AAA-3760-2019	D'Alessandris, Quintino Giorgio/0000-0002-2953-9291; PALLINI, Roberto/0000-0002-4611-8827; Martini, Maurizio/0000-0002-6260-6310; Malinverno, Matteo/0000-0001-8242-7937; Larocca, Luigi Maria/0000-0003-1739-4758; DEJANA, ELISABETTA/0000-0002-0007-0426	Associazione Italiana per la Ricerca sul CancroAssociazione Italiana per la Ricerca sul Cancro (AIRC) [IG 2013 N.14574, IG 2014 N.15584]	This study was partly funded by Associazione Italiana per la Ricerca sul Cancro (IG 2013 N.14574 to RP and IG 2014 N.15584 to LR-V).	Birner P, 2003, BRAIN PATHOL, V13, P133, DOI 10.1111/j.1750-3639.2003.tb00013.x; Brot S, 2013, EXP CELL RES, V319, P588, DOI 10.1016/j.yexcr.2012.12.011; Cheng L, 2013, CELL, V153, P139, DOI 10.1016/j.cell.2013.02.021; Hu BL, 2016, CELL, V167, P1281, DOI 10.1016/j.cell.2016.10.039; Kioi M, 2010, J CLIN INVEST, V120, P694, DOI 10.1172/JCI40283; Louis DN, 2016, WHO CLASSIFICATION T, P28; Montano N, 2011, NEOPLASIA, V13, P1113, DOI 10.1593/neo.111338; Moutal A, 2015, CANCER RES, V75, P3519, DOI 10.1158/0008-5472.CAN-14-0631; Pallini R, 2001, J NEUROSURG, V94, P961, DOI 10.3171/jns.2001.94.6.0961; Perry A, 2006, ACTA NEUROPATHOL, V111, P197, DOI 10.1007/s00401-005-0023-y; Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557; Rodriguez FJ, 2012, ONCOTARGET, V3, P98; Soda Y, 2011, P NATL ACAD SCI USA, V108, P4274, DOI 10.1073/pnas.1016030108; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Sun HQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114246; Tan F, 2014, ONCOL LETT, V7, P1333, DOI 10.3892/ol.2014.1909; Tigges U, 2012, MICROVASC RES, V84, P74, DOI 10.1016/j.mvr.2012.03.008; VERBEEK MM, 1994, AM J PATHOL, V144, P372; Virrey JJ, 2008, AM J PATHOL, V173, P575, DOI 10.2353/ajpath.2008.071079; Wang CF, 2009, AGING CELL, V8, P311, DOI 10.1111/j.1474-9726.2009.00481.x; Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624	21	3	3	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	SEP	2018	31	9					1361	1366		10.1038/s41379-018-0046-2			6	Pathology	Pathology	GT5SG	WOS:000444569400002	29713042				2019-10-28	
J	Alsadoun, N; MacGrogan, G; Truntzer, C; Lacroix-Triki, M; Bedgedjian, I; Koeb, MH; El Alam, E; Medioni, D; Parent, M; Wuithier, P; Robert, I; Boidot, R; Arnould, L				Alsadoun, Nadjla; MacGrogan, Gaetan; Truntzer, Caroline; Lacroix-Triki, Magali; Bedgedjian, Isabelle; Koeb, Marie-Helene; El Alam, Elsy; Medioni, Dan; Parent, Michel; Wuithier, Pascal; Robert, Isabelle; Boidot, Romain; Arnould, Laurent			Solid papillary carcinoma with reverse polarity of the breast harbors specific morphologic, immunohistochemical and molecular profile in comparison with other benign or malignant papillary lesions of the breast: a comparative study of 9 additional cases	MODERN PATHOLOGY			English	Article							TALL CELL VARIANT; ISOCITRATE DEHYDROGENASE MUTATIONS; MONOCLONAL-ANTIBODY MSMAB-1; THYROID-CARCINOMA; IDH2 MUTATIONS; CALRETININ EXPRESSION; TUMOR; CANCER; SUBTYPES; DIFFERENTIATION	Solid papillary carcinoma with reverse polarity is a rare breast cancer of favorable prognosis that can be difficult to diagnose. We report here nine additional cases of this tumor, and we describe its morphologic, immunohistochemical and molecular profile in comparison to other types of papillary and micropapillary lesions of the breast that are intraductal papilloma with usual ductal hyperplasia, encapsulated papillary carcinoma, solid papillary carcinoma and invasive micropapillary carcinoma. We studied nine cases of this special papillary tumor and six of each other types mentioned above. We found that solid papillary carcinoma with reverse polarity harbor specific morphologic features as cuboid or tall cells with abundant eosinophilic cytoplasms located at the basal pole giving the impression of reverse nuclear polarity. Nuclei were sometimes grooved. Immunohistochemistry demonstrated the lack of myoepithelial cells, as in encapsulated papillary carcinoma and solid papillary carcinoma, questioning their invasive nature. Seven of nine solid papillary carcinoma with reverse polarity showed a low Ki67 proliferative index (Ki67 < 5%). They showed expression of CK5/6 as in intraductal papilloma with usual ductal hyperplasia. They showed expression of calretinin and a low or lack of hormonal receptor (HR) expression that were not observed in other breast tumors studied. By whole-exome analysis, seven of nine solid papillary carcinomas with reverse polarity (78%) harbored a hotspot mutation in IDH2 (R172) that was totally absent in other groups. Six of nine tumors (67%) also harbored PRUNE2 mutation, including the two IDH2 wild-type cases. We also demonstrated for the first time in this breast tumor, immunostaining with a specific antibody IDH1/2 mutant R132/R172 (7/9) that can highlight IDH2 mutation. Moreover, transcriptomic analysis showed that proteoglycan pathway was significantly enriched. Our findings support the fact that solid papillary carcinoma with reverse polarity is a singular breast neoplasm that can be distinguished from other papillary breast tumors.	[Alsadoun, Nadjla; Truntzer, Caroline; Boidot, Romain; Arnould, Laurent] Ctr Georges Francois Leclerc Unicanc, Dept Biol & Pathol Tumeurs, 1 Rue Prof Marion, F-21000 Dijon, France; [MacGrogan, Gaetan] Inst Bergonie, Dept Biopathol, 229 Cours Argonne, F-33076 Bordeaux, France; [Lacroix-Triki, Magali] Inst Gustave Roussy, Dept Pathol, 114 Rue Edouard Vaillant, F-94805 Villejuif, France; [Bedgedjian, Isabelle] Ctr Hosp Univ Besancon, Serv Anat & Cytol Pathol, F-25030 Besancon, France; [Koeb, Marie-Helene] Cypath Lyon, 201 Route Genas, F-69100 Villeurbanne, France; [El Alam, Elsy] Inst Curie, Dept Pathol, 35 Rue Dailly, F-92210 St Cloud, France; [Medioni, Dan] Medipath Cannes Antibes Grasse, 80 Allee Ormes, F-06250 Mougins, France; [Parent, Michel] Pathol Nord Unilabs, 60 Blvd Jean Baptiste Lebas, F-59000 Lille, France; [Wuithier, Pascal] Ctr Pathol, 13 Rue Carnot, F-65000 Tarbes, France; [Robert, Isabelle] Atalante Pathol, 10 Rue J Louis Bertrand BP11633, F-35016 Rennes, France	Alsadoun, N (reprint author), Ctr Georges Francois Leclerc Unicanc, Dept Biol & Pathol Tumeurs, 1 Rue Prof Marion, F-21000 Dijon, France.	nadjla.alsadoun@gmail.com					Agoumi M, 2016, ARCH PATHOL LAB MED, V140, P770, DOI 10.5858/arpa.2015-0525-RA; Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Amary MF, 2011, J PATHOL, V224, P334, DOI 10.1002/path.2913; Bhargava R, 2017, AM J CLIN PATHOL, V147, P399, DOI [10.1093/AJCP/AQX016, 10.1093/ajcp/aqx016]; Borger DR, 2012, EXPERT REV ANTICANC, V12, P543, DOI [10.1586/era.12.32, 10.1586/ERA.12.32]; Cameselle-Teijeiro J, 2006, INT J SURG PATHOL, V14, P79, DOI 10.1177/106689690601400116; Chang SY, 2009, BREAST J, V15, P531, DOI 10.1111/j.1524-4741.2009.00773.x; Chiang S, 2016, CANCER RES, V76, P7118, DOI 10.1158/0008-5472.CAN-16-0298; Clark O, 2016, CLIN CANCER RES, V22, P1837, DOI 10.1158/1078-0432.CCR-13-1333; Colella R, 2015, INT J SURG PATHOL, V23, P217, DOI 10.1177/1066896914536222; DiNardo Courtney D, 2017, Am Soc Clin Oncol Educ Book, V37, P495, DOI 10.14694/EDBK_175401; Eusebi V, 2003, AM J SURG PATHOL, V27, P1114, DOI 10.1097/00000478-200308000-00008; Farrag MS, 2017, INDIAN J PATHOL MICR, V60, P8, DOI 10.4103/0377-4929.200046; Fernandez-Vega I, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-24; Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015; Filmus J, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-5-224; Foschini MP, 2017, AM J SURG PATHOL, V41, P887, DOI 10.1097/PAS.0000000000000853; Gendoo DMA, 2016, BIOINFORMATICS, V32, P1097, DOI 10.1093/bioinformatics/btv693; Goff L, 2017, BIOCONDUCTOR; Guinebretiere J-M, 2013, BULLETIN, V57, P39; Hameed O, 2009, MODERN PATHOL, V22, P1236, DOI 10.1038/modpathol.2009.91; Jacob T, 2016, BREAST CANCER RES TR, V159, P575, DOI 10.1007/s10549-016-3962-1; Kaneko MK, 2014, CANCER SCI, V105, P744, DOI 10.1111/cas.12413; Kaneko MK, 2013, TOHOKU J EXP MED, V230, P103, DOI 10.1620/tjem.230.103; Lakhani SREI, 2012, WHO CLASSIFICATION T; Lau SK, 2002, APPL IMMUNOHISTO M M, V10, P97, DOI 10.1097/00022744-200206000-00001; Liu X, 2013, CANCER MED-US, V2, P803, DOI 10.1002/cam4.149; Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860; Lugli A, 2003, HUM PATHOL, V34, P994, DOI 10.1053/S0046-8177(03)00339-3; MacGrogan G, 2003, VIRCHOWS ARCH, V443, P609, DOI 10.1007/s00428-003-0888-x; Masood S, 2012, ADV ANAT PATHOL, V19, P108, DOI 10.1097/PAP.0b013e318249d090; Matsuda K, 2001, CANCER RES, V61, P5562; Medeiros BC, 2017, LEUKEMIA, V31, P272, DOI 10.1038/leu.2016.275; Micello D, 2017, VIRCHOWS ARCH, V471, P13, DOI 10.1007/s00428-017-2149-4; Nielsen TO, 2010, CLIN CANCER RES, V16, P5222, DOI 10.1158/1078-0432.CCR-10-1282; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Rakha EA, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1827; Rakha EA, 2016, HISTOPATHOLOGY, V69, P862, DOI 10.1111/his.13009; Salameh A, 2015, P NATL ACAD SCI USA, V112, P8403, DOI 10.1073/pnas.1507882112; Soh UJK, 2008, J CELL SCI, V121, P1739, DOI 10.1242/jcs.021774; Taliano RJ, 2013, HUM PATHOL, V44, P2743, DOI 10.1016/j.humpath.2013.07.021; Topczewski J, 2001, DEV CELL, V1, P251, DOI 10.1016/S1534-5807(01)00005-3; Tosi AL, 2007, INT J SURG PATHOL, V15, P14, DOI 10.1177/1066896906295689; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Troxell ML, 2010, MODERN PATHOL, V23, P27, DOI 10.1038/modpathol.2009.142; Villar-Taibo R, 2017, ONCOL LETT, V13, P3501, DOI 10.3892/ol.2017.5948; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Yu W, 2015, J CLIN ENDOCR METAB, V100, pE360, DOI 10.1210/jc.2014-3238	48	2	3	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	SEP	2018	31	9					1367	1380		10.1038/s41379-018-0047-1			14	Pathology	Pathology	GT5SG	WOS:000444569400003	29785016	Bronze			2019-10-28	
J	Zhu, EJ; Xie, HK; Dai, CY; Zhang, LP; Huang, Y; Dong, ZW; Guo, JH; Su, H; Ren, YJ; Shi, PF; Fu, RR; Qin, S; Wu, CY; Chen, C				Zhu, Erjia; Xie, Huikang; Dai, Chenyang; Zhang, Liping; Huang, Yan; Dong, Zhengwei; Guo, Junhong; Su, Hang; Ren, Yijiu; Shi, Pingfan; Fu, Ranran; Qin, Shuang; Wu, Chunyan; Chen, Chang			Intraoperatively measured tumor size and frozen section results should be considered jointly to predict the final pathology for lung adenocarcinoma	MODERN PATHOLOGY			English	Article							GROUND-GLASS NODULES; INVASIVE ADENOCARCINOMA; IN-SITU; RESECTION; CANCER; LOBECTOMY; DIAGNOSIS; CLASSIFICATION; ASSOCIATION; TOMOGRAPHY	Invasive adenocarcinoma intraoperatively misdiagnosed as adenocarcinoma in situ or minimally invasive adenocarcinoma is more likely to undergo potentially insufficient resection. The purpose of our study was to evaluate the diagnostic accuracy of frozen section. We retrospectively reviewed 1,111 lung adenocarcinomas from January to March 2016 to evaluate the diagnostic performance of frozen section. A derivation cohort consisting of 436 cases of adenocarcinoma in situ or minimally invasive adenocarcinoma diagnosed by frozen section in the same period were analyzed to find predictive factors for invasive adenocarcinoma as the final diagnosis. Validation cohorts (first: April to June 2016, second: January to March 2015) were included to confirm the results. The overall concordance rate between frozen section and final diagnosis was 92%. Most frozen section errors were underestimation. The sensitivity of frozen section diagnosis for minimally invasive adenocarcinoma (74%) was significantly lower than others. Intraoperatively measured tumor size was the only independent factor for invasive adenocarcinoma as the final diagnosis (< 1 cm: 2%, reference; 1-1.4 cm: 15%, odds ratio, 5.678; > 1.5 cm: 18%, odds ratio, 5.878; P = 0.001) in the derivation cohort, and was confirmed by validation cohorts. Fifty-nine misdiagnosed invasive adenocarcinomas in the three cohorts consisted of 54 lepidic predominant type, 1 papillary and 4 acinar predominant type. There were no positive N1, N2 node, pleural, lymphatic and vascular invasion cases found. Thirty-seven (37/59, 63%) cases of misdiagnosis were attributed to sampling error, which was the main reason. Our study suggests that adenocarcinoma in situ or minimally invasive adenocarcinoma >= 1 cm by frozen section were more likely to be invasive adenocarcinoma because of sampling error. Frozen section diagnosis of adenocarcinoma in situ or minimally invasive adenocarcinoma should be considered cautiously for tumors >= 1 cm to avoid potentially insufficient resection.	[Zhu, Erjia; Dai, Chenyang; Su, Hang; Ren, Yijiu; Chen, Chang] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Thorac Surg, Shanghai, Peoples R China; [Xie, Huikang; Zhang, Liping; Huang, Yan; Dong, Zhengwei; Guo, Junhong; Wu, Chunyan] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Pathol, Shanghai, Peoples R China; [Shi, Pingfan; Fu, Ranran; Qin, Shuang] Tongji Univ, Sch Med, Shanghai, Peoples R China	Chen, C (reprint author), Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Thorac Surg, Shanghai, Peoples R China.; Wu, CY (reprint author), Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Pathol, Shanghai, Peoples R China.	Wuchunyan581@163.com; chenthoracic@163.com			Shanghai Hospital Development Center [SHDC12015116]; Health and Family Planning Commission of Shanghai Municipality [20154Y0097]; Shanghai Pujiang ProgramShanghai Pujiang Program [15PJD034]	This study was supported by the projects from Shanghai Hospital Development Center (SHDC12015116), Health and Family Planning Commission of Shanghai Municipality (20154Y0097) and Shanghai Pujiang Program (15PJD034).	Chae HD, 2014, RADIOLOGY, V273, P285, DOI 10.1148/radiol.14132187; Cox ML, 2017, J THORAC ONCOL, V12, P689, DOI 10.1016/j.jtho.2017.01.003; Dai CY, 2016, J CLIN ONCOL, V34, P3175, DOI 10.1200/JCO.2015.64.6729; Dembitzer FR, 2014, CHEST, V146, P175, DOI 10.1378/chest.13-2506; Ginsberg Robert J., 1995, Annals of Thoracic Surgery, V60, P615, DOI 10.1016/0003-4975(95)00537-U; He P, 2016, J CLIN PATHOL, V69, P1076, DOI 10.1136/jclinpath-2016-203619; Lee KH, 2014, J THORAC ONCOL, V9, P74, DOI 10.1097/JTO.0000000000000019; Lim HJ, 2013, CHEST, V144, P1291, DOI 10.1378/chest.12-2987; Liu SL, 2016, J CLIN ONCOL, V34, P307, DOI 10.1200/JCO.2015.63.4907; Marchevsky AM, 2004, ANN THORAC SURG, V78, P1755, DOI 10.1016/j.athoracsur.2004.05.003; Nakamura H, 2015, LUNG CANCER, V87, P28, DOI 10.1016/j.lungcan.2014.11.010; Stefani A, 2012, MINERVA CHIR, V67, P489; Suzuki K, 2011, J THORAC ONCOL, V6, P751, DOI 10.1097/JTO.0b013e31821038ab; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Walts AE, 2012, ARCH PATHOL LAB MED, V136, P1515, DOI 10.5858/arpa.2012-0042-OA; Wisnivesky JP, 2010, ANN SURG, V251, P550, DOI 10.1097/SLA.0b013e3181c0e5f3; Wolf AS, 2011, ANN THORAC SURG, V92, P1819, DOI 10.1016/j.athoracsur.2011.06.099; Yoshizawa A, 2011, MODERN PATHOL, V24, P653, DOI 10.1038/modpathol.2010.232; Zhong CX, 2012, ANN THORAC SURG, V94, P362, DOI 10.1016/j.athoracsur.2012.04.047	19	0	1	2	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	SEP	2018	31	9					1391	1399		10.1038/s41379-018-0056-0			9	Pathology	Pathology	GT5SG	WOS:000444569400005	29752477				2019-10-28	
J	Chiu, K; Lee, L; Cheung, S; Churg, AM				Chiu, Kenrry; Lee, Lawrence; Cheung, Simon; Churg, Andrew M.			Glypican-1 immunohistochemistry does not separate mesothelioma from pulmonary adenocarcinoma	MODERN PATHOLOGY			English	Article							PATHOLOGICAL DIAGNOSIS; MALIGNANT MESOTHELIOMA; CONSENSUS STATEMENT; POOR-PROGNOSIS; GUIDELINES; CELLS; EXPRESSION; CARCINOMA; CANCER; UPDATE	Immunohistochemistry (IHC) is used to help differentiate pleural mesothelioma from pulmonary adenocarcinoma in pleural biopsies and cytology specimens of pleural effusions due to overlapping morphologic features between these two malignancies. The aim of this study is to evaluate IHC glypican-1, a recently proposed marker for epithelioid mesothelioma, in our cohort of mesotheliomas and pulmonary adenocarcinoma. Tissue microarrays with duplicate cores from 33 cases of mesotheliomas (28 epithelioid type and five sarcomatoid type) and 21 cases of pulmonary adenocarcinoma were stained with glypican-1 antibody. The proportion of cases by tumor type showing staining with glypican-1 and the H-score for each tumor type were evaluated. All 33 cases of mesothelioma and all 20 cases of pulmonary adenocarcinoma with interpretable cores showed positive cytoplasmic staining. All but one case of mesothelioma and all pulmonary adenocarcinomas showed staining in at least 80% of the tumor cells. The mean H-score for glypican-1 of mesothelioma (134 +/- 59, mean +/- SD) was not significantly different from that for pulmonary adenocarcinoma (156 +/- 60; P = 0.21). Neither epithelioid type (mean H-score 135 +/- 57) nor sarcomatoid type (mean H-score 130 +/- 78) of mesothelioma showed different H-scores when compared to pulmonary adenocarcinoma (P = 0.23 and 0.42, respectively). In conclusion, glypican-1 IHC does not differentiate mesothelioma from pulmonary adenocarcinoma.	[Chiu, Kenrry; Lee, Lawrence; Cheung, Simon; Churg, Andrew M.] Vancouver Gen Hosp, Dept Pathol, Vancouver, BC, Canada; [Chiu, Kenrry; Lee, Lawrence; Cheung, Simon; Churg, Andrew M.] Univ British Columbia, Dept Pathol, Vancouver, BC, Canada	Churg, AM (reprint author), Vancouver Gen Hosp, Dept Pathol, Vancouver, BC, Canada.; Churg, AM (reprint author), Univ British Columbia, Dept Pathol, Vancouver, BC, Canada.	achurg@mail.ubc.ca					Amatya VJ, 2018, MODERN PATHOL, V31, P809, DOI 10.1038/modpathol.2017.190; Bishop JA, 2010, HUM PATHOL, V41, P20, DOI 10.1016/j.humpath.2009.06.014; Hara H, 2016, BRIT J CANCER, V115, P66, DOI 10.1038/bjc.2016.183; Husain AN, 2013, ARCH PATHOL LAB MED, V137, P647, DOI 10.5858/arpa.2012-0214-OA; Husain AN, 2009, ARCH PATHOL LAB MED, V133, P1317, DOI 10.1043/1543-2165-133.8.1317; Husain AN, 2018, ARCH PATHOL LAB MED, V142, P89, DOI 10.5858/arpa.2017-0124-RA; Kleeff J, 1998, J CLIN INVEST, V102, P1662, DOI 10.1172/JCI4105; Lonardi S, 2011, DIAGN CYTOPATHOL, V39, P313, DOI 10.1002/dc.21380; Lu HZ, 2017, CANCER MED-US, V6, P1181, DOI 10.1002/cam4.1064; Matsuda K, 2001, CANCER RES, V61, P5562; Matsuzaki S, 2018, INT J CANCER, V142, P1056, DOI 10.1002/ijc.31124; Ordonez NG, 2013, AM J CLIN PATHOL, V139, P611, DOI 10.1309/AJCP0B3YJBXWXJII; Saito T, 2017, WORLD NEUROSURG, V105, P282, DOI 10.1016/j.wneu.2017.05.165; Su G, 2006, AM J PATHOL, V168, P2014, DOI 10.2353/ajpath.2006.050800; Theocharis AD, 2010, FEBS J, V277, P3904, DOI 10.1111/j.1742-4658.2010.07800.x; Yaziji H, 2006, MODERN PATHOL, V19, P514, DOI 10.1038/modpathol.3800534	16	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	SEP	2018	31	9					1400	1403		10.1038/s41379-018-0066-y			4	Pathology	Pathology	GT5SG	WOS:000444569400006	29785020	Bronze			2019-10-28	
J	Suzuki, M; Nakatani, Y; Ito, H; Narimatsu, H; Yamada, K; Yoshioka, E; Washimi, K; Okubo, Y; Kawachi, K; Miyagi, Y; Yokose, T				Suzuki, Masaki; Nakatani, Yukio; Ito, Hiroyuki; Narimatsu, Hiroto; Yamada, Kozo; Yoshioka, Emi; Washimi, Kota; Okubo, Yoichiro; Kawachi, Kae; Miyagi, Yohei; Yokose, Tomoyuki			Pulmonary adenocarcinoma with high-grade fetal adenocarcinoma component has a poor prognosis, comparable to that of micropapillary adenocarcinoma	MODERN PATHOLOGY			English	Article							LUNG ADENOCARCINOMA; GASTRIC-CARCINOMA; ENTEROBLASTIC DIFFERENTIATION; INTERNATIONAL ASSOCIATION; CLASSIFICATION; PHENOTYPE; SUBGROUP; SUBTYPES; IMPACT; CANCER	Fetal adenocarcinoma is a rare variant of lung adenocarcinoma, which is subcategorized into low-grade and high-grade forms. High-grade fetal adenocarcinoma confers worse prognosis than low-grade fetal adenocarcinoma, but the prognostic differences between high-grade fetal adenocarcinoma and conventional lung adenocarcinoma are unknown. We reviewed tissue sections of 3719 cases of surgically resected primary lung cancers and found 53 lung cancers with a high-grade fetal adenocarcinoma component. We analyzed their clinicopathological and immunohistochemical features, and performed a prognostic analysis of adenocarcinomas with the fetal-type component. We further analyzed the prognostic differences between adenocarcinomas with the fetal-type component and conventional adenocarcinomas without the fetal-type component. Lung cancers with the fetal-type component predominantly occurred in elderly men with a smoking history. Twenty-nine patients had stage I disease, 13 patients had stage II, and 11 patients had stage III. The fetal-type histology was combined with conventional-type adenocarcinoma (41 cases), squamous cell carcinoma (5 cases), large cell neuroendocrine carcinoma (5 cases), enteric adenocarcinoma (2 cases), and small cell carcinoma (1 case). The fetal-type component showed immunopositivity for alpha-fetoprotein (39%), glypican-3 (37%), and SALL4 (17%). The 5-year overall survivals of fetal-type-predominant and fetal-type-nonpredominant patients were 44 and 56%, respectively (P = 0.962). The 5-year overall survivals of lepidic-, acinar-, papillary-, solid-, and micropapillary-predominant adenocarcinomas, invasive mucinous adenocarcinomas, and adenocarcinomas with the fetal-type component were 94, 82, 77, 69, 57, 83, and 41%, respectively (P < 0.001). Univariate and multivariate analyses showed that adenocarcinomas with the fetal-type component had a significantly lower overall survival rate than the other histological subtypes, except for the micropapillary-predominant subtype. Our study demonstrated that adenocarcinomas with the fetal-type component had a poor prognosis that was comparable to that of micropapillary adenocarcinoma. The presence of the high-grade fetal adenocarcinoma component in lung adenocarcinomas is an important prognostic marker.	[Suzuki, Masaki; Yoshioka, Emi; Washimi, Kota; Okubo, Yoichiro; Kawachi, Kae; Yokose, Tomoyuki] Kanagawa Canc Ctr, Dept Pathol, Yokohama, Kanagawa, Japan; [Nakatani, Yukio] Chiba Univ, Grad Sch Med, Dept Diagnost Pathol, Chiba, Chiba, Japan; [Ito, Hiroyuki] Kanagawa Canc Ctr, Dept Thorac Surg, Yokohama, Kanagawa, Japan; [Narimatsu, Hiroto] Kanagawa Canc Ctr, Res Inst, Canc Prevent & Control Div, Yokohama, Kanagawa, Japan; [Yamada, Kozo] Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Kanagawa, Japan; [Miyagi, Yohei] Kanagawa Canc Ctr, Res Inst, Mol Pathol & Genet Div, Yokohama, Kanagawa, Japan	Suzuki, M (reprint author), Kanagawa Canc Ctr, Dept Pathol, Yokohama, Kanagawa, Japan.	m-suzuki@kcch.jp		Okubo, Yoichiro/0000-0002-7079-4454			Hishinuma M, 2006, HISTOPATHOLOGY, V49, P479, DOI 10.1111/j.1365-2559.2006.02522.x; Kamiya K, 2008, MODERN PATHOL, V21, P992, DOI 10.1038/modpathol.2008.79; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Leslie HS, 2009, TNM CLASSIFICATION M; MATSUNOU H, 1994, CANCER, V73, P534, DOI 10.1002/1097-0142(19940201)73:3<534::AID-CNCR2820730307>3.0.CO;2-X; Morita S, 2013, AM J SURG PATHOL, V37, P924, DOI 10.1097/PAS.0b013e31827e1e83; Morrisey EE, 2010, DEV CELL, V18, P8, DOI 10.1016/j.devcel.2009.12.010; Murakami T, 2016, GASTRIC CANCER, V19, P498, DOI 10.1007/s10120-015-0497-9; Nakatani Y, 1998, AM J SURG PATHOL, V22, P399, DOI 10.1097/00000478-199804000-00003; NAKATANI Y, 1991, Pediatric Pathology, V11, P31; Sato S, 2006, GEN THORAC CARDIOVAS, V54, P539, DOI 10.1007/s11748-006-0048-8; Suzuki M, 2017, J THORAC DIS, V9, P504, DOI 10.21037/jtd.2017.03.15; Suzuki M, 2015, HISTOPATHOLOGY, V67, P806, DOI 10.1111/his.12711; Travis WD, WHO CLASSIFICATION T; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Tsuta K, 2013, LUNG CANCER, V81, P371, DOI 10.1016/j.lungcan.2013.06.012; Ushiku T, 2010, AM J SURG PATHOL, V34, P533, DOI 10.1097/PAS.0b013e3181d1dcdd; Ushiku T, 2009, CANCER SCI, V100, P626, DOI 10.1111/j.1349-7006.2009.01108.x; Volante M, 2002, J HISTOCHEM CYTOCHEM, V50, P1013, DOI 10.1177/002215540205000803; Warth A, 2012, J CLIN ONCOL, V30, P1438, DOI 10.1200/JCO.2011.37.2185; Wittekind Christian, 2016, TNM CLASSIFICATION M; Yamazawa S, 2017, AM J SURG PATHOL, V41, P989, DOI 10.1097/PAS.0000000000000869; Yanagawa N, 2016, J THORAC ONCOL, V11, P1976, DOI 10.1016/j.jtho.2016.06.014; Yoshizawa A, 2013, J THORAC ONCOL, V8, P52, DOI 10.1097/JTO.0b013e3182769aa8; Yoshizawa A, 2011, MODERN PATHOL, V24, P653, DOI 10.1038/modpathol.2010.232; Zhang J, 2017, J THORAC DIS, V9, P2071, DOI 10.21037/jtd.2017.07.14; Zhao Y, 2016, ANN SURG ONCOL, V23, P2099, DOI 10.1245/s10434-015-5043-9	27	2	2	1	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	SEP	2018	31	9					1404	1417		10.1038/s41379-018-0057-z			14	Pathology	Pathology	GT5SG	WOS:000444569400007	29785018	Bronze			2019-10-28	
J	Hyeon, J; Lee, B; Shin, SH; Yoo, HY; Kim, SJ; Kim, WS; Park, WY; Ko, YH				Hyeon, Jiyeon; Lee, Boram; Shin, So-Hyun; Yoo, Hae Yong; Kim, Seok Jin; Kim, Won Seog; Park, Woong-Yang; Ko, Young-Hyeh			Targeted deep sequencing of gastric marginal zone lymphoma identified alterations of TRAF3 and TNFAIP3 that were mutually exclusive for MALT1 rearrangement	MODERN PATHOLOGY			English	Article							NF-KAPPA-B; HELICOBACTER-PYLORI ERADICATION; MOLECULAR-MECHANISM; RECURRENT MUTATIONS; TISSUE LYMPHOMA; SEZARY-SYNDROME; CELL LYMPHOMA; CAGA PROTEIN; A20; PATHWAY	Gastric extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue is a distinct entity in that Helicobacter pylori infection plays the most important causative role in the development of the disease. To investigate the genomic alteration in gastric marginal zone lymphoma that was resistant to the H. pylori eradication therapy, we analyzed 19 cases of the gastric marginal zone lymphoma using fluorescence in situ hybridization for MALT1, BCL10 rearrangement, and targeted sequencing using an Illumina platform. Major genetic alterations affected genes involved in nuclear factor (NF)-kappa B pathway activation and included MALT1 rearrangement (39%), and somatic mutations of TRAF3 (21%), TNFAIP3 (16%), and NOTCH1 (16%). In the MALT1 rearrangement-negative group, disruptive somatic mutations of TRAF3 were the most common alterations (4/12, 33%), followed by somatic mutations of TNFAIP3 (3/12, 25%), and NOTCH1 (3/12, 25%). The present study confirms that genes involved in activation of NF-kappa B-signaling pathways are a major driver in oncogenesis of H. pylori eradication-resistant gastric marginal zone lymphoma and revealed that TRAF3 mutation is a major contributor in MALT1 rearrangement-negative gastric marginal zone lymphoma.	[Hyeon, Jiyeon; Shin, So-Hyun; Ko, Young-Hyeh] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol & Translat Genom, Seoul, South Korea; [Lee, Boram; Park, Woong-Yang] Samsung Med Ctr, Res Inst Future Med, Samsung Genome Inst, Seoul, South Korea; [Lee, Boram; Yoo, Hae Yong] Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol, Dept Hlth Sci & Technol, Seoul, South Korea; [Kim, Seok Jin; Kim, Won Seog] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Internal Med, Seoul, South Korea	Ko, YH (reprint author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol & Translat Genom, Seoul, South Korea.; Park, WY (reprint author), Samsung Med Ctr, Res Inst Future Med, Samsung Genome Inst, Seoul, South Korea.	woongyang@skku.edu; yhko310@skku.edu	Lee, Boram/L-4178-2018	Lee, Boram/0000-0002-7784-5971; Hyeon, Jiyeon/0000-0003-3074-4142	National Research Foundation of KoreaNational Research Foundation of Korea [NRF-2017R1A2B1010739]	This study was supported by a grant from the National Research Foundation of Korea (NRF-2017R1A2B1010739).	Andersson E, 2014, EXP DERMATOL, V23, P366, DOI 10.1111/exd.12405; Bushell KR, 2015, BLOOD, V125, P999, DOI 10.1182/blood-2014-10-602714; Catrysse L, 2014, TRENDS IMMUNOL, V35, P22, DOI 10.1016/j.it.2013.10.005; Chanudet E, 2010, LEUKEMIA, V24, P483, DOI 10.1038/leu.2009.234; Chanudet E, 2009, J PATHOL, V217, P420, DOI 10.1002/path.2466; Chen SP, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-195; Chu YY, 2011, BLOOD, V117, P2227, DOI 10.1182/blood-2010-09-306019; Cook JR, 2017, WHO CLASSIFICATION T, P259; Copie-Bergman C, 2003, GUT, V52, P1656, DOI 10.1136/gut.52.11.1656; Craig VJ, 2010, LEUKEMIA, V24, P1186, DOI 10.1038/leu.2010.76; Du MQ, 2017, BEST PRACT RES CL HA, V30, P13, DOI 10.1016/j.beha.2016.09.002; Du MQ, 2016, SEMIN CANCER BIOL, V39, P49, DOI 10.1016/j.semcancer.2016.07.003; Du MQ, 2002, LANCET ONCOL, V3, P97, DOI 10.1016/S1470-2045(02)00651-4; Elgueta R, 2009, IMMUNOL REV, V229, P152, DOI 10.1111/j.1600-065X.2009.00782.x; Fischbach W, 2004, GUT, V53, P34, DOI 10.1136/gut.53.1.34; Gonzalez-Aguilar A, 2012, CLIN CANCER RES, V18, P5203, DOI 10.1158/1078-0432.CCR-12-0845; Hatakeyama M, 2004, NAT REV CANCER, V4, P688, DOI 10.1038/nrc1433; Hildebrand JM, 2011, IMMUNOL REV, V244, P55, DOI 10.1111/j.1600-065X.2011.01055.x; Jagadeesh KA, 2016, NAT GENET, V48, P1581, DOI 10.1038/ng.3703; Johansson P, 2016, ONCOTARGET, V7, P62627, DOI 10.18632/oncotarget.11548; Jones CL, 2014, J BIOL CHEM, V289, P20502, DOI 10.1074/jbc.M114.569889; Jost PJ, 2007, BLOOD, V109, P2700, DOI 10.1182/blood-2006-07-025809; Jung H, 2017, ONCOTARGET, V8, P17038, DOI 10.18632/oncotarget.14928; Kiel MJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9470; Kuo SH, 2017, BLOOD, V129, P188, DOI [10.1182/blood-2016-04-713719, 10.1182/blood-2016-04-71371]; Kuo SH, 2017, J PATHOL, V241, P420, DOI 10.1002/path.4852; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Leiserson MDM, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0700-7; Liu HX, 2001, LANCET, V357, P39, DOI 10.1016/S0140-6736(00)03571-6; Liu HX, 2002, GASTROENTEROLOGY, V122, P1286, DOI 10.1053/gast.2002.33047; McAllister-Lucas LM, 2011, CLIN CANCER RES, V17, P6623, DOI 10.1158/1078-0432.CCR-11-0467; Moore CR, 2012, LEUKEMIA, V26, P1122, DOI 10.1038/leu.2011.309; Moore Carissa R, 2015, J Cancer Sci Ther, V7, P67; Rosenquist R, 2017, J INTERN MED, V282, P371, DOI 10.1111/joim.12633; Ruskone -Fourmestraux A, 2011, GUT, V60, P747, DOI 10.1136/gut.2010.224949; Scott DW, 2012, BLOOD, V119, P4949, DOI 10.1182/blood-2012-02-414441; Shembade N, 2010, SCIENCE, V327, P1135, DOI 10.1126/science.1182364; Shin HT, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01470-y; Spina V, 2017, BEST PRACT RES CL HA, V30, P5, DOI 10.1016/j.beha.2016.09.004; Streubel B, 2004, LEUKEMIA, V18, P1722, DOI 10.1038/sj.leu.2403501; Tusche MW, 2009, J EXP MED, V206, P2671, DOI 10.1084/jem.20091802; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794	42	2	2	2	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	SEP	2018	31	9					1418	1428		10.1038/s41379-018-0064-0			11	Pathology	Pathology	GT5SG	WOS:000444569400008	29765142	Bronze			2019-10-28	
J	Sirohi, D; Vaske, C; Sanborn, Z; Smith, SC; Don, MD; Lindsey, KG; Federman, S; Vankalakunti, M; Koo, J; Bose, S; de Peralta-Venturina, M; van Ziffle, J; Grenert, JP; Miller, S; Chiu, C; Amin, MB; Simko, JP; Stohr, BA; Luthringer, DJ				Sirohi, Deepika; Vaske, Charlie; Sanborn, Zack; Smith, Steven C.; Don, Michelle D.; Lindsey, Kathryn G.; Federman, Scot; Vankalakunti, Mahesha; Koo, Jamie; Bose, Shikha; de Peralta-Venturina, Mariza; van Ziffle, Jessica; Grenert, James P.; Miller, Steve; Chiu, Charles; Amin, Mahul B.; Simko, Jeffry P.; Stohr, Bradley A.; Luthringer, Daniel J.			Polyoma virus-associated carcinomas of the urologic tract: a clinicopathologic and molecular study	MODERN PATHOLOGY			English	Article							TRANSITIONAL-CELL CARCINOMA; TRANSPLANT RECIPIENTS; BK-POLYOMAVIRUS; UROTHELIAL CARCINOMA; VIRAL INTEGRATION; EXPRESSION; BLADDER; CANCER; KIDNEY; IDENTIFICATION	In recent years, there has been increased interest in carcinomas of the urologic tract, that demonstrate association with the polyoma virus BK arising in immunosuppressed individuals, though the nature of this association is uncertain. To begin to understand this phenomenon, we reviewed the clinical, morphological, and immunohistochemical features of 11 carcinomas of the urologic tract, mainly urothelial (N = 9) and collecting duct carcinomas (N = 2), occurring during immunosuppression, and expressing polyoma virus T-antigen by immunohistochemistry. These were compared to a control group of carcinomas (N = 8), also arising during immunosuppression, but without T-antigen expression. A subset of both groups were also studied by hybrid capture-based DNA sequencing, probing not only for 479 cancer-related human genes, but also for polyoma and other viral sequences. Polyoma T-antigen-expressing tumors arose in 7 males and 4 females, at a median age of 66, and were aggressive, high-grade tumors with more than 1 variant morphologic pattern identified in 81% of cases, and a majority (73%) presenting at high stage category (>pT3). Diffuse polyoma T-antigen staining was seen in 91% of cases, with co-localization of aberrant p53 staining in 89%. Sequencing detected a lower number of deleterious mutations among T-antigen-expressing cases (average 1.62; 1/8 with TP53 mutation) compared to control cases (average 3.5, 2/4 with TP53 mutation). Only BK virus was detected with clonal integration and breakpoints randomly distributed across the human and viral genomes in 5/5 of the polyoma T-antigen-expressing carcinomas, and in none of the controls (0/4). In summary, these findings identify aggressive clinicopathologic features of polyoma T-antigen-expressing carcinomas, document BK as the strain involved, and associate BK viral integration with T-antigen expression and p53 aberrancy. While the apparent randomness of viral insertion sites is functionally unclear, the differing rates of mutations between T-antigen-expressing and control cases is intriguing.	[Sirohi, Deepika; Federman, Scot; van Ziffle, Jessica; Grenert, James P.; Miller, Steve; Chiu, Charles; Simko, Jeffry P.; Stohr, Bradley A.] Univ Calif San Francisco, Dept Pathol & Lab Med, San Francisco, CA 94143 USA; [Vaske, Charlie; Sanborn, Zack] NantOmics, Santa Cruz, CA USA; [Smith, Steven C.] Virginia Commonwealth Univ, Sch Med, Dept Pathol, Richmond, VA USA; [Smith, Steven C.] Virginia Commonwealth Univ, Sch Med, Dept Urol, Richmond, VA USA; [Don, Michelle D.; Vankalakunti, Mahesha; Koo, Jamie; Bose, Shikha; de Peralta-Venturina, Mariza; Luthringer, Daniel J.] Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USA; [Lindsey, Kathryn G.] Med Univ South Carolina, Charleston, SC 29425 USA; [Amin, Mahul B.] Univ Tennessee Hlth Sci, Dept Pathol & Lab Med & Urol, Memphis, TN USA	Sirohi, D (reprint author), Univ Calif San Francisco, Dept Pathol & Lab Med, San Francisco, CA 94143 USA.	Deepika.Sirohi@hsc.utah.edu	Vaske, Charles/D-6018-2013	Vaske, Charles/0000-0001-8151-6612	Department of Pathology, University of California, San Francisco	Targeted next-generation sequencing was funded by Department of Pathology, University of California, San Francisco.	Alexiev BA, 2013, HUM PATHOL, V44, P908, DOI 10.1016/j.humpath.2012.09.019; Bialasiewicz S, 2013, TRANSPL INFECT DIS, V15, P283, DOI 10.1111/tid.12072; Dalianis T, 2012, CURR CANCER RES, P419, DOI 10.1007/978-1-4614-0016-5_16; Doolittle-Hall JM, 2015, CANCERS, V7, P2217, DOI 10.3390/cancers7040887; Dufek S, 2013, J HEART LUNG TRANSPL, V32, P378, DOI 10.1016/j.healun.2012.11.033; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Engels EA, 2011, JAMA-J AM MED ASSOC, V306, P1891, DOI 10.1001/jama.2011.1592; Favero F, 2015, ANN ONCOL, V26, P880, DOI 10.1093/annonc/mdv127; GARDNER SD, 1984, J CLIN PATHOL, V37, P578, DOI 10.1136/jcp.37.5.578; Gau DM, 2015, CELL CYCLE, V14, P1884, DOI 10.1080/15384101.2015.1036203; Gaziev J, 2010, BIOL BLOOD MARROW TR, V16, P662, DOI 10.1016/j.bbmt.2009.12.009; Geddes CC, 2011, TRANSPL INFECT DIS, V13, P109, DOI 10.1111/j.1399-3062.2010.00566.x; Grippo PJ, 2000, AM J PATHOL, V157, P805, DOI 10.1016/S0002-9440(10)64594-4; Hu L, 2016, ONCOTARGET, V7, P66660, DOI 10.18632/oncotarget.11433; Kenan DJ, 2017, AM J TRANSPLANT, V17, P1674, DOI 10.1111/ajt.14191; Kenan DJ, 2015, J PATHOL, V237, P379, DOI 10.1002/path.4584; Kline CN, 2017, NEURO-ONCOLOGY, V19, P699, DOI 10.1093/neuonc/now254; Kumar V., 2015, ROBBINS COTRAN PATHO, P265; Kwee SA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046591; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; Li JYZ, 2013, TRANSPL INFECT DIS, V15, pE270, DOI 10.1111/tid.12142; Loghavi S, 2011, DIAGN CYTOPATHOL, V39, P531, DOI 10.1002/dc.21490; Martel-Jantin C, 2012, VIROLOGY, V426, P134, DOI 10.1016/j.virol.2012.01.018; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Mohseni M, 2014, P NATL ACAD SCI USA, V111, P17606, DOI 10.1073/pnas.1408650111; Naccache SN, 2014, GENOME RES, V24, P1180, DOI 10.1101/gr.171934.113; Papadimitriou JC, 2016, AM J TRANSPLANT, V16, P398, DOI 10.1111/ajt.13550; Pinto M, 2014, J INFECTION, V68, pS2, DOI 10.1016/j.jinf.2013.09.009; Sanborn JZ, 2013, CANCER RES, V73, P6036, DOI 10.1158/0008-5472.CAN-13-0186; Sawinski D, 2015, NEPHROL DIAL TRANSPL, V30, P209, DOI 10.1093/ndt/gfu023; Seo AN, 2017, ADV ANAT PATHOL, V24, P65, DOI 10.1097/PAP.0000000000000138; SHAH KV, 1973, J INFECT DIS, V128, P784, DOI 10.1093/infdis/128.6.784; Smith SC, 2016, AM J SURG PATHOL, V40, P1457, DOI 10.1097/PAS.0000000000000719; Stojnev S, 2014, INT J CLIN EXP PATHO, V7, P4945; Tsang WY, 2008, CELL CYCLE, V7, P702, DOI 10.4161/cc.7.6.5611; Vanchiere JA, 2018, FEIGIN CHERRYS TXB P, P1345; Wenzel K, 2003, BIOL CHEM, V384, P763, DOI 10.1515/BC.2003.085; Wong ASY, 2007, CLIN INFECT DIS, V44, P830, DOI 10.1086/511863; Zhou HP, 2012, CARCINOGENESIS, V33, P770, DOI 10.1093/carcin/bgs025	39	4	4	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	SEP	2018	31	9					1429	1441		10.1038/s41379-018-0065-z			13	Pathology	Pathology	GT5SG	WOS:000444569400009	29765141				2019-10-28	
J	Kolin, DL; Dong, F; Baltay, M; Lindeman, N; MacConaill, L; Nucci, MR; Crum, CP; Howitt, BE				Kolin, David L.; Dong, Fei; Baltay, Michele; Lindeman, Neal; MacConaill, Laura; Nucci, Marisa R.; Crum, Christopher P.; Howitt, Brooke E.			SMARCA4-deficient undifferentiated uterine sarcoma (malignant rhabdoid tumor of the uterus): a clinicopathologic entity distinct from undifferentiated carcinoma	MODERN PATHOLOGY			English	Article							SMALL-CELL-CARCINOMA; ATYPICAL TERATOID/RHABDOID TUMOR; OF-THE-LITERATURE; MIXED MULLERIAN TUMOR; HYPERCALCEMIC TYPE; ENDOMETRIOID ADENOCARCINOMA; SMARCA4 MUTATIONS; INI1 GENE; OVARY; EXPRESSION	Small cell carcinoma of the ovary, hypercalcemic type is a rare, aggressive malignancy which usually occurs in young women and is characterized by mutations in SMARCA4, with few other alterations. We recently encountered uterine tumors with morphologic, immunohistochemical, and genetic similarities to small cell carcinoma of the ovary, hypercalcemic type. Herein we report the clinicopathologic and molecular features (using a targeted massively parallel sequencing [MPS] assay) of these tumors. The cases were diagnosed on cervical and endometrial biopsies (n = 2, 34, and 29 years) or hysterectomy and bilateral salpingo-oophorectomy (n = 3, 25, 33, and 58 years). The tumors were composed of sheets of large atypical epithelioid cells with prominent rhabdoid morphology, indistinguishable from the "large cell" variant of small cell carcinoma of the ovary, hypercalcemic type. In three cases, the ovaries were pathologically examined to exclude a primary ovarian malignancy. Immunohistochemically, four of four cases showed SMARCA4 loss, and were negative or only focally positive for keratins, EMA, and claudin-4. One of three cases was positive for WT-1. Targeted MPS was successfully performed on 4 of 5 tumors, and showed recurrent mutations in SMARCA4, with few other alterations. Of the cases diagnosed on hysterectomy, all had extensive lymphovascular invasion, extra-uterine spread, and marked infiltrative growth. These tumors were uniformly aggressive; all patients died of disease (median survival 7 months, range 1-43 months). We propose this entity be called "SMARCA4-deficient undifferentiated uterine sarcoma (malignant rhabdoid tumor of the uterus)", a term which describes both the tumor's underlying molecular abnormality and its morphology. Its unique clinicopathologic and molecular features differentiate it from other related malignancies, including undifferentiated endometrial carcinoma, small cell carcinoma of the ovary (hypercalcemic type), and epithelioid sarcoma. We review and discuss previously reported "rhabdoid tumors of the uterus;" while they are a heterogenous group of tumors, some of them are likely examples of this entity. Correctly identifying cases of SMARCA4-deficient uterine sarcoma from histologic mimics is important as it may have prognostic, predictive, and germline implications.	[Kolin, David L.; Nucci, Marisa R.; Crum, Christopher P.; Howitt, Brooke E.] Brigham & Womens Hosp, Dept Pathol, Div Womens & Perinatal Pathol, 75 Francis St, Boston, MA 02115 USA; [Dong, Fei; Baltay, Michele; Lindeman, Neal; MacConaill, Laura] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Howitt, Brooke E.] Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA	Howitt, BE (reprint author), Brigham & Womens Hosp, Dept Pathol, Div Womens & Perinatal Pathol, 75 Francis St, Boston, MA 02115 USA.; Howitt, BE (reprint author), Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA.	bhowitt@stanford.edu	Kolin, David/B-9024-2014	Kolin, David/0000-0002-7631-6525			Al-Hussaini M, 2008, INT J GYNECOL PATHOL, V27, P236, DOI 10.1097/PGP.0b013e31815aca67; Altrabulsi B, 2005, AM J SURG PATHOL, V29, P1316, DOI 10.1097/01.pas.0000171003.72352.9a; Baschinsky DY, 1999, GYNECOL ONCOL, V73, P145, DOI 10.1006/gyno.1998.5302; Brennan B, 2013, LANCET ONCOL, V14, pE329, DOI 10.1016/S1470-2045(13)70088-3; CATTANI MG, 1992, VIRCHOWS ARCH A, V420, P459, DOI 10.1007/BF01600519; Chan-Penebre E, 2017, MOL CANCER THER, V16, P850, DOI 10.1158/1535-7163.MCT-16-0678; CHO KR, 1989, INT J GYNECOL PATHOL, V8, P381, DOI 10.1097/00004347-198912000-00010; CLEMENT PB, 1990, HUM PATHOL, V21, P363, DOI 10.1016/0046-8177(90)90198-E; Conlon N, 2015, J CLIN PATHOL, V68, P418, DOI 10.1136/jclinpath-2015-202945; Donner LR, 2007, HUM PATHOL, V38, P935, DOI 10.1016/j.humpath.2006.12.003; Eaton KW, 2011, PEDIATR BLOOD CANCER, V56, P7, DOI 10.1002/pbc.22831; Estel R, 2011, ARCH GYNECOL OBSTET, V284, P1277, DOI 10.1007/s00404-011-1846-5; Fahiminiya S, 2016, ONCOTARGET, V7, P1732, DOI 10.18632/oncotarget.6459; Florell SR, 1999, MED PEDIATR ONCOL, V32, P304, DOI 10.1002/(SICI)1096-911X(199904)32:4<304::AID-MPO13>3.0.CO;2-M; Foulkes WD, 2014, J PATHOL, V233, P209, DOI 10.1002/path.4362; Gaertner EM, 1999, INT J GYNECOL PATHOL, V18, P396, DOI 10.1097/00004347-199910000-00017; Garcia EP, 2017, ARCH PATHOL LAB MED, V141, P751, DOI 10.5858/arpa.2016-0527-OA; Gorayski P, 2013, J CLIN NEUROSCI, V20, P1466, DOI 10.1016/j.jocn.2013.03.041; Hasegawa T, 2001, MODERN PATHOL, V14, P655, DOI 10.1038/modpathol.3880368; Hasselblatt M, 2011, AM J SURG PATHOL, V35, P933, DOI 10.1097/PAS.0b013e3182196a39; Heck JE, 2013, PEDIATR BLOOD CANCER, V60, P77, DOI 10.1002/pbc.24141; Howitt BE, 2015, J PATHOL, V235, P37, DOI 10.1002/path.4442; Hsueh S, 1996, GYNECOL ONCOL, V61, P142, DOI 10.1006/gyno.1996.0113; Jelinic P, 2018, JNCI-J NATL CANCER I, V110, P787, DOI 10.1093/jnci/djx277; Jelinic P, 2014, NAT GENET, V46, P424, DOI 10.1038/ng.2922; Karnezis AN, 2016, MODERN PATHOL, V29, P302, DOI 10.1038/modpathol.2015.155; Karnezis AN, 2016, J PATHOL, V238, P389, DOI 10.1002/path.4633; Knapik J, 2001, HUM PATHOL, V32, P884, DOI 10.1053/hupa.2001.26476; Kobel M, 2018, AM J SURG PATHOL, V42, P76, DOI 10.1097/PAS.0000000000000941; Kuge A, 2012, BRAIN TUMOR PATHOL, V29, P177, DOI 10.1007/s10014-011-0075-8; Le Loarer F, 2015, NAT GENET, V47, P1200, DOI 10.1038/ng.3399; LITMAN DA, 1993, AM J SURG PATHOL, V17, P729, DOI 10.1097/00000478-199307000-00011; McCluggage WG, 2016, MODERN PATHOL, V29, pS78, DOI 10.1038/modpathol.2015.137; MOUNT SL, 1995, AM J CLIN PATHOL, V103, P235; Niemann T, 1997, GYNECOL ONCOL, V64, P181, DOI 10.1006/gyno.1996.4472; Oliveira E, 2016, CHILD NERV SYST, V32, P1573, DOI 10.1007/s00381-016-3187-y; QUADE BJ, 1995, CURR OPIN OBSTET GYN, V7, P35; Ramos P, 2014, NAT GENET, V46, P427, DOI 10.1038/ng.2928; Schaefer IM, 2017, MODERN PATHOL, V30, P539, DOI 10.1038/modpathol.2016.230; Shah VI, 2015, AM J SURG PATHOL, V39, P722, DOI 10.1097/PAS.0000000000000427; Sholl LM, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87062; Strehl JD, 2015, ANN DIAGN PATHOL, V19, P198, DOI 10.1016/j.anndiagpath.2015.04.001; Sultan I, 2010, PEDIATR BLOOD CANCER, V54, P35, DOI 10.1002/pbc.22285; Tsuda H, 2001, BRIT J OBSTET GYNAEC, V108, P120, DOI 10.1111/j.1471-0528.2001.00019.x; Witkowski L, 2016, GYNECOL ONCOL, V141, P454, DOI 10.1016/j.ygyno.2016.03.013; Witkowski L, 2014, NAT GENET, V46, P438, DOI 10.1038/ng.2931; Yoshida A, 2017, MODERN PATHOL, V30, P797, DOI 10.1038/modpathol.2017.11; YOUNG RH, 1994, AM J SURG PATHOL, V18, P1102, DOI 10.1097/00000478-199411000-00004	48	5	6	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	SEP	2018	31	9					1442	1456		10.1038/s41379-018-0049-z			15	Pathology	Pathology	GT5SG	WOS:000444569400010	29700418				2019-10-28	
J	Marcelis, L; Berghen, C; De Zutter, A; Biesemans, P; Vandenberghe, P; Verhoef, G; Gheysens, O; Sagaert, X; Dierickx, D; Tousseyn, T				Marcelis, Lukas; Berghen, Charlien; De Zutter, Alexandra; Biesemans, Pauline; Vandenberghe, Peter; Verhoef, Gregor; Gheysens, Olivier; Sagaert, Xavier; Dierickx, Daan; Tousseyn, Thomas			Other immunomodulatory agent-related lymphoproliferative diseases: a single-center series of 72 biopsy-confirmed cases	MODERN PATHOLOGY			English	Article							INFLAMMATORY-BOWEL-DISEASE; EPSTEIN-BARR-VIRUS; B-CELL LYMPHOMA; CLASSICAL HODGKIN LYMPHOMA; NECROSIS FACTOR THERAPY; OF-THE-LITERATURE; RHEUMATOID-ARTHRITIS; CROHNS-DISEASE; CLINICOPATHOLOGICAL CHARACTERISTICS; BIOLOGIC THERAPY	Ongoing development of new drugs, as well as novel indications in the treatment of autoimmune diseases leads to the increasing use of immunomodulatory and immunosuppressive drugs. Immunomodulatory agent-related lymphoproliferative disorders are a known and potentially life threatening complication of chronic administration of these drugs, but are less well characterized compared with post-transplant lymphoproliferative disorders. The heterogeneous drug targets, various underlying disease indications, different drug combinations used and relatively low incidence render data collection and interpretation difficult. In this retrospective paper, we describe the clinicopathological characteristics of a larger single-center series of 72 immunomodulatory agent-related lymphoproliferative disorder cases. We divided the cases according to the therapy, administered in the year preceding diagnosis of a lymphoproliferative disorder, in an immunosuppressive drug, an immunomodulatory drug and a combination of immunosuppressive and immunomodulatory drugs group. We observed differences in "time to lymphoproliferative disorder development" with a shorter time for all the immunomodulatory drugrelated cases combined (immunomodulatory and immunomodulatory+immunosuppressive=immunomodulatory-all) vs immunosuppressive-only (p = 0.0031). The proportion of malignant cases in patients receiving immunomodulatory therapy was, however, also significantly lower when compared with the immunosuppressive treated cases (43 vs 88%; p = 0.0184). The immunomodulatory/suppressive agent-related lymphoproliferative disorders were less often associated with the Epstein-Barr virus (EBV) (31 vs 66%; p = 1.829e-05) and the lymphoproliferative disorders incidence in the first year after immunomodulatory/immunosuppressive therapy initiation was lower (18 vs 41%; p = 0.04151)-compared with a published series of 140 post-transplant lymphoproliferative disorder cases from the same center. However, a similar histopathological spectrum from nondestructive, to polymorphic and monomorphic lesions as in post-transplant lymphoproliferative disorders is observed. With increasing use of immunosuppressive and especially immunomodulatory therapy, a higher incidence of immunomodulatory/suppressive agent-related lymphoproliferative disorders is to be expected. Life-long awareness for development of immunomodulatory/suppressive agent-related lymphoproliferative disorders with clinical follow-up and timely biopsies of suspicious lesions is required since these lymphoproliferative disorders arise both early after therapy initiation and many years later. Histopathological confirmation and correct classification is necessary to guide therapy and EBV ISH should be a part of routine pathological diagnostics.	[Marcelis, Lukas; De Zutter, Alexandra; Biesemans, Pauline; Sagaert, Xavier; Tousseyn, Thomas] Katholieke Univ Leuven, Dept Imaging & Pathol, Translat Cell & Tissue Res Lab, Leuven, Belgium; [Berghen, Charlien] Univ Hosp, UZ Leuven, Dept Radiat Oncol, Leuven, Belgium; [Vandenberghe, Peter; Verhoef, Gregor; Dierickx, Daan] Univ Hosp, UZ Leuven, Dept Hematol, Leuven, Belgium; [Verhoef, Gregor] Katholieke Univ Leuven, Ctr Human Genet, Leuven, Belgium; [Gheysens, Olivier] Univ Hosp, UZ Leuven, Dept Nucl Med, Leuven, Belgium; [Sagaert, Xavier; Tousseyn, Thomas] Univ Hosp, UZ Leuven, Dept Pathol, Leuven, Belgium	Tousseyn, T (reprint author), Katholieke Univ Leuven, Dept Imaging & Pathol, Translat Cell & Tissue Res Lab, Leuven, Belgium.; Tousseyn, T (reprint author), Univ Hosp, UZ Leuven, Dept Pathol, Leuven, Belgium.	thomas.tousseyn@uzleuven.be			KU LeuvenKU Leuven [3M040406]; FWO-VlaanderenFWO [G081411N]; Stichting tegen Kanker [2014-083]; Stefanie's Rozen fonds; Fonds Tom Debackere; KU Leuven, Department of Oncology - "Kom op tegen Kanker (Stand up to Cancer), the Flemish cancer society"; KU Leuven, Department of Imaging and Pathology	We are grateful for the fruitful collaboration with Prof. Dr. R. Westhovens (Department of Rheumatology, UZ Leuven university hospital), Prof. Dr. G. Van Assche (Department of Gastro-enterology, UZ Leuven university hospital), Dr. K Segers (department of Pathology, AZ Turnhout), and Dr. F Ballaux (Department of Pathology, Imelda Hospital). This study was supported by the concerted action grant from the KU Leuven no. 3M040406 (T.T.) (http://www.kuleuven.be/) and the research grant from FWO-Vlaanderen (G081411N to G.V. and T.T.). T.T. holds a Mandate for Fundamental and Translational Research from the "Stichting tegen Kanker" (2014-083). D.D. holds a Mandate for Clinical Research from the University Hospitals Leuven and from "Kom op tegen Kanker" and is a cofounder of "Stefanie's Rozen Fonds," "Fonds Tom Debackere voor lymfoomonderzoek" and "Fonds Jos en Mieke Vandevordt-Gaul voor de pathogenese van zeldzame lymfomen." G.V. holds the International Roche Chair in hematology and is a founder of the " Fonds Tom Debackere voor lymfoomonderzoek" and "Fonds Jos en Mieke Vandevordt-Gaul voor de pathogenese van zeldzame lymfomen" and cofounder of "Stefanie's Rozen fonds." L. M. is a PhD student, financially supported by KU Leuven, Department of Imaging and Pathology, "Stefanie's Rozen fonds" and the "Fonds Tom Debackere." CB is a PhD student, financially supported by KU Leuven, Department of Oncology, grant by "Kom op tegen Kanker (Stand up to Cancer), the Flemish cancer society."	Adams AE, 2004, J AM ACAD DERMATOL, V51, P660, DOI 10.1016/j.jaad.2004.03.047; Alobaid A, 2015, WORLD NEUROSURG, V84, DOI 10.1016/j.wneu.2015.07.009; Askling J, 2005, GUT, V54, P617, DOI 10.1136/gut.2004.051771; Baecklund E, 2006, ARTHRITIS RHEUM, V54, P692, DOI 10.1002/art.21675; Baecklund E, 2003, ARTHRITIS RHEUM-US, V48, P1543, DOI 10.1002/art.11144; Brown SL, 2002, ARTHRITIS RHEUM-US, V46, P3151, DOI 10.1002/art.10679; Caillard S, 2005, TRANSPLANTATION, V80, P1233, DOI 10.1097/01.tp.0000179639.98338.39; Chiorean MV, 2011, DIGEST DIS SCI, V56, P1489, DOI 10.1007/s10620-010-1430-z; CONNELL WR, 1994, LANCET, V343, P1249, DOI 10.1016/S0140-6736(94)92150-4; Mackey AC, 2007, J PEDIATR GASTR NUTR, V44, P265, DOI 10.1097/MPG.0b013e31802f6424; Dayharsh GA, 2002, GASTROENTEROLOGY, V122, P72, DOI 10.1053/gast.2002.30328; Deng A, 2006, ARCH DERMATOL, V142, P198, DOI 10.1001/archderm.142.2.198; Dharnidharka VR, 2001, TRANSPLANTATION, V71, P1065, DOI 10.1097/00007890-200104270-00010; Dierickx D, 2018, NEW ENGL J MED, V378, P549, DOI 10.1056/NEJMra1702693; Dierickx D, 2013, LEUKEMIA LYMPHOMA, V54, P2433, DOI 10.3109/10428194.2013.780655; Du MQ, 2002, BLOOD, V100, P3415, DOI 10.1182/blood-2002-02-0487; Dulai PS, 2014, CLIN GASTROENTEROL H, V12, P1443, DOI 10.1016/j.cgh.2014.01.021; Farrell RJ, 2000, GUT, V47, P514, DOI 10.1136/gut.47.4.514; Ferreiro JF, 2015, HAEMATOLOGICA, V100, pE275, DOI 10.3324/haematol.2015.124305; Gaulard P, 2017, WHO CLASSIFICATION T, P462; Gion Y, 2017, CANCER SCI, V108, P1271, DOI 10.1111/cas.13249; Gonzalez-Farre B, 2017, MODERN PATHOL, V30, P745, DOI 10.1038/modpathol.2016.233; Hanauer SB, 2004, ALIMENT PHARM THER, V20, P60, DOI 10.1111/j.1365-2036.2004.02048.x; Hans CP, 2004, BLOOD, V103, P275, DOI 10.1182/blood-2003-05-1545; Hasserjian RP, 2009, MODERN PATHOL, V22, P1532, DOI 10.1038/modpathol.2009.131; Herrinton LJ, 2011, AM J GASTROENTEROL, V106, P2146, DOI 10.1038/ajg.2011.283; Hofscheier A, 2011, MODERN PATHOL, V24, P1046, DOI 10.1038/modpathol.2011.62; Hollander P, 2015, AM J EPIDEMIOL, V182, P624, DOI 10.1093/aje/kwv081; Horie N, 2015, AUST DENT J, V60, P408, DOI 10.1111/adj.12235; Hoshida Y, 2007, J RHEUMATOL, V34, P322; Hurley MY, 2008, DIAGN PATHOL, V3, DOI 10.1186/1746-1596-3-13; Ichikawa A, 2013, EUR J HAEMATOL, V91, P20, DOI 10.1111/ejh.12116; Inui Y, 2015, LEUKEMIA LYMPHOMA, V56, P3045, DOI 10.3109/10428194.2015.1022769; KAMEL OW, 1993, NEW ENGL J MED, V328, P1317, DOI 10.1056/NEJM199305063281806; Kandiel A, 2005, GUT, V54, P1121, DOI 10.1136/gut.2004.049460; Kawahara A, 2015, BIOMARK RES, V3, DOI 10.1186/s40364-015-0035-2; Kotlyar DS, 2011, CLIN GASTROENTEROL H, V9, P36, DOI 10.1016/j.cgh.2010.09.016; Kovarik J, 2013, PATHOBIOLOGY, V80, P275, DOI 10.1159/000346960; Leombruno JP, 2009, ANN RHEUM DIS, V68, P1136, DOI 10.1136/ard.2008.091025; Leoncini L, 2017, WHO CLASSIFICATION T, P334; Lewis JD, 2001, GASTROENTEROLOGY, V121, P1080, DOI 10.1053/gast.2001.28703; Loo EY, 2013, AM J SURG PATHOL, V37, P1290, DOI 10.1097/PAS.0b013e31828e6564; Lopez-Olivo MA, 2012, JAMA-J AM MED ASSOC, V308, P898, DOI 10.1001/2012.jama.10857; Mariette X, 2002, BLOOD, V99, P3909, DOI 10.1182/blood.V99.11.3909; Mariette X, 2011, ANN RHEUM DIS, V70, P1895, DOI 10.1136/ard.2010.149419; Masunaga Y, 2007, ANN PHARMACOTHER, V41, P21, DOI 10.1345/aph.1H219; Mercer LK, 2013, RHEUMATOLOGY, V52, P91, DOI 10.1093/rheumatology/kes350; Miranda RN, 2013, AM J SURG PATHOL, V37, P1895, DOI 10.1097/PAS.0000000000000095; Miyazaki T, 2007, AM J HEMATOL, V82, P1106, DOI 10.1002/ajh.21003; Morscio J, 2013, AM J TRANSPLANT, V13, P1305, DOI 10.1111/ajt.12196; Morscio J, 2017, MODERN PATHOL, V30, P370, DOI 10.1038/modpathol.2016.199; Morscio Julie, 2016, World J Transplant, V6, P505, DOI 10.5500/wjt.v6.i3.505; OPELZ G, 1993, LANCET, V342, P1514, DOI 10.1016/S0140-6736(05)80084-4; Opelz G, 2004, AM J TRANSPLANT, V4, P222, DOI 10.1046/j.1600-6143.2003.00325.x; Oyama T, 2007, CLIN CANCER RES, V13, P5124, DOI 10.1158/1078-0432.CCR-06-2823; Park SH, 2008, RHEUMATOL INT, V28, P475, DOI 10.1007/s00296-007-0467-6; Rizzi R, 2009, MED ONCOL, V26, P1, DOI 10.1007/s12032-008-9069-8; Rosh JR, 2007, INFLAMM BOWEL DIS, V13, P1024, DOI 10.1002/ibd.20169; Said J, 2017, WHO CLASSIFICATION T, P325; Sekiguchi Y, 2012, J CLIN EXP HEMATOP, V52, P211, DOI 10.3960/jslrt.52.211; Simon TA, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0728-9; Swerdlow SH, 2017, WHO CLASSIFICATION T, P453; Thayu M, 2005, J PEDIATR GASTR NUTR, V40, P220, DOI 10.1097/00005176-200502000-00026; Tokuhira M, 2012, LEUKEMIA LYMPHOMA, V53, P616, DOI 10.3109/10428194.2011.625101; van de Meeberg MM, 2016, WORLD J GASTROENTERO, V22, P10465, DOI 10.3748/wjg.v22.i47.10465; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202; Warman JI, 2003, J CLIN GASTROENTEROL, V37, P220, DOI 10.1097/00004836-200309000-00006; Weyand CM, 2006, ARTHRITIS RHEUM, V54, P685, DOI 10.1002/art.21674; Wolfe F, 2007, ARTHRITIS RHEUM, V56, P1433, DOI 10.1002/art.22579; Wong AK, 2012, CLIN RHEUMATOL, V31, P631, DOI 10.1007/s10067-011-1895-y; Yamada K, 2015, HISTOPATHOLOGY, V67, P70, DOI 10.1111/his.12627; Younes BS, 2000, TRANSPLANTATION, V70, P94	72	0	0	1	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	SEP	2018	31	9					1457	1469		10.1038/s41379-018-0054-2			13	Pathology	Pathology	GT5SG	WOS:000444569400011	29765143	Bronze			2019-10-28	
J	Huang, WT; Medeiros, LJ; Lin, P; Wang, W; Tang, GL; Khoury, J; Konoplev, S; Yin, CC; Xu, J; Oki, Y; Li, SY				Huang, Wenting; Medeiros, L. Jeffrey; Lin, Pei; Wang, Wei; Tang, Guilin; Khoury, Joseph; Konoplev, Sergej; Yin, C. Cameron; Xu, Jie; Oki, Yasuhiro; Li, Shaoying			MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas	MODERN PATHOLOGY			English	Article							B-CELL LYMPHOMA; RITUXIMAB PLUS CYCLOPHOSPHAMIDE; CHOP CONSORTIUM PROGRAM; C-MYC; POOR-PROGNOSIS; P53 EXPRESSION; BCL2 TRANSLOCATIONS; BURKITT-LYMPHOMA; REARRANGEMENTS; SURVIVAL	High-grade B-cell lymphomas with MYC, BCL2, and BCL6 rearrangements (triple hit lymphoma) are uncommon. We studied the clinicopathologic features of 40 patients with triple hit lymphoma and compared them to 157 patients with MYC/ BCL2 double hit lymphoma and 13 patients with MYC/BCL6 double hit lymphoma. The triple hit lymphoma group included 25 men and 15 women with a median age of 61 years (range, 34-85). Nine patients had a history of B-cell lymphoma. Histologically, 23 (58%) cases were diffuse large B-cell lymphoma and 17 cases had features of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Most cases of triple hit lymphoma were positive for CD10 (100%), BCL2 (95%), BCL6 (82%), MYC (74%), and 71% with MYC and BCL2 coexpression. P53 was overexpressed in 29% of triple hit lymphoma cases. The clinicopathological features of triple hit lymphoma patients were similar to patients with MYC/BCL2 and MYC/BCL6 double hit lymphoma, except that triple hit lymphoma cases were more often CD10 positive compared with MYC/BCL6 double hit lymphoma (p < 0.05). Induction chemotherapy used was similar for patients with triple hit lymphoma and double hit lymphoma and overall survival in triple hit lymphoma patients was 17.6 months, similar to the overall survival of patients with double hit lymphoma (p = 0.67). Patients with triple hit lymphoma showing P53 overexpression had significantly worse overall survival compared with those without P53 overexpression (p = 0.04). On the other hand, double expressor status and prior history of B-cell lymphoma did not correlate with overall survival. In conclusion, most patients with triple hit lymphoma have an aggressive clinical course and poor prognosis and these tumors have a germinal center B-cell immunophenotype, similar to patients with double hit lymphomas. P53 expression is a poor prognostic factor in patients with triple hit lymphoma.	[Huang, Wenting; Medeiros, L. Jeffrey; Lin, Pei; Wang, Wei; Tang, Guilin; Khoury, Joseph; Konoplev, Sergej; Yin, C. Cameron; Xu, Jie; Li, Shaoying] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA; [Huang, Wenting] Chinese Acad Med Sci, Natl Canc Ctr, Canc Hosp, Dept Pathol, Beijing, Peoples R China; [Huang, Wenting] Peking Union Med Coll, Beijing, Peoples R China; [Oki, Yasuhiro] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA	Li, SY (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA.	SLi6@mdanderson.org	Medeiros, L. Jeffrey/AAB-1018-2019				Aukema SM, 2014, HAEMATOLOGICA, V99, P726, DOI 10.3324/haematol.2013.091827; Aukema SM, 2011, BLOOD, V117, P2319, DOI 10.1182/blood-2010-09-297879; Bacher U, 2011, GENE CHROMOSOME CANC, V50, P43, DOI 10.1002/gcc.20831; Barrans S, 2010, J CLIN ONCOL, V28, P3360, DOI 10.1200/JCO.2009.26.3947; Basso K, 2010, BLOOD, V115, P975, DOI 10.1182/blood-2009-06-227017; Chang CC, 2000, AM J CLIN PATHOL, V113, P512; Clipson A, 2015, J PATHOL CLIN RES, V1, P125, DOI 10.1002/cjp2.10; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Green TM, 2012, J CLIN ONCOL, V30, P3460, DOI 10.1200/JCO.2011.41.4342; Hans CP, 2004, BLOOD, V103, P275, DOI 10.1182/blood-2003-05-1545; Hu ZH, 2017, AM J SURG PATHOL, V41, P216, DOI 10.1097/PAS.0000000000000758; JACOBSON JO, 1993, CANCER, V72, P231, DOI 10.1002/1097-0142(19930701)72:1<231::AID-CNCR2820720141>3.0.CO;2-5; Johnson NA, 2012, J CLIN ONCOL, V30, P3452, DOI 10.1200/JCO.2011.41.0985; Johnson NA, 2009, BLOOD, V114, P2273, DOI 10.1182/blood-2009-03-212191; Kluin PM, 2017, WHO CLASSIFICATION T; Koduru PRK, 1997, BLOOD, V90, P4078, DOI 10.1182/blood.V90.10.4078; Li SY, 2016, ONCOTARGET, V7, P38122, DOI 10.18632/oncotarget.9473; Li SY, 2016, HISTOPATHOLOGY, V68, P1090, DOI 10.1111/his.12884; Li SY, 2016, AM J SURG PATHOL, V40, P253, DOI 10.1097/PAS.0000000000000542; Li SY, 2013, ADV ANAT PATHOL, V20, P315, DOI 10.1097/PAP.0b013e3182a289f2; Li SY, 2012, MODERN PATHOL, V25, P145, DOI 10.1038/modpathol.2011.147; Li Y, 2016, MODERN PATHOL, V29, P444, DOI 10.1038/modpathol.2016.35; McGowan JSA, 2016, INT SYSTEM HUMAN CYT; Miao Y, 2016, HUM PATHOL, V58, P72, DOI 10.1016/j.humpath.2016.07.025; Nie ZQ, 2012, CELL, V151, P68, DOI 10.1016/j.cell.2012.08.033; Oki Y, 2014, BRIT J HAEMATOL, V166, P891, DOI 10.1111/bjh.12982; Parekh S, 2007, BLOOD, V110, P2067, DOI 10.1182/blood-2007-01-069575; Petrich AM, 2014, BLOOD, V124, P2354, DOI 10.1182/blood-2014-05-578963; Pillai RK, 2013, AM J SURG PATHOL, V37, P323, DOI 10.1097/PAS.0b013e31826cebad; Quesada AE, 2017, MODERN PATHOL, V30, P1688, DOI 10.1038/modpathol.2017.93; Savage KJ, 2009, BLOOD, V114, P3533, DOI 10.1182/blood-2009-05-220095; Tomita N, 2009, HAEMATOL-HEMATOL J, V94, P935, DOI 10.3324/haematol.2008.005355; Turakhia SK, 2014, AM J CLIN PATHOL, V142, P339, DOI 10.1309/AJCPBWVHTF7RRSA4; Valera A, 2013, HAEMATOLOGICA, V98, P1554, DOI 10.3324/haematol.2013.086173; Visco C, 2013, HAEMATOLOGICA, V98, P255, DOI 10.3324/haematol.2012.066209; Wang W, 2015, AM J SURG PATHOL, V39, P1132, DOI 10.1097/PAS.0000000000000434; Wang XJ, 2017, MODERN PATHOL, V30, P194, DOI 10.1038/modpathol.2016.178; Wang XJ, 2015, AM J SURG PATHOL, V39, P1250, DOI 10.1097/PAS.0000000000000433; Xie Y, 2014, AM J CLIN PATHOL, V141, P593, DOI 10.1309/AJCPPHMZ6VHF0WQV; Xu-Monette ZY, 2012, BLOOD, V120, P3986, DOI 10.1182/blood-2012-05-433334	41	1	1	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	SEP	2018	31	9					1470	1478		10.1038/s41379-018-0067-x			9	Pathology	Pathology	GT5SG	WOS:000444569400012	29785017	Bronze			2019-10-28	
J	Satpathy, AT; Brown, RA; Gomulia, E; Briseno, CG; Mumbach, MR; Pan, ZG; Murphy, KM; Natkunam, Y; Chang, HY; Kim, J				Satpathy, Ansuman T.; Brown, Ryanne A.; Gomulia, Ellen; Briseno, Carlos G.; Mumbach, Maxwell R.; Pan, Zenggang; Murphy, Kenneth M.; Natkunam, Yasodha; Chang, Howard Y.; Kim, Jinah			Expression of the transcription factor ZBTB46 distinguishes human histiocytic disorders of classical dendritic cell origin	MODERN PATHOLOGY			English	Article							HEALTH-ORGANIZATION CLASSIFICATION; FOLLICULAR LYMPHOMAS; LANGERHANS CELLS; IMMUNE LINEAGES; 2016 REVISION; NEOPLASMS; MACROPHAGES; REVEALS; SARCOMA; LESIONS	Distinguishing classical dendritic cells from other myeloid cell types is complicated by the shared expression of cell surface markers. ZBTB46 is a zinc finger and BTB domain-containing transcription factor, which is expressed by dendritic cells and committed dendritic cell precursors, but not by plasmacytoid dendritic cells, monocytes, macrophages, or other immune cell populations. In this study, we demonstrate that expression of ZBTB46 identifies human dendritic cell neoplasms. We examined ZBTB46 expression in a range of benign and malignant histiocytic disorders and found that ZBTB46 is able to clearly define the dendritic cell identity of many previously unclassified histiocytic disease subtypes. In particular, all examined cases of Langerhans cell histiocytosis and histiocytic sarcoma expressed ZBTB46, while all cases of blastic plasmacytoid dendritic cell neoplasm, chronic myelomonocytic leukemia, juvenile xanthogranuloma, Rosai-Dorfman disease, and Erdheim-Chester disease failed to demonstrate expression of ZBTB46. Moreover, ZBTB46 expression clarified the identity of diagnostically challenging neoplasms, such as cases of indeterminate cell histiocytosis, classifying a fraction of these entities as dendritic cell malignancies. These findings clarify the lineage origins of human histiocytic disorders and distinguish dendritic cell disorders from all other myeloid neoplasms.	[Satpathy, Ansuman T.; Brown, Ryanne A.; Gomulia, Ellen; Natkunam, Yasodha; Kim, Jinah] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; [Satpathy, Ansuman T.; Mumbach, Maxwell R.; Chang, Howard Y.] Stanford Univ, Sch Med, Ctr Personal Dynam Regulomes, Stanford, CA 94305 USA; [Briseno, Carlos G.; Murphy, Kenneth M.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; [Briseno, Carlos G.; Murphy, Kenneth M.] Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; [Mumbach, Maxwell R.] Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; [Pan, Zenggang] Univ Colorado Denver, Dept Pathol, Aurora, CO 80045 USA; [Chang, Howard Y.] Stanford Univ, Sch Med, Dept Dermatol, Stanford, CA 94305 USA	Satpathy, AT (reprint author), Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA.; Satpathy, AT (reprint author), Stanford Univ, Sch Med, Ctr Personal Dynam Regulomes, Stanford, CA 94305 USA.	satpathy@stanford.edu		Satpathy, Ansuman/0000-0002-5167-537X	Stanford Pathology Department; Scleroderma Research Foundation; Parker Bridge Scholar Award from the Parker Institute for Cancer Immunotherapy	This work was supported by the Stanford Pathology Department (to A.T.S., R.A.B., Y.N., and J.K.) and the Scleroderma Research Foundation (to H.Y.C.). A.T.S. was supported by a Parker Bridge Scholar Award from the Parker Institute for Cancer Immunotherapy.	Allen CE, 2010, J IMMUNOL, V184, P4557, DOI 10.4049/jimmunol.0902336; Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Berres ML, 2015, J EXP MED, V212, P281, DOI 10.1084/jem.2013097701202015c; Brown RA, 2015, BLOOD, V126, P2344, DOI 10.1182/blood-2015-07-655530; Broz ML, 2014, CANCER CELL, V26, P638, DOI 10.1016/j.ccell.2014.09.007; Castro ECC, 2010, PEDIATR DEVEL PATHOL, V13, P225, DOI 10.2350/09-03-0622-OA.1; Collin M, 2015, HEMATOL ONCOL CLIN N, V29, P825, DOI 10.1016/j.hoc.2015.06.003; Emile JF, 2016, BLOOD, V127, P2672, DOI [10.1182/blood-2016-01-690636, 10.1182/blood-2016-01690636]; Feldman AL, 2008, BLOOD, V111, P5433, DOI 10.1182/blood-2007-11-124792; Fernandez-Pol S, 2016, HUM PATHOL, V55, P39, DOI 10.1016/j.humpath.2016.04.004; Franklin RA, 2014, SCIENCE, V344, P921, DOI 10.1126/science.1252510; Go H, 2014, HISTOPATHOLOGY, V65, P261, DOI 10.1111/his.12416; Grajales-Reyes GE, 2015, NAT IMMUNOL, V16, P708, DOI 10.1038/ni.3197; Hogstad B, 2018, J EXP MED, V215, P319, DOI 10.1084/jem.20161881; Hruz Tomas, 2008, Advances in Bioinformatics, P420747, DOI 10.1155/2008/420747; Meredith MM, 2012, J EXP MED, V209, P1153, DOI 10.1084/jem.20112675; NEZELOF C, 1973, BIOMEDICINE, V18, P365; O'Malley DP, 2010, MODERN PATHOL, V23, P1616, DOI 10.1038/modpathol.2010.157; Perdiguero EG, 2015, NATURE, V518, P547, DOI 10.1038/nature13989; Satpathy AT, 2013, NAT IMMUNOL, V14, P937, DOI 10.1038/ni.2679; Satpathy AT, 2012, NAT IMMUNOL, V13, P1145, DOI 10.1038/ni.2467; Satpathy AT, 2012, J EXP MED, V209, P1135, DOI 10.1084/jem.20120030; Schreiber HA, 2013, J EXP MED, V210, P2025, DOI 10.1084/jem.20130903; Segura E, 2013, IMMUNITY, V38, P336, DOI 10.1016/j.immuni.2012.10.018; Shao HP, 2011, MODERN PATHOL, V24, P1421, DOI 10.1038/modpathol.2011.102; Stowman AM, 2016, AM J SURG PATHOL, V40, P1270, DOI 10.1097/PAS.0000000000000678; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Wang J, 2018, DEV COMP IMMUNOL, V80, P2, DOI 10.1016/j.dci.2016.11.007; West DS, 2013, AM J SURG PATHOL, V37, P978, DOI 10.1097/PAS.0b013e318283099f; WOOD GS, 1985, J DERMATOL SURG ONC, V11, P1111, DOI 10.1111/j.1524-4725.1985.tb01399.x; Wu XD, 2016, J EXP MED, V213, P2553, DOI 10.1084/jem.20160600	31	0	0	1	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	SEP	2018	31	9					1479	1486		10.1038/s41379-018-0052-4			8	Pathology	Pathology	GT5SG	WOS:000444569400013	29743654	Green Accepted			2019-10-28	
J	Weidner, AS; Twaddell, WS				Weidner, Anna-Sophie; Twaddell, William S.			Topics in Medical and Transplant Liver Pathology-Editors' Remarks	AJSP-REVIEWS AND REPORTS			English	Editorial Material									[Weidner, Anna-Sophie; Twaddell, William S.] Univ Maryland, Med Ctr, 22 S Greene St, Baltimore, MD 21201 USA	Weidner, AS (reprint author), Univ Maryland, Med Ctr, 22 S Greene St, Baltimore, MD 21201 USA.	AnnaSophie.Weidner@umm.edu						0	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	SEP-OCT	2018	23	5					197	198		10.1097/PCR.0000000000000269			2	Pathology	Pathology	GT0II	WOS:000444117800001					2019-10-28	
J	Jessurun, J				Jessurun, Jose			Histopathologic Approach to Cholestatic Diseases of the Liver	AJSP-REVIEWS AND REPORTS			English	Review						liver; cholestasis; biopsy; primary biliary cholangitis; primary sclerosing cholangitis; overlap syndromes	PRIMARY BILIARY-CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; MAGNETIC-RESONANCE CHOLANGIOPANCREATOGRAPHY; HEPATITIS OVERLAP SYNDROME; AUTOIMMUNE HEPATITIS; DIAGNOSIS; FEATURES; THERAPY; CLONORCHIASIS; EPIDEMIOLOGY	Liver biopsy specimens of patients with cholestatic diseases pose a challenge to pathologists since, in most instances, this procedure is performed in a selected group of patients in whom clinical, laboratory, and imaging studies are inconclusive. Proper interpretation of the various histologic features is facilitated by the recognition of the most common patterns, which correlate with a defined group of diseases. Cholestatic disorders are grouped in 2 broad categories: acute and chronic. Four histologic patterns with different clinical implication are recognized within the first category: (1) ductular reaction, (2) pure canalicular cholestasis, (3) cholestasis with intrahepatic bile duct disease, and (4) cholestatic hepatitis. Chronic disorders are recognized by portal-based fibrosis, Mallory-Denk bodies, cholate stasis, accumulation of copper or copper-binding proteins, and biliary-type cirrhosis. Immunohistochemical reactions for cytokeratin 7 help to identify damaged bile ducts, highlight reactive ductules, and, most importantly, provide support for a cholestatic disorder by the staining of periportal hepatocytes (intermediate phenotype). The histologic features of primary biliary cholangitis and primary sclerosing cholangitis are reviewed with special emphasis on overlap syndromes and other entities that enter in the differential diagnosis.	[Jessurun, Jose] Weill Cornell Med, Dept Pathol, New York, NY USA	Jessurun, J (reprint author), 525 E 68th St,Starr 10, New York, NY 10065 USA.	joj9034@med.cornell.edu					Abdalian R, 2006, HEPATOLOGY, V44, P1063, DOI 10.1002/hep.21405; Angulo P, 1999, AM J GASTROENTEROL, V94, P3310, DOI 10.1111/j.1572-0241.1999.01543.x; Bateman AC, 2010, HISTOPATHOLOGY, V56, P415, DOI 10.1111/j.1365-2559.2009.03391.x; Batis KP, 1998, MAYO CLIN PROC, V73, P380; BENNETT WF, 1990, HEPATOLOGY, V12, P761, DOI 10.1002/hep.1840120423; Beuers U, 2015, GASTROENTEROLOGY, V149, P1627, DOI 10.1053/j.gastro.2015.08.031; BOUCHE H, 1993, J HEPATOL, V17, P34, DOI 10.1016/S0168-8278(05)80518-5; Broome U, 1996, GUT, V38, P610, DOI 10.1136/gut.38.4.610; Casali AM, 1998, HISTOPATHOLOGY, V32, P449; Chazouilleres O, 1998, HEPATOLOGY, V28, P296, DOI 10.1002/hep.510280203; Chen XM, 2002, NEW ENGL J MED, V346, P1723, DOI 10.1056/NEJMra013170; Corpechot C, 2005, GASTROENTEROLOGY, V128, P297, DOI 10.1053/j.gastro.2004.11.009; Crawford AR, 1998, HEPATOLOGY, V28, P323, DOI 10.1002/hep.510280206; Czaja AJ, 1996, ANN INTERN MED, V125, P588, DOI 10.7326/0003-4819-125-7-199610010-00009; Czaja AJ, 2000, HEPATOLOGY, V31, P1231, DOI 10.1053/jhep.2000.7878; Czaja AJ, 2017, GASTROENTEROL CLIN N, V46, P345, DOI 10.1016/j.gtc.2017.01.008; Czeczok TW, 2017, AM J SURG PATHOL, V41, P1247, DOI 10.1097/PAS.0000000000000881; Deshpande V, 2009, MODERN PATHOL, V22, P1287, DOI 10.1038/modpathol.2009.94; DEVANEY K, 1993, AM J SURG PATHOL, V17, P1272, DOI 10.1097/00000478-199312000-00009; Feld JJ, 2003, J GASTROEN HEPATOL, V18, P1118, DOI 10.1046/j.1440-1746.2003.03165.x; Floreani A, 2005, AM J GASTROENTEROL, V100, P1516, DOI 10.1111/j.1572-0241.2005.41841.x; Gey T, 2004, REV MAL RESPIR, V21, P997; Ghazale A, 2008, GASTROENTEROLOGY, V134, P706, DOI 10.1053/j.gastro.2007.12.009; Goodman ZD, 2005, DIGEST DIS SCI, V40, P1232; Gossard AA, 2005, AM J GASTROENTEROL, V100, P1330, DOI 10.1111/j.1572-0241.2005.41526.x; Gossard AA, 2017, CLIN LIVER DIS, V21, P725, DOI 10.1016/j.cld.2017.06.004; Graham RPD, 2014, HUM PATHOL, V45, P1722, DOI 10.1016/j.humpath.2014.04.006; Imam MH, 2013, CLIN LIVER DIS, V17, P269, DOI 10.1016/j.cld.2012.11.004; Itoh S, 1998, J GASTROEN HEPATOL, V13, P257, DOI 10.1111/j.1440-1746.1998.01553.x; Kaplan MM, 2005, NEW ENGL J MED, V353, P1261, DOI 10.1056/NEJMra043898; Keiner DA, 2017, GASTROENTEROL CLIN N, V46, P273; Khan FM, 2013, HEPATOLOGY, V57, P700, DOI 10.1002/hep.26020; Kuiper EMM, 2010, CLIN GASTROENTEROL H, V8, P530, DOI 10.1016/j.cgh.2010.03.004; Kwo PY, 2017, AM J GASTROENTEROL, V112, P18, DOI 10.1038/ajg.2016.517; Lazaridis KN, 2016, NEW ENGL J MED, V375, P1161, DOI 10.1056/NEJMra1506330; LEFKOWITCH JH, 1982, HUM PATHOL, V13, P19, DOI 10.1016/S0046-8177(82)80134-2; Lefkowitch JH, 2011, CHOLESTASIS LIVER PA; Lindor KD, 2009, HEPATOLOGY, V50, P291, DOI 10.1002/hep.22906; LUDWIG J, 1978, VIRCHOWS ARCH A, V379, P103, DOI 10.1007/BF00432479; Marcos LA, 2008, CURR OPIN INFECT DIS, V21, P523, DOI 10.1097/QCO.0b013e32830f9818; Moreira RK, 2011, AM J SURG PATHOL, V35, P392, DOI 10.1097/PAS.0b013e3182082ef6; Ohara H, 2012, J HEPATO-BIL-PAN SCI, V19, P536, DOI 10.1007/s00534-012-0521-y; Parray FQ, 2014, INT J SURG, V12, P789, DOI 10.1016/j.ijsu.2014.05.078; PERDIGOTO R, 1992, J HEPATOL, V14, P325, DOI 10.1016/0168-8278(92)90178-R; Portmann B, 2012, HISTOPATHOLOGY, V60, P236, DOI 10.1111/j.1365-2559.2011.03853.x; Reau NS, 2008, CLIN LIVER DIS, V12, P203, DOI 10.1016/j.cld.2007.11.007; Reddy Sarathchandra I, 2002, Clin Liver Dis, V6, P297, DOI 10.1016/S1089-3261(03)00077-1; Rim HJ, 2005, J HELMINTHOL, V79, P269, DOI 10.1079/JOH2005300; Romagnuolo J, 2003, ANN INTERN MED, V139, P547, DOI 10.7326/0003-4819-139-7-200310070-00006; Saini S, 1997, NEW ENGL J MED, V336, P1889, DOI 10.1056/NEJM199706263362607; Salomao M, 2013, AM J SURG PATHOL, V37, P1837, DOI 10.1097/PAS.0b013e31829b626c; SCHEUER PJ, 1967, P ROY SOC MED, V60, P1257, DOI 10.1177/003591576706001205; Selmi C, 2004, J CLIN GASTROENTEROL, V38, P264, DOI 10.1097/00004836-200403000-00013; Stueck AE, 2018, MODERN PATHOL, V31, P442, DOI 10.1038/modpathol.2017.151; Torous VF, 2017, AM J SURG PATHOL, V41, P1607, DOI 10.1097/PAS.0000000000000959; Varghese JC, 1999, CLIN RADIOL, V54, P604, DOI 10.1016/S0009-9260(99)90023-5; Washington MK, 2007, MODERN PATHOL, V20, pS15, DOI 10.1038/modpathol.3800684; Woreta TA, 2014, MED CLIN N AM, V98, P1, DOI 10.1016/j.mcna.2013.09.005; Zen Y, 2016, J GASTROENTEROL, V51, P295, DOI 10.1007/s00535-016-1163-7	59	1	1	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	SEP-OCT	2018	23	5					199	213		10.1097/PCR.0000000000000268			15	Pathology	Pathology	GT0II	WOS:000444117800002					2019-10-28	
J	De Michele, S; Vittorio, JM; Thomas, T; Diaz, GA; Lefkowitch, JH; Lagana, SM				De Michele, Simona; Vittorio, Jennifer M.; Thomas, Tiffany; Diaz, George A.; Lefkowitch, Jay H.; Lagana, Stephen M.			A Rare Case of Neonatal Intrahepatic Cholestasis Caused by Citrin Deficiency in the United States	AJSP-REVIEWS AND REPORTS			English	Article						cholestatic hepatitis; citrin deficiency; NICCD; SLC25A13 gene	ASPARTATE GLUTAMATE CARRIER; II CITRULLINEMIA; HEPATITIS; MUTATIONS; NICCD; CHILD	We describe the case of a 9-week-old female infant of Ashkenazi Jewish descent who presented with failure to thrive, vomiting, and persistent jaundice. Laboratory tests showed positive urine reducing substances as well as an abnormal amino acid profile, with increased arginine, threonine, methionine, tyrosine, lysine, and grossly elevated citrulline levels. Liver biopsy demonstrated the presence of cholestatic hepatitis with mixed steatosis and siderosis. Based on the aforementioned findings, a preliminary diagnosis of neonatal intrahepatic cholestasis caused by citrin deficiency was made. This diagnosis was later confirmed by molecular testing. Neonatal intrahepatic cholestasis caused by citrin deficiency is typically seen in infants of East Asian descent, and to the best of our knowledge, this is the first reported case in an American infant of Ashkenazi Jewish descent.	[De Michele, Simona; Thomas, Tiffany; Lefkowitch, Jay H.; Lagana, Stephen M.] Columbia Univ, Dept Pathol & Cell Biol, Med Ctr, New York, NY USA; [Vittorio, Jennifer M.] Columbia Univ, Dept Pediat, Med Ctr, New York, NY 10027 USA; [Diaz, George A.] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10029 USA	De Michele, S (reprint author), Columbia Univ, Med Ctr, 630 W 168th St, New York, NY 10032 USA.	sd3166@cumc.columbia.edu					Chen R, 2013, WORLD J GASTROENTERO, V19, P4545, DOI 10.3748/wjg.v19.i28.4545; Fiermonte G, 2011, MOL GENET METAB, V104, P501, DOI 10.1016/j.ymgme.2011.08.022; Hayasaka K, 2012, JIMD REP, V2, P37, DOI 10.1007/8904_2011_42; Inui A, 2016, HEPATOL RES, V46, P357, DOI 10.1111/hepr.12559; Kimura A, 2010, HEPATOL RES, V40, P295, DOI 10.1111/j.1872-034X.2009.00594.x; Kobayashi K, GENEREVIEWS R; Saheki T, 2004, MOL GENET METAB, V81, pS20, DOI 10.1016/j.ymgme.2004.01.006; Saheki T, 2002, METAB BRAIN DIS, V17, P335, DOI 10.1023/A:1021961919148; Saheki T, 2002, J HUM GENET, V47, P333, DOI 10.1007/s100380200046; Saheki T, 2010, MOL GENET METAB, V100, pS59, DOI 10.1016/j.ymgme.2010.02.014; Sinasac DS, 1999, GENOMIC STRUCTURE AD, V62; Tabata A, 2008, J HUM GENET, V53, P534, DOI 10.1007/s10038-008-0282-2; Tamamori A, 2002, EUR J PEDIATR, V161, P609, DOI 10.1007/s00431-002-1045-2; Treepongkaruna S, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-141; Vitoria I, 2013, MOL GENET METAB, V110, P181, DOI 10.1016/j.ymgme.2013.06.011	15	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	SEP-OCT	2018	23	5					214	216		10.1097/PCR.0000000000000266			3	Pathology	Pathology	GT0II	WOS:000444117800003					2019-10-28	
J	Tondon, R; Stashek, KM				Tondon, Rashmi; Stashek, Kristen M.			Hyperbilirubinemia in a Hepatitis C Virus Patient After Liver Transplantation	AJSP-REVIEWS AND REPORTS			English	Review						fibrosing cholestatic hepatitis C; hepatitis C; liver transplantation	FIBROSING CHOLESTATIC HEPATITIS; DIRECT-ACTING ANTIVIRALS; RECURRENT-HEPATITIS; CYTOTOXIC CHEMOTHERAPY; FATAL REACTIVATION; INFECTION; RECIPIENTS; REJECTION; ALLOGRAFTS	Fibrosing cholestatic hepatitis C virus is a rare, cholestatic hepatitis that can occur in the setting of immunosuppression or after transplantation in individuals with active hepatitis C infection. Its onset is heralded by hyperbilirubinemia and rapidly progresses to graft failure without treatment. It is characterized histologically by ballooning hepatocyte degeneration, bile duct proliferation, cholestasis, and perisinusoidal fibrosis. It is important to distinguish fibrosing cholestatic hepatitis from other common causes of hyperbilirubinemia in the posttransplant setting, including biliary obstruction and acute cellular rejection.	[Tondon, Rashmi] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA USA; [Stashek, Kristen M.] Univ Maryland, Sch Med, Dept Pathol, 22 S Greene St, Baltimore, MD 21201 USA	Stashek, KM (reprint author), Univ Maryland, Sch Med, Dept Pathol, 22 S Greene St, Baltimore, MD 21201 USA.						BENNER KG, 1992, GASTROENTEROLOGY, V103, P1307, DOI 10.1016/0016-5085(92)91521-5; Ceballos-Viro J, 2009, WORLD J GASTROENTERO, V15, P2290, DOI 10.3748/wjg.15.2290; Chung RT, 2015, HEPATOLOGY, V62, P932, DOI 10.1002/hep.27950; Cotler SJ, 2000, AM J GASTROENTEROL, V95, P753; DAVIES SE, 1991, HEPATOLOGY, V13, P150, DOI 10.1016/0270-9139(91)90228-N; Delladetsima JK, 1999, LIVER TRANSPLANT SUR, V5, P294, DOI 10.1002/lt.500050417; Demetris AJ, 2004, AM J SURG PATHOL, V28, P658, DOI 10.1097/00000478-200405000-00015; Demetris AJ, 1997, HEPATOLOGY, V25, P658; Dixon LR, 2007, LIVER TRANSPLANT, V13, P219, DOI 10.1002/lt.21011; Doughty AL, 1998, LIVER TRANSPLANT SUR, V4, P15, DOI 10.1002/lt.500040102; Garcia-Retortillo M, 2002, HEPATOLOGY, V35, P680, DOI 10.1053/jhep.2002.31773; Kojima H, 2002, EUR J HAEMATOL, V69, P101, DOI 10.1034/j.1600-0609.2002.02719.x; KONIG V, 1992, HEPATOLOGY, V16, P1137, DOI 10.1016/0270-9139(92)90005-T; LAU JYN, 1992, GASTROENTEROLOGY, V102, P956, DOI 10.1016/0016-5085(92)90182-X; Leroy V, 2015, CLIN GASTROENTEROL H, V13, P1993, DOI 10.1016/j.cgh.2015.05.030; Liu CH, 2017, J FORMOS MED ASSOC, V116, P407, DOI 10.1016/j.jfma.2016.12.005; MCIVOR C, 1994, ANN INTERN MED, V121, P274, DOI 10.7326/0003-4819-121-4-199408150-00007; Moreira RK, 2013, AM J SURG PATHOL, V37, P104, DOI 10.1097/PAS.0b013e31826a92ac; Patwardhan VR, 2015, CURR OPIN ORGAN TRAN, V20, P267, DOI 10.1097/MOT.0000000000000191; Ponziani FR, 2011, TRANSPL P, V43, P291, DOI 10.1016/j.transproceed.2010.09.102; Ponziani FR, 2017, WORLD J HEPATOL, V9, P352, DOI 10.4254/wjh.v9.i7.352; Prieto M, 1999, HEPATOLOGY, V29, P250, DOI 10.1002/hep.510290122; Rosenberg PM, 2002, AM J GASTROENTEROL, V97, P478; Salomao M, 2013, AM J SURG PATHOL, V37, P1837, DOI 10.1097/PAS.0b013e31829b626c; Satapathy SK, 2011, HEPATOL RES, V41, P328, DOI 10.1111/j.1872-034X.2011.00781.x; Schluger LK, 1996, HEPATOLOGY, V23, P971, DOI 10.1002/hep.510230505; Souza P, 2009, HUM PATHOL, V40, P92, DOI 10.1016/j.humpath.2008.06.020; Vukotic R, 2017, J VIRAL HEPATITIS, V24, P858, DOI 10.1111/jvh.12712; Wiesner RH, 2003, LIVER TRANSPLANT, V9, pS1, DOI 10.1053/jlts.2003.50268; WRIGHT TL, 1992, GASTROENTEROLOGY, V103, P317, DOI 10.1016/0016-5085(92)91129-R	30	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	SEP-OCT	2018	23	5					217	220		10.1097/PCR.0000000000000262			4	Pathology	Pathology	GT0II	WOS:000444117800004					2019-10-28	
J	Hardy, N; Twaddell, WS				Hardy, Naomi; Twaddell, William S.			A 64-Year-Old Woman With Posttransplant Hepatitis	AJSP-REVIEWS AND REPORTS			English	Review						hepatitis E; liver transplant; nonspecific hepatitis	SUSTAINED VIROLOGICAL RESPONSE; LIVER-TRANSPLANT RECIPIENTS; E VIRUS-INFECTION; REJECTION	Abnormal liver function tests and nonspecific histopathologic findings are relatively common in the post-liver transplant setting. Whereas some cases remain idiopathic and many resolve spontaneously, some carry a risk of chronicity and long-term liver dysfunction including cirrhosis, graft loss, and death. Accurate assessment and follow-up of such findings are therefore crucial in this population. We report a case of a 64-year-old woman who underwent liver transplantation for chronic hepatitis C infection with cirrhosis. Several months after transplantation, she underwent a liver biopsy as part of a workup for abnormal serologic studies and transaminase elevation. The biopsy showed nonspecific hepatitis. Eventually, additional serologic testing demonstrated hepatitis E viral infection. Causes of hepatitis and other forms of posttransplant liver disease, including hepatitis E, are discussed.	[Hardy, Naomi; Twaddell, William S.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA	Twaddell, WS (reprint author), 22 S Greene St, Baltimore, MD 21201 USA.	wtwaddell@umm.edu					Aggarwal A, 2016, WORLD J HEPATOL, V8, P117, DOI 10.4254/wjh.v8.i2.117; Allaire M, 2018, CLIN RES HEPATOL GAS; Bailey RL, 2011, J NUTR, V141, P261, DOI 10.3945/jn.110.133025; Barrows BD, 2016, USCAP ABSTRACT, V244; Behrendt P, 2014, J HEPATOL, V61, P1418, DOI 10.1016/j.jhep.2014.08.047; Choi M, 2018, TRANSPLANT DIRECT, V4, DOI 10.1097/TXD.0000000000000758; Guerra JADA, 2017, J CLIN TRANSL HEPATO, V5, P376, DOI 10.14218/JCTH.2017.00012; Demetris AJ, 2016, AM J TRANSPLANT, V16, P2816, DOI 10.1111/ajt.13909; Demetris AJ, 1997, HEPATOLOGY, V25, P658; Elmasry S, 2017, GASTROENTEROLOGY, V152, P550, DOI 10.1053/j.gastro.2016.11.002; Gehrau R, 2011, MOL MED, V17, P824, DOI 10.2119/molmed.2011.00072; Kwo PY, 2017, AM J GASTROENTEROL, V112, P18, DOI 10.1038/ajg.2016.517; Maylin S, 2008, GASTROENTEROLOGY, V135, P821, DOI 10.1053/j.gastro.2008.05.044; Navarro VJ, 2014, HEPATOLOGY, V60, P1399, DOI 10.1002/hep.27317; Nirei K, 2018, INT J MED SCI, V15, P466, DOI 10.7150/ijms.23147; Pischke S, 2010, LIVER TRANSPLANT, V16, P74, DOI 10.1002/lt.21958; Pratt DS, 2000, NEW ENGL J MED, V342, P1266, DOI 10.1056/NEJM200004273421707; Rein DB, 2012, HEPATOLOGY, V55, P988, DOI 10.1002/hep.25505; Shindo M, 2018, INT MED CASE REP J, V11, P77, DOI 10.2147/IMCRJ.S163865; Skrzypczyk P, 2016, CENT EUR J IMMUNOL, V41, P328, DOI 10.5114/ceji.2016.63135; Syn WK, 2007, LIVER TRANSPLANT, V13, P984, DOI 10.1002/lt.21108; Vukotic R, 2016, WORLD J GASTROENTERO, V22, P2906, DOI 10.3748/wjg.v22.i10.2906	22	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	SEP-OCT	2018	23	5					221	224		10.1097/PCR.0000000000000263			4	Pathology	Pathology	GT0II	WOS:000444117800005					2019-10-28	
J	Twaddell, WS				Twaddell, William S.			Liver Transplant in a 71-Year-Old Man With a Diagnosis of Nonalcoholic Steatohepatitis	AJSP-REVIEWS AND REPORTS			English	Review						fatty liver disease; alpha 1-antitrypsin deficiency; liver transplant	CIRRHOSIS; DEFICIENCY	Fatty liver disease is an increasingly common indication for liver transplantation. Because of its prevalence, it may coexist with other causes of chronic liver disease, many of which may carry implications for treatment or follow-up of patients or their families. An increased degree of suspicion may be required to detect concurrent liver disease. We report a case of a 71-year-old man who underwent liver transplantation for nonalcoholic steatohepatitis. The explanted liver showed evidence of coexisting alpha 1-antitrypsin deficiency disorder. The clinicopathologic features and epidemiology of fatty liver disease and alpha 1-antitrypsin deficiency disorder are discussed, along with other possible coexisting disease.	[Twaddell, William S.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA	Twaddell, WS (reprint author), 22 S Greene St, Baltimore, MD 21201 USA.	wtwaddell@umm.edu					Adinolfi LE, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060803; Basra S, 2011, WORLD J HEPATOL, V3, P108, DOI 10.4254/wjh.v3.i5.108; Cacciottolo TM, 2014, EUR J GASTROEN HEPAT, V26, P412, DOI 10.1097/MEG.0000000000000061; Caldwell S, 2018, J HEPATOL, V68, P391, DOI 10.1016/j.jhep.2017.12.006; de Serres FJ, 2012, THER ADV RESPIR DIS, V6, P277, DOI 10.1177/1753465812457113; DUFFIN JM, 1987, CAN MED ASSOC J, V137, P393; Estes C, 2018, HEPATOLOGY, V67, P123, DOI 10.1002/hep.29466; Fielding Cory M, 2014, Curr Hepatol Rep, V13, P151; Kim WR, 2018, AM J TRANSPLANT, V18, P172, DOI 10.1111/ajt.14559; Le MH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173499; McElvaney NG, 2015, EUR RESPIR REV, V24, P52, DOI 10.1183/09059180.10010814; Neuschwander-Tetri BA, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0806-8; Prado V, 2016, ANN HEPATOL, V15, P463; Thuluvath PJ, 2018, J HEPATOL, V68, P519, DOI 10.1016/j.jhep.2017.11.018	14	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	SEP-OCT	2018	23	5					225	227		10.1097/PCR.0000000000000264			3	Pathology	Pathology	GT0II	WOS:000444117800006					2019-10-28	
J	Pittman, ME				Pittman, Meredith E.			Budd-Chiari Syndrome: What Pathologists Need to Know About Hepatic Venous Outflow Obstruction	AJSP-REVIEWS AND REPORTS			English	Review						Budd-Chiari syndrome; cirrhosis; fulminant liver failure; hepatic vein thrombosis; hepatic venous obstruction	LARGE REGENERATIVE NODULES; SINUSOIDAL DILATATION; VEIN-THROMBOSIS; LIVER; MANAGEMENT; DIAGNOSIS; DISEASE; HISTOLOGY; FAILURE	Hepatic venous outflow obstruction, known as Budd-Chiari syndrome, is a rare but significant cause of hepatic dysfunction. Worldwide, themost common cause of hepatic venous outflowobstruction is thrombosis of the hepatic veins and/or inferior vena cava secondary to an inherited or acquired hypercoagulable state (eg, factor V Leiden deficiency). Depending on the extent and acuity of the thrombosis, patients with Budd-Chiari syndrome may present in acute liver failure or as chronic compensated cirrhosis; almost all will have the classic (but nonspecific) pairing of abdominal pain and ascites. Histologic findings in the liver also vary according to the time course and magnitude of thrombosis and can range from zone 3 congestion to established cirrhosis. The cases reported herein demonstrate 2 variations of Budd-Chiari syndrome encountered in the daily practice of pathology. The aims of this review were to examine the clinical, radiological, and histologic features of Budd-Chiari syndrome and to discuss the differential diagnosis based on the observed histologic pattern.	[Pittman, Meredith E.] Weill Cornell Med, Dept Pathol, New York, NY USA	Pittman, ME (reprint author), 525 E 68th St,Starr 10, New York, NY 10065 USA.	mep9071@med.cornell.edu					BIRGENS HS, 1978, ACTA MED SCAND, V204, P417; Cazals-Hatem D, 2003, HEPATOLOGY, V37, P510, DOI 10.1053/jhep.2003.50076; CLARK R, 1973, LANCET, V1, P66; de la Grandmaison GL, 2001, FORENSIC SCI INT, V119, P149, DOI 10.1016/S0379-0738(00)00401-1; DeLeve LD, 2009, HEPATOLOGY, V49, P1729, DOI 10.1002/hep.22772; Elsayes KM, 2017, RADIOGRAPHICS, V37, P813, DOI 10.1148/rg.2017160161; Falcao Camila Kruschewsky, 2015, Autops Case Rep, V5, P17, DOI 10.4322/acr.2015.009; Garcia-Pagan JC, 2008, GASTROENTEROLOGY, V135, P808, DOI 10.1053/j.gastro.2008.05.051; Harmanci O, 2013, J CLIN GASTROENTEROL, V47, P706, DOI 10.1097/MCG.0b013e31824ffd63; Heller MT, 2012, EMERG RADIOL, V19, P329, DOI 10.1007/s10140-012-1036-1; Horvath B, 2017, GASTROENTEROL RES, V10, P182, DOI 10.14740/gr875e; Janssen HLA, 2003, J HEPATOL, V38, P364, DOI 10.1016/S0168-8278(02)00434-8; Kakar S, 2004, ARCH PATHOL LAB MED, V128, P901; Kim H, 2015, CLIN MOL HEPATOL, V21, P89, DOI 10.3350/cmh.2015.21.1.89; LAFFON A, 1989, J CLIN GASTROENTEROL, V11, P653, DOI 10.1097/00004836-198912000-00011; MacNicholas R, 2012, EXPERT REV GASTROENT, V6, P731, DOI [10.1586/egh.12.56, 10.1586/EGH.12.56]; Martens P, 2015, UNITED EUR GASTROENT, V3, P489, DOI 10.1177/2050640615582293; Menon KVN, 2004, NEW ENGL J MED, V350, P578, DOI 10.1056/NEJMra020282; Mohty M, 2015, BONE MARROW TRANSPL, V50, P781, DOI 10.1038/bmt.2015.52; Murad SD, 2009, ANN INTERN MED, V151, P167, DOI 10.7326/0003-4819-151-3-200908040-00004; Myers RP, 2003, HEPATOLOGY, V37, P393, DOI 10.1053/jhep.2003.50062; Parekh J, 2017, LIVER TRANSPLANT, V23, P135, DOI 10.1002/lt.24643; Rautou PE, 2009, AM J GASTROENTEROL, V104, P1140, DOI 10.1038/ajg.2009.63; Richardson P, 1999, BRIT J HAEMATOL, V107, P485, DOI 10.1046/j.1365-2141.1999.01680.x; Seijo S, 2013, HEPATOLOGY, V57, P1962, DOI 10.1002/hep.26306; Senzolo Marco, 2005, Nat Clin Pract Gastroenterol Hepatol, V2, P182, DOI 10.1038/ncpgasthep0143; Tanaka M, 1998, HEPATOLOGY, V27, P488, DOI 10.1002/hep.510270224; Tang TJ, 2001, J HEPATOL, V35, P338, DOI 10.1016/S0168-8278(01)00131-3; Valla D, 2004, J GASTROEN HEPATOL, V19, P5204, DOI DOI 10.1111/J.1440-1746.2004.03642.X; Valla DC, 2003, HEPATOLOGY, V38, P793, DOI 10.1053/jhep.2003.50415; Valla DC, 2002, SEMIN LIVER DIS, V22, P5, DOI 10.1055/s-2002-23202; Valla DC, 2018, VIRCHOWS ARCH, V473, P3, DOI 10.1007/s00428-018-2331-3; WILLIAMS AT, 1990, SEMIN LIVER DIS, V10, P279, DOI 10.1055/s-2008-1040483; Zimmerman Michael A, 2006, Clin Liver Dis, V10, P259, DOI 10.1016/j.cld.2006.05.005	34	0	0	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	SEP-OCT	2018	23	5					228	233		10.1097/PCR.0000000000000265			6	Pathology	Pathology	GT0II	WOS:000444117800007					2019-10-28	
J	Weidner, AS				Weidner, Anna-Sophie			Incidental Hepatic Granulomas in a Young Woman	AJSP-REVIEWS AND REPORTS			English	Review						hepatic granuloma; hepatic sarcoidosis; liver biopsy	SINGLE-CENTER EXPERIENCE; BUDD-CHIARI-SYNDROME; ANGIOTENSIN-CONVERTING ENZYME; LIVER-TRANSPLANTATION; CLINICAL CHARACTERISTICS; DIFFERENTIAL-DIAGNOSIS; UNITED-STATES; SARCOIDOSIS; MANIFESTATIONS; FEATURES	Hepatic granulomas are identified in approximately 3% to 4% of liver biopsies in theWestern world. Their presence raises a broad differential diagnosis for the pathologist to consider, including infectious, immune-mediated, and drug-induced etiologies. Certain histologic features of granulomas and the adjacent liver parenchyma can help narrow the differential diagnosis, although clinical and laboratory correlation is often necessary to establish a definitive diagnosis. The purpose of this article is to review the morphologic classification of hepatic granulomas and to discuss hepatic sarcoidosis, one of the most common immune-mediated causes.	[Weidner, Anna-Sophie] Univ Maryland, Sch Med, Baltimore, MD 21201 USA	Weidner, AS (reprint author), Univ Maryland, Med Ctr, 22 S Greene St, Baltimore, MD 21201 USA.	AnnaSophie.Weidner@umm.edu					Bakker GJ, 2012, NETH J MED, V70, P349; Baughman RP, 2001, AM J RESP CRIT CARE, V164, P1885, DOI 10.1164/ajrccm.164.10.2104046; Bilal M, 2016, J CLIN EXP HEPATOL, V6, P94, DOI 10.1016/j.jceh.2016.02.005; Blich M, 2004, J GASTROEN HEPATOL, V19, P732, DOI 10.1111/j.1440-1746.2003.03335.x; Cozier YC, 2011, CHEST, V139, P144, DOI 10.1378/chest.10-0413; Cremers J, 2012, EUR J GASTROEN HEPAT, V24, P17, DOI 10.1097/MEG.0b013e32834c7b71; Cremers JP, 2012, CURR OPIN PULM MED, V18, P472, DOI 10.1097/MCP.0b013e3283541626; Delfosse V, 2009, TRANSPL P, V41, P3432, DOI 10.1016/j.transproceed.2009.09.021; Deniz K, 2008, LIVER INT, V28, P580, DOI 10.1111/j.1478-3231.2007.01633.x; DENK H, 1994, HISTOPATHOLOGY, V25, P209, DOI 10.1111/j.1365-2559.1994.tb01320.x; DEVANEY K, 1993, AM J SURG PATHOL, V17, P1272, DOI 10.1097/00000478-199312000-00009; Dourakis SP, 2007, EUR J GASTROEN HEPAT, V19, P101, DOI 10.1097/01.meg.0000243882.09820.d2; Drebber U, 2008, LIVER INT, V28, P828, DOI 10.1111/j.1478-3231.2008.01695.x; Drebber U, 2009, PATHOL INT, V59, P546, DOI 10.1111/j.1440-1827.2009.02405.x; Dulai PS, 2012, J CLIN GASTROENTEROL, V46, P367, DOI 10.1097/MCG.0b013e318247106b; Ebert EC, 2008, AM J GASTROENTEROL, V103, P3184, DOI 10.1111/j.1572-0241.2008.02202.x; Efe C, 2012, RHEUMATOL INT, V32, P3319, DOI 10.1007/s00296-011-2129-y; Ennaifer R, 2015, CLINICS PRACT, V5, DOI 10.4081/cp.2015.768; Everett J, 2017, AM J SURG PATHOL, V41, P134, DOI 10.1097/PAS.0000000000000759; Finnell CW, 2007, SURG ENDOSC, V21, P867, DOI 10.1007/s00464-006-9079-6; Gaspar R, 2018, HISTOPATHOLOGY; Gaya DR, 2003, J CLIN PATHOL, V56, P850, DOI 10.1136/jcp.56.11.850; Geramizadeh B, 2011, ARCH IRAN MED, V14, P288, DOI 0011144/AIM.0012; Greenbaum David, 2005, Surg Obes Relat Dis, V1, P22, DOI 10.1016/j.soard.2004.12.008; HERCULES HD, 1984, ARCH PATHOL LAB MED, V108, P831; Iannuzzi MC, 2007, NEW ENGL J MED, V357, P2153, DOI 10.1056/NEJMra071714; Ishak KG, 1998, MAYO CLIN PROC, V73, P467; IWAI K, 1964, AM REV RESPIR DIS, V90, P612; Judson MA, 2012, SARCOIDOSIS VASC DIF, V29, P119; Judson MA, 2015, CLIN REV ALLERG IMMU, V49, P63, DOI 10.1007/s12016-014-8450-y; Kennedy PT, 2006, EUR J GASTROEN HEPAT, V18, P721, DOI 10.1097/01.meg.0000223911.85739.38; KLATSKIN G, 1950, YALE J BIOL MED, V23, P207; Krishnamoorthy G, 2012, RHEUMATOL INT, V32, P1453, DOI 10.1007/s00296-011-1909-8; Lagana SM, 2010, CLIN LIVER DIS, V14, P605, DOI 10.1016/j.cld.2010.07.005; Lamps LW, 2015, ARCH PATHOL LAB MED, V139, P867, DOI 10.5858/arpa.2014-0123-RA; MINO RA, 1949, ANN SURG, V130, P951, DOI 10.1097/00000658-194911000-00012; Miyamoto R, 2017, INT J SURG CASE REP, V41, P165, DOI 10.1016/j.ijscr.2017.10.032; NATALINO MR, 1978, JAMA-J AM MED ASSOC, V239, P2657; PIETINALHO A, 1995, SARCOIDOSIS, V12, P61; Powell JL, 2005, GYNECOL ONCOL, V99, P770, DOI 10.1016/j.ygyno.2005.08.002; Pungpapong S, 2006, GASTROINTEST ENDOSC, V64, P124, DOI 10.1016/j.gie.2006.01.033; RICKER W, 1949, AM J CLIN PATHOL, V19, P725; RUSSI EW, 1986, AM J GASTROENTEROL, V81, P71; Rybicki BA, 1997, AM J EPIDEMIOL, V145, P234; Saito H, 2017, INTERNAL MED, V56, P2583, DOI 10.2169/internalmedicine.8768-16; Sanai FM, 2008, LIVER INT, V28, P1402, DOI 10.1111/j.1478-3231.2008.01837.x; SATTI MB, 1990, AM J GASTROENTEROL, V85, P669; SILVERSTEIN E, 1977, ISRAEL J MED SCI, V13, P995; Suzuki Keiichi, 2011, Case Rep Gastroenterol, V5, P152, DOI 10.1159/000323546; Tadros M, 2013, J CLIN TRANSL HEPATO, V1, P87, DOI 10.14218/JCTH.2013.00016; Turhan N, 2011, PATHOL RES PRACT, V207, P359, DOI 10.1016/j.prp.2011.03.003; Ungprasert P, 2017, AM J GASTROENTEROL, V112, P1556, DOI 10.1038/ajg.2017.231; Ungprasert P, 2016, LUNG, V194, P91, DOI 10.1007/s00408-015-9826-3; VALLA D, 1987, Q J MED, V63, P531; Van Brusselen D, 2012, PEDIATR TRANSPLANT, V16, P58; Vanatta JM, 2011, LIVER TRANSPLANT, V17, P1027, DOI 10.1002/lt.22339; Yonenaga Y, 2015, ONCOL LETT, V10, P2166, DOI 10.3892/ol.2015.3566; Zhu HF, 2010, WORLD J GASTROENTERO, V16, P5065, DOI 10.3748/wjg.v16.i40.5065	58	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	SEP-OCT	2018	23	5					234	240		10.1097/PCR.0000000000000267			7	Pathology	Pathology	GT0II	WOS:000444117800008					2019-10-28	
J	AlFarkh, W; Torbenson, MS; Mounajjed, T				AlFarkh, Wedad; Torbenson, Michael S.; Mounajjed, Taofic			Benign Hepatic Lesions Arising in Accessory Hepatic Lobes	AJSP-REVIEWS AND REPORTS			English	Review						accessory hepatic lobe; hepatic adenoma; myelolipoma	FOCAL NODULAR HYPERPLASIA; OF-THE-LITERATURE; CONGENITAL ABSENCE; PORTAL-VEIN; LIVER; TORSION; MYELOLIPOMA; GALLBLADDER; MIMICKING; ADENOMA	An accessory hepatic lobe is an uncommon hepatic congenital anomaly that can sometimes mimic a mass lesion clinically and radiologically. Because accessory hepatic lobes are only rarely resected, detailed descriptions of their histologic features are sparse. We report the histologic and immunohistochemical features of 3 cases of resected accessory hepatic lobes, all of which contained benign hepatic lesions (2 hepatic adenomas [HAs] and 1 focal nodular hyperplasia). All accessory lobes were connected to the liver by a pedicle. Histologically, all lesions demonstrated no cytologic or architectural atypia. Based on immunohistochemical analysis, 1 HAwas classified as inflammatory type (positive for C-reactive protein and serum amyloid A), and 1 was unclassified type (negative for C-reactive protein, serum amyloid A, glutamine synthetase, and beta-catenin and positive for liver fatty acid-binding protein); the focal nodular hyperplasia showed the typical map-like staining pattern with glutamine synthetase. Interestingly, multiple foci of myelolipoma were identified within the unclassified-type HA. Of note, in all cases, the nonlesional hepatic parenchyma featured structural vascular abnormalities of the hepatic artery branches, including abnormal thickening of arterial branches and multiple arterial branches per single portal tract. Our findings describe, for the first time, benign hepatic lesions arising in accessory hepatic lobes and suggest that accessory lobes are perhaps prone to such benign lesions because of structural abnormalities in their vasculature.	[AlFarkh, Wedad; Torbenson, Michael S.; Mounajjed, Taofic] Mayo Clin, Dept Lab Med & Pathol, 200 First St SW, Rochester, MN 55905 USA	Mounajjed, T (reprint author), Mayo Clin, Dept Lab Med & Pathol, 200 First St SW, Rochester, MN 55905 USA.	Mounajjed.Taofic@mayo.edu					Agaimy A, 2012, INT J CLIN EXP PATHO, V5, P512; Asran MK, 2012, RADIOLOGY, V262, P364, DOI 10.1148/radiol.11102046; BATTLE WM, 1979, DIGEST DIS SCI, V24, P65, DOI 10.1007/BF01297240; CHAMPETIER J, 1985, ANAT CLIN, V7, P285, DOI 10.1007/BF01784645; Chevallier P, 1999, AM J ROENTGENOL, V172, P1146, DOI 10.2214/ajr.172.4.10587176; Craig JR, 1989, TUMORS LIVER INTRAHE; ELMASALME F, 1995, J PEDIATR SURG, V30, P1348, DOI 10.1016/0022-3468(95)90502-2; Faraj W, 2010, PEDIATR TRANSPLANT, V14, pE1, DOI 10.1111/j.1399-3046.2009.01190.x; Garba ES, 2002, PEDIATR SURG INT, V18, P62, DOI 10.1007/s003830200014; GONZALEZ EM, 1991, HEPATO-GASTROENTEROL, V38, P60; Goodman ZD, 2011, MACSWEENS PATHOLOGY; Hillerer C, 2007, RADIOLOGE, V47, P163, DOI 10.1007/s00117-005-1265-3; Koplewitz BZ, 1999, PEDIATR RADIOL, V29, P799, DOI 10.1007/s002470050698; Koumanidou C, 1998, PEDIATR SURG INT, V13, P526, DOI 10.1007/s003830050391; Massaro M, 2007, J COMPUT ASSIST TOMO, V31, P572, DOI 10.1097/01.rct.0000250107.78176.de; O'Malley DP, 2007, MODERN PATHOL, V20, P405, DOI 10.1038/modpathol.3800768; Ouyang Y, 1994, Radiat Med, V12, P183; PAPKE A, 1967, Patologia Polska, V18, P385; Paradis V, 2004, GASTROENTEROLOGY, V126, P1323, DOI 10.1053/j.gastro.2004.02.005; Parke W W, 1996, Clin Anat, V9, P309, DOI 10.1002/(SICI)1098-2353(1996)9:5<309::AID-CA4>3.0.CO;2-7; Portinari M, 2014, ANN ITAL CHIR, P85; PUJARI BD, 1976, POSTGRAD MED J, V52, P234, DOI 10.1136/pgmj.52.606.234; Pupulim LF, 2013, CLIN RADIOL, V68, pE362, DOI 10.1016/j.crad.2013.01.024; Radhi J, 2010, J GASTROINTEST LIVER, V19, P106; REITEMEIER RJ, 1958, GASTROENTEROLOGY, V34, P1090; RUBIN E, 1984, CANCER, V54, P2043, DOI 10.1002/1097-0142(19841101)54:9<2043::AID-CNCR2820540945>3.0.CO;2-P; SAWHNEY S, 1992, PEDIATR RADIOL, V22, P231, DOI 10.1007/BF02012507; Sirasanagandla SR, 2013, ANAT SCI INT, V88, P246, DOI 10.1007/s12565-013-0189-7; Tateishi Y, 2013, PATHOL INT, V63, P358, DOI 10.1111/pin.12072; Umehara M, 2009, SURG TODAY, V39, P80, DOI 10.1007/s00595-008-3772-0; Wasif N, 2008, AM SURGEON, V74, P1100; Yi W, 2010, ANN THORAC SURG, V89, pE9, DOI 10.1016/j.athoracsur.2009.10.010	32	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	SEP-OCT	2018	23	5					241	245		10.1097/PCR.0000000000000261			5	Pathology	Pathology	GT0II	WOS:000444117800009					2019-10-28	
J	Armstrong, DA; Dessaint, JA; Ringelberg, CS; Hazlett, HF; Howard, L; Abdalla, MAK; Barnaby, RL; Stanton, BA; Cervinski, MA; Ashare, A				Armstrong, David A.; Dessaint, John A.; Ringelberg, Carol S.; Hazlett, Haley F.; Howard, Louisa; Abdalla, Moemen A. K.; Barnaby, Roxanna L.; Stanton, Bruce A.; Cervinski, Mark A.; Ashare, Alix			Pre-Analytical Handling Conditions and Small RNA Recovery from Urine for miRNA Profiling	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							BIOMARKERS; EXOSOMES; MICRORNA; DISCOVERY; PROTEIN	There are currently no standardized protocols for pre-analytical handling of urine to best preserve small RNA for miRNA profiling studies. miRNA is an attractive candidate as a potential biomarker because of the high level of stability in body fluids and its ability to be quantified on multiple high-throughput platforms. We present a comparison of small RNA recovery and stability in urine under alternate pre-analytical handling conditions and extend recommendations on what conditions optimize yield of miRNA from cell-free urine and urine extracellular vesicles (EVs). Using an affinity slurry for isolation of small RNA from urine, we found that urine samples held at room temperature (20 degrees C) for up to 8 hours before processing yield the highest amounts of intact small RNAs from EVs. Some miRNA is lost from urine samples when held 2 degrees C to 4 degrees C and/or frozen before EV isolation, likely because of EV entrapment in uromodulin precipitates. However, we found that a simple 5-minute incubation of urine containing cold-induced precipitate at 37 degrees C resolubilizes much of this precipitate and results in an increased recovery of EVs and miRNAs. Finally, small RNA integrity can be compromised when whole urine is held at 37 degrees C for as little as 4 hours and is not conducive to efficient miRNA profiling.	[Armstrong, David A.; Dessaint, John A.; Ashare, Alix] Dartmouth Hitchcock Med Ctr, Dept Pulm & Crit Care Med, Lebanon, NH 03766 USA; [Cervinski, Mark A.] Dartmouth Hitchcock Med Ctr, Dept Pathol & Lab Med, Lebanon, NH 03766 USA; [Barnaby, Roxanna L.; Stanton, Bruce A.] Geisel Sch Med Dartmouth, Dept Microbiol & Immunol, Hanover, NH USA; [Ringelberg, Carol S.; Hazlett, Haley F.; Howard, Louisa; Cervinski, Mark A.; Ashare, Alix] Geisel Sch Med Dartmouth, Hanover, NH USA; [Abdalla, Moemen A. K.] Alexandria Univ, Fac Sci, Dept Biochem, Alexandria, Egypt	Ashare, A (reprint author), Dartmouth Hitchcock Med Ctr, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	Alix.Ashare@hitchcock.org		Cervinski, Mark/0000-0001-5116-3780	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01HL122372]	Supported by NIH grant R01HL122372 (A.A.).	Alvarez ML, 2014, METHODS MOL BIOL, V1182, P145, DOI 10.1007/978-1-4939-1062-5_13; Alvarez ML, 2012, KIDNEY INT, V82, P1024, DOI 10.1038/ki.2012.256; An MX, 2015, GENOM PROTEOM BIOINF, V13, P345, DOI 10.1016/j.gpb.2015.08.005; Argyropoulos C, 2015, J CLIN MED, V4, P1498, DOI 10.3390/jcm4071498; Armstrong DA, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-017-0355-1; Barreiro K, 2017, CELL TISSUE RES, V369, P217, DOI 10.1007/s00441-017-2621-0; Butz H, 2016, EUR UROL FOCUS, V2, P210, DOI 10.1016/j.euf.2015.11.006; Catalanotto C, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101712; COLLINS ACG, 1993, DIABETOLOGIA, V36, P993, DOI 10.1007/BF02374489; Debernardi S, 2015, AM J CANCER RES, V5, P3455; Fernandez-Llama P, 2010, KIDNEY INT, V77, P736, DOI 10.1038/ki.2009.550; He XB, 2014, BIOMED RES INT, DOI 10.1155/2014/945169; Hsu CY, 2017, KIDNEY INT, V91, P196, DOI 10.1016/j.kint.2016.09.003; Hur K, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju492; Jiang XC, 2017, INT J PHARMACEUT, V521, P167, DOI 10.1016/j.ijpharm.2017.02.038; Khurana R, 2017, RNA, V23, P142, DOI 10.1261/rna.058834.116; Mestdagh P, 2014, NAT METHODS, V11, P809, DOI [10.1038/NMETH.3014, 10.1038/nmeth.3014]; Musante L, 2017, J EXTRACELL VESICLES, V6, DOI 10.1080/20013078.2016.1267896; Musante L, 2014, SCI REP-UK, V4, DOI 10.1038/srep07532; Olivieri F, 2013, IMMUN AGEING, V10, DOI 10.1186/1742-4933-10-11; Oosthuyzen W, 2013, J PHYSIOL-LONDON, V591, P5833, DOI 10.1113/jphysiol.2013.264069; Properzi F, 2013, BIOMARK MED, V7, P769, DOI 10.2217/bmm.13.63; Rames M, 2014, JOVE-J VIS EXP, DOI 10.3791/51087; Ribeiro KCB, 2013, J BRAS PATOL MED LAB, P49; Street JM, 2017, ADV CLIN CHEM, V78, P103, DOI 10.1016/bs.acc.2016.07.003; Wachalska Magda, 2016, J Circ Biomark, V5, P4, DOI 10.5772/62579; Wei JT, 2015, CURR OPIN UROL, V25, P77, DOI 10.1097/MOU.0000000000000133; Wu XQ, 2016, IMMUNOLOGY, V148, P237, DOI 10.1111/imm.12608; Zhang HJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep11805	29	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	SEP	2018	20	5					565	571		10.1016/j.jmoldx.2018.04.003			7	Pathology	Pathology	GS8AR	WOS:000443929200001	29936254	Green Published			2019-10-28	
J	Cleveland, MH; Zook, JM; Salit, M; Vallone, PM				Cleveland, Megan H.; Zook, Justin M.; Salit, Marc; Vallone, Peter M.			Determining Performance Metrics for Targeted Next-Generation Sequencing Panels Using Reference Materials	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							BIOINFORMATICS PIPELINES; GUIDELINES	The National Institute of Standards and Technology has developed reference materials for five human genomes. DNA aliquots are available for purchase, and the data, analyses, and high-confidence small variant and homozygous reference calls are freely available on the web. These reference materials are useful for evaluating whole-genome sequencing methods and also can be used to benchmark targeted sequencing panels, which are used commonly in clinical settings. This article describes how to use the Genome in a Bottle samples to obtain performance metrics on any germline-targeted sequencing panel of interest, as well as the limitations of the reference materials. These materials are useful for understanding the limitations of, and optimizing, targeted sequencing panels and associated bioinformatics pipelines. Example figures are presented to illustrate ways to access the performance metrics of targeted sequencing panels, and a table of best practices is included.	[Cleveland, Megan H.; Zook, Justin M.; Salit, Marc; Vallone, Peter M.] NIST, Mat Measurement Lab, Gaithersburg, MD 20899 USA; [Salit, Marc] Joint Initiat Metrol Biol, Stanford, CA USA	Cleveland, MH (reprint author), NIST, 100 Bur Dr,Mail Stop 8314, Gaithersburg, MD 20899 USA.	megan.cleveland@nist.gov	Zook, Justin/B-7000-2008	Zook, Justin/0000-0003-2309-8402; Cleveland, Megan/0000-0002-5584-9314; Salit, Marc/0000-0003-1624-5195	National Institute of Standards and TechnologyNational Institute of Standards & Technology (NIST) - USA; US Department of Commerce	Supported by internal funding from the National Institute of Standards and Technology and from the US Department of Commerce.	Celestino-Soper PBS, 2017, FRONT CARDIOVASC MED, V4, DOI 10.3389/fcvm.2017.00011; Cleary JG, 2015, BIORXIV, DOI [10.1101/023754, DOI 10.1101/023754]; Cornish A, 2015, BIOMED RES INT, DOI 10.1155/2015/456479; Eggers S, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1105-y; Hwang S, 2015, SCI REP-UK, V5, DOI 10.1038/srep11201; Iqbal Z, 2017, PLOS ONE, V12, P1; Jennings LJ, 2017, J MOL DIAGN, V19, P341, DOI 10.1016/j.jmoldx.2017.01.011; Krusche P, 2018, BIORXIV, DOI [10.1101/270157, DOI 10.1101/270157]; LaDuca H, 2015, NEXT GENERATION SEQU, V2, P459; Laurie S, 2016, HUM MUTAT, V37, P1263, DOI 10.1002/humu.23114; Lincoln S. E., 2017, BIORXIV, DOI [10.1101/218529, DOI 10.1101/218529]; Linderman MD, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-20; Lucarelli M, 2017, J MOL DIAGN, V19, P788, DOI 10.1016/j.jmoldx.2017.06.002; Meynert AM, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-247; Mu WB, 2016, J MOL DIAGN, V18, P923, DOI 10.1016/j.jmoldx.2016.07.006; Omoyinmi E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181874; Quinlan AR, 2014, CURR PROTOC BIOINFOR, V47; Rehm HL, 2013, GENET MED, V15, P733, DOI 10.1038/gim.2013.92; Roy S, 2018, J MOL DIAGN, V20, P4, DOI 10.1016/j.jmoldx.2017.11.003; Wang XJ, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0549-5; Zook J., 2018, BIORXIV, DOI [10.1101/281006, DOI 10.1101/281006]; Zook JM, 2016, SCI DATA, V3, DOI 10.1038/sdata.2016.25; Zook JM, 2014, NAT BIOTECHNOL, V32, P246, DOI 10.1038/nbt.2835	23	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	SEP	2018	20	5					583	590		10.1016/j.jmoldx.2018.04.005			8	Pathology	Pathology	GS8AR	WOS:000443929200003	29959024	Green Accepted			2019-10-28	
J	Myers, C; Swadley, M; Carter, AB				Myers, Charles; Swadley, Matthew; Carter, Alexis B.			Laboratory Information Systems and Instrument Software Lack Basic Functionality for Molecular Laboratories	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							ELECTRONIC HEALTH RECORD; DIAGNOSTICS; CHALLENGES; GENOMICS	Laboratory information systems (LISs) have some basic functionality necessary for molecular workflow that is glaringly absent. This study determined functionality gaps of LISs in molecular laboratories and the associated impact to workflow, efficiency, and security by collecting anonymous survey data from clinical laboratory professionals. A 34-question survey (30 required + 4 optional) was compiled using an online survey tool. Participants were recruited through several professional molecular society listservs and given 4 weeks to complete the survey. Data collected included participant demographics, scope of testing, software capabilities for the LIS and molecular instruments, and comments. Eighty respondents completed the entire survey. Many desired versus actual functionality gaps were identified. Prominent among these were bar coding, LIS interfacing, storage of preanalytical data, Health Insurance Portability and Accountability Act compliance/information security, and reporting. Much basic functionality is lacking in molecular LISs and molecular instrument software. Some of these results indicate that instruments and LISs are not compliant with the Health Insurance Portability and Accountability Act. Collaboration between molecular professionals and manufacturers of instruments and software is necessary to correct these deficits and is critically important to ensure the continued high quality and safety of molecular practice as the volume of testing skyrockets.	[Myers, Charles; Swadley, Matthew; Carter, Alexis B.] Emory Univ Hosp, Dept Pathol & Lab Med, 1364 Clifton Rd NE, Atlanta, GA 30322 USA; [Carter, Alexis B.] Childrens Healthcare Atlanta, Dept Pathol & Lab Med, Atlanta, GA USA	Carter, AB (reprint author), Childrens Healthcare Atlanta, Lab Adm, 1405 Clifton Rd NE, Atlanta, GA 30322 USA.	alexis.carter@choa.org	Carter, Alexis Byrne/D-7843-2011	Carter, Alexis Byrne/0000-0002-0171-2216	American Medical Informatics Association	A.B.C. is a paid teaching faculty member for the Clinical Informatics Board Review Course given by the American Medical Informatics Association.	Amadoz A, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-32; Aronson SJ, 2011, HUM MUTAT, V32, P532, DOI 10.1002/humu.21470; Balogh EP, 2015, IMPROVING DIAGNOSIS, P237; Barillari C, 2016, BIOINFORMATICS, V32, P638, DOI 10.1093/bioinformatics/btv606; Dangott B, 2016, CLIN LAB MED, V36, P41, DOI 10.1016/j.cll.2015.09.005; Gershkovich P, 2015, ADV ANAT PATHOL, V22, P323, DOI 10.1097/PAP.0000000000000088; Kulikowski CA, 2002, METHOD INFORM MED, V41, P20; Kuo FC, 2007, ADV ADM LAB, V16, P16; Lee RE, 2016, ADV ANAT PATHOL, V23, P125, DOI 10.1097/PAP.0000000000000109; Martin-Sanchez F, 2002, METHOD INFORM MED, V41, P25; Pantanowitz L, 2012, PATHOLOGY INFORM THE, P157; Petrides AK, 2017, ARCH PATHOL LAB MED, V141, P410, DOI 10.5858/arpa.2016-0146-OA; Schmidt Megan, 2013, MLO Med Lab Obs, V45, P18; Sharma Mukesh K, 2013, AMIA Jt Summits Transl Sci Proc, V2013, P156; Sinard JH, 2015, ARCH PATHOL LAB MED, V139, P311, DOI 10.5858/arpa.2013-0711-SO; Smith TJ, 2007, ADV ADM LAB, V16, P58; SORACE JM, 1994, J AM MED INFORM ASSN, P293; Strickland-Marmol LB, 2016, ARCH PATHOL LAB MED, V140, P578, DOI 10.5858/arpa.2015-0237-OA; Swertz MA, 2004, BIOINFORMATICS, V20, P2075, DOI 10.1093/bioinformatics/bth206; Terry M, 2005, ADV ADM LAB, V14, P34; Valenstein PN, 2008, ARCH PATHOL LAB MED, V132, P84, DOI 10.1043/1543-2165(2008)132[84:FPRAFD]2.0.CO;2	21	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	SEP	2018	20	5					591	599		10.1016/j.jmoldx.2018.05.011			9	Pathology	Pathology	GS8AR	WOS:000443929200004	30146005				2019-10-28	
J	Callenberg, KM; Santana-Santos, L; Chen, L; Ernst, WL; De Moura, MB; Nikiforov, YE; Nikiforova, MN; Roy, S				Callenberg, Keith M.; Santana-Santos, Lucas; Chen, Liang; Ernst, Wayne L.; De Moura, Michelle B.; Nikiforov, Yuri E.; Nikiforova, Marina N.; Roy, Somak			Clinical Implementation and Validation of Automated Human Genome Variation Society (HGVS) Nomenclature System for Next-Generation Sequencing-Based Assays for Cancer	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							JOINT-CONSENSUS-RECOMMENDATION; FOR-MOLECULAR-PATHOLOGY; VARIANTS; ASSOCIATION; GUIDELINES; STANDARDS; DATABASES; COLLEGE; NAME	Human Genome Variation Society (HGVS) nomenclature is a de facto clinical standard for reporting DNA sequence variants. With increasing use of high-throughput sequencing, manual generation of HGVS nomenclatures for all variants is impractical and error-prone. It is therefore beneficial to include one or more HGVS generator tools in next-generation sequencing (NGS) bioinformatics pipelines to enable automated, consistent, and accurate generation of HGVS nomenclature after appropriate validation. The authors implemented an HGVS nomenclature tool, the hgvs package, by integrating it into their custom developed NGS variant management and reporting software. Use of Docker containers provided a strategic advantage to the integration process. Clinical implementation of the hgvs package was validated using a cohort of 330 variants that appropriately represented cancer-related genes and clinically important variant types. The hgvs package was able to generate HGVS-compliant variant nomenclature (both c. and p.) for 308 of the 330 (93.3%) variants, including all those in the coding and untranslated regions, and 32 of 35 (91.4%) in the consensus splice site region. Discrepant HGVS nomenclature involved variants in the intronic (16 of 40) and consensus splice site (3 of 35) regions with repeat sequences. Overall, implementation of the hgvs package in the clinical NGS workflow improved consistency and accuracy of reporting HGVS nomenclature.	[Callenberg, Keith M.; Santana-Santos, Lucas; Chen, Liang; Ernst, Wayne L.; De Moura, Michelle B.; Nikiforov, Yuri E.; Nikiforova, Marina N.; Roy, Somak] Univ Pittsburgh, Dept Pathol, Med Ctr, Div Mol & Genom Pathol, Pittsburgh, PA USA; [Roy, Somak] Assoc Mol Pathol, Informat Subdiv Leadership, Bethesda, MD USA	Roy, S (reprint author), Univ Pittsburgh, Med Ctr, Div Mol & Genom Pathol, 3477 Euler Way,Room 7028, Pittsburgh, PA 15213 USA.	roys@upmc.edu		Roy, Somak/0000-0002-5681-0112; Nikiforova, Marina Nikolaevna/0000-0001-9976-9378			Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695; Dean DJ, 2017, IEEE WORLD CONGR SER, P21, DOI 10.1109/SERVICES.2017.13; den Dunnen JT, 2016, HUM MUTAT, V37, P564, DOI 10.1002/humu.22981; den Dunnen JT, 2016, CURR PROTOC HUM GENE, V90; Freeman PJ, 2018, HUM MUTAT, V39, P61, DOI 10.1002/humu.23348; Hart RK, 2015, BIOINFORMATICS, V31, P268, DOI 10.1093/bioinformatics/btu630; Karunamurthy A, 2016, ENDOCR-RELAT CANCER, V23, P295, DOI 10.1530/ERC-16-0043; Li MM, 2017, J MOL DIAGN, V19, P4, DOI 10.1016/j.jmoldx.2016.10.002; Lubin IM, 2017, J MOL DIAGN, V19, P417, DOI 10.1016/j.jmoldx.2016.12.001; McLaren W, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0974-4; Merkel D., 2014, LINUX J, V2014, P2, DOI DOI 10.1097/01.NND.0000320699.47006.A3; Pilotto S, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2016.12.33; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Roy S, 2018, J MOL DIAGN, V20, P4, DOI 10.1016/j.jmoldx.2017.11.003; Tack V, 2016, HUM MUTAT, V37, P570, DOI 10.1002/humu.22975; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Yen JL, 2017, GENOME MED, V9, DOI 10.1186/s13073-016-0396-7	18	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	SEP	2018	20	5					628	634		10.1016/j.jmoldx.2018.05.006			7	Pathology	Pathology	GS8AR	WOS:000443929200008	29936258				2019-10-28	
J	Niazi, R; Gonzalez, MA; Balciuniene, J; Evans, P; Sarmady, M; Abou Tayoun, AN				Niazi, Rojeen; Gonzalez, Michael A.; Balciuniene, Jorune; Evans, Perry; Sarmady, Mahdi; Abou Tayoun, Ahmad N.			The Development and Validation of Clinical Exome-Based Panels Using ExomeSlicer Considerations and Proof of Concept Using an Epilepsy Panel	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							GENE; IDENTIFICATION; RESOURCE	Exome-based panels are becoming the preferred diagnostic strategy in clinical laboratories. This approach enables dynamic gene content update and, if needed, cost-effective reflex to whole-exome sequencing. Currently, no guidelines or appropriate resources are available to support the clinical implementation of exome-based panels. Here, we highlight principles and important considerations for the clinical development and validation of exome-based panels. In addition, we developed ExomeSlicer, a novel, web-based resource, which uses empirical exon-level next-generation sequencing quality metrics to predict and visualize technically challenging exome-wide regions in any gene or genes of interest. Exome sequencing data from 100 clinical epilepsy cases were used to illustrate the clinical utility of ExomeSlicer in predicting poor-quality regions and its impact on streamlining the ad hoc Sanger sequencing fill in burden. With the use of ExomeSlicer, >2100 low complexity and/or high-homology regions affecting >1615 genes across the exome were also characterized. These regions can be a source of false-positive or false-negative variant calls, which can lead to misdiagnoses in tested patients and/or inaccurate functional annotations. We provide important considerations and a novel resource for the clinical development of exome-based panels.	[Niazi, Rojeen; Gonzalez, Michael A.; Balciuniene, Jorune; Sarmady, Mahdi; Abou Tayoun, Ahmad N.] Childrens Hosp Philadelphia, Div Genom Diagnost, Philadelphia, PA 19104 USA; [Evans, Perry] Univ Penn, Perelman Sch Med, Dept Biomed & Hlth Informat, Philadelphia, PA 19104 USA; [Sarmady, Mahdi; Abou Tayoun, Ahmad N.] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Abou Tayoun, Ahmad N.] Al Jalila Childrens Specialty Hosp, Dept Genet, Dubai, U Arab Emirates	Sarmady, M (reprint author), Civ Ctr Blvd,Abramson Res Bldg, Philadelphia, PA 19104 USA.; Abou Tayoun, AN (reprint author), Al Jalila Childrens Genet Lab, Al Jaddaf St, Dubai, U Arab Emirates.	sarmadym@email.chop.edu; ahmad.tayoun@ajch.ae	Sarmady/M-9859-2019	Sarmady/0000-0001-6069-804X; Gonzalez, Michael/0000-0002-4957-2910			Abou Tayoun AN, 2016, EXPERT REV MOL DIAGN, V16, P987, DOI 10.1080/14737159.2016.1209411; Abou Tayoun AN, 2016, GENET MED, V18, P545, DOI 10.1038/gim.2015.141; Bamshad MJ, 2011, NAT REV GENET, V12, P745, DOI 10.1038/nrg3031; Bayat A, 2015, EPILEPSIA, V56, pE36, DOI 10.1111/epi.12927; Gilissen C, 2012, EUR J HUM GENET, V20, P490, DOI 10.1038/ejhg.2011.258; Helbig I, 2016, MOL SYNDROMOL, V7, P172, DOI 10.1159/000448530; Kato M, 2007, AM J HUM GENET, V81, P361, DOI 10.1086/518903; Katsanis SH, 2013, NAT REV GENET, V14, P415, DOI 10.1038/nrg3493; Kiiski K, 2016, EUR J HUM GENET, V24, P574, DOI 10.1038/ejhg.2015.166; Klitzman R, 2013, JAMA-J AM MED ASSOC, V310, P369, DOI 10.1001/jama.2013.41709; Ku CS, 2012, ANN NEUROL, V71, P5, DOI 10.1002/ana.22647; Lee H, 2014, JAMA-J AM MED ASSOC, V312, P1880, DOI 10.1001/jama.2014.14604; Mandelker D, 2016, GENET MED, V18, P1282, DOI 10.1038/gim.2016.58; Miller IO, 2007, GENEREVIEWS; Rehm HL, 2013, GENET MED, V15, P733, DOI 10.1038/gim.2013.92; Rehm HL, 2013, NAT REV GENET, V14, P295, DOI 10.1038/nrg3463; Retterer K, 2016, GENET MED, V18, P696, DOI [10.1038/gim.2014.160, 10.1038/gim.2015.148]; Sanghvi RV, 2018, GENET MED, V20, P855, DOI 10.1038/gim.2017.192; Shigemizu D, 2015, SCI REP-UK, V5, DOI 10.1038/srep12742; Strande NT, 2017, AM J HUM GENET, V100, P895, DOI 10.1016/j.ajhg.2017.04.015; Teer JK, 2010, HUM MOL GENET, V19, pR145, DOI 10.1093/hmg/ddq333; Whiffin N, 2017, GENET MED, V19, P1151, DOI 10.1038/gim.2017.26; Yang YP, 2014, JAMA-J AM MED ASSOC, V312, P1870, DOI 10.1001/jama.2014.14601; Yang YP, 2013, NEW ENGL J MED, V369, P1502, DOI 10.1056/NEJMoa1306555; Yu H, 2013, MOL GENET METAB, V110, P465, DOI 10.1016/j.ymgme.2013.09.018; Zook JM, 2014, NAT BIOTECHNOL, V32, P246, DOI 10.1038/nbt.2835	26	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	SEP	2018	20	5					643	652		10.1016/j.jmoldx.2018.05.003			10	Pathology	Pathology	GS8AR	WOS:000443929200010	29936260				2019-10-28	
J	Prieto-Potin, I; Montagut, C; Bellosillo, B; Evans, M; Smith, M; Melchior, L; Reiltin, W; Bennett, M; Pennati, V; Castiglione, F; Burrig, KF; Cooper, U; Dockhorn-Dworniczak, B; Rossenbach, C; Luna-Aguirre, CM; Barrera-Saldana, HA; Machado, JC; Costa, JL; Yacobi, R; Tabibian-Keissar, H; Buglioni, S; Ronchetti, L; Douglas-Berger, L; Dubbink, HJ; Alorini, M; Sabourin, JC; Rojo, F				Prieto-Potin, Ivan; Montagut, Clara; Bellosillo, Beatriz; Evans, Matthew; Smith, Matthew; Melchior, Linea; Reiltin, Werner; Bennett, Michael; Pennati, Veronica; Castiglione, Francesca; Buerrig, Karl-Friedrich; Cooper, Ulrike; Dockhorn-Dworniczak, Barbara; Rossenbach, Christiana; Luna-Aguirre, Claudia M.; Barrera-Saldana, Hugo A.; Machado, Jose C.; Costa, Jose L.; Yacobi, Rinat; Tabibian-Keissar, Hilla; Buglioni, Simonetta; Ronchetti, Livia; Douglas-Berger, Lotte; Dubbink, Hendrikus J.; Alorini, Mohammed; Sabourin, Jean-Christophe; Rojo, Federico			Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							PARAFFIN-EMBEDDED TISSUE; AUTOMATED PCR DETECTION; REAL-TIME PCR; RAS MUTATIONS; AMERICAN SOCIETY; KRAS MUTATIONS; CETUXIMAB; CARCINOMA; THERAPY; PANITUMUMAB	Treatment of colorectal cancer (CRC) with monoclonal antibodies against epidermal growth factor receptor requires the assessment of the mutational status of exons 2, 3, and 4 of the NRAS and KRAS oncogenes. Moreover, the mutational status of exon 15 of the BRAF oncogene is a marker of poor prognosis in CRC. The Idylla NRAS-BRAF Mutation Test is a reliable, simple (<2 minutes hands-on time), and quick (<2 hours turnaround time) sample-to-result solution, enabling the detection of clinically relevant mutations in NRAS (18 mutations) and BRAF (5 mutations). A multicenter study was conducted in 14 centers using the Idylla NRAS-BRAF Mutation Test to assess the NRAS and BRAF mutational status of 418 formalin-fixed, paraffin-embedded tissue samples from CRC patients. Results were compared with those obtained earlier by routine reference methods, including next-generation sequencing, pyrosequencing, mass spectrometry-based assays, PCR-based assays, and Sanger sequencing. In case of discordance, additional tests were performed by digital droplet PCR. Overall, after testing confirmation and excluding invalids/errors by design, concordances between the Idylla NRAS-BRAF Mutation Test and the reference test results were found in almost perfect agreement. In conclusion, the Idylla NRAS-BRAF Mutation Test enables the routine detection of all NRAS and BRAF mutations deemed clinically relevant according to the latest clinical guidelines, without necessitating molecular expertise or infrastructure.	[Prieto-Potin, Ivan; Rojo, Federico] Autonomous Univ Madrid, Fdn Jimenez Diaz, CIBERONC,Univ Hosp, Mol Diagnost Lab,Dept Pathol,CIBERONC,Hlth Res In, Madrid, Spain; [Montagut, Clara] Hosp del Mar, Med Res Inst, Dept Oncol, Barcelona, Spain; [Bellosillo, Beatriz] Hosp del Mar, Med Res Inst, Dept Pathol, Barcelona, Spain; [Evans, Matthew; Smith, Matthew] Queen Elizabeth Hosp, Birmingham, W Midlands, England; [Melchior, Linea] Rigshosp, Dept Pathol, Copenhagen, Denmark; [Reiltin, Werner; Bennett, Michael] Cork Univ Hosp, Cork, Ireland; [Pennati, Veronica; Castiglione, Francesca] Careggis Hosp, Florence, Italy; [Buerrig, Karl-Friedrich; Cooper, Ulrike] Inst Pathol, Hildesheim, Germany; [Dockhorn-Dworniczak, Barbara; Rossenbach, Christiana] Ctr Pathol, Kempten, Germany; [Luna-Aguirre, Claudia M.; Barrera-Saldana, Hugo A.] Vitagenesis Stock Corp Variable Capital, Monterrey, Mexico; [Machado, Jose C.; Costa, Jose L.] Univ Porto, Inst Mol Pathol & Immunol, Porto, Portugal; [Yacobi, Rinat; Tabibian-Keissar, Hilla] Sheba Med Ctr, Ramat Gan, Israel; [Buglioni, Simonetta; Ronchetti, Livia] Regina Elena Inst Canc Res, Dept Pathol, Rome, Italy; [Douglas-Berger, Lotte; Dubbink, Hendrikus J.] Erasmus MC Canc Inst, Dept Pathol, Rotterdam, Netherlands; [Alorini, Mohammed; Sabourin, Jean-Christophe] Rouen Univ Hosp Ctr, Rouen, France	Rojo, F (reprint author), UAM, IIS Fdn Jimenez Diaz, Dept Pathol, Mol Diagnost Lab, Madrid 28040, Spain.	frojo@fjd.es	Costa, Jose Luis/B-7126-2008; Machado, Jose Carlos/C-5907-2009	Costa, Jose Luis/0000-0001-7132-4094; Rojo, Federico/0000-0001-9989-0290; Machado, Jose Carlos/0000-0003-4741-8415	Fund for Technology Innovation Pharmacogenetics and Precision Medicine grant CONACyT [260826]; Institute of Health Carlos Ill (CIBERONC grants) [PI15/00934, PT17/0015/0006]	Supported by each clinical center; work at Vitagenesis, SA de CV (Monterrey, Mexico), was supported by the Fund for Technology Innovation Pharmacogenetics and Precision Medicine grant CONACyT 260826; work at Fundacion Jimenez Diaz University Hospital was supported by Institute of Health Carlos Ill (CIBERONC grants PI15/00934 and PT17/0015/0006). Idylla NRAS-BRAF Mutation Test cartridges were provided by Biocartis.	Allegra CJ, 2016, J ONCOL PRACT, V12, P180, DOI 10.1200/JOP.2015.007898; Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116; Asor E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173760; Barel F, 2018, ACTA DERM-VENEREOL, V98, P44, DOI 10.2340/00015555-2738; Basile D, 2017, EXPERT OPIN BIOL TH, V17, P709, DOI 10.1080/14712598.2017.1315405; Benson AB, 2017, J NATL COMPR CANC NE, V15, P370, DOI 10.6004/jnccn.2017.0036; Boleij A, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2810-3; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Cisowski J, 2016, ONCOGENE, V35, P1328, DOI 10.1038/onc.2015.186; Clark LW, 2002, EP12A NCCLS, V22, P19087; Colling R, 2017, J CLIN PATHOL, V70, P610, DOI 10.1136/jclinpath-2017-204356; Colling R, 2016, J CLIN PATHOL, V69, P398, DOI 10.1136/jclinpath-2015-203345; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; de Biase D, 2016, J CLIN PATHOL, V69, P986, DOI 10.1136/jclinpath-2016-203696; Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786; Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275; Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027; Fernandez-Medarde Alberto, 2011, Genes Cancer, V2, P344, DOI 10.1177/1947601911411084; Fontanges Q, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122117; Grellety T, 2016, VIRCHOWS ARCH, V469, P459, DOI 10.1007/s00428-016-1991-0; Gustavsson B, 2015, CLIN COLORECTAL CANC, V14, P1, DOI 10.1016/j.clcc.2014.11.002; Janku F, 2015, ONCOTARGET, V6, P26886, DOI 10.18632/oncotarget.4723; Johnston L, 2018, J CLIN PATHOL, V71, P336, DOI 10.1136/jclinpath-2017-204629; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Kuipers EJ, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.65; Lin JH, 2009, ANAL BIOCHEM, V395, P265, DOI 10.1016/j.ab.2009.08.016; Melchior L, 2015, EXP MOL PATHOL, V99, P485, DOI 10.1016/j.yexmp.2015.09.004; Montagut C, 2012, NAT MED, V18, P221, DOI 10.1038/nm.2609; Morkel M, 2015, ONCOTARGET, V6, P20785, DOI 10.18632/oncotarget.4750; Peeters M, 2015, EUR J CANCER, V51, P1704, DOI 10.1016/j.ejca.2015.05.017; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Phipps AI, 2012, CANCER EPIDEM BIOMAR, V21, P1792, DOI 10.1158/1055-9965.EPI-12-0674; Schiefer AI, 2016, J MOL DIAGN, V18, P370, DOI 10.1016/j.jmoldx.2015.12.005; Sepulveda AR, 2017, J CLIN ONCOL, V35, P1453, DOI 10.1200/JCO.2016.71.9807; Shao D, 2016, SCI REP-UK, V6, DOI 10.1038/srep22338; Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Solassol J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163444; Tsiatis AC, 2010, J MOL DIAGN, V12, P425, DOI 10.2353/jmoldx.2010.090188; Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235; Van Cutsem E, 2015, J CLIN ONCOL, V33, P692, DOI 10.1200/JCO.2014.59.4812; van Emburgh BO, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13665; van Krieken JHJM, 2008, VIRCHOWS ARCH, V453, P417, DOI 10.1007/s00428-008-0665-y; Weyn C, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3112-0; Wilson EB, 2008, J AM STAT ASSOC, V22, P209; Yao Z, 2017, NATURE, V548, P234, DOI 10.1038/nature23291; Yeo MK, 2017, J CLIN PATHOL, V70, P260, DOI 10.1136/jclinpath-2016-204025	47	4	4	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	SEP	2018	20	5					664	676		10.1016/j.jmoldx.2018.05.008			13	Pathology	Pathology	GS8AR	WOS:000443929200012	29959022				2019-10-28	
J	Clark, TA; Chung, JH; Kennedy, M; Hughes, JD; Chennagiri, N; Lieber, DS; Fendler, B; Young, L; Zhao, M; Coyne, M; Breese, V; Young, G; Donahue, A; Pavlick, D; Tsiros, A; Brennan, T; Zhong, S; Mughal, T; Bailey, M; He, J; Roels, S; Frampton, GM; Spoerke, JM; Gendreau, S; Lackner, M; Schleifman, E; Peters, E; Ross, JS; Ali, SM; Miller, VA; Gregg, JP; Stephens, PJ; Welsh, A; Otto, GA; Lipson, D				Clark, Travis A.; Chung, Jon H.; Kennedy, Mark; Hughes, Jason D.; Chennagiri, Niru; Lieber, Daniel S.; Fendler, Bernard; Young, Lauren; Zhao, Mandy; Coyne, Michael; Breese, Virginia; Young, Geneva; Donahue, Amy; Pavlick, Dean; Tsiros, Alyssa; Brennan, Timothy; Zhong, Shan; Mughal, Tariq; Bailey, Mark; He, Jie; Roels, Steven; Frampton, Garrett M.; Spoerke, Jill M.; Gendreau, Steven; Lackner, Mark; Schleifman, Erica; Peters, Eric; Ross, Jeffrey S.; Ali, Siraj M.; Miller, Vincent A.; Gregg, Jeffrey P.; Stephens, Philip J.; Welsh, Allison; Otto, Geoff A.; Lipson, Doron			Analytical Validation of a Hybrid Capture-Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							METASTATIC BREAST-CANCER; LUNG-CANCER; CLONAL HEMATOPOIESIS; RESISTANCE; MUTATIONS; TRIAL; EVOLUTION; THERAPY; FUSIONS; NSCLC	Genomic profiling of circulating tumor DNA derived from cell-free DNA (cfDNA) in blood can provide a noninvasive method for detecting genomic biomarkers to guide clinical decision making for cancer patients. We developed a hybrid capture-based next-generation sequencing assay for genomic profiling of circulating tumor DNA from blood (FoundationACT). High-sequencing coverage and molecular barcode-based error detection enabled accurate detection of genomic alterations, including short variants (base substitutions, short insertions/deletions) and genomic re-arrangements at low allele frequencies (AFs), and copy number amplifications. Analytical validation was performed on 2666 reference alterations. The assay achieved >99% overall sensitivity (95% CI, 99.1%-99.4%) for short variants at AF >0.5%, >95% sensitivity (95% CI, 94.2%-95.7%) for AF 0.25% to 0.5%, and 70% sensitivity (95% CI, 68.2%-71.5%) for AF 0.125% to 0.25%. No false positives were detected in 62 samples from healthy volunteers. Genomic alterations detected by FoundationACT demonstrated high concordance with orthogonal assays run on the same clinical cfDNA samples. In 860 routine clinical FoundationACT cases, genomic alterations were detected in cfDNA at comparable frequencies to tissue; for the subset of cases with temporally matched tissue and blood samples, 75% of genomic alterations and 83% of short variant mutations detected in tissue were also detected in cfDNA. On the basis of analytical validation results, FoundationACT has been approved for use in our Clinical Laboratory Improvement Amendments-certified/College of American Pathologists-accredited/New York State-approved laboratory.	[Clark, Travis A.; Chung, Jon H.; Kennedy, Mark; Hughes, Jason D.; Chennagiri, Niru; Lieber, Daniel S.; Fendler, Bernard; Young, Lauren; Zhao, Mandy; Coyne, Michael; Breese, Virginia; Young, Geneva; Donahue, Amy; Pavlick, Dean; Tsiros, Alyssa; Brennan, Timothy; Zhong, Shan; Mughal, Tariq; Bailey, Mark; He, Jie; Roels, Steven; Frampton, Garrett M.; Ross, Jeffrey S.; Ali, Siraj M.; Miller, Vincent A.; Stephens, Philip J.; Welsh, Allison; Otto, Geoff A.; Lipson, Doron] Fdn Med Inc, 150 Second St, Cambridge, MA 02141 USA; [Spoerke, Jill M.; Gendreau, Steven; Lackner, Mark; Schleifman, Erica; Peters, Eric] Genentech Inc, San Francisco, CA 94080 USA; [Gregg, Jeffrey P.] Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA	Chung, JH; Lipson, D (reprint author), Fdn Med Inc, 150 Second St, Cambridge, MA 02141 USA.	jchung@foundationmedicine.com; dlipson@foundationmedicine.com	Martens, Geert/F-6920-2015	Martens, Geert/0000-0003-1208-6289; Zhao, Mandy/0000-0002-6833-5291; Chung, Jon/0000-0003-0526-3670	NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30 CA093373]		Abbosh C, 2017, NATURE, V545, P446, DOI 10.1038/nature22364; Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393; Bernabe R, 2017, EUR J CANCER, V81, P66, DOI 10.1016/j.ejca.2017.04.022; Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094; Chung JH, 2017, ANN ONCOL, V28, P2866, DOI 10.1093/annonc/mdx490; Cock PJA, 2009, BIOINFORMATICS, V25, P1422, DOI 10.1093/bioinformatics/btp163; Coombs CC, 2017, CELL STEM CELL, V21, P374, DOI 10.1016/j.stem.2017.07.010; Dawson SJ, 2013, NEW ENGL J MED, V368, P1199, DOI 10.1056/NEJMoa1213261; De Mattos-Arruda L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9839; Eisenberg R, 2017, SCIENCE, V358, P1133, DOI 10.1126/science.aao6708; Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121; Frampton GM, 2013, NAT BIOTECHNOL, V31, P1023, DOI 10.1038/nbt.2696; Garcia-Murillas I, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab0021; GARRISON E, 2012, GENOMICS, V1207, P3907, DOI DOI 10.1101/1207.3907; Genovese G, 2014, NEW ENGL J MED, V371, P2477, DOI 10.1056/NEJMoa1409405; Hartmaier RJ, 2017, CANCER RES, V77, P2464, DOI 10.1158/0008-5472.CAN-16-2479; He J, 2016, BLOOD, V127, P3004, DOI 10.1182/blood-2015-08-664649; Hu YB, 2018, CLIN CANCER RES, V24, P4437, DOI 10.1158/1078-0432.CCR-18-0143; Jamal-Hanjani M, 2017, NEW ENGL J MED, V376, P2109, DOI 10.1056/NEJMoa1616288; Jovelet C, 2016, CLIN CANCER RES, V22, P2960, DOI 10.1158/1078-0432.CCR-15-2470; Katayama R, 2014, CLIN CANCER RES, V20, P5686, DOI 10.1158/1078-0432.CCR-14-1511; Lanman RB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140712; LI H, 2013, 13033997 ARXIV, V1303, P3997, DOI DOI 10.1093/BI0INF0RMATICS/BTP352; Massard C, 2017, CANCER DISCOV, V7, P586, DOI 10.1158/2159-8290.CD-16-1396; Merker JD, 2018, J CLIN ONCOL, V36, P1631, DOI 10.1200/JCO.2017.76.8671; Mok TS, 2017, NEW ENGL J MED, V376, P629, DOI 10.1056/NEJMoa1612674; Newman AM, 2016, NAT BIOTECHNOL, V34, P547, DOI 10.1038/nbt.3520; Newman AM, 2014, NAT MED, V20, P552, DOI 10.1038/nm.3519; Ou SH, 2016, LUNG CANCER, V91, P70, DOI 10.1016/j.lungcan.2015.09.006; Ou SHI, 2017, LUNG CANCER, V111, P61, DOI 10.1016/j.lungcan.2017.07.006; Ou SHI, 2017, LUNG CANCER, V108, P228, DOI 10.1016/j.lungcan.2017.04.003; Phallen J, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan2415; Ratner M, 2017, NAT BIOTECHNOL, V35, P699, DOI 10.1038/nbt0817-699; Robinson DR, 2017, NATURE, V548, P297, DOI 10.1038/nature23306; Ross JS, 2017, ONCOLOGIST, V22, P1444, DOI 10.1634/theoncologist.2016-0488; Rotow J, 2017, NAT REV CANCER, V17, P637, DOI 10.1038/nrc.2017.84; Siena S, 2018, ANN ONCOL, V29, P119, DOI 10.1093/annonc/mdx504; Singhi AD, 2017, J NATL COMPR CANC NE, V15, P555, DOI 10.6004/jnccn.2017.0058; Stransky N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5846; Swisher EM, 2017, LANCET ONCOL, V18, P75, DOI [10.1016/S1470-2045(16)30559-9, 10.1016/s1470-2045(16)30559-9]; Thompson JC, 2016, CLIN CANCER RES, V22, P5772, DOI 10.1158/1078-0432.CCR-16-1231; Toyokawa G, 2014, J THORAC ONCOL, V9, pE86, DOI 10.1097/JTO.0000000000000358; Vuylsteke P, 2016, ANN ONCOL, V27, P2059, DOI 10.1093/annonc/mdw320; Wang VE, 2017, ONCOLOGIST, V22, P768, DOI 10.1634/theoncologist.2017-0054; Wiesner T, 2015, NATURE, V526, P453, DOI 10.1038/nature15258; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333	46	18	18	1	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	SEP	2018	20	5					686	702		10.1016/j.jmoldx.2018.05.004			17	Pathology	Pathology	GS8AR	WOS:000443929200014	29936259	Other Gold, Green Published			2019-10-28	
J	Bettinotti, MP; Ferriola, D; Duke, JL; Mosbruger, TL; Tairis, N; Jennings, L; Kalman, LV; Monos, D				Bettinotti, Maria P.; Ferriola, Deborah; Duke, Jamie L.; Mosbruger, Timothy L.; Tairis, Nikolaos; Jennings, Lawrence; Kalman, Lisa V.; Monos, Dimitri			Characterization of 108 Genomic DNA Reference Materials for 11 Human Leukocyte Antigen Loci A GeT-RM Collaborative Project	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							STEM-CELL TRANSPLANTATION; MHC CLASS-I; RECOMMENDATIONS; ASSOCIATION; RECEPTORS	The highly polymorphic human leukocyte antigen (HLA) genes, located in the human major histocompatibility complex, encode the class I and II antigen-presenting molecules, which are centrally involved in the immune response. HLA typing is used for several clinical applications, such as transplantation, pharmacogenetics, and diagnosis of autoimmune disease. HLA typing is highly complex because of the homology of HLA genes and pseudogenes and the extensive polymorphism in the population. The Centers for Disease Control and Prevention established the Genetic Testing Reference Materials Coordination Program (GeT-RM) in partnership with the genetics community to improve the availability of genomic DNA reference materials necessary for quality assurance of genetic laboratory testing. The GeT-RM together with three clinical laboratories and the Coriell Cell Repositories have characterized genomic DNA obtained from a panel of 108 cell lines for all HLA classic polymorphic loci: HLA-A, B, C, DRB1, DRB3, DRB4, DRB5, DQA1, DQB1, DPA1, and DPB1. The goal was to develop a publicly available and renewable source of well-characterized genomic DNA reference materials to support molecular HLA typing assay development, validation, and verification, quality control, and proficiency testing. These genomic DNA samples are publicly available from the National Institutes of General Medical Science Repository at the Coriell Cell Repositories.	[Bettinotti, Maria P.] Johns Hopkins Sch Med, Immunogenet Lab, Dept Med, Baltimore, MD USA; [Ferriola, Deborah; Duke, Jamie L.; Mosbruger, Timothy L.; Tairis, Nikolaos; Monos, Dimitri] Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Jennings, Lawrence] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA; [Kalman, Lisa V.] Ctr Dis Control & Prevent, Div Lab Syst, Atlanta, GA USA; [Monos, Dimitri] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA USA	Kalman, LV (reprint author), Ctr Dis Control & Prevent, Informat & Data Sci Branch, Div Lab Syst, Off Surveillance Epidemiol & Lab Serv, 1600 Clifton Rd,Mailstop G23, Atlanta, GA 30333 USA.	LKalman@cdc.gov	Tairis, Nikolaos/W-9326-2019		The Children's Hospital of Philadelphia funds	Supported by The Children's Hospital of Philadelphia funds (D.M.).	Anfossi N, 2006, IMMUNITY, V25, P331, DOI 10.1016/j.immuni.2006.06.013; [Anonymous], 2008, MM17 VER VAL MULT NU; [Anonymous], 2012, 15189 ISO; Chen B, 2005, GENET MED, V7, P534, DOI 10.1097/01.GIM.0000183043.94406.81; Chen Bin, 2009, Morbidity and Mortality Weekly Report, V58, P1; Dauvilliers Y, 2007, LANCET, V369, P499, DOI 10.1016/S0140-6736(07)60237-2; Duke JL, 2016, HLA, V87, P141, DOI 10.1111/tan.12736; Gragert L, 2013, HUM IMMUNOL, V74, P1313, DOI 10.1016/j.humimm.2013.06.025; Hilton HG, 2017, IMMUNOGENETICS, V69, P567, DOI 10.1007/s00251-017-1001-y; Horton R, 2004, NAT REV GENET, V5, P889, DOI 10.1038/nrg1489; Howard CA, 2015, BIOL BLOOD MARROW TR, V21, P4, DOI 10.1016/j.bbmt.2014.09.017; Jenkins MK, 2012, J IMMUNOL, V188, P4135, DOI 10.4049/jimmunol.1102661; Kelly A, 2017, IMMUNOGENETICS, V69, P481, DOI 10.1007/s00251-017-0986-6; Latham K, 2014, METHODS MOL BIOL, V1109, P73, DOI 10.1007/978-1-4614-9437-9_5; Lee SJ, 2007, BLOOD, V110, P4576, DOI 10.1182/blood-2007-06-097386; Liu XS, 2017, CELL, V168, P600, DOI 10.1016/j.cell.2017.01.014; Marsh SGE, 2010, TISSUE ANTIGENS, V75, P291, DOI 10.1111/j.1399-0039.2010.01466.x; dos Santos EJM, 2016, HUM IMMUNOL, V77, P238, DOI 10.1016/j.humimm.2015.11.013; Nunes E, 2011, HUM IMMUNOL, V72, P1214, DOI 10.1016/j.humimm.2011.06.002; Pavlos R, 2015, ANNU REV MED, V66, P439, DOI 10.1146/annurev-med-050913-022745; Pratt VM, 2010, J MOL DIAGN, V12, P835, DOI 10.2353/jmoldx.2010.100090; Ranganathan V, 2017, NAT REV RHEUMATOL, V13, P359, DOI 10.1038/nrrheum.2017.56; Robinson J, 2015, NUCLEIC ACIDS RES, V43, pD423, DOI 10.1093/nar/gku1161; Spencer CT, 2015, PROTEOM CLIN APPL, V9, P1035, DOI 10.1002/prca.201500106; Stamnaes J, 2015, SEMIN IMMUNOL, V27, P343, DOI 10.1016/j.smim.2015.11.001; Stanworth SJ, 2015, BRIT J HAEMATOL, V171, P297, DOI 10.1111/bjh.13597; Starr TK, 2003, ANNU REV IMMUNOL, V21, P139, DOI 10.1146/annurev.immunol.21.120601.141107; Whittaker MH, 1999, AM J CLIN PATHOL, V111, P449; Wiebe C, 2016, TRANSPLANTATION, V100, P2048, DOI 10.1097/TP.0000000000001284	29	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	SEP	2018	20	5					703	715		10.1016/j.jmoldx.2018.05.009			13	Pathology	Pathology	GS8AR	WOS:000443929200015	29959025				2019-10-28	
J	Shin, JH; Yu, E; Kim, EN; Kim, CJ				Shin, Jin Ho; Yu, Eunsil; Kim, Eun Na; Kim, Chong Jai			C-reactive Protein Overexpression in the Background Liver of Hepatitis B Virus-Associated Hepatocellular Carcinoma Is a Prognostic Biomarker	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Carcinoma; hepatocellular; C-reactive protein; Hepatitis B virus; Immunohistochemistry; Prognosis	INFLAMMATION; INTEGRATION; SECRETION; SURVIVAL	Background: Chronic hepatitis B virus (HBV) infection is a leading cause of hepatocellular carcinoma (HCC). Peripheral blood C-reactive protein (CRP) concentration and CRP overexpression in HCC cells are proven to be prognostic markers for HCC, but the significance of CRP expression in non-neoplastic hepatocytes, which are the primary origin of CRP, has not been studied. This study was conducted to determine the clinicopathologic significance of CRP immunoreactivity in the background liver of HBV-associated HCC. Methods: CRP immunostaining was done on tissue microarrays of non-neoplastic liver tissues obtained from surgically resected, treatment-naive HBV-associated HCCs (n = 156). The relationship between CRP immunoreactivity and other clinicopathologic parameters including cancer-specific survival was analyzed. CRP immunoreactivity was determined using a 4-tier grading system: grades 0, 1, 2, and 3. Results: CRP was positive in 139 of 156 cases (89.1%) of non-neoplastic liver in patients with HCCs: grade 1 in 83 cases (53.2%); grade 2 in 50 cases (32.1%); and grade 3 in six cases (3.8%). The patients with diffuse CRP immunoreactivity (grade 3) had decreased cancer-specific survival (p = .031) and a tendency for shorter interval before early recurrence (p = .050). The degree of CRP immunoreactivity correlated with serum CRP concentration (p < .001). Conclusions: CRP immunoreactivity in non-neoplastic liver is a novel biomarker for poor cancer-specific survival of HBV-associated HCC and correlates with serum CRP concentration.	[Shin, Jin Ho; Yu, Eunsil; Kim, Eun Na; Kim, Chong Jai] Univ Ulsan, Coll Med, Dept Pathol, Asan Med Ctr, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea	Kim, CJ (reprint author), Univ Ulsan, Coll Med, Dept Pathol, Asan Med Ctr, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea.	ckim@amc.seoul.kr			Asan Institute for Life Sciences, Seoul, Republic of Korea [14-521]	This study was supported by a grant (14-521) from the Asan Institute for Life Sciences, Seoul, Republic of Korea. The authors thank So Won Kim for her assistance in manuscript preparation and editing.	Anuja K, 2017, INFLAMM RES, V66, P119, DOI 10.1007/s00011-016-0985-3; Chen S, 2016, ONCOTARGET, V7, P62123, DOI 10.18632/oncotarget.11389; Eklund CM, 2009, ADV CLIN CHEM, V48, P111, DOI 10.1016/S0065-2423(09)48005-3; El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061; GANTER U, 1989, EMBO J, V8, P3773, DOI 10.1002/j.1460-2075.1989.tb08554.x; Hu RH, 1999, J FORMOS MED ASSOC, V98, P85; Jiang FQ, 2017, CANCER BIOMARK, V20, P17, DOI 10.3233/CBM-160508; Kim JM, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-92; Kinoshita Akiyoshi, 2015, Hepatogastroenterology, V62, P966; Kogo M, 2017, CHEMOTHERAPY, V62, P239, DOI 10.1159/000468508; KUSHNER I, 1978, J EXP MED, V148, P466, DOI 10.1084/jem.148.2.466; Levrero M, 2016, J HEPATOL, V64, pS84, DOI 10.1016/j.jhep.2016.02.021; Li Z, 2016, AM J CANCER RES, V6, P2375; Liu F, 2011, DIABETOLOGIA, V54, P2713, DOI 10.1007/s00125-011-2237-y; Liu YB, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002209; Liu YB, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3220-x; Mori S, 2015, AM J SURG, V209, P187, DOI 10.1016/j.amjsurg.2014.02.015; Nagaoka S, 2007, LIVER INT, V27, P1091, DOI 10.1111/j.1478-3231.2007.01550.x; Shen SS, 2017, INT J ONCOL, V50, P1289, DOI 10.3892/ijo.2017.3911; Shin JH, 2015, J PATHOL TRANSL MED, V49, P105, DOI 10.4132/jptm.2015.01.19; Sicking I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111306; Takeda H, 2017, J GASTROENTEROL, V52, P26, DOI 10.1007/s00535-016-1273-2; Thompson PA, 2015, CARCINOGENESIS, V36, pS232, DOI 10.1093/carcin/bgv038; Yang J, 2007, CANCER CELL, V12, P252, DOI 10.1016/j.ccr.2007.08.008; Yang XB, 2017, INT J CANCER, V140, P1324, DOI 10.1002/ijc.30547; Zhao LH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12992; Zhao XM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116909	27	0	1	2	3	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	SEP	2018	52	5					267	274		10.4132/jptm.2018.07.14			8	Pathology	Pathology	GT3KB	WOS:000444400600001	30056637	DOAJ Gold, Green Published			2019-10-28	
J	Kim, JY; Lee, WJ; Park, HY; Kim, A; Shin, DH; Lee, CH				Kim, Ji Yeon; Lee, Woo Jeong; Park, Ha Young; Kim, Ahrong; Shin, Dong Hoon; Lee, Chang Hun			Differential MicroRNA Expression between EGFR T790M and L858R Mutated Lung Cancer	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						MicroRNAs; Lung neoplasms; EGFR T790M mutation	TYROSINE KINASE INHIBITORS; ACQUIRED-RESISTANCE; ACTIVATING MUTATIONS; DOWN-REGULATION; UP-REGULATION; GROWTH; GEFITINIB; MIR-124; CELLS; ADENOCARCINOMA	Background: MicroRNAs (miRNAs) are short, non-coding RNAs that mediate post-transcriptional gene regulation. They are commonly deregulated in human malignancies, including non-small cell lung cancer (NSCLC). The aim of this study is to investigate miRNA expression in T790M-mutated NSCLC resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Methods: Six cases of resected NSCLC harboring the T790M mutation were examined. We performed miRNA time polymerase chain reaction (PCR) array profiling using EGFR T790M-mutated NSCLC and L858R-mutated NSCLC. Once identified, miRNAs that were differentially expressed between the two groups were validated by quantitative real-time polymerase chain reaction (qRT-PCR). Results: miRNA PCR array profiling revealed three up-regulated miRNAs whose expression levels were altered 4.0-fold or more in the EGFR T790M mutation group than in the L858R group: miR-1 (fold change, 4.384), miR-196a (fold change, 4.138), and miR-124 (fold change, 4.132). The three differentially expressed miRNAs were validated by qRT-PCR, and they were found to be overexpressed in the T790M group relative to L858R group. In particular, expression levels of miR-1 and miR-124 were significantly higher in the T790M group (p-value of miR-1 = .004, miR-124 = .007, miR-196a = .096). Conclusions: MiR-1, miR-124, and miR-196a are overexpressed in EGFR T790M mutated NSCLC.	[Kim, Ji Yeon] Inje Univ, Haeundae Paik Hosp, Dept Pathol, Busan, South Korea; [Lee, Woo Jeong] Pusan Natl Univ, Sch Med, Yangsan, South Korea; [Park, Ha Young] Inje Univ, Busan Paik Hosp, Dept Pathol, Busan, South Korea; [Kim, Ahrong; Lee, Chang Hun] Pusan Natl Univ Hosp, Dept Pathol, 179 Gudeok Ro, Busan 49241, South Korea; [Shin, Dong Hoon] Pusan Natl Univ, Yangsan Hosp, Dept Pathol, Yangsan, South Korea	Lee, CH (reprint author), Pusan Natl Univ Hosp, Dept Pathol, 179 Gudeok Ro, Busan 49241, South Korea.; Lee, CH (reprint author), Sch Med, 179 Gudeok Ro, Busan 49241, South Korea.	cnlee@pusan.ac.kr			2-year research grant of Pusan National UniversityPusan National University	This work was supported by a 2-year research grant of Pusan National University.	Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995; Bloomston M, 2007, JAMA-J AM MED ASSOC, V297, P1901, DOI 10.1001/jama.297.17.1901; Camidge DR, 2014, NAT REV CLIN ONCOL, V11, P473, DOI 10.1038/nrclinonc.2014.104; Chen CY, 2011, J CELL MOL MED, V15, P14, DOI 10.1111/j.1582-4934.2010.01219.x; Chen LY, 2016, LUNG CANCER, V94, P46, DOI 10.1016/j.lungcan.2016.01.019; Chen ZB, 2015, ONCOTARGET, V6, P38139, DOI 10.18632/oncotarget.5709; Cheung HW, 2011, CANCER DISCOV, V1, P608, DOI 10.1158/2159-8290.CD-11-0046; Cho WCS, 2009, EUR J CANCER, V45, P2197, DOI 10.1016/j.ejca.2009.04.039; Chong CR, 2013, NAT MED, V19, P1389, DOI 10.1038/nm.3388; Denis MG, 2015, CLIN CHIM ACTA, V444, P81, DOI 10.1016/j.cca.2015.01.039; Dong LL, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0257-5; Engelman JA, 2008, CLIN CANCER RES, V14, P2895, DOI 10.1158/1078-0432.CCR-07-2248; Fujita Y, 2012, J THORAC ONCOL, V7, P1640, DOI 10.1097/JTO.0b013e3182653d7f; Furuta M, 2010, CARCINOGENESIS, V31, P766, DOI 10.1093/carcin/bgp250; Gao Y, 2014, BIOCHEM BIOPH RES CO, V446, P179, DOI 10.1016/j.bbrc.2014.02.073; Garzon R, 2006, TRENDS MOL MED, V12, P580, DOI 10.1016/j.molmed.2006.10.006; Han C, 2014, BIOMED RES INT, DOI 10.1155/2014/428371; Hata A, 2013, CANCER-AM CANCER SOC, V119, P4325, DOI 10.1002/cncr.28364; Hu ZB, 2010, J CLIN ONCOL, V28, P1721, DOI 10.1200/JCO.2009.24.9342; Inukai M, 2006, CANCER RES, V66, P7854, DOI 10.1158/0008-5472.CAN-06-1951; Kanaan Z, 2012, ANN SURG, V256, P544, DOI 10.1097/SLA.0b013e318265bd6f; Kim SM, 2012, MOL CANCER THER, V11, P2254, DOI 10.1158/1535-7163.MCT-12-0311; Lee Y, 2015, CLIN LUNG CANCER, V16, P46, DOI [10.1016/j.cllc.2014.09.002, 10.1016/j.dlc.2014.09.002]; Lv ZH, 2013, MOL MED REP, V8, P345, DOI 10.3892/mmr.2013.1561; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Nohata N, 2012, ONCOTARGET, V3, P9; Oxnard GR, 2011, CLIN CANCER RES, V17, P1616, DOI 10.1158/1078-0432.CCR-10-2692; Panarelli NC, 2012, PANCREAS, V41, P685, DOI 10.1097/MPA.0b013e318243a905; Pignot G, 2013, INT J CANCER, V132, P2479, DOI 10.1002/ijc.27949; Remon J, 2014, CANCER TREAT REV, V40, P93, DOI 10.1016/j.ctrv.2013.06.002; Rosell R, 2012, J CLIN ONCOL, V30; Sequist LV, 2008, J CLIN ONCOL, V26, P2442, DOI 10.1200/JCO.2007.14.8494; Sin TK, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020237; Sos ML, 2010, CANCER RES, V70, P868, DOI 10.1158/0008-5472.CAN-09-3106; Steele CW, 2011, PANCREAS, V40, P1165, DOI 10.1097/MPA.0b013e3182218ffb; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Wiggins JF, 2010, CANCER RES, V70, P5923, DOI 10.1158/0008-5472.CAN-10-0655; Wu Z, 2017, EUR REV MED PHARMACO, V21, P2338; Xiao HB, 2015, ONCOTARGET, V6, P13201, DOI 10.18632/oncotarget.3915; Xu F, 2014, CLIN TRANSL ONCOL, V16, P980, DOI 10.1007/s12094-014-1183-9; Yang JCH, 2017, J CLIN ONCOL, V35, P1288, DOI 10.1200/JCO.2016.70.3223; Yun CH, 2008, P NATL ACAD SCI USA, V105, P2070, DOI 10.1073/pnas.0709662105	44	1	1	1	2	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	SEP	2018	52	5					275	282		10.4132/jptm.2018.07.29			8	Pathology	Pathology	GT3KB	WOS:000444400600002	30114862	DOAJ Gold, Green Published			2019-10-28	
J	Affandi, KA; Tizen, NMS; Mustangin, M; Zin, RRM				Affandi, Khairunisa Ahmad; Tizen, Nur Maya Sabrina; Mustangin, Muaatamarulain; Zin, Reena Rahayu Md			p40 Immunohistochemistry Is an Excellent Marker in Primary Lung Squamous Cell Carcinoma	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Non-small cell lung carcinoma; Immunohistochemistry; Lung neoplasms; p40; p63	SMALL BIOPSIES; INTERNATIONAL-ASSOCIATION; DIAGNOSIS; CANCER; DELTA-NP63; P63; DIFFERENTIATION; SPECIMENS; TTF-1; PANEL	Background: Lung cancer is the third most common cancer worldwide. With major advances in the molecular testing of lung cancers and the introduction of targeted therapies, the distinction between adenocarcinoma and squamous cell carcinoma as well as pathologic subtyping has become important. Recent studies showed that p40 is highly specific for squamous and basal cells and is superior to p63 for diagnosing lung squamous cell carcinoma. The aim of this study was to evaluate the use of p40 immunohistochemical stain in the diagnosis of non-small cell lung carcinoma and its potential to replace current p63 antibody as the best immunohistochemical squamous marker. Methods: Seventy formalin-fixed paraffin-embedded cases previously diagnosed as primary lung squamous cell carcinoma (n = 35) and lung adenocarcinoma (n = 35) from January 2008 to December 2016 were retrieved. The results of tumour cell immunoreactivity for p40 and p63 antibodies in lung squamous cell carcinoma and lung adenocarcinoma were compared. Results: p40 was expressed in 27 cases of lung squamous cell carcinoma (77.1%). All cases of lung adenocarcinoma (35/35, 100%) were negative for p40. p63 expression was positive in 30 cases of lung squamous cell carcinoma (85.7%) and 13 cases of lung adenocarcinoma (37.1%). Reactivity for both p40 and p63 in lung squamous cell carcinoma was strong and diffuse, whereas variable reactivity was observed in lung adenocarcinoma. Conclusions: p40 is an excellent marker for distinguishing lung squamous cell carcinoma from adenocarcinoma, and p40 expression is equivalent to p63 expression in lung squamous cell carcinoma.	[Affandi, Khairunisa Ahmad; Tizen, Nur Maya Sabrina; Mustangin, Muaatamarulain; Zin, Reena Rahayu Md] Univ Kebangsaan Malaysia, Dept Pathol, Med Ctr, Kuala Lumpur, Malaysia	Zin, RRM (reprint author), UKM, Med Ctr, Fac Med, Dept Pathol, Jalan Yaacob Latif, Kuala Lumpur 56000, Malaysia.	reenarahayu@ppukm.ukm.edu.my	Laim, Nur Maya Sabrina Tizen/C-5421-2017		Faculty of Medicine, Universiti Kebangsaan Malaysia [FF-2016-077]	This study was funded by the Faculty of Medicine, Universiti Kebangsaan Malaysia (project code: FF-2016-077). The authors declare no conflict of interest in the conduct of this study.	Azizah A, 2016, MALAYSIAN NATL CANC; Bishop JA, 2012, MODERN PATHOL, V25, P405, DOI 10.1038/modpathol.2011.173; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Kadota K, 2015, AM J SURG PATHOL, V39, P1170, DOI 10.1097/PAS.0000000000000439; Lindeman NI, 2013, J THORAC ONCOL, V8, P823, DOI 10.1097/JTO.0b013e318290868f; Mukhopadhyay S, 2011, AM J SURG PATHOL, V35, P15, DOI 10.1097/PAS.0b013e3182036d05; Nicholson AG, 2010, J THORAC ONCOL, V5, P436, DOI 10.1097/JTO.0b013e3181c6ed9b; Nobre AR, 2013, ACTA CYTOL, V57, P1, DOI 10.1159/000345245; Nonaka D, 2012, AM J SURG PATHOL, V36, P895, DOI 10.1097/PAS.0b013e3182498f2b; Pelosi G, 2012, J THORAC ONCOL, V7, P281, DOI 10.1097/JTO.0b013e31823815d3; Perez-Moreno P, 2012, CLIN CANCER RES, V18, P2443, DOI 10.1158/1078-0432.CCR-11-2370; Rekhtman N, 2012, CLIN CANCER RES, V18, P1167, DOI 10.1158/1078-0432.CCR-11-2109; Rekhtman N, 2011, MODERN PATHOL, V24, P1348, DOI 10.1038/modpathol.2011.92; Tacha D, 2014, ARCH PATHOL LAB MED, V138, P1358, DOI 10.5858/arpa.2013-0342-OA; Travis WD, 2015, WHO CLASSIFICATION T; Travis WD, 2013, ARCH PATHOL LAB MED, V137, P668, DOI 10.5858/arpa.2012-0263-RA; Travis WD, 2010, J THORAC ONCOL, V5, P411, DOI 10.1097/JTO.0b013e3181d57f6e	17	2	2	0	1	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	SEP	2018	52	5					283	289		10.4132/jptm.2018.08.14			7	Pathology	Pathology	GT3KB	WOS:000444400600003	30235512	DOAJ Gold, Green Published			2019-10-28	
J	Kim, CY; Jung, E; Kim, EN; Kim, CJ; Lee, JY; Hwang, JH; Song, WS; Lee, BS; Kim, EAR; Kim, KS				Kim, Chae Young; Jung, Euiseok; Kim, Eun Na; Kim, Chong Jai; Lee, Joo Yong; Hwang, Ji Hye; Song, Woo Sun; Lee, Byong Sop; Kim, Ellen Ai-Rhan; Kim, Ki-Soo			Chronic Placental Inflammation as a Risk Factor of Severe Retinopathy of Prematurity	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Chronic chorioamnionitis; Villitis; Deciduitis; Retinopathy of prematurity; Infant, very low birth weight	GROWTH-FACTOR; CHRONIC CHORIOAMNIONITIS; PATHOLOGICAL FEATURES; ANGIOGENESIS; CLASSIFICATION; PATHOGENESIS; DEFINITION; LESION	Background: Chronic placental inflammation (CPI) has been implicated in the pathogenesis of diseases in premature infants, whereas retinopathy of prematurity (ROP) is a major complication primarily affecting preterm and very low-birth-weight (VLBW) infants. This study aims to investigate the association between CPI and ROP in VLBW infants. Methods: We performed a retrospective review of clinical records of VLBW infants born between 2013 and 2016. Placental pathology findings including CPI cases were analyzed using logistic regression to study infants' morbidities and other clinical characteristics. Results: A total of 402 infants with a mean (standard deviation) gestational age of 28.5 (2.8) weeks and birth weight of 1,027.2 (304.4) g were included. The incidence of ROP was 24.1%. CPI was found in 90 infants (22.4%), among which 28.9% (26 of 90) developed ROP, and 21.1% (19 of 90) underwent laser photocoagulation. Lower gestational age, lower birth weight, longer duration of oxygen supply, and presence of CPI were associated with the development of ROP. After adjustment for gestational age, birth weight, sex, duration of oxygen supply, and other overlapping placental pathology, CPI was associated with the odds for type 1 ROP that required laser photocoagulation (adjusted odds ratio, 2.739; 95% confidence interval, 1.112 to 6.749; p = .029). Conclusions: CPI was associated with severe ROP requiring treatment with laser photocoagulation in VLBW infants.	[Kim, Chae Young; Jung, Euiseok; Hwang, Ji Hye; Song, Woo Sun; Lee, Byong Sop; Kim, Ellen Ai-Rhan; Kim, Ki-Soo] Univ Ulsan, Coll Med, Dept Pediat, Asan Med Ctr, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea; [Kim, Eun Na; Kim, Chong Jai] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, Seoul, South Korea; [Lee, Joo Yong] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Ophthalmol, Seoul, South Korea	Jung, E (reprint author), Univ Ulsan, Coll Med, Dept Pediat, Asan Med Ctr, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea.	euisjung@amc.seoul.kr		LEE, JOO YONG/0000-0002-2187-196X; Jung, Euiseok/0000-0003-0693-5627			Chen Jing, 2007, Angiogenesis, V10, P133, DOI 10.1007/s10456-007-9066-0; Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591; Costa Carla, 2007, Angiogenesis, V10, P149, DOI 10.1007/s10456-007-9074-0; Dammann O, 2009, EARLY HUM DEV, V85, P325, DOI 10.1016/j.earlhumdev.2008.12.010; FLYNN JT, 1992, NEW ENGL J MED, V326, P1050, DOI 10.1056/NEJM199204163261603; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Galinsky R, 2013, J PREGNANCY, DOI 10.1155/2013/412831; Gole GA, 2005, ARCH OPHTHALMOL-CHIC, V123, P991; Good WV, 2003, ARCH OPHTHALMOL-CHIC, V121, P1684; Hansen RM, 2017, PROG RETIN EYE RES, V56, P32, DOI 10.1016/j.preteyeres.2016.09.004; Hartnett ME, 2017, CURR OPIN OPHTHALMOL, V28, P282, DOI 10.1097/ICU.0000000000000360; Hellstrom A, 2003, PEDIATRICS, V112, P1016, DOI 10.1542/peds.112.5.1016; Kim CJ, 2015, AM J OBSTET GYNECOL, V213, pS53, DOI 10.1016/j.ajog.2015.08.041; Kim CJ, 2015, AM J OBSTET GYNECOL, V213, pS29, DOI 10.1016/j.ajog.2015.08.040; Kim CJ, 2010, MODERN PATHOL, V23, P1000, DOI 10.1038/modpathol.2010.73; Kobayashi Hanako, 2009, V511, P185, DOI 10.1007/978-1-59745-447-6_8; Lazzeri E, 2005, TRANSPLANTATION, V79, P1215, DOI 10.1097/01.TP.0000160759.85080.2E; Lee J, 2013, PLACENTA, V34, P681, DOI 10.1016/j.placenta.2013.04.014; Lee J, 2012, SEMIN FETAL NEONAT M, V17, P26, DOI 10.1016/j.siny.2011.08.007; Liu PM, 2005, AM J PERINAT, V22, P115, DOI 10.1055/s-2005-837276; Luttun A, 2002, ANN NY ACAD SCI, V979, P80, DOI 10.1111/j.1749-6632.2002.tb04870.x; Martin RJ, 2014, FANAROFF MARTINS NEO; Mechoulam Hadas, 2003, Am J Pharmacogenomics, V3, P261, DOI 10.2165/00129785-200303040-00004; Morgan TK, 2016, AM J PERINAT, V33, P258, DOI 10.1055/s-0035-1570379; Najm S, 2017, CLIN NUTR ESPEN, V20, P17, DOI 10.1016/j.clnesp.2017.04.004; Pandya LK, 2017, AM J OBSTET GYNECOL, V217, DOI 10.1016/j.ajog.2017.07.005; Powe CE, 2011, CIRCULATION, V123, P2856, DOI 10.1161/CIRCULATIONAHA.109.853127; Redline RW, 2008, PLACENTA, V29, pS86, DOI 10.1016/j.placenta.2007.09.003; Redline RW, 2015, AM J OBSTET GYNECOL, V213, pS21, DOI 10.1016/j.ajog.2015.05.056; Redline RW, 2005, PLACENTAL DIAGNOSTIC; Romagnani P, 2004, TRENDS IMMUNOL, V25, P201, DOI 10.1016/j.it.2004.02.006; ROMERO R, 1992, AM J OBSTET GYNECOL, V166, P1382, DOI 10.1016/0002-9378(92)91609-E; Romero R, 2017, AM J REPROD IMMUNOL, V78; Smith LEH, 2004, GROWTH HORM IGF RES, V14, pS140, DOI 10.1016/j.ghir.2004.03.030; Sood BG, 2010, PEDIATR RES, V67, P394, DOI 10.1203/PDR.0b013e3181d01a36; Tasman W, 2006, AM J OPHTHALMOL, V141, P167, DOI 10.1016/j.ajo.2005.07.034; Taylor RN, 2003, AM J OBSTET GYNECOL, V188, P177, DOI 10.1067/mob.2003.111; Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100; Woo SJ, 2012, GRAEF ARCH CLIN EXP, V250, P915, DOI 10.1007/s00417-011-1648-2; Zhu T, 2017, PLOS ONE, V12	40	1	1	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	SEP	2018	52	5					290	297		10.4132/jptm.2018.07.09			8	Pathology	Pathology	GT3KB	WOS:000444400600004	30008195	DOAJ Gold, Green Published			2019-10-28	
J	Lee, MY; Shin, E; Kim, H; Kwak, IS; Choi, Y				Lee, Mi Young; Shin, Eun; Kim, Hyunchul; Kwak, In Suk; Choi, Younghee			Interleukin-31, Interleukin-31RA, and OSMR Expression Levels in Post-burn Hypertrophic Scars	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Burns; Cicatrix; Interleukin-31; IL31RA protein; OSMR protein	ATOPIC-DERMATITIS; T-CELLS; MESSENGER-RNA; SKIN; IL-31; PRURITUS; KELOIDS; KERATINOCYTES; PEPTIDE; BURNS	Background: Although several studies have shown the role of interleukin-31 (IL-31) and its receptors in inducing pruritus in certain skin disorders, knowledge of its role in post-burn hypertrophic scars is insufficient. Therefore, the histopathological expression levels of IL-31, IL-31 receptor alpha (IL-31RA), and oncostatin M receptor (OSMR) in post-burn hypertrophic scar tissues were investigated and compared with normal tissue expression levels. Methods: Samples of hypertrophic scar tissue were obtained from 20 burn patients through punch biopsy. Normal samples were obtained from areas adjacent to the burn injury site of the same patients. Samples were placed in 10% neutral buffered formalin, embedded in paraplast, and processed into serial 5-mu m sections. Immunohistochemistry results were semi-quantitatively evaluated for IL-31, IL-31RA, and OSMR. By hematoxylin and eosin staining, epidermal and dermal thickness were assessed with a microscope and digital camera. Intensities were rated on a scale of 1 to 4. Results: Percentages for IL-31, IL-31RA, and OSMR in the epidermal basal layer cell cytoplasm were significantly greater in the burn scar tissue compared to normal skin, as well as the dermal and epidermal thickness (p < .05). There was a significant difference in IL-31 epidermal basal layer intensity in burn scar tissue compared to normal skin (p < .05). Besides the OSMR basal layer intensity, IL-31 and IL-31RA intensities between the burn scar and normal tissues were not significant. However, correlations were significant, indicating that the greater the infiltration percentage, the higher the intensity (p < .05). Conclusions: IL-31, IL-31RA, and OSMR expression levels are increased in hypertrophic scars compared with normal tissue.	[Lee, Mi Young] Hallym Univ, Coll Med, Dept Pathol, Chunchon, South Korea; [Shin, Eun; Kim, Hyunchul] Hallym Univ, Dongtan Sacred Heart Hosp, Dept Pathol, Hwaseong, South Korea; [Kwak, In Suk] Hallym Univ, Hangang Sacred Heart Hosp, Dept Anesthesiol & Pain Med, Seoul, South Korea; [Choi, Younghee] Hallym Univ, Res Inst Complementary & Alternat Med, Dept Pathol, Hangang Sacred Heart Hosp, Seoul, South Korea	Choi, Y (reprint author), Hallym Univ, Dept Pathol, Hangang Sacred Heart Hosp, 12 Beodeunaru Ro 7 Gil, Seoul 07247, South Korea.	yhchoi@hallym.or.kr		Kim, Hyunchul/0000-0002-9322-725X	Hallym Univesirty Medical Center Research Fund [01-2011-28]	This research was supported by the Hallym Univesirty Medical Center Research Fund (01-2011-28).	Amini-Nik S, 2018, ADV DRUG DELIVER REV, V123, P135, DOI 10.1016/j.addr.2017.07.017; BABU M, 1989, MOL CELL BIOL, V9, P1642, DOI 10.1128/MCB.9.4.1642; Bando T, 2006, NEUROSCIENCE, V142, P1263, DOI 10.1016/j.neuroscience.2006.07.009; Bilsborough J, 2006, J ALLERGY CLIN IMMUN, V117, P418, DOI 10.1016/j.jaci.2005.10.046; Bombaro KM, 2003, BURNS, V29, P299, DOI 10.1016/S0305-4179(03)00067-6; Choi YH, 2013, ANN DERMATOL, V25, P428, DOI 10.5021/ad.2013.25.4.428; Cornelissen C, 2012, EUR J CELL BIOL, V91, P552, DOI 10.1016/j.ejcb.2011.07.006; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; Frohm M, 1997, J BIOL CHEM, V272, P15258, DOI 10.1074/jbc.272.24.15258; GHAHARY A, 1993, J LAB CLIN MED, V122, P465; Hawro T, 2014, ALLERGY, V69, P113, DOI 10.1111/all.12316; Kasraie S, 2011, ALLERGY, V66, P845, DOI 10.1111/j.1398-9995.2011.02545.x; Kasutani K, 2014, BRIT J PHARMACOL, V171, P5049, DOI 10.1111/bph.12823; KNAPP TR, 1977, AM J PATHOL, V86, P47; Kwak IS, 2014, BURNS, V40, P1661, DOI 10.1016/j.burns.2014.04.004; Le Saux S, 2010, J BIOL CHEM, V285, P3470, DOI 10.1074/jbc.M109.049189; MCCAULEY RL, 1992, J CLIN IMMUNOL, V12, P300, DOI 10.1007/BF00918154; MURRAY JC, 1994, CLIN DERMATOL, V12, P27, DOI 10.1016/0738-081X(94)90254-2; Nattkemper LA, 2016, ACTA DERM-VENEREOL, V96, P894, DOI 10.2340/00015555-2417; Niyonsaba F, 2006, CRIT REV IMMUNOL, V26, P545, DOI 10.1615/CritRevImmunol.v26.i6.60; Niyonsaba F, 2010, J IMMUNOL, V184, P3526, DOI 10.4049/jimmunol.0900712; Nobbe S, 2012, ACTA DERM-VENEREOL, V92, P24, DOI 10.2340/00015555-1191; Parnell LKS, 2012, J BURN CARE RES, V33, P407, DOI 10.1097/BCR.0b013e318239d206; Poindexter BJ, 2006, BURNS, V32, P402, DOI 10.1016/j.burns.2006.01.021; Profyris C, 2012, J AM ACAD DERMATOL, V66, P1, DOI 10.1016/j.jaad.2011.05.055; Scott JR, 2007, WOUND REPAIR REGEN, V15, pS27, DOI 10.1111/j.1524-475X.2007.00222.x; SHETLAR MR, 1971, P SOC EXP BIOL MED, V138, P298; Singh B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161877; Sonkoly E, 2006, J ALLERGY CLIN IMMUN, V117, P411, DOI 10.1016/j.jaci.2005.10.033; Steinhoff M, 2006, J INVEST DERMATOL, V126, P1705, DOI 10.1038/sj.jid.5700231; SWANN DA, 1985, J INVEST DERMATOL, V84, P527, DOI 10.1111/1523-1747.ep12273517; Szulgit G, 2002, J INVEST DERMATOL, V118, P409, DOI 10.1046/j.0022-202x.2001.01680.x; Van Cromphaut I, 1999, J ENV MED, V1, P47; Van Loey NEE, 2008, BRIT J DERMATOL, V158, P95, DOI 10.1111/j.1365-2133.2007.08278.x; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; Vickery BP, 2007, CURR OPIN PEDIATR, V19, P89, DOI 10.1097/MOP.0b013e328012315a; Xue ML, 2015, ADV WOUND CARE, V4, P119, DOI 10.1089/wound.2013.0485	37	1	1	0	1	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	SEP	2018	52	5					307	313		10.4132/jptm.2018.08.03			7	Pathology	Pathology	GT3KB	WOS:000444400600006	30114861	DOAJ Gold, Green Published			2019-10-28	
J	Khalid, A; Siddiqui, S; Bordoloi, B; Faizi, N; Samadi, F; Saeed, N				Khalid, Aeman; Siddiqui, Safia; Bordoloi, Bharadwaj; Faizi, Nafis; Samadi, Fahad; Saeed, Noora			An Immunohistochemical and Polarizing Microscopic Study of the Tumor Microenvironment in Varying Grades of Oral Squamous Cell Carcinoma	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Myofibroblast; Collagen; Oral squamous cell carcinoma; alpha-Smooth muscle actin; Picrosirius red; Polarizing microscope	COLLAGEN; MYOFIBROBLASTS; PROGRESSION; CANCER; LEUKOPLAKIA; INDUCTION; INVASION; FIBERS; CAVITY; STROMA	Background: Invasion of epithelial cells into the connective tissue brings about massive morphological and architectural changes in the underlying stroma. Myofibroblasts reorganize the stroma to facilitate the movement of tumor cells leading to metastasis. The aim of this study was to determine the number and pattern of distribution of myofibroblasts and the qualitative and quantitative change that they cause in the collagen present in the stroma in various grades of oral squamous cell carcinoma (OSCC). Methods: The study was divided into two groups with group I (test group, 65 cases) consisting of 29 cases of well-differentiated squamous cell carcinoma, 25 moderately differentiated SCC, and 11 poorly differentiated SCC, and group II (control group) consisting of 11 cases of normal mucosa. Sections from each sample were stained with anti-alpha-smooth muscle actin (alpha-SMA) antibodies, hematoxylin and eosin, and Picrosirius red. Several additional sections from each grade of OSCC were stained with Masson's trichrome to observe the changes in collagen. For the statistical analysis, Fisher's exact test, Tukey's post hoc honest significant difference test, ANOVA, and the chi-square test were used, and p < .05 was considered statistically significant. Results: As the tumor stage progressed, an increase in the intensity alpha-SMA expression was seen, and the network pattern dominated in more dedifferentiated carcinomas. The collagen fibers became thin, loosely packed, and haphazardly aligned with progressing cancer. Additionally, the mean area fraction decreased, and the fibers attained a greenish yellow hue and a weak birefringence when observed using polarizing light microscopy. Conclusions: Myofibroblasts bring about numerous changes in collagen. As cancer progresses, there isincrease in pathological collagen, which enhances the movement of cells within the stroma.	[Khalid, Aeman; Saeed, Noora] Jawahar Lal Nehru Med Coll, Dept Pathol, Aligarh, Uttar Pradesh, India; [Siddiqui, Safia; Bordoloi, Bharadwaj] Sardar Patel Post Grad Inst Dent & Med Sci, Dept Oral Pathol & Microbiol, Lucknow 226025, Uttar Pradesh, India; [Faizi, Nafis] AMU, Jawahar Lal Nehru Med Coll, Dept Community Med, Aligarh, Uttar Pradesh, India; [Samadi, Fahad] King George Med Univ, Dept Oral Pathol & Microbiol, Lucknow, Uttar Pradesh, India	Siddiqui, S (reprint author), Sardar Patel Post Grad Inst Dent & Med Sci, Dept Oral Pathol & Microbiol, Lucknow 226025, Uttar Pradesh, India.	safiasidd4@gmail.com	Faizi, Nafis/P-1674-2015	Faizi, Nafis/0000-0002-4634-6790; Saeed, Noora/0000-0002-2287-8573			Alrani D, 2016, AUSTIN J DENT, V3, P1; Bancroft JD, 2008, THEORY PRACTICE HIST; Chauhan H, 2003, J CLIN PATHOL, V56, P271, DOI 10.1136/jcp.56.4.271; Coelho KR, 2012, J CANCER EPIDEMIOL, DOI 10.1155/2012/701932; Conklin MW, 2011, AM J PATHOL, V178, P1221, DOI 10.1016/j.ajpath.2010.11.076; Davies KJ, 2014, INT J BREAST CANCER, DOI 10.1155/2014/839094; DAYAN D, 1989, HISTOCHEMISTRY, V93, P27, DOI 10.1007/BF00266843; Evanko SP, 2015, MATRIX BIOL, V42, P74, DOI 10.1016/j.matbio.2014.12.001; Fang M, 2014, TUMOR BIOL, V35, P2871, DOI 10.1007/s13277-013-1511-7; George Jiji, 2012, Indian J Dent Res, V23, P842, DOI 10.4103/0970-9290.111291; Gopinathan PA, 2015, SCIENTIFICA, DOI 10.1155/2015/802980; Grossman M, 2016, CANCER RES, V76, P4249, DOI 10.1158/0008-5472.CAN-15-2813; Hanley CJ, 2018, JNCI-J NATL CANCER I, V110, DOI 10.1093/jnci/djx121; John Rinju Elsa, 2016, Indian J Dent Res, V27, P242, DOI 10.4103/0970-9290.186242; Kalele PK, 2014, J DENT REV RE, V1, P14, DOI 10.4103/2348-3172. 126159; Kardam Priyanka, 2016, J Oral Maxillofac Pathol, V20, P405; Kellermann MG, 2008, ORAL ONCOL, V44, P509, DOI 10.1016/j.oraloncology.2007.07.001; Khandekar S. P., 2006, Indian Journal of Community Medicine, V31, P157; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Llewellyn CD, 2001, ORAL ONCOL, V37, P401, DOI 10.1016/S1368-8375(00)00135-4; Manjunatha BS, 2015, J CANCER RES THER, V11, P272, DOI 10.4103/0973-1482.154061; Marsh D, 2011, J PATHOL, V223, P470, DOI 10.1002/path.2830; Martins Gabriela Botelho, 2003, Pesqui Odontol Bras, V17, P82, DOI 10.1590/S1517-74912003000100016; MONTES GS, 1991, MEM I OSWALDO CRUZ, V86, P1; Nakayama H, 1998, JPN J CLIN ONCOL, V28, P615, DOI 10.1093/jjco/28.10.615; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC1; Provenzano PP, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-11; Provenzano PP, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-38; Rich Lillian, 2005, Brazilian Journal of Morphological Sciences, V22, P97; Schantz SP, 2002, ARCH OTOLARYNGOL, V128, P268, DOI 10.1001/archotol.128.3.268; Seifi S, 2010, ASIAN PAC J CANCER P, V11, P359; Shimasaki N, 2006, HISTOL HISTOPATHOL, V21, P349, DOI 10.14670/HH-21.347; SHRESTHA P, 1994, ORAL ONCOL, V30B, P132, DOI 10.1016/0964-1955(94)90065-5; SILVERMAN S, 1984, CANCER, V53, P563; Singh Harkanwal Preet, 2012, Natl J Maxillofac Surg, V3, P15, DOI 10.4103/0975-5950.102142; Tuxhorn JA, 2001, J UROLOGY, V166, P2472, DOI 10.1016/S0022-5347(05)65620-0; VANDENHOOFF A, 1988, ADV CANCER RES, V50, P159, DOI 10.1016/S0065-230X(08)60437-6; Venigella A, 2010, J CLIN DIAGN RES, V4, P3444; Vered M, 2009, CANCER MICROENVIRON, V2, P49, DOI 10.1007/s12307-009-0020-0; Warnakulasuriya S, 2010, ORAL ONCOL, V46, P407, DOI 10.1016/j.oraloncology.2010.02.015; Yokoyama M, 2011, J HARD TISSUE BIOL, V20, P23, DOI 10.2485/jhtb.20.23; Zhang ZW, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0458-0; Zhou ZH, 2017, J CANCER, V8, P1466, DOI 10.7150/jca.18466; Ziober BL, 2000, ORAL ONCOL, V36, P365, DOI 10.1016/S1368-8375(00)00019-1	45	0	0	0	1	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	SEP	2018	52	5					314	322		10.4132/jptm.2018.07.17			9	Pathology	Pathology	GT3KB	WOS:000444400600007	30056635	DOAJ Gold, Green Published			2019-10-28	
J	Joung, JW; Oh, HK; Lee, SJ; Kim, YA; Jung, HJ				Joung, Jae Won; Oh, Hoon Kyu; Lee, Sun Jae; Kim, Young Ah; Jung, Hyun Jin			Significance of Intratumoral Fibrosis in Clear Cell Renal Cell Carcinoma	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Carcinoma; renal cell; Fibrosis; Inflammation; Protein-lysine 6-oxidase	INVASIVE DUCTAL CARCINOMA; FIBROTIC FOCUS; BREAST-CANCER; LYSYL OXIDASE; METASTASIS; HETEROGENEITY; MICROENVIRONMENT; PROGRESSION; INCREASE	Background: Intratumoral fibrosis (ITF) is a frequent histologic finding in solid organ tumors. Renal cell carcinoma (RCC) is a highly vascularized tumor with different shapes and degrees of ITF and inflammation. ITF is a poor prognostic factor, especially in breast cancer, and is related to intratumoral necrosis (ITN) and intratumoral inflammation (ITI). However, the significance of ITF in RCC has not been fully studied. In this study, we evaluate the relationships between ITF and other clinicopathologic parameters associated with RCC prognosis. Methods: ITF was evaluated in 204 clear cell renal cell carcinoma (CCRCC) specimens according to presence and grade of fibrosis, degree of ITI, and presence of ITN. Lysyl oxidase (LOX) expression in tumor cells was also evaluated with clinicopathologic parameters. Results: Among 204 CCRCC cases, 167 (81.7%) showed ITF, 71 (34.8%) showed ITI, 35 (17.2%) showed ITN, and 111 (54.4%) showed LOX expression. ITF correlated with Fuhrman nuclear grade (p = .046), lymphovascular invasion (LVI) (p = .027), and ITN (p = .036). Patients with ITF had a poor five-year overall survival rate (p = .104). Conclusions: ITF is related to other poor prognostic factors in CCRCC, such as Fuhrman nuclear grade, ITN, and LVI, but ITF itself had no significant correlation with prognosis of CCRCC.	[Joung, Jae Won; Oh, Hoon Kyu; Lee, Sun Jae; Kim, Young Ah] Catholic Univ Daegu, Dept Pathol, Sch Med, 33 Duryugongwon Ro 17 Gil, Daegu 42472, South Korea; [Jung, Hyun Jin] Catholic Univ Daegu, Dept Urol, Sch Med, Daegu, South Korea	Oh, HK (reprint author), Catholic Univ Daegu, Dept Pathol, Sch Med, 33 Duryugongwon Ro 17 Gil, Daegu 42472, South Korea.	ap510@cu.ac.kr					Beksac AT, 2017, UROL ONCOL-SEMIN ORI, V35, P507, DOI 10.1016/j.urolonc.2017.05.006; Bissell MJ, 2005, CANCER CELL, V7, P17, DOI 10.1016/j.ccr.2004.12.013; Butcher DT, 2009, NAT REV CANCER, V9, P108, DOI 10.1038/nrc2544; Calvo A, 2008, ONCOGENE, V27, P5373, DOI 10.1038/onc.2008.155; Chang HM, 2016, REPRODUCTION, V152, P293, DOI 10.1530/REP-16-0254; Cox TR, 2013, CANCER RES, V73, P1721, DOI 10.1158/0008-5472.CAN-12-2233; Cox TR, 2011, DIS MODEL MECH, V4, P165, DOI 10.1242/dmm.004077; DELAHUNT B, 1987, PATHOLOGY, V19, P258, DOI 10.3109/00313028709066560; Egeblad M, 2010, CURR OPIN CELL BIOL, V22, P697, DOI 10.1016/j.ceb.2010.08.015; Fang LY, 2013, CANCER RES, V73, P5633, DOI 10.1158/0008-5472.CAN-12-3228; Frank I, 2002, J UROLOGY, V168, P2395, DOI 10.1097/01.ju.0000035885.91935.d5; Geissler K, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.985082; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Hasebe T, 2002, MODERN PATHOL, V15, P502, DOI 10.1038/modpathol.3880555; Hasebe T, 2000, PATHOL INT, V50, P263, DOI 10.1046/j.1440-1827.2000.01035.x; Hiley C, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0453-8; Jensen BV, 2002, INT J CANCER, V98, P582, DOI 10.1002/ijc.10187; Joung JY, 2017, CANCER RES TREAT, V49, P607, DOI 10.4143/crt.2016.139; Kagan HM, 2003, J CELL BIOCHEM, V88, P660, DOI 10.1002/jcb.10413; Keeley EC, 2010, INT J BIOCHEM CELL B, V42, P535, DOI 10.1016/j.biocel.2009.10.014; Lucero HA, 2006, CELL MOL LIFE SCI, V63, P2304, DOI 10.1007/s00018-006-6149-9; Ma XJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2222; Minarik I, 2013, IMMUNOL LETT, V152, P144, DOI 10.1016/j.imlet.2013.05.010; Mujtaba SS, 2013, ANN SURG ONCOL, V20, P2842, DOI 10.1245/s10434-013-2955-0; Palsdottir HB, 2012, J UROLOGY, V187, P48, DOI 10.1016/j.juro.2011.09.025; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Qiu TH, 2004, CANCER RES, V64, P5973, DOI 10.1158/0008-5472.CAN-04-0242; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Srigley JR, 2013, AM J SURG PATHOL, V37, P1469, DOI 10.1097/PAS.0b013e318299f2d1; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Wynn TA, 2007, J CLIN INVEST, V117, P524, DOI 10.1172/JCI31487; Yang Z, 2016, ONCOTARGET, V7, P44478, DOI 10.18632/oncotarget.9873	33	1	1	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	SEP	2018	52	5					323	330		10.4132/jptm.2018.07.21			8	Pathology	Pathology	GT3KB	WOS:000444400600008	30121971	DOAJ Gold, Green Published			2019-10-28	
J	Pyo, JS; Sohn, JH; Chang, K				Pyo, Jung-Soo; Sohn, Jin Hee; Chang, Kyungseek			Prognostic Role of Metastatic Lymph Node Ratio in Papillary Thyroid Carcinoma	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Papillary thyroid carcinoma; Lymph node metastasis; Metastatic lymph node ratio; Prognosis; Meta-analysis	NF-KAPPA-B; RISK-FACTORS; GASTRIC-CARCINOMA; PANCREATIC-CANCER; NECK DISSECTION; LATERAL NECK; COLON-CANCER; RECURRENCE; COMPARTMENT; ACTIVATION	Background: The aim of this study is to elucidate the clinicopathological significances, including the prognostic role, of metastatic lymph node ratio (mLNR) and tumor deposit diameter in papillary thyroid carcinoma (PTC) through a retrospective review and meta-analysis. Methods: We categorized the cases into high (>= 0.44) and low mLNR (<0.44) and investigated the correlations with clinicopathological parameters in 64 PTCs with neck level VI lymph node (LN) metastasis. In addition, meta-analysis of seven eligible studies was used to investigate the correlation between mLNR and survival. Results: Among 64 PTCs with neck level VI LN metastasis, high mLNR was found in 34 PTCs (53.1%). High mLNR was significantly correlated with macrometastasis (tumor deposit diameter >= 0.2 cm), extracapsular spread, and number of metastatic LNs. Based on linear regression test, mLNR was significantly increased by the largest LN size but not the largest metastatic LN (mLN) size. High mLNR was not correlated with nuclear factor kappa B or cyclin D1 immunohistochemical expression, Ki-67 labeling index, or other pathological parameters of primary tumor. Based on meta-analysis, high mLNR significantly correlated with worse disease-free survival at the 5-year and 10-year follow-up (hazard ratio [HR], 4.866; 95% confidence interval [CI], 3.527 to 6.714 and HR, 5.769; 95% CI, 2.951 to 11.275, respectively). Conclusions: Our data showed that high mLNR significantly correlated with worse survival, macrometastasis, and extracapsular spread of mLNs. Further cumulative studies for more detailed criteria of mLNR are needed before application in daily practice.	[Pyo, Jung-Soo] Eulji Univ, Sch Med, Eulji Univ Hosp, Dept Pathol, Daejeon, South Korea; [Sohn, Jin Hee; Chang, Kyungseek] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Pathol, 29 Saemunan Ro, Seoul 03181, South Korea	Sohn, JH (reprint author), Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Pathol, 29 Saemunan Ro, Seoul 03181, South Korea.	jhpath.sohn@samsung.com					Amin MB, 2016, AJCC CANC STAGING MA; Beal SH, 2010, AM SURGEON, V76, P28; Chang YW, 2016, INT J CLIN ONCOL, V21, P862, DOI 10.1007/s10147-016-0956-2; DeLellis RA, 2017, PATHOLOGY GENETICS T; Edge S. B., 2009, AJCC CANC STAGING MA; Inoue K, 2002, ANN SURG ONCOL, V9, P27, DOI 10.1245/aso.2002.9.1.27; Ito Y, 2007, WORLD J SURG, V31, P838, DOI 10.1007/s00268-006-0455-0; Kim B, 2010, PATHOLOGY, V42, P58, DOI 10.3109/00313020903356392; Lee CW, 2015, ANN SURG ONCOL, V22, P117, DOI 10.1245/s10434-014-3900-6; Lee KH, 2008, PATHOBIOLOGY, V75, P364, DOI 10.1159/000164221; Lee SG, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002692; Lee YM, 2016, BRIT J SURG, V103, P1020, DOI 10.1002/bjs.10144; Leonard D, 2016, COLORECTAL DIS, V18, pO175, DOI 10.1111/codi.13362; MAZZAFERRI EL, 1993, NEW ENGL J MED, V328, P553; Opfermann KJ, 2014, AM J CLIN ONCOL-CANC, V37, P112, DOI 10.1097/COC.0b013e31826e0570; Pacifico F, 2006, BIOCHEM PHARMACOL, V72, P1142, DOI 10.1016/j.bcp.2006.07.032; Park YM, 2016, ACTA OTO-LARYNGOL, V136, P319, DOI 10.3109/00016489.2015.1116045; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; Partelli S, 2010, ANN SURG, V251, P477, DOI 10.1097/SLA.0b013e3181cf9155; Pawlik TM, 2007, SURGERY, V141, P610, DOI 10.1016/j.surg.2006.12.013; Pyo JS, 2015, ENDOCR PATHOL, V26, P15, DOI 10.1007/s12022-014-9353-4; Pyo JS, 2013, PATHOL RES PRACT, V209, P228, DOI 10.1016/j.prp.2013.02.004; Pyo JS, 2010, J NEUROSCI RES, V88, P2494, DOI 10.1002/jnr.22397; Ryu IS, 2014, ANN SURG ONCOL, V21, P277, DOI 10.1245/s10434-013-3258-1; Santiagoa JMR, 2005, EJSO-EUR J SURG ONC, V31, P59, DOI 10.1016/j.ejso.2004.09.013; Schneider DF, 2013, ONCOLOGIST, V18, P157, DOI 10.1634/theoncologist.2012-0240; Sugimoto K, 2013, DIGEST SURG, V30, P368, DOI 10.1159/000355444; Sugitani I, 2008, WORLD J SURG, V32, P2494, DOI 10.1007/s00268-008-9711-9; Vaccaro CA, 2009, DIS COLON RECTUM, V52, P1244, DOI 10.1007/DCR.0b013e3181a65f0b; Yang K, 2014, CLIN NUCL MED, V39, P675, DOI 10.1097/RLU.0000000000000498; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; Zheng CM, 2018, CLIN EXP OTORHINOLAR, V11, P58, DOI 10.21053/ceo.2017.00472	32	2	2	0	2	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	SEP	2018	52	5					331	338		10.4132/jptm.2018.08.07			8	Pathology	Pathology	GT3KB	WOS:000444400600009	30157618	DOAJ Gold, Green Published			2019-10-28	
J	Jeong, H; Lee, HW; Jung, HR; Hwang, I; Kwon, SY; Kang, YN; Kim, SP; Choe, M				Jeong, Hasong; Lee, Hye Won; Jung, Hye Ra; Hwang, Ilseon; Kwon, Sun Young; Kang, Yu Na; Kim, Sang Pyo; Choe, Misun			Bile Granuloma Mimicking Peritoneal Seeding: A Case Report	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Bile; Granuloma; Cholecystectomy	LAPAROSCOPIC CHOLECYSTECTOMY; LOST GALLSTONES; GALLBLADDER; ASPIRATION; COMPLICATIONS	Laparoscopic cholecystectomy is a widely used treatment method for most cholelithiasis and is a relatively safe procedure. Foreign body granulomatous reaction to bile or gallstone spillage during laparoscopic cholecystectomy has rarely been reported. We report a case of bile granuloma after laparoscopic cholecystectomy, which mimicked peritoneal seeding. A 59-year-old Korean man presented with right upper quadrant pain. He underwent laparoscopic cholecystectomy for acute cholecystitis with cholelithiasis. Pathologic examination revealed an incidental adenocarcinoma invading the lamina propria with acute cholecystitis and cholelithiasis. After 3 months, follow-up abdominal computed tomography revealed a subhepatic nodule, which showed hypermetabolism on positron emission tomography-computed tomography. Suspecting localized peritoneal seeding, wedge resection of the liver, wedge resection of the transverse colon, and omentectomy were performed. Pathologic examination of the resected specimens revealed multiple bile granulomas. Awareness of bile granuloma mimicking malignancy is noteworthy for patient management to reduce unnecessary procedure during postoperative surveillance.	[Jeong, Hasong; Lee, Hye Won; Jung, Hye Ra; Hwang, Ilseon; Kwon, Sun Young; Kang, Yu Na; Kim, Sang Pyo; Choe, Misun] Keimyung Univ, Sch Med, Dept Pathol, 1095 Dalgubeol Daero, Daegu 42601, South Korea	Choe, M (reprint author), Keimyung Univ, Sch Med, Dept Pathol, 1095 Dalgubeol Daero, Daegu 42601, South Korea.	msc@dsmc.or.kr					Calik A, 2007, SURG ENDOSC, V21, P1578, DOI 10.1007/s00464-006-9159-7; Erdogan D, 2013, EUR J PEDIATR SURG R, V1, P60, DOI 10.1055/s-0033-1345278; Ezer A, 2008, AM J SURG, V196, P456, DOI 10.1016/j.amjsurg.2008.02.006; Famularo G, 2012, JSLS-J SOC LAPAROEND, V16, P481, DOI 10.4293/108680812X13462882736015; Kim BS, 2016, WORLD J GASTROENTERO, V22, P4421, DOI 10.3748/wjg.v22.i17.4421; Kim SW, 2009, KOREAN J RADIOL, V10, P313, DOI 10.3348/kjr.2009.10.3.313; Lee Whanbong, 2013, Korean J Hepatobiliary Pancreat Surg, V17, P66, DOI 10.14701/kjhbps.2013.17.2.66; Luo JD, 2014, ONCOTARGETS THER, V7, P2137, DOI 10.2147/OTT.S70705; McVeigh G, 2012, INT J SURG PATHOL, V20, P89, DOI 10.1177/1066896911409930; Merchant SH, 2000, OBSTET GYNECOL, V96, P830, DOI 10.1016/S0029-7844(00)01049-8; Pantiora EV, 2016, CUREUS, V8, DOI 10.7759/cureus.717; Pazouki A, 2014, SURG LAPARO ENDO PER, V24, P213, DOI 10.1097/SLE.0b013e31828fc09e; Radunovic Miodrag, 2016, Open Access Maced J Med Sci, V4, P641, DOI 10.3889/oamjms.2016.128; Siddiqui MRS, 2011, INT SURG, V96, P21, DOI 10.9738/1361.1; Suarez-Zamora DA, 2017, CASE REP PATHOL, DOI 10.1155/2017/4873273; Townsend CM, 2017, SABISTON TXB SURG, P1493; Zehetner J, 2007, AM J SURG, V193, P73, DOI 10.1016/j.amjsurg.2006.05.015	17	0	0	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	SEP	2018	52	5					339	343		10.4132/jptm.2018.06.02			5	Pathology	Pathology	GT3KB	WOS:000444400600010	30008197	DOAJ Gold, Green Published			2019-10-28	
J	Jang, NR; Lee, DH; Jang, EJ; Bae, YK; Baek, J; Jang, MH				Jang, Nu Ri; Lee, Dae Hyung; Jang, Eun Jung; Bae, Young Kyung; Baek, Jina; Jang, Min Hye			Ovarian Gynandroblastoma with a Juvenile Granulosa Cell Tumor Component in a Postmenopausal Woman: A Case Report and Literature Review	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Review						Ovarian gynandroblastoma; Juvenile granulosa cell tumor; Ovary; Postmenopause	CORD-STROMAL TUMORS; FOXL2 MUTATION; ADULT; INSIGHTS; ELEMENTS	Gynandroblastoma is an extremely rare sex cord-stromal tumor with both female (granulosa cell tumor) and male (Sertoli-Leydig cell tumor) elements. Juvenile granulosa cell tumors are also very rare and are so named because they usually occur in children and adolescents. A 71-year-old woman with right upper quadrant abdominal pain visited our hospital. Pelvic computed tomography showed a large multilocular cystic mass, suspected to be of ovarian origin. We performed a total abdominal hysterectomy (total abdominal hysterectomy was performed) with bilateral salpingo-oophorectomy. A 13-cm multilocular cystic mass with serous fluid was observed in her right ovary. Upon microscopic examination, the solid component of the mass showed both Sertoli-Leydig cell and juvenile granulosa cell differentiation, which we diagnosed as gynandroblastoma. Gynandroblastoma with a juvenile granulosa cell tumor component is extremely rare and, until now, only six cases have been reported in the English literature. We report the first gynandroblastoma with a juvenile granulosa cell tumor component diagnosed in an elderly patient, along with a literature review.	[Jang, Nu Ri; Bae, Young Kyung; Baek, Jina; Jang, Min Hye] Yeungnam Univ, Sch Med, Dept Pathol, 170 Hyeonchung Ro, Daegu 42415, South Korea; [Lee, Dae Hyung] Yeungnam Univ, Sch Med, Dept Gynecol & Obstet, Daegu, South Korea; [Jang, Eun Jung] Fatima Hosp, Dept Pathol, Daegu, South Korea	Jang, MH (reprint author), Yeungnam Univ, Sch Med, Dept Pathol, 170 Hyeonchung Ro, Daegu 42415, South Korea.	clodious@naver.com					Auguste A, 2015, HUM MOL GENET, V24, P6687, DOI 10.1093/hmg/ddv373; Broshears JR, 1997, INT J GYNECOL PATHOL, V16, P387, DOI 10.1097/00004347-199710000-00016; Chan R, 2005, PATHOLOGY, V37, P312, DOI 10.1080/00313020500169503; Chen LW, 2013, INT J GYNECOL PATHOL, V32, P156, DOI 10.1097/PGP.0b013e31825a0353; Chivukula M, 2007, INT J GYNECOL PATHOL, V26, P30, DOI 10.1097/01.pgp.0000225387.48868.39; Conlon N, 2015, MODERN PATHOL, V28, P1603, DOI 10.1038/modpathol.2015.115; D'Angelo E, 2011, MODERN PATHOL, V24, P1360, DOI 10.1038/modpathol.2011.95; Heravi-Moussavi A, 2012, NEW ENGL J MED, V366, P234, DOI 10.1056/NEJMoa1102903; Jamieson S, 2010, MODERN PATHOL, V23, P1477, DOI 10.1038/modpathol.2010.145; Kalfa N, 2006, J CLIN ENDOCR METAB, V91, P1842, DOI 10.1210/jc.2005-2710; McCluggage WG, 2013, AM J SURG PATHOL, V37, P1450, DOI 10.1097/PAS.0b013e31828e4f55; McCluggage WG, 1996, HISTOPATHOLOGY, V29, P253, DOI 10.1111/j.1365-2559.1996.tb01399.x; Mechler EA, 1943, AM J PATHOL, V19, P633; Oparka R, 2012, HISTOPATHOLOGY, V60, P838, DOI 10.1111/j.1365-2559.2011.04148.x; Shah SP, 2009, NEW ENGL J MED, V360, P2719, DOI 10.1056/NEJMoa0902542; Takeda A, 2017, J PEDIATR ADOL GYNEC, V30, P251, DOI 10.1016/j.jpag.2016.10.005; Talerman A, 1998, INT J GYNECOL PATHOL, V17, P190, DOI 10.1097/00004347-199804000-00017; Tian WY, 2013, J LOW GENIT TRACT DI, V17, P335, DOI 10.1097/LGT.0b013e3182702796; Wilberger A, 2015, INT J SURG PATHOL, V23, P393, DOI 10.1177/1066896915573569; Zhao CQ, 2009, AM J SURG PATHOL, V33, P354, DOI 10.1097/PAS.0b013e318188373d	20	0	0	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	SEP	2018	52	5					344	348		10.4132/jptm.2018.06.28			5	Pathology	Pathology	GT3KB	WOS:000444400600011	30011982	DOAJ Gold, Green Published			2019-10-28	
J	Lee, T; Choi, S; Han, J; Choi, YL; Lee, K				Lee, Taebum; Choi, Sangjoon; Han, Joungho; Choi, Yoon-La; Lee, Kyungjong			Abrupt Dyskeratotic and Squamoid Cells in Poorly Differentiated Carcinoma: Case Study of Two Thoracic NUT Midline Carcinomas with Cytohistologic Correlation	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						BRD4-NUT fusion oncogene protein; NUT midline carcinoma; Lung; Cytology	SPECIMENS; FEATURES	Cytologic diagnosis of nuclear protein in testis (NUT) midline carcinoma (NMC) is important due to its aggressive behavior and miserable prognosis. Early diagnosis of NMC can facilitate proper management, and here we report two rare cases of thoracic NMC with cytohistologic correlation. In aspiration cytology, the tumor presented with mixed cohesive clusters and dispersed single cells, diffuse background necrosis and many neutrophils. Most of the tumor cells had scanty cytoplasm and medium-sized irregular nuclei, which had fine to granular nuclear chromatin. Interestingly, a few dyskeratotic cells or squamoid cell clusters were present in each case. Biopsy specimen histology revealed more frequent squamous differentiation, and additional immunohistochemistry tests showed nuclear expression of NUT. Because this tumor has a notorious progression and has been previously underestimated in terms of its prevalence, awareness of characteristic findings and proper ancillary tests should be considered in all suspicious cases.	[Lee, Taebum; Choi, Sangjoon; Han, Joungho; Choi, Yoon-La] Sungkyunkwan Univ, Sch Med, Dept Pathol, Samsung Med Ctr, 81 Irwon Ro, Seoul 06351, South Korea; [Lee, Kyungjong] Sungkyunkwan Univ, Dept Med, Div Pulm & Crit Care Med, Samsung Med Ctr,Sch Med, Seoul, South Korea	Han, J (reprint author), Sungkyunkwan Univ, Sch Med, Dept Pathol, Samsung Med Ctr, 81 Irwon Ro, Seoul 06351, South Korea.	hanjho@skku.edu					Bishop JA, 2016, CANCER CYTOPATHOL, V124, P901, DOI 10.1002/cncy.21761; Evans AG, 2012, AM J SURG PATHOL, V36, P1222, DOI 10.1097/PAS.0b013e318258f03b; French CA, 2008, ONCOGENE, V27, P2237, DOI 10.1038/sj.onc.1210852; French CA, 2012, ANNU REV PATHOL-MECH, V7, P247, DOI 10.1146/annurev-pathol-011811-132438; Gray W, 2010, DIAGNOSTIC CYTOPATHO, P68; Marks RA, 2013, DIAGN CYTOPATHOL, V41, P81, DOI 10.1002/dc.21853; Park Heae Surng, 2014, Korean J Pathol, V48, P335, DOI 10.4132/KoreanJPathol.2014.48.4.335; Policarpio-Nicolas MLC, 2015, DIAGN CYTOPATHOL, V43, P739, DOI 10.1002/dc.23291; Schwartz BE, 2011, CANCER RES, V71, P2686, DOI 10.1158/0008-5472.CAN-10-3513; Stelow EB, 2011, HEAD NECK PATHOL, V5, P31, DOI 10.1007/s12105-010-0235-x; Sturgis CD, 2000, AM J CLIN PATHOL, V114, P197	11	0	0	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	SEP	2018	52	5					349	353		10.4132/jptm.2018.07.16			5	Pathology	Pathology	GT3KB	WOS:000444400600012	30056636	DOAJ Gold, Green Published			2019-10-28	
J	Kilicarslan, A; Ozturk, V; Senturk Yikilmaz, A; Dogan, M; Akyol, M				Kilicarslan, Aydan; Ozturk, Vedia; Senturk Yikilmaz, Aysun; Dogan, Mehmet; Akyol, Mesut			Evaluation of the Prognostic Importance of c-Myc and Bcl-2 Expressions and the Presence of Epstein-Barr Virus in Classical Hodgkin Lymphoma	TURKISH JOURNAL OF PATHOLOGY			English	Article						Hodgkin lymphoma; c-Myc; Bcl-2; EBER	REED-STERNBERG CELLS; MEMBRANE-PROTEIN 1; TUMOR-SUPPRESSOR; RETINOBLASTOMA PROTEIN; STEMBERG CELLS; GENE NETWORK; MANTLE CELL; DISEASE; P53; INFECTION	Objective: Although classical Hodgkin lymphoma (c H L) has a relatively good prognosis, it also entails different treatment responses and involves patients who have different clinical courses. Our aim was to investigate c-Myc, Bcl-2 and EBV biomarkers in cHL and their relationship with the IPS score. Material and Method: c-Myc and Bcl-2 immunohistochemical staining with EBER in situ hybridization (EBER-ISH) was applied to the paraffin sections of 94 cases diagnosed as cHL. These cases were classified into two groups as low and high clinical symptoms according to the International Prognostic Scores (IPS). Results: Positive results were obtained in 83 (88.3%) cases with c-Myc and 39 (43.5%) cases with Bcl-2 while EBER-ISII was found positive in 42 (44.7%) cases. No difference was found between the groups of low/high IP scores with respect to the positive or negative results of EBER-ISH, Bcl-2 and c-Myc. When Bcl-2 and c-Myc positive cases were grouped together and compared to the IP scores of the remaining cHL cases, again no difference was seen. Extranodal involvement and bone marrow involvement was observed in 25 (26.5%) and 9 (9.5%) cases, respectively. Similarly, no statistically significant differences was found between these groups according to their positivity with EBER-ISH, Bcl-2 and c-Myc. Conclusion: We could not find any relationship between Bcl-2, c-Myc and EBER-ISH positivity and the low/high IPS groups in cHL. New studies with larger series are needed in which more precise cut-off values are used and clinically and biologically heterogeneous groups of cHL patients are determined more clearly.	[Kilicarslan, Aydan] Ankara Yildirim Beyazit Univ, Sch Med, Dept Pathol, Ankara, Turkey; [Ozturk, Vedia] Van Educ & Res Hosp, Van, Turkey; [Senturk Yikilmaz, Aysun] Ankara Ataturk Educ & Res Hosp, Dept Hematol, Ankara, Turkey; [Dogan, Mehmet] Ankara Dr Abdurrahman Yurtaslan Oncol Educ & Res, Dept Pathol, Ankara, Turkey; [Akyol, Mesut] Ankara Yildirim Beyazit Univ, Dept Biostat, Sch Med, Ankara, Turkey	Kilicarslan, A (reprint author), Ankara Yildirim Beyazit Univ, Dept Pathol, Ankara, Turkey.	dr.kilicaydan@gmail.com	Dogan, Mehmet/A-6890-2015	Dogan, Mehmet/0000-0001-8806-0400			Akyurek N, 2012, CANCER-AM CANCER SOC, V118, P4173, DOI 10.1002/cncr.27396; Al-Kuraya K, 2006, LEUKEMIA LYMPHOMA, V47, P707, DOI 10.1080/10428190500286879; Bellas C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098169; Brink AATP, 1998, MODERN PATHOL, V11, P376; Canellos GP, 2014, J CLIN ONCOL, V32, P163, DOI 10.1200/JCO.2013.53.1194; Canellos GP, 1998, ANN ONCOL, V9, P91, DOI 10.1023/A:1008475921702; Chabay PA, 2008, J PEDIAT HEMATOL ONC, V30, P285, DOI 10.1097/MPH.0b013e3181647bc3; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Ferme C, 1997, CANCER-AM CANCER SOC, V80, P1124; Franklin J, 2000, ANN ONCOL, V11, P617, DOI 10.1023/A:1008325627670; Fu Xiao-Hong, 2006, Ai Zheng, V25, P1013; Garcia JF, 2003, BLOOD, V101, P681, DOI 10.1182/blood-2002-04-1128; Gruss HJ, 1996, BAILLIERE CLIN HAEM, V9, P417, DOI 10.1016/S0950-3536(96)80019-9; Hinz M, 2001, BLOOD, V97, P2798, DOI 10.1182/blood.V97.9.2798; JIWA NM, 1993, J CLIN PATHOL, V46, P211, DOI 10.1136/jcp.46.3.211; Karantanos T, 2017, BLOOD LYMPHAT CANCER, V7, P37, DOI 10.2147/BLCTT.S105458; Keegan THM, 2005, J CLIN ONCOL, V23, P7604, DOI 10.1200/JCO.2005.02.6310; KHAN G, 1993, AM J PATHOL, V143, P1270; Kim LH, 2006, HUM PATHOL, V37, P92, DOI 10.1016/j.humpath.2005.09.028; Kim LH, 2004, HISTOPATHOLOGY, V44, P257, DOI 10.1111/j.0309-0167.2004.01829.x; Kwon JM, 2006, ANN HEMATOL, V85, P463, DOI 10.1007/s00277-006-0081-9; Le Gouill S, 2007, HAEMATOL-HEMATOL J, V92, P1335, DOI 10.3324/haematol.11305; Lee JH, 2014, ARCH MED RES, V45, P417, DOI 10.1016/j.arcmed.2014.06.001; Leong IT, 2001, ORAL SURG ORAL MED O, V92, P184, DOI 10.1067/moe.2001.116155; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Montalban C, 2004, J CLIN ONCOL, V22, P1664, DOI 10.1200/JCO.2004.06.105; Montesinos-Rongen M, 1999, BLOOD, V94, P1755, DOI 10.1182/blood.V94.5.1755.417a26_1755_1760; Morente MM, 1997, BLOOD, V90, P2429; Ohshima K, 1999, PATHOL INT, V49, P506, DOI 10.1046/j.1440-1827.1999.00898.x; Polack A, 1996, P NATL ACAD SCI USA, V93, P10411, DOI 10.1073/pnas.93.19.10411; Rassidakis GZ, 2002, BLOOD, V100, P3935, DOI 10.1182/blood.V100.12.3935; Sieber M, 2000, ANN ONCOL, V11, P81, DOI 10.1023/A:1008317426152; Smolewski P, 2000, CLIN CANCER RES, V6, P1150; Souza EM, 2010, HEMATOL ONCOL, V28, P137, DOI 10.1002/hon.933; Spacek M, 2011, APMIS, V119, P10, DOI 10.1111/j.1600-0463.2010.02685.x; Spieker T, 2000, BLOOD, V96, P3133; Stefancikova L, 2010, INT J ONCOL, V36, P699, DOI 10.3892/ijo_00000545; Sup SJ, 2005, J CLIN ONCOL, V23, P3773, DOI 10.1200/JCO.2005.04.358; Sureda A, 2001, J CLIN ONCOL, V19, P1395, DOI 10.1200/JCO.2001.19.5.1395; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Takada H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174136; Tapia G, 2011, HISTOPATHOLOGY, V59, P672, DOI 10.1111/j.1365-2559.2011.03978.x; Tiacci E, 2012, BLOOD, V120, P4609, DOI 10.1182/blood-2012-05-428896; Trimeche M, 2007, LEUKEMIA LYMPHOMA, V48, P1323, DOI 10.1080/10428190701411177; Vassilakopoulos TP, 2001, EUR J HAEMATOL, V67, P279, DOI 10.1034/j.1600-0609.2001.00561.x; Yan LX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104068; Yuan Y, 2017, AM J PATHOL, V187, P1343, DOI 10.1016/j.ajpath.2017.02.016; Zander T, 2002, ANN ONCOL, V13, P67, DOI 10.1093/annonc/mdf613; Zlamalikova L, 2017, ONCOL REP, V38, P2535, DOI 10.3892/or.2017.5891	49	0	0	0	1	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	SEP	2018	34	3					199	206		10.5146/tjpath.2018.01430			8	Pathology	Pathology	GT1XU	WOS:000444271800001	29708579	DOAJ Gold			2019-10-28	
J	Tepeoglu, M; Ozgun, G; Tunca, MZ; Tezcaner, T; Ozdemir, BH				Tepeoglu, Merih; Ozgun, Gonca; Tunca, M. Zeyneb; Tezcaner, Tugan; Ozdemir, B. Handan			Gastrointestinal Stromal Tumors: A Clinicopathologica and Immunohistochemical Study of 65 Cases	TURKISH JOURNAL OF PATHOLOGY			English	Article						Gastrointestinal stromal tumors; Necrosis; Ki-67; CD-34	TERM-FOLLOW-UP; PROGNOSTIC-FACTORS; DIFFERENTIAL-DIAGNOSIS; DOG1 EXPRESSION; DIFFERENT SITES; RISK CRITERIA; PATHOLOGY; FEATURES; GIST; IMMUNOPHENOTYPE	Objective: Hie clinical behavior of gastrointestinal stromal tumors is divergent. The aim of the present study was to define the clinicopathological features that determine the patient's outcome. Material and Method: Sixty-five gastrointestinal stromal tumors were reviewed with their histological, immunohistochemical and clinical features and compared with their clinical outcome statistically. Results: Tumors were located in the stomach (n=39, 60%), small intestine (n=22, 33.8%) and large intestine (n=4, 6.2%). Immunohistochemically, CD 117 positivity was found in 90.8%, whereas CD34, Smooth muscle actin, Desmin and S100 positivity was found in 73.3%, 61.7%, 11.7% and 28.3% of tumors respectively. All six "CD 117-negative" cases expressed DOG-1. The mean Ki-67 proliferation index was 8.69%+/- 12.76. Liver metastasis was detected in seven cases. A significant association was detected between decreased mean survival time and increased tumor size (p<0.001), large bowel localization (p-0.047), mitosis (p<0.001), the presence of necrosis (p=0.001), metastasis (p=0.033), Ki-67 proliferation index (p-0.002) and risk category (p<0.001). CD 34 positivity was mostly seen in the stomach (p-0.001), and CD 34 positive tumors had longer overall survival (92.85.+/- 5.77 months versus 67.21 +/- 13.68 months) (p=0.046). Higher Ki-67 proliferation index (6%) was also correlated with the presence of metastases (p=0.015). Conclusion: Our study indicates that in addition to well-known risk factors such as increased tumor size, high mitotic activity and metastasis; higher Ki-67 proliferation index, the presence of necrosis, and CD34 negativity also correlate with shorter survival time.	[Tepeoglu, Merih; Ozgun, Gonca; Tunca, M. Zeyneb; Ozdemir, B. Handan] Baskent Univ, Fac Med, Dept Pathol, TR-06490 Ankara, Turkey; [Tezcaner, Tugan] Baskent Univ, Fac Med, Dept Gen Surg, Ankara, Turkey	Tepeoglu, M (reprint author), Baskent Univ, Fac Med, Dept Pathol, TR-06490 Ankara, Turkey.	merihdemirel@yahoo.com.tr	Ozdemir, B Handan/X-8540-2019	Ozdemir, B Handan/0000-0002-7528-3557			DeMatteo RP, 2008, CANCER-AM CANCER SOC, V112, P608, DOI 10.1002/cncr.23199; DeMatteo RP, 2000, ANN SURG, V231, P51, DOI 10.1097/00000658-200001000-00008; Emory TS, 1999, AM J SURG PATHOL, V23, P82, DOI 10.1097/00000478-199901000-00009; Fletcher CDM, 2002, HUM PATHOL, V33, P459, DOI 10.1053/hupa.2002.123545; FRANQUEMONT DW, 1992, AM J SURG PATHOL, V16, P947, DOI 10.1097/00000478-199210000-00004; Fu Y, 2017, ONCOTARGET, V8, P10136, DOI 10.18632/oncotarget.14359; Fujimoto Yoshiya, 2003, Gastric Cancer, V6, P39, DOI 10.1007/s101200300005; Goh BKP, 2008, ANN SURG ONCOL, V15, P2153, DOI 10.1245/s10434-008-9969-z; Guler B, 2015, BALK MED J, V32, P388, DOI 10.5152/balkanmedj.2015.15912; Hamilton SRAL, 2000, PATHOLOGY GENETICS T, P37; Huang HY, 2007, SURGERY, V141, P748, DOI 10.1016/j.surg.2007.01.024; Klieser E, 2016, MOL CLIN ONCOL, V4, P763, DOI 10.3892/mco.2016.819; Miettinen M, 2000, MODERN PATHOL, V13, P1134, DOI 10.1038/modpathol.3880210; Miettinen M, 2006, AM J SURG PATHOL, V30, P477, DOI 10.1097/00000478-200604000-00008; Miettinen M, 2005, AM J SURG PATHOL, V29, P52, DOI 10.1097/01.pas.0000146010.92933.de; Miettinen M, 2006, SEMIN DIAGN PATHOL, V23, P70, DOI 10.1053/j.semdp.2006.09.001; Miettinen M, 2006, ARCH PATHOL LAB MED, V130, P1466; NEWMAN PL, 1991, J PATHOL, V164, P107, DOI 10.1002/path.1711640204; Nilsson B, 2005, CANCER-AM CANCER SOC, V103, P821, DOI 10.1002/cncr.20862; Panizo-Santos A, 2000, INT J SURG PATHOL, V8, P133, DOI 10.1177/106689690000800208; Rudolph P, 1998, HUM PATHOL, V29, P791, DOI 10.1016/S0046-8177(98)90447-6; Rutkowski P, 2007, ANN SURG ONCOL, V14, P2018, DOI 10.1245/s10434-007-9377-9; Sahin S, 2017, TURK J PATHOL, V33, P1, DOI 10.5146/tjpath.2016.01376; SHIU MH, 1982, CANCER, V49, P177, DOI 10.1002/1097-0142(19820101)49:1<177::AID-CNCR2820490136>3.0.CO;2-K; Sobin LH, 2010, TNM CLASSIFICATION M; Sozutek D, 2014, INT J CLIN EXP MED, V7, P1914; Suster S, 1996, SEMIN DIAGN PATHOL, V13, P297	27	0	0	0	0	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	SEP	2018	34	3					207	214		10.5146/tjpath.2018.01427			8	Pathology	Pathology	GT1XU	WOS:000444271800002	29630088	DOAJ Gold			2019-10-28	
J	Ozsen, M; Tolunay, S; Gokgoz, MS				Ozsen, Mine; Tolunay, Sahsine; Gokgoz, M. Sehsuvar			Granulomatous Lobular Mastitis: Clinicopathologic Presentation of 90 Cases	TURKISH JOURNAL OF PATHOLOGY			English	Article						Granulomatous mastitis; Breast diseases; Inflammation	CARCINOMA; DISEASE; EXPERIENCE; MANAGEMENT	Objective: Granulomatous lobular mastitis is a rare benign chronic breast disease first described by Milward in 1970, and then by Kessler and Wolloch in 1972. In this study, we aimed to present clinicopathologic features of granulomatous lobular mastitis with literature data. Material and Method: In this study, the archives of Uludag University Medical Faculty Department of Pathology were screened for granulomatous lobular mastitis cases between 2005 and 2017. Results: A total of 90 patients with granulomatous lobular mastitis diagnosed between 2005 and 2017 were identified. All of the cases were female. The mean age was 34 t8.3 (range 21-60 years). There was sarcoidosis in one case and tuberculosis in another case, but no systemic disease was found in the charts of the other cases. Histopathological evaluation of 90 cases revealed non-necrotizing granulomas involving lobule-restricted, epithelioid histiocytes and Langhans-type multinuclear giant cells. There was no case of necrosis, including our only case with a history of tuberculosis. Conclusion: We conclude that our granulomatous lobular mastitis cases have similar characteristics with the series reported earlier, when all features are taken into consideration.	[Ozsen, Mine; Tolunay, Sahsine] Uludag Univ, Fac Med, Dept Pathol, Bursa, Turkey; [Gokgoz, M. Sehsuvar] Uludag Univ, Fac Med, Dept Breast Surg, Bursa, Turkey	Ozsen, M (reprint author), Uludag Univ, Fac Med, Dept Pathol, Bursa, Turkey.	m.isikoglu@hotmail.com	Cavusoglu, Deniz/C-8188-2018	Cavusoglu, Deniz/0000-0003-2550-3854			Al-Khaffaf B, 2008, J AM COLL SURGEONS, V206, P269, DOI 10.1016/j.jamcollsurg.2007.07.041; Altintoprak Fatih, 2014, World J Clin Cases, V2, P852, DOI 10.12998/wjcc.v2.i12.852; Asoglu O, 2005, BREAST J, V11, P108, DOI 10.1111/j.1075-122X.2005.21576.x; Azlina AF, 2003, WORLD J SURG, V27, P515, DOI 10.1007/s00268-003-6806-1; Bani-Hani Kamal E, 2004, Breast J, V10, P318, DOI 10.1111/j.1075-122X.2004.21336.x; Baslaim MM, 2007, WORLD J SURG, V31, P1677, DOI 10.1007/s00268-007-9116-1; Cheng L, 2015, BREAST J, V21, P403, DOI 10.1111/tbj.12430; Erozgen F, 2010, BREAST CANCER RES TR, V123, P447, DOI 10.1007/s10549-010-1041-6; Gautier N, 2013, EUR J RADIOL, V82, pE165, DOI 10.1016/j.ejrad.2012.11.010; GOING JJ, 1987, J CLIN PATHOL, V40, P535, DOI 10.1136/jcp.40.5.535; Gurleyik G, 2012, J BREAST CANCER, V15, P119, DOI 10.4048/jbc.2012.15.1.119; Handley WS, 1938, BRIT MED J, V2, P113, DOI 10.1136/bmj.2.4045.113; Hoda SA, 2014, ROSENS BREAST PATHOL, P47; Kaviani A, 2017, ARCH BREAST CANC, V4, P32; KESSLER E, 1972, AM J CLIN PATHOL, V58, P642; Kiyak G, 2014, BMC SURG, V14, DOI 10.1186/1471-2482-14-66; Korkut E, 2015, EURASIAN J MED, V47, P165, DOI 10.5152/eurasianjmed.2015.118; Lai ECH, 2005, BREAST J, V11, P454, DOI 10.1111/j.1075-122X.2005.00127.x; Larsen LJH, 2009, AM J ROENTGENOL, V193, P574, DOI 10.2214/AJR.08.1528; Limaiem F, 2013, PATHOLOGICA, V105, P357; Mahlab-Guri K, 2015, ISR MED ASSOC J, V17, P476; Mazlan L, 2012, MALAYS J MED SCI, V19, P82; Nath VG, 2017, J CLIN DIAGN RES, V11, pPD14, DOI 10.7860/JCDR/2017/27016.10089; Poyraz N, 2016, IRAN J RADIOL, V13, DOI 10.5812/iranjradiol.20873; Sakurai K, 2011, SURG TODAY, V41, P333, DOI 10.1007/s00595-009-4292-2; Schnitt SJ, 2013, BIOPSY INTERPRETATIO, P47; Schnitt SJ, 2013, BIOPSY INTERPRETATIO, P186; Vinayagam R, 2009, BREAST CARE, V4, P251, DOI 10.1159/000229541	28	0	0	0	0	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	SEP	2018	34	3					215	219		10.5146/tjpath.2018.01431			5	Pathology	Pathology	GT1XU	WOS:000444271800003	29744854	DOAJ Gold			2019-10-28	
J	Rahrotaban, S; Nikparto, N; Yousefizadeh, P; Kharazifard, MJ; Derakhshan, S				Rahrotaban, Sedigheh; Nikparto, Nariman; Yousefizadeh, Parham; Kharazifard, Mohammad Javad; Derakhshan, Samira			Fascin Expression in Ameloblastoma, Odontogenic Keratocyst and Dentigerous Cyst	TURKISH JOURNAL OF PATHOLOGY			English	Article						Ameloblastoma; Dentigerous cyst; Fascin; Odontogenic keratocyst	ACTIN-BUNDLING PROTEIN; EPITHELIAL-CELLS; MOTILITY; TUMORS; CARCINOMA; FILOPODIA; ADHESION; RANKL	Objective: The purpose of this study was to assess and compare fascin expression in 4 lesions which differ in aggressiveness: odontogenic keratocyst, dentigerous cyst and two types of ameloblastoma (solid and unicystic), and to find out whether fascin expression is associated with aggressiveness of these lesions or not. Material and Method: Nine solid ameloblastomas 12 unicystic ameloblastomas, 13 odontogenic keratocyst and 12 dentigerous cyst were assessed in this study. The slides were examined at x400 magnification. Finally the lesions were divided into two groups based on microscopic examination, "low expression" and "high expression". Results: There were no significant differences between the lesions, except that fascin expression was slightly higher in unicystic ameloblastomas in comparison to other groups in intensity and count of the immunostaining cells. Conclusion: The results of this study suggest that local aggressiveness does not result in fascin expression. We suggest more studies with more samples, assessing expression of different proteins be done in the future.	[Rahrotaban, Sedigheh; Derakhshan, Samira] Univ Tehran Med Sci, Sch Dent, Dept Oral & Maxillofacial Pathol, Tehran, Iran; [Nikparto, Nariman] Univ Tehran Med Sci, Sch Dent, Oral & Maxillofacial Surg Resident, Tehran, Iran; [Kharazifard, Mohammad Javad] Univ Tehran Med Sci, Dent Res Ctr, Dent Res Inst, Tehran, Iran	Derakhshan, S (reprint author), Univ Tehran Med Sci, Dept Oral & Maxillofacial Pathol, Tehran, Iran.	sderakhshan@tums.ac.ir	derakhshan, samira/M-6054-2018	derakhshan, samira/0000-0003-4373-9043			Anilkumar N, 2003, EMBO J, V22, P5390, DOI 10.1093/emboj/cdg521; Arjonen A, 2011, CELL ADHES MIGR, V5, P421, DOI 10.4161/cam.5.5.17723; Bhargava D, 2012, ORAL MAXILLOFAC SURG, V16, P163, DOI 10.1007/s10006-011-0302-9; da Silva TA, 2008, ORAL SURG ORAL MED O, V105, P333, DOI 10.1016/j.tripleo.2007.06.009; Dunsche A, 2003, J ORAL PATHOL MED, V32, P486, DOI 10.1034/j.1600-0714.2003.00118.x; Gonçalves Cláudia Kallás, 2012, Braz. Dent. J., V23, P337, DOI 10.1590/S0103-64402012000400005; Hashimoto Y, 2011, J PATHOL, V224, P289, DOI 10.1002/path.2894; Khurana S, 2011, CELL ADHES MIGR, V5, P409, DOI 10.4161/cam.5.5.17644; Lee TK, 2007, CANCER LETT, V254, P308, DOI 10.1016/j.canlet.2007.03.017; Li A, 2010, CURR BIOL, V20, P339, DOI 10.1016/j.cub.2009.12.035; Lin-Jones J, 2007, INVEST OPHTH VIS SCI, V48, P1380, DOI 10.1167/iovs.06-0763; Ma YF, 2013, BIOL OPEN, V2, P1187, DOI 10.1242/bio.20136031; Machesky Laura M, 2010, Commun Integr Biol, V3, P263; Neville BW, 2016, ORAL MAXILLOFACIAL P, P654; Papaspyrou K, 2014, ONCOL LETT, V7, P2041, DOI 10.3892/ol.2014.2007; Poomsawat S, 2007, ORAL SURG ORAL MED O, V104, P666, DOI 10.1016/j.tripleo.2006.08.025; Qian Y, 2010, J ORAL PATHOL MED, V39, P592, DOI 10.1111/j.1600-0714.2009.00882.x; Sharifi-Sistani N, 2011, J CRANIOFAC SURG, V22, P1652, DOI 10.1097/SCS.0b013e31823188e9; Shear M, 2002, ORAL ONCOL, V38, P407, DOI 10.1016/S1368-8375(01)00067-7; Soluk-Tekkesin M, 2018, TURK J PATHOL, V34, P1, DOI 10.5146/tjpath.2017.01410; Sreedhar Gadiputi, 2014, J Nat Sci Biol Med, V5, P112, DOI 10.4103/0976-9668.127300; Tan VY, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-52; Tekkesin MS, 2011, HEAD NECK PATHOL, V5, P248, DOI 10.1007/s12105-011-0271-1; Tubb B, 2002, EXP CELL RES, V275, P92, DOI 10.1006/excr.2002.5486; Xie JJ, 2005, BIOCHEM BIOPH RES CO, V337, P355, DOI 10.1016/j.bbrc.2005.09.055; Yamashiro S, 1998, MOL BIOL CELL, V9, P993, DOI 10.1091/mbc.9.5.993; Yamashiro S, 2012, CRIT REV IMMUNOL, V32, P11, DOI 10.1615/CritRevImmunol.v32.i1.20; Zhang FR, 2008, J HISTOCHEM CYTOCHEM, V56, P193, DOI 10.1369/jhc.7A7353.2007	28	0	0	2	3	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	SEP	2018	34	3					220	224		10.5146/tjpath.2018.01433			5	Pathology	Pathology	GT1XU	WOS:000444271800004	29926463	DOAJ Gold			2019-10-28	
J	Kimyon Comert, G; Kilic, C; Cavusoglu, D; Turkmen, O; Karalok, A; Turan, T; Basaran, D; Boran, N				Kimyon Comert, Gunsu; Kilic, Cigdem; Cavusoglu, Deniz; Turkmen, Osman; Karalok, Alper; Turan, Taner; Basaran, Derman; Boran, Nurettin			Recurrence in Uterine Tumors with Ovarian Sex-Cord Tumor Resemblance: A Case Report and Systematic Review	TURKISH JOURNAL OF PATHOLOGY			English	Review						Uterine neoplasms; Recurrence; UTROSCT; Surgery; Prognosis	CONSERVATIVE-MANAGEMENT; STROMAL TUMORS; UTROSCT; DIFFERENTIATION; METASTASIS; NEOPLASMS; UTERUS	Objective: The aim of this study was to evaluate the prognostic factors of recurrence in uterine tumors resembling ovarian sex-cord tumors (UTROSCT) and to determine clinical-pathological characteristics, treatment options and outcome. Material and Method: An electronic literature search was conducted from 1976 to 2018. After the comprehensive evaluation and conjunction with our case, the study included 79 cases. Results: The median age at initial diagnosis was 49 years (range; 16-86 years). The age was under 40 years in 21 (26.6%) patients. Whereas 68 patients underwent at least hysterectomy, 9 patients had organ sparing surgery. There was necrosis in 4 (5.1%) patients, atypia in 16 (20.3%) patients, and infiltrative tumor border in 34 (43%) patients. At least one mitosis per 10 high power fields was determined in 36 (45.5%) patients. The tumor involved at least part of the myometrium in 54 (68.3%) patients. Median follow-up time was 30 months (range; 3-296 months). Recurrence was determined in 5 (6.3%) patients. The disease free survival (DFS) was significantly related only to surgery type. None of the pathologic features were associated with DFS. The 5-year DFS was 86% and 96% in patients who underwent organ sparing surgery or not, respectively (p=0.038). Conclusion: The accurate pathologic diagnosis of UTROSCT has great value in shaping surgical management and management during the follow-up period. Organ sparing surgery was related to poor DFS. Although recurrence is rare, it should be kept in mind for patients with UTROSCT.	[Kimyon Comert, Gunsu; Kilic, Cigdem; Turkmen, Osman; Karalok, Alper; Turan, Taner; Basaran, Derman; Boran, Nurettin] Univ Hlth Sci, Etlik Zubeyde Hanim Womens Hlth Training & Res Ho, Fac Med, Dept Gynecol Oncol, Ankara, Turkey; [Cavusoglu, Deniz] Univ Hlth Sci, Etlik Zubeyde Hanim Womens Hlth Training & Res Ho, Fac Med, Dept Pathol, Ankara, Turkey	Kimyon Comert, G (reprint author), Univ Hlth Sci, Etlik Zubeyde Hanim Womens Hlth Training & Res Ho, Fac Med, Dept Gynecol Oncol, Ankara, Turkey.	gunsukimyon@gmail.com					Abdullazade S, 2010, ANN DIAGN PATHOL, V14, P432, DOI 10.1016/j.anndiagpath.2010.07.001; Anastasakis E, 2008, INT J GYNECOL OBSTET, V101, P194, DOI 10.1016/j.ijgo.2007.09.029; Aziz Omar, 2009, Cases J, V2, P55, DOI 10.1186/1757-1626-2-55; Baker RJ, 1999, HUM PATHOL, V30, P671, DOI 10.1016/S0046-8177(99)90093-X; Bakula-Zalewska E, 2014, ANN DIAGN PATHOL, V18, P329, DOI 10.1016/j.anndiagpath.2014.08.009; Berretta R, 2009, INT J GYNECOL CANCER, V19, P808, DOI 10.1111/IGC.0b013e3181a417b4; Biermann K, 2008, INT J GYNECOL PATHOL, V27, P58, DOI 10.1097/pgp.0b013e318057faf5; Blake EA, 2014, EUR J OBSTET GYN R B, V181, P163, DOI 10.1016/j.ejogrb.2014.07.050; CAGLAR H, 1983, AM J OBSTET GYNECOL, V145, P639, DOI 10.1016/0002-9378(83)91213-9; Calisir C, 2007, KOREAN J RADIOL, V8, P438, DOI 10.3348/kjr.2007.8.5.438; Cetinkaya N, 2016, ONCOL LETT, V11, P1496, DOI 10.3892/ol.2016.4076; CLEMENT PB, 1976, AM J CLIN PATHOL, V66, P512; Czernobilsky B, 2008, INT J GYNECOL PATHOL, V27, P229, DOI 10.1097/PGP.0b013e3181569a21; de Leval L, 2010, AM J SURG PATHOL, V34, P1749, DOI 10.1097/PAS.0b013e3181f8120c; ELTABBAKH GH, 1995, INT J GYNECOL OBSTET, V48, P113, DOI 10.1016/0020-7292(94)02243-7; Endo D, 2016, TAIWAN J OBSTET GYNE, V55, P751, DOI 10.1016/j.tjog.2015.04.008; FEKETE PS, 1985, INT J GYNECOL PATHOL, V4, P378, DOI 10.1097/00004347-198512000-00011; Gargiulo MN, 2008, REV HPC, V11, P22; Garuti G, 2009, J MINIM INVAS GYN, V16, P236, DOI 10.1016/j.jmig.2008.12.006; Giordano G, 2010, INT J GYNECOL PATHOL, V29, P459, DOI 10.1097/PGP.0b013e3181dfcfdc; Gomes JR, 2016, GYNECOL ONCOL REP, V15, P22, DOI 10.1016/j.gore.2015.11.003; Gutierrez-Pecharroman A, 2014, INT J GYNECOL PATHOL, V33, P151, DOI 10.1097/PGP.0b013e318286b4d9; Hashmi Atif Ali, 2014, Int Arch Med, V7, P47, DOI 10.1186/1755-7682-7-47; Hauptmann S, 2001, VIRCHOWS ARCH, V439, P97, DOI 10.1007/s004280100455; Hillard JB, 2004, GYNECOL ONCOL, V92, P347, DOI 10.1016/j.ygyno.2003.09.011; Irving JA, 2006, MODERN PATHOL, V19, P17, DOI 10.1038/modpathol.3800475; Jeong Kyung Hee, 2015, Obstet Gynecol Sci, V58, P418, DOI 10.5468/ogs.2015.58.5.418; Kabbani W, 2003, INT J GYNECOL PATHOL, V22, P297, DOI 10.1097/01.PGP.0000070846.25718.97; KANTELIP B, 1986, HUM PATHOL, V17, P91, DOI 10.1016/S0046-8177(86)80161-7; Krishnamurthy S, 1998, AM J SURG PATHOL, V22, P1078, DOI 10.1097/00000478-199809000-00006; Liu CY, 2015, INT J CLIN EXP PATHO, V8, P4158; Macak Jirka, 2014, Cesk Patol, V50, P46; Moore M, 2017, HISTOPATHOLOGY, V71, P751, DOI 10.1111/his.13296; Motiwala Nisrin, 2006, Arch Pathol Lab Med, V130, pe74; Nogales FF, 2009, HISTOPATHOLOGY, V54, P471, DOI 10.1111/j.1365-2559.2009.03244.x; O'Meara AC, 2009, GYNECOL ONCOL, V114, P140, DOI 10.1016/j.ygyno.2009.03.021; Pradhan D, 2013, ARCH PATHOL LAB MED, V137, P1832, DOI 10.5858/arpa.2012-0634-RS; Sadeh R, 2017, CASE REP OBSTET GYNE, V2017; Sitic S, 2007, PATHOL ONCOL RES, V13, P153, DOI 10.1007/BF02893492; Staats PN, 2009, AM J SURG PATHOL, V33, P1206, DOI 10.1097/PAS.0b013e3181a7b9cf; Ucar MG, 2016, J CLIN DIAGN RES, V10, pQD5, DOI 10.7860/JCDR/2016/22152.9061; Umeda S, 2014, INT J CLIN EXP PATHO, V7, P1051; USADI RS, 1995, INT J GYNECOL PATHOL, V14, P360, DOI 10.1097/00004347-199510000-00012; Wang JZ, 2003, DIAGN MOL PATHOL, V12, P174, DOI 10.1097/00019606-200309000-00009; Watrowski R, 2015, GYNECOL ENDOCRINOL, V31, P856, DOI 10.3109/09513590.2015.1080682	45	0	1	0	0	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	SEP	2018	34	3					225	233		10.5146/tjpath.2018.01429			9	Pathology	Pathology	GT1XU	WOS:000444271800005	30421416	DOAJ Gold			2019-10-28	
J	Ozsen, M; Yalcinkaya, U; Bilgen, MS; Yazici, Z				Ozsen, Mine; Yalcinkaya, Ulviye; Bilgen, Muhammed Sadik; Yazici, Zeynep			Fibrous Dysplasia: Clinicopathologic Presentation of 36 Cases	TURKISH JOURNAL OF PATHOLOGY			English	Article						Fibrous dysplasia; Bone; McCune-Albright syndrome	FIBROOSSEOUS LESIONS; NATURAL-HISTORY; BONE; OSTEOSARCOMA; MANAGEMENT; MDM2	Objective: Fibrous dysplasia is a slowly progressing bone lesion resulting from displacement of the normal medullary bone with abnormal fibroosseous tissue. The aim of this study was to assess the similarities and differences of our cases in relation to published reports. Material and Method: In this study, the archives of the Uludag University Medical Faculty Department of Pathology were screened for fibrous dysplasia cases between 2004 and 2016. Results: Within the mentioned period, there were 36 cases diagnosed as fibrous dysplasia. There were 21 male, and 15 female cases with an average age of 27.8 +/- 14.8 years (range 7-79 years). The most frequently affected sites were femur, costae, and craniofacial bones. There was one case localized to metacarpal bone, a very rare affection site. There were 4 polyostotic cases including 2 cases of McCune-Albright syndrome. Pelvic bone was affected in the polyostotic type, similar to published reports. Unlike former reports, however, long tubular bones were affected in male patients in our series. In our series, 32 cases had classical fibrous dysplasia, 3 cases had fibrocartilaginous, and one case had fibroosseous variants. Four cases localized to costae were accompanied by aneurysmal bone cyst. The presenting symptom was pathological fractures in a total of 4 cases, 3 localized to the femur, and 1 to the costa. Recurrence occurred in 5 cases treated with curettage. Two of the monostotic fibrous dysplasia cases developed malignant transformation into osteosarcoma. Conclusion: We conclude that our series of fibrous dysplasia cases have slight differences and mainly similar characteristics with the series reported earlier, when all features are taken into consideration.	[Ozsen, Mine; Yalcinkaya, Ulviye] Uludag Univ, Fac Med, Dept Surg Pathol, Bursa, Turkey; [Bilgen, Muhammed Sadik] Uludag Univ, Fac Med, Dept Orthoped, Bursa, Turkey; [Yazici, Zeynep] Uludag Univ, Fac Med, Dept Radiol, Bursa, Turkey	Ozsen, M (reprint author), Uludag Univ, Fac Med, Dept Surg Pathol, Bursa, Turkey.	m.isikoglu@hotmail.com					Batista Kátia Tôrres, 2016, Rev. bras. ortop., V51, P730, DOI 10.1016/j.rboe.2016.10.008; Bianco P, 2000, J BONE MINER RES, V15, P120, DOI 10.1359/jbmr.2000.15.1.120; Boyce AM, 2016, PLAST RECONSTR SURG, V137, P1833, DOI 10.1097/PRS.0000000000002151; Chapurlat RD, 2000, BEST PRACT RES CL RH, V14, P385, DOI 10.1053/berh.1999.0071; Chapurlat RD, 2006, J BONE MINER RES, V21, pP114, DOI 10.1359/JBMR.06S222; Chapurlat RD, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750-1172-7-S1-S3; Cohen MM, 2001, AM J MED GENET, V98, P290, DOI 10.1002/1096-8628(20010201)98:4<290::AID-AJMG1112>3.0.CO;2-F; DiCaprio MR, 2005, J BONE JOINT SURG AM, V87A, P1848, DOI 10.2106/JBJS.D.02942; Doganavsargil B, 2009, ARCH ORTHOP TRAUM SU, V129, P439, DOI 10.1007/s00402-008-0669-8; Dorfman HD, 2010, INT J SURG PATHOL, V18, p62S, DOI 10.1177/1066896910369924; Dujardin F, 2011, MODERN PATHOL, V24, P624, DOI 10.1038/modpathol.2010.229; Faivre L, 2001, AM J MED GENET, V99, P132, DOI 10.1002/1096-8628(2000)9999:999<00::AID-AJMG1135>3.0.CO;2-A; Fitzpatrick KA, 2004, AM J ROENTGENOL, V182, P1389, DOI 10.2214/ajr.182.6.1821389; Fletcher CDM, 2013, WHO CLASSIFICATION T, P352; Ippolito E, 2003, J PEDIATR ORTHOP B, V12, P155, DOI 10.1097/01.bpb.0000064021.41829.94; Li LY, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-349; Nielsen GP, 2013, DIAGNOSTIC PATHOLOGY, P6; Qu N, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000369; RUGGIERI P, 1994, CANCER, V73, P1411, DOI 10.1002/1097-0142(19940301)73:5<1411::AID-CNCR2820730516>3.0.CO;2-T; Saglik Y, 2007, ACTA ORTHOP BELG, V73, P96; Unni KK, 2010, DAHLINS BONE TUMORS, P310, DOI [10.1136/jcp.2010.078501, DOI 10.1136/JCP.2010.078501]; Yalcinkaya U, 2006, TURK J PATHOL, V22, P68; Yoshida A, 2010, MODERN PATHOL, V23, P1279, DOI 10.1038/modpathol.2010.124	23	1	1	0	0	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	SEP	2018	34	3					234	241		10.5146/tjpath.2018.01428			8	Pathology	Pathology	GT1XU	WOS:000444271800006	29744853	DOAJ Gold			2019-10-28	
J	Ekinci, O				Ekinci, Ozgur			Evaluation of All Surgical Margins in Pancreatic Resection Specimens by Proper Grossing Techniques: Surgical Pathology Experience of 285 Cases	TURKISH JOURNAL OF PATHOLOGY			English	Article						Pancreatic cancer; Surgical margin; Macroscopy	CANCER; PANCREATICODUODENECTOMY; ADENOCARCINOMA; INVOLVEMENT	Objective: The aim of this study was to review our series of pancreatic resection specimen handling results and focus on the positivity of the tumor in various retroperitoneal surgical margins. Material and Method: Our archival cases from 2008 to 2018 were retrospectively examined, especially for the surgical margins. The demographics, tumor locations, and the diagnoses were recorded. The state of all of the retropancreatic surgical margins (anterior, posterior, superior, inferior, superior mesenteric vein and artery) were recorded. Results: There were 285 cases, of which 157 were male and 128 female. The mean and median ages were 63.3 and 64, respectively. Invasive ductal adenocarcinoma was the most common diagnosis [202 cases (70.8%)]. Positivity was observed in 90 (31.5%) margins. The majority was in the superior mesenteric vein margin [n:24 (8.4%)]. This was followed by the anterior, resection and SMA margins. Conclusion: Pancreatic resections should macroscopically be sampled by recommended methods in order to detect positivity in individual margins by proper grossing techniques. When this is applied, the superior mesenteric vein margin is the margin most prone to be positive for the tumor.	[Ekinci, Ozgur] Gazi Univ, Fac Med, Dept Med Pathol, TR-06500 Ankara, Turkey	Ekinci, O (reprint author), Gazi Univ, Fac Med, Dept Med Pathol, TR-06500 Ankara, Turkey.	ozzyekinci@hotmail.com					Adsay NV, 2014, AM J SURG PATHOL, V38, P480, DOI 10.1097/PAS.0000000000000165; Campbell F, 2009, HISTOPATHOLOGY, V55, P277, DOI 10.1111/j.1365-2559.2009.03376.x; Fatima J, 2010, ARCH SURG-CHICAGO, V145, P167, DOI 10.1001/archsurg.2009.282; Strobel O, 2017, ANN SURG, V265, P565, DOI 10.1097/SLA.0000000000001731; Verbeke CS, 2006, BRIT J SURG, V93, P1232, DOI 10.1002/bjs.5397; Verbeke CS, 2012, BRIT J SURG, V99, P1036, DOI 10.1002/bjs.8734; Verbeke CS, 2009, HPB, V11, P282, DOI 10.1111/j.1477-2574.2009.00055.x; Wagner M, 2004, BRIT J SURG, V91, P586, DOI 10.1002/bjs.4484; Westgaard A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-5	9	0	0	0	0	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	SEP	2018	34	3					242	246		10.5146/tjpath.2018.01426			5	Pathology	Pathology	GT1XU	WOS:000444271800007	29630087	DOAJ Gold			2019-10-28	
J	Jaafari-Ashkavandi, Z; Yasamin Shirazi, M; Assar, S				Jaafari-Ashkavandi, Zohreh; Yasamin Shirazi, Mehdi; Assar, Sepideh			Desmoplastic Fibroblastoma in Maxillary Alveolar Bone Mimicking An Odontogenic Lesion: A Novel Case Report with Review of Literature	TURKISH JOURNAL OF PATHOLOGY			English	Review						Desmoplastic fibroblastoma; Collagenous fibroma; Intraosseous; Maxilla; Oral cavity	COLLAGENOUS FIBROMA; PALATE	Desmoplastic fibroblastoma (Collagenous fibroma) is a rare benign soft tissue tumor that disseminates widely and can be intramuscular or subcutaneously. There are seven reported cases in the oral cavity so far. We reported a novel case of collagenous fibroma that has been found in the anterior part of maxilla in a 58-year-old woman as an intraosseous radiolucent lesion that has been discovered during routine radiography. Histopathologically, spindle and stellate-shaped fibroblasts in a collagen-rich stroma as well as binucleated and multinucleated fibroblasts with prominent nucleoli were seen. Desmoplastic fibroblastoma could be found in jaw bones and excision of the lesion is curative, and no aggressive growth has been reported.	[Jaafari-Ashkavandi, Zohreh; Assar, Sepideh] Shiraz Univ Med Sci, Shiraz Dent Sch, Dept Oral & Maxillofacial Pathol, Shiraz, Iran; [Yasamin Shirazi, Mehdi] Birjand Univ Med Sci, Birjand Dent Sch, Dept Endodont, Birjand, Iran	Assar, S (reprint author), Shiraz Univ Med Sci, Shiraz Dent Sch, Dept Oral & Maxillofacial Pathol, Shiraz, Iran.	sepideh1986@yahoo.com	jaafari-ashkavandi, zohreh/D-8294-2019; amiri, omolbanin/G-4425-2017	jaafari-ashkavandi, zohreh/0000-0003-4440-7083; amiri, omolbanin/0000-0002-3815-5716	Vice-Chancellery of Shiraz University of Medical Science	The authors thank the Vice-Chancellery of Shiraz University of Medical Science for supporting this research. The authors would like to thank Dr. Sh. Hamedani (DDS, MSc) from the Dental Research Development Centre for helping with the English and editorial assistance in the manuscript.	Bhagalia Sanjay, 2012, J Oral Maxillofac Pathol, V16, P277, DOI 10.4103/0973-029X.99089; Cazal Claudia, 2005, J. Bras. Patol. Med. Lab., V41, P185, DOI 10.1590/S1676-24442005000300008; EVANS HL, 1995, AM J SURG PATHOL, V19, P1077, DOI 10.1097/00000478-199509000-00012; de Sousa SF, 2011, HEAD NECK PATHOL, V5, P175, DOI 10.1007/s12105-010-0239-6; Jham BC, 2013, INT J ORAL MAXILLOF, V4, P21; Kawaguchi Y, 2015, ANN THORAC SURG, V99, pE85, DOI 10.1016/j.athoracsur.2015.01.055; Merriman DJ, 2010, ORTHOPEDICS, V33; Mesquita RA, 2001, ORAL SURG ORAL MED O, V91, P80, DOI 10.1067/moe.2001.109638; Miettinen M, 1998, HUM PATHOL, V29, P676, DOI 10.1016/S0046-8177(98)90275-1; Nielsen GP, 1996, MODERN PATHOL, V9, P781; Park JS, 2014, UROL J, V11, P1849; Sciot R, 1999, MODERN PATHOL, V12, P565; Shimoyama T, 2005, DENTOMAXILLOFAC RAD, V34, P117, DOI 10.1259/dmfr/22428083; Stacy RC, 2013, OPHTHAL PLAST RECONS, V29, pE101, DOI 10.1097/IOP.0b013e31827deffe; Varghese Thomas, 2014, J Indian Soc Pedod Prev Dent, V32, P238, DOI 10.4103/0970-4388.135834; Wilson C, 2000, Ann Diagn Pathol, V4, P165, DOI 10.1016/S1092-9134(00)90040-6	16	0	0	1	1	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	SEP	2018	34	3					247	250		10.5146/tjpath.2015.01355			4	Pathology	Pathology	GT1XU	WOS:000444271800008	28272664	DOAJ Gold			2019-10-28	
J	Khandakar, B; Maiti, M; Dey, S; Sen Ray, P; Bhattacharyya, P; Sarkar, R				Khandakar, Binny; Maiti, Moumita; Dey, Soumit; Sen Ray, Prasenjit; Bhattacharyya, Palas; Sarkar, Ranu			Primary Paediatric Renal Primitive Neuroectodermal Tumor: A Case Report and Review of the Literature	TURKISH JOURNAL OF PATHOLOGY			English	Review						Ewing sarcoma; Kidney; Primitive neuroectodermal tumor	KIDNEY; CHILD	Ewing sarcoma/primitive neuroectodermal tumor (PNET) is a high-grade malignant neoplasm commonly affecting bones of the thoracic region. Primary Ewing sarcoma/PNET of the kidney is exceptional; it commonly affects young adults and is rarely reported in children. Here we describe a case of renal PNET in a 10-year-old girl who presented at our institute with haematuria and abdominal lump. Computer tomography scan revealed a huge mass in the right kidney. Computer tomography-guided aspiration from the mass showed cytomorphological features of a small blue round cell tumor. The patient underwent right radical nephrectomy. Histopathology with supplementary immunohistochemistry confirmed the diagnosis of PNET. She has been receiving treatment with adjuvant chemotherapy post-surgery and is currently disease free. Primary renal PNET is a distinct and rare entity. This tumor is very aggressive with low survival rate, even with a multi-disciplinary approach. We reported the case because it is rare in children, poses diagnostic challenges, is aggressive in behaviour and responds poorly to treatment.	[Khandakar, Binny; Maiti, Moumita; Dey, Soumit; Sen Ray, Prasenjit; Bhattacharyya, Palas; Sarkar, Ranu] Nil Ratan Sircar Med Coll & Hosp, Dept Pathol, Kolkata, India	Khandakar, B (reprint author), Nil Ratan Sircar Med Coll & Hosp, Dept Pathol, Kolkata, India.	binikhandakar@gmail.com					Aghili M, 2012, RARE TUMORS, V4, P49, DOI 10.4081/rt.2012.e15; Citak EC, 2009, PEDIATR HEMAT ONCOL, V26, P481, DOI 10.1080/08880010902754792; Funahashi Y, 2009, AKTUEL UROL, V40, P247, DOI 10.1055/s-0028-1098827; Giridhar P, 2015, J EGYPT NATL CANCER, V27, P235, DOI 10.1016/j.jnci.2015.05.001; Jimenez RE, 2002, AM J SURG PATHOL, V26, P320, DOI 10.1097/00000478-200203000-00005; Maeda M, 2008, PEDIATR BLOOD CANCER, V50, P180, DOI 10.1002/pbc.20831; Mandal PK, 2012, INDIAN J MED PAEDIAT, V33, P130, DOI 10.4103/0971-5851.99754; Seemayer T A, 1975, Perspect Pediatr Pathol, V2, P151; Stout A. P., 1918, P NY PATHOL SOC, V12, P2; Yang Y, 2007, ANAL QUANT CYTOL, V29, P221	10	1	1	1	1	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	SEP	2018	34	3					251	254		10.5146/tjpath.2015.01340			4	Pathology	Pathology	GT1XU	WOS:000444271800009	28272661	DOAJ Gold			2019-10-28	
J	Tepeoglu, M; Uner, H; Haberal, AN; Ozen, O; Kuscu, E				Tepeoglu, Merih; Uner, Halit; Haberal, A. Nihan; Ozen, Ozlem; Kuscu, Esra			Cloacogenic Adenocarcinoma of the Vulva: A Case Report and Review of the Literature	TURKISH JOURNAL OF PATHOLOGY			English	Review						Vulvar neoplasms; Adenocarcinoma; Cloacogenic; Metastasis	VILLOGLANDULAR ADENOCARCINOMA; ORIGIN	Primary adenocarcinoma of the vulva, unrelated to the native glands of perineum is an extremely rare neoplasm. Despite awareness of this lesion for over 40 years, the origin is not beyond speculation. The most reasonable hypothesis is based on the remnants of cloacal differentiation during early days of life. Here we report the case of a 60-year-old patient with a vulvar mass, who underwent partial vulvectomy and bilateral regional lymph node dissection. The tumor was composed of papillary and complex glandular structures and exhibited diffuse positivity for cytokeratin 20 and polyclonal CEA, CDX2, and focal positivity with cytokeratin 7. Unlike the indolent behavior of this malignant neoplasm according to the literature, we found two metastatic inguinal lymph nodes. She did not receive adjuvant therapy and is still alive, free of disease 38 months after surgery. We present different aspects of vulvar adenocarcinomas with a case report.	[Tepeoglu, Merih; Haberal, A. Nihan; Ozen, Ozlem] Baskent Univ, Dept Pathol, Sch Med, Ankara, Turkey; [Uner, Halit] Hacettepe Univ, Sch Med, Ankara, Turkey; [Kuscu, Esra] Baskent Univ, Sch Med, Dept Obstet & Gynecol, Ankara, Turkey	Tepeoglu, M (reprint author), Baskent Univ, Tip Fak, Patol Anabilim Dali, Ankara, Turkey.	merihdemirel@yahoo.com.tr					Dube V, 2004, HUM PATHOL, V35, P377, DOI 10.1016/j.humpath.2003.05.002; KENNEDY JC, 1993, J REPROD MED, V38, P113; LEE KC, 1990, J AM ACAD DERMATOL, V23, P1005, DOI 10.1016/0190-9622(90)70323-A; Liu SH, 2003, J FORMOS MED ASSOC, V102, P49; Novak ER, 1974, GYNECOLOGIC OBSTET P, P26; Rodriguez A, 2001, GYNECOL ONCOL, V83, P409, DOI 10.1006/gyno.2001.6372; Staats PN, 2014, AM J SURG PATHOL, V38, P593, DOI 10.1097/PAS.0000000000000157; STERN BD, 1969, AM J OBSTET GYNECOL, V104, P255, DOI 10.1016/0002-9378(69)90672-3; TILTMAN AJ, 1978, OBSTET GYNECOL, V51, pS30; Wilkinson EJ, 2011, BLAUSTEIN'S PATHOLOGY OF THE FEMALE GENITAL TRACT, SIXTH EDITION, P55, DOI 10.1007/978-1-4419-0489-8_2; Willen R, 1999, GYNECOL ONCOL, V74, P298, DOI 10.1006/gyno.1999.5433; Zaidi SNH, 2001, SOUTHERN MED J, V94, P744, DOI 10.1097/00007611-200107000-00025	12	0	0	0	0	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	SEP	2018	34	3					255	258		10.5146/tjpath.2015.01359			4	Pathology	Pathology	GT1XU	WOS:000444271800010	28272666	DOAJ Gold			2019-10-28	
J	Kaur, A; Suranagi, V; Patil, K; Bannur, H				Kaur, Amandeep; Suranagi, Vijayalaxmi; Patil, Kamal; Bannur, Hema			Neu-Laxova Syndrome: An Unusual Association with Kyphosis	TURKISH JOURNAL OF PATHOLOGY			English	Article						Neu-Laxova syndrome; Lissencephaly; Kyphosis; PHGDH mutation		The Neu-Laxova syndrome is a rare autosomal recessive condition associated with neuro-ectodermal abnormalities and other patterns of severe malformations leading to prenatal or early postnatal lethality. Association with kyphosis is an extremely rare finding. A fetus born from a 25-year-old gravida at 30 weeks gestation was diagnosed with Dandy Walker syndrome with severe intrauterine growth restriction on ultrasonography. On post-mortem examination after termination of pregnancy, the fetus showed facial dysmorphology with microcephaly, smooth shiny skin and kyphosis. Skin histology showed hyperkeratosis, edema and increased subcutaneous fat suggestive of ichthyosis. On the basis of gross and microscopic features seen, a diagnosis of Neu-Laxova syndrome was made.	[Kaur, Amandeep; Suranagi, Vijayalaxmi; Bannur, Hema] KLE Univ, Dept Pathol, Belgaum, Karnataka, India; [Patil, Kamal] KLE Univ, Dept Obstet & Gynaecol, Belgaum, Karnataka, India	Kaur, A (reprint author), KLE Univ, Dept Pathol, Belgaum, Karnataka, India.	amanprince88@gmail.com	Bannur, Hema/S-3634-2019; patil, kamal/Q-1240-2019				Acuna-Hidalgo R, 2014, AM J HUM GENET, V95, P285, DOI 10.1016/j.ajhg.2014.07.012; Aslan H, 2002, BMC PREGNANCY CHILDB, V2, P1; Ferechte ER, 2015, KEELINGS FETAL NEONA, P709; Hemalatha A, 2013, INT J MED APPL SCI, V2, P186; Jones K, 1997, SMITHS RECOGNIZABLE, P174; KARIMINEJAD MH, 1987, AM J MED GENET, V28, P17, DOI 10.1002/ajmg.1320280104; LAZJUK GI, 1979, AM J MED GENET, V3, P261, DOI 10.1002/ajmg.1320030304; SCOTT CI, 1981, AM J MED GENET, V9, P165, DOI 10.1002/ajmg.1320090211; Squier W, 2014, PEDIATRIC AND PERINATAL AUTOPSY MANUAL, P173; Tarim E, 2010, J TURK-GER GYNECOL A, V11, P225, DOI 10.5152/jtgga.2010.44; Tos T, 2006, AEGEAN PATHOLOGY J, V3, P5	11	0	0	0	0	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	SEP	2018	34	3					259	261		10.5146/tjpath.2015.01353			3	Pathology	Pathology	GT1XU	WOS:000444271800011	28272663	DOAJ Gold			2019-10-28	
J	Shukla, S; Sehgal, S; Prabhat, P; Dewan, K				Shukla, Shailaja; Sehgal, Shivali; Prabhat, Pawani; Dewan, Khushboo			Congenital Presentation of a Solitary Superficial Angiomyxoma in the Parotid Region Masquerading as Parotid Tumor	TURKISH JOURNAL OF PATHOLOGY			English	Article						Congenital; Superficial angiomyxoma; Parotid		Superficial angiomyxoma is a rare cutaneous and benign lesion. We present a case of congenital presentation of a superficial angiomyxoma in the parotid region in a 9-year- old female that was misdiagnosed as a parotid tumor. Appropriate diagnosis is important since such lesions have a good prognosis and rarely affect deeper structures. Possibility of superficial angiomyxoma should be kept in mind in the differential diagnosis of lesions of the parotid region.	[Shukla, Shailaja; Sehgal, Shivali; Prabhat, Pawani; Dewan, Khushboo] Lady Hardinge Med Coll & Hosp, Dept Pathol, Delhi, India	Sehgal, S (reprint author), Lady Hardinge Med Coll & Hosp, Dept Pathol, Delhi, India.	shivalisehgal@gmail.com					ALLEN PW, 1988, AM J SURG PATHOL, V12, P519, DOI 10.1097/00000478-198807000-00003; Bedlow AJ, 1997, CLIN EXP DERMATOL, V22, P237, DOI 10.1046/j.1365-2230.1997.2690682.x; Fetsch JF, 2001, HUM PATHOL, V32, P704, DOI 10.1053/hupa.2001.25903; Khadilkar U N, 2007, Kathmandu Univ Med J (KUMJ), V5, P546; Ravindra SV, 2012, CASE REP MED, DOI 10.1155/2012/859021; Rodriguez PR, 2012, ACTA OTORRINOLAR ESP, V63, P147, DOI 10.1016/j.otorri.2010.11.014; ROSANOWSKI F, 1993, LARYNGO RHINO OTOL, V72, P618, DOI 10.1055/s-2007-997967; Shanthi V, 2011, J BIOSCI TECH, V2, P318	8	0	0	0	0	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	SEP	2018	34	3					262	264		10.5146/tjpath.2015.01358			3	Pathology	Pathology	GT1XU	WOS:000444271800012	28272665	DOAJ Gold			2019-10-28	
J	Zerehpoosh, FB; Samadian, M; Azhari, VS; Barangi, M; Ebrahimzadeh, K; Heidary, M				Zerehpoosh, Farahnaz Bidari; Samadian, Mohammad; Azhari, Vahideh Sadat; Barangi, Maryam; Ebrahimzadeh, Kaveh; Heidary, Mahnaz			A Case Report of Calcifying Pseudoneoplasm of the Neuraxis: An Incidental Finding After a Car Accident	TURKISH JOURNAL OF PATHOLOGY			English	Article						Calcifying pseudoneoplasm of neuraxis; CAPNON	NERVOUS-SYSTEM	Calcifying pseudoneoplasms of the neuraxis arc rare, poorly understood lesions that can occur anywhere in the central nervous system without any age or sex predilection. Their pathogenesis is still controversial. Patients can present with various symptoms due to lesion location and only few cases have been discovered incidentally. We present a 25-year-old male referred to our hospital after a car accident. Computed tomography scan and magnetic resonance imaging was done because of the patient's head trauma and a calcified intracranial lesion was found and excised surgically. Pathologic evaluation of the specimen was consistent with the diagnosis of calcifying pseudoneoplasm of the neuraxis.	[Zerehpoosh, Farahnaz Bidari; Azhari, Vahideh Sadat; Barangi, Maryam; Heidary, Mahnaz] Loghman Hosp, Dept Pathol, Tehran, Iran; [Samadian, Mohammad; Ebrahimzadeh, Kaveh] Loghman Hosp, Neurosurg, Tehran, Iran	Heidary, M (reprint author), Loghman Hosp, Dept Pathol, Tehran, Iran.	mahnaz_h1365@yahoo.com					Aiken AH, 2009, AM J NEURORADIOL, V30, P1256, DOI 10.3174/ajnr.A1505; Alshareef M, 2016, WORLD NEUROSURG, V85, DOI 10.1016/j.wneu.2015.08.055; Bartanusz V, 2013, J NEUROSURG-SPINE, V18, P367, DOI 10.3171/2013.1.SPINE12810; Donev K, 2010, ARCH PATHOL LAB MED, V134, P404, DOI 10.1043/1543-2165-134.3.404; Kerr EE, 2013, J NEUROSURG, V118, P896, DOI 10.3171/2013.1.JNS121755; Lyapichev K, 2014, BMJ CASE REP, V2014; Miller EA, 1922, SURG GYNECOL OBSTET, V34, P786; Mohapatra I, 2010, CLIN NEUROPATHOL, V29, P223; Nonaka Y, 2012, J NEUROL SURG REP, V73, P41, DOI 10.1055/s-0032-1321503; Pereira D B, 2010, AJNR Am J Neuroradiol, V31, pE51, DOI 10.3174/ajnr.A2096; Yan X, 2011, CLIN NEUROPATHOL, V30, P197, DOI 10.5414/NP300360	11	2	2	0	0	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	SEP	2018	34	3					265	268		10.5146/tjpath.2015.01361			4	Pathology	Pathology	GT1XU	WOS:000444271800013	28272667	DOAJ Gold			2019-10-28	
J	Kuzyk, J; Boiko, O; Stetsko, T				Kuzyk, Julia; Boiko, Oksana; Stetsko, Taras			Fibromuscular Dysplasia of the Coronary Arteries: A Case Report and Review of the Literature	TURKISH JOURNAL OF PATHOLOGY			English	Review						Aneurysm; Coronary arteries; Fibromuscular dysplasia; Pulmonary atresia	RENAL-ARTERIES; DISEASE; HYPERTENSION; CLASSIFICATION; DISSECTION; PATIENT; DEATH	Fibromuscular dysplasia is a nonatherosclerotic and non-inflammatory vascular disease with primary lesion of renal and internal carotid arteries. We present a neonatal case of fibromuscular dysplasia who died on the second day of life. The newborn suffered from fibromuscular dysplasia of the coronary arteries and a congenital heart defect. The interesting feature of this case was the formation of aneurysms of the coronary arteries with pulmonary atresia. This case demonstrates a casuistically rare form of association between fibromuscular dysplasia of the coronary arteries and pulmonary artery atresia.	[Kuzyk, Julia] Danylo Halytsky Lviv Natl Med Univ, Dept Med, Lvov, Ukraine; [Boiko, Oksana] Lviv Reg Pathol Bur, Lvov, Ukraine; [Stetsko, Taras] Dist Hosp, Gdansk, Poland	Boiko, O (reprint author), Lviv Reg Pathol Bur, Lvov, Ukraine.	bo_ok.lviv@mail.ru		Kuzyk, Yuliia/0000-0002-5235-5861			Begelman SM, 2000, CURR OPIN RHEUMATOL, V12, P41, DOI 10.1097/00002281-200001000-00007; Biando C, 2014, CARDIOVASCULAR MED, V17, P283; Curry Thomas K, 2003, Semin Vasc Surg, V16, P190, DOI 10.1016/S0895-7967(03)00024-3; DEMENDONCA WC, 1981, AM J CLIN PATHOL, V75, P749, DOI 10.1093/ajcp/75.5.749; HARRISON EG, 1971, MAYO CLIN PROC, V46, P161; Huizar Jose F, 2006, J Invasive Cardiol, V18, pE99; JAMES TN, 1990, AM J CARDIOL, V65, pG12; KINCAID OW, 1968, AMER J ROENTGENOL RA, V104, P271, DOI 10.2214/ajr.104.2.271; Kuzyk YuI, 2006, HEART VESSELS, V4, P101; Leadbetter WF, 1938, J UROLOGY, V39, P611, DOI 10.1016/S0022-5347(17)71895-2; LIE JT, 1987, HUM PATHOL, V18, P654, DOI 10.1016/S0046-8177(87)80368-4; LUSCHER TF, 1986, NEPHRON, V44, P109, DOI 10.1159/000184059; MCCORMACK LJ, 1958, AM J PATHOL, V34, P582; Mortensen KH, 2009, CATHETER CARDIO INTE, V74, P710, DOI 10.1002/ccd.22115; Pannier-Moreau I, 1997, J HYPERTENS, V15, P1797, DOI 10.1097/00004872-199715120-00092; Pate GE, 2005, CATHETER CARDIO INTE, V64, P138, DOI 10.1002/ccd.20246; Persu A, 2012, EUR J CLIN INVEST, V42, P338, DOI 10.1111/j.1365-2362.2011.02577.x; Pretty HC, 1931, BRIT MED J, V1, P667, DOI 10.1136/bmj.1.3667.667; Ropponen KM, 1999, J CLIN PATHOL, V52, P541, DOI 10.1136/jcp.52.7.541; SCHIEVINK WI, 1994, STROKE, V25, P2492, DOI 10.1161/01.STR.25.12.2492; SCHIEVINK WI, 1989, NEUROSURGERY, V25, P482; Slovut DP, 2004, NEW ENGL J MED, V350, P1862, DOI 10.1056/NEJMra032393; STANLEY JC, 1975, ARCH SURG-CHICAGO, V110, P561; Suzuki H, 1999, HEART, V82, P251, DOI 10.1136/hrt.82.2.251; Zack F, 1996, INT J LEGAL MED, V108, P215, DOI 10.1007/BF01369795	25	2	2	0	2	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	SEP	2018	34	3					269	273		10.5146/tjpath.2015.01341			5	Pathology	Pathology	GT1XU	WOS:000444271800014	28272662	DOAJ Gold			2019-10-28	
J	Aida, S; Aida, J; Naoi, M; Kato, M; Tsuura, Y; Natsume, I; Takubo, K				Aida, Shinsuke; Aida, Junko; Naoi, Miho; Kato, Mai; Tsuura, Yukio; Natsume, Ichiro; Takubo, Kaiyo			Measurement of telomere length in cells from pleural effusion: Asbestos exposure causes telomere shortening in pleural mesothelial cells	PATHOLOGY INTERNATIONAL			English	Article						asbestos; malignant mesothelioma; mesothelial cell; pleural effusion; telomere length	MALIGNANT MESOTHELIOMA; DIFFERENTIAL-DIAGNOSIS; LINGUAL EPITHELIUM; FISH; PATHOGENESIS; GUIDELINES; STATEMENT; P16	We estimated the telomere lengths of neoplastic and non-neoplastic mesothelial cells and examined their correlation with asbestos exposure and the expression of markers of mesothelial malignancy. Cell blocks of pleural effusion obtained from 35 cases of non-neoplastic disease (NN), 12 cases of malignant mesothelioma (MM) and 12 cases of carcinomatous effusion due to lung adenocarcinoma (LA) were examined. Fifteen of the 35 NN cases had pleural plaques (NNpp+) suggestive of asbestos exposure, and the other 20 cases had no pleural plaques (NNpp-). Telomere length was measured using the tissue quantitative fluorescence in situ hybridization method, and expressed as normalized telomere-to-centromere ratio. NN cases had significantly longer telomeres than MM (P<0.001) and LA (P<0.001) cases. Telomeres in NNpp+ cases were slightly shorter than those of NNpp- cases (P=0.047). MM and LA showed almost the same telomere length. NN cases with shorter telomeres tended to show aberrant expression of epithelial membrane antigen (EMA), CD146, glucose transporter 1 (GLUT1) and IGF-II messenger RNA-binding protein 3 (IMP3). These results suggest that telomere shortening and subsequent genetic instability play an important role in the development of MM. Measurement of telomere length of cells in pleural effusion might be helpful for earlier detection of MM.	[Aida, Shinsuke; Kato, Mai] Int Univ Hlth & Welf, Mita Hosp, Dept Pathol, Tokyo, Japan; [Aida, Junko; Naoi, Miho; Takubo, Kaiyo] Tokyo Metropolitan Inst Gerontol, Res Team Geriatr Pathol, Tokyo, Japan; [Tsuura, Yukio] Yokosuka Kyosai Hosp, Dept Pathol, Yokosuka, Kanagawa, Japan; [Natsume, Ichiro] Yokosuka Kyosai Hosp, Dept Resp Med, Yokosuka, Kanagawa, Japan	Aida, S (reprint author), Int Univ Hlth & Welf, Mita Hosp, Dept Pathol, Minato Ku, 1-4-3 Mita, Tokyo 1088329, Japan.	aidas@iuhw.ac.jp	Aida, Junko/Q-5697-2019	Aida, Junko/0000-0003-4923-5540	JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JP C26460457]	The authors thank Dr. Minoru Ohkochi for advice about subject selection and Mr. Satoshi Suzuki for technical assistance. This study was supported by JSPS KAKENHI Grant number JP C26460457.	Aida J, 2008, EXP GERONTOL, V43, P833, DOI 10.1016/j.exger.2008.06.001; Aida J, 2007, HUM PATHOL, V38, P1192, DOI 10.1016/j.humpath.2006.11.023; Aida J, 2011, J PATHOL, V223, P410, DOI 10.1002/path.2817; Aida J, 2010, EUR J CANCER, V46, P430, DOI 10.1016/j.ejca.2009.10.018; Aida S, 2015, RESPIRATION, V90, P321, DOI 10.1159/000437357; Choe N, 1998, AM J RESP CELL MOL, V19, P226, DOI 10.1165/ajrcmb.19.2.3111; Galateau-Salle F, 2015, WHO CLASSIFICATION T, P156; Hiroshima K, 2016, DIAGN CYTOPATHOL, V44, P591, DOI 10.1002/dc.23490; Hjerpe A, 2015, CYTOJOURNAL, V12, DOI 10.4103/1742-6413.170726; Huang SXL, 2011, J TOXICOL ENV HEAL B, V14, P179, DOI 10.1080/10937404.2011.556051; Husain AN, 2009, ARCH PATHOL LAB MED, V133, P1317, DOI 10.1043/1543-2165-133.8.1317; Jaouen A, 2016, ANN PATHOL, V36, P111, DOI 10.1016/j.annpat.2016.01.005; Kurabayashi R, 2008, HUM PATHOL, V39, P1647, DOI 10.1016/j.humpath.2008.04.005; Lagniau S, 2017, ONCOTARGET, V8, P53751, DOI 10.18632/oncotarget.17910; LANPHEAR BP, 1992, J OCCUP ENVIRON MED, V34, P718; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; Linton A, 2012, CRIT REV ONCOL HEMAT, V84, P200, DOI 10.1016/j.critrevonc.2012.03.001; Minato H, 2014, AM J CLIN PATHOL, V141, P85, DOI 10.1309/AJCP5KNL7QTELLYI; Nabeshima K, 2016, DIAGN CYTOPATHOL, V44, P774, DOI 10.1002/dc.23501; Nakamura KI, 2002, J INVEST DERMATOL, V119, P1014, DOI 10.1046/j.1523-1747.2002.19523.x; O'Sullivan JN, 2004, CYTOM PART A, V58A, P120, DOI 10.1002/cyto.a.20006; OHASHI M, 1980, EXP GERONTOL, V15, P121, DOI 10.1016/0531-5565(80)90083-2; Qi F, 2013, AM J PATHOL, V183, P1654, DOI 10.1016/j.ajpath.2013.07.029; Sekido Y, 2013, CARCINOGENESIS, V34, P1413, DOI 10.1093/carcin/bgt166; Shiraishi H, 2009, SCAND J GASTROENTERO, V44, P538, DOI 10.1080/00365520902718705; Takubo K, 2002, EXP GERONTOL, V37, P523, DOI 10.1016/S0531-5565(01)00218-2; WAGNER J C, 1960, Br J Ind Med, V17, P260; Yang HN, 2006, P NATL ACAD SCI USA, V103, P10397, DOI 10.1073/pnas.0604008103; Yang HN, 2008, CURR TREAT OPTION ON, V9, P147, DOI 10.1007/s11864-008-0067-z	29	0	0	1	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	SEP	2018	68	9					503	508		10.1111/pin.12710			6	Pathology	Pathology	GS8GQ	WOS:000443947100001	30098092				2019-10-28	
J	Gottlieb, Y; Elhasid, R; Berger-Achituv, S; Brazowski, E; Yerushalmy-Feler, A; Cohen, S				Gottlieb, Yehonatan; Elhasid, Ronit; Berger-Achituv, Sivan; Brazowski, Eli; Yerushalmy-Feler, Anat; Cohen, Shlomi			Neutrophil extracellular traps in pediatric inflammatory bowel disease	PATHOLOGY INTERNATIONAL			English	Article						children; Crohn's disease; neutrophil extracellular traps; ulcerative colitis	EXPERIMENTAL COLITIS; CROHNS-DISEASE; ULCERATIVE-COLITIS; ACTIVITY INDEX; IN-VITRO; EXPRESSION; VALIDATION; MYELOPEROXIDASE; DEPLETION; ELASTASE	Neutrophil extracellular traps (NETs) are fibers composed of chromatin and neutrophil proteins released by activated neutrophils. NETs trap and kill microbes, activate dendritic and T cells, and are implicated in autoimmune and vascular diseases. The pathogenesis of inflammatory bowel disease (IBD) is multifactorial and characterized by chronic active mucosal inflammation with controversial contribution of neutrophils. Our aim is to describe the involvement of NETs in pediatric IBD. We retrospectively examined biopsies from the small bowel and colon of children at diagnosis of Crohn's disease (CD) or ulcerative colitis (UC). The biopsies were labeled for neutrophil elastase, myeloperoxidase, DNA, chromatin and histones in order to identify NETs. Samples of two children with normal colonoscopy served as controls. Twelve patients (5 boys) were included, 6 with CD and 6 with UC. Their average age was 12.2 years (range 5-16). NETs were found in all samples from patients and not in the samples from the two controls. This is the first demonstration of the presence of NETs in biopsies taken from the small bowel and colon of pediatric patients with IBD. More studies are needed in order to identify the role of NETs in CD/UC pathogenesis.	[Gottlieb, Yehonatan; Berger-Achituv, Sivan] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dana Dwek Childrens Hosp, Sackler Fac Med,Res Lab Pediat Hematooncol, Tel Aviv, Israel; [Elhasid, Ronit; Berger-Achituv, Sivan] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dana Dwek Childrens Hosp, Sackler Fac Med,Dept Pediat Hematooncol, Tel Aviv, Israel; [Brazowski, Eli] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dana Dwek Childrens Hosp, Sackler Fac Med,Dept Pathol, Tel Aviv, Israel; [Yerushalmy-Feler, Anat; Cohen, Shlomi] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dana Dwek Childrens Hosp, Sackler Fac Med,Pediat Gastroenterol Unit, Tel Aviv, Israel	Cohen, S (reprint author), Tel Aviv Med Ctr & Sch Med, Dana Dwek Childrens Hosp, Pediat Gastroenterol Unit, 6 Weizman St, IL-6423906 Tel Aviv, Israel.	shlomico@tlvmc.gov.il					ADEYEMI EO, 1992, SCAND J GASTROENTERO, V27, P139, DOI 10.3109/00365529209165434; Bennike TB, 2015, INFLAMM BOWEL DIS, V21, P2052, DOI 10.1097/MIB.0000000000000460; Bernstein CN, 2017, ALIMENT PHARM THER, V46, P911, DOI 10.1111/apt.14338; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Brinkmann V, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00413; Brinkmann V, 2012, J CELL BIOL, V198, P773, DOI 10.1083/jcb.201203170; BUELL MG, 1994, DIGEST DIS SCI, V39, P2575, DOI 10.1007/BF02087693; Daig R, 1996, GUT, V38, P216, DOI 10.1136/gut.38.2.216; Daperno M, 2004, GASTROINTEST ENDOSC, V60, P505, DOI 10.1016/S0016-5107(04)01878-4; Diefenbach KA, 2006, WORLD J GASTROENTERO, V12, P3204, DOI 10.3748/wjg.v12.i20.3204; Fuchs TA, 2007, J CELL BIOL, V176, P231, DOI 10.1083/jcb.200606027; Ginzberg HH, 2001, AM J PHYSIOL-GASTR L, V281, pG705; He ZX, 2016, THROMB HAEMOSTASIS, V115, P738, DOI 10.1160/TH15-09-0710; HYAMS JS, 1991, J PEDIATR GASTR NUTR, V12, P439, DOI 10.1097/00005176-199105000-00005; Kankuri E, 2001, J PHARMACOL EXP THER, V298, P1128; Kaser A, 2010, ANNU REV IMMUNOL, V28, P573, DOI 10.1146/annurev-immunol-030409-101225; Kuhl AA, 2007, GASTROENTEROLOGY, V133, P1882, DOI 10.1053/j.gastro.2007.08.073; Maloy KJ, 2011, NATURE, V474, P298, DOI 10.1038/nature10208; Metzler KD, 2011, BLOOD, V117, P953, DOI 10.1182/blood-2010-06-290171; Nagao Y, 1997, Nihon Yakurigaku Zasshi, V109, P41; Natsui M, 1997, J GASTROEN HEPATOL, V12, P801, DOI 10.1111/j.1440-1746.1997.tb00375.x; Nemoto Y, 2008, INFLAMM BOWEL DIS, V14, P1491, DOI 10.1002/ibd.20531; Nielsen OH, 1997, SCAND J GASTROENTERO, V32, P1028, DOI 10.3109/00365529709011220; Papayannopoulos V, 2010, J CELL BIOL, V191, P677, DOI 10.1083/jcb.201006052; Pilsczek FH, 2010, J IMMUNOL, V185, P7413, DOI 10.4049/jimmunol.1000675; Rutgeerts P, 2005, NEW ENGL J MED, V353, P2462, DOI 10.1056/NEJMoa050516; Sanchez-Munoz F, 2010, INFLAMM BOWEL DIS, V16, P1267, DOI 10.1002/ibd.21155; Savchenko AS, 2011, PATHOL INT, V61, P290, DOI 10.1111/j.1440-1827.2011.02651.x; Skrzeczynska-Moncznik J, 2012, J IMMUNOL, V189, P1611, DOI 10.4049/jimmunol.1103293; Turner D, 2007, GASTROENTEROLOGY, V133, P423, DOI 10.1053/j.gastro.2007.05.029; Turner D, 2018, J PEDIATR GASTR NUTR, V67, P257, DOI 10.1097/MPG.0000000000002035; Turner D, 2010, AM J GASTROENTEROL, V105, P2085, DOI 10.1038/ajg.2010.143; Warnatsch A, 2015, SCIENCE, V349, P316, DOI 10.1126/science.aaa8064; Williams IR, 2007, GASTROENTEROLOGY, V133, P2049, DOI 10.1053/j.gastro.2007.10.031; YAMADA T, 1991, INFLAMMATION, V15, P399, DOI 10.1007/BF00917356; Zhang Rong, 2011, Inflammation & Allergy Drug Targets, V10, P39	36	3	3	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	SEP	2018	68	9					517	523		10.1111/pin.12715			7	Pathology	Pathology	GS8GQ	WOS:000443947100003	30133056				2019-10-28	
J	Hyodo, T; Kanzawa, M; Hara, S; Takahashi, K; Ogawa, S; Furukawa, J; Fujisawa, M; Kobayashi, A; Kuroda, N; Itoh, T				Hyodo, Toshiki; Kanzawa, Maki; Hara, Shigeo; Takahashi, Kosuke; Ogawa, Satoshi; Furukawa, Junya; Fujisawa, Masato; Kobayashi, Anna; Kuroda, Naoto; Itoh, Tomoo			Chromophobe renal cell carcinoma with sarcomatoid differentiation containing various heterologous components	PATHOLOGY INTERNATIONAL			English	Article						chondrosarcoma; chromophobe RCC; osteosarcoma lipomatous area; sarcomatoid	OSTEOSARCOMA-LIKE DIFFERENTIATION; TRANSFORMATION; GRADE	Renal cell carcinoma (RCC) occasionally has sarcomatoid differentiation and rarely contains heterologous components. We report a case of chromophobe RCC with sarcomatoid differentiation that had various heterologous components including a unique lipomatous area. The patient was an 83-year-old woman with a palpable mass in the left lower abdomen. Grossly, the tumor was 14cm in diameter and had yellowish-to-whitish color with focal necrosis and hemorrhage. Histologically, the tumor was composed of an eosinophilic subtype of chromophobe RCC with sarcomatoid differentiation including mainly chondrosarcoma, some osteosarcoma and a lipomatous area. The heterologous components of sarcomatoid RCC are usually osteosarcoma or chondrosarcoma, and sarcomatoid RCC with multiple heterologous components is extremely rare.	[Hyodo, Toshiki; Hara, Shigeo; Itoh, Tomoo] Kobe Univ Hosp, Dept Diagnost Pathol, Kobe, Hyogo, Japan; [Kanzawa, Maki; Takahashi, Kosuke; Ogawa, Satoshi; Furukawa, Junya; Fujisawa, Masato] Kobe Univ Hosp, Dept Urol, Kobe, Hyogo, Japan; [Kobayashi, Anna] Hyogo Canc Ctr, Dept Diagnost Pathol, Akashi, Hyogo, Japan; [Kuroda, Naoto] Japanese Red Cross Kochi Hosp, Dept Diagnost Pathol, Kochi, Japan	Itoh, T (reprint author), Kobe Univ Hosp, Dept Diagnost Pathol, Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	tomitoh@med.kobe-u.ac.jp					Aird JJ, 2017, INT J SURG PATHOL, V25, P745, DOI 10.1177/1066896917716772; Anila KR, 2012, INT J SURG PATHOL, V20, P416, DOI 10.1177/1066896911429298; Bi M, 2016, P NATL ACAD SCI USA, V113, P2170, DOI 10.1073/pnas.1525735113; Cheville JC, 2004, AM J SURG PATHOL, V28, P435, DOI 10.1097/00000478-200404000-00002; Cheville JC, 2012, AM J SURG PATHOL, V36, P851, DOI 10.1097/PAS.0b013e3182496895; Gira FA, 2010, INT J SURG PATHOL, V18, P419, DOI 10.1177/1066896908329414; Husain A, 2014, ANAL QUANT CYTOL, V36, P235; Itoh T, 2002, AM J SURG PATHOL, V26, P1358, DOI 10.1097/01.PAS.0000029062.55439.A7; Jones TD, 2005, CANCER-AM CANCER SOC, V104, P1195, DOI 10.1002/cncr.21288; Kuroda N, 2003, HISTOL HISTOPATHOL, V18, P165, DOI 10.14670/HH-18.165; Li YF, 2010, UROL INT, V85, P470, DOI 10.1159/000319420; Magro G, 2005, VIRCHOWS ARCH, V447, P894, DOI 10.1007/s00428-005-0026-z; Moch H, 2016, WHO CLASSIFICATION T; Paner GP, 2010, AM J SURG PATHOL, V34, P1233, DOI 10.1097/PAS.0b013e3181e96f2a; Petersson F, 2010, INT J CLIN EXP PATHO, V3, P534; Sari A, 2011, TURK J PATHOL, V27, P164, DOI 10.5146/tjpath.2011.01068; Steffens S, 2014, HUM PATHOL, V45, P2411, DOI 10.1016/j.humpath.2014.08.002; Tun HW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010696; Wang ZX, 2017, CLIN CANCER RES, V23, P6686, DOI 10.1158/1078-0432.CCR-17-1057; Ziglioli F, 2013, ANN ITAL CHIR, V84, P1	20	0	0	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	SEP	2018	68	9					524	529		10.1111/pin.12704			6	Pathology	Pathology	GS8GQ	WOS:000443947100004	30015409				2019-10-28	
J	Miyai, K; Takeo, H; Nakayama, T; Obara, K; Aida, S; Sato, K; Matsukuma, S				Miyai, Kosuke; Takeo, Hiroaki; Nakayama, Takefumi; Obara, Kiyohaya; Aida, Shinsuke; Sato, Kimiya; Matsukuma, Susumu			Invasive form of ciliated muconodular papillary tumor of the lung: A case report and review of the literature	PATHOLOGY INTERNATIONAL			English	Review						ciliated moconodular papillary tumor; malignant transformation; peripheral lung; solitary peripheral ciliated glandular papilloma; stromal invasion	GRADE MALIGNANT-TUMOR; ADENOCARCINOMA; PAPILLOMAS	We report a case of a 67-year-old woman with an invasive ciliated muconodular papillary tumor (CMPT) that developed in her right middle lobe. The current tumor was incidentally detected during a follow-up imaging examination for a large cell carcinoma that was resected 10 years previously. Partial removal of the middle lobe showed a 2 cm-sized, solid and myxoid tumor located in the peripheral region. Histologically, this tumor primarily consisted of ciliated columnar cells, mucous cells, and basal cells, all of which had relatively swollen nuclei and were proliferating in a lepidic or papillary/micropapillary manner. These features were consistent with those of previously reported CMPT. In addition, atypical spindle tumor cells with more swollen nuclei, which were partly continuous to less atypical basal tumor cells, were focally found and invaded fibrous stroma in a reticular fashion. Immunohistochemically, both basal cells and atypical spindle tumor cells were positive for pancytokeratin, cytokeratin 5/6, and p40. Increased p53 positivity was found in these invading spindle cells compared with basal tumor cells. Neither BRAF V600E nor V600K mutation was detected. We concluded that this tumor was an extremely rare invasive case of CMPT, possibly representing malignant transformation of basal tumor cell components of CMPT.	[Miyai, Kosuke; Takeo, Hiroaki; Matsukuma, Susumu] Japan Self Def Forces Cent Hosp, Dept Pathol, Tokyo, Japan; [Nakayama, Takefumi; Obara, Kiyohaya] Japan Self Def Forces Cent Hosp, Thorac Surg, Tokyo, Japan; [Aida, Shinsuke] Int Univ Hlth & Welf, Mita Hosp, Dept Pathol, Tokyo, Japan; [Sato, Kimiya] Natl Def Med Coll, Dept Basic Pathol, Saitama, Japan; [Matsukuma, Susumu] Japan Self Def Forces Cent Hosp, Hlth Care Ctr, Tokyo, Japan	Miyai, K (reprint author), Japan Self Def Force Cent Hosp, Dept Pathol, Setagaya Ku, 1-2-24 Ikejiri, Tokyo 1548532, Japan.	mykusu228@nifty.com		Matsukuma, Susumu/0000-0003-0409-7527			Aida S, 2008, AM J SURG PATHOL, V32, P1489, DOI 10.1097/PAS.0b013e31817a9061; Chang JC, 2018, AM J SURG PATHOL, V42, P1010, DOI 10.1097/PAS.0000000000001086; Chu HH, 2017, HUM PATHOL CASE REPO, V7, P8; Chuang HW, 2014, PATHOL INT, V64, P352, DOI 10.1111/pin.12179; Flieder DB, 1998, AM J SURG PATHOL, V22, P1328, DOI 10.1097/00000478-199811000-00003; Flieder DB, 2015, WHO CLASSIFICATION T, P106; Hata Y, 2013, JPN J CLIN ONCOL, V43, P205, DOI 10.1093/jjco/hys218; Ishikawa Y., 2002, PATHOL CLIN MED, V20, P964; Jin Y, 2017, PATHOL INT, V67, P171, DOI 10.1111/pin.12512; Kamata T, 2015, AM J SURG PATHOL, V39, P753, DOI 10.1097/PAS.0000000000000414; Kaseda K, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-149; Lagana SM, 2011, ARCH PATHOL LAB MED, V135, P1353, DOI 10.5858/arpa.2010-0420-CR; Lau KW, 2016, HUM PATHOL, V49, P22, DOI 10.1016/j.humpath.2015.09.038; Liu LP, 2016, AM J SURG PATHOL, V40, P1631, DOI 10.1097/PAS.0000000000000707; Sato S, 2010, INTERACT CARDIOV TH, V11, P685, DOI 10.1510/icvts.2009.229989; SPENCER H, 1980, CANCER, V45, P1486, DOI 10.1002/1097-0142(19800315)45:6<1486::AID-CNCR2820450632>3.0.CO;2-H; Taguchi R, 2017, PATHOL INT, V67, P99, DOI 10.1111/pin.12504; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Tryfon S, 2012, J THORAC ONCOL, V7, P643, DOI 10.1097/JTO.0b013e3182468d06; Udo E, 2017, DIAGN PATHOL, V12, DOI 10.1186/s13000-017-0651-2; Vadasz P, 2000, EUR J CARDIO-THORAC, V17, P566, DOI 10.1016/S1010-7940(00)00386-9	21	1	1	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	SEP	2018	68	9					530	535		10.1111/pin.12708			6	Pathology	Pathology	GS8GQ	WOS:000443947100005	30043539				2019-10-28	
J	Stephanie, M; Irie, R; Sasaki, K; Hirata, Y; Narumoto, S; Fukuda, A; Sakamoto, S; Arai, K; Yoshioka, T; Kasahara, M				Stephanie, Marini; Irie, Rie; Sasaki, Kengo; Hirata, Yoshihiro; Narumoto, Soichi; Fukuda, Akinari; Sakamoto, Seisuke; Arai, Katsuhiro; Yoshioka, Takako; Kasahara, Mureo			Histological changes of the intestinal mucosa in complications following a living donor liver transplantation for progressive familial intrahepatic cholestasis type 1	PATHOLOGY INTERNATIONAL			English	Letter							HEREDITARY CHOLESTASIS; ATP8B1; EXPRESSION		[Stephanie, Marini; Irie, Rie; Yoshioka, Takako] Natl Ctr Child Hlth & Dev, Dept Pathol, Tokyo, Japan; [Stephanie, Marini] Univ Indonesia, Dr Cipto Mangunkusumo Hosp, Fac Med, Dept Anat Pathol, Jl Salemba Raya 6, Jakarta, Indonesia; [Sasaki, Kengo; Hirata, Yoshihiro; Narumoto, Soichi; Fukuda, Akinari; Sakamoto, Seisuke; Kasahara, Mureo] Natl Ctr Child Hlth & Dev Tokyo, Organ Transplantat Ctr, Tokyo, Japan; [Arai, Katsuhiro] Natl Ctr Child Hlth & Dev Tokyo, Div Gastroenterol, Tokyo, Japan	Stephanie, M (reprint author), Natl Ctr Child Hlth & Dev, Dept Pathol, Tokyo, Japan.; Stephanie, M (reprint author), Univ Indonesia, Dr Cipto Mangunkusumo Hosp, Fac Med, Dept Anat Pathol, Jl Salemba Raya 6, Jakarta, Indonesia.						Alvarez L, 2004, HUM MOL GENET, V13, P2451, DOI 10.1093/hmg/ddh261; Bull LN, 1998, NAT GENET, V18, P219, DOI 10.1038/ng0398-219; Demeilliers C, 2006, HEPATOLOGY, V43, P1125, DOI 10.1002/hep.21160; Shillingford NM, 2015, AM J SURG PATHOL, V39, P245, DOI 10.1097/PAS.0000000000000355; Verhulst PM, 2010, HEPATOLOGY, V51, P2049, DOI 10.1002/hep.23586	5	0	0	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	SEP	2018	68	9					536	537		10.1111/pin.12686			2	Pathology	Pathology	GS8GQ	WOS:000443947100006	29935008				2019-10-28	
J	Fujimoto, M; Yamashita, Y; Haga, H; Akasaka, T; Iwahashi, Y; Warigaya, K; Kojima, F; Hama, Y; Tamura, S; Sonoki, T; Murata, S				Fujimoto, Masakazu; Yamashita, Yusuke; Haga, Hironori; Akasaka, Takashi; Iwahashi, Yoshifumi; Warigaya, Kenji; Kojima, Fumiyoshi; Hama, Yuya; Tamura, Shinobu; Sonoki, Takashi; Murata, Shin-ichi			EBV-positive nodal low-grade B-cell lymphoma with BCL3, IgA and IRTA1 expression: Is this a polymorphic lymphoproliferative disorder or an EBV-positive nodal marginal zone lymphoma?	PATHOLOGY INTERNATIONAL			English	Letter									[Fujimoto, Masakazu; Iwahashi, Yoshifumi; Warigaya, Kenji; Kojima, Fumiyoshi; Murata, Shin-ichi] Wakayama Med Univ, Dept Diagnost Pathol, Wakayama, Japan; [Yamashita, Yusuke; Hama, Yuya; Tamura, Shinobu; Sonoki, Takashi] Wakayama Med Univ, Dept Hematol Oncol, Wakayama, Japan; [Haga, Hironori] Kyoto Univ Hosp, Dept Diagnost Pathol, Kyoto, Japan; [Akasaka, Takashi] Tenri Hosp, Dept Hematol, Nara, Japan	Fujimoto, M (reprint author), Wakayama Med Univ, Dept Diagnost Pathol, Wakayama, Japan.						de Jong D, 2017, AM J CLIN PATHOL, V147, P153, DOI 10.1093/ajcp/aqw216; Gibson SE, 2011, AM J SURG PATHOL, V35, P807, DOI 10.1097/PAS.0b013e3182190999; Ikeda JI, 2017, HUM PATHOL, V59, P70, DOI 10.1016/j.humpath.2016.09.011; Martin-Subero J, 2007, LEUKEMIA, V21, P1532, DOI 10.1038/sj.leu.2404695; van den Brand M, 2013, HAEMATOLOGICA, V98, P1003, DOI 10.3324/haematol.2012.083386	5	0	0	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	SEP	2018	68	9					538	540		10.1111/pin.12687			3	Pathology	Pathology	GS8GQ	WOS:000443947100007	29920862				2019-10-28	
J	Souza, VC; Vinhas, CD; Miguel, D; Athanazio, DA; Trpkov, K				Souza, Vinicius Carrera; Vinhas, Christiana de Freitas; Miguel, Diego; Athanazio, Daniel Abensur; Trpkov, Kiril			Renal cell carcinoma morphologically similar to fumarate hydratase-deficient RCC in a patient with BRCA2 germline mutation	PATHOLOGY INTERNATIONAL			English	Letter							HEREDITARY LEIOMYOMATOSIS		[Souza, Vinicius Carrera; Miguel, Diego] AMO Clin, Rua Joao Gomes 225, BR-41950640 Salvador, BA, Brazil; [Vinhas, Christiana de Freitas] Imagepat Lab, Rua Lucaia 209, BR-41940660 Salvador, BA, Brazil; [Athanazio, Daniel Abensur] Univ Fed Bahia, Fac Med, Dept Pathol, Largo Terreiro Jesus S-N, BR-40025010 Salvador, BA, Brazil; [Trpkov, Kiril] Univ Calgary, Dept Pathol & Lab Med, Calgary, AB, Canada; [Trpkov, Kiril] Calgary Lab Serv, Calgary, AB, Canada	Athanazio, DA (reprint author), Univ Fed Bahia, Fac Med, Dept Pathol, Largo Terreiro Jesus S-N, BR-40025010 Salvador, BA, Brazil.						Liede A, 2004, J CLIN ONCOL, V22, P735, DOI 10.1200/JCO.2004.05.055; Merino MJ, 2007, AM J SURG PATHOL, V31, P1578, DOI 10.1097/PAS.0b013e31804375b8; Mersch J, 2015, CANCER-AM CANCER SOC, V121, P269, DOI 10.1002/cncr.29041; Ohe C, 2018, AM J SURG PATHOL, V42, P279, DOI 10.1097/PAS.0000000000001000; Trpkov K, 2016, AM J SURG PATHOL, V40, P865, DOI 10.1097/PAS.0000000000000617	5	2	2	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	SEP	2018	68	9					541	542		10.1111/pin.12688			2	Pathology	Pathology	GS8GQ	WOS:000443947100008	29935000				2019-10-28	
J	Marx, A; Rudiger, T; Rossner, E; Tzankov, A; de Montpreville, VT; Rieker, RR; Strobel, P; Weis, CA				Marx, A.; Ruediger, T.; Roessner, E.; Tzankov, A.; de Montpreville, V. T.; Rieker, R. R.; Stroebel, P.; Weis, C. -A.			Ectopic thymic tissue and ectopic thymic tumors	PATHOLOGE			German	Article						Thymectomy, video-assisted; Thymectomy; robotic-assisted; Myasthenia gravis; Thymoma; Heterotopia	ASSISTED THORACOSCOPIC SURGERY; MYASTHENIA-GRAVIS; CERVICAL THYMUS; EXTENDED THYMECTOMY; PLEURAL THYMOMA; NECK; INFANT; MEDIASTINUM; PREVALENCE; MANAGEMENT	Ectopic thymic tissue outside its core position in the antero- superior mediastinum is quite common owing to the complexity of embryonal thymus development, whereby reported prevalence values ( 1 to 90%) are heavily dependent on the method of investigation and the intensity of the workup. The debated prevalence and relevance of ectopic thymic tissue and its accessibility underlie the ongoing discussion whether modern, minimally invasive thymectomy strategies canmatch the proven benefit of the radical transsternal thymectomy procedure for the treatment of Myasthenia gravis. In this context, the following article covers the etiology, prevalence, and location of normallooking, reactive, and neoplastic ectopic thymic tissue. Furthermore, ectopic tissues and tumors inside or adjacent to the thymus are mentioned.	[Marx, A.; Weis, C. -A.] Heidelberg Univ, Univ Med Mannheim, Inst Pathol, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany; [Ruediger, T.] Klinikum Karlsruhe, Inst Pathol, Karlsruhe, Germany; [Roessner, E.] Univ Med Mannheim, Chirurg Klin, Mannheim, Germany; [Tzankov, A.] Univ Spital Basel, Inst Pathol, Basel, Switzerland; [de Montpreville, V. T.] Ctr Chirurg Marie Lannelongue, Serv Anat & Cytol Pathol, Le Plessis Robinson, France; [Rieker, R. R.] Univ Klinikum Erlangen, Inst Pathol, Erlangen, Germany; [Stroebel, P.] Univ Med Gottingen, Inst Pathol, Gottingen, Germany	Weis, CA (reprint author), Heidelberg Univ, Univ Med Mannheim, Inst Pathol, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.	Cleo-Aron.Weis@medma.uni-heidelberg.de	Tzankov, Alexandar/H-5656-2019	Tzankov, Alexandar/0000-0002-1100-3819			Adam P, 2014, VIRCHOWS ARCH, V465, P313, DOI 10.1007/s00428-014-1606-6; Alexiev BA, 2016, PATHOL RES PRACT, V212, P1076, DOI 10.1016/j.prp.2016.08.011; Ambrogi V, 2012, J THORAC CARDIOV SUR, V143, P601, DOI 10.1016/j.jtcvs.2011.04.050; [Anonymous], 2017, CLASS TUM END ORG; ASHOUR M, 1995, J THORAC CARDIOV SUR, V109, P632, DOI 10.1016/S0022-5223(95)70343-8; Assis AF, 2018, MOL IMMUNOL, V99, P39, DOI 10.1016/j.molimm.2018.04.003; BALE PM, 1993, PEDIATR PATHOL, V13, P181, DOI 10.3109/15513819309048205; Bruno Vito D, 2010, Asian Cardiovasc Thorac Ann, V18, P486, DOI 10.1177/0218492310380280; CHAN JKC, 1991, HUM PATHOL, V22, P349, DOI 10.1016/0046-8177(91)90083-2; Chaudhari J, 2015, ENDOCR PATHOL, V26, P45, DOI 10.1007/s12022-015-9355-x; Cirillo E, 2015, ANN NY ACAD SCI, V1356, P90, DOI 10.1111/nyas.12849; CIVI I, 1989, PLAST RECONSTR SURG, V83, P143, DOI 10.1097/00006534-198901000-00027; Clark JJ, 2009, J PEDIATR SURG, V44, pE19, DOI 10.1016/j.jpedsurg.2009.04.010; Crowley B, 2018, AM J MED GENET A; Oliveira Karen Fernandes de, 2016, Radiol Bras, V49, P403, DOI 10.1590/0100-3984.2014.0025; Dooley J, 2006, J IMMUNOL, V176, P6484, DOI 10.4049/jimmunol.176.11.6484; Drenckhahn D., 2004, HERZ KREISLAUF SYSTE; Escobar FA, 2018, CYTOPATHOLOGY, V29, P241, DOI 10.1111/cyt.12529; Frank J, 1999, NATURE, V398, P473, DOI 10.1038/18997; FUKAI I, 1991, J THORAC CARDIOV SUR, V101, P1099; Fukushima T, 2015, THYROID, V25, P534, DOI 10.1089/thy.2014.0367; Gallo V, 2017, J CLIN IMMUNOL, V37, P751, DOI 10.1007/s10875-017-0445-z; Gilmour JR, 1941, J PATHOL BACTERIOL, V52, P213, DOI 10.1002/path.1700520207; Girard N, 2015, ANN ONCOL, V26, pV40, DOI 10.1093/annonc/mdv277; Goeteyn J, 2014, ACTA CHIR BELG, V114, P358, DOI 10.1080/00015458.2014.11681043; Gordon J, 2011, DEVELOPMENT, V138, P3865, DOI 10.1242/dev.059998; HUSAIN F, 1990, NEUROLOGY, V40, P170, DOI 10.1212/WNL.40.1.170; Ihaya A, 1990, Kyobu Geka, V43, P317; Ishida T, 2013, INT J PEDIATR OTORHI, V77, P1609, DOI 10.1016/j.ijporl.2013.06.030; Jaretzki A, 2004, SEMIN NEUROL, V24, P49, DOI 10.1055/s-2004-829596; Katzberg HD, 2009, MUSCLE NERVE, V40, P137, DOI 10.1002/mus.21282; Kawaguchi K, 2018, SURG TODAY, V48, P195, DOI 10.1007/s00595-017-1567-x; Kinoshita T, 2012, ANN THORAC SURG, V94, pE141, DOI 10.1016/j.athoracsur.2012.05.092; Kotani H, 2014, INT J PEDIATR OTORHI, V78, P1917, DOI 10.1016/j.ijporl.2014.08.024; Lambert MP, 2017, AM J MED GENET A, V2017, P25; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; Lee CY, 2008, YONSEI MED J, V49, P987, DOI 10.3349/ymj.2008.49.6.987; Li J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3959; Liberman M, 2002, J PEDIATR SURG, V37, P685, DOI 10.1053/jpsu.2002.32253; LIN JN, 1991, J PEDIATR SURG, V26, P663, DOI 10.1016/0022-3468(91)90005-E; Lippert H, 2011, LEHRBUCH ANATOMIE; Marandino F, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-322; MASAOKA A, 1982, NEUROLOGY, V32, P83, DOI 10.1212/WNL.32.1.83; MASAOKA A, 1975, J THORAC CARDIOV SUR, V70, P747; Masaoka A, 1996, ANN THORAC SURG, V62, P853, DOI 10.1016/S0003-4975(96)00376-1; Mende S, 2004, VIRCHOWS ARCH, V444, P397, DOI 10.1007/s00428-003-0961-5; Miller DV, 2005, AM J SURG PATHOL, V29, P1208, DOI 10.1097/01.pas.0000158398.65190.7b; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; Noh JM, 2015, CANCER RES TREAT, V47, P436, DOI 10.4143/crt.2013.184; NOWAK P A, 1988, Ear Nose and Throat Journal, V67, P676; Peel JK, 2017, J THORAC DIS, V9, pE1050, DOI 10.21037/jtd.2017.10.141; Ponseti JM, 2008, EUR J CARDIO-THORAC, V34, P1062, DOI 10.1016/j.ejcts.2008.07.049; Qi K, 2016, ACTA CHIR BELG, V116, P282, DOI 10.1080/00015458.2016.1176419; Sanei Behnam, 2015, Adv Biomed Res, V4, P18, DOI 10.4103/2277-9175.149849; Sayit AT, 2016, J THORAC DIS, V8, pE1163, DOI 10.21037/jtd.2016.10.92; Sayit AT, 2016, PEDIATR INT, V58, P943, DOI 10.1111/ped.13027; Schloegel LJ, 2009, INT J PEDIATR OTORHI, V73, P475, DOI 10.1016/j.ijporl.2008.10.031; Scott KJ, 2002, ARCH OTOLARYNGOL, V128, P714, DOI 10.1001/archotol.128.6.714; Shah SS, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.5.e94; Swann JB, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09213-1; Terszowski G, 2006, SCIENCE, V312, P284, DOI 10.1126/science.1123497; van Ewijk W, 1999, SEMIN IMMUNOL, V11, P57, DOI 10.1006/smim.1998.0158; Veits L, 2011, VIRCHOWS ARCH, V459, P221, DOI 10.1007/s00428-011-1117-7; von Gaudecker B, 1979, Adv Exp Med Biol, V114, P19; Weissferdt A, 2016, VIRCHOWS ARCH, V469, P245, DOI 10.1007/s00428-016-1967-0; Wolfe GI, 2016, NEW ENGL J MED, V375, P511, DOI 10.1056/NEJMoa1602489; Wong EHC, 2018, HEAD NECK-J SCI SPEC, V40, pE1, DOI 10.1002/hed.24985; Yajima Toshiki, 2018, BMC Res Notes, V11, P256, DOI 10.1186/s13104-018-3359-9; Yao WT, 2010, ANN THORAC SURG, V90, P666, DOI 10.1016/j.athoracsur.2009.12.078; Yokoyama S, 2015, ANN THORAC CARDIOVAS, V21, P293, DOI 10.5761/atcs.cr.14-00277; Zhu MS, 2012, CHEM-EUR J, V18, P4367, DOI 10.1002/chem.201102595; Zielinski M, 2004, ANN THORAC SURG, V78, P253, DOI 10.1016/j.athoracsur.2003.11.040; Zouvelou Vasiliki, 2014, J Clin Neuromuscul Dis, V16, P42, DOI 10.1097/CND.0000000000000039	73	1	1	2	2	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	SEP	2018	39	5					390	397		10.1007/s00292-018-0485-z			8	Pathology	Pathology	GS5HA	WOS:000443687300004	30159601				2019-10-28	
J	Kreipe, HH; Christgen, M				Kreipe, H. H.; Christgen, M.			Ectopia of mammary tissue	PATHOLOGE			German	Article						Milk ridge; Polymasty; Polythelia; Aberrant mammary gland	OF-THE-LITERATURE; AXILLARY LYMPH-NODES; BREAST-TISSUE; VULVA; CARCINOMA; CANCER; INCLUSIONS	Ectopic breast tissue may represent the complete breast (accessory breast), glandular tissue without areola or nipple (aberrant breast tissue), or exclusively the nipple (polythelia). Localization is along the embryonic milk ridge extending from the axilla to the vulva. Only rarely, is ectopic tissue found outside of the milk ridge. Most frequently affected are the axilla, the breast itself, and its close neighbourhood. Ectopic breast tissuemay rarely give rise to tumours such as fibroadenoma or carcinoma.	[Kreipe, H. H.; Christgen, M.] Hannover Med Sch, Inst Pathol, Carl Neuberg Str 1, D-30625 Hannover, Germany	Kreipe, HH (reprint author), Hannover Med Sch, Inst Pathol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	Kreipe.Hans@MH-Hannover.de					Bassler R, 1984, PATHOLOGIE, P315; Carter JE, 2008, J CUTAN PATHOL, V35, P246, DOI 10.1111/j.1600-0560.2007.00796.x; Chung-Park M, 2002, ARCH PATHOL LAB MED, V126, P1216; Dzodic R, 2010, DIAGN PATHOL, V5, DOI 10.1186/1746-1596-5-17; EDLOW DW, 1973, AM J CLIN PATHOL, V59, P666; Fellegara G, 2011, AM J SURG PATHOL, V35, P1123, DOI 10.1097/PAS.0b013e3182237985; Francone E, 2013, AESTHET PLAST SURG, V37, P746, DOI 10.1007/s00266-013-0125-1; Intra M, 2006, INT J GYNECOL CANCER, V16, P428, DOI 10.1111/j.1525-1438.2006.00237.x; Kalyani R, 2014, Int J Biomed Sci, V10, P143; KENNEY RD, 1987, AM J DIS CHILD, V141, P987, DOI 10.1001/archpedi.1987.04460090064026; Lee J, 2014, J BREAST CANCER, V17, P393, DOI 10.4048/jbc.2014.17.4.393; Lopes G, 2006, CLIN BREAST CANCER, V7, P278, DOI 10.3816/CBC.2006.n.041; Mannan AASR, 2010, AM J DERMATOPATH, V32, P384, DOI 10.1097/DAD.0b013e3181bfce84; Nardello SM, 2015, AM J CASE REP, V16, P153, DOI 10.12659/AJCR.892650; Nihon-Yanagi Y, 2011, SURG ONCOL, V20, P35, DOI 10.1016/j.suronc.2009.09.005; Piura B, 2002, EUR J GYNAECOL ONCOL, V23, P21; RADNER H, 1987, PATHOLOGE, V8, P310; Rosen PP, 2009, ROSENS BREAST PATHOL; SILTON RM, 1979, AM J SURG PATHOL, V3, P285, DOI 10.1097/00000478-197906000-00016; Troupis T, 2012, BREAST, V21, P615, DOI 10.1016/j.breast.2012.06.006	20	0	0	0	6	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	SEP	2018	39	5					398	401		10.1007/s00292-018-0468-0			4	Pathology	Pathology	GS5HA	WOS:000443687300005	30066024				2019-10-28	
J	Offner, FA; Langner, C				Offner, F. A.; Langner, C.			Heterotopic tissue in the gastrointestinal tract	PATHOLOGE			German	Article						Ectopia; Heterotopia; Esophagus; Stomach; Intestine; Gastrointestinal tract	OF-THE-LITERATURE; ECTOPIC PROSTATIC TISSUE; PYLORIC GLAND ADENOMA; GASTRIC-MUCOSA; INLET PATCH; PANCREATIC HETEROTOPIA; DUODENAL BULB; ADENOCARCINOMA; ESOPHAGUS; RECTUM	Heterotopia of the gastrointestinal tract is a common finding. This is due to the complex embryogenesis and the relative ease to detect heterotopic tissue during endoscopy. The reason for biopsy is mostly to rule out neoplasms or to define specific causes of inflammation. Heterotopic tissue can occur in any location of the gastrointestinal tract. The most frequent are gastric heterotopia, pancreatic heterotopia, and heterotopia of Brunner's gland. On rare occasions, heterotopic tissue of salivary gland type as well as heterotopias of apocrine glands, thyroid, and prostatic tissue have been described. The most frequently involved organs are the small intestine, in particular the duodenum, the esophagus, and the stomach. Heterotopia of the large bowel occurs exclusively in the rectum. Most heterotopias do not cause symptoms and are easily diagnosed by biopsy and histology. However, depending on location, size, and the kind of underlying heterotopic tissue, they may cause significant complications, such as inflammation, ulceration and perforation, obstruction, intussusception, and severe life-threatening bleeding. Another rare but significant complication is neoplasia. Gastric heterotopias may give rise to pyloric gland adenomas within the bowel or rarely adenocarcinomas of the esophagus. Pancreatic heterotopia can be complicated by ductal type pancreatic adenocarcinomas, by acinus cell carcinomas, by intraductal papillary mucinous neoplasias, and also by endocrine tumors. The present paper summarizes our current knowledge about heterotopias in a topographic clinico-pathologicalmanner.	[Offner, F. A.] Akad Lehrkrankenhaus Feldkirch, Inst Pathol, Carinagasse 47, A-6800 Feldkirch, Austria; [Langner, C.] Med Univ Graz, Inst Pathol, Graz, Austria	Offner, FA (reprint author), Akad Lehrkrankenhaus Feldkirch, Inst Pathol, Carinagasse 47, A-6800 Feldkirch, Austria.	felix.offner@lkhf.at					Ashida K, 1997, GASTROINTEST ENDOSC, V46, P172, DOI 10.1016/S0016-5107(97)70069-5; Baudet JS, 2006, SCAND J GASTROENTERO, V41, P1398, DOI 10.1080/00365520600763094; Bhattacharya B, 2003, ARCH PATHOL LAB MED, V127, P506; De Petris G, 2010, ARCH PATHOL LAB MED, V134, P378, DOI 10.1043/1543-2165-134.3.378; DEVEREAUX CE, 1994, J CLIN GASTROENTEROL, V19, P41, DOI 10.1097/00004836-199407000-00011; Downs-Kelly Erinn, 2003, Ann Diagn Pathol, V7, P124, DOI 10.1016/S1092-9134(02)91218-9; Eisenberger CF, 2004, HEPATO-GASTROENTEROL, V51, P854; GALLIGAN ML, 1983, ARCH PATHOL LAB MED, V107, P335; GLEDHILL A, 1985, J UROLOGY, V133, P110, DOI 10.1016/S0022-5347(17)48811-2; Huang WS, 1999, EUR J GASTROEN HEPAT, V11, P1175, DOI 10.1097/00042737-199910000-00017; Jimenez JC, 2005, J PEDIATR SURG, V40, P1654, DOI 10.1016/j.jpedsurg.2005.06.010; Kushima R, 1999, VIRCHOWS ARCH, V435, P452, DOI 10.1007/s004280050425; Lambert MP, 2000, PEDIATR DEVEL PATHOL, V3, P277, DOI 10.1007/s100249910036; Lauwers GY, 2005, AM J SURG PATHOL, V29, P437, DOI 10.1097/01.pas.0000155155.46434.da; Lauwers GY, 1998, DIGEST DIS SCI, V43, P901, DOI 10.1023/A:1018855223225; Lemaire J, 2014, ACTA CHIR BELG, V114, P79, DOI 10.1080/00015458.2014.11680983; Lindtner RA, 2007, PATHOL INT, V57, P548, DOI 10.1111/j.1440-1827.2007.02138.x; Makhlouf HR, 1999, ARCH PATHOL LAB MED, V123, P707; Maldonado ME, 1998, GASTROINTEST ENDOSC, V47, P545, DOI 10.1016/S0016-5107(98)70263-9; Mann NS, 2000, J CLIN GASTROENTEROL, V30, P303, DOI 10.1097/00004836-200004000-00020; Matsubara A, 2015, BRIT J CANCER, V112, P1398, DOI 10.1038/bjc.2015.104; Matsushita M, 1997, AM J GASTROENTEROL, V92, P2121; Neumann WL, 2012, DIGEST LIVER DIS, V44, P292, DOI 10.1016/j.dld.2011.11.008; NOFFSINGER AE, 1995, DIGEST DIS SCI, V40, P2373, DOI 10.1007/BF02063240; Poeschl EM, 2011, ENDOSCOPY, V43, pE336, DOI 10.1055/s-0030-1256785; SHINDO K, 1972, DIS COLON RECTUM, V15, P57, DOI 10.1007/BF02587671; SPERLING RM, 1995, AM J GASTROENTEROL, V90, P150; Suttorp AC, 2013, PATHOLOGE, V34, P162, DOI 10.1007/s00292-012-1714-5; Tanemura A, 2005, GASTROINTEST ENDOSC, V62, P324, DOI 10.1016/S0016-5107(05)01571-3; Tang P, 2004, ARCH PATHOL LAB MED, V128, P444; Tekin K, 2002, DIS COLON RECTUM, V45, P979, DOI 10.1097/01.DCR.0000019568.61061.11; Tolentino LF, 2004, EXP MOL PATHOL, V76, P51, DOI 10.1016/j.yexmp.2003.08.005; Vieth M, 2005, VIRCHOWS ARCH, V446, P542, DOI 10.1007/s00428-005-1242-2; von Rahden BHA, 2004, AM J GASTROENTEROL, V99, P543, DOI 10.1111/j.1572-0241.2004.04082.x; Weickert U, 2011, DIS ESOPHAGUS, V24, P63, DOI 10.1111/j.1442-2050.2010.01091.x; WEITZNER S, 1983, DIS COLON RECTUM, V26, P814, DOI 10.1007/BF02554758; Yu L, 2014, SCAND J GASTROENTERO, V49, P138, DOI 10.3109/00365521.2013.860558; Zhang YF, 2016, HUM PATHOL, V55, P135, DOI 10.1016/j.humpath.2016.05.004	38	0	0	0	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	SEP	2018	39	5					402	408		10.1007/s00292-018-0466-2			7	Pathology	Pathology	GS5HA	WOS:000443687300006	30105611				2019-10-28	
J	Mikuz, G				Mikuz, G.			Ectopias of the kidney, urinary tract organs, andmale genitalia. German version.	PATHOLOGE			German	Article						Bladder exstrophy; Choristoma; Embryology; Cloaca; Penoscrotal transposition	CROSSED RENAL ECTOPIA; EPISPADIAS COMPLEX; TESTICULAR ECTOPIA; BLADDER EXSTROPHY; PROSTATIC TISSUE; CHILDREN; MALFORMATIONS; OMPHALOCELE; MALPOSITION; DIAGNOSIS	Themost frequent anomaly of the urogenital tract is a simple renal ectopia with one organ lying in the pelvis. Crossed renal ectopia is a less common condition in which the ectopic kidney is located on the opposite side of the midline from the ureteral insertion in the urinary bladder. The cause of both types of renal ectopia is the arrest or failure of the kidney ascent from the pelvic to the lumbar position. Whereas an accelerated ascent leads to a subdiaphragmal or intrathoracic ectopic position, an ectopic ureter can be defined as one that does not drain into the trigonum vesicae. The ectopic orificium can be located situated in the bladder neck and urethra as well as somewhere in the genital area. Exstrophy of the urinary bladder is not a complete ectopia. Because the abdominal wall and the anterior part of the bladder wall are lacking, the bladder mucosa grows directly into the skin. The complex exstrophy of the bladder and intestine corresponds to a cloacal exstrophy, in which the bladder is split in two halves on either side of the gut portion. Testicular ectopia refers to the location of the testis in a position outside of its normal course of descent. Prostatic ectopia does not refer to the wrong location of the entire organ, but to a scattered group of prostate glands, which are mostly found in the submucosal part of the urinary bladder or proximal urethra. Other described locations are the intestinal wall, anus, pericolic fat tissue, spleen, seminal vesicle, testis, and cervix uteri. The associated ectopic penis, scrotum, and penoscrotal transposition are the least common and probably the absolutely most unknown malformations of the male genitalia. The ectopic penis and scrotum are located in the perineum, whereas in the transposition the penis lies above the scrotum.	[Mikuz, G.] Univ Innsbruck, Inst Pathol, Mullerstr 44, A-6020 Innsbruck, Austria	Mikuz, G (reprint author), Univ Innsbruck, Inst Pathol, Mullerstr 44, A-6020 Innsbruck, Austria.	Gregor.Mikuz@i-med.ac.at					ABESHOUSE B S, 1959, Urol Int, V9, P63; ALIOTTA PJ, 1987, J UROLOGY, V137, P942, DOI 10.1016/S0022-5347(17)44303-5; Arkani Samara, 2018, Hum Genome Var, V5, P18009, DOI 10.1038/hgv.2018.9; Austin PF, 1998, J UROLOGY, V160, P1179, DOI 10.1016/S0022-5347(01)62733-2; Babu V, 2018, ECTOPIC KIDNEY; Bell DJ, 2018, ZUGEGRIFFEN; Cromie WJ, 2001, J UROLOGY, V165, P1677, DOI 10.1016/S0022-5347(05)66391-4; CULP DA, 1964, J UROLOGY, V91, P538, DOI 10.1016/S0022-5347(17)64167-3; Dell'Atti L, 2017, ARCH ITAL UROL ANDRO, V89, P323, DOI 10.4081/aiua.2017.4.323; DELSON B, 1975, NEW YORK STATE J MED, V75, P2522; DRETLER SP, 1971, J UROLOGY, V105, P623, DOI 10.1016/S0022-5347(17)61591-X; Ebert AK, 2009, ORPHANET J RARE DIS, V4, DOI 10.1186/1750-1172-4-23; Fahmy MAB, 2014, INT J SURG, V12, P983, DOI 10.1016/j.ijsu.2014.08.001; Fulton RS, 2001, ARCH PATHOL LAB MED, V125, P286; Gardner JM, 2010, ARCH PATHOL LAB MED, V134, P1271, DOI 10.1043/2009-0338-CR.1; GILL B, 1980, BRIT J UROL, V52, P257, DOI 10.1111/j.1464-410X.1980.tb08913.x; Halat S, 2011, HISTOPATHOLOGY, V58, P750, DOI 10.1111/j.1365-2559.2011.03799.x; Hasan M, 2010, J MED ULTRASOUND, V18, P34, DOI 10.1016/S0929-6441(10)60005-7; HERTZ M, 1977, CLIN RADIOL, V28, P339, DOI 10.1016/S0009-9260(77)80194-3; Hill GS, 1989, UROPATHOLOGY, P1; Hodhod A, 2015, CUAJ-CAN UROL ASSOC, V9, pE333, DOI 10.5489/cuaj.2603; Little MH, 2007, GENE EXPR PATTERNS, V7, P680, DOI 10.1016/j.modgep.2007.03.002; Mackie G G, 1977, Birth Defects Orig Artic Ser, V13, P313; MANDELL J, 1981, J UROLOGY, V126, P219, DOI 10.1016/S0022-5347(17)54452-3; MANGIN P, 1982, NOUV PRESSE MED, V11, P1135; MCDONALD JH, 1957, AM J SURG, V93, P995, DOI 10.1016/0002-9610(57)90680-3; Mikuz G, 2016, PATHOLOGIE UROGENITA; MUECKE EC, 1964, J UROLOGY, V92, P659, DOI 10.1016/S0022-5347(17)64028-X; Natarajan G, 2013, CLIN KIDNEY J, V6, P144, DOI 10.1093/ckj/sfs186; PINCKNEY LE, 1978, RADIOLOGY, V129, P677, DOI 10.1148/129.3.677; Punwani VV, 2017, J PEDIATR SURG, V52, P1842, DOI 10.1016/j.jpedsurg.2016.12.009; Raj V, 2017, INT J SURG CASE REP, V41, P407, DOI 10.1016/j.ijscr.2017.09.032; Reutter H, 2003, AM J MED GENET A, V120A, P215, DOI 10.1002/ajmg.a.20057; Sobral DSR, 2017, EINSTEIN-SAO PAULO, V15, P223, DOI [10.1590/S1679-45082017RC3927, 10.1590/s1679-45082017rc3927]; Singh J, 2015, CASE REP MED, DOI 10.1155/2015/848949; Somoza I, 2012, INDIAN J UROL, V28, P450, DOI 10.4103/0970-1591.105775; SOTOLONGO JR, 1982, J UROLOGY, V127, P1181, DOI 10.1016/S0022-5347(17)54286-X; Wood HM, 2003, J UROLOGY, V169, P1512, DOI 10.1097/01.ju.0000054984.76384.66	38	1	1	2	2	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	SEP	2018	39	5					415	423		10.1007/s00292-018-0474-2			9	Pathology	Pathology	GS5HA	WOS:000443687300008	30135974				2019-10-28	
J	Schuttler, C; Buschhuter, N; Dollinger, C; Ebert, L; Hummel, M; Linde, J; Prokosch, HU; Proynova, R; Lablans, M				Schuettler, C.; Buschhueter, N.; Doellinger, C.; Ebert, L.; Hummel, M.; Linde, J.; Prokosch, H. -U.; Proynova, R.; Lablans, M.			Requirements for a cross-location Biobank IT Infrastructure Survey of Stakeholder Input on the Establishment of a Biobank Network of the German Biobank Alliance (GBA) (2018)	PATHOLOGE			German	Correction									[Schuettler, C.; Prokosch, H. -U.] Friedrich Alexander Univ Erlangen Nurnberg, Lehrstuhl Med Informat, Wetterkreuz 13, D-91058 Erlangen, Germany; [Buschhueter, N.] Rhein Westfal TH Aachen, Fak Med, Zentralisierte Biomat Bank, Aachen, Germany; [Doellinger, C.] Univ Klinikum Heidelberg, BioMat Bank Heidelberg, Heidelberg, Germany; [Ebert, L.; Proynova, R.; Lablans, M.] Deutsch Krebsforschungszentrum, Med Informat Translat Onkol, Heidelberg, Germany; [Hummel, M.] Charite Univ Med Berlin, Zent Biomat Bank ZeBanC, Berlin, Germany; [Hummel, M.] Charite Univ Med Berlin, GBN, Berlin, Germany; [Linde, J.] Univ Klinikum Gottingen, UMG Biobank, Gottingen, Germany	Schuttler, C (reprint author), Friedrich Alexander Univ Erlangen Nurnberg, Lehrstuhl Med Informat, Wetterkreuz 13, D-91058 Erlangen, Germany.	christina.schuettler@fau.de		Ebert, Lars Christian/0000-0002-8215-7006			EBERT L, 2018, DER PATHOLOGE, DOI DOI 10.1007/S00292-018-0435-9	1	0	0	0	3	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	SEP	2018	39	5					423	423		10.1007/s00292-018-0479-x			1	Pathology	Pathology	GS5HA	WOS:000443687300009	30105610				2019-10-28	
J	Otterbach, F; Schmidt, D				Otterbach, F.; Schmidt, D.			Ectopic tissue of the female genital tract	PATHOLOGE			German	Article						Choristoma; Embryology; Female genital neoplasms; Urogenital abnormalities; Female genitalia	ENDOMETRIOSIS; TUMORS; LESIONS; INSTITUTION; ORIGIN; CANCER	Ectopias of female genital tissues are a common event in routine pathology. Mostly they derive from paramesonephric tissues displaced during embryonal development or later. However, gonadal-, mesonephric-, or mesothelial-derived tissues may also appear in unusual localizations in and outside the female genital tract. They may be the source of benign and malignant tumors or tumorlike lesions. This review aims to provide an overview of possible tissue ectopias and to improve the developmental understanding of tumorous diseases of the female genital tract. Ectopias of primarily extragenital tissues in the female genital tract are also reviewed.	[Otterbach, F.; Schmidt, D.] UBAG Pathol Zytol & Dermatol, Gereonstr 14a, D-41747 Viersen, Germany	Otterbach, F (reprint author), UBAG Pathol Zytol & Dermatol, Gereonstr 14a, D-41747 Viersen, Germany.	friedrich.otterbach@pathologie-viersen.de					Anglesio MS, 2015, J PATHOL, V236, P201, DOI 10.1002/path.4516; Bague S, 2004, AM J SURG PATHOL, V28, P601, DOI 10.1097/00000478-200405000-00006; Baker GM, 2013, ARCH PATHOL LAB MED, V137, P1237, DOI 10.5858/arpa.2012-0434-OA; Bean S, 2014, PATHOLOGY FEMALE REP, P135; Borrelli GM, 2016, MOL HUM REPROD, V22, P329, DOI 10.1093/molehr/gaw009; D'Angelo E, 2014, PATHOLOGY FEMALE REP, P733; Dawson A, 2018, ECANCERMEDICALSCIENC, V12, DOI 10.3332/ecancer.2018.803; Gao YP, 2015, INT J CLIN EXP PATHO, V8, P5650; Gupta R, 2016, J PEDIATR ADOL GYNEC, V29, pE5, DOI 10.1016/j.jpag.2015.07.005; Hirschowitz L, 2011, INT J GYNECOL PATHOL, V30, P46, DOI 10.1097/PGP.0b013e3181eaa1ff; Howitt BE, 2015, AM J SURG PATHOL, V39, P1411, DOI 10.1097/PAS.0000000000000471; Jiang XX, 1998, CANCER RES, V58, P1707; Kazakov DV, 2010, INT J GYNECOL PATHOL, V29, P605, DOI 10.1097/PGP.0b013e3181e8ae7d; Kruse AJ, 2011, HUM PATHOL, V42, P743, DOI 10.1016/j.humpath.2010.08.017; Lax S, 2013, PATHOLOGIE MAMMA WEI, P416; Makiyan Z, 2017, ORGANOGENESIS, V13, P95, DOI 10.1080/15476278.2017.1323162; McCluggage WG, 2015, HISTOPATHOLOGY, V66, P555, DOI 10.1111/his.12580; Mirkovic J, 2015, MODERN PATHOL, V28, P1504, DOI 10.1038/modpathol.2015.103; Mutter G. L, 2014, PATHOLOGY FEMALE REP, P1; Prowse AH, 2006, INT J CANCER, V119, P556, DOI 10.1002/ijc.21845; Sampson JA, 1927, AM J PATHOL, V3, P93; Sangoi AR, 2009, MODERN PATHOL, V22, P1228, DOI 10.1038/modpathol.2009.90; Shako-Levy R, 2014, PATHOLOGY FEMALE REP, P523; Singh N, 2014, BMJ CASE REP, V30, P2014; Tiltman AJ, 2001, HISTOPATHOLOGY, V38, P237, DOI 10.1046/j.1365-2559.2001.01086.x; Ulfig N, 2017, KURZLEHRBUCH EMBRYOL, P120; VANDERPUTTE SCJ, 1994, INT J GYNECOL PATHOL, V13, P150, DOI 10.1097/00004347-199404000-00009	27	0	0	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	SEP	2018	39	5					424	430		10.1007/s00292-018-0477-z			7	Pathology	Pathology	GS5HA	WOS:000443687300010	30155695				2019-10-28	
J	Horn, LC; Opitz, S; Handzel, R; Brambs, CE				Horn, L. -C.; Opitz, S.; Handzel, R.; Brambs, C. E.			Histopathology and clinical aspects of extrauterine pregnancy	PATHOLOGE			German	Article						Hydatidiform mole; Choriocarcinoma; Ectopic pregnancy; Fallopian tubes; Gestational trophoblastic disease	COMPLETE HYDATIDIFORM MOLE; ECTOPIC PREGNANCY; RISK-FACTORS; HETEROTOPIC PREGNANCY; TROPHOBLASTIC DISEASE; EXPRESSION; DIAGNOSIS; WOMEN; TISSUES; SITES	Ectopic pregnancies are the main sources of pregnancy-relatedmorbidity and mortality in the first trimester. They are usually located in the ampullary part of the fallopian tube and the incidence increases in the setting of assisted reproductive techniques, older age at the time of the first pregnancy, and prior adnexal procedures. The clinical aspects and diagnostic challenges of an ectopic pregnancy for the pathologist are to be outlined. A review of the relevant literaturewas performed. Proof of gestational tissue is of utmost importance in the pathological-anatomical evaluation of an ectopic pregnancy. A complete evaluation of the specimen of a presumed tubal abruption or after milking out should be performed. Abnormal placentations (blighted ovum, embryonal molar pregnancy) as well as gestational trophoblastic disease (GTD, e. g., partial/ completemolar pregnancy, choriocarcinoma) can occur in the setting of an ectopic pregnancy. Caution must be taken to differentiate a trophoblast hyperplasia secondary to the tubal microenvironment from GTD. p57 immunohistochemistry can help exclude a molar pregnancy. Only 50% of ectopic pregnancies are associated with tubal pathologies (e. g. inflammation, tubal adhesions). Chorionic villi and trophoblast epithelia can demonstrate regressive changes after prior methotrexate treatment. Rarely, immunohistochemistry with GATA-3, p63, ss-HCG, PAX-8, and WT-1 can be used in the differential diagnosis of trophoblastic epithelium. Ectopic pregnancies are associated with significant morbidity and mortality. A thorough evaluation of the specimen can help guide management and follow-up.	[Horn, L. -C.; Opitz, S.] Univ Klinikum Leipzig AoR, Inst Pathol, Abt Mamma Gynako & Perinatalpathol, Liebigstr 26, D-04103 Leipzig, Germany; [Handzel, R.] Univ Klinikum Leipzig AoR, Zentrum Frauen & Kindermed, Triersches Inst, Univ Frauenklin Leipzig, Leipzig, Germany; [Brambs, C. E.] Tech Univ Munich, Klinikums Rechts Isar, Klin & Poliklin Frauenheilkunde, Munich, Germany	Horn, LC (reprint author), Univ Klinikum Leipzig AoR, Inst Pathol, Abt Mamma Gynako & Perinatalpathol, Liebigstr 26, D-04103 Leipzig, Germany.	hornl@medizin.uni-leipzig.de					Al-Serehi A, 2008, J ULTRAS MED, V27, P1623, DOI 10.7863/jum.2008.27.11.1623; Anastasakis E, 2007, FETAL DIAGN THER, V22, P285, DOI 10.1159/000100792; [Anonymous], 2018, Obstet Gynecol, V131, pe91, DOI 10.1097/AOG.0000000000002560; Arts-de Jong M, 2016, EUR J CANCER, V61, P137, DOI 10.1016/j.ejca.2016.03.009; Banet N, 2015, AM J SURG PATHOL, V39, P101, DOI 10.1097/PAS.0000000000000315; Barnhart K, 2011, FERTIL STERIL, V95, P857, DOI 10.1016/j.fertnstert.2010.09.006; Barnhart KT, 2006, FERTIL STERIL, V86, P36, DOI 10.1016/j.fertnstert.2005.12.023; Barnhart KT, 2009, NEW ENGL J MED, V361, P379, DOI 10.1056/NEJMcp0810384; Bouyer J, 2003, AM J EPIDEMIOL, V157, P185, DOI 10.1093/aje/kwf190; Bouyer J, 2002, HUM REPROD, V17, P3224, DOI 10.1093/humrep/17.12.3224; Brunette DD, 2011, AM J EMERG MED, V29, DOI 10.1016/j.ajem.2010.07.028; Bucella D, 2009, ARCH GYNECOL OBSTET, V280, P115, DOI 10.1007/s00404-008-0852-8; Burton JL, 2001, HISTOPATHOLOGY, V38, P409, DOI 10.1046/j.1365-2559.2001.01151.x; Cali G, 2018, ULTRASOUND OBST GYN, V51, P169, DOI 10.1002/uog.17568; Campello TR, 1998, HISTOPATHOLOGY, V32, P562, DOI 10.1046/j.1365-2559.1998.t01-1-00408.x; Chukus A, 2015, RADIOGRAPHICS, V35, P946, DOI 10.1148/rg.2015140202; Cortes-Charry R, 2012, J REPROD MED, V57, P329; Coste J, 2004, HUM REPROD, V19, P2014, DOI 10.1093/humrep/deh399; Einenkel Jens, 2005, Archives of Gynecology and Obstetrics, V271, P178, DOI 10.1007/s00404-004-0683-1; Erfanian M, 2009, J RES MED SCI, V14, P375; Farahani L, 2017, EUR J OBSTET GYN R B, V213, P98, DOI 10.1016/j.ejogrb.2017.04.001; Farquhar CM, 2005, LANCET, V366, P583, DOI 10.1016/S0140-6736(05)67103-6; Ganacharya S, 2003, EUR J OBSTET GYN R B, V111, P78, DOI 10.1016/S0301-2115(03)00208-2; Garrett A M, 1996, Fam Med, V28, P111; Geffen EM, 2017, ABDOM RADIOL, V42, P1524, DOI 10.1007/s00261-016-1020-4; Patrono MG, 2015, GYNECOL ONCOL, V139, P568, DOI 10.1016/j.ygyno.2015.09.018; Hassadia A, 2012, J REPROD MED, V57, P297; HORN LC, 1994, GEBURTSH FRAUENHEILK, V54, P375, DOI 10.1055/s-2007-1022858; Houghton O, 2009, ADV ANAT PATHOL, V16, P316, DOI 10.1097/PAP.0b013e3181b507c6; Ip PPC, 2014, PATHOLOGY OVARY FALL, P395; Jayaram P, 2018, J PERINAT MED, V46, P365, DOI 10.1515/jpm-2017-0189; Juan CW, 2013, INT J GYNECOL OBSTET, V122, P161, DOI 10.1016/j.ijgo.2013.03.007; Kalof Alexandra N, 2004, Arch Pathol Lab Med, V128, pe146; Kanat-Pektas M, 2016, TAIWAN J OBSTET GYNE, V55, P263, DOI 10.1016/j.tjog.2015.03.009; Klein M, 1995, GEBURTSH FRAUENHEILK, V55, P671, DOI 10.1055/s-2007-1022311; Lopez CL, 2018, REV BRAS GINECOL OBS, V40, P294, DOI 10.1055/s-0038-1653976; Lu D, 2017, INT J GYNECOL PATHOL, V36, P428, DOI 10.1097/PGP.0000000000000347; Maheux-Lacroix S, 2017, J MINIM INVAS GYN, V24, P915, DOI 10.1016/j.jmig.2017.05.019; Martin Joyce A, 2007, Natl Vital Stat Rep, V56, P1; Mehra Karishma, 2011, Front Biosci (Elite Ed), V3, P625, DOI 10.2741/e275; Mikolajczyk RT, 2013, PHARMACOEPIDEM DR S, V22, P873, DOI 10.1002/pds.3467; MILCHGRUB S, 1991, AM J CLIN PATHOL, V95, P892, DOI 10.1093/ajcp/95.6.892; Mol F, 2014, LANCET, V383, P1483, DOI 10.1016/S0140-6736(14)60123-9; Ozcan A, 2011, MODERN PATHOL, V24, P751, DOI 10.1038/modpathol.2011.3; Parra-Herran C, 2016, INT J GYNECOL PATHOL, V35, P497, DOI 10.1097/PGP.0000000000000250; Pisarska MD, 1998, LANCET, V351, P1115, DOI 10.1016/S0140-6736(97)11476-3; Sartorius GA, 2010, HUM REPROD UPDATE, V16, P65, DOI 10.1093/humupd/dmp027; Sehn JK, 2013, HUM PATHOL, V44, P2861, DOI 10.1016/j.humpath.2013.07.027; Taran FA, 2015, DTSCH ARZTEBL INT, V112, P693, DOI 10.3238/arztebl.2015.0693; TERADA S, 1993, GYNECOL OBSTET INVES, V35, P240, DOI 10.1159/000292708; Varras M, 2002, Clin Exp Obstet Gynecol, V29, P143; XIONG X, 1995, CONTRACEPTION, V52, P23, DOI 10.1016/0010-7824(95)00120-Y; Yuk JS, 2018, INT J GYNECOL OBSTET, V141, P295, DOI 10.1002/ijgo.12473; Zee J, 2014, HUM REPROD, V29, P441, DOI 10.1093/humrep/det450	54	0	0	1	3	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	SEP	2018	39	5					431	444		10.1007/s00292-018-0471-5			14	Pathology	Pathology	GS5HA	WOS:000443687300011	30135973				2019-10-28	
J	Jahns, R; Schirmacher, P				Jahns, R.; Schirmacher, P.			The current Ethical and Legal Framework for Human Biobanks	PATHOLOGE			German	Editorial Material									[Jahns, R.] Univ Klinikum Wurzburg, Ibdw, Straubmuhlweg 2a, D-97078 Wurzburg, Germany; [Schirmacher, P.] Heidelberg Univ, Inst Pathol, Neuenheimer Feld 224, D-69120 Heidelberg, Germany	Jahns, R (reprint author), Univ Klinikum Wurzburg, Ibdw, Straubmuhlweg 2a, D-97078 Wurzburg, Germany.; Schirmacher, P (reprint author), Heidelberg Univ, Inst Pathol, Neuenheimer Feld 224, D-69120 Heidelberg, Germany.	jahns_r@ukw.de; Peter.Schirmacher@med.uni-heidelberg.de					[Anonymous], 2018, GBN NEXT GEN BIOB; Arbeitskreis medizinischer Ethikkommissionen, 2018, EMPF BEW FORSCH HUM; ArbeitskreisMedizinischer Ethik- Kommissionen in der Bundesrepublik Deutschland e. V, 2018, MUST SPEND EINL NUTZ; BBMRI- ERIC, 2018, MAK NEW TREATM POSS; DSGVO, 2018, DAT GRUNDV; Gaskell G, 2011, NATURE, V471, P159, DOI 10.1038/471159a; ISBER, 2018, WELC INT SOC BIOL EN; Jahns R, 2011, BAYER ARZTEBLATT, V6, P356; Jahns R, 2016, BUNDESGESUNDHEITSBLA, V59, P311, DOI 10.1007/s00103-015-2292-5; Stellungnahme des Deutschen Ethikrats, 2010, HUM FORSCH; Stellungnahme des Deutschen Ethikrats, 2004, BIOB FORSCH; Strech D, 2016, EUR J MED GENET, V59, P295, DOI 10.1016/j.ejmg.2016.04.002	12	0	0	0	2	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	SEP	2018	39	5					445	448		10.1007/s00292-018-0472-4			4	Pathology	Pathology	GS5HA	WOS:000443687300012	30076434				2019-10-28	
J	Offermann, A				Offermann, A.			Influence of enhanced Capacity for Degradation of misfolded Proteins on Tumorigenesis	PATHOLOGE			German	Editorial Material							CANCER		[Offermann, A.] Univ Klinikum Schleswig Holstein, Inst Pathol, Campus Lubeck,Ratzeburger Allee 160, D-23538 Lubeck, Germany; [Offermann, A.] Leibniz Lungenzentrum, Forschungszentrum Borstel, Campus Lubeck,Ratzeburger Allee 160, D-23538 Lubeck, Germany	Offermann, A (reprint author), Univ Klinikum Schleswig Holstein, Inst Pathol, Campus Lubeck,Ratzeburger Allee 160, D-23538 Lubeck, Germany.; Offermann, A (reprint author), Leibniz Lungenzentrum, Forschungszentrum Borstel, Campus Lubeck,Ratzeburger Allee 160, D-23538 Lubeck, Germany.	Anne.Offermann@uksh.de					Hatakeyama S, 2011, NAT REV CANCER, V11, P792, DOI 10.1038/nrc3139; Lianos GD, 2015, CANCER LETT, V360, P114, DOI 10.1016/j.canlet.2015.02.026; Soto C, 2008, ARCH NEUROL-CHICAGO, V65, P184, DOI 10.1001/archneurol.2007.56	3	0	0	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	SEP	2018	39	5					449	450		10.1007/s00292-018-0455-5			2	Pathology	Pathology	GS5HA	WOS:000443687300013	29971458				2019-10-28	
J	Giesche, JP; von Baer, A; Breining, T; Marienfeld, R; Mellert, K; Luke, J; Schultheiss, M; Moller, P; Barth, TFE				Giesche, J. P.; von Baer, A.; Breining, T.; Marienfeld, R.; Mellert, K.; Lueke, J.; Schultheiss, M.; Moeller, P.; Barth, T. F. E.			H3F3A mutated multicentric giant cell tumor of bone. A very rare primary bone disease	PATHOLOGE			German	Editorial Material						Bone tumor; Giant cell rich lesion; Giant cell tumor of bone; Multicentric; H3F3A mutation	MUTATIONS; LESIONS	This article presents the case of a metachronic multicentric giant cell tumor of bone (GCTB). The patient obtained his first diagnosis of GCTB in the left humerus at the age of 47 years. Furthermore, he suffered from a GCTB in the head of his 4th left metacarpal bone and from a recurrence of the latter. All tumors carried the characteristic H3F3A mutation, which was proven by Sanger sequencing and a mutation specific antibody. The case is the first description of amulticentric H3F3A mutated GCTB.	[Giesche, J. P.; Marienfeld, R.; Mellert, K.; Lueke, J.; Moeller, P.; Barth, T. F. E.] Univ Klinikum Ulm, Inst Pathol, Albert Einstein Allee 23, D-89081 Ulm, Germany; [von Baer, A.; Schultheiss, M.] Univ Klinikum Ulm, Klin Unfall Hand Plast & Wiederherstellungschirur, Ulm, Germany; [Breining, T.] Univ Klinikum Ulm, Klin Diagnost & Intervent Radiol, Ulm, Germany	Barth, TFE (reprint author), Univ Klinikum Ulm, Inst Pathol, Albert Einstein Allee 23, D-89081 Ulm, Germany.	thomas.barth@uniklinik-ulm.de					Behjati S, 2013, NAT GENET, V45, P1479, DOI 10.1038/ng.2814; Branstetter DG, 2012, CLIN CANCER RES, V18, P4415, DOI 10.1158/1078-0432.CCR-12-0578; Broehm CJ, 2015, CASE REP MED, DOI 10.1155/2015/767198; Dhillon MS, 2007, ACTA ORTHOP BELG, V73, P289; Ghostine B, 2014, CASE REP MED, DOI 10.1155/2014/678035; Harness NG, 2004, J HAND SURG-AM, V29A, P188, DOI 10.1016/j.jhsa.2003.11.003; Hoch B, 2006, J BONE JOINT SURG AM, V88A, P1998, DOI 10.2106/JBJS.E.01111; Lindor NM, 2012, HUM MUTAT, V33, P8, DOI 10.1002/humu.21627; LODWICK GS, 1980, RADIOLOGY, V134, P577, DOI 10.1148/radiology.134.3.6928321; Luke J, 2018, PATHOLOGE, V39, P125, DOI 10.1007/s00292-017-0391-9; Luke J, 2017, HISTOPATHOLOGY, V71, P125, DOI 10.1111/his.13190; Muheremu A, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-261; Novais EN, 2011, J HAND SURG-AM, V36A, P1610, DOI 10.1016/j.jhsa.2011.06.032; Pal JN, 2018, MOJ ORTHOP RHEUMATOL; Park IH, 2003, SKELETAL RADIOL, V32, P526, DOI 10.1007/s00256-003-0658-5; Presneau N, 2015, J PATHOL CLIN RES, V1, P113, DOI 10.1002/cjp2.13; Tandra VS, 2015, CASE REP ONCOL MED, DOI 10.1155/2015/354158; Vaishya R, 2015, BMJ CASE REP	18	0	0	0	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	SEP	2018	39	5					451	456		10.1007/s00292-018-0460-8			6	Pathology	Pathology	GS5HA	WOS:000443687300014	30046846				2019-10-28	
J	Frerich, B; Prall, F				Frerich, B.; Prall, F.			Basal cell carcinoma of the face and scalp. An update on treatment options	PATHOLOGE			German	Article						Skin neoplasms; Margins of excision; Skin neoplasms/pathology; Histological techniques; Micrographic surgery; Skin neoplasms/surgery	SURGICAL EXCISION; RECURRENCE RATES; SURGERY; MULTICENTER; VISMODEGIB	The treatment of malignant tumors of the facial skin is an important part of the specialty oral and maxillofacial surgery. In two successive CME articles, important aspects of frequent entities are dealt with for the facial area. The current article deals with basal cell carcinoma, the most common localization of which is by far the facial area. Surgical resection is the treatment modality of first choice. A risk- adapted approach involving complete histopathological margin assessment is recommended for basal cell carcinoma at risk for recurrence or aggressive spread in order to spare healthy skin and to control subclinical tumor growth. There are specific caveats for non- surgical treatment options, such as topicalmedication, destructive procedures, and radiotherapy. This article describes indications and treatment methods with a focus on surgical resection techniques.	[Frerich, B.] Univ Med Rostock, Klin & Poliklin Mund Kiefer & Plast Gesichtschiru, Schillingallee 35, D-18057 Rostock, Germany; [Prall, F.] Univ Med Rostock, Inst Pathol, Rostock, Germany	Frerich, B (reprint author), Univ Med Rostock, Klin & Poliklin Mund Kiefer & Plast Gesichtschiru, Schillingallee 35, D-18057 Rostock, Germany.	bernhard.frerich@med.uni-rostock.de					[Anonymous], 2016, CLIN PRACT GUID ONC; Basset-Seguin N, 2015, LANCET ONCOL, V16, P729, DOI 10.1016/S1470-2045(15)70198-1; Bath-Hextall FJ, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003412.pub2; Bath-Hextall F, 2014, LANCET ONCOL, V15, P96, DOI 10.1016/S1470-2045(13)70530-8; Blum A, 2004, HAUTARZT, V55, P869, DOI 10.1007/s00105-004-0752-1; BREUNINGER H, 1984, J DERMATOL SURG ONC, V10, P724, DOI 10.1111/j.1524-4725.1984.tb01280.x; BREUNINGER H, 1991, J DERMATOL SURG ONC, V17, P574, DOI 10.1111/j.1524-4725.1991.tb03655.x; Breuninger H, 2007, DTSCH ARZTEBL, V104, pA427; Codazzi D, 2014, J PLAST SURG HAND SU, V48, P38, DOI 10.3109/2000656X.2013.800526; Cognetta AB, 2012, J AM ACAD DERMATOL, V67, P1235, DOI 10.1016/j.jaad.2012.06.001; DREPPER H, 1963, Hautarzt, V14, P420; DUBIN N, 1983, ARCH DERMATOL, V119, P373, DOI 10.1001/archderm.119.5.373; Gulleth Y, 2010, PLAST RECONSTR SURG, V126, P1222, DOI 10.1097/PRS.0b013e3181ea450d; Hauschild A, 2013, KURZLEITLINIE BASALZ; Jacobsen AA, 2016, JAMA DERMATOL, V152, P816, DOI 10.1001/jamadermatol.2016.0780; Johnson TM, 1997, J AM ACAD DERMATOL, V37, P758, DOI 10.1016/S0190-9622(97)70114-2; Kaatsch P, 2015, KREBS DEUTSCHL 2011; Kuijpers DIM, 2007, DERMATOL SURG, V33, P579, DOI 10.1111/j.1524-4725.2007.33117.x; Kwon GP, 2016, J AM ACAD DERMATOL, V75, P213, DOI 10.1016/j.jaad.2016.02.1235; Loser CR, 2015, J DTSCH DERMATOL GES, V13, P942, DOI 10.1111/ddg.12665; Lott DG, 2010, TRANSPLANTATION, V90, P683, DOI 10.1097/TP.0b013e3181ec7228; Migden MR, 2015, LANCET ONCOL, V16, P716, DOI 10.1016/S1470-2045(15)70100-2; Mohrle Matthias, 2006, J Dtsch Dermatol Ges, V4, P1080, DOI 10.1111/j.1610-0387.2006.06152.x; Patel SS, 2013, ORAL MAXILLOFAC SURG, V17, P115, DOI 10.1007/s10006-012-0348-3; Pritzkuleit P, 2014, KREBS SCHLESWIG HOLS; RIGEL DS, 1981, J DERMATOL SURG ONC, V7, P807, DOI 10.1111/j.1524-4725.1981.tb00171.x; ROWE DE, 1989, J DERMATOL SURG ONC, V15, P315, DOI 10.1111/j.1524-4725.1989.tb03166.x; Bogelund FS, 2007, ACTA DERM-VENEREOL, V87, P330, DOI 10.2340/00015555-0236; Scrivener Y, 2002, BRIT J DERMATOL, V147, P41, DOI 10.1046/j.1365-2133.2002.04804.x; SILVERMAN MK, 1992, J DERMATOL SURG ONC, V18, P471, DOI 10.1111/j.1524-4725.1992.tb03307.x; SILVERMAN MK, 1991, J DERMATOL SURG ONC, V17, P713, DOI 10.1111/j.1524-4725.1991.tb03424.x; Smeets NWJ, 2004, LANCET, V364, P1766, DOI 10.1016/S0140-6736(04)17399-6; Tischendorf L., 1991, THESIS; Tormo A, 2014, J CONTEMP BRACHYTHER, V6, P167, DOI 10.5114/jcb.2014.43247; van Loo E, 2014, EUR J CANCER, V50, P3011, DOI 10.1016/j.ejca.2014.08.018; Wetzig T, 2009, J DTSCH DERMATOL GES, V7, P1075, DOI 10.1111/j.1610-0387.2009.07097.x	36	0	0	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	SEP	2018	39	5					457	472		10.1007/s00292-018-0486-y			16	Pathology	Pathology	GS5HA	WOS:000443687300015	30128742				2019-10-28	
J	[Anonymous]				[Anonymous]			Autumn Conference 2018 of the OEGPath/IAP Austria from 27th to 28th September 2018, Graz Abstracts	PATHOLOGE			English	Article																	0	0	0	0	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	SEP	2018	39	5					480	490		10.1007/s00292-018-0470-6			11	Pathology	Pathology	GS5HA	WOS:000443687300016	30112651				2019-10-28	
J	Wilson, ML				Wilson, Michael L.			An Introduction and a New Era	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Editorial Material									[Wilson, Michael L.] Denver Hlth, Dept Pathol & Lab Serv, Denver, CO USA	Wilson, ML (reprint author), Denver Hlth Med Ctr, 777 Bannock St, Denver, CO 80204 USA.	mwilso01@yahoo.com						0	0	0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	SEP	2018	150	3					189	189		10.1093/ajcp/aqy106			1	Pathology	Pathology	GS3SL	WOS:000443540700001					2019-10-28	
J	Guarner, J; Jenkins, KM; Franks, NM				Guarner, Jeannette; Jenkins, Karen M.; Franks, Nicole M.			Successful and Unsuccessful Point-of-Care Testing in the Emergency Room	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Editorial Material									[Guarner, Jeannette] Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; [Franks, Nicole M.] Emory Univ, Emergency Med Dept, Atlanta, GA 30322 USA; [Jenkins, Karen M.] Emory Healthcare, Atlanta, GA USA	Guarner, J (reprint author), Pathol Dept, 1364 Clifton Rd, Atlanta, GA 30322 USA.	Jguarne@emory.edu	Guarner, Jeannette/B-8273-2013				Dahm MR, 2017, STUD HEALTH TECHNOL, V239, P28, DOI 10.3233/978-1-61499-783-2-28; McKillop DJ, 2017, ANN CLIN BIOCHEM, V54, P158, DOI 10.1177/0004563216651887; Storrow AB, 2008, ACAD EMERG MED, V15, P1130, DOI 10.1111/j.1553-2712.2008.00181.x; The Joint Commission, 2018, NAT PAT SAF GOALS; van de Wijngaart DJ, 2014, DIAGNOSIS, V1, P239, DOI 10.1515/dx-2014-0025	5	0	0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	SEP	2018	150	3					190	192		10.1093/ajcp/aqy079			3	Pathology	Pathology	GS3SL	WOS:000443540700002					2019-10-28	
J	Kansal, R; Grody, WW; Zhou, JM; Dong, L; Li, XM				Kansal, Rina; Grody, Wayne W.; Zhou, Jamie; Dong, Ling; Li, Xinmin			The Value of T-Cell Receptor gamma (TRG) Clonality Evaluation by Next-Generation Sequencing in Clinical Hematolymphoid Tissues	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Clonality; T-cell receptor; Next-generation sequencing; Antigen receptor gene rearrangement; PCR; Lymphoproliferative disorder	POLYMERASE-CHAIN-REACTION; CONCERTED ACTION BMH4-CT98-3936; HUMAN LYMPHOID NEOPLASMS; NON-HODGKINS-LYMPHOMA; GENE REARRANGEMENTS; MYCOSIS-FUNGOIDES; LYMPHOPROLIFERATIVE DISORDERS; CAPILLARY-ELECTROPHORESIS; CUTANEOUS-LYMPHOMAS; IMMUNOGLOBULIN	Objectives: To evaluate feasibility of assessing T-cell receptor. (TRG) clonality by next-generation sequencing (NGS) in hematolymphoid tissues. Methods: We evaluated TRG clonality using NGS and polymerase chain reaction (PCR) assays in blood, bone marrow, and formalin-fixed, paraffin-embedded tissues in 41 archived cases, including 21 benign cases with no history of any lymphoproliferative disorders (LPDs), 16 LPDs (nine mature T-cell neoplasms, seven mature B-cell neoplasms and immune dysregulation-associated LPDs), and four atypical LPDs from 22 females and 19 males with a median age of 58 (range, 9-87) years. Results: (1) NGS analyzed TRG sequence and peak ratios, and it had a greater sensitivity than PCR. (2) NGS identified small clones, including biallelic or monoallelic, and minimum clonal percentages (range, similar to 2.4% to similar to 69%) within all T cells. (3) We provide our strategy and criteria for evaluating NGS results. (4) We describe every case, with definitive evaluation of TRG clonality in 100% cases by NGS. Conclusions: TRG clonality evaluation by NGS provides greater clinical utility than PCR.	[Kansal, Rina; Grody, Wayne W.; Zhou, Jamie; Dong, Ling; Li, Xinmin] Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA USA	Kansal, R (reprint author), Blood Ctr Wisconsin, Mol Oncol & Genet, 638 North 18th St, Milwaukee, WI 53233 USA.	rinakansal@msn.com			Cancer Center Support Grant [P30 CA016042-39]	P30 CA016042-39: Cancer Center Support Grant (principal investigator: Judith Gasson). Time period: December 1, 2013, to November 30, 2018.	Arber DA, 2000, J MOL DIAGN, V2, P178, DOI 10.1016/S1525-1578(10)60636-8; Arber DA, 2001, J MOL DIAGN, V3, P133, DOI 10.1016/S1525-1578(10)60664-2; ARNOLD A, 1983, NEW ENGL J MED, V309, P1593, DOI 10.1056/NEJM198312293092601; BERTNESS V, 1985, NEW ENGL J MED, V313, P534, DOI 10.1056/NEJM198508293130902; Bruggemann M, 2007, LEUKEMIA, V21, P215, DOI 10.1038/sj.leu.2404481; Cushman-Vokoun AM, 2010, J MOL DIAGN, V12, P787, DOI 10.2353/jmoldx.2010.090183; DAVEY MP, 1986, P NATL ACAD SCI USA, V83, P8759, DOI 10.1073/pnas.83.22.8759; DEVILLARTAY JP, 1988, NATURE, V335, P170, DOI 10.1038/335170a0; DEVILLARTAY JP, 1989, BLOOD, V74, P2508; Dojcinov SD, 2010, AM J SURG PATHOL, V34, P405, DOI 10.1097/PAS.0b013e3181cf8622; Genovese G, 2014, NEW ENGL J MED, V371, P2477, DOI 10.1056/NEJMoa1409405; Greiner TC, 2002, J MOL DIAGN, V4, P137, DOI 10.1016/S1525-1578(10)60694-0; Jaiswal S, 2014, NEW ENGL J MED, V371, P2488, DOI 10.1056/NEJMoa1408617; Kirsch IR, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa9122; Krafft AE, 1999, MOL DIAGN, V4, P119, DOI 10.1016/S1084-8592(99)80036-8; Langerak AW, 2007, LEUKEMIA, V21, P222, DOI 10.1038/sj.leu.2404482; Langerak AW, 2012, LEUKEMIA, V26, P2159, DOI 10.1038/leu.2012.246; Lawnicki LC, 2003, J MOL DIAGN, V5, P82, DOI 10.1016/S1525-1578(10)60456-4; LEVY R, 1977, J EXP MED, V145, P1014, DOI 10.1084/jem.145.4.1014; Olsen E, 2007, BLOOD, V110, P1713, DOI 10.1182/blood-2007-03-055749; PICKER LJ, 1987, AM J PATHOL, V128, P181; Said J, 2015, BLOOD, V126, P827, DOI 10.1182/blood-2015-06-648097; Schumacher JA, 2014, AM J CLIN PATHOL, V141, P348, DOI 10.1309/AJCP5TYGBVW4ZITR; Sufficool KE, 2015, J AM ACAD DERMATOL, V73, P228, DOI 10.1016/j.jaad.2015.04.030; Swerdlow SH, 2008, WHO CLASSIFICATION T; Swerdlow SH, 2017, WHO CLASSIFICATION T; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Tan BT, 2008, J MOL DIAGN, V10, P502, DOI 10.2353/jmoldx.2008.080054; Theriault C, 2000, MODERN PATHOL, V13, P1269, DOI 10.1038/modpathol.3880232; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TRAINOR KJ, 1991, BLOOD, V78, P192; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202; van Krieken JHJM, 2007, LEUKEMIA, V21, P201, DOI 10.1038/sj.leu.2404467; VANDONGEN JJM, 1991, CLIN CHIM ACTA, V198, P93; VANDONGEN JJM, 1991, CLIN CHIM ACTA, V198, P1; WALDMANN TA, 1985, NEW ENGL J MED, V313, P776, DOI 10.1056/NEJM198509263131303; WEISS LM, 1985, NEW ENGL J MED, V313, P539, DOI 10.1056/NEJM198508293130903; Willemze R, 2005, BLOOD, V105, P3768, DOI 10.1182/blood-2004-09-3502; Xie MC, 2014, NAT MED, V20, P1472, DOI 10.1038/nm.3733	39	1	1	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	SEP	2018	150	3					193	223		10.1093/AJCP/AQY046			31	Pathology	Pathology	GS3SL	WOS:000443540700003	29982316				2019-10-28	
J	Goldstein, L; Wells, M; Vincent-Lambert, C				Goldstein, Lara; Wells, Mike; Vincent-Lambert, Craig			A Randomized Controlled Trial to Assess the Impact of Upfront Point-of-Care Testing on Emergency Department Treatment Time	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Point-of-care testing; Point-of-care systems; Emergency department	TURNAROUND TIME; STAY; LENGTH; OPERATIONS; SYSTEM	Objectives: To compare standard emergency department (ED) workflow to a protocolized pathway using upfront point-of-care (POC) tests performed prior to doctor evaluation to determine if this could produce a significant reduction in treatment time. Methods: We performed a prospective, randomized, controlled trial. Patients were randomized to receive the standard of care or one of the enhanced workflow pathways with POC tests. Results: There were 1,044 patients enrolled. All workflows, except electrocardiogram and low-dose x-ray (LODOX), exceeded the outcome measure (20% reduction in treatment time). It was significantly shorter compared with the control workflow if the patient received any (i-STAT + CBC)-containing workflows (P =.0001, P =.020, P =.0009, P =.011), as well as the i-STAT + LODOX workflows (P =.0001, P =.034). Conclusions: The full benefit of POC testing can be realized if it is implemented prior to doctor evaluation, as part of a standardized procedure in the ED. This allows for a more rapid availability of investigation results subsequently leading to decreased treatment times.	[Goldstein, Lara] Univ Witwatersrand, Fac Hlth Sci, Div Emergency Med, Johannesburg, South Africa; [Goldstein, Lara; Wells, Mike; Vincent-Lambert, Craig] Univ Johannesburg, Fac Hlth Sci, Dept Emergency Med Care, Johannesburg, South Africa	Goldstein, L (reprint author), Postnet Suite 429,Private Bag X1510, ZA-2058 Glenvista, South Africa.	drg666@gmail.com	Wells, Mike/M-6149-2018; Goldstein, Lara/Y-8540-2019	Wells, Mike/0000-0002-4520-2007; Goldstein, Lara/0000-0002-9427-8710	Abbott Point of Care, Princeton, NJ; Abbott Diagnostics, Johannesburg, South Africa; Lodox Systems, Johannesburg, South Africa; Mxolisi Ncube, Abbott Point-of-Care, South Africa	The authors gratefully acknowledge the sponsorship from Abbott Point of Care, Princeton, NJ (i-STAT machines, cartridges and administrative costs), Abbott Diagnostics, Johannesburg, South Africa (Emerald CBC machine and consumables), and Lodox Systems, Johannesburg, South Africa (provision of radiographers). We appreciate the loan of two ECG machines from Philips South Africa, Johannesburg, as well as the support of Mxolisi Ncube, Abbott Point-of-Care, South Africa. We are thankful for the dedication of our research assistant, Helen de Vos, as well as the support of both the medical and allied staff in the Emergency Department at Helen Joseph Hospital.	Begaz T, 2017, ANN EMERG MED, V69, P298, DOI 10.1016/j.annemergmed.2016.06.040; Boyle A, 2012, EMERG MED INT, DOI 10.1155/2012/838610; Fermann GJ, 2002, J EMERG MED, V22, P393, DOI 10.1016/S0736-4679(02)00429-8; Gardner RL, 2007, AM J EMERG MED, V25, P643, DOI 10.1016/j.ajem.2006.11.037; Goodacre SW, 2013, ANN EMERG MED, V61, P153, DOI 10.1016/j.annemergmed.2012.09.001; Grundgeiger T, 2009, INT J MED INFORM, V78, P293, DOI 10.1016/j.ijmedinf.2008.10.001; Hoffman JR, 2012, ARCH INTERN MED, V172, P1123, DOI 10.1001/archinternmed.2012.3319; Hoot NR, 2008, ANN EMERG MED, V52, P126, DOI 10.1016/j.annemergmed.2008.03.014; Hwang CW, 2016, ADV EMERG MED, V2016; Jang JY, 2013, ANN EMERG MED, V61, P145, DOI 10.1016/j.annemergmed.2012.07.021; Jarvis PRE, 2014, BRIT J HOSP MED, V75, P648, DOI 10.12968/hmed.2014.75.11.648; Kankaanpaa M, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0319-z; Kilgore ML, 1998, CLIN CHEM, V44, P1597; Lee-Lewandrowski E, 2003, ARCH PATHOL LAB MED, V127, P456; McIntosh BW, 2018, AM J EMERG MED, V36, P567, DOI 10.1016/j.ajem.2017.09.018; Mogensen CB, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-49; Murray RP, 1999, J EMERG MED, V17, P811, DOI 10.1016/S0736-4679(99)00107-9; Oredsson S, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-43; Parvin CA, 1996, CLIN CHEM, V42, P711; Peacock WF, 2004, ACAD EMERG MED, V11, P569; Potgieter JH, 2005, P SOC PHOTO-OPT INS, V5745, P1138, DOI 10.1117/12.595216; Quinn AD, 2016, CRIT REV CL LAB SCI, V53, P1, DOI 10.3109/10408363.2015.1054984; Retezar R, 2011, ANN EMERG MED, V57, P89, DOI 10.1016/j.annemergmed.2010.05.016; Rooney KD, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0692-9; SAUNDERS CE, 1989, ANN EMERG MED, V18, P134, DOI 10.1016/S0196-0644(89)80101-5; Schilling UM, 2014, POINT CARE, V13, P21, DOI 10.1097/POC.0000000000000003; St John Andrew, 2013, Clin Biochem Rev, V34, P61; Wiler JL, 2010, ANN EMERG MED, V55, P142, DOI 10.1016/j.annemergmed.2009.05.021; Yang L, 2016, EMERG MED J, V33, P144, DOI 10.1136/emermed-2014-204270; Yoon Philip, 2003, CJEM, V5, P155	30	2	2	1	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	SEP	2018	150	3					224	234		10.1093/ajcp/aqy042			11	Pathology	Pathology	GS3SL	WOS:000443540700004	29931184				2019-10-28	
J	Weinzierl, EP; Jerris, RC; Gonzalez, MD; Piccini, JA; Rogers, BB				Weinzierl, Elizabeth P.; Jerris, Robert C.; Gonzalez, Mark D.; Piccini, Julie A.; Rogers, Beverly B.			Comparison of Alere i Strep A Rapid Molecular Assay With Rapid Antigen Testing and Culture in a Pediatric Outpatient Setting	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Group A Streptococcus; GAS; Rapid antigen; Molecular; Pediatric; Alere; Culture; Pharyngitis	A STREPTOCOCCAL PHARYNGITIS; PYOGENES; POINT	Objectives: Group A Streptococcus (GAS) is the most common bacterial cause of pediatric acute pharyngitis, and its quick identification is important for subsequent treatment. We sought to determine whether molecular GAS-based testing can successfully replace GAS antigen testing and subsequent culture in a pediatric urgent care center. Methods: We tested 160 patient oropharyngeal samples by a rapid antigen GAS test, the Alere i Strep A test, and throat culture in a pediatric urgent care setting and calculated basic statistical metrics. Results: The sensitivity and specificity of the molecular test were 98% and 100%, respectively, compared with culture. There was a 9% false-positive rate with the rapid antigen-based testing. Conclusions: The Alere test is sufficiently sensitive and specific for definitive GAS testing in a pediatric urgent care setting. This implementation has enabled us to provide definitive patient results at the time of each patient encounter.	[Weinzierl, Elizabeth P.; Jerris, Robert C.; Gonzalez, Mark D.; Piccini, Julie A.; Rogers, Beverly B.] Childrens Healthcare Atlanta, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; [Weinzierl, Elizabeth P.; Jerris, Robert C.; Gonzalez, Mark D.; Rogers, Beverly B.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA	Weinzierl, EP (reprint author), Childrens Healthcare Atlanta, Dept Pathol & Lab Med, Atlanta, GA 30322 USA.; Weinzierl, EP (reprint author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA.	elizabeth.weinzierl2@choa.org					Alere, 2015, AL I STREP A; Berry GJ, 2018, J CLIN MICROBIOL, V56, DOI [10.1128/jcm.01310-17, 10.1128/JCM.01310-17]; Bochner RE, 2017, PEDIATR REV, V38, P81, DOI 10.1542/pir.2016-0072; Cohen DM, 2015, J CLIN MICROBIOL, V53, P2258, DOI 10.1128/JCM.00490-15; Gonzalez MD, 2018, INFECT DIS CLIN N AM, V32, P19, DOI 10.1016/j.idc.2017.11.006; Kimberlin DW, 2015, 2015 REPORT COMMITTE; Lean WL, 2014, PEDIATRICS, V134, P771, DOI 10.1542/peds.2014-1094; Roper SM, 2017, CLIN PEDIATR, V56, P675, DOI 10.1177/0009922816678184; Shulman ST, 2012, CLIN INFECT DIS, V55, pE86, DOI [10.1093/cid/cis847, 10.1093/cid/cis629]; Uhl JR, 2016, J CLIN MICROBIOL, V54, P815, DOI 10.1128/JCM.03387-15; Wang FN, 2017, CLIN PEDIATR, V56, P1128, DOI 10.1177/0009922816684602	11	2	2	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	SEP	2018	150	3					235	239		10.1093/AJCP/AQY038			5	Pathology	Pathology	GS3SL	WOS:000443540700005	29931106				2019-10-28	
J	Rusanganwa, V; Gahutu, JB; Nzabahimana, I; Ngendakabaniga, JMV; Hurtig, AK; Evander, M				Rusanganwa, Vincent; Gahutu, Jean Bosco; Nzabahimana, Innocent; Ngendakabaniga, Jean Marie Vianney; Hurtig, Anna-Karin; Evander, Magnus			The Status of Quality Improvement After 7 Years of the SLMTA Program	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Laboratory; Accreditation; Rwanda; SLMTA; Health system; Quality health care	SUB-SAHARAN AFRICA; LABORATORY ACCREDITATION; MEDICAL LABORATORIES; HEALTH; CARE; MANAGEMENT; SYSTEMS	Objectives: We investigated the quality system performance in Rwandan referral laboratories to determine their progress toward accreditation. Methods: We conducted audits across five laboratories in 2017, using the Stepwise Laboratory Quality Improvement Process Towards Accreditation checklist. Laboratories were scored based on the World Health Organization grading scale (0-5 stars scale) and compared with earlier audits. Results: Between 2012 and 2017, only one laboratory progressed (from four to five stars). Four of the five laboratories decreased to one (three laboratories) and zero (one laboratory) stars from four and three stars. Management reviews, evaluation, audits, documents, records, and identification of nonconformities showed a low performance. Conclusions: Four of five laboratories are not moving toward accreditation. However, this target is still achievable by energizing responsibilities of stakeholders and monitoring and evaluation. This would be possible because of the ability that laboratories showed in earlier audits, coupled with existing health policy that enables sustainable quality health care in Rwanda.	[Rusanganwa, Vincent; Gahutu, Jean Bosco] Univ Rwanda, Coll Med & Hlth Sci, Kigali, Rwanda; [Rusanganwa, Vincent; Evander, Magnus] Umea Univ, Dept Clin Microbiol, Virol, SE-90185 Umea, Sweden; [Hurtig, Anna-Karin] Umea Univ, Dept Publ Hlth & Clin Med, Epidemiol & Global Hlth, Umea, Sweden; [Rusanganwa, Vincent] Minist Hlth, Kigali, Rwanda; [Nzabahimana, Innocent] Natl Referral Lab, Kigali, Rwanda; [Ngendakabaniga, Jean Marie Vianney] Butare Univ Teaching Hosp, Huye, Rwanda	Evander, M (reprint author), Umea Univ, Dept Clin Microbiol, Virol, SE-90185 Umea, Sweden.	magnus.evander@umu.se			Swedish International Development Cooperation Agency [51160027-04, 51160059-10]	This work was supported by the Swedish International Development Cooperation Agency (grants 51160027-04 and 51160059-10).	Abbott P., 2011, MILLENNIUM DEV GOALS; Alemnji GA, 2014, TROP MED INT HEALTH, V19, P450, DOI 10.1111/tmi.12269; [Anonymous], 2017, NEWSLETTER 2017 UPDA; Barbe B, 2017, CLIN MICROBIOL INFEC, V23, P426, DOI 10.1016/j.cmi.2017.05.007; Binagwaho A, 2014, LANCET, V384, P371, DOI 10.1016/S0140-6736(14)60574-2; Da Rin G, 2009, CLIN CHIM ACTA, V404, P68, DOI 10.1016/j.cca.2009.03.024; Davies J, 2017, LANCET GLOB HEALTH, V5, pE248, DOI 10.1016/S2214-109X(17)30024-4; Farmer PE, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f65; Forsman RW, 1996, CLIN CHEM, V42, P813; Gershy-Damet GM, 2010, AM J CLIN PATHOL, V134, P393, DOI [10.1309/AJCPTUUC2V1WJOBM, 10.1309/AJCPTUUC2V1WJQBM]; Guzel O, 2009, CLIN BIOCHEM, V42, P274, DOI 10.1016/j.clinbiochem.2008.09.011; International Organization for Standardization (ISO), 2012, 151892012 ISO; Kubono Katsuo, 2004, Rinsho Byori, V52, P274; Kumar M, 2016, E AFRICA PUBLIC HLTH; Luman ET, 2016, AFR J LAB MED, V3, P1; Murray C, 2015, LANCET, V386, P3, DOI 10.1016/S0140-6736(15)61171-0; MURRAY CJL, 1996, GLOBAL BURDEN DIS CO; National Institute of Statistics of Rwanda Ministry of Finance and Economic Planning Ministry of Health TDPII, 2016, RWAND DEM HLTH SURV; Ndihokubwayo JB, 2016, AFR J LAB MED, V5, DOI 10.4102/ajlm.v5i1.280; Nkengasong JN, 2010, SHIFTING PARADIGM ST; Nkengsong J, 2016, AFR J LAB MED, V5, DOI 10.4102/ajlm.v5i2.558; Nzabahimana I, 2016, AFR J LAB MED, V3, P1; Organization  W. H, 2016, WORLD HLTH STAT 2016; Peter TF, 2010, AM J CLIN PATHOL, V134, P550, DOI 10.1309/AJCPH1SKQ1HNWGHF; Petti CA, 2006, CLIN INFECT DIS, V42, P377, DOI 10.1086/499363; Plebani M, 2017, J MED BIOCHEM, V36, P225, DOI 10.1515/jomb-2017-0038; Pouliakis Abraham, 2014, International Journal of Reliable and Quality E-Healthcare, V3, P37, DOI 10.4018/ijrqeh.2014070103; Rwanda Ministry of Health, 2012, 3 HLTH SECT STRAT PL; Rwanda Ministry of Health, 2015, HLTH SECT POL; Schroeder LF, 2014, AM J CLIN PATHOL, V141, P791, DOI 10.1309/AJCPQ5KTKAGSSCFN; Skeels MR, 2001, EMERG INFECT DIS, V7, P531, DOI 10.3201/eid0707.017710; WHO Regional Office for Africa, 2015, WHO GUID STEPW LAB I; World Health Organization- Regional Office for Africa, 2015, STEPW LAB QUAL IMPR; Yao K, 2016, AFR J LAB MED, V3, P1; Yao K, 2010, AM J CLIN PATHOL, V134, P401, DOI 10.1309/AJCPNBBL53FWUIQJ; Zima T., J MED BIOCH	36	0	0	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	SEP	2018	150	3					240	245		10.1093/AJCP/AQY047			6	Pathology	Pathology	GS3SL	WOS:000443540700006	29931081	Green Published, Bronze			2019-10-28	
J	Yang, LH; Su, P; Luedke, C; Lu, CM; Louissaint, A; McCall, CM; Rapisardo, S; Vallangeon, B; Wang, ED				Yang, Lian-He; Su, Pu; Luedke, Catherine; Lu, Chuanyi Mark; Louissaint, Abner, Jr.; McCall, Chad M.; Rapisardo, Sarah; Vallangeon, Bethany; Wang, Endi			Chronic Myeloid Leukemia Following Treatment for Primary Neoplasms or Other Medical Conditions A Report of 21 Cases and Review of the Literature	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Review						Chronic myeloid leukemia; Therapy-related; Philadelphia chromosome; Cytogenetic profile	CHRONIC-MYELOGENOUS-LEUKEMIA; CHRONIC GRANULOCYTIC-LEUKEMIA; CHRONIC LYMPHOCYTIC-LEUKEMIA; CHRONIC MYELOCYTIC-LEUKEMIA; STEM-CELL TRANSPLANTATION; THERAPY-RELATED LEUKEMIA; NON-HODGKIN-LYMPHOMA; PHILADELPHIA-CHROMOSOME; SECONDARY MALIGNANCY; POLYCYTHEMIA-VERA	Objectives: Therapy-related chronic myeloid leukemia (CML) has been reported, but its clinical presentation and pathologic features have not yet been well characterized. Methods: Twenty-one cases of CML following treatment for primary diseases were collected and retrospectively analyzed. Results: The clinical presentation, pathologic features, and cytogenetic profile were similar to de novo CML. In particular, those with an isolated Philadelphia chromosome constituted 88.9% of our cases, and additional aberrations characteristic of therapy-related acute myeloid leukemia/ myelodysplastic syndrome (AML/ MDS) were not identified in this study. The patients responded to imatinib/ derivatives and survived with limited follow-up. Conclusions: Therapy-related CML has a clinical presentation, pathologic features, and cytogenetic profile akin to de novo CML. Absence of additional significant aberrations seems to suggest a pathogenesis different from therapy-related AML/MDS. Therapy-related CML exhibits a robust therapeutic response to imatinib/derivatives and favorable clinical outcomes similar to de novo CML.	[Yang, Lian-He] China Med Univ, Affiliated Hosp 1, Dept Pathol, Shenyang, Liaoning, Peoples R China; [Yang, Lian-He] China Med Univ, Coll Basic Sci, Shenyang, Liaoning, Peoples R China; [Yang, Lian-He; Su, Pu; Luedke, Catherine; McCall, Chad M.; Rapisardo, Sarah; Wang, Endi] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; [Su, Pu] Tongji Univ, Sch Med, East Hosp, Dept Med, Shanghai, Peoples R China; [Lu, Chuanyi Mark] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; [Louissaint, Abner, Jr.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol & Lab Med, Boston, MA USA; [Vallangeon, Bethany] East Carolina Univ, Med Ctr, Dept Pathol, Greenville, NC 27858 USA	Wang, ED (reprint author), Duke Hosp South, Dept Pathol, DUMC Box 3712,M-345 Davison Bldg, Durham, NC 27710 USA.	endi.wang@duke.edu		McCall, Chad/0000-0003-3542-9053			Abu-Ghanem S, 2011, LEUKEMIA LYMPHOMA, V52, P2399, DOI 10.3109/10428194.2011.600483; ADVANI SH, 1992, ACTA ONCOL, V31, P65, DOI 10.3109/02841869209088269; Aguiar RCT, 1998, LEUKEMIA LYMPHOMA, V29, P17, DOI 10.3109/10428199809058378; AGUIAR RCT, 1994, ACTA HAEMATOL-BASEL, V92, P101; Aguiar RCT, 1996, BLOOD, V88, P2808, DOI 10.1182/blood.V88.7.2808.bloodjournal8872808; Alshehry NF, 2015, ACTA HAEMATOL-BASEL, V134, P161, DOI 10.1159/000375150; Alsop S, 2007, HUM PATHOL, V38, P1576, DOI 10.1016/j.humpath.2007.05.018; Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; AUERBACH HE, 1987, CANCER GENET CYTOGEN, V28, P173, DOI 10.1016/0165-4608(87)90367-0; Bahamadi SA, 2009, BLOOD, V114, P4726; Balk B, 2016, CHRONIC MYELOID LEUK, P1; Bansal S, 2013, INDIAN J MED PAEDIAT, V34, P168, DOI 10.4103/0971-5851.123717; Bauduer F, 2002, LEUKEMIA LYMPHOMA, V43, P1057, DOI 10.1080/10428190290021533; BERMAN E, 1991, BLOOD, V78, P2969; BOICE JD, 1985, J NATL CANCER I, V74, P955; Bolanos-Meade J, 2002, AM J HEMATOL, V71, P139, DOI 10.1002/ajh.10187; Bolufer P, 2007, BRIT J HAEMATOL, V136, P590, DOI 10.1111/j.1365-2141.2006.06469.x; BOUABDALLAH K, 1991, CANCER GENET CYTOGEN, V55, P277, DOI 10.1016/0165-4608(91)90091-8; Breccia M, 2008, LEUKEMIA RES, V32, P353, DOI 10.1016/j.leukres.2007.07.023; Buxhofer-Ausch V, 2006, EUR J HAEMATOL, V76, P447, DOI 10.1111/j.1600-0609.2006.00630.x; CAZZOLA M, 1990, HAEMATOLOGICA, V75, P477; CHAP L, 1994, LEUKEMIA LYMPHOMA, V12, P315, DOI 10.3109/10428199409059604; CURTIS RE, 1989, J CLIN ONCOL, V7, P21, DOI 10.1200/JCO.1989.7.1.21; Czarnecka AM, 2015, FUTURE ONCOL, V11, P17, DOI 10.2217/fon.14.135; DASTUGUE N, 1988, CANCER GENET CYTOGEN, V30, P253, DOI 10.1016/0165-4608(88)90192-6; Demiriz IS, 2014, TURK J HEMATOL, V31, P92, DOI 10.4274/Tjh.2013.0180; Felix CA, 1996, BLOOD, V87, P4376, DOI 10.1182/blood.V87.10.4376.bloodjournal87104376; Gale RP, 2014, LEUKEMIA RES, V38, P1162, DOI [10.1016/j.leukres.2014.08.002, 10.1016/j.jeukres.2014.08.002]; Gillis NK, 2017, LANCET ONCOL, V18, P112, DOI 10.1016/S1470-2045(16)30627-1; Gokel Y, 2002, HAEMATOLOGIA, V32, P501; Gong ZM, 2017, BLOOD ADV, V1, P2541, DOI 10.1182/bloodadvances.2017011858; Higuchi Masakazu, 2006, Gan To Kagaku Ryoho, V33, P2049; Hochhaus A, 2017, NEW ENGL J MED, V376, P917, DOI 10.1056/NEJMoa1609324; Hosseini S, 2011, CASE REP HEMATOL, DOI 10.1155/2011/670603; Hsiao HH, 2001, INT J HEMATOL, V73, P126, DOI 10.1007/BF02981915; Huang F, 2016, INDIAN J HEMATOL BLO, V32, pS104, DOI 10.1007/s12288-015-0544-z; Iriyama N, 2017, LEUKEMIA RES, V54, P55, DOI 10.1016/j.leukres.2017.01.003; Ishiyama T, 1985, JPN J CLIN HEMATOL, V26, P756; IURLO A, 1989, BLUT, V59, P503, DOI 10.1007/BF00329496; JACKSON GH, 1994, BRIT J HAEMATOL, V87, P193, DOI 10.1111/j.1365-2141.1994.tb04891.x; Kadikoylu G, 2008, MED ONCOL, V25, P467, DOI 10.1007/s12032-008-9061-3; KALDOR JM, 1990, NEW ENGL J MED, V322, P7, DOI 10.1056/NEJM199001043220102; Kneller A, 2005, CANCER GENET CYTOGEN, V159, P58, DOI 10.1016/j.cancergencyto.2004.09.009; Koller PB, 2017, CANCER-AM CANCER SOC, V123, P609, DOI 10.1002/cncr.30362; Langabeer SE, 2013, BRIT J HAEMATOL, V162, P708, DOI 10.1111/bjh.12396; Larson RA, 2005, CHEM-BIOL INTERACT, V153, P187, DOI 10.1016/j.cbi.2005.03.023; Larson S, 2012, AM J CLIN PATHOL, V138, pA044, DOI 10.1093/ajcp/138.suppl1.042; Lee HY, 2014, KOREAN J INTERN MED, V29, P250, DOI 10.3904/kjim.2014.29.2.250; LEONE G, 1988, ONCOLOGY, V45, P389; Leone G, 2010, CHEM-BIOL INTERACT, V184, P39, DOI 10.1016/j.cbi.2009.12.013; Louis R, 2016, AM J CANC CASE REP, V4, P1; Manabe M, 2013, AM J BLOOD RES, V3, P286; McNerney ME, 2017, NAT REV CANCER, V17, P513, DOI 10.1038/nrc.2017.60; Mele L, 2000, HAEMATOLOGICA, V85, P544; Menon NM, 2015, PEDIATR BLOOD CANCER, V62, P166, DOI 10.1002/pbc.25204; Mirza I, 2007, ARCH PATHOL LAB MED, V131, P1719; MOLONEY WC, 1987, BLOOD, V70, P905; Morton LM, 2014, LEUKEMIA, V28, P2317, DOI 10.1038/leu.2014.132; Nakagawa Y, 2005, INTERNAL MED, V44, P994, DOI 10.2169/internalmedicine.44.994; Nakamura H, 2000, ANN HEMATOL, V79, P396, DOI 10.1007/s002779900151; Noda Masaaki, 2004, Rinsho Ketsueki, V45, P72; Noone AM, SEER CANC STAT REV; Numata A, 2002, BRIT J HAEMATOL, V117, P613, DOI 10.1046/j.1365-2141.2002.03517.x; Pavithran K, 2005, AM J CLIN ONCOL-CANC, V28, P216, DOI 10.1097/01.coc.0000143845.79889.33; Pavithran K, 2002, EUR J HAEMATOL, V69, P105, DOI 10.1034/j.1600-0609.2002.02726.x; PedersenBjergaard J, 1997, LEUKEMIA, V11, P1571, DOI 10.1038/sj.leu.2400769; PEDERSENBJERGAARD J, 1994, BLOOD, V83, P2780, DOI 10.1182/blood.V83.10.2780.2780; Pelloso LAF, 2005, LEUKEMIA RES, V29, P353, DOI 10.1016/j.leukres.2004.07.008; PHILIP P, 1988, CANCER GENET CYTOGEN, V31, P227, DOI 10.1016/0165-4608(88)90221-X; PORTA C, 1993, HAEMATOLOGICA, V78, P56; PUNT CJA, 1987, CANCER, V60, P934, DOI 10.1002/1097-0142(19870901)60:5<934::AID-CNCR2820600503>3.0.CO;2-Y; QUESNEL B, 1993, J CLIN ONCOL, V11, P2370, DOI 10.1200/JCO.1993.11.12.2370; Ragupathi L, 2013, CL LYMPH MYELOM LEUK, V13, P175, DOI 10.1016/j.clml.2012.09.010; Ramanarayanan J, 2006, LEUKEMIA RES, V30, P701, DOI 10.1016/j.leukres.2005.10.015; Reddy KS, 2009, LEUKEMIA LYMPHOMA, V50, P1375, DOI 10.1080/10428190903047761; RITCH PS, 1983, CANCER, V52, P462, DOI 10.1002/1097-0142(19830801)52:3<462::AID-CNCR2820520314>3.0.CO;2-I; Robak T, 1999, LEUKEMIA LYMPHOMA, V35, P193, DOI 10.3109/10428199909145719; Sakamoto E, 2008, INT J HEMATOL, V88, P348, DOI 10.1007/s12185-008-0151-y; SALVAGNO L, 1994, LEUKEMIA LYMPHOMA, V16, P177, DOI 10.3109/10428199409114156; SCHREIBER ZA, 1984, CANCER, V54, P697, DOI 10.1002/1097-0142(1984)54:4<697::AID-CNCR2820540417>3.0.CO;2-C; Shibazaki Mio, 2014, Rinsho Ketsueki, V55, P970; SHIMON I, 1995, CLIN ENDOCRINOL, V43, P651, DOI 10.1111/j.1365-2265.1995.tb02932.x; Specchia G, 2004, LEUKEMIA RES, V28, P115, DOI 10.1016/S0145-2126(03)00182-6; Stuppia L, 1997, CANCER GENET CYTOGEN, V98, P28, DOI 10.1016/S0165-4608(96)00413-X; Takahashi K, 2017, LANCET ONCOL, V18, P100, DOI 10.1016/S1470-2045(16)30626-X; TEICHMANN JV, 1986, LEUKEMIA RES, V10, P361, DOI 10.1016/0145-2126(86)90064-0; TESTER WJ, 1984, J CLIN ONCOL, V2, P762, DOI 10.1200/JCO.1984.2.7.762; Thompson PA, 2015, MAYO CLIN PROC, V90, P1440, DOI 10.1016/j.mayocp.2015.08.010; Tsuzuki M, 2008, INTERNAL MED, V47, P1739, DOI 10.2169/internalmedicine.47.1072; Vakili-Sadeghi M, 2013, CASP J INTERN MED, V4, P739; Vardiman J.W., 2017, WHO CLASSIFICATION T, P30; Vardiman JW, 2017, WHO CLASSIFICATION T, P153; VERHOEF GEG, 1990, CANCER GENET CYTOGEN, V49, P171, DOI 10.1016/0165-4608(90)90139-2; Wahlin A, 2003, EUR J HAEMATOL, V70, P240, DOI 10.1034/j.1600-0609.2003.00043.x; Waldman D, 2004, AM J HEMATOL, V75, P217, DOI 10.1002/ajh.20027; WALGRAEVE D, 1991, CANCER GENET CYTOGEN, V55, P217, DOI 10.1016/0165-4608(91)90080-E; Waller CF, 1999, LEUKEMIA RES, V23, P961, DOI 10.1016/S0145-2126(99)00114-9; Waller CF, 1999, ANN HEMATOL, V78, P341, DOI 10.1007/s002770050527; Wandroo FA, 2000, J CLIN PATHOL, V53, P940, DOI 10.1136/jcp.53.12.940; Wang Kang-Ling, 2005, J Chin Med Assoc, V68, P230; Wang XL, 2013, BLOOD, V121, P1238, DOI 10.1182/blood-2012-11-467787; WHANGPENG J, 1988, BLOOD, V71, P403; Wu B, 2018, AM J CLIN PATHOL, V149, P55, DOI [10.1093/ajcp/aqx133, 10.1093/AJCP/AQX133]; Xu XH, 2013, LEUKEMIA LYMPHOMA, V54, P195, DOI 10.3109/10428194.2012.692788; Yamamura R, 2003, ACTA HAEMATOL-BASEL, V109, P141, DOI 10.1159/000069282; Yoon HS, 2015, J PEDIAT HEMATOL ONC, V37, P572, DOI 10.1097/MPH.0000000000000378; Zahra K, 2012, ONKOLOGIE, V35, P690, DOI 10.1159/000343952	107	0	0	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	SEP	2018	150	3					246	258		10.1093/ajcp/aqy050			13	Pathology	Pathology	GS3SL	WOS:000443540700007	29992292				2019-10-28	
J	Omori, M; Kondo, T; Nakazawa, K; Tagaya, H; Ohgi, M; Fukasawa, H; Nakazawa, T; Hashi, A; Hirata, S				Omori, Makiko; Kondo, Tetsuo; Nakazawa, Kumiko; Tagaya, Hikaru; Ohgi, Maki; Fukasawa, Hiroko; Nakazawa, Tadao; Hashi, Akihiko; Hirata, Shuji			Interpretation of Endocervical Cells With Gastric-Type Mucin on Pap Smears A Proposal for a Cytologic Category "Atypical Endocervical Cells With Gastric-Type Mucin"	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Cervical cancer; Adenocarcinoma; Gastric-type mucinous carcinoma; Lobular endocervical glandular hyperplasia; Papanicolaou smears; Yellow mucin; Atypical endocervical cells; Atypical glandular cells	MINIMAL DEVIATION ADENOCARCINOMA; HUMAN-PAPILLOMAVIRUS INFECTION; CERVICAL GLANDULAR LESIONS; LATEX AGGLUTINATION-TEST; ADENOMA MALIGNUM; UTERINE CERVIX; MONOCLONAL-ANTIBODY; NEOPLASTIC TISSUES; UNITED-STATES; HYPERPLASIA	Objectives: Early detection of endocervical adenocarcinoma is especially important for cancers that are human papillomavirus (HPV) negative. We investigated the clinicopathologic significance of yellow gastric-type mucin observed on Papanicolaou smears. Methods: We described "atypical endocervical cells with gastric-type mucin" (AEC-GAM) when yellow mucin was observed in endocervical cells. We retrieved AECGAM samples from 58,752 cervical smears performed at Yamanashi University Hospital during our study period and reviewed clinical, cytologic, and pathologic features. Results: We detected AEC-GAM in 172 (0.29 %) smears from 65 patients, and 41 of these 65 patients were histologically diagnosed with lobular endocervical glandular hyperplasia (LEGH) (43%) or pyloric gland metaplasia (20%). The prevalence of adenocarcinoma was 25% (7/28) in LEGH cases and 11% (7/65) in AECGAM smears. Conclusions: Yellow mucin is a diagnostic clue for endocervical glandular lesions with gastric differentiation. We recommend describing AEC-GAM on cytologic reports to improve cytologic screening for HPV-negative cervical cancers.	[Omori, Makiko; Tagaya, Hikaru; Ohgi, Maki; Fukasawa, Hiroko; Hashi, Akihiko; Hirata, Shuji] Univ Yamanashi, Fac Med, Dept Obstet & Gynecol, Yamanashi, Japan; [Kondo, Tetsuo; Nakazawa, Kumiko; Nakazawa, Tadao] Univ Yamanashi, Fac Med, Dept Pathol, Yamanashi, Japan	Omori, M (reprint author), Univ Yamanashi, Fac Med, Dept Obstet & Gynecol, Chuo Ku, 1110 Shimokato, Yamanashi 4093898, Japan.	msasaki@yamanashi.ac.jp		Omori, Makiko/0000-0003-4430-5490			Hata S, 2002, DIAGN CYTOPATHOL, V27, P80, DOI 10.1002/dc.10140; HO SB, 1993, CANCER RES, V53, P641; Ishii K, 1998, VIRCHOWS ARCH, V432, P315, DOI 10.1007/s004280050172; Ishii K, 2001, CLIN CHIM ACTA, V312, P231, DOI 10.1016/S0009-8981(01)00611-8; Ishii K, 1999, CANCER CYTOPATHOL, V87, P245, DOI 10.1002/(SICI)1097-0142(19991025)87:5<245::AID-CNCR2>3.0.CO;2-0; Kawauchi S, 2008, AM J SURG PATHOL, V32, P1807, DOI 10.1097/PAS.0b013e3181883722; Kondo T, 2005, MODERN PATHOL, V18, P1199, DOI 10.1038/modpathol.3800403; Krane JF, 2001, CANCER CYTOPATHOL, V93, P8, DOI 10.1002/1097-0142(20010225)93:1<8::AID-CNCR9001>3.0.CO;2-K; Kurman RJ, 2014, WHO CLASSIFICATION T, P183; Kusanagi Y, 2010, AM J PATHOL, V177, P2169, DOI 10.2353/ajpath.2010.100323; Massad LS, 2013, OBSTET GYNECOL, V121, P829, DOI 10.1097/AOG.0b013e3182883a34; Mikami Y, 2004, MODERN PATHOL, V17, P962, DOI 10.1038/modpathol.3800148; Moreira MAR, 2008, DIAGN CYTOPATHOL, V36, P270, DOI 10.1002/dc.20799; Nakajima K, 2003, J HISTOCHEM CYTOCHEM, V51, P1689, DOI 10.1177/002215540305101213; Nakamura N, 1998, J HISTOCHEM CYTOCHEM, V46, P793, DOI 10.1177/002215549804600702; Nara M, 2007, GYNECOL ONCOL, V106, P289, DOI 10.1016/j.ygyno.2007.03.044; Nayar R, 2014, BETHESDA SYSTEM REPO, P226; Nucci MR, 1999, AM J SURG PATHOL, V23, P886, DOI 10.1097/00000478-199908000-00005; Omori M, 2008, AM J CLIN PATHOL, V130, P585, DOI 10.1309/L8XME5JVEJ74C3F1; Pirog EC, 2000, AM J PATHOL, V157, P1055, DOI 10.1016/S0002-9440(10)64619-6; Saraiya M, 2007, OBSTET GYNECOL, V109, P360, DOI 10.1097/01.AOG.0000254165.92653.e8; Takatsu A, 2011, INT J GYNECOL CANCER, V21, P1287, DOI 10.1097/IGC.0b013e31821f746c; Talia KL, 2018, PATHOLOGY, V50, P122, DOI 10.1016/j.pathol.2017.09.009; Tsuda H, 2005, PATHOL INT, V55, P412, DOI 10.1111/j.1440-1827.2005.01846.x; Wang SS, 2004, CANCER-AM CANCER SOC, V100, P1035, DOI 10.1002/cncr.20064; Wright TC, 2004, OBSTET GYNECOL, V103, P304, DOI 10.1097/01.AOG.0000109426.82624.f8; Xu JY, 2005, INT J GYNECOL PATHOL, V24, P296, DOI 10.1097/01.PGP.0000157918.36354.C1	27	1	1	1	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	SEP	2018	150	3					259	266		10.1093/AJCP/AQY055			8	Pathology	Pathology	GS3SL	WOS:000443540700008	29982289				2019-10-28	
J	Jaime-Perez, JC; Vazquez-Hernandez, KE; Jimenez-Castillo, RA; Fernandez, LT; Salazar-Riojas, R; Gomez-Almaguer, D				Jaime-Perez, Jose C.; Vazquez-Hernandez, Karina E.; Jimenez-Castillo, Raul A.; Fernandez, Lucia T.; Salazar-Riojas, Rosario; Gomez-Almaguer, David			Platelet Survival in Hematology Patients Assessed by the Corrected Count Increment and Other Formulas	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Corrected count increment; CCI; Platelet increment; Platelet recovery; Plateletpheresis; Platelet survival; Logistic regression; ROC model	TRANSFUSION; REFRACTORINESS; MANAGEMENT; DEFINITION; RECOVERY; EFFICACY; QUALITY	Objectives: To compare the performance of the corrected count increment (CCI) and three other formulas to assess 24-hour posttransfusion platelet survival in hematology patients. Methods: Twenty-four-hour posttransfusion platelet counts were analyzed after apheresis platelet transfusion. Platelet increment (PI), percent platelet recovery (PPR), and percentage platelet increment (PPI) were compared with CCI by receiver operating characteristic analysis. Clinical factors that influence platelet survival were assessed by logistic regression. Results: In total, 142 apheresis platelet transfusions in 85 hematology patients were studied. Mean (SD) CCI at 24 hours was 11,869 (10,125). Compared with CCI, the sensitivity of other formulas ranged from 89.4% to 95.7% and specificity from 94.7% to 100%. Cutoff values were 15.7 x 10(3)/mu L for PI, 11.4% for PPR, and 17% for PPI. For ABO-compatible vs incompatible transfusions, CCI was 14,070/mu L vs 9,176/mu L (P =.007). Negative factors for all formulas were sepsis, hypotension, and amphotericin B. Conclusions: PI, PPR, and PPI are comparable to CCI for assessing 24-hour platelet survival.	[Jaime-Perez, Jose C.; Vazquez-Hernandez, Karina E.; Jimenez-Castillo, Raul A.; Fernandez, Lucia T.; Salazar-Riojas, Rosario; Gomez-Almaguer, David] Univ Autonoma Nuevo Leon, Sch Med, Dr Jose Eleuterio Gonzalez Univ Hosp, Dept Hematol, Monterrey, Mexico	Jaime-Perez, JC (reprint author), Hosp Univ Dr Jose E Gonzalez, Serv Hematol, Edificio Dr Rodrigo Barragan,2 Piso, Monterrey 64460, NL, Mexico.	carjaime@hotmail.com	ALMAGUER, David GOMEZ/J-2656-2019				Apelseth TO, 2010, TRANSFUSION, V50, P766, DOI 10.1111/j.1537-2995.2009.02540.x; BISHOP JF, 1992, TRANSFUSION MED, V2, P35, DOI 10.1111/j.1365-3148.1992.tb00132.x; BISHOP JF, 1988, BLOOD, V71, P383; DALY PA, 1980, JAMA-J AM MED ASSOC, V243, P435, DOI 10.1001/jama.243.5.435; Davis KB, 1999, TRANSFUSION, V39, P586, DOI 10.1046/j.1537-2995.1999.39060586.x; Delaflor-Weiss E, 2000, TRANSFUS MED REV, V14, P180, DOI 10.1016/S0887-7963(00)80007-3; FILIP DJ, 1976, AM J HEMATOL, V1, P471, DOI 10.1002/ajh.2830010412; Fung MK, 2014, TECHNICAL MANUAL, P117; Goldfinger D, 2013, REFRACTORINESS PLATE; Hod E, 2008, BRIT J HAEMATOL, V142, P348, DOI 10.1111/j.1365-2141.2008.07189.x; Jimenez TM, 2003, TRANSFUSION, V43, P328, DOI 10.1046/j.1537-2995.2003.00326.x; Karafin M, 2012, TRANSFUSION, V52, P1221, DOI 10.1111/j.1537-2995.2011.03476.x; Kelsey P, 2003, BRIT J HAEMATOL, V122, P10; Mallhi RS, 2015, INDIAN J HEMATOL BLO, V31, P453, DOI 10.1007/s12288-014-0476-z; MOSTELLER RD, 1987, NEW ENGL J MED, V317, P1098; Murphy MF, 2014, ISBT SCI SER, V9, P234, DOI 10.1111/voxs.12073; Norma Oficial Mexicana, 2012, DIARIO OFICIAL FEDER; Petz LD, 2000, TRANSFUSION, V40, P1446, DOI 10.1046/j.1537-2995.2000.40121446.x; REBULLA P, 1993, TRANSFUSION MED, V3, P91, DOI 10.1111/j.1365-3148.1993.tb00108.x; Salama OS, 2014, BLOOD TRANSFUS-ITALY, V12, P187, DOI 10.2450/2014.0120-13; Shastry S, 2012, TRANSFUS APHER SCI, V47, P327, DOI 10.1016/j.transci.2012.04.006; Shehata N, 2009, TRANSFUSION, V49, P2442, DOI 10.1111/j.1537-2995.2009.02273.x; Slichter SJ, 2005, BLOOD, V105, P4106, DOI 10.1182/blood-2003-08-2724; Stanworth SJ, 2015, BRIT J HAEMATOL, V171, P297, DOI 10.1111/bjh.13597	24	1	1	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	SEP	2018	150	3					267	272		10.1093/AJCP/AQY052			6	Pathology	Pathology	GS3SL	WOS:000443540700009	29982409				2019-10-28	
J	Dulau-Florea, AE; Young, NS; Maric, I; Calvo, KR; Dunbar, CE; Townsley, DM; Winkler, T; Monreal, M; Jiang, CJ; Jordan, EK; Braylan, RC				Dulau-Florea, Alina E.; Young, Neal S.; Maric, Irina; Calvo, Katherine R.; Dunbar, Cynthia E.; Townsley, Danielle M.; Winkler, Thomas; Monreal, Mariela; Jiang, Chunjie; Jordan, Elaine K.; Braylan, Raul C.			Bone Marrow as a Source of Cells for Paroxysmal Nocturnal Hemoglobinuria Detection	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Paroxysmal nocturnal hemoglobinuria (PNH); Fluorescently labeled aerolysin (FLAER); Bone marrow	PIG-A GENE; APLASTIC-ANEMIA PATIENTS; FLOW-CYTOMETRY; MYELODYSPLASTIC SYNDROMES; ANCHORED PROTEINS; PERIPHERAL-BLOOD; IMMUNOSUPPRESSIVE THERAPY; MINOR POPULATION; DEFICIENCY; DIFFERENTIATION	Objectives: To determine fluorescently labeled aerolysin (FLAER) binding and glycophosphatidylinositolanchored protein expression in bone marrow (BM) cells of healthy volunteers and patients with paroxysmal nocturnal hemoglobinuria (PNH) detected in peripheral blood (PB); compare PNH clone size in BM and PB; and detect PNH in BM by commonly used antibodies. Methods: Flow cytometry analysis of FLAER binding to leukocytes and expression of CD55/CD59 in erythrocytes. Analysis of CD16 in neutrophils and CD14 in monocytes in BM. Results: FLAER binds to all normal BM leukocytes, and binding increases with cell maturation. In PNH, lymphocytic clones are consistently smaller than clones of other BM cells. PNH clones are detectable in mature BM leukocytes with high specificity and sensitivity using common antibodies. Conclusions: PNH clone sizes measured in mature BM leukocytes and in PB are comparable, making BM suitable for PNH assessment. We further demonstrate that commonly used reagents (not FLAER or CD55/CD59) can reliably identify abnormalities of BM neutrophils and monocytes consistent with PNH cells.	[Dulau-Florea, Alina E.; Maric, Irina; Calvo, Katherine R.; Jiang, Chunjie; Jordan, Elaine K.; Braylan, Raul C.] NHLBI, Hematol Lab, Dept Lab Med, NIH, Bldg 10, Bethesda, MD 20892 USA; [Young, Neal S.; Dunbar, Cynthia E.; Townsley, Danielle M.; Winkler, Thomas] NHLBI, Cell Biol Sect, NIH, Bldg 10, Bethesda, MD 20892 USA; [Monreal, Mariela] Interpflow Corp, Miami, FL USA	Dulau-Florea, AE (reprint author), NIH, Clin Ctr, DLM, 10 Ctr Dr,Bldg 10,Rm 2C390C, Bethesda, MD 20892 USA.	alina.dulau-florea@nih.gov			AA/MDS International Foundation (Patricia and Vincent Geczik Legacy Fund); Division of Intramural Research, National Heart, Lung and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health Clinical CenterUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA	This work was supported by a grant from the AA/MDS International Foundation (Patricia and Vincent Geczik Legacy Fund), the Division of Intramural Research, National Heart, Lung and Blood Institute, and the National Institutes of Health Clinical Center.	Boccuni P, 2000, CRIT REV ONCOL HEMAT, V33, P25, DOI 10.1016/S1040-8428(99)00052-9; Borowitz MJ, 2010, CYTOM PART B-CLIN CY, V78B, P211, DOI 10.1002/cyto.b.20525; Brodsky RA, 2000, AM J CLIN PATHOL, V114, P459, DOI 10.1093/ajcp/114.3.459; Brooimans RA, 2009, CYTOM PART B-CLIN CY, V76B, P18, DOI 10.1002/cyto.b.20439; DEHAAS M, 1995, BLOOD, V86, P2403, DOI 10.1182/blood.V86.6.2403.bloodjournal8662403; Dunn DE, 1999, ANN INTERN MED, V131, P401, DOI 10.7326/0003-4819-131-6-199909210-00002; Hernandez-Campo PM, 2007, CYTOM PART B-CLIN CY, V72B, P34, DOI 10.1002/cyto.b.20143; Iwanaga M, 1998, BRIT J HAEMATOL, V102, P465, DOI 10.1046/j.1365-2141.1998.00794.x; Kulagin A, 2014, BRIT J HAEMATOL, V164, P546, DOI 10.1111/bjh.12661; Mannelli F, 2013, CYTOM PART B-CLIN CY, V84B, P71, DOI 10.1002/cyto.b.21064; MIYATA T, 1994, NEW ENGL J MED, V330, P249, DOI 10.1056/NEJM199401273300404; MIYATA T, 1993, SCIENCE, V259, P1318, DOI 10.1126/science.7680492; Mortazavi Y, 2003, BLOOD, V101, P2833, DOI 10.1182/blood-2002-07-2095; Olteanu H, 2006, AM J CLIN PATHOL, V126, P781, DOI 10.1309/AT3Y6WR03PX1K228; Piedras J, 2000, CYTOMETRY, V42, P234, DOI 10.1002/1097-0320(20000815)42:4<234::AID-CYTO3>3.0.CO;2-6; Risitano AM, 2012, IMMUNOBIOLOGY, V217, P1080, DOI 10.1016/j.imbio.2012.07.014; Rollinson S, 1997, BLOOD, V89, P3069, DOI 10.1182/blood.V89.8.3069; ROSSE WF, 1973, BRIT J HAEMATOL, V24, P327, DOI 10.1111/j.1365-2141.1973.tb01657.x; ROSSE WF, 1990, BLOOD, V75, P1595; Rosse WF, 1997, MEDICINE, V76, P63, DOI 10.1097/00005792-199703000-00001; Scheinberg P, 2009, BRIT J HAEMATOL, V144, P206, DOI 10.1111/j.1365-2141.2008.07450.x; SCHREZENMEIER H, 1995, EXP HEMATOL, V23, P81; Stetler-Stevenson M, 2001, BLOOD, V98, P979, DOI 10.1182/blood.V98.4.979; Sugimori C, 2006, BLOOD, V107, P1308, DOI 10.1182/blood-2005-06-2485; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; TERSTAPPEN LWMM, 1992, J LEUKOCYTE BIOL, V52, P652; Thomason RW, 2004, AM J CLIN PATHOL, V122, P128, DOI 10.1309/QQLFQU88XK435EPY; Timeus F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101948; Tomita M, 1999, BBA-MOL BASIS DIS, V1455, P269, DOI 10.1016/S0925-4439(99)00068-X; van de Loosdrecht AA, 2013, J NATL COMPR CANC NE, V11, P892, DOI 10.6004/jnccn.2013.0106; van Lochem EG, 2004, CYTOM PART B-CLIN CY, V60B, P1, DOI 10.1002/cyto.b.20008; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Wang HB, 2002, BLOOD, V100, P3897, DOI 10.1182/blood-2002-03-0799; Westers TM, 2012, LEUKEMIA, V26, P1730, DOI 10.1038/leu.2012.30; Yang HS, 2013, BIOMARK MED, V7, P99, DOI [10.2217/BMM.12.80, 10.2217/bmm.12.80]	35	0	0	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	SEP	2018	150	3					273	282		10.1093/ajcp/aqy053			10	Pathology	Pathology	GS3SL	WOS:000443540700010	29982419	Bronze			2019-10-28	
J	Uguen, A; Troncone, G				Uguen, Arnaud; Troncone, Giancarlo			A review on the Idylla platform: towards the assessment of actionable genomic alterations in one day	JOURNAL OF CLINICAL PATHOLOGY			English	Review						Idylla; BRAF; NRAS; KRAS; EGFR	PARAFFIN-EMBEDDED TISSUE; CLINICAL-PERFORMANCE EVALUATION; MOLECULAR DIAGNOSTICS SYSTEM; FULLY AUTOMATED PLATFORM; BRAF MUTATION TEST; REAL-TIME PCR; LUNG-CANCER; MULTICENTER EVALUATION; COLORECTAL-CANCER; NCCN GUIDELINES		[Uguen, Arnaud] CHRU Brest, Dept Pathol, Brest, France; [Uguen, Arnaud] INSERM, U1053, BaRITOn, Bordeaux, France; [Troncone, Giancarlo] Univ Napoli Federico II, Dept Publ Hlth, Anat Pathol Unit, Naples, Italy	Uguen, A (reprint author), Univ Hosp Morvan, Dept Pathol, F-29609 Brest, France.	arnaud.uguen@chu-brest.fr					Ajani JA, 2016, J NATL COMPR CANC NE, V14, P1286, DOI 10.6004/jnccn.2016.0137; Barel F, 2018, ACTA DERM-VENEREOL, V98, P44, DOI 10.2340/00015555-2738; Benson AB, 2017, J NATL COMPR CANC NE, V15, P370, DOI 10.6004/jnccn.2017.0036; Bisschop C, 2018, MELANOMA RES, V28, P96, DOI 10.1097/CMR.0000000000000421; Capoluongo E, 2017, SEMIN ONCOL, V44, P187, DOI 10.1053/j.seminoncol.2017.08.004; Coit DG, 2016, J NATL COMPR CANC NE, V14, P945, DOI 10.6004/jnccn.2016.0101; Colling R, 2017, J CLIN PATHOL, V70, P610, DOI 10.1136/jclinpath-2017-204356; Colling R, 2016, J CLIN PATHOL, V69, P398, DOI 10.1136/jclinpath-2015-203345; de Biase D, 2016, J CLIN PATHOL, V69, P986, DOI 10.1136/jclinpath-2016-203696; De Luca C, 2017, CYTOJOURNAL, V13, DOI [10.4103/1742-6413.200936, 10.4103/1742-6413.200936of]; De Luca C, 2017, J CLIN PATHOL, V70, P295, DOI 10.1136/jclinpath-2016-203989; De Montpreville VT, 2017, PATHOL RES PRACT, V213, P793, DOI 10.1016/j.prp.2017.03.011; Gradishar WJ, 2015, J NATL COMPR CANC NE, V13, P1475, DOI 10.6004/jnccn.2015.0176; Guo ZY, 2016, HUM PATHOL, V53, P168, DOI 10.1016/j.humpath.2016.03.013; Harle A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153576; Ilie M, 2017, ONCOTARGET, V8, P103055, DOI 10.18632/oncotarget.21476; Janku F, 2016, MOL CANCER THER, V15, P1397, DOI 10.1158/1535-7163.MCT-15-0712; Janku F, 2015, ONCOTARGET, V6, P26886, DOI 10.18632/oncotarget.4723; Johnston L, 2018, J CLIN PATHOL, V71, P336, DOI 10.1136/jclinpath-2017-204629; Lambros L, 2017, J CLIN PATHOL, V70, P544, DOI 10.1136/jclinpath-2016-204202; Le Flahec G, 2017, J CLIN PATHOL, V70, P906, DOI 10.1136/jclinpath-2017-204579; Lindeman NI, 2018, ARCH PATHOL LAB MED, V142, P321, DOI 10.5858/arpa.2017-0388-CP; Maertens G, 2017, ANN ONCOLOGY S5, V28, DOI [10. 1093/annonc/mdx363. 054, DOI 10.1093/ANNONC/MDX363.054]; Melchior L, 2015, EXP MOL PATHOL, V99, P485, DOI 10.1016/j.yexmp.2015.09.004; Schiefer AI, 2016, J MOL DIAGN, V18, P370, DOI 10.1016/j.jmoldx.2015.12.005; Seremet T, 2018, MELANOMA RES, V28, P65, DOI 10.1097/CMR.0000000000000415; Solassol J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163444; von Mehren M, 2014, J NATL COMPR CANC NE, V12, P853, DOI 10.6004/jnccn.2014.0080; Weyn C, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3112-0; Yeo MK, 2017, J CLIN PATHOL, V70, P260, DOI 10.1136/jclinpath-2016-204025	30	8	8	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	SEP	2018	71	9					757	762		10.1136/jclinpath-2018-205189			6	Pathology	Pathology	GS4HG	WOS:000443600700001	29903742				2019-10-28	
J	Autier, B; Dion, S; Robert-Gangneux, F				Autier, Brice; Dion, Sarah; Robert-Gangneux, Florence			The liver as an organ at risk for Toxoplasma transmission during transplantation: myth or reality?	JOURNAL OF CLINICAL PATHOLOGY			English	Article						toxoplasma; transplantation; liver; infections	TIME PCR; MAGNETIC CAPTURE; TISSUE TROPISM; GONDII; INFECTION; DIAGNOSIS; RECIPIENTS; CELLS	Aim Toxoplasmosis following liver transplant with donor-recipient mismatch is rare, but is often life-threatening. However, there are no data on the frequency of cyst carriage in the liver, nor consensual chemoprophylaxis guidelines. This study aimed at describing frequency and localisation of Toxoplasma cysts in the liver in a mouse model of chronic infection to predict the risk in liver transplantation. Methods Heart, brain and liver lobes of 21 mice chronically infected with Toxoplasma were collected for DNA extraction and amplification of Toxoplasma gondii rep529 sequence by real-time PCR. Results Parasite DNA was detected in the liver of 19/21 mice (90.5%), with no preferential anatomical localisation, but with higher parasite loads in the papillary process. Parasite loads in the liver were far lower than in brain and heart. The number of infected lobes was inversely correlated to the total liver weight, but was independent of the brain parasite load and of the parasite strain. Conclusions The liver is a frequent site of cyst carriage, confirming that transplantation of an organ from a seropositive donor to seronegative recipient is at high risk for acquired toxoplasmosis. Systematic serological screening prior to transplantation and chemoprophylaxis in patients at risk are fully justified.	[Autier, Brice; Robert-Gangneux, Florence] CHU Rennes, Lab Parasitol Mycol, F-35033 Rennes, France; [Dion, Sarah; Robert-Gangneux, Florence] INSERM, U0185, Inst Rech Sante Environm & Travail, Rennes, France; [Dion, Sarah; Robert-Gangneux, Florence] Univ Rennes 1, Rennes, France	Robert-Gangneux, F (reprint author), CHU Rennes, Lab Parasitol Mycol, F-35033 Rennes, France.	florence.robert-gangneux@univ-rennes1.fr			European Society of Clinical Microbiology & Infectious Diseases, Study Group of Clinical Parasitology (ESGCP) [P307-09]	The Centre Hospitalier Universitaire de Rennes supports the animal facility for its routine use for toxoplasmosis diagnosis. Molecular analyses were funded by a grant of the European Society of Clinical Microbiology & Infectious Diseases, Study Group of Clinical Parasitology (ESGCP)(#P307-09).	Assi MA, 2007, TRANSPL INFECT DIS, V9, P132, DOI 10.1111/j.1399-3062.2006.00187.x; Batista MV, 2011, TROP MED INT HEALTH, V16, P1134, DOI 10.1111/j.1365-3156.2011.02816.x; Campbell AL, 2006, TRANSPLANTATION, V81, P408, DOI 10.1097/01.tp.0000188183.49025.d5; Caner A, 2008, LIVER TRANSPLANT, V14, P1526, DOI 10.1002/lt.21558; Dadimoghaddam Y, 2014, ASIAN PAC J TROP MED, V7, P521, DOI 10.1016/S1995-7645(14)60087-0; Derouin F, 2008, CLIN MICROBIOL INFEC, V14, P1089, DOI 10.1111/j.1469-0691.2008.02091.x; Djurkovic-Djakovic O, 2012, EXP PARASITOL, V131, P372, DOI 10.1016/j.exppara.2012.05.006; Fernandez-Sabe N, 2012, CLIN INFECT DIS, V54, P355, DOI 10.1093/cid/cir806; Ramirez MLG, 2006, TRANSPL INFECT DIS, V8, P233, DOI 10.1111/j.1399-3062.2006.00140.x; He JJ, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1716-x; He JJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152022; Jauregui LH, 2001, J CLIN MICROBIOL, V39, P2065, DOI 10.1128/JCM.39.6.2065-2071.2001; Jurankova J, 2014, FOOD MICROBIOL, V38, P167, DOI 10.1016/j.fm.2013.08.011; Jurankova J, 2013, VET PARASITOL, V193, P95, DOI 10.1016/j.vetpar.2012.11.016; Miltgen G, 2016, NEW MICROBIOL, V39, P160; Robert-Gangneux F, 2015, J CLIN MICROBIOL, V53, P1677, DOI 10.1128/JCM.03282-14; Robert-Gangneux F, 2012, CLIN MICROBIOL REV, V25, P264, DOI 10.1128/CMR.05013-11; Robert-Gangneux F, 2010, PEDIATR INFECT DIS J, V29, P33, DOI 10.1097/INF.0b013e3181b20ed1; Rodrigues V, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1412-x; Soulard V, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8690; Sun HC, 2017, PARASITE, V24, DOI 10.1051/parasite/2017023; Unno A, 2013, EXP PARASITOL, V134, P160, DOI 10.1016/j.exppara.2013.03.006; Vaessen N, 2007, NETH J MED, V65, P222; Wang HL, 2016, PARASITE, V23, DOI 10.1051/parasite/2016012; Webb GJ, 2016, TRANSPL INFECT DIS, V18, P805, DOI 10.1111/tid.12589; Zoller B, 2013, PARASITOL RES, V112, P1841, DOI 10.1007/s00436-013-3337-z	26	2	2	1	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	SEP	2018	71	9					763	766		10.1136/jclinpath-2018-205066			4	Pathology	Pathology	GS4HG	WOS:000443600700002	29535213				2019-10-28	
J	Fumagalli, C; Vacirca, D; Rappa, A; Passaro, A; Guarize, J; Raviele, PR; de Marinis, F; Spaggiari, L; Casadio, C; Viale, G; Barberis, M; Guerini-Rocco, E				Fumagalli, Caterina; Vacirca, Davide; Rappa, Alessandra; Passaro, Antonio; Guarize, Juliana; Raviele, Paola Rafaniello; de Marinis, Filippo; Spaggiari, Lorenzo; Casadio, Chiara; Viale, Giuseppe; Barberis, Massimo; Guerini-Rocco, Elena			The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics	JOURNAL OF CLINICAL PATHOLOGY			English	Article						lung cancer; molecular pathology; cancer genetics	JOINT-CONSENSUS-RECOMMENDATION; TYROSINE KINASE INHIBITORS; OF-AMERICAN-PATHOLOGISTS; SOLID TUMORS; OPEN-LABEL; GENOMIC ALTERATIONS; NSCLC PATIENTS; PHASE-2 TRIAL; EGFR; MUTATIONS	Background Molecular profiling of advanced non-small cell lung cancers (NSCLC) is essential to identify patients who may benefit from targeted treatments. In the last years, the number of potentially actionable molecular alterations has rapidly increased. Next-generation sequencing allows for the analysis of multiple genes simultaneously. Aims To evaluate the feasibility and the throughput of next-generation sequencing in clinical molecular diagnostics of advanced NSCLC. Methods A single-institution cohort of 535 non-squamous NSCLC was profiled using a next-generation sequencing panel targeting 22 actionable and cancer-related genes. Results 441 non-squamous NSCLC (82.4%) harboured at least one gene alteration, including 340 cases (63.6%) with clinically relevant molecular aberrations. Mutations have been detected in all but one gene (FGFR1) of the panel. Recurrent alterations were observed in KRAS, TP53, EGFR, STK11 and MET genes, whereas the remaining genes were mutated in <5% of the cases. Concurrent mutations were detected in 183 tumours (34.2%), mostly impairing KRAS or EGFR in association with TP53 alterations. Conclusions The study highlights the feasibility of targeted next-generation sequencing in clinical setting. The majority of NSCLC harboured mutations in clinically relevant genes, thus identifying patients who might benefit from different targeted therapies.	[Fumagalli, Caterina; Vacirca, Davide; Rappa, Alessandra; Raviele, Paola Rafaniello; Casadio, Chiara; Viale, Giuseppe; Barberis, Massimo; Guerini-Rocco, Elena] European Inst Oncol, Div Pathol & Lab Med, I-20141 Milan, Italy; [Passaro, Antonio; de Marinis, Filippo] European Inst Oncol, Div Thorac Oncol, Milan, Italy; [Guarize, Juliana; Spaggiari, Lorenzo] European Inst Oncol, Div Thorac Surg, Milan, Italy; [Spaggiari, Lorenzo; Viale, Giuseppe; Guerini-Rocco, Elena] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy	Barberis, M (reprint author), European Inst Oncol, Div Pathol & Lab Med, I-20141 Milan, Italy.	massimo.barberis@ieo.it	Passaro, Antonio/M-1888-2016; Fumagalli, Caterina/J-1048-2018	Passaro, Antonio/0000-0002-7575-3870; Fumagalli, Caterina/0000-0001-5417-7985			Aberle DR, 2011, NEW ENGL J MED, V365, P395, DOI 10.1056/NEJMoa1102873; Baldacci S, 2017, ONCOTARGET, V8, P105103, DOI 10.18632/oncotarget.21707; Casadio C, 2015, AM J CLIN PATHOL, V144, P629, DOI 10.1309/AJCPXGRAIMB4CTQ3; Chapman AM, 2016, LUNG CANCER, V102, P122, DOI 10.1016/j.lungcan.2016.10.010; Chen Z, 2012, NATURE, V483, P613, DOI 10.1038/nature10937; Deans ZC, 2017, VIRCHOWS ARCH, V470, P5, DOI 10.1007/s00428-016-2025-7; Fumagalli C, 2017, ECANCERMEDICALSCIENC, V11, DOI 10.3332/ecancer.2017.717; Gerber David E, 2014, Am Soc Clin Oncol Educ Book, pe353, DOI 10.14694/EdBook_AM.2014.34.e353; Goswami RS, 2016, AM J CLIN PATHOL, V145, P222, DOI 10.1093/ajcp/aqv023; Heuckmann JM, 2015, ANN ONCOL, V26, P1830, DOI 10.1093/annonc/mdv184; Hyman DM, 2017, J CLIN ONCOL, V35, P2251, DOI 10.1200/JCO.2017.73.0143; Illei PB, 2017, ONCOTARGET, V8, P96684, DOI 10.18632/oncotarget.18042; Janne PA, 2015, NEW ENGL J MED, V372, P1689, DOI 10.1056/NEJMoa1411817; Jennings LJ, 2017, J MOL DIAGN, V19, P341, DOI 10.1016/j.jmoldx.2017.01.011; Kerr KM, 2014, ANN ONCOL, V25, P1681, DOI 10.1093/annonc/mdu145; Kim JH, 2017, J PATHOL TRANSL MED, V51, P191, DOI 10.4132/jptm.2017.03.14; Kimura H, 2014, LUNG CANCER, V83, P329, DOI 10.1016/j.lungcan.2013.12.012; Kris MG, 2015, ANN ONCOL, V26, P1421, DOI 10.1093/annonc/mdv186; Lee CK, 2017, LUNG CANCER, V113, P106, DOI 10.1016/j.lungcan.2017.09.005; Li MM, 2017, J MOL DIAGN, V19, P4, DOI 10.1016/j.jmoldx.2016.10.002; Li S, 2014, BRIT J CANCER, V110, P2812, DOI 10.1038/bjc.2014.210; Lih CJ, 2017, J MOL DIAGN, V19, P313, DOI 10.1016/j.jmoldx.2016.10.007; Lindeman NI, 2018, ARCH PATHOL LAB MED, V142, P321, DOI 10.5858/arpa.2017-0388-CP; Linee Guida Neoplasie del polmone, 2016, LIN GUID NEOPL POLM; Malapelle U, 2017, CANCER CYTOPATHOL, V125, P615, DOI 10.1002/cncy.21868; Martorell PM, 2017, CLIN LUNG CANCER, V18, pE395, DOI 10.1016/j.cllc.2017.04.006; Ohashi K, 2013, CLIN CANCER RES, V19, P2584, DOI 10.1158/1078-0432.CCR-12-3173; Passaro A, 2017, PHARMACOL RES, V117, P406, DOI 10.1016/j.phrs.2017.01.003; Planchard D, 2016, LANCET ONCOL, V17, P984, DOI 10.1016/S1470-2045(16)30146-2; Planchard D, 2016, LANCET ONCOL, V17, P642, DOI 10.1016/S1470-2045(16)00077-2; Popper HH, 2014, TRANSL LUNG CANCER R, V3, P291, DOI 10.3978/j.issn.2218-6751.2014.10.01; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Sequist LV, 2013, J CLIN ONCOL, V31, P3327, DOI 10.1200/JCO.2012.44.2806; Shaw AT, 2016, LANCET ONCOL, V17, P234, DOI 10.1016/S1470-2045(15)00488-X; Shaw AT, 2014, NEW ENGL J MED, V370, P1189, DOI 10.1056/NEJMoa1311107; Shaw AT, 2013, NEW ENGL J MED, V368, P2385, DOI 10.1056/NEJMoa1214886; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Skoulidis F, 2015, CANCER DISCOV, V5, P860, DOI 10.1158/2159-8290.CD-14-1236; Suh JH, 2016, ONCOLOGIST, V21, P684, DOI 10.1634/theoncologist.2016-0030; Sukhai MA, 2016, GENET MED, V18, P128, DOI 10.1038/gim.2015.47; VanderLaan PA, 2017, LUNG CANCER, V106, P17, DOI 10.1016/j.lungcan.2017.01.011; Vigneswaran J, 2016, ONCOTARGET, V7, P18876, DOI 10.18632/oncotarget.7739; von Laffert M, 2014, J THORAC ONCOL, V9, P1685, DOI 10.1097/JTO.0000000000000332; Zhang Q, 2016, CANCER CHEMOTH PHARM, V77, P583, DOI 10.1007/s00280-016-2969-y	46	2	2	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	SEP	2018	71	9					767	773		10.1136/jclinpath-2018-205032			7	Pathology	Pathology	GS4HG	WOS:000443600700003	29535211				2019-10-28	
J	Kim, JU; Ryu, DS; Cha, CH; Park, SH				Kim, Jeong-Uk; Ryu, Dae-Shick; Cha, Choong-Hwan; Park, Seon-Hee			Paradigm for diagnosing mycobacterial disease: direct detection and differentiation of Mycobacterium tuberculosis complex and non-tuberculous mycobacteria in clinical specimens using multiplex real-time PCR	JOURNAL OF CLINICAL PATHOLOGY			English	Article						mycobacterium tuberculosiscomplex; nontuberculous mycobacteria; real-time PCR; tuberculosis; nontuberculous mycobacterial disease	TAQMAN MTB PCR; LUNG-DISEASE; RESPIRATORY SPECIMENS; PULMONARY-DISEASE; IDENTIFICATION; ASSAY; INFECTIONS; SAMPLES; PERFORMANCE; KOREA	AimsMycobacterium tuberculosis and non-tuberculous mycobacteria (NTM) are clinically different, and the rapid detection and differentiation of M. tuberculosis complex (MTBC) and NTM is crucial for patient management and infection control. Given the slow growth of most pathogenic mycobacteria, nucleic acid amplification assays are excellent tools for direct identification of mycobacteria in clinical specimens. Recently, a multiplex real-time PCR assay was developed that can directly detect 20 mycobacterial species in clinical specimens. Here, we evaluated the diagnostic performance of the assay for diagnosing mycobacterial disease under routine laboratory conditions. Methods A total of 3334 specimens collected from 1437 patients suspected of tuberculosis infection were subjected to acid-fast bacilli staining, conventional culture and the multiplex real-time PCR assay. To evaluate the sensitivity and specificity of the assay, the overall diagnosis of tuberculosis was defined by positive culture plus medical history, and the 2007 American Thoracic Society and Infectious Disease Society of America diagnostic criteria for NTM disease were applied. Results The sensitivity, specificity, positive predictive value and negative predictive value were 87.5%, 99.6%, 96.1% and 98.5%, respectively, for the detection of MTBC isolates and 53.3%, 99.9%, 95.2%, and 98.9%, respectively, for detecting NTM isolates. Conclusions Thus, the assay can correctly differentiate between MTBC and NTM isolates in clinical specimens and would be a useful tool for the rapid differentiation of tuberculosis and NTM disease, despite its limited sensitivity for the diagnosis of NTM disease.	[Kim, Jeong-Uk; Cha, Choong-Hwan; Park, Seon-Hee] Univ Ulsan, Gangneung Asan Hosp, Coll Med, Dept Lab Med, Kangnung, South Korea; [Ryu, Dae-Shick] Univ Ulsan, Gangneung Asan Hosp, Coll Med, Dept Radiol, Kangnung, South Korea	Kim, JU (reprint author), Univ Ulsan, Gangneung Asan Hosp, Coll Med, Dept Lab Med, Kangnung, South Korea.	jukim@gnah.co.kr	Cha, Choong-Hwan/N-3677-2013	Cha, Choong-Hwan/0000-0002-9413-6763	Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea [A102065]	This study was supported by a grant from the Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (A102065).	Beqaj SH, 2007, DIAGN MOL PATHOL, V16, P169, DOI 10.1097/PDM.0b013e318037552e; Bicmen C, 2011, J CLIN MICROBIOL, V49, P2874, DOI 10.1128/JCM.00612-11; Buijtels PCA, 2005, J MICROBIOL METH, V62, P83, DOI 10.1016/j.mimet.2005.01.010; Chen JHK, 2015, EUR J CLIN MICROBIOL, V34, P1827, DOI 10.1007/s10096-015-2419-5; Cho SY, 2011, YONSEI MED J, V52, P301, DOI 10.3349/ymj.2011.52.2.301; Cho WH, 2015, ANN LAB MED, V35, P356, DOI 10.3343/alm.2015.35.3.356; de Luna FFA, 2006, J CLIN MICROBIOL, V44, P3025, DOI 10.1128/JCM.00068-06; Glassroth J, 2008, CHEST, V133, P243, DOI 10.1378/chest.07-0358; Griffith DE, 2007, AM J RESP CRIT CARE, V175, P367, DOI 10.1164/rccm.200604-571ST; Griffith DE, 2010, CURR OPIN INFECT DIS, V23, P185, DOI 10.1097/QCO.0b013e328336ead6; Hoefsloot W, 2013, EUR RESPIR J, V42, P1604, DOI 10.1183/09031936.00149212; Jeong J, 2008, KOREAN J LAB MED, V28, P24, DOI 10.3343/kjlm.2008.28.1.24; Kim JU, 2015, J APPL MICROBIOL, V118, P1498, DOI 10.1111/jam.12780; Kim JH, 2011, J CLIN MICROBIOL, V49, P173, DOI 10.1128/JCM.00694-10; Kim YK, 2014, INT J TUBERC LUNG D, V18, P725, DOI 10.5588/ijtld.13.0871; Koh WJ, 2006, INT J TUBERC LUNG D, V10, P1001; Koh WJ, 2006, CHEST, V129, P341, DOI 10.1378/chest.129.2.341; Koh WJ, 2013, TUBERC RESPIR DIS, V75, P199, DOI 10.4046/trd.2013.75.5.199; Kwon YS, 2016, J KOREAN MED SCI, V31, P649, DOI 10.3346/jkms.2016.31.5.649; Lee AR, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-558; Lee SK, 2012, SCAND J INFECT DIS, V44, P733, DOI 10.3109/00365548.2012.681695; Martinez S, 2007, AM J ROENTGENOL, V189, P177, DOI 10.2214/AJR.07.2074; Mitarai S, 2012, J CLIN MICROBIOL, V50, P884, DOI 10.1128/JCM.05638-11; Omar SV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024789; Peter-Getzlaff S, 2008, J CLIN MICROBIOL, V46, P4023, DOI 10.1128/JCM.01101-08; Peter-Getzlaff S, 2010, J CLIN MICROBIOL, V48, P3943, DOI 10.1128/JCM.00851-10; Piersimoni C, 2003, J CLIN MICROBIOL, V41, P5355, DOI 10.1128/JCM.41.12.5355-5365.2003; Somoskovi A, 2014, CLIN LAB MED, V34, P271, DOI 10.1016/j.cll.2014.03.001; Tortoli E, 2009, CLIN MICROBIOL INFEC, V15, P906, DOI 10.1111/j.1469-0691.2009.03014.x; Van Ingen J, 2007, AM J RESP CRIT CARE, V176, P418, DOI 10.1164/ajrccm.176.4.418; van Ingen J, 2013, SEMIN RESP CRIT CARE, V34, P103, DOI 10.1055/s-0033-1333569; van Ingen J, 2009, J INFECTION, V59, P324, DOI 10.1016/j.jinf.2009.08.016; WALSH PS, 1991, BIOTECHNIQUES, V10, P506; Weiss CH, 2012, EXPERT REV RESP MED, V6, P597, DOI [10.1586/ers.12.58, 10.1586/ERS.12.58]; WHO, 2017, GLOB TUB REP 2017; Yang YC, 2011, J CLIN MICROBIOL, V49, P797, DOI 10.1128/JCM.01839-10; Yoo JW, 2012, TUBERC RESPIR DIS, V72, P409, DOI 10.4046/trd.2012.72.5.409	37	4	4	2	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	SEP	2018	71	9					774	780		10.1136/jclinpath-2017-204945			7	Pathology	Pathology	GS4HG	WOS:000443600700004	29559518				2019-10-28	
J	Wong, SCY; Poon, RWS; Foo, CH; Ngan, AHY; Tse, H; Lam, VCM; Leung, THY; Wong, CP; Cheng, VCC; Chen, JHK; Yuen, KY				Wong, Sally Cheuk Ying; Poon, Rosana W. S.; Foo, Chuen-Hing; Ngan, Antonio H. Y.; Tse, Herman; Lam, Vivian C. M.; Leung, Tiffany H. Y.; Wong, Chun-Pong; Cheng, Vincent C. C.; Chen, Jonathan H. K.; Yuen, Kwok-Yung			Novel selective medium for the isolation of corynebacterium kroppenstedtii from heavily colonised clinical specimens	JOURNAL OF CLINICAL PATHOLOGY			English	Article						corynebacteria; diagnostics; breast; infections	NEUTROPHILIC GRANULOMATOUS MASTITIS; MASS-SPECTROMETRY; IDENTIFICATION; INFECTION	Aims Granulomatous mastitis due to Corynebacterium kroppenstedtii is an increasingly recognised cause of an indolent and distressing mastitis in non-lactating females. This slow-growing lipophilic organism is not reliably isolated using routine culture methods. A novel selective culture medium (CKSM) is designed to optimise the isolation of this organism from clinical specimens. Methods CKSM contains 10% galactose and Tween 80 (10%) to enhance the growth of C. kroppenstedtii, fosfomycin (100 mu g/mL) to suppress the other bacteria, and differentiate C. kroppenstedtii from non-kroppenstedtii lipophilic corynebacteria by esculin hydrolysis. The medium was evaluated for its ability to support the growth of C. kroppenstedtii, selection and differentiation of C. kroppenstedtii from other bacteria in non-sterile clinical specimens. ResultsC. kroppenstedtii grew as 1-2mm colonies with black halo on CKSM within 72hours of incubation, compared with barely visible pinpoint colonies on routine blood agars. During the four-month period of evaluation with 8896 respiratory specimens, 103 breast specimens, 1903 female genital tract specimens, 617 newborn surface swabs and 10011 miscellaneous specimens, 186 C. kroppenstedtii were isolated, including 127 (1.4%) respiratory and 59 (0.5%) miscellaneous specimens, 184 of them were found only on CKSM. Besides the three (2.9%) positive breast specimens, 27 (1.4%) high vaginal and endocervical swabs, and 11 (1.8%) surface swabs of newborns were positive for C. kroppenstedtii. Conclusions CKSM is a useful addition to routine agar media for the isolation of C. kroppenstedtii, and will be helpful for studying the epidemiology and transmission of this unusual Corynebacterium causing granulomatous mastitis.	[Wong, Sally Cheuk Ying; Poon, Rosana W. S.; Foo, Chuen-Hing; Ngan, Antonio H. Y.; Tse, Herman; Lam, Vivian C. M.; Leung, Tiffany H. Y.; Wong, Chun-Pong; Cheng, Vincent C. C.; Chen, Jonathan H. K.; Yuen, Kwok-Yung] Queen Mary Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China; [Wong, Sally Cheuk Ying; Poon, Rosana W. S.; Ngan, Antonio H. Y.; Tse, Herman; Lam, Vivian C. M.; Leung, Tiffany H. Y.; Wong, Chun-Pong; Cheng, Vincent C. C.; Chen, Jonathan H. K.; Yuen, Kwok-Yung] Univ Hong Kong, Li Ka Shing Fac Med, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China	Yuen, KY (reprint author), Univ Hong Kong, Queen Mary Hosp, Carol Yu Ctr Infect, Hong Kong, Hong Kong, Peoples R China.	kyyuen@hku.hk		Yuen, Kwok-yung/0000-0002-2083-1552	Hong Kong University Foundation	This study was supported by the Hong Kong University Foundation.	Bao R, 2017, J THORAC DIS, V9, P3239, DOI 10.21037/jtd.2017.09.69; Collins MD, 1998, INT J SYST BACTERIOL, V48, P1449, DOI 10.1099/00207713-48-4-1449; Fernandez-Natal I., 2016, New Microbes and New Infections, V14, P93, DOI 10.1016/j.nmni.2016.09.006; Freiwald A, 2009, NAT PROTOC, V4, P732, DOI 10.1038/nprot.2009.37; Johnstone KJ, 2017, PATHOLOGY, V49, P405, DOI 10.1016/j.pathol.2017.01.006; Paviour S, 2002, CLIN INFECT DIS, V35, P1434, DOI 10.1086/344463; Renshaw AA, 2011, AM J CLIN PATHOL, V136, P424, DOI 10.1309/AJCP1W9JBRYOQSNZ; Sridhar S, 2015, J CLIN MICROBIOL, V53, P3377, DOI 10.1128/JCM.01508-15; Tauch A, 2016, INT J INFECT DIS, V48, P33, DOI 10.1016/j.ijid.2016.04.023; Taylor GB, 2003, PATHOLOGY, V35, P109, DOI [10.1080/0031302031000082197, 10.1080/00313020307574]; The European Committee on Antimicrobial Susceptibility Testing, 2017, BREAKP TABL INT MICS; Tsuzukibashi O, 2014, J MICROBIOL METH, V104, P67, DOI 10.1016/j.mimet.2014.06.005; Veloo ACM, 2016, CLIN MICROBIOL INFEC, V22, P793, DOI 10.1016/j.cmi.2016.06.016; Wayne PA, 2017, M100S27 CLIN LAB STA; Wong SCY, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx096; WOOLCOCK JB, 1979, J CLIN MICROBIOL, V9, P640; Yu HJ, 2016, INT J INFECT DIS, V53, P30, DOI 10.1016/j.ijid.2016.10.015; Zapardiel J, 1998, J MED MICROBIOL, V47, P79, DOI 10.1099/00222615-47-1-79	18	1	1	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	SEP	2018	71	9					781	786		10.1136/jclinpath-2017-204834			6	Pathology	Pathology	GS4HG	WOS:000443600700005	29593062				2019-10-28	
J	Robertson, S; Stalhammar, G; Darai-Ramqvist, E; Rantalainen, M; Tobin, NP; Bergh, J; Hartman, J				Robertson, Stephanie; Stalhammar, Gustav; Darai-Ramqvist, Eva; Rantalainen, Mattias; Tobin, Nicholas P.; Bergh, Jonas; Hartman, Johan			Prognostic value of Ki67 analysed by cytology or histology in primary breast cancer	JOURNAL OF CLINICAL PATHOLOGY			English	Article						breast cancer; Ki67; immunocytochemistry; immunohistochemistry	INTERNATIONAL EXPERT CONSENSUS; FACTOR RECEPTOR 2; PROGESTERONE-RECEPTOR; ESTROGEN-RECEPTOR; PRIMARY THERAPY; CLINICAL-IMPLICATIONS; WORKING GROUP; EXPRESSION; SUBTYPES; KI-67	Aims The accuracy of biomarker assessment in breast pathology is vital for therapy decisions. The therapy predictive and prognostic biomarkers oestrogen receptor (ER), progesterone receptor, HER2 and Ki67 may act as surrogates to gene expression profiling of breast cancer. The aims of this study were to investigate the concordance of consecutive biomarker assessment by immunocytochemistry on preoperative fine-needle aspiration cytology versus immunohistochemistry (IHC) on the corresponding resected breast tumours. Further, to investigate the concordance with molecular subtype and correlation to stage and outcome. Methods Two retrospective cohorts comprising 385 breast tumours with clinicopathological data including gene expression-based subtype and up to 10-year overall survival data were evaluated. Results In both cohorts, we identified a substantial variation in Ki67 index between cytology and histology and a switch between low and high proliferation within the same tumour in 121/360 cases. ER evaluations were discordant in only 1.5% of the tumours. From cohort 2, gene expression data with PAM50 subtype were used to correlate surrogate subtypes. IHC-based surrogate classification could identify the correct molecular subtype in 60% and 64% of patients by cytology (n=63) and surgical resections (n=73), respectively. Furthermore, high Ki67 in surgical resections but not in cytology was associated with poor overall survival and higher probability for axillary lymph node metastasis. Conclusions This study shows considerable differences in the prognostic value of Ki67 but not ER in breast cancer depending on the diagnostic method. Furthermore, our findings show that both methods are insufficient in predicting true molecular subtypes.	[Robertson, Stephanie; Stalhammar, Gustav; Tobin, Nicholas P.; Bergh, Jonas; Hartman, Johan] Karolinska Inst, Dept Oncol & Pathol, SE-17176 Stockholm, Sweden; [Robertson, Stephanie; Darai-Ramqvist, Eva; Hartman, Johan] Karolinska Univ Lab, Dept Clin Pathol & Cytol, Stockholm, Sweden; [Stalhammar, Gustav] St Erik Eye Hosp, Stockholm, Sweden; [Rantalainen, Mattias] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden; [Bergh, Jonas] Karolinska Univ Hosp, Karolinska Oncol, Dept Radiumhemmet, Stockholm, Sweden; [Hartman, Johan] Stockholm South Gen Hosp, Stockholm, Sweden	Hartman, J (reprint author), Karolinska Inst, Dept Oncol & Pathol, SE-17176 Stockholm, Sweden.	johan.hartman@ki.se	Hartman, Johan/N-1406-2015	Hartman, Johan/0000-0002-6500-8527; Stalhammar, Gustav/0000-0001-9401-8911	Swedish Society for Medical Research (SSMF); Swedish Cancer SocietySwedish Cancer Society; Stockholm Cancer Society; King Gustaf V Jubilee Fund; Karolinska InstitutetKarolinska Institutet; Stockholm County Council Research Strategy Committee; Swedish Breast Cancer Association (BRO)	This work was supported with grants from Swedish Society for Medical Research (SSMF), Swedish Cancer Society, Stockholm Cancer Society, King Gustaf V Jubilee Fund, Karolinska Institutet, Stockholm County Council Research Strategy Committee and Swedish Breast Cancer Association (BRO).	Bartlett JMS, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw050; Bastien RRL, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-44; Carey LA, 2016, J CLIN ONCOL, V34, P542, DOI 10.1200/JCO.2015.62.1268; Cheang MCU, 2009, JNCI-J NATL CANCER I, V101, P736, DOI 10.1093/jnci/djp082; Coates AS, 2015, ANN ONCOL, V26, P1533, DOI 10.1093/annonc/mdv221; Colozza M, 2005, ANN ONCOL, V16, P1723, DOI 10.1093/annonc/mdi352; Crabb SJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1847; Criscitiello C, 2014, BREAST, V23, P69, DOI 10.1016/j.breast.2013.11.007; Cuzick J, 2011, J CLIN ONCOL, V29, P4273, DOI 10.1200/JCO.2010.31.2835; de Azambuja E, 2007, BRIT J CANCER, V96, P1504, DOI 10.1038/sj.bjc.6603756; Domagala W, 1996, CLIN CANCER RES, V2, P147; Dowsett M, 2011, J NATL CANCER I, V103, P1656, DOI 10.1093/jnci/djr393; Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303; Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304; Grabau D, 2014, QUALITY STANDARDIZAT; Guiu S, 2012, ANN ONCOL, V23, P2997, DOI 10.1093/annonc/mds586; Knutsvik G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112121; Lester S, 2016, PROTOCOL EXAMINATION; Lindstrom LS, 2012, J CLIN ONCOL, V30, P2601, DOI 10.1200/JCO.2011.37.2482; Liu SQ, 2001, CLIN CANCER RES, V7, P1716; Lundberg A, 2017, CLIN CANCER RES, V23, P7512, DOI 10.1158/1078-0432.CCR-17-1535; Marrelli D, 2006, ONCOL REP, V15, P425; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Penault-Llorca F, 2009, J CLIN ONCOL, V27, P2809, DOI 10.1200/JCO.2008.18.2808; Polley MYC, 2013, JNCI-J NATL CANCER I, V105, P1897, DOI 10.1093/jnci/djt306; Prat A, 2015, BREAST, V24, pS26, DOI 10.1016/j.breast.2015.07.008; Prat A, 2014, CLIN CANCER RES, V20, P511, DOI 10.1158/1078-0432.CCR-13-0239; Prat A, 2013, J CLIN ONCOL, V31, P203, DOI 10.1200/JCO.2012.43.4134; Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003; Rantalainen M, 2016, SCI REP-UK, V6, DOI 10.1038/srep38037; Regional Cancer Center, 2018, NAT CAR PROGR BREAST; SIGURDSSON H, 1990, NEW ENGL J MED, V322, P1045, DOI 10.1056/NEJM199004123221505; Simmons C, 2009, ANN ONCOL, V20, P1499, DOI 10.1093/annonc/mdp028; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stalhammar G, 2016, MODERN PATHOL, V29, P318, DOI 10.1038/modpathol.2016.34; Stalhammar G, 2014, HISTOPATHOLOGY, V64, P971, DOI 10.1111/his.12344; Thompson AM, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2771; Trihia H, 2003, CANCER, V97, P1321, DOI 10.1002/cncr.11188; Urruticoechea A, 2005, J CLIN ONCOL, V23, P7212, DOI 10.1200/JCO.2005.07.501; Varga Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037379; Wang M, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0710-8; Yerushalmi R, 2010, LANCET ONCOL, V11, P174, DOI 10.1016/S1470-2045(09)70262-1	43	5	5	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	SEP	2018	71	9					787	794		10.1136/jclinpath-2017-204976			8	Pathology	Pathology	GS4HG	WOS:000443600700006	29588372				2019-10-28	
J	Gong, QX; Wang, Z; Liu, C; Li, X; Lu, TX; Liang, JH; Xu, W; Li, JY; Zhang, ZH				Gong, Qi-Xing; Wang, Zhen; Liu, Chong; Li, Xiao; Lu, Ting-Xun; Liang, Jin-Hua; Xu, Wei; Li, Jian-Yong; Zhang, Zhi-Hong			CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma	JOURNAL OF CLINICAL PATHOLOGY			English	Article						lymphoma; immunophenotyping; fish	RITUXIMAB-CHOP; SURVIVAL; CLASSIFICATION; REARRANGEMENT; CHEMOTHERAPY; PROGNOSIS; FEATURES; DEFINES; BIOLOGY	Aim CD30+ diffuselarge B-cell lymphoma (DLBCL) has emerged as a new immunophenotypic variant of de novo DLBCLs. However, the prevalence of CD30 positivity is variable according to different studies, and the prognostic significance of CD30 is also controversial. This study aimed to investigate the positive expression rate and prognostic impact of CD30 in de novo DLBCLs and try to find the correlated influences. Methods A total of 241 patients with de novo DLBCL in east China from 2008 to 2015 were included to investigate the prevalence, clinicopathological features and outcomes of CD30+ denovo DLBCLs. Immunohistochemical evaluation for CD10, CD30, BCL2, BCL6, MUM1/IRF4, MYC and Ki67, and fluorescence in situ hybridisation for MYC and BCL2 gene alterations were performed. Results Using a >0%threshold, CD30 expression was detected in approximately 10% patient with de novo DLBCL. These predominately presented with centroblastic or anaplastic morphological patterns, less frequently showing immunoblastic morphology or starry sky' pattern, mutually exclusive with MYC gene rearrangement, and negatively associated with BCL2 protein expression. CD30 expression was associated with a favourable prognosis of patients' outcomes. However, the multivariate analysis revealed that it was not an independent prognostic factor in de novo DLBCLs. The impact of CD30 might be influenced by the international prognostic index and the expression of MYC and BCL2 proteins. Conclusion CD30+ DLBCLmay be a subset of de novo DLBCLs with characteristic clinicopathological features, but the prognostic role of CD30 is limited.	[Gong, Qi-Xing; Wang, Zhen; Liu, Chong; Li, Xiao; Zhang, Zhi-Hong] Nanjing Med Univ, Affiliated Hosp 1, Dept Pathol, Nanjing 210029, Jiangsu, Peoples R China; [Lu, Ting-Xun; Liang, Jin-Hua; Xu, Wei; Li, Jian-Yong] Nanjing Med Univ, Affiliated Hosp 1, Dept Haematol, Nanjing 210029, Jiangsu, Peoples R China	Zhang, ZH (reprint author), Nanjing Med Univ, Affiliated Hosp 1, Dept Pathol, Nanjing 210029, Jiangsu, Peoples R China.; Li, JY (reprint author), Nanjing Med Univ, Affiliated Hosp 1, Dept Haematol, Nanjing 210029, Jiangsu, Peoples R China.	lijianyonglm@medmail.com.cn; zhangzhih2001@aliyun.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81773109]; National Scientific Foundation of Jiangsu Provincial of China [BK20151582]; National key Clinical Specialty Construction Project (2014); Fund of the priority Academic Program Development of Jiangsu Higher Education Institution [JX10231801]	This work was supported in part by grants from the National Natural Science Foundation of China (81773109), the National Scientific Foundation of Jiangsu Provincial of China (BK20151582), National key Clinical Specialty Construction Project (2014), and the Fund of the priority Academic Program Development of Jiangsu Higher Education Institution (JX10231801).	Campuzano-Zuluaga G, 2013, LEUKEMIA LYMPHOMA, V54, P2405, DOI 10.3109/10428194.2013.778407; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; Fu K, 2008, J CLIN ONCOL, V26, P4587, DOI 10.1200/JCO.2007.15.9277; Gong QX, 2015, INT J CLIN EXP PATHO, V8, P15825; Hans CP, 2004, BLOOD, V103, P275, DOI 10.1182/blood-2003-05-1545; Hao XX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126615; Hong J, 2012, ANN HEMATOL, V91, P1897, DOI 10.1007/s00277-012-1533-z; Horn H, 2015, AM J SURG PATHOL, V39, P61, DOI 10.1097/PAS.0000000000000319; Hu SM, 2013, BLOOD, V121, P2715, DOI 10.1182/blood-2012-10-461848; Iqbal J, 2004, AM J PATHOL, V165, P159, DOI 10.1016/S0002-9440(10)63284-1; Iqbal J, 2011, CLIN CANCER RES, V17, P7785, DOI 10.1158/1078-0432.CCR-11-0267; Kendrick SL, 2014, HUM PATHOL, V45, P2144, DOI 10.1016/j.humpath.2014.06.005; Korkolopoulou P, 2016, ADV ANAT PATHOL, V23, P202, DOI 10.1097/PAP.0000000000000117; Linderoth J, 2003, CLIN CANCER RES, V9, P722; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Slack GW, 2014, BRIT J HAEMATOL, V167, P608, DOI 10.1111/bjh.13085; Sotomayor EM, 2014, CLIN ADV HEMATOL ONC, V12, P3; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Wang XJ, 2016, EUR J HAEMATOL, V97, P39, DOI 10.1111/ejh.12680; Xu J, 2017, HUM PATHOL, V60, P160, DOI 10.1016/j.humpath.2016.10.009; Xu-Monette ZY, 2015, MODERN PATHOL, V28, P1555, DOI 10.1038/modpathol.2015.118; Xu-Monette ZY, 2015, ONCOTARGET, V6, P5615, DOI 10.18632/oncotarget.3479; Yamaguchi M, 2002, BLOOD, V99, P815, DOI 10.1182/blood.V99.3.815	23	0	0	1	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	SEP	2018	71	9					795	801		10.1136/jclinpath-2018-205039			7	Pathology	Pathology	GS4HG	WOS:000443600700007	29666157				2019-10-28	
J	Rakha, EA; Abbas, A; Ahumada, PP; ElSayed, ME; Colman, D; Pinder, SE; Ellis, IO				Rakha, Emad A.; Abbas, Areeg; Pinto Ahumada, Pablo; ElSayed, Maysa E.; Colman, Derek; Pinder, Sarah E.; Ellis, Ian O.			Diagnostic concordance of reporting lymphovascular invasion in breast cancer	JOURNAL OF CLINICAL PATHOLOGY			English	Article						interobserver agreement; lymphovascular invasion; breast cancer	BLOOD-VESSEL INVASION; OBSERVER AGREEMENT; VASCULAR INVASION; PATHOLOGY; PERFORMANCE; CARCINOMA; SCHEME; MODEL; EQA; UK	Aims This study aims to assess the diagnostic agreement of lymphovascular invasion (LVI) in invasive breast cancer (BC). Methods Data on LVI were collected from the UK National Health Service Breast Screening Programme pathology external quality assurance scheme database. 101 BCs assessed over a 10-year period (2004-2014) were included. Cases were scored by an average of 600 pathologists. Three H&E stained slides from each case were reviewed by three pathologists and additional variables were evaluated. Results In the whole series, the overall value was 0.4 (range 0.26-0.53). On review, LVI was detected in all three slides in 20 cases (20%), in two slides in 12 cases and in one of the three slides in 9 cases and was not seen in 60 cases. For concordance analysis, the first and last groups were used to represent cases with definite (LVI+) and absent LVI (LVI-), respectively. In the LVI+group (n=20), the level of agreement ranged from 0.54 to 0.99 (median 0.86). In the LVI- group (n=60), the level of agreement ranged from 0.52 to 1.00 (median 0.93), with 44% of cases showing interobserver concordance of >95%. There was a correlation between increasing number of involved lymphovascular spaces in the section and higher LVI reporting concordance. Some degree of retraction/fixation artefacts was observed in 35% of cases; this was associated with a lower concordance rate. Conclusions The concordance of reporting LVI is variable. Cases without LVI and those with multiple involved vessels are likely to have the highest concordance and the highest detection rates.	[Rakha, Emad A.; Abbas, Areeg; Colman, Derek; Ellis, Ian O.] Univ Nottingham, Nottingham Univ Hosp NHS Trust, Sch Med, Dept Histopathol, Nottingham, England; [Rakha, Emad A.] Menoufia Univ, Fac Med, Histopathol Dept, Shibin Al Kawm, Egypt; [Pinto Ahumada, Pablo] Hosp Clin Magallanes, Punta Arenas, Chile; [ElSayed, Maysa E.] Menoufia Univ, Fac Med, Publ Hlth Dept, Shibin Al Kawm, Egypt; [Pinder, Sarah E.] Kings Coll London, Guys Hosp, Canc Studies, London, England	Rakha, EA (reprint author), Nottingham Univ Hosp NHS Trust, Dept Histopathol, Nottingham NG5 1PB, England.	emadrakha@yahoo.com	Rakha, Emad/Q-5554-2019	/0000-0003-4167-8910; Rakha, Emad/0000-0002-5009-5525; Ellis, Ian/0000-0001-5292-8474			Aleskandarany MA, 2015, PATHOBIOLOGY, V82, P113, DOI 10.1159/000433583; [Anonymous], 2003, NHS BSP PUBLICATION, V57; BRENNAN P, 1992, BMJ-BRIT MED J, V304, P1491, DOI 10.1136/bmj.304.6840.1491; Choi Seung-Hye, 2003, Breast J, V9, P153, DOI 10.1046/j.1524-4741.2003.09304.x; Colleoni M, 2007, ANN ONCOL, V18, P1632, DOI 10.1093/annonc/mdm268; Debled M, 2010, J NATL CANCER I, V102, P275, DOI 10.1093/jnci/djp490; Ellis IO, 2006, J CLIN PATHOL, V59, P138, DOI 10.1136/jcp.2004.025551; Ellis IO, 2016, PATHOLOGY REPORTING, P160; Giuliano AE, 2017, CA-CANCER J CLIN, V67, P291, DOI 10.3322/caac.21393; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LAURIA R, 1995, CANCER-AM CANCER SOC, V76, P1772, DOI 10.1002/1097-0142(19951115)76:10<1772::AID-CNCR2820761014>3.0.CO;2-O; LEE AKC, 1990, J CLIN ONCOL, V8, P1457, DOI 10.1200/JCO.1990.8.9.1457; Mohammed RAA, 2011, J PATHOL, V223, P358, DOI 10.1002/path.2810; Olivotto IA, 2005, J CLIN ONCOL, V23, P2716, DOI 10.1200/JCO.2005.06.178; Parham DM, 2006, J CLIN PATHOL, V59, P130, DOI 10.1136/jcp.2004.025619; Pathology NCgFBS, 1995, PATH REP BREAST CANC; Rakha EA, 2017, J CLIN PATHOL, V70, P51, DOI 10.1136/jclinpath-2016-203800; Rakha EA, 2012, CANCER-AM CANCER SOC, V118, P3670, DOI 10.1002/cncr.26711; Royal College of Pathologists Working Group on Breast Screening, 1990, BREAST CANC SCREEN G; Shaw EC, 2012, J CLIN PATHOL, V65, P403, DOI 10.1136/jclinpath-2011-200369; Song YJ, 2011, J BREAST CANCER, V14, P198, DOI 10.4048/jbc.2011.14.3.198; Stacker SA, 2014, NAT REV CANCER, V14, P159, DOI 10.1038/nrc3677; Truong PT, 2005, J AM COLL SURGEONS, V200, P912, DOI 10.1016/j.jamcollsurg.2005.02.010; Ugras S, 2014, ANN SURG ONCOL, V21, P3780, DOI 10.1245/s10434-014-3851-y; Wishart GC, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-908	25	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	SEP	2018	71	9					802	805		10.1136/jclinpath-2017-204981			4	Pathology	Pathology	GS4HG	WOS:000443600700008	29599396				2019-10-28	
J	Rehman, A; Kim, Y; Kim, H; Sim, J; Ahn, H; Chung, MS; Shin, SJ; Jang, K				Rehman, Abdul; Kim, Yeseul; Kim, Hyunsung; Sim, Jongmin; Ahn, Hyein; Chung, Min Sung; Shin, Su-Jin; Jang, Kiseok			FOXO3a expression is associated with lymph node metastasis and poor disease-free survival in triple-negative breast cancer	JOURNAL OF CLINICAL PATHOLOGY			English	Article						breast cancer; metastasis; immunohistochemistry	TRANSCRIPTION FACTORS; UP-REGULATION; PACLITAXEL; APOPTOSIS; CELLS; GENE	Aims Forkhead box O (FOXO) transcription factors, consisting of FOXO1, FOXO3a, FOXO4 and FOXO6, are involved in carcinogenesis and tumour progression. Recent studies have suggested that FOXOs act as tumour suppressors in a variety of human cancers. This study investigated the clinicopathological significance of FOXOs in triple-negative breast cancer (TNBC). Methods FOXO protein expressions were assessed by immunohistochemistry in 125 TNBC tissues. Correlations between FOXO protein expression and various clinicopathological parameters, including patients' survival, were investigated. MDA-MB-468 cell line was used for in vitro cell proliferation and migration assay. Results FOXO1 protein expression was not observed in all 125 TNBC tissues. FOXO4 and FOXO6 protein expressions were detected in 11 (8.8%) and 14 (11.2%) TNBC tissues, respectively. Loss of FOXO4 expression was significantly associated with high histological grade (P=0.014, (2) test), and TNBCs with positive FOXO6 expression correlated with high grade (P=0.020, (2) test). FOXO3a expression was detected in 40 (32%) TNBC cases and correlated with adverse clinicopathological features, such as lymph node metastasis (P=0.021, (2) test), perineural invasion (P=0.013, (2) test) and higher Ki-67 proliferation index (P=0.048, t-test). Additionally, FOXO3a expression was significantly associated with poor disease-free survival (P=0.015, log-rank test). In the in vitro study, siRNA-mediated FOXO3a knockdown in the MDA-MB-468 cell line inhibited cell proliferation and migration. Conclusion Among FOXO members, FOXO3a may have a potential role in promoting tumour cell migration and proliferation and may serve as a prognostic biomarker and a potential therapeutic target for TNBC.	[Rehman, Abdul; Kim, Yeseul; Kim, Hyunsung; Sim, Jongmin; Shin, Su-Jin; Jang, Kiseok] Hanyang Univ, Coll Med, Dept Pathol, Seoul 04763, South Korea; [Ahn, Hyein] Konyang Univ, Coll Med, Dept Pathol, Daejeon, South Korea; [Chung, Min Sung] Hanyang Univ, Coll Med, Dept Surg, Seoul, South Korea	Jang, K (reprint author), Hanyang Univ, Coll Med, Dept Pathol, Seoul 04763, South Korea.	medartisan@hanyang.ac.kr			National Research Foundation of Korea (NRF) - Korean government (MSIP) [2015R1C1A1A01056091]	This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIP) (No. 2015R1C1A1A01056091).	Boyle P, 2005, BREAST, V14, P429, DOI 10.1016/j.breast.2005.10.001; Chen HY, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003708; Chen JP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013903; de Brachene AC, 2016, CELL MOL LIFE SCI, V73, P1159, DOI 10.1007/s00018-015-2112-y; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Goto T, 2008, BRIT J CANCER, V98, P1068, DOI 10.1038/sj.bjc.6604279; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Hu HJ, 2015, MOL MED REP, V12, P575, DOI 10.3892/mmr.2015.3362; Jiang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070746; Karadedou CT, 2012, ONCOGENE, V31, P1845, DOI 10.1038/onc.2011.368; Kim TH, 2009, J KOREAN MED SCI, V24, P468, DOI 10.3346/jkms.2009.24.3.468; Li J, 2016, ONCOTARGET, V7, P25585, DOI 10.18632/oncotarget.8339; Li QY, 2013, FEBS LETT, V587, P2105, DOI 10.1016/j.febslet.2013.05.027; Li R, 2007, HUM PATHOL, V38, P1501, DOI 10.1016/j.humpath.2007.02.016; Oh CM, 2016, CANCER RES TREAT, V48, P436, DOI 10.4143/crt.2016.089; Queiroz EAIF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098207; Santamaria CM, 2009, LEUKEMIA RES, V33, P1706, DOI 10.1016/j.leukres.2009.04.024; Sharma P, 2016, ONCOLOGIST, V21, P1050, DOI 10.1634/theoncologist.2016-0067; Sisci D, 2013, CELL CYCLE, V12, P3405, DOI 10.4161/cc.26421; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Stan SD, 2008, CANCER RES, V68, P7661, DOI 10.1158/0008-5472.CAN-08-1510; Su B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101411; Sunters A, 2006, CANCER RES, V66, P212, DOI 10.1158/0008-5472.CAN-05-1997; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Wu YY, 2012, CANCER RES, V72, DOI 10.1158/1538-7445.AM2012-704; Xiang-qiang Liu, 2011, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V27, P969; Xu MM, 2014, ASIAN PAC J CANCER P, V15, P4013, DOI 10.7314/APJCP.2014.15.9.4013; Yang JY, 2009, CLIN CANCER RES, V15, P752, DOI 10.1158/1078-0432.CCR-08-0124	29	5	6	1	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	SEP	2018	71	9					806	813		10.1136/jclinpath-2018-205052			8	Pathology	Pathology	GS4HG	WOS:000443600700009	29588373				2019-10-28	
J	Rea, B; Haun, P; Emerson, R; Vignali, M; Farooqi, M; Samimi, S; Elenitsas, R; Kirsch, I; Bagg, A				Rea, Bryan; Haun, Paul; Emerson, Ryan; Vignali, Marissa; Farooqi, Midhat; Samimi, Sara; Elenitsas, Rosalie; Kirsch, Ilan; Bagg, Adam			Role of high-throughput sequencing in the diagnosis of cutaneous T-cell lymphoma	JOURNAL OF CLINICAL PATHOLOGY			English	Article						molecular pathology; dermatopathology; haematopathology; lymphoma	MYCOSIS-FUNGOIDES; GENE REARRANGEMENT; CLONALITY; PCR; DISEASE; CLASSIFICATION; CANCER; TISSUE; EORTC; TCRG	Aims Substantial clinicopathological overlap exists between cutaneous T-cell lymphoma (CTCL) and benign conditions, leading to diagnostic difficulties. We sought to delineate the utility of high-throughput sequencing (HTS) across a spectrum of histological findings in CTCL and reactive mimics. Methods One hundred skin biopsies obtained for clinical concern for CTCL were identified, comprising 25 cases each from four histological categories: definitive CTCL', atypical lymphoid infiltrate, concerning for CTCL', atypical lymphoid infiltrate, favour reactive' or reactive lymphoid infiltrate'. T-cell receptor gamma chain gene (TRG) PCR and T-cell receptor beta chain gene HTS were performed on both skin biopsy and concurrently collected peripheral blood; most peripheral blood samples were also analysed by flow cytometry. Results Histologically defined CTCL specimens had significantly higher clonality scores and T-cell fractions via HTS than all other groups (all p<0.002and p<0.03, respectively). HTS was more diagnostically specific than TRG PCR in skin (100% vs 88%), while diagnostic sensitivity (68% vs 72%) and accuracy (84% vs 80%) were similar. TRG PCR and flow cytometry performed on blood were the least diagnostically useful assays. Some identically sized peaks detected by TRG PCR in concurrent skin and peripheral blood specimens were non-identical by HTS analysis. Conclusions HTS, by assessing both clonality and T-cell fractions in skin biopsies, is a powerful tool to aid in the diagnosis of CTCL. It is more specific than TRG PCR in distinguishing definitive CTCL from reactive and indeterminate histology. Identically sized peaks by TRG PCR, typically interpreted to be clonally related, are not always clonally identical by sequencing.	[Rea, Bryan; Haun, Paul; Farooqi, Midhat; Samimi, Sara; Elenitsas, Rosalie; Bagg, Adam] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA; [Emerson, Ryan; Vignali, Marissa; Kirsch, Ilan] Adapt Biotechnol, Seattle, WA USA	Rea, B (reprint author), Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA.	bryan.rea@uphs.upenn.edu	Bagg, Adam/R-8450-2019				Assaf C, 2005, BLOOD, V105, P503, DOI 10.1182/blood-2004-06-2220; Bernengo MG, 2001, BRIT J DERMATOL, V144, P125, DOI 10.1046/j.1365-2133.2001.04014.x; Carlson CS, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3680; Hsu MS, 2016, CANCER IMMUNOL RES, V4, P412, DOI 10.1158/2326-6066.CIR-15-0240; Jawed SI, 2014, J AM ACAD DERMATOL, V70, DOI 10.1016/j.jaad.2013.07.049; Kempf W, 2015, DERMATOL CLIN, V33, P655, DOI [10.1016/j.det.2015.05.002, 10.1016/j.det.2015.06.002]; Kirsch I, 2015, MOL ONCOL, V9, P2063, DOI 10.1016/j.molonc.2015.09.003; Kirsch IR, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa9122; Luo V, 2001, MOL DIAGN, V6, P169, DOI 10.1054/modi.2001.27056; Massone C, 2005, AM J SURG PATHOL, V29, P550, DOI 10.1097/01.pas.0000153121.57515.c6; Olsen E, 2007, BLOOD, V110, P1713, DOI 10.1182/blood-2007-03-055749; Olsen EA, 2015, DERMATOL CLIN, V33, P643, DOI 10.1016/j.det.2015.06.001; Page DB, 2016, CANCER IMMUNOL RES, V4, P835, DOI 10.1158/2326-6066.CIR-16-0013; Ponti R, 2005, BRIT J DERMATOL, V153, P565, DOI 10.1111/j.1365-2133.2005.06649.x; Ponti R, 2008, J INVEST DERMATOL, V128, P1030, DOI 10.1038/sj.jid.5701109; Raess Philipp W, 2012, Patholog Res Int, V2012, P913523, DOI 10.1155/2012/913523; Robins H, 2012, J IMMUNOL METHODS, V375, P14, DOI 10.1016/j.jim.2011.09.001; Robins HS, 2009, BLOOD, V114, P4099, DOI 10.1182/blood-2009-04-217604; Schumacher JA, 2014, AM J CLIN PATHOL, V141, P348, DOI 10.1309/AJCP5TYGBVW4ZITR; Sherwood AM, 2013, CANCER IMMUNOL IMMUN, V62, P1453, DOI 10.1007/s00262-013-1446-2; Skov AG, 2015, ACTA DERM-VENEREOL, V95, P472, DOI 10.2340/00015555-1971; Subudhi SK, 2016, P NATL ACAD SCI USA, V113, P11919, DOI 10.1073/pnas.1611421113; Sufficool KE, 2015, J AM ACAD DERMATOL, V73, P228, DOI 10.1016/j.jaad.2015.04.030; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Weng WK, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007420; Wilcox RA, 2014, AM J HEMATOL, V89, P838, DOI 10.1002/ajh.23756; Willemze R, 2005, BLOOD, V105, P3768, DOI 10.1182/blood-2004-09-3502; Wu D, 2014, CLIN CANCER RES, V20, P4540, DOI 10.1158/1078-0432.CCR-13-3231; Zhang B, 2010, J MOL DIAGN, V12, P320, DOI 10.2353/jmoldx.2010.090123	29	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	SEP	2018	71	9					814	820		10.1136/jclinpath-2018-205004			7	Pathology	Pathology	GS4HG	WOS:000443600700010	29636372				2019-10-28	
J	Saleh-Gohari, N; Saeidi, K; Zeighaminejad, R				Saleh-Gohari, Nasrollah; Saeidi, Kolsoum; Zeighaminejad, Roya			A novel homozygous frameshift mutation in the FUCA1 gene causes both severe and mild fucosidosis	JOURNAL OF CLINICAL PATHOLOGY			English	Article						brain; Dna; chromosomes; genetics	PATIENT	Aims Fucosidosis is a rare autosomal recessive lysosomal storage disorder caused by -L-fucosidase deficiency as a result of FUCA1 gene mutations. Here, we studied clinical features and the molecular basis of fucosidosis in a family from Iran, including two probands and nine family members. Methods DNA sample of two probands were screened for gene defects using a next generation sequencing technique. The sequencing processes were performed on an Illumina Hiseq 4000 platform. Sequence reads were analysed using BWA-GATK. Results Next generation sequencing revealed a frameshift mutation caused by 2bp deletion (c.837_838 delTG; p.Cys279) in the FUCA1 gene. The identified mutation was tested in all participants. Homozygous patients had almost all the complications associated with fucosidosis, while heterozygous carriers were unaffected. Conclusions The variant c.837_838 delTG; p.Cys279 has not been reported previously and is predicted to be pathogenic due to a premature stop codon.	[Saleh-Gohari, Nasrollah] Kerman Univ Med Sci, Afzalipour Sch Med, Dept Med Genet, Kerman, Iran; [Saeidi, Kolsoum] Kerman Univ Med Sci, Inst Neuropharmacol, Neurosci Res Ctr, Kerman, Iran; [Zeighaminejad, Roya] Samen al Hojaj Char, Genet Lab, Kerman, Iran	Saeidi, K (reprint author), Kerman Univ Med Sci, Afzalipour Sch Med, Kerman 7616913555, Iran.	kolsoum.saeidi@gmail.com					Akagi M, 1999, J HUM GENET, V44, P323, DOI 10.1007/s100380050169; Cragg H, 1997, J MED GENET, V34, P105, DOI 10.1136/jmg.34.2.105; DURAND P, 1966, LANCET, V2, P1313; Galluzzi P, 2001, AM J NEURORADIOL, V22, P777; Ip P, 2002, J INHERIT METAB DIS, V25, P415, DOI 10.1023/A:1020116220624; Kau T, 2011, NEURORADIOLOGY, V53, P509, DOI 10.1007/s00234-011-0855-1; KOUSSEFF BG, 1976, PEDIATRICS, V57, P205; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Muthusamy K, 2014, J PEDIATR NEUROSCI, V9, P156, DOI 10.4103/1817-1745.139331; Panmontha W, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15038733; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; SEO HC, 1993, HUM MOL GENET, V2, P423, DOI 10.1093/hmg/2.4.423; SEO HC, 1994, HUM MUTAT, V3, P407, DOI 10.1002/humu.1380030416; WILLEMS PJ, 1988, AM J HUM GENET, V43, P756; WILLEMS PJ, 1991, AM J MED GENET, V38, P111, DOI 10.1002/ajmg.1320380125; Willems PJ, 1999, EUR J HUM GENET, V7, P60, DOI 10.1038/sj.ejhg.5200272; Winchester B, 2000, BIOCHEM SOC T, V28, P150, DOI 10.1042/bst0280150	17	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	SEP	2018	71	9					821	824		10.1136/jclinpath-2018-205074			4	Pathology	Pathology	GS4HG	WOS:000443600700011	29588375				2019-10-28	
J	Hussein, S; Gindin, T; Lagana, SM; Arguelles-Grande, C; Krishnareddy, S; Alobeid, B; Lewis, SK; Mansukhani, MM; Green, PHR; Bhagat, G				Hussein, Shafinaz; Gindin, Tatyana; Lagana, Stephen M.; Arguelles-Grande, Carolina; Krishnareddy, Suneeta; Alobeid, Bachir; Lewis, Suzanne K.; Mansukhani, Mahesh M.; Green, Peter H. R.; Bhagat, Govind			Clonal T cell receptor gene rearrangements in coeliac disease: implications for diagnosing refractory coeliac disease	JOURNAL OF CLINICAL PATHOLOGY			English	Article						coeliac disease; flow cytometry; molecular diagnostics	INTESTINAL INTRAEPITHELIAL LYMPHOCYTES; TCR-GAMMA CLONALITY; LYMPHOMA; SPRUE; LYMPHOPROLIFERATIONS; CLASSIFICATION; STRATEGIES; GUIDELINES; MANAGEMENT; GLUTEN	Aims Refractory coeliac disease type II (RCDII), a rare complication of coeliac disease (CD) associated with high morbidity, requires identification of a clonal population of phenotypically aberrant intraepithelial lymphocytes (IELs) for diagnosis. However, data regarding the frequency and significance of clonal T cell receptor (TCR) gene rearrangements (TCR-GRs) in small bowel (SB) biopsies of patients without RCDII are limited. Methods We analysed results of TCR-GR analyses performed on SB biopsies at our institution over a 3-year period, which were obtained from eight active CD, 172CD on gluten-free diet (GFD), 33 RCDI, and three RCDII patients and 14 patients without CD. TCR-GR patterns were divided into clonal, polyclonal and prominent clonal peaks (PCPs) and these patterns were correlated with clinical and pathological features. Results Clonal TCR-GR products were detected in biopsies from 67% of patients with RCDII, 17% of patients with RCDI and 6% of patients with GFD. PCPs were observed in all disease phases (range 12%-33%). There was no significant difference in the TCR-GR patterns between the non-RCDII disease categories (p=0.39). A higher frequency of surface CD3(-) IELs was noted in cases with clonal TCR-GR, but the PCP pattern did not show associations with any clinical or pathological feature. Persistence of clonal or PCP pattern on repeat biopsy was seen for up to 2 years without evidence of RCDII. Conclusions Clonal TCR-GRs are not infrequent in cases lacking features of RCDII, while PCPs are frequent in all disease phases. TCR-GR results should be assessed in conjunction with immunophenotypic, histological and clinical findings for appropriate diagnosis and classification of RCD.	[Hussein, Shafinaz; Gindin, Tatyana; Lagana, Stephen M.; Alobeid, Bachir; Mansukhani, Mahesh M.; Bhagat, Govind] Columbia Univ, Med Ctr, New York Presbyterian Hosp, Dept Pathol & Cell Biol, New York, NY USA; [Arguelles-Grande, Carolina; Krishnareddy, Suneeta; Lewis, Suzanne K.; Green, Peter H. R.; Bhagat, Govind] Columbia Univ, Med Ctr, New York Presbyterian Hosp, Dept Med,Celiac Dis Ctr, New York, NY USA	Bhagat, G (reprint author), New York Presbyterian Hosp, Dept Pathol & Cell Biol, New York, NY 10032 USA.	gb96@cumc.columbia.edu		Bhagat, Govind/0000-0001-6250-048X			Arguelles-Grande C, 2013, J CLIN GASTROENTEROL, V47, P593, DOI 10.1097/MCG.0b013e31828a3c44; Biagi F, 2004, NUTR REV, V62, P360, DOI 10.1301/nr.2004.sept.360-363; Bruins MJ, 2013, NUTRIENTS, V5, P4614, DOI 10.3390/nu5114614; Cellier C, 1998, GASTROENTEROLOGY, V114, P471, DOI 10.1016/S0016-5085(98)70530-X; Cellier C, 2000, LANCET, V356, P203, DOI 10.1016/S0140-6736(00)02481-8; Christensen M, 2006, J CLIN PATHOL, V59, P645, DOI 10.1136/jcp.2005.025809; Daum S, 2005, BEST PRACT RES CL GA, V19, P413, DOI 10.1016/j.bpg.2005.02.001; Daum S, 2001, GUT, V49, P804, DOI 10.1136/gut.49.6.804; Di Sabatino A, 2012, BLOOD, V119, P2458, DOI 10.1182/blood-2011-10-385559; Ettersperger J, 2016, IMMUNITY, V45, P610, DOI 10.1016/j.immuni.2016.07.018; Green PHR, 2007, NEW ENGL J MED, V357, P1731, DOI 10.1056/NEJMra071600; Hollon JR, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-40; Langerak AW, 2012, LEUKEMIA, V26, P2159, DOI 10.1038/leu.2012.246; Lionetti E, 2011, INT REV IMMUNOL, V30, P219, DOI 10.3109/08830185.2011.602443; Liu H, 2010, GUT, V59, P452, DOI 10.1136/gut.2009.186007; Ludvigsson JF, 2014, GUT, V63, P1210, DOI 10.1136/gutjnl-2013-306578; Malamut G, 2009, GASTROENTEROLOGY, V136, P81, DOI 10.1053/j.gastro.2008.09.069; Nijeboer P, 2013, GASTROENT RES PRACT, DOI 10.1155/2013/518483; Oberhuber G, 1999, EUR J GASTROEN HEPAT, V11, P1185, DOI 10.1097/00042737-199910000-00019; Perfetti V, 2012, J CLIN GASTROENTEROL, V46, P675, DOI 10.1097/MCG.0b013e31823eff20; Ritter J, 2018, GUT, V67, P644, DOI 10.1136/gutjnl-2016-311816; Rubio-Tapia A, 2010, GUT, V59, P547, DOI 10.1136/gut.2009.195131; Sanchez-Munoza LB, 2008, EUR J GASTROEN HEPAT, V20, P478, DOI 10.1097/MEG.0b013e3282f16a4b; Schmitz F, 2016, GUT, V65, P1269, DOI 10.1136/gutjnl-2014-308153; Ubiali A, 2007, J CLIN GASTROENTEROL, V41, P275, DOI 10.1097/01.mcg.0000212616.66713.61; van de Water JMW, 2010, BEST PRACT RES CL GA, V24, P43, DOI 10.1016/j.bpg.2009.11.002; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202; van Wanrooij RLJ, 2014, J CLIN IMMUNOL, V34, P828, DOI 10.1007/s10875-014-0075-7; van Wanrooij RLJ, 2010, GUT, V59, P1732, DOI 10.1136/gut.2010.223438; Woodward J, 2016, CLIN EXP GASTROENTER, V9, P225, DOI 10.2147/CEG.S87200	30	6	6	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	SEP	2018	71	9					825	831		10.1136/jclinpath-2018-205023			7	Pathology	Pathology	GS4HG	WOS:000443600700012	29703761				2019-10-28	
J	Lin, YB; Seger, N; Tsagkozis, P; Hesla, AC; Ghaderi, M; Chen, Y; Ehnman, M; Warsito, D; Wejde, J; Larsson, O; Haglund, F				Lin, Yingbo; Seger, Nelly; Tsagkozis, Panagiotis; Hesla, Asle C.; Ghaderi, Mehran; Chen, Yi; Ehnman, Monika; Warsito, Dudi; Wejde, Johan; Larsson, Olle; Haglund, Felix			Telomerase promoter mutations and copy number alterations in solitary fibrous tumours	JOURNAL OF CLINICAL PATHOLOGY			English	Article						sarcomas; soft tissue tumours; cancer genetics	NAB2-STAT6 FUSION; RISK-ASSESSMENT; EXPRESSION; MIMICS; CELLS; MODEL; P53	Aims Solitary fibrous tumour (SFT) is an infrequently metastasising mesenchymal tumour defined by the NAB2-STAT6 fusion gene. Activating mutations in the telomerase reverse transcriptase (hTERT) gene promoter has been reported to associate with adverse patient outcome in SFTs. Methods We analysed the hTERT gene for promoter mutations and copy number alterations in 43 primary extrameningeal SFTs (9 malignant and 34 benign tumours according to WHO 2013 criteria), six local recurrences and three metastatic lesions. Results Activating -124 C>T (n=12) or -148 C>T (n=2) mutations were found in 33% of the tumours and associated with older age (P=0.006), necrosis (P=0.009), higher mitotic rate (P=0.003), nuclear atypia (P=0.002), malignant histological diagnosis (P=0.04) and worse progression-free survival (P=0.023). We also observed frequent (24%) hTERT promoter mutations in histologically benign tumours without metastasis (mean follow-up >9 years), and in 14%-18% of low-risk SFTs as determined by three risk-stratification models. Mutations were seen in 2/6 metastatic tumours and metastatic lesions. hTERT copy number gain was seen in 11/28 hTERT promoter wild-type cases. Conclusions Activating hTERT promoter mutations associate with aggressive histopathological features, indicating a role in tumour progression. Given the comparatively high prevalence of hTERT promoter mutations in low-risk and non-metastasising lesions, further studies are required to clarify the prognostic value of hTERT promoter analysis before implementing the analysis in clinical diagnostics.	[Lin, Yingbo; Seger, Nelly; Ghaderi, Mehran; Chen, Yi; Ehnman, Monika; Warsito, Dudi; Wejde, Johan; Larsson, Olle; Haglund, Felix] Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, Stockholm, Sweden; [Tsagkozis, Panagiotis; Hesla, Asle C.] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden; [Tsagkozis, Panagiotis; Hesla, Asle C.] Karolinska Univ Hosp Solna, Dept Orthoped Surg, Stockholm, Sweden; [Ghaderi, Mehran; Wejde, Johan; Larsson, Olle; Haglund, Felix] Karolinska Univ Hosp Solna, Dept Clin Pathol & Cytol, Stockholm, Sweden	Haglund, F (reprint author), Karolinska Univ Hosp Solna, S-17176 Stockholm, Sweden.	Felix.Haglund@ki.se	Ehnman, Monika/R-3687-2016	Ehnman, Monika/0000-0003-0468-2531	Swedish Cancer SocietySwedish Cancer Society; Swedish Research CouncilSwedish Research Council; Cancer Society in Stockholm; Swedish Childhood Cancer Foundation; Stockholm County CouncilStockholm County Council; Karolinska InstitutetKarolinska Institutet	This study was supported by the Swedish Cancer Society, the Swedish Research Council, the Cancer Society in Stockholm, the Swedish Childhood Cancer Foundation, the Stockholm County Council and Karolinska Institutet.	Akaike K, 2015, HUM PATHOL, V46, P347, DOI 10.1016/j.humpath.2014.11.018; Bahrami A, 2016, MODERN PATHOL, V29, P1511, DOI 10.1038/modpathol.2016.126; Baldi GG, 2013, CLIN SARCOMA RES, V3, DOI 10.1186/2045-3329-3-4; Cheah AL, 2014, PATHOLOGY, V46, P389, DOI 10.1097/PAT.0000000000000122; Chiodi I, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00133; Chmielecki J, 2013, NAT GENET, V45, P131, DOI 10.1038/ng.2522; Cranshaw IM, 2009, EJSO-EUR J SURG ONC, V35, P994, DOI 10.1016/j.ejso.2009.02.015; Dagrada GP, 2015, MODERN PATHOL, V28, P1074, DOI 10.1038/modpathol.2015.70; Demicco EG, 2017, MODERN PATHOL, V30, P1433, DOI 10.1038/modpathol.2017.54; Demicco EG, 2015, AM J CLIN PATHOL, V143, P672, DOI 10.1309/AJCPN25NJTOUNPNF; Demicco EG, 2012, MODERN PATHOL, V25, P1298, DOI 10.1038/modpathol.2012.83; Doyle LA, 2014, MODERN PATHOL, V27, P390, DOI 10.1038/modpathol.2013.164; ENGLAND DM, 1989, AM J SURG PATHOL, V13, P640, DOI 10.1097/00000478-198908000-00003; Fletcher CDM, 2013, WHO CLASSIFICATION T, P80; Gold JS, 2002, CANCER, V94, P1057, DOI 10.1002/cncr.10328; Haglund F, 2015, ENDOCR-RELAT CANCER, V22, pL9, DOI 10.1530/ERC-15-0121; Henson JD, 2010, FEBS LETT, V584, P3800, DOI 10.1016/j.febslet.2010.06.009; Killela PJ, 2013, P NATL ACAD SCI USA, V110, P6021, DOI 10.1073/pnas.1303607110; Koelsche C, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756-9966-33-33; Kurisaki-Arakawa A, 2014, VIRCHOWS ARCH, V465, P615, DOI 10.1007/s00428-014-1625-3; Liau JY, 2015, MODERN PATHOL, V28, P1545, DOI 10.1038/modpathol.2015.114; Morimitsu Y, 2000, APMIS, V108, P617, DOI 10.1034/j.1600-0463.2000.d01-105.x; Mosquera JM, 2009, AM J SURG PATHOL, V33, P1314, DOI 10.1097/PAS.0b013e3181a6cd33; Pasquali S, 2016, EJSO-EUR J SURG ONC, V42, P1064, DOI 10.1016/j.ejso.2016.01.023; Robinson DR, 2013, NAT GENET, V45, P180, DOI 10.1038/ng.2509; Salas S, 2017, ANN ONCOL, V28, P1979, DOI 10.1093/annonc/mdx250; Schweizer L, 2013, ACTA NEUROPATHOL, V125, P651, DOI 10.1007/s00401-013-1117-6; Tani E, 2018, CANCER CYTOPATHOL, V126, P36, DOI 10.1002/cncy.21923; Yokoi T, 1998, HISTOPATHOLOGY, V32, P423	29	1	1	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	SEP	2018	71	9					832	839		10.1136/jclinpath-2018-205132			8	Pathology	Pathology	GS4HG	WOS:000443600700013	29703757				2019-10-28	
J	Malik, ST; Birch, BR; Voegeli, D; Fader, M; Foria, V; Cooper, AJ; Walls, AF; Lwaleed, BA				Malik, Shabana T.; Birch, Brian R.; Voegeli, David; Fader, Mandy; Foria, Vipul; Cooper, Alan J.; Walls, Andrew F.; Lwaleed, Bashir A.			Distribution of mast cell subtypes in interstitial cystitis: implications for novel diagnostic and therapeutic strategies?	JOURNAL OF CLINICAL PATHOLOGY			English	Article						mast cell; painful bladder; cystitis; inflammation	BLADDER; MASTOCYTOSIS; PAIN	Aims To identify the presence and geographical distribution of mast cell (MC) subtypes: MCT (tryptase positive-chymase negative) and MCTC (tryptase positive-chymase positive) in bladder tissue. Methods Bladder tissue was obtained from patients with painful bladder syndrome/interstitial cystitis (n=14) and normal histology from University Hospital Southampton tissue bank. Sequential tissue slices were immunohistochemically stained for MC subtypes using anti-MC tryptase (for MCT and MCTC) and anti-MC chymase (for MCTC). Stained sections were photographed, and positively stained MCs were quantified using ImageJ. Data were analysed using descriptive statistics and individual paired t-tests. Results There was a significant difference in the density of MCs between each layer of the disease bladder, with the greatest accumulation within the detrusor (p<0.001). There was a significant increase in MCTC subtype in the lamina (p=0.009) in painful bladder syndrome/interstitial cystitis. Conclusions Our results suggest that mastocytosis is present within all layers of disease bladder, especially the muscle layer. The varying increase in MC subtypes in the lamina and mucosa may explain the variability in painful bladder syndrome/interstitial cystitis symptoms. A high influx of MCTC in the mucosa of individuals who also had ulceration noted within their diagnostic notes may be of the Hunner's ulcer subclassification. These findings suggest a relationship between the pathogenesis of MC subtypes and the clinical presentation of painful bladder syndrome/interstitial cystitis. A cohort study would further elucidate the diagnostic and/or therapeutic potential of MCs in patients with painful bladder syndrome/interstitial cystitis.	[Malik, Shabana T.; Voegeli, David; Fader, Mandy; Lwaleed, Bashir A.] Univ Southampton, Fac Hlth Sci, Southampton SO16 6YD, Hants, England; [Birch, Brian R.; Walls, Andrew F.] Univ Southampton, Fac Med, Southampton, Hants, England; [Foria, Vipul] Univ Hosp Southampton NHS Fdn Trust, Dept Histopathol, Southampton, Hants, England; [Cooper, Alan J.] Univ Portsmouth, Fac Pharm & Biomed Sci, Portsmouth, Hants, England	Lwaleed, BA (reprint author), Univ Southampton, Fac Hlth Sci, Southampton SO16 6YD, Hants, England.	bashir@soton.ac.uk		Voegeli, David/0000-0003-3457-7177	Department of HealthDiabetes UK [H039]; Medical Research CouncilMedical Research Council UK (MRC) [G0500729]		Bassi PF, 2011, EUR UROL SUPPL, V10, P451, DOI 10.1016/j.eursup.2011.06.001; Bjorling DE, 1999, J UROLOGY, V162, P231, DOI 10.1097/00005392-199907000-00073; Bouchelouche K, 2006, UROLOGY, V67, P214, DOI 10.1016/j.urology.2005.07.049; CHRISTMAS TJ, 1990, VIRCHOWS ARCH A, V416, P447, DOI 10.1007/BF01605152; McCary C, 2010, J NEUROIMMUNOL, V220, P17, DOI 10.1016/j.jneuroim.2009.12.006; Metcalfe DD, 2008, BLOOD, V112, P946, DOI 10.1182/blood-2007-11-078097; MOLLER M, 1984, J HISTOCHEM CYTOCHEM, V32, P37, DOI 10.1177/32.1.6690599; Nigro DA, 1997, UROLOGY, V49, P86, DOI 10.1016/S0090-4295(99)80337-9; PANG X, 1995, BRIT J UROL, V75, P744, DOI 10.1111/j.1464-410X.1995.tb07384.x; Parsons CL, 2011, BJU INT, V107, P370, DOI 10.1111/j.1464-410X.2010.09843.x; Peeker R, 2000, J UROLOGY, V163, P1009, DOI 10.1016/S0022-5347(05)67873-1; Rossberger J, 2010, SCAND J UROL NEPHROL, V44, P433, DOI 10.3109/00365599.2010.515613; Roth TM, 2007, INT UROGYNECOL J, V18, P963, DOI 10.1007/s00192-006-0266-8; Sant GR, 2007, UROLOGY, V69, P34, DOI 10.1016/j.urology.2006.08.1109; Stav K, 2012, UROLOGY, V80, P61, DOI 10.1016/j.urology.2012.03.030; Theoharides TC, 2001, UROLOGY, V57, P47, DOI 10.1016/S0090-4295(01)01129-3; Theoharides TC, 2012, BBA-MOL BASIS DIS, V1822, P21, DOI 10.1016/j.bbadis.2010.12.014; Yamada T, 2000, INT J UROL, V7, P292, DOI 10.1046/j.1442-2042.2000.00197.x; Yeo JC, 2013, BIOTECHNIQUES, V55, P115, DOI 10.2144/000114075	19	4	4	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	SEP	2018	71	9					840	844		10.1136/jclinpath-2017-204881			5	Pathology	Pathology	GS4HG	WOS:000443600700014	29764932				2019-10-28	
J	Kurzer, JH; Weinberg, OK				Kurzer, Jason H.; Weinberg, Olga K.			Identification of early B cell precursors (stage 1 and 2 hematogones) in the peripheral blood	JOURNAL OF CLINICAL PATHOLOGY			English	Article						flow cytometry; hematopathology; leukaemia	4-COLOR FLOW-CYTOMETRY; HUMAN BONE-MARROW; LYMPHOCYTE PRECURSORS; IMMUNOPHENOTYPIC ANALYSIS; EXPRESSION; SUBSETS	Differentiating malignant B-lymphoblasts from early benign B cell precursors (hematogones) is a vital component of the diagnosis of B-lymphoblastic leukaemia. It has been previously reported that only late-stage B cell precursors circulate in the peripheral blood. Consequently, flow cytometric detection of cells with immunophenotypic findings similar to earlier stage precursors in the peripheral blood justifiably raises concern for involvement by B-lymphoblastic leukaemia. We report here, however, that benign early B cell precursors can indeed be detected in the peripheral blood, thus complicating the interpretation of flow cytometric findings derived from these sample types. A retrospective search of our collective databases identified 13 cases containing circulating early stage B cell precursors. The patients ranged in age from 15 days to 85years old. All positive cases demonstrated that the earlier B cell precursors were associated with later stage precursors, a finding that could help differentiate these cells from B-lymphoblastic leukaemia.	[Kurzer, Jason H.] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA; [Weinberg, Olga K.] Boston Childrens Hosp, Dept Pathol, Boston, MA USA	Kurzer, JH (reprint author), Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA.	kurzer@stanford.edu					Agrawal S, 2013, CLIN EXP IMMUNOL, V174, P53, DOI 10.1111/cei.12149; Blom B, 2006, ANNU REV IMMUNOL, V24, P287, DOI 10.1146/annurev.immunol.24.021605.090612; Brady KA, 1999, BRIT J HAEMATOL, V107, P712, DOI 10.1046/j.1365-2141.1999.01775.x; Coustan-Smith E, 2002, BLOOD, V100, P2399, DOI 10.1182/blood-2002-04-1130; Fuda FS, 2009, AM J CLIN PATHOL, V132, P733, DOI 10.1309/AJCPU5E3NXEKLFIY; Ghia P, 1996, J EXP MED, V184, P2217, DOI 10.1084/jem.184.6.2217; Hulspas R, 2009, CYTOM PART B-CLIN CY, V76B, P355, DOI 10.1002/cyto.b.20485; Hystad ME, 2007, J IMMUNOL, V179, P3662, DOI 10.4049/jimmunol.179.6.3662; Juranovic T, 2014, PEDIATR DEVEL PATHOL, V17, P393, DOI 10.2350/14-03-1448-CR.1; Kroft SH, 2004, BRIT J HAEMATOL, V126, P209, DOI 10.1111/j.1365-2141.2004.05011.x; LeBien TW, 2008, BLOOD, V112, P1570, DOI 10.1182/blood-2008-02-078071; LOKEN MR, 1988, PATHOL IMMUNOPATH R, V7, P357, DOI 10.1159/000157129; LONGACRE TA, 1989, BLOOD, V73, P543; McKenna RW, 2001, BLOOD, V98, P2498, DOI 10.1182/blood.V98.8.2498; McKenna RW, 2004, LEUKEMIA LYMPHOMA, V45, P277, DOI 10.1080/1042819031000151950; Sevilla DW, 2010, LEUKEMIA LYMPHOMA, V51, P10, DOI 10.3109/10428190903370346; Sims GP, 2005, BLOOD, V105, P4390, DOI 10.1182/blood-2004-11-4284; Suryani S, 2010, BLOOD, V115, P519, DOI 10.1182/blood-2009-07-234799; van Zelm MC, 2005, J IMMUNOL, V175, P5912, DOI 10.4049/jimmunol.175.9.5912; Vogel P, 1937, AM J CLIN PATHOL, V7, P498	20	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	SEP	2018	71	9					845	850		10.1136/jclinpath-2018-205172			6	Pathology	Pathology	GS4HG	WOS:000443600700015	29802226				2019-10-28	
J	Aloisio, E; Carnevale, A; Pasqualetti, S; Birindelli, S; Dolci, A; Panteghini, M				Aloisio, Elena; Carnevale, Assunta; Pasqualetti, Sara; Birindelli, Sarah; Dolci, Alberto; Panteghini, Mauro			Implementation of an internal quality control programme for the photometric determination of icteric index	JOURNAL OF CLINICAL PATHOLOGY			English	Letter						quality control; safety; automation	TOTAL BILIRUBIN VALUES		[Aloisio, Elena; Carnevale, Assunta; Pasqualetti, Sara; Birindelli, Sarah; Dolci, Alberto; Panteghini, Mauro] ASST Fatebenefratelli Sacco, Clin Pathol Unit, Milan, Italy	Aloisio, E (reprint author), Luigi Sacco Univ Hosp, Clin Pathol Unit, I-20157 Milan, Italy.	elena.aloisio@unimi.it					Braga F, 2014, CLIN CHIM ACTA, V432, P55, DOI 10.1016/j.cca.2013.11.022; Clinical and Laboratory Standards Institute (CLSI), 2012, C56A CLSI; Dolci A, 2014, CLIN CHIM ACTA, V432, P38, DOI 10.1016/j.cca.2013.10.012; Pasqualetti S, 2015, BIOCHIM CLIN, V39, P270; Salinas M, 2012, J CLIN PATHOL, V65, P928, DOI 10.1136/jclinpath-2012-200811; Sandberg S, 2015, CLIN CHEM LAB MED, V53, P833, DOI 10.1515/cclm-2015-0067; Szoke D, 2013, J CLIN PATHOL, V66, P1095, DOI 10.1136/jclinpath-2013-201544	7	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	SEP	2018	71	9					851	852		10.1136/jclinpath-2017-204937			2	Pathology	Pathology	GS4HG	WOS:000443600700016	29858233				2019-10-28	
J	Maguire, A; Sheahan, K				Maguire, Aoife; Sheahan, Kieran			Primary small bowel adenomas and adenocarcinomas-recent advances	VIRCHOWS ARCHIV			English	Review						Small bowel adenocarcinoma; Small bowel adenoma; Molecular; Ampulla of Vater	POPULATION-BASED COHORT; SMALL-INTESTINE; AMPULLARY CANCER; CROHNS-DISEASE; ADJUVANT THERAPY; PROGNOSTIC-FACTORS; RISK-FACTORS; MICROSATELLITE INSTABILITY; CLINICAL CHARACTERISTICS; DUODENAL ADENOCARCINOMA	The small intestine represents 75% of the length and 90% of the absorptive surface area of the gastrointestinal tract (GIT), yet only 2% of digestive system cancers occur at this site. Adenocarcinoma accounts for half of small bowel malignancies. There have been a number of important recent advances in our understanding, classification and treatment of small bowel tumours. Over recent years, ampullary tumours have become recognised as a form of small bowel carcinoma, distinct from head of pancreas and lower biliary tract tumours. This is reflected in separate TNM systems and increasing interest in separating intestinal from pancreatobiliary subtypes. The recognition of the importance of microsatellite (MSI) status and the advent of molecular pathology has also changed our approach to these neoplasms.	[Maguire, Aoife] St James Hosp, Histopathol Dept, Dublin 2, Ireland; [Sheahan, Kieran] St Vincents Univ Hosp, UCD Med Sch, Pathol Dept, Dublin, Ireland; [Sheahan, Kieran] St Vincents Univ Hosp, UCD Med Sch, Ctr Colorectal Dis, Dublin, Ireland	Sheahan, K (reprint author), St Vincents Univ Hosp, UCD Med Sch, Pathol Dept, Dublin, Ireland.; Sheahan, K (reprint author), St Vincents Univ Hosp, UCD Med Sch, Ctr Colorectal Dis, Dublin, Ireland.	k.sheahan@st-vincents.ie					Adsay V, 2012, AM J SURG PATHOL, V36, P1592, DOI 10.1097/PAS.0b013e31826399d8; Agaimy A, 2012, INT J CLIN EXP PATHO, V5, P852; Ahn DW, 2013, GUT LIVER, V7, P239, DOI 10.5009/gnl.2013.7.2.239; Alvi MA, 2015, ONCOTARGET, V6, P20863, DOI 10.18632/oncotarget.4576; Amin MB, 2017, AJCC CANC STAGING MA; Ang DC, 2014, AM J SURG PATHOL, V38, P1371, DOI 10.1097/PAS.0000000000000230; Aparicio T, 2014, DIGEST LIVER DIS, V46, P97, DOI 10.1016/j.dld.2013.04.013; Arber N, 1997, CANCER EPIDEM BIOMAR, V6, P745; Askling J, 2002, GASTROENTEROLOGY, V123, P1428, DOI 10.1053/gast.2002.36585; Azih LC, 2013, WORLD J GASTROENTERO, V19, P511, DOI 10.3748/wjg.v19.i4.511; Balachandran P, 2006, PANCREAS, V32, P390, DOI 10.1097/01.mpa.0000220864.80034.63; Balmforth DC, 2012, FAM CANCER, V11, P553, DOI 10.1007/s10689-012-9546-2; BAUER RL, 1994, ANN SURG ONCOL, V1, P183, DOI 10.1007/BF02303522; Bellizzi AM, 2009, AM J CLIN PATHOL, V132, P506, DOI 10.1309/AJCPUZWJ8WA2IHBG; Bhatia S, 2006, INT J RADIAT ONCOL, V66, P514, DOI 10.1016/j.ijrobp.2006.04.018; Bilimoria KY, 2009, ANN SURG, V249, P63, DOI [10.1097/SLA.0b013e31818c4641, 10.1097/SLA.0b013e31818e4641]; Blaker H, 2002, ONCOGENE, V21, P158, DOI 10.1038/sj.onc.1205041; Bogaerts J, 2015, EUR J CANCER, V51, P271, DOI 10.1016/j.ejca.2014.10.027; Bronsert P, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-428; Brosens LAA, 2005, GUT, V54, P1034, DOI 10.1136/gut.2004.053843; Brueckl WM, 2004, CANCER LETT, V203, P181, DOI 10.1016/j.canlet.2003.08.013; Canavan C, 2006, ALIMENT PHARM THER, V23, P1097, DOI 10.1111/j.1365-2036.2006.02854.x; Carter JT, 2008, J AM COLL SURGEONS, V207, P210, DOI 10.1016/j.jamcollsurg.2008.01.028; Chang DK, 2013, J CLIN ONCOL, V31, P1348, DOI 10.1200/JCO.2012.46.8868; CHEN CC, 1994, CANCER EPIDEM BIOMAR, V3, P205; Cheng CL, 2004, GASTROINTEST ENDOSC, V60, P757, DOI 10.1016/S0016-5107(04)02029-2; CIRESI DL, 1995, AM SURGEON, V61, P698; Dabaja BS, 2004, CANCER, V101, P518, DOI 10.1002/cncr.20404; Delaunoit T, 2005, AM J GASTROENTEROL, V100, P703, DOI 10.1111/j.1572-0241.2005.40605.x; DISARIO JA, 1994, AM J GASTROENTEROL, V89, P699; Egan L, 2014, J CROHNS COLITIS, V8, P19, DOI 10.1016/j.crohns.2013.04.009; Genta RM, 2013, BEST PRACT RES CL GA, V27, P225, DOI 10.1016/j.bpg.2013.03.013; Guo XC, 2014, CANCER INVEST, V32, P178, DOI 10.3109/07357907.2014.896013; Halfdanarson TR, 2010, AM J SURG, V199, P797, DOI 10.1016/j.amjsurg.2009.05.037; Han JM, 2006, GASTROINTEST ENDOSC, V63, P292, DOI 10.1016/j.gie.2005.07.022; Haselkorn T, 2005, CANCER CAUSE CONTROL, V16, P781, DOI 10.1007/s10552-005-3635-6; Hatzaras I, 2007, ARCH SURG-CHICAGO, V142, P229, DOI 10.1001/archsurg.142.3.229; Hechtman JF, 2015, MODERN PATHOL, V28, P1123, DOI 10.1038/modpathol.2015.57; Heinrich S, 2010, CURR OPIN GASTROEN, V26, P280, DOI 10.1097/MOG.0b013e3283378eb0; Howdle PD, 2003, QJM-INT J MED, V96, P345, DOI 10.1093/qjmed/hcg058; Howe JR, 1999, CANCER-AM CANCER SOC, V86, P2693, DOI 10.1002/(SICI)1097-0142(19991215)86:12<2693::AID-CNCR14>3.0.CO;2-U; Howe JR, 1998, ANN SURG, V228, P87, DOI 10.1097/00000658-199807000-00013; Hsu HP, 2007, J FORMOS MED ASSOC, V106, P432, DOI 10.1016/S0929-6646(09)60292-8; Hsu HP, 2007, ANN SURG ONCOL, V14, P50, DOI 10.1245/s10434-006-9136-3; Jabbour SK, 2014, SEMIN RADIAT ONCOL, V24, P85, DOI 10.1016/j.semradonc.2013.11.001; Jess T, 2005, AM J GASTROENTEROL, V100, P2724, DOI 10.1111/j.1572-0241.2005.00287.x; Kadmon M, 2001, INT J COLORECTAL DIS, V16, P63, DOI 10.1007/s003840100290; Kahaleh M, 2004, AM J GASTROENTEROL, V99, P2335, DOI 10.1111/j.1572-0241.2004.40391.x; Kang HJ, 2014, SURGERY, V155, P74, DOI 10.1016/j.surg.2013.08.004; Kastrinos F, 2011, CANCER J, V17, P405, DOI 10.1097/PPO.0b013e318237e408; Khan K, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1014-6; Kim K, 2009, INT J RADIAT ONCOL, V75, P436, DOI 10.1016/j.ijrobp.2008.11.067; Kim RD, 2006, J AM COLL SURGEONS, V202, P112, DOI 10.1016/j.jamcollsurg.2005.08.002; Kim WS, 2012, J SURG ONCOL, V105, P266, DOI 10.1002/jso.22090; KIMURA W, 1994, JPN J CANCER RES, V85, P161, DOI 10.1111/j.1349-7006.1994.tb02077.x; Kohler I, 2011, AM J CLIN PATHOL, V135, P202, DOI 10.1309/AJCPCTCUQSYI89YT; Koo DH, 2011, ONCOLOGY-BASEL, V80, P208, DOI 10.1159/000328506; Koo DH, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-205; Laforest A, 2014, EUR J CANCER, V50, P1740, DOI 10.1016/j.ejca.2014.04.007; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Lee JH, 2000, INT J RADIAT ONCOL, V47, P945, DOI 10.1016/S0360-3016(00)00537-X; LOWENFELS AB, 1973, LANCET, V1, P24; LOWENFELS AB, 1978, LANCET, V2, P239; Martin John A, 2003, Gastrointest Endosc Clin N Am, V13, P649; Mizushima T, 2013, MOL CLIN ONCOL, V1, P820, DOI 10.3892/mco.2013.150; Neoptolemos JP, 2012, JAMA-J AM MED ASSOC, V308, P147, DOI 10.1001/jama.2012.7352; Nicholl MB, 2010, ANN SURG ONCOL, V17, P2728, DOI 10.1245/s10434-010-1109-x; Ohike N, 2010, AM J SURG PATHOL, V34, P1417, DOI 10.1097/PAS.0b013e3181f0b05a; Overman Michael J, 2013, Am Soc Clin Oncol Educ Book, P189, DOI 10.1200/EdBook_AM.2013.33.189; Overman MJ, 2010, CANCER-AM CANCER SOC, V116, P5374, DOI 10.1002/cncr.25324; Overman MJ, 2010, ACTA ONCOL, V49, P474, DOI 10.3109/02841860903490051; Palta M, 2012, ANN SURG ONCOL, V19, P1535, DOI 10.1245/s10434-011-2117-1; Pan SY, 2011, WORLD J GASTRO ONCOL, V3, P33, DOI 10.4251/wjgo.v3.i3.33; Patel R, 2012, J CLIN GASTROENTEROL, V46, P8, DOI 10.1097/MCG.0b013e318233a844; Perysinakis I, 2014, HISTOPATHOLOGY, V64, P759, DOI 10.1111/his.12324; PERZIN KH, 1981, CANCER, V48, P799, DOI 10.1002/1097-0142(19810801)48:3<799::AID-CNCR2820480324>3.0.CO;2-Q; Piton G, 2008, AM J GASTROENTEROL, V103, P1730, DOI 10.1111/j.1572-0241.2008.01847.x; Planck M, 2003, CANCER, V97, P1551, DOI 10.1002/cncr.11197; Roh YH, 2007, HEPATO-GASTROENTEROL, V54, P1641; ROSS RK, 1991, BRIT J CANCER, V63, P143, DOI 10.1038/bjc.1991.29; Rosty C, 2015, HISTOPATHOLOGY, V66, P333, DOI 10.1111/his.12469; Sanders LM, 2004, CANCER LETT, V208, P155, DOI 10.1016/j.canlet.2003.12.007; Schiergens TS, 2015, SURGERY, V158, P151, DOI 10.1016/j.surg.2015.02.001; Schirmacher P, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-251; Schottenfeld D, 2009, ANN EPIDEMIOL, V19, P58, DOI 10.1016/j.annepidem.2008.10.004; Schrock AB, 2017, JAMA ONCOL, V3, P1546, DOI 10.1001/jamaoncol.2017.1051; Schueneman A, 2015, BRIT J CANCER, V113, P64, DOI 10.1038/bjc.2015.172; Schultz NA, 2012, PANCREAS, V41, P759, DOI 10.1097/MPA.0b013e31823cd9df; Schwameis K, 2014, ONCOL LETT, V7, P1613, DOI 10.3892/ol.2014.1919; SELLNER F, 1990, CANCER, V66, P702, DOI 10.1002/1097-0142(19900815)66:4<702::AID-CNCR2820660419>3.0.CO;2-Z; SPIGELMAN AD, 1989, LANCET, V2, P783; Svrcek M, 2014, INFLAMM BOWEL DIS, V20, P1584, DOI 10.1097/MIB.0000000000000112; Talamonti MS, 2002, ARCH SURG-CHICAGO, V137, P564, DOI 10.1001/archsurg.137.5.564; Todoroki T, 2003, ANN SURG ONCOL, V10, P1176, DOI 10.1245/ASO.2003.07.512; Ushiku T, 2014, AM J SURG PATHOL, V38, P1484, DOI 10.1097/PAS.0000000000000278; Valsangkar NP, 2015, SURGERY, V157, P260, DOI 10.1016/j.surg.2014.08.092; von Roon AC, 2007, DIS COLON RECTUM, V50, P839, DOI 10.1007/s10350-006-0848-z; Westgaard A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-5; Westgaard A, 2013, ANN SURG ONCOL, V20, P430, DOI 10.1245/s10434-012-2603-0; Wheeler JMD, 2002, GUT, V50, P218, DOI 10.1136/gut.50.2.218; Winter JM, 2010, J GASTROINTEST SURG, V14, P379, DOI 10.1007/s11605-009-1080-7; Woo SM, 2007, ANN SURG ONCOL, V14, P3195, DOI 10.1245/s10434-007-9537-y; Xie JL, 2008, WORLD J GASTROENTERO, V14, P378, DOI 10.3748/wjg.14.378; Xue Y, 2017, AM J SURG PATHOL, V41, P865, DOI 10.1097/PAS.0000000000000863; YAMAGUCHI K, 1990, GASTROINTEST ENDOSC, V36, P588, DOI 10.1016/S0016-5107(90)71170-4; Zaanan A, 2010, ANN ONCOL, V21, P1786, DOI 10.1093/annonc/mdq038; Zhou H, 2004, AM J SURG PATHOL, V28, P875, DOI 10.1097/00000478-200407000-00005	107	1	1	3	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	SEP	2018	473	3					265	273		10.1007/s00428-018-2400-7			9	Pathology	Pathology	GS2RQ	WOS:000443403100001	29998424				2019-10-28	
J	Takahashi, S; Thike, AA; Koh, VCY; Sasano, H; Tan, PH				Takahashi, Satoshi; Thike, Aye Aye; Koh, Valerie Cui Yun; Sasano, Hironobu; Tan, Puay Hoon			Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile	VIRCHOWS ARCHIV			English	Article						DCIS; Triple-negative; HER2; Clinicopathological features; Biomarkers; Recurrence	INVASIVE RECURRENCE; CONSERVING THERAPY; MOLECULAR SUBTYPES; GENETIC PATHWAYS; LOCAL RECURRENCE; CANCER SUBTYPES; RISK-FACTORS; DCIS; P53; RECEPTOR	We compared the characteristics, clinical behavior, and biomarker profile between HER2 positive (HER2+) and triple-negative (TN) ductal carcinoma in situ (DCIS) which are considered more aggressive than other DCIS subtypes. In addition, we explored the impact of these features on its potential of progression to invasive breast carcinomas. Cases of DCIS diagnosed at the Department of Pathology, Singapore General Hospital from 1994 to 2010 were identified. TN and HER2+ DCIS cases formed the study cohort. Immunohistochemistry (IHC) was performed for ER, PR, HER2, CK14, EGFR, and p53. Comparisons of clinicopathological features, IHC results, and clinical outcomes were performed between the two groups. We evaluated 145 HER2+ and 85 TN DCIS cases. HER2 positive DCIS had significantly higher nuclear grade (p < 0.001) and more frequent necrosis (p < 0.001) than TN DCIS. HER2 positive DCIS also harbored significantly higher rates of nuclear p53 immunoreactivity (p = 0.002) than TN DCIS. Younger patients (age < 40) with HER2+ and TN DCIS demonstrated statistically significant worse invasive DFS than older women (p < 0.001). Multivariate cox regression analysis (HR 15.08, 95% CI 12.79-81.45, p = 0.002) also confirmed these findings. In addition, younger patients (age < 40) with HER2+ DCIS experienced significantly poorer prognosis when p53 was also positive (p = 0.033). HER2+ DCIS had more aggressive pathological characteristics compared to TN DCIS; accumulation of mutant p53 could possibly be contributory. Age was an independent predictor of aggressive biological behavior of HER2+ and TN DCIS. We demonstrated that younger patients with p53 positive HER2+ DCIS had significantly adverse clinical outcome.	[Takahashi, Satoshi; Sasano, Hironobu] Tohoku Univ, Dept Pathol, Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan; [Takahashi, Satoshi; Thike, Aye Aye; Koh, Valerie Cui Yun; Tan, Puay Hoon] Singapore Gen Hosp, Dept Anat Pathol, 20 Coll Rd,Acad,Diagnost Tower, Singapore 169856, Singapore; [Thike, Aye Aye; Tan, Puay Hoon] Duke NUS Med Sch, 8 Coll Rd, Singapore 169857, Singapore; [Sasano, Hironobu] Tohoku Univ Hosp, Dept Pathol, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan; [Tan, Puay Hoon] Singapore Gen Hosp, Div Pathol, 20 Coll Rd,Acad,Diagnost Tower, Singapore 169856, Singapore; [Tan, Puay Hoon] Natl Univ Singapore, Dept Anat, Yong Loo Lin Sch Med, 14 Med Dr,MD6,14-02T, Singapore 117599, Singapore	Tan, PH (reprint author), Singapore Gen Hosp, Dept Anat Pathol, 20 Coll Rd,Acad,Diagnost Tower, Singapore 169856, Singapore.; Tan, PH (reprint author), Duke NUS Med Sch, 8 Coll Rd, Singapore 169857, Singapore.; Tan, PH (reprint author), Singapore Gen Hosp, Div Pathol, 20 Coll Rd,Acad,Diagnost Tower, Singapore 169856, Singapore.; Tan, PH (reprint author), Natl Univ Singapore, Dept Anat, Yong Loo Lin Sch Med, 14 Med Dr,MD6,14-02T, Singapore 117599, Singapore.	tan.puay.hoon@singhealth.com.sg			Ministry of Health, Singapore [HSRG/0009/2010]	This study was funded by the Health Services Research Competitive Research Grant, HSRG/0009/2010, from the Ministry of Health, Singapore.	Allred DC, 1998, MODERN PATHOL, V11, P155; Bijker N, 2001, J CLIN ONCOL, V19, P2263, DOI 10.1200/JCO.2001.19.8.2263; Blows FM, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000279; Boughey JC, 2007, ONCOLOGIST, V12, P1276, DOI 10.1634/theoncologist.12-11-1276; Bryan BB, 2006, MODERN PATHOL, V19, P617, DOI 10.1038/modpathol.3800570; Buerger H, 1999, J PATHOL, V189, P521, DOI 10.1002/(SICI)1096-9896(199912)189:4<521::AID-PATH472>3.0.CO;2-B; Buerger H, 1999, J PATHOL, V187, P396, DOI 10.1002/(SICI)1096-9896(199903)187:4<396::AID-PATH286>3.0.CO;2-L; Caldarella A, 2011, PATHOL ONCOL RES, V17, P753, DOI 10.1007/s12253-011-9381-z; Carey LA, 2007, CLIN CANCER RES, V13, P2329, DOI 10.1158/1078-0432.CCR-06-1109; Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492; Cheang MCU, 2009, JNCI-J NATL CANCER I, V101, P736, DOI 10.1093/jnci/djp082; Cowell CF, 2013, MOL ONCOL, V7, P859, DOI 10.1016/j.molonc.2013.07.005; Curigliano G, 2015, ANN ONCOL, V26, P682, DOI 10.1093/annonc/mdv013; de Roos MA, 2007, J SURG RES, V140, P109, DOI 10.1016/j.jss.2006.10.045; Di Cesare P, 2017, BREAST J, V23, P307, DOI 10.1111/tbj.12735; Evans AJ, 2001, J MED SCREEN, V8, P149, DOI 10.1136/jms.8.3.149; Fulford LG, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1636; Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304; Harada S, 2011, J SURG ONCOL, V104, P458, DOI 10.1002/jso.21973; Ishikawa Y, 2011, CANCER SCI, V102, P656, DOI 10.1111/j.1349-7006.2011.01858.x; Jasar D, 2015, Pril (Makedon Akad Nauk Umet Odd Med Nauki), V36, P69; Kikuchi S, 2014, J CYTOL HISTOL, V5, DOI [10.4172/2157-7099.1000269, DOI 10.4172/2157-7099.1000269]; Koh VCY, 2015, BREAST CANCER RES TR, V152, P293, DOI 10.1007/s10549-015-3472-6; Kong I, 2014, CURR ONCOL, V21, pE96, DOI 10.3747/co.21.1604; Kurbel S, 2013, TUMOR BIOL, V34, P1, DOI 10.1007/s13277-012-0602-1; Lakhani SREI, 2012, WHO CLASSIFICATION T; Liao N, 2011, PATHOL RES PRACT, V207, P1, DOI 10.1016/j.prp.2010.08.005; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Munoz M, 2009, ARCH GYNECOL OBSTET, V280, P43, DOI 10.1007/s00404-008-0867-1; Mustafa RE, 2017, ANN SURG ONCOL, V24, P2999, DOI 10.1245/s10434-017-5941-0; Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220; Nofech-Mozes S, 2008, CLIN MED INSIGHTS-ON, V2, P7; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Rajan PB, 1997, BREAST CANCER RES TR, V42, P283, DOI 10.1023/A:1005741723479; Roka S, 2004, EJSO, V30, P243, DOI 10.1016/j.ejso.2003.11.004; Roses RE, 2009, CANCER EPIDEM BIOMAR, V18, P1386, DOI 10.1158/1055-9965.EPI-08-1101; Rouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421; Sanders ME, 2005, CANCER, V103, P2481, DOI 10.1002/cncr.21069; Sarode VR, 2011, INT J BREAST CANCER, DOI 10.4061/2011/217060; Shamliyan Tatyana, 2010, Journal of the National Cancer Institute Monographs, P121, DOI 10.1093/jncimonographs/lgq034; Subbaramaiah K, 2006, CANCER RES, V66, P5504, DOI 10.1158/0008-5472.CAN-05-4076; Tan PH, 2001, ANN ACAD MED SINGAP, V30, P671; Thike AA, 2013, J CLIN PATHOL, V66, P665, DOI 10.1136/jclinpath-2012-201428; Thike AA, 2010, AM J SURG PATHOL, V34, P956, DOI 10.1097/PAS.0b013e3181e02f45; Thike AA, 2010, MODERN PATHOL, V23, P123, DOI 10.1038/modpathol.2009.145; Van Bockstal M, 2014, VIRCHOWS ARCH, V465, P275, DOI 10.1007/s00428-014-1609-3; Vicini FA, 2013, BREAST J, V19, P365, DOI 10.1111/tbj.12127; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Williams KE, 2015, ANN ONCOL, V26, P1019, DOI 10.1093/annonc/mdv062; Wolf-Yadlin A, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100094; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Zhou WJ, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-512; Zhou WJ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-653	53	0	0	1	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	SEP	2018	473	3					275	283		10.1007/s00428-018-2416-z			9	Pathology	Pathology	GS2RQ	WOS:000443403100002	30033510				2019-10-28	
J	Pinilla-Pagnon, I; Perez-Mies, B; Reguero, ME; Martinez, MT; Chiva, M; Perez-Rodrigo, S; Illarramendi, OA; Martin, MER; Collado, MV; Sanchez, MC; Rosa-Rosa, JM; Palacios, J				Pinilla-Pagnon, Ignacio; Perez-Mies, Belen; Eugenia Reguero, Maria; Martinez, Marco-Tulio; Chiva, Miguel; Perez-Rodrigo, Silvia; Ajuria Illarramendi, Odile; Rioja Martin, Maria Eugenia; Vicenta Collado, Maria; Concepcin Sanchez, Maria; Manuel Rosa-Rosa, Juan; Palacios, Jose			Histological changes secondary to wire coil placement in breast tissue and lymph nodes	VIRCHOWS ARCHIV			English	Article						Spiral coil wire; Histological breast changes; Coil placement; Breast lesions	RADIOACTIVE SEED LOCALIZATION; MUCOCELE-LIKE LESIONS; SONOGRAPHIC VISIBILITY; BIOPSY; MARKER; SILICONE	We describe the histological and immunohistochemical features of the changes produced by spiral coil localization wires in the breast parenchyma and lymph nodes of a total of 100 patients undergoing surgery for different breast lesions. Coil wires produced cystic lesions containing a hyaline, mucous-like, PAS-negative fluid. Cavities were lined by cells of variable morphology ranging from synovial-like cells (with a conspicuous epithelial appearance) to mononuclear or multinucleate histiocytic cells that expressed CD68, but were negative for keratins. CD3-positive/CD8-positive T lymphocytes predominated in the inflammatory reaction. Pathologists should be aware of these changes in order to differentiate coil-related lesions from other granulomatous or epithelial lesions, including mucocele-like and ductal carcinoma in situ lesions.	[Pinilla-Pagnon, Ignacio; Perez-Mies, Belen; Eugenia Reguero, Maria; Martinez, Marco-Tulio; Palacios, Jose] Hosp Univ Ramon y Cajal, Pathol Dept, Madrid, Spain; [Perez-Mies, Belen; Eugenia Reguero, Maria; Chiva, Miguel; Perez-Rodrigo, Silvia; Rioja Martin, Maria Eugenia; Vicenta Collado, Maria; Concepcin Sanchez, Maria; Palacios, Jose] Hosp Univ Ramon y Cajal, Breast Pathol Unit, Madrid, Spain; [Chiva, Miguel; Perez-Rodrigo, Silvia] Hosp Univ Ramon y Cajal, Radiol Dept, Madrid, Spain; [Ajuria Illarramendi, Odile; Rioja Martin, Maria Eugenia] Hosp Univ Ramon y Cajal, Nucl Med Dept, Madrid, Spain; [Vicenta Collado, Maria] Hosp Univ Ramon y Cajal, Gen Surg Dept, Madrid, Spain; [Concepcin Sanchez, Maria] Hosp Univ Ramon y Cajal, Obstet & Gynecol Dept, Madrid, Spain; [Manuel Rosa-Rosa, Juan; Palacios, Jose] Inst Salud Carlos III, Centro Invest Biomed Red Canc CIBERONC, Madrid, Spain; [Palacios, Jose] Hosp Univ Ramon y Cajal, IRyCIS, Inst Ramon y Cajal Invest, Madrid, Spain; [Palacios, Jose] Univ Alcala De Henares, Madrid, Spain	Palacios, J (reprint author), Hosp Univ Ramon y Cajal, Pathol Dept, Madrid, Spain.; Palacios, J (reprint author), Hosp Univ Ramon y Cajal, Breast Pathol Unit, Madrid, Spain.; Palacios, J (reprint author), Inst Salud Carlos III, Centro Invest Biomed Red Canc CIBERONC, Madrid, Spain.; Palacios, J (reprint author), Hosp Univ Ramon y Cajal, IRyCIS, Inst Ramon y Cajal Invest, Madrid, Spain.; Palacios, J (reprint author), Univ Alcala De Henares, Madrid, Spain.	jose.palacios@salud.madrid.org			Instituto Carlos III (ISCIII)Instituto de Salud Carlos III [PI16/00887, PT13/0010/0056, PIE15/00050]; CIBERONC [CB16/12/00316]; European Development Regional Fund. 'A way to achieve Europe' (FEDER); AECC (AIO-AECC 2016); Fundacio La Marato de TV3 [2/C2013]; ISCIIIInstituto de Salud Carlos III [CB16/12/00316]	This project was supported by grants from Instituto Carlos III (ISCIII) (PI16/00887, PT13/0010/0056, PIE15/00050) and CIBERONC (CB16/12/00316), co-financed by the European Development Regional Fund. 'A way to achieve Europe' (FEDER), by the AECC (AIO-AECC 2016), and by Fundacio La Marato de TV3 (2/C2013). JMRR is a PhD investigator funded by ISCIII (CB16/12/00316).	Blumencranz PW, 2014, ANN SURG ONCOL, V21, P3273, DOI 10.1245/s10434-014-3917-x; Chase DR, 1996, PLAST RECONSTR SURG, V97, P249, DOI 10.1097/00006534-199601000-00050; Cheng Juan, 2013, Zhonghua Bing Li Xue Za Zhi, V42, P665; Dal F, 2017, EUR J BREAST HEALTH, V13, P159, DOI 10.5152/ejbh.2017.3428; Dash N, 1999, AJ R AM J ROENTGENOL, V173, P120; Demiral Gokhan, 2016, J Clin Med Res, V8, P389, DOI 10.14740/jocmr2498w; Garcia MF, 2014, CIR ESPAN, V92, pE7, DOI 10.1016/j.ciresp.2013.09.009; Follacchio GA, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0230-x; Gentile LF, 2016, ANN SURG ONCOL, V23, P3284, DOI 10.1245/s10434-016-5325-x; Ha D, 2015, AM J ROENTGENOL, V204, P204, DOI 10.2214/AJR.13.11988; Klein RL, 2012, J SURG ONCOL, V105, P591, DOI 10.1002/jso.22146; Krug KB, 2013, INVEST RADIOL, V48, P445, DOI 10.1097/RLI.0b013e3182856a91; Layfield LJ, 2015, BREAST J, V21, P370, DOI 10.1111/tbj.12414; Meares AL, 2016, HUM PATHOL, V49, P33, DOI 10.1016/j.humpath.2015.10.004; Oh JH, 2016, PRS-GLOB OPEN, V4, DOI 10.1097/GOX.0000000000001011; Pinkney DM, 2013, J DIAGN MED SONOG, V29, P151, DOI 10.1177/8756479313486962; Sakamoto N, 2017, BREAST CANCER-TOKYO, V24, P585, DOI 10.1007/s12282-016-0741-0; Tavassoli F, 1999, PATHOLOGY BREAST, P187; Thomassin-Naggara I, 2012, BREAST CANCER RES TR, V132, P881, DOI 10.1007/s10549-011-1847-x; Torous VF, 2017, PATHOLOGY, V49, P181, DOI 10.1016/j.pathol.2016.12.002; Tramm T, 2011, AM J SURG PATHOL, V35, P202, DOI 10.1097/PAS.0b013e31820598a2; Velazco CS, 2017, AM J SURG, V214, P1091, DOI 10.1016/j.amjsurg.2017.08.025; Tran VT, 2017, CAN ASSOC RADIOL J, V68, P447, DOI 10.1016/j.carj.2017.04.006; Zhang G, 2018, BREAST J, V24, P314, DOI 10.1111/tbj.12929; Zhang YM, 2017, ANN SURG ONCOL, V24, P3567, DOI 10.1245/s10434-017-6084-z	25	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	SEP	2018	473	3					285	291		10.1007/s00428-018-2399-9			7	Pathology	Pathology	GS2RQ	WOS:000443403100003	29984379				2019-10-28	
J	Bal, M; Rane, S; Talole, S; Ramadwar, M; Deodhar, K; Patil, P; Goel, M; Shrikhande, S				Bal, Munita; Rane, Swapnil; Talole, Sanjay; Ramadwar, Mukta; Deodhar, Kedar; Patil, Prachi; Goel, Mahesh; Shrikhande, Shailesh			Tumour origin and R1 rates in pancreatic resections: towards consilience in pathology reporting	VIRCHOWS ARCHIV			English	Article						Resection margin; R1 rate; Pancreatoduodenectomy; Tumour origin; Standardised pathology evaluation protocol	DUCTAL ADENOCARCINOMA; NEOADJUVANT THERAPY; CURATIVE RESECTION; CANCER RESECTIONS; MARGIN STATUS; PANCREATICODUODENECTOMY; SURVIVAL; IMPACT; INVOLVEMENT; CHALLENGES	To evaluate differences in the R1 rates of ampullary (AC), pancreatic (PC), and distal bile duct (DBD) cancers in pancreatoduodenectomies (PD) using standardised pathology assessment. Data of PD (2010-2011) analysed in accordance with the Royal College of Pathologists (UK) protocol, were retrieved. Clinicopathologic features, including frequency, topography, and mode of margin involvement in AC (n = 87), PC (n = 18), and DBD (n = 5) cancers were evaluated. The R1 rate was 7%, 67%, and 20% in the AC, PC, and DBD cancers (p < 0.001). Within the PC cohort, R1 rate was heterogeneous (chemo-na < ve, 77%; post-neoadjuvant, 40%). Commonest involved margins were as follows: posterior in overall PD (35%), AC (43%), overall PC (33%), and post-neoadjuvant PC (100%); superior mesenteric artery margin in chemo-na < ve PC (38%) and common bile duct margin in DBD (100%) cancers. In AC, majority (66%) of R1 were signet ring cell type. Indirect margin involvement due to tumour within lymph node, perineural sheath or lymphovascular space was observed in 26% cases, and altered R1 rate in AC, PC, and DBD cohorts by 1%, 12%, and 0%, respectively. Although not statistically significant, patients with R1 had lower disease-free survival than those with R0 (mean, 25.4 months versus 44.4 months). Tumour origin impacts R1 data in PD necessitating its accurate classification by pathologists. Indirect involvement, histology, and neoadjuvant therapy influence the R1 rate, albeit in a minority of cases. Generating cogent R1 data based on standardised pathology reporting is the foremost need of the hour.	[Bal, Munita; Rane, Swapnil; Ramadwar, Mukta; Deodhar, Kedar] Tata Mem Hosp, Dept Pathol, Bombay 400012, Maharashtra, India; [Talole, Sanjay] Tata Mem Hosp, Dept Epidemiol & Stat, Bombay, Maharashtra, India; [Patil, Prachi] Tata Mem Hosp, Dept Digest Dis & Nutr, Bombay, Maharashtra, India; [Goel, Mahesh; Shrikhande, Shailesh] Tata Mem Hosp, Dept Surg Oncol, Bombay, Maharashtra, India	Bal, M (reprint author), Tata Mem Hosp, Dept Pathol, Bombay 400012, Maharashtra, India.	munitamenon@gmail.com	Rane, Swapnil U/H-4694-2011	Rane, Swapnil U/0000-0002-5374-3903; Bal, Munita/0000-0002-0345-5620			Adsay NV, 2014, AM J SURG PATHOL, V38, P480, DOI 10.1097/PAS.0000000000000165; Adsay V, 2012, AM J SURG PATHOL, V36, P1592, DOI 10.1097/PAS.0b013e31826399d8; Batra S, 2016, DIGEST SURG, V33, P146, DOI 10.1159/000443217; Cameron JL, 2006, ANN SURG, V244, P10, DOI 10.1097/01.sla.0000217673.04165.ea; Campbell F, 2009, HISTOPATHOLOGY, V55, P277, DOI 10.1111/j.1365-2559.2009.03376.x; Chandrasegaram MD, 2015, BRIT J SURG, V102, P1459, DOI 10.1002/bjs.9892; Conlon KC, 1996, ANN SURG, V223, P273, DOI 10.1097/00000658-199603000-00007; Delpero JR, 2014, HPB, V16, P20, DOI 10.1111/hpb.12061; Demir IE, 2018, ANN SURG, V268, P1058, DOI 10.1097/SLA.0000000000002345; Esposito I, 2008, ANN SURG ONCOL, V15, P1651, DOI 10.1245/s10434-008-9839-8; Katz MHG, 2011, ANN SURG ONCOL, V18, P337, DOI 10.1245/s10434-010-1282-y; Khalifa Mahmoud A, 2007, HPB (Oxford), V9, P146, DOI 10.1080/13651820701278273; Khalifa MA, 2009, VIRCHOWS ARCH, V454, P125, DOI 10.1007/s00428-008-0711-9; Klempnauer J, 1998, HPB Surg, V11, P1, DOI 10.1155/1998/60259; Konstantinidis IT, 2013, ANN SURG, V257, P731, DOI 10.1097/SLA.0b013e318263da2f; Menon KV, 2009, HPB, V11, P18, DOI 10.1111/j.1477-2574.2008.00013.x; Morris-Stiff G, 2009, EJSO-EUR J SURG ONC, V35, P746, DOI 10.1016/j.ejso.2008.10.010; Raut CP, 2007, ANN SURG, V246, P52, DOI 10.1097/01.sla.0000259391.84304.2b; Schlitter Anna Melissa, 2010, Cancers (Basel), V2, P2001, DOI 10.3390/cancers2042001; Shrikhande SV, 2008, LANGENBECK ARCH SURG, V393, P87, DOI 10.1007/s00423-007-0221-2; Shrikhande SV, 2013, PANCREATOLOGY, V13, P63, DOI 10.1016/j.pan.2012.11.302; Strobel O, 2017, ANN SURG, V265, P565, DOI 10.1097/SLA.0000000000001731; Sugiura T, 2013, SURGERY, V154, P1078, DOI 10.1016/j.surg.2013.04.015; Tampi CS, 2017, INDIAN J GASTROENTER, V36, P81, DOI 10.1007/s12664-017-0742-8; The Royal College of Pathologists, 2017, STAND MIN DAT REP CA; van Geenen RCI, 2001, EUR J SURG ONCOL, V27, P549, DOI 10.1053/ejso.2001.1162; Verbeke C, 2015, CANCER TREAT REV, V41, P17, DOI 10.1016/j.ctrv.2014.11.002; Verbeke CS, 2008, HISTOPATHOLOGY, V52, P787, DOI 10.1111/j.1365-2559.2007.02935.x; Verbeke CS, 2006, BRIT J SURG, V93, P1232, DOI 10.1002/bjs.5397; Verbeke CS, 2012, BRIT J SURG, V99, P1036, DOI 10.1002/bjs.8734; Wagner M, 2004, BRIT J SURG, V91, P586, DOI 10.1002/bjs.4484; Washington K, 2016, PROTOCOL EXAMINATION; Westgaard A, 2011, APMIS, V119, P689, DOI 10.1111/j.1600-0463.2011.02783.x; Westgaard A, 2009, EUR J CANCER, V45, P2850, DOI 10.1016/j.ejca.2009.03.019; WILLETT CG, 1993, ANN SURG, V217, P144, DOI 10.1097/00000658-199302000-00008; Winner M, 2015, SEMIN ONCOL, V42, P86, DOI 10.1053/j.seminoncol.2014.12.008; Zhang YJ, 2012, J GASTROINTEST SURG, V16, P1875, DOI 10.1007/s11605-012-1985-4	37	3	3	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	SEP	2018	473	3					293	303		10.1007/s00428-018-2429-7			11	Pathology	Pathology	GS2RQ	WOS:000443403100004	30091124				2019-10-28	
J	Yamanoi, K; Ishii, K; Tsukamoto, M; Asaka, S; Nakayama, J				Yamanoi, Kazuhiro; Ishii, Keiko; Tsukamoto, Michihiko; Asaka, Shiho; Nakayama, Jun			Gastric gland mucin-specific O-glycan expression decreases as tumor cells progress from lobular endocervical gland hyperplasia to cervical mucinous carcinoma, gastric type	VIRCHOWS ARCHIV			English	Article						LEGH; MDA; Cervical cancer; Gastric type; Gastric mucin; aGlcNAc; MUC6	ADENOMA MALIGNUM; UTERINE CERVIX; HUMAN-PAPILLOMAVIRUS; N-ACETYLGLUCOSAMINE; MUCOUS CELLS; ADENOCARCINOMA; LESIONS; CANCER; DIFFERENTIATION; IMMUNOPHENOTYPE	Gastric gland mucin-specific O-glycans are unique in having alpha 1,4-linked N-acetylglucosamine (alpha GlcNAc) attached to MUC6. We previously reported decreased expression of alpha GlcNAc relative to MUC6 in gastric and pancreatic neoplasms, but its significance in cervical glandular lesions remained unclear. Here, we analyzed MUC5AC, MUC6, alpha GlcNAc, and p16 expression in 9 lesions of mucinous carcinoma, gastric type with minimal deviation adenocarcinoma (GAS-MDA), 5 of GAS with nonMDA (GAS-nonMDA), 14 of typical lobular endocervical gland hyperplasia (LEGH), and 5 of atypical LEGH (33 total lesions). All 33 were MUC5AC-positive. Moreover, all 14 typical LEGH, 5 atypical LEGH, 8 of 9 GAS-MDA, and 3 of 5 GAS-nonMDA were MUC6-positive. All 14 typical LEGH, 2 of 5 atypical LEGH, 3 of 9 GAS-MDA, and 1 of 5 GAS-nonMDA were alpha GlcNAc-positive. The proportion of alpha GlcNAc-positive atypical LEGH or GAS-MDA or GAS-nonMDA lesions was significantly smaller than that seen in typical LEGH lesions (P < 0.001 and P < 0.01, respectively). Of 33 lesions, 32 were p16-negative. Furthermore, when we evaluated MUC6 and alpha GlcNAc immunoreactivity semi-quantitatively in all 33 lesions, in typical LEGH and GAS-MDA, the immunohistochemical score for alpha GlcNAc was significantly lower than that for MUC6 (P < 0.01). We did not observe significantly decreased alpha GlcNAc expression relative to MUC6 in typical LEGH lesions. These studies suggest that alpha GlcNAc expression decreases as typical LEGH progresses to GAS. Given the difficulty in distinguishing MDA and atypical LEGH from typical LEGH in H.E. staining, we propose that immunohistochemical analysis of alpha GlcNAc and MUC6 could be useful.	[Yamanoi, Kazuhiro; Tsukamoto, Michihiko; Nakayama, Jun] Shinshu Univ, Sch Med, Dept Mol Pathol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan; [Yamanoi, Kazuhiro; Nakayama, Jun] Shinshu Univ, Inst Biomed Sci, Interdisciplinary Cluster Cutting Edge Res, Matsumoto, Nagano 3908621, Japan; [Ishii, Keiko; Asaka, Shiho] Shinshu Univ Hosp, Dept Lab Med, Matsumoto, Nagano 3908621, Japan; [Ishii, Keiko] Okaya City Hosp, Dept Pathol, Okaya 3948512, Japan	Yamanoi, K (reprint author), Shinshu Univ, Sch Med, Dept Mol Pathol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	kazyam@shinshu-u.ac.jp	Yamanoi, Kazuhiro/N-6147-2019; Asaka, Shiho/W-2061-2018	Yamanoi, Kazuhiro/0000-0002-5361-8053; Asaka, Shiho/0000-0003-2697-114X	Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [17K15640, 15H04712]	This work was supported by Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (nos. 17K15640 (K.Y.) and 15H04712 (J.N.)).	Chang HJ, 2004, PATHOL INT, V54, P576, DOI 10.1111/j.1440-1827.2004.01666.x; Ishihara K, 1996, BIOCHEM J, V318, P409, DOI 10.1042/bj3180409; Ishii K, 1998, VIRCHOWS ARCH, V432, P315, DOI 10.1007/s004280050172; Karasawa F, 2012, J CLIN INVEST, V122, P923, DOI 10.1172/JCI59087; Kojima A, 2007, AM J SURG PATHOL, V31, P664, DOI 10.1097/01.pas.0000213434.91868.b0; Kurman RJ, 2011, BLAUSTEIN'S PATHOLOGY OF THE FEMALE GENITAL TRACT, SIXTH EDITION, P1, DOI 10.1007/978-1-4419-0489-8; Kurman RJ, 1992, ATLAS TUMOR PATHOL, P91; Matsubara A, 2014, AM J SURG PATHOL, V38, P370, DOI 10.1097/PAS.0000000000000093; Matsukita S, 2003, HISTOPATHOLOGY, V42, P26, DOI 10.1046/j.1365-2559.2003.01530.x; MATSUZAWA K, 1992, HUM PATHOL, V23, P925, DOI 10.1016/0046-8177(92)90407-T; McCluggage WG, 2010, J CLIN PATHOL, V63, P935, DOI 10.1136/jcp.2010.080150; Mikami Y, 2004, MODERN PATHOL, V17, P962, DOI 10.1038/modpathol.3800148; Mikami Y, 2000, AM J SURG PATHOL, V24, P323, DOI 10.1097/00000478-200002000-00042; Mikami Y, 2001, HISTOPATHOLOGY, V39, P364, DOI 10.1046/j.1365-2559.2001.01239.x; Mikami Y, 2013, ADV ANAT PATHOL, V20, P227, DOI 10.1097/PAP.0b013e31829c2d66; Nakayama J, 1999, P NATL ACAD SCI USA, V96, P8991, DOI 10.1073/pnas.96.16.8991; Nishiwaki M, 2008, J CLIN MICROBIOL, V46, P1161, DOI 10.1128/JCM.00793-07; Nucci MR, 1999, AM J SURG PATHOL, V23, P886, DOI 10.1097/00000478-199908000-00005; Ohta Y, 2008, PATHOL RES PRACT, V204, P683, DOI 10.1016/j.prp.2008.02.009; Ohya A, 2017, CANCER SCI, V108, P1897, DOI 10.1111/cas.13317; OTA H, 1991, HISTOCHEM J, V23, P22, DOI 10.1007/BF01886504; Park KJ, 2011, AM J SURG PATHOL, V35, P633, DOI 10.1097/PAS.0b013e31821534b9; Sano T, 1998, AM J PATHOL, V153, P1741, DOI 10.1016/S0002-9440(10)65689-1; Shiratsu K, 2014, CANCER SCI, V105, P126, DOI 10.1111/cas.12305; Smith HO, 2000, GYNECOL ONCOL, V78, P97, DOI 10.1006/gyno.2000.5826; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F; Wells M, 2003, PATHOLOGY GENETICS T, P262; Wilbur DC, 2014, WHO CLASSIFICATION T, P184; Yamanoi K, 2018, HISTOCHEM CELL BIOL, V149, P569, DOI 10.1007/s00418-018-1667-8; Yamanoi K, 2015, HISTOPATHOLOGY, V67, P898, DOI 10.1111/his.12728; Zappa M, 2004, BRIT J CANCER, V90, P1784, DOI 10.1038/sj.bjc.6601754; Zhang MX, 2001, J HISTOCHEM CYTOCHEM, V49, P587, DOI 10.1177/002215540104900505	32	3	3	2	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	SEP	2018	473	3					305	311		10.1007/s00428-018-2381-6			7	Pathology	Pathology	GS2RQ	WOS:000443403100005	29845361				2019-10-28	
J	Silva, J; Canao, P; Espinheira, MC; Trindade, E; Carneiro, F; Dias, JA				Silva, Jorge; Canao, Pedro; Espinheira, Maria Ceu; Trindade, Eunice; Carneiro, Fatima; Dias, Jorge Amil			Eosinophils in the gastrointestinal tract: how much is normal?	VIRCHOWS ARCHIV			English	Article						Eosinophil; Gastrointestinal tract; Normal; Endoscopy; Histology	DUODENAL EOSINOPHILIA; FUNCTIONAL DYSPEPSIA; MUCOSAL EOSINOPHILS; MAST-CELLS; CHILDREN; ADULTS; DISORDERS; ESOPHAGITIS; DISEASES; COHORT	The normal density of eosinophils in the digestive mucosa of children has been rarely addressed despite being important to provide baseline counts for the diagnosis of eosinophilic gastrointestinal disorders (EGID). Histopathological criteria for EGID remain undefined and there has been little consistency of results in different populations. We aimed to establish the eosinophil density of the normal digestive mucosa in a paediatric population submitted to endoscopic procedures with normal histological features. Biopsies from endoscopies of 33 patients were evaluated. Quantification of eosinophils was performed manually. Review of the pathology reports confirmed absence of abnormality in the biopsy specimens. Counts were expressed in eosinophils per high power field and per mm(2). Oesophagus (n = 33): eosinophils were uniformly absent in all biopsies. Stomach: counting was performed, separately, in the superficial and deep lamina propria of the fundus (n = 13), corpus (n = 13) and antrum (n = 16). Mean eosinophilic density was higher in the deep lamina propria. Small intestine: eosinophil counts revealed 18.1 +/- 17.0, 14.4 +/- 12.0, and 51.5 +/- 35.3 in the lamina propria of the bulb (n = 13), D2 (n = 13), and ileum (n = 16), respectively. Large intestine: the highest peak count was observed in the caecum (125 mm(2); n = 16) with a mean of 51.8 +/- 33.5. The eosinophil counts were lower in the ascending (n = 16; 40.9 +/- 27.4), transverse (n = 14; 34.3 +/- 21.9), descending (n = 15; 40.0 +/- 26.6), and sigmoid (n = 17; 25.8 +/- 17.8) colon and in the rectum (n = 17; 13.9 +/- 10.1). These data provide a baseline count and distribution of eosinophils in the gastrointestinal tract of paediatric patients with normal mucosa, thus expanding the scarce published data.	[Silva, Jorge] Med Sch Porto, Alameda Prof Hernani Monteiro, P-4200319 Porto, Portugal; [Canao, Pedro; Carneiro, Fatima] Ctr Hosp Sao Joao, Dept Pathol, Porto, Portugal; [Espinheira, Maria Ceu; Trindade, Eunice; Dias, Jorge Amil] Ctr Hosp Sao Joao, Dept Paediat, Porto, Portugal; [Carneiro, Fatima] Med Sch Porto, Dept Pathol, Porto, Portugal; [Carneiro, Fatima] IPATIMUP, Porto, Portugal; [Carneiro, Fatima] i3S, Porto, Portugal	Silva, J (reprint author), Med Sch Porto, Alameda Prof Hernani Monteiro, P-4200319 Porto, Portugal.	jorge.ramos.neves.silva@gmail.com	Carneiro, Fatima/J-6432-2013	Carneiro, Fatima/0000-0002-1964-1006; Silva, Jorge/0000-0002-8165-4043			ASHORN M, 1994, J PEDIATR GASTR NUTR, V18, P146, DOI 10.1097/00005176-199402000-00005; Bafutto M, 2009, GASTROENTEROLOGY, V136, pA434; Bastos J, 2013, DIGEST LIVER DIS, V45, P290, DOI 10.1016/j.dld.2012.11.009; Beorlegui M, 2012, ACTA PEDIAT PORTUGUE, V43; Binesh F, 2013, JCPSP-J COLL PHYSICI, V23, P326, DOI 05.2013/JCPSP.326329; Chernetsova E, 2016, HUM PATHOL, V54, P55, DOI 10.1016/j.humpath.2016.03.004; Cianferoni A, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0558-5; Collins MH, 2018, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00261; Collins MH, 2009, IMMUNOL ALLERGY CLIN, V29, P109, DOI 10.1016/j.iac.2008.10.005; Costa JM, 2004, ACTA PEDIAT PORTUGUE, V35; Cruz AL da S, 2003, PARASITOSES INTESTIN; DeBrosse CW, 2006, PEDIATR DEVEL PATHOL, V9, P210, DOI 10.2350/11-05-0130.1; Du L, 2018, NEUROGASTROENT MOTIL, V30, DOI 10.1111/nmo.13304; Du LJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep34305; Faure C, 2010, GASTROENTEROLOGY, V139, P249, DOI 10.1053/j.gastro.2010.03.032; Furuta GT, 2015, NEW ENGL J MED, V373, P1640, DOI 10.1056/NEJMra1502863; Genta RM, 2018, ALIMENT PHARM THER, V47, P1143, DOI 10.1111/apt.14558; Jung Y, 2014, J IMMUNOL, V193, P999, DOI 10.4049/jimmunol.1400413; Kiss Z, 2018, J PEDIATR GASTR NUTR, V67, P6, DOI 10.1097/MPG.0000000000001904; Lee EH, 2016, J NEUROGASTROENTEROL, V22, P459, DOI 10.5056/jnm15174; Lia Gata LG, 2008, PARASITOSES INTESTIN; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Lowichik A, 1996, MODERN PATHOL, V9, P110; Lwin T, 2011, MODERN PATHOL, V24, P556, DOI 10.1038/modpathol.2010.221; Matsushita T, 2015, AM J SURG PATHOL, V39, P521, DOI 10.1097/PAS.0000000000000370; Mehta P, 2015, IMMUNOL ALLERGY CLIN, V35, P413, DOI 10.1016/j.iac.2015.04.003; Pascal RR, 1997, MODERN PATHOL, V10, P363; Polydorides AD, 2008, HUM PATHOL, V39, P832, DOI 10.1016/j.humpath.2007.10.012; Rothenberg ME, 2004, J ALLERGY CLIN IMMUN, V113, P11, DOI 10.1016/j.jaci.2003.10.047; Saad AG, 2011, PEDIATR DEVEL PATHOL, V14, P294, DOI 10.2350/10-07-0878-OA.1; Turner KO, 2017, AM J SURG PATHOL, V41, P225, DOI 10.1097/PAS.0000000000000760; Wauters L, 2017, ALIMENT PHARM THER, V45, P1358, DOI 10.1111/apt.14045	32	1	1	1	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	SEP	2018	473	3					313	320		10.1007/s00428-018-2405-2			8	Pathology	Pathology	GS2RQ	WOS:000443403100006	29987614				2019-10-28	
J	Andreasen, S; Tan, QH; Agander, TK; Hansen, TVO; Steiner, P; Bjorndal, K; Hogdall, E; Larsen, SR; Erentaite, D; Olsen, CH; Ulhoi, BP; Heegaard, S; Wessel, I; Homoe, P				Andreasen, Simon; Tan, Qihua; Agander, Tina Klitmoller; Hansen, Thomas V. O.; Steiner, Petr; Bjorndal, Kristine; Hogdall, Estrid; Larsen, Stine Rosenkilde; Erentaite, Daiva; Olsen, Caroline Holkmann; Ulhoi, Benedicte Parm; Heegaard, Steffen; Wessel, Irene; Homoe, Preben			MicroRNA dysregulation in adenoid cystic carcinoma of the salivary gland in relation to prognosis and gene fusion status: a cohort study	VIRCHOWS ARCHIV			English	Article						Adenoid cystic carcinoma; Salivary gland; microRNA; Prognosis; MYB; MYBL1	CANCER GROUP DAHANCA; DENMARK 1990-2005; LUNG-CANCER; DANISH HEAD; NECK; EXPRESSION; METASTASIS; RECURRENCE; FEATURES; MANAGEMENT	Adenoid cystic carcinoma (ACC) is among the most frequent malignancies of the salivary gland, and is notorious for its prolonged clinical course characterized by frequent recurrences often years after initial treatment. No molecular marker has been shown to have independent prognostic value in ACC, including characteristic gene fusions involving MYB, MYBL1, and NFIB. MicroRNA has been shown to be associated with clinical outcome in numerous malignancies, including one study of ACC, warranting further validation of this class of markers in this disease. Here, we investigate the prognostic value of microRNA in two ACC cohorts: a training cohort (n = 64) and a validation cohort (n = 120) with microarray and qPCR. In the training cohort, multivariate analysis of microarray data found high expression of hsa-miR-6835-3p to be associated with reduced recurrence-free survival (RFS) (p = 0.016). Measuring the highest ranking microRNAs identified in survival analysis in the same cohort, qPCR identified high expression of hsa-miR-4676 to be associated with reduced overall survival (OS) and high expression of hsa-mir-1180 to be associated with improved RFS. This was not confirmed in the validation cohort, in which qPCR identified high expression of hsa-mir-21, hsa-mir-181a-2, and hsa-mir-152 to be associated with reduced OS and high expression of hsa-miR-374c to be associated with improved RFS. Interestingly, two distinct subsets of ACC separated in microRNA expression irrespective of gene fusion status, but without significant difference in outcome. Collectively, qPCR identified several microRNAs associated with OS and RFS, and different subsets of ACC separated according to microRNA expression, suggestive of ACC being a heterogeneous group of malignancies in its microRNA profile.	[Andreasen, Simon; Homoe, Preben] Zealand Univ Hosp, Dept Otorhinolaryngol & Maxillofacial Surg, Koge, Denmark; [Andreasen, Simon; Wessel, Irene] Rigshosp, Dept Otorhinolaryngol Head & Neck Surg & Audiol, Copenhagen, Denmark; [Tan, Qihua] Univ Southern Denmark, Unit Human Genet, Dept Clin Res, Odense, Denmark; [Agander, Tina Klitmoller; Heegaard, Steffen] Rigshosp, Dept Pathol, Copenhagen, Denmark; [Hansen, Thomas V. O.] Copenhagen Univ Hosp, Rigshosp, Genom Med, Copenhagen, Denmark; [Steiner, Petr] Charles Univ Prague, Dept Pathol, Fac Med, Plzen, Czech Republic; [Steiner, Petr] Biopt Lab Ltd, Mol Pathol Lab, Plzen, Czech Republic; [Bjorndal, Kristine] Odense Univ Hosp, Dept ORL Head & Neck Surg, Odense, Denmark; [Hogdall, Estrid] Univ Copenhagen, Dept Pathol, Herlev Hosp, Herlev, Denmark; [Larsen, Stine Rosenkilde] Odense Univ Hosp, Dept Pathol, Odense, Denmark; [Erentaite, Daiva] Aalborg Univ Hosp, Dept Pathol, Aalborg, Denmark; [Olsen, Caroline Holkmann] Zealand Univ Hosp, Dept Pathol, Roskilde, Denmark; [Ulhoi, Benedicte Parm] Aarhus Univ Hosp, Dept Pathol, Aarhus, Denmark; [Heegaard, Steffen] Rigshosp Glostrup, Dept Ophthalmol, Copenhagen, Denmark	Andreasen, S (reprint author), Zealand Univ Hosp, Dept Otorhinolaryngol & Maxillofacial Surg, Koge, Denmark.	Simon@Andreasen.pm	Hansen, Thomas v. O./J-9361-2014; Tan, Qihua/F-1349-2015	Hansen, Thomas v. O./0000-0003-4635-2653; Hogdall, Estrid/0000-0003-4689-5658; Tan, Qihua/0000-0003-3194-0030; Andreasen, Simon/0000-0002-1528-4988	Einar Willumsen Foundation; Merchant Kristjan Kjaer and wife Margrethe Kjaer's Foundation; Danielsen Foundation; Else and Mogens Wedell-Wedellsborg's Foundation; Region Zealand's Research Fund; Hans Skouby and wife Emma Skouby's Foundation; A. P. Moller Foundation for the Advancement of Medical Research	SA was supported by Einar Willumsen Foundation, Merchant Kristjan Kjaer and wife Margrethe Kjaer's Foundation, The Danielsen Foundation, Else and Mogens Wedell-Wedellsborg's Foundation, Region Zealand's Research Fund, Hans Skouby and wife Emma Skouby's Foundation, and the A. P. Moller Foundation for the Advancement of Medical Research.	Adelstein DJ, 2012, SEMIN RADIAT ONCOL, V22, P245, DOI 10.1016/j.semradonc.2012.03.009; Amit M, 2015, HEAD NECK-J SCI SPEC, V37, P1038, DOI 10.1002/hed.23710; Andersson MK, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx017; Andreasen S, 2018, CANCER CYTOPATHOL, V126, P275, DOI 10.1002/cncy.21959; Andreasen S, 2017, HISTOPATHOLOGY, V70, P880, DOI 10.1111/his.13162; Andreasen S, 2016, EUR ARCH OTO-RHINO-L, V273, P3847, DOI 10.1007/s00405-016-4000-y; Balamucki CJ, 2012, AM J OTOLARYNG, V33, P510, DOI 10.1016/j.amjoto.2011.11.006; Barrett AW, 2009, ORAL ONCOL, V45, P936, DOI 10.1016/j.oraloncology.2009.07.001; Bass BP, 2014, ARCH PATHOL LAB MED, V138, P1520, DOI 10.5858/arpa.2013-0691-RA; Bishop JA, 2017, AM J SURG PATHOL, V41, P1690, DOI 10.1097/PAS.0000000000000944; Bjorndal K, 2015, ORAL ONCOL, V51, P1138, DOI 10.1016/j.oraloncology.2015.10.002; Bjorndal K, 2011, ORAL ONCOL, V47, P677, DOI 10.1016/j.oraloncology.2011.04.020; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chen AM, 2006, INT J RADIAT ONCOL, V66, P152, DOI 10.1016/j.ijrobp.2006.04.014; Dillon PM, 2016, HEAD NECK-J SCI SPEC, V38, P620, DOI 10.1002/hed.23925; Erichsen Rune, 2010, Clin Epidemiol, V2, P51; Ferrarotto R, 2017, J CLIN ONCOL, V35, P352, DOI 10.1200/JCO.2016.67.5264; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Frerich CA, 2017, ONCOTARGET, V9, P7341, DOI [10.18632/oncotarget.23641, DOI 10.18632/ONCOTARGET.23641]; Hall JS, 2012, BRIT J CANCER, V107, P684, DOI 10.1038/bjc.2012.294; Helweg-Larsen K, 2011, SCAND J PUBLIC HEALT, V39, P26, DOI 10.1177/1403494811399958; Ho AS, 2013, NAT GENET, V45, P791, DOI 10.1038/ng.2643; Howe K, 2017, METHODS MOL BIOL, V1509, P17, DOI 10.1007/978-1-4939-6524-3_3; Hudson JB, 2014, ARCH PATHOL LAB MED, V138, P403, DOI 10.5858/arpa.2012-0736-OA; Jang JS, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-144; Kokemueller H, 2004, INT J ORAL MAX SURG, V33, P25, DOI 10.1054/ijom.2003.0448; Kong YW, 2012, LANCET ONCOL, V13, pE249, DOI 10.1016/S1470-2045(12)70073-6; Liu B, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx033; Ma W, 2017, EXP THER MED, V14, P2853, DOI 10.3892/etm.2017.4847; McShane LM, 2005, BRIT J CANCER, V93, P387, DOI 10.1038/sj.bjc.6602678; Mestdagh P, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn725; Mitani Y, 2016, CLIN CANCER RES, V22, P725, DOI 10.1158/1078-0432.CCR-15-2867-T; Mitani Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066778; Moore HM, 2011, J PROTEOME RES, V10, P3429, DOI 10.1021/pr200021n; Oplatek A, 2010, LARYNGOSCOPE, V120, P65, DOI 10.1002/lary.20684; Pedersen CB, 2011, SCAND J PUBLIC HEALT, V39, P22, DOI 10.1177/1403494810387965; Perez-Rivas LG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091884; Persson M, 2009, P NATL ACAD SCI USA, V106, P18740, DOI 10.1073/pnas.0909114106; Sajed DP, 2017, AM J SURG PATHOL, V41, P1473, DOI 10.1097/PAS.0000000000000945; Schetter AJ, 2008, JAMA-J AM MED ASSOC, V299, P425, DOI 10.1001/jama.299.4.425; Skalova A, 2010, AM J SURG PATHOL, V34, P599, DOI 10.1097/PAS.0b013e3181d9efcc; Spahn M, 2010, INT J CANCER, V127, P394, DOI 10.1002/ijc.24715; Spiro RH, 1997, AM J SURG, V174, P495; Stenman G, 2017, WHO CLASSIFICATION H, P164; Thomson JM, 2006, GENE DEV, V20, P2202, DOI 10.1101/gad.1444406; Ul Hussain M, 2012, CELL TISSUE RES, V349, P405, DOI 10.1007/s00441-012-1438-0; Xi YG, 2007, RNA, V13, P1668, DOI 10.1261/rna.642907; Yu SL, 2008, CANCER CELL, V13, P48, DOI 10.1016/j.ccr.2007.12.008; Zheng Q, 2009, BMC GENOMICS, V10, DOI [10.1186/1471-2164-10-87, 10.1186/1471-2164-10-407]	50	5	5	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	SEP	2018	473	3					329	340		10.1007/s00428-018-2423-0			12	Pathology	Pathology	GS2RQ	WOS:000443403100008	30069755				2019-10-28	
J	Reinke, S; Richter, J; Fend, F; Feller, A; Hansmann, ML; Huttl, K; Oschlies, I; Ott, G; Moller, P; Rosenwald, A; Stein, H; Altenbuchinger, M; Spang, R; Klapper, W				Reinke, Sarah; Richter, Julia; Fend, Falko; Feller, Alfred; Hansmann, Martin-Leo; Huettl, Katrin; Oschlies, Ilske; Ott, German; Moeller, Peter; Rosenwald, Andreas; Stein, Harald; Altenbuchinger, Michael; Spang, Rainer; Klapper, Wolfram			Round-robin test for the cell-of-origin classification of diffuse large B-cell lymphoma-a feasibility study using full slide staining	VIRCHOWS ARCHIV			English	Article						Diffuse large B-cell lymphoma; ABC; GCB; Cell of origin; Immunohistochemistry; Hans classifier	GENE-EXPRESSION; MOLECULAR CLASSIFICATION; BIOMARKER CONSORTIUM; TISSUE MICROARRAY; IMMUNOHISTOCHEMISTRY; SURVIVAL; SUBTYPES	Diffuse large B-cell lymphoma (DLBCL) is subdivided by gene expression analysis (GEP) into two molecular subtypes named germinal center B-cell-like (GCB) and activated B-cell-like (ABC) after their putative cell-of-origin (COO). Determination of the COO is considered mandatory in any new-diagnosed DLBCL, not otherwise specified according to the updated WHO classification. Despite the fact that pathologists are free to choose the method for COO classification, immunohistochemical (IHC) assays are most widely used. However, to the best of our knowledge, no round-robin test to evaluate the interlaboratory variability has been published so far. Eight hematopathology laboratories participated in an interlaboratory test for COO classification of 10 DLBCL tumors using the IHC classifier comprising the expression of CD10, BCL6, and MUM1 (so-called Hans classifier). The results were compared with GEP for COO signature and, in a subset, with results obtained by image analysis. In 7/10 cases (70%), at least seven laboratories assigned a given case to the same COO subtype (one center assessed one sample as not analyzable), which was in agreement with the COO subtype determined by GEP. The results in 3/10 cases (30%) revealed discrepancies between centers and/or between IHC and GEP subtype. Whereas the CD10 staining results were highly reproducible, staining for MUM1 was inconsistent in 50% and for BCL6 in 40% of cases. Image analysis of 16 slides stained for BCL6 (N = 8) and MUM1 (N = 8) of the two cases with the highest disagreement in COO classification were in line with the score of the pathologists in 14/16 stainings analyzed (87.5%). This study describes the first round-robin test for COO subtyping in DLBCL using IHC and demonstrates that COO classification using the Hans classifier yields consistent results among experienced hematopathologists, even when variable staining protocols are used. Data from this small feasibility study need to be validated in larger cohorts.	[Reinke, Sarah; Richter, Julia; Oschlies, Ilske; Klapper, Wolfram] Univ Hosp Schleswig Holstein, Dept Pathol, Hematopathol Sect, Campus Kiel,Arnold Heller Str 3, D-24105 Kiel, Germany; [Fend, Falko] Eberhard Karls Univ Tubingen, Univ Hosp Tubingen, Inst Pathol & Neuropathol, Tubingen, Germany; [Feller, Alfred] Hematopathol Lubeck, Lubeck, Germany; [Hansmann, Martin-Leo] Goethe Univ, Univ Hosp Frankfurt, Dr Senckenberg Inst Pathol, Frankfurt, Germany; [Huettl, Katrin; Ott, German] Robert Bosch Krankenhaus & Dr Margarete Fischer B, Dept Clin Pathol, Stuttgart, Germany; [Moeller, Peter] Univ Hosp Ulm, Dept Pathol, Ulm, Germany; [Rosenwald, Andreas] Univ Wurzburg, Inst Pathol, Wurzburg, Germany; [Rosenwald, Andreas] Comprehens Canc Ctr Mainfranken, Wurzburg, Germany; [Stein, Harald] Pathodiagnostik, Berlin, Germany; [Altenbuchinger, Michael; Spang, Rainer] Univ Regensburg, Inst Funct Genom, Regensburg, Germany	Reinke, S (reprint author), Univ Hosp Schleswig Holstein, Dept Pathol, Hematopathol Sect, Campus Kiel,Arnold Heller Str 3, D-24105 Kiel, Germany.	S.Reinke@uksh.de		Michael, Altenbuchinger/0000-0003-1102-6532	German Federal Ministry of Education and Research (BMBF) as a part of the MMML-Demonstrators project within the e:Med framework [031A428D]	This study was funded by the German Federal Ministry of Education and Research (BMBF) as a part of the MMML-Demonstrators project (grant 031A428D) within the e:Med framework.	Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Choi WWL, 2009, CLIN CANCER RES, V15, P5494, DOI 10.1158/1078-0432.CCR-09-0113; de Jong D, 2007, J CLIN ONCOL, V25, P805, DOI 10.1200/JCO.2006.09.4490; Gutierrez-Garcia G, 2011, BLOOD, V117, P4836, DOI 10.1182/blood-2010-12-322362; Hans CP, 2004, BLOOD, V103, P275, DOI 10.1182/blood-2003-05-1545; Lawrie CH, 2012, HISTOPATHOLOGY, V61, P18, DOI 10.1111/j.1365-2559.2012.04179.x; Lenz G, 2010, NEW ENGL J MED, V362, P1417, DOI 10.1056/NEJMra0807082; Masque-Soler N, 2013, BLOOD, V122, P1985, DOI 10.1182/blood-2013-06-508937; Meyer PN, 2011, J CLIN ONCOL, V29, P200, DOI 10.1200/JCO.2010.30.0368; Muris JJF, 2006, J PATHOL, V208, P714, DOI 10.1002/path.1924; Paul U, 2018, LEUKEMIA LYMPHOMA, V59, P1213, DOI 10.1080/10428194.2017.1365851; Reddy A, 2017, CELL, V171, P481, DOI 10.1016/j.cell.2017.09.027; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Salles G, 2011, BLOOD, V117, P7070, DOI 10.1182/blood-2011-04-345256; Scott DW, 2014, BLOOD, V123, P1214, DOI 10.1182/blood-2013-11-536433; Sehn LH, 2015, BLOOD, V125, P22, DOI 10.1182/blood-2014-05-577189; Staiger AM, 2017, J CLIN ONCOL, V35, P2515, DOI 10.1200/JCO.2016.70.3660; Swerdlow SH, 2008, WHO CLASSIFICATION T	18	1	1	2	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	SEP	2018	473	3					341	349		10.1007/s00428-018-2367-4			9	Pathology	Pathology	GS2RQ	WOS:000443403100009	29730836				2019-10-28	
J	Erber, R; Agaimy, A				Erber, Ramona; Agaimy, Abbas			Misses and near misses in diagnosing nodular fasciitis and morphologically related reactive myofibroblastic proliferations: experience of a referral center with emphasis on frequency of USP6 gene rearrangements	VIRCHOWS ARCHIV			English	Article						Myxofibrosarcoma; USP6 translocation; Nodular fasciitis; Myositis ossificans; Heterotopic ossification; Sarcoma; Proliferative fasciitis; Myofibroblastic sarcoma; Fibroma of tendon sheath	ANEURYSMAL BONE-CYST; SOFT-TISSUE; TENDON SHEATH; OSSIFICANS; CHILDHOOD; ONCOGENES; MYOSITIS; FIBROMA; LESIONS; FUSION	Although harmless, reactive and benign neoplastic myo-/fibroblastic proliferations represent a diagnostic challenge in routine surgical pathology practice as reflected by their frequency among consultation cases. In addition to resembling each other, the prototypical nodular fasciitis (NF) and NF-like lesions can be mistaken for low-grade or aggressive sarcomas. USP6 translocation was reported recently as the molecular driver and potential diagnostic marker of NF. We reviewed 71 lesions with a diagnosis of NF (n = 48) or NF-like myofibroblastic proliferations (n = 23) and screened them for USP6 translocation by fluorescence in situ hybridization (FISH). Only one third of NFs were correctly diagnosed by submitting pathologists while one third was initially judged as malignant. NF was mentioned in the differential diagnosis in only half of the cases. A high Ki67/mitotic index, misleading immunohistochemistry (false-positive h-caldesmon), and unusual sites/circumscription were main causes behind overdiagnosis as malignant. FISH analysis revealed USP6 translocation in 74.4% of NF cases. None of the reactive/reparative myofibroblastic proliferations showed USP6 translocation. NF is still significantly misdiagnosed by general surgical pathologists, with a higher tendency toward overdiagnosis of malignancy. Inclusion of NF in the differential diagnosis of any fibromyxoid soft tissue lesion and awareness of its diverse morphology are mandatory to avoid misdiagnoses with the risk of disastrous overtreatment. In the appropriate clinicopathological context, USP6 gene translocation is a valuable adjunct for diagnosis of NF, particularly in limited biopsies. Absence of the USP6 gene translocation in NF-like reparative pseudosarcomatous myofibroblastic proliferations underlines their reactive nature and distinguishes them from NF which is currently considered a benign neoplasm with a self-limiting "transient" growth phase.	[Erber, Ramona; Agaimy, Abbas] Friedrich Alexander Univ Erlangen Nurnberg FAU, Inst Pathol, Krankenhausstr 8-10, D-91054 Erlangen, Germany	Agaimy, A (reprint author), Friedrich Alexander Univ Erlangen Nurnberg FAU, Inst Pathol, Krankenhausstr 8-10, D-91054 Erlangen, Germany.	abbas.agaimy@uk-erlangen.de					ALLEN PW, 1972, PATHOLOGY, V4, P61, DOI 10.3109/00313027209068925; ALLEN PW, 1994, AUST NZ J SURG, V64, P273, DOI 10.1111/j.1445-2197.1994.tb02201.x; Amaranathan A, 2016, J CLIN DIAGN RES, V10, pPD13, DOI 10.7860/JCDR/2016/18399.8012; Amary MF, 2013, VIRCHOWS ARCH, V463, P97, DOI 10.1007/s00428-013-1418-0; Bekers EM, 2018, ANN DIAGN PATHOL, V34, P56, DOI 10.1016/j.anndiagpath.2018.01.006; Carter JM, 2016, MODERN PATHOL, V29, P865, DOI 10.1038/modpathol.2016.83; Chaudhry IH, 2010, J CUTAN PATHOL, V37, P323, DOI 10.1111/j.1600-0560.2009.01385.x; CHUNG EB, 1975, CANCER-AM CANCER SOC, V36, P1450, DOI 10.1002/1097-0142(197510)36:4<1450::AID-CNCR2820360437>3.0.CO;2-4; CHUNG EB, 1979, CANCER, V44, P1945, DOI 10.1002/1097-0142(197911)44:5<1945::AID-CNCR2820440558>3.0.CO;2-T; DAROCA PJ, 1982, ARCH PATHOL LAB MED, V106, P682; de Feraudy S, 2010, AM J SURG PATHOL, V34, P1377, DOI 10.1097/PAS.0b013e3181ed7374; Erickson-Johnson MR, 2011, LAB INVEST, V91, P1427, DOI 10.1038/labinvest.2011.118; Eversole LR, 1999, ORAL SURG ORAL MED O, V87, P471, DOI 10.1016/S1079-2104(99)70247-7; Fletcher C, 2013, WHO CLASSIFICATION T; Funakoshi Y, 2014, J CELL SCI, V127, P4750, DOI 10.1242/jcs.156786; Guo RF, 2016, GENE CHROMOSOME CANC, V55, P640, DOI 10.1002/gcc.22366; Hansen T, 2006, PATHOLOGE, V27, P198, DOI 10.1007/s00292-005-0798-6; Hornick JL, 2006, AM J SURG PATHOL, V30, P237, DOI 10.1097/01.pas.0000180441.48904.50; Kumar E, 2016, J CUTAN PATHOL, V43, P1143, DOI 10.1111/cup.12828; KWITTKEN J, 1969, AM J CLIN PATHOL, V51, P251; Magro G, 2011, J CUTAN PATHOL, V38, P59, DOI 10.1111/j.1600-0560.2009.01460.x; MEIS JM, 1992, AM J SURG PATHOL, V16, P364, DOI 10.1097/00000478-199204000-00005; OConnell JX, 1997, INT J GYNECOL PATHOL, V16, P117, DOI 10.1097/00004347-199704000-00006; Oliveira AM, 2004, CANCER RES, V64, P1920, DOI 10.1158/0008-5472.CAN-03-2827; Oliveira AM, 2004, AM J PATHOL, V165, P1773, DOI 10.1016/S0002-9440(10)63432-3; Oliveira AM, 2014, HUM PATHOL, V45, P1, DOI 10.1016/j.humpath.2013.03.005; Patel NR, 2017, MODERN PATHOL, V30, P1577, DOI 10.1038/modpathol.2017.78; Perez-Montiel MD, 2006, AM J DERMATOPATH, V28, P105, DOI 10.1097/01.dad.0000200009.02939.cc; SHIMIZU S, 1984, PATHOLOGY, V16, P161, DOI 10.3109/00313028409059097; Shin C, 2016, HISTOPATHOLOGY, V69, P784, DOI 10.1111/his.13011; Sukov WR, 2008, SKELETAL RADIOL, V37, P321, DOI 10.1007/s00256-007-0442-z; Thompson L D, 2001, Ann Diagn Pathol, V5, P191, DOI 10.1053/adpa.2001.26969	32	3	3	1	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	SEP	2018	473	3					351	360		10.1007/s00428-018-2350-0			10	Pathology	Pathology	GS2RQ	WOS:000443403100010	29623468				2019-10-28	
J	Komforti, MK; Sokolovskaya, E; D'Agostino, CA; Benayed, R; Thomas, RM				Komforti, Miglena K.; Sokolovskaya, Evgeniya; D'Agostino, Catherine A.; Benayed, Ryma; Thomas, Rebecca M.			Extra-osseous Ewing sarcoma of the pancreas: case report with radiologic, pathologic, and molecular correlation, and brief review of the literature	VIRCHOWS ARCHIV			English	Review						Ewing sarcoma; Ewing family of tumors; Pancreas; Molecular analysis; FISH	PRIMITIVE NEUROECTODERMAL TUMOR; EXTREMELY RARE TUMOR; PRECOCIOUS PUBERTY; ENTITY	In 2002, due to extensive histomorphologic, immunohistochemical, and cytogenetic similarities, the World Health Organization unified undifferentiated small round blue cell neoplasms of soft tissue and bone (previously segregated as Ewing sarcoma or Primitive Neuroectodermal tumor) into one category: Ewing family of tumors (EFT). Osseous EFT are more common, and while extra-osseous EFT can occur anywhere in the body, those of the pancreas are rare and likely to be seen in the second decade of life in the head of the pancreas. We report the case of a 39-year-old Caucasian male with a large heterogeneously enhancing mass in the pancreatic body. Pathologic examination showed a malignant round blue cell tumor diffusely positive for CD99, chromogranin, and synaptophysin; Ki-67 proliferation index was greater than 80%. FISH showed EWSR1 gene rearrangement in 90% of cells and Archer FusionPlexTM-targeted RNA sequencing analysis identified the EWSR1-FLI1 fusion transcript. The diagnosis of EFT of the pancreas was rendered. Unfortunately, the patient had minimal improvement and was transitioned to oral pain medications to continue care at a different institution.	[Komforti, Miglena K.; Thomas, Rebecca M.] Northwell Hlth, Dept Pathol, 6 Ohio Dr,Suite 202, Lake Success, NY 11042 USA; [Sokolovskaya, Evgeniya; D'Agostino, Catherine A.] Northwell Hlth, Dept Radiol, Manhasset, NY USA; [Benayed, Ryma] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA	Komforti, MK (reprint author), Northwell Hlth, Dept Pathol, 6 Ohio Dr,Suite 202, Lake Success, NY 11042 USA.	mdzhupanova@gmail.com		Komforti, Miglena/0000-0002-1522-2541			ANGERVALL L, 1975, CANCER, V36, P240, DOI 10.1002/1097-0142(197507)36:1<240::AID-CNCR2820360127>3.0.CO;2-H; ASKIN FB, 1979, CANCER, V43, P2438, DOI 10.1002/1097-0142(197906)43:6<2438::AID-CNCR2820430640>3.0.CO;2-9; Bose P, 2012, INT J CLIN ONCOL, V17, P399, DOI 10.1007/s10147-011-0311-6; Bulchmann G, 2000, KLIN PADIATR, V212, P185, DOI 10.1055/s-2000-9675; Changal KH, 2014, MALAYS J MED SCI, V21, P65; DANNER DB, 1994, MODERN PATHOL, V7, P200; Dias AR, 2013, ABCD-ARQ BRAS CIR DI, V26, P159, DOI 10.1590/S0102-67202013000200021; Doi H, 2009, INTERNAL MED, V48, P329, DOI 10.2169/internalmedicine.48.1484; Ewing J, 1921, P NY PATHOL SOC, V21, P24; Gemechu T, 2002, ETHIOPIAN MED J, V40, P69; Goldblum JR, 2014, ENZINGER WEISSS SOFT, P1028; Golhar Ankush, 2017, BMJ Case Rep, V2017, DOI 10.1136/bcr-2017-219219; JAFFE R, 1984, AM J SURG PATHOL, V8, P885, DOI 10.1097/00000478-198412000-00001; Jayant K, 2016, J PANCREAS, V17, P574; Jing HL, 2011, CLIN NUCL MED, V36, P54, DOI 10.1097/RLU.0b013e3181feeffa; Kumar J, 2013, AM J CANC PREV, V3, P24, DOI DOI 10.12691/AJCP-1-3-2; Kumar V, 2015, ROBBINS COTRAN PATHO, P1179; Luttges J, 1997, PATHOLOGE, V18, P233, DOI 10.1007/s002920050211; Mao Yilei, 2013, Hepatobiliary Surg Nutr, V2, P51, DOI 10.3978/j.issn.2304-3881.2012.08.01; Maxwell L, 2011, J PEDIAT HEMATOL ONC, V33, P543, DOI 10.1097/MPH.0b013e31821041af; Menon BS, 2009, PEDIATR BLOOD CANCER, V53, P518, DOI 10.1002/pbc.22099; Movahedi-Lankarani S, 2002, AM J SURG PATHOL, V26, P1040, DOI 10.1097/01.PAS.0000019964.50665.E1; Nishizawa N, 2015, SURG CASE REP, V1, DOI 10.1186/s40792-015-0084-7; O'Sullivan MJ, 2001, HUM PATHOL, V32, P1109, DOI 10.1053/hupa.2001.28247; Perek S, 2003, PANCREATOLOGY, V3, P352, DOI 10.1159/000071776; Rao L, 2012, KOREAN J INTERN MED, V27, P91, DOI 10.3904/kjim.2012.27.1.91; Reilly C, 2013, J GASTROINTEST SURG, V17, P1015, DOI 10.1007/s11605-012-2098-9; Saif MW, 2017, CUREUS, V9, DOI 10.7759/cureus.1882; Scarpa A, 2017, NATURE, V543, P65, DOI 10.1038/nature21063; Schutte WP, 2006, J PEDIATR SURG, V41, P1916, DOI 10.1016/j.jpedsurg.2006.05.046; Seemayer T A, 1975, Perspect Pediatr Pathol, V2, P151; Stout A. P., 1918, P NY PATHOL SOC, V12, P2; Teixeira U, 2015, CASE REP SURG, DOI 10.1155/2015/276869; Tekeuchi M, 2003, ARCH HISTOPATHOL D D, V10, P23; Wakao J, 2011, JPN SOC PEDIAT HEMAT, V48, P7; Welsch T, 2006, WORLD J GASTROENTERO, V12, P6070, DOI 10.3748/wjg.v12.i37.6070	36	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	SEP	2018	473	3					361	369		10.1007/s00428-018-2344-y			9	Pathology	Pathology	GS2RQ	WOS:000443403100011	29611053				2019-10-28	
J	Zhu, ML; Zhou, L; Sadri, N				Zhu, Meng-Lei; Zhou, Lan; Sadri, Navid			Comparison of targeted next generation sequencing (NGS) versus isolated BRAF V600E analysis in patients with metastatic melanoma	VIRCHOWS ARCHIV			English	Article						Melanoma; BRAF; Targeted NGS; Allele-specific PCR; Target therapy	UVEAL MELANOMA; OPEN-LABEL; TRIAL; PANEL; MUTATIONS; SURVIVAL; NRAS; KIT	Molecular testing on advanced metastatic melanoma is critical for guiding targeted therapy. Traditionally, this analysis has relied on isolated BRAF V600E analysis; however, more recently targeted next generation sequencing (NGS) is being utilized. The clinical utility of BRAF V600E allele-specific PCR and targeted NGS were compared for metastatic melanoma samples sent to UHCMC pathology during a two and half year span. In two thirds of cases, negative for BRAF V600E, additional mutations were detected that may stratify patients for potential or approved targeted therapies. Targeted-NGS testing is feasible and cost-affordable and provides additional potentially actionable information for patients with BRAF V600E/K negative metastatic melanoma. Based on this analysis, we have adopted to screen patients with advanced melanoma with allele-specific V600E/K PCR and reflex negative cases for targeted NGS to maximize patient benefit.	[Zhu, Meng-Lei; Zhou, Lan; Sadri, Navid] Case Western Reserve Univ, Sch Med, Dept Pathol & Lab Med, Cleveland, OH 44106 USA; [Zhu, Meng-Lei; Zhou, Lan; Sadri, Navid] Univ Hosp Cleveland, Med Ctr, Dept Pathol, 7100 Euclid Ave, Cleveland, OH 44103 USA	Sadri, N (reprint author), Case Western Reserve Univ, Sch Med, Dept Pathol & Lab Med, Cleveland, OH 44106 USA.; Sadri, N (reprint author), Univ Hosp Cleveland, Med Ctr, Dept Pathol, 7100 Euclid Ave, Cleveland, OH 44103 USA.	navid.sadri@uhhospitals.org		sadri, navid/0000-0001-5051-717X			Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Ascierto PA, 2013, J CLIN ONCOL, V31, P3205, DOI 10.1200/JCO.2013.49.8691; Ascierto PA, 2013, LANCET ONCOL, V14, P249, DOI 10.1016/S1470-2045(13)70024-X; Bustos BDU, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00606-w; Carvajal RD, 2017, BRIT J OPHTHALMOL, V101, P38, DOI 10.1136/bjophthalmol-2016-309034; Carvajal RD, 2014, JAMA-J AM MED ASSOC, V311, P2397, DOI 10.1001/jama.2014.6096; Curtin JA, 2006, J CLIN ONCOL, V24, P4340, DOI 10.1200/JCO.2006.06.2984; Dahlman KB, 2012, CANCER DISCOV, V2, P791, DOI 10.1158/2159-8290.CD-12-0097; Dummer R, 2017, LANCET ONCOL, V18, P435, DOI 10.1016/S1470-2045(17)30180-8; Hodi FS, 2013, J CLIN ONCOL, V31, P3182, DOI 10.1200/JCO.2012.47.7836; Klein O, 2013, EUR J CANCER, V49, P1073, DOI 10.1016/j.ejca.2012.11.004; Miraflor AP, 2017, EXP MOL PATHOL, V103, P172, DOI 10.1016/j.yexmp.2017.08.006; Reiman A, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3149-0; Siroy AE, 2015, J INVEST DERMATOL, V135, P508, DOI 10.1038/jid.2014.366; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302	15	3	3	1	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	SEP	2018	473	3					371	377		10.1007/s00428-018-2393-2			7	Pathology	Pathology	GS2RQ	WOS:000443403100012	29926184				2019-10-28	
J	Carney, JM; Mammarappallil, JG; Sporn, TA; Pavlisko, EN				Carney, John M.; Mammarappallil, Joseph G.; Sporn, Thomas A.; Pavlisko, Elizabeth N.			Dendriform pulmonary ossification leading to bilateral lung transplant: a case report	VIRCHOWS ARCHIV			English	Article						Dendriform; Ossification; Lung; Transplant	USUAL INTERSTITIAL PNEUMONIA; DISEASE	Metaplastic ossification within the lung is seen in a variety of diseases, usually as sequela of either a separate primary pulmonary parenchymal disease or an underlying cardiac disorder such as valvular disease. Primary intraalveolar ossification or ossification within the alveolar septa is a rare entity. Similarly, it is unusual to see overt, diffuse disease affecting the lung to the point of respiratory failure leading to lung transplant. We present a case of an adult male who underwent bilateral lung transplantation, with the native lung pathology showing diffuse, severe dendriform ossification of the bilateral upper and lower lung lobes. The gross and histologic findings along with the radiographic imaging are reviewed herein. Overall, primary ossification of the lung leading to lung transplant is a rare condition that pulmonologists caring for patients with interstitial lung disease should be aware of as a possible cause of the patient's symptoms and lung dysfunction.	[Carney, John M.; Sporn, Thomas A.; Pavlisko, Elizabeth N.] Duke Univ, Med Ctr, Dept Pathol, 40 Duke Med Circle,DUMC 3721, Durham, NC 27710 USA; [Mammarappallil, Joseph G.] Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA	Carney, JM (reprint author), Duke Univ, Med Ctr, Dept Pathol, 40 Duke Med Circle,DUMC 3721, Durham, NC 27710 USA.	john.carney@duke.edu					Bisceglia M, 2015, ADV ANAT PATHOL, V22, P59, DOI 10.1097/PAP.0000000000000051; Chan ED, 2002, AM J RESP CRIT CARE, V165, P1654, DOI 10.1164/rccm.2108054; Fernandez-Bussy S, 2015, RESP CARE, V60, pE64, DOI 10.4187/respcare.03531; GEVENOIS PA, 1994, AM J ROENTGENOL, V162, P1303, DOI 10.2214/ajr.162.6.8191986; Jamjoom Lamia, 2013, Indian J Radiol Imaging, V23, P15, DOI 10.4103/0971-3026.113613; JOINES RW, 1989, AM J CLIN PATHOL, V91, P398, DOI 10.1093/ajcp/91.4.398; Kanne JP, 2004, J THORAC IMAG, V19, P98, DOI 10.1097/00005382-200404000-00007; Kim DU, 2015, SEMIN ROENTGENOL, V50, P4, DOI 10.1053/j.ro.2014.04.005; Kim TS, 2005, EUR RADIOL, V15, P1581, DOI 10.1007/s00330-005-2671-7; Konoglou M, 2013, J THORAC DIS, V5, P101, DOI 10.3978/j.issn.2072-1439.2013.01.09; Lara JF, 2005, ARCH PATHOL LAB MED, V129, P348; Nicholson AG, 2013, INTERSTITIAL LUNG DI, P392; Peros-Golubicic T, 2008, CURR OPIN PULM MED, V14, P488, DOI 10.1097/MCP.0b013e3283043e1b; Pracyk JB, 1996, RESPIRATION, V63, P254; Reinehr M, 2003, PATHOLOGE, V24, P114, DOI 10.1007/s00292-002-0589-2; Tseung J, 2006, PATHOLOGY, V38, P45, DOI 10.1080/00313020500464912	16	1	1	1	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	SEP	2018	473	3					379	383		10.1007/s00428-018-2412-3			5	Pathology	Pathology	GS2RQ	WOS:000443403100013	30014289				2019-10-28	
J	Gayhart, MG; Richard, H; Wiles, AB; Smith, SC				Gayhart, Matthew George; Richard, Hope; Wiles, Austin Blackburn; Smith, Steven Christopher			Aberrant expression of TdT in seminomatous germ cell neoplasia	VIRCHOWS ARCHIV			English	Letter									[Gayhart, Matthew George; Richard, Hope; Wiles, Austin Blackburn; Smith, Steven Christopher] VCU Sch Med, Dept Pathol, 1200 E Marshall St,Gateway 6-205,POB 980622, Richmond, VA 23298 USA; [Smith, Steven Christopher] VCU Sch Med, Dept Surg, Div Urol, Richmond, VA 23298 USA	Smith, SC (reprint author), VCU Sch Med, Dept Pathol, 1200 E Marshall St,Gateway 6-205,POB 980622, Richmond, VA 23298 USA.; Smith, SC (reprint author), VCU Sch Med, Dept Surg, Div Urol, Richmond, VA 23298 USA.	steven.c.smith@vcuhealth.org					Brobeil A, 2018, VIRCHOWS ARCH, V472, P433, DOI 10.1007/s00428-018-2313-5	1	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	SEP	2018	473	3					385	386		10.1007/s00428-018-2402-5			2	Pathology	Pathology	GS2RQ	WOS:000443403100014	29968181				2019-10-28	
J	Brobeil, A; Wagenlehner, F; Gattenlohner, S				Brobeil, Alexander; Wagenlehner, Florian; Gattenloehner, Stefan			Response to 'Aberrant expression of TdT in seminomatous germ cell neoplasia'	VIRCHOWS ARCHIV			English	Letter									[Brobeil, Alexander; Gattenloehner, Stefan] Justus Liebig Univ, Inst Pathol, D-35392 Giessen, Germany; [Wagenlehner, Florian] Justus Liebig Univ, Dept Urol Pediat Urol & Androl, D-35392 Giessen, Germany	Brobeil, A (reprint author), Justus Liebig Univ, Inst Pathol, D-35392 Giessen, Germany.	alexander.brobeil@patho.med.uni-giessen.de						0	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	SEP	2018	473	3					387	387		10.1007/s00428-018-2403-4			1	Pathology	Pathology	GS2RQ	WOS:000443403100015	29980856	Bronze			2019-10-28	
J	Cibula, D; Potter, R; Planchamp, F; Avall-Lundqvist, E; Fischerova, D; Haie-Meder, C; Kohler, C; Landoni, F; Lax, S; Lindegaard, JC; Mahantshetty, U; Mathevet, P; McCluggage, WG; McCormack, M; Naik, R; Nout, R; Pignata, S; Ponce, J; Querleu, D; Raspagliesi, F; Rodolakis, A; Tamussino, K; Wimberger, P; Raspollini, MR				Cibula, David; Poetter, Richard; Planchamp, Francois; Avall-Lundqvist, Elisabeth; Fischerova, Daniela; Haie-Meder, Christine; Koehler, Christhardt; Landoni, Fabio; Lax, Sigurd; Lindegaard, Jacob Christian; Mahantshetty, Umesh; Mathevet, Patrice; McCluggage, W. Glenn; McCormack, Mary; Naik, Raj; Nout, Remi; Pignata, Sandro; Ponce, Jordi; Querleu, Denis; Raspagliesi, Francesco; Rodolakis, Alexandros; Tamussino, Karl; Wimberger, Pauline; Raspollini, Maria Rosaria			The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer (vol 472, pg 919, 2018)	VIRCHOWS ARCHIV			English	Correction									[Cibula, David; Fischerova, Daniela] Charles Univ Prague, Fac Med 1, Dept Obstet & Gynecol, Gynecol Oncol Ctr, Katerinska 32, Prague 12108, Czech Republic; [Cibula, David; Fischerova, Daniela] Gen Univ Hosp, Katerinska 32, Prague 12108, Czech Republic; [Poetter, Richard] Med Univ Vienna, Dept Radiotherapy, Vienna, Austria; [Planchamp, Francois; Querleu, Denis] Inst Bergonie, Bordeaux, France; [Avall-Lundqvist, Elisabeth] Linkoping Univ, Linkoping, Sweden; [Haie-Meder, Christine] Inst Gustave Roussy, Dept Radiotherapy, Villejuif, France; [Koehler, Christhardt] Asklepios Hambourg Altona, Dept Gynecol, Med Fac, Hamburg, Germany; [Koehler, Christhardt] Univ Cologne, Hamburg, Germany; [Landoni, Fabio] Univ Milano Bicocca, Monza, Italy; [Lax, Sigurd] Gen Hosp Graz Sued West, Graz, Austria; [Lindegaard, Jacob Christian] Aarhus Univ, Dept Oncol, Aarhus, Denmark; [Mahantshetty, Umesh] Tata Mem Hosp, Dept Radiat Oncol, Bombay, Maharashtra, India; [Mathevet, Patrice] Lausanne Univ, Lausanne, Switzerland; [McCluggage, W. Glenn] Belfast Hlth & Social Care Trust, Dept Pathol, Belfast, Antrim, North Ireland; [McCormack, Mary] Univ Coll London Hosp, London, England; [Naik, Raj] Queen Elizabeth Hosp, Gateshead, England; [Nout, Remi] Leiden Univ, Dept Radiat Oncol, Leiden, Netherlands; [Pignata, Sandro] IRCCS, Fdn G Pascale, Ist Nazl Studio & Cura Tumori, Naples, Italy; [Ponce, Jordi] Univ Hosp Bellvitge IDIBELL, Barcelona, Spain; [Raspagliesi, Francesco] Fdn IRCCS Ist Nazl Tumori, Milan, Italy; [Rodolakis, Alexandros] Univ Athens, Athens, Greece; [Tamussino, Karl] Med Univ Graz, Graz, Austria; [Wimberger, Pauline] Dresden Univ, TU Dresden, Dresden, Germany; [Raspollini, Maria Rosaria] Univ Hosp, Florence, Italy	Cibula, D (reprint author), Charles Univ Prague, Fac Med 1, Dept Obstet & Gynecol, Gynecol Oncol Ctr, Katerinska 32, Prague 12108, Czech Republic.; Cibula, D (reprint author), Gen Univ Hosp, Katerinska 32, Prague 12108, Czech Republic.	dc@davidcibula.cz					Cibula D, 2018, VIRCHOWS ARCH, V472, P919, DOI 10.1007/s00428-018-2362-9	1	0	0	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	SEP	2018	473	3					391	391		10.1007/s00428-018-2419-9			1	Pathology	Pathology	GS2RQ	WOS:000443403100016	30043108	Bronze			2019-10-28	
J	Campbell, FC; Loughrey, MB; McClements, J; Deevi, RK; Javadi, A; Rainey, L				Campbell, Frederick C.; Loughrey, Maurice Bernard; McClements, Jane; Deevi, Ravi Kiran; Javadi, Arman; Rainey, Lisa			Mechanistic Insights into Colorectal. Cancer Phenomics from Fundamental and Organotypic Model Studies	AMERICAN JOURNAL OF PATHOLOGY			English	Review							DROSOPHILA EPITHELIAL-CELLS; CHROMOSOMAL INSTABILITY; SPINDLE ORIENTATION; ADHERENS JUNCTIONS; BETA-CATENIN; IN-VIVO; CAENORHABDITIS-ELEGANS; EXTRACELLULAR-MATRIX; MOLECULAR-FEATURES; POOR-PROGNOSIS	Colorectal cancer (CRC) diagnosis and prognostic stratification are based on histopathologic assessment of cell or nuclear pleomorphism, aberrant mitotic figures, altered glandular architecture, and other phenomic abnormalities. This complexity is driven by oncogenic perturbation of tightly coordinated spatiotemporal signaling to disrupt multiple scales of tissue organization. This review clarifies molecular and cellular mechanisms underlying common CRC histologic features and helps understand how the CRC genome controls core aspects of tumor aggressiveness. It further explores a spatiotemporal framework for CRC phenomics based on regulation of living cells in fundamental and organotypic model systems. The review also discusses tissue homeostasis, considers distinct classes of oncogenic perturbations, and evolution of cellular or multicellular cancer phenotypes. It further explores the molecular controls of cribriform, micropapillary, and high-grade CRC morphology in organotypic culture models and assesses relevant translational studies. In addition, the review delves into complexities of morphologic plasticity whereby a single molecular signature generates heterogeneous cancer phenotypes, and, conversely, morphologically homogeneous tumors show substantive molecular diversity. Principles outlined may aid mechanistic interpretation of omics data in a setting of cancer pathology, provide insight into CRC consensus molecular subtypes, and better define principles for CRC prognostic stratification.	[Campbell, Frederick C.; Loughrey, Maurice Bernard; McClements, Jane; Deevi, Ravi Kiran; Javadi, Arman; Rainey, Lisa] Queens Univ Belfast, Ctr Canc Res & Cell Biol, 97 Lisburn Rd, Belfast BT9 7AE, Antrim, North Ireland; [Campbell, Frederick C.; Loughrey, Maurice Bernard] Belfast Hlth & Social Care Trust, Belfast, Antrim, North Ireland; [Loughrey, Maurice Bernard] Northern Ireland Mol Pathol Lab, Belfast, Antrim, North Ireland	Campbell, FC (reprint author), Queens Univ Belfast, Ctr Canc Res & Cell Biol, 97 Lisburn Rd, Belfast BT9 7AE, Antrim, North Ireland.	f.c.campbell@qub.ac.uk			Cancer Research UKCancer Research UK [C9136/A15342]; Medical Research CouncilMedical Research Council UK (MRC) [MR/L015110/1]; Belfast Trust Charitable Funds grant [GE-15-065]	Supported by Cancer Research UK grant C9136/A15342 (F.C.C.), Medical Research Council grant MR/L015110/1 (F.C.C. and L.R.), and Belfast Trust Charitable Funds grant GE-15-065 (F.C.C.).	Bahmanyar S, 2010, J CELL SCI, V123, P3125, DOI 10.1242/jcs.064782; Bananis E, 2004, MOL BIOL CELL, V15, P3688, DOI 10.1091/mbc.E04-04-0278; Brown IS, 2016, J CLIN PATHOL, V69, P292, DOI 10.1136/jclinpath-2015-203203; Bryant DM, 2008, NAT REV MOL CELL BIO, V9, P887, DOI 10.1038/nrm2523; Bryant DM, 2014, DEV CELL, V31, P171, DOI 10.1016/j.devcel.2014.08.027; Calon A, 2015, NAT GENET, V47, P320, DOI 10.1038/ng.3225; CAMPBELL FC, 1993, GUT, V34, P1153, DOI 10.1136/gut.34.9.1153; Campbell HK, 2017, EXP CELL RES, V358, P39, DOI 10.1016/j.yexcr.2017.03.061; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762; Compton CC, 2003, MODERN PATHOL, V16, P376, DOI 10.1097/01.MP.0000062859.46942.93; Cserni G, 2014, PATHOLOGY, V46, P527, DOI 10.1097/PAT.0000000000000144; de Lau W, 2011, NATURE, V476, P293, DOI 10.1038/nature10337; Deevi RK, 2016, ONCOTARGET, V7, P49042, DOI 10.18632/oncotarget.8863; Deevi RK, 2018, J PATHOL, V244, P445, DOI 10.1002/path.5035; Durgan J, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.174235; Eisenhoffer GT, 2012, NATURE, V484, P546, DOI 10.1038/nature10999; Elbediwy A, 2012, J CELL BIOL, V198, P677, DOI 10.1083/jcb.201202094; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Faragher AJ, 2003, MOL BIOL CELL, V14, P2876, DOI 10.1091/mbc.E03-02-0108; Feng Y, 2011, GASTROENTEROLOGY, V141, P1003, DOI 10.1053/j.gastro.2011.05.007; Fleming ES, 2009, MOL CARCINOGEN, V48, P592, DOI 10.1002/mc.20506; Fu JY, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a015800; Furlan D, 2011, MODERN PATHOL, V24, P126, DOI 10.1038/modpathol.2010.179; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Giesen C, 2014, NAT METHODS, V11, P417, DOI [10.1038/NMETH.2869, 10.1038/nmeth.2869]; Glotzer M, 2009, NAT REV MOL CELL BIO, V10, P9, DOI 10.1038/nrm2609; Gonczy P, 2008, NAT REV MOL CELL BIO, V9, P355, DOI 10.1038/nrm2388; Gotta M, 2001, CURR BIOL, V11, P482, DOI 10.1016/S0960-9822(01)00142-7; Gudjonsson T, 2003, METHODS, V30, P247, DOI 10.1016/S1046-2023(03)00031-8; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Hadjihannas MV, 2006, P NATL ACAD SCI USA, V103, P10747, DOI 10.1073/pnas.0604206103; Harandi OF, 2015, P NATL ACAD SCI USA, V112, pE287, DOI 10.1073/pnas.1422852112; Harris TJC, 2010, NAT REV MOL CELL BIO, V11, P502, DOI 10.1038/nrm2927; Hebert AM, 2012, GENE DEV, V26, P2709, DOI 10.1101/gad.194027.112; Heng YJ, 2017, J PATHOL, V241, P375, DOI 10.1002/path.4847; Hoadley KA, 2018, CELL, V173, P291, DOI 10.1016/j.cell.2018.03.022; Huebner RJ, 2014, DEVELOPMENT, V141, P1085, DOI 10.1242/dev.103333; Hugen N, 2014, ANN ONCOL, V25, P651, DOI 10.1093/annonc/mdt591; Hynes SO, 2017, HISTOPATHOLOGY, V71, P12, DOI 10.1111/his.13181; Isella C, 2015, NAT GENET, V47, P312, DOI 10.1038/ng.3224; Jaffe AB, 2008, J CELL BIOL, V183, P625, DOI 10.1083/jcb.200807121; Jagan I, 2013, ONCOGENE, V32, P1305, DOI 10.1038/onc.2012.140; Jagan IC, 2013, NEOPLASIA, V15, P1218, DOI 10.1593/neo.121516; Jass JR, 2007, HISTOPATHOLOGY, V50, P113, DOI 10.1111/j.1365-2559.2006.02549.x; Javadi A, 2017, ELIFE, V6, DOI 10.7554/eLife.24578; Karsenti E, 2008, NAT REV MOL CELL BIO, V9, P255, DOI 10.1038/nrm2357; Kay AJ, 2001, CURR BIOL, V11, P474, DOI 10.1016/S0960-9822(01)00141-5; Kholodenko BN, 2010, NAT REV MOL CELL BIO, V11, P414, DOI 10.1038/nrm2901; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kleylein-Sohn J, 2007, DEV CELL, V13, P190, DOI 10.1016/j.devcel.2007.07.002; Lechler T, 2005, NATURE, V437, P275, DOI 10.1038/nature03922; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Magudia K, 2012, J CELL BIOL, V198, P185, DOI 10.1083/jcb.201202108; Martin-Belmonte F, 2007, CELL, V128, P383, DOI 10.1016/j.cell.2006.11.051; Mbom BC, 2014, MOL BIOL CELL, V25, P977, DOI 10.1091/mbc.E13-06-0349; Morais-de-Sa E, 2010, CELL, V141, P509, DOI 10.1016/j.cell.2010.02.040; Motegi F, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2013.0010; Munjal A, 2014, DEVELOPMENT, V141, P1789, DOI 10.1242/dev.091645; Naguib A, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-123; Nance J, 2011, DEVELOPMENT, V138, P799, DOI 10.1242/dev.053538; Neel NF, 2012, MOL CELL BIOL, V32, P1374, DOI 10.1128/MCB.06291-11; Novellasdemunt L, 2017, CELL REP, V21, P612, DOI 10.1016/j.celrep.2017.09.072; Nowak MA, 2002, P NATL ACAD SCI USA, V99, P16226, DOI 10.1073/pnas.202617399; Patel HRH, 1996, GUT, V38, P679, DOI 10.1136/gut.38.5.679; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; Prall F, 2007, HUM PATHOL, V38, P1696, DOI 10.1016/j.humpath.2007.04.002; Qin Y, 2010, J CELL BIOL, V189, P661, DOI 10.1083/jcb.201002097; Resch A, 2016, INT J COLORECTAL DIS, V31, P535, DOI 10.1007/s00384-015-2495-0; Rosenblatt J, 2004, CELL, V117, P361, DOI 10.1016/S0092-8674(04)00341-1; Salazar-Ciudad I, 2003, DEVELOPMENT, V130, P2027, DOI 10.1242/dev.00425; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Sattar A, 1999, J PATHOL, V187, P229, DOI 10.1002/(SICI)1096-9896(199901)187:2<229::AID-PATH218>3.0.CO;2-8; Schluter MA, 2009, MOL BIOL CELL, V20, P4652, DOI 10.1091/mbc.E09-02-0137; Slorach EM, 1999, J CELL SCI, V112, P3029; Snippert HJ, 2010, CELL, V143, P134, DOI 10.1016/j.cell.2010.09.016; Sparks AB, 1998, CANCER RES, V58, P1130; Spira F, 2017, ELIFE, V6, DOI 10.7554/eLife.30867; Sripathy S, 2011, MOL CELL BIOL, V31, P2920, DOI 10.1128/MCB.05431-11; St Johnston D, 2011, CURR OPIN CELL BIOL, V23, P540, DOI 10.1016/j.ceb.2011.07.005; Stenzinger A, 2012, HUM PATHOL, V43, P1471, DOI 10.1016/j.humpath.2011.10.023; Tada M, 2012, DEVELOPMENT, V139, P3897, DOI 10.1242/dev.073007; TAIT IS, 1994, DIFFERENTIATION, V56, P91, DOI 10.1007/s002580050025; TAIT IS, 1994, CELL TRANSPLANT, V3, P33; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tan CY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063970; Tepass U, 2012, ANNU REV CELL DEV BI, V28, P655, DOI 10.1146/annurev-cellbio-092910-154033; Thunnissen FBJM, 2001, HISTOPATHOLOGY, V39, P1, DOI 10.1046/j.1365-2559.2001.01187.x; Ueno H, 2012, AM J SURG PATHOL, V36, P193, DOI 10.1097/PAS.0b013e318235edee; van de Wetering M, 2015, CELL, V161, P933, DOI 10.1016/j.cell.2015.03.053; Vincent JP, 2013, NAT REV MOL CELL BIO, V14, P581, DOI 10.1038/nrm3639; Walther A, 2009, NAT REV CANCER, V9, P489, DOI 10.1038/nrc2645; Wang YC, 2012, NATURE, V484, P390, DOI 10.1038/nature10938; Williams SE, 2014, NAT CELL BIOL, V16, P758, DOI 10.1038/ncb3001; Wu JC, 2007, MOL BIOL CELL, V18, P4470, DOI 10.1091/mbc.E07-02-0105; Wyckoff JB, 2000, CANCER RES, V60, P2504; Yan KS, 2017, NATURE, V545, P238, DOI 10.1038/nature22313; Yu W, 2008, EMBO REP, V9, P923, DOI 10.1038/embor.2008.135; Zernicka-Goetz M, 2002, DEVELOPMENT, V129, P815	100	1	1	1	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	SEP	2018	188	9					1936	1948		10.1016/j.ajpath.2018.05.021			13	Pathology	Pathology	GR5XP	WOS:000442715500001	30028958	Green Published			2019-10-28	
J	Kennedy, L; Alpini, G				Kennedy, Lindsey; Alpini, Gianfranco			Therapeutic Role of Sphingosine-1-Phosphate Receptor 2 in the Progression of Esophageal Adenocarcinoma COMMENTARY	AMERICAN JOURNAL OF PATHOLOGY			English	Editorial Material							BILE-ACID; SPHINGOSINE 1-PHOSPHATE; BARRETTS-ESOPHAGUS; CANCER-CELLS; CYCLOOXYGENASE-2; STATISTICS; ACTIVATION; EXPRESSION; GROWTH; MODEL		[Kennedy, Lindsey; Alpini, Gianfranco] Cent Texas Vet Hlth Care Syst, Res Serv, Temple, TX USA; [Kennedy, Lindsey; Alpini, Gianfranco] Texas A&M Hlth Sci Ctr, Dept Med Physiol, Coll Med, Temple, TX USA; [Alpini, Gianfranco] Baylor Scott & White Hlth, Digest Dis Res Ctr, Temple, TX USA	Alpini, G (reprint author), Cent Texas Vet Hlth Care Syst, Texas A&M Hlth Sci Ctr, Olin E Teague Med Ctr, 1901 S First St,Bldg 205,1R60, Temple, TX 76504 USA.	galpini@tamu.edu			Central Texas Veterans Health Care System; Baylor Scott White Heath; Veterans Affairs Research Career Scientist AwardUS Department of Veteran Affairs	Supported by the Central Texas Veterans Health Care System, the Dr. Nicholas C. Hightower Centennial Chair of Gastroenterology from Baylor Scott & White Heath (G.A.), and a Veterans Affairs Research Career Scientist Award (G.A.).	Adada M, 2013, FEBS J, V280, P6354, DOI 10.1111/febs.12446; Azzolin L, 2014, CELL, V158, P157, DOI 10.1016/j.cell.2014.06.013; Chen KH, 2007, CANCER SCI, V98, P1683, DOI 10.1111/j.1349-7006.2007.00605.x; Contino G, 2017, GASTROENTEROLOGY, V153, P657, DOI 10.1053/j.gastro.2017.07.007; Dulak AM, 2013, NAT GENET, V45, P478, DOI 10.1038/ng.2591; GOTLEY DC, 1991, GUT, V32, P1093, DOI 10.1136/gut.32.10.1093; GRAFFNER H, 1984, SCAND J GASTROENTERO, V19, P116; Liu RP, 2018, AM J PATHOL, V188, P2042, DOI 10.1016/j.ajpath.2018.05.015; Liu RP, 2015, J BIOL CHEM, V290, P30988, DOI 10.1074/jbc.M115.668277; Liu RP, 2014, HEPATOLOGY, V60, P908, DOI 10.1002/hep.27085; Matula K, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1718-7; Miller AV, 2008, MOL CELL BIOL, V28, P4142, DOI 10.1128/MCB.01465-07; Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349; Nagahashi M, 2015, HEPATOLOGY, V61, P1216, DOI 10.1002/hep.27592; Nehra D, 1999, GUT, V44, P598, DOI 10.1136/gut.44.5.598; Pan J, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-157; Pyne NJ, 2010, NAT REV CANCER, V10, P489, DOI 10.1038/nrc2875; Quante M, 2012, CANCER CELL, V21, P36, DOI 10.1016/j.ccr.2011.12.004; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Song SM, 2014, CANCER RES, V74, P4170, DOI 10.1158/0008-5472.CAN-13-3569; Souza RF, 2009, GASTROENTEROLOGY, V137, P1776, DOI 10.1053/j.gastro.2009.07.055; Tselepis C, 2003, GUT, V52, P174, DOI 10.1136/gut.52.2.174; Wang YQ, 2017, HEPATOLOGY, V65, P2005, DOI 10.1002/hep.29076; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Zhang F, 2001, GASTROENTEROLOGY, V121, P1391, DOI 10.1053/gast.2001.29781	25	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	SEP	2018	188	9					1949	1952		10.1016/j.ajpath.2018.07.001			4	Pathology	Pathology	GR5XP	WOS:000442715500002	30026028				2019-10-28	
J	Ebrahim, M; Anders, HJ				Ebrahim, Martrez; Anders, Hans-Joachim			Murine Double Minute-2 Links Cell Cycle Control and Inflammation in Homeostasis and Disease COMMENTARY	AMERICAN JOURNAL OF PATHOLOGY			English	Editorial Material							CANCER-THERAPY; MDM2; INJURY		[Ebrahim, Martrez; Anders, Hans-Joachim] LMU Munchen, Klinikum Univ Munchen, Med Klin & Poliklin 4, Munich, Germany	Anders, HJ (reprint author), Klinikum Univ Munchen, Med Klin & Poliklin 4, Ziemssenstr 1, D-80336 Munich, Germany.	hjanders@med.uni-muenchen.de			Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [AN372/23-1, AN372/24-1]	Supported by the Deutsche Forschungsgemeinschaft grants AN372/23-1 and AN372/24-1.	Allam R, 2011, J AM SOC NEPHROL, V22, P2016, DOI 10.1681/ASN.2011010045; Clegg HV, 2008, CELL CYCLE, V7, P287, DOI 10.4161/cc.7.3.5358; Ebrahim M, 2015, HISTOL HISTOPATHOL, V30, P1271, DOI 10.14670/HH-11-636; Eischen CM, 2014, HUM MUTAT, V35, P728, DOI 10.1002/humu.22524; Fan V, 2018, AM J PATHOL, V188, P2087, DOI 10.1016/j.ajpath.2018.05.017; Ganguli G, 2003, MOL CANCER RES, V1, P1027; Gupta SC, 2010, BBA-GENE REGUL MECH, V1799, P775, DOI 10.1016/j.bbagrm.2010.05.004; Impicciatore G, 2010, CURR PHARM DESIGN, V16, P1427, DOI 10.2174/138161210791033932; Lazzeri E, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03753-4; Liu G, 2009, J IMMUNOL, V182, P5063, DOI 10.4049/jimmunol.0803526; Marine JC, 2010, CELL DEATH DIFFER, V17, P93, DOI 10.1038/cdd.2009.68; Mulay SR, 2016, AM J PATHOL, V186, P1442, DOI 10.1016/j.ajpath.2016.01.017; Mulay SR, 2016, J AM SOC NEPHROL, V27, P27, DOI 10.1681/ASN.2015040405; Mulay SR, 2013, J PATHOL, V230, P322, DOI 10.1002/path.4193; Mulay SR, 2012, KIDNEY INT, V81, P1199, DOI 10.1038/ki.2011.482; Saito R, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87877; Shi Dingding, 2012, Genes Cancer, V3, P240, DOI 10.1177/1947601912455199; Thomasova D, 2012, NEOPLASIA, V14, P1097, DOI 10.1593/neo.121534; Tsang CK, 2007, DRUG DISCOV TODAY, V12, P112, DOI 10.1016/j.drudis.2006.12.008; Zheng TS, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3996	20	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	SEP	2018	188	9					1953	1955		10.1016/j.ajpath.2018.06.004			3	Pathology	Pathology	GR5XP	WOS:000442715500003	29963992				2019-10-28	
J	van Ooijen, H; Hornsveld, M; Dam-de Veen, C; Velter, R; Dou, M; Verhaegh, W; Burgering, B; van de Stolpe, A				van Ooijen, Henk; Hornsveld, Marten; Dam-de Veen, Christa; Velter, Rick; Dou, Meng; Verhaegh, Wim; Burgering, Boudewijn; van de Stolpe, Anja			Assessment of Functional Phosphatidylinositol 3-Kinase Pathway Activity in Cancer Tissue Using Forkhead Box-O Target Gene Expression in a Knowledge-Based Computational Model	AMERICAN JOURNAL OF PATHOLOGY			English	Article							FOXO TRANSCRIPTION FACTORS; PROTEIN-KINASE-B; NF-KAPPA-B; CAVEOLIN-1 EXPRESSION; REDOX REGULATION; FACTORS INDUCE; CELL-SURVIVAL; FACTOR AFX; INHIBITORS; APOPTOSIS	The phosphatidylinositol 3-kinase (PI3K) pathway is commonly activated in cancer. Tumors are potentially sensitive to PI3K pathway inhibitors, but reliable diagnostic tests that assess functional PI3K activity are lacking. Because PI3K pathway activity negatively regulates forkhead box-O (FOXO) transcription factor activity, FOXO target gene expression is inversely correlated with PI3K activity. A knowledge-based Bayesian computational model was developed to infer PI3K activity in cancer tissue samples from FOXO target gene mRNA levels and validated in cancer cell lines treated with PI3K inhibitors. However, applied to patient tissue samples, FOXO was often active in cancer types with expected active PI3K. SOD2 was differentially expressed between FOXO-active healthy and cancer tissue samples, indicating that cancer-associated cellular oxidative stress alternatively activated FOXO. To enable correct interpretation of active FOXO in cancer tissue, threshold levels for normal SOD2 expression in healthy tissue were defined above which FOXO activity is oxidative stress induced and below which PI3K regulated. In slow-growing turning A breast cancer and Low Gleason score prostate cancer, FOXO was active in a PI3K-regulated manner, indicating inactive PI3K. In aggressive luminal B, HER2, and basal breast cancer, FOXO was increasingly inactive or actively induced by oxidative stress, indicating PI3K activity. We provide a decision tree that facilitates functional PI3K pathway activity assessment in tissue samples from patients with cancer for therapy response prediction and prognosis.	[van Ooijen, Henk; Dam-de Veen, Christa; Velter, Rick; Dou, Meng; Verhaegh, Wim; van de Stolpe, Anja] Philips Res, High Tech Campus 11, Eindhoven, Netherlands; [Hornsveld, Marten; Burgering, Boudewijn] Univ Med Ctr Utrecht, Utrecht, Netherlands	van de Stolpe, A (reprint author), Philips Res, High Tech Campus 11, Eindhoven, Netherlands.	anja.van.de.stolpe@philips.com		van Ooijen, Hendrik Jan/0000-0001-9607-7317	Cancer genomics Nederland; Royal Philips	Supported by Cancer genomics Nederland (M.H. and B.B.) and Royal Philips funding for the Pathway Diagnostics Research program within Philips Research.	Andre F, 2005, J CLIN ONCOL, V23, P2996, DOI 10.1200/JCO.2005.08.046; Arnedos M, 2015, NAT REV CLIN ONCOL, V12, P693, DOI 10.1038/nrclinonc.2015.123; Ashley EA, 2016, NAT REV GENET, V17, P507, DOI 10.1038/nrg.2016.86; Bakker WJ, 2004, J CELL BIOL, V164, P175, DOI 10.1083/jcb.200307056; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Chang JT, 2009, MOL CELL, V34, P104, DOI 10.1016/j.molcel.2009.02.030; Chen J, 2006, J IMMUNOL, V176, P2711, DOI 10.4049/jimmunol.176.5.2711; Chiribau CB, 2008, J BIOL CHEM, V283, P8211, DOI 10.1074/jbc.M710610200; Ciechomska I, 2003, ONCOGENE, V22, P7617, DOI 10.1038/sj.onc.1207137; Czymai T, 2010, J BIOL CHEM, V285, P10163, DOI 10.1074/jbc.M109.056663; Daitoku H, 2003, DIABETES, V52, P642, DOI 10.2337/diabetes.52.3.642; de Brachene AC, 2016, CELL MOL LIFE SCI, V73, P1159, DOI 10.1007/s00018-015-2112-y; Delpuech O, 2007, MOL CELL BIOL, V27, P4917, DOI 10.1128/MCB.01789-06; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Dull T, 1998, J VIROL, V72, P8463; Eijkelenboom A, 2013, NAT REV MOL CELL BIO, V14, P83, DOI 10.1038/nrm3507; Eijkelenboom A, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2012.74; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Fernandez D.E., 2004, MOL CELL BIOL, V24, P10058, DOI DOI 10.1128/MCB.24.22.10058-10071.2004; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Furukawa-Hibi Y, 2002, J BIOL CHEM, V277, P26729, DOI 10.1074/jbc.C200256200; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Gruosso T, 2016, EMBO MOL MED, V8, P527, DOI 10.15252/emmm.201505891; Guo SQ, 2004, MOL CELL BIOL, V24, P8681, DOI 10.1128/MCB.24.19.8681-8690.2004; Han JM, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00245; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harada M, 2006, J EXP MED, V203, P2929, DOI 10.1084/jem.20062206; Homsveld M, 2017, SEMIN CANCER BIOL, V50, P90; Hornsveld M, 2016, CELL DEATH DIFFER, V23, P1483, DOI 10.1038/cdd.2016.33; Hornsveld M, 2018, CANCER RES, V78, P2356, DOI 10.1158/0008-5472.CAN-17-2511; Hornsveld M, 2016, ANTIOXID REDOX SIGN, V25, P300, DOI 10.1089/ars.2015.6580; Kawahara T, 2015, ORG LETT, V17, P5476, DOI 10.1021/acs.orglett.5b02842; Kim HJ, 2017, ONCOTARGET, V8, P6608, DOI 10.18632/oncotarget.14245; Kim MS, 2006, NAT NEUROSCI, V9, P901, DOI 10.1038/nn1731; Kirouac DC, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004008; Kitamura T, 2006, NAT MED, V12, P534, DOI 10.1038/nm1392; Klotz LO, 2015, REDOX BIOL, V6, P51, DOI 10.1016/j.redox.2015.06.019; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kops GJPL, 1999, NATURE, V398, P630; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Kwiatkowski DJ, 2015, EBIOMEDICINE, V2, P2, DOI 10.1016/j.ebiom.2014.12.011; Langlet F, 2017, CELL, V171, P824, DOI 10.1016/j.cell.2017.09.045; Lin A, 2014, ONCOGENE, V33, P3183, DOI 10.1038/onc.2013.273; Liu L, 2009, CANCER RES, V69, P6871, DOI 10.1158/0008-5472.CAN-08-4490; Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001; Martinez-Gac L, 2004, MOL CELL BIOL, V24, P2181, DOI 10.1128/MCB.24.5.2181-2189.2004; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Meerbrey KL, 2011, P NATL ACAD SCI USA, V108, P3665, DOI 10.1073/pnas.1019736108; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; Morgan MJ, 2011, CELL RES, V21, P103, DOI 10.1038/cr.2010.178; Nagashima T, 2010, MOL PHARMACOL, V78, P961, DOI 10.1124/mol.110.065714; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Potente M, 2005, J CLIN INVEST, V115, P2382, DOI 10.1172/JCI23126; Puig O, 2005, GENE DEV, V19, P2435, DOI 10.1101/gad.1340505; Rodon J, 2013, NAT REV CLIN ONCOL, V10, P143, DOI 10.1038/nrclinonc.2013.10; Roy UKB, 2008, MOL CARCINOGEN, V47, P947, DOI 10.1002/mc.20451; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Sekine K, 2007, EMBO J, V26, P3607, DOI 10.1038/sj.emboj.7601784; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Shmelkov E, 2011, BIOL DIRECT, V6, DOI 10.1186/1745-6150-6-15; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Tang TTL, 2002, J BIOL CHEM, V277, P14255, DOI 10.1074/jbc.M110901200; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; van de Stolpe A, 2013, AM J CANCER RES, V3, P107; van den Berg MCW, 2013, J BIOL CHEM, V288, P21729, DOI 10.1074/jbc.M113.463885; van den Berg MCW, 2011, ANTIOXID REDOX SIGN, V14, P607, DOI 10.1089/ars.2010.3415; van den Heuvel APJ, 2005, BIOCHEM J, V385, P795, DOI 10.1042/BJ20041449; van der Horst A, 2007, NAT REV MOL CELL BIO, V8, P440, DOI 10.1038/nrm2190; van der Vos KE, 2011, ANTIOXID REDOX SIGN, V14, P579, DOI 10.1089/ars.2010.3419; Vanhaesebroeck B, 2012, NAT REV MOL CELL BIO, V13, P195, DOI 10.1038/nrm3290; Verhaegh W, 2014, ONCOTARGET, V5, P5196, DOI 10.18632/oncotarget.2276; Verhaegh W, 2014, CANCER RES, V74, P2936, DOI 10.1158/0008-5472.CAN-13-2515; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wang LX, 2011, P NATL ACAD SCI USA, V108, pE803, DOI 10.1073/pnas.1103423108; Webb AE, 2016, AGING CELL, V15, P673, DOI 10.1111/acel.12479; Webb AE, 2014, TRENDS BIOCHEM SCI, V39, P159, DOI 10.1016/j.tibs.2014.02.003; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Zhao J, 2007, CELL METAB, V6, P472, DOI 10.1016/j.cmet.2007.11.004	85	3	3	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	SEP	2018	188	9					1956	1972		10.1016/j.ajpath.2018.05.020			17	Pathology	Pathology	GR5XP	WOS:000442715500004	30030980				2019-10-28	
J	Moek, KL; Fehrmann, RSN; van der Vegt, B; de Vries, EGE; de Groot, DJA				Moek, Kirsten L.; Fehrmann, Rudolf S. N.; van der Vegt, Bert; de Vries, Elisabeth G. E.; de Groot, Derk J. A.			Glypican 3 Overexpression across a Broad Spectrum of Tumor Types Discovered with Functional Genomic mRNA Profiling of a Large Cancer Database	AMERICAN JOURNAL OF PATHOLOGY			English	Article							HEPATOCELLULAR-CARCINOMA; PHASE-I; HUMANIZED ANTIBODY; ALPHA-FETOPROTEIN; EXPRESSION; SALL4; STRATEGIES; DIAGNOSIS; DENSITY; RANGE	Glypican 3 (GPC3), a membrane-bound heparan sulfate proteoglycan, is overexpressed in approximately 70% to 80% of hepatocellular carcinomas, but is not expressed commonly in healthy tissues. This raised interest in GPC3 as a drug target and several GPC3-targeting drugs are in clinical development. We therefore predicted GPC3 protein overexpression across tumors and validated these predictions. Functional genomic mRNA profiling was applied to the expression profiles of 18,055 patient-derived tumor samples to predict GPC3 overexpression at the protein level in 60 tumor types and subtypes using healthy tissues as reference. For validation, predictions were compared with immunohistochemical (IHC) staining of a breast cancer tissue microarray and literature data reporting IHC GPC3 over expression in various solid, hematologic, and pediatric tumors. The percentage of samples with predicted GPC3 overexpression was 77% for hepatocellular carcinomas (n = 364), 45% for squamous cell lung cancers (n = 405), and 19% for head and neck squamous cell cancers (n = 344). Breast cancer tissue microarray analysis showed GPC3 expression ranged from 12% to 17% in subgroups based on estrogen receptor and human epidermal growth factor receptor 2 status. In 28 of 34 tumor types for which functional genomic mRNA data could be compared with INC there was a relative difference of <= 10%. This study provides a data-driven prioritization of tumor types and subtypes for future research with GPC3-targeting therapies.	[Moek, Kirsten L.; Fehrmann, Rudolf S. N.; de Vries, Elisabeth G. E.; de Groot, Derk J. A.] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, Groningen, Netherlands; [van der Vegt, Bert] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol, Groningen, Netherlands	de Groot, DJA (reprint author), Univ Med Ctr Groningen, Dept Med Oncol, POB 30-001, NL-9700 RB Groningen, Netherlands.	d.j.a.de.groot@umcg.nl	van der Vegt, Bert/N-2085-2019; Fehrmann, Rudolf/E-2551-2011	van der Vegt, Bert/0000-0002-2613-1506; Fehrmann, Rudolf/0000-0002-7516-315X; de Vries, Elisabeth/0000-0002-8949-7425	Netherlands Organisation for Scientific Research (NWO)-VENI grant [916-16025]; Bas Mulder award from the Alpe d'HuZes/Dutch Cancer Society [RUG 2013-5960]; Mandema stipend; advanced European Research Council grant OnQview	Supported by The Netherlands Organisation for Scientific Research (NWO)-VENI grant 916-16025 (R.S.N.F.), Bas Mulder award RUG 2013-5960 (R.S.N.F.) from the Alpe d'HuZes/Dutch Cancer Society, a Mandema stipend (R.S.N.F.), and the advanced European Research Council grant OnQview (E.G.E.d.V.).	Abdul-Al HM, 2008, HUM PATHOL, V39, P209, DOI 10.1016/j.humpath.2007.06.004; Abou-Alfa GK, 2016, J HEPATOL, V65, P289, DOI 10.1016/j.jhep.2016.04.004; Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Baumhoer D, 2008, AM J CLIN PATHOL, V129, P899, DOI 10.1309/HCQWPWD50XHD2DW6; Bense RD, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw192; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Cai MY, 2011, GUT, V60, P967, DOI 10.1136/gut.2010.231993; Camp RL, 2000, LAB INVEST, V80, P1943, DOI 10.1038/labinvest.3780204; Cao DF, 2009, AM J SURG PATHOL, V33, P1065, DOI 10.1097/PAS.0b013e3181a13eef; Crijns APG, 2009, PLOS MED, V6, P181, DOI 10.1371/journal.pmed.1000024; Damelin M, 2015, PHARM RES-DORDR, V32, P3494, DOI 10.1007/s11095-015-1624-3; Denkert C, 2017, LANCET, V389, P2430, DOI 10.1016/S0140-6736(16)32454-0; Fehrmann RSN, 2015, NAT GENET, V47, P115, DOI 10.1038/ng.3173; Foda AARM, 2015, TUMOR BIOL, V36, P4671, DOI 10.1007/s13277-015-3115-x; Gaber R, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0165-0; Gao HP, 2014, CLIN CANCER RES, V20, P6418, DOI 10.1158/1078-0432.CCR-14-1170; Heijink DM, 2011, ONCOGENE, V30, P2026, DOI 10.1038/onc.2010.578; Hirabayashi K, 2015, ANN DIAGN PATHOL, V19, P45, DOI 10.1016/j.anndiagpath.2015.02.002; Honsova Eva, 2011, Cas Lek Cesk, V150, P37; Iglesias BV, 2008, HISTOL HISTOPATHOL, V23, P1333, DOI 10.14670/HH-23.1333; Ikeda H, 2012, HUM PATHOL, V43, P1955, DOI 10.1016/j.humpath.2011.11.022; Ikeda M, 2014, CANCER SCI, V105, P455, DOI 10.1111/cas.12368; Koller M, 2017, J NUCL MED, V58, P1899, DOI 10.2967/jnumed.117.198440; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Lamberts LE, 2015, ONCOTARGET, V6, P28164, DOI 10.18632/oncotarget.4461; Lee JH, 2015, BRIT J CANCER, V113, P1666, DOI 10.1038/bjc.2015.430; Liu XY, 2015, CARCINOGENESIS, V36, P232, DOI 10.1093/carcin/bgu245; Llovet JM, 2006, GASTROENTEROLOGY, V131, P1758, DOI 10.1053/j.gastro.2006.09.014; MANKOFF DA, 2007, J NUCL MED, V48; Moek KL, 2017, ANN ONCOL, V28, P3083, DOI 10.1093/annonc/mdx541; Moek KL, 2017, J NUCL MED, V58, p83S, DOI 10.2967/jnumed.116.186940; Morford LA, 2007, HEPATOLOGY, V46, P1541, DOI 10.1002/hep.21825; Sawada Y, 2012, CLIN CANCER RES, V18, P3686, DOI 10.1158/1078-0432.CCR-11-3044; Suzuki S, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1238542; Swanson BJ, 2015, ARCH PATHOL LAB MED, V139, P537, DOI 10.5858/arpa.2013-0645-OA; Nguyen T, 2015, ARCH PATHOL LAB MED, V139, P1028, DOI 10.5858/arpa.2014-0479-OA; Wang FH, 2009, AM J SURG PATHOL, V33, P1529, DOI 10.1097/PAS.0b013e3181ad25d5; Yamanaka K, 2007, ONCOLOGY-BASEL, V73, P389, DOI 10.1159/000136159; Yu X, 2015, GENET MOL RES, V14, P10185, DOI 10.4238/2015.August.28.2; Zhu AX, 2013, CLIN CANCER RES, V19, P920, DOI 10.1158/1078-0432.CCR-12-2616	40	2	2	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	SEP	2018	188	9					1973	1981		10.1016/j.ajpath.2018.05.014			9	Pathology	Pathology	GR5XP	WOS:000442715500005	29935166				2019-10-28	
J	Beltrami, C; Simpson, K; Jesky, M; Wonnacott, A; Carrington, C; Holmans, P; Newbury, L; Jenkins, R; Ashdown, T; Dayan, C; Satchell, S; Corish, P; Cockwell, P; Fraser, D; Bowen, T				Beltrami, Cristina; Simpson, Kate; Jesky, Mark; Wonnacott, Alexa; Carrington, Christopher; Holmans, Peter; Newbury, Lucy; Jenkins, Robert; Ashdown, Thomas; Dayan, Colin; Satchell, Simon; Corish, Peter; Cockwell, Paul; Fraser, Donald; Bowen, Timothy			Association of Elevated Urinary miR-126, miR-155, and miR-29b with Diabetic Kidney Disease	AMERICAN JOURNAL OF PATHOLOGY			English	Article							EXPRESSION; MICRORNAS; HYPERGLYCEMIA; INHIBITION; PODOCYTES; NEPHRIN; SAMPLES; INJURY; RNA	Effective diabetic kidney disease (DKD) biomarkers remain elusive, and urinary miRNAs represent a potential source of novel noninvasive disease sentinels. We profiled 754 miRNAs in pooled urine samples from DKD patients (n = 20), detecting significantly increased miR-126, miR-155, and miR-29b compared with controls (n = 20). These results were confirmed in an independent cohort of 89 DKD patients, 62 diabetic patients without DKD, and 41 controls: miR-126 (2.8-fold increase; P < 0.0001), miR-155 (1.8-fold increase; P < 0.001), and miR-29b (4.6-fold increase; P = 0.024). Combined receiver operating characteristic curve analysis resulted in an area under the curve of 0.8. A relative quantification threshold equivalent to 80% sensitivity for each miRNA gave a positive signal for 48% of DKD patients compared with 3.6% of diabetic patients without DKD. Laser-capture microdissection of renal biopsy specimens, followed by quantitative RT-PCR, detected miR-155 in glomeruli and proximal and distal tubules, whereas miR-126 and miR-29b were most abundant in glomerular extracts. Subsequent experiments showed miR-126 and miR-29b enrichment in glomerular endothelial cells (GEnCs) compared with podocytes, proximal tubular epithelial cells, and fibroblasts. Significantly increased miR-126 and miR-29b were detected in GEnC conditioned medium in response to tumor necrosis factor-alpha and transforming growth factor-beta 1, respectively. Our data reveal an altered urinary miRNA profile associated with DKD and link these variations to miRNA release from GEnCs.	[Beltrami, Cristina; Simpson, Kate; Wonnacott, Alexa; Carrington, Christopher; Newbury, Lucy; Jenkins, Robert; Ashdown, Thomas; Fraser, Donald; Bowen, Timothy] Cardiff Univ, Wales Kidney Res Unit, Cardiff, S Glam, Wales; [Holmans, Peter] Cardiff Univ, Div Infect & Immun, MRC Ctr Neuropsychiat Genet & Genom, Cardiff, S Glam, Wales; [Dayan, Colin] Cardiff Univ, Div Psychol Med & Clin Neurosci, Cardiff, S Glam, Wales; [Dayan, Colin] Cardiff Univ, Diabet Res Grp, Cardiff, S Glam, Wales; [Simpson, Kate; Newbury, Lucy; Fraser, Donald; Bowen, Timothy] Cardiff Univ, Coll Biomed & Life Sci, Sch Med, Div Infect & Immun, Cardiff, S Glam, Wales; [Simpson, Kate; Newbury, Lucy; Fraser, Donald; Bowen, Timothy] Cardiff Univ, Cardiff Inst Tissue Engn & Repairt, Cardiff, S Glam, Wales; [Jesky, Mark; Cockwell, Paul] Queen Elizabeth Hosp Birmingham, Dept Renal Med, Birmingham, W Midlands, England; [Satchell, Simon] Univ Bristol, Bristol Med Sch, Bristol Renal, Bristol, Avon, England; [Corish, Peter] BBI Grp, Cardiff, S Glam, Wales	Bowen, T (reprint author), Cardiff Univ, Coll Biomed & Life Sci, Sch Med, Div Infect & Immun,Wales Kidney Res Unit, Heath Pk Campus, Cardiff CF14 4XN, S Glam, Wales.	bowent@cf.ac.uk	; Holmans, Peter/F-4518-2015	Simpson, Kate/0000-0003-2441-3312; Holmans, Peter/0000-0003-0870-9412	National Institute for Health Research Invention for Innovation (i4i) Programme [II-LA-0712-20003]; Kidney Research UK Project [RP44/2014, IN4/2013]; JABBS Foundation; Health and Care Research Wales	Supported by the National Institute for Health Research Invention for Innovation (i4i) Programme grant II-LA-0712-20003 (T.B. is the principal investigator for the grant) and the Kidney Research UK Project grant awards RP44/2014 (T.B.) and IN4/2013 (S.S.). The JABBS Foundation funded collection of the Renal Impairment in Secondary Care cohort (P.Coc.). The Wales Kidney Research Unit is funded by core support from Health and Care Research Wales (D.F.).	Al-Kafaji G, 2016, EXP THER MED, V12, P815, DOI 10.3892/etm.2016.3395; Asgeirsdottir SA, 2012, AM J PHYSIOL-RENAL, V302, pF1630, DOI 10.1152/ajprenal.00400.2011; Barutta F, 2017, ACTA DIABETOL, V54, P133, DOI 10.1007/s00592-016-0915-4; Barutta F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073798; Beltrami Cristina, 2015, Non-Coding RNA, V1, P151, DOI 10.3390/ncrna1020151; Brosius FC, 2014, ADV CHRONIC KIDNEY D, V21, P304, DOI 10.1053/j.ackd.2014.03.011; Chen HY, 2014, MOL THER, V22, P842, DOI 10.1038/mt.2013.235; Coward RJM, 2011, CURR DIABETES REV, V7, P22, DOI 10.2174/157339911794273883; COWIE CC, 1989, NEW ENGL J MED, V321, P1074, DOI 10.1056/NEJM198910193211603; Harris TA, 2008, P NATL ACAD SCI USA, V105, P1516, DOI 10.1073/pnas.0707493105; Huang YQ, 2014, BMC NEPHROL, V15, DOI 10.1186/1471-2369-15-142; Jenkins RH, 2014, AM J PATHOL, V184, P996, DOI 10.1016/j.ajpath.2013.12.028; Jha V, 2013, LANCET, V382, P260, DOI 10.1016/S0140-6736(13)60687-X; Kendziorski C, 2005, P NATL ACAD SCI USA, V102, P4252, DOI 10.1073/pnas.0500607102; Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group, 2013, KIDNEY INT S, V3, P1, DOI [DOI 10.1038/kisup.2012.73, 10.1038/ki.2013.243]; Krupa A, 2010, J AM SOC NEPHROL, V21, P438, DOI 10.1681/ASN.2009050530; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Lin X, 2015, INFLAMMATION, V38, P546, DOI 10.1007/s10753-014-9961-7; MAKITA Z, 1991, NEW ENGL J MED, V325, P836, DOI 10.1056/NEJM199109193251202; Midgley AC, 2014, AGING CELL, V13, P235, DOI 10.1111/acel.12167; Mocharla P, 2013, BLOOD, V121, P226, DOI 10.1182/blood-2012-01-407106; Navarro Juan F, 2005, Kidney Int Suppl, pS98, DOI 10.1111/j.1523-1755.2005.09918.x; Ohga S, 2007, AM J PHYSIOL-RENAL, V292, pF1141, DOI 10.1152/ajprenal.00288.2005; Olivieri F, 2015, ONCOTARGET, V6, P35372, DOI 10.18632/oncotarget.6164; Osipova J, 2014, J CLIN ENDOCR METAB, V99, pE1661, DOI 10.1210/jc.2013-3868; Parving HH, 2015, DIABETES RES CLIN PR, V107, P1, DOI 10.1016/j.diabres.2014.10.014; Prowle JR, 2015, RENAL FAILURE, V37, P408, DOI 10.3109/0886022X.2014.1001303; Regele F, 2015, NEPHROL DIAL TRANSPL, V30, P26, DOI 10.1093/ndt/gfv087; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; Rocco MV, 2012, AM J KIDNEY DIS, V60, P857, DOI 10.1053/j.ajkd.2012.07.005; Rodriguez-Iturbe Bernardo, 2005, Kidney Int Suppl, pS82, DOI 10.1111/j.1523-1755.2005.09915.x; */* S  81, 2014, DIABETES CARE S1, V37, pS8, DOI DOI 10.2337/DC14-S081; Salama A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106153; Saleem MA, 2002, J AM SOC NEPHROL, V13; Satchell SC, 2006, KIDNEY INT, V69, P1633, DOI 10.1038/sj.ki.5000277; Schley G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145042; Schrijvers BF, 2004, ENDOCR REV, V25, P971, DOI 10.1210/er.2003-0018; Silambarasan M, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040518; Simpson K, 2016, CURR DIABETES REP, V16, DOI 10.1007/s11892-016-0724-8; Smith DA, 2017, SENSOR ACTUAT B-CHEM, V253, P335, DOI 10.1016/j.snb.2017.06.069; Stringer S, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-95; Toyono T, 2016, CORNEA, V35, P1466, DOI 10.1097/ICO.0000000000000954; Trionfini P, 2015, NAT REV NEPHROL, V11, P23, DOI 10.1038/nrneph.2014.202; Wang B, 2012, J AM SOC NEPHROL, V23, P252, DOI 10.1681/ASN.2011010055; Wang SS, 2008, DEV CELL, V15, P261, DOI 10.1016/j.devcel.2008.07.002; Welten SMJ, 2016, CARDIOVASC RES, V110, P6, DOI 10.1093/cvr/cvw039; Zhang SD, 2005, BIOINFORMATICS, V21, P4378, DOI 10.1093/bioinformatics/bti717; Zhu HQ, 2014, INT J CARDIOL, V176, P764, DOI 10.1016/j.ijcard.2014.07.095	49	3	4	1	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	SEP	2018	188	9					1982	1992		10.1016/j.ajpath.2018.06.006			11	Pathology	Pathology	GR5XP	WOS:000442715500006	29981742				2019-10-28	
J	Sakurai, T; Kamio, K; Sasaki, K; Nishimoto, T; Yamaguchi, J; Sasaki, M; Tsutsumi, S				Sakurai, Takanobu; Kamio, Kyohei; Sasaki, Kazuhiko; Nishimoto, Tomohiro; Yamaguchi, Jun-ichi; Sasaki, Minoru; Tsutsumi, Shunsuke			Imaging Mass Microscopy of Kidneys from Azithromycin-Treated Rats with Phospholipidosis	AMERICAN JOURNAL OF PATHOLOGY			English	Article							DRUG-INDUCED PHOSPHOLIPIDOSIS; ELECTRON-MICROSCOPY; TISSUE DISTRIBUTION; HIGH-RESOLUTION; MOUSE-BRAIN; SPECTROMETRY; ACCUMULATION; MS; DI-22/6-BIS(MONOACYLGLYCEROL)PHOSPHATE; IDENTIFICATION	Drug-induced phospholipidosis is a lysosomal storage disorder characterized by the excess accumulation of tissue phospholipids. Although azithromycin can be used to induce phospholipidosis, no experimental studies evaluating the relationship between drug accumulation and phospholipid localization have been performed. In this study, azithromycin was orally administered to rats for 7 days, and the relationship between drug and phospholipid accumulation was performed using imaging mass microscopy. The administration of azithromycin induced tubular epithelial vacuolation in the inner stripe of the outer medulla of the kidney, consistent with the lamellar bodies that are typical manifestations of drug-induced phospholipidosis. Azithromycin and phospholipid tissue levels were extensively elevated in the kidneys of azithromycin-treated rats. Imaging mass microscopy revealed that both azithromycin and its metabolites were found in the kidneys of azithromycin-treated rats but not in control animals. The vacuolated areas of the kidneys were primarily found in the inner stripe of the outer medulla, consistent with the areas of high azithromycin concentration. Azithromycin was colocalized with several phospholipids-phosphatidylinositol (18:0/20:4), phosphatidylethanotamine (18:0/20:4 and 16:0/20:4), and possibly didocosahexaenoyl. (C22:6)-bis(monoacylglycerol) phosphate, a putative biomarker of drug-induced phospholipidosis. In summary, we found correlations between regions of kidney damage and the accumulation of azithromycin, its metabolites, and phospholipids using imaging mass microscopy. Such analyses may help reveal the mechanism and identify putative biomarkers of drug induced phospholipidosis.	[Sakurai, Takanobu; Kamio, Kyohei; Sasaki, Kazuhiko; Nishimoto, Tomohiro; Yamaguchi, Jun-ichi; Sasaki, Minoru; Tsutsumi, Shunsuke] Taisho Pharmaceut Co Ltd, Drug Safety & Pharmacokinet Labs, Saitama, Japan	Sakurai, T (reprint author), Taisho Pharmaceut Co Ltd, Drug Safety & Pharmacokinet Labs, Kita Ku, 1-403 Yoshino Cho, Saitama, Saitama 3319530, Japan.	t-sakurai@taisho.co.jp					Anderson N, 2006, FEBS LETT, V580, P5533, DOI 10.1016/j.febslet.2006.08.061; Asaoka Y, 2013, EXP TOXICOL PATHOL, V65, P817, DOI 10.1016/j.etp.2012.11.008; Baronas ET, 2007, TOXICOL APPL PHARM, V218, P72, DOI 10.1016/j.taap.2006.10.015; Berry KAZ, 2011, CHEM REV, V111, P6491, DOI 10.1021/cr200280p; BONNET M, 1992, ANTIMICROB AGENTS CH, V36, P1302, DOI 10.1128/AAC.36.6.1302; BRIGHT GM, 1988, J ANTIBIOT, V41, P1029, DOI 10.7164/antibiotics.41.1029; Cartwright ME, 2009, TOXICOL PATHOL, V37, P902, DOI 10.1177/0192623309348521; Castellino S, 2011, BIOANALYSIS, V3, P2427, DOI [10.4155/BIO.11.232, 10.4155/bio.11.232]; COX JW, 1988, PHARMACOL TOXICOL, V62, P337, DOI 10.1111/j.1600-0773.1988.tb01900.x; Dilillo M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00703-w; Frazier KS, 2013, TOXICOL PATHOL, P422; Garrett TJ, 2007, INT J MASS SPECTROM, V260, P166, DOI 10.1016/j.ijms.2006.09.019; GIRARD AE, 1987, ANTIMICROB AGENTS CH, V31, P1948, DOI 10.1128/AAC.31.12.1948; GLADUE RP, 1990, ANTIMICROB AGENTS CH, V34, P1056, DOI 10.1128/AAC.34.6.1056; Groseclose MR, 2015, J AM SOC MASS SPECTR, V26, P887, DOI 10.1007/s13361-015-1103-4; Hamaguchi R, 2014, J CHROMATOGR B, V967, P110, DOI 10.1016/j.jchromb.2014.07.018; Hatae T, 1997, CELL TISSUE RES, V288, P317, DOI 10.1007/s004410050817; Hunter RP, 2003, J VET PHARMACOL THER, V26, P117, DOI 10.1046/j.1365-2885.2003.00464.x; Jiang HB, 2017, CHEM COMMUN, V53, P1506, DOI 10.1039/c6cc08549k; Khatib-Shahidi S, 2006, ANAL CHEM, V78, P6448, DOI 10.1021/ac060788p; Kitakaze K, 2016, J CLIN INVEST, V126, P1691, DOI 10.1172/JCI85300; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Lenz B, 2018, TOXICOL SCI, V163, P409, DOI 10.1093/toxsci/kfx044; Liu NJ, 2014, TOXICOL APPL PHARM, V279, P467, DOI 10.1016/j.taap.2014.06.014; Liu Y, 2014, TOXICOLOGY, V320, P1, DOI 10.1016/j.tox.2014.02.014; Matijasic M, 2012, PHARMACOL RES, V66, P332, DOI 10.1016/j.phrs.2012.06.001; Muto H, 1995, JPN J CHEMOTHER, V43, P110; Nilsson A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047353; Nonoyama T, 2008, J TOXICOL PATHOL, V21, P9, DOI 10.1293/tox.21.9; Obert LA, 2007, TOXICOL PATHOL, V35, P728, DOI 10.1080/01926230701481956; Omosu M, 2003, JPN J CHEMOTHER S1, V51, P115; Parnham MJ, 2014, PHARMACOL THERAPEUT, V143, P225, DOI 10.1016/j.pharmthera.2014.03.003; PFALLER W, 1982, ADV ANAT EMBRYOL CEL, V70, P1; Rompp A, 2011, ANAL BIOANAL CHEM, V401, P65, DOI 10.1007/s00216-011-4990-7; Ruh H, 2013, J LIPID RES, V54, P2785, DOI 10.1194/jlr.M040014; Rzagalinski I, 2017, BBA-PROTEINS PROTEOM, V1865, P726, DOI 10.1016/j.bbapap.2016.12.011; Shepard RM, 1992, LIV 1 INT C MACR AZ; Shimma S, 2008, ANAL CHEM, V80, P878, DOI 10.1021/ac071301v; Solon EG, 2010, AAPS J, V12, P11, DOI 10.1208/s12248-009-9158-4; Spraggins JM, 2016, PROTEOMICS, V16, P1678, DOI 10.1002/pmic.201600003; Sugiura Y, 2009, J LIPID RES, V50, P1776, DOI 10.1194/jlr.M900047-JLR200; Tanaka K, 1988, RAPID COMMUN MASS SP, V2, P151, DOI DOI 10.1002/RCM.1290020802; THELMO WL, 1978, AM J PATHOL, V91, P355; Thompson KL, 2012, INT J TOXICOL, V31, P14, DOI 10.1177/1091581811430167; TOUBEAU G, 1986, VIRCHOWS ARCH B, V51, P475, DOI 10.1007/BF02899053; Trim PJ, 2016, METHODS, V104, P127, DOI 10.1016/j.ymeth.2016.01.011; Turner M, 2006, ANN INTERN MED, V144, P447, DOI 10.7326/0003-4819-144-6-200603210-00014; Van Bambeke F, 1998, J ANTIMICROB CHEMOTH, V42, P761, DOI 10.1093/jac/42.6.761; Yao I, 2008, PROTEOMICS, V8, P3692, DOI 10.1002/pmic.200701121; Yasunaga M, 2013, SCI REP-UK, V3, DOI 10.1038/srep03050	50	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	SEP	2018	188	9					1993	2003		10.1016/j.ajpath.2018.05.018			11	Pathology	Pathology	GR5XP	WOS:000442715500007	29981744				2019-10-28	
J	Richardson, L; Menon, R				Richardson, Lauren; Menon, Ramkumar			Proliferative, Migratory, and Transition Properties Reveal Metastate of Human Amnion Cells	AMERICAN JOURNAL OF PATHOLOGY			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; HUMAN FETAL MEMBRANES; OXIDATIVE STRESS; PREMATURE RUPTURE; PRETERM; SENESCENCE; EXPRESSION; VIMENTIN; ADHESIVE; FLUID	Amnion epithelial cell (AEC) shedding causes microfractures in human placental membranes during gestation. However, microfractures are healed to maintain membrane integrity. To better understand the cellular mechanisms of healing and tissue remodeling, scratch assays were performed using primary AECs derived from normal term not in labor membranes. AECs were grown under different conditions: i) normal cultures (control), ii) oxidative stress (OS) induction by cigarette smoke extract (CSE), iii) co-treatment of CSE and antioxidant N-acetyl-L-cysteine, and iv) treatment with amniotic fluid (AF). Cell migration time and distance, changes in intermediate filament (cytokeratin-18 and vimentin) expressions, and cellular senescence were determined. Control AECs in culture exhibited a metastate with the expression of both cytokeratin-18 and vimentin. During healing, AECs proliferated, migrated, and transitioned from epithelial to mesenchymal phenotype with increased vimentin. Wound healing was associated with mesenchymal to epithelial transition (MET). CSE-induced OS and senescence prevented wound healing in which cells sustained mesenchymal state. N-acetyl-L-cysteine reversed CSE's effect to aid wound closure through MET. AF accelerated cellular transitions and healing. Our data suggest that AECs undergo epithelial to mesenchymal transition during proliferation and migration and MET at the injury site to promote healing. AF accelerated whereas OS diminished cellular transitions and healing. OS-inducing pregnancy risk factors may diminish remodeling capacity contributing to membrane dysfunction, leading to preterm birth.	[Richardson, Lauren; Menon, Ramkumar] Univ Texas Med Branch, Div Maternal Fetal Med & Perinatal Res, Dept Obstet & Gynecol, Galveston, TX 77555 USA; [Richardson, Lauren] Univ Texas Med Branch, Dept Neurosci Cell Biol & Anat, Galveston, TX 77555 USA	Menon, R (reprint author), Univ Texas Med Branch, Dept Obstet & Gynecol, 11-138 Med Res Bldg, Galveston, TX 77555 USA.	ra2menon@utmb.edu		Richardson, Lauren/0000-0001-8392-2833	NIH National Institute of Child Health and Human Development grant [1R01HD084532-01A1]; NIH National Institute of Environmental Health Sciences grant [T32ES007254]	Supported by NIH National Institute of Child Health and Human Development grant 1R01HD084532-01A1 (R.M.). L.R. is an appointed predoctoral trainee in the Environmental Toxicology Training Program supported by NIH National Institute of Environmental Health Sciences grant T32ES007254 and administered through The University of Texas Medical Branch in Galveston, Texas.	Asea A, 2008, J REPROD IMMUNOL, V79, P12, DOI 10.1016/j.jri.2008.06.001; Behnia F, 2015, AM J REPROD IMMUNOL, V74, P398, DOI 10.1111/aji.12414; Behnia F, 2015, AM J OBSTET GYNECOL, V213, DOI 10.1016/j.ajog.2015.05.041; Bonney EA, 2016, PLACENTA, V43, P26, DOI 10.1016/j.placenta.2016.04.018; Borgida AF, 2000, AM J OBSTET GYNECOL, V183, P937, DOI 10.1067/mob.2000.108872; Bredeson S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113799; Carvalho NS, 2017, EXP THER MED, V14, P3732, DOI 10.3892/etm.2017.4976; Chaffer CL, 2006, CANCER RES, V66, P11271, DOI 10.1158/0008-5472.CAN-06-2044; Dixon CL, 2018, AM J REPROD IMMUNOL, V79, DOI 10.1111/aji.12790; FAULK WP, 1980, LANCET, V1, P1156; Fernando RI, 2011, CANCER RES, V71, P5296, DOI 10.1158/0008-5472.CAN-11-0156; Gratacos E, 2006, PLACENTA, V27, P452, DOI 10.1016/j.placenta.2005.03.008; Gupta A, 2015, INT J BIOMATER, DOI 10.1155/2015/274082; Hadley EE, 2018, AM J REPROD IMMUNOL, V79, DOI 10.1111/aji.12776; Itahana Koji, 2007, Methods Mol Biol, V371, P21; Jabareen M, 2009, EUR J OBSTET GYN R B, V144, pS134, DOI 10.1016/j.ejogrb.2009.02.032; Janzen C, 2017, J CLIN ENDOCR METAB, V102, P1261, DOI 10.1210/jc.2016-3150; Kim MS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09543-0; Landen NX, 2016, CELL MOL LIFE SCI, V73, P3861, DOI 10.1007/s00018-016-2268-0; Lappas M, 2011, ANTIOXID REDOX SIGN, V15, P3061, DOI 10.1089/ars.2010.3765; LAURILA P, 1982, J CELL BIOL, V94, P308, DOI 10.1083/jcb.94.2.308; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Litwiniuk M, 2014, WOUND REPAIR REGEN, V22, P451, DOI 10.1111/wrr.12188; Liu CY, 2015, ONCOTARGET, V6, P15966, DOI 10.18632/oncotarget.3862; Mann LK, 2012, ACTA BIOMATER, V8, P2160, DOI 10.1016/j.actbio.2012.02.014; Mauri A, 2015, J BIOMECH, V48, P1606, DOI 10.1016/j.jbiomech.2015.01.045; Maymo JL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191489; Mendez MG, 2010, FASEB J, V24, P1838, DOI 10.1096/fj.09-151639; Menon R, 2017, SEMIN PERINATOL, V41, P409, DOI 10.1053/j.semperi.2017.07.012; Menon R, 2016, HUM REPROD UPDATE, V22, P535, DOI 10.1093/humupd/dmw022; Menon R, 2016, PLACENTA, V44, P1, DOI 10.1016/j.placenta.2016.05.013; Menon R, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00567; Menon R, 2014, AM J PATHOL, V184, P1740, DOI 10.1016/j.ajpath.2014.02.011; Menon R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083416; Menon R, 2011, OBSTET GYNECOL, V118, P121, DOI 10.1097/AOG.0b013e3182204eaa; Mogami H, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13296-1; Moore RM, 2006, PLACENTA, V27, P1037, DOI 10.1016/j.placenta.2006.01.002; Moreno-Bueno G, 2009, NAT PROTOC, V4, P1591, DOI 10.1038/nprot.2009.152; Nery FC, 2008, J CELL SCI, V121, P3476, DOI 10.1242/jcs.029454; Papadopulos NA, 2006, FETAL DIAGN THER, V21, P494, DOI 10.1159/000095660; Papanna R, 2015, PLACENTA, V36, P888, DOI 10.1016/j.placenta.2015.05.015; Papanna R, 2015, PEDIATR RES, V78, P247, DOI 10.1038/pr.2015.105; Perrini M, 2015, J BIOMECH ENG-T ASME, V137, DOI 10.1115/1.4030054; Pierce J, 2016, CELL TISSUE BANK, V17, P413, DOI 10.1007/s10561-016-9572-7; Polettini J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137188; Quintero RA, 1999, AM J OBSTET GYNECOL, V181, P744, DOI 10.1016/S0002-9378(99)70522-3; REGAUER S, 1985, J CELL BIOL, V100, P997, DOI 10.1083/jcb.100.4.997; Rennekampff HO, 2000, J SURG RES, V93, P41, DOI 10.1006/jsre.2000.5892; Richardson L, 2018, ENCY REPROD, P387; Richardson L, 2017, PLACENTA, V53, P66, DOI 10.1016/j.placenta.2017.03.017; Richardson LS, 2017, AM J PATHOL, V187, P2821, DOI 10.1016/j.ajpath.2017.08.019; Sheller S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157614; Sheller-Miller S, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00432; Zhao B, 2016, CELL TISSUE RES, V365, P85, DOI 10.1007/s00441-016-2366-1	54	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	SEP	2018	188	9					2004	2015		10.1016/j.ajpath.2018.05.019			12	Pathology	Pathology	GR5XP	WOS:000442715500008	29981743	Bronze, Green Published			2019-10-28	
J	Satitpitakul, V; Sun, ZM; Suri, K; Amouzegar, A; Katikireddy, KR; Jurkunas, UV; Kheirkhah, A; Dana, R				Satitpitakul, Vannarut; Sun, Zhongmou; Suri, Kunal; Amouzegar, Afsaneh; Katikireddy, Kishore R.; Jurkunas, Ula, V; Kheirkhah, Ahmad; Dana, Reza			Vasoactive Intestinal Peptide Promotes Corneal Allograft Survival	AMERICAN JOURNAL OF PATHOLOGY			English	Article							ENDOTHELIAL-CELL SURVIVAL; PENETRATING KERATOPLASTY; REPERFUSION INJURY; ORGAN-CULTURES; TROPHIC FACTOR; BINDING-SITES; AQUEOUS-HUMOR; RABBIT MODEL; N-CADHERIN; IN-VITRO	Corneal transplantation is the most prevalent form of tissue transplantation. The success of corneal transplantation mainly relies on the integrity of corneal endothelial cells (CEnCs), which maintain graft transparency. CEnC density decreases significantly after corneal transplantation even in the absence of graft rejection. To date, different strategies have been used to enhance CEnC survival. The neuropeptide vasoactive intestinal peptide (VIP) improves CEnC integrity during donor cornea tissue storage and protects CEnCs against oxidative stress induced apoptosis. However, little is known about the effect of exogenous administration of VIP on corneal transplant outcomes. We found that VIP significantly accelerates endothelial wound closure and suppresses interferon-gamma- and tumor necrosis factor-a induced CEnC apoptosis in vitro in a dose-dependent manner. In addition, we found that intracameral administration of VIP to mice undergoing syngeneic corneal transplantation with endothelial injury increases CEnC density and decreases graft opacity scores. Finally, using a mouse model of allogeneic corneal transplantation, we found for the first time that treatment with VIP significantly suppresses posttransplantation CEnC loss and improves corneal allograft survival.	[Satitpitakul, Vannarut; Sun, Zhongmou; Suri, Kunal; Amouzegar, Afsaneh; Katikireddy, Kishore R.; Jurkunas, Ula, V; Kheirkhah, Ahmad; Dana, Reza] Harvard Med Sch, Dept Ophthalmol, Massachusetts Eye & Ear, Schepens Eye Res Inst, 243 Charles St, Boston, MA 02114 USA; [Satitpitakul, Vannarut] Chulalongkorn Univ, Fac Med, Dept Ophthalmol, Bangkok, Thailand; [Satitpitakul, Vannarut] King Chulalongkorn Mem Hosp, Bangkok, Thailand	Kheirkhah, A; Dana, R (reprint author), Harvard Med Sch, Dept Ophthalmol, Massachusetts Eye & Ear, Schepens Eye Res Inst, 243 Charles St, Boston, MA 02114 USA.	ahmad_kheirkhah@meei.harvard.edu; reza_dana@meei.harvard.edu		Jurkunas, Ula/0000-0002-5059-608X	Eye Bank Association of America; Eversight grant award; New England Cornea Transplant Fund; Harvard Cornea Center of Excellence Fellowship; Massachusetts Lions Club	Supported in part by the Eye Bank Association of America (A.K.), Eversight grant award (A.K.), the New England Cornea Transplant Fund (A.K.), the Harvard Cornea Center of Excellence Fellowship (A.K.), and the Massachusetts Lions Club (A.K., U.V.J., and R.D.).	Acar BT, 2011, INT J OPHTHALMOL-CHI, V4, P644, DOI 10.3980/j.issn.2222-3959.2011.06.14; Adeghate EA, 1997, BRAIN RES, V758, P127, DOI 10.1016/S0006-8993(97)00215-1; Amouzegar A, 2016, J IMMUNOL, V196, P3983, DOI 10.4049/jimmunol.1600251; Ao XX, 2011, REGUL PEPTIDES, V168, P1, DOI 10.1016/j.regpep.2011.02.006; Chauhan SK, 2015, EYE, V29, P136, DOI 10.1038/eye.2014.248; Claerhout Ilse, 2008, International Ophthalmology, V28, P165, DOI 10.1007/s10792-007-9087-0; Dana MR, 1997, TRANSPLANTATION, V63, P1501, DOI 10.1097/00007890-199705270-00022; Dartt DA, 1996, EXP EYE RES, V63, P27, DOI 10.1006/exer.1996.0088; Delgado M, 2013, AMINO ACIDS, V45, P25, DOI 10.1007/s00726-011-1184-8; DENIS P, 1991, EXP EYE RES, V52, P357, DOI 10.1016/0014-4835(91)90101-J; Di Zazzo A, 2017, SURV OPHTHALMOL, V62, P816, DOI 10.1016/j.survophthal.2016.12.010; ElKitkat RS, 2016, CORNEA, V35, P72, DOI 10.1097/ICO.0000000000000682; Gain P, 2016, JAMA OPHTHALMOL, V134, P167, DOI 10.1001/jamaophthalmol.2015.4776; Gozes I, 1996, P NATL ACAD SCI USA, V93, P427, DOI 10.1073/pnas.93.1.427; Han SB, 2013, MOL VIS, V19, P1222; Hu J, 2012, ACTA BIOMATER, V8, P1156, DOI 10.1016/j.actbio.2011.09.013; Inomata T, 2015, J BIOL METHODS, V2, pe27, DOI DOI 10.14440/JBM.2015.78; Ji HF, 2013, LIVER TRANSPLANT, V19, P945, DOI 10.1002/lt.23681; Jiang W, 2011, TRANSPL P, V43, P1462, DOI 10.1016/j.transproceed.2011.01.191; KAUFMAN HE, 1966, AM J OPHTHALMOL, V61, P835, DOI 10.1016/0002-9394(66)90921-4; Koh SWM, 2008, INVEST OPHTH VIS SCI, V49, P3491, DOI 10.1167/iovs.07-1543; Koh SWM, 2007, NEUROSCI LETT, V423, P89, DOI 10.1016/j.neulet.2007.05.067; Koh SWM, 2017, CORNEA, V36, P476, DOI 10.1097/ICO.0000000000001136; Koh SWM, 2011, INVEST OPHTH VIS SCI, V52, P5632, DOI 10.1167/iovs.10-5983; Koh SWM, 2009, J NEUROCHEM, V109, P792, DOI 10.1111/j.1471-4159.2009.06012.x; Koh SWM, 2012, EXP EYE RES, V95, P48, DOI 10.1016/j.exer.2011.10.005; Koh SWM, 2005, CURR EYE RES, V30, P189, DOI 10.1080/02713680490908715; Koh SWM, 2002, CORNEA, V21, P270, DOI 10.1097/00003226-200204000-00007; Koh SWM, 2000, INVEST OPHTH VIS SCI, V41, P4085; Lahdou I, 2014, INVEST OPHTH VIS SCI, V55, P1213, DOI 10.1167/iovs.13-11930; Mathioudakis AG, 2013, HIPPOKRATIA, V17, P12; Matthaei M, 2014, EXP EYE RES, V129, P13, DOI 10.1016/j.exer.2014.10.011; MITTAG TW, 1987, J PHARMACOL EXP THER, V241, P230; Moody TW, 2003, PEPTIDES, V24, P163, DOI 10.1016/S0196-9781(02)00290-5; MUSCH DC, 1991, AM J OPHTHALMOL, V111, P739, DOI 10.1016/S0002-9394(14)76782-0; Nagahiro I, 1998, J HEART LUNG TRANSPL, V17, P617; Nakagawa H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136802; Nicholls SM, 2006, EXP EYE RES, V83, P339, DOI 10.1016/j.exer.2005.12.018; Niederkorn JY, 1999, TRANSPLANTATION, V67, P1503, DOI 10.1097/00007890-199906270-00001; OBATA H, 1991, JPN J OPHTHALMOL, V35, P411; Offen D, 2000, BRAIN RES, V854, P257, DOI 10.1016/S0006-8993(99)02375-6; Okumura N, 2017, J OPHTHALMOL, DOI 10.1155/2017/2646904; Okumura N, 2009, INVEST OPHTH VIS SCI, V50, P3680, DOI 10.1167/iovs.08-2634; Patel SV, 2005, AM J OPHTHALMOL, V139, P311, DOI 10.1016/j.ajo.2004.09.045; Plskova J, 2004, BRIT J OPHTHALMOL, V88, P1209, DOI 10.1136/bjo.2003.038703; Sabatino F, 2017, OCUL SURF, V15, P2, DOI 10.1016/j.jtos.2016.10.003; Sagoo P, 2004, INVEST OPHTH VIS SCI, V45, P3964, DOI 10.1167/iovs.04-0439; SAID SI, 1970, SCIENCE, V169, P1217, DOI 10.1126/science.169.3951.1217; SAID SI, 1976, SCIENCE, V192, P907, DOI 10.1126/science.1273576; Schmedt T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051427; Silva L, 2018, SURV OPHTHALMOL, V63, P665, DOI 10.1016/j.survophthal.2018.01.001; SONODA Y, 1992, TRANSPLANTATION, V54, P694, DOI 10.1097/00007890-199210000-00026; Souza-Moreira Luciana, 2012, Endocrine Metabolic & Immune Disorders-Drug Targets, V12, P333; STARK WJ, 1992, ARCH OPHTHALMOL-CHIC, V110, P1392; TAYLOR AW, 1994, J IMMUNOL, V153, P1080; Tuncel N, 2016, INT J OPHTHALMOL-CHI, V9, P204, DOI 10.18240/ijo.2016.02.04; Zhang WJ, 2017, CORNEA, V36, P1274, DOI 10.1097/ICO.0000000000001324	57	3	3	2	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	SEP	2018	188	9					2016	2024		10.1016/j.ajpath.2018.05.010			9	Pathology	Pathology	GR5XP	WOS:000442715500009	30097165	Green Published			2019-10-28	
J	Tawiah, A; Moreau, F; Kumar, M; Tiwari, S; Falguera, J; Chadee, K				Tawiah, Adelaide; Moreau, France; Kumar, Manish; Tiwari, Sameer; Falguera, Jan; Chadee, Kris			High MUC2 Mucin Biosynthesis in Goblet Cells Impedes Restitution and Wound Healing by Elevating Endoplasmic Reticulum Stress and Altered Production of Growth Factors	AMERICAN JOURNAL OF PATHOLOGY			English	Article							INTESTINAL EPITHELIAL-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; ANTIMICROBIAL DEFENSE; MIGRATION; ACTIVATION; IL-22; PROLIFERATION; EXPRESSION; COLITIS; STAT3	Intestinal epithelial cell wound healing involves cell migration, proliferation, and differentiation. Although numerous studies have analyzed the migration of absorptive epithelial cells during wound healing, it remains unclear how goblet cells restitute and how MUC2 mucin production affects this process. In this study, we examined the role of high MUC2 production in goblet cell migration during wound healing and demonstrated that during high MUC2 output, goblet cells migrated slower because of impaired production of wound healing factors and endoplasmic reticulum (ER) stress. Two goblet cell lines, HT29-H and HT29-L, that produced high and low MUC2 mucin, respectively, were used. HT29-L healed wounds faster than HT29-H cells by producing significantly higher amounts of fibroblast growth factor (FGF) 1, FGF2, vascular endothelial growth factor-C, and matrix metallopeptidase 1. Predictably, treatment of HT29-H cells with recombinant FGF2 significantly enhanced migration and wound healing. High MUC2 biosynthesis in HT29-H cells induced ER stress and delayed migration that was abrogated by inhibiting ER stress with tauroursodeoxycholic acid and IL-22. FGF2- and IL-22 induced wound repair was dependent on STAT1 and STAT3 signaling. During wound healing after dextran sulfate sodium-induced colitis, restitution of Math1(M1GFP+) goblet cells occurred earlier in the proximal colon, followed by the middle and then distal colon, where ulceration was severe. We conclude that high MUC2 output during colitis impairs goblet cell migration and wound healing by reducing production of growth factors critical in wound repair.	[Tawiah, Adelaide; Moreau, France; Kumar, Manish; Tiwari, Sameer; Falguera, Jan; Chadee, Kris] Univ Calgary, Fac Med, Dept Microbiol Immunol & Infect Dis, Snyder Inst Chron Dis,Gastrointestinal Res Grp, Calgary, AB, Canada	Chadee, K (reprint author), Univ Calgary, Dept Microbiol Immunol & Infect Dis, Hlth Sci Ctr, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	kchadee@ucalgary.ca		Falguera, Jan Vincent/0000-0001-6465-7798	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [KC MOP-142776]; Crohn's and Colitis Canada; Eleanor Mackie Doctoral Scholarship in Women's Health	Supported by Canadian Institutes of Health Research operating grant KC MOP-142776 (K.C.), Crohn's and Colitis Canada operating grant (K.C.), and the Eleanor Mackie Doctoral Scholarship in Women's Health (A.T).	Cobo ER, 2015, MUCOSAL IMMUNOL, V8, P1360, DOI 10.1038/mi.2015.27; DAVIDSON JM, 1991, ANN NY ACAD SCI, V638, P306, DOI 10.1111/j.1749-6632.1991.tb49041.x; Denning TL, 2013, P NATL ACAD SCI USA, V110, P12509, DOI 10.1073/pnas.1310907110; Dieckgraefe BK, 1999, AM J PHYSIOL-GASTR L, V276, pG322; DIGNASS AU, 1994, BIOCHEM BIOPH RES CO, V202, P701, DOI 10.1006/bbrc.1994.1987; DIGNASS AU, 1993, GASTROENTEROLOGY, V105, P1323, DOI 10.1016/0016-5085(93)90136-Z; DIGNASS AU, 1994, GASTROENTEROLOGY, V106, P1254, DOI 10.1016/0016-5085(94)90017-5; Dise RS, 2008, AM J PHYSIOL-GASTR L, V294, pG276, DOI 10.1152/ajpgi.00340.2007; Dorscheid DR, 2001, AM J PHYSIOL-LUNG C, V281, pL982; Dudakov JA, 2015, ANNU REV IMMUNOL, V33, P747, DOI 10.1146/annurev-immunol-032414-112123; Ebong S, 2004, INVEST OPHTH VIS SCI, V45, P872, DOI 10.1167/iovs.03-0311; El-Assal ON, 2005, GASTROENTEROLOGY, V129, P609, DOI 10.1053/j.gastro.2005.05.054; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; GIPSON IK, 1984, DEV BIOL, V101, P212, DOI 10.1016/0012-1606(84)90131-3; Goke M, 1998, AM J PHYSIOL-GASTR L, V274, pG809, DOI 10.1152/ajpgi.1998.274.5.G809; Guo S, 2010, J DENT RES, V89, P219, DOI 10.1177/0022034509359125; Hasnain SZ, 2014, NAT MED, V20, P1417, DOI 10.1038/nm.3705; Ji YH, 2014, INT J CLIN EXP PATHO, V7, P3694; Kermorgant S, 2001, CARCINOGENESIS, V22, P1035, DOI 10.1093/carcin/22.7.1035; Kim Young S, 2010, Curr Gastroenterol Rep, V12, P319, DOI 10.1007/s11894-010-0131-2; McGuckin MA, 2010, AM J PHYSIOL-GASTR L, V298, pG820, DOI 10.1152/ajpgi.00063.2010; McGuckin MA, 2009, INFLAMM BOWEL DIS, V15, P100, DOI 10.1002/ibd.20539; Moyer RA, 2007, LAB INVEST, V87, P807, DOI 10.1038/labinvest.3700595; Nagalakshmi ML, 2004, INT IMMUNOPHARMACOL, V4, P679, DOI 10.1016/j.intimp.2004.01.008; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Okamoto R, 2004, J GASTROENTEROL, V39, P1, DOI 10.1007/s00535-003-1259-8; Ortega S, 1998, P NATL ACAD SCI USA, V95, P5672, DOI 10.1073/pnas.95.10.5672; Pickert G, 2009, J EXP MED, V206, P1465, DOI 10.1084/jem.20082683; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; PULLAN RD, 1994, GUT, V35, P353, DOI 10.1136/gut.35.3.353; Rorth P, 2009, ANNU REV CELL DEV BI, V25, P407, DOI 10.1146/annurev.cellbio.042308.113231; Salmela MT, 2004, SCAND J GASTROENTERO, V39, P1095, DOI 10.1080/00365520410003470; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Schlessinger J, 2004, SCIENCE, V306, P1506, DOI 10.1126/science.1105396; Sheng H, 2003, GUT, V52, P1472, DOI 10.1136/gut.52.10.1472; Song XY, 2015, IMMUNITY, V43, P488, DOI 10.1016/j.immuni.2015.06.024; Sturm A, 2008, WORLD J GASTROENTERO, V14, P348, DOI 10.3748/wjg.14.348; Su LP, 2013, GASTROENTEROLOGY, V145, P407, DOI 10.1053/j.gastro.2013.04.011; Taupin D, 2003, NAT REV MOL CELL BIO, V4, P721, DOI 10.1038/nrm1203; Tawiah A, 2018, AM J PATHOL, V188, P1354, DOI 10.1016/j.ajpath.2018.02.007; van Es JH, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1017; Vitorino P, 2008, GENE DEV, V22, P3268, DOI 10.1101/gad.1725808; Wolk K, 2006, EUR J IMMUNOL, V36, P1309, DOI 10.1002/eji.200535503; Yang XH, 2009, CANCER RES, V69, P1668, DOI 10.1158/0008-5472.CAN-07-6385; Yi N, 2012, ANAT REC, V295, P1462, DOI 10.1002/ar.22539; Zindl CL, 2013, P NATL ACAD SCI USA, V110, P12768, DOI 10.1073/pnas.1300318110	46	1	1	1	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	SEP	2018	188	9					2025	2041		10.1016/j.ajpath.2018.05.013			17	Pathology	Pathology	GR5XP	WOS:000442715500010	29935164				2019-10-28	
J	Liu, RP; Li, XJY; Hylemon, PB; Zhou, HP				Liu, Runping; Li, Xiaojiaoyang; Hylemon, Phillip B.; Zhou, Huiping			Conjugated Bile Acids Promote Invasive Growth of Esophageal Adenocarcinoma Cells and Cancer Stem Cell Expansion via Sphingosine 1-Phosphate Receptor 2-Mediated Yes-Associated Protein Activation	AMERICAN JOURNAL OF PATHOLOGY			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; GASTROESOPHAGEAL-REFLUX DISEASE; BARRETTS-ESOPHAGUS; IN-VIVO; COUPLED RECEPTOR; LIVER-INJURY; TGF-BETA; CD44; EXPRESSION; PATHWAY	Esophageal adenocarcinoma (EAC) is the sixth Leading cause of cancer deaths worldwide and has been dramatically increasing in incidence over the past decade. Gastroesophageal reflux and Barrett esophagus are well-established risk factors for disease progression. Conjugated bile acids (CBAs), including taurocholate (TCA), represent the major bile acids in the gastroesophageal refluxate of advanced Barrett esophagus and EAC patients. Our previous studies suggested that CBA-induced activation of sphingosine 1-phosphate receptor 2 (S1PR2) plays a critical role in promoting choLangiocarcinoma cell invasive growth. However, the role of CBAs in EAC development and underlying mechanisms remains elusive. In the current study, we identified that the expression level of S1PR2 is correlated to invasiveness of EAC cells. TCA significantly promoted cell proliferation, migration, invasion, transformation, and cancer stem cell expansion in highly invasive EAC cells (OE-33 cells), but had less effect on the lower invasive EAC cells (OE-19 cells). Pharmacologic inhibition of S1PR2 with specific antagonist JTE-O13 or knockdown of S1PR2 expression significantly reduced TCA-induced invasive growth of OE-33 cells, whereas overexpression of S1PR2 sensitized OE-19 cells to TCA-induced invasive growth. Furthermore, TCA-induced activation of S1PR2 was closely associated with YAP and p-catenin signaling pathways. In conclusion, CBA-induced activation of the S1PR2 signaling pathway is critically involved in invasive growth of EAC cells and represents a novel therapeutic target for EAC.	[Liu, Runping; Li, Xiaojiaoyang; Hylemon, Phillip B.; Zhou, Huiping] Virginia Commonwealth Univ, Dept Microbiol & Immunol, McGuire Vet Affairs Med Ctr, 1217 E Marshall St,MSB 533, Richmond, VA 23298 USA	Zhou, HP (reprint author), Virginia Commonwealth Univ, Dept Microbiol & Immunol, McGuire Vet Affairs Med Ctr, 1217 E Marshall St,MSB 533, Richmond, VA 23298 USA.	huiping.zhou@vcuhealth.org	Zhou, Huiping/H-6875-2019	Zhou, Huiping/0000-0002-0050-372X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 DK104893, R01 DK-057543]; Veterans Affairs Merit AwardsUS Department of Veteran Affairs [I01BX004033, 1I01BX001390]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81070245, 81270489]; Wenzhou Medical University Research Fund	Supported by NIH grants R01 DK104893 (H.Z. and P.B.H.) and R01 DK-057543 (H.Z. and P.B.H.), Veterans Affairs Merit Awards I01BX004033 (H.Z.) and 1I01BX001390 (H.Z.), National Natural Science Foundation of China grants 81070245 (H.Z.) and 81270489 (H.Z.), and Wenzhou Medical University Research Fund (H.Z.).	Ahmed M, 2017, STEM CELLS, V35, P839, DOI 10.1002/stem.2579; Arish M, 2017, J RECEPT SIG TRANSD, V37, P437, DOI 10.1080/10799893.2017.1358282; Azzolin L, 2014, CELL, V158, P157, DOI 10.1016/j.cell.2014.06.013; Beckham TH, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.14; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Bryan L, 2008, BBA-MOL CELL BIOL L, V1781, P459, DOI 10.1016/j.bbalip.2008.04.008; Cai J, 2015, GENE DEV, V29, P1493, DOI 10.1101/gad.264515.115; Chaffer CL, 2016, CANCER METAST REV, V35, P645, DOI 10.1007/s10555-016-9648-7; Chen KH, 2007, CANCER SCI, V98, P1683, DOI 10.1111/j.1349-7006.2007.00605.x; Cheng CH, 2006, GENE DEV, V20, P1715, DOI 10.1101/gad.1430906; Coleman HG, 2018, GASTROENTEROLOGY, V154, P390, DOI 10.1053/j.gastro.2017.07.046; Contino G, 2017, GASTROENTEROLOGY, V153, P657, DOI 10.1053/j.gastro.2017.07.007; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Du W, 2010, CANCER RES, V70, P772, DOI 10.1158/0008-5472.CAN-09-2722; Dulak AM, 2013, NAT GENET, V45, P478, DOI 10.1038/ng.2591; Fein M, 1998, J Gastrointest Surg, V2, P260, DOI 10.1016/S1091-255X(98)80021-8; Gao Y, 2015, ONCOTARGET, V6, P7828, DOI 10.18632/oncotarget.3488; Godar S, 2008, CELL, V134, P62, DOI 10.1016/j.cell.2008.06.006; Hait NC, 2017, MEDIAT INFLAMM, DOI 10.1155/2017/4806541; Hindley CJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep23208; Honjo S, 2014, INT J ONCOL, V45, P567, DOI 10.3892/ijo.2014.2450; Huang DZ, 2009, STEM CELLS DEV, V18, P465, DOI 10.1089/scd.2008.0033; IFTIKHAR SY, 1993, ANN ROY COLL SURG, V75, P411; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Imajo M, 2015, NAT CELL BIOL, V17, P7, DOI 10.1038/ncb3084; JOHNSSON F, 1988, SCAND J GASTROENTERO, V23, P712, DOI 10.3109/00365528809093938; Karlsson MC, 2017, MOL ONCOL, V11, P781, DOI 10.1002/1878-0261.12092; Kauer WKH, 1997, SURGERY, V122, P874, DOI 10.1016/S0039-6060(97)90327-5; Kunkel GT, 2013, NAT REV DRUG DISCOV, V12, P688, DOI 10.1038/nrd4099; Li XJY, 2017, HEPATOLOGY, V66, P869, DOI 10.1002/hep.29145; Li Y, 2007, DIS ESOPHAGUS, V20, P372, DOI 10.1111/j.1442-2050.2007.00713.x; Liu R., 2017, HEPATOLOGY BALTIMORE, V67, P1441; Liu RP, 2015, J BIOL CHEM, V290, P30988, DOI 10.1074/jbc.M115.668277; Liu RP, 2014, HEPATOLOGY, V60, P908, DOI 10.1002/hep.27085; Mokrowiecka A, 2017, PATHOL RES PRACT, V213, P205, DOI 10.1016/j.prp.2016.12.018; Mori S, 2009, ONCOGENE, V28, P2796, DOI 10.1038/onc.2009.139; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; Nagahashi M, 2015, HEPATOLOGY, V61, P1216, DOI 10.1002/hep.27592; Nair N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07144-5; Nehra D, 1999, GUT, V44, P598, DOI 10.1136/gut.44.5.598; Patmanathan SN, 2016, SCI REP-UK, V6, DOI 10.1038/srep25650; Pyne Nigel J., 2015, Advances in Biological Regulation, V60, P151, DOI 10.1016/j.jbior.2015.09.001; Pyne NJ, 2012, BIOCHEM SOC T, V40, P94, DOI 10.1042/BST20110602; Pyne NJ, 2010, NAT REV CANCER, V10, P489, DOI 10.1038/nrc2875; Quante M, 2012, CANCER CELL, V21, P36, DOI 10.1016/j.ccr.2011.12.004; Rees JRE, 2006, CANCER RES, V66, P9583, DOI 10.1158/0008-5472.CAN-06-1842; Ren K, 2017, J PHYSIOL BIOCHEM, V73, P287, DOI 10.1007/s13105-017-0553-5; Salama MF, 2015, FASEB J, V29, P2803, DOI 10.1096/fj.15-270413; Secrier M, 2016, NAT GENET, V48, P1131, DOI 10.1038/ng.3659; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Song SM, 2014, CANCER RES, V74, P4170, DOI 10.1158/0008-5472.CAN-13-3569; Spechler SJ, 2010, GASTROENTEROLOGY, V138, P854, DOI 10.1053/j.gastro.2010.01.002; Stamp D, 2010, MED HYPOTHESES, V75, P338, DOI 10.1016/j.mehy.2010.03.034; Sukocheva OA, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020420; Tomizawa Y, 2012, ONCOL LETT, V3, P1059, DOI 10.3892/ol.2012.632; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Wang YQ, 2017, HEPATOLOGY, V65, P2005, DOI 10.1002/hep.29076; Xu HX, 2015, ONCOTARGETS THER, V8, P3783, DOI 10.2147/OTT.S95470; Yamashita H, 2006, J SURG RES, V130, P80, DOI 10.1016/j.jss.2005.08.004; Yan YM, 2015, STEM CELL TRANSL MED, V4, P1033, DOI 10.5966/sctm.2015-0048; Yang L, 2014, MODERN PATHOL, V27, P775, DOI 10.1038/modpathol.2013.189; Yen CJ, 2008, CANCER RES, V68, P2632, DOI 10.1158/0008-5472.CAN-07-5460; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhang GQ, 2013, BLOOD, V122, P443, DOI 10.1182/blood-2012-11-467191; Zhao JW, 2015, CURR ATHEROSCLER REP, V17, DOI 10.1007/s11883-015-0504-y	66	3	3	1	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	SEP	2018	188	9					2042	2058		10.1016/j.ajpath.2018.05.015			17	Pathology	Pathology	GR5XP	WOS:000442715500011	29963993	Green Published			2019-10-28	
J	Matsui, S; Harada, K; Miyata, N; Okochi, H; Miyajima, A; Tanaka, M				Matsui, Satoshi; Harada, Kenichi; Miyata, Naoko; Okochi, Hitoshi; Miyajima, Atsushi; Tanaka, Minoru			Characterization of Peribiliary Gland-Constituting Cells Based on Differential Expression of Trophoblast Cell Surface Protein 2 in Biliary Tract	AMERICAN JOURNAL OF PATHOLOGY			English	Article							STEM/PROGENITOR CELLS; STEM-CELLS; FUNCTIONAL-CHARACTERIZATION; MOUSE-LIVER; TREE; IDENTIFICATION; REGENERATION; CHOLANGIOCYTES; EPITHELIUM; HUMANS	Peribiliary glands (PBGs) are accessory glands with mucinous and serous acini in the biliary tree. The PBG is composed of a heterogeneous cell population, such as mucus- and pancreatic enzyme producing epithelial cells, whereas it constitutes niches for multipotential stem/progenitor cells in the human extrahepatic bite duct (EHBD). By contrast, the nature of PBGs in the mouse EHBD remains unclear. Our aim was to establish a method for isolating and characterizing PBG-constituting cells in the mouse EHBD. We found that trophoblast cell surface protein 2 (Trop2) was expressed in the luminal epithelium of mouse EHBD exclusively, but not in the PBG. On the basis of the differential expression profile of Trop2, lumen-forming biliary epithelial cells (LBECs) and PBG-constituting epithelial cells (PBECs) were separately isolated for further characterization. Gene expression analysis revealed that the isolated mouse PBECs expressed several marker genes related to human PBGs. In the colony formation assay, PBECs showed significantly higher colony formation capacity than LBECs. In the organoid formation assay, PBECs formed cystic organoid with LBEC-Like phenotype. Interestingly, PBECs proliferated, accompanied by reexpression of Trop2 in vivo after bile duct Ligation. Furthermore, the unique expression profile of Trop2 was conserved in human EHBD. Our findings indicate that Trop2 is a useful marker in investigating the pathophysiological roles and characteristics of mouse and human PBGs in biliary diseases.	[Matsui, Satoshi; Miyajima, Atsushi] Univ Tokyo, Labs Stem Cell Therapy, Inst Quantitat Biosci, Tokyo, Japan; [Tanaka, Minoru] Univ Tokyo, Lab Stem Cell Regulat, Inst Quantitat Biosci, Tokyo, Japan; [Matsui, Satoshi; Miyata, Naoko; Okochi, Hitoshi; Tanaka, Minoru] Natl Ctr Global Hlth & Med, Dept Regenerat Med, Res Inst, Tokyo, Japan; [Harada, Kenichi] Kanazawa Univ, Grad Sch Med, Dept Human Pathol, Kanazawa, Ishikawa, Japan	Matsui, S (reprint author), Natl Ctr Global Hlth & Med, Dept Regenerat Med, Res Inst, Shinjuku Ku, 1-21-1 Toyama, Tokyo 1628655, Japan.	m-tanaka@ri.ncgm.go.jp			Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [26110007, 26253023]; Japan Agency for Medical Research and Development Research ProgramJapan Agency for Medical Research and Development (AMED) [JP17be0304201]	Supported in part by the Japan Society for the Promotion of Science, grants-in-aid for Scientific Research on Innovative Areas 26110007 (M.T.) and Scientific Research A 26253023 (A.M.); and by the Japan Agency for Medical Research and Development Research Program JP17be0304201 (M.T.).	Cardinale V, 2011, HEPATOLOGY, V54, P2159, DOI 10.1002/hep.24590; Carpino G, 2015, J HEPATOL, V63, P1220, DOI 10.1016/j.jhep.2015.06.018; Carpino G, 2012, J ANAT, V220, P186, DOI 10.1111/j.1469-7580.2011.01462.x; DiPaola F, 2013, HEPATOLOGY, V58, P1486, DOI 10.1002/hep.26485; Fukuda A, 2006, GASTROENTEROLOGY, V130, P855, DOI 10.1053/j.gastro.2005.11.031; Furuyama K, 2011, NAT GENET, V43, P34, DOI 10.1038/ng.722; Gigliozzi A, 2000, GASTROENTEROLOGY, V119, P1113, DOI 10.1053/gast.2000.18156; Goldstein AS, 2008, P NATL ACAD SCI USA, V105, P20882, DOI 10.1073/pnas.0811411106; Huch M, 2013, EMBO J, V32, P2708, DOI 10.1038/emboj.2013.204; Igarashi S, 2013, WORLD J HEPATOL, V5, P425, DOI 10.4254/wjh.v5.i8.425; ISHIDA F, 1989, LAB INVEST, V60, P260; Kaneko K, 2015, HEPATOLOGY, V61, P2056, DOI 10.1002/hep.27685; Ke MT, 2013, NAT NEUROSCI, V16, P1154, DOI 10.1038/nn.3447; KURUMAYA H, 1989, ARCH PATHOL LAB MED, V113, P143; Lanzoni G, 2016, HEPATOLOGY, V64, P277, DOI 10.1002/hep.28326; Liu QX, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0463-z; Miyajima A, 2014, CELL STEM CELL, V14, P561, DOI 10.1016/j.stem.2014.04.010; Mustata RC, 2013, CELL REP, V5, P421, DOI 10.1016/j.celrep.2013.09.005; Nakagawa H, 2017, P NATL ACAD SCI USA, V114, pE3806, DOI 10.1073/pnas.1619416114; NAKANUMA Y, 1994, J GASTROEN HEPATOL, V9, P75, DOI 10.1111/j.1440-1746.1994.tb01220.x; Nakanuma Y, 1997, MICROSC RES TECHNIQ, V38, P552, DOI 10.1002/(SICI)1097-0029(19970915)38:6<552::AID-JEMT2>3.0.CO;2-H; Nakanuma Y, 2016, EXPERT REV GASTROENT, V10, P113, DOI 10.1586/17474124.2016.1104246; Nakatsukasa M, 2010, AM J PATHOL, V177, P1344, DOI 10.2353/ajpath.2010.100149; Okabe M, 2009, DEVELOPMENT, V136, P1951, DOI 10.1242/dev.031369; Op den Dries S, 2014, J HEPATOL, V60, P1172, DOI 10.1016/j.jhep.2014.02.010; Sampaziotis F, 2017, NAT MED, V23, P954, DOI 10.1038/nm.4360; Sampaziotis F, 2015, NAT BIOTECHNOL, V33, P845, DOI 10.1038/nbt.3275; Stoyanova T, 2012, GENE DEV, V26, P2271, DOI 10.1101/gad.196451.112; Sutton ME, 2012, LIVER INT, V32, P554, DOI 10.1111/j.1478-3231.2011.02721.x; Tanimizu N, 2003, J CELL SCI, V116, P1775, DOI 10.1242/jcs.00388; Tanimizu N, 2014, J BIOL CHEM, V289, P7589, DOI 10.1074/jbc.M113.517243; TERADA T, 1993, HEPATOLOGY, V18, P803, DOI 10.1002/hep.1840180409; Trerotola M, 2013, ONCOGENE, V32, P222, DOI 10.1038/onc.2012.36; Tsukahara Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028607; Vallone VF, 2016, DEVELOPMENT, V143, P1452, DOI 10.1242/dev.131490; Venter J, 2015, DIGEST LIVER DIS, V47, P964, DOI 10.1016/j.dld.2015.07.012; Wang JB, 2008, MOL CANCER THER, V7, P280, DOI 10.1158/1535-7163.MCT-07-2003	37	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	SEP	2018	188	9					2059	2073		10.1016/j.ajpath.2018.05.016			15	Pathology	Pathology	GR5XP	WOS:000442715500012	30126547				2019-10-28	
J	Koral, K; Haynes, M; Bowen, WC; Orr, A; Mars, W; Michalopoulos, GK				Koral, Kelly; Haynes, Meagan; Bowen, William C.; Orr, Anne; Mars, Wendy; Michalopoulos, George K.			Lymphocyte-Specific Protein-1 Controls Sorafenib Sensitivity and Hepatocellular Proliferation through Extracellular Signal-Regulated Kinase 1/2 Activation	AMERICAN JOURNAL OF PATHOLOGY			English	Article							LEUKOCYTE-SPECIFIC PROTEIN-1; LIVER-REGENERATION; TARGETED THERAPIES; TRANSGENIC MICE; CARCINOMA; GROWTH; INHIBITION; LSP1; CYTOSKELETON; REGORAFENIB	The gene Leukocyte-specific protein-1 (LSP1), encodes an F-actin binding protein that directly interacts with the mitogen-activated protein kinase pathway. LSP1 has copy number variations in 52% of human hepatocellular carcinoma (HCC). LSP1 suppresses proliferation and migration in hepatocytes. LSP1 binds to the rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein/extracellular signal-regulated kinase (ERK)/ERK signaling cassette, the target for sorafenib, a crucial chemotherapeutic agent for HCC. This study addresses the role of LSP1 in liver regeneration and sensitivity to sorafenib in normal and neoplastic hepatocytes. Two mouse models, an Lsp1 global knockout (LSP1KO) and a hepatocyte-specific Lsp1 transgenic (LSP1TG) mouse, were used. After two-thirds hepatectomy (PHx), LSP1KO mice displayed increased proliferation and ERK activation, whereas LSP1TG mice displayed suppressed proliferation and decreased ERK activation. LSP1KO hepatocytes cultured without growth factors exhibited increased proliferation, whereas LSP1TG hepatocytes showed decreased proliferation. Rat and human hepatoma cells expressing Lsp1 shRNA displayed increased sensitivity to sorafenib, as evidenced by decreased cell numbers and phosphorylated ERK expression compared with control. LSP1 KO mice treated with sorafenib before PHx displayed decreased hepatocyte proliferation. Our data show that loss of LSP1 function, observed in HCC, leads to increased sensitivity to sorafenib treatment and enhanced hepatocellular proliferation after PHx in vivo and in cultured cells.	[Koral, Kelly; Haynes, Meagan; Bowen, William C.; Orr, Anne; Mars, Wendy; Michalopoulos, George K.] Univ Pittsburgh, Dept Pathol, Sch Med, S-410 Biomed Sci Tower,203 Lothrop St, Pittsburgh, PA 15261 USA	Michalopoulos, GK (reprint author), Univ Pittsburgh, Dept Pathol, Sch Med, S-410 Biomed Sci Tower,203 Lothrop St, Pittsburgh, PA 15261 USA.	michalopoulosgk@upmc.edu			Department of DefenseUnited States Department of Defense [CA160119]; University of Pittsburgh Menten Endowment; Cleveland Foundation Morningstar Fund	Supported by Department of Defense grant CA160119, the University of Pittsburgh Menten Endowment, and the Cleveland Foundation Morningstar Fund.	Apte U, 2009, HEPATOLOGY, V50, P844, DOI 10.1002/hep.23059; Bruix J, 2017, LANCET, V389, P56, DOI 10.1016/S0140-6736(16)32453-9; Bupathi M, 2015, MOL ONCOL, V9, P1501, DOI 10.1016/j.molonc.2015.06.005; Cao MY, 2001, J BIOL CHEM, V276, P24506, DOI 10.1074/jbc.M103883200; Carr BI, 2013, J CELL PHYSIOL, V228, P292, DOI 10.1002/jcp.24148; Cheng AL, 2012, EUR J CANCER, V48, P1452, DOI 10.1016/j.ejca.2011.12.006; GERLYNG P, 1993, CELL PROLIFERAT, V26, P557, DOI 10.1111/j.1365-2184.1993.tb00033.x; Haga S, 2010, LAB INVEST, V90, P1718, DOI 10.1038/labinvest.2010.119; Harrison RE, 2004, J CELL SCI, V117, P2151, DOI 10.1242/jcs.00955; Ittner LM, 2007, NAT PROTOC, V2, P1206, DOI 10.1038/nprot.2007.145; Jongstra-Bilen J, 2000, BLOOD, V96, P1827, DOI 10.1182/blood.V96.5.1827.h8001827_1827_1835; Jongstra-Bilen J, 2006, IMMUNOL RES, V35, P65, DOI 10.1385/IR:35:1:65; JONGSTRABILEN J, 1992, J CELL BIOL, V118, P1443, DOI 10.1083/jcb.118.6.1443; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Koral K, 2015, HEPATOLOGY, V61, P537, DOI 10.1002/hep.27444; Lathia C, 2006, CANCER CHEMOTH PHARM, V57, P685, DOI 10.1007/s00280-005-0068-6; Liu B, 2010, HEPATOLOGY, V52, P1060, DOI 10.1002/hep.23794; Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Llovet JM, 2008, HEPATOLOGY, V48, P1312, DOI 10.1002/hep.22506; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Nalesnik MA, 2012, AM J PATHOL, V180, P1495, DOI 10.1016/j.ajpath.2011.12.021; NOVICKI DL, 1983, IN VITRO CELL DEV B, V19, P191; Shaul YD, 2007, BBA-MOL CELL RES, V1773, P1213, DOI 10.1016/j.bbamcr.2006.10.005; Sonntag R, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.557; Villanueva A, 2011, GASTROENTEROLOGY, V140, P1410, DOI 10.1053/j.gastro.2011.03.006; Wang JF, 2007, J LEUKOCYTE BIOL, V82, P1554, DOI 10.1189/0507306; Zhang HY, 2016, FEBS OPEN BIO, V6, P1227, DOI 10.1002/2211-5463.12139	28	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	SEP	2018	188	9					2074	2086		10.1016/j.ajpath.2018.06.005			13	Pathology	Pathology	GR5XP	WOS:000442715500013	30126548	Bronze			2019-10-28	
J	Fan, V; Zhang, W; Ni, AG; Mahato, B; Chavala, SH				Fan, Van; Zhang, Wei; Ni, Aiguo; Mahato, Biraj; Chavala, Sai H.			Inhibition of Noncanonical Murine Double Minute 2 Homolog Abrogates Ocular Inflammation through NF-kappa B Suppression	AMERICAN JOURNAL OF PATHOLOGY			English	Article							MDM2; P53; UVEITIS; ACTIVATION; EXPRESSION; APOPTOSIS; DISEASE; CANCER; SP1	Uveitis is estimated to account for 10% of all cases of blindness in the United States, including 30,000 new cases of legal blindness each year. Intraocular and oral corticosteroids are the effective mainstay treatment, but they carry the risk of serious long-term ocular and systemic morbidity. New noncorticosteroid therapies with a favorable side effect profile are necessary for the treatment of chronic uveitis, given the paucity of existing treatment choices. We have previously demonstrated that Nutlin-3, a small-molecule inhibitor of murine double minute 2 (MDM2) homolog, suppresses pathologic retinal angiogenesis through a p53-dependent mechanism, but the noncanonical p53-independent functions have not been adequately elucidated. Herein, we demonstrate an unanticipated function of MDM2 inhibition, where Nutlin-3 potently abrogates lipopolysaccharide-induced ocular inflammation. Furthermore, we identified a mechanism by which transcription and translation of NF-kappa B is mediated by MDM2, independent of p53, in ocular inflammation. Small-molecule MDM2 inhibition is a novel noncorticosteroid strategy for inhibiting ocular inflammation, which may potentially benefit patients with chronic uveitis.	[Fan, Van; Zhang, Wei; Ni, Aiguo; Mahato, Biraj; Chavala, Sai H.] Univ North Texas Hlth Sci Ctr, Dept Pharmacol & Neurosci, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA	Chavala, SH (reprint author), Univ North Texas Hlth Sci Ctr, Dept Pharmacol & Neurosci, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA.	sai.chavala@unthsc.edu			Nancy Lee and Perry R. Bass Endowment; Foundation Fighting Blindness; National Eye InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [EY021171, EY025667]	Supported by the Nancy Lee and Perry R. Bass Endowment, the Foundation Fighting Blindness, and National Eye Institute awards EY021171 and EY025667 (S.H.C.).	Bhattacharya S, 2012, INVEST OPHTH VIS SCI, V53, P8350, DOI 10.1167/iovs.12-10495; Bhattacharya S, 2011, INVEST OPHTH VIS SCI, V52, P3368, DOI 10.1167/iovs.10-6991; Bouska A, 2008, MOL CELL BIOL, V28, P4862, DOI 10.1128/MCB.01584-07; Burgess A, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00007; Chavala SH, 2013, J CLIN INVEST, V123, P4170, DOI 10.1172/JCI67315; FORRESTER JV, 1991, LANCET, V338, P1498, DOI 10.1016/0140-6736(91)92309-P; Gritz DC, 2004, OPHTHALMOLOGY, V111, P491, DOI 10.1016/j.ophtha.2003.06.014; Gu LB, 2002, BLOOD, V99, P3367, DOI 10.1182/blood.V99.9.3367; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; Jobling Andrew I, 2002, Clin Exp Optom, V85, P61; Kawai H, 2003, MOL CELL BIOL, V23, P4939, DOI 10.1128/MCB.23.14.4939-4947.2003; Li H, 2014, CELL DEATH DIFFER, V21, P1493, DOI 10.1038/cdd.2014.69; Liu DR, 2013, ALLERGY ASTHMA CL IM, V9, DOI 10.1186/1710-1492-9-30; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Menezo V, 2005, CLIN EXP OPHTHALMOL, V33, P16, DOI 10.1111/j.1442-9071.2005.00904.x; Mulay SR, 2012, KIDNEY INT, V81, P1199, DOI 10.1038/ki.2011.482; Nussenblatt RB, 1996, J AUTOIMMUN, V9, P575, DOI 10.1006/jaut.1996.0077; Sapir-Pichhadze R, 2003, HAREFUAH, V142, P157; Sparrrow JR, 2010, CURR MOL MED, V10, P802; Thomasova D, 2012, NEOPLASIA, V14, P1097, DOI 10.1593/neo.121534; Tisato V, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0500-5; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676	23	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	SEP	2018	188	9					2087	2096		10.1016/j.ajpath.2018.05.017			10	Pathology	Pathology	GR5XP	WOS:000442715500014	30126549				2019-10-28	
J	Shimizu, H; Shimoda, M; Mochizuki, S; Miyamae, Y; Abe, H; Chijiiwa, M; Yoshida, H; Shiozawa, J; Ishijima, M; Kaneko, K; Kanaji, A; Nakamura, M; Toyama, Y; Okada, Y				Shimizu, Hidenori; Shimoda, Masayuki; Mochizuki, Satsuki; Miyamae, Yuka; Abe, Hitoshi; Chijiiwa, Miyuki; Yoshida, Hiroyuki; Shiozawa, Jun; Ishijima, Muneaki; Kaneko, Kazuo; Kanaji, Arihiko; Nakamura, Masaya; Toyama, Yoshiaki; Okada, Yasunori			Hyaluronan-Binding Protein Involved in Hyaluronan Depolymerization Is Up-Regulated and Involved in Hyaluronan Degradation in Human Osteoarthritic Cartilage	AMERICAN JOURNAL OF PATHOLOGY			English	Article							ARTICULAR CHONDROCYTES; EXPRESSION; AGGRECANASES; METABOLISM; ACTIVATION; KIAA1199; GENE; HYALURONIDASE-2; CLASSIFICATION; COLLAGENASES	Hyaluronan (HA)-binding protein involved in HA depolymerization (HYBID), also called cell migration inducing protein (CEMIP; alias KIAA1199), plays a key role in the degradation of HA in skin and arthritic synovial fibroblasts, but its functions in osteoarthritic (OA) cartilage remain elusive. Here, we investigated the expression and roles of HYBID in human OA cartilage. HYBID was highly expressed by chondrocytes in the HA-depleted area of OA cartilage, and HYBID immunoreactivity was correlated with Mankin score, the histopathologic severity of OA lesions of cartilage. Real-time quantitative PCR indicated that HYBID expression was significantly higher in OA cartilage than in control cartilage. In addition, OA chondrocytes exhibited HA-degrading activity, which was abolished by knock-down of HYBID by siRNAs. Although OA chondrocytes also expressed certain levels of hyaluronidases 1 and 2 and CD44, knock-down of these molecules exhibited negligible effects on HA degradation. Double immunostaining of HYBID and clathrin heavy chain revealed that HYBID was localized in the clathrin-coated vesicles, and HA was endocytosed within the vesicles of OA chondrocytes. Among eight factors including cytokines and growth factors examined, only tumor necrosis factor a stimulated OA chondrocytes to overexpress HYBID. These data are the first to demonstrate that HYBID is up-regulated in OA cartilage, and suggest that tumor necrosis factor alpha-stimulated HYBID plays a role in HA degradation in OA cartilage.	[Shimizu, Hidenori; Shimoda, Masayuki; Mochizuki, Satsuki; Miyamae, Yuka; Abe, Hitoshi; Chijiiwa, Miyuki; Okada, Yasunori] Keio Univ, Sch Med, Dept Pathol, Tokyo, Japan; [Shimizu, Hidenori; Kanaji, Arihiko; Nakamura, Masaya; Toyama, Yoshiaki] Keio Univ, Sch Med, Dept Orthopaed Surg, Tokyo, Japan; [Yoshida, Hiroyuki] Kao Corp, Kawasaki, Kanagawa, Japan; [Shiozawa, Jun; Ishijima, Muneaki; Kaneko, Kazuo] Juntendo Univ, Grad Sch Med, Dept Med Orthopaed & Motor Organ, Tokyo, Japan; [Shiozawa, Jun; Ishijima, Muneaki; Kaneko, Kazuo; Okada, Yasunori] Juntendo Univ, Grad Sch Med, Dept Pathophysiol Locomot & Neoplast Dis, Tokyo, Japan	Okada, Y (reprint author), Juntendo Univ, Grad Sch Med, Dept Pathophysiol Locomot & Neoplast Dis, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138241, Japan.	ya-okada@juntendo.ac.jp	Okada, Yasunori/B-5550-2014	Okada, Yasunori/0000-0001-9208-4755	Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [16H05454, 16K08719]	Supported by the Japan Society for the Promotion of Science Grants-in-aid for Scientific Research 16H05454 (Y.O.) and 16K08719 (M.S.).	Abe S, 2003, J HUM GENET, V48, P564, DOI 10.1007/s10038-003-0079-2; ALTMAN R, 1991, ARTHRITIS RHEUM, V34, P505, DOI 10.1002/art.1780340502; ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; Bau B, 2002, ARTHRITIS RHEUM, V46, P2648, DOI 10.1002/art.10531; Bourguignon LYW, 2004, J BIOL CHEM, V279, P26991, DOI 10.1074/jbc.M311838200; Chijiiwa M, 2015, ARTHRITIS RHEUMATOL, V67, P1557, DOI 10.1002/art.39078; Chow G, 2006, OSTEOARTHR CARTILAGE, V14, P849, DOI 10.1016/j.joca.2006.02.009; Csoka AB, 1999, GENOMICS, V60, P356, DOI 10.1006/geno.1999.5876; Dicker KT, 2014, ACTA BIOMATER, V10, P1558, DOI 10.1016/j.actbio.2013.12.019; Enomoto H, 2003, AM J PATHOL, V162, P171, DOI 10.1016/S0002-9440(10)63808-4; Evensen NA, 2015, ONCOTARGET, V6, P20723, DOI 10.18632/oncotarget.3978; Flannery CR, 1998, BIOCHEM BIOPH RES CO, V251, P824, DOI 10.1006/bbrc.1998.9561; Fosang AJ, 2008, NAT CLIN PRACT RHEUM, V4, P420, DOI 10.1038/ncprheum0841; Fujita Y, 2006, ARTHRITIS RHEUM-US, V54, P3233, DOI 10.1002/art.22140; Grunke M, 2006, ANN RHEUM DIS, V65, P555, DOI 10.1136/ard.2006.053272; Harada H, 2007, J BIOL CHEM, V282, P5597, DOI 10.1074/jbc.M608358200; Hascall VC, 2014, MATRIX BIOL, V35, P14, DOI 10.1016/j.matbio.2014.01.014; Hida D, 2015, MATRIX BIOL, V48, P42, DOI 10.1016/j.matbio.2015.04.002; Imai K, 1997, AM J PATHOL, V151, P245; Kalliolias GD, 2016, NAT REV RHEUMATOL, V12, P49, DOI 10.1038/nrrheum.2015.169; Kuscu C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044661; MANKIN HJ, 1971, J BONE JOINT SURG AM, VA 53, P523, DOI 10.2106/00004623-197153030-00009; MEYER LJM, 1994, J INVEST DERMATOL, V102, P385, DOI 10.1111/1523-1747.ep12371800; Michishita E, 2006, CANCER LETT, V239, P71, DOI 10.1016/j.canlet.2005.07.028; Mwale F, 2000, DEV DYNAM, V218, P648, DOI 10.1002/1097-0177(200008)218:4<648::AID-DVDY1022>3.0.CO;2-P; Nagaoka A, 2015, J BIOL CHEM, V290, P30910, DOI 10.1074/jbc.M115.673566; Nagase H, 2003, ARTHRITIS RES THER, V5, P94, DOI 10.1186/ar630; Naito S, 2007, PATHOL INT, V57, P703, DOI 10.1111/j.1440-1827.2007.02167.x; Okada Y, 2017, KELLEY FIRESTEINS TX, P106; Pratta MA, 2003, J BIOL CHEM, V278, P45539, DOI 10.1074/jbc.M303737200; Salter DM, 1996, J PATHOL, V179, P396; Shimoda M, 2017, AM J PATHOL, V187, P1162, DOI 10.1016/j.ajpath.2017.01.005; Shiomi T, 2010, PATHOL INT, V60, P477, DOI 10.1111/j.1440-1827.2010.02547.x; Shlopov BV, 1997, ARTHRITIS RHEUM-US, V40, P2065, DOI 10.1002/art.1780401120; Triggs-Raine B, 1999, P NATL ACAD SCI USA, V96, P6296, DOI 10.1073/pnas.96.11.6296; Urech DM, 2010, ANN RHEUM DIS, V69, P443, DOI 10.1136/ard.2008.105775; van der Kraan PM, 2012, OSTEOARTHR CARTILAGE, V20, P223, DOI 10.1016/j.joca.2011.12.003; Yoshida H, 2013, P NATL ACAD SCI USA, V110, P5612, DOI 10.1073/pnas.1215432110	38	4	4	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	SEP	2018	188	9					2109	2119		10.1016/j.ajpath.2018.05.012			11	Pathology	Pathology	GR5XP	WOS:000442715500016	29935163				2019-10-28	
J	Ichii, O; Nakamura, T; Horino, T; Yabuki, A; Elewa, YHA; Kon, Y				Ichii, Osamu; Nakamura, Teppei; Horino, Taro; Yabuki, Akira; Elewa, Yaser H. A.; Kon, Yasuhiro			Abnormal Morphology of Distal Tubular Epithelial Cells Is Regulated by Genetic Factors Derived from Mouse Chromosome 12	AMERICAN JOURNAL OF PATHOLOGY			English	Article							POLYCYSTIC KIDNEY-DISEASE; CYST FORMATION; MICE; NEPHRONOPHTHISIS; ASSOCIATION; MUTATIONS; MRL/MPJ; GREB1; FIBROSIS; ACIDOSIS	The distal tubule (DT) helps regulate blood pressure and electrolytes. We describe a novel, autosomal recessive, morphofunctional DT abnormality in inbred mice evident as columnar alternations and age related cystic changes. This abnormality developed in both sexes of DBA/2Cr. Similar phenotypes were observed in A/J, C3H/He, DBA/1J, and FVB/N strains, but not in AKR/N, BALB/c, or C57BL/6N strains. In DBA/2Cr, abnormal DT localized to straight and convoluted segments and showed IL-36 alpha DT injury marker expression. However, DT epithelial proliferation, examined by bromodeoxyuridine incorporation, was not remarkably altered with the progression of abnormality. Abnormal DT epithelial cells in DBA/2Cr displayed elongated primary cilia, loose intercellular adhesions, and numerous vesicles with altered localization of CD9, Na+/K+ ATPase, and E-cadherin, indicating altered cell function, adhesion, and polarity. DBA/2Cr-type D12Mit182-012Mit83 was identified as a candidate locus designated DBA/2 renal cyst (drecy). Within drecy, the gene regulated by estrogen in breast cancer protein (Greb1) transcript variant 2 was significantly up-regulated in DBA/2Cr kidney versus C57BL/6N. Greb1 localized to DT cytoplasm in C57BL/6 and to cytoplasm and nucleus in DBA/2Cr. Grebl-overexpressing M-1 kidney cells showed an altered epithelial-mesenchyme phenotype. B6.D2-(D12Mit182-D12Mit83) congenic mice carrying drecy did not show DT abnormalities, whereas DBA/2Cr x B6.02-(012Mit182-012Mit83) mice did. Identification of this novel DT abnormality regulated by a DBA/2Cr mouse chromosome 12 derived locus and additional genetic factors improve the understanding of DT pathogenesis.	[Ichii, Osamu; Nakamura, Teppei; Elewa, Yaser H. A.; Kon, Yasuhiro] Hokkaido Univ, Fac Vet Med, Dept Basic Vet Sci, Lab Anat, Sapporo, Hokkaido, Japan; [Nakamura, Teppei] Japan Food Res Labs, Chitose Lab, Sect Biol Sci, Chitose, Japan; [Horino, Taro] Kochi Univ, Kochi Med Sch, Dept Endocrinol Metab & Nephrol, Nankoku, Kochi, Japan; [Yabuki, Akira] Kagoshima Univ, Joint Fac Vet Med, Lab Clin Pathol, Kagoshima, Japan; [Elewa, Yaser H. A.] Zagazig Univ, Fac Vet Med, Dept Histol & Cytol, Zagazig, Egypt	Ichii, O (reprint author), Hokkaido Univ, Dept Basic Vet Sci, Lab Anat, Fac Vet Med,Kita Ku, Kita 18,Nishi 9, Sapporo, Hokkaido 0600818, Japan.	ichi-o@vetmed.hokudai.ac.jp		NAKAMURA, Teppei/0000-0003-3204-0245	Inamori Foundation; Kazato Research grants; JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [13J00961, 15K14873, 18H02331]	Supported in part by Inamori Foundation grants, Kazato Research grants, and JSPS KAKENHI grants 13J00961, 15K14873, and 18H02331.	Braun DA, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a028191; De Tomasi L, 2017, AM J HUM GENET, V101, P803, DOI 10.1016/j.ajhg.2017.09.026; Gurley SB, 2005, AJP REN PHYSL, V290, pF214; Hayek SS, 2017, NAT MED, V23, P945, DOI 10.1038/nm.4362; HILDEBRANDT F, 1993, AM J HUM GENET, V53, P1256; Horibe H, 2015, NEPHROLOGY, V20, P273, DOI 10.1111/nep.12381; Hucthagowder V, 2012, EUR J MED GENET, V55, P485, DOI 10.1016/j.ejmg.2012.04.003; IAKOUBOVA OA, 1995, GENOMICS, V26, P107, DOI 10.1016/0888-7543(95)80088-4; Ichii O, 2008, HISTOL HISTOPATHOL, V23, P411, DOI 10.14670/HH-23.411; Ichii O, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01346; Ichii O, 2017, AUTOIMMUNITY, V50, P114, DOI 10.1080/08916934.2016.1261831; Ichii O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027783; Ichii O, 2010, LAB INVEST, V90, P459, DOI 10.1038/labinvest.2009.148; IGARASHI T, 1994, NEPHRON, V66, P474, DOI 10.1159/000187869; Kolb RJ, 2008, FRONT BIOSCI-LANDMRK, V13, P4451, DOI 10.2741/3016; Kumar PS, 2015, J BIOMOL STRUCT DYN, V33, P2094, DOI 10.1080/07391102.2014.999704; LI JL, 1987, CANCER RES, V47, P1867; Lia SZ, 2017, GENE, V627, P176, DOI 10.1016/j.gene.2017.06.016; Mao S, 2015, RENAL FAILURE, V37, P304, DOI 10.3109/0886022X.2015.1077324; Mohammed H, 2013, CELL REP, V3, P342, DOI 10.1016/j.celrep.2013.01.010; Mozes E, 1997, CLIN IMMUNOL IMMUNOP, V85, P28, DOI 10.1006/clin.1997.4423; NAGAO S, 1991, EXP ANIM TOKYO, V40, P45, DOI 10.1538/expanim1978.40.1_45; OGBORN MR, 1991, J STEROID BIOCHEM, V39, P181, DOI 10.1016/0960-0760(91)90060-I; Olbrich H, 2003, NAT GENET, V34, P455, DOI 10.1038/ng1216; Omran H, 2001, NEPHROL DIAL TRANSPL, V16, P755, DOI 10.1093/ndt/16.4.755; Park JH, 2015, POLYCYSTIC KIDNEY DISEASE, P375; Rae JM, 2006, PROSTATE, V66, P886, DOI 10.1002/pros.20403; Sanna-Cherchi S, 2017, AM J HUM GENET, V101, P789, DOI 10.1016/j.ajhg.2017.09.018; Sasaki H, 2015, BIOMED RES-TOKYO, V36, P323, DOI 10.2220/biomedres.36.323; Sheehan S, 2007, AM J PHYSIOL-RENAL, V293, pF1649, DOI 10.1152/ajprenal.00233.2007; Sheikh-Hamad D, 2000, AM J PHYSIOL-CELL PH, V279, pC136; Shibazaki S, 2008, HUM MOL GENET, V17, P1505, DOI 10.1093/hmg/ddn039; Shiozuru D, 2016, HISTOL HISTOPATHOL, V31, P189, DOI 10:14670/HH-11-662; Slaats GG, 2016, PEDIATR NEPHROL, V31, P545, DOI 10.1007/s00467-015-3162-y; Takada D, 2018, CLIN NEPHROL, V89, P223, DOI 10.5414/CN109175; Upadhya P, 1999, GENOMICS, V58, P129, DOI 10.1006/geno.1999.5830; van den Broek FAR, 1998, LAB ANIM, V32, P206, DOI 10.1258/002367798780599929; Verghese E, 2008, NEPHROL DIAL TRANSPL, V23, P834, DOI 10.1093/ndt/gfm743; Wang L, 2008, J ANAT, V213, P79, DOI 10.1111/j.1469-7580.2008.00918.x; Wilson PD, 2011, BBA-MOL BASIS DIS, V1812, P1239, DOI 10.1016/j.bbadis.2011.05.008; Wu M, 2016, KIDNEY DIS-BASEL, V2, P128, DOI 10.1159/000444839; Yabuki A, 2003, EXP ANIM TOKYO, V52, P159, DOI 10.1538/expanim.52.159; Yu ASL, 2008, J PATHOL, V216, P120, DOI 10.1002/path.2392	43	0	0	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	SEP	2018	188	9					2120	2138		10.1016/j.ajpath.2018.05.011			19	Pathology	Pathology	GR5XP	WOS:000442715500017	29935167				2019-10-28	
J	Yang, YY				Yang, Ying-Ying			Beneficial Effects of the Peroxisome Proliferator-Activated Receptor alpha/gamma Agonist Aleglitazar on Progressive Hepatic and Splanchnic Abnormalities in Cirrhotic Rats with Portal Hypertension (vol 188, pg 1608, 2018)	AMERICAN JOURNAL OF PATHOLOGY			English	Correction											yangyy@vghtpe.gov.tw					Tsai HC, 2018, AM J PATHOL, V188, P1608, DOI 10.1016/j.ajpath.2018.03.018	1	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	SEP	2018	188	9					2139	2139		10.1016/j.ajpath.2018.06.007			1	Pathology	Pathology	GR5XP	WOS:000442715500018		Bronze			2019-10-28	
J	He, X; Pang, ZG; Zhang, XL; Lan, T; Chen, HJ; Chen, M; Yang, H; Huang, J; Chen, YH; Zhang, Z; Jing, WY; Peng, R; Zhang, HY				He, Xin; Pang, Zongguo; Zhang, Xianliang; Lan, Ting; Chen, Huijiao; Chen, Min; Yang, Hong; Huang, Juan; Chen, Yihua; Zhang, Zhang; Jing, Wenyi; Peng, Ran; Zhang, Hongying			Consistent Amplification of FRS2 and MDM2 in Low-grade Osteosarcoma A Genetic Study of 22 Cases With Clinicopathologic Analysis	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						FRS2; MDM2; low-grade osteosarcoma; low-grade central osteosarcoma; parosteal osteosarcoma	DEDIFFERENTIATED PAROSTEAL OSTEOSARCOMA; GENE AMPLIFICATION; THERAPEUTIC TARGETS; EXTRASKELETAL OSTEOSARCOMA; CONVENTIONAL OSTEOSARCOMA; DIFFERENTIAL-DIAGNOSIS; SIGNALING PATHWAY; 12Q13-15 GENES; CDK4; SEQUENCES	Low-grade osteosarcoma (LGOS) encompasses low-grade central osteosarcoma (LGCOS) and parosteal osteosarcoma (POS). LGOSs are characterized by a supernumerary ring and giant rod chromosomes containing the 12q13-15 amplicon. The fibroblast growth factor receptor substrate 2 (FRS2) gene is located close to MDM2 and CDK4. Recent studies identified consistent amplification of FRS2 gene in atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma. The aim of this study was to evaluate the frequency of FRS2 amplification and its relationship with the clinicopathologic features of LGOSs. The amplification of FRS2 and MDM2 genes were analyzed by fluorescence in situ hybridization using 22 LGOSs (3 LGCOSs, 14 classic POSs, and 5 dedifferentiated POSs) and 85 control samples of bone and soft tissue. The clinicopathologic features of the 22 LGOSs were described. Amplification of FRS2 was detected in 21/22 (95%) of the LGOSs, including 3 (100%) LGCOSs and 18 (95%) POSs. All 22 LGOSs showed MDM2 amplification (100%). The only MDM2(+)/FRS2(-) LGOS was dedifferentiated POS (the dedifferentiated component was conventional osteosarcoma). In the control group, all of the atypical lipomatous tumor/well-differentiated liposarcoma/dedifferentiated liposarcomas (DDLs) (10/10, 100%) were FRS2-amplified, whereas the remaining 75 control cases were FRS2-nonamplified. These findings indicate that the FRS2 gene is consistently amplified in classic and dedifferentiated LGOSs but not in their histologic mimics. These results offer another avenue for investigating the biology of LGOSs. Whether FRS2-nonamplified tumors exhibit unusual clinicopathologic features needs further investigation. Some so-called "high-grade osteosarcomas harboring 12q13-15 amplification" may be unrecognized dedifferentiated LGOSs.	[He, Xin; Pang, Zongguo; Zhang, Xianliang; Chen, Huijiao; Chen, Min; Zhang, Zhang; Jing, Wenyi; Peng, Ran; Zhang, Hongying] Sichuan Univ, Dept Pathol, West China Hosp, Guoxuexiang 37, Chengdu 610041, Sichuan, Peoples R China; [Lan, Ting; Yang, Hong] Univ Elect Sci & Technol China, Dept Pathol, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Chengdu, Sichuan, Peoples R China; [Chen, Yihua] Chengdu Mil Gen Hosp, Dept Pathol, Chengdu, Sichuan, Peoples R China; [Huang, Juan] Southwest Med Univ, Dept Pathol, Affiliated Hosp, Luzhou, Sichuan, Peoples R China	Zhang, HY (reprint author), Sichuan Univ, Dept Pathol, West China Hosp, Guoxuexiang 37, Chengdu 610041, Sichuan, Peoples R China.	hy_zhang@scu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81472510, 81272944]	Supported by the National Natural Science Foundation of China (No. 81472510 and 81272944). The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Bertoni F, 2005, CANCER, V103, P2373, DOI 10.1002/cncr.21039; Bousquet M, 2016, ANN ONCOL, V27, P738, DOI 10.1093/annonc/mdw009; Cardona DM, 2008, SKELETAL RADIOL, V37, P367, DOI 10.1007/s00256-007-0440-1; Dei Tos AP, 2013, WHO CLASSIFICATION T, P33; Desai A, 2016, J THORAC ONCOL, V11, P9, DOI 10.1016/j.jtho.2015.08.003; Dickson MA, 2013, J CLIN ONCOL, V31, P2024, DOI 10.1200/JCO.2012.46.5476; Duhamel LAE, 2012, HISTOPATHOLOGY, V60, P357, DOI 10.1111/j.1365-2559.2011.04023.x; Dujardin F, 2011, MODERN PATHOL, V24, P624, DOI 10.1038/modpathol.2010.229; Erickson-Johnson MR, 2009, MODERN PATHOL, V22, P1541, DOI 10.1038/modpathol.2009.149; Gamberi G, 2000, CLIN ORTHOP RELAT R, P195; Gisselsson D, 1998, GENE CHROMOSOME CANC, V23, P203, DOI 10.1002/(SICI)1098-2264(199811)23:3<203::AID-GCC1>3.0.CO;2-5; Gisselsson D, 2002, GENE CHROMOSOME CANC, V33, P133, DOI 10.1002/gcc.1219; Goldblum JR, 2013, ENZINGER WEISSS SOFT, P484; Gotoh N, 2008, CANCER SCI, V99, P1319, DOI 10.1111/j.1349-7006.2008.00840.x; Grimer R J, 2001, Sarcoma, V5, P89, DOI 10.1155/S1357714X01000172; Guerin M, 2016, HUM PATHOL, V50, P70, DOI 10.1016/j.humpath.2015.11.012; Hadari YR, 2001, P NATL ACAD SCI USA, V98, P8578, DOI 10.1073/pnas.161259898; Hanes R, 2016, ONCOTARGET, V7, P54583, DOI 10.18632/oncotarget.10518; Hang JF, 2014, ARCH PATHOL LAB MED, V138, P694, DOI 10.5858/arpa.2013-0030-RS; Hayashi K, 2014, INT J CLIN ONCOL, V19, P731, DOI 10.1007/s10147-013-0592-z; Hirose K, 2017, HISTOPATHOLOGY, V70, P1171, DOI 10.1111/his.13141; Inwards CY, 2013, WHO CLASSIFICATION T, P281; Jeon DG, 2015, J ORTHOP SCI, V20, P529, DOI 10.1007/s00776-015-0701-0; Jing WY, 2018, HISTOPATHOLOGY, V72, P1145, DOI 10.1111/his.13473; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Kyriazoglou AI, 2012, CANCER GENET-NY, V205, P332, DOI 10.1016/j.cancergen.2012.04.011; LADANYI M, 1993, CANCER RES, V53, P16; Lazar A, 2013, WHO CLASSIFICATION T, P292; Lonardo F, 1997, CANCER, V79, P1541, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1541::AID-CNCR15>3.0.CO;2-Y; Lopes MA, 2001, ORAL ONCOL, V37, P566, DOI 10.1016/S1368-8375(00)00130-5; Makise N, 2018, HISTOPATHOLOGY, V73, P147, DOI 10.1111/his.13506; Malhas A. M., 2012, Sarcoma, P764796, DOI 10.1155/2012/764796; Mejia-Guerrero S, 2010, GENE CHROMOSOME CANC, V49, P518, DOI 10.1002/gcc.20761; Muller CR, 2007, INT J CANCER, V121, P199, DOI 10.1002/ijc.22643; NAKAYAMA T, 1995, INT J CANCER, V64, P342, DOI 10.1002/ijc.2910640511; Nielsen GP, 2017, DIAGNOSTIC PATHOLOGY, P52; Sabatier R, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-645; Sato T, 2009, EXPERT OPIN THER TAR, V13, P689, DOI 10.1517/14728220902942330; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/S0092-8674(00)00114-8; Schwab JH, 2008, CLIN ORTHOP RELAT R, V466, P1318, DOI 10.1007/s11999-008-0251-2; Szymanska J, 1996, GENE CHROMOSOME CANC, V16, P31; Tabareau-Delalande F, 2015, MODERN PATHOL, V28, P48, DOI 10.1038/modpathol.2014.80; Touat M, 2015, CLIN CANCER RES, V21, P2684, DOI 10.1158/1078-0432.CCR-14-2329; Unni KK, 2005, TUMORS BONES JOINTS, P119; Unni KK, 2010, DAHLINS BONE TUMORS, P310, DOI [10.1136/jcp.2010.078501, DOI 10.1136/JCP.2010.078501]; von Baer A, 2014, PATHOL RES PRACT, V210, P698, DOI 10.1016/j.prp.2014.05.010; Wang B, 2012, ACTA BIOCH BIOPH SIN, V44, P685, DOI 10.1093/abbs/gms053; Wang XK, 2011, GENE CHROMOSOME CANC, V50, P849, DOI 10.1002/gcc.20906; Ware PL, 2014, AM J CLIN PATHOL, V141, P334, DOI 10.1309/AJCPLYU89XHSNHQO; Weaver J, 2008, MODERN PATHOL, V21, P943, DOI 10.1038/modpathol.2008.84; Wei G, 1999, INT J CANCER, V80, P199, DOI 10.1002/(SICI)1097-0215(19990118)80:2<199::AID-IJC7>3.0.CO;2-4; Wunder JS, 1999, ONCOGENE, V18, P783, DOI 10.1038/sj.onc.1202346; Yamashita K, 2018, HISTOPATHOLOGY, V72, P729, DOI 10.1111/his.13421; Yamashita Kyoko, 2017, Hum Pathol, V63, P63, DOI 10.1016/j.humpath.2017.02.007; Yashiro M, 2016, WORLD J GASTROENTERO, V22, P2415, DOI 10.3748/wjg.v22.i8.2415; Yokoyama R, 1998, PATHOL RES PRACT, V194, P615, DOI 10.1016/S0344-0338(98)80096-4; Yoshida A, 2012, AM J SURG PATHOL, V36, P423, DOI 10.1097/PAS.0b013e31824230d0; Yoshida A, 2010, MODERN PATHOL, V23, P1279, DOI 10.1038/modpathol.2010.124; Zhang HY, 2010, AM J SURG PATHOL, V34, P1304, DOI 10.1097/PAS.0b013e3181e92d0b; Zhang KQ, 2013, CANCER RES, V73, P1298, DOI 10.1158/0008-5472.CAN-12-2086; Zhou WY, 2016, CANCER BIOL MED, V13, P260, DOI 10.20892/j.issn.2095-3941.2015.0102; Zhou WC, 2009, CELL RES, V19, P1165, DOI 10.1038/cr.2009.95	62	3	3	1	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	SEP	2018	42	9					1143	1155		10.1097/PAS.0000000000001125			13	Pathology; Surgery	Pathology; Surgery	GR3QM	WOS:000442509200003	30001240				2019-10-28	
J	Przybycin, CG; Harper, HL; Reynolds, JP; Magi-Galluzzi, C; Nguyen, JK; Wu, A; Sangoi, AR; Liu, PS; Umar, S; Mehra, R; Zhang, XC; Cox, RM; McKenney, JK				Przybycin, Christopher G.; Harper, Holly L.; Reynolds, Jordan P.; Magi-Galluzzi, Cristina; Nguyen, Jane K.; Wu, Angela; Sangoi, Ankur R.; Liu, Peter S.; Umar, Saleem; Mehra, Rohit; Zhang, Xiaochun; Cox, Roni M.; McKenney, Jesse K.			Acquired Cystic Disease-associated Renal Cell Carcinoma (ACD-RCC) A Multiinstitutional Study of 40 Cases With Clinical Follow-up	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						renal cell carcinoma; acquired cystic disease; end-stage renal disease	IN-SITU HYBRIDIZATION; KIDNEY-DISEASE; HEREDITARY LEIOMYOMATOSIS; HEMODIALYSIS-PATIENTS; DIALYSIS; TUMORS; NEOPLASIA; SPECTRUM; DURATION; OXALOSIS	The incidence of renal cell carcinoma (RCC) is known to be higher in patients with end-stage renal disease, including those with acquired cystic kidney disease due to dialysis. Acquired cystic disease (ACD)-associated RCC was recently incorporated into the 2016 WHO Classification of Tumors of the Urinary System and Male Genital Tract as a distinct entity and is reportedly the most common RCC arising in end-stage renal disease. In this study, we sought to further describe clinicopathologic findings in a large series of ACD-RCC, emphasizing histologic features, immunophenotype, clinical outcome, and patterns of disease spread. We collected 40 previously unpublished cases of ACD-RCC with mean clinical follow-up of 27 months (median, 19mo; range, 1 to 126 mo). Mean tumor size was 2.7 cm (median, 2.4 cm), and 32 tumors (80%) were confined to the kidney (pT stage less than pT3a). International Society of Urological Pathology grade was 3 in 37 cases (92.5%), grade 2 in 1 case (2.5%), and grade 4 in 2 cases (5%). Architectural variability among ACD-RCC was common, as 39 cases (98%) showed varying combinations of tubular, cystic, solid, and/or papillary growth. ACD-RCC frequently occurred in association with other renal tumor subtypes within the same kidney, including papillary RCC (14 patients), papillary adenomas (7 cases), clear cell papillary RCC (5 cases), clear cell RCC (1 case), and RCC, unclassified type (1 case). A previously undescribed pattern of perinephric and renal sinus adipose tissue involvement by dilated epithelial cysts with minimal or absent intervening capsule or renal parenchyma was identified in 20 cases (50%); these cysts were part of the tumor itself in 5 cases (25%) and were part of the non-neoplastic acquired cystic change in the background kidney in the remaining 15 cases (75%). Of the 24 cases (60%) with tissue available for immunohistochemical stains, 19 (79%) were positive for PAX8, 20 (83%) showed negative to patchy expression of cytokeratin 7, and 24 (100%) were both positive for AMACR and negative for CD117. Fumarate hydratase expression was retained in all tumors, including those with nuclear features resembling fumarate hydratase-deficient RCCs. Of the 36 patients (90%) with available follow-up information, 4 (11%) experienced adverse events: 2 patients developed a local recurrence, 1 patient experienced multiple visceral metastases and subsequently died of disease, and 1 patient developed metastases to regional lymph nodes only. One local recurrence and the lymph node only metastasis both had an unusual, exclusively cystic pattern of growth. In summary, we present the largest clinicopathologic series of ACD-RCC to date and describe previously unreported cystic patterns of local soft tissue involvement and recurrence/metastases.	[Przybycin, Christopher G.; Reynolds, Jordan P.; Magi-Galluzzi, Cristina; Zhang, Xiaochun; Cox, Roni M.; McKenney, Jesse K.] Cleveland Clin, Robert J Tomsich Pathol & Lab, Inst Med, Cleveland, OH 44106 USA; [Harper, Holly L.] Univ Hosp Cleveland, Med Ctr, Dept Pathol, Cleveland, OH 44106 USA; [Liu, Peter S.] Cleveland Clin, Imaging Inst, Cleveland, OH 44106 USA; [Nguyen, Jane K.] MetroHlth Med Ctr, Cleveland, OH USA; [Wu, Angela; Mehra, Rohit] Univ Michigan Hlth Syst, Dept Pathol, Ann Arbor, MI USA; [Sangoi, Ankur R.] El Camino Hosp, Dept Pathol, 2500 Grant Rd, Mountain View, CA 94040 USA; [Umar, Saleem] Bethesda Mem Hosp, Dept Pathol, Boynton Beach, FL USA	Przybycin, CG (reprint author), Cleveland Clin, Dept Pathol, 9500 Euclid Ave,L25, Cleveland, OH 44195 USA.	przybyc@ccf.org					BRETAN PN, 1986, CANCER, V57, P1871, DOI 10.1002/1097-0142(19860501)57:9<1871::AID-CNCR2820570929>3.0.CO;2-3; Cheuk W, 2002, HUM PATHOL, V33, P761, DOI 10.1053/hupa.2002.125370; Cossu-Rocca P, 2006, MODERN PATHOL, V19, P780, DOI 10.1038/modpathol.3800604; Denton MD, 2002, KIDNEY INT, V61, P2201, DOI 10.1046/j.1523-1755.2002.00374.x; FAYEMI AO, 1979, ARCH PATHOL LAB MED, V103, P58; Goh A, 2011, AM J TRANSPLANT, V11, P86, DOI 10.1111/j.1600-6143.2010.03303.x; Hes O, 2008, VIRCHOWS ARCH, V453, P313, DOI 10.1007/s00428-008-0661-2; Hosseini M, 2014, HUM PATHOL, V45, P1406, DOI 10.1016/j.humpath.2014.02.014; HUGHSON MD, 1980, LAB INVEST, V42, P475; HUGHSON MD, 1986, ARCH PATHOL LAB MED, V110, P592; ISHIKAWA I, 1990, AM J KIDNEY DIS, V16, P452, DOI 10.1016/S0272-6386(12)80058-8; ISHIKAWA I, 1993, HISTOPATHOLOGY, V22, P135, DOI 10.1111/j.1365-2559.1993.tb00091.x; Kuroda N, 2011, MED MOL MORPHOL, V44, P228, DOI 10.1007/s00795-010-0496-1; Kuroda N, 2011, ANN DIAGN PATHOL, V15, P282, DOI 10.1016/j.anndiagpath.2010.03.007; Merino MJ, 2007, AM J SURG PATHOL, V31, P1578, DOI 10.1097/PAS.0b013e31804375b8; Moch H, 2016, WHO CLASSIFICATION T; Nishihara K, 2008, INT J UROL, V15, P543, DOI 10.1111/j.1442-2042.2008.02039.x; Nouh MAAM, 2010, BJU INT, V105, P620, DOI 10.1111/j.1464-410X.2009.08817.x; POPE JC, 1994, UROLOGY, V44, P497, DOI 10.1016/S0090-4295(94)80046-4; Rioux-Leclercq Nathalie C, 2003, Arch Pathol Lab Med, V127, pE89; SALYER WR, 1973, KIDNEY INT, V4, P61, DOI 10.1038/ki.1973.80; Srigley JR, 2013, AM J SURG PATHOL, V37, P1469, DOI 10.1097/PAS.0b013e318299f2d1; Sule N, 2005, AM J SURG PATHOL, V29, P443, DOI 10.1097/01.pas.0000152131.58492.97; Tickoo SK, 2006, AM J SURG PATHOL, V30, P141, DOI 10.1097/01.pas.0000185382.80844.b1; Trpkov K, 2016, AM J SURG PATHOL, V40, P865, DOI 10.1097/PAS.0000000000000617; TURANI H, 1983, ISRAEL J MED SCI, V19, P614	26	2	2	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	SEP	2018	42	9					1156	1165		10.1097/PAS.0000000000001091			10	Pathology; Surgery	Pathology; Surgery	GR3QM	WOS:000442509200004	29851703				2019-10-28	
J	Palsgrove, DN; Li, YJ; Pratilas, CA; Lin, MT; Pallavajjalla, A; Gocke, C; De Marzo, AM; Matoso, A; Netto, GJ; Epstein, JI; Argani, P				Palsgrove, Doreen N.; Li, Yunjie; Pratilas, Christine A.; Lin, Ming-Tseh; Pallavajjalla, Aparna; Gocke, Christopher; De Marzo, Angelo M.; Matoso, Andres; Netto, George J.; Epstein, Jonathan I.; Argani, Pedram			Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations Molecular Analysis Supports an Expanding Clinicopathologic Spectrum	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						pediatric; renal cell carcinoma; TSC; eosinophilic solid and cystic RCC	TUBEROUS SCLEROSIS COMPLEX; CATHEPSIN-K EXPRESSION; TRANSLOCATION CARCINOMAS; GERMLINE MUTATIONS; UNRELATED PATIENTS; GENE; NEOPLASMS; NEUROBLASTOMA; EVEROLIMUS; KIDNEY	Eosinophilic solid and cystic (ESC) renal cell carcinoma (RCC) has recently been described as a potentially new subtype of RCC based upon morphologic and immunohistochemical features. These neoplasms typically demonstrate solid and cystic architecture, and the neoplastic cells contain voluminous eosinophilic cytoplasm with granular cytoplasmic stippling. There is frequently focal immunoreactivity for cytokeratin 20. Although the initial cases all occurred in adult females and had benign outcome, we recently expanded the proposed spectrum of this neoplasm to include pediatric cases, multifocal neoplasms, and a case with hematogenous metastasis. ESC has been postulated to be analogous to a subtype of RCC consistently identified in tuberous sclerosis complex patients, and while previous work has demonstrated loss of heterozygosity at the TSC1 locus and copy number gains at TSC2 in ESC RCC, these genes have not been sequenced in ESC RCC. Using capture-based and amplicon-based next-generation sequencing, we now demonstrate the consistent presence of either TSC1 or TSC2 gene mutations in pediatric ESC RCC (8/9 cases) and adult ESC RCC (6/6 cases). These included a metastatic ESC RCC which had a complete response to mTOR targeted therapy. We also found these mutations in some neoplasms with variant morphology and thus potentially expand the spectrum of ESC RCC. These include one of our adult cases which demonstrated dominant "type 2" papillary RCC morphology and 2 of 3 previously unclassified pediatric RCC with features of ESC RCC minus granular cytoplasmic stippling. We also demonstrate TSC mutations in a case of so-called oncocytoid RCC after neuroblastoma with identical morphology and immunoprofile, providing a molecular link between the latter and ESC RCC. In summary, ESC RCC consistently harbors actionable TSC1 or TSC2 mutations, which are infrequently seen in established subtypes of RCC. These findings support TSC1/2 mutation as a molecular marker of ESC RCC, and suggest expansion of the clinicopathologic spectrum to include neoplasms with papillary architecture, occasional cases lacking well-developed granular cytoplasmic stippling, and a subset of RCC with oncocytic features in patients who have survived neuroblastoma.	[Palsgrove, Doreen N.; Li, Yunjie; Pratilas, Christine A.; Lin, Ming-Tseh; Pallavajjalla, Aparna; Gocke, Christopher; De Marzo, Angelo M.; Matoso, Andres; Netto, George J.; Epstein, Jonathan I.; Argani, Pedram] Johns Hopkins Univ, Sch Med Pathol & Oncol, Baltimore, MD USA; [Netto, George J.] Univ Alabama Birmingham, Sch Med, Pathol, Birmingham, AL USA	Argani, P (reprint author), Johns Hopkins Univ Hosp, Surg Pathol, Weinberg Bldg,Room 2242,401 N Broadway, Baltimore, MD 21231 USA.	pargani@jhmi.edu			National Institutes of Health GrantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5T32CA193145-02]; Gary Hill Award; Joey's Wings; Dahan Translocation Carcinoma Fund	Supported in part by the National Institutes of Health Grant 5T32CA193145-02 (D.N.P.), the Gary Hill Award (Y.L.), Joey's Wings (P.A.), and Dahan Translocation Carcinoma Fund (P.A.). The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	An KS, 2007, GENET MED, V9, P88, DOI 10.1097/GIM.0b013e31803068c7; Andre F, 2017, CANCER DISCOV, V7, P818, DOI 10.1158/2159-8290.CD-17-0151; Argani P, 2006, J CLIN ONCOL, V24, P1529, DOI 10.1200/JCO.2005.04.4693; Beauchamp RL, 1998, HUM MUTAT, V12, P408, DOI 10.1002/(SICI)1098-1004(1998)12:6<408::AID-HUMU7>3.0.CO;2-P; Bessis D, 2018, BRIT J DERMATOL, V178, pE53, DOI 10.1111/bjd.15868; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen YB, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13131; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Crino PB, 2006, NEW ENGL J MED, V355, P1345, DOI 10.1056/NEJMra055323; Dabora SL, 1998, ANN HUM GENET, V62, P491, DOI 10.1046/j.1469-1809.1998.6260491.x; Dabora SL, 2001, AM J HUM GENET, V68, P64, DOI 10.1086/316951; Davis CF, 2014, CANCER CELL, V26, P319, DOI 10.1016/j.ccr.2014.07.014; Durinck S, 2015, NAT GENET, V47, P13, DOI 10.1038/ng.3146; Falzarano SM, 2016, AM J SURG PATHOL, V40, P989, DOI 10.1097/PAS.0000000000000632; Flader M, 2017, CURR ONCOL, V24, pE423, DOI 10.3747/co.24.3555; Fokkema IFAC, 2011, HUM MUTAT, V32, P557, DOI 10.1002/humu.21438; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gerlinger M, 2014, NAT GENET, V46, P225, DOI 10.1038/ng.2891; Guo GW, 2012, NAT GENET, V44, P17, DOI 10.1038/ng.1014; Guo J, 2014, AM J SURG PATHOL, V38, P1457, DOI 10.1097/PAS.0000000000000248; Hung CC, 2006, BMC MED GENET, V7, DOI 10.1186/1471-2350-7-72; Ismail NFD, 2017, J MOL DIAGN, V19, P265, DOI 10.1016/j.jmoldx.2016.10.009; Kneissel M, 2004, BONE, V35, P1144, DOI 10.1016/j.bone.2004.07.013; Kwiatkowski DJ, 2015, EUR J HUM GENET, V23, P1665, DOI 10.1038/ejhg.2015.47; Li YJ, 2018, HISTOPATHOLOGY, V72, P588, DOI 10.1111/his.13395; Martignoni G, 2009, MODERN PATHOL, V22, P1016, DOI 10.1038/modpathol.2009.58; Martignoni G, 2012, MODERN PATHOL, V25, P100, DOI 10.1038/modpathol.2011.136; Martignoni G, 2011, MODERN PATHOL, V24, P1313, DOI 10.1038/modpathol.2011.93; Martignoni G, 2010, ARCH PATHOL LAB MED, V134, P33, DOI 10.1043/2008-0542-RAR1.1; McKenney JK, 2018, HISTOPATHOLOGY, V72, P1066, DOI 10.1111/his.13457; Medeiros LJ, 1999, AM J SURG PATHOL, V23, P772, DOI 10.1097/00000478-199907000-00004; Medendorp K, 2007, CYTOGENET GENOME RES, V118, P157, DOI 10.1159/000108296; Moch H, 2016, WHO CLASSIFICATION T; Niida Y, 1999, HUM MUTAT, V14, P412, DOI 10.1002/(SICI)1098-1004(199911)14:5<412::AID-HUMU7>3.0.CO;2-K; Peron A, 2016, AM J MED GENET A, V170, P1538, DOI 10.1002/ajmg.a.37644; Sancak O, 2005, EUR J HUM GENET, V13, P731, DOI 10.1038/sj.ejhg.5201402; Sato Y, 2013, NAT GENET, V45, P860, DOI 10.1038/ng.2699; Trpkov K, 2017, AM J SURG PATHOL, V41, P1299, DOI 10.1097/PAS.0000000000000838; Trpkov K, 2016, AM J SURG PATHOL, V40, P60, DOI 10.1097/PAS.0000000000000508; Tsai TS, 2011, GENET TEST MOL BIOMA, V15, P415, DOI 10.1089/gtmb.2010.0133; vanSlegtenhorst M, 1997, SCIENCE, V277, P805; Yang P, 2014, AM J SURG PATHOL, V38, P895, DOI 10.1097/PAS.0000000000000237; Young JM, 1998, ANN HUM GENET, V62, P203, DOI 10.1046/j.1469-1809.1998.6230203.x	43	7	7	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	SEP	2018	42	9					1166	1181		10.1097/PAS.0000000000001111			16	Pathology; Surgery	Pathology; Surgery	GR3QM	WOS:000442509200005	29975249	Green Accepted			2019-10-28	
J	Chapman, E; Skalova, A; Ptakova, N; Martinek, P; Goytain, A; Tucker, T; Xiong, W; Leader, M; Kudlow, BA; Haimes, JD; Hayes, MM; Bohus, P; Miesbauerova, M; Lee, CH; Ng, TL				Chapman, Erin; Skalova, Alena; Ptakova, Nikola; Martinek, Petr; Goytain, Angela; Tucker, Tracy; Xiong, Wei; Leader, Mary; Kudlow, Brian A.; Haimes, Josh D.; Hayes, Malcolm M.; Bohus, Peter; Miesbauerova, Marketa; Lee, Cheng-Han; Ng, Tony L.			Molecular Profiling of Hyalinizing Clear Cell Carcinomas Revealed a Subset of Tumors Harboring a Novel EWSR1-CREM Fusion Report of 3 Cases	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article; Proceedings Paper	16th Annual Spring Seminar of the Korean-Pathologists-Association-of-North-America (KOPANA) held in conjunction with the 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP)	MAR 02-10, 2017	San Antonio, TX	Korean Pathologists Assoc N Amer, US & Canadian Acad Pathol		salivary; hyalinizing clear cell carcinoma; EWSR1-CREM fusion transcript	GENE REARRANGEMENT; EWSR1-ATF1 FUSION; SALIVARY-GLAND; SOFT-TISSUE; SARCOMA; HEAD; CREB	We describe a novel gene fusion, EWSR1-CREM, identified in 3 cases of clear cell carcinoma (CCC) using anchored multiplex polymerase chain reaction, a next-generation sequencing-based technique. CCC is a low-grade salivary tumor recently characterized to have EWSR1-ATF1 fusions in the majority of cases. Three cases of malignant tumor presenting in the base of tongue, lung, and nasopharynx were studied. All cases shared a clear cell morphology with hyalinized stroma, presence of mucin and p63 positivity and were initially diagnosed as mucoepidermoid carcinoma but were negative for evidence of any of the expected gene fusions. Anchored multiplex polymerase chain reaction demonstrated a EWSR1-CREM fusion in all 3 cases to confirm a diagnosis of CCC. This finding is biologically justified as CREM and ATF1 both belong to the CREB family of transcription factors. EWSR1-CREM fusions have not been previously reported in CCC and have only rarely been reported in other tumors. We show that the ability to discover novel gene variants with next-generation sequencing-based assays has clinical utility in the pathologic classification of fusion gene-associated tumors.	[Chapman, Erin; Goytain, Angela; Hayes, Malcolm M.; Lee, Cheng-Han; Ng, Tony L.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada; [Tucker, Tracy; Hayes, Malcolm M.; Lee, Cheng-Han; Ng, Tony L.] BC Canc Agcy, Vancouver, BC, Canada; [Ng, Tony L.] Vancouver Gen Hosp, Dept Anat Pathol, 910 W 10th Ave, Vancouver, BC V5Z 1M9, Canada; [Xiong, Wei] St Pauls Hosp, Anat Pathol, Vancouver, BC, Canada; [Leader, Mary] Beaumont Hosp, Dept Pathol, Dublin, Ireland; [Leader, Mary] Royal Coll Surg, Dublin, Ireland; [Kudlow, Brian A.; Haimes, Josh D.] ArcherDX Inc, Boulder, CO USA; [Skalova, Alena; Miesbauerova, Marketa] Charles Univ Prague, Dept Pathol, Fac Med Plzen, Plzen, Czech Republic; [Skalova, Alena; Miesbauerova, Marketa] CO Biopt Lab Ltd, Plzen, Czech Republic; [Ptakova, Nikola; Martinek, Petr] Czech Republ Biopt Lab Ltd, Mol Pathol Lab, Plzen, Czech Republic; [Bohus, Peter] Czech Republ Medicyt Ltd, Kosice, Slovakia	Ng, TL (reprint author), Vancouver Gen Hosp, Dept Anat Pathol, 910 W 10th Ave, Vancouver, BC V5Z 1M9, Canada.	tony.ng@vch.ca					Altarejos JY, 2011, NAT REV MOL CELL BIO, V12, P141, DOI 10.1038/nrm3072; Amatu A, 2015, BRIT J CANCER, V113, P1730, DOI 10.1038/bjc.2015.401; Antonescu CR, 2014, PATHOLOGY, V46, P105, DOI 10.1097/PAT.0000000000000049; Antonescu CR, 2011, GENE CHROMOSOME CANC, V50, P559, DOI 10.1002/gcc.20881; Badar T, 2017, APPL IMMUNOHISTOCHEM; Bale TA, 2018, BRAIN PATHOL, V28, P183, DOI 10.1111/bpa.12504; Bilodeau EA, 2013, AM J SURG PATHOL, V37, P1001, DOI 10.1097/PAS.0b013e31828a6727; Saenz CC, 2014, INT J SURG PATHOL, V22, P667, DOI 10.1177/1066896914526778; Coindre JM, 2006, CANCER, V107, P1055, DOI 10.1002/cncr.22099; De Cesare D, 2000, PROG NUCLEIC ACID RE, V64, P343, DOI 10.1016/S0079-6603(00)64009-6; Giacomini CP, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003464; Hsieh MS, 2017, HUM PATHOL, V61, P9, DOI 10.1016/j.humpath.2016.06.029; Jain A, 2016, J CLIN DIAGN RES, V10, pZE18, DOI 10.7860/JCDR/2016/14394.7867; Jin RY, 2012, HEAD NECK PATHOL, V6, P389, DOI 10.1007/s12105-012-0338-7; Kao YC, 2017, AM J SURG PATHOL, V41, P482, DOI 10.1097/PAS.0000000000000788; Li XD, 2016, HISTOPATHOLOGY, V69, P551, DOI 10.1111/his.12966; Loyola AM, 2015, OR SURG OR MED OR PA, V120, P483, DOI 10.1016/j.oooo.2015.06.005; Nakano T, 2015, VIRCHOWS ARCH, V466, P37, DOI 10.1007/s00428-014-1676-5; Patel RM, 2005, MODERN PATHOL, V18, P1585, DOI 10.1038/modpathol.3800503; Said-Al-Naief N, 2008, HEAD NECK PATHOL, V2, P111, DOI 10.1007/s12105-008-0052-7; Shah AA, 2013, AM J SURG PATHOL, V37, P571, DOI 10.1097/PAS.0b013e3182772a15; Simpson RHW, 2014, VIRCHOWS ARCH, V465, P371, DOI 10.1007/s00428-014-1639-x; Skalova A, 2017, AM J SURG PATHOL, V42, pe11; Skalova A, 2017, MODERN PATHOL, V30, pS27, DOI 10.1038/modpathol.2016.167; Skalova A, 2015, AM J SURG PATHOL, V39, P338, DOI 10.1097/PAS.0000000000000364; Tanguay J, 2013, HEAD NECK PATHOL, V7, P28, DOI 10.1007/s12105-013-0427-2; Taylor BS, 2011, NAT REV CANCER, V11, P541, DOI 10.1038/nrc3087; Thway K, 2012, AM J SURG PATHOL, V36, pE1, DOI 10.1097/PAS.0b013e31825485c5; Weinreb I, 2013, HEAD NECK PATHOL, V7, pS20, DOI 10.1007/s12105-013-0466-8; Yamashita K, 2009, ORAL SURG ORAL MED O, V107, P819, DOI 10.1016/j.tripleo.2009.01.034; Zheng ZL, 2014, NAT MED, V20, P1479, DOI 10.1038/nm.3729	31	2	3	2	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	SEP	2018	42	9					1182	1189		10.1097/PAS.0000000000001114			8	Pathology; Surgery	Pathology; Surgery	GR3QM	WOS:000442509200006	29975250				2019-10-28	
J	Marchio, C; Dell'Orto, P; Annaratone, L; Geyer, FC; Venesio, T; Berrino, E; di Cantogno, LV; Garofoli, A; Rangel, N; Casorzo, L; dell'Aglio, C; Gugliotta, P; Trisolini, E; Beano, A; Pietribiasi, F; Orlassino, R; Cassoni, P; Pich, A; Montemurro, F; Mottolese, M; Vincent-Salomon, A; Penault-Llorca, F; Medico, E; Ng, CK; Viale, G; Sapino, A				Marchio, Caterina; Dell'Orto, Patrizia; Annaratone, Laura; Geyer, Felipe C.; Venesio, Tiziana; Berrino, Enrico; di Cantogno, Ludovica Verdun; Garofoli, Andrea; Rangel, Nelson; Casorzo, Laura; dell'Aglio, Carmine; Gugliotta, Patrizia; Trisolini, Elena; Beano, Alessandra; Pietribiasi, Francesca; Orlassino, Renzo; Cassoni, Paola; Pich, Achille; Montemurro, Filippo; Mottolese, Marcella; Vincent-Salomon, Anne; Penault-Llorca, Frederique; Medico, Enzo; Ng, Charlotte K. Y.; Viale, Giuseppe; Sapino, Anna			The Dilemma of HER2 Double-equivocal Breast Carcinomas Genomic Profiling and Implications for Treatment	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						breast carcinoma; HER2; equivocal result; molecular subtype; risk of recurrence; mutations	IN-SITU HYBRIDIZATION; CHROMOSOME-17 CENTROMERE; NEOADJUVANT CHEMOTHERAPY; DISTANT RECURRENCE; AMERICAN SOCIETY; COPY NUMBER; PAM50 RISK; CANCER; FISH; AGTR1	The American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) 2013 guidelines for HER2 assessment have increased the number of HER2 equivocal breast carcinomas following in situ hybridization reflex testing, that is, HER2 "double equivocal" (equivocal protein expression and equivocal gene copy number). Forty-five double-equivocal carcinomas were subjected to Prosigna analysis. Twenty-seven cases were investigated for the expression of genes found to be differentially expressed between estrogen receptor (ER)-positive/HER2-positive (N=22) and ER-positive/HER2-negative (N=22) control cases. Twenty-nine of the 45 cases were also analyzed by targeted sequencing using a panel of 14 genes. We then explored the pathologic complete response rates in an independent series of double-equivocal carcinoma patients treated with trastuzumab-containing chemotherapy. All cases were ER-positive, with a mean Ki67 of 28%. Double-equivocal carcinomas were predominantly luminal B (76%); 9 cases (20%) were luminal A, and 2 cases (4%) HER2-enriched. The majority (73%) showed a high risk of recurrence by Prosigna, even when the carcinomas were small (<2 cm), node-negative/micrometastatic, and/or grade 2. Double-equivocal carcinomas showed TP53 (6/29, 20%), PIK3CA (3/29, 10%), HER2 (1/29, 3%), and MAP2K4 (1/29, 3%) mutations. Compared with grade-matched ER-positive/HER2-negative breast carcinomas from METABRIC, double-equivocal carcinomas harbored more frequently TP53 mutations and less frequently PIK3CA mutations (P<0.05). No significant differences were observed with grade-matched ER-positive/HER2-positive carcinomas. Lower pathologic complete response rates were observed in double-equivocal compared with HER2-positive patients (10% vs. 60%, P=0.009). Double-equivocal carcinomas are preferentially luminal B and show a high risk of recurrence. A subset of these tumors can be labeled as HER2-enriched by transcriptomic analysis. HER2 mutations can be identified in HER2 double-equivocal cases.	[Marchio, Caterina; Annaratone, Laura; Gugliotta, Patrizia; Trisolini, Elena; Cassoni, Paola; Sapino, Anna] Univ Turin, Dept Med Sci, Via Verdi 8, I-10100 Turin, Italy; [Pich, Achille] Univ Turin, Dept Mol Biotechnol, Turin, Italy; [Pich, Achille] Univ Turin, Dept Hlth Sci, Turin, Italy; [Medico, Enzo] Univ Turin, Dept Oncol, Turin, Italy; [di Cantogno, Ludovica Verdun] Univ Hosp Citta Salute & Sci Torino, Pathol Unit, Turin, Italy; [Beano, Alessandra] Univ Hosp Citta Salute & Sci Torino, Oncol Unit, Turin, Italy; [Orlassino, Renzo] Ivrea Community Hosp SL TO4, Dept Pathol, Turin, Italy; [Dell'Orto, Patrizia] Univ Milan, Dept Pathol, European Inst Oncol, Milan, Italy; [Viale, Giuseppe] Univ Milan, Dept Oncol & Oncohematol, Milan, Italy; [Venesio, Tiziana; Berrino, Enrico; Casorzo, Laura; dell'Aglio, Carmine; Medico, Enzo; Sapino, Anna] IRCCS, FPO, Candiolo Canc Inst, Candiolo, Italy; [Montemurro, Filippo] IRCCS, Investigat Clin Oncol, FPO, Candiolo Canc Inst, Candiolo, Italy; [Pietribiasi, Francesca] Santa Croce Hosp, Div Pathol, Moncalieri, Italy; [Mottolese, Marcella] Regina Elena Inst Canc Res, Dept Pathol, Rome, Italy; [Marchio, Caterina; Vincent-Salomon, Anne] Inst Curie, Pathol Genet Immunol Dept, Paris, France; [Penault-Llorca, Frederique] Jean Perrin Ctr, Clermont Ferrand, France; [Penault-Llorca, Frederique] Univ Auvergne, UMR U1240, INSERM, Clermont Ferrand, France; [Geyer, Felipe C.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA; [Garofoli, Andrea; Ng, Charlotte K. Y.] Univ Hosp Basel, Inst Pathol, Basel, Switzerland; [Rangel, Nelson] Univ Rosario, Nat & Math Sci Fac, Bogota, Colombia; [Marchio, Caterina] IRCCS, Pathol Unit, Candiolo Canc Inst, FPO, Candiolo, Italy; [Trisolini, Elena] Univ Piemonte Orientale, Dept Hlth Sci, Novara, Italy	Marchio, C (reprint author), Univ Turin, Dept Med Sci, Via Verdi 8, I-10100 Turin, Italy.	caterina.marchio@unito.it	Annaratone, Laura/J-9261-2016; Montemurro, Filippo/AAC-1957-2019; Trisolini, Elena/J-2698-2017	Annaratone, Laura/0000-0001-5750-1445; CASORZO, LAURA/0000-0002-2509-7369; Venesio, Tiziana/0000-0002-9035-056X; DELL'AGLIO, CARMINE/0000-0003-2089-1077; Berrino, Enrico/0000-0001-6728-5619; Trisolini, Elena/0000-0003-0919-3630	Italian Ministry of Education, University and Research (MIUR)Ministero dell' Istruzione, dell' Universita e della Ricerca (MIUR) [2015HAJH8E]; AIRC-Associazione Italiana per la Ricerca sul CancroAssociazione Italiana per la Ricerca sul Cancro (AIRC) [MFAG13310]; 5xMille Ministero Salute; FPRC onlus AIRC 5xMille Molecular Clinical Oncology Extension programAssociazione Italiana per la Ricerca sul Cancro (AIRC) [9970]; MIUR project "Dipartimenti di Eccellenza"; Fondazione Umberto VeronesiFondazione Umberto Veronesi; Colciencias Scholarship [617]; FPRC (onlus) 5 X 1000 Ministero della Salute	Supported by the Italian Ministry of Education, University and Research (MIUR ex-60%-2015 and 2015HAJH8E) to C.M., AIRC-Associazione Italiana per la Ricerca sul Cancro (MFAG13310) to C.M., 5xMille Ministero Salute 2011 and FPRC onlus AIRC 5xMille Molecular Clinical Oncology Extension program-Ref 9970 to A.S. This research also received funding by MIUR project "Dipartimenti di Eccellenza 2018-2022." L.A. is funded by Fondazione Umberto Veronesi (Post-Doctoral Fellowship 2018). N.R. is the recipient of a Colciencias Scholarship (Grant No. 617). F.M. is supported in part by FPRC (onlus) 5 X 1000 Ministero della Salute 2013. The remaining authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Anderson WF, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju165; Ateeq B, 2009, CELL CYCLE, V8, P3794, DOI 10.4161/cc.8.23.9976; Ballard M, 2017, MODERN PATHOL, V30, P227, DOI 10.1038/modpathol.2016.175; Balmativola D, 2014, BREAST CANCER RES TR, V148, P511, DOI 10.1007/s10549-014-3192-3; Biserni GB, 2016, HISTOPATHOLOGY, V69, P871, DOI 10.1111/his.13010; Carey LA, 2016, J CLIN ONCOL, V34, P542, DOI 10.1200/JCO.2015.62.1268; Criscitiello C, 2016, ANTICANCER RES, V36, P3537; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; de Ronde JJ, 2013, BREAST CANCER RES TR, V137, P213, DOI 10.1007/s10549-012-2340-x; Dowsett M, 2013, J CLIN ONCOL, V31, P2783, DOI 10.1200/JCO.2012.46.1558; Fu LM, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-3; Gnant M, 2014, ANN ONCOL, V25, P339, DOI 10.1093/annonc/mdt494; Hou YJ, 2017, BREAST CANCER RES TR, V166, P447, DOI 10.1007/s10549-017-4453-8; Hyman DM, 2018, NATURE, V554, P189, DOI 10.1038/nature25475; Landmann A, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.612; Llombart-Cussac A, 2017, LANCET ONCOL, V18, P545, DOI 10.1016/S1470-2045(17)30021-9; Long TH, 2015, AM J CLIN PATHOL, V144, P253, DOI 10.1309/AJCP3Q9WFOQTKUVV; Marchio C, 2009, J PATHOL, V219, P16, DOI 10.1002/path.2574; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Perez EA, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw207; Pinder SE, 2007, HISTOPATHOLOGY, V50, P409, DOI 10.1111/j.1365-2559.2006.02419.x; Press MF, 2016, J CLIN ONCOL, V34, P3518, DOI 10.1200/JCO.2016.66.6693; Ragazzi M, 2017, BREAST, V34, P65, DOI 10.1016/j.breast.2017.05.001; Rhodes DR, 2009, P NATL ACAD SCI USA, V106, P10284, DOI 10.1073/pnas.0900351106; Rondon-Lagos M, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-922; Sapino A, 2014, ONCOLOGIST, V19, P1118, DOI 10.1634/theoncologist.2014-0195; Sapino A, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00129; Shah MV, 2016, J CLIN ONCOL, V34, P3502, DOI 10.1200/JCO.2015.61.8983; Sneige N, 2017, CANCER-AM CANCER SOC, V123, P1115, DOI 10.1002/cncr.30460; Swanson PE, 2015, AM J CLIN PATHOL, V144, P181, DOI 10.1309/AJCP95QBHQWGGNJP; Wallden B, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0129-6; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984	32	1	1	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	SEP	2018	42	9					1190	1200		10.1097/PAS.0000000000001100			11	Pathology; Surgery	Pathology; Surgery	GR3QM	WOS:000442509200007	29975246	Green Published			2019-10-28	
J	Joseph, NM; Brunt, EM; Marginean, C; Nalbantoglu, I; Snover, DC; Thung, SN; Yeh, MM; Umetsu, SE; Ferrell, LD; Gill, RM				Joseph, Nancy M.; Brunt, Elizabeth M.; Marginean, Celia; Nalbantoglu, ILKe; Snover, Dale C.; Thung, Swan N.; Yeh, Matthew M.; Umetsu, Sarah E.; Ferrell, Linda D.; Gill, Ryan M.			Frequent GNAQ and GNA14 Mutations in Hepatic Small Vessel Neoplasm	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						GNAQ; GNA14; small vessel neoplasm; hemangioma; vascular tumors; liver	ANASTOMOSING HEMANGIOMA; SOMATIC MUTATION; VASCULAR TUMORS; READ ALIGNMENT; PAIRED-END; KIDNEY	Hepatic small vessel neoplasm (HSVN) is a recently described infiltrative vascular neoplasm of the liver, composed of small vessels. Although the infiltrative nature can mimic angiosarcoma, HSVN are thought to be benign or low-grade neoplasms because they lack cytologic atypia and increased proliferation. To characterize the molecular pathogenesis of HSVN, we performed both targeted panel sequencing and exome sequencing on 18 benign or low-grade vascular neoplasms in the liver including 8 HSVN, 6 classic cavernous hemangioma (CH), and 4 variant lesions (VL) with overlapping features between HSVN and CH. All 18 lesions had simple genomes without copy number alterations. In total, 75% (6/8) of HSVN demonstrated known activating hotspot mutations in GNAQ (2/8, p.Q209H) or GNA14 (4/8, p.Q205L), and the remaining 2 had the same missense mutation in GNAQ, p.G48L, which has not been previously described. 25% (1/4) of VL had a hotspot GNAQ p.Q209H mutation and another VL had a GNAQ p.G48L mutation. Known pathogenic mutations were not identified in any of the 6 CH. These data suggest that HSVN share a similar molecular biology to several other vascular lesions (congenital hemangioma, tufted angioma, anastomosing hemangioma, lobular capillary hemangioma, and kaposiform hemangioendothelioma) recently reported to have GNAQ, GNA11, or GNA14 mutations.	[Joseph, Nancy M.; Umetsu, Sarah E.; Ferrell, Linda D.; Gill, Ryan M.] Univ Calif San Francisco, Dept Pathol, 505 Parnassus Ave,M545,POB 0102, San Francisco, CA 94143 USA; [Brunt, Elizabeth M.] Washington Univ, Dept Pathol & Immunol, St Louis, MO USA; [Marginean, Celia] Ottawa Hosp, Dept Pathol, Ottawa, ON, Canada; [Nalbantoglu, ILKe] Yale Sch Med, Dept Pathol, New Haven, CT USA; [Snover, Dale C.] Univ Minnesota, Sch Med, Fairview Southdale Hosp, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; [Thung, Swan N.] Mt Sinai Hlth Syst, Dept Pathol, New York, NY USA; [Yeh, Matthew M.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA	Joseph, NM (reprint author), Univ Calif San Francisco, Dept Pathol, 505 Parnassus Ave,M545,POB 0102, San Francisco, CA 94143 USA.	nancy.joseph@ucsf.edu			UCSF Department of Pathology Research Endowment awards	Supported by the UCSF Department of Pathology Research Endowment awards to N.M.J. and R.M.G. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Ayturk UM, 2016, AM J HUM GENET, V98, P789, DOI 10.1016/j.ajhg.2016.03.009; Bean GR, 2017, MODERN PATHOL, V30, P722, DOI 10.1038/modpathol.2016.234; Behjati S, 2014, NAT GENET, V46, P376, DOI 10.1038/ng.2921; Brown JG, 2010, AM J SURG PATHOL, V34, P942, DOI 10.1097/PAS.0b013e3181e4f32a; Couto JA, 2016, PLAST RECONSTR SURG, V137, p77E, DOI 10.1097/PRS.0000000000001868; GARRISON E, 2012, GENOMICS, V1207, P3907, DOI DOI 10.1101/1207.3907; Gill RM, 2016, HUM PATHOL, V54, P143, DOI 10.1016/j.humpath.2016.03.018; Kryvenko ON, 2011, AM J CLIN PATHOL, V136, P450, DOI 10.1309/AJCPJPW34QCQYTMT; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Lim YH, 2016, AM J HUM GENET, V99, P443, DOI 10.1016/j.ajhg.2016.06.010; Lin JM, 2013, AM J SURG PATHOL, V37, P1761, DOI 10.1097/PAS.0b013e3182967e6c; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Montgomery E, 2009, AM J SURG PATHOL, V33, P1364, DOI 10.1097/PAS.0b013e3181ad30a7; Murali R, 2015, ONCOTARGET, V6, P36041, DOI 10.18632/oncotarget.5936; Nakashima M, 2014, J HUM GENET, V59, P691, DOI 10.1038/jhg.2014.95; Rausch T, 2012, BIOINFORMATICS, V28, pI333, DOI 10.1093/bioinformatics/bts378; Shirley MD, 2013, NEW ENGL J MED, V368, P1971, DOI 10.1056/NEJMoa1213507; Talevich E, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004873; Van der Auwera Geraldine A, 2013, Curr Protoc Bioinformatics, V43, DOI 10.1002/0471250953.bi1110s43; Van Raamsdonk CD, 2010, NEW ENGL J MED, V363, P2191, DOI 10.1056/NEJMoa1000584; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; Walcott-Sapp S, 2018, HUM PATHOL, V78, P159, DOI 10.1016/j.humpath.2018.01.013; Yang H, 2015, NAT PROTOC, V10, P1556, DOI 10.1038/nprot.2015.105; Ye K, 2009, BIOINFORMATICS, V25, P2865, DOI 10.1093/bioinformatics/btp394	25	6	6	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	SEP	2018	42	9					1201	1207		10.1097/PAS.0000000000001110			7	Pathology; Surgery	Pathology; Surgery	GR3QM	WOS:000442509200008	29975248				2019-10-28	
J	Zare, S; Lin, L; Alghamdi, AG; Daehne, S; Roma, AA; Hasteh, F; Dell'Aquila, M; Fadare, O				Zare, Somaye; Lin, Leo; Alghamdi, Abrar G.; Daehne, Svenja; Roma, Andres A.; Hasteh, Farnaz; Dell'Aquila, Marie; Fadare, Oluwole			Comparative Pathologic Analysis of Breast Cancers Classified as HER2/neu-Amplified by FISH Using a Standard HER2/CEP17 Dual Probe and an Alternative Chromosome 17 Control Probe	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						breast cancer; human epidermal growth factor receptor 2; fluorescence in situ hybridization; centromere enumeration probe for chromosome 17; alternative chromosome 17 probe; amplification	IN-SITU HYBRIDIZATION; 2013 AMERICAN SOCIETY; GENE AMPLIFICATION; HER-2/NEU GENE; CLINICAL ONCOLOGY/COLLEGE; TESTING EXPERIENCE; COPY NUMBER; HER2; GUIDELINES; IMMUNOHISTOCHEMISTRY	At our institution, breast cancer cases that generate an equivocal HER2/neu (HER2) result by fluorescence in situ hybridization (FISH) using the dual HER2/chromosome enumeration probe (CEP17) are reflexed to an assay that utilizes an alternative control probe (lissencephaly gene1 [LIS1] [17p13.3]/retinoic acid receptor [RARA] [17q21.2]). This study examines whether cancers that are classified as HER2-amplified with an alternate probe are clinicopathologically similar to those that are classified as such using the HER2/CEP17 probe. Reports for 1201 breast cancers were reviewed, and clinicopathologic findings were compared between HER2/CEP17-equivocal cases that became HER2-amplified using the alternate probe (group A: n=48), HER2-amplified cases using the HER2/CEP17 probe (group B: n=169), and HER2-nonamplified cases using the HER2/CEP17 probe (group C: n=910). Of 1201 cases tested using the HER2/CEP17 probe, 169 (14%) were HER2-amplified, 122 (10%) were equivocal, and 910 (76%) were nonamplified. Additional testing with the alternative probe on the 122 equivocal cases reclassified 48 (39%) of them to HER2-amplified, and such cases comprised 22% of all HER2-amplified tumors. A higher proportion of tumors with HER2 copy number between 5.0 and 5.9 became positive upon additional testing when compared with those with a priori HER2 copy numbers between 4.0 and 4.9 (P=0.0362). Group A cases, compared with group B cases, were more frequently positive for estrogen receptor (97.91% vs. 72.18%, P<0.0001) and progesterone receptor (85.41% vs. 59.17%, P=0.0009). Most group A cases (71%) were HER2 equivocal (score 2+) by immunohistochemistry, whereas most group B cases (60%) were positive (score 3+). Groups A and B showed no significant differences regarding patient age, lymph node status, tumor grade, histotype, and stage distribution. In summary, among our HER2-amplified cohort of breast cancers, alternative probe-detected cases were more frequently estrogen receptor and progesterone receptor positive than HER2/CEP17-detected cases, and were more frequently discordant with HER2 immunohistochemistry results. These findings raise the possibility of underlying biologic differences between these 2 groups, which warrants further study. However, the tumors were largely comparable regarding all other clinicopathologic variables. As it is unknown whether HER2-targeted therapy is truly beneficial in this subgroup of patients, future clinical trials should specifically evaluate this subset.	[Zare, Somaye; Lin, Leo; Alghamdi, Abrar G.; Daehne, Svenja; Roma, Andres A.; Hasteh, Farnaz; Dell'Aquila, Marie; Fadare, Oluwole] Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA	Fadare, O (reprint author), Univ Calif San Diego, Dept Pathol, Div Anat Pathol, 9300 Campus Point Dr,Suite 1-200,MC 7723, La Jolla, CA 92037 USA.	ofadare@ucsd.edu					Ballinger TJ, 2015, CLIN BREAST CANCER, V15, P171, DOI 10.1016/j.clbc.2014.11.009; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Dal Lago L, 2006, MOL CANCER THER, V5, P2572, DOI 10.1158/1535-7163.MCT-06-0129; Donaldson AR, 2017, CANCER-AM CANCER SOC, V123, P2230, DOI 10.1002/cncr.30592; Figueroa-Magalhaes MC, 2014, BREAST, V23, P128, DOI 10.1016/j.breast.2013.11.011; Gilcrease MZ, 2009, AM J SURG PATHOL, V33, P759, DOI 10.1097/PAS.0b013e31819437f9; Hanna WM, 2014, MODERN PATHOL, V27, P4, DOI 10.1038/modpathol.2013.103; Holzschuh MA, 2017, HISTOPATHOLOGY, V71, P610, DOI 10.1111/his.13253; Hui L, 2017, ARCH PATHOL LAB MED, V141, P274, DOI 10.5858/arpa.2016-0201-OA; Jang MH, 2015, BREAST CANCER RES TR, V153, P67, DOI 10.1007/s10549-015-3522-0; Jensen KC, 2008, BREAST CANCER RES TR, V112, P453, DOI 10.1007/s10549-007-9887-y; Lim TH, 2016, ARCH PATHOL LAB MED, V140, P140, DOI 10.5858/arpa.2015-0108-OA; Long TH, 2015, AM J CLIN PATHOL, V144, P253, DOI 10.1309/AJCP3Q9WFOQTKUVV; Marchio C, 2009, J PATHOL, V219, P16, DOI 10.1002/path.2574; Owens Marilyn A, 2004, Clin Breast Cancer, V5, P63, DOI 10.3816/CBC.2004.n.011; Pai T, 2018, ARCH PATHOL LAB MED, V142, P626, DOI 10.5858/arpa.2017-0252-OA; Press MF, 1997, J CLIN ONCOL, V15, P2894, DOI 10.1200/JCO.1997.15.8.2894; Press MF, 2016, J CLIN ONCOL, V34, P3518, DOI 10.1200/JCO.2016.66.6693; Ross JS, 2003, ONCOLOGIST, V8, P307, DOI 10.1634/theoncologist.8-4-307; Shah MV, 2016, J CLIN ONCOL, V34, P3502, DOI 10.1200/JCO.2015.61.8983; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sneige N, 2017, CANCER-AM CANCER SOC, V123, P1115, DOI 10.1002/cncr.30460; Solomon JP, 2017, AM J CLIN PATHOL, V147, P432, DOI [10.1093/AJCP/AQW224, 10.1093/ajcp/aqw224]; Tse CH, 2011, J CLIN ONCOL, V29, P4168, DOI 10.1200/JCO.2011.36.0107; Varga Z, 2012, BREAST CANCER RES TR, V132, P925, DOI 10.1007/s10549-011-1642-8; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Yarden Y, 2001, ONCOLOGY-BASEL, V61, P1, DOI 10.1159/000055396; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yaziji H, 2004, JAMA-J AM MED ASSOC, V291, P1972, DOI 10.1001/jama.291.16.1972	29	1	1	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	SEP	2018	42	9					1208	1215		10.1097/PAS.0000000000001106			8	Pathology; Surgery	Pathology; Surgery	GR3QM	WOS:000442509200009	29923906				2019-10-28	
J	Volaric, A; Gentzler, R; Hall, R; Mehaffey, JH; Stelow, EB; Bullock, TN; Martin, LW; Mills, AM				Volaric, Ashley; Gentzler, Ryan; Hall, Richard; Mehaffey, James H.; Stelow, Edward B.; Bullock, Timothy N.; Martin, Linda W.; Mills, Anne M.			Indoleamine-2,3-Dioxygenase in Non-Small Cell Lung Cancer A Targetable Mechanism of Immune Resistance Frequently Coexpressed With PD-L1	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article; Proceedings Paper	Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP)	MAR, 2018	Vancouver, CANADA	US & Canadian Acad Pathol		IDO; IDO-1; indoleamine-2, 3-dioxygenase; non-small cell lung carcinoma; NSCLC; lung cancer; immunotherapy; PD-L1	TUMOR-INFILTRATING LYMPHOCYTES; PD-L1 EXPRESSION; INDOLEAMINE 2,3-DIOXYGENASE; NEOANTIGEN LOAD; ASSAYS; IDO; IMMUNOHISTOCHEMISTRY; ASSOCIATION; INHIBITION; SURVIVAL	The immune regulatory enzyme indoleamine-2,3-dioxygenase (IDO-1) suppresses T cell responses and may reduce efficacy of therapies targeting immune checkpoints such as programmed death receptor-1/programmed death ligand-1 (PD-1/PD-L1). Early phase clinical trials combining IDO-1 and PD-1/PD-L1 inhibitors have shown some promise in non-small cell lung cancers (NSCLCs). However, the coexpression of IDO-1 and PD-L1 has not been thoroughly investigated, and the potential for IDO-1 immunohistochemical expression as a therapeutic biomarker is unknown. One hundred two cases of NSCLC (51 adenocarcinomas, 9 adenosquamous carcinomas, and 42 squamous cell carcinomas) were evaluated for IDO-1 and PD-L1 expression by immunohistochemistry. IDO-1 expression was identified in 43% of NSCLC (42% of adenocarcinomas, 44% of adenosquamous carcinomas, and 43% of squamous cell carcinomas). Coexpression with PD-L1 (>= 1%) was common (27% overall; 27% of adenocarcinomas, 33% of adenosquamous carcinomas, and 26% of squamous cell carcinomas). A smaller population of tumors showed isolated PD-L1 (25% overall; 16% of adenocarcinomas, 44% of adenosquamous carcinomas, and 33% of squamous cell carcinomas) or IDO-1 expression (15% overall; 14% of adenocarcinomas, 11% of adenosquamous carcinomas, and 17% of squamous cell carcinomas). In summary, IDO-1 is commonly expressed by NSCLC, and its frequent coexpression with PD-L1 may account for the increased efficacy seen with dual blockade of PD-1/PD-L1 and IDO in clinical studies. IDO-1 immunohistochemistry may be a useful biomarker for selection of patients who could benefit from dual-agent therapy and should be evaluated in prospective clinical trials using PD-1/PD-L1 and IDO inhibitors.	[Volaric, Ashley; Stelow, Edward B.; Bullock, Timothy N.; Mills, Anne M.] Univ Virginia, Dept Pathol, Charlottesville, VA 22903 USA; [Mehaffey, James H.; Martin, Linda W.] Univ Virginia, Dept Surg, Div Thorac Surg, Charlottesville, VA USA; [Gentzler, Ryan; Hall, Richard] Univ Virginia, Dept Internal Med, Div Hematol Oncol, Charlottesville, VA USA	Mills, AM (reprint author), Univ Virginia, Dept Pathol, Charlottesville, VA 22903 USA.	amm7r@virginia.edu	Mehaffey, James/L-5385-2019	Mills, Anne/0000-0002-2686-4857			Amin MB, 2017, AJCC CANC STAGING MA; Buttner R, 2017, J CLIN ONCOL, V35, P3867, DOI 10.1200/JCO.2017.74.7642; Cooper WA, 2015, LUNG CANCER, V89, P181, DOI 10.1016/j.lungcan.2015.05.007; Cree IA, 2016, HISTOPATHOLOGY, V69, P177, DOI 10.1111/his.12996; Creelan B, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.23428; Dill EA, 2018, MODERN PATHOL, V31, P1513, DOI 10.1038/s41379-018-0061-3; Eggink FA, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1264565; Friedman K, 2016, MODERN PATHOL, V29, P528, DOI 10.1038/modpathol.2016.54; Frumento G, 2002, J EXP MED, V196, P459, DOI 10.1084/jem.20020121; Gangadhar TC, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.9014; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Gottfried E, 2012, SEMIN CANCER BIOL, V22, P335, DOI 10.1016/j.semcancer.2012.02.009; Guan J, 2017, ARCH PATHOL LAB MED, V141, P851, DOI 10.5858/arpa.2016-0361-RA; Hamid O, 2017, ANN ONCOL, V28, pv428; Hamid O, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.6010; Hamid O, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.3012; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Howitt BE, 2015, JAMA ONCOL, V1, P1319, DOI 10.1001/jamaoncol.2015.2151; Ilie M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183023; Iversen TZ, 2015, BASIC CLIN PHARMACOL, V116, P19, DOI 10.1111/bcpt.12320; Kris MG, 2014, JAMA-J AM MED ASSOC, V311, P1998, DOI 10.1001/jama.2014.3741; Lara P, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.4515; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; LECHEVALIER T, 1991, JNCI-J NATL CANCER I, V83, P417, DOI 10.1093/jnci/83.6.417; Marchetti A, 2017, J THORAC ONCOL, V12, P1654, DOI 10.1016/j.jtho.2017.07.031; Mills A, 2018, MODERN PATHOL, V31, P1282, DOI 10.1038/s41379-018-0039-1; Moon YW, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0094-9; Muller AJ, 2005, NAT MED, V11, P312, DOI 10.1038/nm1196; Munn DH, 2016, TRENDS IMMUNOL, V37, P193, DOI 10.1016/j.it.2016.01.002; Munn DH, 2013, TRENDS IMMUNOL, V34, P137, DOI 10.1016/j.it.2012.10.001; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; Paz-Ares LG, 2013, J CLIN ONCOL, V31, P2895, DOI 10.1200/JCO.2012.47.1102; Platten M, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00673; Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033; Rothschild SI, 2015, CANCERS, V7, P930, DOI 10.3390/cancers7020816; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Schafer K, 2017, CHEM-EUR J, V23, P370, DOI 10.1002/chem.201603807; Scheel AH, 2016, MODERN PATHOL, V29, P1165, DOI 10.1038/modpathol.2016.117; Smith C, 2012, CANCER DISCOV, V2, P722, DOI 10.1158/2159-8290.CD-12-0014; Smith DC, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.4503; Stewart BW, 2014, WORLD CANC REPORT 20; Strickland KC, 2016, ONCOTARGET, V7, P13587, DOI 10.18632/oncotarget.7277; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Uyttenhove C, 2003, NAT MED, V9, P1269, DOI 10.1038/nm934; Vacchelli E, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.957994; Wainwright DA, 2014, CLIN CANCER RES, V20, P5290, DOI 10.1158/1078-0432.CCR-14-0514; Wang A, 2015, EJSO-EUR J SURG ONC, V41, P450, DOI 10.1016/j.ejso.2015.01.020; Wang WL, 2018, CANCER RES, V78, P809, DOI 10.1158/0008-5472.CAN-17-2995; Zhai LJ, 2015, CLIN CANCER RES, V21, P5427, DOI 10.1158/1078-0432.CCR-15-0420; Zhong AY, 2015, ONCOTARGETS THER, V8, P3595, DOI 10.2147/OTT.S91469	51	4	4	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	SEP	2018	42	9					1216	1223		10.1097/PAS.0000000000001099			8	Pathology; Surgery	Pathology; Surgery	GR3QM	WOS:000442509200010	29901571				2019-10-28	
J	Suster, D; Pihan, G; Mackinnon, AC; Suster, S				Suster, David; Pihan, German; Mackinnon, Alexander C.; Suster, Saul			Poorly Differentiated Nonkeratinizing Squamous Cell Carcinoma of the Thymus Clinicopathologic and Molecular Genetic Study of 25 Cases	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						thymic carcinoma; lymphoepithelioma-like carcinoma; poorly differentiated nonkeratinizing squamous cell carcinoma; next-generation sequencing	EPITHELIAL TUMORS; NEUROENDOCRINE DIFFERENTIATION; IMMUNOHISTOCHEMICAL MARKERS; THORACIC SURGEONS; CD117 EXPRESSION; EUROPEAN-SOCIETY; ATYPICAL THYMOMA; MUTATIONS; CLASSIFICATION; FEATURES	Thymic carcinoma represents a rare and poorly understood type of thymic epithelial neoplasm that has been the subject of much controversy. Poorly differentiated nonkeratinizing squamous cell carcinoma, also known as lymphoepithelioma-like thymic carcinoma, is a rare variant of thymic carcinoma that has not been adequately characterized in the literature. The clinicopathologic, immunohistochemical, ultrastructural, and molecular features of 25 cases are reported. The patients were 19 men and 6 women, ranging in age from 20 to 85 years (mean: 60 y). The tumors presented clinically as anterior mediastinal masses with chest pain and shortness of breath or were found incidentally on imaging studies. Tumor size ranged from 2.0 to 13.5 cm in greatest diameter. Most of the tumors were small, well-circumscribed and confined to the mediastinum. Five cases presented with large, bulky, and infiltrative masses. Histologically, the hallmark of these tumors was a neoplastic proliferation of large, round to oval cells with vesicular nuclei, prominent eosinophilic nucleoli, and scant cytoplasm. Two histologic growth patterns were identified: tumors with a heavy lymphoplasmacytic stroma (lymphoepithelioma-like pattern), and tumors showing abundant desmoplastic stroma (desmoplastic pattern). Immunohistochemical stains showed strong positivity of the tumor cells for cytokeratin AE1/AE3, CK5/6, CK18, MOC31, p16, p40, and p63. MIB-1 showed on average 35% nuclear positivity. CD117 was positive in 21/25 cases and CD5 in 20/25 cases. Epstein-Barr encoded RNA in situ hybridization was positive in only 1 case. Electron microscopy in 4 cases showed primitive round to oval cells with prominent nucleoli, scant cytoplasm and immature cell junctions. Molecular features were studied by next-generation sequencing using high quality sequence data obtained from 18 patients. Variants with allele frequency between 5% and 45% and quality scores > 50 were classified as somatic. A total of 16/18 cases had one or more somatic variants of unknown significance. One case showed an IDH1 p. R132C mutation, also of unknown significance. No "actionable" genes amenable to currently available targeted therapies were identified in this cohort. Clinical follow-up was obtained in 20 patients; 14 patients were alive and well with no evidence of disease between 1.5 and 16 years after diagnosis (median survival: 4 y; mean: 5.5 y). Most survivors had relatively small tumors (< 5 cm. diameter), were in stage I and II at diagnosis and showed clear surgical margins. Five patients died of their tumors with metastases to bone, brain, chest wall, lungs and lymph nodes; all were in advanced stages and showed positive margins. Prognosis for these tumors appears to be correlated with the staging and status of the margins at the time of initial surgery.	[Suster, David; Pihan, German] Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave, Boston, MA 02215 USA; [Suster, David; Pihan, German] Harvard Med Sch, Boston, MA USA; [Mackinnon, Alexander C.; Suster, Saul] Med Coll Wisconsin, Dept Pathol, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA	Suster, S (reprint author), Med Coll Wisconsin, Dept Pathol, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.	ssuster@mcw.edu	Pihan, German/L-9895-2019				Ahmad U, 2015, J THORAC CARDIOV SUR, V149, P95, DOI 10.1016/j.jtcvs.2014.09.124; Asao T, 2016, LUNG CANCER, V93, P77, DOI 10.1016/j.lungcan.2016.01.004; Chalabreysse L, 2004, HISTOPATHOLOGY, V44, P367, DOI 10.1111/j.1365-2559.2004.01796.x; de Jong WK, 2008, EUR J CANCER, V44, P123, DOI 10.1016/j.ejca.2007.11.004; de Montpreville VT, 2013, VIRCHOWS ARCH, V462, P307, DOI 10.1007/s00428-013-1371-y; Di Cataldo A, 2000, PEDIATR HEMAT ONCOL, V17, P701; Engel PJH, 2000, APMIS, V108, P393, DOI 10.1034/j.1600-0463.2000.d01-74.x; Feng YF, 2017, LUNG CANCER, V110, P48, DOI 10.1016/j.lungcan.2017.05.020; Filosso PL, 2016, EUR J CARDIO-THORAC, V50, P766, DOI 10.1093/ejcts/ezw107; HARTMANN CA, 1990, J CANCER RES CLIN, V116, P69, DOI 10.1007/BF01612643; Hayashi A, 2013, J CLIN EXP HEMATOP, V53, P9, DOI 10.3960/jslrt.53.9; Hishima T, 1998, HUM PATHOL, V29, P330, DOI 10.1016/S0046-8177(98)90112-5; Hsueh C, 2006, J PEDIAT HEMATOL ONC, V28, P785, DOI 10.1097/MPH.0b013e31802d3a83; Karube Y, 2016, J CARDIOTHORAC SURG, V11, DOI 10.1186/s13019-016-0468-1; Kilis-Pstrusinska K, 2008, PEDIATR NEPHROL, V23, P1001, DOI 10.1007/s00467-007-0666-0; KOGA K, 1994, PATHOL INT, V44, P359; Kompier LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013821; Kriegsmann M, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0441-7; Kwan W H, 1996, Clin Oncol (R Coll Radiol), V8, P55, DOI 10.1016/S0936-6555(05)80041-X; Lauriola L, 1998, AM J SURG PATHOL, V22, P1059, DOI 10.1097/00000478-199809000-00003; Lee GD, 2016, J THORAC DIS, V8, P901, DOI 10.21037/jtd.2016.03.53; Lee HS, 2017, CLIN CANCER RES, V23, P4855, DOI 10.1158/1078-0432.CCR-17-0066; Leisibach P, 2016, J THORAC DIS, V8, P2580, DOI 10.21037/jtd.2016.08.82; Mondesir J, 2016, J BLOOD MED, V7, P171, DOI 10.2147/JBM.S70716; Nakagawa K, 2005, CHEST, V128, P140, DOI 10.1378/chest.128.1.140; Pan CC, 2004, J PATHOL, V202, P375, DOI 10.1002/path.1514; Petrini I, 2014, NAT GENET, V46, P844, DOI 10.1038/ng.3016; Radovich M, 2018, CANCER CELL, V33, P244, DOI 10.1016/j.ccell.2018.01.003; Rohle D, 2013, SCIENCE, V340, P626, DOI 10.1126/science.1236062; Ronchetti D, 2001, ONCOGENE, V20, P3553, DOI 10.1038/sj.onc.1204465; Ruffini E, 2014, J THORAC ONCOL, V9, P541, DOI 10.1097/JTO.0000000000000128; Saito M, 2017, CARCINOGENESIS, V38, P1084, DOI 10.1093/carcin/bgx094; Sekihara K, 2014, ONCOL LETT, V8, P2183, DOI 10.3892/ol.2014.2475; Shih AH, 2012, NAT REV CANCER, V12, P599, DOI 10.1038/nrc3343; Shima H, 2016, MOL CLIN ONCOL, V4, P715, DOI 10.3892/mco.2016.803; Shitara M, 2014, LUNG CANCER, V86, P174, DOI 10.1016/j.lungcan.2014.08.020; Song ZB, 2016, ONCOTARGETS THER, V9, P6337, DOI 10.2147/OTT.S108749; Suster S, 1999, AM J CLIN PATHOL, V111, P826; SUSTER S, 1991, CANCER-AM CANCER SOC, V67, P1025, DOI 10.1002/1097-0142(19910215)67:4<1025::AID-CNCR2820670427>3.0.CO;2-F; Suster S, 1996, AM J SURG PATHOL, V20, P1469, DOI 10.1097/00000478-199612000-00006; Suster S, 2008, HEMATOL ONCOL CLIN N, V22, P381, DOI 10.1016/j.hoc.2008.03.001; Suster S, 2005, SEMIN DIAGN PATHOL, V22, P198, DOI 10.1053/j.semdp.2006.02.006; Tateyama H, 1999, AM J CLIN PATHOL, V111, P235; Travis WD, 2015, WHO CLASSIFICATION T; Tsongalis GJ, 2014, CLIN CHEM LAB MED, V52, P707, DOI 10.1515/cclm-2013-0883; Wang YS, 2014, SCI REP-UK, V4, DOI 10.1038/srep07336; Weissferdt A, 2016, AM J CLIN PATHOL, V145, P393, DOI [10.1093/ajcp/aqv095, 10.1093/AJCP/AQV095]; Weissferdt A, 2012, AM J CLIN PATHOL, V138, P103, DOI 10.1309/AJCP88FZTWANLRCB	48	0	0	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	SEP	2018	42	9					1224	1236		10.1097/PAS.0000000000001101			13	Pathology; Surgery	Pathology; Surgery	GR3QM	WOS:000442509200011	29975245				2019-10-28	
J	He, C; Fukumura, Y; Toriyama, A; Ogura, K; Sasahara, N; Mitani, K; Yao, T				He, Cong; Fukumura, Yuki; Toriyama, Akane; Ogura, Kanako; Sasahara, Noriko; Mitani, Keiko; Yao, Takashi			Pyloric Gland Adenoma (PGA) of the Gallbladder A Unique and Distinct Tumor from PGAs of the Stomach, Duodenum, and Pancreas	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						pyloric gland adenoma; CTNNB1; GNAS; KRAS; beta-catenin	GASTRIC TYPE; FEATURES; CARCINOMAS; EXPRESSION; MUTATIONS; NEOPLASMS; DIFFERENTIATION; METAPLASIA; PHENOTYPE; MALIGNUM	Twenty-four surgically resected, gallbladder pyloric gland adenomas (GB-PGAs) were examined and their features were compared with the reported features of stomach, duodenum, and pancreatic PGAs to better understand GB-PGAs. Clinical information on background gallbladder lesions and histologic data, including tumor grade, existence of squamoid morules, intratumoral cholesterosis, and intracytoplasmic mucins were collected. Immunohistochemical staining for MUC2, MUC5AC, MUC6, CDX2, pepsinogen I, p53, and MIB-1/nuclear beta-catenin were evaluated. Targeted mutational analyses of KRAS exon2, GNAS exon 7, and CTNNB1 exon 3 were conducted. We found that 29.2% of the GB-PGAs were histologically high-grade dysplasias/carcinomas; 70.8% were low grade; and 20.8% and 33.3% contained squamoid morules and intratumoral cholesterosis, respectively. In addition, 45.8% and 54.2% of GB-PGAs were mucin-rich and mucin-poor types, respectively. Immunohistochemically, MUC6 was diffusely positive in all GB-PGAs; MUC2, MUC5AC, and CDX2 were only focally positive, and no pepsinogen-I positive cells were observed. Nuclear beta-catenin accumulation was observed in all cases; however, the ratio varied among cases. Mucin-poor types were significantly associated with high histologic grade dysplasias/carcinomas and high nuclear beta-catenin labeling indices. Mutational analyses identified CTNNB1 mutations in 100% of GB-PGAs (21/21), KRAS in 4.2% (1/23), and GNAS in 0% (0/22). The present study clarified the unique histologic features, phenotypic differentiation, and molecular statuses frequently associated with GB-PGAs. Altogether, our data suggest that tumorigenesis of GB-PGA is distinct from that of stomach, duodenum, and pancreatic PGAs.	[He, Cong; Fukumura, Yuki; Sasahara, Noriko; Mitani, Keiko; Yao, Takashi] Juntendo Univ, Dept Human Pathol, Sch Med, Tokyo, Japan; [Toriyama, Akane] Juntendo Urayasu Hosp, Dept Pathol, Tokyo, Japan; [Ogura, Kanako] Juntendo Nerima Hosp, Dept Pathol, Tokyo, Japan	Fukumura, Y (reprint author), Juntendo Univ, Sch Med, Dept Human Pathol, Bunkyo Ku, Motomachi Bldg 3F,Hongo 1-1-19, Tokyo 1130033, Japan.	yfuku@juntendo.ac.jp			 [16K11247]	Supported by the Grant-in-Aid for Japan Society for the promotion of Sciences (JSPS) KAKENHI (Grant number #16K11247 to Y.F. and H.M.). The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Adsay V, 2012, AM J SURG PATHOL, V36, P1279, DOI 10.1097/PAS.0b013e318262787c; Albores-Saavedra J, 2010, WHO CLASSIFICATION T, V3, P266; Albores-Saavedra J, 2012, HUM PATHOL, V43, P1506, DOI 10.1016/j.humpath.2011.11.011; Bakotic BW, 1999, AM J SURG PATHOL, V23, P227, DOI 10.1097/00000478-199902000-00013; Chen ZM, 2009, AM J SURG PATHOL, V33, P186, DOI 10.1097/PAS.0b013e31817d7ff4; Choi WT, 2018, HISTOPATHOLOGY, V72, P1007, DOI 10.1111/his.13460; Gao C, 2018, ONCOTARGET, V9, P5492, DOI 10.18632/oncotarget.23695; Hida R, 2017, AM J SURG PATHOL, V41, P343, DOI 10.1097/PAS.0000000000000785; Ishii K, 1999, ULTRASTRUCT PATHOL, V23, P375, DOI 10.1080/019131299281347; Itoi T, 1996, PATHOL INT, V46, P333, DOI 10.1111/j.1440-1827.1996.tb03618.x; Kushima R, 1996, PATHOL RES PRACT, V192, P963, DOI 10.1016/S0344-0338(96)80081-1; Kushima R, 1999, VIRCHOWS ARCH, V435, P452, DOI 10.1007/s004280050425; Kushima R, 2013, PATHOL INT, V63, P318, DOI 10.1111/pin.12070; Mamat O, 2016, HISTOPATHOLOGY, V69, P570, DOI 10.1111/his.12967; Manie E, 2009, CANCER RES, V69, P663, DOI 10.1158/0008-5472.CAN-08-1560; Matsubara A, 2013, J PATHOL, V229, P579, DOI 10.1002/path.4153; Mikami Y, 1999, GYNECOL ONCOL, V74, P504, DOI 10.1006/gyno.1999.5462; Nagata S, 2007, ONCOL REP, V17, P721; Saegusa M, 2012, LAB INVEST, V92, P511, DOI 10.1038/labinvest.2011.196; Takei K, 1996, PATHOL INT, V46, P908, DOI 10.1111/j.1440-1827.1996.tb03569.x; Vieth M, 2003, VIRCHOWS ARCH, V442, P317, DOI 10.1007/s00428-002-0750-6; Wani Y, 2008, VIRCHOWS ARCH, V453, P521, DOI 10.1007/s00428-008-0680-z; Yamaguchi H, 2013, J PATHOL, V231, P335, DOI 10.1002/path.4242; Yanagisawa N, 2001, CANCER RES, V61, P19	24	0	0	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	SEP	2018	42	9					1237	1245		10.1097/PAS.0000000000001117			9	Pathology; Surgery	Pathology; Surgery	GR3QM	WOS:000442509200012	29975247				2019-10-28	
J	Weissferdt, A				Weissferdt, Annikka			Pulmonary Carcinomas With Mucinous and Neuroendocrine Differentiation Expanding the Spectrum of Amphicrine Carcinomas	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						lung; amphicrine carcinoma; combined neuroendocrine carcinoma; adenocarcinoma; large cell neuroendocrine carcinoma	GASTRIC-CARCINOMA; CELL-CARCINOMA; FEATURES; TUMORS; LUNG	Amphicrine carcinoma is a distinct type of carcinoma characterized by synchronous exocrine and endocrine differentiation within the same tumor cell. Such tumors are exceedingly rare and most commonly recognized in the gastrointestinal tract. In the lung, sporadic descriptions of such lesions exist. This report presents 3 more such tumors, expanding the spectrum of amphicrine carcinomas in this organ. The patients were 3 men, 53 to 78 years of age (mean: 63 y) and all were current or former smokers. In one patient the tumor was an incidental finding, the others presented with lower respiratory symptoms. Microscopically, the lesions had an organoid pattern, consisting of nests of large tumor cells with peripheral palisading, vesicular nuclei and prominent nucleoli reminiscent of large cell neuroendocrine carcinoma. In addition, the tumor nests also showed glandular features, characterized by gland-like lumina filled with mucin and intracytoplasmic mucin droplets. Immunohistochemical studies showed diffuse reactivity of the tumor cells with synaptophysin and chromogranin and variable reactivity with TTF-1. Mucin stains highlighted extracellular and intracellular mucin deposition. Clinical follow-up demonstrated that one patient had died of his disease 12 months after surgery while another was alive and free of disease 21 months after surgery. The third patient was alive with widespread metastatic disease 8 months after diagnosis. This series highlights a rare variant of pulmonary carcinoma showing synchronous exocrine and endocrine differentiation. Recognition of this type of tumor is important in terms of tumor classification and to identify an entity with potential aggressive behavior.	[Weissferdt, Annikka] MD Anderson Canc Ctr, Dept Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA	Weissferdt, A (reprint author), MD Anderson Canc Ctr, Dept Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	aweissferdt@mdanderson.org					CHEJFEC G, 1985, CANCER, V56, P2683, DOI 10.1002/1097-0142(19851201)56:11<2683::AID-CNCR2820561127>3.0.CO;2-L; Cho Kyung-Ja, 1996, Journal of Korean Medical Science, V11, P188; Feyrter F., 1938, DIFFUSE ENDOKRINE EP; Ganesan K, 2011, ANN DIAGN PATHOL, V15, P355, DOI 10.1016/j.anndiagpath.2010.05.001; Ginori A, 2015, TUMORI J, V101, pE70, DOI 10.5301/tj.5000254; HAMMAR SP, 1992, AM J CLIN PATHOL, V97, P516, DOI 10.1093/ajcp/97.4.516; HIDVEGI J, 1988, PATHOL RES PRACT, V183, P505, DOI 10.1016/S0344-0338(88)80102-X; Ionescu DN, 2007, AM J SURG PATHOL, V31, P26, DOI 10.1097/01.pas.0000213319.04919.97; LEWIN K, 1987, AM J SURG PATHOL, V11, P71, DOI 10.1097/00000478-198700111-00007; Ludmir EB, 2016, AM J CLIN PATHOL, V145, P703, DOI [10.1093/AJCP/AQW028, 10.1093/ajcp/aqw028]; Mandoky L, 1999, Pathol Oncol Res, V5, P239, DOI 10.1053/paor.1999.0211; MCCLUGGAGE WG, 1994, HISTOPATHOLOGY, V24, P182, DOI 10.1111/j.1365-2559.1994.tb01302.x; Minakawa K, 2006, APMIS, V114, P720, DOI 10.1111/j.1600-0463.2006.apm_407.x; PASQUINELLI G, 1993, ULTRASTRUCT PATHOL, V17, P9, DOI 10.3109/01913129309015398; Prendeville S, 2017, HISTOPATHOLOGY, V71, P926, DOI 10.1111/his.13330; RATZENHOFER M, 1965, Z ZELLFORSCH MIK ANA, V67, P113, DOI 10.1007/BF00339280; Reddy V, 1990, Cytopathology, V1, P45, DOI 10.1111/j.1365-2303.1990.tb00325.x; Reis JS, 2001, ARCH PATHOL LAB MED, V125, P1513; Reyes CV, 1999, DIAGN CYTOPATHOL, V20, P257; SHEPPARD MN, 1994, ULTRASTRUCT PATHOL, V18, P437, DOI 10.3109/01913129409023215; TRAVIS WD, 1991, AM J SURG PATHOL, V15, P529, DOI 10.1097/00000478-199106000-00003; Travis WD, 2015, PATHOLOGY GENETICS T; YANG GCH, 1991, AM J SURG PATHOL, V15, P592, DOI 10.1097/00000478-199106000-00008; Yu R, 2013, PANCREAS, V42, P429, DOI 10.1097/MPA.0b013e318264d073	24	0	0	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	SEP	2018	42	9					1246	1252		10.1097/PAS.0000000000001127			7	Pathology; Surgery	Pathology; Surgery	GR3QM	WOS:000442509200013	30001241				2019-10-28	
J	Williamson, SR; Rao, P; Hes, O; Epstein, JI; Smith, SC; Picken, MM; Zhou, M; Tretiakova, MS; Tickoo, SK; Chen, YB; Reuter, VE; Fleming, S; Maclean, FM; Gupta, NS; Kuroda, N; Delahunt, B; Mehra, R; Przybycin, CG; Cheng, L; Eble, JN; Grignon, DJ; Moch, H; Lopez, JI; Kunju, LP; Tamboli, P; Srigley, JR; Amin, MB; Martignoni, G; Hirsch, MS; Bonsib, SM; Trpkov, K				Williamson, Sean R.; Rao, Priya; Hes, Ondrej; Epstein, Jonathan I.; Smith, Steven C.; Picken, Maria M.; Zhou, Ming; Tretiakova, Maria S.; Tickoo, Satish K.; Chen, Ying-Bei; Reuter, Victor E.; Fleming, Stewart; Maclean, Fiona M.; Gupta, Nilesh S.; Kuroda, Naoto; Delahunt, Brett; Mehra, Rohit; Przybycin, Christopher G.; Cheng, Liang; Eble, John N.; Grignon, David J.; Moch, Holger; Lopez, Jose I.; Kunju, Lakshmi P.; Tamboli, Pheroze; Srigley, John R.; Amin, Mahul B.; Martignoni, Guido; Hirsch, Michelle S.; Bonsib, Stephen M.; Trpkov, Kiril			Challenges in Pathologic Staging of Renal Cell Carcinoma A Study of Interobserver Variability Among Urologic Pathologists	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						renal cell carcinoma; pathologic staging; vein invasion; renal sinus invasion; perinephric invasion	VEIN INVASION; SINUS; ONCOCYTOMA	Staging criteria for renal cell carcinoma differ from many other cancers, in that renal tumors are often spherical with subtle, finger-like extensions into veins, renal sinus, or perinephric tissue. We sought to study interobserver agreement in pathologic stage categories for challenging cases. An online survey was circulated to urologic pathologists interested in kidney tumors, yielding 89% response (31/35). Most questions included 1 to 4 images, focusing on: vascular and renal sinus invasion (n=24), perinephric invasion (n=9), and gross pathology/specimen handling (n=17). Responses were collapsed for analysis into positive and negative/equivocal for upstaging. Consensus was regarded as an agreement of 67% (2/3) of participants, which was reached in 20/33 (61%) evaluable scenarios regarding renal sinus, perinephric, or vein invasion, of which 13/33 (39%) had >= 80% consensus. Lack of agreement was especially encountered regarding small tumor protrusions into a possible vascular lumen, close to the tumor leading edge. For gross photographs, most were interpreted as suspicious but requiring histologic confirmation. Most participants (61%) rarely used special stains to evaluate vascular invasion, usually endothelial markers (81%). Most agreed that a spherical mass bulging well beyond the kidney parenchyma into the renal sinus (71%) or perinephric fat (90%) did not necessarily indicate invasion. Interobserver agreement in pathologic staging of renal cancer is relatively good among urologic pathologists interested in kidney tumors, even when selecting cases that test the earliest and borderline thresholds for extrarenal extension. Disagreements remain, however, particularly for tumors with small, finger-like protrusions, closely juxtaposed to the main mass.	[Williamson, Sean R.; Gupta, Nilesh S.] Henry Ford Canc Inst, Henry Ford Hlth Syst, Dept Pathol & Lab Med, Detroit, MI USA; [Williamson, Sean R.] Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA; [Mehra, Rohit; Kunju, Lakshmi P.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Rao, Priya; Tamboli, Pheroze] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Zhou, Ming] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX USA; [Hes, Ondrej] Charles Univ Prague, Dept Pathol, Univ Hosp Plzen, Plzen, Czech Republic; [Epstein, Jonathan I.] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; [Smith, Steven C.] VCU Sch Med, Dept Pathol, Richmond, VA USA; [Picken, Maria M.] Loyola Univ Med Ctr, Dept Pathol, Maywood, IL 60153 USA; [Tretiakova, Maria S.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA; [Tickoo, Satish K.; Chen, Ying-Bei; Reuter, Victor E.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA; [Fleming, Stewart] Univ Dundee, Dept Pathol, Dundee, Scotland; [Maclean, Fiona M.] Douglass Hanly Moir Pathol, Sydney, NSW, Australia; [Kuroda, Naoto] Kochi Red Cross Hosp, Dept Diagnost Pathol, Kochi, Kochi, Japan; [Delahunt, Brett] Univ Otago, Dept Pathol, Wellington, New Zealand; [Przybycin, Christopher G.] Cleveland Clin, Robert J Tomsich Pathol & Lab Med Inst, Dept Pathol, Cleveland, OH 44106 USA; [Cheng, Liang; Eble, John N.; Grignon, David J.] Indiana Univ Sch Med, Dept Pathol, Indianapolis, IN 46202 USA; [Moch, Holger] Univ Zurich, Dept Pathol & Mol Pathol, Zurich, Switzerland; [Moch, Holger] Univ Hosp Zurich, Zurich, Switzerland; [Lopez, Jose I.] Univ Basque Country, Cruces Univ Hosp, Biocruces Inst, Baracaldo, Spain; [Srigley, John R.] Trillium Hlth Partners, Mississauga, ON, Canada; [Trpkov, Kiril] Univ Calgary, Calgary, AB, Canada; [Trpkov, Kiril] Calgary Lab Serv, Calgary, AB, Canada; [Amin, Mahul B.] Univ Tennessee, Ctr Hlth Sci, Dept Pathol, Memphis, TN 38163 USA; [Martignoni, Guido] Univ Verona, Hosp Pederzoli Verona, Verona, Italy; [Martignoni, Guido] Univ Verona, Dept Diagnost & Publ Hlth, Verona, Italy; [Hirsch, Michelle S.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Hirsch, Michelle S.] Harvard Med Sch, Boston, MA USA; [Bonsib, Stephen M.] Arkana Labs, Little Rock, AR USA	Williamson, SR (reprint author), Henry Ford Hosp, Dept Pathol, K6,2799 West Grand Blvd, Detroit, MI 48202 USA.	swilli25@hfhs.org	Lopez, Jose Ignacio/L-3884-2019	Lopez, Jose Ignacio/0000-0003-0842-5348			Ball MW, 2016, BJU INT, V118, P112, DOI 10.1111/bju.13349; Bonsib SM, 2005, J UROLOGY, V174, P1199, DOI 10.1097/01.ju.0000173631.01329.1f; Bonsib SM, 2004, AM J SURG PATHOL, V28, P1594, DOI 10.1097/00000478-200412000-00007; Bonsib SM, 2000, AM J SURG PATHOL, V24, P451, DOI 10.1097/00000478-200003000-00015; Bonsib SM, 2011, MODERN PATHOL, V24, P1578, DOI 10.1038/modpathol.2011.124; Gress DM, 2017, AJCC CANC STAGING MA, P3; Hamilton Z, 2018, J CLIN ONCOL S6S, V36; Hes O, 2008, VIRCHOWS ARCH, V452, P193, DOI 10.1007/s00428-007-0541-1; Jacob JM, 2015, UROLOGY, V86, P956, DOI 10.1016/j.urology.2015.06.015; Reddy M, 2018, J CLIN ONCOL S6S, V36; Rini BI, 2017, AJCC CANC STAGING MA, P739; Sugino T, 2004, BMC MED, V2, DOI 10.1186/1741-7015-2-9; Thompson RH, 2007, AM J SURG PATHOL, V31, P1089; Trpkov K, 2013, AM J SURG PATHOL, V37, P1505, DOI 10.1097/PAS.0b013e31829a85d0; Wobker SE, 2017, J KIDNEY CANCER VHL, V4, P1, DOI 10.15586/jkcvhl.2017.96; Wobker SE, 2016, HUM PATHOL, V58, P1, DOI 10.1016/j.humpath.2016.07.020	16	3	3	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	SEP	2018	42	9					1253	1261		10.1097/PAS.0000000000001087			9	Pathology; Surgery	Pathology; Surgery	GR3QM	WOS:000442509200014	29878933				2019-10-28	
J	Schroder, S; Gunther, T				Schroeder, Soeren; Guenther, Thomas			Cytology Preparations of Formalin Fixative Aid Detection of Giardia in Duodenal Biopsy Samples A Helpful Tool for Diagnosing Esophageal Candidiasis as Well?	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Letter									[Schroeder, Soeren; Guenther, Thomas] Lademannbogen Labs, Dept Pathol, Hamburg, Germany	Schroder, S (reprint author), Lademannbogen Labs, Dept Pathol, Hamburg, Germany.						Panarelli NC, 2017, AM J SURG PATHOL, V41, P570, DOI 10.1097/PAS.0000000000000817; Schroder S, Z GASTROENTEROL	2	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	SEP	2018	42	9					1273	1274		10.1097/PAS.0000000000001078			2	Pathology; Surgery	Pathology; Surgery	GR3QM	WOS:000442509200016	29762142				2019-10-28	
J	Robert, ME; Crowe, SE; Burgart, L; Yantiss, RK; Lebwohl, B; Greenson, JK; Guandalini, S; Murray, JA				Robert, Marie E.; Crowe, Sheila E.; Burgart, Lawrence; Yantiss, Rhonda K.; Lebwohl, Benjamin; Greenson, Joel K.; Guandalini, Stefano; Murray, Joseph A.			Statement on Best Practices in the Use of Pathology as a Diagnostic Tool for Celiac Disease A Guide for Clinicians and Pathologists	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						celiac disease; tissue transglutaminase; intraepithelial lymphocytes; duodenal biopsy; drug injury	GLUTEN-SENSITIVE ENTEROPATHY; DUODENAL BULB BIOPSIES; WATER-IMMERSION TECHNIQUE; PATCHY VILLOUS ATROPHY; SMALL-INTESTINAL INFLAMMATION; INTRAEPITHELIAL LYMPHOCYTES; ENDOSCOPIC MARKERS; MULTIPLE BIOPSY; ZOOM ENDOSCOPY; FREE DIET	Small intestinal biopsy interpretation has been the cornerstone for the diagnosis of celiac disease for over 50 years. Despite the existence of sensitive and specific serological tests, duodenal mucosal biopsies continue to be obtained in the vast majority of patients in whom a diagnosis of celiac disease is being considered. The accurate evaluation of these biopsies requires coordination and information sharing between the gastroenterologist, laboratory, and pathologist in order to optimize tissue sampling, preparation and interpretation. This document, a collaboration between the Rodger C. Haggitt Gastrointestinal Pathology Society and the North American Association for the Study of Celiac Disease, is intended to provide clinicians and pathologists with a summary of best practices in the use of endoscopy and biopsy for patients with suspected celiac disease. The authors present a comprehensive and critical appraisal of the literature with respect to the topics of endoscopic findings, best methods for the obtaining biopsies, completing the pathology form and pathologic assessment, including evaluating intraepithelial lymphocytes and villous architecture. A discussion of conditions with overlapping pathologic findings in duodenal mucosal biopsies is presented. In order to provide additional guidance for challenging situations, the authors include an appendix containing practical suggestions. This review may be utilized in interdisciplinary discussions to optimize care for patients with possible celiac disease.	[Robert, Marie E.; Burgart, Lawrence; Yantiss, Rhonda K.; Greenson, Joel K.] Univ Michigan Hosp, Rodger C Haggitt Gastrointestinal Pathol Soc GIPS, Ann Arbor, MI 48109 USA; [Crowe, Sheila E.; Lebwohl, Benjamin; Guandalini, Stefano; Murray, Joseph A.] Univ Michigan Hosp, NASSCD, Ann Arbor, MI 48109 USA; [Greenson, Joel K.] Univ Michigan Hosp, Dept Pathol, Ann Arbor, MI 48109 USA; [Crowe, Sheila E.] Univ Calif San Diego, Div Gastroenterol, San Diego, CA 92103 USA; [Burgart, Lawrence] Univ Minnesota, Dept Pathol, Minneapolis, MN 55455 USA; [Murray, Joseph A.] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA; [Yantiss, Rhonda K.] Columbia Univ, Dept Pathol & Lab Med, Weill Cornell Med, New York, NY USA; [Lebwohl, Benjamin] Columbia Univ, Celiac Dis Ctr, New York, NY USA; [Robert, Marie E.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; [Guandalini, Stefano] Univ Chicago, Sect Pediat Gastroenterol, Chicago, IL USA	Robert, ME (reprint author), Yale Univ, Sch Med, 310 Cedar St,POB 208023, New Haven, CT 06520 USA.	marie.robert@yale.edu	Guandalini, Stefano/G-8084-2011				Adler DG, 2015, ODZE GOLDBLUMS SURG; Allen JI, 2015, GASTROENTEROLOGY, V149, P1088, DOI 10.1053/j.gastro.2015.07.040; Asmussen Lisa, 2009, Ugeskr Laeger, V171, P2646; Aziz I, 2017, GUT, V66, P1563, DOI 10.1136/gutjnl-2016-312271; Badreldin R, 2005, ENDOSCOPY, V37, P994, DOI 10.1055/s-2005-870245; Bardella MT, 2000, GASTROINTEST ENDOSC, V51, P714, DOI 10.1067/mge.2000.104653; Biagi F, 2004, J CLIN PATHOL, V57, P835, DOI 10.1136/jcp.2003.013607; BJARNASON I, 1987, GASTROENTEROLOGY, V93, P480, DOI 10.1016/0016-5085(87)90909-7; BJARNASON I, 1987, LANCET, V2, P711; BJARNASON I, 1987, SCAND J RHEUMATOL, P55; Bonamico M, 2004, J PEDIATR GASTR NUTR, V38, P204, DOI 10.1097/00005176-200402000-00019; Bonamico M, 2008, J PEDIATR GASTR NUTR, V47, P618, DOI 10.1097/MPG.0b013e3181677d6e; Brar P, 2007, DIGEST LIVER DIS, V39, P26, DOI 10.1016/j.dld.2006.07.014; BROCCHI E, 1988, NEW ENGL J MED, V319, P741, DOI 10.1056/NEJM198809223191202; Brown I, 2006, ARCH PATHOL LAB MED, V130, P1020; Cammarota G, 2007, ENDOSCOPY, V39, P46, DOI 10.1055/s-2006-945044; Cammarota G, 2009, J PEDIATR GASTR NUTR, V49, P411, DOI 10.1097/MPG.0b013e318198ca88; Cammarota G, 2009, J CLIN GASTROENTEROL, V43, P244, DOI 10.1097/MCG.0b013e318159c654; Caruso R, 2014, DIGEST LIVER DIS, V46, P323, DOI 10.1016/j.dld.2013.12.005; Chang FJ, 2005, APMIS, V113, P385, DOI 10.1111/j.1600-0463.2005.apm_204.x; Collin P, 2005, EUR J GASTROEN HEPAT, V17, P85, DOI 10.1097/00042737-200501000-00017; Corazza GR, 2007, CLIN GASTROENTEROL H, V5, P838, DOI 10.1016/j.cgh.2007.03.019; CORAZZA GR, 1993, GASTROINTEST ENDOSC, V39, P543, DOI 10.1016/S0016-5107(93)70167-4; Dickey W, 1999, AM J GASTROENTEROL, V94, P2182; Dickey W, 1998, SCAND J GASTROENTERO, V33, P612, DOI 10.1080/00365529850171882; Dickey W, 2001, AM J GASTROENTEROL, V96, P2126, DOI 10.1016/S0002-9270(01)02510-2; Emami Mohammad Hassan, 2008, Indian J Gastroenterol, V27, P183; Ensari A, 2010, ARCH PATHOL LAB MED, V134, P826, DOI 10.1043/1543-2165-134.6.826; Evans KE, 2011, AM J GASTROENTEROL, V106, P1837, DOI 10.1038/ajg.2011.171; FERGUSON A, 1977, GUT, V18, P921, DOI 10.1136/gut.18.11.921; Gasbarrini A, 2003, GASTROINTEST ENDOSC, V57, P348, DOI 10.1067/mge.2003.116; Gentile NM, 2013, MAYO CLIN PROC, V88, P414, DOI 10.1016/j.mayocp.2013.01.015; Goldstein NS, 2001, AM J CLIN PATHOL, V116, P63; Gonzalez RS, 2017, HISTOPATHOLOGY, V70, P223, DOI 10.1111/his.13068; Gonzalez S, 2010, GASTROINTEST ENDOSC, V72, P758, DOI 10.1016/j.gie.2010.06.026; HAGGITT RC, 1982, LAB MED, V13, P272; Hayashi Y, 2005, WORLD J GASTROENTERO, V11, P4861, DOI 10.3748/wjg.v11.i31.4861; Hayat M, 2002, J CLIN PATHOL, V55, P393, DOI 10.1136/jcp.55.5.393; Hopper AD, 2008, ENDOSCOPY, V40, P219, DOI 10.1055/s-2007-995361; Hudacko R, 2013, MODERN PATHOL, V26, P1241, DOI 10.1038/modpathol.2013.57; Iovino P, 2013, GASTROINTEST ENDOSC, V77, P233, DOI 10.1016/j.gie.2012.09.036; JABBARI M, 1988, GASTROENTEROLOGY, V95, P1518, DOI 10.1016/S0016-5085(88)80071-4; Jarvinen TT, 2004, SCAND J GASTROENTERO, V39, P428, DOI 10.1080/00365520310008773; Jehangir A, 2016, ACG CASE REP J, V3, P101, DOI [10.14309/crj.2016.13, 10.14309/crj.2015.13]; JENKINS D, 1985, J CLIN PATHOL, V38, P1119, DOI 10.1136/jcp.38.10.1119; Kakar S, 2003, AM J GASTROENTEROL, V98, P2027, DOI 10.1016/S0002-9270(03)00542-2; Katzin WE, 2012, HISTOLOGY PATHOLOGIS, P664; Kessler WF, 1997, J AM COLL SURGEONS, V185, P250, DOI 10.1016/S1072-7515(97)00067-7; KREUNING J, 1989, SCAND J GASTROENTERO, V24, P16, DOI 10.3109/00365528909091303; KREUNING J, 1978, J CLIN PATHOL, V31, P69, DOI 10.1136/jcp.31.1.69; Kurien M, 2012, GASTROINTEST ENDOSC, V75, P1190, DOI 10.1016/j.gie.2012.02.025; Latorre M, 2015, GASTROINTEST ENDOSC, V81, P1228, DOI 10.1016/j.gie.2014.10.024; Lebwohl B, 2011, GASTROINTEST ENDOSC, V74, P103, DOI 10.1016/j.gie.2011.03.1236; Lee SK, 2003, GASTROINTEST ENDOSC, V57, P187, DOI 10.1067/mge.2003.54; Lonardi S, 2013, VIRCHOWS ARCH, V463, P409, DOI 10.1007/s00428-013-1448-7; Louie CY, 2015, AM J SURG PATHOL, V39, P1653, DOI 10.1097/PAS.0000000000000525; Bosca MM, 2008, WORLD J GASTROENTERO, V14, P7009, DOI 10.3748/wjg.14.7009; MARSH MN, 1992, GASTROENTEROLOGY, V102, P330, DOI 10.1016/0016-5085(92)91819-P; MAURINO E, 1993, DIGEST DIS SCI, V38, P2028, DOI 10.1007/BF01297080; Memeo L, 2005, MODERN PATHOL, V18, P1134, DOI 10.1038/modpathol.3800404; Mino M, 2003, AM J SURG PATHOL, V27, P1237, DOI 10.1097/00000478-200309000-00007; Mooney PD, 2016, GASTROENTEROLOGY, V150, P1125, DOI 10.1053/j.gastro.2016.01.029; Moran CJ, 2012, AM J SURG PATHOL, V36, P1339, DOI 10.1097/PAS.0b013e318254f413; N Marsh Michael, 2015, Gastroenterol Hepatol Bed Bench, V8, P99; Nasseri-Moghaddam S, 2008, ARCH IRAN MED, V11, P136, DOI 08112/AIM.003; Oberhuber G, 1999, EUR J GASTROEN HEPAT, V11, P1185, DOI 10.1097/00042737-199910000-00019; Oble DA, 2008, AM J SURG PATHOL, V32, P1130, DOI 10.1097/PAS.0b013e31817150e3; Oxentenko AS, 2002, AM J GASTROENTEROL, V97, P933; Pais WP, 2008, GASTROINTEST ENDOSC, V67, P1082, DOI 10.1016/j.gie.2007.10.015; Pellegrino S, 2013, DIGESTION, V87, P254, DOI 10.1159/000350436; PERERA DR, 1975, HUM PATHOL, V6, P157, DOI 10.1016/S0046-8177(75)80176-6; Piazzi L, 2008, Minerva Gastroenterol Dietol, V54, P335; Prasad KK, 2009, J CLIN GASTROENTEROL, V43, P307, DOI 10.1097/MCG.0b013e31815b9d11; Ravelli A, 2005, AM J GASTROENTEROL, V100, P177, DOI 10.1111/j.1572-0241.2005.40669.x; Ravelli A, 2010, AM J GASTROENTEROL, V105, P2103, DOI 10.1038/ajg.2010.153; Ravelli AM, 2001, GASTROINTEST ENDOSC, V54, P736, DOI 10.1067/mge.2001.119217; Rostami K, 2017, GUT, V66, P2080, DOI 10.1136/gutjnl-2017-314297; Rostami K, 2015, WORLD J GASTROENTERO, V21, P2593, DOI 10.3748/wjg.v21.i9.2593; Rostom A, 2006, GASTROENTEROLOGY, V131, P1981, DOI 10.1053/j.gastro.2006.10.004; Rubio-Tapia A, 2013, AM J GASTROENTEROL, V108, P656, DOI 10.1038/ajg.2013.79; Rubio-Tapia A, 2012, MAYO CLIN PROC, V87, P732, DOI 10.1016/j.mayocp.2012.06.003; Sheiko MA, 2015, GASTROINTEST ENDOSC, V81, P1385, DOI 10.1016/j.gie.2014.09.010; Shmidt E, 2014, GASTROINTEST ENDOSC, V80, P105, DOI 10.1016/j.gie.2014.01.008; Stoven SA, 2016, CLIN GASTROENTEROL H, V14, P1582, DOI 10.1016/j.cgh.2016.02.026; Taavela J, 2016, AM J GASTROENTEROL, V111, P124, DOI 10.1038/ajg.2015.387; Valitutti F, 2014, DIGEST LIVER DIS, V46, P1099, DOI 10.1016/j.dld.2014.08.039; Veress B, 2004, SCAND J GASTROENTERO, V39, P138, DOI 10.1080/00365520310007675; Walker MM, 2010, GASTROENTEROLOGY, V139, P112, DOI 10.1053/j.gastro.2010.04.007; Weidner AS, 2015, AM J SURG PATHOL, V39, P1661, DOI 10.1097/PAS.0000000000000522; WYATT JI, 1987, J CLIN PATHOL, V40, P841, DOI 10.1136/jcp.40.8.841; Yardley J H, 1990, Monogr Pathol, P69; Yousef MM, 2006, CLIN GASTROENTEROL H, V4, P631, DOI 10.1016/j.cgh.2005.12.014; Ziegler TR, 2003, GASTROENTEROLOGY, V124, P1950, DOI 10.1016/S0016-5085(03)00405-0	93	3	4	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	SEP	2018	42	9					E44	E58		10.1097/PAS.0000000000001107			15	Pathology; Surgery	Pathology; Surgery	GR3QM	WOS:000442509200001	29923907				2019-10-28	
J	[Anonymous]				[Anonymous]			Image Challenge in Veterinary Pathology	VETERINARY PATHOLOGY			English	Editorial Material																	0	0	0	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	SEP	2018	55	5					605	+		10.1177/0300985818784148			3	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GR5JY	WOS:000442667700001	30139321				2019-10-28	
J	Lohr, CV				Lohr, Christiane V.			From Hyraxes to Bioinformatics and Award-Winning Presentations-An Exciting Program Is Awaiting You at the Focused Scientific Sessions of the Combined 2018 ACVP and ASVCP Meeting in Washington, DC	VETERINARY PATHOLOGY			English	Editorial Material									[Lohr, Christiane V.] ACVP Educ Comm, Madison, WI 53704 USA	Lohr, CV (reprint author), ACVP Educ Comm, Madison, WI 53704 USA.							0	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	SEP	2018	55	5					606	606		10.1177/0300985818789471			1	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GR5JY	WOS:000442667700002	30139323	Bronze			2019-10-28	
J	Raposo-Ferreira, TMM; Brisson, BK; Durham, AC; Laufer-Amorim, R; Kristiansen, V; Pure, E; Volk, SW; Sorenmo, K				Raposo-Ferreira, Talita M. M.; Brisson, Becky K.; Durham, Amy C.; Laufer-Amorim, Renee; Kristiansen, Veronica; Pure, Ellen; Volk, Susan W.; Sorenmo, Karin			Characteristics of the Epithelial-Mesenchymal Transition in Primary and Paired Metastatic Canine Mammary Carcinomas	VETERINARY PATHOLOGY			English	Article						dog; epithelial-mesenchymal transition; mammary tumors; metastasis; prognostic factor; transcriptional factors	LYMPH-NODE METASTASES; E-CADHERIN EXPRESSION; HUMAN BREAST-CANCER; BETA-CATENIN; GLAND TUMORS; IMMUNOHISTOCHEMICAL EXPRESSION; CLINICOPATHOLOGICAL FEATURES; GASTRIC-CANCER; PET DOGS; SURVIVAL	The epithelial-mesenchymal transition (EMT) is a dynamic process linked to metastasis in many tumor types, including mammary tumors. In this study, we evaluated E-cadherin and vimentin immunolocalization in primary canine mammary carcinomas (20 cases) and their respective metastases, as well as their relationship with the core regulators SNAIL/SLUG. To assess the number of cells undergoing the process of EMT, we quantitated double-positive (E-cadherin(+)/vinnentin(+)) cells using immunofluorescence, via cell counting and image analysis. In addition, SNAIL/SLUG expression was evaluated by established immunohistochemical methods. Primary tumors had significantly more E-cadherin(+)/vinnentin(+) co-expression than their paired respective lymph node or distant metastasis, respectively. Furthermore, the percentage of E-cadherin(+)/vinnentin(+) cells in grade II and III carcinomas was significantly higher than in grade I tumors. Primary tumors had significantly higher SNAIL/SLUG expression when analyzed based on the percentage of positive cells compared with their respective distant metastases in pairwise comparisons. An inverse correlation was noted between SNAIL/SLUG immunoreactivity and percentage of E-cadherin(+)/vinnentin(+) immunopositive cells in primary tumor samples when SNAIL/SLUG immunoreactivity was grouped into 2 categories (high versus low) based on percentage-positive staining. These results show a positive correlation between E-cadherin(+)/vinnentin(+) cells and higher tumor grade, establish differences between primary tumor and their respective metastases, and provide further support that EMT plays a critical role in the metastasis of canine mammary carcinoma. Furthermore, these data suggest that modulation of this process could provide greater therapeutic control and provide support for further research to determine if E-cadherin(+)/vinnentin(+) co-immunoreactivity imparts predictive value in the clinical outcome of patients with canine mammary carcinomas.	[Raposo-Ferreira, Talita M. M.] Sao Paulo State Univ, UNESP, Sch Agr & Veterinarian Sci, Dept Vet Clin & Surg, Jaboticabal, Brazil; [Brisson, Becky K.; Volk, Susan W.] Univ Penn, Sch Vet Med, Dept Clin Sci & Adv Med, Philadelphia, PA 19104 USA; [Durham, Amy C.] Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA; [Durham, Amy C.; Pure, Ellen; Volk, Susan W.; Sorenmo, Karin] Univ Penn, Penn Vet Canc Ctr, Philadelphia, PA 19104 USA; [Laufer-Amorim, Renee] Sao Paulo State Univ, Sch Vet Med & Anim Sci, Dept Vet Clin, UNESP, Botucatu, SP, Brazil; [Kristiansen, Veronica] Norwegian Univ Life Sci, Fac Vet Med & Biosci, Dept Compan Anim Clin Sci, Oslo, Norway; [Pure, Ellen; Volk, Susan W.; Sorenmo, Karin] Univ Penn, Sch Vet Med, Dept Biomed Sci, Philadelphia, PA 19104 USA	Sorenmo, K (reprint author), Ryan Vet Hosp, Dept Biomed Sci, 3900 Delancey St, Philadelphia, PA 19104 USA.; Volk, SW (reprint author), Dept Clin Sci & Adv Med, 312 Hill Pavil,380 S Univ Ave, Philadelphia, PA 19104 USA.; Volk, SW (reprint author), Dept Biomed Sci, 312 Hill Pavil,380 S Univ Ave, Philadelphia, PA 19104 USA.	swvolk@vet.upenn.edu; karins@vet.upenn.edu			Penn Vet Shelter Canine Mammary Tumor Program School of Veterinary Medicine, University of Pennsylvania by the Petco Foundation; Blue Buffalo Foundation; Jack and Mina Ebrahimi Foundation; Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2015/09046-9]	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Penn Vet Shelter Canine Mammary Tumor Program School of Veterinary Medicine, University of Pennsylvania, through funding provided by the Petco Foundation and the Blue Buffalo Foundation. Additional funding was provided by the Jack and Mina Ebrahimi Foundation, as well as a grant from the Sao Paulo Research Foundation (FAPESP; grant 2015/09046-9).	Alenza DP, 1998, J VET INTERN MED, V12, P132, DOI 10.1111/j.1939-1676.1998.tb02108.x; Andrade FHE, 2010, DIAGN PATHOL, V5, DOI 10.1186/1746-1596-5-45; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Brilliant Yu. M., 2017, Arkhiv Patologii, V79, P12, DOI 10.17116/patol201779112-18; Brisson BK, 2015, AM J PATHOL, V185, P1471, DOI 10.1016/j.ajpath.2015.01.029; Bronden LB, 2010, VET REC, V166, P586, DOI 10.1136/vr.b4808; Brunetti B, 2005, VET PATHOL, V42, P781, DOI 10.1354/vp.42-6-781; Brunetti B, 2003, J VET MED A, V50, P496, DOI 10.1111/j.1439-0442.2003.00577.x; da Costa A, 2011, VET J, V190, P165, DOI 10.1016/j.tvjl.2010.09.027; de Araujo MR, 2015, J VET INTERN MED, V29, P1360, DOI 10.1111/jvim.13576; Dobson JM, 2002, J SMALL ANIM PRACT, V43, P240, DOI 10.1111/j.1748-5827.2002.tb00066.x; DORN CR, 1968, JNCI-J NATL CANCER I, V40, P307; Drasin DJ, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3037; Egenvall A, 2005, PREV VET MED, V69, P109, DOI 10.1016/j.prevetmed.2005.01.014; De Matos AJF, 2007, APMIS, V115, P327, DOI 10.1111/j.1600-0463.2007.apm_544.x; Gama A, 2003, VET PATHOL, V40, P412, DOI 10.1354/vp.40-4-412; Gama A, 2008, VIRCHOWS ARCH, V453, P123, DOI 10.1007/s00428-008-0644-3; Gamba CO, 2015, J COMP PATHOL, V153, P256, DOI 10.1016/j.jcpa.2015.08.006; Goldschmidt M, 2011, VET PATHOL, V48, P117, DOI 10.1177/0300985810393258; Gruntzig K, 2015, J COMP PATHOL, V152, P161, DOI 10.1016/j.jcpa.2015.02.005; Gupta GP, 2007, NATURE, V446, P765, DOI 10.1038/nature05760; Harigopal Malini, 2005, World J Surg Oncol, V3, P73, DOI 10.1186/1477-7819-3-73; Heimann R, 2000, CANCER RES, V60, P298; Hemalatha A, 2013, INDIAN J CANCER, V50, P189, DOI 10.4103/0019-509X.118724; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Im KS, 2012, J COMP PATHOL, V147, P121, DOI 10.1016/j.jcpa.2011.12.002; Jin HY, 2010, INT J CANCER, V126, P2102, DOI 10.1002/ijc.24901; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Karayannopoulou M, 2005, J COMP PATHOL, V133, P246, DOI 10.1016/j.jcpa.2005.05.003; Karihtala P, 2013, BREAST CANCER RES TR, V138, P81, DOI 10.1007/s10549-013-2442-0; Klopfleisch R, 2011, VET J, V190, P236, DOI [10.1016/j.tvjl.2010.10.018, 10.1016/j.tvjl.2011.04.010]; Klopfleisch R, 2009, VET PATHOL, V46, P416, DOI 10.1354/vp.08-VP-0212-K-FL; Komazawa S, 2016, J VET MED SCI, V78, P1269, DOI 10.1292/jvms.15-0584; Kowalski PJ, 2003, BREAST CANCER RES, V5, pR217, DOI 10.1186/bcr651; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Lazar D, 2008, ROM J MORPHOL EMBRYO, V49, P459; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Liu T, 2013, J SURG ONCOL, V107, P188, DOI 10.1002/jso.23240; Markiewicz A, 2014, AM J TRANSL RES, V6, P793; Matos AJF, 2006, J COMP PATHOL, V134, P182, DOI 10.1016/j.jcpa.2005.10.004; Merlo DF, 2008, J VET INTERN MED, V22, P976, DOI 10.1111/j.1939-1676.2008.0133.x; Misdorp W., 2002, Tumors in domestic animals, P575, DOI 10.1002/9780470376928.ch12; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Park D, 2007, APMIS, V115, P52, DOI 10.1111/j.1600-0463.2007.apm_524.x; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pena L, 2014, VET PATHOL, V51, P127, DOI 10.1177/0300985813509388; Pena L, 2013, VET PATHOL, V50, P94, DOI 10.1177/0300985812447830; Peng Z, 2014, WORLD J GASTROENTERO, V20, P5403, DOI 10.3748/wjg.v20.i18.5403; Philibert JC, 2003, J VET INTERN MED, V17, P102, DOI 10.1892/0891-6640(2003)017<0102:IOHFOS>2.3.CO;2; Pinho SS, 2012, TRANSL RES, V159, P165, DOI 10.1016/j.trsl.2011.11.005; Rakha EA, 2005, HISTOPATHOLOGY, V46, P685, DOI 10.1111/j.1365-2559.2005.02156.x; Rao NAS, 2009, J PHYSIOL PHARMACOL, V60, P73; Restucci B, 2007, ANTICANCER RES, V27, P3083; Rismanchi S, 2014, BIOMED REP, V2, P725, DOI 10.3892/br.2014.312; SCHNEIDER R, 1969, JNCI-J NATL CANCER I, V43, P1249; Sleeckx N, 2011, REPROD DOMEST ANIM, V46, P1112, DOI 10.1111/j.1439-0531.2011.01816.x; SONNENSCHEIN EG, 1991, AM J EPIDEMIOL, V133, P694, DOI 10.1093/oxfordjournals.aje.a115944; Sorenmo K, 2003, VET CLIN N AM-SMALL, V33, P573, DOI 10.1016/S0195-5616(03)00020-2; Sorenmo KU, 2013, SMALL ANIMAL CLIN ON, P538; Tanaka K, 2016, CLIN BREAST CANCER, V16, P520, DOI 10.1016/j.clbc.2016.06.015; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tsuji T, 2009, CANCER RES, V69, P7135, DOI 10.1158/0008-5472.CAN-09-1618; Vascellari M, 2016, PREV VET MED, V126, P183, DOI 10.1016/j.prevetmed.2016.02.008; Vascellari M, 2009, BMC VET RES, V5, DOI 10.1186/1746-6148-5-39; Yao DB, 2011, MOL CANCER RES, V9, P1608, DOI 10.1158/1541-7786.MCR-10-0568; Yoshida K, 2014, J VET MED SCI, V76, P1321, DOI 10.1292/jvms.14-0104; Zappulli V, 2012, J COMP PATHOL, V147, P161, DOI 10.1016/j.jcpa.2012.02.004	69	4	4	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	SEP	2018	55	5					622	633		10.1177/0300985818776054			12	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GR5JY	WOS:000442667700004	29788797	Bronze, Green Published			2019-10-28	
J	Kishimoto, TE; Uchida, K; Thongtharb, A; Shibato, T; Chambers, JK; Nibe, K; Kagawa, Y; Nakayama, H				Kishimoto, Takuya E.; Uchida, Kazuyuki; Thongtharb, Atigan; Shibato, Tokuhiro; Chambers, James K.; Nibe, Kazumi; Kagawa, Yumiko; Nakayama, Hiroyuki			Expression of Oligodendrocyte Precursor Cell Markers in Canine Oligodendrogliomas	VETERINARY PATHOLOGY			English	Article						anaplastic oligodendroglioma; brain; cell of origin; dog; glioma; oligodendrocyte precursor cell	CENTRAL-NERVOUS-SYSTEM; CANCER STEM-CELLS; HUMAN GLIOMAS; SUBVENTRICULAR ZONE; GLIAL PROGENITORS; LINEAGE GENES; BRAIN-TUMORS; IN-VITRO; ASTROCYTES; OLIG2	Oligodendroglioma is a common brain tumor in dogs, particularly brachycephalic breeds. Oligodendrocyte precursor cells (OPCs) are suspected to be a possible origin of oligodendroglioma, although it has not been well elucidated. In the present study, 27 cases of canine brain oligodendrogliomas were histologically and immunohistochemically examined. The most commonly affected breed was the French Bulldog (n = 19 of 27, 70%). Seizure was the most predominant clinical sign (n = 17 of 25, 68%). The tumors were located mainly in the cerebrum, particularly in the frontal lobe (n = 10 of 27, 37%). All cases were diagnosed as anaplastic oligodendroglioma (AO) and had common histologic features characterized by the proliferation of round to polygonal cells with pronounced atypia and conspicuous mitotic activity (average, 10.7 mitoses per 10 high-power fields). Honeycomb pattern (n = 5 of 27, 19%), myxoid matrix (n = 1 0, 37%), cyst formation (n = 6, 22%), necrosis (n = 19, 70%), pseudopalisading (n = 5, 18.5%), glomeruloid vessels (n = 16, 59%), and microcalcification (n = 5, 19%) were other histopathologic features of the present tumors. Immunohistochemically, the tumor cells were positive for Olig2 in all cases and for other markers of OPCs in most cases, including SOX 10 (n = 24 of 27, 89%), platelet-derived growth factor receptor( )alpha (n = 24, 89%), and NG2 (n = 23, 85%). The present AO also consisted of heterogeneous cell populations that were positive for nestin (n = 13 of 27, 48%), glial fibrillary acidic protein (n = 5, 19%), doublecortin (n = 22, 82%), and beta III-tubulin (n = 15, 56%). Moreover, cultured AO cells obtained from 1 case retained expression of OPC markers and exhibited multipotent characteristics in a serum culture condition. Overall, the findings suggest that transformed multipotent OPCs may be a potential origin of canine AO.	[Kishimoto, Takuya E.; Uchida, Kazuyuki; Thongtharb, Atigan; Chambers, James K.; Nakayama, Hiroyuki] Univ Tokyo, Lab Vet Pathol, Grad Sch Agr & Life Sci, Tokyo, Japan; [Shibato, Tokuhiro] Minori Anim Clin, Tokyo, Japan; [Nibe, Kazumi] Japan Anim Referral Med Ctr Kawasaki, Kawasaki, Kanagawa, Japan; [Kagawa, Yumiko] North Lab, Sapporo, Hokkaido, Japan	Uchida, K (reprint author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Pathol, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	auchidak@mail.ecc.u-tokyo.ac.jp					Bannykh SI, 2006, J NEURO-ONCOL, V76, P115, DOI 10.1007/s11060-005-5533-x; Baracskay KL, 2007, GLIA, V55, P1001, DOI 10.1002/glia.20519; Beier D, 2008, BRAIN PATHOL, V18, P370, DOI 10.1111/j.1750-3639.2008.00130.x; Briancon-Marjollet A, 2010, CARCINOGENESIS, V31, P1718, DOI 10.1093/carcin/bgq154; Cai N, 2012, CEREBELLUM, V11, P181, DOI 10.1007/s12311-011-0294-x; Canoll P, 2008, ACTA NEUROPATHOL, V116, P465, DOI 10.1007/s00401-008-0432-9; Cassiani-Ingoni R, 2006, EXP NEUROL, V201, P349, DOI 10.1016/j.expneurol.2006.04.030; Chen LP, 2012, NEUROSCIENCE, V221, P96, DOI 10.1016/j.neuroscience.2012.06.063; Chojnacki A, 2008, NAT PROTOC, V3, P935, DOI 10.1038/nprot.2008.55; Colin C, 2006, NEUROPATH APPL NEURO, V32, P189, DOI 10.1111/j.1365-2990.2006.00740.x; Cuddapah VA, 2014, NAT REV NEUROSCI, V15, P455, DOI 10.1038/nrn3765; Dawson MRL, 2003, MOL CELL NEUROSCI, V24, P476, DOI 10.1016/S1044-7431(03)00210-0; Eliasson C, 1999, J BIOL CHEM, V274, P23996, DOI 10.1074/jbc.274.34.23996; Fernandez F, 2016, VET J, V209, P125, DOI 10.1016/j.tvjl.2015.10.039; Gibson EM, 2014, SCIENCE, V344, P487, DOI 10.1126/science.1252304; Goldman SA, 2015, DEVELOPMENT, V142, P3983, DOI 10.1242/dev.126409; Griffin CA, 2006, J NEUROPATH EXP NEUR, V65, P988, DOI 10.1097/01.jnen.0000235122.98052.8f; Haas C, 2012, EXP NEUROL, V233, P717, DOI 10.1016/j.expneurol.2011.11.002; Herranz C, 2016, J COMP PATHOL, V154, P169, DOI 10.1016/j.jcpa.2015.12.001; Higgins RJ, 2010, J NEURO-ONCOL, V98, P49, DOI 10.1007/s11060-009-0072-5; Ide T, 2010, VET PATHOL, V47, P741, DOI 10.1177/0300985810363486; Jenkins RB, 2006, CANCER RES, V66, P9852, DOI 10.1158/0008-5472.CAN-06-1796; Koestner A., 2002, Tumors in domestic animals, P697, DOI 10.1002/9780470376928.ch14; Koestner A., 1999, HISTOLOGICAL CLASSIF; Koestner A, 1997, VET PATHOL, P1259; Kondo T, 2000, SCIENCE, V289, P1754, DOI 10.1126/science.289.5485.1754; Lindberg N, 2009, ONCOGENE, V28, P2266, DOI 10.1038/onc.2009.76; Liu C, 2011, CELL, V146, P209, DOI 10.1016/j.cell.2011.06.014; Louis D, 2007, WHO CLASSIFICATION T; LOUIS JC, 1992, J NEUROSCI RES, V31, P193, DOI 10.1002/jnr.490310125; Lu QR, 2000, NEURON, V25, P317, DOI 10.1016/S0896-6273(00)80897-1; Menn B, 2006, J NEUROSCI, V26, P7907, DOI 10.1523/JNEUROSCI.1299-06.2006; Nishiyama A, 2009, NAT REV NEUROSCI, V10, P9, DOI 10.1038/nrn2495; Ohnishi A, 2003, J NEUROPATH EXP NEUR, V62, P1052, DOI 10.1093/jnen/62.10.1052; Persson AI, 2010, CANCER CELL, V18, P669, DOI 10.1016/j.ccr.2010.10.033; Riemenschneider MJ, 2004, ACTA NEUROPATHOL, V107, P277, DOI 10.1007/s00401-003-0809-8; Rissi DR, 2015, J VET DIAGN INVEST, V27, P396, DOI 10.1177/1040638715584619; Rowitch DH, 2004, NAT REV NEUROSCI, V5, P409, DOI 10.1038/nrn1389; Scherer HJ, 1940, J NEUROL PSYCHIATRY, V3, P147, DOI 10.1136/jnnp.3.2.147; Shoshan Y, 1999, P NATL ACAD SCI USA, V96, P10361, DOI 10.1073/pnas.96.18.10361; Simon C, 2011, GLIA, V59, P869, DOI 10.1002/glia.21156; Snyder JM, 2006, J VET INTERN MED, V20, P669, DOI 10.1892/0891-6640(2006)20[669:CIPNC]2.0.CO;2; Song RB, 2013, J VET INTERN MED, V27, P1143, DOI 10.1111/jvim.12136; Spitzbarth I, 2017, VET PATHOL, V54, P369, DOI 10.1177/0300985816688745; Stoica G, 2009, VET PATHOL, V46, P391, DOI 10.1354/vp.08-VP-0218-S-FL; Takebayashi H, 2000, MECH DEVELOP, V99, P143, DOI 10.1016/S0925-4773(00)00466-4; VANDEVELDE M, 1985, ACTA NEUROPATHOL, V66, P111, DOI 10.1007/BF00688685; von Bohlen und Halbach O, 2007, CELL TISSUE RES, V329, P409, DOI 10.1007/s00441-007-0432-4; Wegner M, 2008, J MOL NEUROSCI, V35, P3, DOI 10.1007/s12031-007-9008-8; Wesseling P, 2015, ACTA NEUROPATHOL, V129, P809, DOI 10.1007/s00401-015-1424-1; Wilson HC, 2006, J NEUROIMMUNOL, V176, P162, DOI 10.1016/j.jneuroim.2006.04.014; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Young BD, 2011, VET RADIOL ULTRASOUN, V52, P132, DOI 10.1111/j.1740-8261.2010.01758.x; Zhou Q, 2002, CELL, V109, P61, DOI 10.1016/S0092-8674(02)00677-3	54	0	0	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	SEP	2018	55	5					634	644		10.1177/0300985818777794			11	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GR5JY	WOS:000442667700005	29852819	Bronze			2019-10-28	
J	Sabattini, S; Lopparelli, RM; Rigillo, A; Giantin, M; Renzi, A; Matteo, C; Capitani, O; Dacasto, M; Mengoli, M; Bettini, G				Sabattini, Silvia; Lopparelli, Rosa Maria; Rigillo, Antonella; Giantin, Mery; Renzi, Andrea; Matteo, Chiara; Capitani, Ombretta; Dacasto, Mauro; Mengoli, Marisa; Bettini, Giuliano			Canine Splenic Nodular Lymphoid Lesions: Immunophenotyping, Proliferative Activity, and Clonality Assessment	VETERINARY PATHOLOGY			English	Article						dogs; clonality; immunophenotype; indolent lymphoma; hyperplasia; Ki-67 proliferation index; spleen	MARGINAL ZONE LYMPHOMA; INFLAMMATORY-BOWEL-DISEASE; NON-HODGKINS-LYMPHOMAS; FIBROHISTIOCYTIC NODULES; CELL LYMPHOMA; KI67; DOGS; ANTIGEN; TUMORS; ASSOCIATION	Canine splenic lymphoid nodules are currently classified as indolent lymphomas (marginal zone lymphoma [MZL], mantle cell lymphoma [MCL]) or nodular hyperplasia (lymphoid [LNH] or complex [CNH] type). Their differentiation can be difficult on morphology, because of similar histologic appearance and poorly defined diagnostic criteria. Thirty-five surgical samples of splenic lymphoid nodules were reviewed in order to assess the diagnostic contribution of immunophenotyping, proliferative activity and clonality (PARR) in differentiating between hyperplastic and neoplastic lesions. Proliferative activity was evaluated by double immunolabeling for Ki-67 and CD79a, in order to separately assess the proliferative activity of B cells and non-B cells. Definitive diagnoses were MZL (n = 11), MCL (n = 4), LNH (n = 10), and CNH (n = 10). The overall concordance between histology and PARR was above 90%. Lymphomas had a significantly higher percentage of CD79a-positive areas (mean, 36.30%; P = .0004) and a higher B-cell proliferative activity (median Ki-67 index, 5.49%; P = .0012). The threshold value most accurately predicting a diagnosis of lymphoma was >= 28% of B-cell areas, with a Ki-67 index above 3%. Dogs were monitored for a median follow-up time of 870 days (IQR, 569-1225), and no relapses were documented. Overall median survival time was 1282 days. The combination of histology, immunohistochemistry and PARR can improve the diagnostic accuracy for canine splenic lymphoid nodules, although the long-term behavior of these lesions appears similar.	[Sabattini, Silvia; Rigillo, Antonella; Renzi, Andrea; Matteo, Chiara; Capitani, Ombretta; Mengoli, Marisa; Bettini, Giuliano] Univ Bologna, Alma Mater Studiorum, Dept Vet Med Sci, Ozzano Dellemilia, BO, Italy; [Lopparelli, Rosa Maria; Giantin, Mery; Dacasto, Mauro] Univ Padua, Dept Comparat Biomed & Food Sci, Padua, Italy	Bettini, G (reprint author), Univ Bologna, Dept Vet Med Sci, Via Tolara di Sopra 50, I-40064 Ozzano Dellemilia, BO, Italy.	giuliano.bettini@unibo.it					Aresu L, 2014, VET J, V200, P318, DOI 10.1016/j.tvjl.2014.03.006; Bauer NB, 2007, J VET INTERN MED, V21, P928, DOI 10.1892/0891-6640(2007)21[928:ANORAK]2.0.CO;2; Bergin IL, 2011, VET PATHOL, V48, P41, DOI 10.1177/0300985810388947; Bettini G., 2001, European Journal of Veterinary Pathology, V7, P101; Burnett RC, 2003, VET PATHOL, V40, P32, DOI 10.1354/vp.40-1-32; Carrasco V, 2015, VET PATHOL, V52, P668, DOI 10.1177/0300985814559398; Flood-Knapik KE, 2013, VET COMP ONCOL, V11, P272, DOI 10.1111/j.1476-5829.2011.00317.x; FournelFleury C, 1997, J COMP PATHOL, V117, P61, DOI 10.1016/S0021-9975(97)80066-7; HALL PA, 1988, J PATHOL, V154, P223, DOI 10.1002/path.1711540305; Keller SM, 2016, VET PATHOL, V53, P711, DOI 10.1177/0300985815626576; Keller SM, 2012, VET IMMUNOL IMMUNOP, V145, P410, DOI 10.1016/j.vetimm.2011.12.019; Kisseberth WC, 2007, LEUKEMIA RES, V31, P1709, DOI 10.1016/j.leukres.2007.04.003; Kiupel M, 2011, VET PATHOL, V48, P212, DOI 10.1177/0300985810389479; Maglennon GA, 2008, VET COMP ONCOL, V6, P268, DOI 10.1111/j.1476-5829.2008.00168.x; Mazloom A, 2010, CANCER-AM CANCER SOC, V116, P4291, DOI 10.1002/cncr.25325; MILLER TP, 1994, BLOOD, V83, P1460; Moore AS, 2012, J VET INTERN MED, V26, P1164, DOI 10.1111/j.1939-1676.2012.00986.x; O'Brien D, 2013, J VET INTERN MED, V27, P949, DOI 10.1111/jvim.12116; Olszewski AJ, 2013, CANCER-AM CANCER SOC, V119, P629, DOI 10.1002/cncr.27773; Poggi A, 2015, VET COMP ONCOL, V13, P475, DOI 10.1111/vco.12078; Rutgen BC, 2010, LEUKEMIA RES, V34, P932, DOI 10.1016/j.leukres.2010.01.021; Sabattini S, 2016, J SMALL ANIM PRACT, V57, P396, DOI 10.1111/jsap.12494; Sabattini S, 2015, J COMP PATHOL, V152, P145, DOI 10.1016/j.jcpa.2014.12.011; Spangler WL, 1998, VET PATHOL, V35, P488, DOI 10.1177/030098589803500603; Stefanello D, 2011, J VET INTERN MED, V25, P90, DOI 10.1111/j.1939-1676.2010.0639.x; Valli V. E., 2017, Tumors in domestic animals, P203; Valli VE, 2011, VET PATHOL, V48, P198, DOI 10.1177/0300985810379428; Valli VE, 2006, VET PATHOL, V43, P241, DOI 10.1354/vp.43-3-241; van Stee LL, 2015, VET SURG, V44, P976, DOI 10.1111/vsu.12405; Vascellari M, 2013, VET PATHOL, V50, P110, DOI 10.1177/0300985812447829	30	1	1	1	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	SEP	2018	55	5					645	653		10.1177/0300985818777035			9	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GR5JY	WOS:000442667700006	29807508	Bronze, Green Published			2019-10-28	
J	Saito, T; Chambers, JK; Nakashima, K; Uchida, E; Ohno, K; Tsujimoto, H; Uchida, K; Nakayama, H				Saito, Tsubasa; Chambers, James K.; Nakashima, Ko; Uchida, Eri; Ohno, Koichi; Tsujimoto, Hajime; Uchida, Kazuyuki; Nakayama, Hiroyuki			Histopathologic Features of Colorectal Adenoma and Adenocarcinoma Developing Within Inflammatory Polyps in Miniature Dachshunds	VETERINARY PATHOLOGY			English	Article						beta-catenin; colorectal tumor; dogs; familial adenomatous polyposis; immunohistochemistry; inflammatory polyp	FOCAL SQUAMOUS METAPLASIA; BETA-CATENIN; MORULA FORMATION; EXPRESSION; APC; TUMORIGENESIS; TUMORS; GENES; CHROMOSOME-5Q21; IDENTIFICATION	Biopsy samples of colorectal polyps were collected and examined from 67 Miniature Dachshund dogs (including 35 cases with an additional biopsy). Histopathologic diagnoses of the initial biopsy samples were "inflammatory polyp" in 52 cases (78%), "adenoma" in 10 cases (15%), and "adenocarcinoma" in 5 cases (8%). Eight of 10 cases (80%) diagnosed as adenoma also had inflammatory polyp lesions in the same specimen. A second biopsy was performed in 25 cases (48%) initially diagnosed with inflammatory polyp. Pathologic diagnoses for the second biopsy were inflammatory polyp in II cases (44%), adenoma in 9 cases (36%), and adenocarcinoma in 5 cases (20%). The number of beta-catenin-positive nuclei in epithelial cells was significantly higher in adenoma (46%) and adenocarcinoma (75%) as compared with inflammatory polyp (6%). Normal epithelial cells and hyperplastic goblet cells in inflammatory polyps showed homogeneous positive cytoplasmic immunoreactivity for adenomatous polyposis coli (APC) antigen. However, APC expression was decreased in areas of intense nuclear beta-catenin expression in adenoma and adenocarcinoma lesions. Foci of cytokeratin 5/6-positive squamous cell-like neoplastic cells showed intense beta-catenin nuclear expression that was similar to squamous morules described in human colorectal tumors. The results of the present study suggest that the inflammatory polyp in Miniature Dachshunds is a progressive disease that may develop into adenoma and/or adenocarcinoma. In addition, immunohistochemical findings suggest that aberrations of APC and beta-catenin expression may be involved in tumor development within the inflammatory polyp lesions.	[Saito, Tsubasa; Chambers, James K.; Uchida, Eri; Uchida, Kazuyuki; Nakayama, Hiroyuki] Univ Tokyo, Lab Vet Pathol, Grad Sch Agr & Life Sci, Bunkyo Ku, Tokyo, Japan; [Nakashima, Ko] Japan Small Anim Med Ctr, Saitama, Japan; [Ohno, Koichi; Tsujimoto, Hajime] Univ Tokyo, Grad Sch Agr & Life Sci, Lab Vet Internal Med, Bunkyo Ku, Tokyo, Japan	Uchida, K (reprint author), Univ Tokyo, Lab Vet Pathol, Grad Sch Agr & Life Sci, Tokyo 8657, Japan.	auchidak@mail.ecc.u-tokyo.ac.jp		Nakashima, Ko/0000-0002-4823-4821	Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [15K14863]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported in part by the Japan Society for the Promotion of Science (grant 15K14863).	ALMAGRO UA, 1984, CANCER, V53, P2679, DOI 10.1002/1097-0142(19840615)53:12<2679::AID-CNCR2820531219>3.0.CO;2-6; BANSAL M, 1984, AM J PATHOL, V115, P253; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Buckey CH, 2003, HAINES TAYLOR OBSTET, P391; CHEN KTK, 1981, HUM PATHOL, V12, P848, DOI 10.1016/S0046-8177(81)80090-1; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; De Petris G, 2014, INT J CLIN EXP PATHO, V7, P1241; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Frgelecova L, 2013, ACTA VET BRNO, V82, P387, DOI 10.2754/avb201382040387; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAYASHI I, 1985, ACTA PATHOL JAPON, V35, P507; Head K. W., 2003, HISTOLOGICAL CLASSIF, VX; Head KW, 2002, TUMORS DOMESTIC ANIM, P461; HOLT PE, 1985, VET REC, V116, P400, DOI 10.1136/vr.116.15.400; Houghton O, 2008, HISTOPATHOLOGY, V53, P156, DOI 10.1111/j.1365-2559.2008.03083.x; Igarashi H, 2015, J VET MED SCI, V77, P439, DOI 10.1292/jvms.14-0505; Igarashi H, 2014, VET IMMUNOL IMMUNOP, V159, P1, DOI 10.1016/j.vetimm.2014.03.003; Igarashi H, 2013, J VET MED SCI, V75, P535, DOI 10.1292/jvms.12-0166; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kolligs FT, 2002, DIGESTION, V66, P131, DOI 10.1159/000066755; KONTOZOGLOU T, 1985, J SURG ONCOL, V29, P31, DOI 10.1002/jso.2930290110; McEntee MF, 1999, VET PATHOL, V36, P228, DOI 10.1354/vp.36-3-228; Mochizuki K, 2015, PATHOL RES PRACT, V211, P797, DOI 10.1016/j.prp.2015.05.002; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Ohmi A, 2012, J VET MED SCI, V74, P59, DOI 10.1292/jvms.11-0352; Ohta H, 2013, VET IMMUNOL IMMUNOP, V155, P259, DOI 10.1016/j.vetimm.2013.07.006; Pantanowitz L, 2009, INT J SURG PATHOL, V17, P340, DOI 10.1177/1066896908322551; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Restucci B, 2009, ANTICANCER RES, V29, P2919; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Tamura Y, 2013, VET IMMUNOL IMMUNOP, V156, P32, DOI 10.1016/j.vetimm.2013.09.017; TSAO JI, 1994, AM J PATHOL, V145, P531; Tsukamoto A, 2012, J VET MED SCI, V74, P503, DOI 10.1292/jvms.11-0404; Uchida E, 2016, VET PATHOL, V53, P833, DOI 10.1177/0300985815618436; Uzal FA, 2015, JUBB KENNEDY PALMERS, P100; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Wani Y, 2008, HUM PATHOL, V39, P1072, DOI 10.1016/j.humpath.2007.07.019; Youmans L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050813	41	1	1	1	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	SEP	2018	55	5					654	662		10.1177/0300985818777798			9	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GR5JY	WOS:000442667700007	29852840	Bronze			2019-10-28	
J	Matsumoto, I; Chambers, JK; Nibe, K; Kinoshita, R; Nishimura, R; Nakayama, H; Uchida, K				Matsumoto, Isao; Chambers, James K.; Nibe, Kazumi; Kinoshita, Ryohei; Nishimura, Ryohei; Nakayama, Hiroyuki; Uchida, Kazuyuki			Histopathologic and Immunohistochemistry Findings in Feline Renal Cell Carcinoma	VETERINARY PATHOLOGY			English	Article						cats; epithelial mesenchymal transition (EMT); kidney; renal cell carcinoma; survival	EPITHELIAL-MESENCHYMAL TRANSITION; PROGNOSTIC-SIGNIFICANCE; COORDINATE EXPRESSION; KIT EXPRESSION; CYTOKERATINS 7; NEOPLASMS; TUMOR; ADENOCARCINOMA; TISSUES; KIDNEY	The biological behavior and immunohistochemical features of feline renal cell carcinoma (RCC) have not been well characterized. In the present study, immunohistochemical examinations were performed in 12 feline cases of RCC. The RCC consisted of solid (n = 2), solid-tubular (n = 2), tubular (n = 3), papillary (n = 2), tubulopapillary (n = 2), and sarcomatoid (n = 1) type lesions. Of the cases with RCC, I developed metastatic disease and 6 cases had no evidence of recurrence at 80 to 2292 days after surgery. One papillary-type tumor had cuboidal cells with scant cytoplasm and monomorphic nuclei, and the other had pseudostratified columnar cells with abundant cytoplasm. Immunohistochemistry revealed that the tumor cells in most cases were positive for cytokeratin (CK)7, CK20, KIT, and CD10, with the exception of cases of the solid type with clear cytoplasm (solid anaplastic), papillary type with columnar cells, and sarcomatoid types. A small number of tumor cells in the solid anaplastic and in the sarcomatoid types were positive for aquaporin- 1 . Increased expression of N-cadherin and Twist along with nuclear accumulation of beta-catenin were observed in the sarcomatoid type. These results indicated that CK, KIT, and CD10 are relatively strongly expressed in most feline RCC. The solid anaplastic RCC exhibited CD10 expression with the absence of distal tubule marker expression. Although immunohistochemistry profiles were relatively consistent with those described in human RCC, the histopathologic features were different from those seen in humans. Epithelial-mesenchymal transition (EMT) marker expression in the current cases may suggest the involvement of an EMT-like mechanism in the development of sarcomatoid RCC in cats.	[Matsumoto, Isao; Chambers, James K.; Nakayama, Hiroyuki; Uchida, Kazuyuki] Univ Tokyo, Lab Vet Pathol, Grad Sch Agr & Life Sci, Tokyo, Japan; [Nibe, Kazumi] Japan Anim Referral Med Ctr, Takatsu Ku, Kawasaki, Kanagawa, Japan; [Kinoshita, Ryohei; Nishimura, Ryohei] Univ Tokyo, Grad Sch Agr & Life Sci, Lab Vet Surg, Bunkyo Ku, Tokyo, Japan	Chambers, JK (reprint author), Univ Tokyo, Grad Sch Agr & Life Sci, Lab Vet Pathol, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	achamber@mail.ecc.u-tokyo.ac.jp		Matsumoto, Isao/0000-0002-7400-961X			BARD RH, 1986, UROLOGY, V27, P447, DOI 10.1016/0090-4295(86)90412-7; Bedford JJ, 2003, J AM SOC NEPHROL, V14, P2581, DOI 10.1097/01.ASN.0000089566.28106.F6; Bonsembiante F, 2016, J VET MED SCI, V78, P1039, DOI 10.1292/jvms.15-0697; BRITT JO, 1985, VET PATHOL, V22, P514, DOI 10.1177/030098588502200514; BURCHILL SA, 1995, BRIT J CANCER, V71, P278, DOI 10.1038/bjc.1995.56; Chu PG, 2000, AM J CLIN PATHOL, V113, P374; Cianciolo R, 2015, JUBB KENNEDY PALMERS, P444; Conant JL, 2011, J CLIN PATHOL, V64, P1088, DOI 10.1136/jclinpath-2011-200216; da Costa RMG, 2011, VET PATHOL, V48, P427, DOI 10.1177/0300985810381909; David SG, 2005, J UROLOGY, V173, P292, DOI 10.1097/01.ju.0000141594.99139.3d; De Los Monteros AE, 1999, VET PATHOL, V36, P179, DOI 10.1354/vp.36-3-179; Delahunt B, 1997, MODERN PATHOL, V10, P537; Delahunt B, 2001, HUM PATHOL, V32, P590, DOI 10.1053/hupa.2001.24984; Delahunt B, 1997, BRIT J UROL, V80, P401, DOI 10.1046/j.1464-410X.1997.00374.x; Edmondson EF, 2015, VET PATHOL, V52, P260, DOI 10.1177/0300985814533803; Evans D, 2016, J VET DIAGN INVEST, V28, P315, DOI 10.1177/1040638716638126; Val-Bernal JF, 2013, ANN DIAGN PATHOL, V17, P226, DOI 10.1016/j.anndiagpath.2011.11.001; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Grignon D, 2007, HEPTINSTALLS PATHOLO, P1504; Haase VH, 2006, AM J PHYSIOL-RENAL, V291, pF271, DOI 10.1152/ajprenal.00071.2006; Han AC, 1999, CANCER, V86, P2327, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2327::AID-CNCR21>3.0.CO;2-D; He HY, 2014, ADV ANAT PATHOL, V21, P174, DOI 10.1097/PAP.0000000000000018; Henry C J, 1999, J Feline Med Surg, V1, P165, DOI 10.1016/S1098-612X(99)90205-X; Huang Y, 2009, EUR UROL, V56, P690, DOI 10.1016/j.eururo.2008.10.014; Iliopoulos O, 2006, J CLIN ONCOL, V24, P5593, DOI 10.1200/JCO.2006.08.8948; Kajiyama H, 2006, ONCOLOGY-BASEL, V71, P394, DOI 10.1159/000107108; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kato N, 2005, PATHOL INT, V55, P479, DOI 10.1111/j.1440-1827.2005.01856.x; Klainbart S, 2008, J FELINE MED SURG, V10, P264, DOI 10.1016/j.jfms.2007.11.006; Klein A, 1998, CANCER, V82, P349, DOI 10.1002/(SICI)1097-0142(19980115)82:2<355::AID-CNCR16>3.3.CO;2-1; Langner C, 2004, VIRCHOWS ARCH, V444, P127, DOI 10.1007/s00428-003-0948-2; Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4; Merrick CH, 2013, J AM ANIM HOSP ASSOC, V49, P385, DOI 10.5326/JAAHA-MS-5895; Meuten D. J., 2017, Tumors in domestic animals, P632; Meuten DJ, 2004, HISTOLOGICAL CLASSIF; Miliaras D, 2004, J CLIN PATHOL, V57, P463, DOI 10.1136/jcp.2003.013532; Palapattu Ganesh S, 2002, Rev Urol, V4, P163; Ramos-Vara JA, 2017, J COMP PATHOL, V157, P115, DOI 10.1016/j.jcpa.2017.06.004; Rini BI, 2005, J CLIN ONCOL, V23, P1028, DOI 10.1200/JCO.2005.01.186; Sabo E, 2001, CLIN CANCER RES, V7, P533; Shen SS, 2012, ARCH PATHOL LAB MED, V136, P410, DOI 10.5858/arpa.2011-0472-RA; Skinnider BE, 2005, AM J SURG PATHOL, V29, P747, DOI 10.1097/01.pas.0000163362.78475.63; Takenawa J, 1998, INT J CANCER, V79, P1, DOI 10.1002/(SICI)1097-0215(19980220)79:1<1::AID-IJC1>3.0.CO;2-5; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Truong LD, 2011, ARCH PATHOL LAB MED, V135, P92, DOI 10.1043/2010-0478-RAR.1; VANNIEKERK CC, 1991, J PATHOL, V165, P145, DOI 10.1002/path.1711650210; Verkman AS, 2005, J CELL SCI, V118, P3225, DOI 10.1242/jcs.02519; WANG NP, 1995, APPL IMMUNOHISTOCHEM, V3, P99; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0	51	1	1	1	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	SEP	2018	55	5					663	672		10.1177/0300985818776055			10	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GR5JY	WOS:000442667700008	29759053	Bronze			2019-10-28	
J	Lin, SJH; Kao, CF; Wang, FI; Jeng, CR; Lee, JJ; Wang, LY; Chang, HW; Chen, YJ; Liu, CH; Pang, VF				Lin, Susanne Je-Han; Kao, Chi-Fei; Wang, Fun-In; Jeng, Chian-Ren; Lee, Jih-Jong; Wang, Lei-Ya; Chang, Hui-Wen; Chen, Yi-Jiun; Liu, Chen-Hsuan; Pang, Victor Fei			Urothelial Carcinomas of the Urinary Bladder With Plasmacytoid or Rhabdoid Features and Tendency of Epithelial-Mesenchymal Transition in 3 Dogs	VETERINARY PATHOLOGY			English	Article						dogs; urothelial carcinoma; transitional cell carcinoma; plasmacytoid; rhabdoid; epithelial-mesenchymal transition; urinary bladder	CELL-CARCINOMA; VARIANT; MORPHOLOGY; CANCER	Plasmacytoid and rhabdoid variants of urothelial carcinomas (UCs) of the urinary bladder have been described in humans with plasma cell-like or rhabdoid cellular appearance and aggressive clinical outcome. Canine UC of the bladder is generally classified as papillary/nonpapillary and infiltrating/noninfiltrating with limited information regarding other histological patterns. We report 3 cases of UC of the urinary bladder showing a unique discohesive cellular morphology with malignant behavior resembling the human plasmacytoid and rhabdoid variants of UC, which may raise some difficulties in diagnosis. Epithelial-mesenchymal transition and reduced E-cadherin expression were revealed by immunohistochemistry in 2 cases, possibly explaining the discohesive and invasive behavior of the tumor cells. The findings broaden the morphological spectrum as well as the distinct clinical features of canine UC of the urinary bladder.	[Lin, Susanne Je-Han; Kao, Chi-Fei; Wang, Fun-In; Jeng, Chian-Ren; Wang, Lei-Ya; Chang, Hui-Wen; Liu, Chen-Hsuan; Pang, Victor Fei] Natl Taiwan Univ, Sch Vet Med, Grad Inst Mol & Comparat Pathobiol, 1,Sect 4,Roosevelt Rd, Taipei 1061, Taiwan; [Lee, Jih-Jong; Chen, Yi-Jiun] Natl Taiwan Univ, Sch Vet Med, Grad Inst Vet Clin Sci, Taipei, Taiwan	Pang, VF (reprint author), Natl Taiwan Univ, Sch Vet Med, Grad Inst Mol & Comparat Pathobiol, 1,Sect 4,Roosevelt Rd, Taipei 1061, Taiwan.	pang@ntu.edu.tw		Lin, Susanne Je-Han/0000-0002-0947-7388			Al-Ahmadie HA, 2016, NAT GENET, V48, P356, DOI 10.1038/ng.3503; Amin MB, 2009, MODERN PATHOL, V22, pS96, DOI 10.1038/modpathol.2009.26; Baldwin L, 2005, HISTOPATHOLOGY, V46, P50, DOI 10.1111/j.1365-2559.2005.02051.x; Fritsche HM, 2008, J UROLOGY, V180, P1923, DOI 10.1016/j.juro.2008.07.035; Humphrey PA, 2016, EUR UROL, V70, P106, DOI 10.1016/j.eururo.2016.02.028; Kagotani A, 2015, CYTOPATHOLOGY, V26, P54, DOI 10.1111/cyt.12139; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Knapp DW, 2000, UROL ONCOL, V5, P47, DOI 10.1016/S1078-1439(99)00006-X; KUMAR S, 1992, AM J SURG PATHOL, V16, P515, DOI 10.1097/00000478-199205000-00011; Lopez-Beltran A, 2009, HUM PATHOL, V40, P1023, DOI 10.1016/j.humpath.2009.01.001; Meuten DJ, 2016, TUMORS DOMESTIC ANIM, P632; Nigwekar P, 2009, AM J SURG PATHOL, V33, P417, DOI 10.1097/PAS.0b013e318186c45e; O'Connell FP, 2004, AM J CLIN PATHOL, V121, P254, DOI 10.1309/617DWB5GNFWXHW4L; Parwani AV, 2006, HUM PATHOL, V37, P168, DOI 10.1016/j.humpath.2005.10.002; Ro JY, 2008, AM J SURG PATHOL, V32, P752, DOI 10.1097/PAS.0b013e318159af9e; SAHIN AA, 1991, ACTA CYTOL, V35, P277; Tajima S, 2015, INT J CLIN EXP PATHO, V8, P9638; ZUKERBERG LR, 1991, AM J SURG PATHOL, V15, P569, DOI 10.1097/00000478-199106000-00005	18	0	0	1	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	SEP	2018	55	5					673	677		10.1177/0300985818771151			5	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GR5JY	WOS:000442667700009	29661121				2019-10-28	
J	Pellegrino, V; Muscatello, LV; Sarli, G; Avallone, G				Pellegrino, Valeria; Muscatello, Luisa, V; Sarli, Giuseppe; Avallone, Giancarlo			Canine Gastrointestinal Spindle Cell Tumors Efficiently Diagnosed by Tissue Microarray-Based Immunohistochemistry	VETERINARY PATHOLOGY			English	Article						alpha-SMA; dogs; CD 117; desmin; gastrointestinal spindle cell tumor; immunohistochemistry; smooth muscle tumor	LYMPHOMAS	Tissue microarray (TMA) is a time- and cost-saving technique allowing the simultaneous immunohistochemical evaluation of multiple tissue samples. The aim of this study was to assess the efficacy of TMA at classifying canine gastrointestinal spindle cell tumors as gastrointestinal stromal tumor (GIST), smooth muscle tumor (SMT), and non-GIST/non-SMT based on the expression of alpha-smooth muscle actin (alpha-SMA), desmin, and CD 117. Thirty-four cases were investigated on TMAs, sampling 2 cores each. Immunohistochemistry was performed on TMAs and full sections, and the results were compared. Comparing full sections, TMA specificity and sensitivity were 100% and 93.8%, respectively, for alpha-SMA; 100% and 80.8% for desmin; and 100% and 100% for CD 117. TMA allowed the identification of 6 of 6 GISTs, 25 of 26 SMTs, and 2 of 2 non-GIST/non-SMTs. One SMT was misdiagnosed as non-GIST/non-SMT. Based on these results, TMA-based immunohistochemistry is efficient at diagnosing canine gastrointestinal spindle cell tumors and might be applied on large caseloads in a research setting.	[Pellegrino, Valeria; Muscatello, Luisa, V; Sarli, Giuseppe; Avallone, Giancarlo] Univ Bologna, Dept Vet Med Sci DIMEVET, Via Tolara di Sopra 50, I-40064 Ozzano Dellemilia, Italy	Avallone, G (reprint author), Univ Bologna, Dept Vet Med Sci DIMEVET, Via Tolara di Sopra 50, I-40064 Ozzano Dellemilia, Italy.	giancarlo.avallone@unibo.it		Sarli, Giuseppe/0000-0001-6405-3484; AVALLONE, Giancarlo/0000-0002-5203-7679			Buishand FO, 2014, VET J, V201, P57, DOI 10.1016/j.tvjl.2014.05.004; Dettwiler M, 2013, VET PATHOL, V50, P789, DOI 10.1177/0300985813478212; Fonseca-Alves CE, 2015, RES VET SCI, V102, P122, DOI 10.1016/j.rvsc.2015.08.007; Hammer AS, 2007, VET PATHOL, V44, P196, DOI 10.1354/vp.44-2-196; Hayes S, 2013, VET PATHOL, V50, P779, DOI 10.1177/0300985813478211; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Muscatello LV, 2015, J COMP PATHOL, V152, P153, DOI 10.1016/j.jcpa.2014.12.014; Parsons M, 2009, DIAGN HISTOPATHOL, V15, P142; Selting K.A., 2013, SMALL ANIMAL CLIN ON, P412; Spitzbarth I, 2017, VET PATHOL, V54, P369, DOI 10.1177/0300985816688745	10	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	SEP	2018	55	5					678	681		10.1177/0300985818777793			4	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GR5JY	WOS:000442667700010	29807498	Bronze			2019-10-28	
J	Susta, L; Segovia, D; Olivier, TL; Dimitrov, KM; Shittu, I; Marcano, V; Miller, PJ				Susta, Leonardo; Segovia, Diego; Olivier, Timothy L.; Dimitrov, Kiril M.; Shittu, Ismaila; Marcano, Valerie; Miller, Patti J.			Newcastle Disease Virus Infection in Quail	VETERINARY PATHOLOGY			English	Article						avian avulavirus I; Newcastle disease; Newcastle disease virus; virulent NDV; quail; pathogenesis; clinico-pathological assessment; immunohistochemistry	CLINICOPATHOLOGICAL CHARACTERIZATION; GENETIC DIVERSITY; CHICKENS; GENOTYPES; VIRULENT; STRAINS; CHALLENGE; PATHOGENESIS; VACCINATION; OUTBREAKS	Newcastle disease (ND), caused by virulent strains of Newcastle disease virus (NDV), is a devastating disease of poultry worldwide. The pathogenesis of ND in quail is poorly documented. To characterize the ability of virulent NDV strains to replicate and cause disease in quail, groups of 14 two-week-old Japanese quail (Coturnix japonica) were experimentally inoculated with 10(8) EID50 (embryo infectious dose 50%) units of 1 of 4 virulent NDV strains: 2 isolated from quail (N2, N23) and 2 from chickens (Israel, Pakistan). At day 2 postinfection, noninfected quail (contact group) were added to each infection group to assess the efficacy of virus transmission. Tested NDV strains showed moderate pathogenicity, with highest mortality being 28% for the N2 strain and below 10% for the others. Two N2-inoculated birds showed neurological signs, such as head tremor and ataxia. Microscopic lesions were present in N2-, Israel-, and Pakistan-inoculated birds and consisted of nonsuppurative encephalitis. Contact birds showed no clinical signs or lesions. In both inoculated and contact birds, virus replication was moderate to minimal, respectively, as observed by immunohistochemistry in tissues and virus isolation from oropharyngeal and cloacal swabs. Strains originally isolated from quail resulted in higher numbers of birds shedding in the inoculation group; however, transmission appeared slightly more efficient with chicken-derived isolates. This study shows that virulent NDV strains have limited replicative potential and mild to moderate disease-inducing ability in Japanese quail.	[Susta, Leonardo; Segovia, Diego] Univ Guelph, Ontario Vet Coll, Dept Pathobiol, Guelph, ON, Canada; [Olivier, Timothy L.; Dimitrov, Kiril M.; Marcano, Valerie; Miller, Patti J.] ARS, Southeast Poultry Res Lab, USDA, Athens, GA USA; [Shittu, Ismaila] Natl Vet Res Inst, Reg Lab Anim Influenza & Transboundary Anim Dis, Vom, Nigeria; [Marcano, Valerie] Univ Georgia, Coll Vet Med, Dept Vet Pathol, Athens, GA USA; [Miller, Patti J.] Univ Georgia, Coll Vet Med, Dept Populat Hlth, Athens, GA 30602 USA	Miller, PJ (reprint author), Univ Georgia, Coll Vet Med, Dept Populat Hlth, Athens, GA 30602 USA.	pjmdvm97@uga.edu	Dimitrov, Kiril/I-4280-2019; Susta, Leonardo/I-2968-2019; Shittu, Ismaila/C-3092-2016	Dimitrov, Kiril/0000-0002-5525-4492; Susta, Leonardo/0000-0002-4578-6145; Shittu, Ismaila/0000-0002-2977-9578	USDA-ARS CRISUnited States Department of Agriculture (USDA) [6040-32000-072]; Undergraduate Research Assistantship (URA) program of the University of Guelph	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by USDA-ARS CRIS 6040-32000-072. Mr. Segovia's salary was partly funded through the Undergraduate Research Assistantship (URA) program of the University of Guelph.	Afonso CL, 2013, DEV BIOLOGICALS, V135, P95, DOI 10.1159/000178459; Aldous EW, 2007, VET REC, V160, P482, DOI 10.1136/vr.160.14.482; Alexander D.J., 2008, LAB MANUAL ISOLATION, P135; Alexander D.J., 1998, LAB MANUAL ISOLATION, P156; ALEXANDER DJ, 1992, VET REC, V130, P65, DOI 10.1136/vr.130.4.65; Amarasinghe GK, 2017, ARCH VIROL, V162, P2493, DOI 10.1007/s00705-017-3311-7; Cattoli G, 2011, J VET DIAGN INVEST, V23, P637, DOI 10.1177/1040638711407887; COLLINS PL, 1980, J VIROL, V35, P682; Czegledi A, 2006, VIRUS RES, V120, P36, DOI 10.1016/j.virusres.2005.11.009; Dai YB, 2014, BMC VET RES, V10, DOI 10.1186/1746-6148-10-164; Diel DG, 2012, INFECT GENET EVOL, V12, P1770, DOI 10.1016/j.meegid.2012.07.012; Diel DG, 2012, J CLIN MICROBIOL, V50, P378, DOI 10.1128/JCM.06018-11; Dimitrov KM, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0741-5; Dimitrov KM, 2016, INFECT GENET EVOL, V39, P22, DOI 10.1016/j.meegid.2016.01.008; Dortmans JCFM, 2011, J GEN VIROL, V92, P336, DOI 10.1099/vir.0.026344-0; Ecco R, 2011, AVIAN PATHOL, V40, P145, DOI 10.1080/03079457.2010.544289; El Tayeb AB, 2002, AVIAN DIS, V46, P660, DOI 10.1637/0005-2086(2002)046[0660:IBECAN]2.0.CO;2; El-Tarabili MM, 2009, SUEZ CANAL VET MED J, V16, P67; ERICKSON GA, 1980, AVIAN DIS, V24, P257, DOI 10.2307/1589785; ERICKSON GA, 1978, AM J VET RES, V39, P105; Gowthaman V, 2013, ADVANC ANIMAL VET SC, V1, P17; Hierholzer JC, 1996, VIROLOGY METHODS MAN, P37; Kommers GD, 2001, AVIAN DIS, V45, P906, DOI 10.2307/1592870; Kuiken T, 1998, AVIAN PATHOL, V27, P541, DOI 10.1080/03079459808419381; Lima F. S., 2004, International Journal of Poultry Science, V3, P483; McGinnes Lori W, 2006, Curr Protoc Microbiol, VChapter 15, DOI 10.1002/9780471729259.mc15f02s01; Miller PJ, 2007, VACCINE, V25, P7238, DOI 10.1016/j.vaccine.2007.07.017; Miller Patti J, 2015, Front Public Health, V3, P235, DOI 10.3389/fpubh.2015.00235; Miller PJ, 2015, INFECT GENET EVOL, V29, P216, DOI 10.1016/j.meegid.2014.10.032; Miller PJ, 2013, DEV COMP IMMUNOL, V41, P505, DOI 10.1016/j.dci.2013.06.007; Miller PJ, 2010, INFECT GENET EVOL, V10, P26, DOI 10.1016/j.meegid.2009.09.012; Miller PJ, 2013, DIS POULTRY, P250; Mohamed M. A., 2016, Journal of Advanced Veterinary Research, V6, P37; Moura VMBD, 2016, VET PATHOL, V53, P53, DOI 10.1177/0300985815600504; Nishizawa M, 2007, BRAZ J POULT SCI, V9, P123, DOI 10.1590/S1516-635X2007000200008; OIE World Organisation for Animal Health, 2008, MANUAL DIAGNOSTIC TE; Oladele S. B., 2008, International Journal of Poultry Science, V7, P165; Pandarangga P, 2016, VET PATHOL, V53, P792, DOI 10.1177/0300985815622972; SHARAWI S., 2015, BENHA VET MED J, V29, P218; Snoeck CJ, 2013, J CLIN MICROBIOL, V51, P2250, DOI 10.1128/JCM.00684-13; Susta L, 2015, VET PATHOL, V52, P120, DOI 10.1177/0300985814521247; Susta L, 2011, VET PATHOL, V48, P349, DOI 10.1177/0300985810375806; Terregino C, 2009, AVIAN INFLUENZA NEWC; TOYODA T, 1987, VIROLOGY, V158, P242, DOI 10.1016/0042-6822(87)90261-3; Wakamatsu N, 2006, VET PATHOL, V43, P925, DOI 10.1354/vp.43-6-925; Wan HQ, 2004, AVIAN PATHOL, V33, P216, DOI 10.1080/0307945042000195803	46	0	0	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	SEP	2018	55	5					682	692		10.1177/0300985818767996			11	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GR5JY	WOS:000442667700011	29661124				2019-10-28	
J	Verhoef, JNC; Allen, AL; Harding, JCS; Al-Dissi, AN				Verhoef, Jolanda N. C.; Allen, Andrew L.; Harding, John C. S.; Al-Dissi, Ahmad N.			Metallothionein Expression in Horses With Chronic Liver Disease and Its Correlation With Ki-67 Immunoreactivity	VETERINARY PATHOLOGY			English	Article						bile duct; chronic hepatitis; equine; fibrosis; immunohistochemistry; Kupffer cells; liver; lymphocytes; metallothionein	KUPFFER CELLS; CHRONIC HEPATITIS; PROTECTIVE ROLE; LOCALIZATION; INJURY; FIBROSIS; PLASMA; HEPATOTOXICITY; PROLIFERATION; INFLAMMATION	Chronic liver disease is an important cause of illness in horses, and treatment is mainly supportive. Research into new treatment modalities for humans has shown promising data regarding metallothionein (MT), which has been shown to possess regenerative, antifibrotic, and anti-inflammatory properties. This study aimed to examine the relationship between hepatic MT expression and the histopathologic markers of hepatic inflammation, fibrosis and bile duct proliferation, as well as cellular regeneration in 77 selected cases of chronic liver disease in horses. We hypothesized that higher MT expression would be associated with increased heptocellular proliferation and decreased fibrosis, inflammation, and bile duct proliferation. Hepatocellular MT expression was evaluated with immunohistochemistry. Additionally, cellular regeneration was evaluated with immunohistochemistry for Ki-67, a protein expressed during all active stages of the cell cycle. The severity of inflammation and fibrosis was scored, and bile duct proliferation was assessed by counting bile duct profiles. MT expression was observed in 73 of 77 (94.8%) cases of chronically diseased livers. Ki-67 expression was seen in resident Kupffer cells (n = 42, 54.6%), lymphocytes (n = 39, 50.7%), bile duct epithelium (n = 10, 13.0%), and hepatocytes (n = 8, 10.4%). MT expression was significantly associated with Ki-67 staining in bile duct epithelium and Kupffer cells. Additionally, median MT expression was higher in cases containing lymphocytic infiltrates as compared with cases with no lymphocytic infiltrate (P < .05). These findings are the first known report of MT expression within chronic equine hepatic disease.	[Verhoef, Jolanda N. C.; Allen, Andrew L.; Al-Dissi, Ahmad N.] Univ Saskatchewan, Western Coll Vet Med, Dept Vet Pathol, 52 Campus Dr, Saskatoon, SK S7N 5B4, Canada; [Harding, John C. S.] Univ Saskatchewan, Western Coll Vet Med, Dept Large Anim Clin Sci, Saskatoon, SK, Canada	Al-Dissi, AN (reprint author), Univ Saskatchewan, Western Coll Vet Med, Dept Vet Pathol, 52 Campus Dr, Saskatoon, SK S7N 5B4, Canada.	ahmad.aldissi@usask.ca		Al-Dissi, Ahmad/0000-0002-3124-3502	Townsend Equine Health Research Fund; Western College of Veterinary Medicine Interprovincial Graduate Fellowship	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Funding was kindly provided by the Townsend Equine Health Research Fund and the Western College of Veterinary Medicine Interprovincial Graduate Fellowship (J. N. C. V.).	Abraham S, 2012, LIFE SCI, V90, P140, DOI 10.1016/j.lfs.2011.10.021; Aleman M, 2005, J VET INTERN MED, V19, P120, DOI 10.1892/0891-6640(2005)19<120:SHAWCP>2.0.CO;2; Andres D, 2003, BIOCHEM PHARMACOL, V66, P917, DOI 10.1016/S0006-2952(03)00443-X; ARMARIO A, 1987, PHYSIOL BEHAV, V39, P277, DOI 10.1016/0031-9384(87)90022-9; AUER DE, 1989, AUST VET J, V66, P191, DOI 10.1111/j.1751-0813.1989.tb09803.x; Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282; Bergero D, 2008, J ANIM PHYSIOL AN N, V92, P345, DOI 10.1111/j.1439-0396.2007.00798.x; Borghesi LA, 1996, TOXICOLOGY, V108, P129, DOI 10.1016/S0300-483X(95)03243-9; Cherian MG, 2003, MUTAT RES-FUND MOL M, V533, P201, DOI 10.1016/j.mrfmmm.2003.07.013; Cherian MG, 2000, CELL MOL BIOL, V46, P347; CHERIAN MG, 1994, ENVIRON HEALTH PERSP, V102, P131, DOI 10.2307/3431776; Cohen J., 1988, STAT POWER ANAL BEHA, P109; CYSEWSKI SJ, 1982, TOXICOL APPL PHARM, V65, P354, DOI 10.1016/0041-008X(82)90381-7; Czaja AJ, 2014, WORLD J GASTROENTERO, V20, P2515, DOI 10.3748/wjg.v20.i10.2515; Davis SR, 2000, J NUTR, V130, P1085; DE SK, 1990, J BIOL CHEM, V265, P15267; Durham AE, 2003, EQUINE VET J, V35, P534, DOI 10.2746/042516403775467171; Gao B, 2011, GASTROENTEROLOGY, V141, P1572, DOI 10.1053/j.gastro.2011.09.002; Gouw ASH, 2011, HEPATOLOGY, V54, P1853, DOI 10.1002/hep.24613; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; Hubscher SG, 1998, J HEPATOL, V29, P1015, DOI 10.1016/S0168-8278(98)80134-7; Inoue K, 2009, MEDIAT INFLAMM, V2009, P1; Inoue K, 2013, CURR PHARM BIOTECHNO, V14, P414, DOI 10.2174/1389201011314040005; Ito Y, 2003, MICROCIRCULATION, V10, P391, DOI 10.1038/sj.mn.7800204; Jiang YC, 2004, MOL THER, V10, P1130, DOI 10.1016/j.ymthe.2004.08.011; Ju C, 2002, CHEM RES TOXICOL, V15, P1504, DOI 10.1021/tx0255976; KAGI JHR, 1960, J BIOL CHEM, V235, P3460; KOJIMA Y, 1978, ACTA HISTOCHEM CYTOC, V11, P205, DOI 10.1267/ahc.11.205; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LASKIN DL, 1986, TOXICOL APPL PHARM, V86, P216, DOI 10.1016/0041-008X(86)90052-9; LYNES MA, 1990, MOL IMMUNOL, V27, P211, DOI 10.1016/0161-5890(90)90132-J; Milnerowicz H, 2005, ACTA PAEDIATR, V94, P402, DOI 10.1080/08035250410025078; Miyaoka Y, 2012, CURR BIOL, V22, P1166, DOI 10.1016/j.cub.2012.05.016; Moffatt P, 1997, DRUG METAB REV, V29, P261, DOI 10.3109/03602539709037585; NATION PN, 1991, CAN VET J, V32, P602; NORDBERG GF, 1982, ENVIRON RES, V28, P179, DOI 10.1016/0013-9351(82)90167-0; Oliver JR, 2005, EXP BIOL MED, V230, P61; Palmiter RD, 1998, P NATL ACAD SCI USA, V95, P8428, DOI 10.1073/pnas.95.15.8428; Pankhurst MW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031185; Peek SF, 2000, EQUINE VET J, V32, P301, DOI 10.2746/042516400777032156; Sheehan D.C., 1980, THEORY PRACTICE HIST; Shimada A, 1997, J COMP PATHOL, V116, P1, DOI 10.1016/S0021-9975(97)80038-2; SMITH JD, 1975, J ANIM SCI, V41, P1645; Sridharan S, 2015, VET PATHOL, V52, P1127, DOI 10.1177/0300985815588607; Studer R, 1997, BIOCHEM J, V328, P63, DOI 10.1042/bj3280063; Takano H, 2004, THORAX, V59, P1057, DOI 10.1136/thx.2004.024232; Tang WF, 1999, J ANAL TOXICOL, V23, P153, DOI 10.1093/jat/23.3.153; Tennant B C, 1972, Mod Vet Pract, V53, P40; Thirumoorthy N, 2007, WORLD J GASTROENTERO, V13, P993, DOI 10.3748/wjg.v13.i7.993; Thirumoorthy N, 2011, WORLD J SURG ONCOL, V9, DOI 10.1186/1477-7819-9-54; TOHYAMA C, 1981, TOXICOLOGY, V20, P289, DOI 10.1016/0300-483X(81)90036-6; TSUJIKAWA K, 1994, EUR J CELL BIOL, V63, P240; Van Hul N, 2011, AM J PATHOL, V179, P1839, DOI 10.1016/j.ajpath.2011.06.042; WINWOOD PJ, 1993, SEMIN LIVER DIS, V13, P50, DOI 10.1055/s-2007-1007337; Yin XY, 2005, BMC IMMUNOL, V6, DOI 10.1186/1471-2172-6-21	55	0	0	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	SEP	2018	55	5					703	710		10.1177/0300985818777802			8	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GR5JY	WOS:000442667700013	29865992				2019-10-28	
J	Bayley, C; Cheng, C; Lynch, M				Bayley, Christine; Cheng, Christina; Lynch, Michael			Pathological and Microbiological Study of Mortality in a Captive Breeding Colony of the Endangered Lord Howe Island Stick Insect (Dryococelus australis)	VETERINARY PATHOLOGY			English	Article						captive breeding; conservation; inflammation; innate immunity; Pseudomonas aeruginosa; Serratia marcescens; stick insect; Dryococelus australis; histopathology; invertebrates	DROSOPHILA-MELANOGASTER; PHASMATODEA; CONSERVATION; PROVIDENCIA; REDISCOVERY; INFECTIONS	The authors describe pathological and microbiological features of mortalities in a captive breeding colony of Lord Howe Island stick insects (Dryococelus australis) over a period of 18 months. There were 2 peaks of mortality in this period. In the first, insects presented dead with minimal premonitory signs of illness. In the second, affected insects were ataxic with contracted limbs and inability to climb or right themselves. Gross lesions were uncommon but included pigmented plaques on the gut and cloacal prolapse. Histological lesions in both outbreaks indicated a cellular innate immune response including nodulation characterized by Gram-negative bacterial bacilli entrapped within nodules of pigmented hemocytes, and melanization characterized by melanin within hemocyte nodules and around bacteria. Hemolymph culture findings varied and often yielded a mixed growth. Pure growth of Serratia marcescens was cultured in 44% of animals in Outbreak 1, while pure growth of Pseudomonas aeruginosa was cultured in 30% of animals in Outbreak 2. Cases with S. marcescens-positive culture often showed inflammation at the foregut-midgut junction. The frequency of mixed bacterial culture results did not allow firm conclusions about causality to be made, and may indicate primary bacterial infection or increased susceptibility to hemolymph colonization with an opportunistic pathogen. These findings highlight the utility of histopathology combined with ancillary testing when investigating mortality in captive insect colonies.	[Bayley, Christine] Gribbles Vet Pathol, 1868 Dandenong Rd, Clayton, Vic 3168, Australia; [Cheng, Christina; Lynch, Michael] Melbourne Zoo, Parkville, Vic, Australia	Bayley, C (reprint author), Gribbles Vet Pathol, 1868 Dandenong Rd, Clayton, Vic 3168, Australia.	chris_trezise@hotmail.com		Bayley, Christine/0000-0001-7361-4036; Cheng, Christina/0000-0002-2615-6957			Aggarwal C, 2017, J INVERTEBR PATHOL, V143, P115, DOI 10.1016/j.jip.2016.12.004; Andrejko M, 2014, J INVERTEBR PATHOL, V115, P14, DOI 10.1016/j.jip.2013.10.006; [Anonymous], 2017, DRYOC AUSTR IUCN RED, DOI [10. 2305/IUCN. UK. 2017-3. RLTS. T6852A21426226. en, DOI 10.2305/IUCN.UK.2017-3.RLTS.T6852A21426226]; Carlile Nicholas, 2009, Ecological Management & Restoration, V10, pS124, DOI 10.1111/j.1442-8903.2009.00450.x; Clark J. T., 1976, Journal biol Educ, V10, P31, DOI 10.1080/00219266.1976.9654053; Department of Environment and Climate Change (NSW), 2007, LORD HOW ISL BIOD MA; Galac MR, 2011, MICROBES INFECT, V13, P673, DOI 10.1016/j.micinf.2011.02.005; Gandhe AS, 2007, J IMMUNOL, V179, P6943, DOI 10.4049/jimmunol.179.10.6943; GREANY PD, 1977, J INVERTEBR PATHOL, V29, P153, DOI 10.1016/0022-2011(77)90188-4; Hillyer JF, 2016, DEV COMP IMMUNOL, V58, P102, DOI 10.1016/j.dci.2015.12.006; Honan P, 2008, J INSECT CONSERV, V12, P399, DOI 10.1007/s10841-008-9162-5; James RR, 2012, INSECT PATHOLOGY, 2ND EDITION, P425, DOI 10.1016/B978-0-12-384984-7.00012-9; Jiang H, 2010, ADV EXP MED BIOL, V708, P181; Jurat-Fuentes JL, 2012, INSECT PATHOLOGY, 2ND EDITION, P265, DOI 10.1016/B978-0-12-384984-7.00008-7; Low P, 2016, ATL AN AN HIST; Lundgren JG, 2012, INSECT PATHOLOGY, 2ND EDITION, P461, DOI 10.1016/B978-0-12-384984-7.00013-0; Mahlen SD, 2011, CLIN MICROBIOL REV, V24, P755, DOI 10.1128/CMR.00017-11; Nehme NT, 2007, PLOS PATHOG, V3, P1694, DOI 10.1371/journal.ppat.0030173; O'Hara CM, 2000, CLIN MICROBIOL REV, V13, P534, DOI 10.1128/CMR.13.4.534-546.2000; Pizzi R, 2012, INVERTEBRATE MED, P187; Priddel D, 2003, BIODIVERS CONSERV, V12, P1391, DOI 10.1023/A:1023625710011; Shelomi Matan, 2015, Journal of Orthoptera Research, V24, P29; Theodorou K, 2006, GENET SEL EVOL, V38, P371, DOI 10.1051/gse:2006010	23	0	0	0	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	SEP	2018	55	5					719	730		10.1177/0300985818766210			12	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GR5JY	WOS:000442667700015	29661123				2019-10-28	
J	Sula, MJM; Frank, LA; Ramsay, EC				Sula, Mee-Ja M.; Frank, Linda A.; Ramsay, Edward C.			Lymphocytic Mural Folliculitis Resembling Epitheliotropic Lymphoma in Tigers (Panthera tigris)	VETERINARY PATHOLOGY			English	Article						allergic skin disease; epitheliotropic T-cell lymphoma; lymphocytic mural folliculitis; Panthera tigris; tiger	EXFOLIATIVE DERMATITIS; SKIN; CAT	A striking form of lymphocytic mural folliculitis is described in 6 tigers (Panthera tigris). Clinically, all tigers exhibited regionally extensive chronic, variably waxing and waning alopecia with minimal scaling and crusting most pronounced over the head, neck, and shoulders. More severely affected tigers exhibited marked hyperpigmentation and lichenification. Pruritus was not a feature. Tigers generally lacked signs of systemic illness and clinical pathology findings were unremarkable. Histologic examination of skin biopsies revealed infiltrative lymphocytic mural folliculitis extending the length of the hair follicle. Mild epidermal lymphocytic infiltrates were frequent. The surrounding dermis was histologically unremarkable in 4 of 6 tigers or associated with mild perifollicular and periadnexal mixed inflammation in 2 of 6 tigers. The cause of the mural folliculitis was not identified, and tigers responded poorly to immunomodulatory therapy. Lymphocytic mural folliculitis might be a nonspecific hypersensitivity reaction pattern in tigers, and care should be taken to differentiate this reaction pattern from epitheliotropic T-cell lymphoma.	[Sula, Mee-Ja M.] Univ Tennessee, Coll Vet Med, Dept Biomed & Diagnost Sci, Knoxville, TN 37996 USA; [Frank, Linda A.; Ramsay, Edward C.] Univ Tennessee, Coll Vet Med, Small Anim Clin Sci, Knoxville, TN 37996 USA	Sula, MJM (reprint author), Univ Tennessee, Coll Vet Med, Dept Biomed & Diagnost Sci, Knoxville, TN 37996 USA.	msula@utk.edu					DECLERCQ J, 1995, VLAAMS DIERGEN TIJDS, V64, P177; Declercq J, 2000, VET DERMATOL, V11, P75, DOI 10.1046/j.1365-3164.2000.00162.x; Fontaine J, 2011, VET DERMATOL, V22, P454, DOI 10.1111/j.1365-3164.2011.00972.x; Frank LA, 2013, VET DERMATOL, V24, P367, DOI 10.1111/vde.12030; Glos K, 2016, VET DERMATOL, V27, P57, DOI 10.1111/vde.12282; Gross TL, 2005, SKIN DISEASES OF THE DOG AND CAT: CLINICAL AND HISTOPATHOLOGIC DIAGNOSIS, 2ND EDITION, P460; Gross TL, 2005, SKIN DIS DOG CAT CLI, P876; Linek M, 2015, VET DERMATOL, V26, P40, DOI 10.1111/vde.12169; Lobetti R, 2015, J FELINE MED SURG, V17, P548, DOI 10.1177/1098612X14559955; Marsella R., 2013, MULLER KIRKS SMALL A, P363; Mauldin EA, 1997, VET DERMATOL, V8, P191, DOI 10.1046/j.1365-3164.1997.d01-15.x; Olivry T, 1997, AM J DERMATOPATH, V19, P477, DOI 10.1097/00000372-199710000-00008; Olivry T, 2000, VET DERMATOL, V11, P261, DOI 10.1046/j.1365-3164.2000.00198.x; Roosje PJ, 1998, VET PATHOL, V35, P268, DOI 10.1177/030098589803500405; Rosenberg AS, 2010, J FELINE MED SURG, V12, P80, DOI 10.1016/j.jfms.2009.05.015; Rottenberg S, 2004, VET PATHOL, V41, P429, DOI 10.1354/vp.41-4-429; Tobin DJ, 2003, BRIT J DERMATOL, V149, P1; Yasuda K, 2009, EQUINE VET J, V41, P824, DOI 10.2746/042516409X471430	18	0	0	2	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	SEP	2018	55	5					731	735		10.1177/0300985818766213			5	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GR5JY	WOS:000442667700016	29661122				2019-10-28	
J	Thongkamkoon, P; Tohmee, N; Morris, EK; Inamnuay, L; Lombardini, ED				Thongkamkoon, Pacharee; Tohmee, Nopporn; Morris, Erin K.; Inamnuay, Laksanee; Lombardini, Eric D.			Combined Fatal Systemic Chlamydia sp and Aeromonas sobria Infection in Juvenile Siamese Crocodiles (Crocodylus siamensis)	VETERINARY PATHOLOGY			English	Article						Aeromonas sobria; Chlamydia sp.; crocodile; Crocodylus siamensis; hepatitis; sequencing		Chlamydial infections in crocodiles have been described in several countries and in several different species. These are typically associated with severe pharyngitis and conjunctivitis, with death occurring secondary to compromise of the upper respiratory tract due to obstruction of the trachea. A population of ranched Siamese crocodiles in central Thailand experienced an epizootic of sudden death in juvenile animals. The affected animals had fulminant systemic disease primarily involving the liver and spleen but also affecting the kidneys, heart, and the whole of the respiratory tract. Chlamydia sp. were noted in liver and spleen during histopathological examination and confirmed with transmission electron microscopy and polymerase chain reaction (PCR). The sequence of the PCR product suggested a novel Chlamydia sp. of Siamese crocodiles. Crocodile farming represents an important economy in several parts of the world. Epizootics, such as the one described in this manuscript in association with Chlamydia sp., can have devastating impact on the industry and represent a potential zoonosis of significant public health concern. This is the first report of Chlamydia sp. and Aeromonas sobria causing systemic disease in crocodiles as well as the first histopathological and ultrastructural description of Chlamydia infection in Siamese crocodiles.	[Thongkamkoon, Pacharee; Tohmee, Nopporn] Natl Inst Anim Hlth, Bangkok, Thailand; [Morris, Erin K.] Joint Pathol Ctr, Dept Vet Pathol, Silver Spring, MD USA; [Inamnuay, Laksanee; Lombardini, Eric D.] AFRIMS, Dept Vet Med, 315-6 Ratchathewi, Bangkok 10400, Thailand	Lombardini, ED (reprint author), AFRIMS, Dept Vet Med, 315-6 Ratchathewi, Bangkok 10400, Thailand.	axolotlman2001@gmail.com					Beeckman DSA, 2010, VET MICROBIOL, V141, P342, DOI 10.1016/j.vetmic.2009.09.032; Eidson M, 2002, J AM VET MED ASSOC, V221, P1710, DOI 10.2460/javma.2002.221.1710; Harkinezhad T, 2009, VET MICROBIOL, V135, P68, DOI 10.1016/j.vetmic.2008.09.046; Huchzermeyer FW, 2008, J S AFR VET ASSOC, V79, P99; HUCHZERMEYER FW, 1994, J S AFR VET ASSOC, V65, P20; Jarrett I, 2008, RIRDC PUBLICATION, V08/188; Jarrett I, 2006, AHNNT, P1; Pudjiatmoko, 1997, INT J SYST BACTERIOL, V47, P425; Sariya L, 2015, JPN J VET RES, V63, P5; Vanrompay D, 2013, DIS POULTRY, P1055	10	0	0	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	SEP	2018	55	5					736	740		10.1177/0300985818768382			5	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GR5JY	WOS:000442667700017	29661119				2019-10-28	
J	Laing, ST; Merriam, D; Shock, BC; Mills, S; Spinner, A; Reader, R; Hartigan-O'Connor, DJ				Laing, Steven T.; Merriam, David; Shock, Barbara C.; Mills, Sarah; Spinner, Abbie; Reader, Rachel; Hartigan-O'Connor, Dennis J.			Idiopathic Colitis in Rhesus Macaques Is Associated With Dysbiosis, Abundant Enterochromaffin Cells and Altered T-Cell Cytokine Expression	VETERINARY PATHOLOGY			English	Article						Macaca mulatto; diarrhea; colon; enterochronnaffin cells; serotonin; Campylobacter; Helicobacter; cytokines; inflammation; inflammatory bowel diseases; intestine; irritable bowel disease; microscopic colitis	IRRITABLE-BOWEL-SYNDROME; MICROSCOPIC COLITIS; NONHUMAN-PRIMATES; DNA EXTRACTION; DIARRHEA; DISEASE; COLON; RATES; TERM	Idiopathic chronic diarrhea (ICD) is a common ailment affecting captive rhesus macaques (Macaca mulatto). ICD cases are characterized by diarrhea in the absence of commonly identified diarrheal pathogens and multiple recurrences even after supportive therapy. Histologically, the disease is characterized by lymphoplasmacytic colitis. We identified 35 rhesus macaques euthanized for ICD during a 7-month period and described demographic, clinical, histologic, and immunologic commonalities. We found a trend of historic Campylobacter spp. and trichomonad infections. Furthermore, rhesus macaques with ICD demonstrated loss of normal colonic adherent bacterium, identified in this study as Helicobacter macacae; increased abundance of Pentatrichomonas hominis; and increased frequency of colonic serotonin-positive enterochronnaffin cells. Interestingly, colonic and ileal T-helper cells of animals with ICD manifested decreased capacity for expression of certain cytokines, in particular interleukin (IL)-4 and IL-13. These data further describe a common ailment and suggest new avenues to identify complex interactions involved in the etiology of recurring diarrhea in young rhesus macaques.	[Laing, Steven T.] Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA; [Merriam, David; Mills, Sarah; Spinner, Abbie; Reader, Rachel; Hartigan-O'Connor, Dennis J.] Univ Calif Davis, Calif Natl Primate Res Ctr, Davis, CA 95616 USA; [Merriam, David; Hartigan-O'Connor, Dennis J.] Univ Calif Davis, Dept Med Microbiol & Immunol, Davis, CA 95616 USA; [Shock, Barbara C.] Lincoln Mem Univ, Dept Biol, Harrogate, TN USA; [Hartigan-O'Connor, Dennis J.] Univ Calif San Francisco, Dept Med, Div Expt Med, San Francisco, CA USA	Laing, ST (reprint author), Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.	laing.steven@gene.com			Office of the Director of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P51 OD011107]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Office of the Director of the National Institutes of Health under grant P51 OD011107.	Ardeshir A, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008791; Ardeshir A, 2013, ANAT REC, V296, P1169, DOI 10.1002/ar.22727; Arreola R, 2015, J IMMUNOL RES, DOI 10.1155/2015/354957; Baker GC, 2003, J MICROBIOL METH, V55, P541, DOI 10.1016/j.mimet.2003.08.009; Bashashati M, 2012, CYTOKINE, V57, P201, DOI 10.1016/j.cyto.2011.11.019; Broadhurst MJ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003000; BUNTON TE, 1983, VET PATHOL, V20, P491, DOI 10.1177/030098588302000412; Chen J, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-91; Coura R, 2005, J CLIN PATHOL, V58, P894, DOI 10.1136/jcp.2004.021352; Duhamel GE, 2003, ANAEROBE, V9, P45, DOI 10.1016/S1075-9964(03)00044-1; Dunlop SP, 2003, GASTROENTEROLOGY, V125, P1651, DOI 10.1053/j.gastro.2003.09.028; Dunlop SP, 2003, AM J GASTROENTEROL, V98, P1578, DOI 10.1016/S0002-9270(03)000375-7; El-Salhy M, 2011, MOL MED REP, V4, P603, DOI 10.3892/mmr.2011.492; El-Salhy M, 2012, WORLD J GASTROENTERO, V18, P5151, DOI 10.3748/wjg.v18.i37.5151; ELMORE DB, 1992, LAB ANIM SCI, V42, P356; Fischer H, 2015, GUT, V64, P1185, DOI 10.1136/gutjnl-2014-308956; Gillio-Tos A, 2007, PATHOLOGY, V39, P345, DOI 10.1080/00313020701329757; Hayes DC, 2003, J VET DIAGN INVEST, V15, P390, DOI 10.1177/104063870301500417; Hilmi I, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-80; HIRD DW, 1984, LAB ANIM SCI, V34, P465; HOLMBERG CA, 1982, VET PATHOL, V19, P163, DOI 10.1177/030098588201907s12; Institute for Laboratory Animal Research, 2011, GUIDE CARE USE LAB A; Ivanov II, 2009, CELL, V139, P485, DOI 10.1016/j.cell.2009.09.033; Jalanka-Tuovinen J, 2014, GUT, V63, P1737, DOI 10.1136/gutjnl-2013-305994; KARTTUNNEN R, 1994, J CLIN PATHOL, V47, P1015, DOI 10.1136/jcp.47.11.1015; Keithlin J, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1203; Kumawat AK, 2013, MOL IMMUNOL, V55, P355, DOI 10.1016/j.molimm.2013.03.007; Li WC, 2016, PARASITOL RES, V115, P569, DOI 10.1007/s00436-015-4773-8; Madisch A, 2005, WORLD J GASTROENTERO, V11, P6409, DOI 10.3748/wjg.v11.i41.6409; Mawe GM, 2013, NAT REV GASTRO HEPAT, V10, P473, DOI 10.1038/nrgastro.2013.105; McKenna P, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040020; Nielsen HL, 2012, CLIN MICROBIOL INFEC, V18, pE459, DOI 10.1111/j.1469-0691.2012.03990.x; Pardi DS, 2002, AM J GASTROENTEROL, V97, P794; Park E, 2015, GUT LIVER, V9, P381, DOI 10.5009/gnl13439; Prongay K, 2013, AM J PRIMATOL, V75, P872, DOI 10.1002/ajp.22150; Rahimi R, 2008, CLIN THER, V30, P884, DOI 10.1016/j.clinthera.2008.05.002; Riddle Mark S, 2012, Curr Gastroenterol Rep, V14, P395, DOI 10.1007/s11894-012-0278-0; Scallan E, 2011, EMERG INFECT DIS, V17, P16, DOI [10.3201/eid1701.P21101, 10.3201/eid1701.091101p2]; Sestak K, 2003, INFECT IMMUN, V71, P4079, DOI 10.1128/IAI.71.7.4079-4086.2003; Smith JL, 2007, J FOOD PROTECT, V70, P1762, DOI 10.4315/0362-028X-70.7.1762; Spiller RC, 2000, GUT, V47, P804, DOI 10.1136/gut.47.6.804; Spiller RC, 2003, GASTROENTEROLOGY, V124, P1662, DOI 10.1016/S0016-5085(03)00324-X; Spiller R, 2009, GASTROENTEROLOGY, V136, P1979, DOI 10.1053/j.gastro.2009.02.074; Spiller RC, 2009, DIGEST DIS, V27, P48, DOI 10.1159/000268121; Sundin J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134836; Sundin J, 2014, SCAND J GASTROENTERO, V49, P1068, DOI 10.3109/00365521.2014.926982; Thornley JP, 2001, J INFECT DIS, V184, P606, DOI 10.1086/322845; TOFT JD, 1982, VET PATHOL, V19, P44, DOI 10.1177/030098588201907s06; Tolbert MK, 2016, J VET INTERN MED, V30, P516, DOI 10.1111/jvim.13920; Walker MM, 2009, ALIMENT PHARM THER, V29, P765, DOI 10.1111/j.1365-2036.2009.03937.x; Xiong J, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-165; Zaragoza MM, 2011, J IMMUNOL, V186, P1589, DOI 10.4049/jimmunol.1002021	52	2	2	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	SEP	2018	55	5					741	752		10.1177/0300985818780449			12	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GR5JY	WOS:000442667700018	29929446				2019-10-28	
J	Williams, B				Williams, Bruce			In Memoriam: Robert M. McCully (1927-2017)	VETERINARY PATHOLOGY			English	Biographical-Item									[Williams, Bruce] Joint Pathol Ctr, 606 Stephen Sitter Ave, Rockville, MD 20852 USA	Williams, B (reprint author), Joint Pathol Ctr, 606 Stephen Sitter Ave, Rockville, MD 20852 USA.	bruce.h.williams@hotmail.com					[Anonymous], PUBLICATION LIST	1	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	SEP	2018	55	5					759	761		10.1177/0300985818776053			3	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GR5JY	WOS:000442667700020	29759038	Bronze			2019-10-28	
J	Schwartz, CJ; Schandl, CA; Morse, J; Ralston, J; Rapkiewicz, A; Darvishian, F				Schwartz, Christopher J.; Schandl, Cynthia A.; Morse, Jennifer; Ralston, Jonathan; Rapkiewicz, Amy; Darvishian, Farbod			Benign Fibromyxoid Lesion of the Breast: A Distinct Entity From Benign Spindle Cell Tumors of the Mammary Stroma?	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						breast; myxoid; mammary myofibroblastoma; CD34+; Rb	USP6 GENE REARRANGEMENT; SOLITARY FIBROUS TUMOR; NODULAR FASCIITIS; IN-SITU; MYOFIBROBLASTOMA; EXPRESSION; MYXOMA; LIPOMA; CD34	Myxoid lesions of the breast can be diagnostically challenging entities. We report 4 cases of CD34+ fibromyxoid lesion that have been previously diagnosed as benign myxoid lesion, nodular mucinosis, or mammary myofibroblastoma, myxoid type on the basis of CD34-positivity. The lesions were microscopically well circumscribed and composed of a paucicellular spindle cell proliferation in a background of myxoid stroma. No epithelial component was identified. The spindle cells showed immunohistochemical reactivity for CD34 and smooth muscle actin. Based on morphologic and immunohistochemical similarities between these cases and myxoid myofibroblastoma, we compared 4 myxoid lesions with cases of typical myofibroblastoma, utilizing retinoblastoma (Rb) antibody and fluorescent in situ hybridization for 13q14 gene rearrangement (encoding the Rb gene). The myxoid lesions showed retention of Rb protein by immunohistochemistry, whereas Rb expression was lost in cases of myofibroblastoma. We identified loss of 13q14 in 3 of 4 cases of myofibroblastoma. Notably, 13q14 gene rearrangement was not observed in any of the myxoid lesions. Our data show that there is at least a subset of CD34+ fibromyxoid lesions that, despite overlapping morphologic and immunohistochemical phenotype and proposed common histogenesis with myofibroblastomas, is genetically distinct from the latter based on Rb analysis.	[Schwartz, Christopher J.; Rapkiewicz, Amy; Darvishian, Farbod] NYU, Med Ctr, New York, NY 10016 USA; [Schandl, Cynthia A.; Morse, Jennifer] Med Univ South Carolina, Charleston, SC 29425 USA; [Ralston, Jonathan] Miraca Life Sci, Irving, TX USA	Darvishian, F (reprint author), NYU Pathol Associates, 550 1st Ave,Suite TH461, New York, NY 10016 USA.	farbod.darvishian@nyumc.org			NYU Department of Pathology	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by intramural support from the NYU Department of Pathology.	Amary MF, 2013, VIRCHOWS ARCH, V463, P97, DOI 10.1007/s00428-013-1418-0; ARIHIRO K, 1993, ACTA PATHOL JAPON, V43, P340; Balci P, 2007, BREAST J, V13, P88, DOI 10.1111/j.1524-4741.2006.00370.x; CARNEY JA, 1991, AM J SURG PATHOL, V15, P713, DOI 10.1097/00000478-199108000-00001; Chauhan H, 2003, J CLIN PATHOL, V56, P271, DOI 10.1136/jcp.56.4.271; Chen BJ, 2012, AM J SURG PATHOL, V36, P1119, DOI 10.1097/PAS.0b013e31825d532d; Erickson-Johnson MR, 2011, LAB INVEST, V91, P1427, DOI 10.1038/labinvest.2011.118; Ho SK, 2013, HISTOPATHOLOGY, V63, P393, DOI 10.1111/his.12177; Howitt BE, 2016, AM J SURG PATHOL, V40, P361, DOI 10.1097/PAS.0000000000000540; Koide Norimasa, 2002, Breast Cancer, V9, P261, DOI 10.1007/BF02967600; Maggiam F, 2007, HISTOPATHOLOGY, V51, P410, DOI 10.1111/j.1365-2559.2007.02775.x; Magro G, 2002, VIRCHOWS ARCH, V440, P249, DOI 10.1007/s00428-001-0572-y; Magro G, 2001, PATHOL RES PRACT, V197, P453, DOI 10.1078/0344-0338-00112; Magro G, 2007, VIRCHOWS ARCH, V450, P483, DOI 10.1007/s00428-007-0373-z; Magro G, 2016, PATHOL RES PRACT, V212, P463, DOI 10.1016/j.prp.2015.12.013; Magro G, 2014, PATHOL RES PRACT, V210, P1106, DOI 10.1016/j.prp.2014.08.004; Magro G, 2012, HUM PATHOL, V43, P1887, DOI 10.1016/j.humpath.2012.01.015; Magro G, 2010, VIRCHOWS ARCH, V456, P581, DOI 10.1007/s00428-010-0902-z; Michal M, 1998, PATHOL INT, V48, P542, DOI 10.1111/j.1440-1827.1998.tb03946.x; Paliogiannis P, 2016, BREAST CARE, V11, P270, DOI 10.1159/000448185; PIETILAINEN T, 1995, EUR J CANCER, V31A, P329, DOI 10.1016/0959-8049(94)00463-F; Sanati Souzan, 2005, Arch Pathol Lab Med, V129, pe58; Shin C, 2016, HISTOPATHOLOGY, V69, P784, DOI 10.1111/his.13011; WEE A, 1989, VIRCHOWS ARCH A, V416, P163, DOI 10.1007/BF01606322; Weiss SW, 2008, ENZINGER WEISSS SOFT, P1066	25	1	1	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	SEP	2018	26	6					488	493		10.1177/1066896918763901			6	Pathology; Surgery	Pathology; Surgery	GP6XS	WOS:000441033800001	29552929				2019-10-28	
J	Nguyen, JK; Magi-Galluzzi, C				Nguyen, Jane Kim; Magi-Galluzzi, Cristina			Unfavorable Pathology, Tissue Biomarkers and Genomic Tests With Clinical Implications in Prostate Cancer Management	ADVANCES IN ANATOMIC PATHOLOGY			English	Review						prostate cancer; cribriform; intraductal; genomic tests; circulating tumor cells; ConfirmMDx; OncotypeDX; Prolaris; Decipher; 3 beta HSD1	ANDROGEN-DEPRIVATION THERAPY; CYCLE PROGRESSION-SCORE; ATYPICAL CRIBRIFORM LESIONS; DISEASE-SPECIFIC SURVIVAL; ISUP CONSENSUS-CONFERENCE; RECURRENCE-FREE SURVIVAL; HIGH-GRADE PIN; INTRADUCTAL-CARCINOMA; RADICAL PROSTATECTOMY; BIOCHEMICAL RECURRENCE	Prostate cancer management has traditionally relied upon risk stratification of patients based on Gleason score, pretreatment prostate-specific antigen and clinical tumor stage. However, these factors alone do not adequately reflect the inherent complexity and heterogeneity of prostate cancer. Accurate and individualized risk stratification at the time of diagnosis is instrumental to facilitate clinical decision-making and treatment selection tailored to each patient. The incorporation of tissue and genetic biomarkers into current prostate cancer prediction models may optimize decision-making and improve patient outcomes. In this review we discuss the clinical significance of unfavorable morphologic features such as cribriform architecture and intraductal carcinoma of the prostate, tissue biomarkers and genomic tests and assess their potential use in prostate cancer risk assessment and treatment selection.	[Nguyen, Jane Kim; Magi-Galluzzi, Cristina] Cleveland Clin, Robert J Tomsich Pathol & Lab Med Inst, Cleveland, OH 44106 USA; [Magi-Galluzzi, Cristina] Cleveland Clin, Glickman Urol & Kidney Inst, Cleveland, OH 44106 USA	Magi-Galluzzi, C (reprint author), Cleveland Clin, Pathol & Lab Med Inst, 9500 Euclid Ave,L25, Cleveland, OH 44195 USA.	magic@ccf.org					Agarwal N, 2017, JAMA ONCOL, V3, P856, DOI 10.1001/jamaoncol.2017.0147; Ahearn TU, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv346; Antonarakis ES, 2017, J CLIN ONCOL, V35, P2149, DOI 10.1200/JCO.2016.70.1961; Antonarakis ES, 2015, JAMA ONCOL, V1, P582, DOI 10.1001/jamaoncol.2015.1341; Antonarakis ES, 2015, EXPERT REV ANTICANC, V15, P143, DOI 10.1586/14737140.2015.999044; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Antonarakis ES, 2012, CANCER-AM CANCER SOC, V118, P6063, DOI 10.1002/cncr.27689; Ayala G, 2013, ANN CLIN LAB SCI, V43, P11; Ayala GE, 2011, AM J PATHOL, V178, P79, DOI 10.1016/j.ajpath.2010.09.042; Bastos DA, 2016, DRUG DES DEV THER, V10, DOI 10.2147/DDDT.S93941; Berney DM, 2016, BRIT J CANCER, V114, P1078, DOI 10.1038/bjc.2016.86; Bishoff JT, 2014, J UROLOGY, V192, P409, DOI 10.1016/j.juro.2014.02.003; Bottcher R, 2018, BMC CANCER, V18, DOI 10.1186/s12885-017-3976-z; Brand TC, 2016, UROLOGY, V89, P69, DOI 10.1016/j.urology.2015.12.008; CARVALHO FLF, 2014, J CLIN ONCOL S, V32; Chang KH, 2013, CELL, V154, P1074, DOI 10.1016/j.cell.2013.07.029; Chen ZB, 2015, PROSTATE, V75, P1247, DOI 10.1002/pros.23005; Chinnaiyan AM, 2008, NEOPLASIA, V10, P177, DOI 10.1593/neo.07822; Choy B, 2016, AM J SURG PATHOL, V40, P1400, DOI 10.1097/PAS.0000000000000691; Chua MLK, 2017, EUR UROL, V72, P665, DOI 10.1016/j.eururo.2017.04.034; Cooper CS, 2015, NAT GENET, V47, P367, DOI 10.1038/ng.3221; Cooperberg MR, 2015, EUR UROL, V67, P326, DOI 10.1016/j.eururo.2014.05.039; Crawford ED, 2014, CURR MED RES OPIN, V30, P1025, DOI 10.1185/03007995.2014.899208; Crowley E, 2013, NAT REV CLIN ONCOL, V10, P472, DOI 10.1038/nrclinonc.2013.110; Cucchiara V, 2018, EUR UROL, V73, P572, DOI 10.1016/j.eururo.2017.10.036; Cullen J, 2015, EUR UROL, V68, P123, DOI 10.1016/j.eururo.2014.11.030; Cuzick J, 2013, BRIT J CANCER, V108, P2582, DOI 10.1038/bjc.2013.248; Cuzick J, 2012, BRIT J CANCER, V106, P1095, DOI 10.1038/bjc.2012.39; Cuzick Jack, 2014, Recent Results Cancer Res, V202, P133, DOI 10.1007/978-3-642-45195-9_16; Cuzick J, 2011, LANCET ONCOL, V12, P245, DOI 10.1016/S1470-2045(10)70295-3; Dalela D, 2017, J CLIN ONCOL, V35, P1982, DOI 10.1200/JCO.2016.69.9918; Davis JW, 2015, TREND UROL MENS HEAL, V6, P36, DOI 10.1002/tre.461; De Vivar AD, 2017, HUM PATHOL, V63, P202, DOI 10.1016/j.humpath.2017.02.019; Den RB, 2015, J CLIN ONCOL, V33, P944, DOI 10.1200/JCO.2014.59.0026; Den RB, 2014, INT J RADIAT ONCOL, V89, P1038, DOI 10.1016/j.ijrobp.2014.04.052; DeSantis CE, 2016, CA-CANCER J CLIN, V66, P290, DOI 10.3322/caac.21340; Downes MR, 2017, PATHOL RES PRACT, V213, P34, DOI 10.1016/j.prp.2016.10.007; Epstein JI, 2016, WHO CLASSIFICATION T, P164; Epstein JI, 2017, AM J SURG PATHOL, V41, pE1, DOI 10.1097/PAS.0000000000000820; Epstein JI, 2016, AM J SURG PATHOL, V40, P244, DOI 10.1097/PAS.0000000000000530; Epstein JI, 2016, EUR UROL, V69, P428, DOI 10.1016/j.eururo.2015.06.046; Erho N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066855; Flood TA, 2018, VIRCHOWS ARCH, V472, P205, DOI 10.1007/s00428-017-2241-9; Freedland SJ, 2016, EUR UROL, V70, P588, DOI 10.1016/j.eururo.2016.01.008; Freedland SJ, 2013, INT J RADIAT ONCOL, V86, P848, DOI 10.1016/j.ijrobp.2013.04.043; Gore JL, 2017, CANCER-AM CANCER SOC, V123, P2850, DOI 10.1002/cncr.30665; Guedes LB, 2017, J UROLOGY, V197, P1054, DOI 10.1016/j.juro.2016.09.084; Guo CC, 2006, MODERN PATHOL, V19, P1528, DOI 10.1038/modpathol.3800702; Haffner MC, 2016, J PATHOL, V238, P31, DOI 10.1002/path.4628; Han B, 2010, AM J SURG PATHOL, V34, P478, DOI 10.1097/PAS.0b013e3181d6827b; Hearn JWD, 2018, JAMA ONCOL, V4, P558, DOI 10.1001/jamaoncol.2017.3164; Hearn JWD, 2016, LANCET ONCOL, V17, P1435, DOI 10.1016/S1470-2045(16)30227-3; Iczkowski KA, 2018, ADV ANAT PATHOL, V25, P31, DOI 10.1097/PAP.0000000000000168; Karnes RJ, 2013, J UROLOGY, V190, P2047, DOI 10.1016/j.juro.2013.06.017; Kato M, 2016, MODERN PATHOL, V29, P166, DOI 10.1038/modpathol.2015.146; Kicinski M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027130; Klein EA, 2016, UROLOGY, V90, P148, DOI 10.1016/j.urology.2016.01.012; Klein EA, 2015, EUR UROL, V67, P778, DOI 10.1016/j.eururo.2014.10.036; Klein EA, 2014, EUR UROL, V66, P550, DOI 10.1016/j.eururo.2014.05.004; Klotz L, 2017, UROL CLIN N AM, V44, P565, DOI 10.1016/j.ucl.2017.07.005; Knezevic D, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-690; Knudsen BS, 2016, J MOL DIAGN, V18, P395, DOI 10.1016/j.jmoldx.2015.12.006; Kretschmer A, 2017, CRIT REV ONCOL HEMAT, V120, P180, DOI 10.1016/j.critrevonc.2017.11.007; Krohn A, 2012, AM J PATHOL, V181, P401, DOI 10.1016/j.ajpath.2012.04.026; Kryvenko ON, 2013, ARCH PATHOL LAB MED, V137, P610, DOI 10.5858/arpa.2012-0128-OA; Kweldam CF, 2017, MODERN PATHOL, V30, P1126, DOI 10.1038/modpathol.2017.29; Kweldam CF, 2016, MODERN PATHOL, V29, P630, DOI 10.1038/modpathol.2016.49; Kweldam CF, 2015, MODERN PATHOL, V28, P457, DOI 10.1038/modpathol.2014.116; Lahdensuo K, 2016, MODERN PATHOL, V29, P1565, DOI 10.1038/modpathol.2016.154; Leapman MS, 2017, EUR UROL, V71, P750, DOI 10.1016/j.eururo.2016.11.032; Li H, 2018, MODERN PATHOL, V31, P198, DOI 10.1038/modpathol.2017.74; Loeb S, 2017, CURR OPIN UROL, V27, P495, DOI 10.1097/MOU.0000000000000419; Lokman U, 2017, EUR UROL FOCUS; Lotan TL, 2016, EUR UROL FOCUS, V2, P180, DOI 10.1016/j.euf.2015.07.005; Lotan TL, 2015, MODERN PATHOL, V28, P128, DOI 10.1038/modpathol.2014.85; Lotan TL, 2013, MODERN PATHOL, V26, P587, DOI 10.1038/modpathol.2012.201; Magi-Galluzzi C, 2016, CURR OPIN UROL, V26, P488, DOI 10.1097/MOU.0000000000000320; McKenney JK, 2016, AM J SURG PATHOL, V40, P1439, DOI 10.1097/PAS.0000000000000736; Mehra R, 2016, EUR UROL, V70, P549, DOI 10.1016/j.eururo.2015.12.003; Mehra R, 2014, NEOPLASIA, V16, P1121, DOI 10.1016/j.neo.2014.11.006; Morais CL, 2016, HUM PATHOL, V55, P117, DOI 10.1016/j.humpath.2016.04.017; Morais CL, 2015, AM J SURG PATHOL, V39, P169, DOI 10.1097/PAS.0000000000000348; Mottet N, 2017, EUR UROL, V71, P618, DOI 10.1016/j.eururo.2016.08.003; Mucci LA, 2016, JAMA-J AM MED ASSOC, V315, P68, DOI 10.1001/jama.2015.17703; National Comprehensive Cancer Network, 2017, NCCN GUID VERS 2 201; Nguyen PL, 2017, PROSTATE CANCER P D, V20, P186, DOI 10.1038/pcan.2016.58; Nguyen PL, 2017, EUR UROL, V72, P845, DOI 10.1016/j.eururo.2017.05.009; Oderda M, 2017, UROLOGY, V102, P73, DOI 10.1016/j.urology.2016.11.038; Olkhov-Mitsel E, 2017, ONCOL LETT, V14, P390, DOI [10.3892/o1.2017.6140, 10.3892/ol.2017.6140]; Onstenk W, 2015, EUR UROL, V68, P939, DOI 10.1016/j.eururo.2015.07.007; Partin AW, 2014, J UROLOGY, V192, P1081, DOI 10.1016/j.juro.2014.04.013; Perner S, 2007, AM J SURG PATHOL, V31, P882, DOI 10.1097/01.pas.0000213424.38503.aa; Porter LH, 2018, BJU INT, V121, P971, DOI 10.1111/bju.14043; Porter LH, 2017, EUR UROL, V72, P492, DOI 10.1016/j.eururo.2017.03.013; Prensner JR, 2014, LANCET ONCOL, V15, P1469, DOI 10.1016/S1470-2045(14)71113-1; Prensner JR, 2013, NAT GENET, V45, P1392, DOI 10.1038/ng.2771; Risbridger GP, 2015, EUR UROL, V67, P496, DOI 10.1016/j.eururo.2014.08.007; Ritch E, 2017, UROL ONCOL; Robinson BD, 2010, J UROLOGY, V184, P1328, DOI 10.1016/j.juro.2010.06.017; Ross AE, 2016, PROSTATE CANCER P D, V19, P277, DOI 10.1038/pcan.2016.15; Ross AE, 2016, PROSTATE CANCER P D, V19, P1, DOI 10.1038/pcan.2015.31; Ross AE, 2014, PROSTATE CANCER P D, V17, P64, DOI 10.1038/pcan.2013.49; Ross AE, 2016, J NATL COMPR CANC NE, V14, P659, DOI 10.6004/jnccn.2016.0185; Ross AE, 2016, EUR UROL, V69, P157, DOI 10.1016/j.eururo.2015.05.042; Sanda MG, 2018, J UROLOGY, V199, P990, DOI 10.1016/j.juro.2018.01.002; Sanda MG, 2018, J UROLOGY, V199, P683, DOI 10.1016/j.juro.2017.11.095; Shah RB, 2012, ADV ANAT PATHOL, V19, P270, DOI 10.1097/PAP.0b013e31825c6c0e; SHIOTA M, 2018, J CLIN ONCOL S, V36; Shore N, 2014, CURR MED RES OPIN, V30, P547, DOI 10.1185/03007995.2013.873398; Shore ND, 2016, J UROLOGY, V195, P612, DOI 10.1016/j.juro.2015.09.072; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Simard J, 2005, ENDOCR REV, V26, P525, DOI 10.1210/er.2002-0050; Spratt DE, 2017, J CLIN ONCOL, V35, P1991, DOI 10.1200/JCO.2016.70.2811; Spratt DE, 2016, BJU INT, V118, P763, DOI 10.1111/bju.13488; Spratt DE, 2017, EUR UROL; Stewart GD, 2013, J UROLOGY, V189, P1110, DOI 10.1016/j.juro.2012.08.219; Taplin ME, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.tps5069; Taylor RA, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13671; To SQ, 2018, EUR UROL; Trock BJ, 2016, MODERN PATHOL, V29, P764, DOI 10.1038/modpathol.2016.63; Trudel D, 2014, EUR J CANCER, V50, P1610, DOI 10.1016/j.ejca.2014.03.009; Van Den Eeden SK, 2018, EUR UROL, V73, P129, DOI 10.1016/j.eururo.2017.09.013; Van Neste L, 2016, PROSTATE, V76, P1078, DOI 10.1002/pros.23191; Vandekerkhove G, 2017, CANC GENET; Watts K, 2013, HISTOPATHOLOGY, V63, P574, DOI 10.1111/his.12198; WOJNO KJ, 2014, AM HEALTH DRUG BENEF, V7, P129; Yanagisawa N, 2007, HUM PATHOL, V38, P1611, DOI 10.1016/j.humpath.2007.04.008; Zhang T, 2016, CURR ONCOL REP, V18, DOI 10.1007/s11912-015-0490-9; Zhao JG, 2017, ONCOTARGET, V8, P55374, DOI 10.18632/oncotarget.19520; Zhao T, 2015, PROSTATE, V75, P225, DOI 10.1002/pros.22906	131	5	6	2	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-4109	1533-4031		ADV ANAT PATHOL	Adv. Anat. Pathol.	SEP	2018	25	5					293	303		10.1097/PAP.0000000000000192			11	Pathology	Pathology	GQ7HD	WOS:000441906500001	29727322				2019-10-28	
J	Weissferdt, A				Weissferdt, Annikka			Pulmonary Sarcomatoid Carcinomas: A Review	ADVANCES IN ANATOMIC PATHOLOGY			English	Review						lung; non-small cell carcinoma; sarcomatoid carcinoma; spindle cell carcinoma; pleomorphic carcinoma; giant cell carcinoma	GIANT-CELL CARCINOMA; RESEMBLING FETAL LUNG; DEATH LIGAND-1 PD-L1; END RESULTS DATABASE; SHOW HIGH-LEVELS; SPINDLE-CELL; PLEOMORPHIC CARCINOMA; POOR-PROGNOSIS; INTERMEDIATE FILAMENTS; CLINICAL-OUTCOMES	Pulmonary sarcomatoid carcinomas belong to a group of neoplasms that remain incompletely understood. They are rare tumors of the bronchopulmonary system that incorporate a wide range of neoplasms that by definition contain a sarcomatoid component characterized by spindle or giant cells. Such classification has led to a heterogenous tumor category that includes neoplasms with different clinical, morphologic, and prognostic features. To date, the histopathologic diagnosis of pulmonary sarcomatoid carcinomas does not require the use of ancillary testing and is based on light microscopic criteria alone. However, with recent advances in immunohistochemical and molecular methods, it is becoming increasingly clear that pulmonary sarcomatoid carcinomas represent poorly differentiated or dedifferentiated variants of conventional non-small cell carcinomas with similar immunophenotype and molecular signatures. This review summarizes the latest insights and concepts of these unusual tumors and outlines future directions with emphasis on tumor classification and patient management.	[Weissferdt, Annikka] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	Weissferdt, A (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.	aweissferdt@mdanderson.org					ADDIS BJ, 1985, J PATHOL, V147, P291, DOI 10.1002/path.1711470407; Bae HM, 2007, LUNG CANCER, V58, P112, DOI 10.1016/j.lungcan.2007.05.006; BARNARD WG, 1952, THORAX, V7, P299, DOI 10.1136/thx.7.4.299; Barnett N, 1945, BRIT J SURG, V32, P447; BARSON AJ, 1968, J CLIN PATHOL, V21, P480, DOI 10.1136/jcp.21.4.480; BATTIFORA H, 1976, CANCER, V37, P2275, DOI 10.1002/1097-0142(197605)37:5<2275::AID-CNCR2820370518>3.0.CO;2-3; Chaft JE, 2012, J THORAC ONCOL, V7, P1400, DOI 10.1097/JTO.0b013e3182614856; Chang YL, 2011, ANN SURG ONCOL, V18, P2952, DOI 10.1245/s10434-011-1621-7; Dacic S, 2002, AM J SURG PATHOL, V26, P510, DOI 10.1097/00000478-200204000-00015; de Kock L, 2016, EUR RESPIR J, V47, P1879, DOI 10.1183/13993003.00172-2016; Fallet V, 2015, ANN ONCOL, V26, P1748, DOI 10.1093/annonc/mdv232; FISHBACK NF, 1994, CANCER-AM CANCER SOC, V73, P2936, DOI 10.1002/1097-0142(19940615)73:12<2936::AID-CNCR2820731210>3.0.CO;2-U; Force S, 2003, J THORAC CARDIOV SUR, V126, P1247, DOI 10.1016/S0022-5223(03)00079-5; Forest F, 2016, HUM PATHOL, V49, P99, DOI 10.1016/j.humpath.2015.10.006; FUNG CH, 1977, CANCER-AM CANCER SOC, V39, P153, DOI 10.1002/1097-0142(197701)39:1<153::AID-CNCR2820390126>3.0.CO;2-#; GINSBERG SS, 1992, CANCER-AM CANCER SOC, V70, P606, DOI 10.1002/1097-0142(19920801)70:3<606::AID-CNCR2820700311>3.0.CO;2-L; Gu LP, 2015, BIOMED PHARMACOTHER, V76, P134, DOI 10.1016/j.biopha.2015.10.009; Hansen T, 2003, LUNG, V181, P193, DOI 10.1007/s00408-003-1021-2; HELLSTROM HR, 1963, CANCER, V16, P1080, DOI 10.1002/1097-0142(196308)16:8<1080::AID-CNCR2820160816>3.0.CO;2-V; HERMAN DL, 1966, CANCER, V19, P1337, DOI 10.1002/1097-0142(196610)19:10<1337::AID-CNCR2820191003>3.0.CO;2-3; Holst VA, 1997, AM J SURG PATHOL, V21, P801, DOI 10.1097/00000478-199707000-00008; Huang SY, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-252; Hummel P, 2001, CANCER CYTOPATHOL, V93, P187, DOI 10.1002/cncr.9028; HUMPHREY PA, 1988, HUM PATHOL, V19, P155, DOI 10.1016/S0046-8177(88)80343-5; HUSZAR M, 1984, HUM PATHOL, V15, P532, DOI 10.1016/S0046-8177(84)80006-4; Italiano A, 2009, INT J CANCER, V125, P2479, DOI 10.1002/ijc.24610; Jiang XL, 2012, CLIN LUNG CANCER, V13, P288, DOI 10.1016/j.cllc.2011.11.004; Johansson Leif, 2004, Ann Diagn Pathol, V8, P259, DOI 10.1016/j.anndiagpath.2004.07.001; Kika G, 1908, JPN J CANCER RES, V2, P574; KODAMA T, 1984, AM J SURG PATHOL, V8, P735, DOI 10.1097/00000478-198410000-00002; Koss MN, 1999, AM J SURG PATHOL, V23, P1514, DOI 10.1097/00000478-199912000-00009; KOSS MN, 1991, CANCER, V67, P2368, DOI 10.1002/1097-0142(19910501)67:9<2368::AID-CNCR2820670926>3.0.CO;2-G; KRADIN RL, 1982, AM J SURG PATHOL, V6, P165, DOI 10.1097/00000478-198203000-00009; Lee S, 2011, J CANCER RES CLIN, V137, P1203, DOI 10.1007/s00432-011-0986-0; Lin Y, 2014, PATHOLOGY, V1, P14; Liu XW, 2016, J CLIN ONCOL, V34, P794, DOI 10.1200/JCO.2015.62.0674; Lucas DR, 2003, HISTOPATHOLOGY, V42, P270, DOI 10.1046/j.1365-2559.2003.01583.x; Martin LW, 2007, ANN THORAC SURG, V84, P973, DOI 10.1016/j.athoracsur.2007.03.099; MATSUI K, 1991, CANCER-AM CANCER SOC, V67, P2361, DOI 10.1002/1097-0142(19910501)67:9<2361::AID-CNCR2820670925>3.0.CO;2-3; Mochizuki T, 2008, AM J SURG PATHOL, V32, P1727, DOI 10.1097/PAS.0b013e3181804302; Mukhopadhyay S, 2011, AM J SURG PATHOL, V35, P15, DOI 10.1097/PAS.0b013e3182036d05; Nakajima M, 1999, CANCER-AM CANCER SOC, V86, P608, DOI 10.1002/(SICI)1097-0142(19990815)86:4<608::AID-CNCR9>3.3.CO;2-T; Nakatani Y, 1998, AM J SURG PATHOL, V22, P399, DOI 10.1097/00000478-199804000-00003; Nakatani Y, 2004, AM J SURG PATHOL, V28, P921, DOI 10.1097/00000478-200407000-00012; NAKATANI Y, 1990, HUM PATHOL, V21, P1097, DOI 10.1016/0046-8177(90)90145-U; NAPPI O, 1993, SEMIN DIAGN PATHOL, V10, P137; NAPPI O, 1994, AM J CLIN PATHOL, V102, P331, DOI 10.1093/ajcp/102.3.331; NASH AD, 1958, CANCER, V11, P369, DOI 10.1002/1097-0142(195803/04)11:2<369::AID-CNCR2820110222>3.0.CO;2-8; Nishida K, 2002, ANTICANCER RES, V22, P3477; Pacinda SJ, 1996, HUM PATHOL, V27, P542, DOI 10.1016/S0046-8177(96)90159-8; Pardo J, 2008, DIAGN MOL PATHOL, V17, P151, DOI 10.1097/PDM.0b013e31815d05b3; Park JS, 2011, ONCOLOGY-BASEL, V81, P206, DOI 10.1159/000333095; Pelosi G, 2003, AM J SURG PATHOL, V27, P1203, DOI 10.1097/00000478-200309000-00003; Pelosi G, 2010, INT J SURG PATHOL, V18, P103, DOI 10.1177/1066896908330049; Pomplun S, 2002, HISTOPATHOLOGY, V40, P152, DOI 10.1046/j.1365-2559.2002.01328.x; Rahouma M, 2018, EUR J CARDIO-THORAC, V53, P828, DOI 10.1093/ejcts/ezx417; Rapicetta C, 2016, LUNG, V194, P653, DOI 10.1007/s00408-016-9904-1; Raveglia F, 2004, ANN THORAC SURG, V78, P1742, DOI 10.1016/j.athoracsur.2004.04.084; RO JY, 1992, CANCER-AM CANCER SOC, V69, P376, DOI 10.1002/1097-0142(19920115)69:2<376::AID-CNCR2820690218>3.0.CO;2-U; Roesel C, 2017, INTERACT CARDIOV TH, V24, P407, DOI 10.1093/icvts/ivw392; Rossi G, 2003, AM J SURG PATHOL, V27, P311, DOI 10.1097/00000478-200303000-00004; Saphir O, 1938, AM J CANCER, V33, P331; Schrock AB, 2017, J THORAC ONCOL, V12, P932, DOI 10.1016/j.jtho.2017.03.005; Schrock AB, 2016, J THORAC ONCOL, V11, P1493, DOI 10.1016/j.jtho.2016.06.004; Sekine S, 2003, J PATHOL, V200, P214, DOI 10.1002/path.1352; Shimosato Y, 1981, HISTOLOGICAL TYPING; SHIN MS, 1986, CHEST, V89, P366, DOI 10.1378/chest.89.3.366; SPENCER H, 1961, J PATHOL BACTERIOL, V82, P161, DOI 10.1002/path.1700820119; Steuer CE, 2017, CLIN LUNG CANCER, V18, P286, DOI 10.1016/j.cllc.2016.11.016; Takahashi K, 2007, LUNG CANCER, V57, P103, DOI 10.1016/j.lungcan.2007.01.026; Takeshima Y, 2009, HISTOPATHOLOGY, V54, P667, DOI 10.1111/j.1365-2559.2009.03298.x; Terra SBSP, 2016, MODERN PATHOL, V29, P824, DOI 10.1038/modpathol.2016.89; Terra SBSP, 2014, HUM PATHOL, V45, P294, DOI 10.1016/j.humpath.2013.09.005; Thompson L, 1996, AM J SURG PATHOL, V20, P277, DOI 10.1097/00000478-199603000-00003; Travis WD, 1999, WHO HISTOLOGICAL CLA; Travis WD, 2015, PATHOLOGY GENETICS T; Travis WE, 2004, PATHOLOGY GENETICS T; Ung M, 2016, CLIN LUNG CANCER, V17, P391, DOI 10.1016/j.cllc.2016.03.001; Van Loo S, 2011, LUNG CANCER, V73, P127, DOI 10.1016/j.lungcan.2011.03.018; Velcheti V, 2013, J THORAC ONCOL, V8, P803, DOI 10.1097/JTO.0b013e318292be18; Venissac N, 2007, J THORAC CARDIOV SUR, V134, P619, DOI 10.1016/j.jtcvs.2007.05.031; Vieira T, 2016, LUNG CANCER, V98, P51, DOI 10.1016/j.lungcan.2016.05.013; Vieira T, 2014, LUNG CANCER, V85, P276, DOI 10.1016/j.lungcan.2014.06.004; Virchow RL, 1865, KRANKHAFTEN GESCHWUL, P181; WADDELL WR, 1949, ARCH PATHOL, V47, P227; Weissferdt A, 2017, HUM PATHOL, V63, P14, DOI 10.1016/j.humpath.2016.12.010; Weissferdt A, 2017, HUM PATHOL, V59, P1, DOI 10.1016/j.humpath.2016.08.003; Weissferdt A, 2016, HISTOPATHOLOGY, V68, P680, DOI 10.1111/his.12798; WICK MR, 1995, HUM PATHOL, V26, P1014, DOI 10.1016/0046-8177(95)90092-6; Wick MR, 1997, AM J CLIN PATHOL, V108, P40; Yendamuri S, 2012, SURGERY, V152, P397, DOI 10.1016/j.surg.2012.05.007; Yuki T, 2007, J THORAC CARDIOV SUR, V134, P399, DOI 10.1016/j.jtcvs.2007.04.018	92	2	2	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-4109	1533-4031		ADV ANAT PATHOL	Adv. Anat. Pathol.	SEP	2018	25	5					304	313		10.1097/PAP.0000000000000202			10	Pathology	Pathology	GQ7HD	WOS:000441906500002	29912718				2019-10-28	
J	Kilpatrick, SE; Reith, JD; Rubin, B				Kilpatrick, Scott E.; Reith, John D.; Rubin, Brian			Ewing Sarcoma and the History of Similar and Possibly Related Small Round Cell Tumors: From Whence Have We Come and Where are We Going?	ADVANCES IN ANATOMIC PATHOLOGY			English	Review						Ewing sarcoma; neuroectodermal tumor; small round cell tumor	EWS/FLI-1 FUSION TRANSCRIPT; BCOR-CCNB3 GENE FUSION; REGION ASKIN TUMOR; MESENCHYMAL CHONDROSARCOMA; THORACOPULMONARY REGION; NEUROECTODERMAL TUMOR; SOFT-TISSUE; PERIPHERAL NEUROEPITHELIOMA; CHROMOSOME-TRANSLOCATION; MALIGNANT-TUMOR	The diagnosis of small round cell tumors always has been extremely difficult, and our current classification systems continue to evolve. Since its initial discovery by Dr James Ewing, the historical context of what is acceptably included under the designation Ewing sarcoma has changed. Although Ewing sarcoma and primitive neuroectodermal tumor were both initially described in the early 20th century, these tumors were considered likely distinct entities until the end of that same century, almost 75 years later. With modern immunohistochemistry and more recent advances in molecular techniques, the understanding of Ewing sarcoma and Ewing-like tumors has improved dramatically but also raises new questions and challenges. We now know that this category of tumors is remarkably more heterogenous than initially thought, especially in regards to its cytogenetics and molecular properties, and some of these differences likely have prognostic relevance. Whether we are now expanding the spectrum of Ewing sarcoma or simply recognizing new entities is controversial. Therapeutic approaches to address these new categories and/or entities need further focus and attention. Herein, we provide a comprehensive historical perspective on Ewing sarcoma, Ewing-like tumors (CIC and BCOR-rearranged sarcomas), and related and/or similar small round cell tumors, often included in the differential diagnosis, including mesenchymal chondrosarcoma, desmoplastic small round cell tumor, and small cell osteosarcoma. We also seek to provide updates and insights into the evolving classification and clinical relevance of the Ewing family of tumors.	[Kilpatrick, Scott E.; Reith, John D.; Rubin, Brian] Cleveland Clin, Dept Anat Pathol L25, Cleveland, OH 44195 USA	Kilpatrick, SE (reprint author), Cleveland Clin, Dept Anat Pathol L25, Cleveland, OH 44195 USA.	kilpats@ccf.org					ANGERVALL L, 1975, CANCER, V36, P240, DOI 10.1002/1097-0142(197507)36:1<240::AID-CNCR2820360127>3.0.CO;2-H; Antonescu CR, 2017, AM J SURG PATHOL, V41, P941, DOI 10.1097/PAS.0000000000000846; Argani P, 2017, AM J SURG PATHOL, V41, P1702, DOI 10.1097/PAS.0000000000000926; Arnold MA, 2014, AM J SURG PATHOL, V38, P1220, DOI 10.1097/PAS.0000000000000231; ASKIN FB, 1979, CANCER, V43, P2438, DOI 10.1002/1097-0142(197906)43:6<2438::AID-CNCR2820430640>3.0.CO;2-9; AURIAS A, 1983, NEW ENGL J MED, V309, P496; Bridge JA, 1999, AM J SURG PATHOL, V23, P159, DOI 10.1097/00000478-199902000-00004; Brohl AS, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004475; Chen S, 2016, GENE CHROMOSOME CANC, V55, P340, DOI 10.1002/gcc.22336; Codman EA, 1925, BONE SARCOMA, P78; CONTESSO G, 1992, CANCER, V69, P1012, DOI 10.1002/1097-0142(19920215)69:4<1012::AID-CNCR2820690431>3.0.CO;2-V; DAHLIN DC, 1962, CANCER, V15, P410, DOI 10.1002/1097-0142(196203/04)15:2<410::AID-CNCR2820150225>3.0.CO;2-L; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; DUMONT J, 1979, BIOMED EXPRESS, V31, P271; Ewing J., 1921, P NEW YORK PATHOL S, V21, P17; Ewing J, 2006, CLIN ORTHOP RELAT R, P25, DOI 10.1097/01.blo.0000229311.36007.c7; Fisher C, 2014, HISTOPATHOLOGY, V64, P134, DOI 10.1111/his.12269; FRIEDMAN B, 1968, CANCER, V22, P307, DOI 10.1002/1097-0142(196808)22:2<307::AID-CNCR2820220208>3.0.CO;2-F; GERALD W L, 1989, Pediatric Pathology, V9, P177; GERALD WL, 1991, AM J SURG PATHOL, V15, P499, DOI 10.1097/00000478-199106000-00001; Ginsberg JP, 1999, J CLIN ONCOL, V17, P1809, DOI 10.1200/JCO.1999.17.6.1809; GONZALEZCRUSSI F, 1984, CANCER, V54, P2519, DOI 10.1002/1097-0142(19841201)54:11<2519::AID-CNCR2820541135>3.0.CO;2-V; Granter SR, 1996, HUM PATHOL, V27, P1273, DOI 10.1016/S0046-8177(96)90336-6; Jackson H., 1939, SURG GYNECOL OBSTET, V68, P45; JACOBSON SA, 1975, AM J PATHOL, V78, pA41; JACOBSON SA, 1977, CANCER, V40, P2116, DOI 10.1002/1097-0142(197711)40:5<2116::AID-CNCR2820400522>3.0.CO;2-L; Jaffe HL, 1958, TUMORS TUMOROUS COND, P350; JAFFE R, 1984, AM J SURG PATHOL, V8, P885, DOI 10.1097/00000478-198412000-00001; Kao YC, 2018, AM J SURG PATHOL, V42, P604, DOI 10.1097/PAS.0000000000000965; Kao YC, 2016, AM J SURG PATHOL, V40, P1670, DOI 10.1097/PAS.0000000000000697; Katz RL, 1997, HUM PATHOL, V28, P502, DOI 10.1016/S0046-8177(97)90042-3; Kawamura-Saito M, 2006, HUM MOL GENET, V15, P2125, DOI 10.1093/hmg/ddl136; KISSANE JM, 1983, HUM PATHOL, V14, P773, DOI 10.1016/S0046-8177(83)80300-1; Lichtenstein I, 1959, CANCER, V12, P1142; Lichtenstein L, 1965, BONE TUMORS, P241; LINNOILA RI, 1986, AM J SURG PATHOL, V10, P124, DOI 10.1097/00000478-198602000-00005; LLOMBARTBOSCH A, 1978, CANCER, V41, P1362, DOI 10.1002/1097-0142(197804)41:4<1362::AID-CNCR2820410421>3.0.CO;2-F; Machado I, 2010, HISTOPATHOLOGY, V57, P162, DOI 10.1111/j.1365-2559.2010.03589.x; Mastrangelo T, 2000, ONCOGENE, V19, P3799, DOI 10.1038/sj.onc.1203762; Nakajima H, 1997, CANCER, V79, P2095, DOI 10.1002/(SICI)1097-0142(19970601)79:11<2095::AID-CNCR6>3.0.CO;2-O; NASCIMENTO AG, 1980, AM J SURG PATHOL, V4, P29, DOI 10.1097/00000478-198004010-00003; Naumann S, 2002, MODERN PATHOL, V15, P572, DOI 10.1038/modpathol.3880565; NOGUERA R, 1990, CANCER GENET CYTOGEN, V45, P121, DOI 10.1016/0165-4608(90)90074-K; Oberling C, 1929, B ASS FRANC CANC, V17, P259; Ordi J, 1998, AM J SURG PATHOL, V22, P1026, DOI 10.1097/00000478-199808000-00014; Parham DM, 1999, HUM PATHOL, V30, P911, DOI 10.1016/S0046-8177(99)90244-7; Pierron G, 2012, NAT GENET, V44, P461, DOI 10.1038/ng.1107; Puls F, 2014, AM J SURG PATHOL, V38, P1307, DOI 10.1097/PAS.0000000000000223; Richkind KE, 1996, CANCER GENET CYTOGEN, V87, P71, DOI 10.1016/0165-4608(95)00240-5; Righi A, 2015, AM J SURG PATHOL, V39, P691, DOI 10.1097/PAS.0000000000000412; SAINATI L, 1993, CANCER GENET CYTOGEN, V71, P144, DOI 10.1016/0165-4608(93)90020-M; SALVADOR AH, 1971, CANCER, V28, P605, DOI 10.1002/1097-0142(197109)28:3<605::AID-CNCR2820280312>3.0.CO;2-R; Sankar S, 2011, CANCER GENET-NY, V204, P351, DOI 10.1016/j.cancergen.2011.07.008; SAWYER JR, 1992, AM J SURG PATHOL, V16, P411, DOI 10.1097/00000478-199204000-00010; SCHAJOWICZ F, 1959, J BONE JOINT SURG AM, V41, P349, DOI 10.2106/00004623-195941020-00017; SCHLOSSMAN SF, 1994, J IMMUNOL, V152, P1; SCHMIDT D, 1991, CANCER, V68, P2251, DOI 10.1002/1097-0142(19911115)68:10<2251::AID-CNCR2820681025>3.0.CO;2-X; Seemayer T A, 1975, Perspect Pediatr Pathol, V2, P151; SEEMAYER TA, 1985, VIRCHOWS ARCH A, V408, P289, DOI 10.1007/BF00707991; SESTERHENN I, 1987, J UROLOGY, V137, pA214, DOI 10.1016/S0022-5347(17)75592-9; Siebenrock KA, 1996, CLIN ORTHOP RELAT R, P288; Siegele B, 2017, AM J SURG PATHOL, V41, P423, DOI 10.1097/PAS.0000000000000772; SIM FH, 1979, J BONE JOINT SURG AM, V61, P207, DOI 10.2106/00004623-197961020-00008; Specht K, 2016, AM J SURG PATHOL, V40, P433, DOI 10.1097/PAS.0000000000000591; Spjut H, 1971, TUMORS BONE CARTILAG, P218; STEVENSON AJ, 1994, APPL IMMUNOHISTOCHEM, V2, P231; Stout A. P., 1918, P NY PATHOL SOC, V12, P2; Stout AP, 1943, AM J ROENTGENOL RADI, V50, P334; Stout Arthur Purdy, 1942, REV CANADIENNE BIOL, V1, P651; Sugita S, 2014, AM J SURG PATHOL, V38, P1571, DOI 10.1097/PAS.0000000000000286; Sumegi J, 2011, MODERN PATHOL, V24, P333, DOI 10.1038/modpathol.2010.201; Szuhai K, 2009, CLIN CANCER RES, V15, P2259, DOI 10.1158/1078-0432.CCR-08-2184; TEFFT M, 1969, RADIOLOGY, V92, P1501, DOI 10.1148/92.7.1501; TERRIER P, 1995, EUR J CANCER, V31A, P307, DOI 10.1016/0959-8049(94)00417-4; Thorner P, 1996, AM J PATHOL, V148, P1125; TRICHE TJ, 1978, CANCER, V41, P1425, DOI 10.1002/1097-0142(197804)41:4<1425::AID-CNCR2820410430>3.0.CO;2-9; TURCCAREL C, 1983, NEW ENGL J MED, V309, P497; USHIGOME S, 1989, CANCER, V64, P52, DOI 10.1002/1097-0142(19890701)64:1<52::AID-CNCR2820640110>3.0.CO;2-6; Wang L, 2007, J MOL DIAGN, V9, P498, DOI 10.2353/jmoldx.2007.070053; Wang L, 2012, GENE CHROMOSOME CANC, V51, P127, DOI 10.1002/gcc.20937; WEIDNER N, 1994, AM J SURG PATHOL, V18, P486, DOI 10.1097/00000478-199405000-00008; WHANGPENG J, 1986, CANCER GENET CYTOGEN, V21, P185, DOI 10.1016/0165-4608(86)90001-4; WHANGPENG J, 1984, NEW ENGL J MED, V311, P584, DOI 10.1056/NEJM198408303110907; WILLIS R. A., 1940, AMER JOUR PATH, V16, P317; Yamaguchi S, 2005, GENE CHROMOSOME CANC, V43, P461; Yoshida A, 2016, AM J SURG PATHOL, V40, P313, DOI 10.1097/PAS.0000000000000570; YUNIS EJ, 1979, AM J SURG PATHOL, V3, P313, DOI 10.1097/00000478-197908000-00003	87	1	1	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-4109	1533-4031		ADV ANAT PATHOL	Adv. Anat. Pathol.	SEP	2018	25	5					314	326		10.1097/PAP.0000000000000203			13	Pathology	Pathology	GQ7HD	WOS:000441906500003	29911999				2019-10-28	
J	Fine, SW				Fine, Samson W.			Evolution in Prostate Cancer Staging: Pathology Updates From AJCC 8th Edition and Opportunities That Remain	ADVANCES IN ANATOMIC PATHOLOGY			English	Review						prostate cancer; staging; TNM; AJCC; grading; quantitation; extraprostatic extension; surgical margin	ISUP CONSENSUS CONFERENCE; INDEPENDENT PROGNOSTIC-FACTOR; TERM-FOLLOW-UP; POSITIVE SURGICAL MARGINS; BLADDER NECK INVOLVEMENT; RECURRENCE-FREE SURVIVAL; GRADE-GROUPING SYSTEM; RADICAL PROSTATECTOMY; BIOCHEMICAL RECURRENCE; EXTRAPROSTATIC EXTENSION	The Tumor-Nodes-Metastasis system at the core of prognostic staging has been recently updated in the American Joint Committee on Cancer (AJCC) 8th edition, published in 2016. For prostate cancer, significant changes in staging of organ-confined disease, inclusion of a new grade grouping, and provision of levels of evidence for these modifications are part of what differentiates the 8th edition AJCC from prior iterations. Herein, the rationale underlying these changes is detailed. In addition, data elements not well represented in the present system are highlighted as opportunities for fresh study that may impact future AJCC classifications.	[Fine, Samson W.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave,Room C502, New York, NY 10065 USA	Fine, SW (reprint author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave,Room C502, New York, NY 10065 USA.	fines@mskcc.org					Amin MB, 2017, AJCC CANC STAGING MA; [Anonymous], 2017, NCCN CLIN PRACTICE G; [Anonymous], 2017, CANC PROT TEMPL PROS; AYALA AG, 1989, AM J SURG PATHOL, V13, P21, DOI 10.1097/00000478-198901000-00003; Bailar J C 3rd, 1966, Cancer Chemother Rep, V50, P129; Ball MW, 2015, UROLOGY, V85, P161, DOI 10.1016/j.urology.2014.08.025; Beahrs OH, 1992, AJCC CANC STAGING MA; Berney DM, 2016, BRIT J CANCER, V114, P1078, DOI 10.1038/bjc.2016.86; Bhindi B, 2017, J UROLOGY, V198, P1287, DOI 10.1016/j.juro.2017.06.085; Bolla M, 2012, LANCET, V380, P2018, DOI 10.1016/S0140-6736(12)61253-7; Brimo F, 2010, UROLOGY, V76, P1206, DOI 10.1016/j.urology.2010.03.090; Cao DF, 2011, UROLOGY, V77, P1409, DOI 10.1016/j.urology.2010.10.059; Cao DF, 2010, AM J SURG PATHOL, V34, P994, DOI 10.1097/PAS.0b013e3181e103bf; Chan TY, 2000, UROLOGY, V56, P823, DOI 10.1016/S0090-4295(00)00753-6; Chun FKH, 2006, EUR UROL, V49, P273, DOI 10.1016/j.eururo.2005.12.009; Dash A, 2002, UROLOGY, V60, P276, DOI 10.1016/S0090-4295(02)01727-2; Edge SB, 2010, AJCC CANC STAGING MA; Egevad L, 2017, PROSTATE CANC RADICA; Eichelberger LE, 2004, CANCER-AM CANCER SOC, V100, P2573, DOI 10.1002/cncr.20305; Epstein JI, 2005, AM J SURG PATHOL, V29, P1228, DOI 10.1097/01.pas.0000173646.99337.b1; EPSTEIN JI, 1993, J UROLOGY, V150, P135, DOI 10.1016/S0022-5347(17)35415-0; Epstein JI, 2016, AM J SURG PATHOL, V40, P244, DOI 10.1097/PAS.0000000000000530; Epstein JI, 2016, EUR UROL, V69, P428, DOI 10.1016/j.eururo.2015.06.046; Epstein JI, 2011, J UROLOGY, V186, P790, DOI 10.1016/j.juro.2011.02.2695; Ettel M, 2016, HUM PATHOL, V56, P57, DOI 10.1016/j.humpath.2016.05.016; Evans AJ, 2008, AM J SURG PATHOL, V32, P1503, DOI 10.1097/PAS.0b013e31817fb3a0; Fleming ID, 1997, AJCC CANC STAGING MA; Freedland SJ, 2004, CANCER-AM CANCER SOC, V100, P1646, DOI 10.1002/cncr.20145; Gandaglia G, 2017, EUR UROL, V72, P689, DOI 10.1016/j.eururo.2017.01.039; Gillessen S, 2018, EUR UROL, V73, P178, DOI 10.1016/j.eururo.2017.06.002; GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022-5347(17)59889-4; Greene FL, 2002, AJCC CANC STAGING MA; Halabi S, 2014, J CLIN ONCOL, V32, P671, DOI 10.1200/JCO.2013.52.3696; Halabi S, 2013, JNCI-J NATL CANCER I, V105, P1729, DOI 10.1093/jnci/djt280; Huang JG, 2013, BJU INT, V111, P921, DOI 10.1111/j.1464-410X.2012.11665.x; Jeong BC, 2015, EUR UROL, V67, P342, DOI 10.1016/j.eururo.2014.06.015; Kates M, 2016, J UROLOGY, V195, P337, DOI 10.1016/j.juro.2015.08.002; Kattan MW, 2016, CA-CANCER J CLIN, V66, P370, DOI 10.3322/caac.21339; Kikuchi E, 2004, J UROLOGY, V172, P508, DOI 10.1097/01.ju.0000130481.04082.1a; Kordan Y, 2009, J UROLOGY, V182, P2291, DOI 10.1016/j.juro.2009.07.020; Loeb S, 2016, EUR UROL, V70, P1083, DOI 10.1016/j.eururo.2016.05.039; Loeb S, 2016, EUR UROL, V69, P1135, DOI 10.1016/j.eururo.2015.11.036; Magi-Galluzzi C, 2011, MODERN PATHOL, V24, P26, DOI 10.1038/modpathol.2010.158; Miyake H, 2013, UROL ONCOL-SEMIN ORI, V31, P1511, DOI 10.1016/j.urolonc.2012.05.001; Moch H, 2016, WHO CLASSIFICATION T; Netto GJ, 2011, UROLOGY, V77, P1155, DOI 10.1016/j.urology.2010.08.031; Ochiai A, 2008, UROLOGY, V71, P308, DOI 10.1016/j.urology.2007.08.042; Pierorazio PM, 2013, BJU INT, V111, P753, DOI 10.1111/j.1464-410X.2012.11611.x; Ploussard G, 2014, WORLD J UROL, V32, P1393, DOI 10.1007/s00345-014-1243-3; Salomon L, 2003, EUR UROL, V43, P39, DOI 10.1016/S0302-2838(02)00493-1; Servoll E, 2014, UROL INT, V93, P289, DOI 10.1159/000362342; Shikanov S, 2009, J UROLOGY, V182, P139, DOI 10.1016/j.juro.2009.02.139; Spratt DE, 2016, PROSTATE CANCER P D, V19, P292, DOI 10.1038/pcan.2016.18; Spratt DE, 2016, BJU INT, V118, P763, DOI 10.1111/bju.13488; Stephenson AJ, 2009, J UROLOGY, V182, P1357, DOI 10.1016/j.juro.2009.06.046; Thompson IM, 2009, J UROLOGY, V181, P956, DOI 10.1016/j.juro.2008.11.032; Udo K, 2013, J UROLOGY, V189, P1302, DOI 10.1016/j.juro.2012.10.004; van der Kwast TH, 2006, EUR UROL, V49, P209, DOI 10.1016/j.eururo.2005.12.027; van der Kwast TH, 2011, MODERN PATHOL, V24, P16, DOI 10.1038/modpathol.2010.156; van Oort IM, 2010, HISTOPATHOLOGY, V56, P464, DOI 10.1111/j.1365-2559.2010.03497.x; Wheeler TM, 1998, HUM PATHOL, V29, P856, DOI 10.1016/S0046-8177(98)90457-9; Wiegel T, 2014, EUR UROL, V66, P243, DOI 10.1016/j.eururo.2014.03.011; Yossepowitch O, 2002, J UROLOGY, V168, P2011, DOI 10.1097/01.ju.0000033909.09204.c6; Zhou M, 2009, MODERN PATHOL, V22, P385, DOI 10.1038/modpathol.2008.190; Zietman A, 2016, EUR UROL, V70, P1, DOI 10.1016/j.eururo.2016.03.007	65	3	3	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-4109	1533-4031		ADV ANAT PATHOL	Adv. Anat. Pathol.	SEP	2018	25	5					327	332		10.1097/PAP.0000000000000200			6	Pathology	Pathology	GQ7HD	WOS:000441906500004	29870405				2019-10-28	
J	Bonsib, SM				Bonsib, Stephen M.			Urologic Diseases Germane to the Medical Renal Biopsy: Review of a Large Diagnostic Experience in the Context of the Renal Architecture and Its Environs	ADVANCES IN ANATOMIC PATHOLOGY			English	Review						cystic kidney disease; renal cysts; renal cell carcinoma; renal adenoma; renal anatomy	POLYCYSTIC KIDNEY-DISEASE; CELL CARCINOMA; CONGENITAL-ANOMALIES; CYSTIC-DISEASE; SINUS VEIN; PART II; CLASSIFICATION; PATHOLOGY; STAGE; NEOPLASMS	The kidney is one of the most complicated organs in development and is susceptible to more types of diseases than other organs. The disease spectrum includes developmental and cystic diseases, involvement by systemic diseases, iatrogenic complications, ascending infections and urinary tract obstruction, and neoplastic diseases. The diagnosis of kidney disease is unique involving 2 subspecialties, urologic pathology and renal pathology. Both renal and urologic pathologists employ the renal biopsy as a diagnostic modality. However, urologic pathologists commonly have a generous specimen in the form of a nephrectomy or partial nephrectomy while a renal pathologist requires ancillary modalities of immunofluorescence and electron microscopy. The 2 subspecialties differ in the disease spectrum they diagnose. This separation is not absolute as diseases of one subspecialty not infrequently appear in the diagnostic materials of the other. The presence of medical renal diseases in a nephrectomy specimen is well described and recommendations for reporting these findings have been formalized. However, urologic diseases appearing in a medical renal biopsy have received less attention. This review attempts to fill that gap by first reviewing the perirenal anatomy to illustrate why inadvertent biopsy of adjacent organs occurs and determine its incidence in renal biopsies followed by a discussion of gross anatomic features relevant to the microscopic domain of the medical renal biopsy. Unsuspected neoplasms and renal cysts and cystic kidney diseases will then be discussed as they create a diagnostic challenge for the renal pathologist who often has limited training and experience in these diseases.	[Bonsib, Stephen M.] Arkana Labs, 10810 Execut Ctr Dr,Suite 100, Little Rock, AR 72211 USA	Bonsib, SM (reprint author), Arkana Labs, 10810 Execut Ctr Dr,Suite 100, Little Rock, AR 72211 USA.	stephen.bonsib@arkanalabs.com					Arts HH, 2013, PEDIATR NEPHROL, V28, P863, DOI 10.1007/s00467-012-2259-9; BAERT L, 1978, KIDNEY INT, V13, P519, DOI 10.1038/ki.1978.75; Batson OV, 1940, ANN SURG, V112, P138, DOI 10.1097/00000658-194007000-00016; Beckwith JB, 1988, PEDATR DEV PATHOL, V1, P79; Bergmann C, 2015, PEDIATR NEPHROL, V30, P15, DOI 10.1007/s00467-013-2706-2; BERNSTEIN J, 1987, AM J PATHOL, V129, P92; BERNSTEIN J, 1993, PEDIATR NEPHROL, V7, P490, DOI 10.1007/BF00857581; Bex A, 2011, WORLD J UROL, V29, P793, DOI 10.1007/s00345-010-0615-6; Bharnagar R, 2012, INT J SURG PATHOL, V20, P19; Bisceglia M, 2006, ADV ANAT PATHOL, V13, P26, DOI 10.1097/01.pap.0000201831.77472.d3; Bonsib SM, 2006, MODERN PATHOL, V19, P746, DOI 10.1038/modpathol.3800589; Bonsib SM, 2004, AM J SURG PATHOL, V28, P1594, DOI 10.1097/00000478-200412000-00007; Bonsib SM, 2015, GENITOURINARY PATHOL, P280; Bonsib SM, 2009, UROLOGIC SURG PATHOL; Bonsib SM, 2008, ARCH PATHOL LAB MED, V134, P554; Bonsib SM, 2015, HEPTINSTALLS PATHOLO, P1; Bonsib SM, 2007, MODERN PATHOL, V20, P44, DOI 10.1038/modpathol.3800726; Bonsib SM, 2016, PATHOL RES PRACT, V212, P972, DOI 10.1016/j.prp.2016.04.005; Bonsib SM, 2011, MODERN PATHOL, V24, P1578, DOI 10.1038/modpathol.2011.124; Bonsib SM, 2010, ADV ANAT PATHOL, V17, P235, DOI 10.1097/PAP.0b013e3181e3c02d; Bonsib SM, 2009, CLIN J AM SOC NEPHRO, V4, P1998, DOI 10.2215/CJN.02020309; Bosniak MA, 2012, RADIOLOGY, V262, P781, DOI 10.1148/radiol.11111595; Calio A, 2016, HUM PATHOL, V58, P41, DOI 10.1016/j.humpath.2016.07.024; Chauveau D, 1996, KIDNEY INT, V50, P944, DOI 10.1038/ki.1996.395; Chebib FT, 2016, AM J KIDNEY DIS, V67, P792, DOI 10.1053/j.ajkd.2015.07.037; Chen K, 2015, SCAND J UROL, V49, P200, DOI 10.3109/21681805.2015.1019561; Chen LW, 2013, PATHOLOGY, V45, P657, DOI 10.1097/PAT.0000000000000006; Chen XD, 2016, ONCOL LETT, V12, P4001, DOI 10.3892/ol.2016.5173; Chen YB, 2012, ARCH PATHOL LAB MED, V136, P400, DOI 10.5858/arpa.2011-0485-RA; Chung EM, 2014, RADIOGRAPHICS, V34, P155, DOI 10.1148/rg.341135179; Costa MZD, 2006, APPL IMMUNOHISTO M M, V14, P348; Deck MA, 1988, SURG PATHOL, V1, P391; Denamur E, 2010, KIDNEY INT, V77, P350, DOI 10.1038/ki.2009.440; Eble JN, 2016, WHO CLASSIFICATION T, P42; Eckardt KU, 2015, KIDNEY INT, V88, P676, DOI 10.1038/ki.2015.28; Eknoyan G, 2009, J AM SOC NEPHROL, V20, P1874, DOI 10.1681/ASN.2008040441; Fabris A, 2013, NEPHROL DIAL TRANSPL, V28, P1111, DOI 10.1093/ndt/gfs505; FARAGGIANA T, 1985, LAB INVEST, V53, P575; Feldmann Y, 2018, CLIN NEPHROL, V89, P260, DOI 10.5414/CN109223; Gascue C, 2011, PEDIATR NEPHROL, V26, P1181, DOI 10.1007/s00467-010-1697-5; GLASSBERG KI, 1987, J UROLOGY, V138, P1085, DOI 10.1016/S0022-5347(17)43510-5; GRANTHAM JJ, 1987, KIDNEY INT, V31, P1145, DOI 10.1038/ki.1987.121; Heller MT, 2012, EMERG RADIOL, V19, P245, DOI 10.1007/s10140-012-1022-7; Henriksen KJ, 2007, AM J KID DIS, V31, P575; Herts BR, 2018, J AM COLL RADIOL, V15, P264, DOI 10.1016/j.jacr.2017.04.028; Hindman NM, 2016, ABDOM RADIOL, V41, P1020, DOI 10.1007/s00261-016-0761-4; Hodson C J, 1978, Curr Probl Diagn Radiol, V7, P1; Hosseini M, 2014, HUM PATHOL, V45, P1406, DOI 10.1016/j.humpath.2014.02.014; Huang H, 2016, HUM PATHOL, V52, P55, DOI 10.1016/j.humpath.2015.12.028; HUGHSON MD, 1980, LAB INVEST, V42, P475; Hwang DY, 2014, KIDNEY INT, V85, P1429, DOI 10.1038/ki.2013.508; Kabaria R, 2016, INT J NEPHROL RENOV, V9, P45, DOI 10.2147/IJNRD.S75916; Kambham N, 2016, DIAGNOSTIC PATHOLOGY; Katabathina VS, 2010, RADIOGRAPHICS, V30, P1525, DOI 10.1148/rg.306105517; Kates M, 2012, ANN SURG ONCOL, V19, P2693, DOI 10.1245/s10434-012-2330-6; KAYE KW, 1982, UROL CLIN N AM, V9, P3; Khan M, 2015, INT J PSYCHIAT MED, V50, P290, DOI 10.1177/0091217415610309; Korbet SM, 2014, AM J NEPHROL, V39, P153, DOI 10.1159/000358334; Kryvenko ON, 2014, ARCH PATHOL LAB MED, V138, P1531, DOI 10.5858/arpa.2013-0653-RA; Lee CT, 2013, KIDNEY INT, V83, P924, DOI 10.1038/ki.2012.481; Leone AR, 2016, ONCOLOGY-NY, V30, P507; Liu JS, 2000, NEPHRON, V84, P142, DOI 10.1159/000045562; Markowitz GS, 2000, J AM SOC NEPHROL, V11, P1439; Mehta V, 2013, ARCH PATHOL LAB MED, V137, P1584, DOI 10.5858/arpa.2012-0485-OA; Menogue SR, 2012, BJU INT, V111, pE146; Mirilas P, 2010, AM SURGEON, V76, P33; Moch H, 2016, WHO CLASSIFICATION T, V2016, P11; Molema G, 2012, SEMIN NEPHROL, V32, P145, DOI 10.1016/j.semnephrol.2012.02.001; Moron FE, 2007, BRIT J RADIOL, V80, P841, DOI 10.1259/bjr/64292252; Muglia Valdair F, 2014, Radiol Bras, V47, P368, DOI 10.1590/0100-3984.2013.1797; Nakanishi K, 2000, J AM SOC NEPHROL, V11, P760; Nathoo N, 2011, NEUROSURGERY, V69, P1007, DOI 10.1227/NEU.0b013e3182274865; Neumann HPH, 1997, KIDNEY INT, V51, P16, DOI 10.1038/ki.1997.3; O'Callaghan FJ, 2004, BJU INT, V94, P853, DOI 10.1111/j.1464-410X.2004.05046.x; Pankhurst T, 2006, NEPHROL DIAL TRANSPL, V21, P64, DOI 10.1093/ndt/gfi149; Park H, 2015, KOREAN J UROL, V56, P351, DOI 10.4111/kju.2015.56.5.351; Parker AE, 1935, AM J ANAT, V56, P409, DOI 10.1002/aja.1000560305; Pei Y, 2009, J AM SOC NEPHROL, V20, P205, DOI 10.1681/ASN.2008050507; Phan DC, 2010, PATHOL RES PRACT, V206, P310, DOI 10.1016/j.prp.2010.02.002; Phillips CK, 2004, UROL ONCOL-SEMIN ORI, V22, P214, DOI 10.1016/j.urolonc.2004.04.028; Potts JW, 2017, AM J HEALTH-SYST PH, V74, P1959, DOI 10.2146/ajhp160886; Purysko AS, 2016, RADIOGRAPHICS, V36, P1038, DOI 10.1148/rg.2016150213; Rangan GK, 2015, SEMIN NEPHROL, V35, P524, DOI 10.1016/j.semnephrol.2015.10.002; Reddy BV, 2017, PEDIATR NEPHROL, V32, P31, DOI 10.1007/s00467-016-3364-y; Reuter VE, 2014, AM J SURG PATHOL, V38, pE35, DOI 10.1097/PAS.0000000000000258; Rodriguez MM, 2014, FETAL PEDIATR PATHOL, V33, P293, DOI 10.3109/15513815.2014.959678; Rookmaaker MB, 2012, CLIN KIDNEY J, V5, P412, DOI 10.1093/ckj/sfs091; SAMPAIO FJB, 1990, J UROLOGY, V144, P1089, DOI 10.1016/S0022-5347(17)39665-9; SATYAPAL KS, 1995, J ANAT, V186, P329; Sheety S, 2016, J CLIN DIAGN RADIOL, V10, P5; Silverman SG, 2015, RADIOLOGY, V275, P28, DOI 10.1148/radiol.14141144; Simms RJ, 2014, NEPHROL DIAL TRANSPL, V29, P106, DOI 10.1093/ndt/gfu106; SOLOMON D, 1988, HUM PATHOL, V19, P1072, DOI 10.1016/S0046-8177(88)80089-3; Srigley JR, 2013, AM J SURG PATHOL, V37, P1469, DOI 10.1097/PAS.0b013e318299f2d1; Stokamn M, 1993, NEPHRONOPHTHISIS GEN, V2016; Tamboli P, 2000, ADV ANAT PATHOL, V7, P47, DOI 10.1097/00125480-200007010-00007; Tickoo SK, 2006, AM J SURG PATHOL, V30, P141, DOI 10.1097/01.pas.0000185382.80844.b1; Vivante A, 2014, PEDIATR NEPHROL, V29, P695, DOI 10.1007/s00467-013-2684-4; Wang R, 2009, UROLOGY, V73, P586, DOI 10.1016/j.urology.2008.08.519; Warren KS, 2005, BJU INT, V95, P939, DOI 10.1111/j.1464-410X.2005.05442.x; Wolf MTF, 2015, CURR OPIN PEDIATR, V27, P201, DOI 10.1097/MOP.0000000000000194; Wood CG, 2015, RADIOGRAPHICS, V35, P125, DOI 10.1148/rg.351130016; Wu AJ, 2015, HISTOPATHOLOGY, V66, P587, DOI 10.1111/his.12524; Xiao XL, 2017, ARCH PATHOL LAB MED, V141, P1181, DOI 10.5858/arpa.2016-0530-RA; Zaidan M, 2014, KIDNEY INT, V86, P184, DOI 10.1038/ki.2014.2; Zhou C, 2016, BJU INT, V117, P775, DOI 10.1111/bju.13194	106	0	0	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-4109	1533-4031		ADV ANAT PATHOL	Adv. Anat. Pathol.	SEP	2018	25	5					333	352		10.1097/PAP.0000000000000199			20	Pathology	Pathology	GQ7HD	WOS:000441906500005	30036201	Green Published			2019-10-28	
J	Longo, JF; Weber, SM; Turner-Ivey, BP; Carroll, SL				Longo, Jody F.; Weber, Shannon M.; Turner-Ivey, Brittany P.; Carroll, Steven L.			Recent Advances in the Diagnosis and Pathogenesis of Neurofibromatosis Type 1 (NF1)-associated Peripheral Nervous System Neoplasms	ADVANCES IN ANATOMIC PATHOLOGY			English	Review						neurofibroma; malignant peripheral nerve sheath tumor; RASopathies; tumor genomics; epigenetic regulation	COMPARATIVE GENOMIC HYBRIDIZATION; RECEPTOR TYROSINE KINASES; SPINDLE-CELL NEOPLASMS; GROWTH-FACTOR RECEPTOR; OPTIC PATHWAY GLIOMAS; SOFT-TISSUE SARCOMAS; SHEATH TUMORS MPNST; NF1 GENE-MUTATIONS; PHASE-I TRIAL; SCHWANN-CELLS	The diagnosis of a neurofibroma or a malignant peripheral nerve sheath tumor (MPNST) often raises the question of whether the patient has the genetic disorder neurofibromatosis type 1 (NF1) as well as how this will impact the patient's outcome, what their risk is for developing additional neoplasms and whether treatment options differ for NF1-associated and sporadic peripheral nerve sheath tumors. Establishing a diagnosis of NF1 is challenging as this disorder has numerous neoplastic and non-neoplastic manifestations which are variably present in individual patients. Further, other genetic diseases affecting the Ras signaling cascade (RASopathies) mimic many of the clinical features of NF1. Here, we review the clinical manifestations of NF1 and compare and contrast them with those of the RASopathies. We also consider current approaches to genetic testing for germline NF1 mutations. We then focus on NF1-associated neurofibromas, considering first the complicated clinical behavior and pathology of these neoplasms and then discussing our current understanding of the genomic abnormalities that drive their pathogenesis, including the mutations encountered in atypical neurofibromas. As several neurofibroma subtypes are capable of undergoing malignant transformation to become MPNSTs, we compare and contrast patient outcomes in sporadic, NF1-associated and radiation-induced MPNSTs, and review the challenging pathology of these lesions. The mutations involved in neurofibroma-MPNST progression, including the recent identification of mutations affecting epigenetic regulators, are then considered. Finally, we explore how our current understanding of neurofibroma and MPNST pathogenesis is informing the design of new therapies for these neoplasms.	[Longo, Jody F.; Weber, Shannon M.; Turner-Ivey, Brittany P.; Carroll, Steven L.] Med Univ South Carolina, Dept Pathol & Lab Med, 171 Ashley Ave,MSC 908, Charleston, SC 29425 USA; [Carroll, Steven L.] Med Univ South Carolina, Ctr Genom Med, Charleston, SC 29425 USA; [Weber, Shannon M.] Med Univ South Carolina, Med Scientist Training Program, Charleston, SC 29425 USA	Carroll, SL (reprint author), Med Univ South Carolina, Dept Pathol & Lab Med, 171 Ashley Ave,MSC 908, Charleston, SC 29425 USA.	carrolst@musc.edu			National Institute of Neurological Diseases and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS048353]; National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01 CA122804]; Department of DefenseUnited States Department of Defense [X81XWH-09-1-0086, W81XWH-12-1-0164, W81XWH-14-1-0073, W81XWH-15-1-0193]; Children's Tumor Foundation [2015-05-007, 2016-04-001]	Supported by the National Institute of Neurological Diseases and Stroke (R01 NS048353), the National Cancer Institute (R01 CA122804), the Department of Defense (X81XWH-09-1-0086, W81XWH-12-1-0164, W81XWH-14-1-0073, and W81XWH-15-1-0193) and the Children's Tumor Foundation (2015-05-007 and 2016-04-001).	Afsar CU, 2013, CRIT REV ONCOL HEMAT, V86, P191, DOI 10.1016/j.critrevonc.2012.11.001; Anghileri M, 2006, CANCER-AM CANCER SOC, V107, P1065, DOI 10.1002/cncr.22098; Aoki Y, 2016, J HUM GENET, V61, P33, DOI 10.1038/jhg.2015.114; Asano N, 2017, HISTOPATHOLOGY, V70, P385, DOI 10.1111/his.13072; Badache A, 1998, ONCOGENE, V17, P795, DOI 10.1038/sj.onc.1201978; Badache A, 1998, J CELL PHYSIOL, V177, P334, DOI 10.1002/(SICI)1097-4652(199811)177:2<334::AID-JCP15>3.0.CO;2-9; Balcer LJ, 2001, AM J OPHTHALMOL, V131, P442, DOI 10.1016/S0002-9394(00)00852-7; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; Barahona-Garrido J, 2009, AM J GASTROENTEROL, V104, P797, DOI 10.1038/ajg.2008.133; Bausch B, 2006, J CLIN ENDOCR METAB, V91, P3478, DOI 10.1210/jc.2006-0780; Beert E, 2011, GENE CHROMOSOME CANC, V50, P1021, DOI 10.1002/gcc.20921; Bertola DR, 2005, AM J MED GENET A, V136A, P242, DOI 10.1002/ajmg.a.30813; Birindelli S, 2001, LAB INVEST, V81, P833, DOI 10.1038/labinvest.3780293; BOGNANNO JR, 1988, AM J ROENTGENOL, V151, P381; BOLLAG G, 1993, EMBO J, V12, P1923, DOI 10.1002/j.1460-2075.1993.tb05841.x; Bradtmoller M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047595; BRAFFMAN BH, 1988, RADIOL CLIN N AM, V26, P773; Brems H, 2009, CANCER RES, V69, P7393, DOI 10.1158/0008-5472.CAN-09-1752; Brennan MF, 2014, ANN SURG, V260, P416, DOI 10.1097/SLA.0000000000000869; Brohl AS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15183-1; Brosius SN, 2014, ACTA NEUROPATHOL, V127, P573, DOI 10.1007/s00401-013-1209-3; Brossier NM, 2015, J NEUROPATH EXP NEUR, V74, P568, DOI 10.1097/NEN.0000000000000201; Brossier NM, 2012, BRAIN RES BULL, V88, P58, DOI 10.1016/j.brainresbull.2011.08.005; Carroll SL, 2008, GLIA, V56, P1590, DOI 10.1002/glia.20776; Carroll SL, 2012, ACTA NEUROPATHOL, V123, P321, DOI 10.1007/s00401-011-0928-6; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Clementi M, 1999, AM J MED GENET, V87, P317, DOI 10.1002/(SICI)1096-8628(19991203)87:4<317::AID-AJMG7>3.0.CO;2-X; Cleven AHG, 2016, MODERN PATHOL, V29, P582, DOI 10.1038/modpathol.2016.45; COHEN PR, 1993, J CUTAN PATHOL, V20, P15, DOI 10.1111/j.1600-0560.1993.tb01243.x; Courtois-Cox S, 2006, CANCER CELL, V10, P459, DOI 10.1016/j.ccr.2006.10.003; Cox Adrienne D, 2010, Small GTPases, V1, P2; Crucis A, 2015, PEDIATR BLOOD CANCER, V62, P1733, DOI 10.1002/pbc.25556; Cutting LE, 2010, CHILD NEUROPSYCHOL, V16, P417, DOI 10.1080/09297041003761985; D'Angelo I, 2006, EMBO REP, V7, P174, DOI 10.1038/sj.embor.7400602; D'Arco F, 2014, RADIOL MED, V119, P415, DOI 10.1007/s11547-013-0358-8; Dang I, 2005, J NEUROSCI RES, V79, P318, DOI 10.1002/jnr.20334; Dang I, 2011, NEUROCHEM RES, V36, P1697, DOI 10.1007/s11064-011-0433-2; Dasgupta B, 2003, J NEUROSCI, V23, P8949; De Luca A, 2005, AM J HUM GENET, V77, P1092, DOI 10.1086/498454; De Raedt T, 2006, NAT GENET, V38, P1419, DOI 10.1038/ng1920; DeClue JE, 2000, J CLIN INVEST, V105, P1233, DOI 10.1172/JCI7610; DIPAOLO DP, 1995, RADIOLOGY, V195, P721, DOI 10.1148/radiology.195.3.7754001; Dorschner MO, 2000, HUM MOL GENET, V9, P35, DOI 10.1093/hmg/9.1.35; DUCATMAN BS, 1986, CANCER-AM CANCER SOC, V57, P2006, DOI 10.1002/1097-0142(19860515)57:10<2006::AID-CNCR2820571022>3.0.CO;2-6; EASTON DF, 1993, AM J HUM GENET, V53, P305; Eckert JM, 2009, GLIA, V57, P1501, DOI 10.1002/glia.20866; Eisenhofer G, 2011, CLIN CHEM, V57, P411, DOI 10.1373/clinchem.2010.153320; Elefteriou F, 2009, AM J MED GENET A, V149A, P2327, DOI 10.1002/ajmg.a.33045; Emmerich D, 2015, EUR J HUM GENET, V23, P870, DOI 10.1038/ejhg.2014.210; Evans DGR, 2002, J MED GENET, V39, P311, DOI 10.1136/jmg.39.5.311; Faden DL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170348; Fan Q, 2014, CLIN TRANSL ONCOL, V16, P191, DOI 10.1007/s12094-013-1061-x; Ferner RE, 2007, J MED GENET, V44, P81, DOI 10.1136/jmg.2006.045906; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P8, DOI 10.1002/gcc.2870140103; Friedman JM, 2002, GENET MED, V4, P105, DOI 10.1097/00125817-200205000-00002; Fukuda T, 1998, PATHOL INT, V48, P757, DOI 10.1111/j.1440-1827.1998.tb03834.x; Garg S, 2013, PEDIATRICS, V132, pE1642, DOI 10.1542/peds.2013-1868; Gregorian C, 2009, P NATL ACAD SCI USA, V106, P19479, DOI 10.1073/pnas.0910398106; Griffiths PD, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.4.e49; Hawes JJ, 2007, NEUROGENETICS, V8, P121, DOI 10.1007/s10048-006-0078-5; HIROTA S, 1993, ARCH PATHOL LAB MED, V117, P996; Holtkamp N, 2006, CARCINOGENESIS, V27, P664, DOI 10.1093/carcin/bgi273; Holtkamp N, 2007, NEOPLASIA, V9, P671, DOI 10.1593/neo.07304; Holtkamp N, 2008, NEURO-ONCOLOGY, V10, P946, DOI 10.1215/15228517-2008-053; Huijbregts RPH, 2003, J NEUROSCI, V23, P7269; Ingram DA, 2000, J EXP MED, V191, P181, DOI 10.1084/jem.191.1.181; Ingram DA, 2001, J EXP MED, V194, P57, DOI 10.1084/jem.194.1.57; ITOH T, 1994, AM J NEURORADIOL, V15, P1513; JADAYEL D, 1990, NATURE, V343, P558, DOI 10.1038/343558a0; Jenne DE, 2001, AM J HUM GENET, V69, P516, DOI 10.1086/323043; Jessen WJ, 2013, J CLIN INVEST, V123, P340, DOI 10.1172/JCI60578; Johannessen CM, 2005, P NATL ACAD SCI USA, V102, P8573, DOI 10.1073/pnas.0503224102; Johansson G, 2008, MOL CANCER THER, V7, P1237, DOI 10.1158/1535-7163.MCT-07-2335; KADONO T, 1994, BIOCHEM BIOPH RES CO, V198, P827, DOI 10.1006/bbrc.1994.1118; Kawaguchi K, 2005, HUM PATHOL, V36, P357, DOI 10.1016/j.humpath.2005.01.017; Kehrer-Sawatzki H, 2004, AM J HUM GENET, V75, P410, DOI 10.1086/423624; Kim A, 2013, PEDIATR BLOOD CANCER, V60, P396, DOI 10.1002/pbc.24281; Kim HA, 2001, J NEUROSCI, V21, P1110; Kluwe L, 1999, GENE CHROMOSOME CANC, V24, P283, DOI 10.1002/(SICI)1098-2264(199903)24:3<283::AID-GCC15>3.0.CO;2-K; Koelsch B, 2016, G3-GENES GENOM GENET, V6, P59, DOI 10.1534/g3.115.021170; Kolberg M, 2013, NEURO-ONCOLOGY, V15, P135, DOI 10.1093/neuonc/nos287; Korkiamaki T, 2002, AM J PATHOL, V160, P1981, DOI 10.1016/S0002-9440(10)61148-0; Kourea HP, 1999, AM J PATHOL, V155, P1855, DOI 10.1016/S0002-9440(10)65504-6; Kweh F, 2009, MOL CARCINOGEN, V48, P1005, DOI 10.1002/mc.20552; LaFemina J, 2013, ANN SURG ONCOL, V20, P66, DOI 10.1245/s10434-012-2573-2; Lammert M, 2006, J MED GENET, V43, P810, DOI 10.1136/jmg.2006.041095; Le LQ, 2009, CELL STEM CELL, V4, P453, DOI 10.1016/j.stem.2009.03.017; Lee W, 2014, NAT GENET, V46, P1227, DOI 10.1038/ng.3095; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; LEGIUS E, 1994, GENE CHROMOSOME CANC, V10, P250, DOI 10.1002/gcc.2870100405; Lin AE, 2000, AM J MED GENET, V95, P108, DOI 10.1002/1096-8628(20001113)95:2<108::AID-AJMG4>3.0.CO;2-0; Ling BC, 2005, CANCER CELL, V7, P65, DOI 10.1016/j.ccr.2004.10.016; LISTERNICK R, 1994, J PEDIATR-US, V125, P63, DOI 10.1016/S0022-3476(94)70122-9; LISTERNICK R, 1995, J PEDIATR-US, V127, P718, DOI 10.1016/S0022-3476(95)70159-1; Lopez-Correa C, 2001, HUM MOL GENET, V10, P1387, DOI 10.1093/hmg/10.13.1387; Lothe RA, 1996, CANCER RES, V56, P4778; Maki RG, 2009, J CLIN ONCOL, V27, P3133, DOI 10.1200/JCO.2008.20.4495; Mannelli M, 2009, J CLIN ENDOCR METAB, V94, P1541, DOI 10.1210/jc.2008-2419; Mantripragada KK, 2008, CLIN CANCER RES, V14, P1015, DOI 10.1158/1078-0432.CCR-07-1305; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; Mattingly RR, 2006, J PHARMACOL EXP THER, V316, P456, DOI 10.1124/jpet.105.091454; Mawrin C, 2002, VIRCHOWS ARCH, V440, P610, DOI 10.1007/s00428-001-0550-4; McCoughan A, 2007, J MED GENET, V44, P463, DOI 10.1136/jmg.2006.048140; McGaughran JM, 1999, J MED GENET, V36, P197; Mechtersheimer G, 1999, GENE CHROMOSOME CANC, V25, P362, DOI 10.1002/(SICI)1098-2264(199908)25:4<362::AID-GCC8>3.0.CO;2-Q; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; Mertens F, 2000, J PATHOL, V190, P31, DOI 10.1002/(SICI)1096-9896(200001)190:1<31::AID-PATH505>3.0.CO;2-#; MERTENS F, 1995, INT J CANCER, V61, P793, DOI 10.1002/ijc.2910610609; Messiaen LM, 2000, HUM MUTAT, V15, P541, DOI 10.1002/1098-1004(200006)15:6<541::AID-HUMU6>3.0.CO;2-N; Miettinen M, 2006, AM J SURG PATHOL, V30, P90, DOI 10.1097/01.pas.0000176433.81079.bd; Mito JK, 2017, AM J CLIN PATHOL, V148, P179, DOI [10.1093/AJCP/AQX060, 10.1093/ajcp/aqx060]; Ng VY, 2013, ANTICANCER RES, V33, P2597; Nielsen GP, 1999, AM J PATHOL, V155, P1879, DOI 10.1016/S0002-9440(10)65507-1; Nystrom AM, 2009, CLIN GENET, V76, P524, DOI 10.1111/j.1399-0004.2009.01233.x; Oderich GS, 2007, J VASC SURG, V46, P475, DOI 10.1016/j.jvs.2007.03.055; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; Pasmant E, 2010, HUM MUTAT, V31, pE1506, DOI 10.1002/humu.21271; Patil S, 2012, ONCOLOGIST, V17, P101, DOI 10.1634/theoncologist.2010-0181; Pemov A, 2017, ONCOGENE, V36, P3168, DOI 10.1038/onc.2016.464; Perrone F, 2009, NEURO-ONCOLOGY, V11, P725, DOI 10.1215/15228517-2009-003; Perry A, 2002, J NEUROPATH EXP NEUR, V61, P702, DOI 10.1093/jnen/61.8.702; Pillay V, 2009, NEOPLASIA, V11, P448, DOI 10.1593/neo.09230; Plaat BEC, 1999, INT J CANCER, V83, P171, DOI 10.1002/(SICI)1097-0215(19991008)83:2<171::AID-IJC5>3.0.CO;2-S; Porter D. E., 2009, Sarcoma, P1, DOI 10.1155/2009/756395; Prada CE, 2013, ACTA NEUROPATHOL, V125, P159, DOI 10.1007/s00401-012-1056-7; Rao UNM, 1997, HUM PATHOL, V28, P1066, DOI 10.1016/S0046-8177(97)90060-5; Rasmussen SA, 2001, AM J HUM GENET, V68, P1110, DOI 10.1086/320121; Rea D, 2009, PEDIATRICS, V124, pE476, DOI 10.1542/peds.2009-0152; Reuss DE, 2014, ACTA NEUROPATHOL, V127, P565, DOI 10.1007/s00401-014-1246-6; RICCARDI VM, 1991, NEW ENGL J MED, V324, P1283, DOI 10.1056/NEJM199105023241812; Rodriguez FJ, 2008, J NEUROPATH EXP NEUR, V67, P240, DOI 10.1097/NEN.0b013e318165eb75; Rutkowski JL, 2000, HUM MOL GENET, V9, P1059, DOI 10.1093/hmg/9.7.1059; RYAN JJ, 1994, J NEUROSCI RES, V37, P415, DOI 10.1002/jnr.490370314; Schaefer IM, 2016, MODERN PATHOL, V29, P4, DOI 10.1038/modpathol.2015.134; Schmidt H, 1999, GENE CHROMOSOME CANC, V25, P205, DOI 10.1002/(SICI)1098-2264(199907)25:3<205::AID-GCC2>3.0.CO;2-B; Schmidt H, 2000, CANCER LETT, V155, P181, DOI 10.1016/S0304-3835(00)00426-2; Schmidt H, 2001, CANCER GENET CYTOGEN, V128, P14, DOI 10.1016/S0165-4608(01)00393-4; Schwetye KE, 2014, EXPERT REV NEUROTHER, V14, P1139, DOI 10.1586/14737175.2014.953931; Serra E, 2000, HUM MOL GENET, V9, P3055, DOI 10.1093/hmg/9.20.3055; Shen MH, 1996, J MED GENET, V33, P2, DOI 10.1136/jmg.33.1.2; Shimada S, 2007, PATHOL INT, V57, P60, DOI 10.1111/j.1440-1827.2006.02059.x; Simanshu DK, 2017, CELL, V170, P17, DOI 10.1016/j.cell.2017.06.009; SMIRNIOTOPOULOS JG, 1992, AM J NEURORADIOL, V13, P725; Steinmann K, 2007, AM J HUM GENET, V81, P1201, DOI 10.1086/522089; Stevenson DA, 2006, CLIN GENET, V69, P246, DOI 10.1111/j.1399-0004.2006.00576.x; STILLER CA, 1994, BRIT J CANCER, V70, P969, DOI 10.1038/bjc.1994.431; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Stonecypher MS, 2005, ONCOGENE, V24, P5589, DOI 10.1038/sj.onc.1208730; Stucky CCH, 2012, ANN SURG ONCOL, V19, P878, DOI 10.1245/s10434-011-1978-7; Su WP, 2004, GLIA, V45, P297, DOI 10.1002/glia.10340; Szudek J, 2000, AM J MED GENET, V92, P224, DOI 10.1002/(SICI)1096-8628(20000529)92:3<224::AID-AJMG12>3.0.CO;2-J; Szudek J, 2000, J MED GENET, V37, P933, DOI 10.1136/jmg.37.12.933; Thiagalingam S, 2004, OPHTHALMOLOGY, V111, P568, DOI 10.1016/j.ophtha.2003.06.008; Nupan MMT, 2017, FRONT PEDIATR, V5, DOI 10.3389/fped.2017.00227; Upadhyaya M, 2008, HUM MUTAT, V29, P74, DOI 10.1002/humu.20793; Upadhyaya M, 2007, AM J HUM GENET, V80, P140, DOI 10.1086/510781; Uusitalo E, 2017, BRIT J CANCER, V116, P211, DOI 10.1038/bjc.2016.403; Valentin T, 2016, EUR J CANCER, V56, P77, DOI 10.1016/j.ejca.2015.12.015; van den Berg L, 2015, INT J CANCER, V136, P2099, DOI 10.1002/ijc.29256; VanEs S, 1996, PEDIATR RADIOL, V26, P478, DOI 10.1007/BF01377205; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; Walther MM, 1999, J UROLOGY, V162, P1582, DOI 10.1016/S0022-5347(05)68171-2; Wang X, 2018, GENE CHROMOSOME CANC, V57, P19, DOI 10.1002/gcc.22503; Watson KL, 2017, J NEUROSURG, V126, P319, DOI 10.3171/2015.12.JNS152443; WEISS SW, 1993, AM J SURG PATHOL, V17, P1039, DOI 10.1097/00000478-199310000-00009; Welti S, 2007, J MOL BIOL, V366, P551, DOI 10.1016/j.jmb.2006.11.055; Welti S, 2011, HUM MUTAT, V32, P191, DOI 10.1002/humu.21405; Widemann BC, 2006, J CLIN ONCOL, V24, P507, DOI 10.1200/JCO.2005.03.8638; Williams VC, 2009, PEDIATRICS, V123, P124, DOI 10.1542/peds.2007-3204; Wimmer K, 2007, HUM MUTAT, V28, P599, DOI 10.1002/humu.20493; Wimmer K, 2006, GENE CHROMOSOME CANC, V45, P265, DOI 10.1002/gcc.20289; Wu JQ, 2008, CANCER CELL, V13, P105, DOI 10.1016/j.ccr.2007.12.027; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; Yang FC, 2003, J CLIN INVEST, V112, P1851, DOI 10.1172/JCI200319195; Yang FC, 2008, CELL, V135, P437, DOI 10.1016/j.cell.2008.08.041; Yang FC, 2006, HUM MOL GENET, V15, P2421, DOI 10.1093/hmg/ddl165; Zhang M, 2014, NAT GENET, V46, P1170, DOI 10.1038/ng.3116; Zhu Y, 2002, SCIENCE, V296, P920, DOI 10.1126/science.1068452; Zietsch J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011858; Zou CY, 2009, ANN SURG, V249, P1014, DOI 10.1097/SLA.0b013e3181a77e9a	182	4	4	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-4109	1533-4031		ADV ANAT PATHOL	Adv. Anat. Pathol.	SEP	2018	25	5					353	368		10.1097/PAP.0000000000000197			16	Pathology	Pathology	GQ7HD	WOS:000441906500006	29762158				2019-10-28	
J	Gunawardane, DN; Allen, PW				Gunawardane, Dimuth N.; Allen, Philip W.			Selected Case From the Arkadi M. Rywlin International Pathology Slide Club: Peritoneal Lipofuscinosis and Deciduosis in Pregnancy	ADVANCES IN ANATOMIC PATHOLOGY			English	Article						peritoneal lipofuscinosis; deciduosis in pregnancy; benign peritoneal pigmentation		Peritoneal lipofuscinosis is a very rarely recognized condition occurring during pregnancy characterized by brown pigmentation of the omentum and peritoneum, a decidual reaction and benign mesothelial cells. The iron negative pigment, which is likely to be confused with hemosiderin in the hematoxylin and eosin stain, is lipofuscin. The seminar case, apparently the third published, arose in a 37-year-old woman who presented in October 2015 at 24 weeks pregnancy with abdominal pain. Investigations revealed a ruptured left ovarian cyst and rising serum carcinoembryonic antige levels. At laparotomy, there was no free intraperitoneal blood but the omentum and uterine serosa were black. Histology showed lipofuscinosis and a decidual reaction. The patient delivered a normal baby in February 2016 and was clinically well after delivery. A left ovarian endometriotic cyst was removed in February 2017. The patient made a good recovery with no clinically apparent symptoms from the liposuscinosis. We postulate that the endometriotic cyst had ruptured and released blood into the peritoneal cavity in 2015. The iron from the red cells breakdown was then rapidly resorbed because of the pregnancy requirements for iron, leaving lipofuscin in peritoneal macrophages.	[Gunawardane, Dimuth N.; Allen, Philip W.] Flinders Med Ctr, SA Pathol, Dept Anat Pathol, Bedford Pk, SA 5042, Australia	Allen, PW (reprint author), Flinders Med Ctr, SA Pathol, Dept Anat Pathol, Bedford Pk, SA 5042, Australia.	phil.allen@health.sa.gov.au					BANNATYNE P, 1994, HISTOPATHOLOGY, V25, P598, DOI 10.1111/j.1365-2559.1994.tb01388.x; Kim NR, 2002, PATHOL INT, V52, P724, DOI 10.1046/j.1440-1827.2002.01405.x; Michal M, 2016, AM J SURG PATHOL, V40, P1507, DOI 10.1097/PAS.0000000000000687; Russell P, 1989, SURG PATHOLOGY OVARI, P168; WHITE J, 1994, HISTOPATHOLOGY, V25, P83, DOI 10.1111/j.1365-2559.1994.tb00602.x	5	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-4109	1533-4031		ADV ANAT PATHOL	Adv. Anat. Pathol.	SEP	2018	25	5					369	371		10.1097/PAP.0000000000000193			3	Pathology	Pathology	GQ7HD	WOS:000441906500007	29727323				2019-10-28	
J	Magliocca, KR; Williams, MD				Magliocca, Kelly R.; Williams, Michelle D.			Introduction to Ear and Temporal Bone Special Issue	HEAD & NECK PATHOLOGY			English	Editorial Material									[Magliocca, Kelly R.] Emory Univ, Dept Pathol & Lab Med, 550 Peachtree St NE, Atlanta, GA 30308 USA; [Williams, Michelle D.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Div Pathol Lab Med, Houston, TX 77030 USA	Magliocca, KR (reprint author), Emory Univ, Dept Pathol & Lab Med, 550 Peachtree St NE, Atlanta, GA 30308 USA.	kmagliocca@emory.edu; mdwillia@mdanderson.org		Williams, Michelle D./0000-0002-9133-7332				0	2	2	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	SEP	2018	12	3			SI		301	301		10.1007/s12105-018-0930-6			1	Pathology	Pathology	GP7WG	WOS:000441120700001	30069847	Bronze, Green Published			2019-10-28	
J	Juliano, AF				Juliano, Amy F.			Cross Sectional Imaging of the Ear and Temporal Bone	HEAD & NECK PATHOLOGY			English	Article						Temporal bone; CT; MRI; Anatomy	SEMICIRCULAR CANAL DEHISCENCE; SENSORINEURAL HEARING-LOSS; COMPUTED-TOMOGRAPHY SCAN; HIPPEL-LINDAU-DISEASE; PETROUS APEX; FACIAL-NERVE; VESTIBULAR AQUEDUCT; RESIDUAL CHOLESTEATOMA; OVAL WINDOW; CT	CT and MR imaging are essential cross-sectional imaging modalities for assessment of temporal bone anatomy and pathology. The choice of CT versus MR depends on the structures and the disease processes that require assessment, delineation, and characterization. A thorough knowledge of the two imaging modalities' capabilities and of temporal bone anatomy greatly facilitates imaging interpretation of pathologic conditions.	[Juliano, Amy F.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA; [Juliano, Amy F.] Harvard Med Sch, Boston, MA 02115 USA	Juliano, AF (reprint author), Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.; Juliano, AF (reprint author), Harvard Med Sch, Boston, MA 02115 USA.	amy_juliano@meei.harvard.edu					Abdel-Aziz M, 2014, J CRANIOFAC SURG, V25, P1076, DOI 10.1097/SCS.0000000000000468; Anand Akash G, 2009, J La State Med Soc, V161, P25; Aralasmak A, 2009, DIAGN INTERV RADIOL, V15, P239, DOI 10.4261/1305-3825.DIR.1621-08.1; Ayadi K, 2000, AM J ROENTGENOL, V175, P925, DOI 10.2214/ajr.175.3.1750925; Barath K, 2011, AM J NEURORADIOL, V32, P221, DOI 10.3174/ajnr.A2052; Benoit MM, 2010, OTOLARYNG HEAD NECK, V142, P108, DOI 10.1016/j.otohns.2009.10.007; Berrettini S, 2005, AM J OTOLARYNG, V26, P363, DOI 10.1016/j.amjoto.2005.02.013; Booth TN, 2000, AM J NEURORADIOL, V21, P171; Braun T, 2013, INT J AUDIOL, V52, P495, DOI 10.3109/14992027.2013.786191; Carey JP, 2000, ARCH OTOLARYNGOL, V126, P137, DOI 10.1001/archotol.126.2.137; Carlson ML, 2012, LARYNGOSCOPE, V122, P378, DOI 10.1002/lary.22411; COKER NJ, 1991, OTOLARYNG CLIN N AM, V24, P215; Collins JM, 2012, SEMIN ULTRASOUND CT, V33, P418, DOI 10.1053/j.sult.2012.06.006; Connor SEJ, 2008, BRIT J RADIOL, V81, P427, DOI 10.1259/bjr/54160649; Dahiya R, 1999, J TRAUMA, V47, P1079, DOI 10.1097/00005373-199912000-00014; De Foer B, 2008, OTOL NEUROTOL, V29, P513, DOI 10.1097/MAO.0b013e31816c7c3b; Dewan K, 2009, OTOLARYNG HEAD NECK, V140, P552, DOI 10.1016/j.otohns.2008.12.035; Dremmen MHG, 2012, AM J NEURORADIOL, V33, P439, DOI 10.3174/ajnr.A2824; Dubach P, 2008, OTOL NEUROTOL, V29, P941, DOI 10.1097/MAo.0b013e318185fb20; Eibenberger K, 2014, OTOL NEUROTOL, V35, P329, DOI 10.1097/MAO.0000000000000199; El-Bitar MA, 2003, INT J PEDIATR OTORHI, V67, P231, DOI 10.1016/S0165-5876(02)00373-7; Fatterpekar GM, 2006, RADIOGRAPHICS, V26, pS117, DOI 10.1148/rg.26si065502; Gadre AK, 2018, LARYNGOSCOPE, V128, P195, DOI 10.1002/lary.26571; Gaurano JL, 2004, ANN SAUDI MED, V24, P442, DOI 10.5144/0256-4947.2004.442; Ginat DT, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.6.FOCUS12150; Hu XD, 2015, INT J CLIN EXP MED, V8, P2979; Ishman SL, 2004, LARYNGOSCOPE, V114, P1734, DOI 10.1097/00005537-200410000-00011; Juliano AF, 2016, AM J NEURORADIOL, V37, P1331, DOI 10.3174/ajnr.A4735; Juliano AF, 2013, RADIOLOGY, V269, P16, DOI 10.1148/radiol.13120733; LAMBERT PR, 1984, LARYNGOSCOPE, V94, P1022; Lee TC, 2009, AM J NEURORADIOL, V30, P1435, DOI 10.3174/ajnr.A1558; Lemmerling M, 2001, EUR RADIOL, V11, P1210, DOI 10.1007/s003300000703; Levine Harold R, 2012, Proc (Bayl Univ Med Cent), V25, P372; Majumder A, 2017, INT J PEDIATR OTORHI, V99, P135, DOI 10.1016/j.ijporl.2017.06.011; Malis DJ, 1998, OTOLARYNG HEAD NECK, V119, P689, DOI 10.1016/S0194-5998(98)70037-3; Mansour S, 2011, OTOL NEUROTOL, V32, P384, DOI 10.1097/MAO.0b013e3182096e80; Marioni G, 2001, INT J PEDIATR OTORHI, V61, P173, DOI 10.1016/S0165-5876(01)00564-X; MartinDuverneuil N, 1997, NEURORADIOLOGY, V39, P207, DOI 10.1007/s002340050395; Meriot P, 1997, RADIOGRAPHICS, V17, P1445, DOI 10.1148/radiographics.17.6.9397457; Minor LB, 2005, LARYNGOSCOPE, V115, P1717, DOI 10.1097/01.mlg.0000178324.55729.b7; Minor LB, 1998, ARCH OTOLARYNGOL, V124, P249, DOI 10.1001/archotol.124.3.249; Naganawa S, 1999, RADIOLOGY, V213, P819, DOI 10.1148/radiology.213.3.r99dc05819; Nemzek WR, 1998, AM J NEURORADIOL, V19, P701; Nevoux J, 2014, OTOL NEUROTOL, V35, P899, DOI 10.1097/MAO.0000000000000299; PARKER GD, 1991, RADIOGRAPHICS, V11, P383, DOI 10.1148/radiographics.11.3.1852933; PIEPERGERDES JC, 1980, LARYNGOSCOPE, V90, P383, DOI 10.1002/lary.5540900303; Pisaneschi M J, 2000, Top Magn Reson Imaging, V11, P87, DOI 10.1097/00002142-200004000-00004; Purohit B, 2014, INSIGHTS IMAGING, V5, P245, DOI 10.1007/s13244-014-0313-9; Razek AA, 2012, RADIOGRAPHICS, V32, P151, DOI 10.1148/rg.321105758; Reinshagen KL, 2017, AM J NEURORADIOL, V38, P2003, DOI 10.3174/ajnr.A5335; Rubinstein D, 1996, AM J NEURORADIOL, V17, P1099; Saraiya PV, 2009, EMERG RADIOL, V16, P255, DOI 10.1007/s10140-008-0777-3; Schmalfuss IM, 2009, NEUROIMAG CLIN N AM, V19, P367, DOI 10.1016/j.nic.2009.06.009; Shetty PG, 1998, AM J NEURORADIOL, V19, P633; SWARTZ JD, 1989, RADIOLOGY, V171, P779, DOI 10.1148/radiology.171.3.2717751; Tran LP, 1996, OTOLARYNG CLIN N AM, V29, P807; Tringali S, 2010, OTOL NEUROTOL, V31, P1518, DOI 10.1097/MAO.0b013e3181d279c3; Tuccar E, 2000, CLIN ANAT, V13, P83, DOI 10.1002/(SICI)1098-2353(2000)13:2<83::AID-CA2>3.0.CO;2-Y; VALVASSORI GE, 1993, OTOLARYNG CLIN N AM, V26, P359; Vazquez E, 2003, RADIOGRAPHICS, V23, P359, DOI 10.1148/rg.232025076; Vercruysse JP, 2006, EUR RADIOL, V16, P1461, DOI 10.1007/s00330-006-0160-2; VIRAPONGSE C, 1985, AM J NEURORADIOL, V6, P561; Vitale M, 2017, AM J EMERG MED, V35, DOI 10.1016/j.ajem.2017.07.020; Yew A, 2012, J NEUROL SURG PART B, V73, P365, DOI 10.1055/s-0032-1324397; Zeifer B, 2000, AM J NEURORADIOL, V21, P322; Zevallos JP, 2009, LARYNGOSCOPE, V119, P1610, DOI 10.1002/lary.20259	66	0	1	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	SEP	2018	12	3			SI		302	320		10.1007/s12105-018-0901-y			19	Pathology	Pathology	GP7WG	WOS:000441120700002	30069846	Green Published			2019-10-28	
J	Isaacson, B				Isaacson, Brandon			Anatomy and Surgical Approach of the Ear and Temporal Bone	HEAD & NECK PATHOLOGY			English	Article						Temporal bone; Ear; Tympanoplasty; Mastoidectomy; Petrous bone; Paraganglioma; Skull base	PETROUS APEX; CASE SERIES; RECONSTRUCTION; CHOLESTEATOMA; TYMPANOPLASTY; MANAGEMENT; CAVITY; NERVE	The temporal bone is one of the more complex structures at the skull base that houses the hearing and vestibular organs, numerous nerves, and vessels. A host of inflammatory and neoplastic processes can occur within the temporal bone that often necessitate permanent and frozen section pathologic examination. A number of simple to complex surgical procedures are used to manage temporal bone pathology. This chapter will provide a brief overview of normal temporal bone anatomy, common surgical approaches, normal histology, and indications for pathologic examination.	[Isaacson, Brandon] UT Southwestern Med Ctr, Dept Otolaryngol HNS, 5323 Harry Hines Blvd, Dallas, TX 75390 USA	Isaacson, B (reprint author), UT Southwestern Med Ctr, Dept Otolaryngol HNS, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Brandon.isaacson@utsouthwestern.edu		Isaacson, Brandon/0000-0003-4725-1555			Anzola JF, 2016, OTOLARYNG CLIN N AM, V49, P1253, DOI 10.1016/j.otc.2016.05.016; BARROW HN, 1992, ARCH OTOLARYNGOL, V118, P94; Blyth CC, 2011, CLIN MICROBIOL INFEC, V17, P306, DOI 10.1111/j.1469-0691.2010.03231.x; Breen JT, 2018, LARYNGOSCOPE, V128, P1425, DOI 10.1002/lary.26785; Carlson ML, 2016, OTOL NEUROTOL, V37, P940, DOI 10.1097/MAO.0000000000001037; FERLITO A, 1993, J LARYNGOL OTOL, V107, P483, DOI 10.1017/S0022215100123539; Gidley PW, 2009, EXPERT REV ANTICANC, V9, P1277, DOI 10.1586/era.09.93; Goycoolea MV, 1999, OTOLARYNG CLIN N AM, V32, P513, DOI 10.1016/S0030-6665(05)70149-3; Isaacson B, 2007, OTOLARYNG CLIN N AM, V40, P479, DOI 10.1016/j.otc.2007.03.003; Isaacson B, 2018, OTOLARYNG CLIN N AM, V51, P415, DOI 10.1016/j.otc.2017.11.011; Jufas N, 2016, OTOLARYNG CLIN N AM, V49, P1107, DOI 10.1016/j.otc.2016.05.009; Killeen DE, 2017, OTOL NEUROTOL, V38, P408, DOI 10.1097/MAO.0000000000001320; Kircher ML, 2014, LARYNGOSCOPE, V124, P538, DOI 10.1002/lary.24282; Kwong Y, 2012, AM J ROENTGENOL, V199, P428, DOI 10.2214/AJR.11.8012; Lim D. J., 1995, Acta Oto-Rhino-Laryngologica Belgica, V49, P101; Marchioni D, 2010, LARYNGOSCOPE, V120, P1028, DOI 10.1002/lary.20841; McRackan TR, 2015, OTOLARYNG CLIN N AM, V48, P491, DOI 10.1016/j.otc.2015.02.008; Sozen E, 2012, OTOL NEUROTOL, V33, pE37, DOI 10.1097/MAO.0b013e3182338984; Tarabichi M, 2013, OTOLARYNG CLIN N AM, V46, P131, DOI 10.1016/j.otc.2013.02.001; Vercruysse JP, 2016, OTOL NEUROTOL, V37, P698, DOI 10.1097/MAO.0000000000001006; Wick CC, 2017, OTOLARYNG HEAD NECK, V157, P683, DOI 10.1177/0194599817709436; Wick CC, 2017, OTOL NEUROTOL, V38, P876, DOI 10.1097/MAO.0000000000001422; Wick CC, 2015, OTOLARYNG CLIN N AM, V48, P317, DOI 10.1016/j.otc.2014.12.006; Yawn RJ, 2017, OTOL NEUROTOL, V38, P1296, DOI 10.1097/MAO.0000000000001527	24	0	0	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	SEP	2018	12	3			SI		321	327		10.1007/s12105-018-0926-2			7	Pathology	Pathology	GP7WG	WOS:000441120700003	30069845	Green Published			2019-10-28	
J	Magliocca, KR; Vivas, EX; Griffith, CC				Magliocca, Kelly R.; Vivas, Esther X.; Griffith, Christopher C.			Idiopathic, Infectious and Reactive Lesions of the Ear and Temporal Bone	HEAD & NECK PATHOLOGY			English	Article						Otitis externa; Otitis media; Aural polyp; Tympanosclerosis; Otomycosis; Myospherulosis	EOSINOPHILIC OTITIS-MEDIA; MALIGNANT EXTERNAL OTITIS; SKULL BASE OSTEOMYELITIS; OF-THE-LITERATURE; MIDDLE-EAR; AURAL POLYPS; TYMPANIC MEMBRANE; CASE SERIES; TREATMENT OUTCOMES; HUMAN OTOACARIASIS	A number of infectious, inflammatory and idiopathic lesions develop within otologic tissues that may share similar clinical and/or microscopic features. This review first provides a working classification for otitis externa, and then otitis media and includes two recently described entities, eosinophilic otitis media and otitis media with ANCA-associated vasculitis. Next, the microscopic findings of a spectrum of otopathologic conditions are described, including post-inflammatory conditions such as tympanosclerosis and aural polyps, an overview of animate aural foreign body as well as iatrogenic aural foreign body reactions. Finally, a review of fungal disease affecting the ear with a brief synopsis of Candida auris, a recently described and virulent organism, is presented.	[Magliocca, Kelly R.; Griffith, Christopher C.] Emory Univ, Dept Pathol & Lab Med, 550 Peachtree St NE, Atlanta, GA 30308 USA; [Vivas, Esther X.] Emory Univ, Dept Otolaryngol Head & Neck Surg, 550 Peachtree St NE, Atlanta, GA 30308 USA	Magliocca, KR (reprint author), Emory Univ, Dept Pathol & Lab Med, 550 Peachtree St NE, Atlanta, GA 30308 USA.	kmagliocca@emory.edu	Vivas, Esther X./AAC-1008-2019	Vivas, Esther X./0000-0001-5740-2391			Akyigit A, 2016, J LARYNGOL OTOL, V130, P928, DOI 10.1017/S0022215116008732; Ariyarathne S, 2016, EXP APPL ACAROL, V70, P99, DOI 10.1007/s10493-016-0056-z; Azadarmaki R, 2015, ANN OTO RHINOL LARYN, V124, P752, DOI 10.1177/0003489415577988; AZADEH B, 1991, HISTOPATHOLOGY, V19, P276, DOI 10.1111/j.1365-2559.1991.tb00035.x; Bahmad F, 2007, ANN OTO RHINOL LARYN, V116, P181, DOI 10.1177/000348940711600304; BERNHEIM J, 1989, J LARYNGOL OTOL, V103, P366, DOI 10.1017/S0022215100108977; BHAYA MH, 1993, OTOLARYNG HEAD NECK, V109, P413, DOI 10.1177/019459989310900305; Bhutta MF, 2017, DIS MODEL MECH, V10, P1289, DOI 10.1242/dmm.029983; Blake DM, 2014, ENT-EAR NOSE THROAT, V93, P238; Bojrab DI, 1996, OTOLARYNG CLIN N AM, V29, P761; Bowles PF, 2017, BMJ CASE REP; Branco C, 2017, ACTA OTORRINOLAR ESP, V68, P323, DOI 10.1016/j.otorri.2017.02.003; Brobst R, 2009, INT J OTOLARYNGOL; Cevik C, 2014, J LARYNGOL OTOL, V128, P698, DOI 10.1017/S0022215114001510; CHANDLER JR, 1968, LARYNGOSCOPE, V78, P1257, DOI 10.1288/00005537-196808000-00002; Chawdhary G, 2015, J LARYNGOL OTOL, V129, P600, DOI 10.1017/S002221511500105X; Chen CM, 2013, LARYNGOSCOPE, V123, P1040, DOI 10.1002/lary.23582; Chen CN, 2010, ACTA OTO-LARYNGOL, V130, P89, DOI 10.3109/00016480902971247; Chen DS, 1999, AM J OTOL, V20, P561; Childers AL, 2014, OTOL NEUROTOL, V35, pE206, DOI 10.1097/MAO.0000000000000369; Culviner WT, 2000, AM J RHINOL, V14, P131, DOI 10.2500/105065800781692877; Dana AN, 2009, DERMATOL THER, V22, P293, DOI 10.1111/j.1529-8019.2009.01244.x; EVANS I T G, 1973, Journal of Laryngology and Otology, V87, P13, DOI 10.1017/S0022215100076568; Ferguson BJ, 2007, LARYNGOSCOPE, V117, P2036, DOI 10.1097/MLG.0b013e318123f2d7; FERLITO A, 1974, ORL J OTO-RHINO-LARY, V36, P257; FERLITO A, 1979, J LARYNGOL OTOL, V93, P25, DOI 10.1017/S0022215100086680; Franco-Vidal V, 2007, OTOL NEUROTOL, V28, P771, DOI 10.1097/MAO.0b013e31805153bd; GILLESPIE C A, 1990, Auris Nasus Larynx, V16, P199; GLIKLICH RE, 1993, ARCH OTOLARYNGOL, V119, P669; Glikson E, 2017, DIAGN MICR INFEC DIS, V87, P74, DOI 10.1016/j.diagmicrobio.2016.10.017; Goh JPN, 2017, AM J OTOLARYNG, V38, P466, DOI 10.1016/j.amjoto.2017.04.007; Gokdogan O, 2016, BRAZ J OTORHINOLAR, V82, P416, DOI 10.1016/j.bjorl.2015.07.018; Gruber M, 2015, OTOL NEUROTOL, V36, P733, DOI 10.1097/MAO.0000000000000563; Harabuchi Y, 2017, MOD RHEUMATOL, V27, P87, DOI 10.1080/14397595.2016.1177926; Hatten K, 2010, ANN OTO RHINOL LARYN, V119, P436, DOI 10.1177/000348941011900702; Hisata Y, 2017, J GEN FAM MED, V18, P428, DOI 10.1002/jgf2.112; HUSSAIN SSM, 1991, J LARYNGOL OTOL, V105, P268, DOI 10.1017/S0022215100115579; Iino Y, 2011, AURIS NASUS LARYNX, V38, P456, DOI 10.1016/j.anl.2010.11.016; Indudharan R, 1999, ANN TROP MED PARASIT, V93, P163; Jervis-Bardy J, 2015, ANN OTO RHINOL LARYN, V124, P345, DOI 10.1177/0003489414557021; Kahn SL, 2016, DERMATOL SURG, V42, P137, DOI 10.1097/DSS.0000000000000560; Kamimura M, 2000, ANN OTO RHINOL LARYN, V109, P467, DOI 10.1177/000348940010900505; Kanazawa H, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0577-2; Kesser BW, 2011, CURR OPIN OTOLARYNGO, V19, P341, DOI 10.1097/MOO.0b013e328349a125; Klemm E, 2009, ACTA DERMATOVEN ALP, V18, P73; Kukushev Georgi, 2017, Reumatologia (Warsaw), V55, P256, DOI 10.5114/reum.2017.71643; Kumar MS, 2016, ANN OTO RHINOL LARYN, V125, P862, DOI 10.1177/0003489416660112; KYRIAKOS M, 1977, AM J CLIN PATHOL, V67, P118; Lara-Sanchez H, 2017, NEW ENGL J MED, V376, pE10, DOI 10.1056/NEJMicm1510852; Lin HW, 2010, AM J OTOLARYNG, V31, P205, DOI 10.1016/j.amjoto.2009.01.002; Ling SS, 2008, INT J INFECT DIS, V12, P550, DOI 10.1016/j.ijid.2008.03.003; Magliulo G, 2000, OTOLARYNG HEAD NECK, V122, P777, DOI 10.1016/S0194-5998(00)70218-X; MAKEK M, 1988, ARCH OTOLARYNGOL, V114, P1127; MAKISHIMA K, 1982, AM J OTOL, V3, P260; Mathison BA, 2014, CLIN MICROBIOL REV, V27, P48, DOI 10.1128/CMR.00008-13; Matsuo R, 2015, J DERMATOL, V42, P1023, DOI 10.1111/1346-8138.13021; MATTUCCI KF, 1986, LARYNGOSCOPE, V96, P264; McCadden L, 2018, J LARYNGOL OTOL, V132, P372, DOI 10.1017/S0022215118000324; MCCLATCHIE S, 1969, AM J CLIN PATHOL, V51, P699; McGraw TA, 2008, J AM ACAD DERMATOL, V58, P907, DOI 10.1016/j.jaad.2008.03.014; Meltzer PE, 1959, LARYNGOSCOPE, V169, P1300; MENACHOF MR, 1990, OTOLARYNG HEAD NECK, V102, P285, DOI 10.1177/019459989010200315; Michal M, 2017, HUM PATHOL, V61, P199, DOI 10.1016/j.humpath.2016.09.020; Mills R, 2016, J LARYNGOL OTOL, V130, P418, DOI 10.1017/S0022215116000943; MILROY CM, 1989, J CLIN PATHOL, V42, P460, DOI 10.1136/jcp.42.5.460; Nader ME, 2017, OTOL NEUROTOL, V38, pE364, DOI 10.1097/MAO.0000000000001541; Narozny W, 2006, OTOL NEUROTOL, V27, P1047, DOI 10.1097/01.mao.0000235372.39998.7c; Nishizawa H, 2012, ACTA OTO-LARYNGOL, V132, P838, DOI 10.3109/00016489.2012.668708; Okada M, 2017, OTOL NEUROTOL, V38, pE506, DOI 10.1097/MAO.0000000000001563; OSTFELD E, 1981, LARYNGOSCOPE, V91, P965; Phillip V, 2013, ANN DIAGN PATHOL, V17, P383, DOI 10.1016/j.anndiagpath.2012.12.003; Praveen CV, 2002, J LARYNGOL OTOL, V116, P288, DOI 10.1258/0022215021910555; Russell JD, 2002, LARYNGOSCOPE, V112, P1663, DOI 10.1097/00005537-200209000-00025; Saliba I, 2018, ACTA OTO-LARYNGOL, V138, P110, DOI 10.1080/00016489.2017.1385845; Salvinelli F, 1999, Eur Rev Med Pharmacol Sci, V3, P175; Satoh K, 2009, MICROBIOL IMMUNOL, V53, P41, DOI 10.1111/j.1348-0421.2008.00083.x; Schilder AGM, 2017, OTOLARYNG HEAD NECK, V156, pS88, DOI 10.1177/0194599816633697; Schilder AGM, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.63; SHARAN R, 1978, J LARYNGOL OTOL, V92, P705, DOI 10.1017/S0022215100085972; Shavit SS, 2016, AM J OTOLARYNG, V37, P425, DOI 10.1016/j.amjoto.2016.04.005; Shen J, 2012, OTOL NEUROTOL, V33, P774, DOI 10.1097/MAO.0b013e318259522f; Shew M, 2017, OTOL NEUROTOL, V38, pE211, DOI 10.1097/MAO.0000000000001470; Song JE, 2014, ENT-EAR NOSE THROAT, V93, P332, DOI 10.1177/014556131409300811; Spielmann PM, 2013, J LARYNGOL OTOL, V127, P246, DOI 10.1017/S0022215112003155; Stevens SM, 2015, OTOL NEUROTOL, V36, P1492, DOI 10.1097/MAO.0000000000000839; Tay HL, 1997, J LARYNGOL OTOL, V111, P212, DOI 10.1017/S002221510013693X; Tomioka S, 1997, CHOLESTEATOMA MASTOI, P851; Tukaj C, 2014, ULTRASTRUCT PATHOL, V38, P69, DOI 10.3109/01913123.2013.833563; Vallabhaneni S, 2016, MMWR-MORBID MORTAL W, V65, P1234, DOI 10.15585/mmwr.mm6544e1; Van der Poel NA, 2017, INT J PEDIATR OTORHI, V102, P56, DOI 10.1016/j.ijporl.2017.08.034; VEITCH D, 1988, CLIN OTOLARYNGOL, V13, P395, DOI 10.1111/j.1365-2273.1988.tb00772.x; Vennewald I, 2005, CLIN DERMATOL, V23, P565, DOI 10.1016/j.clindermatol.2005.01.003; Vennewald I, 2003, MYCOSES, V46, P12, DOI 10.1046/j.1439-0507.2003.00835.x; Vennewald I, 2010, CLIN DERMATOL, V28, P202, DOI 10.1016/j.clindermatol.2009.12.003; Villwock JA, 2014, J EMERG MED, V47, pE37, DOI 10.1016/j.jemermed.2014.04.024; Williams RA, 2017, OTOL NEUROTOL, V38, P563, DOI 10.1097/MAO.0000000000001354; Wipperman J, 2014, PRIMARY CARE, V41, P1, DOI 10.1016/j.pop.2013.10.001; Xenellis J, 2011, AURIS NASUS LARYNX, V38, P325, DOI 10.1016/j.anl.2010.10.002; Yang B, 2017, OTOLARYNG CLIN N AM, V50, P1091, DOI 10.1016/j.otc.2017.08.005; YOUNGS R, 1992, CLIN OTOLARYNGOL, V17, P505, DOI 10.1111/j.1365-2273.1992.tb01706.x; Yuca K, 2005, TOHOKU J EXP MED, V206, P125, DOI 10.1620/tjem.206.125; Zhu BZ, 2017, OTOL CASE REP, V2, P4	102	0	0	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	SEP	2018	12	3			SI		328	349		10.1007/s12105-018-0952-0			22	Pathology	Pathology	GP7WG	WOS:000441120700004	30069844	Green Published			2019-10-28	
J	Nagarajan, P				Nagarajan, Priyadharsini			Ceruminous Neoplasms of the Ear	HEAD & NECK PATHOLOGY			English	Article						Ceruminous; Adenoma; Carcinoma	ADENOID CYSTIC CARCINOMA; MUCOEPIDERMOID CARCINOMA; PLEOMORPHIC ADENOMA; NEVUS SEBACEUS; GLAND TUMORS; SYRINGOCYSTADENOMA PAPILLIFERUM; MALIGNANT-MELANOMA; SALIVARY-GLANDS; ADENOCARCINOMA; MENINGIOMA	Ceruminous glands are modified apocrine glands located in the external auditory canal (EAC). Neoplastic lesions arising from these glands are rare in humans and constitute a major differential diagnosis for glandular neoplasms of the EAC. Due to anatomic restrictions, benign and malignant neoplasms present with similar symptoms and to some extent even comparable radiologic features, particularly when the tumors are localized. Biopsies are frequently limited by small size, fragmentation and improper anatomic and architectural orientation, thereby hampering our ability to appreciate the relationship of peripheral edges of the tumor to the surrounding tissue. Benign and malignant tumors may also have overlapping histomorphologic features, which further magnifies the challenges in accurate diagnosis and management strategies. This article summarizes the salient clinical, radiologic and histologic features of common ceruminous gland tumors, in addition to discussing features that can aid in differentiating ceruminous tumors from other EAC tumors and to distinguish benign from malignant entities.	[Nagarajan, Priyadharsini] Univ Texas MD Anderson Canc Ctr, Dept Pathol, 1515 Holcombe Blvd,Unit 85,B3-4621, Houston, TX 77030 USA	Nagarajan, P (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, 1515 Holcombe Blvd,Unit 85,B3-4621, Houston, TX 77030 USA.	pnagarajan@mdanderson.org		Nagarajan, Priyadharsini/0000-0002-5346-2669			Agaimy A, 2013, AM J SURG PATHOL, V37, P128, DOI 10.1097/PAS.0b013e31826731e0; ARATO J, 1980, J OTOLARYNGOL, V9, P482; Arechvo A, 2013, CASE REP OTOLARYNGOL, DOI 10.1155/2013/541679; Ayers Lisa Skultety, 2010, Ear Nose Throat J, V89, pE1; Bared A, 2007, ACTA OTO-LARYNGOL, V127, P280, DOI 10.1080/00016480600818120; Bell D, 2013, HEAD NECK PATHOL, V7, P23, DOI 10.1007/s12105-013-0432-5; BENDE M, 1981, J LARYNGOL OTOL, V95, P11, DOI 10.1017/S0022215100090344; Bridges Megan Nichole, 2009, Dermatol Online J, V15, P13; BRUNNER H, 1953, AMA ARCH OTOLARYNGOL, V58, P665; Bruschini L, 2017, AM J CASE REP, V18, P520, DOI 10.12659/AJCR.902900; Chung JH, 2012, CANCER RES TREAT, V44, P275, DOI 10.4143/crt.2012.44.4.275; Crain N, 2009, HEAD NECK PATHOL, V3, P1, DOI 10.1007/s12105-008-0095-9; DEHNER LP, 1980, ARCH OTOLARYNGOL, V106, P13; Dixon J, 2017, J LARYNGOL OTOL, V131, P273, DOI 10.1017/S0022215117000044; Dong F, 2008, LARYNGOSCOPE, V118, P1591, DOI 10.1097/MLG.0b013e31817c42a8; Ebelhar AE, 2017, J INT ADV OTOL, V13, P292, DOI 10.5152/iao.2017.3929; FLIGIEL Z, 1975, CANCER, V36, P1072, DOI 10.1002/1097-0142(197509)36:3<1072::AID-CNCR2820360334>3.0.CO;2-W; Fujii K, 2017, HISTOPATHOLOGY, V71, P823, DOI 10.1111/his.13281; Garin P, 1999, J OTOLARYNGOL, V28, P99; Giuseppe M, 2011, OTOL NEUROTOL, V32, pE14, DOI 10.1097/MAO.0b013e3181db7545; Grover N, 2012, J LARYNGOL OTOL, V126, P1278, DOI 10.1017/S0022215112002162; Hannan SA, 2006, LANCET, V368, P1680, DOI 10.1016/S0140-6736(06)69702-X; Hasan Z, 2016, CASE REP OTOLARYNGOL, DOI 10.1155/2016/9834750; HICKS GW, 1983, LARYNGOSCOPE, V93, P326; HICKS MJ, 1995, HEAD NECK-J SCI SPEC, V17, P89, DOI 10.1002/hed.2880170203; Hynes B, 2004, J OTOLARYNGOL, V33, P401, DOI 10.2310/7070.2004.03119; Idriss MH, 2014, J AM ACAD DERMATOL, V70, P332, DOI 10.1016/j.jaad.2013.10.004; Ishida M, 2016, PATHOL INT, V66, P710, DOI 10.1111/pin.12475; Jan JC, 2008, ARCH OTOLARYNGOL, V134, P663, DOI 10.1001/archotol.134.6.663; Judson BL, 2012, ARCH OTOLARYNGOL, V138, P871, DOI 10.1001/archoto.2012.1668; KAWABATA I, 1964, Arch Histol Jpn, V25, P165; Kundu I, 2001, Indian J Otolaryngol Head Neck Surg, V53, P304, DOI 10.1007/BF02991555; Kuwabara H, 2006, PATHOL INT, V56, P51, DOI 10.1111/j.1440-1827.2006.01918.x; LAM KY, 1993, J CLIN PATHOL, V46, P1011, DOI 10.1136/jcp.46.11.1011; Lassaletta L, 2003, AURIS NASUS LARYNX, V30, P287, DOI 10.1016/S0385-8146(03)00055-5; Lee CK, 2005, J LARYNGOL OTOL, V119, P1004, DOI 10.1258/002221505775010706; Lott Limbach AA, 2012, HEAD NECK PATHOL, V6, P345; Luna MA, 2006, ADV ANAT PATHOL, V13, P293, DOI 10.1097/01.pap.0000213058.74509.d3; Magliulo G, 2012, OTOL NEUROTOL, V33, pE21, DOI 10.1097/MAO.0b013e31821a8577; Magliulo G, 2010, OTOLARYNG HEAD NECK, V143, P459, DOI 10.1016/j.otohns.2010.05.016; Magliulo G, 2010, OTOLARYNG HEAD NECK, V142, P624, DOI 10.1016/j.otohns.2009.11.032; MANSOUR P, 1992, J LARYNGOL OTOL, V106, P727, DOI 10.1017/S0022215100120717; Markou K, 2008, AM J OTOLARYNG, V29, P142, DOI 10.1016/j.amjoto.2007.04.005; MILLS RG, 1995, J LARYNGOL OTOL, V109, P180, DOI 10.1017/S0022215100129652; Mitani Y, 2016, CLIN CANCER RES, V22, P725, DOI 10.1158/1078-0432.CCR-15-2867-T; Moisan PG, 1996, J AM ANIM HOSP ASSOC, V32, P448, DOI 10.5326/15473317-32-5-448; Mourad WF, 2013, J LARYNGOL OTOL, V127, P203, DOI 10.1017/S0022215112003015; Niemczyk E, 2015, INT J PEDIATR OTORHI, V79, P1932, DOI 10.1016/j.ijporl.2015.07.019; Parekh V, 2016, AM J DERMATOPATH, V38, P56, DOI 10.1097/DAD.0000000000000370; Pelosi S, 2015, OTOLARYNG CLIN N AM, V48, P305, DOI 10.1016/j.otc.2014.12.005; PERRY ET, 1955, J INVEST DERMATOL, V25, P439, DOI 10.1038/jid.1955.149; PERZIN KH, 1982, CANCER, V50, P2873, DOI 10.1002/1097-0142(19821215)50:12<2873::AID-CNCR2820501230>3.0.CO;2-R; PERZIN KH, 1978, CANCER, V42, P265, DOI 10.1002/1097-0142(197807)42:1<265::AID-CNCR2820420141>3.0.CO;2-Z; Psillas G, 2015, CASE REP MED, DOI 10.1155/2015/359627; PULEC JL, 1977, LARYNGOSCOPE, V87, P1601; Rabinov CR, 1997, ANN OTO RHINOL LARYN, V106, P589, DOI 10.1177/000348949710600711; Ribeiro A, 2015, EUR ANN OTORHINOLARY, V132, P243, DOI 10.1016/j.anorl.2015.03.004; Ruhl DS, 2016, AM J OTOLARYNG, V37, P70, DOI 10.1016/j.amjoto.2015.11.005; Sandison A, 2017, WHO CLASSIFICATION H, P265; Schwarz David, 2016, BMJ Case Rep, V2016, DOI 10.1136/bcr-2015-212035; Seethala RR, 2009, HEAD NECK PATHOL, V3, P69, DOI 10.1007/s12105-009-0102-9; SHELLEY WB, 1956, J INVEST DERMATOL, V26, P13, DOI 10.1038/jid.1956.2; Stoeckelhuber M, 2006, ANAT REC PART A, V288A, P877, DOI 10.1002/ar.a.20356; Su TC, 2011, HEAD NECK ONCOL, V3, DOI 10.1186/1758-3284-3-36; Thompson LDR, 2004, AM J SURG PATHOL, V28, P308, DOI 10.1097/00000478-200403000-00003; Thompson LDR, 2017, HEAD NECK PATHOL, V11, P78, DOI 10.1007/s12105-017-0790-5; van Weert S, 2015, ORAL ONCOL, V51, P71, DOI 10.1016/j.oraloncology.2014.10.007; Vandeweyer E, 2002, ACTA CHIR BELG, V102, P137; Vickers TW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143211; WETLI CV, 1972, CANCER, V29, P1169, DOI 10.1002/1097-0142(197205)29:5<1169::AID-CNCR2820290507>3.0.CO;2-8; Zainuddin N, 2015, Malays Fam Physician, V10, P52	71	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	SEP	2018	12	3			SI		350	361		10.1007/s12105-018-0909-3			12	Pathology	Pathology	GP7WG	WOS:000441120700005	30069843	Green Published			2019-10-28	
J	Katabi, N				Katabi, Nora			Neuroendocrine Neoplasms of the Ear	HEAD & NECK PATHOLOGY			English	Article						Neuroendocrine neoplasms; Middle ear; Middle ear adenoma; Carcinoid	MIDDLE-EAR; CARCINOID-TUMOR; EXPRESSION; ADENOMA	Neuroendocrine neoplasms of the ear are uncommon primary tumors. There is a reported debate in the literature as to the true nature of these tumors and how to classify them. However, there is a kind of consensus that they can represent a spectrum of a common entity with dual glandular and neuroendocrine differentiation. The differential diagnosis of these tumors is broad but their morphologic, immunohistochemical, and radiographic features help to differentiate them from other entities. The tumors have mostly bland histology and indolent biological behavior, yet they may recur and metastasize. It is important to accurately recognize these tumors in order to perform the right management and limit their morbidity. In this article, we review the pathogenesis, histology, immunohistochemical features of neurornedocrine neoplasms of the ear and we discuss their differential diagnosis, clinical behavior and management.	[Katabi, Nora] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA	Katabi, N (reprint author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA.	katabin@mskcc.org					Agaimy A, 2015, HISTOPATHOLOGY, V66, P182, DOI 10.1111/his.12447; Bahrami A, 2008, MODERN PATHOL, V21, P795, DOI 10.1038/modpathol.2008.86; Barnes L., 2009, SURG PATHOLOGY HEAD; Bell D, 2017, VIRCHOWS ARCH, V471, P667, DOI 10.1007/s00428-017-2155-6; Bierry G, 2010, J NEURORADIOLOGY, V37, P116, DOI 10.1016/j.neurad.2009.05.003; Cardoso FA, 2017, INT ARCH OTORHINOLAR, V21, P308, DOI 10.1055/s-0037-1601400; El Naggar AK, 2017, WHO CLASSIFICAITON H; HYAMS VJ, 1976, CLIN OTOLARYNGOL, V1, P17, DOI 10.1111/j.1365-2273.1976.tb00637.x; MURPHY GF, 1980, AM J CLIN PATHOL, V73, P816; Nader M, 2017, OTOLOGY NEUROTOL, DOI [10.1097/mao.0000000000001541, DOI 10.1097/MAO.0000000000001541.]; Pelosi S, 2015, OTOLARYNG CLIN N AM, V48, P305, DOI 10.1016/j.otc.2014.12.005; Ramsey MJ, 2005, LARYNGOSCOPE, V115, P1660, DOI 10.1097/01.mlg.0000175069.13685.37; Saliba I, 2009, CASES J, DOI [10.1186/1757-1627-2-6508.2, DOI 10.1186/1757-1627-2-6508.2]; Torske KR, 2002, MODERN PATHOL, V15, P543, DOI 10.1038/modpathol.3880561; Wenig BM, 2016, ATLAS HEAD NECK PATH	15	2	2	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	SEP	2018	12	3			SI		362	366		10.1007/s12105-018-0924-4			5	Pathology	Pathology	GP7WG	WOS:000441120700006	30069842	Green Published			2019-10-28	
J	Martinez, AP; Torres-Mora, J				Martinez, Anthony P.; Torres-Mora, Jorge			Selected Giant Cell Rich Lesions of the Temporal Bone	HEAD & NECK PATHOLOGY			English	Article						Temporal bone; Sarcoidosis; Chondroblastoma; Tenosynovial giant cell tumor; Giant cell reparative granuloma; Langerhans cell histiocytosis	PIGMENTED VILLONODULAR SYNOVITIS; REPARATIVE GRANULOMA; HISTIOCYTOSIS-X; TENDON SHEATH; BENIGN CHONDROBLASTOMA; CRYPTOCOCCAL INFECTION; NODULAR TENOSYNOVITIS; CUTANEOUS SARCOIDOSIS; NEOPLASTIC-CELLS; GREEK PATIENTS	Giant cell rich lesions of the temporal bone encompass a wide spectrum of disease that includes infectious, reactive, and neoplastic processes. When dealing with any lesion that can potentially involve bone, it is important to understand both the clinical presentation and to correlate the histologic findings with the radiologic imaging. This review discusses the clinical, the pathologic features including the differential diagnosis, and the treatment of some of the more commonly encountered giant cell rich entities in this region.	[Martinez, Anthony P.; Torres-Mora, Jorge] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55902 USA	Martinez, AP (reprint author), Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55902 USA.	anthonymartinezmd@gmail.com					Abdel-Aziz M, 2014, J CRANIOFAC SURG, V25, P1076, DOI 10.1097/SCS.0000000000000468; Abla O, 2010, CANCER TREAT REV, V36, P354, DOI 10.1016/j.ctrv.2010.02.012; Agaram NP, 2014, HUM PATHOL, V45, P1147, DOI 10.1016/j.humpath.2014.01.020; Akpalo H, 2012, HISTOPATHOLOGY, V60, P1099, DOI 10.1111/j.1365-2559.2011.04152.x; Amary F, 2017, AM J SURG PATHOL, V41, P1059, DOI 10.1097/PAS.0000000000000859; Amary MF, 2016, HISTOPATHOLOGY, V69, P121, DOI 10.1111/his.12945; AUCLAIR PL, 1988, ORAL SURG ORAL MED O, V66, P197, DOI 10.1016/0030-4220(88)90094-1; Badalian-Very G, 2010, BLOOD, V116, P1919, DOI 10.1182/blood-2010-04-279083; Bernstrand C, 2005, ACTA PAEDIATR, V94, P1073, DOI 10.1080/08035250510028263; BERTONI F, 1987, AM J CLIN PATHOL, V88, P1; Bird P, 2015, OTOL NEUROTOL, V36, P1296, DOI 10.1097/MAO.0000000000000773; Boland JM, 2009, AM J SURG PATHOL, V33, P1225, DOI 10.1097/PAS.0b013e3181a6d86f; Bousdras K, 2007, HISTOPATHOLOGY, V51, P414, DOI 10.1111/j.1365-2559.2007.02777.x; Brahmi M, 2016, CURR TREAT OPTION ON, V17, DOI 10.1007/s11864-015-0385-x; Bredell M, 2018, J ORAL MAXIL SURG, V76, P775, DOI 10.1016/j.joms.2017.09.013; Campos MK, 2007, J PEDIAT, V83, P79, DOI 10.2223/JPED.1581; Carlson ML, 2017, LARYNGOSCOPE, V127, P2340, DOI 10.1002/lary.26435; Chakraborty R, 2014, BLOOD, V124, P3007, DOI 10.1182/blood-2014-05-577825; Cleven AHG, 2015, AM J SURG PATHOL, V39, P1576, DOI 10.1097/PAS.0000000000000512; COCCHIA D, 1983, VIRCHOWS ARCH A, V402, P139, DOI 10.1007/BF00695055; Codman EA, 2006, CLIN ORTHOP RELAT R, P12, DOI 10.1097/01.blo.0000229309.90265.df; Cohen PR, 2007, CLIN DERMATOL, V25, P326, DOI 10.1016/j.clindermatol.2007.03.010; Coppes-Zantinga A, 2002, BRIT J HAEMATOL, V116, P3, DOI 10.1046/j.1365-2141.2002.03232.x; CUMMINGS MM, 1958, AM J MED SCI, V236, P311, DOI 10.1097/00000441-195823630-00005; DAHLIN DC, 1972, CANCER, V30, P401, DOI 10.1002/1097-0142(197208)30:2<401::AID-CNCR2820300216>3.0.CO;2-B; DALLEY RW, 1987, J COMPUT ASSIST TOMO, V11, P884, DOI 10.1097/00004728-198709000-00028; Damodar D, 2015, HEAD NECK-J SCI SPEC, V37, pE194, DOI 10.1002/hed.24056; Demirhan H, 2015, J CRANIOFAC SURG, V26, pE689, DOI 10.1097/SCS.0000000000002052; Dimitakopoulos I, 2006, J ORAL MAXIL SURG, V64, P531, DOI 10.1016/j.joms.2005.11.006; EDEL G, 1992, VIRCHOWS ARCH A, V421, P355, DOI 10.1007/BF01660984; EISIG S, 1992, ORAL SURG ORAL MED O, V73, P328, DOI 10.1016/0030-4220(92)90130-I; El-Naggar A, 2017, WHO CLASSIFICATION H; Fernandez-Faith E, 2007, CLIN DERMATOL, V25, P276, DOI 10.1016/j.clindermatol.2007.03.004; Fernandez-Latorre F, 2000, AM J ROENTGENOL, V174, P217, DOI 10.2214/ajr.174.1.1740217; Fisher M, 2013, OTOL NEUROTOL, V34, pE49, DOI 10.1097/MAO.0b013e31827d06f6; Fletcher C, 2013, WHO CLASSIFICATION T; Folpe AL, 1998, MODERN PATHOL, V11, P939; Gazouli M, 2005, J CLIN MICROBIOL, V43, P4858, DOI 10.1128/JCM.43.9.4858-4861.2005; Gazouli M, 2002, J CLIN MICROBIOL, V40, P3060, DOI 10.1128/JCM.40.8.3060-3063.2002; Ginat DT, 2016, HEAD NECK PATHOL, V10, P209, DOI 10.1007/s12105-015-0629-x; Haupt R, 2013, PEDIATR BLOOD CANCER, V60, P175, DOI 10.1002/pbc.24367; Hicks J, 2005, ORAL SURG ORAL MED O, V100, pS42, DOI 10.1016/j.tripleo.2005.06.016; HIRSCHL S, 1974, HUM PATHOL, V5, P171, DOI 10.1016/S0046-8177(74)80064-X; Jaffe HL, 1942, AM J PATHOL, V18, P969; JAFFE HL, 1953, ORAL SURG ORAL MED O, V6, P159, DOI 10.1016/0030-4220(53)90151-0; Jaffe HL, 1941, ARCH PATHOL, V31, P731; Janssen D, 2005, AM J SURG PATHOL, V29, P21, DOI 10.1097/01.pas.0000147395.01229.06; Kiess AP, 2015, SARCOIDOSIS VASC DIF, V32, P200; Koch B L, 2000, Top Magn Reson Imaging, V11, P66; Kong YY, 2007, AM J SURG PATHOL, V31, P341, DOI 10.1097/01.pas.0000213387.70783.b6; Konishi E, 2010, HUM PATHOL, V41, P208, DOI 10.1016/j.humpath.2009.07.014; Lazarus A, 2009, DM-DIS MON, V55, P648, DOI [10.1016/j.disamonth.2009.04.007, 10.1016/j.disamonth.2009.04.008]; Lin PP, 2005, CLIN ORTHOP RELAT R, P103, DOI 10.1097/01.blo.0000179591.72844.c3; Ma YY, 2012, ACTA OTO-LARYNGOL, V132, P657, DOI 10.3109/00016489.2012.654853; Majumder A, 2017, INT J PEDIATR OTORHI, V99, P135, DOI 10.1016/j.ijporl.2017.06.011; Mashhour MA, 2014, INT ORTHOP, V38, P1019, DOI 10.1007/s00264-013-2178-9; MCCAFFREY TV, 1979, LARYNGOSCOPE, V89, P1735; Modest MC, 2016, LARYNGOSCOPE, V126, P1899, DOI 10.1002/lary.25773; Monaghan H, 2001, J CLIN PATHOL, V54, P404, DOI 10.1136/jcp.54.5.404; Murakami I, 2002, HUM PATHOL, V33, P555, DOI 10.1053/hupa.2002.124035; Nackos JS, 2006, AM J NEURORADIOL, V27, P1651; Newman LS, 2004, AM J RESP CRIT CARE, V170, P1324, DOI 10.1164/rccm.200402-249OC; Ng M, 2002, AM J OTOLARYNG, V23, P241, DOI 10.1053/ajot.2002.123457; Nishiwaki T, 2004, AM J PATHOL, V165, P631, DOI 10.1016/S0002-9440(10)63327-5; Oda Y, 2007, MODERN PATHOL, V20, P545, DOI 10.1038/modpathol.3800770; Oliveira AM, 2004, AM J PATHOL, V165, P1773, DOI 10.1016/S0002-9440(10)63432-3; Palmerini E, 2015, EUR J CANCER, V51, P210, DOI 10.1016/j.ejca.2014.11.001; Park SW, 2017, HEAD NECK-J SCI SPEC, V39, P2171, DOI 10.1002/hed.24880; Ramappa AJ, 2000, J BONE JOINT SURG AM, V82A, P1140, DOI 10.2106/00004623-200008000-00011; Roden AC, 2014, AM J SURG PATHOL, V38, P548, DOI 10.1097/PAS.0000000000000129; Rootjes PA, 2016, MED J AUSTRALIA, V204, P353, DOI 10.5694/mja16.00139; Ruocco E, 2015, INT J DERMATOL, V54, P1, DOI 10.1111/ijd.12566; SCHAJOWICZ F, 1970, Journal of Bone and Joint Surgery British Volume, V52, P205; Scheer M, 2011, J ORAL MAXIL SURG, V69, P222, DOI 10.1016/j.joms.2010.07.006; Schurmann M, 2000, AM J RESP CRIT CARE, V162, P861, DOI 10.1164/ajrccm.162.3.9901099; Shanmugam V, 2017, AM J SURG PATHOL, V41, P1390, DOI 10.1097/PAS.0000000000000897; Stalemark H, 2008, PEDIATR BLOOD CANCER, V51, P76, DOI 10.1002/pbc.21504; Thomas KW, 2003, JAMA-J AM MED ASSOC, V289, P3300, DOI 10.1001/jama.289.24.3300; Tiefenboeck TM, 2016, ORTHOP TRAUMATOL-SUR, V102, P473, DOI 10.1016/j.otsr.2016.01.025; USHIJIMA M, 1986, CANCER, V57, P875, DOI 10.1002/1097-0142(19860215)57:4<875::AID-CNCR2820570432>3.0.CO;2-Y; Van Buren N, 2014, OTOL NEUROTOL, V35, pE211, DOI 10.1097/MAO.0000000000000273; Verse T, 1997, LARYNGO RHINO OTOL, V76, P312, DOI 10.1055/s-2007-997433; Weintraub M, 1998, J PEDIAT HEMATOL ONC, V20, P12, DOI 10.1097/00043426-199801000-00002; WEISS APC, 1986, J BONE JOINT SURG AM, V68A, P521, DOI 10.2106/00004623-198668040-00006; West RB, 2006, P NATL ACAD SCI USA, V103, P690, DOI 10.1073/pnas.0507321103; Wiles AB, 2011, ARCH OTOLARYNGOL, V137, P942, DOI 10.1001/archoto.2011.145; WILLMAN CL, 1994, NEW ENGL J MED, V331, P154, DOI 10.1056/NEJM199407213310303; Xie C, 2015, EUR RADIOL, V25, P1127, DOI 10.1007/s00330-014-3506-1; Xie GP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121451; Yollu U, 2013, J CRANIOFAC SURG, V24, P1495, DOI 10.1097/SCS.0b013e3182700d0a; Yu JL, 2010, SKULL BASE-INTERD AP, V20, P443, DOI 10.1055/s-0030-1265822; YU RC, 1994, LANCET, V343, P767, DOI 10.1016/S0140-6736(94)91842-2	92	0	0	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	SEP	2018	12	3			SI		367	377		10.1007/s12105-018-0906-6			11	Pathology	Pathology	GP7WG	WOS:000441120700007	30069841	Green Published			2019-10-28	
J	Sabharwal, A; Magliocca, KR; Williams, MD				Sabharwal, Amarpreet; Magliocca, Kelly R.; Williams, Michelle D.			Ear and Temporal Bone: Cartilaginous and Osseous Pathologies	HEAD & NECK PATHOLOGY			English	Article						Ear; Temporal bone; Idiopathic cystic chondromalacia; Protuberant fibro-osseous lesion of temporal bone; Chondromyxoid lesions; Synovial chondromatosis	OF-THE-LITERATURE; PROTUBERANT FIBROOSSEOUS LESIONS; SKULL BASE CHORDOMA; SYNOVIAL CHONDROMATOSIS; RELAPSING POLYCHONDRITIS; TEMPOROMANDIBULAR-JOINT; PAROSTEAL OSTEOSARCOMA; CHONDROMYXOID FIBROMA; CHONDROID CHORDOMA; AUDITORY EXOSTOSES	Although the majority of conditions involving the ear and temporal bone are inflammatory or epithelial based, cartilage and osseous entities will also be encountered. The pathologic examination of these underlying cartilaginous and osseous structures and their histologic findings and associated differential diagnoses will be discussed. Correlation with clinical and imaging findings are also critical for accurate determination of the pathologic entity.	[Sabharwal, Amarpreet] SUNY Buffalo, Sch Dent Med, Dept Periodont & Endodont, Buffalo, NY USA; [Magliocca, Kelly R.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; [Williams, Michelle D.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Div Pathol & Lab Med, Houston, TX 77030 USA	Williams, MD (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, Div Pathol & Lab Med, Houston, TX 77030 USA.	mdwillia@mdanderson.org	Sabharwal, Amarpreet/Z-3933-2019	Williams, Michelle D./0000-0002-9133-7332			Agrawal A, 2008, J CANC RES THER, V4, P91, DOI 10.4103/0973-1482.42256; Ahmed S, 2014, J COMPUT ASSIST TOMO, V38, P662, DOI 10.1097/RCT.0000000000000096; Ardekian L, 2005, J ORAL MAXIL SURG, V63, P941, DOI 10.1016/j.joms.2005.03.009; Arnaud L, 2014, AUTOIMMUN REV, V13, P90, DOI 10.1016/j.autrev.2013.07.005; Awad M, 2016, J CLIN NEUROSCI, V24, P1, DOI 10.1016/j.jocn.2015.10.029; BLANKESTIJN J, 1985, CANCER-AM CANCER SOC, V55, P479, DOI 10.1002/1097-0142(19850115)55:2<479::AID-CNCR2820550232>3.0.CO;2-N; Bohman LE, 2014, WORLD NEUROSURG, V82, P806, DOI 10.1016/j.wneu.2014.07.005; Brea B, 2013, ACTA OTORRINOLAR ESP, V64, P6, DOI 10.1016/j.otorri.2012.06.004; Carbone PN, 2012, HEAD NECK PATHOL, V6, P244, DOI 10.1007/s12105-011-0314-7; Chole RA, 2001, OTOL NEUROTOL, V22, P249, DOI 10.1097/00129492-200103000-00023; CODY DTR, 1978, ANN OTO RHINOL LARYN, V87, P778, DOI 10.1177/000348947808700605; DORFMAN HD, 1994, HUM PATHOL, V25, P1234, DOI 10.1016/0046-8177(94)90041-8; ENGEL D, 1966, ARCHIV OTOLARYNGOL, V83, P197; Fenton JE, 1996, LARYNGOSCOPE, V106, P624, DOI 10.1097/00005537-199605000-00020; FOIDART JM, 1978, NEW ENGL J MED, V299, P1203, DOI 10.1056/NEJM197811302992202; Frisch CD, 2015, LARYNGOSCOPE, V125, P1438, DOI 10.1002/lary.25078; FULLING KH, 1981, J CUTAN PATHOL, V8, P79, DOI 10.1111/j.1600-0560.1981.tb00990.x; Goh EK, 2006, AM J OTOLARYNG, V27, P358, DOI 10.1016/j.amjoto.2005.11.022; Gros A, 2003, OTOL NEUROTOL, V24, P43, DOI 10.1097/00129492-200301000-00010; Guadagnolo BA, 2009, CANCER-AM CANCER SOC, V115, P3262, DOI 10.1002/cncr.24297; Ha PK, 1999, LARYNGOSCOPE, V109, P964, DOI 10.1097/00005537-199906000-00023; Hasselblatt M, 2005, J NEUROSURG, V102, P1151, DOI 10.3171/jns.2005.102.6.1151; HEFFELFINGER MJ, 1973, CANCER-AM CANCER SOC, V32, P410, DOI 10.1002/1097-0142(197308)32:2<410::AID-CNCR2820320219>3.0.CO;2-S; HERZOG S, 1990, AM J NEURORADIOL, V11, P742; House JW, 2008, OTOLARYNG HEAD NECK, V138, P672, DOI 10.1016/j.otohns.2008.01.023; Hsieh Shun-Ta, 2004, J Chin Med Assoc, V67, P314; IEMOTO Y, 1991, SKELETAL RADIOL, V20, P59; JAFFE HL, 1948, ARCH PATHOL, V45, P541; Jiang BW, 2018, J NEUROSURG-PEDIATR, V21, P107, DOI 10.3171/2017.8.PEDS17391; Jones PS, 2014, J CLIN NEUROSCI, V21, P1497, DOI 10.1016/j.jocn.2014.02.005; Kassir RR, 1997, LARYNGOSCOPE, V107, P56, DOI 10.1097/00005537-199701000-00013; KENNEDY GE, 1986, AM J PHYS ANTHROPOL, V71, P401, DOI 10.1002/ajpa.1330710403; Kent Peter D., 2004, Current Opinion in Rheumatology, V16, P56, DOI 10.1097/00002281-200401000-00011; Koyama J, 2001, AM J NEURORADIOL, V22, P1203; LAZAR RH, 1986, OTOLARYNG HEAD NECK, V94, P360, DOI 10.1177/019459988609400318; Lee M, 2014, AM J SURG PATHOL, V38, P1510, DOI 10.1097/PAS.0000000000000302; Lee RJ, 2015, JAMA OTOLARYNGOL, V141, P470, DOI 10.1001/jamaoto.2015.0340; Letko E, 2002, SEMIN ARTHRITIS RHEU, V31, P384, DOI 10.1053/sarh.2002.32586; Mariniello G, 2003, CLIN NEUROL NEUROSUR, V105, P135, DOI 10.1016/S0303-8467(02)00130-0; MARK RJ, 1993, CANCER, V72, P887, DOI 10.1002/1097-0142(19930801)72:3<887::AID-CNCR2820720338>3.0.CO;2-5; McCadden L, 2018, J LARYNGOL OTOL, V132, P372, DOI 10.1017/S0022215118000324; Ming LC, 2004, LARYNGOSCOPE, V114, P1281, DOI 10.1097/00005537-200407000-00026; Mohanty PP, 2003, CLIN ONCOL-UK, V15, P365, DOI 10.1016/S0936-6555(03)00151-1; Murphey MD, 2007, RADIOGRAPHICS, V27, DOI 10.1148/rg.275075116; NADOL JB, 1993, NEW ENGL J MED, V329, P1092, DOI 10.1056/NEJM199310073291507; Nakashima T, 2006, CLIN OTOLARYNGOL, V31, P110, DOI 10.1111/j.1749-4486.2006.01151.x; Oakley GJ, 2008, MODERN PATHOL, V21, P1461, DOI 10.1038/modpathol.2008.144; Otto BA, 2007, ANN OTO RHINOL LARYN, V116, P922, DOI 10.1177/000348940711601209; Pamir MN, 2006, EUR J RADIOL, V58, P461, DOI 10.1016/j.ejrad.2006.03.020; Park Sung Joon, 2012, Korean J Audiol, V16, P95, DOI 10.7874/kja.2012.16.2.95; Polizzotto MN, 2006, BRIT J HAEMATOL, V132, P114, DOI 10.1111/j.1365-2141.2005.05833.x; Purohit B, 2014, INSIGHTS IMAGING, V5, P245, DOI 10.1007/s13244-014-0313-9; Ramadass T, 2006, INDIAN J OTOLARYNGOL, V58, P156, DOI 10.1007/BF03050773; Razek AA, 2012, RADIOGRAPHICS, V32, P151, DOI 10.1148/rg.321105758; Romeo S, 2006, J PATHOL, V209, P143, DOI 10.1002/path.1987; Rosenberg AE, 1999, AM J SURG PATHOL, V23, P1370, DOI 10.1097/00000478-199911000-00007; Sato N, 2017, VIRCHOWS ARCH, V470, P717, DOI 10.1007/s00428-017-2111-5; Seely DR, 1997, ANN OTO RHINOL LARYN, V106, P729, DOI 10.1177/000348949710600902; Selesnick SH, 1999, AM J OTOL, V20, P394; Sharon JD, 2014, OTOL NEUROTOL, V35, P1207, DOI 10.1097/MAO.0000000000000321; Sia SF, 2010, AM J SURG PATHOL, V34, P1217, DOI 10.1097/PAS.0b013e3181df9672; STRUNK CL, 1992, OTOLARYNG HEAD NECK, V106, P202; Swartz JD, 2004, SEMIN ULTRASOUND CT, V25, P305, DOI 10.1053/j.sult.2004.04.001; Tarhan NC, 2000, EUR RADIOL, V10, P1678, DOI 10.1007/s003300000323; Thompson LDR, 2007, ENT-EAR NOSE THROAT, V86, P734, DOI 10.1177/014556130708601208; Thompson Lester D R, 2002, Ear Nose Throat J, V81, P705; VALENZUELA R, 1980, HUM PATHOL, V11, P19, DOI 10.1016/S0046-8177(80)80101-8; Vujovic S, 2006, J PATHOL, V209, P157, DOI 10.1002/path.1969; Wagner G, 2011, J DTSCH DERMATOL GES, V9, P287, DOI 10.1111/j.1610-0387.2011.07601.x; Wang P, 2012, DENTOMAXILLOFAC RAD, V41, P110, DOI 10.1259/dmfr/36144602; Wong BJF, 1999, ARCH OTOLARYNGOL, V125, P969, DOI 10.1001/archotol.125.9.969; WURSTER CF, 1982, OTOLARYNG HEAD NECK, V90, P126, DOI 10.1177/019459988209000121	72	0	0	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	SEP	2018	12	3			SI		378	391		10.1007/s12105-018-0949-8			14	Pathology	Pathology	GP7WG	WOS:000441120700008	30069840	Green Published			2019-10-28	
J	Flaman, AN; Wasserman, JK; Gravel, DH; Purgina, BM				Flaman, A. N.; Wasserman, J. K.; Gravel, D. H.; Purgina, B. M.			Ear and Temporal Bone Pathology: Neural, Sclerosing and Myofibroblastic Lesions	HEAD & NECK PATHOLOGY			English	Article						Temporal bone; Ear; Neurilemmoma; Meningioma; Encephalocele; Rhabdomyosarcoma; Solitary fibrous tumor; Paraganglioma; Fibrosarcoma	GRADE-FIBROMYXOID-SARCOMA; SOLITARY FIBROUS TUMOR; OF-THE-LITERATURE; NERVE SHEATH TUMORS; EPITHELIOID FIBROSARCOMA; SPINDLE-CELL; IGG4-RELATED DISEASE; HISTOLOGIC MIMICS; IMMUNOHISTOCHEMICAL ANALYSIS; CLINICOPATHOLOGICAL SERIES	Neural, sclerosing, and myofibroblastic lesions of the ear and temporal bone present diagnostic challenges for both clinicians and pathologists due to significant overlap in their clinical presentations, histologic appearances, and immunohistochemical profiles. While some of these lesions, such as schwannomas, are relatively common, others are rendered even more difficult because they are encountered very rarely in routine surgical pathology practice. This review is intended to provide an update on the pathology of some of the most commonly encountered primary diagnostic entities for the ear and temporal bone, and includes the following neural lesions: schwannoma, meningioma, and encephalocele/meningocele. Sclerosing lesions that will be discussed include spindle cell and sclerosing rhabdomyosarcoma, sclerosing epithelioid fibrosarcoma, and sclerosing paraganglioma. Finally, myofibroblastic lesions that will be reviewed are nodular fasciitis, IgG4-related disease, and solitary fibrous tumor. For each of these lesions, the differential diagnosis and useful ancillary tests will be discussed in the context of a broad range of additional primary and secondary lesions.	[Flaman, A. N.; Wasserman, J. K.; Gravel, D. H.; Purgina, B. M.] Univ Ottawa, Ottawa Hosp, Dept Pathol & Lab Med, Div Anat Pathol, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada	Purgina, BM (reprint author), Univ Ottawa, Ottawa Hosp, Dept Pathol & Lab Med, Div Anat Pathol, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.	bpurgina@ottawahospital.on.ca					Agaram NP, 2014, GENE CHROMOSOME CANC, V53, P779, DOI 10.1002/gcc.22187; Antonescu CR, 2001, AM J SURG PATHOL, V25, P699, DOI 10.1097/00000478-200106000-00001; Bari ME, 2002, BRIT J NEUROSURG, V16, P284, DOI 10.1080/02688690220148888; Bhatti RM, 2013, ADV ANAT PATHOL, V20, P10, DOI 10.1097/PAP.0b013e31827b619e; Bishop JA, 2015, HEAD NECK PATHOL, V9, P507, DOI 10.1007/s12105-015-0624-2; Carlson ML, 2016, J NEUROSURG, V125, P1120, DOI 10.3171/2015.7.JNS151056; Cowan ML, 2016, HEAD NECK PATHOL, V10, P161, DOI 10.1007/s12105-015-0647-8; Cox DP, 2010, ORAL SURG ORAL MED O, V110, P79, DOI 10.1016/j.tripleo.2010.01.023; Demicco EG, 2015, AM J CLIN PATHOL, V143, P672, DOI 10.1309/AJCPN25NJTOUNPNF; Deshpande V, 2015, HEAD NECK PATHOL, V9, P24, DOI 10.1007/s12105-015-0620-6; Deshpande V, 2012, MODERN PATHOL, V25, P1181, DOI 10.1038/modpathol.2012.72; Devaney KO, 2012, EUR ARCH OTO-RHINO-L, V269, P2461, DOI 10.1007/s00405-012-2026-3; Dixon J, 2017, J LARYNGOL OTOL, V131, P273, DOI 10.1017/S0022215117000044; Doyle LA, 2014, MODERN PATHOL, V27, P390, DOI 10.1038/modpathol.2013.164; Doyle LA, 2012, AM J SURG PATHOL, V36, P1444, DOI 10.1097/PAS.0b013e3182562bf8; Doyle LA, 2011, AM J SURG PATHOL, V35, P733, DOI 10.1097/PAS.0b013e318210c268; Ereno C, 2006, PATHOL RES PRACT, V202, P481, DOI 10.1016/j.prp.2005.12.010; Erickson-Johnson MR, 2011, LAB INVEST, V91, P1427, DOI 10.1038/labinvest.2011.118; Folk GS, 2007, HEAD NECK PATHOL, V1, P13, DOI 10.1007/s12105-007-0002-9; Folpe AL, 2002, AM J SURG PATHOL, V26, P1175, DOI 10.1097/01.PAS.0000024996.88486.CA; Gibson TC, 2015, HEAD NECK PATHOL, V9, P334, DOI 10.1007/s12105-014-0594-9; Gyure KA, 2000, LARYNGOSCOPE, V110, P1731, DOI 10.1097/00005537-200010000-00032; Hahn HP, 2006, AM J CLIN PATHOL, V125, P203, DOI 10.1309/G659FVVBMG7U4RPQ; Hasan Z, 2011, ANZ J SURG, V81, P947, DOI 10.1111/j.1445-2197.2011.05913.x; He CY, 2015, EUR ARCH OTO-RHINO-L, V272, P789, DOI 10.1007/s00405-014-3026-2; Izumaru S, 2004, AURIS NASUS LARYNX, V31, P65, DOI 10.1016/j.anl.2003.07.010; Jo VY, 2015, AM J SURG PATHOL, V39, P673, DOI 10.1097/PAS.0000000000000379; Kunzel J, 2016, EUR ARCH OTO-RHINO-L, V273, P1589, DOI 10.1007/s00405-015-3670-1; Lau PPL, 2013, AM J SURG PATHOL, V37, P734, DOI 10.1097/PAS.0b013e31827560f8; Lazaridou M, 2014, ORAL MAXILLOFAC SURG, V18, P111, DOI 10.1007/s10006-013-0409-2; Lee CK, 2016, J AUDIOL OTOL, V20, P120, DOI 10.7874/jao.2016.20.2.120; Liu YG, 2015, INT J CLIN EXP PATHO, V8, P5624; Mawrin C, 2010, J NEURO-ONCOL, V99, P379, DOI 10.1007/s11060-010-0342-2; Mentzel T, 2000, VIRCHOWS ARCH, V436, P305, DOI 10.1007/s004280050451; Mentzel T, 2006, VIRCHOWS ARCH, V449, P554, DOI 10.1007/s00428-006-0284-4; Mingo K, 2016, OTOL NEUROTOL, V37, pE317, DOI 10.1097/MAO.0000000000000860; Mohamed M, 2017, ANN DIAGN PATHOL, V28, P60, DOI 10.1016/j.anndiagpath.2017.04.001; Mulholland GB, 2015, J OTOLARYNGOL-HEAD N, V44, DOI 10.1186/s40463-015-0071-9; Nascimento AF., 2013, WHO CLASSIFICATION T; Nielsen GP, 2013, WHO CLASSIFICATION T; Ong HS, 2012, ORAL ONCOL, V48, P141, DOI 10.1016/j.oraloncology.2011.09.004; Ossendorf C, 2008, CLIN ORTHOP RELAT R, V466, P1485, DOI 10.1007/s11999-008-0205-8; Owosho AA, 2016, ORAL ONCOL, V58, pE6, DOI 10.1016/j.oraloncology.2016.05.009; Perry A, 2016, WHO CLASSIFICATION T; Pierry C, 2015, AM J CLIN PATHOL, V144, P511, DOI 10.1309/AJCPCG8D6JAQBVLG; Plaza JA, 2006, AM J SURG PATHOL, V30, P7, DOI 10.1097/01.pas.0000174012.37439.c7; Pravdenkova S, 2006, J NEUROSURG, V105, P163, DOI 10.3171/jns.2006.105.2.163; Prieto-Granada CN, 2016, AM J SURG PATHOL, V40, P479, DOI 10.1097/PAS.0000000000000564; Rekhi B, 2014, APMIS, V122, P1144, DOI 10.1111/apm.12272; Rezk Sherif, 2004, Arch Pathol Lab Med, V128, pe169; Sandison A, 2017, WHO CLASSIFICATION H; Schaefer IM, 2016, MODERN PATHOL, V29, P4, DOI 10.1038/modpathol.2015.134; Seferis C, 2014, J NEUROSURG, V121, P160, DOI 10.3171/2014.7.GKS141311; Shim HJ, 2016, J AUDIOL OTOL, V20, P179, DOI 10.7874/jao.2016.20.3.179; Takano K, 2017, AURIS NASUS LARYNX, V44, P7, DOI [10.1016/j.anl.2016.10.011, 10.1016/j.an1.2016.10.011]; Thompson LDR, 2003, MODERN PATHOL, V16, P236, DOI 10.1097/01.MP.0000056631.15739.1B; Thompson LDR, 2016, ENT-EAR NOSE THROAT, V95, P146, DOI 10.1177/014556131609504-504; Turner JH, 2011, OTOLARYNG HEAD NECK, V145, P967, DOI 10.1177/0194599811417063; Vallicioni JM, 1999, AM J OTOL, V20, P390; Weinreb I, 2009, J CUTAN PATHOL, V36, P1168, DOI 10.1111/j.1600-0560.2009.01252.x; Weissinger SE, 2014, MODERN PATHOL, V27, P524, DOI 10.1038/modpathol.2013.162; Williams MD, 2017, HEAD NECK PATHOL, V11, P278, DOI 10.1007/s12105-017-0803-4; Williams MD, 2017, HEAD NECK PATHOL, V11, P88, DOI 10.1007/s12105-017-0786-1; Yoshida A, 2014, AM J SURG PATHOL, V38, P552, DOI 10.1097/PAS.0000000000000137	64	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	SEP	2018	12	3			SI		392	406		10.1007/s12105-018-0891-9			15	Pathology	Pathology	GP7WG	WOS:000441120700009	30069839	Green Published			2019-10-28	
J	Castle, JT				Castle, James T.			Cholesteatoma Pearls: Practical Points and Update	HEAD & NECK PATHOLOGY			English	Article						Cholesteatoma; Middle ear cholesteatoma; Congenital cholesteatoma; Acquired cholesteatoma	MIDDLE-EAR CHOLESTEATOMA; CONGENITAL CHOLESTEATOMA; ACQUIRED CHOLESTEATOMA; RESIDUAL CHOLESTEATOMA; CLEFT-PALATE; SURGICAL-MANAGEMENT; PEDIATRIC-PATIENTS; BONE DESTRUCTION; TURNER SYNDROME; CHILDREN	The European Academy of Otology and Neurotology in collaboration with the Japanese Otological Society (EAONO/JOS) recently produced a joint consensus document outlining the definitions, classification and staging of middle ear cholesteatoma. The goals were to provide terminologies in the description of cholesteatoma, classify cholesteatoma into distinct categories to facilitate the comparison of surgical outcomes and to provide a staging system that reflects the severity, difficulty of complete removal and restoration of normal function. Cholesteatoma is considered a benign, expanding and destructive epithelial lesion of the temporal bone that is the result of a multifactorial process. If undetected and left treated, cholesteatoma may lead to significant complications including hearing loss, temporal bone destruction and cranial invasion. Recent advances in imaging modalities have allowed for high sensitivity and specificity in identifying the presence of cholesteatoma. Despite these advances, deficiencies exist around the world with access to health care facilities meaning cholesteatoma remains a serious and challenging entity to manage whether found within the pediatric or adult population. Proper diagnosis and management of each form of cholesteatoma is achieved by a thorough understanding of the etiology, classification, clinical presentation and histology, thereby facilitating prevention, early detection and appropriate treatment.	[Castle, James T.] Naval Postgrad Dent Sch, Dept Oral & Maxillofacial Pathol, Naval Med Profess Dev Ctr, 8955 Wood Rd, Bethesda, MD 20889 USA	Castle, JT (reprint author), Naval Postgrad Dent Sch, Dept Oral & Maxillofacial Pathol, Naval Med Profess Dev Ctr, 8955 Wood Rd, Bethesda, MD 20889 USA.	James.T.Castle4.mil@mail.mil					AHN JM, 1990, AM J OTOLARYNG, V11, P71, DOI 10.1016/0196-0709(90)90001-C; AIMI K, 1983, LARYNGOSCOPE, V93, P1140; de Aquino JEAP, 2011, BRAZ J OTORHINOLAR, V77, P341, DOI 10.1590/S1808-86942011000300012; Bacciu A, 2005, OTOL NEUROTOL, V26, P1007, DOI 10.1097/01.mao.0000185042.46523.9b; Barath K, 2011, AM J NEURORADIOL, V32, P221, DOI 10.3174/ajnr.A2052; Bassiouny M, 2012, EGYPT J EAR NOSE THR, V13, P7, DOI DOI 10.1016/J.EJENTA.2012.02.007; Bennett M, 2006, OTOLARYNG CLIN N AM, V39, P1081, DOI 10.1016/j.otc.2006.08.001; Bois E, 2018, EUR ANN OTORHINOLARY, V135, P21, DOI 10.1016/j.anorl.2017.08.006; BUCHNER SA, 1992, ARCH DERMATOL, V128, P1078, DOI 10.1001/archderm.128.8.1078; Caponetti G, 2009, ENT-EAR NOSE THROAT, V88, P1196, DOI 10.1177/014556130908801104; Chen AP, 2015, ACTA OTO-LARYNGOL, V135, P655, DOI 10.3109/00016489.2015.1011789; CHOLE RA, 1985, LARYNGOSCOPE, V95, P270; Corrales CE, 2013, CURR OPIN OTOLARYNGO, V21, P461, DOI 10.1097/MOO.0b013e328364b473; DeVerney JG, 1683, TRAITE ORGANIE OUIE; Djurhuus BD, 2015, LARYNGOSCOPE, V125, P1225, DOI 10.1002/lary.25022; Falcioni M, 2004, J LARYNGOL OTOL, V118, P165, DOI 10.1258/002221504772784694; Ferlito A, 1997, ANN OTO RHINOL LARYN, V106, P79; Fukudome S, 2013, JAMA OTOLARYNGOL, V139, P273, DOI 10.1001/jamaoto.2013.1750; Hall JE, 2009, INT J PEDIATR OTORHI, V73, P57, DOI 10.1016/j.ijporl.2008.09.022; Hamed MA, 2017, CLIN EXP OTORHINOLAR, V10, P213, DOI 10.21053/ceo.2016.01263; Harris L, 2013, INT J PEDIATR OTORHI, V77, P695, DOI 10.1016/j.ijporl.2013.01.020; Haruyama T, 2010, ORL-J OTO-RHIN-LARYN, V72, P325, DOI 10.1159/000319897; Henninger B, 2017, WORLD J RADIOL, V9, P217, DOI 10.4329/wjr.v9.i5.217; Imbery TE, 2017, OTOLARYNG HEAD NECK, V157, P676, DOI 10.1177/0194599817707514; James AL, 2013, CURR OPIN OTOLARYNGO, V21, P431, DOI 10.1097/MOO.0b013e328364b457; Jennings BA, 2018, CLIN OTOLARYNGOL, V43, P55, DOI 10.1111/coa.12900; Karmody CS, 2012, OTOL NEUROTOL, V33, P42, DOI 10.1097/MAO.0b013e31823c919c; Kopcsanyi G, 2015, INT J PEDIATR OTORHI, V79, P698, DOI 10.1016/j.ijporl.2015.02.020; Kuo CL, 2018, LARYNGOSCOPE, V128, P547, DOI 10.1002/lary.26220; Kuo CL, 2015, EUR ARCH OTO-RHINO-L, V272, P3601, DOI 10.1007/s00405-014-3291-0; Kuo CL, 2015, BIOMED RES INT, DOI 10.1155/2015/854024; Kuo CL, 2015, LARYNGOSCOPE, V125, P234, DOI 10.1002/lary.24890; Kuo CL, 2013, INT J PEDIATR OTORHI, V77, P1403, DOI 10.1016/j.ijporl.2013.07.015; LAU C C, 1988, Annals Academy of Medicine Singapore, V17, P372; LEVENSON MJ, 1988, LARYNGOSCOPE, V98, P949; Lim DBN, 2014, ACTA PAEDIATR, V103, pe282, DOI 10.1111/apa.12622; Maniu A, 2014, ROM J MORPHOL EMBRYO, V55, P7; Mann W, 2014, AURIS NASUS LARYNX, V41, P101, DOI 10.1016/j.anl.2013.05.005; Mas-Estelles F, 2012, RADIOGRAPHICS, V32, P1197, DOI 10.1148/rg.324115109; MICHAELS L, 1988, INT J PEDIATR OTORHI, V15, P51, DOI 10.1016/0165-5876(88)90050-X; Morita Y, 2017, OTOL NEUROTOL, V38, P1463, DOI 10.1097/MAO.0000000000001587; Muller J, 1838, UEBER FEINEREN BAU F; Nash R, 2014, INT J PEDIATR OTORHI, V78, P1747, DOI 10.1016/j.ijporl.2014.07.038; Olszewska E, 2004, EUR ARCH OTO-RHINO-L, V261, P6, DOI 10.1007/s00405-003-0623-x; Olszewska E, 2016, HISTOL HISTOPATHOL, V31, P307, DOI 10.14670/HH-11-677; Paulson LM, 2014, INT J PEDIATR OTORHI, V78, P223, DOI 10.1016/j.ijporl.2013.10.062; Preciado DA, 2012, INT J PEDIATR OTORHI, V76, P319, DOI 10.1016/j.ijporl.2011.12.014; Rothschild S, 2009, AM J OTOLARYNG, V30, P256, DOI 10.1016/j.amjoto.2008.06.011; Shohet JA, 2002, OTOLARYNG CLIN N AM, V35, P841, DOI 10.1016/S0030-6665(02)00052-X; Sudhoff H, 2000, AM J OTOL, V21, P786; Sudhoff H, 2000, AM J OTOL, V21, P793; Suzuki C, 2004, OTOL NEUROTOL, V25, P674, DOI 10.1097/00129492-200409000-00005; Tomlin J, 2013, AUDIOL NEURO-OTOL, V18, P135, DOI 10.1159/000346140; Tos M, 2000, LARYNGOSCOPE, V110, P1890, DOI 10.1097/00005537-200011000-00023; Venail F, 2008, AM J NEURORADIOL, V29, P1363, DOI 10.3174/ajnr.A1100; Vercruysse JP, 2006, EUR RADIOL, V16, P1461, DOI 10.1007/s00330-006-0160-2; Vital V, 2011, OTORHINOLARYNGOL HEA, V45, P5; Yung M, 2017, J INT ADV OTOL, V13, P1, DOI 10.5152/iao.2017.3363; Zhang H, 2018, EUR ARCH OTO-RHINO-L, V275, P301, DOI 10.1007/s00405-017-4783-5	59	1	1	1	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	SEP	2018	12	3			SI		419	429		10.1007/s12105-018-0915-5			11	Pathology	Pathology	GP7WG	WOS:000441120700011	30069838	Green Published			2019-10-28	
J	Hamza, A; Sakhi, R; Alrajjal, A; Ibrar, W; Miller, S; Salehi, S; Edens, J; Ockner, D				Hamza, Ameer; Sakhi, Ramen; Alrajjal, Ahmed; Ibrar, Warda; Miller, Shelby; Salehi, Sajad; Edens, Jacob; Ockner, Daniel			Tumor Size in Breast Carcinoma: Gross Measurement Is Important!	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						breast carcinoma; tumor size; gross tumor size; microscopic tumor size; pathologic staging; stage migration	SENTINEL LYMPH-NODE; NEOADJUVANT CHEMOTHERAPY; STAGE MIGRATION; CANCER SIZE; RESIDUAL DISEASE; NEEDLE-BIOPSY; MRI; MAMMOGRAPHY; ULTRASONOGRAPHY; SONOGRAPHY	Introduction. The staging of breast carcinoma is mainly dependent on tumor size and lymph node status. Small increments in tumor size upstage the patient. An accurate determination of the tumor size is therefore critically important. Although the final staging is based on microscopic size, pathologists rely on gross measurements in a considerable number of cases. Methods. We investigated the concordance between gross and microscopic measurements of breast carcinoma as well as factors affecting this concordance. This study is a retrospective review of surgical pathology reports of invasive breast carcinomas. Data were collected for 411 cases. Concordance was defined as a size difference within +/- 2 mm. Results. Gross and microscopic sizes were identical in 33.1% of cases. Gross and microscopic size difference was within +/- 2 mm in 56% of cases. Despite the size difference, stage classification ended up being the same in 68.6% of cases. Tumor stage was over estimated by gross measurement in 17.0% of cases and underestimated in 14.4% of cases. The concordance was significantly higher for those tumors in which final pathologic tumor (pT) size was greater than 2 cm (pT2) as compared with those less than or equal to 2 cm (pT1; P < .0001). A higher proportion of mastectomy specimens (61.4%) were concordant as compared with lumpectomy specimens (52.1%). Conclusion. Gross and microscopic tumor sizes were concordant in 56% of cases. Stage classification based on gross and microscopic tumor size was different in nearly one third (31.4%) of cases. Gross tumor size is critically important in accurate staging at least in cases where tumor size cannot be confirmed microscopically.	[Hamza, Ameer; Sakhi, Ramen; Alrajjal, Ahmed; Ibrar, Warda; Miller, Shelby; Salehi, Sajad; Edens, Jacob; Ockner, Daniel] St John Hosp & Med Ctr, 22101 Moross Rd, Detroit, MI 48236 USA	Hamza, A (reprint author), St John Hosp & Med Ctr, 22101 Moross Rd, Detroit, MI 48236 USA.	ameerhamza7@hotmail.com					Akazawa K, 2006, BREAST J, V12, P130, DOI 10.1111/j.1075-122X.2006.00220.x; Amano G, 2000, BREAST CANCER RES TR, V60, P43, DOI 10.1023/A:1006342711426; Amin MB, 2016, AJCC CANC STAGING MA; Bhattacharyya M, 2008, BRIT J CANCER, V98, P289, DOI 10.1038/sj.bjc.6604171; Blair S, 2006, J SURG ONCOL, V94, P220, DOI 10.1002/jso.20561; Bodini M, 2004, BREAST CANCER RES TR, V85, P211, DOI 10.1023/B:BREA.0000025409.69516.23; Bosch AM, 2003, EUR J RADIOL, V48, P285, DOI 10.1016/S0720-048X(03)00081-0; Bossuyt V, 2015, ANN ONCOL, V26, P1280, DOI 10.1093/annonc/mdv161; Cheung YC, 2004, ANN SURG ONCOL, V11, P756, DOI 10.1245/ASO.2004.12.008; Davis PL, 1996, BREAST CANCER RES TR, V37, P1, DOI 10.1007/BF01806626; de Widt-Levert LM, 2003, EUR J SURG ONCOL, V29, P216, DOI 10.1053/ejso.2002.1401; Edwards HD, 2013, AM J SURG PATHOL, V37, P739, DOI 10.1097/PAS.0b013e31828c63d0; Esserman L, 2001, ANN SURG ONCOL, V8, P549, DOI 10.1245/aso.2001.8.6.549; FEINSTEIN AR, 1985, NEW ENGL J MED, V312, P1604, DOI 10.1056/NEJM198506203122504; FORNAGE BD, 1987, CANCER, V60, P765, DOI 10.1002/1097-0142(19870815)60:4<765::AID-CNCR2820600410>3.0.CO;2-5; Galvis CO, 2001, AM J CLIN PATHOL, V116, P816; Hamza A, 2018, INT J SURG PATHOL, V26, P392, DOI 10.1177/1066896918755008; Hieken TJ, 2001, AM J SURG, V182, P351, DOI 10.1016/S0002-9610(01)00726-7; Kim HJ, 2007, ACTA ONCOL, V46, P996, DOI 10.1080/02841860701373587; Kumar S, 2014, J CLIN DIAGN RES, V8, pFC9, DOI 10.7860/JCDR/2014/7594.4283; Kuroki Yoshifumi, 2002, Magn Reson Med Sci, V1, P73, DOI 10.2463/mrms.1.73; Londero V, 2004, EUR RADIOL, V14, P1371, DOI 10.1007/s00330-004-2246-z; MADJAR H, 1993, ULTRASOUND OBST GYN, V3, P185, DOI 10.1046/j.1469-0705.1993.03030185.x; Moatamed NA, 2006, BREAST J, V12, P511, DOI 10.1111/j.1524-4741.2006.00338.x; Montemurro F, 2005, EUR RADIOL, V15, P1224, DOI 10.1007/s00330-005-2656-6; NCCN Clinical Practice Guidelines in Oncology, NCCN CLIN PRACT GUID; Partridge SC, 2002, AM J ROENTGENOL, V179, P1193, DOI 10.2214/ajr.179.5.1791193; Pritt B, 2005, HUM PATHOL, V36, P756, DOI 10.1016/j.humpath.2005.04.018; Rahman RL, 2009, AM J SURG, V197, P491, DOI 10.1016/j.amjsurg.2008.07.052; Rakha EA, 2009, EUR J CANCER, V45, P1162, DOI 10.1016/j.ejca.2008.12.002; Ramirez SI, 2012, AM SURGEON, V78, P440; Rosen EL, 2003, AM J ROENTGENOL, V181, P1275, DOI 10.2214/ajr.181.5.1811275; Segara D, 2007, J SURG ONCOL, V96, P474, DOI 10.1002/jso.20856; Shin S J, 2000, Am J Clin Pathol, V113, pS19; Tvedskov TF, 2011, EUR J CANCER, V47, P872, DOI 10.1016/j.ejca.2010.11.022; Varma S, 2014, ADV ANAT PATHOL, V21, P420, DOI 10.1097/PAP.0000000000000040; Wasif N, 2009, AM SURGEON, V75, P970; Weatherall PT, 2001, J MAGN RESON IMAGING, V13, P868, DOI 10.1002/jmri.1124; Yang WT, 1997, J ULTRAS MED, V16, P791; Zaidi M, 2014, INT J BREAST CANCER, DOI 10.1155/2014/121838	40	3	3	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	SEP	2018	26	6					494	499		10.1177/1066896918765663			6	Pathology; Surgery	Pathology; Surgery	GP6XS	WOS:000441033800002	29569502				2019-10-28	
J	Guo, L; DeRoche, TC; Salih, ZT; Qasem, SA				Guo, Ling; DeRoche, Tom C.; Salih, Ziyan T.; Qasem, Shadi A.			Routine Hematoxylin and Eosin Stain Is Specific for the Diagnosis of Cytomegalovirus Infection in Gastrointestinal Biopsy Specimens	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						CMV; viral inclusions; gastrointestinal; immunohistochemistry; hematoxylin and eosin	ACQUIRED-IMMUNODEFICIENCY-SYNDROME; TRANSPLANT RECIPIENTS; VIRUS-INFECTION; COLITIS; HYBRIDIZATION; TRACT; ENTERITIS; DISEASE; RISK	Background. Gastrointestinal cytomegalovirus (CMV) infection is a serious complication in immunocompromised patients; clinicians often expect expedited results for biopsy specimens. Our goal is to determine the accuracy of identification of CMV on hematoxylin and eosin (H&E) stain. Methods and Results. A total of 361 biopsy specimens from 273 patients with suspicion for CMV infection were retrieved. CMV was detected by immunohistochemistry (IHC) in 37 specimens acquired from 33 individual patients (average age = 54 years). Among the CMV-positive patients, 29 (88%) were reported to be immunosuppressed. Colon was the most common affected location. Of 37 CMV-positive specimens by IHC, 28 were positive by H&E (76%), 6 were negative (16%), and 3 were suspicious (8%). Of the 29 positive specimens on H&E, 28 were confirmed by IHC (97%) and 1 was indeterminate (3%). The sensitivity and specificity of H&E were 84% and 94%, respectively; the positive predictive value was 97%, and the negative predictive value was 93% (P < .00001). Conclusion. Our results show that a preliminary diagnosis of CMV infection, based on H&E stains, can be reported with high specificity and low risk for false-positive results. Suspicious cases should be deferred pending the result of IHC stains.	[Guo, Ling] Ohio State Univ, Columbus, OH 43210 USA; [DeRoche, Tom C.; Salih, Ziyan T.] Wake Forest Univ, Winston Salem, NC 27109 USA; [Qasem, Shadi A.] Univ Kentucky, Lexington, KY USA	Qasem, SA (reprint author), Univ Kentucky, Coll Med, Dept Pathol & Lab Med, 800 Rose St,MS 141, Lexington, KY 40506 USA.	s.qasem@uky.edu					ALEXANDER JA, 1988, TRANSPLANTATION, V46, P378, DOI 10.1097/00007890-198809000-00008; Bate SL, 2010, CLIN INFECT DIS, V50, P1439, DOI 10.1086/652438; BONACINI M, 1991, ARCH INTERN MED, V151, P1567, DOI 10.1001/archinte.151.8.1567; CHETTY R, 1994, J CLIN PATHOL, V47, P968, DOI 10.1136/jcp.47.11.968; CLAYTON F, 1989, ARCH PATHOL LAB MED, V113, P1124; COHEN EB, 1985, SURGERY, V97, P606; CULPEPPERMORGAN JA, 1987, AM J GASTROENTEROL, V82, P1264; FRANCIS ND, 1989, J CLIN PATHOL, V42, P1055, DOI 10.1136/jcp.42.10.1055; GOODGAME RW, 1993, ANN INTERN MED, V119, P924, DOI 10.7326/0003-4819-119-9-199311010-00010; GORENSEK MJ, 1988, J INFECT DIS, V157, P515, DOI 10.1093/infdis/157.3.515; GORENSEK MJ, 1988, J INFECT DIS, V158, P884, DOI 10.1093/infdis/158.4.884; Kalkan IH, 2010, TURK J GASTROENTEROL, V21, P83, DOI 10.4318/tjg.2010.0061; Lin Wey-Ran, 2005, Chang Gung Med J, V28, P476; Mccoy MH, 2014, HUM PATHOL, V45, P48, DOI 10.1016/j.humpath.2013.07.040; Minami M, 2007, WORLD J GASTROENTERO, V13, P754, DOI 10.3748/wjg.v13.i5.754; Monkemuller KE, 2000, AM J CLIN PATHOL, V114, P387; NANKERVIS GA, 1978, MED CLIN N AM, V62, P1021, DOI 10.1016/S0025-7125(16)31752-7; Peter A, 2004, CLIN TRANSPLANT, V18, P580, DOI 10.1111/j.1399-0012.2004.00230.x; RENE E, 1988, DIGEST DIS SCI, V33, P741, DOI 10.1007/BF01540440; RENE E, 1989, DIGEST DIS SCI, V34, P773, DOI 10.1007/BF01540353; SCHWARTZ DA, 1992, HUM PATHOL, V23, P1019, DOI 10.1016/0046-8177(92)90263-3; SURAWICZ CM, 1988, GASTROENTEROLOGY, V94, P194, DOI 10.1016/0016-5085(88)90630-0; Taylor GH, 2003, AM FAM PHYSICIAN, V67, P519; WU GD, 1989, AM J GASTROENTEROL, V84, P1517; Yoshida M, 1996, GASTROINTEST ENDOSC, V44, P482, DOI 10.1016/S0016-5107(96)70107-4	25	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	SEP	2018	26	6					500	506		10.1177/1066896918761601			7	Pathology; Surgery	Pathology; Surgery	GP6XS	WOS:000441033800003	29532684				2019-10-28	
J	Jeong, H; Jung, HR; Hwang, I; Kwon, SY; Choe, M; Kang, YN; Jung, E; Kim, SP				Jeong, Hasong; Jung, Hye Ra; Hwang, Ilseon; Kwon, Sun Young; Choe, Misun; Kang, Yu Na; Jung, Eunyoung; Kim, Sang Pyo			Diagnostic Accuracy of Combined Acetylcholinesterase Histochemistry and Calretinin Immunohistochemistry of Rectal Biopsy Specimens in Hirschsprung's Disease	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						diagnostic accuracy; rectal suction biopsies; acetylcholinesterase; calretinin; Hirschsprung's disease	SUCTION BIOPSIES; AGANGLIONOSIS; PATHOLOGY	Background. Acetylcholinesterase (AchE) histochemistry has been established as an accurate diagnostic tool for Hirschsprung's disease (HD). In addition, calretinin immunohistochemistry is also reported as a reliable and adjunctive method to diagnose HD. We investigated the diagnostic value of combined AchE histochemistry and calretinin immunohistochemistry in rectal suction biopsies from HD and non-HD patients. Methods. We retrospectively reviewed 99 rectal suction biopsy specimens including 4 repeat biopsies from 95 patients (34 HD and 61 non-HD). Each specimen was evaluated with hematoxylin-eosin, AchE histochemistry, and calretinin immunohistochemistry. Results. Of 95 patients, only 21 (22.1%) showed some ganglion cells. All 61 non-HD cases revealed no abnormal AchE-positive fibers. Of 34 HD patients, 32 exhibited abnormal AchE fibers, but 2 showed no stained fibers. None of the tissues from the HD patients exhibited calretinin immunoreactivity. Test sensitivity and specificity of AchE histochemistry alone were 93.5% and 100.0%, respectively, while calretinin immunohistochemistry were 100.0% and 85.2%, respectively. Conclusions. AchE histochemistry is a good diagnostic method for HD, if feasible, and a combination of AchE histochemistry and calretinin immunohistochemistry will help increase the accuracy of the diagnosis of HD.	[Jeong, Hasong; Jung, Hye Ra; Hwang, Ilseon; Kwon, Sun Young; Choe, Misun; Kang, Yu Na; Jung, Eunyoung; Kim, Sang Pyo] Keimyung Univ, Daegu, South Korea	Kim, SP (reprint author), Keimyung Univ, Dept Pathol, Sch Med, Dalsung Ro 56, Daegu, South Korea.	smkim5@kmu.ac.kr			Keimyung University Dongsan Medical Center	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the research promoting grant from the Keimyung University Dongsan Medical Center.	Agrawal RK, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0443-5; ATHOW AC, 1990, J PEDIATR SURG, V25, P520, DOI 10.1016/0022-3468(90)90564-P; BAIMBRIDGE KG, 1992, TRENDS NEUROSCI, V15, P303, DOI 10.1016/0166-2236(92)90081-I; Barshack I, 2004, J CLIN PATHOL, V57, P712, DOI 10.1136/jcp.2004.016030; BODIAN M, 1949, LANCET, V256, P6; CHOW CW, 1977, J PEDIATR SURG, V12, P675, DOI 10.1016/0022-3468(77)90392-X; Cinel L, 2015, PATHOL RES PRACT, V211, P50, DOI 10.1016/j.prp.2014.08.012; DEBRITO IA, 1987, J PEDIATR SURG, V22, P425, DOI 10.1016/S0022-3468(87)80262-2; Feichter S, 2009, SEMIN PEDIATR SURG, V18, P206, DOI 10.1053/j.sempedsurg.2009.07.002; Guinard-Samuel V, 2009, MODERN PATHOL, V22, P1379, DOI 10.1038/modpathol.2009.110; HAMOUDI AB, 1982, ARCH PATHOL LAB MED, V106, P670; Holland SK, 2011, ANN DIAGN PATHOL, V15, P323, DOI 10.1016/j.anndiagpath.2011.02.010; Kapur RR, 2009, PEDIATR DEVEL PATHOL, V12, P6, DOI 10.2350/08-02-0424.1; Kapur RP, 2009, SEMIN PEDIAT SURG, V18, P212, DOI 10.1053/j.sempedsurg.2009.07.003; KARNOVSKY MJ, 1964, J HISTOCHEM CYTOCHEM, V12, P219, DOI 10.1177/12.3.219; Knowles CH, 2010, GUT, V59, P882, DOI 10.1136/gut.2009.200444; Lim KH, 2014, WORLD J PATHOL, V3, P14; Martucciello Giuseppe, 2005, J Pediatr Surg, V40, P1527, DOI 10.1016/j.jpedsurg.2005.07.053; Meier-Ruge W, 2008, HIRSCHSPRUNGS DIS AL, P185; MEIERRUG.W, 1972, J PEDIATR SURG, V7, P11, DOI 10.1016/0022-3468(72)90394-6; Monforte-Munoz H, 1998, ARCH PATHOL LAB MED, V122, P721; Montedonico S, 2008, PEDIATR SURG INT, V24, P785, DOI 10.1007/s00383-008-2173-1; Moore SW, 2005, PEDIATR SURG INT, V21, P255, DOI 10.1007/s00383-005-1383-z; NOBLETT HR, 1969, J PEDIATR SURG, V4, P406, DOI 10.1016/0022-3468(69)90606-X; Park Woo Hyun, 1992, Journal of Korean Medical Science, V7, P353; Qualman SJ, 1999, PEDIATR DEVEL PATHOL, V2, P588, DOI 10.1007/s100249900167; Santos MM, 2008, PEDIATR SURG INT, V24, P715, DOI 10.1007/s00383-008-2141-9; SCHOFIELD DE, 1990, J PEDIATR GASTR NUTR, V11, P221, DOI 10.1097/00005176-199008000-00012; Takawira C, 2015, J PEDIATR GASTR NUTR, V60, P598, DOI 10.1097/MPG.0000000000000679; Lourencao PLTD, 2013, ANN DIAGN PATHOL, V17, P352, DOI 10.1016/j.anndiagpath.2013.04.004; WALTERS JRF, 1993, GASTROENTEROLOGY, V104, P1381, DOI 10.1016/0016-5085(93)90346-E; Yang WI, 2013, J PEDIATR SURG, V48, P2112, DOI 10.1016/j.jpedsurg.2013.02.067; ZUELZER WW, 1948, AM J DIS CHILD, V75, P40	33	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	SEP	2018	26	6					507	513		10.1177/1066896918761235			7	Pathology; Surgery	Pathology; Surgery	GP6XS	WOS:000441033800004	29532690				2019-10-28	
J	Cardili, L; Viana, CR; Germano, A; Fernandes, M; Barcellos, D; Landman, G				Cardili, Leonardo; Viana, Cristiano Ribeiro; Germano, Andressa; Fernandes, Mariana; Barcellos, Denise; Landman, Gilles			Immunoexpression of BAP1, ROS1, and ALK in Spitzoid Melanocytic Tumors	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						spitzoid; melanocytic; BAP1; ROS1; ALK	EXPRESSION; NEOPLASMS; MUTATION; FEATURES; MELANOMA; PREDISPOSES; FUSIONS; NTRK1; BRAF	Background. Spitzoid tumors are a heterogeneous group of melanocytic neoplasms that frequently imposes diagnostic difficulties. Lately, several advances in molecular biology afforded significant discoveries on the pathogenesis of these tumors. BAP1 (BRCA-1 associated protein-1) inactivation and anomalous expression of kinase translocation-related proteins are among the main criteria launched by new classification proposals. Our aim was to systematically assess the immunoexpression of BAP1, ROS1 (receptor tyrosine kinase c-Ros oncogene 1), and ALK (anaplastic lymphoma receptor tyrosine kinase) proteins in an unpublished series of spitzoid tumors. Methods. Retrospective study based on 47 formalin-fixed paraffin-embedded tissue samples from 3 different institutions. BAP1, ROS1, and ALK immunostains were performed in all cases. We included 27 Spitz tumors without significant abnormality, 15 atypical spitzoid tumors, and 5 spitzoid melanomas. Results. We observed loss of BAP1 nuclear immunolabeling in 4.3% of evaluable cases (2/46), both of them atypical spitzoid tumors. The proportional frequency of BAP1-inactivated cases among atypical spitzoid tumors was 14.2% (2/14). No immunoexpression of ROS1 or ALK was found. Conclusions. Our study revealed 2 additional BAP1-inactived cases and described its respective frequency. The absence of anomalous expression of translocation-related proteins ALK and ROS1 in this series, composed predominantly of low-grade/low-risk tumors, indicates that translocated spitzoid lesions may not be as prevalent as initially suggested, at least in some populations. Furthermore, our findings encourage additional investigation on unequal occurrence of such immunomarkers among different diagnostic categories of spitzoid neoplasms.	[Cardili, Leonardo] Inst Canc Estado Sao Paulo, Sao Paulo, Brazil; [Cardili, Leonardo; Germano, Andressa; Fernandes, Mariana; Barcellos, Denise; Landman, Gilles] Univ Fed Sao Paulo, Sao Paulo, Brazil; [Viana, Cristiano Ribeiro] Hosp Canc Barretos, Fundacao Pio 12, Barretos, Brazil	Cardili, L (reprint author), R Botucatu,740 Ed Lemos Torres,1st Floor, BR-04023900 Sao Paulo, SP, Brazil.	leonardo.cardili@gmail.com	LANDMAN, GILLES/D-5071-2012; Barcelos, Denise/I-1368-2012	LANDMAN, GILLES/0000-0001-7441-3068; Barcelos, Denise/0000-0002-4010-4109	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2014/21860-0]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was partially funded by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) through Grant 2014/21860-0.	Abdel-Rahman MH, 2011, J MED GENET, V48, P856, DOI 10.1136/jmedgenet-2011-100156; Amin SM, 2017, AM J SURG PATHOL, V41, P491, DOI 10.1097/PAS.0000000000000761; Barnhill RL, 2006, MODERN PATHOL, V19, pS21, DOI 10.1038/modpathol.3800519; Bastian BC, 2014, ANNU REV PATHOL-MECH, V9, P239, DOI 10.1146/annurev-pathol-012513-104658; Busam KJ, 2014, AM J SURG PATHOL, V38, P925, DOI 10.1097/PAS.0000000000000187; Busam KJ, 2013, AM J SURG PATHOL, V37, P193, DOI 10.1097/PAS.0b013e318263648c; Capper D, 2011, ACTA NEUROPATHOL, V122, P11, DOI 10.1007/s00401-011-0841-z; Carbone M, 2013, NAT REV CANCER, V13, P153, DOI 10.1038/nrc3459; Carbone M, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-179; Farley MN, 2013, MOL CANCER RES, V11, P1061, DOI 10.1158/1541-7786.MCR-13-0111; Gammon B, 2013, J CUTAN PATHOL, V40, P538, DOI 10.1111/cup.12133; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Kiuru M, 2016, INT J SURG PATHOL, V24, P200, DOI 10.1177/1066896916630375; Lee CY, 2017, AM J DERMATOPATH, V39, P181, DOI 10.1097/DAD.0000000000000629; Liu CH, INT J SURG PATHOL, DOI [10.20944/preprints201703.0167.v1, DOI 10.20944/PREPRINTS201703.0167.V1]; Pins A, 2015, HUM PATHOL, V46, P239, DOI 10.1016/j.humpath.2014.10.015; Rand AJ, 2018, J CUTAN PATHOL, V45, P136, DOI 10.1111/cup.13057; Requena C, 2015, J CUTAN PATHOL, V42, P564, DOI 10.1111/cup.12519; Tetzlaff MT, 2017, CLIN LAB MED, V37, P431, DOI 10.1016/j.cll.2017.05.003; Ventii KH, 2008, CANCER RES, V68, P6953, DOI 10.1158/0008-5472.CAN-08-0365; Wiesner T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4116; Wiesner T, 2012, AM J SURG PATHOL, V36, P818, DOI 10.1097/PAS.0b013e3182498be5; Wiesner T, 2011, NAT GENET, V43, P1018, DOI 10.1038/ng.910; Yeh I, 2015, AM J SURG PATHOL, V39, P581, DOI 10.1097/PAS.0000000000000387	24	0	1	1	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	SEP	2018	26	6					514	520		10.1177/1066896918768089			7	Pathology; Surgery	Pathology; Surgery	GP6XS	WOS:000441033800005	29623743				2019-10-28	
J	Kokohaare, EK; Riva, FMG; Bernstein, JM; Miah, AB; Thway, K				Kokohaare, Eva Kolson; Riva, Francesco M. G.; Bernstein, Jonathan M.; Miah, Aisha B.; Thway, Khin			Malignant Solitary Fibrous Tumor Metastatic to Widely Invasive Hurthle Cell Thyroid Carcinoma: A Distinct Tumor-to-Tumor Metastasis	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						malignant solitary fibrous tumor; dedifferentiated solitary fibrous tumor; follicular carcinoma; Hurthle cell carcinoma; NAB2-STAT6; metastasis; sarcoma; STAT6; thyroid	EXPRESSION; MIMICS	We illustrate a case of synchronous malignant solitary fibrous tumor of the thoracic cavity, and widely invasive thyroid Hurthle cell carcinoma. The Hurthle cell carcinoma was found to harbor distinct areas of malignant solitary fibrous tumor. This is a unique case of tumor-to-tumor metastasis that, to the best of our knowledge, has not been previously reported.	[Kokohaare, Eva Kolson; Riva, Francesco M. G.; Bernstein, Jonathan M.; Miah, Aisha B.; Thway, Khin] Royal Marsden NHS Fdn Trust, London, England; [Bernstein, Jonathan M.] Imperial Coll London, London, England; [Thway, Khin] Inst Canc Res, London, England	Thway, K (reprint author), Royal Marsden NHS Fdn Trust, Sarcoma Unit, 203 Fulham Rd, London SW3 6JJ, England.	khin.thway@rmh.nhs.uk			NIHR Royal Marsden/ICR Biomedical Research Centre	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: We acknowledge support from the NIHR Royal Marsden/ICR Biomedical Research Centre.	Cheah AL, 2014, PATHOLOGY, V46, P389, DOI 10.1097/PAT.0000000000000122; Dagrada GP, 2015, MODERN PATHOL, V28, P1074, DOI 10.1038/modpathol.2015.70; Doyle LA, 2014, MODERN PATHOL, V27, P390, DOI 10.1038/modpathol.2013.164; Ricciuti B, 2016, TUMORI S2, V102, DOI [10.5301/tj.5000514., DOI 10.5301/TJ.5000514.]; Schneider N, 2017, INT J SURG PATHOL, V25, P58, DOI 10.1177/1066896916650257; Thway K, 2016, INT J SURG PATHOL, V24, P281, DOI 10.1177/1066896915627485; Yoshida A, 2014, AM J SURG PATHOL, V38, P552, DOI 10.1097/PAS.0000000000000137	7	0	0	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	SEP	2018	26	6					521	524		10.1177/1066896918767321			4	Pathology; Surgery	Pathology; Surgery	GP6XS	WOS:000441033800006	29616597				2019-10-28	
J	Kokohaare, EK; Strauss, DC; Jones, RL; Thway, K				Kokohaare, Eva Kolson; Strauss, Dirk C.; Jones, Robin L.; Thway, Khin			Endometrial Stromal Sarcoma With Hyalinizing Giant Rosettes, Mimicking Low-Grade Fibromyxoid Sarcoma	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						endometrial stromal sarcoma; collagenous rosettes; JAZF1-SUZ12; hyalinizing spindle cell tumor with giant rosettes; low-grade fibromyxoid sarcoma; mimic; sarcoma	UTERUS	We highlight a rare variant pattern of low-grade endometrial stromal sarcoma showing extensive collagenous rosette formation, closely mimicking low-grade fibromyxoid sarcoma. Additionally, this neoplasm showed diffuse and strong expression of muscle markers, favoring an initial diagnosis of leiomyosarcoma. Reverse transcription-polymerase chain reaction showed the presence of JAZF1-SUZ12 fusion transcripts, and this highlights the broad morphologic and immunophenotypic spectrum of endometrial stromal sarcoma.	[Kokohaare, Eva Kolson; Strauss, Dirk C.; Jones, Robin L.; Thway, Khin] Royal Marsden Hosp, London, England; [Jones, Robin L.; Thway, Khin] Inst Canc Res, London, England	Thway, K (reprint author), Royal Marsden NHS Fdn Trust, Sarcoma Unit, 203 Fulham Rd, London SW3 6JJ, England.	khin.thway@rmh.nhs.uk			NIHR Royal Marsden/ICR Biomedical Research Centre	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: We acknowledge support from the NIHR Royal Marsden/ICR Biomedical Research Centre.	Cady FM, 2006, INT J SURG PATHOL, V14, P326, DOI 10.1177/1066896906291537; Doyle LA, 2011, AM J SURG PATHOL, V35, P733, DOI 10.1097/PAS.0b013e318210c268; Dundr P, 2012, Cesk Patol, V48, P103; EVANS HL, 1982, CANCER-AM CANCER SOC, V50, P2170, DOI 10.1002/1097-0142(19821115)50:10<2170::AID-CNCR2820501033>3.0.CO;2-K; Mohamed M, 2017, ANN DIAGN PATHOL, V28, P60, DOI 10.1016/j.anndiagpath.2017.04.001; Oliva E, 1998, AM J SURG PATHOL, V22, P997, DOI 10.1097/00000478-199808000-00010	6	0	0	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	SEP	2018	26	6					525	527		10.1177/1066896918767547			3	Pathology; Surgery	Pathology; Surgery	GP6XS	WOS:000441033800007	29623744				2019-10-28	
J	DeRoche, TC; Huber, AR				DeRoche, Tom C.; Huber, Aaron R.			The Great Imitator: Syphilis Presenting as an Inflammatory Pseudotumor of Liver	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Editorial Material									[DeRoche, Tom C.] Kaiser Airport Way Reg Lab, Portland, OR USA; [Huber, Aaron R.] Univ Rochester, Med Ctr, Rochester, NY 14642 USA	Huber, AR (reprint author), Univ Rochester, Med Ctr, Dept Pathol & Lab Med, 601 Elmwood Dr,Box 626, Rochester, NY 14642 USA.	aaron_huber@urmc.rochester.edu					Carlson JA, 2011, AM J DERMATOPATH, V33, P433, DOI 10.1097/DAD.0b013e3181e8b587; Hagen CE, 2014, AM J SURG PATHOL, V38, P1636, DOI 10.1097/PAS.0000000000000264; Makhlouf H, 2011, MOD PATHOL S1, V23, p364A; Zen Y, 2007, MODERN PATHOL, V20, P884, DOI 10.1038/modpathol.3800836	4	0	0	1	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	SEP	2018	26	6					528	529		10.1177/1066896917745665			2	Pathology; Surgery	Pathology; Surgery	GP6XS	WOS:000441033800008	29198144				2019-10-28	
J	Akagi, NE; Jorns, JM				Akagi, Naomi E.; Jorns, Julie M.			Glycogen-Rich Clear Cell Carcinoma: A Rare Variant of Breast Carcinoma of Uncertain Significance	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Editorial Material									[Akagi, Naomi E.; Jorns, Julie M.] Med Coll Wisconsin, Milwaukee, WI 53226 USA	Jorns, JM (reprint author), Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA.	jjorns@mcw.edu					Ma XM, 2014, BREAST J, V20, P166, DOI 10.1111/tbj.12231; Markopoulos C, 2008, WORLD J SURG ONCOL, V6, DOI 10.1186/1477-7819-6-44; Ratti Vilma, 2015, Case Rep Oncol, V8, P472, DOI 10.1159/000441838; Yerushalmi R, 2009, ANN ONCOL, V20, P1763, DOI 10.1093/annonc/mdp245	4	0	0	2	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	SEP	2018	26	6					530	531		10.1177/1066896917748743			2	Pathology; Surgery	Pathology; Surgery	GP6XS	WOS:000441033800009	29254403				2019-10-28	
J	Penuela, L; Villaggio, B; Raiteri, R; Fiocca, R; Vellone, VG				Penuela, Leonardo; Villaggio, Barbara; Raiteri, Roberto; Fiocca, Roberto; Vellone, Valerio Gaetano			Kidney Ultrastructure by Atomic Force Microscopy Imaging Directly From Formalin Fixed-Paraffin Embedded Biopsy: Is This a Dream Come True?	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Editorial Material									[Penuela, Leonardo; Villaggio, Barbara; Raiteri, Roberto; Fiocca, Roberto; Vellone, Valerio Gaetano] Univ Genoa, Genoa, Italy; [Penuela, Leonardo] Ist Giannina Gaslini, Genoa, Italy; [Villaggio, Barbara; Fiocca, Roberto; Vellone, Valerio Gaetano] San Martino Hosp, Genoa, Italy	Vellone, VG (reprint author), Univ Genoa, Dept Integrated Surg & Diagnost Sci DISC, Via Toni 14, I-16132 Genoa, Italy.	valerio.vellone@unige.it	Vellone, Valerio Gaetano/A-4342-2018; Vellone, Valerio Gaetano/M-6139-2019	Vellone, Valerio Gaetano/0000-0002-5107-1584; Vellone, Valerio Gaetano/0000-0002-5107-1584			Penuela L, 2014, J BIOMECH, V47, P2157, DOI 10.1016/j.jbiomech.2013.10.056; Tiribilli B, 2005, ULTRAMICROSCOPY, V102, P227, DOI 10.1016/j.ultramic.2004.10.003	2	1	1	1	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	SEP	2018	26	6					532	533		10.1177/1066896917749930			2	Pathology; Surgery	Pathology; Surgery	GP6XS	WOS:000441033800010	29278966				2019-10-28	
J	Kumar, R; Joshi, R; Rohilla, M; Jain, V				Kumar, Rajesh; Joshi, Rasmi; Rohilla, Manish; Jain, Vanita			Simultaneous Mature Cystic Teratoma and Hydatid Cyst in a Young Female: An Unusual Coincidence	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Editorial Material							EXPERIENCE; DISEASE		[Kumar, Rajesh; Joshi, Rasmi; Rohilla, Manish; Jain, Vanita] Postgrad Inst Med Educ & Res, Chandigarh, India	Rohilla, M (reprint author), Postgrad Inst Med Educ & Res, Dept Cytol & Gynaec Pathol, Chandigarh 160012, India.	rohillamanishpgi@gmail.com					BICKERS WM, 1970, AM J OBSTET GYNECOL, V107, P477, DOI 10.1016/0002-9378(70)90580-6; Dziri C, 2001, WORLD J SURG, V25, P1, DOI 10.1007/s002680020000; McManus DP, 2003, LANCET, V362, P1295, DOI 10.1016/S0140-6736(03)14573-4; Mehra B R, 2007, Singapore Med J, V48, pe284; Milingos S, 2004, J AM ASSOC GYN LAP, V11, P478, DOI 10.1016/S1074-3804(05)60079-5; Shalev E, 1998, HUM REPROD, V13, P1810, DOI 10.1093/humrep/13.7.1810	6	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	SEP	2018	26	6					534	535		10.1177/1066896917751045			2	Pathology; Surgery	Pathology; Surgery	GP6XS	WOS:000441033800011	29295660				2019-10-28	
J	Jamal, M; Taneja, K; Arora, S; Barod, R; Rogers, CG; Sanchez, J; Gupta, NS; Williamson, SR				Jamal, Mohsin; Taneja, Kanika; Arora, Sohrab; Barod, Ravi; Rogers, Craig G.; Sanchez, Jessica; Gupta, Nilesh S.; Williamson, Sean R.			Chromophobe Renal Cell Carcinoma With Retrograde Venous Invasion and Gain of Chromosome 21: Potential Harbingers of Aggressive Clinical Behavior	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						kidney neoplasms; chromophobe renal cell carcinoma; kidney cancer staging; vascular invasion; retrograde venous invasion	ONCOCYTOMA; EXTENSION; FEATURES; SINUS; VEIN	Occasionally, renal cell carcinoma (RCC) with renal vein extension spreads against the flow of blood within vein branches into the kidney, forming multifocal nodules throughout the renal parenchyma. These foci are not regarded as multiple tumors but rather reverse spread of tumor along the venous system. This intravascular spread has previously been reported in clear cell RCC and RCC unclassified. However, to our knowledge, this has never been reported in chromophobe RCC. Chromophobe RCC is a unique histologic subtype of renal cancer, generally thought to have less aggressive behavior. However, it nonetheless has the potential to undergo sarcomatoid dedifferentiation, which is associated with poor prognosis. We report a unique case of a 65-year-old man with chromophobe RCC (pT3a) showing classic morphology (nonsarcomatoid), yet presenting with retrograde venous invasion and hilar lymph node metastasis at the time of right radical nephrectomy. Fluorescence in situ hybridization revealed gain of chromosome 21 with loss of multiple other chromosomes. Partial hepatectomy was performed to resect metastatic RCC 7 months after nephrectomy, revealing chromophobe RCC with classic morphology. Bone biopsy confirmed skeletal metastases 38 months after initial diagnosis. Although invasion of the renal vein and retrograde venous invasion are characteristically seen in clear cell RCC, this unusual phenomenon may also occur in chromophobe RCC, despite its unique tumor biology. This and gain of chromosome 21, which was postulated to be associated with aggressive behavior in a previous report, were associated with adverse behavior in our patient, who had short-term progression to multi-organ metastatic disease.	[Jamal, Mohsin; Taneja, Kanika; Arora, Sohrab; Barod, Ravi; Rogers, Craig G.; Sanchez, Jessica; Gupta, Nilesh S.; Williamson, Sean R.] Henry Ford Hlth Syst, Detroit, MI USA; [Williamson, Sean R.] Wayne State Univ, Detroit, MI USA; [Barod, Ravi] Royal Free London NHS Fdn Trust, London, England	Williamson, SR (reprint author), Henry Ford Hosp, Dept Pathol K6, 2799 West Grand Blvd, Detroit, MI 48202 USA.	swilli25@hfhs.org		Williamson, Sean/0000-0002-3898-1460			Abbosh P, EUR UROL FOCUS, DOI [10.1016/j.euf.2017.01.003., DOI 10.1016/J.EUF.2017.01.003.]; Amin MB, 2008, AM J SURG PATHOL, V32, P1822, DOI 10.1097/PAS.0b013e3181831e68; Bonsib SM, 2005, J UROLOGY, V174, P1199, DOI 10.1097/01.ju.0000173631.01329.1f; Bonsib SM, 2004, AM J SURG PATHOL, V28, P1594, DOI 10.1097/00000478-200412000-00007; Bonsib SM, 2007, MODERN PATHOL, V20, P44, DOI 10.1038/modpathol.3800726; Bonsib SM, 2011, MODERN PATHOL, V24, P1578, DOI 10.1038/modpathol.2011.124; Cindolo L, 2005, UROLOGY, V65, P681, DOI 10.1016/j.urology.2004.11.005; Davis CF, 2014, CANCER CELL, V26, P319, DOI 10.1016/j.ccr.2014.07.014; Frees S, 2016, UROLOGY, V98, P81, DOI 10.1016/j.urology.2016.05.048; Hes O, 2008, VIRCHOWS ARCH, V452, P193, DOI 10.1007/s00428-007-0541-1; Klatte T, 2008, UROL ONCOL-SEMIN ORI, V26, P604, DOI 10.1016/j.urolonc.2007.07.015; Kuroda N, 2011, MED MOL MORPHOL, V44, P168, DOI 10.1007/s00795-009-0467-6; Larkin JMG, 2011, J CLIN ONCOL, V29, pE241, DOI 10.1200/JCO.2010.33.4375; Leibovich BC, 2010, J UROLOGY, V183, P1309, DOI 10.1016/j.juro.2009.12.035; Malouf GG, 2016, EUR UROL, V70, P348, DOI 10.1016/j.eururo.2016.01.051; Paner G, 2016, WHO CLASSIFICATION T, V4, P27; Przybycin CG, 2011, AM J SURG PATHOL, V35, P962, DOI 10.1097/PAS.0b013e31821a455d; Trpkov K, 2013, AM J SURG PATHOL, V37, P1505, DOI 10.1097/PAS.0b013e31829a85d0; Trpkov K, 2010, HISTOPATHOLOGY, V57, P893, DOI 10.1111/j.1365-2559.2010.03726.x; Williamson SR, 2017, HUM PATHOL, V63, P149, DOI 10.1016/j.humpath.2017.03.004; Williamson SR, 2016, INT J SURG PATHOL, V24, P625, DOI 10.1177/1066896916648382; Wobker SE, 2017, J KIDNEY CANCER VHL, V4, P1, DOI 10.15586/jkcvhl.2017.96; Wobker SE, 2016, HUM PATHOL, V58, P1, DOI 10.1016/j.humpath.2016.07.020	23	1	1	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	SEP	2018	26	6					536	541		10.1177/1066896918763948			6	Pathology; Surgery	Pathology; Surgery	GP6XS	WOS:000441033800012	29560759				2019-10-28	
J	Chua, D; Chiow, AKH; Ang, TL; Wang, LM				Chua, Darren; Chiow, Adrian Kah Heng; Ang, Tiing Leong; Wang, Lai Mun			Malignant Transformation Arising Within Unusual and Rare Hepatic Lesions: Fibropolycystic Disease Form of Ductal Plate Malformation and Biliary Adenofibroma	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						cholangiocarcinoma; ductal plate malformation; biliary adenofibroma; precursor lesions; hepatobiliary	LIVER-DISEASE; TUMOR; CHOLANGIOCARCINOMA; FEATURES; RISK; CT	Cholangiocarcinoma is the second most common hepatobiliary cancer following hepatocellular carcinoma, and 20% to 25% are intrahepatic. We describe 2 cases of intrahepatic cholangiocarcinoma arising within unusual and rare hepatic lesions, fibropolycystic liver disease form of ductal plate malformation and biliary adenofibroma, whose association with malignancy is rarely reported in the literature.	[Chua, Darren; Chiow, Adrian Kah Heng; Ang, Tiing Leong; Wang, Lai Mun] Changi Gen Hosp SingHlth, Singapore, Singapore; [Wang, Lai Mun] Univ Oxford, Nuffield Dept Med, Ludwig Inst, Oxford, England	Wang, LM (reprint author), Changi Gen Hosp, Dept Lab Med, 2 Simei St 3, Singapore 529889, Singapore.	Lai_Mun_Wang@cgh.com.sg					Akin O, 2002, AM J ROENTGENOL, V179, P280, DOI 10.2214/ajr.179.1.1790280; Arnason T, 2017, AM J SURG PATHOL, V41, P499, DOI 10.1097/PAS.0000000000000773; Awasthi A, 2004, HISTOPATHOLOGY, V45, P260, DOI 10.1111/j.1365-2559.2004.01945.x; Bergquist A, 2002, J HEPATOL, V36, P321, DOI 10.1016/S0168-8278(01)00288-4; Bhalla A, 2017, HUM PATHOL, V67, P217, DOI 10.1016/j.humpath.2017.08.004; Brancatelli G, 2005, RADIOGRAPHICS, V25, P659, DOI 10.1148/rg.253045114; Burak K, 2004, AM J GASTROENTEROL, V99, P523, DOI 10.1111/j.1572-0241.2004.04067.x; de Groen PC, 1999, NEW ENGL J MED, V341, P1368, DOI 10.1056/NEJM199910283411807; de Groen PC, 2000, HEPATOLOGY, V31, P247, DOI 10.1002/hep.510310137; DESMET VJ, 1992, HEPATOLOGY, V16, P1069, DOI 10.1002/hep.1840160434; Elpek GO, 2016, TURK J PATHOL, V32, P60, DOI 10.5146/tjpath.2015.01331; Garduno-Lopez AL, 2002, CLIN TRANSL ONCOL, V4, P271; Godambe A, 2016, CASE REP PATHOL, DOI 10.1155/2016/8068513; Gurrera Alessandra, 2010, Patholog Res Int, V2010, P504584, DOI 10.4061/2010/504584; Haberal AN, 2001, TURK J GASTROENTEROL, V12, P149; Kai K, 2012, PATHOL INT, V62, P506, DOI 10.1111/j.1440-1827.2012.02830.x; Kaminsky P, 2017, HEPATOLOGY, V65, P380, DOI 10.1002/hep.28818; Khan SA, 2005, LANCET, V366, P1303, DOI 10.1016/S0140-6736(05)67530-7; Khan SA, 2002, GUT, V51, P1; Kwon JH, 2014, KOREAN J RADIOL, V15, P54, DOI 10.3348/kjr.2014.15.1.54; LEE YM, 1995, NEW ENGL J MED, V332, P924, DOI 10.1056/NEJM199504063321406; LIPSETT PA, 1994, ANN SURG, V220, P644, DOI 10.1097/00000658-199411000-00007; Nguyen NT, 2012, CASE REPORTS HEPATOL, V2012; Parada LA, 1997, CANCER GENET CYTOGEN, V93, P183, DOI 10.1016/S0165-4608(96)00224-5; TAGUCHI J, 1993, ARCH PATHOL LAB MED, V117, P944; Thai E, 2016, PATHOL RES PRACT, V212, P468, DOI 10.1016/j.prp.2015.12.015; Thompson SM, 2016, J GASTROINTEST ONCOL, V7, pE107, DOI 10.21037/jgo.2016.09.14; TSUI WMS, 1993, AM J SURG PATHOL, V17, P186, DOI 10.1097/00000478-199302000-00010; Tsutsui A, 2014, CLIN J GASTROENTEROL, V7, P441, DOI 10.1007/s12328-014-0523-1; Varnholt H, 2003, AM J SURG PATHOL, V27, P693, DOI 10.1097/00000478-200305000-00014; Veigel MC, 2009, PEDIATR RADIOL, V39, P317, DOI 10.1007/s00247-008-1070-z; Venkatanarasimha N, 2011, CLIN RADIOL, V66, P1086, DOI 10.1016/j.crad.2011.05.008; Watanapa P, 2002, BRIT J SURG, V89, P962, DOI 10.1046/j.1365-2168.2002.02143.x; Yeung Yuk Pang, 2003, J Hepatobiliary Pancreat Surg, V10, P390, DOI 10.1007/s00534-002-0837-0	34	1	1	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	SEP	2018	26	6					542	550		10.1177/1066896918758172			9	Pathology; Surgery	Pathology; Surgery	GP6XS	WOS:000441033800013	29464972				2019-10-28	
J	Madelung, AB; Detlefsen, S				Madelung, Ann Brinch; Detlefsen, Soenke			Synchronous Pancreatic Serous Cystic Neoplasm and Duodenal Neuroendocrine Tumor: Case Report and Review of the Literature	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Review						pancreatic cystic tumor; serous cystic neoplasm; duodenal tumor; neuroendocrine neoplasm	HIPPEL-LINDAU-DISEASE; ISLET-CELL TUMOR; MICROCYSTIC ADENOMA; ENDOCRINE TUMOR; CYSTADENOMA; ASSOCIATION; COEXISTENT; CLASSIFICATION; INVOLVEMENT; CARCINOMA	Simultaneous presence of pancreatic serous cystic neoplasms and neuroendocrine neoplasms is rare. We present a case with the incidental finding of a duodenal neuroendocrine tumor (NET) with 2 lymph node metastases in a Whipple resection specimen performed to remove a pancreatic cystic neoplasm that postoperatively turned out to represent a serous cystic neoplasm (SCN). The patient was a 75-year-old female. She presented with loss of appetite and weight. Preoperative contrast-enhanced computed tomography scan of the abdomen showed a multicystic lesion in the head of pancreas. On histologic examination of the resection specimen, a pancreatic SCN was found, and in addition in 2 peripancreatic lymph nodes, metastases from a NET. Further examination of the resected specimen revealed a duodenal NET. Review of the literature revealed only one prior study with 4 cases of pancreatic SCN associated with a duodenal NET. In 1 of the 4 cases, the patient had von Hippel-Lindau disease. Our report emphasizes the importance of careful examination of pancreatic resection specimens including the peripancreatic lymph nodes also when dealing with SCNs, as coexisting and more malignant tumors may otherwise be missed.	[Madelung, Ann Brinch; Detlefsen, Soenke] Odense Univ Hosp, Dept Pathol, JB Winslows Vej 15, DK-5000 Odense C, Denmark	Madelung, AB (reprint author), Odense Univ Hosp, Dept Pathol, JB Winslows Vej 15, DK-5000 Odense C, Denmark.	ann.brinch.madelung@rsyd.dk					Agarwal N, 2009, J PANCREAS, V10, P55; Alasio Teresa M, 2005, Ann Diagn Pathol, V9, P234; ALPERT LC, 1988, AM J SURG PATHOL, V12, P251, DOI 10.1097/00000478-198804000-00001; Alzaraa Ahmed, 2007, World J Surg Oncol, V5, P103, DOI 10.1186/1477-7819-5-103; Baek SY, 2000, BRIT J RADIOL, V73, P83, DOI 10.1259/bjr.73.865.10721327; Blandamura S, 2007, J CLIN PATHOL, V60, P278, DOI 10.1136/jcp.2006.036954; De Marchi G, 2016, J GASTROINTEST ONCOL, V7, pE52, DOI 10.21037/jgo.2016.01.04; Del Chiaro M, 2013, DIGEST LIVER DIS, V45, P703, DOI 10.1016/j.dld.2013.01.010; Galanis C, 2007, J GASTROINTEST SURG, V11, P820, DOI 10.1007/s11605-007-0157-4; Goh BKP, 2006, DIGEST DIS SCI, V51, P422, DOI 10.1007/s10620-006-3147-6; Gucer H, 2013, VIRCHOWS ARCH, V463, P593, DOI 10.1007/s00428-013-1465-6; Hammel PR, 2000, GASTROENTEROLOGY, V119, P1087, DOI 10.1053/gast.2000.18143; HERESBACH D, 1993, GASTROEN CLIN BIOL, V17, P968; HOUGH DM, 1994, AM J ROENTGENOL, V162, P1091, DOI 10.2214/ajr.162.5.8165988; Hsieh MS, 2009, J FORMOS MED ASSOC, V108, P739, DOI 10.1016/S0929-6646(09)60399-5; Igarashi H, 2014, J GASTROENTEROL, V49, P511, DOI 10.1007/s00535-013-0794-1; Jais B, 2016, GUT, V65, P305, DOI 10.1136/gutjnl-2015-309638; Jung HK, 2001, J CLIN GASTROENTEROL, V32, P441, DOI 10.1097/00004836-200105000-00018; Kakkar A, 2016, PATHOL RES PRACT, V212, P747, DOI 10.1016/j.prp.2016.04.008; Keel SB, 1996, AM J SURG PATHOL, V20, P471, DOI 10.1097/00000478-199604000-00010; Kim SW, 2017, HUM PATHOL, V60, P104, DOI 10.1016/j.humpath.2016.10.011; Kim Youn Wha, 1997, Journal of Korean Medical Science, V12, P469; Kimura W, 2012, PANCREAS, V41, P380, DOI 10.1097/MPA.0b013e31822a27db; Kloppel G, 2010, WHO CLASSIFICATION T, P92; Kosmahl M, 2004, VIRCHOWS ARCH, V445, P168, DOI 10.1007/s00428-004-1043-z; Le Borgne J, 1999, ANN SURG, V230, P152, DOI 10.1097/00000658-199908000-00004; Liu HY, 2012, ANN CLIN LAB SCI, V42, P109; Matsubayashi Hiroyuki, 2010, J Gastrointest Cancer, V41, P197, DOI 10.1007/s12029-010-9134-3; Mohan H, 2007, J PANCREAS, V8, P453; Mohr VH, 2000, AM J PATHOL, V157, P1615, DOI 10.1016/S0002-9440(10)64799-2; MONTAG AG, 1990, AM J SURG PATHOL, V14, P352, DOI 10.1097/00000478-199004000-00006; PERSAUD V, 1971, ARCH PATHOL, V92, P28; POSNIAK HV, 1991, CLIN IMAG, V15, P220, DOI 10.1016/0899-7071(91)90083-8; Reid MD, 2015, AM J SURG PATHOL, V39, P1597, DOI 10.1097/PAS.0000000000000559; Sandvik OM, 2016, BRIT J SURG, V103, P226, DOI 10.1002/bjs.10034; Slukvin II, 2003, ARCH PATHOL LAB MED, V127, P1369; Solcia E, 2014, ENDOCR PATHOL, V25, P165, DOI 10.1007/s12022-014-9312-0; Strobel O, 2003, DIGESTION, V68, P24, DOI 10.1159/000073222; Turcotte S, 2012, SURGERY, V152, P1106, DOI 10.1016/j.surg.2012.08.010; Ustun MO, 2000, J CLIN PATHOL, V53, P800, DOI 10.1136/jcp.53.10.800; Valsangkar NP, 2012, SURGERY, V152, pS4, DOI 10.1016/j.surg.2012.05.033; Vortmeyer AO, 2004, J CLIN ENDOCR METAB, V89, P1934, DOI 10.1210/jc.2003-031575	42	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	SEP	2018	26	6					551	557		10.1177/1066896918766245			7	Pathology; Surgery	Pathology; Surgery	GP6XS	WOS:000441033800014	29623746				2019-10-28	
J	Fassan, M; Brignola, S; Sarzo, G; Cappellesso, R; Rugge, M				Fassan, Matteo; Brignola, Stefano; Sarzo, Giacomo; Cappellesso, Rocco; Rugge, Massimo			Long-Standing Ulcerative Colitis May Trigger a Multilineage Cancerization Field	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						neuroendocrine carcinoma; inflammatory bowel disease; ulcerative colitis		Longstanding/relapsing inflammation characterizing ulcerative colitis (UC) has been associated to an increased risk of colon mucosa neoplastic transformation. We describe the clinicopathological features of a UC-related poorly-differentiated neuroendocrine carcinoma coexisting with a conventional adenocarcinoma. This case supports UC as a multilineage cancerization field.	[Fassan, Matteo; Brignola, Stefano; Cappellesso, Rocco; Rugge, Massimo] Univ Padua, Surg Pathol Unit, Dept Med DIMED, Padua, Italy; [Sarzo, Giacomo] St Antonio Hosp, Dept Gen Surg, Padua, Italy; [Rugge, Massimo] Veneto Canc Registry, Padua, Italy	Fassan, M (reprint author), Univ Padua, Dept Med DIMED, Surg Pathol & Cytopathol Unit, Via Gabelli 61, I-35121 Padua, Italy.	matteo.fassan@unipd.it	Fassan, Matteo/F-5152-2012	Fassan, Matteo/0000-0001-6515-5482			Bolzacchini E, 2018, INT J SURG PATHOL, V26, P479, DOI 10.1177/1066896917752443; Saraggi D, 2017, DIGEST LIVER DIS, V49, P326, DOI 10.1016/j.dld.2016.12.011; Shigaki K, 2013, HUM PATHOL, V44, P2393, DOI 10.1016/j.humpath.2013.06.008	3	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	SEP	2018	26	6					558	560		10.1177/1066896918764830			3	Pathology; Surgery	Pathology; Surgery	GP6XS	WOS:000441033800015	29580126				2019-10-28	
J	Nassereddine, H; Pote, N; Tammaro, P; Couvelard, A				Nassereddine, Hussein; Pote, Nicolas; Tammaro, Pasquale; Couvelard, Anne			Peritoneal Pulse Granulomas With Spiral Bodies Mimicking Peritoneal Carcinomatosis: A Case Report	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						peritoneum; pulse granuloma; hyaline ring; spiral bodies; helical xylem elements		Pulse (hyaline ring) granuloma, a rare entity first described in lung and oral cavity, has been reported under various names before the identification of hyaline rings as fragments of pulses (the edible seeds of legumes). Similar lesions were thereafter described in extra-oral localizations, mainly the gastrointestinal tract, or localizations having potential communication with the gastrointestinal tract. Recently, 2 reports described spiral bodies surrounded by foreign body-type multinucleated giant cell reaction in pulse granulomas, corresponding to remnant plant vascular structures (helical xylem elements). In this article, we report a case of a 70-year-old male patient presenting to our hospital for an incisional hernia repair. He had a history of antrectomy 2 years previously for perforated duodenal ulcer complicated with fecal peritonitis. During the hernia repair procedure, multiple peritoneal whitish nodules and one subserosal appendiceal nodule were found. Appendectomy and biopsy of a peritoneal nodule were performed. Microscopic examination showed nodular lesions located in the subserosa to be pulse granulomas. Also surrounded by histiocytes, spiraled thin and rigid foreign bodies were identified. In this article, we report a case of pulse granuloma with spiral bodies complicating perforated duodenal ulcer and mimicking a peritoneal carcinomatosis. We also provide a discussion on the origin of spiral bodies in light of relevant literature.	[Nassereddine, Hussein; Tammaro, Pasquale; Couvelard, Anne] Hop Xavier Bichat, AP HP, Paris, France; [Nassereddine, Hussein] Paris Descartes Univ, Paris, France; [Pote, Nicolas] Beaujon Hosp, AP HP, Clichy, France; [Couvelard, Anne] Paris Diderot Univ, Paris, France	Nassereddine, H (reprint author), Hop Xavier Bichat, AP HP, Dept Pathol, 46 Rue Henri Huchard, F-75018 Paris, France.	Hussein.nassereddine@hotmail.com					Gupta A, 2016, HISTOPATHOLOGY, V68, P938, DOI 10.1111/his.12875; Karamurzin YS, 2009, HISTOPATHOLOGY, V54, P268, DOI 10.1111/j.1365-2559.2008.03208.x; KNOBLICH R, 1969, AM REV RESPIR DIS, V99, P380; Lewars P H, 1971, Br J Oral Surg, V8, P264; Nowacki NB, 2015, AM J SURG PATHOL, V39, P84, DOI 10.1097/PAS.0000000000000308; Philipsen HP, 2010, CLIN ORAL INVEST, V14, P121, DOI 10.1007/s00784-009-0322-0; Razavi Amir, 2014, Swiss Dent J, V124, P665; Rhee DD, 2006, ARCH PATHOL LAB MED, V130, P1839; Stewart Colin J R, 2005, Ann Diagn Pathol, V9, P305, DOI 10.1016/j.anndiagpath.2005.07.002; Williams AS, 2015, PATHOLOGY, V47, P599, DOI 10.1097/PAT.0000000000000312	10	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	SEP	2018	26	6					561	563		10.1177/1066896918761234			3	Pathology; Surgery	Pathology; Surgery	GP6XS	WOS:000441033800016	29529891				2019-10-28	
J	Commander, LA; Ollila, DW; O'Connor, SM; Hertel, JD; Calhoun, BC				Commander, Leah A.; Ollila, David W.; O'Connor, Siobhan M.; Hertel, Johann D.; Calhoun, Benjamin C.			Ductal Carcinoma In Situ Simultaneously Involving the Breast and Epithelial Inclusions in an Ipsilateral Axillary Lymph Node	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						breast cancer; lymph node; diagnosis; screening; pathology; surgery	OF-THE-LITERATURE; MIMICKING METASTATIC CARCINOMA; TISSUE; TRANSPORT; CANCER	Benign cystic epithelial inclusions with squamous, glandular, or Mullerian phenotypes are known to occur in the axillary lymph nodes of patients with benign and malignant breast disease. Careful evaluation of hematoxylin and eosin-stained slides and correlation with the histologic findings in the ipsilateral breast are paramount in evaluation of suspected benign inclusions. In this case of ductal carcinoma in situ (DCIS) of the breast in a 73-year-old woman, DCIS also involved epithelial inclusions in an ipsilateral axillary lymph node. The recognition of these benign epithelial elements, and awareness that they can be involved by DCIS, is crucial to avoid the overdiagnosis of metastatic carcinoma.	[Commander, Leah A.; O'Connor, Siobhan M.; Hertel, Johann D.; Calhoun, Benjamin C.] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27515 USA; [Ollila, David W.] Univ N Carolina, Dept Surg, Chapel Hill, NC 27515 USA	Calhoun, BC (reprint author), NC Womens Hosp, Anat Pathol, 3rd Floor,Room 30212,101 Manning Dr, Chapel Hill, NC 27514 USA.	Ben.Calhoun@unchealth.unc.edu		Calhoun, Benjamin/0000-0001-6505-5430			Bleiweiss IJ, 2006, J CLIN ONCOL, V24, P2013, DOI 10.1200/JCO.2005.04.7076; Boulos FI, 2014, AM J SURG PATHOL, V38, P383, DOI 10.1097/PAS.0000000000000115; BROOKS JSJ, 1990, AM J CLIN PATHOL, V93, P741, DOI 10.1093/ajcp/93.6.741; Carter BA, 2000, AM J CLIN PATHOL, V113, P259; Corben AD, 2010, AM J SURG PATHOL, V34, P1211, DOI 10.1097/PAS.0b013e3181e5e03e; EDLOW DW, 1973, AM J CLIN PATHOL, V59, P666; Fellegara G, 2011, AM J SURG PATHOL, V35, P1123, DOI 10.1097/PAS.0b013e3182237985; FISHER CJ, 1994, J CLIN PATHOL, V47, P245, DOI 10.1136/jcp.47.3.245; Fitzpatrick-Swallow VL, 2013, HUM PATHOL, V44, P142, DOI 10.1016/j.humpath.2012.07.012; GARRET R, 1957, CANCER, V10, P173, DOI 10.1002/1097-0142(195701/02)10:1<173::AID-CNCR2820100125>3.0.CO;2-8; HORN LC, 1995, PATHOL RES PRACT, V191, P991, DOI 10.1016/S0344-0338(11)80597-2; Iken S, 2012, BREAST CANCER RES TR, V132, P621, DOI 10.1007/s10549-011-1923-2; Jaffer S, 2008, ARCH PATHOL LAB MED, V132, P1940, DOI 10.1043/1543-2165-132.12.1940; LONGO S, 1976, HUM PATHOL, V7, P349, DOI 10.1016/S0046-8177(76)80045-7; Maiorano E, 2003, AM J SURG PATHOL, V27, P513, DOI 10.1097/00000478-200304000-00012; Markopoulos C, 2001, EUR J GYNAECOL ONCOL, V22, P157; Sanguinetti A, 2010, G CHIR, V31, P383; Srinivasan B, 2007, PATHOLOGY, V39, P268, DOI 10.1080/00313020701230815; Tjalma WAA, 2006, EUR J GYNAECOL ONCOL, V27, P414	19	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	SEP	2018	26	6					564	568		10.1177/1066896918763899			5	Pathology; Surgery	Pathology; Surgery	GP6XS	WOS:000441033800017	29560779				2019-10-28	
J	Solanki, MH; Derylo, AF; Jorns, JM				Solanki, Malvika H.; Derylo, Amanda F.; Jorns, Julie M.			Invasive Mammary Carcinoma With Mixed Invasive Papillary and Glycogen Rich Clear Cell Features	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						papillary carcinoma; invasive; glycogen rich	BREAST	Invasive papillary carcinoma (IPC) and glycogen-rich clear cell carcinoma (GRCCC) are rare primary breast carcinomas. IPC typically have favorable prognosis, whereas the prognosis of GRCCC is less established. We report a unique case of high-grade invasive mammary carcinoma with mixed IPC and GRCCC features. We review the imaging and pathologic features and discuss prognosis of these unusual breast cancer subtypes.	[Solanki, Malvika H.; Derylo, Amanda F.; Jorns, Julie M.] Med Coll Wisconsin, Milwaukee, WI 53226 USA	Jorns, JM (reprint author), Med Coll Wisconsin, Dept Pathol, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.	jjorns@mcw.edu					HAYES MMM, 1995, AM J SURG PATHOL, V19, P904, DOI 10.1097/00000478-199508000-00005; HULL MT, 1981, CANCER, V48, P2003, DOI 10.1002/1097-0142(19811101)48:9<2003::AID-CNCR2820480916>3.0.CO;2-Q; Kuroda Hajime, 2005, Breast Cancer, V12, P189, DOI 10.2325/jbcs.12.189; Ma XM, 2014, BREAST J, V20, P166, DOI 10.1111/tbj.12231; MITNICK JS, 1990, RADIOLOGY, V177, P803, DOI 10.1148/radiology.177.3.2243993; National Cancer Institute Surveillance Epidemiology and End results Program, CANC STAT FACTS FEM; Pal SK, 2010, BREAST CANCER RES TR, V122, P637, DOI 10.1007/s10549-010-0961-5	7	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	SEP	2018	26	6					569	572		10.1177/1066896918765651			4	Pathology; Surgery	Pathology; Surgery	GP6XS	WOS:000441033800018	29580112				2019-10-28	
J	Domoto, H; Watanabe, A; Sakata, M; Shimada, A; Mukai, K				Domoto, Hideharu; Watanabe, Akiko; Sakata, Michio; Shimada, Akihiko; Mukai, Kiyoshi			Invasive Solid Papillary Carcinoma of the Nipple With Pagetoid Extension and Nodal Metastasis	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						solid papillary carcinoma; nipple; Pagetoid extension; nodal metastasis; breast	LYMPHATIC INVASION; BREAST; TUMOR	We report a case of invasive solid papillary carcinoma (SPC) of the nipple with Pagetoid extension to the skin and lymph node metastasis. SPC is an uncommon primary breast cancer accounting for less than 1% of all breast cancers. Only 2 cases occurring in the nipple have been reported. However, both cases were without Pagetoid extension or lymph node metastasis. The presently reported tumor consisted of irregularly shaped solid cell nests with delicate fibrovascular cores. The tumor cells had round nuclei with low-grade atypia and eosinophilic cytoplasm. Neuroendocrine differentiation was confirmed by immunohistochemical positivity for CD56, synaptophysin, and chromogranin A. Immunohistochemistry also confirmed the absence of myoepithelial cells around the tumor cell nests. Therefore, a diagnosis of invasive SPC was made. Additionally, tumor cell deposits in the intramammary and axillary lymph nodes were identified, and these deposits had the same histological characteristics as the invasive SPC of the nipple. The invasiveness of SPC can be difficult to determine. However, the tumor cell nests in the current case exhibited a retraction artifact, which is known to be associated with invasive carcinoma and a poor prognosis, as well as morphological patterns that have been previously identified as characteristic of invasive SPC. Although SPC is widely recognized as having a favorable outcome, the existence of exceptionally aggressive cases occurring in the nipple must be recognized. Additional cases of invasive SPC of the nipple are needed to analyze the clinicopathological correlation.	[Domoto, Hideharu; Watanabe, Akiko; Sakata, Michio; Shimada, Akihiko; Mukai, Kiyoshi] Keiyu Hosp, Yokohama, Kanagawa, Japan	Domoto, H (reprint author), Keiyu Hosp, Dept Diagnost Pathol, Nishi Ku, 3-7-3 Minatomirai, Yokohama, Kanagawa 2208521, Japan.	ku.pathology@keiyu-hospital.com					Acs G, 2007, AM J SURG PATHOL, V31, P129, DOI 10.1097/01.pas.0000213316.59176.9b; Acs G, 2015, AM J SURG PATHOL, V39, P325, DOI 10.1097/PAS.0000000000000339; Clement ZVK, 2017, INT J SURG MED, V3, P57; Dieci MV, 2014, ONCOLOGIST, V19, P805, DOI 10.1634/theoncologist.2014-0108; Guo SP, 2016, BREAST, V26, P67, DOI 10.1016/j.breast.2015.12.015; Leena JB, 2013, J CLIN DIAGN RES, V7, P1150, DOI 10.7860/JCDR/2013/5134.3045; MALUF HM, 1995, AM J SURG PATHOL, V19, P1237, DOI 10.1097/00000478-199511000-00003; Nassar H, 2006, AM J SURG PATHOL, V30, P501, DOI 10.1097/00000478-200604000-00011; Nicolas MM, 2007, HISTOPATHOLOGY, V51, P657, DOI 10.1111/j.1365-2559.2007.02849.x; Otsuki Y, 2007, PATHOL INT, V57, P421, DOI 10.1111/j.1440-1827.2007.02118.x; Rakha EA, 2011, AM J SURG PATHOL, V35, P1093, DOI 10.1097/PAS.0b013e31821b3f65; Saremian J, 2012, ARCH PATHOL LAB MED, V136, P1308, DOI 10.5858/arpa.2011-0227-RS; Sundaram S, 2010, INDIAN J PATHOL MICR, V53, P537, DOI 10.4103/0377-4929.68293; Tacchini D, 2016, PATHOLOGICA, V108, P136; Tan BY, 2016, AM J SURG PATHOL, V40, P1334, DOI 10.1097/PAS.0000000000000702; Tan PH, 2015, HISTOPATHOLOGY, V66, P761, DOI 10.1111/his.12463; Visscher D, 2012, WHO CLASSIFICATION T, V4, P108	17	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	SEP	2018	26	6					573	577		10.1177/1066896918766237			5	Pathology; Surgery	Pathology; Surgery	GP6XS	WOS:000441033800019	29580118				2019-10-28	
J	Yin, ZW; Peters, S; Chokshi, R; Heller, D				Yin, Zhiwei; Peters, Stephen; Chokshi, Ravi; Heller, Debra			Ovarian Clear Cell Adenofibroma of Low Malignant Potential Developing Into Clear Cell Adenocarcinoma	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						clear cell adenocarcinoma; adenofibroma; pathology; ovarian neoplasms	COMPONENTS; CARCINOMA; FEATURES; TUMOR	Ovarian clear cell adenofibroma is uncommon, and borderline clear cell adenofibroma (low malignant potential) is extremely rare. Borderline clear cell adenofibromas may represent the precursor lesion of clear cell adenocarcinoma of the ovary, but this has not been established. We present a case of a woman in her mid-50s with a clear cell adenofibroma ranging from benign to borderline to frankly invasive. While some clear cell adenocarcinomas are thought to arise from endometriosis, this range of findings supports the theory that some ovarian clear cell adenocarcinomas originate from borderline tumors.	[Yin, Zhiwei; Peters, Stephen; Chokshi, Ravi; Heller, Debra] Rutgers New Jersey Med Sch, 185 South Orange Ave, Newark, NJ 07103 USA	Heller, D (reprint author), Rutgers New Jersey Med Sch, 185 South Orange Ave, Newark, NJ 07103 USA.	hellerds@njms.rutgers.edu					Cho I, 2016, J PATHOL TRANSL MED, V50, P155, DOI 10.4132/jptm.2015.08.07; Crum CP, 2011, DIAGNOSTIC GYNECOLOG, P876; Sangoi AR, 2008, AM J SURG PATHOL, V32, P269, DOI 10.1097/PAS.0b013e31814fa9b0; Shaista MV, 2013, MIDDLE E J CANC, V4, P87; Yamamoto S, 2007, AM J SURG PATHOL, V31, P999, DOI 10.1097/01.pas.0000249449.13466.3c; Zhao CQ, 2011, J CANCER, V2, P94, DOI 10.7150/jca.2.107	6	0	0	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	SEP	2018	26	6					578	580		10.1177/1066896918763547			3	Pathology; Surgery	Pathology; Surgery	GP6XS	WOS:000441033800020	29551085				2019-10-28	
J	Chua, D; Chiow, AKH; Ang, TL; Wang, LM				Chua, D.; Chiow, A. K. H.; Ang, T. L.; Wang, L. M.			Malignant transformation arising within unusual and rare hepatic lesions: fibropolycystic disease form of ductal plate malformation and biliary fibroadenoma (vol 26, pg 542, 2018)	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Correction																Chua D, 2018, INT J SURG PATHOL, V26, P542, DOI 10.1177/1066896918758172	1	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	SEP	2018	26	6					581	581		10.1177/1066896918767982			1	Pathology; Surgery	Pathology; Surgery	GP6XS	WOS:000441033800021		Bronze			2019-10-28	
J	Ruan, M; Tian, T; Rao, J; Xu, XL; Yu, BH; Yang, WT; Shui, R				Ruan, Miao; Tian, Tian; Rao, Jia; Xu, Xiaoli; Yu, Baohua; Yang, Wentao; Shui, Ruohong			Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers	DIAGNOSTIC PATHOLOGY			English	Article						Tumor-infiltrating lymphocytes; Breast cancer; Triple-negative; Pathological complete response; Predictive factor	PROGNOSTIC VALUE; CHEMOTHERAPY; SURVIVAL; RECOMMENDATIONS; THERAPY; TILS	Background: Triple-negative breast cancers (TNBCs) are a group of heterogeneous diseases with various morphology, prognosis, and treatment response. Therefore, it is important to identify valuable biomarkers to predict the therapeutic response and prognosis for TNBCs. Tumor-infiltrating lymphocytes (TILs) may have predictive value to pathological complete response (pCR) in neoadjuvant treated TNBCs. However, absence of standardized methodologies for TILs measurement has limited its evaluation and application in practice. In 2014, the International TILs Working Group formulated the recommendations of pathologic evaluation for TILs in breast cancers. Methods: To evaluate the predictive value of TILs scored by methods recommended by International TILs Working Group 2014, we performed a retrospective study of TILs in 166 core needle biopsy specimens of primary invasive TNBCs with neoadjuvant chemotherapy (NAC) in a Chinese population. Intratumoral TILs (TILs) and stromal TILs (sTILs) were scored respectively. The associations between TILs and pCR were analyzed. Results: Both sTILs (p = 0.0001) and iTILs (P = 0.001) were associated with pCR in univariate logistic regression analysis. Multivariate logistic regression analysis indicated that both sTILs (P = 0.006) and TILs (P= 0.04) were independent predictors for pCR. Receiver operating characteristics (ROC) curve analysis was used to identify the optimal thresholds of TILs. TNBCs with more than 20% sTILs (P = 0.001) or with more than 10% iTILs (P = 0.003) were associated with higher pCR rates in univariate analysis. Multivariate analysis showed that a 20% threshold of sTILs (P= 0.005) was an independent predictive factor for pCR. Conclusions: Our study indicated that Its scored by recommendations of International Its Working Group 2014 in pre-NAC core needle biopsy specimens was significantly correlated with pCR in TNBCs, higher TILs scores predicting higher pCR rate. Both sTILs and iTILs were independent predictors for pCR in TNBCs. A 20% threshold for sILs may be feasible to predict pCR to NAC in TNBCs.	[Ruan, Miao; Tian, Tian; Rao, Jia; Xu, Xiaoli; Yu, Baohua; Yang, Wentao; Shui, Ruohong] Fudan Univ, Dept Pathol, Shanghai Canc Ctr, Shanghai, Peoples R China; [Ruan, Miao; Tian, Tian; Rao, Jia; Xu, Xiaoli; Yu, Baohua; Yang, Wentao; Shui, Ruohong] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China	Shui, R (reprint author), Fudan Univ, Dept Pathol, Shanghai Canc Ctr, Shanghai, Peoples R China.; Shui, R (reprint author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China.	shuiruohong2014@163.com			Research Project of the Science and Technology Commission of Shanghai Municipality [15411965100]	This work was supported by grants from Research Project of the Science and Technology Commission of Shanghai Municipality (Project No: 15411965100, for Ruohong Shui).	Adams S, 2014, J CLIN ONCOL, V32, P2959, DOI 10.1200/JCO.2013.55.0491; Asano Y, 2016, BRIT J SURG, V103, P845, DOI 10.1002/bjs.10127; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; Castaneda CA, 2016, WORLD J CLIN ONCOL, V7, P387, DOI 10.5306/wjco.v7.i5.387; Chung YR, 2017, BREAST CANCER RES TR, V161, P409, DOI 10.1007/s10549-016-4072-9; Denkert C, 2013, CANCER RES, V73; Denkert C, 2015, J CLIN ONCOL, V33, P983, DOI 10.1200/JCO.2014.58.1967; Denkert C, 2010, J CLIN ONCOL, V28, P105, DOI 10.1200/JCO.2009.23.7370; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Fisher CS, 2012, ANN SURG ONCOL, V19, P253, DOI 10.1245/s10434-011-1877-y; Garcia-Martinez E, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0488-5; Hammond MEH, 2010, J ONCOL PRACT, V6, P195, DOI 10.1200/JOP.777003; Heppner BI, 2016, CLIN CANCER RES, V22, P5747, DOI 10.1158/1078-0432.CCR-15-2338; Hida AI, 2016, BREAST CANCER RES TR, V158, P1, DOI 10.1007/s10549-016-3848-2; Issa-Nummer Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079775; Jung YY, 2016, J BREAST CANCER, V19, P261, DOI 10.4048/jbc.2016.19.3.261; Khoury T, 2017, PROGNOSTIC SIGNIFICA, P1; Kong XN, 2011, EUR J CANCER, V47, P2084, DOI 10.1016/j.ejca.2011.06.014; Krishnamurti U, 2017, HUM PATHOL, V64, P7, DOI 10.1016/j.humpath.2017.01.004; Kumar P, 2016, ARCH GYNECOL OBSTET, V293, P247, DOI 10.1007/s00404-015-3859-y; Lakhani SR, 2012, WHO CLASSIFICATION T, P4; Lee HJ, 2016, J CLIN PATHOL, V69, P422, DOI 10.1136/jclinpath-2015-203089; Li XB, 2016, AM J CLIN PATHOL, V145, P871, DOI 10.1093/ajcp/aqw045; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Loi S, 2014, ANN ONCOL, V25, P1544, DOI 10.1093/annonc/mdu112; Loi S, 2013, J CLIN ONCOL, V31, P860, DOI 10.1200/JCO.2011.41.0902; Mao Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115103; Ogston KN, 2003, BREAST, V12, P320, DOI 10.1016/S0960-9776(03)00106-1; Ono M, 2012, BREAST CANCER RES TR, V132, P793, DOI 10.1007/s10549-011-1554-7; Pan B J, 2016, Zhonghua Bing Li Xue Za Zhi, V45, P540, DOI 10.3760/cma.j.issn.0529-5807.2016.08.009; Park HS, 2016, J SURG ONCOL, V114, P17, DOI 10.1002/jso.24275; Podo F, 2010, MOL ONCOL, V4, P209, DOI 10.1016/j.molonc.2010.04.006; Pruneri G, 2016, ANN ONCOL, V27, P249, DOI 10.1093/annonc/mdv571; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; Seo AN, 2013, BRIT J CANCER, V109, P2705, DOI 10.1038/bjc.2013.634; Stagg J, 2013, THER ADV MED ONCOL, V5, P169, DOI 10.1177/1758834012475152; Swisher SK, 2016, ANN SURG ONCOL, V23, P2242, DOI 10.1245/s10434-016-5173-8; Tian T, 2016, ONCOTARGET, V7, P44395, DOI 10.18632/oncotarget.10054; van Rooijen JM, 2015, PHARMACOL THERAPEUT, V156, P90, DOI 10.1016/j.pharmthera.2015.09.003; Wang K, 2016, ONCOTARGET, V7, P44288, DOI 10.18632/oncotarget.9988; Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775	42	3	3	1	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	AUG 31	2018	13								66	10.1186/s13000-018-0743-7			11	Pathology	Pathology	GS3MK	WOS:000443515300001	30170605	DOAJ Gold, Green Published			2019-10-28	
J	Volker, HU; Weigel, M; Strehl, A; Frey, L				Volker, Hans-Ullrich; Weigel, Michael; Strehl, Annette; Frey, Lea			Levels of uPA and PAI-1 in breast cancer and its correlation to Ki67-index and results of a 21-multigene-array	DIAGNOSTIC PATHOLOGY			English	Article						Breast cancer; uPA; PAI-1; Multigene-array; OncotypeDX (R)	UROKINASE PLASMINOGEN-ACTIVATOR; CLINICAL-PRACTICE; AMERICAN SOCIETY; INHIBITOR TYPE-1; FOLLOW-UP; INVASION; RECEPTOR; SYSTEM; PROGNOSIS; THERAPY	Background: Conventional parameters including Ki67, hormone receptor and Her2/neu status are used for risk stratification for breast cancer. The serine protease urokinase plasminogen activator (uPA) and the plasminogen activator inhibitor type-1 (PAI-1) play an important role in tumour invasion and metastasis. Increased concentrations in tumour tissue are associated with more aggressive potential of the disease. Multigene tests provide detailed insights into tumour biology by simultaneously testing several prognostically relevant genes. With OncotypeDX (R), a panel of 21 genes is tested by means of quantitative real-time polymerase chain reaction. The purpose of this pilot study was to analyse whether a combination of Ki67 and uPA/PAI-1 supplies indications of the result of the multigene test Methods: The results of Ki67, uPA/PAI-1 and OncotypeDX (R) were analysed in 25 breast carcinomas (luminal type, pT1/2, max pN1a, G2). A statistical and descriptive analysis was performed. Results: With a proliferation index Ki67 of < 14%, the recurrence score (RS) from the multigene test was on average in the low risk range, with an intermediate RS usually resulting if Ki67 was > 14%. Not elevated values of uPA and PAI-1 showed a lower rate of proliferation (average 8.5%) than carcinomas with an increase of uPA and/or PAI-1 (average 13.9%); p = 0.054, Student's t-test When Ki67 was > 14% and uPA and/or PAI-1 was raised, an intermediate RS resulted. These differences were significant when compared to cases with Ki67 < 14% with non-raised uPA/PAI-1 (p < 0.03, Student's t-test). Without taking into account the proliferative activity, an intermediate RS was also verifiable if both uPA and PAI-1 showed raised values. Conclusion: A combination of the values Ki67 and uPA/PAI-1 tended to depict the RS to be expected. From this it can be deduced that an appropriate analysis of this parameter combination may be undertaken before the multigene test in routine clinical practice. The increasing cost pressure makes it necessary to base the implementation of a multigene test on ancillary variables and to potentially leave it out if not required in the event of a certain constellation of results (Ki67 raised, uPA and PAI-1 raised).	[Volker, Hans-Ullrich; Strehl, Annette] Leopoldina Krankenhaus GmbH, Pathol, Gustav Adolf Str 8, D-97422 Schweinfurt, Germany; [Weigel, Michael] Leopoldina Krankenhaus GmbH, Dept Gynecol, Gustav Adolf Str 8, D-97422 Schweinfurt, Germany; [Frey, Lea] Univ Wurzburg, Inst Pathol, Josef Schneider Str 2, D-97080 Wurzburg, Germany	Frey, L (reprint author), Univ Wurzburg, Inst Pathol, Josef Schneider Str 2, D-97080 Wurzburg, Germany.	lea.frey@uni-wuerzburg.de			German Research Foundation (DFG)German Research Foundation (DFG); University of Wuerzburg	This publication was funded by the German Research Foundation (DFG) and the University of Wuerzburg in the funding programme Open Access Publishing.	Abu Rabi Z, 2015, CANCER BIOMARK, V15, P745, DOI 10.3233/CBM-150516; Albain KS, 2010, LANCET ONCOL, V11, P55, DOI 10.1016/S1470-2045(09)70314-6; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Bellocq JP, 2014, ANN PATHOL, V34, P349, DOI 10.1016/j.annpat.2014.04.010; Binder BR, 2008, IMMUNOL LETT, V118, P116, DOI 10.1016/j.imlet.2008.03.017; Buta M, 2015, TUMOR BIOL, V36, P8193, DOI 10.1007/s13277-015-3573-1; Carlson JJ, 2013, BREAST CANCER RES TR, V141, P13, DOI 10.1007/s10549-013-2666-z; Chen YB, 2004, J CELL BIOCHEM, V92, P178, DOI 10.1002/jcb.20058; Cronin M, 2007, CLIN CHEM, V53, P1084, DOI 10.1373/clinchem.2006.076497; de Cremoux P, 2009, ANTICANCER RES, V29, P1475; Deluche E, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3648-z; Goldstein LJ, 2008, J CLIN ONCOL, V26, P4063, DOI 10.1200/JCO.2007.14.4501; Harbeck N, 2013, EUR J CANCER, V49, P1825, DOI 10.1016/j.ejca.2013.01.007; Harris LN, 2016, J CLIN ONCOL, V34, P1134, DOI 10.1200/JCO.2015.65.2289; Hildenbrand R, 2009, INT J ONCOL, V34, P15, DOI 10.3892/ijo_00000124; JANICKE F, 1993, BREAST CANCER RES TR, V24, P195, DOI 10.1007/BF01833260; Lampelj M, 2015, RADIOL ONCOL, V49, P357, DOI 10.2478/raon-2014-0049; Lang DS, 2013, BREAST, V22, P736, DOI 10.1016/j.breast.2012.12.011; Look MP, 2002, J NATL CANCER I, V94, P116, DOI 10.1093/jnci/94.2.116; Mamounas EP, 2010, J CLIN ONCOL, V28, P1677, DOI 10.1200/JCO.2009.23.7610; Meo S, 2004, INT J BIOL MARKER, V19, P282; Paik S, 2006, J CLIN ONCOL, V24, P3726, DOI 10.1200/JCO.2005.04.7985; Preissner KT, 2000, CURR OPIN CELL BIOL, V12, P621, DOI 10.1016/S0955-0674(00)00141-1; Reuning U, 1998, INT J ONCOL, V13, P893; Rosenberg S, 2003, CURR PHARM DESIGN, V9; Ulisse S, 2009, CURR CANCER DRUG TAR, V9, P32, DOI 10.2174/156800909787314002; Witzel Isabell, 2014, Onco Targets Ther, V7, P2205, DOI 10.2147/OTT.S65344; Wolff AC, 2018, ARCH PATHOL LAB MED, V142, P1364, DOI 10.5858/arpa.2018-0902-SA	28	4	4	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	AUG 31	2018	13								67	10.1186/s13000-018-0737-5			8	Pathology	Pathology	GS3MK	WOS:000443515300002	30170623	DOAJ Gold, Green Published			2019-10-28	
J	Davis, GG; Winters, GL; Fyfe, BS; Hooper, JE; Iezzoni, JC; Johnson, RL; Markwood, PS; Naritoku, WY; Nashelsky, M; Sampson, BA; Steinberg, JJ; Stubbs, JR; Timmons, C; Hoffman, RD				Davis, Gregory G.; Winters, Gayle L.; Fyfe, Billie S.; Hooper, Jody E.; Iezzoni, Julia C.; Johnson, Rebecca L.; Markwood, Priscilla S.; Naritoku, Wesley Y.; Nashelsky, Marcus; Sampson, Barbara A.; Steinberg, Jacob J.; Stubbs, James R.; Timmons, Charles; Hoffman, Robert D.			Report and Recommendations of the Association of Pathology Chairs' Autopsy Working Group	ACADEMIC PATHOLOGY			English	Article						autopsy; pathology training; residency; anatomic pathology; autopsy service director; entrustable activities; rapid autopsy		Autopsy has been a foundation of pathology training for many years, but hospital autopsy rates are notoriously low. At the 2014 meeting of the Association of Pathology Chairs, some pathologists suggested removing autopsy from the training curriculum of pathology residents to provide additional months for training in newer disciplines, such as molecular genetics and informatics. At the same time, the American Board of Pathology received complaints that newly hired pathologists recently certified in anatomic pathology are unable to perform an autopsy when called upon to do so. In response to a call to abolish autopsy from pathology training on the one hand and for more rigorous autopsy training on the other, the Association of Pathology Chairs formed the Autopsy Working Group to examine the role of autopsy in pathology residency training. After 2 years of research and deliberation, the Autopsy Working Group recommends the following: Autopsy should remain a component of anatomic pathology training. A training program must have an autopsy service director with defined responsibilities, including accountability to the program director to record every autopsy performed by every resident. Specific entrustable activities should be defined that a resident must master in order to be deemed competent in autopsy practice, as well as criteria for gaining the trust to perform the tasks without direct supervision. Technical standardization of autopsy performance and reporting must be improved. The current minimum number of 50 autopsies should not be reduced until the changes recommended above have been implemented.	[Davis, Gregory G.] Univ Alabama Birmingham, Dept Pathol, Forens Div, 1515 Sixth Ave South,Room 220, Birmingham, AL 35233 USA; [Winters, Gayle L.] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA USA; [Fyfe, Billie S.] UMDNJ Robert Wood Johnson Med Sch, New Brunswick, NJ USA; [Hooper, Jody E.] Johns Hopkins Univ, Dept Pathol, Baltimore, MD USA; [Iezzoni, Julia C.] Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA; [Johnson, Rebecca L.] Amer Board Pathol, Tampa, FL USA; [Markwood, Priscilla S.] Assoc Pathol Chairs, Wilmington, DE USA; [Naritoku, Wesley Y.] USC, LAC, Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA USA; [Nashelsky, Marcus] Univ Iowa, Dept Pathol, Carver Coll Med, Iowa City, IA 52242 USA; [Sampson, Barbara A.] City New York Off Chief Med Examiner, New York, NY USA; [Steinberg, Jacob J.] Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10467 USA; [Steinberg, Jacob J.] Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA; [Stubbs, James R.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA; [Timmons, Charles] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol & Lab Med, Dallas, TX 75390 USA; [Hoffman, Robert D.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37212 USA	Davis, GG (reprint author), Univ Alabama Birmingham, Dept Pathol, Forens Div, 1515 Sixth Ave South,Room 220, Birmingham, AL 35233 USA.	gdavis@uabmc.edu					Accreditation Council for Graduate Medical Education, 2018, ACGME PROGR REQ GRAD, P18; Aiello Vera Demarchi, 2016, Autops Case Rep, V6, P1, DOI 10.4322/acr.2016.055; American Board of Pathology, 2018, ABPATH BOOKLET INFOR, P27; Decker LA, 2018, J FORENSIC SCI, V63, P1401, DOI 10.1111/1556-4029.13760; Hoyert Donna L, 2011, NCHS Data Brief, P1; Levy Bruce, 2015, Surg Pathol Clin, V8, P159, DOI 10.1016/j.path.2015.02.010; McCloskey CB, 2017, ACAD PATHOL, V4, DOI 10.1177/2374289517714283; Naritoku WY, 2016, ACAD PATHOL, V3, DOI 10.1177/2374289516667746; Rebecca L, 2015, 2015 ANN APC PRODS M; Rutty GN, 2017, LANCET, V390, P145, DOI 10.1016/S0140-6736(17)30333-1	10	2	2	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	AUG 30	2018	5								UNSP 2374289518793988	10.1177/2374289518793988			10	Pathology	Pathology	GS1KW	WOS:000443283600001	30186954	DOAJ Gold, Green Published			2019-10-28	
J	Ayad, E; Soliman, A; Anis, SE; Ben Salem, A; Hu, PC; Dong, YH				Ayad, Essam; Soliman, Ahmed; Anis, Shady Elia; Ben Salem, Amira; Hu, Pengchao; Dong, Youhong			Ki 67 assessment in breast cancer in an Egyptian population: a comparative study between manual assessment on optical microscopy and digital quantitative assessment	DIAGNOSTIC PATHOLOGY			English	Article						Breast; Cancer; Ki67; Manual; Automated; Assessment	INTERNATIONAL EXPERT CONSENSUS; PRIMARY THERAPY; KI-67 INDEX; PROGNOSTIC VALUE; PROLIFERATION; EXPRESSION; PATHOLOGY; ANASTROZOLE; HIGHLIGHTS; CARCINOMA	Background: Breast cancer is by far the most frequent cancer among women. The proliferative index, Ki-67, is more and more taken into consideration for treatment decisions. However, the reliability of the established Ki-67 scoring is limited. Digital pathology is currently suggested to be a potential solution to Ki 67 assessment problems. Methods: This is a retrospective and prospective study including 100 patients diagnosed with invasive breast cancer. Three senior pathologists have been asked to estimate the Ki-67 proliferative index for each of the 100 cases by examining the whole glass slides on optical microscope and providing a continuous score then a categorical score ('high' and 'low' Ki 67 index) using once 14%, once 20% as threshold indicative of high Ki67 status. Finally, a digital quantitative assessment of Ki67 was performed. Results: A high inter-observer agreement was found when using optical microscopy for Ki 67 assessment, with correlation coefficient (CC) estimated at 0.878 (p value < 0.01). The overall agreement between manual and automated evaluation of Ki 67 was only substantial (CC estimated at 0.745 (p value < 0.01)). When using categorical scores, the inter-observers concordance was substantial using both cutoff points with kappa value estimated at 0.796 ([0.696-0.925] while using 14% as a cut off point and at 0.766 ([0.672-0.938] while using 20% as a cutoff point (p value < 0). The inter-observers agreement was better while using 14% as cutoff point. Agreement between manual and automated assessment of Ki 67 indices using both cutoff points was only substantial (Kappa estimated at 0.623, p value < 0.01). In comparison to automated assessment of Ki 67 index, while using 14% as a cutoff point, the overall tendency of all observers was to overestimate the Ki 67 values but to underestimate the proliferation index while using 20% as a cutoff point. Conclusion: Automated assessment of Ki 67 value would appear to be comparable to visual Ki 67 assessment on optical microscopy. Such study would help define the role of digital pathology as a potential easy-to use tool for a robust and standardized fully automated Ki 67 scoring.	[Ayad, Essam; Soliman, Ahmed; Anis, Shady Elia; Ben Salem, Amira] Cairo Univ, Dept Pathol, Cairo, Egypt; [Hu, Pengchao; Dong, Youhong] Hubei Univ Med, Dept Oncol, XiangYang Peoples Hosp 1, Xiangyang 441000, Hubei, Peoples R China	Ayad, E (reprint author), Cairo Univ, Dept Pathol, Cairo, Egypt.	essamayad@yahoo.com		AYAD, ESSAM/0000-0002-4822-1676			Abubakar M, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0765-6; Al-Janabi S, 2012, HISTOPATHOLOGY, V61, P1, DOI 10.1111/j.1365-2559.2011.03814.x; American Cancer Society, 2015, GLOB CANC FACTS FIG, P37; Ayad E, 2016, VIRCHOWS ARCH, V469, pS191; Bustreo S, 2016, BREAST CANCER RES TR, V157, P363, DOI 10.1007/s10549-016-3817-9; Cheang MCU, 2009, JNCI-J NATL CANCER I, V101, P736, DOI 10.1093/jnci/djp082; Coates AS, 2015, ANN ONCOL, V26, P1533, DOI 10.1093/annonc/mdv221; Dowsett M, 2005, J CLIN ONCOL, V23, P2477, DOI 10.1200/JCO.2005.07.559; Dowsett M, 2011, J NATL CANCER I, V103, P1656, DOI 10.1093/jnci/djr393; Ellis MJ, 2011, J CLIN ONCOL, V29, P2342, DOI 10.1200/JCO.2010.31.6950; Fasanella S, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-S1-S7; FLEISS JL, 1973, EDUC PSYCHOL MEAS, V33, P613, DOI 10.1177/001316447303300309; Gnant M, 2017, BREAST CARE, V12, P102, DOI 10.1159/000475698; Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303; Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304; Gudlaugsson E, 2012, HISTOPATHOLOGY, V61, P1134, DOI 10.1111/j.1365-2559.2012.04329.x; Kayser K, 2012, ANAL CELL PATHOL, V35, P3, DOI 10.3233/ACP-2011-0044; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Luporsi E, 2012, BREAST CANCER RES TR, V132, P895, DOI 10.1007/s10549-011-1837-z; Maisonneuve P, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3679; Mohammed ZMA, 2012, BRIT J CANCER, V106, P383, DOI 10.1038/bjc.2011.569; Montemurro F, 2013, ANN ONCOL, V24, P2715, DOI 10.1093/annonc/mdt287; Nishimura R, 2014, MOL CLIN ONCOL, V2, P1062, DOI 10.3892/mco.2014.400; Pathmanathan N, 2014, J CLIN PATHOL, V67, DOI 10.1136/jclinpath-2013-201793; Polley MYC, 2013, JNCI-J NATL CANCER I, V105, P1897, DOI 10.1093/jnci/djt306; Purdie CA, 2014, BRIT J CANCER, V110, P565, DOI 10.1038/bjc.2013.756; Shui RH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125131; Soenksen D, 2009, ARCH PATHOL LAB MED, V133, P555, DOI 10.1043/1543-2165-133.4.555; Stalhammar G, 2016, MODERN PATHOL, V29, P318, DOI 10.1038/modpathol.2016.34; Stuart-Harris R, 2008, BREAST, V17, P323, DOI 10.1016/j.breast.2008.02.002; Suciu C, 2014, ONCOL LETT, V7, P107; Tan QX, 2014, INT J CLIN EXP PATHO, V7, P6862; Tashima R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119565; Trihia H, 2003, CANCER, V97, P1321, DOI 10.1002/cncr.11188; Urruticoechea A, 2005, J CLIN ONCOL, V23, P7212, DOI 10.1200/JCO.2005.07.501; Varga Z, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123435; Varga Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037379; Weinstein RS, 2009, HUM PATHOL, V40, P1057, DOI 10.1016/j.humpath.2009.04.006; Zhong FF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150505	39	1	2	2	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	AUG 28	2018	13								63	10.1186/s13000-018-0735-7			9	Pathology	Pathology	HM8TS	WOS:000459755300001	30153851	DOAJ Gold, Green Published			2019-10-28	
J	Kurose, N; Yamashita, M; Nakano, M; Guo, X; Shioya, A; Nakada, S; Minato, H; Yamada, S				Kurose, Nozomu; Yamashita, Manabu; Nakano, Mariko; Guo, Xin; Shioya, Akihiro; Nakada, Satoko; Minato, Hiroshi; Yamada, Sohsuke			Cytopathological findings of proliferating pilomatricoma misdiagnosed as a malignant parotid gland tumor	DIAGNOSTIC PATHOLOGY			English	Review						Proliferating pilomatricoma; Basophilic cells; Shadow cells; Cytology		Background: Pilomatricoma is a relatively common benign cutaneous adnexal neoplasm with differentiation towards the hair matrix, inner sheath of hair follicle and hair cortex. Proliferating pilomatricoma is a rare variant of pilomatricoma that can rapidly increase and may be misidentified as a malignant tumor. We herein report the cytopathological findings of proliferating pilomatricoma misdiagnosed as a malignant parotid tumor. Case presentation: A 64-year-old man noticed an acne-like nodule in the left parotid region. It was painless, but it increased to a maximum diameter of 4.5 cm over 2 years. Clinically, left parotid gland carcinoma was suspected, and fine-needle aspiration cytology was performed. Clusters of epithelial cells were observed in a necrotic background, and malignant epithelial cells derived from salivary glands were suspected. Histologically, the resected tumor was diagnosed as proliferating pilomatricoma composed of basophilic cells and shadow cells apart from the parotid gland. However, on a re-evaluation of the cytological specimens, the irregular-shaped epithelial cells were considered to be from basophilic cells. Shadow cells with nuclear disappearance were also confirmed. Tumor recurrence and metastasis have not been observed in the four years since surgery. Conclusion: The present case was first interpreted as a malignant parotid gland tumor, but it was actually a benign skin appendage tumor. Pilomatricoma sometimes rapidly increases and may be mistaken for a malignant tumor. Although it is critical to recognize not only basophilic cells but also shadow cells, it cannot be diagnosed by cytological findings. The final diagnosis should be made on excision specimen only.	[Kurose, Nozomu; Guo, Xin; Shioya, Akihiro; Nakada, Satoko; Yamada, Sohsuke] Kanazawa Med Univ, Dept Pathol & Lab Med, 1-1 Daigaku, Uchinada, Ishikawa 9200293, Japan; [Yamashita, Manabu; Nakano, Mariko] Kanazawa Med Univ, Dept Pathol, Kanazawa, Ishikawa, Japan; [Minato, Hiroshi] Ishikawa Prefectural Cent Hosp, Dept Diagnost Pathol, Kanazawa, Ishikawa, Japan	Kurose, N (reprint author), Kanazawa Med Univ, Dept Pathol & Lab Med, 1-1 Daigaku, Uchinada, Ishikawa 9200293, Japan.	k-nozomu@kanazawa-med.ac.jp						0	0	0	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	AUG 28	2018	13								65	10.1186/s13000-018-0738-4			4	Pathology	Pathology	GR8FG	WOS:000442949400003	30153836	DOAJ Gold, Green Published			2019-10-28	
J	Pena-Jaimes, L; Gonzalez-Garcia, I; Reguero-Callejas, ME; Pinilla-Pagnon, I; Perez-Mies, B; Albarran-Artahona, V; Martinez-Janez, N; Rosa-Rosa, JM; Palacios, J				Pena-Jaimes, Lourdes; Gonzalez-Garcia, Irene; Eugenia Reguero-Callejas, Maria; Pinilla-Pagnon, Ignacio; Perez-Mies, Belen; Albarran-Artahona, Victor; Martinez-Janez, Noelia; Manuel Rosa-Rosa, Juan; Palacios, Jose			Pleomorphic lobular carcinoma of the breast with osteoclast-like giant cells: a case report and review of the literature	DIAGNOSTIC PATHOLOGY			English	Review						Pleomorphic carcinoma; Osteoclast-like giant cells; Breast cancer; Lobular carcinoma	INTERNATIONAL EXPERT CONSENSUS; PRIMARY THERAPY; DIGITAL PATHOLOGY; CANCER HIGHLIGHTS; PROGNOSTIC VALUE; KI67; KI-67; PROLIFERATION; EXPRESSION; REPRODUCIBILITY	Background: Breast carcinoma with osteoclast-like giant cells (OGCs) is infrequent, being most reported cased described as ductal invasive carcinomas. Invasive pleomorphic lobular carcinoma (PLC) is a distinct morphological variant of invasive lobular carcinoma characterized by higher nuclear atypia and pleomorphism than the classical type. In the best of our knowledge, a PLC with OGCs has not been previously reported. Case presentation: We report the case of a 72-year-old woman presenting with a pleomorphic tumor of the left breast with a dense infiltration by OGCs and T lymphocytes with a 10:1 predominance of CD8+ over CD4+ cells. The diagnosis of a lymphoid or mesenchymal neoplasia was excluded after demonstrating keratin expression by the neoplastic cells. The absence of E-cadherin expression and the morphological features were consistent with the diagnosis PLC with OGCs. In addition, we demonstrated the deleterious mutation C.del866C in CDH1gene, but no mutations in any of the other 33 genes analyzed by next generation sequencing. Conclusions: Breast carcinoma with stromal osteoclast-like giant cells is a very rare tumor, for that reason, the use of the cytologic features and growth patterns in combination with immunohistochemically studies is mandatory for a correct diagnosis of lobular carcinoma. In addition, further studies are necessary to clarify the influence of OGCs in the prognosis of these patients.	[Pena-Jaimes, Lourdes; Gonzalez-Garcia, Irene; Eugenia Reguero-Callejas, Maria; Pinilla-Pagnon, Ignacio; Perez-Mies, Belen; Palacios, Jose] Hosp Ramon & Cajal, Dept Pathol, Madrid, Spain; [Albarran-Artahona, Victor; Martinez-Janez, Noelia] Hosp Ramon & Cajal, Dept Oncol, Madrid, Spain; [Manuel Rosa-Rosa, Juan; Palacios, Jose] Insituto Salud Carlos III, CIBER ONC, Madrid, Spain; [Eugenia Reguero-Callejas, Maria; Perez-Mies, Belen; Martinez-Janez, Noelia; Manuel Rosa-Rosa, Juan; Palacios, Jose] Inst Ramon & Cajal Invest Sanitaria, Madrid, Spain; [Palacios, Jose] Univ Alcala de Henares, Madrid, Spain	Palacios, J (reprint author), Hosp Ramon & Cajal, Dept Pathol, Madrid, Spain.; Palacios, J (reprint author), Insituto Salud Carlos III, CIBER ONC, Madrid, Spain.	jose.palacios@salud.madrid.org			Instituto de Salud Carlos IIIInstituto de Salud Carlos III [PT13/0010/0056, PIE15/00050, PI16/00887, CB16/12/00316]; Fundacion Cientifica Asociacion Espanola Contra el Cancer [AIO-AECC 2016]; Fundacio la Marato de TV3 [2/C2013]		Abubakar M, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0765-6; Al-Janabi S, 2012, HISTOPATHOLOGY, V61, P1, DOI 10.1111/j.1365-2559.2011.03814.x; American Cancer Society, 2015, GLOB CANC FACTS FIG, P37; Ayad E, 2016, VIRCHOWS ARCH, V469, pS191; Bustreo S, 2016, BREAST CANCER RES TR, V157, P363, DOI 10.1007/s10549-016-3817-9; Cheang MCU, 2009, JNCI-J NATL CANCER I, V101, P736, DOI 10.1093/jnci/djp082; Coates AS, 2015, ANN ONCOL, V26, P1533, DOI 10.1093/annonc/mdv221; Dowsett M, 2005, J CLIN ONCOL, V23, P2477, DOI 10.1200/JCO.2005.07.559; Dowsett M, 2011, J NATL CANCER I, V103, P1656, DOI 10.1093/jnci/djr393; Ellis MJ, 2011, J CLIN ONCOL, V29, P2342, DOI 10.1200/JCO.2010.31.6950; Fasanella S, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-S1-S7; FLEISS JL, 1973, EDUC PSYCHOL MEAS, V33, P613, DOI 10.1177/001316447303300309; Gnant M, 2017, BREAST CARE, V12, P102, DOI 10.1159/000475698; Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303; Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304; Gudlaugsson E, 2012, HISTOPATHOLOGY, V61, P1134, DOI 10.1111/j.1365-2559.2012.04329.x; Kayser K, 2012, ANAL CELL PATHOL, V35, P3, DOI 10.3233/ACP-2011-0044; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Luporsi E, 2012, BREAST CANCER RES TR, V132, P895, DOI 10.1007/s10549-011-1837-z; Maisonneuve P, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3679; Mohammed ZMA, 2012, BRIT J CANCER, V106, P383, DOI 10.1038/bjc.2011.569; Montemurro F, 2013, ANN ONCOL, V24, P2715, DOI 10.1093/annonc/mdt287; Nishimura R, 2014, MOL CLIN ONCOL, V2, P1062, DOI 10.3892/mco.2014.400; Pathmanathan N, 2014, J CLIN PATHOL, V67, DOI 10.1136/jclinpath-2013-201793; Polley MYC, 2013, JNCI-J NATL CANCER I, V105, P1897, DOI 10.1093/jnci/djt306; Purdie CA, 2014, BRIT J CANCER, V110, P565, DOI 10.1038/bjc.2013.756; Shui RH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125131; Soenksen D, 2009, ARCH PATHOL LAB MED, V133, P555, DOI 10.1043/1543-2165-133.4.555; Stalhammar G, 2016, MODERN PATHOL, V29, P318, DOI 10.1038/modpathol.2016.34; Stuart-Harris R, 2008, BREAST, V17, P323, DOI 10.1016/j.breast.2008.02.002; Suciu C, 2014, ONCOL LETT, V7, P107; Tan QX, 2014, INT J CLIN EXP PATHO, V7, P6862; Tashima R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119565; Trihia H, 2003, CANCER, V97, P1321, DOI 10.1002/cncr.11188; Urruticoechea A, 2005, J CLIN ONCOL, V23, P7212, DOI 10.1200/JCO.2005.07.501; Varga Z, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123435; Varga Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037379; Weinstein RS, 2009, HUM PATHOL, V40, P1057, DOI 10.1016/j.humpath.2009.04.006; Zhong FF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150505	39	1	1	2	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	AUG 28	2018	13								62	10.1186/s13000-018-0744-6			15	Pathology	Pathology	GR8FG	WOS:000442949400001	30153845	DOAJ Gold, Green Published			2019-10-28	
J	Weis, CA; Kather, JN; Melchers, S; Al-ahmdi, H; Pollheimer, MJ; Langner, C; Gaiser, T				Weis, Cleo-Aron; Kather, Jakob Nikolas; Melchers, Susanne; Al-ahmdi, Hanaa; Pollheimer, Marion J.; Langner, Cord; Gaiser, Timo			Automatic evaluation of tumor budding in immunohistochemically stained colorectal carcinomas and correlation to clinical outcome	DIAGNOSTIC PATHOLOGY			English	Review						Colorectal carcinoma; Digital pathology; Tumor budding; Image processing; Convolutional neural network	LYMPH-NODE METASTASIS; PREDICTIVE FACTORS; CANCER; ENTROPY; SYSTEM; METAANALYSIS	Background: Tumor budding, meaning a detachment of tumor cells at the invasion front of colorectal carcinoma (CRC) into single cells or clusters (<=5 tumor cells), has been shown to correlate to an inferior clinical outcome by several independent studies. Therefore, it has been discussed as a complementary prognostic factor to the TNM staging system, and it is already included in national guidelines as an additional prognostic parameter. However, its application by manual evaluation in routine pathology is hampered due to the use of several slightly different assessment systems, a time-consuming manual counting process and a high inter-observer variability. Hence, we established and validated an automatic image processing approach to reliably quantify tumor budding in immunohistochemically (IHC) stained sections of CRC samples. Methods: This approach combines classical segmentation methods (like morphological operations) and machine learning techniques (k-means and hierarchical clustering, convolutional neural networks) to reliably detect tumor buds in colorectal carcinoma samples immunohistochemically stained for pan-cytokeratin. As a possible application, we tested it on whole-slide images as well as on tissue microarrays (TMA) from a clinically well-annotated CRC cohort. Results: Our automatic tumor budding evaluation tool detected the absolute number of tumor buds per image with a very good correlation to the manually segmented ground truth (R2 value of 0.86). Furthermore the automatic evaluation of whole-slide images from 20 CRC-patients, we found that neither the detected number of tumor buds at the invasion front nor the number in hotspots was associated with the nodal status. However, the number of spatial clusters of tumor buds (budding hotspots) significantly correlated to the nodal status (p-value = 0.003 for N0 vs. N1/N2). TMAs were not feasible for tumor budding evaluation, as the spatial relationship of tumor buds (especially hotspots) was not preserved. Conclusions: Automatic image processing is a feasible and valid assessment tool for tumor budding in CRC on whole-slide images. Interestingly, only the spatial clustering of the tumor buds in hotspots (and especially the number of hotspots) and not the absolute number of tumor buds showed a clinically relevant correlation with patient outcome in our data.	[Weis, Cleo-Aron; Al-ahmdi, Hanaa; Gaiser, Timo] Heidelberg Univ, Univ Med Ctr Mannheim, Inst Pathol, D-68167 Mannheim, Germany; [Kather, Jakob Nikolas] Heidelberg Univ, Univ Heidelberg Hosp, Dept Med Oncol & Internal Med 6, Natl Ctr Tumor Dis, Heidelberg, Germany; [Melchers, Susanne] Heidelberg Univ, Univ Med Ctr Mannheim, Dept Dermatol Venereol & Allergol, Mannheim, Germany; [Pollheimer, Marion J.; Langner, Cord] Med Univ Graz, Inst Pathol, Graz, Austria	Weis, CA (reprint author), Heidelberg Univ, Univ Med Ctr Mannheim, Inst Pathol, D-68167 Mannheim, Germany.	cleo-aron.weis@medma.uni-heidelberg.de			Medical Faculty Mannheim, Heidelberg University [SEED fellowship]		Altman Y. M, 2014, ACCELERATING MATLAB; [Anonymous], 2015, MATLAB OBJ OR PROGR; Bosman Fred, 2010, CLASS TUM DIG SYST; Caie PD, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-156; Cromey DW, 2010, SCI ENG ETHICS, V16, P639, DOI 10.1007/s11948-010-9201-y; GABBERT H, 1985, CLIN EXP METASTAS, V3, P257, DOI 10.1007/BF01585081; Glasgow SC, 2012, J GASTROINTEST SURG, V16, P1019, DOI 10.1007/s11605-012-1827-4; Gonzalez R. C., 2013, DIGITAL IMAGE PROCES; Gospodarowicz M.K., 2017, TNM CLASSIFICATION M; Graham RP, 2015, AM J SURG PATHOL, V39, P1340, DOI 10.1097/PAS.0000000000000504; Harbaum L, 2015, MODERN PATHOL, V28, P403, DOI 10.1038/modpathol.2014.104; HASE K, 1993, DIS COLON RECTUM, V36, P627, DOI 10.1007/BF02238588; Hengl T., 2011, PRACTICAL GUIDE GEOS; Imai T., 1954, FUKUOKA IGAKU ZASSHI, V45, P102; Johnson R., 2002, US DATATOOL VERSION, P1; Johnson R., 2014, DATATOOL; Karamitopoulou E, 2013, MODERN PATHOL, V26, P295, DOI 10.1038/modpathol.2012.155; Kather JN, 2015, ONCOTARGET, V6, P19163, DOI 10.18632/oncotarget.4383; Kawachi H, 2015, MODERN PATHOL, V28, P872, DOI 10.1038/modpathol.2015.36; Kayser K, 1997, PROG HISTOCHEM CYTOC, V32, P1; Kayser K, 2007, ANAL QUANT CYTOL, V29, P296; Kayser K, 2009, DIAGN PATHOL, V4, DOI 10.1186/1746-1596-4-6; Koelzer VH, 2017, J PATHOL CLIN RES, V3, P171, DOI 10.1002/cjp2.73; Koelzer VH, 2016, HUM PATHOL, V47, P4, DOI 10.1016/j.humpath.2015.08.007; Koelzer VH, 2015, VIRCHOWS ARCH, V466, P485, DOI 10.1007/s00428-015-1740-9; Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft Deutsche Krebshilfe AWMF): S3-Leitlinie Kolorektales Karzinom, 2017, LEITL ONK DTSCH KREB; Magee D., 2009, P OPT TISS IM AN MIC; Mahajan S., 2010, STREET FIGHTING MATH; Max N, 2016, BRIT J CANCER, V114, P368, DOI 10.1038/bjc.2015.454; Mitrovic B, 2012, MODERN PATHOL, V25, P1315, DOI 10.1038/modpathol.2012.94; Mou S, 2013, SURG ENDOSC, V27, P2692, DOI 10.1007/s00464-013-2835-5; Nakamura T, 2005, HEPATO-GASTROENTEROL, V52, P1432; Okuyama T, 2003, DIS COLON RECTUM, V46, P1400, DOI 10.1097/01.DCR.0000084413.78455.89; OMERO, MATL TOOLB; Park KJ, 2005, DIS COLON RECTUM, V48, P1597, DOI 10.1007/s10350-005-0060-6; PINCUS SM, 1991, P NATL ACAD SCI USA, V88, P2297, DOI 10.1073/pnas.88.6.2297; Prall F, 2005, HISTOPATHOLOGY, V47, P17, DOI 10.1111/j.1365-2559.2005.02161.x; Prall F, 2007, HISTOPATHOLOGY, V50, P151, DOI 10.1111/j.1365-2559.2006.02551.x; Puppa G, 2010, ARCH PATHOL LAB MED, V134, P837, DOI 10.1043/1543-2165-134.6.837; Reinhard E, 2001, IEEE COMPUT GRAPH, V21, P34, DOI 10.1109/38.946629; Ruifrok AC, 2001, ANAL QUANT CYTOL, V23, P291; Satoh K, 2014, CANCER SCI, V105, P1487, DOI 10.1111/cas.12530; SHANNON CE, 1948, BELL SYST TECH J, V27, P623, DOI 10.1002/j.1538-7305.1948.tb00917.x; Taylor C, 2013, IMMUNOHISTOCHEMICAL; Trauth M., 2007, MATLAB RECIPES EARTH; Ueno H, 2002, HISTOPATHOLOGY, V40, P127, DOI 10.1046/j.1365-2559.2002.01324.x; Wada H, 2015, J GASTROENTEROL, V50, P727, DOI 10.1007/s00535-015-1057-0; Wainwright J., 2013, ENV MODELLING FINDIN; Weis CA, 2017, HISTOPATHOLOGY UNPUB; Weis CA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197435; Weis CA, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0383-0; Welsch U, 2010, ROMEIS MIKROSKOPISCH; Wittekind C, 2017, TNM KLASSIFIKATION M	53	1	1	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	AUG 28	2018	13								64	10.1186/s13000-018-0739-3			12	Pathology	Pathology	GR8FG	WOS:000442949400002	30153844	DOAJ Gold, Green Published			2019-10-28	
J	Chandra, S; Puri, N; Harsh, M; Juyal, AK				Chandra, Smita; Puri, Neeti; Harsh, Meena; Juyal, Anil Kumar			Cytological diagnosis of osteoblastoma of the talus: Case report with unusual presentation and diagnostic pitfalls	CYTOJOURNAL			English	Article						Diagnostic pitfalls; fine-needle aspiration cytology; osteoblastoma; talus	FINE-NEEDLE-ASPIRATION; LESIONS	Osteoblastoma is a rare bone tumor mostly affecting the young adults and commonly involving the spinal cord and long bones. Talus is the uncommon site of presentation, and if involved, then the neck is more commonly involved than the body of talus. The cytological diagnosis of osteoblastoma is limited, and to the best of our knowledge, its fine-needle aspiration (FNA) in the talus has still not been reported in the literature. The present case of osteoblastoma is, therefore, being reported due to the unusual presentation in elderly male in the body of talus and showing extensive involvement on X-ray. The case was initially diagnosed on FNA cytology excluding the possibility of giant-cell tumor and osteosarcoma. The case also highlights the importance of vigilant observation of subtle cytological features of this rare tumor which may be helpful in avoiding diagnostic pitfalls, especially at an uncommon site and with unusual presentation. An early precise diagnosis by cytology may be followed by appropriate treatment and thus avoiding any further complications.	[Chandra, Smita; Puri, Neeti; Harsh, Meena] Himalayan Inst Med Sci, Dept Pathol, Dehra Dun, Uttarakhand, India; [Juyal, Anil Kumar] Himalayan Inst Med Sci, Dept Orthopaed, Dehra Dun, Uttarakhand, India	Chandra, S (reprint author), Himalayan Inst Med Sci, Dept Pathol, Dehra Dun, Uttarakhand, India.	smita_harish@yahoo.com; neetipuri20@yahoo.com; harshmeena2@rediffmail.com; aniljuyal@srhu.edu.in					Akerman M, 2010, MONOGR CLIN CYTOL, V19, P18, DOI 10.1159/000242484; Bokhari K, 2012, CASE REP DENT, DOI 10.1155/2012/351241; CAPANNA R, 1986, SKELETAL RADIOL, V15, P360, DOI 10.1007/BF00348862; Domanski HA, 2010, DIAGNOSTIC CYTOPATHO, P797; El-Badawi Zeinab H, 2012, Malays J Pathol, V34, P15; Gupta N, 2011, ACTA CYTOL, V55, P135, DOI 10.1159/000320907; Khan L, 2012, INT J CASE REP IMAG, V3, P34; Kunze Ekkehard, 1996, General and Diagnostic Pathology, V141, P377; LAYFIELD LJ, 1993, DIAGN CYTOPATHOL, V9, P168, DOI 10.1002/dc.2840090212; Malcolm AJ, 2002, WHO CLASSIFICATION T, P262; Mir Naseer Ahmed, 2010, Foot Ankle Surg, V16, pe24, DOI 10.1016/j.fas.2009.05.007; Patil Kiran S, 2014, J Orthop Case Rep, V4, P22, DOI 10.13107/jocr.2250-0685.218; Rhode MG, 2006, DIAGN CYTOPATHOL, V34, P295, DOI 10.1002/dc.20436; Sathiyamoorthy S, 2012, ACTA CYTOL, V56, P481, DOI 10.1159/000339196; Unni KK, 1996, DAHLINS BONE TUMORS, P131; Venugopal SB, 2015, DIAGN CYTOPATHOL, V43, P218, DOI 10.1002/dc.23175; Villalobos CE, 2010, BULL HOSP JT DIS, V68, P55	17	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0974-5963	1742-6413		CYTOJOURNAL	CytoJournal	AUG 27	2018	15								20	10.4103/cytojournal.cytojournal_39_17			5	Pathology	Pathology	GT3IS	WOS:000444395900002	30197661	DOAJ Gold, Green Published			2019-10-28	
J	Kumar, V; Agarwal, P; Marwah, S; Nigam, AS; Tiwari, A				Kumar, Vijay; Agarwal, Poojan; Marwah, Sadhna; Nigam, A. S.; Tiwari, Awantika			Spectrum of clinicohematological profile and its correlation with average parasite density in visceral leishmaniasis	CYTOJOURNAL			English	Article						Average parasite density; bone marrow aspirate; hemophagocytosis; Leishman-Donovan body; visceral leishmaniasis	KALA-AZAR; BONE-MARROW; UTTARAKHAND; DIAGNOSIS; CHILDREN; ANEMIA; INDIA; AREA	Background: Leishmaniasis is the prevalent in tropical and subtropical regions of the world. Demonstration of Leishman-Donovan (LD) bodies in the bone marrow aspirates (BMA) is vital to diagnosis of visceral leishmaniasis (VL). In the present study, we studied the clinicohematological parameters encountered in VL and correlated them with parasite load on BMA. Methods: Retrospective analysis over 3 years was done; clinical details, biochemical profile, complete hemogram with peripheral smear findings, and BMA smears were reviewed and average parasite density (APD) calculated in each case. Multivariate analysis and tests of significance were applied. Results: The study included 28 patients. Splenomegaly showed a positive trend with APD. rK39 antigen detection test was 100% positive in select cases. A strong negative correlation was observed between albumin to globulin ratio and grade of APD. BMA revealed hemophagocytosis (HPS) in 78.57% cases and it had a significant strong correlation with APD (P = 0.014). A significant correlation was also observed between APD and bone marrow plasma cell percentage (P = 0.01). LD bodies were noted in unusual locations such as within myelocytes (14.2%), plasma cells (7.1%), and megakaryocytes (10.7%). Conclusion: HPS and bone marrow plasmacytosis were two statistically significant findings, which showed positive correlation with parasite load. The presence of these two findings should prompt hematopathologists for more focused search of hemoparasites in BMA to arrive at a definitive diagnosis. This will avoid unnecessary workups and improve the prognosis. To the best of our knowledge, a statistical correlation between APD and clinicohematological parameters has never been previously studied.	[Kumar, Vijay; Agarwal, Poojan; Marwah, Sadhna; Nigam, A. S.; Tiwari, Awantika] PGIMER, Dr RML Hosp, Dept Pathol, New Delhi, India	Agarwal, P (reprint author), PGIMER, Dr RML Hosp, Dept Pathol, New Delhi, India.	vijaypgi1@gmail.com; poojanagarwal@gmail.com; marwah.sadhna@gmail.com; abhaysnigam@yahoo.co.in; awantika9dat@gmail.com					AIKAT BK, 1979, INDIAN J MED RES, V70, P571; Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671; Ashok Kumar, 2012, Journal of Communicable Diseases, V44, P145; Bhatia P, 2011, MEDITERR J HEMATOL I, V3, DOI 10.4084/MJHID.2011.035; Canavate C, 2011, AM J TROP MED HYG, V84, P102, DOI 10.4269/ajtmh.2011.10-0229; CARTWRIGHT GE, 1948, BLOOD, V3, P249, DOI 10.1182/blood.V3.3.249.249; Chakrabarti S, 2013, SE ASIAN J TROP MED, V44, P143; Chufal SS, 2016, J CLIN DIAGN RES, V10, pEC39, DOI 10.7860/JCDR/2016/15438.7885; Daneshbod Y, 2010, ACTA CYTOL, V54, P12, DOI 10.1159/000324961; Dhingra KK, 2010, INDIAN J PATHOL MICR, V53, P96, DOI 10.4103/0377-4929.59193; ELHAG IA, 1994, J CLIN PATHOL, V47, P547, DOI 10.1136/jcp.47.6.547; Ezra N, 2010, J GLOB INFECT DIS, V2, P248, DOI 10.4103/0974-777X.68528; Hamid GA, 2009, TURK J HEMATOL, V26, P25; HICSONMEZ G, 1977, CLIN PEDIATR, V16, P733, DOI 10.1177/000992287701600811; Kafetzis DA, 2002, CURR OPIN INFECT DIS, V15, P289, DOI 10.1097/00001432-200206000-00012; MARWAHA N, 1991, TROP GEOGR MED, V43, P357; Nandi M, 2012, S AFR J CHILD HEALTH, V6, P88, DOI 10.7196/SAJCH.446; Oligilvie C, 1987, CHAMBERLAINES SYMPTO, P490; Pati B, 2009, ROUT STUD S ASIA HIS, P1; Ponirovsky E N, 2015, Med Parazitol (Mosk), P62; Rajagopala S, 2008, J INFECTION, V56, P381, DOI 10.1016/j.jinf.2008.02.013; Sarkari B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150406; SCHAEFER KU, 1995, TROP GEOGR MED, V47, P111; Shahriar D, 1999, DIAGN CYTOPATHOL, V20, P208, DOI 10.1002/(SICI)1097-0339(199904)20:4<208::AID-DC5>3.0.CO;2-N; Singh ZN, 2005, CLIN LAB HAEMATOL, V27, P312, DOI 10.1111/j.1365-2257.2005.00717.x; Sula B, 2015, J MICROBIOLOGY INFEC, V5, P167; Sundar S, 2002, CLIN DIAGN LAB IMMUN, V9, P951, DOI 10.1128/CDLI.9.5.951-958.2002; Temiz F, 2014, INDIAN J HEMATOL BLO, V30, P19, DOI 10.1007/s12288-012-0189-0; van Griensven J, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002916; Varma N, 2010, INDIAN J HEMATOL BLO, V26, P78, DOI 10.1007/s12288-010-0027-1; WICKRAMASINGHE SN, 1987, J CLIN PATHOL, V40, P267, DOI 10.1136/jcp.40.3.267; WOODRUFF AW, 1972, BRIT J HAEMATOL, V22, P319, DOI 10.1111/j.1365-2141.1972.tb05678.x; Yarali N, 2002, AM J HEMATOL, V71, P191, DOI 10.1002/ajh.10200	33	1	1	0	2	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0974-5963	1742-6413		CYTOJOURNAL	CytoJournal	AUG 27	2018	15								19	10.4103/cytojournal.cytojournal_38_17			7	Pathology	Pathology	GT3IS	WOS:000444395900001	30197660	DOAJ Gold, Green Published			2019-10-28	
J	Mir, M; Parmley, M; Molberg, K; Hinson, S; Thibodeaux, J; Lucas, E				Mir, Mariam; Parmley, Michelle; Molberg, Kyle; Hinson, Stacy; Thibodeaux, Joel; Lucas, Elena			Lung tumor in a young African American patient with sickle trait: Pieces of a puzzle	CYTOJOURNAL			English	Editorial Material							RENAL MEDULLARY CARCINOMA; DIAGNOSIS; CYTOLOGY; FEATURES		[Mir, Mariam; Parmley, Michelle; Molberg, Kyle; Hinson, Stacy; Thibodeaux, Joel; Lucas, Elena] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA	Lucas, E (reprint author), Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA.	mariam.mir@utsouthwestern.edu; michelle.parmley@phhs.org; kyle.molberg@utsouthwestern.edu; stacy.hinson@utsouthwestern.edu; joel.thibodeaux@utsouthwestern.edu; elena.lucas@utsouthwestern.edu					Albadine R, 2009, J UROLOGY, V182, P735, DOI 10.1016/j.juro.2009.03.078; Alvarez O, 2015, PEDIATR BLOOD CANCER, V62, P1694, DOI 10.1002/pbc.25592; Assad L, 2005, CANCER CYTOPATHOL, V105, P28, DOI 10.1002/cncr.20764; DAVIS CJ, 1995, AM J SURG PATHOL, V19, P1, DOI 10.1097/00000478-199501000-00001; DeMay RM, 2012, ART SCI CYTOPATHOLOG; Dimashkieh Haytham, 2003, Arch Pathol Lab Med, V127, pe135; Ellis CL, 2009, DIAGN CYTOPATHOL, V37, P843, DOI 10.1002/dc.21111; Gupta R, 2012, AM J SURG PATHOL, V36, P1265, DOI 10.1097/PAS.0b013e3182635954; Hollmann TJ, 2011, AM J SURG PATHOL, V35, pE47, DOI 10.1097/PAS.0b013e31822b325b; Iacovelli R, 2015, CUAJ-CAN UROL ASSOC, V9, pE172, DOI 10.5489/cuaj.2373; Larson DM, 1998, DIAGN CYTOPATHOL, V18, P276, DOI 10.1002/(SICI)1097-0339(199804)18:4<276::AID-DC5>3.0.CO;2-A; Liu QY, 2013, AM J SURG PATHOL, V37, P368, DOI 10.1097/PAS.0b013e3182770406; Mathur SC, 2000, ARCH PATHOL LAB MED, V124, P1561; Qi JF, 2001, ACTA CYTOL, V45, P735, DOI 10.1159/000328296; Shah AY, 2017, BJU INT, V120, P782, DOI 10.1111/bju.13705; Shetty A, 2014, OCHSNER J, V14, P270; Swartz MA, 2002, UROLOGY, V60, P1083, DOI 10.1016/S0090-4295(02)02154-4; Tripathy K, 2015, CYTOPATHOLOGY, V26, P328, DOI 10.1111/cyt.12225; Wartchow EP, 2008, ULTRASTRUCT PATHOL, V32, P252, DOI 10.1080/01913120802591875; Watanabe IC, 2007, MODERN PATHOL, V20, P914, DOI 10.1038/modpathol.3800934; Yang XMJ, 2004, CANCER-AM CANCER SOC, V100, P976, DOI 10.1002/cncr.20049	21	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0974-5963	1742-6413		CYTOJOURNAL	CytoJournal	AUG 27	2018	15								21	10.4103/cytojournal.cytojournal_57_17			5	Pathology	Pathology	GT3IS	WOS:000444395900003	30197662	DOAJ Gold, Green Published			2019-10-28	
J	Dogan, HT; Kiran, M; Bilgin, B; Kilicarslan, A; Sendur, MAN; Yalcin, B; Ardicoglu, A; Atmaca, AF; Gumuskaya, B				Dogan, Hayriye Tatli; Kiran, Merve; Bilgin, Burak; Kilicarslan, Aydan; Sendur, Mehmet Ali Nahit; Yalcin, Bulent; Ardicoglu, Arslan; Atmaca, Ali Fuat; Gumuskaya, Berrak			Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression	DIAGNOSTIC PATHOLOGY			English	Article						PD-L1; PD-1; HIF; Renal cell carcinoma	PD-L1 EXPRESSION; METAANALYSIS; CANCER; B7-H1; IMMUNOTHERAPY; ACTIVATION; SUNITINIB; BIOMARKER; IMMUNITY; ESCAPE	Background: Clear cell renal cell carcinoma (ccRCC) is the most common renal malignancy. Hypoxia-inducible factors, HIF-1 alpha and HIF-2 alpha, are expressed in the majority of ccRCC. Targeting immune checkpoints with the blockade of PD-1 and its ligand PD-L1 reorganizes T-cell activity in tumor microenvironment and provides important antitumor responses. PD-L1 upregulation has been found to be hypoxia-inducible factor (HIF) dependent. Our aim is to demonstrate the association between PD-L1 and HIF expression and to reveal the role of PD-L1 in prognosis and its association with tumor microenvironment. Methods: Surgical specimens from 145 patients diagnosed with ccRCC, who had undergone radical or partial nephrectomy, were retrospectively analyzed. Immunohistochemistry on tissue microarrays (TMA) was performed to demonstrate expressions of PD-L1, HIF-1 alpha, and HIF-2 alpha in tumor cells and PD-1, CD4, and CD8 in lymphocytes to assess lymphocyte density in tumor microenvironment. Results: PD-L1 tumor cell expression was detected in 20/125 (13.8%) cases, which correlated with higher levels of PD-1, CD4, CD8 and HIF-2 alpha expression. Low or high expression of HIF-1 alpha was similar in PD-L1-positive cases. When PD-L1-positive cases were compared with negative ones, there was no significant difference in terms of prognostic factors. However, the number of WHO/ISUP grade 3-4 tumors was significantly higher in PD-L1positive cases than in negative ones. Conclusion: PD-L1 tumor cell expression is strongly associated with increased HIF-2 alpha expression and presence of dense lymphocytic infiltration in ccRCCs. Our findings confirm that PD-L1 positivity is associated with high ISUP nucleolar grade. The association between PD-L1, HIF, and lymphocyte density in tumor microenvironment must be clarified and especially taken into account in combination treatment.	[Dogan, Hayriye Tatli; Kilicarslan, Aydan; Gumuskaya, Berrak] Ankara Yildirim Beyazit Univ, Dept Pathol, Fac Med, Ankara, Turkey; [Kiran, Merve] Usak Univ, Educ & Res Hosp, Dept Pathol, Usak, Turkey; [Bilgin, Burak] Ankara Ataturk Educ & Res Hosp, Dept Oncol, Ankara, Turkey; [Sendur, Mehmet Ali Nahit; Yalcin, Bulent] Ankara Yildirim Beyazit Univ, Dept Oncol, Fac Med, Ankara, Turkey; [Ardicoglu, Arslan; Atmaca, Ali Fuat] Ankara Yildirim Beyazit Univ, Dept Urol, Fac Med, Ankara, Turkey	Dogan, HT (reprint author), Ankara Yildirim Beyazit Univ, Dept Pathol, Fac Med, Ankara, Turkey.	hayriyetatli@gmail.com					Baldewijns MM, 2010, J PATHOL, V221, P125, DOI 10.1002/path.2689; Barsoum IB, 2014, CANCER RES, V74, P7185, DOI 10.1158/0008-5472.CAN-14-2598; Barsoum IB, 2014, CANCER RES, V74, P665, DOI 10.1158/0008-5472.CAN-13-0992; Beuselinck B, 2015, CLIN CANCER RES, V21, P1329, DOI 10.1158/1078-0432.CCR-14-1128; Biswas S, 2012, CARCINOGENESIS, V33, P1717, DOI 10.1093/carcin/bgs222; Callea M, 2015, CANCER IMMUNOL RES, V3, P1158, DOI 10.1158/2326-6066.CIR-15-0043; Chen WF, 2016, NATURE, V539, P112, DOI 10.1038/nature19796; Choueiri TK, 2015, CLIN CANCER RES, V21, P1071, DOI 10.1158/1078-0432.CCR-14-1993; Fan Y, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001646; Frew IJ, 2015, ANNU REV PATHOL-MECH, V10, P263, DOI 10.1146/annurev-pathol-012414-040306; Frigola X, 2011, CLIN CANCER RES, V17, P1915, DOI 10.1158/1078-0432.CCR-10-0250; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Giraldo NA, 2017, CLIN CANCER RES, V23, P4416, DOI 10.1158/1078-0432.CCR-16-2848; Iacovelli R, 2016, TARGET ONCOL, V11, P143, DOI 10.1007/s11523-015-0392-7; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; Kammerer-Jacquet SF, 2017, INT J CANCER, V140, P142, DOI 10.1002/ijc.30429; Keir ME, 2007, CURR OPIN IMMUNOL, V19, P309, DOI 10.1016/j.coi.2007.04.012; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Leite KRM, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0414-x; Messai Y, 2016, EUR UROL, V70, P623, DOI 10.1016/j.eururo.2015.11.029; Miyazaki T, 2017, J NEURO-ONCOL, V133, P277, DOI 10.1007/s11060-017-2451-7; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Ning XH, 2017, ONCOTARGET, V8, P3355, DOI 10.18632/oncotarget.13765; Noman MZ, 2014, J EXP MED, V211, P781, DOI 10.1084/jem.20131916; Patel SP, 2015, MOL CANCER THER, V14, P847, DOI 10.1158/1535-7163.MCT-14-0983; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Robb VA, 2007, J UROLOGY, V177, P346, DOI 10.1016/j.juro.2006.08.076; Ruf M, 2016, INT J CANCER, V139, P396, DOI 10.1002/ijc.30077; Thompson RH, 2007, CLIN CANCER RES, V13, P1757, DOI 10.1158/1078-0432.CCR-06-2599; Thompson RH, 2006, CANCER RES, V66, P3381, DOI 10.1158/0008-5472.CAN-05-4303; Thompson RH, 2005, CANCER, V104, P2084, DOI 10.1002/cncr.21470; Thompson RH, 2004, P NATL ACAD SCI USA, V101, P17174, DOI 10.1073/pnas.0406351101; Udall M, 2018, DIAGN PATHOL, V13, DOI 10.1186/s13000-018-0689-9; Wang Z, 2018, CLIN EXP MED, V18, P165, DOI 10.1007/s10238-018-0488-3; World Health Organization, 2016, CLASS TUM UR SYST MA; Xu F, 2015, INT J CLIN EXP MED, V8, P14595; Zhu J, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0314-1	37	8	8	0	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	AUG 25	2018	13								60	10.1186/s13000-018-0742-8			9	Pathology	Pathology	GR4RK	WOS:000442604000002	30144808	DOAJ Gold, Green Published			2019-10-28	
J	Chang, J; Chen, Q; Jian, Y; Wei, P; Yang, GZ; Wang, Y; Fang, XY; Sun, QM				Chang, Jing; Chen, Qing; Jian, Yuan; Wei, Ping; Yang, Guang-Zhong; Wang, Ying; Fang, Xiang-Yang; Sun, Qian-Mei			Simultaneous occurrence of splenic diffuse large B cell lymphoma and gastrointestinal stromal tumor in the stomach: a case report	DIAGNOSTIC PATHOLOGY			English	Article						Lymphoma; Diffuse large B-cell lymphoma; Gastrointestinal stromal tumor; Splenectomy	SYNCHRONOUS OCCURRENCE; SPLEEN	Background: Although the primary malignant spleen tumor is relatively rare, lymphoma is the most common splenic malignancy. It can have quite different clinical manifestations that usually lead to relatively poor outcomes, and thus early and accurate diagnosis are of utmost importance. Case presentation: The present study reports a case of a 67-year-old female with high fever, abnormal spleen (diagnosed by PET/CT) and no obvious lymph node enlargement. After being subjected to splenectomy, the patient was diagnosed with splenic diffuse large B cell lymphoma coexisting with gastrointestinal stromal tumor in the stomach. Conclusions: To our knowledge, splenic lymphoma accompanied by gastrointestinal stromal tumor in the stomach is rarely reported. This case report discusses the diagnosis and case management of a patient referring to the existing literature.	[Chang, Jing; Chen, Qing; Fang, Xiang-Yang; Sun, Qian-Mei] Capital Med Univ, Beijing Chao Yang Hosp, Dept Internal Med, Gong Ti South Rd 8, Beijing, Peoples R China; [Jian, Yuan; Yang, Guang-Zhong] Capital Med Univ, Beijing Chao Yang Hosp, Dept Hematol, Beijing, Peoples R China; [Wei, Ping; Wang, Ying] Capital Med Univ, Beijing Chao Yang Hosp, Dept Pathol, Beijing, Peoples R China	Sun, QM (reprint author), Capital Med Univ, Beijing Chao Yang Hosp, Dept Internal Med, Gong Ti South Rd 8, Beijing, Peoples R China.	sunqianmei5825@126.com					Gao N, 2016, ONCOL LETT, V11, P2977, DOI 10.3892/ol.2016.4353; Han SM, 2008, J CHIN MED ASSOC, V71, P210, DOI 10.1016/S1726-4901(08)70106-0; Iannitto E, 2011, BLOOD, V117, P2585, DOI 10.1182/blood-2010-09-271437; Iorio N, 2014, ALIMENT PHARM THER, V39, P1376, DOI 10.1111/apt.12761; KEHOE J, 1988, CANCER, V62, P1433, DOI 10.1002/1097-0142(19881001)62:7<1433::AID-CNCR2820620731>3.0.CO;2-V; Li M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080264; Ma J, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2016.125; Mollejo M, 2003, AM J SURG PATHOL, V27, P895, DOI 10.1097/00000478-200307000-00004; Murphy JD, 2015, CANCER-AM CANCER SOC, V121, P2960, DOI 10.1002/cncr.29434; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Takahashi T, 2016, INTERNAL MED, V55, P2951, DOI 10.2169/internalmedicine.55.6712	11	0	0	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	AUG 25	2018	13								61	10.1186/s13000-018-0741-9			5	Pathology	Pathology	GR4RK	WOS:000442604000003	30144813	DOAJ Gold, Green Published			2019-10-28	
J	Pan, ZY; Chen, J; Wu, Q; Hu, TT; Lu, LY; Ju, Q				Pan, Zhan-Yan; Chen, Jia; Wu, Qiong; Hu, Ting-Ting; Lu, Lingyi; Ju, Qiang			Activation and overexpression of the aryl hydrocarbon receptor contribute to cutaneous squamous cell carcinomas: an immunohistochemical study	DIAGNOSTIC PATHOLOGY			English	Article						Aryl hydrocarbon receptor; Nonmelanoma skin cancer; Immunohistochemical study	NONMELANOMA SKIN-CANCER; AHR; RADIATION; MICE	Background: In vitro studies showed that the aryl hydrocarbon receptor (AHR) contributed to the development of cutaneous squamous cell carcinomas, but supporting clinical data are lacking. Methods: Immunohistochemical analysis was used to detect the expression of AHR, CYP1A1, EGFR, and Ki-67 in 10 actinic keratosis (AK) cases, 10 Bowen disease (BD) cases, 20 cutaneous squamous cell carcinoma (cSCC) cases and 20 normal skin samples. H-scores were used to assess the immunoreactivity. Results: Weak positive AHR immunoreactivity was found in all normal skin samples, while strong positive AHR immunoreactivity was found in atypical squamous proliferation (AK, BD and cSCC) cases. H-scores and the rate of strong immunostaining of the atypical squamous proliferation cases were higher than those of normal controls (p < 0.01). Nuclear expression of AHR was higher in atypical squamous proliferation cases than in normal controls (p < 0.01). H-scores and the nuclear expression rate of AHR were significantly higher in AK and BD cases than cSCC cases (p < 0.01). CYP1A1 expression was low and showed no differences among the four studied groups (p > 0.05). The H-score of AHR was positively correlated with EGFR expression (r = 0.54, p < 0.01) in atypical squamous proliferation cases but was not correlated with CYP1A1 (r = -0.17, p = 0.295) and Ki-67 (r = -0.48, p = 0.222) expression. Conclusion: AHR plays a vital role in cSCC pathogenesis. The overexpression and activation of AHR are involved in the early development of skin cancers. AHR expression correlates with EGFR expression and may influence cell proliferation. AHR is a valuable therapeutic target for skin cancers.	[Pan, Zhan-Yan; Wu, Qiong; Hu, Ting-Ting; Ju, Qiang] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Dermatol, Pujian Rd 160, Shanghai 200127, Peoples R China; [Chen, Jia] Tongji Univ, Shanghai Skin Dis Hosp, Shanghai, Peoples R China; [Lu, Lingyi] Ningbo First Hosp, Dept Dermatol, Ningbo, Zhejiang, Peoples R China	Ju, Q (reprint author), Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Dermatol, Pujian Rd 160, Shanghai 200127, Peoples R China.	qiangju401@sina.com			National Science Foundation of China Research project [81602772]; Project of Shanghai Municipal Commission of Health and Family Planning [20134381]	The work was supported by the National Science Foundation of China Research project (No. 81602772). And Project of Shanghai Municipal Commission of Health and Family Planning (No. 20134381).	Bahnassy AA, 2004, BMC GASTROENTEROL, V4, DOI 10.1186/1471-230X-4-22; Bode Ann M, 2003, Sci STKE, V2003, pRE2, DOI 10.1126/stke.2003.167.re2; Cooper SJ, 2007, CURR CANCER DRUG TAR, V7, P325, DOI 10.2174/156800907780809714; Dhanalakshmi S, 2004, CARCINOGENESIS, V25, P1459, DOI 10.1093/carcin/bgh152; Dickel H, 2016, J DTSCH DERMATOL GES, V14, P1284, DOI 10.1111/ddg.13003; Esser C, 2013, SEMIN IMMUNOPATHOL, V35, P677, DOI 10.1007/s00281-013-0394-4; Feng SL, 2013, BBA-REV CANCER, V1836, P197, DOI 10.1016/j.bbcan.2013.05.001; Frauenstein K, 2013, CELL DEATH DIFFER, V20, P1425, DOI 10.1038/cdd.2013.102; Frauenstein K, 2014, PHOTODERMATOL PHOTO, V30, P343; Fritsche E, 2007, P NATL ACAD SCI USA, V104, P8851, DOI 10.1073/pnas.0701764104; Halpern AC, 2004, INT J DERMATOL, V43, P638, DOI 10.1111/j.1365-4632.2004.02124.x; Ikuta T, 2009, BIOCHEM PHARMACOL, V77, P588, DOI 10.1016/j.bcp.2008.10.003; Ishibashi H, 2003, J CLIN ENDOCR METAB, V88, P2309, DOI 10.1210/jc.2002-021353; Mescher M, 2017, J INVEST DERMATOL, V137, pS125, DOI 10.1016/j.jid.2017.02.751; Nebert DW, 2004, J BIOL CHEM, V279, P23847, DOI 10.1074/jbc.R400004200; Nestor Mark S, 2012, J Clin Aesthet Dermatol, V5, P20; Opitz CA, 2011, NATURE, V478, P197, DOI 10.1038/nature10491; Ray S, 2009, BIOCHEM PHARMACOL, V77, P681, DOI 10.1016/j.bcp.2008.11.022; Seleit I, 2015, ULTRASTRUCT PATHOL, V39, P306, DOI 10.3109/01913123.2015.1022241; Shaik S, 2016, J INVEST DERMATOL, V136, pS101, DOI 10.1016/j.jid.2016.02.609; Shimizu Y, 2000, P NATL ACAD SCI USA, V97, P779, DOI 10.1073/pnas.97.2.779; Stern RS, 2010, ARCH DERMATOL, V146, P279, DOI 10.1001/archdermatol.2010.4; Wollina U, 2012, EXPERT OPIN BIOL TH, V12, P949, DOI 10.1517/14712598.2012.681374; Yang XH, 2008, J CELL BIOCHEM, V104, P402, DOI 10.1002/jcb.21630	24	0	0	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	AUG 25	2018	13								59	10.1186/s13000-018-0740-x			7	Pathology	Pathology	GR4RK	WOS:000442604000001	30144817	DOAJ Gold, Green Published			2019-10-28	
J	Williams, HJ				Williams, H. James			Educational Case: Fibroadenoma of the Breast	ACADEMIC PATHOLOGY			English	Article						pathology competencies; organ system pathology; disease mechanisms; breast; neoplasia; fibroadenoma; palpable breast lesion; mammographic findings; phyllodes tumor		The following fictional case is intended as a learning tool within the Pathology Competencies for Medical Education (PCME), a set of national standards for teaching pathology. These are divided into three basic competencies: Disease Mechanisms and Processes, Organ System Pathology, and Diagnostic Medicine and Therapeutic Pathology. For additional information, and a full list of learning objectives for all three competencies, see http://journals.sagepub.com/doi/10.1177/2374289517715040.	[Williams, H. James] West Virginia Univ, Hlth Sci Ctr, POB 9203, Morgantown, WV 26506 USA	Williams, HJ (reprint author), West Virginia Univ, Hlth Sci Ctr, POB 9203, Morgantown, WV 26506 USA.	hjwilliams@hsc.wvu.edu					Hubbard JL, 2015, AM J SURG, V209, P297, DOI 10.1016/j.amjsurg.2013.12.037; Kuijper A, 2001, AM J CLIN PATHOL, V115, P736; Kumar V, 2014, ROBBINS COTRAN PATHO, P1069	3	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	AUG 24	2018	5								UNSP 2374289518790926	10.1177/2374289518790926			4	Pathology	Pathology	GR4ET	WOS:000442556000001	30159386	DOAJ Gold, Green Published			2019-10-28	
J	Rivkine, E; Marciano, L; Polliand, C; Valenti, A; Ziol, M; Poncelet, C; Barrat, C				Rivkine, Emmanuel; Marciano, Lea; Polliand, Claude; Valenti, Antonio; Ziol, Marianne; Poncelet, Christophe; Barrat, Christophe			Ileocolic intussusception due to a cecal endometriosis: Case report and review of literature (vol 7, 62, 2012)	DIAGNOSTIC PATHOLOGY			English	Correction									[Rivkine, Emmanuel; Polliand, Claude; Valenti, Antonio; Barrat, Christophe] Univ Hosp Jean Verdier, AP HP, Dept Digest & Endocrine Surg, Ave 14 Juillet, F-93140 Paris, France; [Marciano, Lea; Ziol, Marianne] Univ Hosp Jean Verdier, AP HP, Dept Pathol, Ave 14 Juillet, F-93143 Bondy, France; [Poncelet, Christophe] Univ Hosp Jean Verdier, AP HP, Dept Obstet & Gynaecol, Ave 14 Juillet, F-93143 Bondy, France; [Poncelet, Christophe] Univ Hosp Jean Verdier, AP HP, ART Ctr, Ave 14 Juillet, F-93143 Bondy, France	Rivkine, E (reprint author), Univ Hosp Jean Verdier, AP HP, Dept Digest & Endocrine Surg, Ave 14 Juillet, F-93140 Paris, France.	emmanuel.rivkine@jvr.aphp.fr	Ziol, Marianne/AAC-5801-2019	Ziol, Marianne/0000-0001-5117-4842			Emmanuel R, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-62	1	0	0	0	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	AUG 24	2018	13								58	10.1186/s13000-018-0723-y			1	Pathology	Pathology	GR4RJ	WOS:000442603800001	30143007	DOAJ Gold, Green Published			2019-10-28	
J	Westover, C; Conran, RM				Westover, Clinton; Conran, Richard Michael			Educational Case: Pheochromocytoma	ACADEMIC PATHOLOGY			English	Article						pathology competencies; organ system pathology; endocrine; pheochromocytoma; paraganglioma; adrenal tumor; multiple endocrine neoplasia; secondary hypertension; familial pheochromocytoma-paraganglioma syndrome		The following fictional case is intended as a learning tool within the Pathology Competencies for Medical Education (PCME), a set of national standards for teaching pathology. These are divided into three basic competencies: Disease Mechanisms and Processes, Organ System Pathology, and Diagnostic Medicine and Therapeutic Pathology. For additional information, and a full list of learning objectives for all three competencies, see http://journals.sagepub.com/doi/10.1177/2374289517715040.	[Westover, Clinton; Conran, Richard Michael] Eastern Virginia Med Sch, 700 West Olney, Norfolk, VA 23507 USA	Conran, RM (reprint author), Eastern Virginia Med Sch, 700 West Olney, Norfolk, VA 23507 USA.	conranrm@evms.edu					[Anonymous], GEN HOM REF; Arnold David T, 2003, Proc (Bayl Univ Med Cent), V16, P7; DeLellis RA, 2004, WHO CLASSIFICATION T; Kirmani A, 2008, GENE REV; Maitra A, 2015, THE ENDOCRINE SYSTEM, P1134; McKenney JK, 2018, ADRENAL GLAND OTHER, P1205; McNicol AM, 2004, TUMOURS ENDOCRINE OR, P151; NATHANSON K, 2004, WHO CLASSIFICATION T, V4, P238; Pawlu C, 2005, ANN ENDOCRINOL-PARIS, V66, P178; Shuch Brian, 2014, Urology, V83, P1225, DOI 10.1016/j.urology.2014.01.007; Tischler AS, 2008, ARCH PATHOL LAB MED, V132, P1272, DOI 10.1043/1543-2165(2008)132[1272:PAEPU]2.0.CO;2; Welander J, 2011, ENDOCR-RELAT CANCER, V18, pR253, DOI 10.1530/ERC-11-0170	12	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	AUG 23	2018	5								UNSP 2374289518780500	10.1177/2374289518780500			6	Pathology	Pathology	GR4ES	WOS:000442555900001	30151422	DOAJ Gold, Green Published			2019-10-28	
J	Ma, SR; Fan, LN; Liu, YX; Wang, YM; Yu, KJ; Wang, LF; Fang, N; Liu, F; Guo, SP; Wang, Z				Ma, Shirong; Fan, Linni; Liu, Yixiong; Wang, Yingmei; Yu, Kangjie; Wang, Lifeng; Fang, Na; Liu, Fang; Guo, Shuangping; Wang, Zhe			MET-overexpressing myxofibrosarcoma frequently exhibit polysomy of chromosome 7 but not MET amplification, especially in high-grade cases: clinical and pathological review of 30 myxofibrosarcoma cases	DIAGNOSTIC PATHOLOGY			English	Review						Myxofibrosarcoma; MET; FISH; Chromosome 7 polysomy	CELL LUNG-CANCER; GENE AMPLIFICATION; PROTEIN OVEREXPRESSION; PROGNOSTIC-FACTORS; TUMOR PROGRESSION; COPY NUMBER; RECURRENCE; SURVIVAL; SERIES; CARCINOMAS	Background: Myxofibrosarcoma (MFS) is one of the most common soft tissue sarcomas. Previous studies have shown that MET protein overexpressed in MFS patients and can serve as a prognostic factor. The reasons for MET protein overexpression include amplification of the MET gene, which is located on chromosome 7q. Triggered by an index case harboring chromosome 7 polysomy rather than MET gene amplification in myxofibrosarcoma, we investigated chromosome 7 polysomy in more cases. Methods: Immunohistochemistry and fluorescence in situ hybridization (FISH) were performed in 30 MFS cases (including 2 epithelioid variant) to detect the expression of MET protein and gene status. Results: MET was overexpressed in 14 cases out of 30, while thirteen cases were in higher FNCLCC grades (Grade 2-3). FISH showed that 11 cases having 3 signals on average of Met and more than 3 signals (Mean: 4.6) of centromere 7q (CEP7q). The MET/CEP7 ratio was about 0.65 on average, suggesting that chromosome 7 polysomy, rather than Met gene amplification, leading to the overexpression of MET protein in MFS. MET overexpression and chromosome 7 polysomy are positively correlated with higher Ki-67 index and higher grade and might have a high risk of local recurrence and metastasis. Conclusions: It might reveals another explain of MET overexpression in myxofibrosarcoma, providing a clue for the therapy of MFS.	[Ma, Shirong; Fan, Linni; Liu, Yixiong; Wang, Yingmei; Guo, Shuangping; Wang, Zhe] Fourth Mil Med Univ, Xijing Hosp, State Key Lab Canc Biol, Dept Pathol, West Rd 169, Xian 710032, Changle, Peoples R China; [Yu, Kangjie] Fourth Mil Med Univ, Class 3, Student Team 1, West Rd 169, Xian 710032, Changle, Peoples R China; [Wang, Lifeng] Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, Dept Pathol, Kongjiang Rd 1665, Shanghai 200092, Peoples R China; [Fang, Na] Hubei Prov Canc Hosp, Dept Pathol, Zhuodaoquan South Rd 116, Wuhan 430079, Hubei, Peoples R China; [Liu, Fang] Sun Yat Sen Univ, Foshan Hosp, Dept Pathol, Lingnan North Rd 81, Foshan 528000, Peoples R China	Wang, Z (reprint author), Fourth Mil Med Univ, Xijing Hosp, State Key Lab Canc Biol, Dept Pathol, West Rd 169, Xian 710032, Changle, Peoples R China.	zhwang@fmmu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81472402, 81272651, 81570180]	This work was supported by National Natural Science Foundation of China (grant numbers 81472402, 81272651 and 81570180).	Abou-Bakr A A, 2013, Gulf J Oncolog, V1, P28; Buckingham LE, 2007, J THORAC ONCOL, V2, P414, DOI 10.1097/01.JTO.0000268675.02744.b0; Castronovo C, 2013, RARE TUMORS, V5, DOI 10.4081/rt.2013.e15; Chen YY, 2007, GENE CHROMOSOME CANC, V46, P348, DOI 10.1002/gcc.20416; Fletcher CD, 2013, BJAHPCEA WHO CLASSIF; Glukhova L, 2000, ONCOGENE, V19, P754, DOI 10.1038/sj.onc.1203397; Grabellus F, 2010, TUMOR BIOL, V31, P157, DOI 10.1007/s13277-010-0021-0; Ha SY, 2013, MODERN PATHOL, V26, P1632, DOI 10.1038/modpathol.2013.108; Haglund KE, 2012, INT J RADIAT ONCOL, V82, P361, DOI 10.1016/j.ijrobp.2010.08.042; Hong NJL, 2013, ANN SURG ONCOL, V20, P80, DOI 10.1245/s10434-012-2572-3; Kikuta K, 2013, JPN J CLIN ONCOL, V43, P1093, DOI 10.1093/jjco/hyt119; Lee JC, 2010, MODERN PATHOL, V23, P1379, DOI 10.1038/modpathol.2010.128; Li YQ, 2015, ONCOTARGET, V6, P13309, DOI 10.18632/oncotarget.3751; Mutter RW, 2012, CANCER-AM CANCER SOC, V118, P518, DOI 10.1002/cncr.26296; Nascimento AF, 2007, AM J SURG PATHOL, V31, P99, DOI 10.1097/01.pas.0000213379.94547.e7; Paliga A, 2015, AM J CLIN ONCOLOGY; Patane S, 2006, CANCER RES, V66, P4750, DOI 10.1158/0008-5472.CAN-05-4422; Park S, 2012, HISTOL HISTOPATHOL, V27, P197, DOI 10.14670/HH-27.197; Refaat T, 2015, AM J CLIN ONCOL; Riouallon G, 2013, ORTHOP TRAUMATOL-SUR, V99, P473, DOI 10.1016/j.otsr.2012.11.020; Sanfilippo R, 2011, ANN SURG ONCOL, V18, P720, DOI 10.1245/s10434-010-1341-4; Seo AN, 2015, TUMOUR BIOL; Spigel DR, 2013, J CLIN ONCOL, V31, P4105, DOI 10.1200/JCO.2012.47.4189; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; Willems SM, 2006, MODERN PATHOL, V19, P407, DOI 10.1038/modpathol.3800550; Willems SM, 2009, J CELL MOL MED, V13, P1291, DOI 10.1111/j.1582-4934.2009.00747.x; Yamamoto S, 2011, MODERN PATHOL, V24, P1146, DOI 10.1038/modpathol.2011.70; Yang Y, 2015, GASTRIC CANC	28	2	2	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	AUG 21	2018	13								56	10.1186/s13000-018-0733-9			8	Pathology	Pathology	GQ9YU	WOS:000442162000001	30126419	DOAJ Gold, Green Published			2019-10-28	
J	Gagne, A; Tetu, B; Orain, M; Turcotte, S; Plante, M; Gregoire, J; Renaud, MC; Bairati, I; Trueel, D				Gagne, Andreanne; Tetu, Bernard; Orain, Michele; Turcotte, Stephane; Plante, Marie; Gregoire, Jean; Renaud, Marie-Claude; Bairati, Isabelle; Trueel, Dominique			HtrA1 expression and the prognosis of high-grade serous ovarian carcinoma: a cohort study using digital analysis	DIAGNOSTIC PATHOLOGY			English	Article						Ovarian high grade serous carcinoma; High temperature requirement factor A1; Immunohistochemistry; Digital image analysis; Prognosis	SERINE-PROTEASE HTRA1; CANCER INTERGROUP GCIG; CLINICAL-TRIALS; CHEMOTHERAPY; ANOIKIS; TUMORS; CELLS; MMP-2	Background: The expression of high temperature requirement factor A1 (Htral) has been reported to be decreased in ovarian carcinoma, but its prognostic effect remains undetermined. Methods: We evaluated the impact of HtrA1 downregulation in tumoral tissues on cancer progression and death in women with serous ovarian carcinoma. HtrA1 staining was performed on tissue microarrays (TMA) comprised of tumor samples from a cohort of 106 women who were diagnosed with primary high-grade serous ovarian carcinoma and receiving standard treatment at the Quebec University Hospital between 1993 and 2006. HtrA1 expression was assessed visually (percentage of positive nuclei) and by digital image analysis (percentage of positive area). Cox regression multivariate models included standard prognostic factors and were used to estimate adjusted hazard ratios (aHR) for progression or death in the cohort. Results: By visual analysis, a low percentage of HtrA1-positive nuclei (< 10% vs >= 10%) tend to be associated with a lower risk of progression (aHR = 0.71; 95% Confidence interval (CI) = 0.46-1.09; P = 0.11) and mortality (aHR = 0. 65; 95% CI = 0.41-1.04; P = 0.07). Low nuclear HtrAl expression assessed by digital image analysis (< median % vs >= median %) showed a significant association with lower risk of progression (aHR = 0.62; 95% CI = 0.40-0.95; p = 0.03) and death (aHR = 0.60; 95% CI = 038-0.95; p= 0.03). Conclusion: Altogether, our results demonstrate that nuclear downregulation of HtrA1 is associated with a better prognosis in women with high grade serous ovarian carcinoma.	[Gagne, Andreanne; Tetu, Bernard; Orain, Michele; Turcotte, Stephane; Plante, Marie; Gregoire, Jean; Renaud, Marie-Claude; Bairati, Isabelle; Trueel, Dominique] Laval Univ, Canc Res Ctr, Hotel Dieu De Quebec, Ctr Hosp Univ CHU Quebec, 11 Cote Palais, Quebec City, PQ G1R 2J6, Canada; [Tetu, Bernard; Orain, Michele] Laval Univ, Anat Pathol & Cytol Dept, Hop St Sacrement, Ctr Hosp Univ CHU Quebec, 1050 Chemin Ste Foy, Quebec City, PQ G1S 4L8, Canada; [Plante, Marie; Gregoire, Jean; Renaud, Marie-Claude] Ctr Hosp Univ CHU Quebec, Gynecol Oncol Div, Hotel Dieu De Quebec, 11 Cote Palais, Quebec City, PQ G1R 2J6, Canada; [Trueel, Dominique] Ctr Hosp Univ Montreal, Hop St Luc, Dept Pathol, 058 Rue St Denis, Montreal, PQ H2X 3J4, Canada; [Trueel, Dominique] Univ Montreal Teaching Hosp CR CHUM, Res Ctr, Montreal Canc Inst, 900 Rue St Denis, Montreal, PQ H2X 0A9, Canada; [Trueel, Dominique] Univ Montreal, Dept Pathol & Cellular Biol, 2900 Blvd Edouard Montpetit, Montreal, PQ H3T 1J4, Canada; [Tetu, Bernard] Ctr Hosp Univ Quebec, Dept Pathol, Hop St Sacrement, 1050 Chemin Ste Foy, Quebec City, PQ G1S 4L8, Canada	Tetu, B (reprint author), Laval Univ, Canc Res Ctr, Hotel Dieu De Quebec, Ctr Hosp Univ CHU Quebec, 11 Cote Palais, Quebec City, PQ G1R 2J6, Canada.; Tetu, B (reprint author), Laval Univ, Anat Pathol & Cytol Dept, Hop St Sacrement, Ctr Hosp Univ CHU Quebec, 1050 Chemin Ste Foy, Quebec City, PQ G1S 4L8, Canada.	bernard.tetu@fmed.ulaval.ca		Gagne, Andreanne/0000-0002-3833-4159	Fonds de la recherche du Quebec-Sante (FRQS)	Dominique Trudel has been supported by the Fonds de la recherche du Quebec-Sante (FRQS) (doctoral training for applicants with a professional degree and Clinical Research Scholar, Junior 1).	Baldi A, 2008, PHARMACOGENOMICS, V9, P1069, DOI 10.2217/14622416.9.8.1069; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Benoit MH, 2007, INT J ONCOL, V30, P5; Campioni M, 2010, MOL CANCER RES, V8, P1248, DOI 10.1158/1541-7786.MCR-09-0473; Catalano V, 2011, HISTOPATHOLOGY, V58, P669, DOI 10.1111/j.1365-2559.2011.03818.x; Chien J, 2004, ONCOGENE, V23, P1636, DOI 10.1038/sj.onc.1207271; Chien J, 2009, MOL CELL BIOL, V29, P4177, DOI 10.1128/MCB.00035-09; Chien J, 2006, J CLIN INVEST, V116, P1994, DOI 10.1172/JCI27698; Clawson GA, 2008, J CELL BIOCHEM, V105, P81, DOI 10.1002/jcb.21804; De Luca A, 2003, J HISTOCHEM CYTOCHEM, V51, P1279, DOI 10.1177/002215540305101004; Desmeules P, 2015, HUM PATHOL, V46, P739, DOI 10.1016/j.humpath.2015.01.014; du Bois A, 2005, ANN ONCOL, V16, P7, DOI 10.1093/annonc/mdi961; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Ferlay J, 2013, GLOBOCAN 2012 V1 0 C; Guadamillas MC, 2011, J CELL SCI, V124, P3189, DOI 10.1242/jcs.072165; Hajra KM, 2008, ADV EXP MED BIOL, V622, P197, DOI 10.1007/978-0-387-68969-2_16; He XP, 2012, INT J CANCER, V130, P1029, DOI 10.1002/ijc.26044; He XP, 2010, CANCER RES, V70, P3109, DOI 10.1158/0008-5472.CAN-09-3557; Lehner A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060359; Lorenzi T, 2013, INT J CANCER, V133, P2650, DOI 10.1002/ijc.28280; Narklewicz J, 2008, CLIN BIOCHEM, V41, P561, DOI 10.1016/j.clinbiochem.2008.01.004; Ouellet V, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-152; Perigny M, 2008, AM J CLIN PATHOL, V129, P226, DOI 10.1309/49LA9XCBGWJ8F2KM; Rustin GJS, 2011, INT J GYNECOL CANCER, V21, P419, DOI 10.1097/IGC.0b013e3182070f17; Shridhar V, 2002, CANCER RES, V62, P262; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Sood AK, 2002, CLIN CANCER RES, V8, P2924; Stuart GCE, 2011, INT J GYNECOL CANCER, V21, P750, DOI 10.1097/IGC.0b013e31821b2568; Torre LA, 2018, CA CANC J CLIN; Trudel D, 2014, MODERN PATHOL, V27, P1394, DOI 10.1038/modpathol.2014.32; Zhu F, 2010, HEPATOB PANCREAT DIS, V9, P508	31	1	1	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	AUG 21	2018	13								57	10.1186/s13000-018-0736-6			9	Pathology	Pathology	GR3AK	WOS:000442459000001	30131069	DOAJ Gold, Green Published			2019-10-28	
J	Black-Schaffer, WS; Gross, DJ; Crawford, JM; Robboy, SJ; Johnson, K; Cohen, MB; Austin, M; Sanfrancesco, J; Karcher, DS; Powell, SZ; Johnson, RL				Black-Schaffer, W. Stephen; Gross, David J.; Crawford, James M.; Robboy, Stanley J.; Johnson, Kristen; Cohen, Michael B.; Austin, Melissa; Sanfrancesco, Joseph; Karcher, Donald S.; Powell, Suzanne Z.; Johnson, Rebecca L.			Evidence-Based Alignment of Pathology Residency With Practice: Methodology and General Consideration of Results	ACADEMIC PATHOLOGY			English	Article						new-in-practice; pathology; graduate medical education; residency; specialty training; training	WORKFORCE	Few medical specialties engage in ongoing, organized data collection to assess how graduate medical education in their disciplines align with practice. Pathology educators, the American Board of Pathology, and major pathology organizations undertook an evidence-based, empirical assessment of what all pathologists need to learn in categorical residency. Two challenges were known when we commenced and we encountered 2 others during the project; all were ultimately satisfactorily addressed. Initial challenges were (1) ensuring broad representation of the new-in-practice pathologist experience and (2) adjusting for the effect on this experience of subspecialty fellowship(s) occurring between residency and practice. Additional challenges were (3) needing to assess and quantify degree and extent of subspecialization in different practice settings and (4) measuring changing practice responsibilities with increasing time in practice. We instituted annual surveys of pathologists who are relatively new (<10 years) in practice and a survey of physician employers of new pathologists. The purpose of these surveys was to inform (1) the American Board of Pathology certification process, which needs to assess the most critical knowledge, judgment, and skills required by newly practicing pathologists, and (2) pathology graduate medical education training requirements, which need to be both efficient and effective in graduating competent practitioners. This article presents a survey methodology to evaluate alignment of graduate medical education training with the skills needed for new-in-practice physicians, illustrates an easily interpreted graphical format for assessing survey data, and provides high-level results showing consistency of findings between similar populations of respondents, and between new-in-practice physicians and physician-employers.	[Black-Schaffer, W. Stephen] Massachusetts Gen Hosp, MGH Pathol Serv, Warren 210, Boston, MA 02114 USA; [Black-Schaffer, W. Stephen] Harvard Med Sch, Warren 210, Boston, MA 02114 USA; [Gross, David J.] Coll Amer Pathologists, Policy Roundtable, Washington, DC USA; [Crawford, James M.] Hofstra Northwell Sch Med, Dept Pathol & Lab Med, Lake Success, NY USA; [Robboy, Stanley J.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; [Johnson, Kristen] Coll Amer Pathologists, CAP Learning, Northfield, IL USA; [Cohen, Michael B.] Wake Forest Sch Med, Dept Pathol, Winston Salem, NC USA; [Austin, Melissa] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Sanfrancesco, Joseph] Charleston Pathol PA, Charleston, SC USA; [Karcher, Donald S.] George Washington Univ, Med Ctr, Washington, DC 20037 USA; [Powell, Suzanne Z.] Weill Cornell Med Coll, Houston, TX USA; [Powell, Suzanne Z.] Texas A&M Univ, Houston, TX USA; [Johnson, Rebecca L.] Amer Board Pathol, Tampa, FL USA	Black-Schaffer, WS (reprint author), Massachusetts Gen Hosp, MGH Pathol Serv, Warren 210, Boston, MA 02114 USA.; Black-Schaffer, WS (reprint author), Harvard Med Sch, Warren 210, Boston, MA 02114 USA.	sblackschaffer@partners.org					Accreditation Council for Graduate Medical Education, 2018, ACGME PROGR REQ GRAD; Althouse LA, 2006, J PEDIATR-US, V148, P166, DOI 10.1016/j.jpeds.2005.11.038; American Board of Pathology, CONT CERT CC BOOKL I; Asch DA, 2014, ACAD MED, V89, P24, DOI 10.1097/ACM.0000000000000067; Asch DA, 2009, JAMA-J AM MED ASSOC, V302, P1277, DOI 10.1001/jama.2009.1356; Domen RE, 2014, HUM PATHOL, V45, P1125, DOI 10.1016/j.humpath.2014.02.026; Frank K., 2017, ASCP FELLOWSHIP JOB; Kass ME, 2007, ARCH PATHOL LAB MED, V131, P545; Robboy SJ, 2013, ARCH PATHOL LAB MED, V137, P1723, DOI 10.5858/arpa.2013-0200-OA; Smith BR, 2006, HUM PATHOL, V37, P934, DOI 10.1016/j.humpath.2006.01.034; Wick MB, 2003, HUM PATHOL, V34, P1083, DOI 10.1016/S0046-8177(03)00497-0	11	2	2	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	AUG 21	2018	5								UNSP 2374289518790501	10.1177/2374289518790501			11	Pathology	Pathology	GR2GW	WOS:000442386000001	30151423	DOAJ Gold, Green Published			2019-10-28	
J	Zhang, Y; He, Y; Li, L; Liang, ST; Yan, M; Ren, DY; Yang, ZM; Zhao, WL; Miao, LY; Zhang, HJ; Liu, YJ				Zhang, Yao; He, Ye; Li, Ling; Liang, Shutian; Yan, Mei; Ren, Dongyan; Yang, Zengmin; Zhao, Wenli; Miao, Luyan; Zhang, Haijiang; Liu, Yongjiang			Development and characterization of an HPV18 detection kit using two novel HPV18 type-specific monoclonal antibodies	DIAGNOSTIC PATHOLOGY			English	Article						ELISA kit; HPV; Monoclonal antibody; Vaccine	HUMAN-PAPILLOMAVIRUS TYPE-1; VIRUS-LIKE PARTICLES; NEUTRALIZING EPITOPES; CERVICAL-CANCER; CAPSID PROTEIN; VACCINE; BINDING; ASSAY; L1	Background: HPV 18 is one of the most prevalent oncogenic types, only second to HPV 16, and included in the licensed vaccines on the market. In this study, we describe the production and characterization of a panel of monoclonal antibodies (mAb) to HPV18. Methods: The immunocompetence of 1B1 and 4C2 mAbs for HPV L1 protein was evaluated by SDS-PAGE analysis, neutralization assays, affinity identification, and ELISA. The 1B1 and 4C2 genes were sequenced and analyzed. Finally, the detection kit with the two mAbs was assessed for linearity, repeatability and specificity. Results: Both mAbs specifically recognized HPV18 L1 and virus-like particles (VLPs). These mAbs are conformation neutralizing antibodies that have high affinity and type specificity. Based on these characteristics of these mAbs, we developed an ELISA kit for specifically detecting HPV 18 antigen. We showed that this kit displayed good linearity, repeatability and sensitivity for detecting HPV18 L1 pentamer and HPV18 VLP. Conclusions: We characterized two monoclonal neutralizing antibodies for HPV L1 protein, and developed an ELISA kit for specifically detecting HPV 18 antigen. This newly developed kit can be used to monitor the potency of HPV vaccines throughout the entire production process as well as preliminary analysis of HPV18 infections.	[Zhang, Yao; He, Ye; Li, Ling; Liang, Shutian; Yan, Mei; Ren, Dongyan; Yang, Zengmin; Zhao, Wenli; Miao, Luyan; Zhang, Haijiang; Liu, Yongjiang] Beijing Hlth Guard Biotechnol Co Ltd, Beijing Econ & Technol Dev Area, Unit 201 & 202,Block 2,Longsheng Ind Pk, Beijing 100176, Peoples R China	Miao, LY; Zhang, HJ (reprint author), Beijing Hlth Guard Biotechnol Co Ltd, Beijing Econ & Technol Dev Area, Unit 201 & 202,Block 2,Longsheng Ind Pk, Beijing 100176, Peoples R China.	haijiang_z@hotmail.com; lyj9999@126.com		Liang, Shutian/0000-0001-6614-6748	Beijing Major Science & Technology Project [D090507043409008]; Special Technology Innovation Funding Project from Beijing Economic-Technological Developmental Area [JSYF2010150]; Beijing Health Guard Biotechnology Co., Ltd.	This work was supported by Beijing Major Science & Technology Project (grant number D090507043409008) and Special Technology Innovation Funding Project from Beijing Economic-Technological Developmental Area (grant number JSYF2010150). Beijing Health Guard Biotechnology Co., Ltd. was the primary source of funding for this study. Beijing Health Guard Biotechnology Co., Ltd. designed this study, collected and analyzed the data, and wrote the manuscript.	Bishop B, 2007, J BIOL CHEM, V282, P31803, DOI 10.1074/jbc.M706380200; Brendle SA, 2010, J GEN VIROL, V91, P1834, DOI 10.1099/vir.0.017228-0; Brown MJ, 2014, CLIN VACCINE IMMUNOL, V21, P587, DOI 10.1128/CVI.00773-13; Cardone G, 2014, MBIO, V5, DOI 10.1128/mBio.01104-14; Chatterjee A, 2014, EXPERT REV VACCINES, V13, P1279, DOI 10.1586/14760584.2014.963561; Chen XJS, 2001, J MOL BIOL, V307, P173, DOI 10.1006/jmbi.2000.4464; Dias D, 2005, CLIN DIAGN LAB IMMUN, V12, P959, DOI 10.1128/CDLI.12.8.959-969.2005; Giroglou T, 2001, VACCINE, V19, P1783, DOI 10.1016/S0264-410X(00)00370-4; Guan J, 2017, STRUCTURE, V25, P253, DOI 10.1016/j.str.2016.12.001; Handisurya A, 2009, J DTSCH DERMATOL GES, V7, P453, DOI 10.1111/j.1610-0387.2009.06988.x; MCLEAN CS, 1990, J CLIN PATHOL, V43, P488, DOI 10.1136/jcp.43.6.488; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; Opalka D, 2003, CLIN DIAGN LAB IMMUN, V10, P108, DOI 10.1128/CDLI.10.108-115-2003; Pastrana DV, 2004, VIROLOGY, V321, P205, DOI 10.1016/j.virol.2003.12.027; Riethmuller D, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1779-1; ROSETO A, 1984, J GEN VIROL, V65, P1319, DOI 10.1099/0022-1317-65-8-1319; Seitz H, 2015, CANCER PREV RES, V8, P932, DOI 10.1158/1940-6207.CAPR-15-0164; Tsakogiannis D, 2016, MOL CELL PROBE, V30, P6, DOI 10.1016/j.mcp.2015.11.004; Valentino K, 2016, J PEDIATR NURS, V31, pE155, DOI 10.1016/j.pedn.2015.10.005; Wang DN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123944; Wang Y, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-101; YAEGASHI N, 1991, J VIROL, V65, P1578; Zhao QJ, 2012, NANOMED-NANOTECHNOL, V8, P1182, DOI 10.1016/j.nano.2012.01.007	23	2	2	1	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	AUG 17	2018	13								55	10.1186/s13000-018-0727-7			8	Pathology	Pathology	GQ6EA	WOS:000441795100001	30115088	DOAJ Gold, Green Published			2019-10-28	
J	Ding, Y; Wang, C; Li, XJ; Jiang, YY; Mei, P; Huang, WB; Song, GX; Wang, JS; Ping, GQ; Hu, R; Miao, C; He, X; Chen, G; Li, H; Zhu, Y; Zhang, ZH				Ding, Ying; Wang, Cong; Li, Xuejie; Jiang, Yangyang; Mei, Ping; Huang, Wenbin; Song, Guoxin; Wang, Jinsong; Ping, Guoqiang; Hu, Ran; Miao, Chen; He, Xiao; Chen, Gang; Li, Hai; Zhu, Yan; Zhang, Zhihong			Novel clinicopathological and molecular characterization of metanephric adenoma: a study of 28 cases	DIAGNOSTIC PATHOLOGY			English	Article						Metanephric adenoma; Next-generation sequencing (NGS); BRAF V600E mutation; Mitogen-activated protein kinase (MAPK) pathway	RENAL-CELL CARCINOMA; BRAF(V600E) MUTATION; BRAF MUTATIONS; SOLID VARIANT; WILMS-TUMOR; SENESCENCE; CANCER; DIAGNOSIS; MELANOMA; LESIONS	Background: Metanephric adenoma is a rare, benign renal neoplasm with occasional misdiagnosis. However, its molecular characterization is not fully understood. Methods: In this study, we use the hybrid capture-based Next-Generation Sequencing to sequence a panel of 295 well-established oncogene or tumor suppressor genes in 28 cases of MA patients in China. Novel clinicopathological markers associated with the mitogen-activated protein kinase (MAPK) pathway in metanephric adenoma were detected by immunohistochemistry. Results: It was found that except for BRAF (22/28) mutations (c.1799 T > A, p.V600E), NF1 (6/28), NOTCH1 (5/28), SPEN (5/28), AKT2 (4/28), APC (4/28), ATRX (3/28), and ETV4 (3/28) mutations could also be detected. Meanwhile, a novel and rare gene fusion of STARD9-BRAF, CUX1-BRAF, and LOC100507389-BRAF was detected in one MA patient In addition, although MEK phosphorylation was normally activated, the phosphorylation level of ERK was low in metanephric adenoma cases. Highly expressed p16 and DUSP6 may have contributed to these results, which maintained MA as a benign renal tumor. Conclusions: This study provides novel molecular and pathological markers for metanephric adenoma, which could improve its diagnosis and increase the understanding of its pathologic mechanism.	[Ding, Ying; Wang, Cong; Song, Guoxin; Ping, Guoqiang; Hu, Ran; Miao, Chen; He, Xiao; Chen, Gang; Li, Hai; Zhu, Yan; Zhang, Zhihong] Nanjing Med Univ, Dept Pathol, Affiliated Hosp 1, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China; [Li, Xuejie] Zhejiang Univ, Sch Med, Dept Pathol, Affiliated Hosp 1, Hangzhou 310003, Zhejiang, Peoples R China; [Jiang, Yangyang] Shenzhen Peoples Hosp, Dept Pathol, Shenzhen 518020, Peoples R China; [Mei, Ping] Guangdong Acad Med Sci, Dept Pathol, Guangdong Gen Hosp, Guangzhou 510000, Guangdong, Peoples R China; [Huang, Wenbin; Wang, Jinsong] Nanjing First Hosp, Dept Pathol, Nanjing 210000, Jiangsu, Peoples R China	Zhang, ZH (reprint author), Nanjing Med Univ, Dept Pathol, Affiliated Hosp 1, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.	zhangzh@njmu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81502089]; Natural Science Foundation of Jiangsu ProvinceJiangsu Planned Projects for Postdoctoral Research FundsNatural Science Foundation of Jiangsu Province [BK20151582, BK20151024]; Fund of the priority Academic Program Development of Jiangsu Higher Education Institution [JX1023-1801]; Training Program of Medical talents of Jiangsu Province [QNRC2016589]	This work is supported by the National Natural Science Foundation of China (No. 81502089), the Natural Science Foundation of Jiangsu Province (BK20151582, BK20151024), the Fund of the priority Academic Program Development of Jiangsu Higher Education Institution (JX1023-1801), the Training Program of Medical talents of Jiangsu Province (QNRC2016589).	Argani P, 2016, AM J SURG PATHOL, V40, P719, DOI 10.1097/PAS.0000000000000603; Arroyo MR, 2001, AM J SURG PATHOL, V25, P433, DOI 10.1097/00000478-200104000-00002; Bastide C, 2009, BJU INT, V103, P1544, DOI 10.1111/j.1464-410X.2009.08357.x; Brown JA, 1997, J UROLOGY, V158, P370, DOI 10.1016/S0022-5347(01)64482-3; Calio A, 2016, ONCOTARGET; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Choueiri TK, 2012, EUR UROL, V62, P917, DOI 10.1016/j.eururo.2012.05.051; Cisowski J, 2016, ONCOGENE, V35, P1328, DOI 10.1038/onc.2015.186; DAVIS CJ, 1995, AM J SURG PATHOL, V19, P1101, DOI 10.1097/00000478-199510000-00001; Fang MG, 2016, P NATL ACAD SCI USA, V113, P1250, DOI 10.1073/pnas.1525619113; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Griffith M, 2017, NAT GENET, V49, P170, DOI 10.1038/ng.3774; Hsiao SJ, 2017, CSH MOL CASE STUD, V3, DOI 10.1101/mcs.a001396; Kim A, 2016, EXPERT OPIN DRUG DIS, V11, P907, DOI 10.1080/17460441.2016.1201057; Kim HS, 2017, ONCOGENE; Kim SW, 2013, ENDOCR RES, V38, P89, DOI 10.3109/07435800.2012.723292; Kinney SN, 2015, MODERN PATHOL, V28, P1236, DOI 10.1038/modpathol.2015.81; Kluska A, 2017, BMC MED GENOMICS, V10, DOI 10.1186/s12920-017-0251-8; Korphaisarn K, 2016, CANCER J, V22, P175, DOI 10.1097/PPO.0000000000000189; Kovac M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7336; Kumar SM, 2014, ONCOGENE, V33, P832, DOI 10.1038/onc.2012.642; Ma B, 2016, ONCOTARGETS THER, V9, P2255, DOI 10.2147/OTT.S103554; Mahajan A, 2016, HUM PATHOL, V51, P64, DOI 10.1016/j.humpath.2015.12.021; Padilha M, 2013, HISTOPATHOLOGY, V62, P941, DOI 10.1111/his.12106; Marsden L, 2017, HUM PATHOL, V60, P32, DOI 10.1016/j.humpath.2016.09.025; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Movassagh M, 2017, NEW ENGL J MED, V376, P2090, DOI 10.1056/NEJMc1701592; Muir TE, 2001, AM J SURG PATHOL, V25, P1290, DOI 10.1097/00000478-200110000-00010; Obaid NM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030585; Paner GP, 2005, ARCH PATHOL LAB MED, V129, P1317; Pinto A, 2015, HISTOPATHOLOGY, V66, P901, DOI 10.1111/his.12509; Raabe EH, 2011, CLIN CANCER RES, V17, P3590, DOI 10.1158/1078-0432.CCR-10-3349; Straume O, 2002, AM J PATHOL, V161, P229, DOI 10.1016/S0002-9440(10)64174-0; Tan JM, 2015, JAMA DERMATOL, V151, P417, DOI 10.1001/jamadermatol.2014.3775; Tomic TT, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175638; Udager AM, 2015, AM J SURG PATHOL, V39, P549, DOI 10.1097/PAS.0000000000000377; Zhang H, 2015, J BIOL CHEM, V290, P1129, DOI 10.1074/jbc.M114.590943	37	0	0	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	AUG 16	2018	13								54	10.1186/s13000-018-0732-x			14	Pathology	Pathology	GQ6DX	WOS:000441794500002	30111351	DOAJ Gold, Green Published			2019-10-28	
J	Guan, HW; Zhang, LZ; Zhang, QP; Qi, WJ; Xie, SL; Hou, JP; Wang, HL				Guan, Hongwei; Zhang, Lizhi; Zhang, Qiuping; Qi, Wenjing; Xie, Suling; Hou, Jinping; Wang, Huali			Primary angiosarcoma arising in an angiomyolipoma of the kidney: case report and literature review	DIAGNOSTIC PATHOLOGY			English	Review						Primary angiosarcoma; Angiomyolipoma; Kidney; Pathology	TUBEROUS SCLEROSIS GENE; TUMOR-LIKE LESIONS; OF-THE-LITERATURE; SOFT-TISSUE; EPITHELIOID ANGIOSARCOMA; IDENTIFICATION; ACTIVATION; SCHWANNOMA; NEOPLASMS; FEATURES	Background: Primary angiosarcoma of the kidney is a rare and aggressive malignant tumor presenting with a recognizable vascular differentiation. Its prognosis is fatal and the pathogenesis remains unclear. Renal angiomyolipoma is a relatively infrequent renal cortical neoplasm and is composed of variable proportions of adipose tissue, spindle cells, epithelioid smooth muscle cells and abnormal thick-walled blood vessels. Case presentation: Here, we reported a case in which a 64-year-old woman presenting with the chief complaint of a progressively enlarged mass in the left abdomen. Abdominal computed tomography confirmed presence of a tumor measuring 18 cm x 11 cm in the left posterior renal fascia. Microscopic examination and immunohistochemical staining confirmed co-existence of angiomyolipoma and angiosarcoma. Furthermore, the two components interspersed with each other and there were transitional zones between them. Conclusions: In this case, we described for the first time a primary renal angiosarcoma possibly arising in a pre-existing angiomyolipoma of the kidney.	[Guan, Hongwei; Zhang, Lizhi; Zhang, Qiuping; Qi, Wenjing; Xie, Suling; Hou, Jinping; Wang, Huali] Dalian Med Univ, Hosp 2, Dept Pathol, 222 Zhongshan Rd, Dalian 116011, Liaoning, Peoples R China	Wang, HL (reprint author), Dalian Med Univ, Hosp 2, Dept Pathol, 222 Zhongshan Rd, Dalian 116011, Liaoning, Peoples R China.	yaya1167@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81502274]	This project was supported by the National Natural Science Foundation of China (Nos 81502274).	Akkad T, 2006, INT J UROL, V13, P1112, DOI 10.1111/j.1442-2042.2006.01490.x; Brown JG, 2010, AM J SURG PATHOL, V34, P942, DOI 10.1097/PAS.0b013e3181e4f32a; BROWN RW, 1992, CANCER-AM CANCER SOC, V70, P1141, DOI 10.1002/1097-0142(19920901)70:5<1141::AID-CNCR2820700519>3.0.CO;2-Q; Cohen SM, 2009, TOXICOL SCI, V111, P4, DOI 10.1093/toxsci/kfp131; Deyrup AT, 2009, AM J SURG PATHOL, V33, P264, DOI 10.1097/PAS.0b013e3181875a5f; FLETCHER CDM, 1991, AM J SURG PATHOL, V15, P915, DOI 10.1097/00000478-199110000-00001; Hayashi T, 2012, HUM PATHOL, V43, P1777, DOI 10.1016/j.humpath.2012.03.020; Iacovelli R, 2014, CUAJ-CAN UROL ASSOC, V8, pE223, DOI 10.5489/cuaj.1585; Italiano A, 2012, CANCER-AM CANCER SOC, V118, P5878, DOI 10.1002/cncr.27614; Kenerson H, 2007, HUM PATHOL, V38, P1361, DOI 10.1016/j.humpath.2007.01.028; Kwiatkowski DJ, 2003, ANN HUM GENET, V67, P87, DOI 10.1046/j.1469-1809.2003.00012.x; Lahat G, 2010, ANN SURG, V251, P1098, DOI 10.1097/SLA.0b013e3181dbb75a; Martignoni G, 2008, VIRCHOWS ARCH, V452, P119, DOI 10.1007/s00428-007-0509-1; Meis-Kindblom JM, 1998, AM J SURG PATHOL, V22, P683, DOI 10.1097/00000478-199806000-00005; Moch H, 2016, WHO CLASSIFICATION T, P62; NELLIST M, 1993, CELL, V75, P1305; Omiyale AO, 2015, TRANSL ANDROL UROL, V4, P464, DOI 10.3978/j.issn.2223-4683.2015.05.04; Papadimitriou VD, 2009, UROL J, V6, P223; Penel N, 2011, CRIT REV ONCOL HEMAT, V80, P257, DOI 10.1016/j.critrevonc.2010.10.007; Pillay K, 2003, J CLIN PATHOL, V56, P544, DOI 10.1136/jcp.56.7.544; POPPER H, 1978, AM J PATHOL, V92, P349; TALLINI G, 1993, AM J CLIN PATHOL, V100, P514, DOI 10.1093/ajcp/100.5.514; Tamboli P, 2000, ADV ANAT PATHOL, V7, P47, DOI 10.1097/00125480-200007010-00007; Trassard M, 1996, AM J SURG PATHOL, V20, P1412, DOI 10.1097/00000478-199611000-00014; ULBRIGHT TM, 1985, HUM PATHOL, V16, P268, DOI 10.1016/S0046-8177(85)80013-7; vanSlegtenhorst M, 1997, SCIENCE, V277, P805; Yang JM, 2012, CANCER RES, V72, P4682, DOI 10.1158/0008-5472.CAN-12-0440; Young RJ, 2010, LANCET ONCOL, V11, P983, DOI 10.1016/S1470-2045(10)70023-1; Zapardiel I, 2011, GYNECOL OBSTET INVES, V72, P217, DOI 10.1159/000329328; Zenico Teo, 2011, Tumori, V97, pe6, DOI 10.1700/950.10412	30	0	0	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	AUG 16	2018	13								53	10.1186/s13000-018-0730-z			6	Pathology	Pathology	GQ6DX	WOS:000441794500001	30111336	DOAJ Gold, Green Published			2019-10-28	
J	Sunitsch, S; Gilg, MM; Kashofer, K; Gollowitsch, F; Leithner, A; Liegl-Atzwanger, B				Sunitsch, Sandra; Gilg, Magdalena Maria; Kashofer, Karl; Gollowitsch, Franz; Leithner, Andreas; Liegl-Atzwanger, Bernadette			Detection of GNAS mutations in intramuscular / cellular myxomas as diagnostic tool in the classification of myxoid soft tissue tumors	DIAGNOSTIC PATHOLOGY			English	Article						Soft tissue pathology; Intramuscular / cellular myxoma; Myxofibrosarcoma; GNAS mutation	FIBROUS DYSPLASIA; MYXOFIBROSARCOMA; BONE	Background: Intramuscular / cellular myxomas and low-grade myxofibrosarcomas are two different tumor entities with a significant histological overlap, especially if dealing with small biopsies. Despite the morphological similarities, they differ considerably in their biological behaviour. Intramuscular / cellular myxoma rarely shows signs of recurrence and never metastasizes, in contrast to myxofibrosarcoma that tends to recur more aggressively and to metastasize haematologically. Therefore, it is of great importance to distinguish these lesions - evaluation of GNAS mutation status could be of tremendous help. Methods: We reviewed 13 cases with intramuscular / cellular myxomas. The 13 cases included 5 men and 8 women, aged from 33 to 71 years (mean age 55.5 years). Immunohistochemistry was performed as well as next generation sequencing. Ten cases were located in the lower extremities and three cases were located in the upper extremities. Two lesions were initially misdiagnosed as a low-grade myxofibrosarcoma. Results: Performing next generation sequencing 12 out of 13 specimens showed a GNAS mutation. Conclusions: Our findings demonstrate that GNAS mutations are more common in intramuscular / cellular myxomas, than had been reported in literature in the past Next generation sequencing for determining GNAS mutation status on small biopsies or diagnostically challenging cases facilitates the diagnosis of intramuscular / cellular myxoma and separates this tumor entity from its mimics.	[Sunitsch, Sandra] Klinikum Klagenfurt Worthersee, Inst Pathol, Feschnigstr 11, A-9020 Klagenfurt, Austria; [Sunitsch, Sandra; Kashofer, Karl; Gollowitsch, Franz; Liegl-Atzwanger, Bernadette] Med Univ Graz, Inst Pathol, Neue Stiftingtalstr 6, A-8010 Graz, Austria; [Gilg, Magdalena Maria; Leithner, Andreas] Med Univ Graz, Dept Orthoped & Trauma Surg, Auenbruggerpl 5, A-8036 Graz, Austria	Liegl-Atzwanger, B (reprint author), Med Univ Graz, Inst Pathol, Neue Stiftingtalstr 6, A-8010 Graz, Austria.; Gilg, MM (reprint author), Med Univ Graz, Dept Orthoped & Trauma Surg, Auenbruggerpl 5, A-8036 Graz, Austria.	magdalena.gilg@medunigraz.at; bernadette.liegi-atzwanger@medunigraz.at			ONB Jubilaumsfond [16192]	The study was funded by the ONB Jubilaumsfond Nr. 16192.	CANDELIERE GA, 1995, NEW ENGL J MED, V332, P1546, DOI 10.1056/NEJM199506083322304; Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695; Delaney D, 2009, MODERN PATHOL, V22, P718, DOI 10.1038/modpathol.2009.32; ENSINGER FM, 1965, AM J CLIN PATHOL, V43, P104; Fletcher C, 2013, WHO CLASSIFICATION T; HASHIMOTO H, 1986, CANCER, V58, P740, DOI 10.1002/1097-0142(19860801)58:3<740::AID-CNCR2820580322>3.0.CO;2-K; Heitzer E, 2017, MODERN PATHOL, V30, P1698, DOI 10.1038/modpathol.2017.94; Hornick J, 2013, PRACTICAL SOFT TISSU; Luebke AM, 2013, PATHOLOGE, V34, P360, DOI 10.1007/s00292-012-1718-1; Mentzel T, 1996, AM J SURG PATHOL, V20, P391, DOI 10.1097/00000478-199604000-00001; Ogilvie CM, 2006, CLIN ORTHOP RELAT R, P95, DOI 10.1097/01.blo.0000229302.52147.c7; Okamoto S, 2000, VIRCHOWS ARCH, V437, P133, DOI 10.1007/s004280000217; Smith SC, 2013, J CUTAN PATHOL, V40, P639, DOI 10.1111/cup.12158; van Roggen JFG, 2001, HISTOPATHOLOGY, V39, P287, DOI 10.1046/j.1365-2559.2001.01209.x; van Roggen JFG, 1999, HISTOPATHOLOGY, V35, P291; Walther I, 2014, PATHOL RES PRACT, V210, P1, DOI 10.1016/j.prp.2013.09.003; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Willems SM, 2009, J CELL MOL MED, V13, P1291, DOI 10.1111/j.1582-4934.2009.00747.x	18	2	2	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	AUG 15	2018	13								52	10.1186/s13000-018-0734-8			5	Pathology	Pathology	GQ6DU	WOS:000441794200001	30111377	DOAJ Gold, Green Published			2019-10-28	
J	Roth, CG				Roth, Christine G.			Educational Case: Chronic Lymphocytic Leukemia	ACADEMIC PATHOLOGY			English	Article						pathology competencies; organ system pathology; chronic lymphocytic leukemia; classification; hematopathology; morphology		The following fictional case is intended as a learning tool within the Pathology Competencies for Medical Education (PCME), a set of national standards for teaching pathology. These are divided into three basic competencies: Disease Mechanisms and Processes, Organ System Pathology, and Diagnostic Medicine and Therapeutic Pathology. For additional information, and a full list of learning objectives for all three competencies, see http://journals.sagepub.com/doi/10.1177/2374289517715040.	[Roth, Christine G.] Baylor Coll Med, Dept Pathol & Immunol, One Baylor Plaza, Houston, TX 77030 USA	Roth, CG (reprint author), Baylor Coll Med, Dept Pathol & Immunol, One Baylor Plaza, Houston, TX 77030 USA.	christine.roth@bcm.edu					[Anonymous], 2014, AM HEMATOLOGY CHOOSI; Aster JC, 2017, PATHOPHYSIOLOGY BLOO, P280; Chabot-Richards DS, 2014, INT J LAB HEMATOL, V36, P279, DOI 10.1111/ijlh.12212; Hallek M, 2017, AM J HEMATOL, V92, P946, DOI 10.1002/ajh.24826; Kumar V, 2015, ROBBINS COTRAN PATHO, P593	5	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	AUG 14	2018	5								UNSP 2374289518776011	10.1177/2374289518776011			4	Pathology	Pathology	GQ5HY	WOS:000441713400001	30140733	DOAJ Gold, Green Published			2019-10-28	
J	Williams, HJ				Williams, H. James			Educational Case: Bladder Carcinoma In Situ	ACADEMIC PATHOLOGY			English	Editorial Material						pathology competencies; organ system pathology; bladder neoplasia; bladder washings; carcinoma in situ (CIS) of the urinary bladder; FISH; screening urine cytology; voided urine cytology		The following fictional case is intended as a learning tool within the Pathology Competencies for Medical Education (PCME), a set of national standards for teaching pathology. These are divided into three basic competencies: Disease Mechanisms and Processes, Organ System Pathology, and Diagnostic Medicine and Therapeutic Pathology. For additional information, and a full list of learning objectives for all three competencies, see http://journals.sagepub.com/doi/10.1177/2374289517715040.	[Williams, H. James] West Virginia Univ, Robert C Byrd Hlth Sci Ctr, Dept Pathol, POB 9203, Morgantown, WV 26506 USA	Williams, HJ (reprint author), West Virginia Univ, Robert C Byrd Hlth Sci Ctr, Dept Pathol, POB 9203, Morgantown, WV 26506 USA.	hjwilliams@hsc.wvu.edu					Kumar V, 2015, ROBBINS COTRAN PATHO, P964; Nese N, 2009, J NATL COMPR CANC NE, V7, P48, DOI 10.6004/jnccn.2009.0004; Tetu B, 2009, MODERN PATHOL, V22, pS53, DOI 10.1038/modpathol.2008.193	3	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	AUG 14	2018	5								UNSP 2374289517719858	10.1177/2374289517719858			3	Pathology	Pathology	GQ5HX	WOS:000441713300001	30140732	DOAJ Gold, Green Published			2019-10-28	
J	Rivera, GR; Segura, S; Suhrland, M				Rivera, Gloria Ramos; Segura, Sheila; Suhrland, Mark			Educational Case: Thyroid Neoplasms: Pathogenesis, Diagnosis, and Treatment	ACADEMIC PATHOLOGY			English	Article						pathology competencies; organ system pathology; endocrine; follicular adenoma; follicular carcinoma; papillary thyroid carcinoma; thyroid neoplasms	CANCER	The following fictional case is intended as a learning tool within the Pathology Competencies for Medical Education (PCME), a set of national standards for teaching pathology. These are divided into three basic competencies: Disease Mechanisms and Processes, Organ System Pathology, and Diagnostic Medicine and Therapeutic Pathology. For additional information, and a full list of learning objectives for all three competencies, see http://journals.sagepub.com/doi/10.1177/2374289517715040.	[Rivera, Gloria Ramos; Segura, Sheila; Suhrland, Mark] Montefiore Hosp & Med Ctr, Bronx, NY 10461 USA	Rivera, GR (reprint author), Montefiore Hosp & Med Ctr, Bronx, NY 10461 USA.	gramosr@montefiore.org					Cibas ES, 2017, THYROID, V27, P1341, DOI 10.1089/thy.2017.0500; Cibas ES, 2014, CYTOLOGY DIAGNOSTIC; Haugen BR, 2016, THYROID, V26, P1, DOI 10.1089/thy.2015.0020; Nguyen QT, 2015, AM HEALTH DRUG BENEF, V8, P30; Nikiforov YE, 2008, MODERN PATHOL, V21, pS37, DOI 10.1038/mpath.2008.10; Sherman S., UP TO DATE; Thompson L, 2016, DIAGNOSTIC PATHOLOGY; Tuttle MR., UP TO DATE	8	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	AUG 14	2018	5								UNSP 2374289518777471	10.1177/2374289518777471			5	Pathology	Pathology	GQ5IC	WOS:000441713800001	30140734	DOAJ Gold, Green Published			2019-10-28	
J	Huppmann, AR				Huppmann, Alison R.			Educational Case: Wilms Tumor	ACADEMIC PATHOLOGY			English	Article						pathology competencies; organ system pathology; kidney; renal neoplasia; Wilms tumor; pediatric; syndrome		The following fictional case is intended as a learning tool within the Pathology Competencies for Medical Education (PCME), a set of national standards for teaching pathology. These are divided into three basic competencies: Disease Mechanisms and Processes, Organ System Pathology, and Diagnostic Medicine and Therapeutic Pathology. For additional information, and a full list of learning objectives for all three competencies, see http://journals.sagepub.com/doi/10.1177/2374289517715040.	[Huppmann, Alison R.] Uniformed Serv Univ Hlth Sci, Sch Med, Dept Pathol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA	Huppmann, AR (reprint author), Uniformed Serv Univ Hlth Sci, Sch Med, Dept Pathol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	alison.huppmann@usuhs.edu					Davidoff A, 2008, COMMON SURG DIS, P251; Daw NC, 2015, NELSON TXB PEDIAT, P2464; Dome Jeffrey S, 2014, Am Soc Clin Oncol Educ Book, P215, DOI 10.14694/EdBook_AM.2014.34.215; Maitra A, 2015, ROBBINS COTRAN PATHO, P479	4	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	AUG 13	2018	5								UNSP 2374289518781582	10.1177/2374289518781582			5	Pathology	Pathology	GQ5JB	WOS:000441717200001	30140735	DOAJ Gold, Green Published			2019-10-28	
J	Chetty, R; Kamil, ZS; Wang, A; Al Habeeb, A; Ghazarian, D				Chetty, Runjan; Kamil, Zaid S.; Wang, Ami; Al Habeeb, Ayman; Ghazarian, Danny			Cutaneous epithelioid angiomatous nodule: a report of a series including a case with moderate cytologic atypia and immunosuppression	DIAGNOSTIC PATHOLOGY			English	Article						Cutaneous; Vascular tumour; Epithelioid; Immunosuppression; Angiomatous nodule	CAPILLARY MALFORMATION; VASCULAR TUMORS; HEMANGIOMA	Background: Cutaneous epithelioid angiomatous nodule (CEAN) is a very rare and relatively recently recognized vascular proliferation characterized usually by minimal cytological atypia and accompanying mitotic activity. As such, CEAN represents an important diagnostic pitfall, which could lead to significant misdiagnosis and unnecessary treatment. Methods: The clinicopathologic findings of 5 cases of CEAN were reviewed including a unique case with typical findings but also moderate cytologic atypia and brisk mitotic activity in a patient on immunosuppression. Results: The cases were in 3 women and 2 men ranging in age from 18 to 61 years with lesions in the neck (2 cases), upper arm, back and shoulder. In 4 of the cases, the patients did not have any relevant potentially contributory clinical history, and in 1 case the patient was on immunosuppressive treatment. All 5 cases were superficially located within the dermis, well-circumscribed and similarly composed of epithelioid cells displaying minimal (in 4 cases) and moderate (1 case) atypia. The mitotic count ranged from 1 to 3 per 10 high power fields (HPF) in 4 cases and up to 9 per 10 HPF in the immunosuppressed patient Atypical mitoses were not encountered in any of the cases. Two lesions that were incompletely excised recurred, but none of the patients showed distant metastases. Conclusion: While cytologically alarming, CEAN has a characteristic microscopic appearance and if completely excised follows an indolent course.	[Chetty, Runjan] Univ Hlth Network, Lab Med Program, Dept Pathol, 11th Floor Eaton wing, Toronto, ON M5G 2C4, Canada; Univ Toronto, 11th Floor Eaton wing, Toronto, ON M5G 2C4, Canada	Chetty, R (reprint author), Univ Hlth Network, Lab Med Program, Dept Pathol, 11th Floor Eaton wing, Toronto, ON M5G 2C4, Canada.	Runjan.chetty@gmail.com		Ghazarian, Danny/0000-0002-3531-1074; Chetty, Runjan/0000-0002-2124-515X; Saeed Kamil, Zaid/0000-0003-1067-9881			Al-Daraji W I, 2009, Dermatol Online J, V15, P2; Alvarez-Arguelles-Cabrera H, 2008, J EUR ACAD DERMATOL, V22, P1383, DOI 10.1111/j.1468-3083.2008.02647.x; Antonescu CR, 2014, GENE CHROMOSOME CANC, V53, P951, DOI 10.1002/gcc.22206; Brenn T, 2004, AM J DERMATOPATH, V26, P14, DOI 10.1097/00000372-200402000-00003; Chen CH, 2009, DERMATOL SURG, V35, P150, DOI 10.1111/j.1524-4725.2008.34398.x; Chokoeva AA, 2017, ACTA DERM-VENEREOL, V97, P135, DOI 10.2340/00015555-2487; Dastgheib Ladan, 2013, Dermatol Online J, V19, P1; Fernandez-Flores A, 2005, AM J DERMATOPATH, V27, P175, DOI 10.1097/01.dad.0000142241.71086.b6; Fernandez-Flores A, 2008, AM J DERMATOPATH, V30, P302, DOI 10.1097/DAD.0b013e31816ddb45; Goh SGN, 2008, HISTOPATHOLOGY, V52, P661, DOI 10.1111/j.1365-2559.2007.02924.x; Huang SC, 2015, AM J SURG PATHOL, V39, P1313, DOI 10.1097/PAS.0000000000000469; Kantrow S, 2007, J CUTAN PATHOL, V34, P515, DOI 10.1111/j.1600-0560.2006.00629.x; Kaushal S, 2011, J CUTAN PATHOL, V38, P369, DOI 10.1111/j.1600-0560.2010.01651.x; Labbene Imen, 2012, Dermatol Online J, V18, P8; Leroy X, 2008, PATHOL RES PRACT, V204, P929, DOI 10.1016/j.prp.2008.06.003; Lo CS, 2013, J DERMATOL, V40, P480, DOI 10.1111/1346-8138.12109; McLemore MS, 2011, J CUTAN PATHOL, V38, P818, DOI 10.1111/j.1600-0560.2011.01743.x; Misago N, 2006, J DERMATOL, V33, P73, DOI 10.1111/j.1346-8138.2006.00016.x; Okano S, 2015, EUR J DERMATOL, V25, P268, DOI 10.1684/ejd.2015.2527; Pavlidakey PG, 2011, AM J DERMATOPATH, V33, P831, DOI 10.1097/DAD.0b013e3181fef12c; Requena C, 2009, ACTAS DERMO-SIFILOGR, V100, P137, DOI 10.1016/S0001-7310(09)70232-7; Sangueza OP, 2008, AM J DERMATOPATH, V30, P16, DOI 10.1097/DAD.0b013e31815f2b07; Segura-Palacios JM, 2010, ACTAS DERMO-SIFILOGR, V101, P892, DOI 10.1016/j.ad.2010.04.008; Shiomi T, 2011, J CUTAN PATHOL, V38, P372, DOI 10.1111/j.1600-0560.2010.01573.x; Wang A, 2015, USCAP, V192, p497A	25	1	1	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	AUG 13	2018	13								50	10.1186/s13000-018-0729-5			5	Pathology	Pathology	GQ6DR	WOS:000441793700002	30103782	DOAJ Gold, Green Published			2019-10-28	
J	Jing, HB; Wei, H; Yuan, HT; Li, YH; Li, N; Mu, DB				Jing, Hongbiao; Wei, Hong; Yuan, Hongtu; Li, Yahong; Li, Ning; Mu, Dianbin			Melanotic Xp11 translocation renal cancer: a report of a distinctive case and a review of the literature	DIAGNOSTIC PATHOLOGY			English	Review						Kidney; Melanin; Neoplasm; TFE3; Translocation; Xp11	PRIMARY MALIGNANT-MELANOMA; BREAK-APART FISH; CELL CARCINOMA; OVERLAPPING-FEATURES; GENE FUSION; TFE3; NEOPLASM; ENTITY; TUMOR; ASSAY	Background: Melanotic Xp11 translocation renal cancer (TRC) is a newly described exceedingly rare tumor, and its characterization remains controversial. This study aimed to describe a case of distinctive melanotic Xp11 TRC and to elucidate its clinicopathological and molecular genetic features. Case presentation: A 44-year-old Chinese female presented with a left renal mass. Abdominal ultrasonography and computed tomography (CT) scans revealed a 4.5 cm x 4.0 cm mass in the left kidney. Grossly, the well-demarcated mass was black with moderately firm consistency. Microscopic examination indicated that the tumor was characterized by the presence of nests and cords of polygonal cells with clear and granular eosinophilic cytoplasm, central round to oval nuclei and occasional nucleoli. Intracytoplasmic melanin was observed in approximately 45% of tumor cells. Uniquely, the tumor presented with intranuclear eosinophilic pseudoinclusions and thick-walled stromal blood vessels. IHC showed that tumor cells were diffusely positive for TFE3 and exhibited patchy and weak HMB45 staining. FISH confirmed the presence of TFE3 rearrangement. Conclusion: This case is the twentieth published case of melanotic Xp11 TRC. Moreover, the present patient had a favorable prognosis given that she was disease free at her 113-month postoperative follow-up. Our case adds to the small body of literature on these exceptionally rare tumors and widens their clinicopathological spectrum.	[Jing, Hongbiao; Yuan, Hongtu; Mu, Dianbin] Shandong Univ, Dept Pathol, Shandong Canc Hosp, 440 Jiyan Rd, Jinan 250117, Shandong, Peoples R China; [Wei, Hong; Li, Ning] Sixth People Hosp Jinan City, 308 Huiquan Rd, Zhangqiu 250200, Peoples R China; [Li, Yahong] Guangzhou LBP Med Technol Co Ltd, 11 Nanxiang Third Rd, Guangzhou 510663, Guangdong, Peoples R China	Mu, DB (reprint author), Shandong Univ, Dept Pathol, Shandong Canc Hosp, 440 Jiyan Rd, Jinan 250117, Shandong, Peoples R China.	mudianbin@163.com					Antic T, 2017, AM J SURG PATHOL, V41, P1576, DOI 10.1097/PAS.0000000000000927; Argani P, 2003, AM J SURG PATHOL, V27, P750, DOI 10.1097/00000478-200306000-00005; Argani P, 2016, AM J SURG PATHOL, V40, P723, DOI 10.1097/PAS.0000000000000631; Argani P, 2015, SEMIN DIAGN PATHOL, V32, P103, DOI 10.1053/j.semdp.2015.02.003; Argani P, 2009, AM J SURG PATHOL, V33, P609, DOI 10.1097/PAS.0b013e31818fbdff; Bayazit Y, 2002, SCAND J UROL NEPHROL, V36, P77, DOI 10.1080/003655902317259427; Cardili L, 2017, PATHOL INT, V67, P208, DOI 10.1111/pin.12517; Chang IW, 2009, AM J SURG PATHOL, V33, P1894, DOI 10.1097/PAS.0b013e3181ba7a5f; Green WM, 2013, AM J SURG PATHOL, V37, P1150, DOI 10.1097/PAS.0b013e31828a69ae; Khourdaji IS, 2017, UROL CASE REP, V10, P42, DOI 10.1016/j.eucr.2016.11.009; LeGallo RD, 2012, AM J SURG PATHOL, V36, P1410, DOI 10.1097/PAS.0b013e31826277a9; Martignoni G, 2016, WHO CLASSIFICATION T, P59; Oliva E, 2000, AM J SURG PATHOL, V24, P785, DOI 10.1097/00000478-200006000-00003; Rao Q, 2015, AM J SURG PATHOL, V39, P1181, DOI 10.1097/PAS.0000000000000502; Rao Q, 2013, AM J SURG PATHOL, V37, P804, DOI 10.1097/PAS.0b013e31827e17cb; Ritterhouse LL, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-81; Ross H, 2010, PATHOLOGY, V42, P369, DOI 10.3109/00313021003767348; Varinot J, 2011, INT J SURG PATHOL, V19, P285, DOI 10.1177/1066896911400736	18	0	0	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	AUG 13	2018	13								51	10.1186/s13000-018-0731-y			6	Pathology	Pathology	GQ6DR	WOS:000441793700003	30103811	DOAJ Gold, Green Published			2019-10-28	
J	Li, CG; Jia, R; Liu, HL; Zhang, B; Wang, CL				Li, Chenguang; Jia, Rui; Liu, Hailin; Zhang, Bin; Wang, Changli			EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors	DIAGNOSTIC PATHOLOGY			English	Article						NSCLC; ctDNA; Epidermal growth factor receptor; T790M	CIRCULATING TUMOR DNA; MUTATION STATUS; THERAPY; AZD9291; TKI	Background: Lung adenocarcinoma with EGFR activating mutations will inevitably acquire resistance to first generation TKIs. Acquired EGFR T790M mutation causes about 50% of these resistance cases. Droplet digital PCR (ddPCR) and cobas enables quantification of T790M mutation. Whether these methods can predict clinical response of osimertinib treatment is unknown. Methods: Tumor and blood samples from 69 stage IIIB-1V NSCLC patients acquired resistance to EGFR-TKI were collected. Cobas (R) Mutation Test v2 kit was used to detect EGFR mutations in FFPE or plasma samples. Plasma T790M mutation of both osimertinib naive and treated patients were quantified by Droplet digital PCR (ddPCR). Results: T790M mutation rate detected by FFPE tissue cobas, plasma ctDNA cobas and plasma ctDNA ddPCR test were 54.5, 21.3 and 30.4% respectively. The T790M positive rate was 52.2% considering all testing methods. The objective response rate (ORR) was 60.9% in 23 patients received osimertinib treatment. Quantification of T790M after treatment decreased to very low level, but no association was observed between clinical response and T790M mutation level decrease. Conclusion: ddPCR is more sensitive in plama ctDNA testing and should be performed even in tumor tissue T790M test negative cases. EGFR T790M mutation level is not associated with clinical response after osimertinib treatment.	[Li, Chenguang; Jia, Rui; Liu, Hailin; Zhang, Bin; Wang, Changli] Tianjin Med Univ Canc Inst & Hosp, Dept Lung Canc, Tianjin, Peoples R China; [Li, Chenguang; Jia, Rui; Liu, Hailin; Zhang, Bin; Wang, Changli] Natl Clin Res Ctr Canc, Tianjin, Peoples R China; [Li, Chenguang; Jia, Rui; Liu, Hailin; Zhang, Bin; Wang, Changli] Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China; [Li, Chenguang; Jia, Rui; Liu, Hailin; Zhang, Bin; Wang, Changli] Tianjin Lung Canc Ctr, Tianjin, Peoples R China	Li, CG (reprint author), Tianjin Med Univ Canc Inst & Hosp, Dept Lung Canc, Tianjin, Peoples R China.; Li, CG (reprint author), Natl Clin Res Ctr Canc, Tianjin, Peoples R China.; Li, CG (reprint author), Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China.; Li, CG (reprint author), Tianjin Lung Canc Ctr, Tianjin, Peoples R China.	cgli82@yeah.net			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81302001, 81772484]; National Key Research and Development Program of China [2016YFC0905501, 2016YFC0905500]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2014 M550147, 2015 T80225]; Cancer translational medicine seed fund of Tianjin medical university cancer institute and hospital [1606]	This work was supported by the National Natural Science Foundation of China (81302001, 81772484), National Key Research and Development Program of China (2016YFC0905501, 2016YFC0905500), China Postdoctoral Science Foundation (2014 M550147, 2015 T80225), Cancer translational medicine seed fund of Tianjin medical university cancer institute and hospital (Fund No. 1606).	Belchis DA, 2016, ONCOTARGET, V7, P45237, DOI 10.18632/oncotarget.9931; Chia PL, 2016, LUNG CANCER, V98, P29, DOI 10.1016/j.lungcan.2016.05.003; Cross DAE, 2014, CANCER DISCOV, V4, P1046, DOI 10.1158/2159-8290.CD-14-0337; Diaz LA, 2014, J CLIN ONCOL, V32, P579, DOI 10.1200/JCO.2012.45.2011; Jenkins S, 2017, J THORAC ONCOL, V12, P1247, DOI 10.1016/j.jtho.2017.05.002; Knol AC, 2016, EXP DERMATOL, V25, P783, DOI 10.1111/exd.13065; Li C, 2017, J THORAC ONCOL, V12, pS2141; Mok TS, 2017, NEW ENGL J MED, V376, P629, DOI 10.1056/NEJMoa1612674; Murtaza M, 2013, NATURE, V497, P108, DOI 10.1038/nature12065; Oxnard GR, 2011, CLIN CANCER RES, V17, P5530, DOI 10.1158/1078-0432.CCR-10-2571; Satouchi M, 2017, LUNG CANCER, V111, P190, DOI 10.1016/j.lungcan.2017.07.015; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Thress KS, 2017, J THORAC ONCOL, V12, P1588, DOI 10.1016/j.jtho.2017.07.011; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Wan R, 2017, J THORAC ONCOL, V12, P1376, DOI 10.1016/j.jtho.2017.05.011; Xiong LW, 2017, ONCOTARGET, V8, P63846, DOI 10.18632/oncotarget.19139; Yu HA, 2013, CLIN CANCER RES, V19, P2240, DOI 10.1158/1078-0432.CCR-12-2246	17	4	4	0	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	AUG 13	2018	13								49	10.1186/s13000-018-0728-6			6	Pathology	Pathology	GQ6DR	WOS:000441793700001	30103780	DOAJ Gold, Green Published			2019-10-28	
J	Magid, MS				Magid, Margret S.			Educational Case: A Uterine Neoplasm: LeiomyomaA Benign Neoplasm	ACADEMIC PATHOLOGY			English	Article						pathology competencies; disease mechanisms; neoplasia; anaplasia; benign; hyperchromatic; hysterectomy; invasion; leiomyoma; leiomyosarcoma; malignant; metastasis; myomectomy; myometrium; normochromatic; nuclear:cytoplasmic ratio; paraneoplastic syndrome; pleomorphic; poorly differentiated; smooth muscle tumor; well-differentiated		The following fictional case is intended as a learning tool within the Pathology Competencies for Medical Education (PCME), a set of national standards for teaching pathology. These are divided into three basic competencies: Disease Mechanisms and Processes, Organ System Pathology, and Diagnostic Medicine and Therapeutic Pathology. For additional information, and a full list of learning objectives for all three competencies, see http://journals.sagepub.com/doi/10.1177/2374289517715040.	[Magid, Margret S.] NYU, Sch Med, 560 First Ave, New York, NY 10016 USA	Magid, MS (reprint author), NYU, Sch Med, 560 First Ave, New York, NY 10016 USA.	margret.magid@nyumc.org					Kumar V, 2015, ROBBINS COTRAN PATHO; Marret H, 2012, EUR J OBSTET GYN R B, V165, P156, DOI 10.1016/j.ejogrb.2012.07.030; Stewart EA, 2015, NEW ENGL J MED, V372, P1646, DOI 10.1056/NEJMcp1411029; Strayer DS, 2015, RUBINS PATHOLOGY	4	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	AUG 9	2018	5								UNSP 2374289517721193	10.1177/2374289517721193			3	Pathology	Pathology	GP9TL	WOS:000441259200001	30116773	DOAJ Gold, Green Published			2019-10-28	
J	Meyers, S				Meyers, Sarah			Educational Case: Death Certification and the Role of the Medical Examiner/Coroner	ACADEMIC PATHOLOGY			English	Article						pathology competencies; diagnostic medicine; autopsy; death certificate; forensic autopsy; reportable deaths; cause of death; manner of death; coroner; medical examiner		The following fictional case is intended as a learning tool within the Pathology Competencies for Medical Education (PCME), a set of national standards for teaching pathology. These are divided into three basic competencies: Disease Mechanisms and Processes, Organ System Pathology, and Diagnostic Medicine and Therapeutic Pathology. For additional information, and a full list of learning objectives for all three competencies, see http://journals.sagepub.com/doi/10.1177/2374289517715040.	[Meyers, Sarah] Hennepin Cty Med Examiners Off, 530 Chicago Ave, Minneapolis, MN 55415 USA	Meyers, S (reprint author), Hennepin Cty Med Examiners Off, 530 Chicago Ave, Minneapolis, MN 55415 USA.	sarah.meyers@hennepin.us					Death certification, DEATH CERT; Dimaio VJ, 2001, CRC SER PR CRIM, P3; Dolinak D, 2005, FORENSIC PATHOLOGY P, P663; Spitz WU, 2006, MED INVESTIGATION DE, P436	4	0	0	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	AUG 9	2018	5								UNSP 2374289517724724	10.1177/2374289517724724			3	Pathology	Pathology	GP9TQ	WOS:000441259700001	30116774	DOAJ Gold, Green Published			2019-10-28	
J	Li, SH; Harro, D; Alfsen, J; Bolterman, J; Ketha, H; Schroeder, LF; Giacherio, DA; Keren, DF				Li, Shih-Hon; Harro, David; Alfsen, John; Bolterman, Janet; Ketha, Hemamalini; Schroeder, Lee F.; Giacherio, Donald A.; Keren, David F.			Effect of Diabetes Mellitus on Sickle Hemoglobin Quantitation in Sickle Cell Trait	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Sickle cell trait; Diabetes; HPLC; Capillary electrophoresis; Hemoglobin S; Hemoglobin A(1c)	LIQUID-CHROMATOGRAPHY; ALPHA-THALASSEMIA; IDENTIFICATION; VARIANTS	Objectives: We evaluated the effect of diabetes on sickle hemoglobin (HbS) measurement on two common clinical hemoglobin separation platforms. Methods: We performed a method comparison between the Bio-Rad Variant II high-performance liquid chromatography (HPLC) and Sebia Capillarys 2 Flex Piercing capillary electrophoresis (CE) using clinical specimens from 38 patients without hemoglobin variants and 57 patients with sickle cell trait (AS) (HbA(1c) %, 4.1%-15.4%). We investigated the effect of intermethod Hb% differences on result interpretation by a panel of expert clinical observers. Results: In diabetic specimens, HPLC undermeasured HbS% up to 7.4% vs CE, due to S-1c eluting closely with A(0) in HPLC. This increased concern for underlying alpha-thalassemia in diabetic patients with AS based on HPLC results. HPLC P2% was linearly related to HbA(1c) % and can be a screen for diabetic AS samples. Conclusions: Glycosylation can interfere with HbS% measurement by HPLC. Susceptible specimens should be identified and preferentially analyzed via CE.	[Li, Shih-Hon; Harro, David; Alfsen, John; Bolterman, Janet; Ketha, Hemamalini; Schroeder, Lee F.; Giacherio, Donald A.; Keren, David F.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA	Li, SH (reprint author), Univ Michigan, Blood Bank UH 2F225,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	shihhon@med.umich.edu					BRITTENHAM G, 1980, BLOOD, V55, P706; Carnethon MR, 2017, CIRCULATION, V136, pE393, DOI 10.1161/CIR.0000000000000534; Chui DHK, 2003, BLOOD, V101, P791, DOI 10.1182/blood-2002-07-1975; College of American Pathologists, 2017, CHEM TOX CHECKL; Head CE, 2004, J CLIN PATHOL, V57, P276, DOI 10.1136/jcp.2003.008037; Keren DF, 2008, AM J CLIN PATHOL, V130, P824, DOI 10.1309/AJCPQY80HZWHHGZF; KUTLAR A, 1984, AM J HEMATOL, V17, P39, DOI 10.1002/ajh.2830170106; Loh TP, 2014, J CLIN PATHOL, V67, P712, DOI 10.1136/jclinpath-2014-202346; Naik RP, 2017, J AM SOC NEPHROL, V28, P2180, DOI 10.1681/ASN.2016101086; Ojodu J, 2014, MMWR-MORBID MORTAL W, V63, P1155; Perkins SL, 2017, HEMOGLOBINOPATHY HG; Piel FB, 2014, NEW ENGL J MED, V371, P1908, DOI 10.1056/NEJMra1404415; Riou J, 1997, CLIN CHEM, V43, P34; Sebia, 2015, CAP HEMOGLOBINE; STEINBERG MH, 1975, BRIT J HAEMATOL, V30, P31, DOI 10.1111/j.1365-2141.1975.tb00514.x; STEINBERG MH, 1991, HEMATOL ONCOL CLIN N, V5, P453; Thogmartin JR, 2011, J FORENSIC SCI, V56, P1352, DOI 10.1111/j.1556-4029.2011.01774.x; Tosoh Biosciences, 2014, G8 VAR AN MOD TRAIN	18	0	0	2	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	AUG	2018	150	2					105	115		10.1093/AJCP/AQY027			11	Pathology	Pathology	GN4ZQ	WOS:000439051600003	29850781	Bronze			2019-10-28	
J	Refaai, MA; Conley, GW; Henrichs, KF; McRae, H; Schmidt, AE; Phipps, RP; Spinelli, SL; Masel, D; Cholette, JM; Pietropaoli, A; Eaton, MP; Blumberg, N				Refaai, Majed A.; Conley, Grace W.; Henrichs, Kelly F.; McRae, Hannah; Schmidt, Amy E.; Phipps, Richard P.; Spinelli, Sherry L.; Masel, Debra; Cholette, Jill M.; Pietropaoli, Anthony; Eaton, Michael P.; Blumberg, Neil			Decreased Hemolysis and Improved Platelet Function in Blood Components Washed With Plasma-Lyte A Compared to 0.9% Sodium Chloride	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Plasma-Lyte A; Normal saline; Platelet function; Blood products; Hemolysis; Transfusion reactions	RED-CELL STORAGE; CRITICALLY-ILL PATIENTS; OLDER STORED-BLOOD; ACUTE LUNG INJURY; IN-VITRO; RANDOMIZED-TRIAL; CARDIAC-SURGERY; TRANSFUSION; SALINE; COMPLICATIONS	Objectives: Washing cellular blood products is accepted to ameliorate repeated severe allergic reactions but is associated with RBC hemolysis and suboptimal platelet function. We compared in vitro hemolysis and platelet function in blood components after washing with Plasma-Lyte A (PL-A) vs normal saline (NS). Methods: RBC (n = 14) were washed/resuspended in NS or PL-A. Free hemoglobin and heme were determined at 0, 24, 48, and 72 hours. Platelet concentrates (PCs; n = 21) were washed with NS or PL-A and resuspended in same washing solution (n = 13) or ABO-identical plasma (n = 8). Platelet aggregation and spreading were evaluated. Results: The 24-hour free hemoglobin and heme levels were higher in NS (P<.05). Improved platelet function was observed in PL-A-washed PCs (P<.001). Discussion: PL-A showed less RBC hemolysis and better platelet function than NS. Whether such differences would occur in vivo is unknown.	[Refaai, Majed A.; Conley, Grace W.; Henrichs, Kelly F.; McRae, Hannah; Schmidt, Amy E.; Phipps, Richard P.; Spinelli, Sherry L.; Masel, Debra; Blumberg, Neil] Golisano Childrens Hosp, Dept Pathol & Lab Med, Transfus Med Div, Rochester, NY USA; [Phipps, Richard P.] Golisano Childrens Hosp, Dept Environm Med, Rochester, NY USA; [Phipps, Richard P.] Golisano Childrens Hosp, Dept Microbiol & Immunol, Rochester, NY USA; [Phipps, Richard P.; Cholette, Jill M.] Golisano Childrens Hosp, Dept Pediat & Crit Care, Rochester, NY USA; [Phipps, Richard P.; Cholette, Jill M.] Golisano Childrens Hosp, Div Cardiol, Rochester, NY USA; [Phipps, Richard P.; Pietropaoli, Anthony] Univ Rochester, Med Ctr, Dept Med, Pulm & Crit Care Div, Rochester, NY 14642 USA; [Eaton, Michael P.] Univ Rochester, Med Ctr, Sch Med & Dent, Dept Anesthesia, Rochester, NY 14642 USA	Refaai, MA (reprint author), Univ Rochester, Med Ctr, 601 Elmwood Ave,Box 608, Rochester, NY 14642 USA.	m.refaai@rochester.edu		Eaton, Michael/0000-0002-3705-9933			Allen CH, 2016, BMC PEDIATR, V16, DOI 10.1186/s12887-016-0652-4; Aubron C, 2012, TRANSFUSION, V52, P1196, DOI 10.1111/j.1537-2995.2011.03437.x; AuBuchon JP, 2004, TRANSFUSION, V44, P36, DOI 10.1046/j.0041-1132.2004.00604.x; Ballas SK, 2006, TRANSFUSION, V46, P105, DOI 10.1111/j.1537-2995.2006.00679.x; BALLAS SK, 1991, AM J HEMATOL, V36, P122, DOI 10.1002/ajh.2830360211; Blumberg N, 2004, BMC BLOOD DISORD, V4, P6, DOI DOI 10.1186/1471-2326-4-6; Blumberg N, 2010, TRANSFUSION, V50, P2738, DOI 10.1111/j.1537-2995.2010.02748.x; Cholette JM, 2012, PEDIATR CRIT CARE ME, V13, P290, DOI 10.1097/PCC.0b013e31822f173c; Chowdhury AH, 2012, ANN SURG, V256, P18, DOI 10.1097/SLA.0b013e318256be72; Flegel WA, 2014, BRIT J HAEMATOL, V165, P3, DOI 10.1111/bjh.12747; Harm SK, 2012, TRANSFUSION MED, V22, P181, DOI 10.1111/j.1365-3148.2011.01127.x; HCUP, 2011, FACTS FIG STAT HOSP; KALMIN ND, 1982, TRANSFUSION, V22, P125, DOI 10.1046/j.1537-2995.1982.22282177118.x; Kim-Shapiro DB, 2011, TRANSFUSION, V51, P844, DOI 10.1111/j.1537-2995.2011.03100.x; Koch CG, 2008, NEW ENGL J MED, V358, P1229, DOI 10.1056/NEJMoa070403; Larsen R, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001118; Lelubre C, 2013, CRIT CARE, V17, DOI 10.1186/cc12600; Masalunga C, 2007, J PERINATOL, V27, P380, DOI 10.1038/sj.jp.7211748; Murphy S, 2004, TRANSFUSION, V44, P618, DOI 10.1111/j.1537-2995.2004.00355.x; Noritomi DT, 2011, CLINICS, V66, P1969, DOI 10.1590/S1807-59322011001100019; POPOVSKY MA, 1991, BLOOD, V77, P2299; Prescott LS, 2016, CANCER TREAT REV, V46, P1, DOI 10.1016/j.ctrv.2016.03.010; Refaai MA, 2013, TRANSFUSION, V53, P382, DOI 10.1111/j.1537-2995.2012.03718.x; Sasaki J, 2018, PERFUSION-UK, V33, P130, DOI 10.1177/0267659117730134; Schaer DJ, 2013, BLOOD, V121, P1276, DOI 10.1182/blood-2012-11-451229; Schoenfeld H, 2004, ANESTH ANALG, V99, P17, DOI 10.1213/01.ANE.0000116930.28250.15; Seitz KP, 2017, CRIT CARE MED, V45, P271, DOI 10.1097/CCM.0000000000002077; Smith T, 2013, PERFUSION-UK, V28, P34, DOI 10.1177/0267659112458960; Solomon SB, 2013, BLOOD, V121, P1663, DOI 10.1182/blood-2012-10-462945; Spinelli SL, 2014, TRANSFUSION, V54, P1569, DOI 10.1111/trf.12485; Stapley R, 2015, FREE RADICAL BIO MED, V85, P207, DOI [10.1016/j.freeradbiomed.2015.0.1.025, 10.1016/j.freeradbiomed.2015.04.025]; Story DA, 2000, ANAESTH INTENS CARE, V28, P287, DOI 10.1177/0310057X0002800306; Tartter PI, 1998, AM J SURG, V176, P462, DOI 10.1016/S0002-9610(98)00245-1; Tinmouth A, 2006, TRANSFUSION, V46, P2014, DOI 10.1111/j.1537-2995.2006.01026.x; van de Watering L, 2011, VOX SANG, V100, P36, DOI 10.1111/j.1423-0410.2010.01441.x; Verma B, 2016, CRIT CARE RESUSC, V18, P205; Wang D, 2012, TRANSFUSION, V52, P1184, DOI 10.1111/j.1537-2995.2011.03466.x; Yunos NM, 2010, CRIT CARE, V14, DOI 10.1186/cc9052; Zhou J, 2016, BRAZ J MED BIOL RES, V49, DOI [10.1590/1414-431x20165493, 10.1590/1414-431X20165493]	39	4	4	1	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	AUG	2018	150	2					146	153		10.1093/AJCP/AQY036			8	Pathology	Pathology	GN4ZQ	WOS:000439051600008	29878038				2019-10-28	
J	Shin, DW; Kim, H; Chung, Y; Kim, JN; Hong, YJ; Park, KU; Han, KS				Shin, Dong Woo; Kim, Hyungsuk; Chung, Yousun; Kim, Jun Nyun; Hong, Yun Ji; Park, Kyoung Un; Han, Kyou-Sup			Establishment and Utilization of a Transfusion Recipient Registry in Korea Estimating the Frequencies of Specific Antigen-Negative Blood Units	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Transfusion registry; Antibody identification; Blood group antigen; Unexpected antibody		Objectives: This study was conducted to establish the Korean national registry, to evaluate the distribution of unexpected antibodies, and to determine the frequencies of specific antigen-negative blood units. Methods: Data added to the Korean national registry between July 2013 and April 2016 were analyzed. The distribution of unexpected antibodies and frequencies of specific antigen-negative blood units were estimated. Results: In total, 3,513 cases from 22 institutes were registered. The most common single alloantibodies were anti-E, anti-Le(a), and anti-M. The most common multiple alloantibodies were anti-E with anti-c, anti-C with anti-e, and anti-Le(a) with anti-Le(b). The frequencies of E-, Le(a)-, and M-negative units were 42.3%, 56.9%, and 20.2%, respectively. Conclusions: The distribution of unexpected antibodies and frequencies of specific antigen-negative blood units were investigated using data from the Korean national registry. The results provide useful data to predict the number of blood units to be tested to obtain compatible blood units.	[Shin, Dong Woo; Kim, Hyungsuk; Chung, Yousun; Hong, Yun Ji; Park, Kyoung Un; Han, Kyou-Sup] Seoul Natl Univ, Dept Lab Med, Coll Med, Seoul, South Korea; [Chung, Yousun] Kangdong Sacred Heart Hosp, Dept Lab Med, Seoul, South Korea; [Kim, Jun Nyun] Korea Ctr Dis Control & Prevent, Div Human Blood Safety Surveillance, Cheongju, South Korea; [Hong, Yun Ji; Park, Kyoung Un] Seoul Natl Univ, Dept Lab Med, Bundang Hosp, 82 Gumi Ro 173, Seongnam 13620, South Korea	Hong, YJ; Park, KU (reprint author), Seoul Natl Univ, Dept Lab Med, Bundang Hosp, 82 Gumi Ro 173, Seongnam 13620, South Korea.	aeiea@snu.ac.kr; m91w95pf@snu.ac.kr		Shin, Dong Woo/0000-0002-3398-3707	Korea Centers for Disease Control and Prevention [20160343804-00]	This work was supported by the research fund for Operation of the Korean Rare Blood Program for Personalized Transfusion (No. 20160343804-00) from the Korea Centers for Disease Control and Prevention.	Alcantara Ramir, 2016, Immunohematology, V32, P55; Belsito A, 2017, TRANSFUS APHER SCI, V56, P206, DOI 10.1016/j.transci.2016.11.007; Castilho Lilian, 2016, Immunohematology, V32, P11; Chen CX, 2016, TRANSFUSION, V56, P975, DOI 10.1111/trf.13430; Chung KW, 2015, TRANSFUSION, V55, P703, DOI 10.1111/trf.12980; Daniels GL, 2004, VOX SANG, V87, P304, DOI 10.1111/j.1423-0410.2004.00564.x; Delaney M, 2015, TRANSFUSION, V55, P2369, DOI 10.1111/trf.13163; Figueroa Dolores, 2013, Immunohematology, V29, P73; Flickinger Cynthia, 2016, Immunohematology, V32, P71; Fung MK, 2014, TECHNICAL MANUAL, p[352, 391, 393]; Goldman Mindy, 2016, Immunohematology, V32, P15; Gounder D, 2016, Immunohematology, V32, P53; Han KS, 2014, TRANSFUSION MED, P224; Hong YJ, 2016, ANN HEMATOL, V95, P985, DOI 10.1007/s00277-016-2645-7; Hustinx Hein, 2016, Immunohematology, V32, P63; ISEKI S, 1970, VOX SANG, V19, P483, DOI 10.1111/j.1423-0410.1970.tb01780.x; Korean Redcross Blood Services, 2016, BLOOD INF, V198; Luken Jessie S, 2016, Immunohematology, V32, P51; Mochizuki K, 2006, TRANSFUSION, V46, P454, DOI 10.1111/j.1537-2995.2006.00743.x; Moghaddam Mostafa, 2016, Immunohematology, V32, P27; Muniz-Diaz Eduardo, 2016, Immunohematology, V32, P59; Paccapelo Cinzia, 2016, Immunohematology, V32, P47; Peyrard Thierry, 2016, Immunohematology, V32, P23; Ruseckaite R, 2017, VOX SANG, V112, P240, DOI 10.1111/vox.12487; Sareneva Inna M, 2016, Immunohematology, V32, P21; Soeker Ruwayda, 2016, Immunohematology, V32, P57; Storry J R, 2016, ISBT Sci Ser, V11, P118, DOI 10.1111/voxs.12280; Tani Yoshihiko, 2016, Immunohematology, V32, P49; Thornton Nicole M, 2016, Immunohematology, V32, P67; Thornton Nicole M, 2016, Immunohematology, V32, P3; Vanhonsebrouck A, 2016, Immunohematology, V32, P9; Wendel Silvano, 2016, Immunohematology, V32, P13; Yahalom Vered, 2016, Immunohematology, V32, P11; Zhu Ziyan, 2016, Immunohematology, V32, P17; 김경희, 2015, [The Korean Journal of Blood Transfusion, 대한수혈학회지], V26, P54, DOI 10.17945/kjbt.2015.26.1.54; 박경운, 2014, [The Korean Journal of Blood Transfusion, 대한수혈학회지], V25, P34; 김형회, 2013, [The Korean Journal of Blood Transfusion, 대한수혈학회지], V24, P64; 윤승규, 2009, [The Korean Journal of Blood Transfusion, 대한수혈학회지], V20, P220	38	0	0	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	AUG	2018	150	2					154	161		10.1093/AJCP/AQY044			8	Pathology	Pathology	GN4ZQ	WOS:000439051600009	29893771				2019-10-28	
J	Kuric, E; Krogvold, L; Hanssen, KF; Dahl-Jorgensen, K; Skog, O; Korsgren, O				Kuric, Enida; Krogvold, Lars; Hanssen, Kristian F.; Dahl-Jorgensen, Knut; Skog, Oskar; Korsgren, Olle			No Evidence for Presence of Mucosal-Associated Invariant T Cells in the Insulitic Lesions in Patients Recently Diagnosed with Type 1 Diabetes	AMERICAN JOURNAL OF PATHOLOGY			English	Article							MAIT CELLS; MULTIPLE-SCLEROSIS; ADULT PATIENTS; ONSET	Mucosal-associated invariant T (MAIT) cells are innate T cells that recognize bacteria-infected cells and are thought to play a role in autoimmune diseases. Translocation of duodenal bacteria and viruses to the pancreas through the pancreatic duct has been hypothesized to initiate an innate inflammatory response that could contribute to the development of type 1 diabetes, a process that could involve MAIT cells. In this study, we used immunohistochemistry and quantitative PCR to search for evidence of MAIT cells in the insulitic lesions in the pancreas of human patients recently diagnosed with type 1 diabetes. Only a few scattered MAIT cells were found within the exocrine parenchyma in all pancreatic samples, but no MAIT cells were found in association to the islets. Also, only low gene expression levels of the MAIT T-cell receptor V alpha 7.2-3 alpha 33 were found in the pancreas of patients with type 1 diabetes, in similar Levels as that in nondiabetic organ donors used as control. The absence of MAIT cells shown in insulitic lesions in humans questions the direct cytotoxic role of these cells in beta-cell destruction.	[Kuric, Enida; Skog, Oskar; Korsgren, Olle] Uppsala Univ, Dept Immunol Genet & Pathol, Rudbeck Lab C11, S-75185 Uppsala, Sweden; [Krogvold, Lars; Dahl-Jorgensen, Knut] Oslo Univ Hosp, Div Paediat & Adolescent Med, Oslo, Norway; [Hanssen, Kristian F.] Oslo Univ Hosp, Dept Endocrinol, Oslo, Norway; [Hanssen, Kristian F.; Dahl-Jorgensen, Knut] Univ Oslo, Fac Med, Oslo, Norway; [Krogvold, Lars] Univ Oslo, Fac Odontol, Oslo, Norway; [Korsgren, Olle] Univ Gothenburg, Dept Biomed, Gothenburg, Sweden	Skog, O (reprint author), Uppsala Univ, Dept Immunol Genet & Pathol, Rudbeck Lab C11, S-75185 Uppsala, Sweden.	oskar.skog@igp.uu.se		Skog, Oskar/0000-0001-9713-722X	Swedish Medical Research CouncilSwedish Medical Research Council (SMRC) [65X-12219-15-6, K'2015-54X-12219-19-4]; Novo Nordic Insulin Fund; Ake Wiberg Foundation; Tore Nilsson Foundation; Emfors Family Fund; Barndiabetesfonden; Swedish Diabetes Association; Diabetes Wellness Foundation [720-747 JDWG]; Juvenile Diabetes Foundation International; South-Eastern Norway Regional Health Authority; Novo Nordisk FoundationNovo Nordisk; Persistent Virus Infection in Diabetes Network Study Group - European Union's Seventh Framework Programme (FP7/2007-2013) [26441 PEVNET]	Supported by Swedish Medical Research Council grants 65X-12219-15-6 (O.K.) and K'2015-54X-12219-19-4 (O.K.), the Novo Nordic Insulin Fund (O.K.), the Ake Wiberg Foundation (O.S.), the Tore Nilsson Foundation (O.S.), the Emfors Family Fund (O.K.), Barndiabetesfonden (O.K., O.S.), the Swedish Diabetes Association (O.K.), the Diabetes Wellness Foundation grant 720-747 JDWG (O.S.), and the Juvenile Diabetes Foundation International (O.K.). The Diabetes Virus Detection study was funded by the South-Eastern Norway Regional Health Authority (K.D.-J.), the Novo Nordisk Foundation (K.D.-J.), and through the Persistent Virus Infection in Diabetes Network Study Group (K.D.-J.), which was funded by the European Union's Seventh Framework Programme (FP7/2007-2013) under agreement 26441 PEVNET.	Campbell-Thompson ML, 2013, DIABETOLOGIA, V56, P2541, DOI 10.1007/s00125-013-3043-5; Cho YN, 2014, J IMMUNOL, V193, P3891, DOI 10.4049/jimmunol.1302701; Corbett AJ, 2014, NATURE, V509, P361, DOI 10.1038/nature13160; Harms RZ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117335; Kjer-Nielsen L, 2012, NATURE, V491, P717, DOI 10.1038/nature11605; Korsgren S, 2012, AM J PATHOL, V181, P1735, DOI 10.1016/j.ajpath.2012.07.022; Krogvold L, 2016, DIABETOLOGIA, V59, P492, DOI 10.1007/s00125-015-3820-4; Krogvold L, 2014, DIABETOLOGIA, V57, P841, DOI 10.1007/s00125-013-3155-y; Kuric E, 2017, AM J PATHOL, V187, P581, DOI 10.1016/j.ajpath.2016.11.002; Ling LM, 2016, SCI REP-UK, V6, DOI 10.1038/srep20358; Lundberg M, 2017, DIABETOLOGIA, V60, P346, DOI 10.1007/s00125-016-4140-z; Magalhaes I, 2015, J CLIN INVEST, V125, P1752, DOI 10.1172/JCI78941; Miyazaki Y, 2011, INT IMMUNOL, V23, P529, DOI 10.1093/intimm/dxr047; Roep BO, 2004, DIABETOLOGIA, V47, P1650, DOI 10.1007/s00125-004-1517-1; Rouxel O, 2017, NAT IMMUNOL, V18, P1321, DOI 10.1038/ni.3854; Skog O, 2018, DIABETES OBES METAB, V20, P775, DOI 10.1111/dom.13144; Tilloy F, 1999, J EXP MED, V189, P1907, DOI 10.1084/jem.189.12.1907; Willcox A, 2009, CLIN EXP IMMUNOL, V155, P173, DOI 10.1111/j.1365-2249.2008.03860.x; Willing A, 2014, EUR J IMMUNOL, V44, P3119, DOI 10.1002/eji.201344160	19	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	AUG	2018	188	8					1744	1748		10.1016/j.ajpath.2018.04.009			5	Pathology	Pathology	GP3SI	WOS:000440773100002	29803829				2019-10-28	
J	Jensen, N; Schroder, HD; Hejbol, EK; Thomsen, JS; Bruel, A; Larsen, FT; Vinding, MC; Orlowski, D; Fuchtbauer, EM; Oliveira, JRM; Pedersen, L				Jensen, Nina; Schroder, Henrik D.; Hejbol, Eva K.; Thomsen, Jesper S.; Bruel, Annemarie; Larsen, Frederik T.; Vinding, Mikkel C.; Orlowski, Dariusz; Fuchtbauer, Ernst-Martin; Oliveira, Joao R. M.; Pedersen, Lene			Mice Knocked Out for the Primary Brain Calcification-Associated Gene Slc20a2 Show Unimpaired Prenatal Survival but Retarded Growth and Nodules in the Brain that Grow and Calcify Over Time	AMERICAN JOURNAL OF PATHOLOGY			English	Article							BASAL GANGLIA CALCIFICATION; TRANSPORT FUNCTION; RETROVIRUS RECEPTOR; CEREBROSPINAL-FLUID; MORTALITY RISK; FAHRS DISEASE; CELL-SURFACE; MAJOR CAUSE; MUTATIONS; PATIENT	Brain calcification of especially the basal ganglia characterizes primary familial brain calcification (PFBC). PFBC is a rare neurodegenerative disorder with neuropsychiatric and motor symptoms, and only symptomatic treatment is available. Four PFBC-associated genes are known; approximately 40% of patients carry mutations in the gene SLC20A2, which encodes the type III sodium-dependent inorganic phosphate transporter PiT2. To investigate the role of PiT2 in PFBC development, we studied Slc20a2-knockout (KO) mice using histology, microcomputed tomography, electron microscopy, and energy-dispersive X-ray spectroscopy. Slc20a2-KO mice showed histologically detectable nodules in the brain already at 8 weeks of age, which contained organic material and were weakly calcified. In 15-week-old mice, the nodules were increased in size and number and were markedly more calcified. The major minerals in overt calcifications were Ca and P, but Fe, Zn, and Al were also generally present. Electron microscopy suggested that the calcifications initiate intracellularly, mainly in pericytes and astrocytes. As the calcification grew, they incorporated organic material. Furthermore, endogenous IgG was detected around nodules, suggesting local increased blood-brain barrier permeabilities. Nodules were found in all 8-week-old Slc20a2-KO mice, but no prenatal or marked postnatal lethality was observed. Thus, besides allowing for the study of PFBC development, the Slc20a2-KO mouse is a potential solid preclinical model for evaluation of PFBC treatments.	[Jensen, Nina; Orlowski, Dariusz; Pedersen, Lene] Aarhus Univ, Dept Clin Med, Ctr Functionally Integrat Neurosci MindLab, Aarhus, Denmark; [Jensen, Nina; Larsen, Frederik T.; Fuchtbauer, Ernst-Martin; Pedersen, Lene] Aarhus Univ, Dept Mol Biol & Genet, Ctr Functionally Integrat Neurosci MindLab, Aarhus, Denmark; [Thomsen, Jesper S.; Bruel, Annemarie] Aarhus Univ, Dept Biomed, Ctr Functionally Integrat Neurosci MindLab, Aarhus, Denmark; [Vinding, Mikkel C.] Aarhus Univ, Cognit Neurosci Res Unit, Ctr Functionally Integrat Neurosci MindLab, Aarhus, Denmark; [Schroder, Henrik D.; Hejbol, Eva K.] Odense Univ Hosp, Dept Pathol, Odense, Denmark; [Orlowski, Dariusz] Aarhus Univ Hosp, Dept Neurosurg, Ctr Expt Neurosci Grp, Aarhus, Denmark; [Oliveira, Joao R. M.] Univ Fed Pernambuco, Dept Neuropsychiat, Keizo Asami Lab, Recife, PE, Brazil	Pedersen, L (reprint author), Aarhus Univ, Dept Mol Biol & Genet, CF Mollers Alle 3,Bldg 1130, DK-8000 Aarhus C, Denmark.	lp@mbg.au.dk	Schroder, Henrik Daa/E-2077-2013	Schroder, Henrik Daa/0000-0001-7588-235X; Hejbol, Eva Kildall/0000-0002-3462-321X; Bruel, Annemarie/0000-0003-4833-0888; Jensen, Nina/0000-0002-0975-8366; Thomsen, Jesper Skovhus/0000-0001-9386-6679; Vinding, Mikkel/0000-0002-7954-2886	Danish Council for Independent Research/Medical SciencesDet Frie Forskningsrad (DFF) [09-066064]; Brazilian National Council for Scientific and Technological DevelopmentNational Council for Scientific and Technological Development (CNPq) [480255/2013-0, 440770/2016-5, 470781/2014-9, 307909/2012-3]; The Graduate School of Health at Aarhus University; Danish Heart Association [15-R99-A5905-22947]	Supported by the Danish Council for Independent Research/Medical Sciences grant 09-066064 (L.P.); Brazilian National Council for Scientific and Technological Development grants 480255/2013-0, 440770/2016-5, 470781/2014-9, and 307909/2012-3 (J.R.M.O.); and in part by The Graduate School of Health at Aarhus University and the Danish Heart Association grant 15-R99-A5905-22947 (N.J.).	Alvarez JI, 2013, GLIA, V61, P1939, DOI 10.1002/glia.22575; Baker M, 2014, NEUROGENETICS, V15, P23, DOI 10.1007/s10048-013-0378-5; Batla A, 2017, PARKINSONISM RELAT D, V37, P1, DOI 10.1016/j.parkreldis.2016.12.024; Beck L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009148; Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176; Bottger P, 2005, FEBS J, V272, P3060, DOI 10.1111/j.1742-4658.2005.04720.x; Bottger P, 2002, J BIOL CHEM, V277, P42741, DOI 10.1074/jbc.M207096200; Bottger P, 2011, BMC BIOCHEM, V12, DOI 10.1186/1471-2091-12-21; Bugnicourt JM, 2013, J AM SOC NEPHROL, V24, P353, DOI 10.1681/ASN.2012050536; Bugnicourt JM, 2009, CLIN J AM SOC NEPHRO, V4, P284, DOI 10.2215/CJN.02140508; Burden N, 2015, J AM ASSOC LAB ANIM, V54, P198; Cantarow A, 1932, ARCH INTERN MED, V49, P981, DOI 10.1001/archinte.1932.00150130104009; Collett GDM, 2005, CIRC RES, V96, P930, DOI 10.1161/01.RES.0000163634.51301.0d; Covic A, 2009, NEPHROL DIAL TRANSPL, V24, P1506, DOI 10.1093/ndt/gfn613; David S, 2016, EUR J HUM GENET, V24, P1630, DOI 10.1038/ejhg.2016.50; Ferreira JB, 2014, J MOL NEUROSCI, V54, P748, DOI 10.1007/s12031-014-0357-9; Festing MH, 2009, GENESIS, V47, P858, DOI 10.1002/dvg.20577; Gagliardi M, 2017, J NEUROL SCI, V372, P70, DOI 10.1016/j.jns.2016.11.038; Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131; Geschwind DH, 1999, AM J HUM GENET, V65, P764, DOI 10.1086/302558; Giovannini D, 2013, CELL REP, V3, P1866, DOI 10.1016/j.celrep.2013.05.035; Grutz K, 2016, MOVEMENT DISORD, V31, P1901, DOI 10.1002/mds.26768; Guerreiro PM, 2014, AM J PHYSIOL-RENAL, V306, pF1275, DOI 10.1152/ajprenal.00458.2013; Hellemans J, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-2-r19; Hsu SC, 2013, NEUROGENETICS, V14, P11, DOI 10.1007/s10048-012-0349-2; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Jensen N, 2016, NEUROGENETICS, V17, P125, DOI 10.1007/s10048-015-0469-6; Jensen N, 2013, J MOL NEUROSCI, V51, P994, DOI 10.1007/s12031-013-0085-6; Keller A, 2013, NAT GENET, V45, P1077, DOI 10.1038/ng.2723; Kimura T, 2016, NEUROPATHOLOGY, V36, P365, DOI 10.1111/neup.12280; Kiroglu Y, 2010, DIAGN INTERV RADIOL, V16, P263, DOI 10.4261/1305-3825.DIR.2626-09.1; KOBAYASHI S, 1987, ACTA NEUROPATHOL, V73, P62, DOI 10.1007/BF00695503; Kumar N, 2017, CAN J NEUROL SCI, V44, P322, DOI 10.1017/cjn.2016.428; Larsen FT, 2017, J MOL NEUROSCI, V61, P215, DOI 10.1007/s12031-016-0868-7; Legati A, 2015, NAT GENET, V47, P579, DOI 10.1038/ng.3289; Lemos RR, 2015, HUM MUTAT, V36, P489, DOI 10.1002/humu.22778; Liu XM, 2016, J NEUROL SCI, V360, P1, DOI 10.1016/j.jns.2015.11.036; Lundorf MD, 1998, J VIROL, V72, P4524; Mi TM, 2017, J NEUROGENET, V31, P149, DOI 10.1080/01677063.2017.1336235; Miklossy J, 2005, ACTA NEUROPATHOL, V109, P643, DOI 10.1007/s00401-005-1007-7; MILLER DG, 1994, P NATL ACAD SCI USA, V91, P78, DOI 10.1073/pnas.91.1.78; Monckeberg JG, 1903, VIRCHOWS ARCH A, V171, P141; Nicolas G, 2015, AM J MED GENET B, V168, P586, DOI 10.1002/ajmg.b.32336; Nicolas G, 2014, EUR J HUM GENET, V22, P1236, DOI 10.1038/ejhg.2014.9; Nicolas G, 2013, BRAIN, V136, P3395, DOI 10.1093/brain/awt255; Nicolas G, 2013, NEUROLOGY, V80, P181, DOI 10.1212/WNL.0b013e31827ccf34; Pasanen P, 2017, ACTA NEUROL SCAND, V136, P59, DOI 10.1111/ane.12697; Paucar M, 2017, J NEUROL SCI, V375, P245, DOI 10.1016/j.jns.2017.02.007; Pinheiro J.C., 2000, MIXED EFFECTS MODELS; Ramos EM, 2004, GENEREVIEWS; Rosby O, 2016, J NEUROL, V263, P594, DOI 10.1007/s00415-016-8033-3; Rubino E, 2017, J NEUROL SCI, V377, P62, DOI 10.1016/j.jns.2017.03.053; Salaun C, 2004, J MOL BIOL, V340, P39, DOI 10.1016/j.jmb.2004.04.050; Salaun C, 2002, J VIROL, V76, P4304, DOI 10.1128/JVI.76.9.4304-4311.2002; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Seluanov A., 2010, JOVE-J VIS EXP, DOI [10.3791/2033, DOI 10.3791/2033]; Shanahan CM, 2011, CIRC RES, V109, P697, DOI 10.1161/CIRCRESAHA.110.234914; SMEYERSVERBEKE J, 1975, NEUROLOGY, V25, P48, DOI 10.1212/WNL.25.1.48; Sondergaard CS, 2009, HUM GENE THER, V20, P337, DOI 10.1089/hum.2008.140; Taglia I, 2015, NEUROL SCI, V36, P787, DOI 10.1007/s10072-015-2110-8; Takeuchi T, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-3390-z; Toyoda K, 2015, J STROKE, V17, P31, DOI 10.5853/jos.2015.17.1.31; Vanlandewijck M, 2018, NATURE, V554, P475, DOI 10.1038/nature25739; VANZEIJL M, 1994, P NATL ACAD SCI USA, V91, P1168, DOI 10.1073/pnas.91.3.1168; Villasenor R, 2016, SCI REP-UK, V6, DOI 10.1038/srep25658; Wallingford MC, 2016, REPROD BIOL, V16, P13, DOI 10.1016/j.repbio.2015.12.004; Wallingford MC, 2017, BRAIN PATHOL, V27, P64, DOI 10.1111/bpa.12362; Wang C, 2012, NAT GENET, V44, P254, DOI 10.1038/ng.1077; Wider C, 2009, J NEUROL, V256, P839, DOI 10.1007/s00415-009-5025-6; Yamada M, 2014, NEUROLOGY, V82, P705, DOI 10.1212/WNL.0000000000000143; Zhang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057060	71	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	AUG	2018	188	8					1865	1881		10.1016/j.ajpath.2018.04.010			17	Pathology	Pathology	GP3SI	WOS:000440773100012	29803831				2019-10-28	
J	Yamada, KH; Kang, H; Malik, AB				Yamada, Kaori H.; Kang, Hojin; Malik, Asrar B.			Antiangiogenic Therapeutic Potential of Peptides Derived from the Molecular Motor KIF13B that Transports VEGFR2 to Plasmalemma in Endothelial Cells (vol 187, pg 214, 2017)	AMERICAN JOURNAL OF PATHOLOGY			English	Correction																Yamada KH, 2017, AM J PATHOL, V187, P214, DOI 10.1016/j.ajpath.2016.09.010	1	0	0	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	AUG	2018	188	8					1934	1934		10.1016/j.ajpath.2018.06.002			1	Pathology	Pathology	GP3SI	WOS:000440773100018		Bronze, Green Published			2019-10-28	
J	Chang, JC; Montecalvo, J; Borsu, L; Lu, SH; Larsen, BT; Wallace, WD; Sae-Ow, W; Mackinnon, AC; Kim, HR; Bowman, A; Sauter, JL; Arcila, ME; Ladanyi, M; Travis, WD; Rekhtman, N				Chang, Jason C.; Montecalvo, Joseph; Borsu, Laetitia; Lu, Shaohua; Larsen, Brandon T.; Wallace, William Dean; Sae-Ow, Wichit; Mackinnon, Alexander C.; Kim, Hyunjae R.; Bowman, Anita; Sauter, Jennifer L.; Arcila, Maria E.; Ladanyi, Marc; Travis, William D.; Rekhtman, Natasha			Bronchiolar Adenoma Expansion of the Concept of Ciliated Muconodular Papillary Tumors With Proposal for Revised Terminology Based on Morphologic, Immunophenotypic, and Genomic Analysis of 25 Cases	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						bronchiolar adenoma; ciliated muconodular papillary tumor; CMPT; bilayered; BRAF	HARBORING BRAF MUTATIONS; GRADE MALIGNANT-TUMOR; CELL LUNG-CANCER; CLINICOPATHOLOGICAL FEATURES; HIGH PREVALENCE; EGFR MUTATIONS; ADENOCARCINOMAS; DISEASE; PAPILLOMAS; CARCINOMAS	We have identified 25 lesions involving alveolar lung parenchyma characterized by nodular proliferation of bland bilayered bronchiolar-type epithelium containing a continuous layer of basal cells. These lesions shared some histologic features with the recently described entity of ciliated muconodular papillary tumor (CMPT); however, the majority did not fit all diagnostic criteria in that they exhibited only focal or absent papillary architecture, and they had variable number of ciliated and mucinous cells, with some lesions entirely lacking 1 or both of these components. The morphologic and immunohistochemical features ranged from those resembling proximal bronchioles (proximal-type: moderate to abundant mucinous and ciliated cells; negative or weak TTF1 in luminal cells; n=8) to those resembling respiratory bronchioles (distal-type: scant or absent mucinous and ciliated cells; positive TTF1 in luminal cells; n=17). The hallmark of all lesions was a continuous layer of basal cells (p40 and CK5/6-positive). We provisionally designated these lesions as bronchiolar adenomas (BAs) and analyzed their clinicopathologic and molecular features. All BAs were discrete, sharply circumscribed lesions with a median size of 0.5 cm (range, 0.2 to 2.0 cm). Most lesions were either entirely flat (n=14) or contained focal papillary architecture (n=7); only 4 lesions, all proximal-type, were predominantly papillary, fitting the classic description of CMPT. Notably, of 9 lesions submitted for frozen section evaluation, 7 were diagnosed as adenocarcinoma. No postsurgical recurrences were observed for any lesions (median follow-up, 11 mo). Twenty-one BAs underwent next-generation sequencing and/or immunohistochemistry for BRAF V600E, revealing mutation profiles similar to those previously described for CMPTs, including BRAF V600E mutations (n=8, 38%), unusual EGFR exon 19 deletions (n=2, 10%), EGFR exon 20 insertions (n=2, 10%), KRAS mutations (n=5, 24%), and HRAS mutations (n=1, 5%). The mutation profiles were similar in proximal-type and distal-type lesions. In conclusion, we describe a family of putatively benign clonal proliferations with a spectrum of morphology recapitulating various levels of the bronchiolar tree, of which only a minor subset fits the classic description of CMPT. Comparable mutation profiles and partially overlapping morphologic features across the spectrum of these lesions support their nosological relationship. We propose designating this entire family of lesions as BAs, and that lesions currently designated CMPTs represent a subgroup of this family.	[Chang, Jason C.; Montecalvo, Joseph; Borsu, Laetitia; Kim, Hyunjae R.; Bowman, Anita; Sauter, Jennifer L.; Arcila, Maria E.; Ladanyi, Marc; Travis, William D.; Rekhtman, Natasha] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA; [Lu, Shaohua] Fudan Univ, Zhongshan Hosp, Dept Pathol, Shanghai, Peoples R China; [Larsen, Brandon T.] Mayo Clin, Dept Lab Med & Pathol, Phoenix, AZ USA; [Wallace, William Dean] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA; [Sae-Ow, Wichit] Queens Med Ctr, Dept Pathol, Honolulu, HI USA; [Mackinnon, Alexander C.] Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA; [Kim, Hyunjae R.] Baylor Coll Med, Texas Childrens Canc & Hematol Ctr, Houston, TX 77030 USA	Rekhtman, N (reprint author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA.	rekhtman@mskcc.org		Bowman, Anita S./0000-0002-8651-5317	Memorial Sloan Kettering Cancer Center, Department of Pathology Research and Development grant; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01 CA129243, P30 CA008748]; Marie-Josee and Henry R. Kravis Center for Molecular Oncology at MSKCC; Cycle for Survival	Supported in part by a Memorial Sloan Kettering Cancer Center, Department of Pathology Research and Development grant (to N.R.). The MSK-IMPACT program is supported in part by NIH P01 CA129243 (M.L., L.B., N.R.), NIH P30 CA008748 (MSKCC), the Marie-Josee and Henry R. Kravis Center for Molecular Oncology at MSKCC, and Cycle for Survival. The authors have disclosed that they have no significant relationship with, or financial interest in, any commercial companies pertaining to this article.	Aida S, 2008, AM J SURG PATHOL, V32, P1489, DOI 10.1097/PAS.0b013e31817a9061; Arai Y, 2010, HISTOPATHOLOGY, V56, P265, DOI 10.1111/j.1365-2559.2009.03463.x; Arcila ME, 2013, MOL CANCER THER, V12, P220, DOI 10.1158/1535-7163.MCT-12-0620; Badalian-Very G, 2010, BLOOD, V116, P1919, DOI 10.1182/blood-2010-04-279083; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Choueiri TK, 2012, EUR UROL, V62, P917, DOI 10.1016/j.eururo.2012.05.051; Chu HH, 2017, HUM PATHOL CASE REPO, V7, P8; Chuang HW, 2014, PATHOL INT, V64, P352, DOI 10.1111/pin.12179; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Emerson LL, 2012, PATHOL RES PRACT, V208, P726, DOI 10.1016/j.prp.2012.09.007; Flieder DB, 1998, AM J SURG PATHOL, V22, P1328, DOI 10.1097/00000478-199811000-00003; Fukuoka J, 2005, AM J SURG PATHOL, V29, P948, DOI 10.1097/01.pas.0000168177.71405.ac; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Harada T, 2008, RESP MED CME, V1, P176; Haroche J, 2012, BLOOD, V120, P2700, DOI 10.1182/blood-2012-05-430140; Hata Y, 2013, JPN J CLIN ONCOL, V43, P205, DOI 10.1093/jjco/hys218; Inamura K, 2011, PATHOL INT, V61, P252, DOI 10.1111/j.1440-1827.2011.02659.x; Ishikawa M, 2016, J SURG CASE REP, V8, P1; Ishikawa Y., 2002, PATHOL CLIN MED, V20, P964; Jin Y, 2017, PATHOL INT, V67, P171, DOI 10.1111/pin.12512; Jordan EJ, 2017, CANCER DISCOV, V7, P596, DOI 10.1158/2159-8290.CD-16-1337; Jr Tomashefski JF, 2008, DAIL HAMMARS PULMONA, V1; Kamata T, 2016, J THORAC ONCOL, V11, P261, DOI 10.1016/j.jtho.2015.10.021; Kamata T, 2015, AM J SURG PATHOL, V39, P753, DOI 10.1097/PAS.0000000000000414; Kimura ET, 2003, CANCER RES, V63, P1454; Kinno T, 2014, ANN ONCOL, V25, P138, DOI 10.1093/annonc/mdt495; Kon T, 2016, PATHOL INT, V66, P633, DOI 10.1111/pin.12460; Lau KW, 2016, HUM PATHOL, V49, P22, DOI 10.1016/j.humpath.2015.09.038; Leslie KO, 2017, VOLUME PATTERN RECOG; Liu LP, 2016, AM J SURG PATHOL, V40, P1631, DOI 10.1097/PAS.0000000000000707; Maldonado JL, 2003, J NATL CANCER I, V95, P1878, DOI 10.1093/jnci/djg123; Marchetti A, 2011, J CLIN ONCOL, V29, P3574, DOI 10.1200/JCO.2011.35.9638; MILLER RR, 1990, AM J SURG PATHOL, V14, P904, DOI 10.1097/00000478-199010000-00002; Nakajima M, 1998, PATHOL INT, V48, P944; NAKAMURA S, 1992, ACTA PATHOL JAPON, V42, P745; Paik PK, 2011, J CLIN ONCOL, V29, P2046, DOI 10.1200/JCO.2010.33.1280; Sato S, 2010, INTERACT CARDIOV TH, V11, P685, DOI 10.1510/icvts.2009.229989; Schindler G, 2011, ACTA NEUROPATHOL, V121, P397, DOI 10.1007/s00401-011-0802-6; Sun S, 2007, NAT REV CANCER, V7, P778, DOI 10.1038/nrc2190; Taguchi R, 2017, PATHOL INT, V67, P99, DOI 10.1111/pin.12504; Tiacci E, 2011, NEW ENGL J MED, V364, P2305, DOI 10.1056/NEJMoa1014209; TOKER C, 1966, CANCER, V19, P1943, DOI 10.1002/1097-0142(196612)19:12<1943::AID-CNCR2820191222>3.0.CO;2-O; Tol J, 2010, EUR J CANCER, V46, P1997, DOI 10.1016/j.ejca.2010.03.036; Travis WD, 2015, WHO CLASSIFICATION T; Udager AM, 2015, CANCER RES, V75, P2600, DOI 10.1158/0008-5472.CAN-15-0340; Udo E, 2017, DIAGN PATHOL, V12, DOI 10.1186/s13000-017-0651-2; Villaruz LC, 2015, CANCER-AM CANCER SOC, V121, P448, DOI 10.1002/cncr.29042; Wiatrak BJ, 2004, LARYNGOSCOPE, V114, P1, DOI 10.1097/01.mlg.000148224.83491.0f; Yamamoto H, 2009, LUNG CANCER, V63, P315, DOI 10.1016/j.lungcan.2008.06.021; Yatabe Y, 2002, AM J SURG PATHOL, V26, P767, DOI 10.1097/00000478-200206000-00010; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333	51	4	6	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	AUG	2018	42	8					1010	1026		10.1097/PAS.0000000000001086			17	Pathology; Surgery	Pathology; Surgery	GN9MU	WOS:000439526000003	29846186				2019-10-28	
J	Hodgson, A; Slodkowska, E; Jungbluth, A; Liu, SK; Vesprini, D; Enepekides, D; Higgins, K; Katabi, N; Xu, B; Downes, MR				Hodgson, Anjelica; Slodkowska, Elzbieta; Jungbluth, Achim; Liu, Stanley K.; Vesprini, Danny; Enepekides, Danny; Higgins, Kevin; Katabi, Nora; Xu, Bin; Downes, Michelle R.			PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						PD-L1 immunohistochemistry assays; assay comparison; urothelial carcinoma; hypopharyngeal carcinoma	CANCER; EXPRESSION; HEAD; HETEROGENEITY; ATEZOLIZUMAB; BIOMARKER; ANTIBODIES; INFECTION; NIVOLUMAB; BLOCKADE	Programmed death ligand-1 (PD-L1) immunohistochemistry is used to guide treatment decisions regarding the use of checkpoint immunotherapy in the management of urothelial carcinoma of the bladder and hypopharyngeal (HP) squamous cell carcinoma. With increasing PD-L1 testing options, a need has arisen to assess the analytical comparability of diagnostic assays in order to develop a more sustainable testing strategy. Using tissue microarrays, PD-L1 expression in tumor cells (TCs) and immune cells (ICs) was manually scored in 197 cases and 27 cases of bladder and HP cancer, respectively. Three commercial kits (Ventana SP263, Ventana SP142, Dako 22C3) and 1 platform-independent test (Cell Signalling Technologies E1L3N) were utilized. Across the 3 commercially available clones, 14% and 74% of urothelial carcinomas were positive and negative, respectively, whereas 7% and 78% of HP carcinomas were positive and negative, respectively. Twelve percent of bladder and 15% HP cases showed discrepant PD-L1 classification results. Regardless of the scoring algorithm used, E1L3N provided comparable PD-L1 staining results. Fleiss' kappa and intraclass correlation coefficient (ICC) analyses demonstrated substantial agreement among all antibody clones (k=0.639 to 0.791) and excellent reliability among SP263, 22C3, and E1L3N antibodies (ICC, 0.929 to 0.949) in TC staining. Compared with the other 3 clones, SP142 TC staining was lower with only moderate correlation (ICC, 0.500 to 0.619). Generally, the reliability of immune cell staining was lower compared with TC staining (ICC, 0.519 to 0.866). Our results demonstrate good analytic comparability of all 4 antibodies. The results are encouraging and support growing optimism in the pathology and oncology communities concerning strategies in PD-L1 assay use.	[Hodgson, Anjelica; Slodkowska, Elzbieta; Xu, Bin; Downes, Michelle R.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Anat Pathol, Toronto, ON, Canada; [Vesprini, Danny; Enepekides, Danny; Higgins, Kevin] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Head & Neck Surg, Toronto, ON, Canada; [Hodgson, Anjelica; Slodkowska, Elzbieta; Xu, Bin; Downes, Michelle R.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Liu, Stanley K.] Univ Toronto, Dept Radiat Oncol, Toronto, ON, Canada; [Jungbluth, Achim; Katabi, Nora] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA	Downes, MR (reprint author), Sunnybrook Hlth Sci Ctr, Dept Anat Pathol, Room E417,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	michelle.downes@sunnybrook.ca		Xu, Bin/0000-0003-4638-9835; Liu, Stanley/0000-0001-6851-0857	Cancer Center Support Grant of the National Institutes of Health/National Cancer Institute [P30CA008748]; Hoffman-La Roche; Astra ZenecaAstraZeneca	The SP263 antibody was purchased using a Sunnybrook Health Sciences Centre departmental Educational Grant courtesy of Astra Zeneca. Research reported in this publication was supported in part by the Cancer Center Support Grant of the National Institutes of Health/National Cancer Institute under award number P30CA008748. M. R. D. has received compensation from Hoffman-La Roche and Astra Zeneca for participating on advisory boards and honoraria from Astra Zeneca. B.X. has received honoraria from Merck. The remaining authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Balar AV, 2017, LANCET, V389, P67, DOI 10.1016/S0140-6736(16)32455-2; Bellmunt J, 2017, CANCER TREAT REV, V54, P58, DOI 10.1016/j.ctrv.2017.01.007; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Casadevall D, 2017, CLIN LUNG CANCER, V18, P682, DOI [10.1016/j.cllc.2017.04.014, 10.1016/j.dlc.2017.04.014]; Cooper JS, 2009, HEAD NECK-J SCI SPEC, V31, P748, DOI 10.1002/hed.21022; Crist M, 2017, EXPERT REV CLIN PHAR, V10, P1295, DOI 10.1080/17512433.2017.1389275; Day D, 2016, CURR ONCOL, V23, P221, DOI 10.3747/co.23.3242; De Meulenaere A, 2017, ORAL ONCOL, V70, P34, DOI 10.1016/j.oraloncology.2017.05.002; Economopoulou P, 2016, ESMO OPEN, V1, DOI 10.1136/esmoopen-2016-000122; Ferris RL, 2016, NEW ENGL J MED, V375, P1856, DOI 10.1056/NEJMoa1602252; Gaule P, 2017, JAMA ONCOL, V3, P256, DOI 10.1001/jamaoncol.2016.3015; Hirsch FR, 2017, J THORAC ONCOL, V12, P208, DOI 10.1016/j.jtho.2016.11.2228; Hodgson A, 2017, HISTOPATHOLOGY, V71, P296, DOI 10.1111/his.13225; Ilie M, 2016, ANN ONCOL, V27, P147, DOI 10.1093/annonc/mdv489; Kerr KM, 2016, ARCH PATHOL LAB MED, V140, P326, DOI 10.5858/arpa.2015-0522-SA; Liu YW, 2018, CLIN LUNG CANCER, V19, pE421, DOI 10.1016/j.cllc.2018.02.008; Madore J, 2015, PIGM CELL MELANOMA R, V28, DOI 10.1111/pcmr.12340; Muller T, 2017, ONCOTARGET, V8, P52889, DOI 10.18632/oncotarget.17547; Munari E, 2017, ONCOTARGET, V8, P90123, DOI 10.18632/oncotarget.21485; Ning YM, 2017, ONCOLOGIST, V22, P743, DOI 10.1634/theoncologist.2017-0087; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Patel SP, 2015, MOL CANCER THER, V14, P847, DOI 10.1158/1535-7163.MCT-14-0983; Pauken KE, 2015, TRENDS IMMUNOL, V36, P265, DOI 10.1016/j.it.2015.02.008; Postow MA, 2015, J CLIN ONCOL, V33, P1974, DOI 10.1200/JCO.2014.59.4358; Powles T, 2014, NATURE, V515, P558, DOI 10.1038/nature13904; Prasad V, 2017, SEMIN ONCOL, V44, P132, DOI 10.1053/j.seminoncol.2017.06.007; Ratcliffe MJ, 2017, CLIN CANCER RES, V23, P3585, DOI 10.1158/1078-0432.CCR-16-2375; Rehman JA, 2017, MODERN PATHOL, V30, P340, DOI 10.1038/modpathol.2016.186; Rimm DL, 2017, JAMA ONCOL, V3, P1051, DOI 10.1001/jamaoncol.2017.0013; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Scheel AH, 2018, HISTOPATHOLOGY, V72, P449, DOI 10.1111/his.13375; Scott M, 2017, J CLIN ONCOL, V35; Sheffield BS, 2016, J HISTOCHEM CYTOCHEM, V64, P587, DOI 10.1369/0022155416665338; Speiser DE, 2014, NAT REV IMMUNOL, V14, P768, DOI 10.1038/nri3740; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tretiakova M, 2018, MODERN PATHOL, V31, P623, DOI 10.1038/modpathol.2017.188; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954	37	12	12	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	AUG	2018	42	8					1059	1066		10.1097/PAS.0000000000001084			8	Pathology; Surgery	Pathology; Surgery	GN9MU	WOS:000439526000008	29750666				2019-10-28	
J	Michalova, K; Michal, M; Sedivcova, M; Kazakov, DV; Bacchi, C; Antic, T; Miesbauerova, M; Hes, O; Michal, M				Michalova, Kvetoslava; Michal, Michael; Sedivcova, Monika; Kazakov, Dmitry V.; Bacchi, Carlos; Antic, Tatjana; Miesbauerova, Marketa; Hes, Ondrej; Michal, Michal			Solid pseudopapillary neoplasm (SPN) of the testis: Comprehensive mutational analysis of 6 testicular and 8 pancreatic SPNs	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Solid pseudopapillary neoplasm; Primary signet ring cell stromal tumor; Testis; Pancreas; SPN; Analogue	MICROCYSTIC STROMAL TUMOR; PRIMARY OVARIAN ORIGIN; BETA-CATENIN MUTATION; OF-THE-LITERATURE; ENTITY	Background: Recently, we came with the theory of a possible relationship between a group of testicular and pancreatic tumors. We used one case of a pancreatic analogue solid pseudopapillary neoplasm of the testis composed partially of areas reminiscent of solid pseudopapillary neoplasm (SPN) of the pancreas and partially of structures identical to primary signet ring stromal tumor of the testis (PSRSTT) as a connecting link between these two entities. After demonstrating that PSRSTT and pancreatic analogue SPN of the testis share the same immunoprofile and genetic features characteristic for pancreatic SPN, we came to the conclusion that pancreatic analogue SPN of the testis and PSRSTT represent a morphological spectrum of a single entity and that both are related to the pancreatic SPN. Design: The aim of this study is to present a series of 6 cases of testicular tumors, which lacked the signet ring cell component and were thus morphologically very similar to the SPN of the pancreas. The goal of this study is to compare the genetic background of these testicular tumors that are obviously related to the PSRSTT/pancreatic analogue SPN of the testis with the series of 8 pancreatic SPN. Results: The mutational analysis revealed an oncogenic somatic mutation in the exon 3 of the CTNNB1 (beta-catenin) gene in all analyzable (5/6) testicular and all pancreatic (8/8) tumors. The immunoprofile (positivity with beta-catenin, CD10, vimentin, NSE, CD56, and negativity with inhibin, calretinin, chromogranin) was identical in all testicular and pancreatic tumors. Conclusion: This study expanded the morphological spectrum of the PSRSTT/pancreatic analogue SPN of the testis by adding 6 cases without the signet ring cell component. Considering the obvious analogy of PSRSTT/pancreatic analogue SPN of the testis/SPN of the testis and their relationship to the pancreatic SPN we propose the collective term "solid pseudopapillary neoplasm of the testis" for these tumors. The mutational profile of the SPN of the testis and pancreas was the same in both groups of tumors which we consider as a final proof that SPN of the testis is identical to the SPN of the pancreas.	[Michalova, Kvetoslava; Michal, Michael; Kazakov, Dmitry V.; Miesbauerova, Marketa; Hes, Ondrej; Michal, Michal] Charles Univ Prague, Fac Med Pilsen, Dept Pathol, Plzen 32300, Czech Republic; [Michal, Michael] Charles Univ Prague, Fac Med Pilsen, Biomed Ctr, Plzen 32300, Czech Republic; [Sedivcova, Monika] Biopt Lab Ltd, Plzen 30100, Czech Republic; [Bacchi, Carlos] Consultoria Patol, Botucatu, SP, Brazil; [Antic, Tatjana] Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA	Michalova, K (reprint author), Charles Univ Prague, Med Fac, Dept Pathol, Plzen 30460, Czech Republic.; Michalova, K (reprint author), Charles Univ Hosp Plzen, Plzen 30460, Czech Republic.	kveta.michalova@medima.cz	Michal, Michael/I-3497-2017	Michal, Michael/0000-0003-4403-7027	National Sustainability Program I (NPU I) by the Ministry of Education Youth and Sports of the Czech Republic [LO1503]; Charles University Fund [SW 2017-260391]	This study was supported by the National Sustainability Program I (NPU I) Nr. LO1503 provided by the Ministry of Education Youth and Sports of the Czech Republic and by Charles University Fund SW 2017-260391.	Abe A, 2018, HISTOPATHOLOGY, V72, P216, DOI 10.1111/his.13376; Cheuk W, 2011, INT J GYNECOL PATHOL, V30, P539, DOI 10.1097/PGP.0b013e31821724fb; Deshpande V, 2010, AM J SURG PATHOL, V34, P1514, DOI 10.1097/PAS.0b013e3181f133e9; Estrella JS, 2014, AM J SURG PATHOL, V38, P147, DOI 10.1097/PAS.0000000000000141; He SQ, 2015, INT J CLIN EXP PATHO, V8, P8645; Irving JA, 2015, AM J SURG PATHOL, V39, P1420, DOI 10.1097/PAS.0000000000000482; Irving JA, 2009, AM J SURG PATHOL, V33, P367, DOI 10.1097/PAS.0b013e31818479c3; Kazakov DV, 2009, AM J DERMATOPATH, V31, P248, DOI 10.1097/DAD.0b013e318198922a; Kominami A, 2014, PATHOL INT, V64, P460, DOI 10.1111/pin.12194; Kopczynski J, 2016, APPL IMMUNOHISTO M M, V24, pE28, DOI 10.1097/PAI.0000000000000271; Kosmahl M, 2000, VIRCHOWS ARCH, V436, P473, DOI 10.1007/s004280050475; Kuo CY, 2009, HUM PATHOL, V40, P584, DOI 10.1016/j.humpath.2008.07.012; Maeda D, 2011, AM J SURG PATHOL, V35, P1429, DOI 10.1097/PAS.0b013e31822d6c71; McCluney S, 2018, ANZ J SURG; Mengoli MC, 2017, APPL IMMUNOHISTO M M, V25, pE95, DOI 10.1097/PAI.0000000000000480; Mengoli MC, 2017, HUM PATHOL, V62, P242, DOI 10.1016/j.humpath.2016.08.011; Michal M, 2005, VIRCHOWS ARCH, V447, P107, DOI 10.1007/s00428-005-1218-2; Michal M, 2016, HUM PATHOL, V56, P52, DOI 10.1016/j.humpath.2016.06.007; Michalova K, 2017, HUM PATHOL, V67, P85, DOI 10.1016/j.humpath.2017.07.010; Michalova K, 2017, HUM PATHOL, V62, P243, DOI 10.1016/j.humpath.2016.08.012; Notohara K, 2000, AM J SURG PATHOL, V24, P1361, DOI 10.1097/00000478-200010000-00005; Serra S, 2008, J CLIN PATHOL, V61, P1153, DOI 10.1136/jcp.2008.057828; Singh K, 2018, INT J GYNECOL PATHOL, V37, P110, DOI 10.1097/PGP.0000000000000396; Stoll LM, 2012, HUM PATHOL, V43, P1339, DOI 10.1016/j.humpath.2011.12.018; Syriac S, 2012, ANN DIAGN PATHOL, V16, P498, DOI 10.1016/j.anndiagpath.2011.04.007; Tanaka Y, 2001, CANCER RES, V61, P8401; Zhu P, 2017, CANC RES TREAT	27	4	4	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	AUG	2018	35						42	47		10.1016/j.anndiagpath.2018.04.003			6	Pathology	Pathology	GP5ZJ	WOS:000440955900008	29705715				2019-10-28	
J	Kojima, YA; Wang, XH; Sun, HX; Compton, F; Covinsky, M; Zhang, SL				Kojima, Yumi A.; Wang, Xiaohong; Sun, Hongxia; Compton, Frances; Covinsky, Michael; Zhang, Songlin			Reproducible evaluation of tumor-infiltrating lymphocytes (TILs) using the recommendations of International TILs Working Group 2014	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Tumor infiltrating lymphocytes; International TILs Working Group; Breast cancer; Pathology trainees; Inter-observer agreement; Kappa value	BREAST-CANCER; TRIAL	Tumor infiltrating lymphocytes (TILs) in breast cancer play an important role in predicting the outcome of breast cancer. The goal of our current study is to investigate the consistency and reproducibility of the recommendations published by the International TILs Working Group 2014 among pathology trainees and pathologists. Hematoxylin & Eosin (H&E) slides from 129 breast cancer cases (one slide each) from 2009 to 2014 were evaluated. Each case was blindly and independently reviewed by two observers following the International TILs Working Group 2014 recommendations. Three pathology trainees (PGY2, PGY3 and PGY4) and three pathologists (2 general pathologists and 1 breast pathologist) were involved in this study. Of the 129 cases, 10 (10/129, 7.8%) cases had TILs > 50%, 90 (90/129, 69.8%) cases had < 10% of TILs, and 29 (29/129, 22.4%) cases had TILs ranging from 10 to 50%. Our results showed that in 104 cases (104/129, 80.6%) the TILs percentage was identical between the 2 observers. In 18 cases (18/129, 14%), the difference between the two observers was by 10% and in 7 cases (7/129, 5.4%) there was a difference of 20% or more. The inter-observer kappa value was 0.776 between two observers, and the kappa score improved to 0.86 if using the 3 categoric groups ( < 10%, 10-50%, and > 50%). Our study showed that the recommendations and instructions for TILs evaluation by the International TILs Working Group 2014 were sufficiently detailed to be applied for TILs evaluation in breast cancer.	[Wang, Xiaohong; Compton, Frances; Covinsky, Michael; Zhang, Songlin] Univ Texas Hlth Sci Ctr Houston, Dept Pathol, 6431 Fannin S4, Houston, TX 77030 USA; [Kojima, Yumi A.; Sun, Hongxia] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	Zhang, SL (reprint author), 6431 Fannin St MSB2-216, Houston, TX 77030 USA.	Songlin.Zhang@uth.tmc.edu		Covinsky, Michael/0000-0002-0530-6418	Department of Defense, Breast cancer idea awardUnited States Department of Defense [BC120177]; Department of Pathology and Laboratory Medicine, University of Texas Health Science Center, Houston, TX	The study was funded by Department of Defense, Breast cancer idea award, grant# BC120177; Department of Pathology and Laboratory Medicine, University of Texas Health Science Center, Houston, TX.	Adams S, 2014, J CLIN ONCOL, V32, P2959, DOI 10.1200/JCO.2013.55.0491; Coates AS, 2015, ANN ONCOL, V26, P1533, DOI 10.1093/annonc/mdv221; Denkert C, 2016, MODERN PATHOL, V29, P1155, DOI 10.1038/modpathol.2016.109; Denkert C, 2010, J CLIN ONCOL, V28, P105, DOI 10.1200/JCO.2009.23.7370; Disis ML, 2010, J CLIN ONCOL, V28, P4531, DOI 10.1200/JCO.2009.27.2146; Hida AI, 2015, ANN ONCOL, V26, P2351, DOI 10.1093/annonc/mdv363; Loi S, 2014, ANN ONCOL, V25, P1544, DOI 10.1093/annonc/mdu112; Loi S, 2013, J CLIN ONCOL, V31, P860, DOI 10.1200/JCO.2011.41.0902; Perez EA, 2016, JAMA ONCOL, V2, P56, DOI 10.1001/jamaoncol.2015.3239; Pruneri G, 2016, ANN ONCOL, V27, P249, DOI 10.1093/annonc/mdv571; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; Swisher SK, 2016, ANN SURG ONCOL, V23, P2242, DOI 10.1245/s10434-016-5173-8; Tramm T, 2017, ACTA ONCOL, V57, P90	13	3	3	1	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	AUG	2018	35						77	79		10.1016/j.anndiagpath.2018.05.007			3	Pathology	Pathology	GP5ZJ	WOS:000440955900014	29886396				2019-10-28	
J	Zhu, YP; Sheng, LL; Wu, J; Yang, M; Chen, XF; Wu, NN; Ye, XB; Cai, J; Wang, L; Shen, Q; Wu, JQ				Zhu, Yi Ping; Sheng, Li Li; Wu, Jing; Yang, Mo; Chen, Xian Feng; Wu, Ning Ni; Ye, Xiao Bing; Cai, Juan; Wang, Lu; Shen, Qian; Wu, Jian Qiu			Loss of ARID1A expression is associated with poor prognosis in patients with gastric cancer	HUMAN PATHOLOGY			English	Article						Gastric cancer; ARID1A; Immunohistochemistry; Prognosis; Pathology	CLEAR-CELL CARCINOMA; PHASE-III TRIAL; CLINICOPATHOLOGICAL SIGNIFICANCE; GASTROESOPHAGEAL JUNCTION; TUMOR-SUPPRESSOR; SWI/SNF COMPLEX; DOUBLE-BLIND; ADENOCARCINOMA; MUTATIONS; TUMORIGENESIS	Deletion of the frequently mutated AT-rich interacting domain-containing protein 1A (ARID1A), an SWI/SNF subunit, is associated with poor prognosis in various tumors. This study observed and analyzed ARID1A expression and its correlation with prognosis in gastric carcinoma. Postoperative sections of 98 patients with primary gastric cancer and 40 patients with gastric benign lesions were examined by immunohistochemistry. ARID1A deficiency was observed in 19.39% of gastric cancer tissues, 4.08% of matched paracancerous tissues, and 2.5% of normal gastric mucosa tissues. ARID1A expression was significantly down-regulated in gastric cancer tissues compared with paracancerous tissues (P=.001) and normal gastric mucosa tissues (P=.011). ARID1A deletion significantly correlated with tumor size (P=.022), lymph node metastasis (P=.030), and tumor differentiation (P=.009). In the 90 gastric cancer tissues with tumor stages II and III, the clinical outcome of the ARID1A-negative patients was significantly poorer than that of the ARID1A-positive patients (P=.005). Univariate analysis revealed that tumor invasion depth (P=.025), stage (P=.032), poor differentiation (P=.046), lymph node metastasis (P=.038), and AR1D1A expression (P=.023) were significantly related to the overall survival of gastric cancer patients. Multivariate analysis demonstrated that tumor invasion depth (P=.029) and ARID1A expression (P=.031) were independent factors that indicate poor prognosis. In conclusion, the loss of ARID1A expression in gastric cancer patients significantly correlated with poor survival. (C) 2018 Elsevier Inc. All rights reserved.	[Zhu, Yi Ping; Sheng, Li Li; Yang, Mo; Wu, Ning Ni; Ye, Xiao Bing; Cai, Juan; Wang, Lu] Wannan Med Coll, Yijishan Hosp, Dept Oncol, Wuhu 241001, Anhui, Peoples R China; [Wu, Jing] Soochow Univ, Affiliated Hosp 1, Dept Oncol, Suzhou 215006, Peoples R China; [Chen, Xian Feng] Chinese Acad Med Sci, Hosp Dermatol, Dept Clin Lab, Nanjing 210000, Jiangsu, Peoples R China; [Chen, Xian Feng] Peking Union Med Coll, Nanjing 210000, Jiangsu, Peoples R China; [Shen, Qian] Nantong Canc Hosp, Dept Oncol, Nantong 226000, Jiangsu, Peoples R China; [Wu, Jian Qiu] Jiangsu Canc Hosp, Dept Oncol, Nanjing 210000, Jiangsu, Peoples R China	Shen, Q (reprint author), Nantong Canc Hosp, Dept Oncol, Nantong 226000, Jiangsu, Peoples R China.; Wu, JQ (reprint author), Jiangsu Canc Hosp, Dept Oncol, Nanjing 210000, Jiangsu, Peoples R China.	doctor_jw@126.com; drwujq@vip.126.com			Key Fund of Wannan Medical College [WK2015ZF09]; Natural Science Research Project of College and Universities in Anhui Province [KJ2017A262]	This research was supported by Key Fund of Wannan Medical College (WK2015ZF09) and Natural Science Research Project of College and Universities in Anhui Province (KJ2017A262).	Abe H, 2012, VIRCHOWS ARCH, V461, P367, DOI 10.1007/s00428-012-1303-2; Ali SM, 2015, ONCOLOGIST, V20, P499, DOI 10.1634/theoncologist.2014-0378; Bang YJ, 2010, LANCET, V376, P1302; Chandler RL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7118; Cho HD, 2015, J BREAST CANCER, V18, P339, DOI 10.4048/jbc.2015.18.4.339; Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Guan B, 2011, CANCER RES, V71, P6718, DOI 10.1158/0008-5472.CAN-11-1562; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Inada R, 2015, WORLD J GASTROENTERO, V21, P2159, DOI 10.3748/wjg.v21.i7.2159; Jongerius EJ, 2016, BRIT J SURG, V103, P1497, DOI 10.1002/bjs.10149; Kang C, 2014, WORLD J GASTROENTERO, V20, P6433, DOI 10.3748/wjg.v20.i21.6433; Katagiri A, 2012, MODERN PATHOL, V25, P282, DOI 10.1038/modpathol.2011.161; Kim KJ, 2015, J GASTRIC CANCER, V15, P201, DOI 10.5230/jgc.2015.15.3.201; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; Li J, 2016, J CLIN ONCOL, V34, P1448, DOI 10.1200/JCO.2015.63.5995; Ma JL, 2016, ONCOL LETT, V11, P2959, DOI 10.3892/ol.2016.4337; Mrklic I, 2012, HEPATO-GASTROENTEROL, V59, P300, DOI 10.5754/hge10776; Nagymanyoki Z, 2015, CANCER CYTOPATHOL, V123, P253, DOI 10.1002/cncy.21514; Nie ZQ, 2000, MOL CELL BIOL, V20, P8879, DOI 10.1128/MCB.20.23.8879-8888.2000; Nishikimi K, 2015, HISTOPATHOLOGY, V67, P866, DOI 10.1111/his.12721; Reisman D, 2009, ONCOGENE, V28, P1653, DOI 10.1038/onc.2009.4; Shen JF, 2015, CANCER DISCOV, V5, P752, DOI 10.1158/2159-8290.CD-14-0849; SINICROPE FA, 1995, CANCER RES, V55, P237; Smith-Roe SL, 2015, ONCOTARGET, V6, P732, DOI 10.18632/oncotarget.2715; Washington K, 2010, ANN SURG ONCOL, V17, P3077, DOI 10.1245/s10434-010-1362-z; Wilke H, 2014, LANCET ONCOL, V15, P1224, DOI 10.1016/S1470-2045(14)70420-6; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068; Wu JN, 2013, CANCER DISCOV, V3, P35, DOI 10.1158/2159-8290.CD-12-0361; Yamamoto S, 2012, MODERN PATHOL, V25, P615, DOI 10.1038/modpathol.2011.189; Ychou M, 2011, J CLIN ONCOL, V29, P1715, DOI 10.1200/JCO.2010.33.0597; Zang ZJ, 2012, NAT GENET, V44, P570, DOI 10.1038/ng.2246; Zhao J, 2016, PATHOL ONCOL RES, V22, P453, DOI 10.1007/s12253-015-0022-9; Zhao J, 2014, TUMOR BIOL, V35, P4813, DOI 10.1007/s13277-014-1632-7; Zu HL, 2014, INT J CLIN EXP PATHO, V7, P5692	35	5	6	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	AUG	2018	78						28	35		10.1016/j.humpath.2018.04.003			8	Pathology	Pathology	GR0GG	WOS:000442191800004	29689245				2019-10-28	
J	Wang, LM; Li, Z; Zhang, M; Piao, YS; Chen, L; Liang, HY; Wei, YK; Hu, ZL; Zhao, LH; Teng, LH; Lu, DH				Wang, Leiming; Li, Zhuo; Zhang, Ming; Piao, Yueshan; Chen, Li; Liang, Huiying; Wei, Yukui; Hu, Zeliang; Zhao, Lihong; Teng, Lianghong; Lu, Dehong			H3 K27M-mutant diffuse midline gliomas in different anatomical locations	HUMAN PATHOLOGY			English	Article						H3 K27M; Glioma; IDH; Overall survival; ATRX	INTRINSIC PONTINE GLIOMAS; ACTIVATING ACVR1 MUTATIONS; H3F3A K27M MUTATIONS; HIGH-GRADE GLIOMAS; SPINAL-CORD; GENETIC ALTERATIONS; HISTONE H3F3A; SUBGROUPS; GLIOBLASTOMAS; ASTROCYTOMA	The histone H3 K27M mutation has been frequently reported in most diffuse midline gliomas. However, the relationship between the H3 K27M mutation and clinical outcomes of gliomas from different anatomical locations is still not fully understood. A total of 120 patients with diffuse midline gliomas were selected for this retrospective observational study. The status of H3 K27M, ATRX, TP53, and IDH was evaluated using immunohistochemistry and Sanger sequencing. Of the 120 patients aged from 4 to 76 years (median, 27 years), 61 (50.8%) were harboring the H3 K27M mutation. Tumors were mainly located in the brainstem, ATRX thalamus, and spinal cord, but also in the cerebellum, corpus callosum, and the lateral ventricle. Patients with H3 K27M mutant diffuse midline gliomas had a significantly shorter overall survival than H3 wild-type counterparts (P=.001). However, the H3 K27M mutation was mainly associated with a poorer prognosis in infratentorial gliomas compared with the corresponding H3 wild-type gliomas (P<.0001), but not in supratentorial gliomas (P=.603). Moreover, patients with H3 K27M mutant gliomas in unusual anatomical locations had a better prognosis than did those with corresponding tumors in the brainstem. This study may provide guidance for better treatment stratification decisions for diffuse gliomas bearing the H3 K27M mutation, which arise in different locations of the brainstem, thalamus, spinal cord, or other sites. (C) 2018 Elsevier Inc. All rights reserved.	[Wang, Leiming; Li, Zhuo; Piao, Yueshan; Chen, Li; Hu, Zeliang; Zhao, Lihong; Teng, Lianghong; Lu, Dehong] Capital Med Univ, Xuanwu Hosp, Dept Pathol, 45 Changchun St, Beijing, Peoples R China; [Zhang, Ming] Peking Univ, Dept Pathol, Int Hosp, Beijing, Peoples R China; [Liang, Huiying] Guangzhou Med Univ, Guangzhou Women & Childrens Med Ctr, Inst Pediat, Guangzhou, Guangdong, Peoples R China; [Wei, Yukui] Capital Med Univ, Xuanwu Hosp, Dept Neurosurg, Beijing, Peoples R China	Teng, LH; Lu, DH (reprint author), Capital Med Univ, Xuanwu Hosp, Dept Pathol, 45 Changchun St, Beijing, Peoples R China.	tenglh2012@163.com; ludehong05@sina.com		Liang, Huiying/0000-0002-9987-8002	National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81401040]; Beijing Excellent Talent Training Project Grant [201600026833ZK07]; Capital Health Research and Development of Special Funds [2016-1-2011]	This study was supported by the National Natural Science Foundation of China (81401040) and Beijing Excellent Talent Training Project Grant (201600026833ZK07) to Leiming Wang, and Capital Health Research and Development of Special Funds (2016-1-2011) to Yueshan Piao.	Aihara K, 2014, NEURO-ONCOLOGY, V16, P140, DOI 10.1093/neuonc/not144; Banan R, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-017-0500-2; Bechet D, 2014, ACTA NEUROPATHOL, V128, P733, DOI 10.1007/s00401-014-1337-4; Buczkowicz P, 2014, ACTA NEUROPATHOL, V128, P573, DOI 10.1007/s00401-014-1319-6; Buczkowicz P, 2014, NAT GENET, V46, P451, DOI 10.1038/ng.2936; Castel D, 2015, ACTA NEUROPATHOL, V130, P815, DOI 10.1007/s00401-015-1478-0; Khuong-Quang DA, 2012, ACTA NEUROPATHOL, V124, P439, DOI 10.1007/s00401-012-0998-0; Feng J, 2015, HUM PATHOL, V46, P1626, DOI 10.1016/j.humpath.2015.07.002; Gessi M, 2015, ACTA NEUROPATHOL, V130, P435, DOI 10.1007/s00401-015-1463-7; Hawkins C, 2016, WHO CLASSIFICATION T, P57; Joyon N, 2017, NEUROPATH APPL NEURO, V43, P271, DOI 10.1111/nan.12329; Karremann M, 2018, NEURO-ONCOLOGY, V20, P123, DOI 10.1093/neuonc/nox149; Kleinschmidt-DeMasters BK, 2017, BRAIN PATHOL, V27, P846, DOI 10.1111/bpa.12455; Lopez G, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-017-0440-x; Lopez GY, 2017, ACTA NEUROPATHOL, V134, P961, DOI 10.1007/s00401-017-1780-0; Meyronet D, 2017, NEURO-ONCOLOGY, V19, P1127, DOI 10.1093/neuonc/now274; Pages M, 2018, BRAIN PATHOL, V28, P103, DOI 10.1111/bpa.12473; Reuss DE, 2015, ACTA NEUROPATHOL, V129, P133, DOI 10.1007/s00401-014-1370-3; Ryall S, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0353-0; Shankar GM, 2016, ACTA NEUROPATHOL, V131, P147, DOI 10.1007/s00401-015-1492-2; Shows J, 2016, BRAIN PATHOL, V26, P120, DOI 10.1111/bpa.12327; Solomon DA, 2016, BRAIN PATHOL, V26, P569, DOI 10.1111/bpa.12336; Sturm D, 2012, CANCER CELL, V22, P425, DOI 10.1016/j.ccr.2012.08.024; Tanboon J, 2016, J NEUROPATH EXP NEUR, V75, P4, DOI 10.1093/jnen/nlv009; Taylor KR, 2014, NAT GENET, V46, P457, DOI 10.1038/ng.2925; Venneti S, 2014, ACTA NEUROPATHOL, V128, P743, DOI 10.1007/s00401-014-1338-3; Wang LM, 2017, J CLIN PATHOL, V70, P1079, DOI 10.1136/jclinpath-2017-204620; Wu G, 2014, NAT GENET, V46, P444, DOI 10.1038/ng.2938; Wu G, 2012, NAT GENET, V44, P251, DOI 10.1038/ng.1102	29	4	7	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	AUG	2018	78						89	96		10.1016/j.humpath.2018.04.015			8	Pathology	Pathology	GR0GG	WOS:000442191800011	29727696				2019-10-28	
J	Kim, H; Kim, CY; Park, KH; Kim, A				Kim, Hayeon; Kim, Chung-Yeul; Park, Kyong Hwa; Kim, Aeree			Clonality analysis of multifocal ipsilateral breast carcinomas using X-chromosome inactivation patterns	HUMAN PATHOLOGY			English	Article						Breast neoplasm; Multifocal tumor; Multiple tumor; Clonality analysis; HUMARA assay	TERM-FOLLOW-UP; TUMOR SIZE; CANCER; RECEPTOR; SURVIVAL; METHYLATION; WOMEN; MULTICENTRICITY; SECTIONS; DISEASE	The definition of multifocal breast cancer is ambiguous, and its incidence varies depending on the definition and detection methods. Multifocal breast cancers either have the same clonal origin or arise from completely distinct progenitor cells. The current American Joint Committee on Cancer Staging system and College of American Pathologists breast tumor guidelines state that only the largest tumor needs to be staged and studied immunohistochemically, on the assumption that they are of the same origin. However, some multifocal tumors have been proved to have arisen from different clones. In the present study, 71 cases of surgically resected multifocal breast cancers were selected. To detect and characterize the tumors of each clonal origin, a human androgen receptor gene (HUMARA) assay to compare the X-chromosome inactivation patterns of multiple tumors was conducted. Twenty-nine of 71 (40.8%) patients were revealed to be heterozygous for HUMARA. Sixty-four (90.1%) patients had the same X chromosome inactivated in different tumors. Seven (9.9%) cases had different inactivated X chromosomes between multifocal tumors, indicating that those tumors were from separate progenitor cells. Five (7.0%) cases showed identical histologic features but had different inactivated HUMARA alleles. According to these results, 2 separate tumors might be synchronous primary tumors, although their histopathologic characteristics are similar. Furthermore, multifocal tumors can be of different origins despite being closely located to each other. These findings suggest that separate grouping of multiple breast tumors based on their clonal origin is needed for future studies. (C) 2018 Elsevier Inc. All rights reserved.	[Kim, Hayeon; Kim, Chung-Yeul; Kim, Aeree] Korea Univ, Dept Pathol, Guro Hosp, 148 Gurodong Ro, Seoul 08308, South Korea; [Park, Kyong Hwa] Korea Univ, Dept Internal Med, Div Oncol Hematol, Coll Med, Seoul 02841, South Korea	Kim, A (reprint author), Korea Univ, Dept Pathol, Guro Hosp, 148 Gurodong Ro, Seoul 08308, South Korea.	ark@korea.ac.kr					ALLEN RC, 1992, AM J HUM GENET, V51, P1229; Amin MB, 2017, AJCC CANC STAGING MA; Andea AA, 2002, CANCER, V94, P1383, DOI 10.1002/cncr.10331; Arihiro K, 1996, BREAST CANC, V3, P181; Berletch JB, 2011, HUM GENET, V130, P237, DOI 10.1007/s00439-011-1011-z; Boudewijns M, 2007, J MOL DIAGN, V9, P337, DOI 10.2353/jmoldx.2007.060155; Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492; Chaligne R, 2015, GENOME RES, V25, P488, DOI 10.1101/gr.185926.114; Chang KC, 2014, MODERN PATHOL, V27, P823, DOI 10.1038/modpathol.2013.202; Choi Y, 2012, HUM PATHOL, V43, P48, DOI 10.1016/j.humpath.2010.08.026; Comertpay S, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0301-3; Desmedt C, 2015, J PATHOL, V236, P457, DOI 10.1002/path.4540; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; HOLLAND R, 1985, CANCER, V56, P979, DOI 10.1002/1097-0142(19850901)56:5<979::AID-CNCR2820560502>3.0.CO;2-N; Khan SA, 2010, BREAST J, V16, P219, DOI 10.1111/j.1524-4741.2010.00929.x; Kim JW, 2004, J KOREAN MED SCI, V19, P258, DOI 10.3346/jkms.2004.19.2.258; Ko Hyang Mi, 1997, Journal of Korean Medical Science, V12, P322; Kopp P, 1997, MOL CELL PROBE, V11, P217, DOI 10.1006/mcpr.1997.0099; Kubota T, 1999, HUM GENET, V104, P49, DOI 10.1007/s004390050909; Lakhani SREI, 2012, WHO CLASSIFICATION T; LASPADA AR, 1991, NATURE, V352, P77; Litton JK, 2007, CANCER, V110, P1445, DOI 10.1002/cncr.22928; Lynch SP, 2012, ANN ONCOL, V23, P3063, DOI 10.1093/annonc/mds136; Middleton LP, 2002, CANCER, V94, P1910, DOI 10.1002/cncr.10452; MUTTER GL, 1995, NUCLEIC ACIDS RES, V23, P1411; NOGUCHI S, 1994, CANCER, V74, P872, DOI 10.1002/1097-0142(19940801)74:3<872::AID-CNCR2820740313>3.0.CO;2-P; Pekar G, 2013, CANCER-AM CANCER SOC, V119, P1132, DOI 10.1002/cncr.27877; Rezo A, 2011, BREAST, V20, P259, DOI 10.1016/j.breast.2011.01.005; Sharp A, 2000, HUM GENET, V107, P343, DOI 10.1007/s004390000382; Swierczek SI, 2012, BLOOD, V119, pE100, DOI 10.1182/blood-2011-11-390351; Tot T, 2007, CANCER, V110, P2551, DOI 10.1002/cncr.23052; TSUDA H, 1995, CANCER RES, V55, P3395; Vlastos G, 2000, ANN SURG ONCOL, V7, P581, DOI 10.1007/BF02725337; WILLMAN CL, 1994, NEW ENGL J MED, V331, P154, DOI 10.1056/NEJM199407213310303; Wolters R, 2013, BREAST CANCER RES TR, V142, P579, DOI 10.1007/s10549-013-2772-y; Yerushalmi R, 2009, BREAST CANCER RES TR, V117, P365, DOI 10.1007/s10549-008-0265-1	36	3	3	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	AUG	2018	78						106	114		10.1016/j.humpath.2018.04.016			9	Pathology	Pathology	GR0GG	WOS:000442191800013	29727695				2019-10-28	
J	Hemminger, JA; Pearlman, R; Haraldsdottir, S; Knight, D; Jonasson, JG; Pritchard, CC; Hampel, H; Frankel, WL				Hemminger, Jessica A.; Pearlman, Rachel; Haraldsdottir, Sigurdis; Knight, Deborah; Jonasson, Jon Gunnlaugur; Pritchard, Colin C.; Hampel, Heather; Frankel, Wendy L.			Histology of colorectal adenocarcinoma with Check for double somatic mismatch-repair mutations is indistinguishable from those caused by Lynch syndrome	HUMAN PATHOLOGY			English	Article						Double somatic mutations; Biallelic mutations; Lynch syndrome; MMR deficiency; Lynch-like syndrome	MICROSATELLITE INSTABILITY; CANCER-RISK; DEFICIENCY; CARCINOMAS; GERMLINE; IMMUNOHISTOCHEMISTRY; TUMORS; PMS2	Lynch syndrome (LS) is the most common form of hereditary colon cancer. Germline mutations in the mismatch-repair (MMR) genes MLH1, MSH2 (EPCAM), MSH6, and PMS2, followed by a second hit to the remaining allele, lead to cancer development. Universal tumor screening for LS is routinely performed on colon cancer, and screening has identified patients with unexplained MMR deficiency that lack MLH1 methylation and a germline mutation. Tumor sequencing has since identified double somatic (DS) mutations in the MMR gene corresponding with the absent protein in 69% of these patients. We assessed whether histomorphology could distinguish patients with DS mutations from those with LS. Colorectal cancer patients with DS mutations were identified from population-based cohorts from Iceland (2000-2009); Columbus, Ohio (1999-2005); and the state of Ohio (2013-2016). Next-generation sequencing was performed on tumors with unexplained MMR deficiency. Patients with LS from Ohio cohorts were the comparison group. The histologic features associated with MMR deficiency (tumor-infiltrating lymphocytes, Crohn-like reaction, histologic subtype, necrosis) were evaluated. We identified 43 tumors with DS mutations and 48 from patients with LS. There was no significant difference in histologic features between tumors in LS patients and tumors with DS mutations. Because histology of tumors with DS mutations is indistinguishable from those caused by LS, tumor sequencing for evaluation of DS mutations should be considered to help clarify sporadic versus hereditary causes of unexplained MMR deficiency. (C) 2018 Elsevier Inc. All rights reserved.	[Hemminger, Jessica A.; Knight, Deborah; Frankel, Wendy L.] Ohio State Univ, Wexner Med Ctr, Dept Pathol, Columbus, OH 43210 USA; [Pearlman, Rachel; Hampel, Heather] Ohio State Univ, Wexner Med Ctr, Dept Internal Med, Div Human Genet, Columbus, OH 43210 USA; [Haraldsdottir, Sigurdis] Stanford Univ, Med Ctr, Dept Med Oncol, Stanford, CA 94305 USA; [Jonasson, Jon Gunnlaugur] Landspitali Univ Hosp, IS-101 Reykjavik, Iceland; [Pritchard, Colin C.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA	Frankel, WL (reprint author), Ohio State Univ, Wexner Med Ctr, 129 Hamilton Hall, Columbus, OH 43210 USA.	wendy.frankel@osumc.edu			Pelotonia, an annual cycling event in Columbus, Ohio; National Cancer Institute, Bethesda, MDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30 CA016058]	The data reported here were derived from the Ohio Colorectal Cancer Prevention Initiative, which is supported by a grant from Pelotonia, an annual cycling event in Columbus, Ohio, that supports cancer research at The Ohio State University Comprehensive Cancer Center James Cancer Hospital and Solove Research Institute. This study was supported in part by a grant from National Cancer Institute, Bethesda, MD (P30 CA016058).	Barrow E, 2013, FAM CANCER, V12, P229, DOI 10.1007/s10689-013-9615-1; Bhattacharya P., 2018, LYNCH SYNDROME; Buchanan DD, 2014, APPL CLIN GENET, V7, P183, DOI 10.2147/TACG.S48625; de Jong AE, 2004, CLIN CANCER RES, V10, P972, DOI 10.1158/1078-0432.CCR-0956-3; Geurts-Giele WRR, 2014, J PATHOL, V234, P548, DOI 10.1002/path.4419; Greenson JK, 2003, AM J SURG PATHOL, V27, P563, DOI 10.1097/00000478-200305000-00001; Hampel H, 2005, NEW ENGL J MED, V352, P1851, DOI 10.1056/NEJMoa043146; Hampel H, 2008, J CLIN ONCOL, V26, P5783, DOI 10.1200/JCO.2008.17.5950; Haraldsdottir S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14755; Haraldsdottir S, 2014, GASTROENTEROLOGY, V147, P1308, DOI 10.1053/j.gastro.2014.08.041; Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242; Mas-Moya J, 2015, HUM PATHOL, V46, P1616, DOI 10.1016/j.humpath.2015.06.022; Mensenkamp AR, 2014, GASTROENTEROLOGY, V146, P643, DOI 10.1053/j.gastro.2013.12.002; Mills AM, 2016, AM J SURG PATHOL, V40, P155, DOI 10.1097/PAS.0000000000000544; Morak M, 2014, EUR J HUM GENET, V22, P1334, DOI 10.1038/ejhg.2014.15; Pai RK, 2016, AM J SURG PATHOL, V40, pE17, DOI 10.1097/PAS.0000000000000620; Pearlman R, 2017, JAMA ONCOL, V3, P464, DOI 10.1001/jamaoncol.2016.5194; Pritchard CC, 2012, J MOL DIAGN, V14, P357, DOI 10.1016/j.jmoldx.2012.03.002; Renkonen-Sinisalo L, 2000, CANCER DETECT PREV, V24, P137; Rodriguez-Soler M, 2013, GASTROENTEROLOGY, V144, P926, DOI 10.1053/j.gastro.2013.01.044; Shia J, 2003, AM J SURG PATHOL, V27, P1407, DOI 10.1097/00000478-200311000-00002; Shia JR, 2015, SEMIN DIAGN PATHOL, V32, P352, DOI 10.1053/j.semdp.2015.02.018; Sourrouille I, 2013, FAM CANCER, V12, P27, DOI 10.1007/s10689-012-9568-9; Southey MC, 2005, J CLIN ONCOL, V23, P6524, DOI 10.1200/JCO.2005.04.671; U.S. Cancer Statistics Working Group, 2017, US CANC STAT 1999 20; Win AK, 2015, GUT, V64, P101, DOI 10.1136/gutjnl-2013-306567	26	5	5	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	AUG	2018	78						125	130		10.1016/j.humpath.2018.04.017			6	Pathology	Pathology	GR0GG	WOS:000442191800015	29723603	Green Accepted			2019-10-28	
J	Cai, HQ; Cheng, ZJ; Zhang, HP; Wang, PF; Zhang, Y; Hao, JJ; Wang, MR; Wan, JH				Cai, Hong-Qing; Cheng, Zhi-Jian; Zhang, Hai-Peng; Wang, Peng-Fei; Zhang, Yu; Hao, Jia-Jie; Wang, Ming-Rong; Wan, Jing-Hai			Overexpression of MCM6 predicts poor survival in patients with glioma	HUMAN PATHOLOGY			English	Article						Minichromosome maintenance proteins; Glioma; Biomarker; Molecular subtype; MCM6	MINICHROMOSOME MAINTENANCE PROTEIN-7; PROGNOSTIC TUMOR-MARKERS; DNA-DAMAGE SITES; HOMOLOGOUS RECOMBINATION; UNITED-STATES; RECRUITMENT; REPLICATION; COMPLEX; BRAIN	Minichromosome maintenance proteins (MCMs) play an essential role in DNA replication and other cellular activities. However, their expression levels and clinical value in glioma are unclear. In the present study, we analyzed the relationship between MCM mRNA expression and clinical parameters in 325 gliomas and found that MCM6 presented high expression and was associated with poor survival. Immunohistochemistry analysis of an independent data set of 423 glioma tissues confirmed the overexpression of MCM6 protein, especially in glioblastomas with shorter overall survival. Importantly, a combination of MCM6 overexpression with IDH1 mutation further improved the prediction of the prognosis of glioblastomas. Patients with IDH1 mutation and low MCM6 expression exhibited the longest survival, whereas those with high MCM6 expression and wild-type IDH1 showed the shortest. Collectively, our observation indicates that MCM6 is a novel potential biomarker for predicting poor prognosis of the patients with glioma. (C) 2018 Elsevier Inc. All rights reserved.	[Cai, Hong-Qing; Cheng, Zhi-Jian; Zhang, Hai-Peng; Wan, Jing-Hai] Chinese Acad Med Sci, Canc Hosp, Natl Canc Ctr, Dept Neurosurg, Beijing 100021, Peoples R China; [Cai, Hong-Qing; Cheng, Zhi-Jian; Zhang, Hai-Peng; Zhang, Yu; Hao, Jia-Jie; Wang, Ming-Rong; Wan, Jing-Hai] Peking Union Med Coll, Beijing 100021, Peoples R China; [Zhang, Yu; Hao, Jia-Jie; Wang, Ming-Rong] Chinese Acad Med Sci, Canc Hosp, Natl Canc Ctr, State Key Lab Mol Oncol, Beijing 100021, Peoples R China; [Wang, Peng-Fei] Capital Med Univ, Sanbo Brain Hosp, Dept Neurosurg, Beijing 100093, Peoples R China	Wan, JH (reprint author), Chinese Acad Med Sci, Canc Hosp, Natl Canc Ctr, Dept Neurosurg, Beijing 100021, Peoples R China.; Wang, MR; Wan, JH (reprint author), Peking Union Med Coll, Beijing 100021, Peoples R China.; Wang, MR (reprint author), Chinese Acad Med Sci, Canc Hosp, Natl Canc Ctr, State Key Lab Mol Oncol, Beijing 100021, Peoples R China.	wanginr2015@126.com; wanjinghai@sina.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81470112]	This study was supported by the National Natural Science Foundation of China (81470112).	Berte N, 2016, MOL CANCER THER, V15, P2665, DOI 10.1158/1535-7163.MCT-16-0176; Chatterjee N, 2017, ENVIRON MOL MUTAGEN, V58, P235, DOI 10.1002/em.22087; Chien LN, 2016, FRONT PUBLIC HEALTH, V4, DOI 10.3389/fpubh.2016.00151; Erkan EP, 2014, ONCOGENE, V33, P4778, DOI 10.1038/onc.2013.423; Facoetti A, 2006, ANTICANCER RES, V26, P3513; Facoetti A, 2006, ANTICANCER RES, V26, P1071; Feng YB, 2009, INT J CANCER, V124, P578, DOI 10.1002/ijc.23990; Giaginis C, 2010, HISTOL HISTOPATHOL, V25, P351, DOI 10.14670/HH-25.351; Han XZ, 2015, J BIOL CHEM, V290, P12370, DOI 10.1074/jbc.M114.621532; Hua C, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-526; Kim JS, 2005, J CELL BIOL, V170, P341, DOI 10.1083/jcb.200411083; Lee KY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8744; Lim YC, 2014, MOL ONCOL, V8, P1603, DOI 10.1016/j.molonc.2014.06.012; Lim YC, 2012, MOL CANCER THER, V11, P1863, DOI 10.1158/1535-7163.MCT-11-1044; Maiorano D, 2006, CURR OPIN CELL BIOL, V18, P130, DOI 10.1016/j.ceb.2006.02.006; Ostrom QT, 2016, NEURO-ONCOLOGY, V18, pv1, DOI 10.1093/neuonc/now207; Park J, 2013, MOL CELL BIOL, V33, P1632, DOI 10.1128/MCB.01503-12; Passerini V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10754; Riera A, 2017, GENE DEV, V31, P1073, DOI 10.1101/gad.298232.117; Simon NE, 2014, BIOMED RES INT, DOI 10.1155/2014/549719; Sottile ML, 2018, CELL STRESS CHAPERON, V23, P303, DOI 10.1007/s12192-017-0843-4; Sulkowski PL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal2463; Takahashi N, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000817; Tatsumi R, 2017, J BIOCHEM, V161, P259, DOI 10.1093/jb/mvw065; Traver S, 2015, MOL CELL, V59, P831, DOI 10.1016/j.molcel.2015.07.010; Tsai FL, 2015, MOL CELL BIOL, V35, P2131, DOI 10.1128/MCB.01357-14; Tubbs A, 2017, CELL, V168, DOI 10.1016/j.cell.2017.01.002; Waitkus MS, 2016, NEURO-ONCOLOGY, V18, P16, DOI 10.1093/neuonc/nov136	28	3	3	1	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	AUG	2018	78						182	187		10.1016/j.humpath.2018.04.024			6	Pathology	Pathology	GR0GG	WOS:000442191800024	29753008				2019-10-28	
J	de Souza, BR; Chuffa, LGD; Simao, VA; Camargo, ICC				de Souza, Bianca R.; de Almeida Chuffa, Luiz Gustavo; Simao, Vinicius Augusto; Camargo, Isabel C. C.			Histopathological changes in androgenized ovaries are recovered by melatonin treatment	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY			English	Article						melatonin; morphometry; nandrolone decanoate; ovarian histology; sex steroid receptors	SEX STEROID-RECEPTORS; NANDROLONE DECANOATE; OXIDATIVE STRESS; ESTROUS-CYCLE; PHYSICAL EFFORT; UTERINE TISSUE; LUTEAL CELLS; BODY-WEIGHT; RATS; PROGESTERONE	Nandrolone decanoate (ND) is a synthetic steroid, which promotes adverse effects on the ovarian tissue, and melatonin (MLT) exhibits a number of beneficial properties in the reproductive system. This study evaluated the general features of the ovarian tissue and the immunoexpression of sex steroid receptors in ND-treated rats that were submitted to short-term melatonin treatment. Adult rats received mineral oil (control group) and ND at doses of 7.5 mg/kg for 15 days (ND-treated group). The treatment with MLT (10mg/kg for 7 days) was given alone, before or in combination with ND. All ND-treated animals showed persistent dioestrus. In the androgenized groups that received MLT, ovarian morphology and size, and the number/area of corpora lutea were recovered. The number of healthy and atretic follicles was recovered when MLT was administered prior to ND; this was similar to the ovaries of control and MLT groups. There was a decrease in estrogen receptors immunostaining in the follicles of androgenized rats that were treated with MLT, and pretreatment with MLT reduced the expression of androgen receptor in atretic follicles and corpora lutea, when compared with ND-treated group. We conclude that MLT treatment recovered the histopathological aspects of the androgenized ovaries, and MLT pretreatment was the most effective.	[de Souza, Bianca R.; Simao, Vinicius Augusto] Univ Estadual Paulista UNESP, Dept Biotecnol, Programa Posgrad Biociencias, Assis, SP, Brazil; [de Almeida Chuffa, Luiz Gustavo] Univ Estadual Paulista UNESP, Inst Biociencias, Dept Anat, Botucatu, SP, Brazil; [Camargo, Isabel C. C.] Univ Estadual Paulista UNESP, Fac Ciencias & Letras, Dept Biotecnol, Av Dom Antonio 2100, BR-19806170 Assis, SP, Brazil	Camargo, ICC (reprint author), Univ Estadual Paulista UNESP, Fac Ciencias & Letras, Dept Biotecnol, Av Dom Antonio 2100, BR-19806170 Assis, SP, Brazil.	camargo@assis.unesp.br	Simao, Vinicius Augusto/Y-6827-2018; Chuffa, Luiz Gustavo/A-4085-2010	Simao, Vinicius Augusto/0000-0002-3915-2795; Souza Sasaki, Bianca/0000-0001-9373-6989; Chuffa, Luiz Gustavo/0000-0002-0199-3396			Abd-Allah ARA, 2003, PHARMACOL RES, V47, P349, DOI 10.1016/S1043-6618(03)00014-8; Adriaens I, 2006, TOXICOLOGY, V228, P333, DOI 10.1016/j.tox.2006.09.018; Apolloni LB, 2016, ACTA SCI VET, V44; Arlt W, 2006, EUR J ENDOCRINOL, V154, P1, DOI 10.1530/eje.1.02062; Barcelos IDES, 2013, REPROD CLIM, V28, P51; Baykara B, 2009, ACTA HISTOCHEM, V111, P42, DOI 10.1016/j.acthis.2008.03.002; Belardin LB, 2014, BIRTH DEFECTS RES B, V101, P168, DOI 10.1002/bdrb.21104; Blasberg ME, 1997, PHYSIOL BEHAV, V61, P265, DOI 10.1016/S0031-9384(96)00409-X; Bondi CD, 2014, EUR J OBSTET GYN R B, V174, P80, DOI 10.1016/j.ejogrb.2013.11.027; Bordbar H, 2014, IRAN J MED SCI, V39, P44; Cannavo S, 2001, J ENDOCRINOL INVEST, V24, P823, DOI 10.1007/BF03343935; Chabra A, 2014, HUM EXP TOXICOL, V33, P185, DOI 10.1177/0960327113489052; CHADHA S, 1994, HUM PATHOL, V25, P1198, DOI 10.1016/0046-8177(94)90037-X; Chaves EA, 2006, J STEROID BIOCHEM, V99, P223, DOI 10.1016/j.jsbmb.2006.01.004; Camargo ICC, 2014, EXP TOXICOL PATHOL, V66, P195, DOI 10.1016/j.etp.2014.01.005; Camargo ICC, 2009, ACTA BIOL HUNG, V60, P253, DOI 10.1556/ABiol.60.2009.3.2; Chuffa L., 2011, REPROD BIOL ENDOCRIN, V9, P1; Chuffa LGA, 2011, BRAZ J MED BIOL RES, V44, P217, DOI 10.1590/S0100-879X2011007500018; Chuffa LGA, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1032-4; Chuffa LGA, 2013, REPROD TOXICOL, V39, P40, DOI 10.1016/j.reprotox.2013.04.001; Cunningham RL, 2009, ENDOCRINOLOGY, V150, P5539, DOI 10.1210/en.2009-0640; Chuffa LGD, 2011, ANAT REC, V294, P335, DOI 10.1002/ar.21314; Drummond AE, 2012, SEMIN REPROD MED, V30, P32, DOI 10.1055/s-0031-1299595; Dubocovich ML, 2010, PHARMACOL REV, V62, P343, DOI 10.1124/pr.110.002832; Costa EMF, 2014, ARQ BRAS ENDOCRINOL, V58, P188, DOI 10.1590/0004-2730000003091; Galano A, 2011, J PINEAL RES, V51, P1, DOI 10.1111/j.1600-079X.2011.00916.x; Gayan-Ramirez G, 2000, J APPL PHYSIOL, V88, P26; Gerez JR, 2005, CONTRACEPTION, V72, P77, DOI 10.1016/j.contraception.2005.02.001; Gervasio Catiele Garcia, 2014, ISRN Obstet Gynecol, V2014, P818010, DOI 10.1155/2014/818010; Goldman JM, 2007, BIRTH DEFECTS RES B, V80, P84, DOI 10.1002/bdrb.20106; Guney M, 2008, FERTIL STERIL, V89, P934, DOI 10.1016/j.fertnstert.2007.04.023; HIRSHFIELD AN, 1991, INT REV CYTOL, V124, P43; Karbalay-Doust S, 2012, FOLIA HISTOCHEM CYTO, V50, P275, DOI 10.5603/FHC.2012.0037; Kicman AT, 2008, BRIT J PHARMACOL, V154, P502, DOI 10.1038/bjp.2008.165; Kim JK, 2000, MUTAT RES-FUND MOL M, V449, P33, DOI 10.1016/S0027-5107(00)00027-0; Macchi MM, 2004, FRONT NEUROENDOCRIN, V25, P177, DOI 10.1016/j.yfrne.2004.08.001; Masana M I, 2001, Sci STKE, V2001, ppe39; Minaii Bagher, 2014, Acta Med Iran, V52, P496; Mohammadghasemi Fahimeh, 2012, J Reprod Infertil, V13, P143; Mostafavi SA, 2017, CURR PHARM DESIGN, V23, P3445, DOI 10.2174/1381612822666161129145618; OSMAN P, 1985, J REPROD FERTIL, V73, P261; Pai SA, 2014, J PHARM PHARMACOL, V66, P1710, DOI 10.1111/jphp.12297; PEDERSEN T, 1968, J REPROD FERTIL, V17, P555; Rao MV, 2010, FOOD CHEM TOXICOL, V48, P7, DOI 10.1016/j.fct.2009.06.038; Riezzo I, 2014, TOXICOL APPL PHARM, V280, P97, DOI 10.1016/j.taap.2014.06.031; Romeu LRG, 2011, FERTIL STERIL, V95, P1379, DOI 10.1016/j.fertnstert.2010.04.042; Saadat Seyedeh Nazanin Seyed, 2014, Interdiscip Toxicol, V7, P41, DOI 10.2478/intox-2014-0007; Shagirtha K, 2011, EUR REV MED PHARMACO, V15, P1039; Silva HO, 2016, REV CIENC FARM BASIC, V37, P1; Simao VA, 2016, REPRODUCTION, V152, P545, DOI 10.1530/REP-16-0233; Simao VA, 2015, INT J EXP PATHOL, V96, P338, DOI 10.1111/iep.12144; Tahtamouni L. H., 2010, Jordan Journal of Biological Sciences (JJBS), V3, P165; Takasaki Akihisa, 2003, Reprod Med Biol, V2, P139, DOI 10.1111/j.1447-0578.2003.00035.x; Taketani T, 2011, J PINEAL RES, V51, P207, DOI 10.1111/j.1600-079X.2011.00878.x; Tamura H, 2013, ENDOCR J, V60, P1; Tamura H, 2009, FERTIL STERIL, V92, P328, DOI 10.1016/j.fertnstert.2008.05.016; Tarumi W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099423; Terron MP, 2013, PHYSIOL BEHAV, V118, P8, DOI 10.1016/j.physbeh.2013.04.006; van Amsterdam J, 2010, REGUL TOXICOL PHARM, V57, P117, DOI 10.1016/j.yrtph.2010.02.001; Vijayalaxmi, 2004, INT J RADIAT ONCOL, V59, P639, DOI 10.1016/j.ijrobp.2004.02.006; Vilela MG, 2007, FEMINA, V35, P61; VOORDOUW BCG, 1992, J CLIN ENDOCR METAB, V74, P108, DOI 10.1210/jc.74.1.108; Walters KA, 2008, BIOL REPROD, V78, P380, DOI 10.1095/biolreprod.107.064089; Woo MMM, 2001, J CLIN ENDOCR METAB, V86, P4789, DOI 10.1210/jc.86.10.4789; Wu HJ, 2013, MUTAT RES-GEN TOX EN, V752, P57, DOI 10.1016/j.mrgentox.2013.01.005	65	0	0	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-9673	1365-2613		INT J EXP PATHOL	Int. J. Exp. Pathol.	AUG	2018	99	4					158	171		10.1111/iep.12283			14	Pathology	Pathology	GU8TE	WOS:000445614400002	30256483	Green Published			2019-10-28	
J	Santi, R; Martini, A; Villari, D; Nesi, G				Santi, Raffaella; Martini, Alberto; Villari, Donata; Nesi, Gabriella			Ureteritis Cystica Presenting as a Single Polypoid Mass	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Editorial Material									[Santi, Raffaella; Martini, Alberto; Villari, Donata; Nesi, Gabriella] Univ Florence, Florence, Italy; [Martini, Alberto] Univ Vita Salute San Raffaele, Milan, Italy	Nesi, G (reprint author), Univ Florence, Dept Surg & Translat Med, Div Pathol Anat, Largo Brambilla 3, I-50134 Florence, Italy.	gabriella.nesi@unifi.it	Martini, Alberto/W-4604-2019	Martini, Alberto/0000-0003-1272-7154			Ordon M, 2010, J ENDOUROL, V24, P1391, DOI 10.1089/end.2009.0651; Ozdamar A. S., 1997, International Urology and Nephrology, V29, P415, DOI 10.1007/BF02551106; Padilla-Fernandez B, 2012, CLIN MED INSIGHT-CAS, V5, P29, DOI 10.4137/CCRep.S9189; Parker B, 2002, J UROLOGY, V168, P195, DOI 10.1016/S0022-5347(05)64866-5; PETERSEN UE, 1991, SCAND J UROL NEPHROL, V25, P1, DOI 10.3109/00365599109024519; Tan A, 2010, THESCIENTIFICWORLDJO, V10, P1535, DOI 10.1100/tsw.2010.145	6	1	1	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	AUG	2018	26	5					437	438		10.1177/1066896917745593			2	Pathology; Surgery	Pathology; Surgery	GM9OF	WOS:000438578500009	29198158				2019-10-28	
J	Karamchandani, DM; Chetty, R				Karamchandani, Dipti M.; Chetty, Runjan			Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists' perspective	JOURNAL OF CLINICAL PATHOLOGY			English	Review							ADVERSE EVENTS; CLINICOPATHOLOGICAL-FEATURES; COLLAGENOUS COLITIS; LYMPHOCYTIC COLITIS; IPILIMUMAB; NIVOLUMAB; MANAGEMENT; BLOCKADE; ANTIBODY; CANCER	Immune checkpoint inhibitors (CPIs) are a relatively new class of 'miracle' dugs that have revolutionised the treatment and prognosis of some advanced-stage malignancies, and have increased the survival rates significantly. This class of drugs includes cytotoxic T lymphocyte antigen-4 inhibitors such as ipilimumab; programmed cell death protein-1 inhibitors such as nivolumab, pembrolizumab and avelumab; and programmed cell death protein ligand-1 inhibitors such as atezolizumab. These drugs stimulate the immune system by blocking the coinhibitory receptors on the T cells and lead to antitumoural response. However, a flip side of these novel drugs is immune-related adverse events (irAEs), secondary to immune-mediated process due to disrupted self-tolerance. The irAEs in the gastrointestinal (GI) tract/liver may result in diarrhoea, colitis or hepatitis. An accurate diagnosis of CPI-induced colitis and/or hepatitis is essential for optimal patient management. As we anticipate greater use of these drugs in the future given the significant clinical response, pathologists need to be aware of the spectrum of histological findings that may be encountered in GI and/or liver biopsies received from these patients, as well as differentiate them from its histopathological mimics. This present review discusses the clinical features, detailed histopathological features, management and the differential diagnosis of the luminal GI and hepatic irAEs that may be encountered secondary to CPI therapy.	[Karamchandani, Dipti M.] Penn State Hlth Milton S Hershey Med Ctr, Div Anat Pathol, Dept Pathol, Hershey, PA 17033 USA; [Chetty, Runjan] Univ Hlth Network, Dept Pathol, Lab Med Program, Toronto, ON, Canada	Karamchandani, DM (reprint author), Penn State Hlth Milton S Hershey Med Ctr, Div Anat Pathol, Dept Pathol, Hershey, PA 17033 USA.	dkaramchandani@pennstatehealth.psu.edu		Chetty, Runjan/0000-0002-2124-515X			Aivazian K, 2017, PATHOLOGY, V49, P789, DOI 10.1016/j.pathol.2017.07.010; Assarzadegan N, 2018, VIRCHOWS ARCH, V472, P125, DOI 10.1007/s00428-017-2267-z; Baroudjian B, 2016, MELANOMA RES, V26, P308, DOI 10.1097/CMR.0000000000000252; Bavi P, 2017, HISTOPATHOLOGY, V71, P494, DOI 10.1111/his.13224; Beck KE, 2006, J CLIN ONCOL, V24, P2283, DOI 10.1200/JCO.2005.04.5716; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Chen JH, 2017, AM J SURG PATHOL, V41, P643, DOI 10.1097/PAS.0000000000000829; Cramer Peyton, 2017, Curr Gastroenterol Rep, V19, P3, DOI 10.1007/s11894-017-0540-6; Di Giacomo AM, 2010, SEMIN ONCOL, V37, P499, DOI 10.1053/j.seminoncol.2010.09.007; Eigentler TK, 2016, CANCER TREAT REV, V45, P7, DOI 10.1016/j.ctrv.2016.02.003; Everett J, 2017, AM J SURG PATHOL, V41, P134, DOI 10.1097/PAS.0000000000000759; Fecher LA, 2013, ONCOLOGIST, V18, P733, DOI 10.1634/theoncologist.2012-0483; Foppen MHG, 2018, ESMO OPEN, V3, DOI 10.1136/esmoopen-2017-000278; Garcia-Varona A, 2013, INFLAMM BOWEL DIS, V19, pE15, DOI 10.1002/ibd.22846; Gonzalez RS, 2017, HISTOPATHOLOGY, V70, P558, DOI 10.1111/his.13118; Gupta A, 2015, ALIMENT PHARM THER, V42, P406, DOI 10.1111/apt.13281; Hofmann L, 2016, EUR J CANCER, V60, P190, DOI 10.1016/j.ejca.2016.02.025; Johncilla M, 2015, AM J SURG PATHOL, V39, P1075, DOI 10.1097/PAS.0000000000000453; Johnston RL, 2009, DIGEST DIS SCI, V54, P2538, DOI 10.1007/s10620-008-0641-z; Kim KW, 2013, INVEST NEW DRUG, V31, P1071, DOI 10.1007/s10637-013-9939-6; Kleiner DE, 2012, DIGEST DIS SCI, V57, P2233, DOI 10.1007/s10620-012-2140-5; Korman AJ, 2006, ADV IMMUNOL, V90, P297, DOI 10.1016/S0065-2776(06)90008-X; Larkin J, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Lee S, 2013, J CLIN PATHOL, V66, P8, DOI 10.1136/jclinpath-2012-200888; Louie CY, 2015, AM J SURG PATHOL, V39, P1653, DOI 10.1097/PAS.0000000000000525; Mahajan D, 2012, ADV ANAT PATHOL, V19, P28, DOI 10.1097/PAP.0b013e31823d7705; Melosky B, 2016, J CLIN ONCOL, V34, P1676, DOI 10.1200/JCO.2015.63.8049; Mitchell KA, 2013, J CLIN GASTROENTEROL, V47, P781, DOI 10.1097/MCG.0b013e31828f1d51; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Motzer RJ, 2015, J CLIN ONCOL, V33, P1430, DOI 10.1200/JCO.2014.59.0703; Naidoo J, 2016, ANN ONCOL, V27, P1362, DOI 10.1093/annonc/mdw141; Oble DA, 2008, AM J SURG PATHOL, V32, P1130, DOI 10.1097/PAS.0b013e31817150e3; Parfitt JR, 2008, AM J SURG PATHOL, V32, P1367, DOI 10.1097/PAS.0b013e31816bf3fe; Prieux-Klotz C, 2017, TARGET ONCOL, V12, P301, DOI 10.1007/s11523-017-0495-4; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Schadendorf D, 2015, J CLIN ONCOL, V33, P1889, DOI 10.1200/JCO.2014.56.2736; Simonelli M, 2016, IMMUNOTHERAPY-UK, V8, P1363, DOI 10.2217/imt-2016-0057; Soldini D, 2014, J CLIN PATHOL, V67, P582, DOI 10.1136/jclinpath-2014-202199; Topalian SL, 2016, NAT REV CANCER, V16, P275, DOI 10.1038/nrc.2016.36; Verschuren EC, 2016, CLIN GASTROENTEROL H, V14, P836, DOI 10.1016/j.cgh.2015.12.028; Weber JS, 2016, ONCOLOGIST, V21, P1230, DOI 10.1634/theoncologist.2016-0055; Weber JS, 2015, J CLIN ONCOL, V33, P2092, DOI 10.1200/JCO.2014.60.0379; Weber JS, 2013, CANCER-AM CANCER SOC, V119, P1675, DOI 10.1002/cncr.27969; Weber JS, 2012, J CLIN ONCOL, V30, P2691, DOI 10.1200/JCO.2012.41.6750; Weidner AS, 2015, AM J SURG PATHOL, V39, P1661, DOI 10.1097/PAS.0000000000000522; Wolchok JD, 2010, LANCET ONCOL, V11, P155, DOI 10.1016/S1470-2045(09)70334-1; Zen Y, 2018, MODERN PATHOL, V31, P965, DOI 10.1038/s41379-018-0013-y	48	14	14	1	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	AUG	2018	71	8					665	671		10.1136/jclinpath-2018-205143			7	Pathology	Pathology	GR3CW	WOS:000442467400002	29703758				2019-10-28	
J	Rakha, EA; Aleskandarani, M; Toss, MS; Green, AR; Ball, G; Ellis, IO; Dalton, LW				Rakha, Emad A.; Aleskandarani, Mohamed; Toss, Michael S.; Green, Andrew R.; Ball, Graham; Ellis, Ian O.; Dalton, Leslie W.			Breast cancer histologic grading using digital microscopy: concordance and outcome association	JOURNAL OF CLINICAL PATHOLOGY			English	Article							OBSERVER AGREEMENT; PATHOLOGY; CARCINOMA; VALIDATION; FUTURE; MODEL	Aims Virtual microscopy utilising digital whole slide imaging (WSI) is increasingly used in breast pathology. Histologic grade is one of the strongest prognostic factors in breast cancer (BC). This study aims at investigating the agreement between BC grading using traditional light microscopy (LM) and digital WSI with consideration of reproducibility and impact on outcome prediction. Methods A large (n=1675) well-characterised cohort of BC originally graded by LM was re-graded using WSI. Two separate virtual-based grading sessions (V1 and V2) were performed with a 3-month washout period. Outcome was assessed using BC-specific and distant metastasis-free survival. Results The concordance between LM grading and WSI was strong (LM/WSI Cramer's V: V1=0.576, and V2=0.579). The agreement regarding grade components was as follows: tubule formation=0.538, pleomorphism=0.422 and mitosis=0.514. Greatest discordance was observed between adjacent grades, whereas high/low grade discordance was uncommon (1.5%). The intraobserver agreement for the two WSI sessions was substantial for grade (V1N2 Cramer's V=0.676; kappa=0.648) and grade components (Cramer's V T=0.628, p=0.573 and M=0.580). Grading using both platforms showed strong association with outcome (all p values <0.001). Although mitotic scores assessed using both platforms were strongly associated with outcome, WSI tends to underestimate mitotic counts. Conclusions Virtual microscopy is a reliable and reproducible method for assessing BC histologic grade. Regardless of the observer or assessment platform, histologic grade is a significant predictor of outcome. Continuing advances in imaging technology could potentially provide improved performance of WSI BC grading and in particular mitotic count assessment.	[Rakha, Emad A.; Aleskandarani, Mohamed; Toss, Michael S.; Green, Andrew R.; Ellis, Ian O.] Univ Nottingham, Sch Med, Nottingham City Hosp, Div Canc & Stem Cells, Nottingham, England; [Ball, Graham] Nottingham Trent Univ, Sch Sci & Technol, John van Geest Canc Res Ctr, Nottingham, England; [Dalton, Leslie W.] South Austin Hosp, Dept Histopathol, Austin, TX USA	Rakha, EA (reprint author), Nottingham Univ Hosp NHS Trust, Dept Histopathol, Nottingham NG5 1PB, England.	emad.rakha@nuh.nhs.uk	Rakha, Emad/Q-5554-2019	Rakha, Emad/0000-0002-5009-5525; Ellis, Ian/0000-0001-5292-8474; Green, Andrew/0000-0002-0488-5913			Al-Janabi S, 2012, HISTOPATHOLOGY, V61, P1, DOI 10.1111/j.1365-2559.2011.03814.x; Allen TC, 2014, ARCH PATHOL LAB MED, V138, P162, DOI 10.5858/arpa.2013-0258-ED; [Anonymous], 2017, AJCC CANC STAGING MA; [Anonymous], 2013, R LANG ENV STAT COMP; Bartlett JMS, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw050; Brachtel E, 2012, J BIOPHOTONICS, V5, P327, DOI 10.1002/jbio.201100103; Carlson Robert W, 2006, J Natl Compr Canc Netw, V4 Suppl 3, pS1; Curigliano G, 2017, ANN ONCOL, V28, P1700, DOI 10.1093/annonc/mdx308; Dalton LW, 2017, AM J SURG PATHOL, V41, P1105, DOI 10.1097/PAS.0000000000000886; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Fan C, 2006, NEW ENGL J MED, V355, P560, DOI 10.1056/NEJMoa052933; GALEA MH, 1992, BREAST CANCER RES TR, V22, P207, DOI 10.1007/BF01840834; Giuliano AE, 2017, CA-CANCER J CLIN, V67, P291, DOI 10.3322/caac.21393; Haibe-Kains B, 2012, JNCI-J NATL CANCER I, V104, P311, DOI 10.1093/jnci/djr545; Hedvat CV, 2010, ARCH PATHOL LAB MED, V134, P1666, DOI 10.1043/2009-0579-RAR1.1; Kayser K, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-48; Kundel HL, 2003, RADIOLOGY, V228, P303, DOI 10.1148/radiol.2282011860; Lester SC, 2009, ARCH PATHOL LAB MED, V133, P1515, DOI 10.1043/1543-2165-133.10.1515; McHugh ML, 2013, BIOCHEM MEDICA, V23, P143, DOI 10.11613/BM.2013.018; Pantanowitz L, 2013, ARCH PATHOL LAB MED, V137, P1710, DOI 10.5858/arpa.2013-0093-CP; Rakha EA, 2008, J CLIN ONCOL, V26, P3153, DOI 10.1200/JCO.2007.15.5986; Rakha EA, 2017, J CLIN PATHOL, V70, P51, DOI 10.1136/jclinpath-2016-203800; Rakha EA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2607; Rocha R, 2009, PATHOL RES PRACT, V205, P735, DOI 10.1016/j.prp.2009.05.004; Schuh F, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0320-2; Shaw EC, 2012, J CLIN PATHOL, V65, P403, DOI 10.1136/jclinpath-2011-200369; Sloane JP, 1999, VIRCHOWS ARCH, V434, P3; Varga Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037379; Wishart GC, 2012, BRIT J CANCER, V107, P800, DOI 10.1038/bjc.2012.338; Zhong FF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150505	30	3	4	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	AUG	2018	71	8					680	686		10.1136/jclinpath-2017-204979			7	Pathology	Pathology	GR3CW	WOS:000442467400004	29535212	Green Accepted			2019-10-28	
J	Kufova, ZC; Sevcikova, T; Januska, J; Vojta, P; Boday, A; Vanickova, P; Filipova, J; Growkova, K; Jelinek, T; Hajduch, M; Hajek, R				Kufova, Zuzana Chyra; Sevcikova, Tereza; Januska, Jaroslav; Vojta, Petr; Boday, Arpad; Vanickova, Pavla; Filipova, Jana; Growkova, Katerina; Jelinek, Tomas; Hajduch, Marian; Hajek, Roman			Newly designed 11-gene panel reveals first case of hereditary amyloidosis captured by massive parallel sequencing	JOURNAL OF CLINICAL PATHOLOGY			English	Article							INTEGRATIVE GENOMICS VIEWER; SYSTEMIC AMYLOIDOSIS; CARDIAC AMYLOIDOSIS; PRION PROTEIN; MUTATIONS; RECOMMENDATIONS; PREDICTION; PEPTIDE	Aims Amyloidosis is caused by deposition of abnormal protein fibrils, leading to damage of organ function. Hereditary amyloidosis represents a monogenic disease caused by germline mutations in 11 amyloidogenic precursor protein genes. One of the important but non-specific symptoms of amyloidosis is hypertrophic cardiomyopathy. Diagnostics of hereditary amyloidosis is complicated and the real cause can remain overlooked. We aimed to design hereditary amyloidosis gene panel and to introduce new next-generation sequencing (NGS) approach to investigate hereditary amyloidosis in a cohort of patients with hypertrophic cardiomyopathy of unknown significance. Methods Design of target enrichment DNA library preparation using Haloplex Custom Kit containing 11 amyloidogenic genes was followed by MiSeq Illumina sequencing and bioinformatics identification of germline variants using tool VarScan in a cohort of 40 patients. Results We present design of NGS panel for 11 genes (TTR, FGA, APOA1, APOA2, LYZ, GSN, CST3, PRNP, APP, 82M, ITM28) connected to various forms of amyloidosis. We detected one mutation, which is responsible for hereditary amyloidosis. Some other single nucleotide variants are so far undescribed or rare variants or represent common polymorphisms in European population. Conclusions We report one positive case of hereditary amyloidosis in a cohort of patients with hypertrophic cardiomyopathy of unknown significance and set up first panel for NGS in hereditary amyloidosis. This work may facilitate successful implementation of the NGS method by other researchers or clinicians and may improve the diagnostic process after validation	[Kufova, Zuzana Chyra; Sevcikova, Tereza; Filipova, Jana; Growkova, Katerina; Jelinek, Tomas; Hajek, Roman] Univ Hosp Ostrava, Dept Haematooncol, Ostrava 70852, Czech Republic; [Kufova, Zuzana Chyra; Sevcikova, Tereza; Filipova, Jana; Growkova, Katerina; Jelinek, Tomas; Hajek, Roman] Univ Ostrava, Dept Clin Studies, Fac Med, Ostrava, Czech Republic; [Kufova, Zuzana Chyra] Masaryk Univ, Dept Expt Biol, Fac Sci, Brno, Czech Republic; [Januska, Jaroslav] Cardioctr Podlesi, Trinec, Czech Republic; [Vojta, Petr; Hajduch, Marian] Palacky Univ, Inst Mol & Translat Med, Fac Med & Dent, Olomouc, Czech Republic; [Boday, Arpad; Vanickova, Pavla] Lab AGEL, Dept Med Genet, Lab Mol Biol, Novy Jicin, Czech Republic; [Filipova, Jana; Growkova, Katerina; Jelinek, Tomas] Univ Ostrava, Dept Biol & Ecol, Fac Sci, Ostrava, Czech Republic	Kufova, ZC (reprint author), Univ Hosp Ostrava, Dept Haematooncol, Ostrava 70852, Czech Republic.	zuzana.chyra@fno.cz	Sevcikova, Tereza/C-2743-2019; Hajduch, Marian/J-4015-2014; Hajek, Roman/I-6639-2017	Sevcikova, Tereza/0000-0002-8704-0106; Hajduch, Marian/0000-0002-4834-908X; Hajek, Roman/0000-0001-6955-6267; Vojta, Petr/0000-0003-0036-1853	Ministry of HealthMinistry of Health - Turkey [15-29667A, 01211/2016/RRC]; Ministry of School and Education (LO1304) and Specific university research of the Faculty of Medicine (University of Ostrava) [SGS 02/LF/2014-2015, SGS 09/LF/2016-2017]; AmgenAmgen;  [IRP03_2018_2020]	This work has been realised with the support of the IRP03_2018_2020, MH CZ-DRO-FNOs/2016 and with the support by the Ministry of Health 15-29667A project: Strengthening international cooperation in science, research and education 01211/2016/RRC and Ministry of School and Education (LO1304) and Specific university research of the Faculty of Medicine (University of Ostrava) project numbers SGS 02/LF/2014-2015, SGS 09/LF/2016-2017. The project was supported by Amgen.	Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393; Ando Y, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-31; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Briani C, 2012, J NEUROL, V259, P2226, DOI 10.1007/s00415-012-6529-z; Choi Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046688; Conceicao I, 2007, MUSCLE NERVE, V35, P116, DOI 10.1002/mus.20644; Fikrle M, 2013, COR VASA, V55, pE60, DOI 10.1016/j.crvasa.2012.11.018; Gillmore JD, 2013, NAT REV NEPHROL, V9, P574, DOI 10.1038/nrneph.2013.171; Ikejiri M, 2017, CLIN APPL THROMB HEM, V23; Ko YL, 2006, HUM GENET, V119, P84, DOI 10.1007/s00439-005-0102-0; Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111; Laurila K, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-122; Li H, 2014, BIOINFORMATICS, V30, P2843, DOI 10.1093/bioinformatics/btu356; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Liu XM, 2016, HUM MUTAT, V37, P235, DOI 10.1002/humu.22932; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Narotsky DL, 2016, CAN J CARDIOL, V32, DOI 10.1016/j.cjca.2016.05.008; Nuvolone M, 2017, NEPHROL DIAL TRANSPL, V32, P770, DOI 10.1093/ndt/gfw305; Parman Y, 2016, CURR OPIN NEUROL, V29, pS3, DOI 10.1097/WCO.0000000000000288; PERRY RT, 1995, AM J MED GENET, V60, P12, DOI 10.1002/ajmg.1320600104; Pfeffer G, 2012, BRAIN, V135, P1695, DOI 10.1093/brain/aws102; Rapezzi C, 2015, HEART FAIL REV, V20, P117, DOI 10.1007/s10741-015-9480-0; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Rowczenio DM, 2014, HUM MUTAT, V35, pE2403, DOI 10.1002/humu.22619; Sant'Anna R, 2016, FEBS LETT, V590, P644, DOI 10.1002/1873-3468.12093; Schwarz JM, 2014, NAT METHODS, V11, P361, DOI 10.1038/nmeth.2890; Shih-Jen Hwang GC, 2016, CIRCULATION, V134, P134; Sipe JD, 2016, AMYLOID, V23, P209, DOI 10.1080/13506129.2016.1257986; Sipe JD, 2010, AMYLOID, V17, P101, DOI 10.3109/13506129.2010.526812; Sonati T, 2013, NATURE, V501, P102, DOI 10.1038/nature12402; Symoens S, 2009, HUM MUTAT, V30, pE395, DOI 10.1002/humu.20887; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017	32	1	1	2	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	AUG	2018	71	8					687	694		10.1136/jclinpath-2017-204978			8	Pathology	Pathology	GR3CW	WOS:000442467400005	29455155	Other Gold, Green Published			2019-10-28	
J	Cai, HQ; Wang, PF; Zhang, HP; Cheng, ZJ; Li, SW; He, J; Zhang, Y; Hao, JJ; Wang, MR; Yan, CX; Wan, JH				Cai, Hong-Qing; Wang, Peng-Fei; Zhang, Hai-Peng; Cheng, Zhi-Jian; Li, Shou-Wei; He, Jie; Zhang, Yu; Hao, Jia-Jie; Wang, Ming-Rong; Yan, Chang-Xiang; Wan, Jing-Hai			Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1(R132H )mutation and may predict better prognosis among glioblastomas without the IDH1 mutation and ATRX loss	JOURNAL OF CLINICAL PATHOLOGY			English	Article							HEAT-SHOCK PROTEINS; CENTRAL-NERVOUS-SYSTEM; EXPRESSION; APOPTOSIS; SURVIVAL; TUMORS; WORLD; ASTROCYTOMAS; CARCINOMA; CANCER	Aim To identify biomarkers for accurate classification of glioma. Patients and methods We evaluated the heat shock protein 27 (Hsp27), phosphorylated Hsp27 (p-Hsp27), ATRX and IDH1(R132H ) proteins using immunohistochemistry in 421 glioma tissues. The chi(2) test was used to assess the relationship between molecular alterations and clinicopathological parameters. Kaplan-Meier survival curves were constructed, and differences were detected by the log-rank test. Results We found that Hsp27 and p-Hsp27 were mainly expressed in aggressive astrocytic gliomas. However, neither Hsp27 nor p-Hsp27 expression was related to survival time for any grade of glioma. Interestingly, p-Hsp27 was mutually exclusive with ATRX loss (ATRX(-)) and the IDH1(R132H )mutation, except for one case of anaplastic astrocytoma. We classified glioblastomas (GBMs) into three subtypes: ATRX(-)/IDH1(R132H), high p-Hsp27 expression (p-Hsp27(+))and none of these three markers. ATRX(-)/IDH1(R132H )showed the longest median survival (19.6 months). The prognostic difference between p-Hsp27(+) and none of these three markers was significant (15.0 vs 13.1 months, P=0.045). Moreover, p-Hsp27(+) predicted better sensitivity for standard therapy among GBMs without the IDH1 mutation and ATRX loss (26.3 vs 15.5 months, P=0.008). Conclusion p-Hsp27 is a novel biomarker of glioma and might have important clinical value for further classification of patients with wild-type IDH1 and normal ATRX expression, for evaluating prognosis and for guidance for adjuvant therapy	[Cai, Hong-Qing; Wan, Jing-Hai] Chinese Acad Med Sci, Dept Neurosurg, Natl Canc Ctr, Canc Hosp, Beijing 100021, Peoples R China; [Cai, Hong-Qing; Zhang, Yu; Hao, Jia-Jie; Wang, Ming-Rong; Wan, Jing-Hai] Peking Union Med Coll, Beijing 100021, Peoples R China; [Cai, Hong-Qing; Zhang, Yu; Hao, Jia-Jie; Wang, Ming-Rong] Chinese Acad Med Sci, Natl Canc Ctr, State Key Lab Mol Oncol, Canc Hosp, Beijing, Peoples R China; [Wang, Peng-Fei; Li, Shou-Wei; Yan, Chang-Xiang] Capital Med Univ, Sanbo Brain Hosp, Dept Neurosurg, Beijing 100093, Peoples R China; [Zhang, Hai-Peng; Cheng, Zhi-Jian; He, Jie] Anhui Med Univ, Dept Neurosurg, Affiliated Hosp 2, Hefei, Anhui, Peoples R China	Wan, JH (reprint author), Chinese Acad Med Sci, Dept Neurosurg, Natl Canc Ctr, Canc Hosp, Beijing 100021, Peoples R China.; Wan, JH (reprint author), Peking Union Med Coll, Beijing 100021, Peoples R China.; Yan, CX (reprint author), Capital Med Univ, Sanbo Brain Hosp, Dept Neurosurg, Beijing 100093, Peoples R China.	yancx65828@sina.com; wanjinghai@sina.com		He, Jie/0000-0001-5001-664X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81470112]; CAMS Innovation Fund for Medical Sciences [2016-I2M-1-001]	This study was supported by the National Natural Science Foundation of China (81470112) and the CAMS Innovation Fund for Medical Sciences (2016-I2M-1-001).	Bai H, 2016, NAT GENET, V48, P59, DOI 10.1038/ng.3457; Cairncross JG, 2014, J CLIN ONCOL, V32, P783, DOI 10.1200/JCO.2013.49.3726; Carra S, 2017, CELL STRESS CHAPERON, V22, P601, DOI 10.1007/s12192-017-0787-8; Charette SJ, 2000, MOL CELL BIOL, V20, P7602, DOI 10.1128/MCB.20.20.7602-7612.2000; Chen N, 2016, PATHOLOGY, V48, P675, DOI 10.1016/j.pathol.2016.07.010; Chien LN, 2016, FRONT PUBLIC HEALTH, V4, DOI 10.3389/fpubh.2016.00151; Ciocca DR, 2013, ARCH TOXICOL, V87, P19, DOI 10.1007/s00204-012-0918-z; Ebrahimi A, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0331-6; Eto D, 2016, ANTICANCER RES, V36, P3775; Feng YB, 2009, INT J CANCER, V124, P578, DOI 10.1002/ijc.23990; Gimenez M, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1473-9; Goldberg AD, 2010, CELL, V140, P678, DOI 10.1016/j.cell.2010.01.003; Golembieski WA, 2008, GLIA, V56, P1061, DOI 10.1002/glia.20679; Hattori N, 2016, CANCER SCI, V107, P1159, DOI 10.1111/cas.12969; Knapinska AM, 2011, MOL CELL BIOL, V31, P1419, DOI 10.1128/MCB.00907-10; Koschmann C, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aac8228; Li JY, 2012, J NEURO-ONCOL, V110, P187, DOI 10.1007/s11060-012-0963-8; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Makela KS, 2014, HISTOL HISTOPATHOL, V29, P1161, DOI 10.14670/HH-29.1161; Mounier N, 2002, CELL STRESS CHAPERON, V7, P167, DOI 10.1379/1466-1268(2002)007<0167:ACASHS>2.0.CO;2; Castro GN, 2015, CELL STRESS CHAPERON, V20, P253, DOI 10.1007/s12192-014-0537-0; Ohba S, 2016, CANCER RES, V76, P6680, DOI 10.1158/0008-5472.CAN-16-0696; Okuno M, 2016, ONCOTARGET, V7, P14291, DOI 10.18632/oncotarget.7424; Paul C, 2010, EXP CELL RES, V316, P1535, DOI 10.1016/j.yexcr.2010.03.006; Reifenberger G, 2017, NAT REV CLIN ONCOL, V14, P434, DOI 10.1038/nrclinonc.2016.204; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; Sulkowski PL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal2463; Tran AN, 2014, NEURO-ONCOLOGY, V16, P414, DOI 10.1093/neuonc/not198; Wu JM, 2017, TRENDS PHARMACOL SCI, V38, P226, DOI 10.1016/j.tips.2016.11.009; Ye HX, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164285	31	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	AUG	2018	71	8					702	707		10.1136/jclinpath-2018-205000			6	Pathology	Pathology	GR3CW	WOS:000442467400007	29550762	Green Published			2019-10-28	
J	Slaba, K; Krystufek, B; Nemec, A				Slaba, K.; Krystufek, B.; Nemec, A.			Oral and Dental Examination Findings in Beech Martens (Martes foina)	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						beech martin; oral pathology; radiography; teeth	FULL-MOUTH RADIOGRAPHY; SEXUAL-DIMORPHISM; DIAGNOSTIC-VALUE; STONE MARTENS; M. MARTES; PINE; DIFFERENTIATION; MUSTELIDAE; CARNIVORA; PATHOLOGY	Detailed clinical and radiographical descriptions of oral/dental pathology in the beech marten (Martes foina) are lacking. In the present study, skulls of M. foina from a museum collection (n = 109) were examined macroscopically according to predefined criteria and full-mouth dental radiographs were obtained. Occlusion was diagnosed as 'scissor bite' in 22.5% of evaluated skulls, 77% of evaluated skulls showed 'level bite' of incisors and 9.2% of evaluated skulls had 'open bites'. In three skulls, class III malocclusion was diagnosed. Linguoversion of the mandibular second incisor teeth was noted in all skulls. Ofthe maximum possible number of teeth (i.e. full set of teeth in each skull), 90.4% were available for examination, 6.4% were missing artifactually, 2.0% were absent presumably congenitally and in 1.2 % the absence was presumably acquired. In three skulls supernumerary teeth were noted, all being incisor teeth. In four skulls, unerupted maxillary canine teeth were noted and in one skull odontodysplasia of the maxillary canine teeth was diagnosed. All other teeth were considered normal in morphology. The number of roots per tooth varied in the mandibular second premolar, maxillary first molar and mandibular second molar teeth. The most common dental pathology was attrition/abrasion with 72 skulls (66%) and 857 teeth (24.1% of evaluated teeth) affected, followed by periodontal disease affecting 52 (47.7%) of skulls and 773 teeth (18.9% of evaluated teeth). Dental fractures were present in 49 (45%) skulls and 148 teeth (3.8% of evaluated teeth). Radiographically evident periapical lesions were detected in 11 (10.1%) skulls and 18 teeth (0.5% of evaluated teeth). Other rare abnormal findings included tooth resorption, enamel hypoplasia/hypocalcification, fenestrations at palatal root of maxillary first molar tooth and different bony changes. (C) 2018 Elsevier Ltd. All rights reserved.	[Slaba, K.] Vet Klin Arvet, Pisek, Czech Republic; [Krystufek, B.] Slovenian Museum Nat Hist, Ljubljana, Slovenia; [Nemec, A.] Univ Ljubljana, Vet Fac, Small Anim Clin, Ljubljana, Slovenia	Slaba, K (reprint author), Vet Klin Arvet, Pisek, Czech Republic.	slaba.katerina@seznam.cz					AVDC Nomenclature Committee, 2012, TOOTH FRACT CLASS; AVDC Nomenclature Committee, 2012, MAL; Dierks K, 2001, WISSENSCHAFTLICHE MI, V14, P113; DuPont GA, 2008, ATLAS DENT RADIOGRAP, P11; Gimranov D, 2015, CR PALEVOL, V14, P647, DOI 10.1016/j.crpv.2015.06.007; Helldin JO, 1997, WILDLIFE SOC B, V25, P83; Konjevic Dean, 2011, Natura Croatica, V20, P215; Lanszki Jozsef, 2009, Natura Somogyiensis, V15, P231; Lopez-Martin JM, 2006, MAMM BIOL, V71, P13, DOI 10.1016/j.mambio.2005.08.006; Loy A, 2004, ITAL J ZOOL, V71, P27, DOI 10.1080/11250000409356547; Nemec A, 2015, P 9 INT S WILD FAUN, P107; Peralta S, 2010, AM J VET RES, V71, P784, DOI 10.2460/ajvr.71.7.784; Polak S, 1996, SMALL CARNIVORE CONS, V14, P14; Verstraete FJM, 1998, AM J VET RES, V59, P692; Verstraete FJM, 1996, J COMP PATHOL, V115, P283, DOI 10.1016/S0021-9975(96)80085-5; Verstraete FJM, 1998, AM J VET RES, V59, P686; Verstraete FJM, 2015, SELF ASSESSMENT COLO, P167; Winer JN, 2013, J COMP PATHOL, V149, P346, DOI 10.1016/j.jcpa.2012.11.243; WOLSAN M, 1985, ACTA THERIOL, V30, P79, DOI 10.4098/AT.arch.85-3; WOLSAN M, 1989, ACTA THERIOL, V34, P545, DOI 10.4098/AT.arch.89-55; WOLSAN M, 1984, ZOOL ANZ, V213, P119	21	0	0	2	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	AUG	2018	163						10	17		10.1016/j.jcpa.2018.06.004			8	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GV3HE	WOS:000445984200003	30213368				2019-10-28	
J	Toss, MS; Miligy, I; Al-Kawaz, A; Alsleem, M; Khout, H; Rida, PC; Aneja, R; Green, AR; Ellis, IO; Rakha, EA				Toss, Michael S.; Miligy, I.; Al-Kawaz, Abdubaqi; Alsleem, Mansour; Khout, Hazem; Rida, Padmashree C.; Aneja, Ritu; Green, Andrew R.; Ellis, Ian O.; Rakha, Emad A.			Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast	MODERN PATHOLOGY			English	Article							REGULATORY T-CELLS; LOCAL RECURRENCE; IMMUNE MICROENVIRONMENT; CONSERVING SURGERY; CANCER; PROGRESSION; EXPRESSION; MELANOMA; INVASION; FEATURES	Tumor-infiltrating lymphocytes (TILs) provide prognostic value in invasive breast cancer and guidelines for their assessment have been published. This study aims to evaluate: (a) methods of TILs assessment, and (b) their prognostic significance in breast ductal carcinoma in situ (DCIS). Hematoxylin and eosin sections from two clinically annotated DCIS cohorts; a training set (n = 150 pure DCIS) and a validation set (n = 666 comprising 534 pure DCIS and 132 cases wherein DCIS and invasive breast carcinoma were co-existent) were assessed. Seven different scoring methods were applied to the training set to identify the most optimal reproducible method associated with strongest prognostic value. Among different methods, TILs touching ducts' basement membrane or away from it by one lymphocyte cell thickness provided the strongest significant association with outcome and highest concordance rate [inter-cluster correlation coefficient = 0.95]. Assessment of periductal TILs at increasing distances from DCIS (0.2, 0.5, and 1 mm) as well as percent of stromal TILs were practically challenging and showed lower concordance rates than touching TILs. TILs hotspots and lymphoid follicles did not show prognostic significance. Within the pure DCIS validation set, dense TILs were associated with younger age, symptomatic presentation, larger size, higher nuclear grade, comedo necrosis and estrogen receptor negativity as well as shorter recurrence-free interval (p = 0.002). In multivariate survival analysis, dense TILs were independent predictor of shorter recurrence-free interval (p = 0.002) in patients treated with breast conservation. DCIS associated with invasive carcinoma showed denser TILs than pure DCIS (p = 9.0 x 10(-13)). Dense TILs is an independent prognostic variable in DCIS. Touching TILs provides a reproducible method for their assessment that can potentially be used to guide management	[Toss, Michael S.; Miligy, I.; Al-Kawaz, Abdubaqi; Alsleem, Mansour; Khout, Hazem; Green, Andrew R.; Ellis, Ian O.; Rakha, Emad A.] Univ Nottingham, Sch Med, Acad Pathol, Div Canc & Stem Cells, Nottingham, England; [Toss, Michael S.] Asyut Univ, South Egypt Canc Inst, Dept Histopathol, Asyut, Egypt; [Miligy, I.; Rakha, Emad A.] Menoufia Univ, Fac Med, Dept Histopathol, Shibin Al Kawm, Egypt; [Khout, Hazem; Ellis, Ian O.; Rakha, Emad A.] Nottingham Univ Hosp NHS Trust, City Hosp Nottingham, Breast Inst, Hucknall Rd, Nottingham NG5 1PB, England; [Rida, Padmashree C.; Aneja, Ritu] Georgia State Univ, Dept Biol, Atlanta, GA USA	Rakha, EA (reprint author), Univ Nottingham, Sch Med, Acad Pathol, Div Canc & Stem Cells, Nottingham, England.; Rakha, EA (reprint author), Menoufia Univ, Fac Med, Dept Histopathol, Shibin Al Kawm, Egypt.; Rakha, EA (reprint author), Nottingham Univ Hosp NHS Trust, City Hosp Nottingham, Breast Inst, Hucknall Rd, Nottingham NG5 1PB, England.	emad.rakha@nottingham.ac.uk	Rakha, Emad/Q-5554-2019	Ellis, Ian/0000-0001-5292-8474; Green, Andrew/0000-0002-0488-5913; Rakha, Emad/0000-0002-5009-5525			Adams S, 2014, J CLIN ONCOL, V32, P2959, DOI 10.1200/JCO.2013.55.0491; Campbell MJ, 2017, BREAST CANCER RES TR, V161, P17, DOI 10.1007/s10549-016-4036-0; Carraro DM, 2014, BIOSCIENCE REP, V34, P18, DOI 10.1042/BSR20130077; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Dieci MV, 2018, SEMIN CANCER BIOL, V52, P16, DOI 10.1016/j.semcancer.2017.10.003; Doebar SC, 2016, BREAST, V27, P15, DOI 10.1016/j.breast.2016.02.014; Francis A, 2015, EUR J CANCER, V51, P2296, DOI 10.1016/j.ejca.2015.07.017; Furnival C, 2006, ANZ J SURG, V76, P4, DOI 10.1111/j.1445-2197.2006.03637.x; Gannot G, 2002, BRIT J CANCER, V86, P1444, DOI 10.1038/sj/bjc/6600282; Gobert M, 2009, CANCER RES, V69, P2000, DOI 10.1158/0008-5472.CAN-08-2360; Hendry S, 2017, ADV ANAT PATHOL, V24, P311, DOI 10.1097/PAP.0000000000000161; Hendry S, 2017, CLIN CANCER RES, V23, P5210, DOI 10.1158/1078-0432.CCR-17-0743; Hiraoka N, 2006, CLIN CANCER RES, V12, P5423, DOI 10.1158/1078-0432.CCR-06-0369; Ibrahim EM, 2014, BREAST CANCER RES TR, V148, P467, DOI 10.1007/s10549-014-3185-2; Jiang B, 2013, INT J MED SCI, V10, P475, DOI 10.7150/ijms.5798; Kerlikowske K, 2003, JNCI-J NATL CANCER I, V95, P1692, DOI 10.1093/jnci/djg097; Knopfelmacher A, 2015, MODERN PATHOL, V28, P1167, DOI 10.1038/modpathol.2015.79; Kong I, 2014, CURR ONCOL, V21, pE96, DOI 10.3747/co.21.1604; Lee AHS, 2006, HISTOPATHOLOGY, V48, P692, DOI 10.1111/j.1365-2559.2006.02410.x; Lee N, 2016, PATHOLOGY, V48, P177, DOI 10.1016/j.pathol.2015.12.006; Lee RJ, 2012, INT J SURG ONCOL, DOI 10.1155/2012/123549; Man YG, 2013, J CANCER, V4, P84, DOI 10.7150/jca.5482; Man YG, 2003, BREAST CANCER RES, V5, pR231, DOI 10.1186/bcr653; Mechera R, 2009, BREAST CANCER RES TR, V116, P171, DOI 10.1007/s10549-008-0187-y; Miligy I, 2017, HISTOPATHOLOGY, V71, P258, DOI 10.1111/his.13217; Muggerud AA, 2010, MOL ONCOL, V4, P357, DOI 10.1016/j.molonc.2010.06.007; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Pruneri G, 2017, ANN ONCOL, V28, P321, DOI 10.1093/annonc/mdw623; Rudloff U, 2010, J CLIN ONCOL, V28, P3762, DOI 10.1200/JCO.2009.26.8847; Sabatier R, 2015, ONCOTARGET, V6, P5449, DOI 10.18632/oncotarget.3216; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Solin LJ, 2013, JNCI-J NATL CANCER I, V105, P701, DOI 10.1093/jnci/djt067; Stallard S, 2001, EUR J SURG ONCOL, V27, P373; Thompson E, 2016, MODERN PATHOL, V29, P249, DOI 10.1038/modpathol.2015.158; Van Bockstal M, 2013, HISTOPATHOLOGY, V63, P520, DOI 10.1111/his.12188; Virnig BA, 2010, J NATL CANCER I, V102, P170, DOI 10.1093/jnci/djp482	37	12	12	1	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	AUG	2018	31	8					1226	1236		10.1038/s41379-018-0040-8			11	Pathology	Pathology	GR8SZ	WOS:000443000300006	29559742	Green Accepted			2019-10-28	
J	Koelsche, C; Hartmann, W; Schrimpf, D; Stichel, D; Jabar, S; Ranft, A; Reuss, DE; Sahm, F; Jones, DTW; Bewerunge-Hudler, M; Trautmann, M; Klingebiel, T; Vokuhl, C; Gessler, M; Wardelmann, E; Petersen, I; Baumhoer, D; Flucke, U; Antonescu, C; Esteller, M; Frohling, S; Kool, M; Pfister, SM; Mechtersheimer, G; Dirksen, U; von Deimling, A				Koelsche, Christian; Hartmann, Wolfgang; Schrimpf, Daniel; Stichel, Damian; Jabar, Susanne; Ranft, Andreas; Reuss, David E.; Sahm, Felix; Jones, David T. W.; Bewerunge-Hudler, Melanie; Trautmann, Marcel; Klingebiel, Thomas; Vokuhl, Christian; Gessler, Manfred; Wardelmann, Eva; Petersen, Iver; Baumhoer, Daniel; Flucke, Uta; Antonescu, Cristina; Esteller, Manel; Froehling, Stefan; Kool, Marcel; Pfister, Stefan M.; Mechtersheimer, Gunhild; Dirksen, Uta; von Deimling, Andreas			Array-based DNA-methylation profiling in sarcomas with small blue round cell histology provides valuable diagnostic information	MODERN PATHOLOGY			English	Article							IN-SITU HYBRIDIZATION; BCOR-CCNB3 GENE FUSION; EWING-LIKE-SARCOMA; MOLECULAR CLASSIFICATION; UP-REGULATION; TUMORS; TRANSLOCATION; SUBGROUPS; ENTITIES; GENOME	Undifferentiated solid tumors with small blue round cell histology and expression of CD99 mostly resemble Ewing sarcoma. However, they also may include other tumors such as mesenchymal chondrosarcoma, synovial sarcoma, or small cell osteosarcoma. Definitive classification usually requires detection of entity-specific mutations. While this approach identifies the majority of Ewing sarcomas, a subset of lesions remains unclassified and, therefore, has been termed " Ewing-like sarcomas" or small blue round cell tumors not otherwise specified. We developed an approach for further characterization of small blue round cell tumors not otherwise specified using an array-based DNA-methylation profiling approach. Data were analyzed by unsupervised clustering and t-distributed stochastic neighbor embedding analysis and compared with a reference methylation data set of 460 well-characterized prototypical sarcomas encompassing 18 subtypes. Verification was performed by additional FISH analyses, RNA sequencing from formalin-fixed paraffin-embedded material or immunohistochemical marker analyses. In a cohort of more than 1,000 tumors assumed to represent Ewing sarcomas, 30 failed to exhibit the typical EWS translocation. These tumors were subjected to methylation profiling and could be assigned to Ewing sarcoma in 14 (47%), to small blue round cell tumors with CIC alteration in 6 (20%), to small blue round cell tumors with BCOR alteration in 4 (13%), to synovial sarcoma and to malignant rhabdoid tumor in 2 cases each. One single case each was allotted to mesenchymal chondrosarcoma and adamantinoma. 12/14 tumors classified as Ewing sarcoma could be verified by demonstrating either a canonical EWS translocation evading initial testing, by identifying rare breakpoints or fusion partners. The methylation-based assignment of the remaining small blue round cell tumors not otherwise specified also could be verified by entity-specific molecular alterations in 13/16 cases. In conclusion, array-based DNA-methylation analysis of undifferentiated tumors with small blue round cell histology is a powerful tool for precisely classifying this diagnostically challenging tumor group.	[Koelsche, Christian; Schrimpf, Daniel; Stichel, Damian; Reuss, David E.; Sahm, Felix; von Deimling, Andreas] German Canc Res Ctr, Clin Cooperat Unit Neuropathol, Heidelberg, Germany; [Koelsche, Christian; Schrimpf, Daniel; Reuss, David E.; Sahm, Felix; von Deimling, Andreas] Heidelberg Univ Hosp, Inst Pathol, Dept Neuropathol, Heidelberg, Germany; [Koelsche, Christian; Schrimpf, Daniel; Stichel, Damian; Reuss, David E.; Sahm, Felix; Jones, David T. W.; Bewerunge-Hudler, Melanie; Froehling, Stefan; Kool, Marcel; Pfister, Stefan M.; von Deimling, Andreas] German Canc Consortium DKTK Core Ctr Heidelberg, Heidelberg, Germany; [Hartmann, Wolfgang; Trautmann, Marcel; Wardelmann, Eva] Muenster Univ Hosp, Gerhard Domagk Inst Pathol, Munster, Germany; [Jabar, Susanne; Ranft, Andreas; Dirksen, Uta] Univ Hosp Essen, West German Canc Ctr, Pediat Pediat Hematol Oncol Immunol Cardiol Pulmo, Essen, Germany; [Jabar, Susanne; Ranft, Andreas; Dirksen, Uta] German Canc Consortium DKTK Ctr Essen, Essen, Germany; [Jabar, Susanne; Ranft, Andreas; Dirksen, Uta] Univ Duisburg Essen, West German Canc Ctr, Int Ewing Sarcoma Study Grp, Sarcoma Ctr, Essen, Germany; [Jones, David T. W.; Kool, Marcel; Pfister, Stefan M.] NCT Heidelberg KiTZ, Hopp Childrens Canc Ctr, Heidelberg, Germany; [Jones, David T. W.; Kool, Marcel; Pfister, Stefan M.] German Canc Res Ctr, Div Pediat Neurooncol, Heidelberg, Germany; [Pfister, Stefan M.] Heidelberg Univ Hosp, Dept Pediat Oncol Hematol & Immunol, Heidelberg, Germany; [Bewerunge-Hudler, Melanie] German Canc Res Ctr, Genom & Prote Core Facil, Heidelberg, Germany; [Klingebiel, Thomas] Univ Childrens Hosp, Dept Pediat Hematol & Oncol, Frankfurt, Germany; [Vokuhl, Christian] Univ Hosp Schleswig Holstein, Dept Pediat Pathol, Kiel, Germany; [Gessler, Manfred] Wuerzburg Univ, Dev Biochem, Theodor Boveri Inst, Bioctr, Wurzburg, Germany; [Gessler, Manfred] Wuerzburg Univ, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany; [Petersen, Iver] SRH Poliklin Gera GmbH, Inst Pathol, Gera, Germany; [Baumhoer, Daniel] Univ Hosp Basel, Inst Pathol, Bone Tumour Reference Ctr, Basel, Switzerland; [Baumhoer, Daniel] Univ Basel, Basel, Switzerland; [Flucke, Uta] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, Nijmegen, Netherlands; [Antonescu, Cristina] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA; [Esteller, Manel] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program, Barcelona, Catalonia, Spain; [Esteller, Manel] Univ Barcelona, Sch Med, Dept Physiol Sci 2, Barcelona, Catalonia, Spain; [Esteller, Manel] ICREA, Barcelona, Catalonia, Spain; [Froehling, Stefan] Natl Ctr Tumor Dis NCT Heidelberg, Dept Translat Oncol, Heidelberg, Germany; [Froehling, Stefan] German Canc Res Ctr, Heidelberg, Germany; [Froehling, Stefan] Heidelberg Univ Hosp, Sect Personalized Oncol, Heidelberg, Germany; [Mechtersheimer, Gunhild] Heidelberg Univ Hosp, Inst Pathol, Dept Gen Pathol, Heidelberg, Germany	von Deimling, A (reprint author), German Canc Res Ctr, Clin Cooperat Unit Neuropathol, Heidelberg, Germany.; von Deimling, A (reprint author), Heidelberg Univ Hosp, Inst Pathol, Dept Neuropathol, Heidelberg, Germany.; von Deimling, A (reprint author), German Canc Consortium DKTK Core Ctr Heidelberg, Heidelberg, Germany.; Dirksen, U (reprint author), Univ Hosp Essen, West German Canc Ctr, Pediat Pediat Hematol Oncol Immunol Cardiol Pulmo, Essen, Germany.; Dirksen, U (reprint author), German Canc Consortium DKTK Ctr Essen, Essen, Germany.; Dirksen, U (reprint author), Univ Duisburg Essen, West German Canc Ctr, Int Ewing Sarcoma Study Grp, Sarcoma Ctr, Essen, Germany.	uta.dirksen@uk-essen.de; andreas.vondeimling@med.uni-heidelberg.de	Jones, David TW/G-9588-2013; Trautmann, Marcel/B-4627-2015; Kolsche, Christian/Q-8854-2019; Sahm, Felix/W-8050-2019; Pfister, Stefan M/F-6860-2013; von Deimling, Andreas/F-7774-2013; Vokuhl, Christian/M-1511-2017; Jones, David/Z-1963-2019; Hartmann, Wolfgang/G-1893-2017	Jones, David TW/0000-0002-2036-5141; Trautmann, Marcel/0000-0002-5842-1196; Sahm, Felix/0000-0001-5441-1962; Pfister, Stefan M/0000-0002-5447-5322; von Deimling, Andreas/0000-0002-5863-540X; Hartmann, Wolfgang/0000-0002-7609-5021; Koelsche, Christian/0000-0001-8763-8864; Ranft, Andreas/0000-0003-4424-7569	German Cancer AidDeutsche Krebshilfe [70112499, 108128]; ERA-Net-TRANSCAN consortium under the European Commission Seventh Framework Program FP7-HEALTH [01KT1310]; Euro Ewing Consortium EEC under the European Commission Seventh Framework Program FP7-HEALTH [EU-FP7 602856]	We thank Simone Kocher, Jochen Meyer, Antje Habel, Petra Fischer, Birgit Schulte and Maria Wolters for excellent technical support. We also thank Dr. Meybrit Rasper and Regina Kloss from the CESS study group for helpful assistance. We thank the Tissue Bank of the National Center for Tumor Diseases Heidelberg for providing samples, and the Microarray unit of the Genomics and Proteomics Core Facility, German Cancer Research Center (DKFZ), for providing excellent methylation services. This study was supported by a German Cancer Aid grant 70112499 (to CK, AvD) and grant 108128 (to UD); ERA-Net-TRANSCAN consortium, project number 01KT1310, and Euro Ewing Consortium EEC, project number EU-FP7 602856, both funded under the European Commission Seventh Framework Program FP7-HEALTH (to UD).	Antonescu C, 2014, HISTOPATHOLOGY, V64, P26, DOI 10.1111/his.12281; Antonescu CR, 2017, AM J SURG PATHOL, V41, P941, DOI 10.1097/PAS.0000000000000846; Arbajian E, 2013, AM J SURG PATHOL, V37, P613, DOI 10.1097/PAS.0b013e31827ae13b; Argani P, 2017, AM J SURG PATHOL, V41, P1702, DOI 10.1097/PAS.0000000000000926; Braun M, 2012, J MOL DIAGN, V14, P322, DOI 10.1016/j.jmoldx.2012.01.017; De Alava E., 2013, WHO CLASSIFICATION T, V5, P305; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Folpe AL, 2000, AM J SURG PATHOL, V24, P1657, DOI 10.1097/00000478-200012000-00010; Gaspar N, 2015, J CLIN ONCOL, V33, P3036, DOI 10.1200/JCO.2014.59.5256; Heyn H, 2012, NAT REV GENET, V13, P679, DOI 10.1038/nrg3270; Hovestadt V, 2013, ACTA NEUROPATHOL, V125, P913, DOI 10.1007/s00401-013-1126-5; Huang SC, 2016, GENE CHROMOSOME CANC, V55, P767, DOI 10.1002/gcc.22376; Italiano A, 2012, GENE CHROMOSOME CANC, V51, P207, DOI 10.1002/gcc.20945; Johann PD, 2016, CANCER CELL, V29, P379, DOI 10.1016/j.ccell.2016.02.001; Kao YC, 2017, GENE CHROMOSOME CANC, V56, P501, DOI 10.1002/gcc.22454; Kao YC, 2017, GENE CHROMOSOME CANC, V56, P296, DOI 10.1002/gcc.22435; Kao YC, 2016, AM J SURG PATHOL, V40, P1670, DOI 10.1097/PAS.0000000000000697; Kao YC, 2016, AM J SURG PATHOL, V40, P1009, DOI 10.1097/PAS.0000000000000629; Kawamura-Saito M, 2006, HUM MOL GENET, V15, P2125, DOI 10.1093/hmg/ddl136; Kim D, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r72; Koelsche C, 2015, BRAIN PATHOL, V25, P202, DOI 10.1111/bpa.12228; Ladenstein R, 2010, J CLIN ONCOL, V28, P3284, DOI 10.1200/JCO.2009.22.9864; Le Deley MC, 2014, J CLIN ONCOL, V32, P2440, DOI 10.1200/JCO.2013.54.4833; Le Guellec S, 2016, MODERN PATHOL, V29, P1523, DOI 10.1038/modpathol.2016.155; Mahoney SE, 2012, EPIGENETICS-US, V7, P400, DOI 10.4161/epi.19463; McPherson A, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1001138; Pajtler KW, 2015, CANCER CELL, V27, P728, DOI 10.1016/j.ccell.2015.04.002; Pierron G, 2012, NAT GENET, V44, P461, DOI 10.1038/ng.1107; Reik W, 2007, NATURE, V447, P425, DOI 10.1038/nature05918; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Rohrich M, 2016, ACTA NEUROPATHOL, V131, P877, DOI 10.1007/s00401-016-1540-6; Sadri N, 2014, VIRCHOWS ARCH, V465, P233, DOI 10.1007/s00428-014-1613-7; Sahm F, 2017, LANCET ONCOL, V18, P682, DOI 10.1016/S1470-2045(17)30155-9; Sahm F, 2016, ACTA NEUROPATHOL, V131, P903, DOI 10.1007/s00401-015-1519-8; Schwalbe EC, 2013, ACTA NEUROPATHOL, V125, P359, DOI 10.1007/s00401-012-1077-2; Seki M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8557; Smith SC, 2017, HISTOPATHOLOGY, V70, P657, DOI 10.1111/his.13112; Solomon DA, 2014, AM J SURG PATHOL, V38, P1724, DOI 10.1097/PAS.0000000000000335; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Specht K, 2016, AM J SURG PATHOL, V40, P433, DOI 10.1097/PAS.0000000000000591; Specht K, 2014, GENE CHROMOSOME CANC, V53, P622, DOI 10.1002/gcc.22172; Straussman R, 2009, NAT STRUCT MOL BIOL, V16, P564, DOI 10.1038/nsmb.1594; Sturm D, 2016, CELL, V164, P1060, DOI 10.1016/j.cell.2016.01.015; Sturm D, 2012, CANCER CELL, V22, P425, DOI 10.1016/j.ccr.2012.08.024; Sugita S, 2014, AM J SURG PATHOL, V38, P1571, DOI 10.1097/PAS.0000000000000286; Sumegi J, 2011, MODERN PATHOL, V24, P333, DOI 10.1038/modpathol.2010.201; Szuhai K, 2009, CLIN CANCER RES, V15, P2259, DOI 10.1158/1078-0432.CCR-08-2184; Ueno-Yokohata H, 2015, NAT GENET, V47, P861, DOI 10.1038/ng.3338; Wang L, 2012, GENE CHROMOSOME CANC, V51, P127, DOI 10.1002/gcc.20937; Yoshida A, 2017, HISTOPATHOLOGY, V71, P461, DOI 10.1111/his.13252; Yoshida Y, 2018, BRAIN PATHOL, V28, P710, DOI 10.1111/bpa.12585	51	13	13	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	AUG	2018	31	8					1246	1256		10.1038/s41379-018-0045-3			11	Pathology	Pathology	GR8SZ	WOS:000443000300008	29572501				2019-10-28	
J	Vatrano, S; Volante, M; Duregon, E; Giorcelli, J; Izzo, S; Rapa, I; Votta, A; Germano, A; Scagliotti, G; Berruti, A; Terzolo, M; Papotti, M				Vatrano, Simona; Volante, Marco; Duregon, Eleonora; Giorcelli, Jessica; Izzo, Stefania; Rapa, Ida; Votta, Arianna; Germano, Antonina; Scagliotti, Giorgio; Berruti, Alfredo; Terzolo, Massimo; Papotti, Mauro			Detailed genomic characterization identifies high heterogeneity and histotype-specific genomic profiles in adrenocortical carcinomas	MODERN PATHOLOGY			English	Article							CELL LUNG-CANCER; HELSINKI SCORE; PRIMARY TUMOR; BETA-CATENIN; MUTATIONS; METASTASES; REVEALS; SAMPLES	Molecular characterization of adrenocortical carcinoma has been recently established, but the correlation between molecular profiles and clinical and pathological characteristics is still poorly defined with no data available about genetic heterogeneity along disease progression. In this scenario, a detailed molecular profile was correlated with clinical and pathological characteristics in adrenocortical carcinoma patients to identify potentially novel biomarkers. Targeted next-generation sequencing and copy number variation analyses for 18 most frequently altered genes in adrenocortical carcinoma were assessed on 62 adult cases (including 10 with matched primary and metastatic/recurrence samples) and results correlated with major clinical and pathological characteristics of tumors. A total of 433 somatic deleterious genetic alterations (328 gene mutations and 105 copy number variations) were identified in 57/62 cases, five resulted wild type for all genes tested. TERT, CDK4, ZNRF3, and RB1 were altered in more than 30% of cases. Among histological variants genotypes were significantly different. Lowest mutation burden was found in the oncocytic type (p = 0.006), whereas the highest with a prevalence of RB1 (p = 0.001) and CDK4 (p = 0.002) was found in the conventional and myxoid ones, respectively. None of the 10 cases with matched samples showed a stable genotype along tumor progression, although allelic frequencies or percentages of altered nuclei at fluorescence in situ hybridization were in most cases similar among different tumor samples for genes that were stable along tumor progression. Among individual genes, an altered p53/Rb1 pathway was the strongest adverse molecular signature, being associated with high Ki-67 index, high tumor stage, aggressive disease status, and shorter disease-free survival. The genomic signature in adrenocortical carcinoma is changing along tumor progression and is associated with specific clinical and pathological features, including histological variant and prognosis.	[Vatrano, Simona; Volante, Marco; Duregon, Eleonora; Giorcelli, Jessica; Izzo, Stefania; Rapa, Ida; Votta, Arianna; Germano, Antonina; Scagliotti, Giorgio] Univ Turin, San Luigi Hosp, Dept Oncol, Turin, Italy; [Berruti, Alfredo] Univ Brescia, Oncol Unit, Brescia, Italy; [Terzolo, Massimo] Univ Turin, San Luigi Hosp, Dept Clin & Biol Sci, Internal Med, Turin, Italy; [Papotti, Mauro] Univ Turin, Molinette Hosp, Dept Oncol, Turin, Italy	Volante, M (reprint author), Univ Turin, San Luigi Hosp, Dept Oncol, Turin, Italy.	marco.volante@unito.it	Berruti, Alfredo/AAC-2069-2019	Germano, Antonina/0000-0002-6488-7814	Associazione Italiana per la Ricerca sul Cancro (AIRC, Milan)Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG/14820/2013]	This work was supported by grants from Associazione Italiana per la Ricerca sul Cancro (AIRC, Milan; No. IG/14820/2013 to MP).	Assie G, 2014, NAT GENET, V46, P607, DOI 10.1038/ng.2953; Bisceglia M, 2004, INT J SURG PATHOL, V12, P231, DOI 10.1177/106689690401200304; Bourgon R, 2014, CLIN CANCER RES, V20, P2080, DOI 10.1158/1078-0432.CCR-13-3114; Choudhary A, 2014, BMC MED GENOMICS, V7, DOI 10.1186/s12920-014-0062-0; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Cirillo E, 2017, FRONT GENET, V8, DOI 10.3389/fgene.2017.00174; Cohen JA, 1997, HUM PATHOL, V28, P893, DOI 10.1016/S0046-8177(97)90003-4; de Krijger RR, 2012, VIRCHOWS ARCH, V460, P9, DOI 10.1007/s00428-011-1166-y; De Martino MC, 2013, J CLIN ENDOCR METAB, V98, P4080, DOI 10.1210/jc.2013-2165; Duregon E, 2017, HUM PATHOL, V62, P1, DOI 10.1016/j.humpath.2016.09.035; Duregon E, 2011, AM J SURG PATHOL, V35, P1882, DOI 10.1097/PAS.0b013e31822da401; El-Mokadem I, 2014, BRIT J CANCER, V111, P1381, DOI 10.1038/bjc.2014.420; Erickson LA, 2014, ADV ANAT PATHOL, V21, P151, DOI 10.1097/PAP.0000000000000019; Gaujoux S, 2011, CLIN CANCER RES, V17, P328, DOI 10.1158/1078-0432.CCR-10-2006; Giacomazzi J, 2013, CANCER-AM CANCER SOC, V119, P4341, DOI 10.1002/cncr.28346; Giordano TJ, 2017, WHO CLASSIFICATION T, P163; Juhlin CC, 2015, J CLIN ENDOCR METAB, V100, pE493, DOI 10.1210/jc.2014-3282; Kim S, 2006, J BIOL CHEM, V281, P14066, DOI 10.1074/jbc.M602696200; Kumar A, 2011, P NATL ACAD SCI USA, V108, P17087, DOI 10.1073/pnas.1108745108; Lau SK, 2009, HUM PATHOL, V40, P757, DOI 10.1016/j.humpath.2009.03.010; Libe R, 2007, CLIN CANCER RES, V13, P844, DOI 10.1158/1078-0432.CCR-06-2085; Mascarello JT, 2011, GENET MED, V13, P667, DOI 10.1097/GIM.0b013e3182227295; Papathomas TG, 2016, HUM PATHOL, V58, P113, DOI 10.1016/j.humpath.2016.08.006; Papotti M, 2014, ENDOCR PATHOL, V25, P35, DOI 10.1007/s12022-013-9291-6; Papotti M, 2010, AM J SURG PATHOL, V34, P973, DOI 10.1097/PAS.0b013e3181e2b726; Pennanen M, 2015, HUM PATHOL, V46, P404, DOI 10.1016/j.humpath.2014.11.015; Ragazzon B, 2011, ENDOCR-RELAT CANCER, V18, pR15, DOI 10.1530/ERC-10-0220; Ragazzon B, 2010, CANCER RES, V70, P8276, DOI 10.1158/0008-5472.CAN-10-2014; Raymond VM, 2013, J CLIN ONCOL, V31, P3012, DOI 10.1200/JCO.2012.48.0988; Righi L, 2016, J THORAC ONCOL, V11, P504, DOI 10.1016/j.jtho.2016.01.004; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Tissier F, 2005, CANCER RES, V65, P7622, DOI 10.1158/0008-5472.CAN-05-0593; Vakiani E, 2012, J CLIN ONCOL, V30, P2956, DOI 10.1200/JCO.2011.38.2994; Vatrano S, 2016, TARGET ONCOL, V11, P157, DOI 10.1007/s11523-015-0383-8; Vignot S, 2013, J CLIN ONCOL, V31, P2167, DOI 10.1200/JCO.2012.47.7737; Vignot S, 2012, CRIT REV ONCOL HEMAT, V84, P301, DOI 10.1016/j.critrevonc.2012.05.002; Walter MJ, 2012, NEW ENGL J MED, V366, P1090, DOI 10.1056/NEJMoa1106968; Weissferdt A, 2013, AM J CLIN PATHOL, V139, P780, DOI 10.1309/AJCPCDZLC13RSXRZ; Zheng SY, 2016, CANCER CELL, V29, P723, DOI 10.1016/j.ccell.2016.04.002	39	7	7	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	AUG	2018	31	8					1257	1269		10.1038/s41379-018-0042-6			13	Pathology	Pathology	GR8SZ	WOS:000443000300009	29581542				2019-10-28	
J	Moktefi, A; Pouessel, D; Liu, J; Sirab, N; Maille, P; Soyeux, P; Bergman, CC; Auriault, ML; Vordos, D; De la Taille, A; Culine, S; Allory, Y				Moktefi, Anissa; Pouessel, Damien; Liu, Jing; Sirab, Nanor; Maille, Pascale; Soyeux, Pascale; Bergman, Christiane Copie; Auriault, Marie Luce; Vordos, Dimitri; De la Taille, Alexandre; Culine, Stephane; Allory, Yves			Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility	MODERN PATHOLOGY			English	Article							TRANSITIONAL-CELL CARCINOMA; IN-SITU HYBRIDIZATION; HER-2/NEU PROTEIN OVEREXPRESSION; INVASIVE BLADDER-CARCINOMA; GENE AMPLIFICATION; BREAST-CANCER; CLINICAL-ONCOLOGY/COLLEGE; AMERICAN-SOCIETY; MICROPAPILLARY VARIANT; TRIAL	Although human epidermal growth factor receptor 2 (HER2) may represent a therapeutic target, its evaluation in urothelial carcinoma of the bladder does not rely on a standardized scoring system by immunohistochemistry or fluorescent in situ hybridization (FISH), as reflected by various methodology in the literature and clinical trials. Our aim was to improve and standardize HER2 amplification detection in bladder cancer. We assessed immunohistochemical criteria derived from 2013 American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAPs) guidelines for breast cancer and investigated intratumoral heterogeneity in a retrospective multicentric cohort of 188 patients with locally advanced urothelial carcinoma of the bladder. Immunohistochemistry was performed on 178 primary tumors and 126 lymph node metastases, eligible cases (moderate/strong, complete/incomplete membrane staining) were assessed by FISH. HER2 overexpression was more frequent with 2013 ASCO/CAP than 2007 ASCO/CAP guidelines (p < 0.0001). The rate of positive HER2 FISH was similar between primary tumor and lymph node metastases (8%). Among positive FISH cases, 48% were associated with moderate/strong incomplete membrane staining that were not scored eligible for FISH by 2007 ASCO/CAP criteria. Among 3+ immunohistochemistry score cases, 67% were associated with HER2-positive FISH. Concordance between primary tumors and matched lymph node metastases was moderate for immunohistochemistry (kappa = 0.54 (CI 95%, 0.41-0.67)) and FISH (kappa = 0.50 (CI 95%, 0.20-0.79)). HER2-positive FISH was more frequent in micropapillary carcinomas (12%) and carcinoma with squamous differentiation (11%) than in pure conventional carcinoma (6%). Intratumoral heterogeneity for HER2 immunohistochemistry was observed in 7% primary tumor and 6% lymph node metastases; 24% positive HER2 FISH presented intratumoral heterogeneity. Our study suggests that HER2 evaluation should include an immunohistochemistry screening step with eligibility for FISH including incomplete/complete and moderate/ strong membrane staining. Spatial or temporal intratumoral heterogeneity prompts to perform evaluation on both tumor and lymph node, and for each histological variant observed.	[Moktefi, Anissa; Bergman, Christiane Copie] Grp Hosp Henri Mondor Albert Chenevier, APHP, Dept Pathol, F-94010 Creteil, France; [Pouessel, Damien; Sirab, Nanor; Maille, Pascale; Soyeux, Pascale; Vordos, Dimitri; De la Taille, Alexandre; Allory, Yves] Univ Paris Est Creteil, Equipe Translat Res Genitourinary Oncogenesis 7, INSERM, DHU,VIC,IMRB,U955, F-94010 Creteil, France; [Pouessel, Damien] Inst Univ Canc Oncopole Toulouse, Dept Med Oncol, F-31053 Toulouse, France; [Liu, Jing] PSL Res Univ, Inst Curie, CNRS, UMR144,Equipe Labellisee Ligue Canc, F-75005 Paris, France; [Liu, Jing] UPMC Univ Paris 06, Sorbonne Univ, CNRS, UMR144, F-75005 Paris, France; [Liu, Jing] Univ Paris Saclay, Univ Paris Sud, F-91405 Orsay, France; [Auriault, Marie Luce] Ctr Hosp La Rochelle, Dept Pathol, F-17000 La Rochelle, France; [Vordos, Dimitri; De la Taille, Alexandre] Grp Hosp Henri Mondor Albert Chenevier, APHP, Dept Urol, F-94010 Creteil, France; [Culine, Stephane] Hop St Louis, APHP, Dept Med Oncol, F-75010 Paris, France; [Culine, Stephane] Univ Paris Diderot Paris 7, F-75010 Paris, France; [Allory, Yves] Inst Curie, Dept Pathol, F-92210 St Cloud, France	Allory, Y (reprint author), Univ Paris Est Creteil, Equipe Translat Res Genitourinary Oncogenesis 7, INSERM, DHU,VIC,IMRB,U955, F-94010 Creteil, France.; Allory, Y (reprint author), Inst Curie, Dept Pathol, F-92210 St Cloud, France.	yves.allory@curie.fr		copie bergman, christiane/0000-0001-5408-894X			Abd el-Latif A, 2013, J UROLOGY, V189, P1263, DOI 10.1016/j.juro.2012.10.054; Bellmunt J, 2015, CANCER MED-US, V4, P844, DOI 10.1002/cam4.432; Bianchini G, 2015, ANN ONCOL, V26, P2429, DOI 10.1093/annonc/mdv395; Caner V, 2008, PATHOL ONCOL RES, V14, P261, DOI 10.1007/s12253-008-9027-y; Ching CB, 2011, MODERN PATHOL, V24, P1111, DOI 10.1038/modpathol.2011.69; Choudhury NJ, 2016, J CLIN ONCOL, V34, P2165, DOI 10.1200/JCO.2015.66.3047; Coogan CL, 2004, UROLOGY, V63, P786, DOI 10.1016/j.urology.2003.10.040; Dadhania V, 2016, EBIOMEDICINE, V12, P105, DOI 10.1016/j.ebiom.2016.08.036; de Pinieux G, 2004, VIRCHOWS ARCH, V444, P415, DOI 10.1007/s00428-004-0986-4; Fleischmann A, 2011, EUR UROL, V60, P350, DOI 10.1016/j.eururo.2011.05.035; Grillo F, 2016, WORLD J GASTROENTERO, V22, P5879, DOI 10.3748/wjg.v22.i26.5879; Guo CC, 2016, EUR UROL, V70, P611, DOI 10.1016/j.eururo.2016.02.056; Hanker AB, 2017, CLIN CANCER RES, V23, P4323, DOI 10.1158/1078-0432.CCR-16-2287; Hanna WM, 2014, MODERN PATHOL, V27, P4, DOI 10.1038/modpathol.2013.103; Hansel DE, 2008, AM J CLIN PATHOL, V130, P274, DOI 10.1309/41VLTFX3YPP1HF6F; Hauser-Kronberger C, 2006, J UROLOGY, V175, P875, DOI 10.1016/S0022-5347(05)00411-8; Hofmann M, 2008, HISTOPATHOLOGY, V52, P797, DOI 10.1111/j.1365-2559.2008.03028.x; Hou YJ, 2018, CLIN BREAST CANCER, V18, pE237, DOI 10.1016/j.clbc.2017.11.001; Hou YJ, 2017, BREAST CANCER RES TR, V166, P447, DOI 10.1007/s10549-017-4453-8; Humphrey PA, 2016, EUR UROL, V70, P106, DOI 10.1016/j.eururo.2016.02.028; Hussain MHA, 2007, J CLIN ONCOL, V25, P2218, DOI 10.1200/JCO.2006.08.0994; Jimenez RE, 2001, CLIN CANCER RES, V7, P2440; Keck B, 2014, UROL ONCOL-SEMIN ORI, V32, P1234, DOI 10.1016/j.urolonc.2014.06.016; Kim B, 2016, DIS MARKERS, DOI 10.1155/2016/8463731; Kiss B, 2017, SCI REP-UK, V7, DOI 10.1038/srep42713; Kruger S, 2002, INT J ONCOL, V21, P981; Lae M, 2010, ANN ONCOL, V21, P815, DOI 10.1093/annonc/mdp488; Latif Z, 2004, EUR J CANCER, V40, P56, DOI 10.1016/j.ejca.2003.08.027; Latif Z, 2003, BRIT J CANCER, V89, P1305, DOI 10.1038/sj.bjc.6601245; Lim TH, 2016, ARCH PATHOL LAB MED, V140, P140, DOI 10.5858/arpa.2015-0108-OA; Matsubara H, 2008, ONCOL REP, V19, P57; Moch H, 2016, WHO CLASSIFICATION T, P77; Nedjadi T, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2703-5; Oudard S, 2015, EUR J CANCER, V51, P45, DOI 10.1016/j.ejca.2014.10.009; Perez-Montiel D, 2006, MODERN PATHOL, V19, P494, DOI 10.1038/modpathol.3800559; Pouessel Damien, 2017, Clin Genitourin Cancer, V15, pe45, DOI 10.1016/j.clgc.2016.07.012; Powles T, 2017, J CLIN ONCOL, V35, P48, DOI 10.1200/JCO.2015.66.3468; Ross JS, 2014, CLIN CANCER RES, V20, P68, DOI 10.1158/1078-0432.CCR-13-1992; Schneider SA, 2014, MODERN PATHOL, V27, P758, DOI 10.1038/modpathol.2013.201; Simon R, 2003, INT J CANCER, V107, P764, DOI 10.1002/ijc.11477; Stoss OC, 2015, MODERN PATHOL, V28, P1528, DOI 10.1038/modpathol.2015.112; Tschui J, 2015, VIRCHOWS ARCH, V466, P703, DOI 10.1007/s00428-015-1729-4; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984	45	2	2	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	AUG	2018	31	8					1270	1281		10.1038/s41379-018-0023-9			12	Pathology	Pathology	GR8SZ	WOS:000443000300010	29467478				2019-10-28	
J	Mills, A; Zadeh, S; Sloan, E; Chinn, Z; Modesitt, SC; Ring, KL				Mills, Anne; Zadeh, Sara; Sloan, Emily; Chinn, Zachary; Modesitt, Susan C.; Ring, Kari L.			Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas	MODERN PATHOLOGY			English	Article							TUMOR-INFILTRATING LYMPHOCYTES; GRAFT-VERSUS-HOST; DENDRITIC CELLS; PD-1 BLOCKADE; T-CELLS; EXPRESSION; IDO; ASSOCIATION; RESPONSES; ANTIBODY	Mismatch repair-deficient endometrial carcinomas are optimal candidates for immunotherapy given their high neoantigen loads, robust lymphoid infiltrates, and frequent PD-L1 expression. However, co-opting the PD-1/PD-L1 pathway is just one mechanism that tumors can utilize to evade host immunity. Another immune modulatory molecule that has been demonstrated in endometrial carcinoma is indoleamine 2,3-dioxygenase (IDO). We herein evaluate IDO expression in 60 endometrial carcinomas and assess results in relation to PD-L1 and mismatch repair status. IDO immunohistochemistry was performed on 60 endometrial carcinomas (20 Lynch syndrome (LS)-associated, 20 MLH1 promoter hypermethylated, and 20 mismatch repair-intact). Eight-five percent of endometrial carcinomas showed IDO tumor staining in > 1% of cells. Twenty-five percent were positive in > 25% of tumor cells and only 7% exceeded 50% staining. Mismatch repair-deficient cancers were more likely than mismatch repair-intact cancers to be > 25% IDO-positive (35% vs. 5% p = 0.024). Differences were amplified when Lynch syndrome-associated cases were evaluated in isolation (50% Lynch syndrome-associated vs. 10% mismatch repair-intact and MLH1-hypermethylated, p= 0.001). Of the four cases showing > 50% staining, three were Lynch syndrome-associated and one was MLH1-hypermethylated; no mismatch repair-intact cases had > 50% staining. Forty-three percent of IDO-positive tumors were also positive for PD-L1, whereas only two cases showed tumoral PD-L1 in the absence of IDO. In summary, IDO expression is prevalent in endometrial carcinomas and diffuse staining is significantly more common in mismatch repair-deficient cancers, particularly Lynch syndrome-associated cases. Given that the majority of PD-L1 positive cancers also express IDO, synergistic combination therapy with anti-IDO and anti-PD1/PD-L1 may be relevant in this tumor type. Furthermore, anti-IDO therapy may be an option for a small subset of mismatch repair-intact cancers.	[Mills, Anne; Zadeh, Sara; Sloan, Emily; Chinn, Zachary; Modesitt, Susan C.; Ring, Kari L.] Univ Virginia, Dept Pathol, Charlottesville, VA 22903 USA; [Mills, Anne; Zadeh, Sara; Sloan, Emily; Chinn, Zachary; Modesitt, Susan C.; Ring, Kari L.] Univ Virginia, Dept Gynecol & Obstet, Div Gynecol Oncol, Charlottesville, VA 22908 USA	Mills, A (reprint author), Univ Virginia, Dept Pathol, Charlottesville, VA 22903 USA.; Mills, A (reprint author), Univ Virginia, Dept Gynecol & Obstet, Div Gynecol Oncol, Charlottesville, VA 22908 USA.	amm7r@virginia.edu		Mills, Anne/0000-0002-2686-4857			Butte MJ, 2007, IMMUNITY, V27, P111, DOI 10.1016/j.immuni.2007.05.016; de Jong RA, 2012, GYNECOL ONCOL, V126, P474, DOI 10.1016/j.ygyno.2012.05.034; Fallarino F, 2009, J IMMUNOL, V183, P6303, DOI 10.4049/jimmunol.0901577; Friedman K, 2016, MODERN PATHOL, V29, P528, DOI 10.1038/modpathol.2016.54; Gurtner GJ, 2003, GASTROENTEROLOGY, V125, P1762, DOI 10.1053/j.gastro.2003.08.031; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Honig A, 2004, J REPROD IMMUNOL, V61, P79, DOI 10.1016/j.jri.2003.11.002; Howitt BE, 2015, JAMA ONCOL, V1, P1319, DOI 10.1001/jamaoncol.2015.2151; Hughes PE, 2016, TRENDS IMMUNOL, V37, P462, DOI 10.1016/j.it.2016.04.010; Ino K, 2006, BRIT J CANCER, V95, P1555, DOI 10.1038/sj.bjc.6603477; Ino K, 2008, CLIN CANCER RES, V14, P2310, DOI 10.1158/1078-0432.CCR-07-4144; Jasperson LK, 2008, BLOOD, V111, P3257, DOI 10.1182/blood-2007-06-096081; Lan Z, 2010, TRANSPLANTATION, V90, P1286, DOI 10.1097/TP.0b013e3182007bbf; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Lee V, 2016, IMMUNOTHERAPY-UK, V8, P1, DOI 10.2217/imt.15.97; Liu J, 2015, EXP THER MED, V10, P1947, DOI 10.3892/etm.2015.2714; Longoria Teresa C, 2015, Gynecol Oncol Res Pract, V2, P11, DOI 10.1186/s40661-015-0020-3; Lu Y, 2012, BLOOD, V119, P1075, DOI 10.1182/blood-2010-12-322891; Mellor AL, 2003, J IMMUNOL, V171, P1652, DOI 10.4049/jimmunol.171.4.1652; Moon YW, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0094-9; Munn DH, 2016, TRENDS IMMUNOL, V37, P193, DOI 10.1016/j.it.2016.01.002; Munn DH, 2013, TRENDS IMMUNOL, V34, P137, DOI 10.1016/j.it.2012.10.001; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; Reiss KA, 2014, IMMUNOTHERAPY-UK, V6, P459, DOI 10.2217/imt.14.9; Sloan EA, 2017, AM J SURG PATHOL, V41, P326, DOI 10.1097/PAS.0000000000000783; Suzuki S, 2001, BIOCHEM J, V355, P425, DOI 10.1042/0264-6021:3550425; Szanto S, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2205; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Vanderstraeten A, 2014, CANCER IMMUNOL IMMUN, V63, P545, DOI 10.1007/s00262-014-1537-8; Yan YP, 2010, J IMMUNOL, V185, P5953, DOI 10.4049/jimmunol.1001628	34	8	8	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	AUG	2018	31	8					1282	1290		10.1038/s41379-018-0039-1			9	Pathology	Pathology	GR8SZ	WOS:000443000300011	29559741				2019-10-28	
J	Menguy, S; Frison, E; Prochazkova-Carlotti, M; Dalle, S; Dereure, O; Boulinguez, S; Dalac, S; Machet, L; Ram-Wolff, C; Verneuil, L; Gros, A; Vergier, B; Beylot-Barry, M; Merlio, JP; Pham-Ledard, A				Menguy, Sarah; Frison, Eric; Prochazkova-Carlotti, Martina; Dalle, Stephane; Dereure, Olivier; Boulinguez, Serge; Dalac, Sophie; Machet, Laurent; Ram-Wolff, Caroline; Verneuil, Laurence; Gros, Audrey; Vergier, Beatrice; Beylot-Barry, Marie; Merlio, Jean-Philippe; Pham-Ledard, Anne			Double-hit or dual expression of MYC and BCL2 in primary cutaneous large B-cell lymphomas	MODERN PATHOLOGY			English	Article							RITUXIMAB PLUS CYCLOPHOSPHAMIDE; WHO-EORTC CLASSIFICATION; FOLLICLE CENTER CELL; TREATMENT-OF-CANCER; LEG-TYPE; PROGNOSTIC VALUE; POOR-PROGNOSIS; DISTINCT TYPES; IMMUNOHISTOCHEMISTRY; REARRANGEMENT	In nodal diffuse large B-cell lymphoma, the search for double-hit with MYC and BCL2 and/or BCL6 rearrangements or for dual expression of BCL2 and MYC defines subgroups of patients with altered prognosis that has not been evaluated in primary cutaneous large B-cell lymphoma. Our objectives were to assess the double-hit and dual expressor status in a cohort of 44 patients with primary cutaneous large B-cell lymphoma according to the histological subtype and to evaluate their prognosis relevance. The 44 cases defined by the presence of more than 80% of large B-cells in the dermis corresponded to 21 primary cutaneous follicle centre lymphoma with large cell morphology and 23 primary cutaneous diffuse large B-cell lymphoma, leg type. Thirty-one cases (70%) expressed BCL2 and 29 (66%) expressed MYC. Dual expressor profile was observed in 25 cases (57%) of either subtypes (n = 6 or n = 19, respectively). Only one primary cutaneous follicle centre lymphoma, large-cell case had a double-hit status (2%). Specific survival was significantly worse in primary cutaneous diffuse large B-cell lymphoma, leg type than in primary cutaneous follicle centre lymphoma, large cell (p = 0.021) and for the dual expressor primary cutaneous large B-cell lymphoma group (p = 0.030). Both overall survival and specific survival were worse for patients belonging to the dual expressor primary cutaneous diffuse large B-cell lymphoma, leg type subgroup (p = 0.001 and p = 0.046, respectively). Expression of either MYC and/or BCL2 negatively impacted overall survival (p = 0.017 and p = 0.018 respectively). As the differential diagnosis between primary cutaneous follicle centre lymphoma, large cell and primary cutaneous diffuse large B-cell lymphoma, leg type has a major impact on prognosis, dual-expression of BCL2 and MYC may represent a new diagnostic criterion for primary cutaneous diffuse large B-cell lymphoma, leg type subtype and further identifies patients with impaired survival. Finally, the double-hit assessment does not appear clinically relevant in primary cutaneous large B-cell lymphoma.	[Menguy, Sarah; Prochazkova-Carlotti, Martina; Gros, Audrey; Vergier, Beatrice; Beylot-Barry, Marie; Merlio, Jean-Philippe; Pham-Ledard, Anne] Univ Bordeaux, INSERM, U1053, F-33000 Bordeaux, France; [Menguy, Sarah; Vergier, Beatrice] CHU Bordeaux, Dept Pathol, F-33600 Pessac, France; [Frison, Eric] CHU, ISPED, F-33000 Bordeaux, France; [Frison, Eric] Univ Bordeaux, F-33000 Bordeaux, France; [Dalle, Stephane] CHU Lyon HCL GH Sud, Dept Dermatol, F-69495 Pierre Benite, France; [Dereure, Olivier] Univ Montpellier, Hop St Eloi, Dept Dermatol, F-34295 Montpellier, France; [Dereure, Olivier] INSERM 1058, F-34295 Montpellier, France; [Boulinguez, Serge] CHU Toulouse, Hop Larrey, Dept Dermatol, F-31059 Toulouse 9, France; [Dalac, Sophie] CHU Dijon, Dept Dermatol, Complexe Bocage, F-21079 Dijon, France; [Machet, Laurent] CHU Tours, Hop Trousseau, Dept Dermatol, F-37044 Tours 9, France; [Ram-Wolff, Caroline] Hop St Louis, APHP, Dept Dermatol, F-75475 Paris 10, France; [Verneuil, Laurence] CHU Caen, Hop Clemenceau, Dept Dermatol, F-14033 Caen, France; [Gros, Audrey; Merlio, Jean-Philippe] CHU Bordeaux, Tumor Bank, F-33600 Pessac, France; [Gros, Audrey; Merlio, Jean-Philippe] CHU Bordeaux, Tumor Biol Lab, F-33600 Pessac, France; [Beylot-Barry, Marie; Pham-Ledard, Anne] CHU Bordeaux, Dept Dermatol, F-33000 Bordeaux, France	Merlio, JP (reprint author), Univ Bordeaux, INSERM, U1053, F-33000 Bordeaux, France.; Merlio, JP (reprint author), CHU Bordeaux, Tumor Bank, F-33600 Pessac, France.; Merlio, JP (reprint author), CHU Bordeaux, Tumor Biol Lab, F-33600 Pessac, France.	jp.merlio@u-bordeaux.fr	Dalle, Stephane/E-4552-2018; Frison, Eric/G-5608-2018	Dalle, Stephane/0000-0002-3423-4548; Frison, Eric/0000-0001-5844-1886; Beylot-Barry, Marie/0000-0001-6150-1229; Prochazkova-Carlotti, Martina/0000-0002-7719-7679	Fondation pour la Recherche MedicaleFondation pour la Recherche Medicale; Societe Francaise de Dermatologie [06/2016]; Program Hospitalier de Recherche Clinique from the French National Cancer Institute INCa [11-6236]	SM was supported by a grant from the Fondation pour la Recherche Medicale. This project was partly supported by a grant from the Societe Francaise de Dermatologie number 06/2016 and by the Program Hospitalier de Recherche Clinique from the French National Cancer Institute INCa number 11-6236.	Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Aukema SM, 2011, BLOOD, V117, P2319, DOI 10.1182/blood-2010-09-297879; Barrans S, 2010, J CLIN ONCOL, V28, P3360, DOI 10.1200/JCO.2009.26.3947; Copie-Bergman C, 2009, J CLIN ONCOL, V27, P5573, DOI 10.1200/JCO.2009.22.7058; Dewar R, 2015, ARCH PATHOL LAB MED, V139, P338, DOI 10.5858/arpa.2014-0018-CP; Grange F, 2014, JAMA DERMATOL, V150, P535, DOI 10.1001/jamadermatol.2013.7452; Green TM, 2012, J CLIN ONCOL, V30, P3460, DOI 10.1200/JCO.2011.41.4342; Hallermann C, 2004, J INVEST DERMATOL, V123, P213, DOI 10.1111/j.0022-202X.2004.22720.x; Hallermann C, 2004, J INVEST DERMATOL, V122, P1495, DOI 10.1111/j.0022-202X.2003.12635.x; Hans CP, 2004, BLOOD, V103, P275, DOI 10.1182/blood-2003-05-1545; Hoefnagel JJ, 2005, BLOOD, V105, P3671, DOI 10.1182/blood-2004-04-1594; Hoefnagel JJ, 2003, BRIT J DERMATOL, V149, P1183, DOI 10.1111/j.1365-2133.2003.05649.x; Hu SM, 2013, BLOOD, V121, P4021, DOI 10.1182/blood-2012-10-460063; Johnson NA, 2012, J CLIN ONCOL, V30, P3452, DOI 10.1200/JCO.2011.41.0985; Johnson NA, 2009, BLOOD, V114, P2273, DOI 10.1182/blood-2009-03-212191; Kim YJ, AUSTRALASIAN J DERMA, DOI [10.1111/ajd, DOI 10.1111/AJD]; Kim YH, 2007, BLOOD, V110, P479, DOI 10.1182/blood-2006-10-054601; Klapper W, 2008, LEUKEMIA, V22, P2226, DOI 10.1038/leu.2008.230; Kodama K, 2005, BLOOD, V106, P2491, DOI 10.1182/blood-2005-03-1175; Li SY, 2016, HISTOPATHOLOGY, V68, P1090, DOI 10.1111/his.12884; Lin P, 2012, CANCER-AM CANCER SOC, V118, P1566, DOI 10.1002/cncr.26433; Lucioni M, 2016, CANCER MED-US, V5, P2740, DOI 10.1002/cam4.865; Mareschal S, 2017, J INVEST DERMATOL, V137, P1984, DOI 10.1016/j.jid.2017.04.010; Menguy S, 2016, J INVEST DERMATOL, V136, P1741, DOI 10.1016/j.jid.2016.04.018; Mitteldorf C, 2017, AM J SURG PATHOL, V41, P998, DOI 10.1097/PAS.0000000000000851; Pham-Ledard A, 2015, AM J CLIN PATHOL, V143, P362, DOI 10.1309/AJCP4SUBR4NPSPTN; Pham-Ledard A, 2014, JAMA DERMATOL, V150, P1173, DOI 10.1001/jamadermatol.2014.821; Pham-Ledard A, 2014, MODERN PATHOL, V27, P402, DOI 10.1038/modpathol.2013.156; Plaza JA, 2011, AM J DERMATOPATH, V33, P649, DOI 10.1097/DAD.0b013e3181eeb433; Quesada AE, 2017, MODERN PATHOL, V30, P1688, DOI 10.1038/modpathol.2017.93; Robson A, 2016, HISTOPATHOLOGY, V69, P11, DOI 10.1111/his.12855; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Savage KJ, 2016, BLOOD, V127, P2182, DOI 10.1182/blood-2015-10-676700; Savage KJ, 2009, BLOOD, V114, P3533, DOI 10.1182/blood-2009-05-220095; Senff NJ, 2008, BLOOD, V112, P1600, DOI 10.1182/blood-2008-04-152850; Senff NJ, 2007, J CLIN ONCOL, V25, P1581, DOI 10.1200/JCO.2006.09.6396; Sesques P, 2017, BLOOD, V129, P280, DOI 10.1182/blood-2016-02-636316; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Swerdlow SH, 2013, AM J CLIN PATHOL, V139, P515, DOI 10.1309/AJCPNLC9NC9WTQYY; Szablewski V, 2016, AM J SURG PATHOL, V40, P127, DOI 10.1097/PAS.0000000000000567; Tsang HC, 2017, AM J DERMATOPATH, V39, pE44, DOI 10.1097/DAD.0000000000000738; Vergier A, 2004, AM J SURG PATHOL, V28, P748, DOI 10.1097/01.pas.0000126775.27698.6e; Wiesner T, 2005, AM J SURG PATHOL, V29, P666, DOI 10.1097/01.pas.0000155163.40668.e7; Willemze R, 2005, BLOOD, V105, P3768, DOI 10.1182/blood-2004-09-3502; Xie XY, 2008, MODERN PATHOL, V21, P653, DOI 10.1038/modpathol.2008.30; Ye Q, 2016, ONCOTARGET, V7, P2401, DOI 10.18632/oncotarget.6262; Zinzani PL, 2006, J CLIN ONCOL, V24, P1376, DOI 10.1200/JCO.2005.03.6285	47	5	5	1	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	AUG	2018	31	8					1332	1342		10.1038/s41379-018-0041-7			11	Pathology	Pathology	GR8SZ	WOS:000443000300015	29581544				2019-10-28	
J	Kriegsmann, J; Casadonte, R; Kriegsmann, K; Longuespee, R; Kriegsmann, M				Kriegsmann, Joerg; Casadonte, Rita; Kriegsmann, Katharina; Longuespee, Remi; Kriegsmann, Mark			Mass spectrometry in pathology - Vision for a future workflow	PATHOLOGY RESEARCH AND PRACTICE			English	Review						MALDI Imaging; Mass Spectrometry; Molecular Pathology; Pathology Workflow	MALDI-TOF MS; IMAGING-BASED IDENTIFICATION; DESORPTION IONIZATION-TIME; SCALE TISSUE MICROARRAYS; CELL LUNG-CANCER; CLINICAL MICROBIOLOGY; INTRATUMOR HETEROGENEITY; SPECIES IDENTIFICATION; RELEVANT SIGNALS; HIGH-RESOLUTION	Mass spectrometric (MS) techniques are applied in various areas of medical diagnostics. For the detection of microbiological germs and genetic mutations, MS is a method used in routine. Since MS also allows the analysis of proteins and peptides, it seems an ideal candidate to supplement histopatholological diagnostics. Matrix assisted laser desorption/ionization time-of-flight Imaging MS links molecular analysis of numerous analytes with morphological information about their spatial distribution in cells or tissues. Herein, we review principle MS techniques as well as potential applications in pathology and discuss our vision for a future workflow.	[Kriegsmann, Joerg] MVZ Histol Cytol & Mol Diagnost Trier, Trier, Germany; [Kriegsmann, Joerg; Casadonte, Rita] Proteopath GmbH, Trier, Germany; [Kriegsmann, Katharina] Univ Hosp Heidelberg, Dept Hematol Oncol & Rheumatol, Heidelberg, Germany; [Longuespee, Remi; Kriegsmann, Mark] Univ Hosp Heidelberg, Inst Pathol, Neuenheimer Feld 224, Heidelberg, Germany	Kriegsmann, M (reprint author), Univ Hosp Heidelberg, Inst Pathol, Neuenheimer Feld 224, Heidelberg, Germany.	mark.kriegsmann@med.uni-heidelberg.de	Casadonte, Rita/N-9177-2019	Casadonte, Rita/0000-0002-9054-4786; Kriegsmann, Mark/0000-0002-7319-3646	Eurostars-2 Programme, the German Aerospace Center (DLR); Federal Ministry of Education and Research (BMBF)Federal Ministry of Education & Research (BMBF)	This manuscript was supported by the Eurostars-2 Programme, the German Aerospace Center (DLR) and the Federal Ministry of Education and Research (BMBF).	Alberts D, 2018, PROTEOM CLIN APPL, V12, DOI 10.1002/prca.201700062; Andersson M., 2010, NEUROPROTEOMICS; Baker TC, 2017, CURR OPIN BIOTECH, V43, P62, DOI 10.1016/j.copbio.2016.09.003; Balluff B, 2015, J PATHOL, V235, P3, DOI 10.1002/path.4436; Boggio KJ, 2011, EXPERT REV PROTEOMIC, V8, P591, DOI [10.1586/EPR.11.53, 10.1586/epr.11.53]; Brown NW, 2017, BRIT J BIOMED SCI, V74, P110, DOI 10.1080/09674845.2017.1331521; Buck A, 2017, ADV CANCER RES, V134, P117, DOI 10.1016/bs.acr.2016.11.004; Calligaris D, 2015, INT J MASS SPECTROM, V377, P690, DOI 10.1016/j.ijms.2014.06.024; Caprioli RM, 1997, ANAL CHEM, V69, P4751, DOI 10.1021/ac970888i; Casadonte R, 2017, ADV CANCER RES, V134, P173, DOI 10.1016/bs.acr.2016.11.007; Casadonte R, 2015, ANAL BIOANAL CHEM, V407, P5323, DOI 10.1007/s00216-015-8689-z; Casadonte R, 2014, PROTEOMICS, V14, P956, DOI 10.1002/pmic.201300430; Charretier Y, 2016, PROTEOM CLIN APPL, V10, P964, DOI 10.1002/prca.201600041; Chaurand P, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.O110.004259; Choi JH, 2012, HISTOL HISTOPATHOL, V27, P1439, DOI 10.14670/HH-27.1439; Christiansen MN, 2014, PROTEOMICS, V14, P525, DOI 10.1002/pmic.201300387; Clark AE, 2013, CLIN MICROBIOL REV, V26, P547, DOI 10.1128/CMR.00072-12; Dekker TJA, 2014, J PROTEOME RES, V13, P4730, DOI 10.1021/pr500253j; Djidja MC, 2014, J PROTEOME RES, V13, P2297, DOI 10.1021/pr401056c; Drake RR, 2017, ADV CANCER RES, V134, P85, DOI 10.1016/bs.acr.2016.11.009; Dreisewerd K, 2014, ANAL BIOANAL CHEM, V406, P2261, DOI 10.1007/s00216-014-7646-6; Dufresne M, 2017, ADV CANCER RES, V134, P67, DOI 10.1016/bs.acr.2016.11.003; Duncan MW, 2016, CLIN CHEM, V62, P134, DOI 10.1373/clinchem.2015.239491; Eberlin LS, 2012, CANCER RES, V72, P645, DOI 10.1158/0008-5472.CAN-11-2465; Everest-Dass AV, 2016, MOL CELL PROTEOMICS, V15, P3003, DOI 10.1074/mcp.M116.059816; Feuchtinger A, 2016, HISTOCHEM CELL BIOL, V146, P781, DOI 10.1007/s00418-016-1495-7; Fiorentino M, 2017, EXPERT REV MOL DIAGN, V17, P47, DOI 10.1080/14737159.2017.1266258; Francese S, 2017, ANALYST, V142, P2518, DOI 10.1039/c7an00569e; Gessel MM, 2014, J PROTEOMICS, V107, P71, DOI 10.1016/j.jprot.2014.03.021; Giannini R, 2016, ONCOL REP, V36, P1166, DOI 10.3892/or.2016.4874; Gode D, 2013, ANALYST, V138, P1289, DOI 10.1039/c2an36337b; Gravius S, 2015, INT ORTHOP, V39, P559, DOI 10.1007/s00264-014-2544-2; Griffin J, 2017, HISTOPATHOLOGY, V70, P134, DOI 10.1111/his.12993; Groseclose MR, 2008, PROTEOMICS, V8, P3715, DOI 10.1002/pmic.200800495; Groseclose MR, 2013, ANAL CHEM, V85, P10099, DOI 10.1021/ac400892z; Hajduk J, 2016, CLIN CHIM ACTA, V458, P84, DOI 10.1016/j.cca.2016.04.033; Harvey DJ, 2015, MASS SPECTROM REV, V34, P268, DOI 10.1002/mas.21411; Honisch C, 2007, P NATL ACAD SCI USA, V104, P10649, DOI 10.1073/pnas.0704152104; Horn PJ, 2014, PROG LIPID RES, V54, P32, DOI 10.1016/j.plipres.2014.01.003; Kriegsmann J, 2015, INT J ONCOL, V46, P893, DOI 10.3892/ijo.2014.2788; Kriegsmann M, 2014, HAEMOPHILIA, V20, P446, DOI 10.1111/hae.12377; Kriegsmann M, 2017, BBA-PROTEINS PROTEOM, V1865, P858, DOI 10.1016/j.bbapap.2016.11.018; Kriegsmann M, 2017, J CLIN PATHOL, V70, P417, DOI 10.1136/jclinpath-2016-204017; Kriegsmann M, 2016, MOL CELL PROTEOMICS, V15, P3081, DOI 10.1074/mcp.M115.057513; Kriegsmann M, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0364-3; Loffler H, 2016, ONCOTARGET, V7, P44322, DOI 10.18632/oncotarget.10035; Longuespee R, 2016, PROTEOM CLIN APPL, V10, P701, DOI 10.1002/prca.201500140; Longuespee R, 2016, METHODS, V104, P154, DOI 10.1016/j.ymeth.2015.12.008; Magliacane G, 2015, ONCOTARGET, V6, P30592, DOI 10.18632/oncotarget.5190; Manier ML, 2014, J MASS SPECTROM, V49, P665, DOI 10.1002/jms.3411; Mbughuni Michael M, 2016, EJIFCC, V27, P272; McDonnell LA, 2017, ADV CANCER RES, V134, P283, DOI 10.1016/bs.acr.2016.11.010; Meding S, 2012, J PROTEOME RES, V11, P1996, DOI 10.1021/pr200784p; Morita Y, 2010, CANCER SCI, V101, P267, DOI 10.1111/j.1349-7006.2009.01384.x; Murugaiyan J, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00184; Norris JL, 2013, CHEM REV, V113, P2309, DOI 10.1021/cr3004295; Okamoto I, 2014, ONCOTARGET, V5, P2293, DOI 10.18632/oncotarget.1906; Patel R, 2013, CLIN CHEM, V59, P340, DOI 10.1373/clinchem.2012.183558; Paueksakon P, 2014, HUM PATHOL, V45, P1445, DOI 10.1016/j.humpath.2014.02.020; Petzold J, 2015, Z RHEUMATOL, V74, P438, DOI 10.1007/s00393-014-1468-y; Pfarr N, 2016, GENE CHROMOSOME CANC, V55, P30, DOI 10.1002/gcc.22297; Powers TW, 2015, BIOMOLECULES, V5, P2554, DOI 10.3390/biom5042554; Quanico J, 2017, METHODS MOL BIOL, V1598, P21, DOI 10.1007/978-1-4939-6952-4_2; Rocha B, 2017, NAT REV RHEUMATOL, V13, P52, DOI 10.1038/nrrheum.2016.184; Rompp A, 2011, ANAL BIOANAL CHEM, V401, P65, DOI 10.1007/s00216-011-4990-7; Said SM, 2013, CLIN J AM SOC NEPHRO, V8, P1515, DOI 10.2215/CJN.10491012; Schone C, 2013, CLIN BIOCHEM, V46, P539, DOI 10.1016/j.clinbiochem.2013.01.018; Schwamborn K, 2017, BBA-PROTEINS PROTEOM, V1865, P776, DOI 10.1016/j.bbapap.2016.10.014; Sethi S, 2013, CURR OPIN NEPHROL HY, V22, P273, DOI 10.1097/MNH.0b013e32835fe37c; Sparvero LJ, 2012, CHEM PHYS LIPIDS, V165, P545, DOI 10.1016/j.chemphyslip.2012.06.001; Stenzinger A, 2014, RADIOLOGE, V54, P124, DOI 10.1007/s00117-013-2546-x; Steurer S, 2014, UROL ONCOL-SEMIN ORI, V32, P1225, DOI 10.1016/j.urolonc.2014.06.007; Steurer S, 2014, ANTICANCER RES, V34, P2255; Steurer S, 2013, INT J CANCER, V133, P920, DOI 10.1002/ijc.28080; Tian HX, 2016, CANCER BIOL MED, V13, P68, DOI 10.28092/j.issn.2095-3941.2015.0094; van Belkum A, 2015, EXPERT REV PROTEOMIC, V12, P595, DOI 10.1586/14789450.2015.1091731; Willems SM, 2010, J PATHOL, V222, P400, DOI 10.1002/path.2771; Xiu LS, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01510	78	5	5	4	14	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	AUG	2018	214	8					1057	1063		10.1016/j.prp.2018.05.009			7	Pathology	Pathology	GR9QG	WOS:000443104700001	29910062				2019-10-28	
J	Lopez, JI; Pulido, R; Cortes, JM; Angulo, JC; Lawrie, CH				Lopez, Jose, I; Pulido, Rafael; Cortes, Jesus M.; Angulo, Javier C.; Lawrie, Charles H.			Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Clear cell renal cell carcinoma; Immune checkpoint; PD-L1; Immunohistochemistry; Intratumor heterogeneity; Multisite tumor sampling; Targeted therapy	IMMUNE CHECKPOINT INHIBITORS; INTRATUMOR HETEROGENEITY; INTERNATIONAL-SOCIETY; EXPRESSION; METAANALYSIS; EVOLUTION	Intratumor heterogeneity (ITH) detection remains a challenge in modern oncology because it can have a direct impact on the success of new therapies. Anti-PD-1/PD-L1 immunotherapy is an emerging treatment modality that is showing great promise for clear cell renal cell carcinoma (CCRCC) patients with advanced disease. Patient selection for such therapy relies upon the immunohistochemical detection of PD-1/PD-L1, however the degree of ITH for these markers among tumor cells and/or inflammatory mononuclear infiltrates remains unknown. Therefore, we analyzed PD-L1 (SP-142) expression in the tumor inflammatory cells of 22 CCRCC cases with the aim to define the pattern of PD-L1 expression, and to compare the reliability of current tumor sampling protocols (RS) with a multisite tumor sampling strategy (MSTS). While the RS protocol identified 5/22 (22.7%) of cases that were positive for PD-L1 expression, MSTS identified 10/22 (45.45%) of cases. This suggests that RS may miss a proportion of CCRCC patients that might benefit from immunotherapy. In addition, MSTS demonstrated that positive and negative regions of PD-L1 expression are very variable within each tumor.	[Lopez, Jose, I] Cruces Univ Hosp, Dept Pathol, Plaza Cruces S-N, Baracaldo 48903, Bizkaia, Spain; [Lopez, Jose, I; Pulido, Rafael] Biocruces Res Inst, Biomarkers Canc Unit, Baracaldo, Spain; [Lopez, Jose, I] Univ Basque Country, UPV EHU, Dept Med Surg Specialties, Leioa, Spain; [Pulido, Rafael; Cortes, Jesus M.; Lawrie, Charles H.] Basque Fdn Sci, IKERBASQUE, Bilbao, Spain; [Cortes, Jesus M.] Biocruces Res Inst, Quantitat Biomed Unit, Baracaldo, Spain; [Cortes, Jesus M.] Univ Basque Country, UPV EHU, Dept Cell Biol & Histol, Leioa, Spain; [Angulo, Javier C.] Univ Hosp Getafe, Dept Urol, Madrid, Spain; [Angulo, Javier C.] European Univ Madrid, Laureate Univ, Clin Dept, Madrid, Spain; [Lawrie, Charles H.] Biodonostia Res Inst, Mol Oncol, Donostia San Sebastthn, Spain; [Lawrie, Charles H.] Univ Basque Country, UPV EHU, Dept Physiol, Leioa, Spain; [Lawrie, Charles H.] Univ Oxford, Radcliffe Dept Med, Oxford, England	Lopez, JI (reprint author), Cruces Univ Hosp, Dept Pathol, Plaza Cruces S-N, Baracaldo 48903, Bizkaia, Spain.	joseignacio.lopez@osakidetza.eus	Cortes, Jesus/D-9949-2012; Lopez, Jose Ignacio/L-3884-2019	Cortes, Jesus/0000-0002-9059-8194; Lopez, Jose Ignacio/0000-0003-0842-5348; Angulo, Javier/0000-0002-1735-8792	Ministerio de Economia y Competitividad (MINECO), Spain [SAF 2016-79847-R]	This work is supported by the grant SAF 2016-79847-R from Ministerio de Economia y Competitividad (MINECO), Spain.	Alaghehbandan R, 2017, ANN DIAGN PATHOL, V29, P17, DOI 10.1016/j.anndiagpath.2017.04.007; Atkins MB, 2017, ANN ONCOL, V28, P1484, DOI 10.1093/annonc/mdx151; Callea M, 2015, CANCER IMMUNOL RES, V3, P1158, DOI 10.1158/2326-6066.CIR-15-0043; Chang K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02005-7; CORMEN T. H, 2001, INTRO ALGORITHMS; Cortes JM, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00025; Eisenstein M, 2006, NATURE, V441, P1179, DOI 10.1038/4411179a; Ellsworth RE, 2017, SEMIN CELL DEV BIOL, V64, P65, DOI 10.1016/j.semcdb.2016.08.025; Erlmeier F, 2016, MED ONCOL, V33, DOI 10.1007/s12032-016-0833-x; Erramuzpe A, 2018, VIRCHOWS ARCH, V472, P187, DOI 10.1007/s00428-017-2223-y; Gagne A, 2018, AM J SURG PATHOL, V42, P687, DOI 10.1097/PAS.0000000000001013; Gandini S, 2016, CRIT REV ONCOL HEMAT, V100, P88, DOI 10.1016/j.critrevonc.2016.02.001; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Guarch R, 2018, ANN DIAGN PATHOL, V34, P27, DOI 10.1016/j.anndiagpath.2018.01.001; Guarch Rosa, 2016, F1000Res, V5, P2020; Iacovelli R, 2016, TARGET ONCOL, V11, P143, DOI 10.1007/s11523-015-0392-7; Jilaveanu LB, 2014, J CANCER, V5, P166, DOI 10.7150/jca.8167; Khagi Y, 2017, CANCER METAST REV, V36, P179, DOI 10.1007/s10555-016-9652-y; Kristensen VN, 2011, EMBO MOL MED, V3, P183, DOI 10.1002/emmm.201100128; Lopez JI, 2018, ANN DIAGN PATHOL, V34, P89, DOI 10.1016/j.anndiagpath.2018.03.007; Lopez JI, 2017, HUM PATHOL, V64, P1, DOI 10.1016/j.humpath.2017.02.010; Lopez JI, 2013, APMIS, V121, P1187, DOI 10.1111/apm.12073; McGranahan N, 2017, CELL, V170, P825, DOI 10.1016/j.cell.2017.08.012; Ming D, 2008, J CHEM PHYS, V128, DOI 10.1063/1.2834500; Motoshima T, 2017, BMC UROL, V17, DOI 10.1186/s12894-016-0195-x; Nassar A, 2010, APPL IMMUNOHISTO M M, V18, P433, DOI 10.1097/PAI.0b013e3181dddb20; Palsdottir HB, 2012, J UROLOGY, V187, P48, DOI 10.1016/j.juro.2011.09.025; Patel SP, 2015, MOL CANCER THER, V14, P847, DOI 10.1158/1535-7163.MCT-14-0983; Ross K, 2017, CLIN SCI, V131, P2627, DOI 10.1042/CS20160894; Runa F, 2017, Curr Mol Biol Rep, V3, P218, DOI 10.1007/s40610-017-0073-7; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Srigley JR, 2013, AM J SURG PATHOL, V37, P1469, DOI 10.1097/PAS.0b013e318299f2d1; Trpkov K, 2013, AM J SURG PATHOL, V37, P1505, DOI 10.1097/PAS.0b013e31829a85d0; Turajlic S, 2017, NAT REV UROL, V14, P575, DOI 10.1038/nrurol.2017.112; Verbiest A., 2017, CLIN GENITOURIN CANC, DOI [10.1016/j.clgc.2017.10, DOI 10.1016/J.CLGC.2017.10]; Wang Z, 2018, CLIN EXP MED, V18, P165, DOI 10.1007/s10238-018-0488-3; Zaldumbide L, 2015, VIRCHOWS ARCH, V466, P61, DOI 10.1007/s00428-014-1673-8	37	6	6	0	4	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	AUG	2018	214	8					1110	1114		10.1016/j.prp.2018.06.003			5	Pathology	Pathology	GR9QG	WOS:000443104700008	29910061				2019-10-28	
J	Kang, YY; Zhang, Y; Sun, Y				Kang, Yuanyuan; Zhang, Ying; Sun, Yan			Macrophage migration inhibitory factor is a novel prognostic marker for human oral squamous cell carcinoma	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Oral squamous cell carcinomas; Macrophage migration inhibitory factor; CD74; Proliferation; Invasion	HUMAN BREAST-CANCER; FACTOR MIF; INFLAMMATION; EXPRESSION; GROWTH; CD74	Macrophage migration inhibitory factor (MIF) is considered a pro-tumour factor. However, its clinical relevance in oral squamous cell carcinoma (OSCC) remains unclear. The objective of this study was to investigate the expression of MIF and its receptor CD74 in OSCC tissues, and to study the function of MIF in OSCC cells. Tissues of 90 patients with OSCC from the School of Stomatology, China Medical University were collected, and immunohistochemical staining and quantitative reverse transcription polymerase chain reaction were performed for MIF and CD74. The possible correlations between MIF and CD74 and clinical characteristics were analysed. The Kaplan-Meier analysis was used to determine the survival rates of patients. In addition, the proliferation and invasion of OSCC cells were evaluated after transfection with siRNA against MIF. MIF and CD74 levels were significantly higher in tissues of patients with OSCC than in control tissues. Moreover, MIF levels in patients with OSCC were significantly associated with cell differentiation and TNM classification. MIF expression was closely related to CD74 expression. Kaplan-Meier analysis indicated that OSCC patients with high MIF levels showed reduced overall survival and recurrenc-free survival. Furthermore, MIF expression promoted proliferation and invasion of OSCC cells. Collectively, our results reveal that MIF expression is a significant independent prognostic factor for patients with OSCC and may be a novel prognostic marker for OSCC.	China Med Univ, Dept Emergency & Oral med, Sch Stomatol, Shenyang 110001, Liaoning, Peoples R China; Liaoning Inst Dent Res, Shenyang 110001, Liaoning, Peoples R China; Liaoning Prov Key Lab Oral Dis, Shenyang 110001, Liaoning, Peoples R China; Liaoning Prov Translat Med Res Ctr Oral Dis, Shenyang 110001, Liaoning, Peoples R China	Kang, YY (reprint author), China Med Univ, Sch Stomatol, Dept Emergency & Oral Med, 117 Nanjing North St, Shenyang 110002, Liaoning, Peoples R China.	kyandly@sina.com			Natural Science Foundation of Liaoning ProvinceNatural Science Foundation of Liaoning Province [20170541012]; Basic Scientific Research Project of Liaoning University [LFWK201716]; Youth Research Fund of the school of Stomatology, China Medical University [K101593-16-05]	This study was supported by grants from the Natural Science Foundation of Liaoning Province (20170541012), The Basic Scientific Research Project of Liaoning University (LFWK201716) and the Youth Research Fund of the school of Stomatology, China Medical University (K101593-16-05).	Adamali H, 2012, AM J RESP CRIT CARE, V186, P162, DOI 10.1164/rccm.201110-1864OC; Arenberg D, 2010, AM J RESP CRIT CARE, V182, P1030, DOI 10.1164/rccm.201001-0120OC; Bando H, 2002, JPN J CANCER RES, V93, P389, DOI 10.1111/j.1349-7006.2002.tb01269.x; Beswick EJ, 2009, WORLD J GASTROENTERO, V15, P2855, DOI 10.3748/wjg.15.2855; Bucala R, 2007, IMMUNITY, V26, P281, DOI 10.1016/j.immuni.2007.03.005; de Souza MB, 2014, ONCOL LETT, V8, P2267, DOI 10.3892/ol.2014.2513; Donn RP, 2004, J ENDOCRINOL, V182, P1, DOI 10.1677/joe.0.1820001; Duivenvoorden WC, 2013, BRIT J CANCER, V108, P327, DOI 10.1038/bjc.2012.574; Funamizu N, 2013, INT J CANCER, V132, P785, DOI 10.1002/ijc.27736; Grieb G, 2010, DRUG NEWS PERSPECT, V23, P257, DOI 10.1358/dnp.2010.23.4.1453629; Huang XH, 2014, ONCOTARGET, V5, P5570, DOI 10.18632/oncotarget.2141; Pei XJ, 2014, INT J MED SCI, V11, P106, DOI 10.7150/ijms.7264; Pindborg J. J., 1997, WHO INT HIST CLASSIF; Richard V, 2014, ONCOL REP, V32, P523, DOI 10.3892/or.2014.3272; Shekhar Saurabh, 2017, J Oral Maxillofac Pathol, V21, P318, DOI 10.4103/jomfp.JOMFP_98_17; van Zyl Aw, 2012, SADJ, V67, P566; Verjans E, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-230; Wu DW, 2014, CARCINOGENESIS, V35, P1823, DOI 10.1093/carcin/bgu102; Zeng J, 2016, MOL MED REP, V13, P174, DOI 10.3892/mmr.2015.4525; Zhang QM, 2017, EXP THER MED, V14, P2329, DOI 10.3892/etm.2017.4720	20	0	0	0	5	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	AUG	2018	214	8					1192	1198		10.1016/j.prp.2018.06.020			7	Pathology	Pathology	GR9QG	WOS:000443104700020	30041958				2019-10-28	
J	Gutierrez, FJQ; Panizo, A; Tienza, A; Rodriguez, I; Sola, JJ; Temprana-Salvador, J; de Torres, I; Pardo-Mindan, J				Queipo Gutierrez, Francisco Javier; Panizo, Angel; Tienza, Antonio; Rodriguez, Irene; Javier Sola, Jesus; Temprana-Salvador, Jordi; de Torres, Ines; Pardo-Mindan, Javier			Cytogenetic and immunohistochemical study of 42 pigmented microcystic chromophobe renal cell carcinoma (PMChRCC)	VIRCHOWS ARCHIV			English	Article						Chromophobe pigmented; Microcystic; Renal carcinoma; SISH; Cytogenetic	IN-SITU HYBRIDIZATION; COMPARATIVE GENOMIC HYBRIDIZATION; DIFFERENTIAL-DIAGNOSIS; GRADING SYSTEM; ONCOCYTOMA; VARIANT; TUMORS; MELANOMA; KIDNEY; CHROMOSOMES	Pigmented microcystic chromophobe renal cell carcinoma (PMChRCC) is a recently described morphologic variant of ChRCC. We have identified 42 cases in 40 patients in the last 24 years. We have investigated their clinical, morphologic, immunohistochemical, and cytogenetic features. Chromosomal abnormalities of chromosomes 7 and 17 were evaluated by automated dual-color silver-enhanced in situ hybridization on paraffin-embedded tissue. Chromosomal imbalance was defined on the basis of changes in both chromosomal index and signal distribution. The main age was 60.20 years, being 34 males and 6 women. The mean tumor diameter was 4.84 cm, with 39 intrarenal tumors. Grossly, the tumors were solid with a brown dark colored. Microscopically, tumors consisted of pale and eosinophilic cells arranged in microcysts or microalveolar in a cribriform pattern; there were microcalcifications and a dark brown pigment, mostly extracellular. One case showed sarcomatoid transformation. All tumors were positive for epithelial membrane antigen (EMA), Claudin 7, and E-cadherin. Monosomy of 7 and 17 chromosomes was present in 1/36 cases and 2/37 cases, respectively. Polysomy of chromosome 7 and 17 was found in 26/36 cases and in 4/37, respectively. With a median follow-up of 74.05 months, 37 patients were alive without disease and two were alive with disease progression. PMChRCCs expand the morphologic spectrum of the ChRCC with an unusual immunohistochemical profile. Cytogenetically, they showed monosomy to chromosome (CHR) 17 as other ChRCCs and polysomy of CHR 7 infrequent to ChRCCs. We present the probably largest series of PMCRCC, confirming their low aggressive behavior, with exceptional sarcomatoid transformation and distant metastases.	[Queipo Gutierrez, Francisco Javier] Hosp San Jorge, Ave Martinez de Velasco 36, Huesca 22004, Spain; [Panizo, Angel] Complejo Hosp Navarra, Calle Irunlarrea 3, Pamplona 31008, Spain; [Tienza, Antonio] Hosp Univ Son Espases, Carr Valldemossa 79, Palma De Mallorca, Islas Baleares, Spain; [Rodriguez, Irene] Hosp Univ HM Puerta Sur, Ave Carlos V 70, Mostoles 28938, Spain; [Javier Sola, Jesus] Hosp San Pedro, Calle Piqueras 98, Logrono 26006, La Rioja, Spain; [Temprana-Salvador, Jordi; de Torres, Ines] Hosp Univ Vall DHebron, Passeig Vall dHebron 119-129, Barcelona 08035, Spain; [Pardo-Mindan, Javier] Univ Navarra, Calle Irunlarrea 1, Pamplona 31008, Spain	Gutierrez, FJQ (reprint author), Hosp San Jorge, Ave Martinez de Velasco 36, Huesca 22004, Spain.	patxiqueipo@gmail.com		Tienza, Antonio/0000-0003-0183-5598; Temprana Salvador, Jordi/0000-0001-9516-1680			Argani P, 2007, AM J SURG PATHOL, V31, P1149, DOI 10.1097/PAS.0b013e318031ffff; Argani P, 2012, AM J SURG PATHOL, V36, P1516, DOI 10.1097/PAS.0b013e3182613d8f; Argani P, 2010, AM J SURG PATHOL, V34, P1295, DOI 10.1097/PAS.0b013e3181e8ce5b; Argani P, 2009, AM J SURG PATHOL, V33, P609, DOI 10.1097/PAS.0b013e31818fbdff; Barocas DA, 2007, BJU INT, V99, P290, DOI 10.1111/j.1464-410X.2006.06607.x; Bing ZY, 2013, ANN DIAGN PATHOL, V17, P58, DOI 10.1016/j.anndiagpath.2012.07.002; Brunelli M, 2005, MODERN PATHOL, V18, P161, DOI 10.1038/modpathol.3800286; Brunelli M, 2010, AM J CLIN PATHOL, V133, P116, DOI 10.1309/AJCPSATJTKBI6J4N; Carvalho JC, 2011, HISTOPATHOLOGY, V58, P169, DOI 10.1111/j.1365-2559.2011.03753.x; Delahunt B, 2013, AM J SURG PATHOL, V37, P311, DOI 10.1097/PAS.0b013e318270f71c; DHINGRA K, 1994, CYTOMETRY, V16, P100, DOI 10.1002/cyto.990160203; Dundr P, 2007, PATHOL RES PRACT, V203, P593, DOI 10.1016/j.prp.2007.05.005; Gill AJ, 2014, AM J SURG PATHOL, V38, P1588, DOI 10.1097/PAS.0000000000000292; Gill AJ, 2011, AM J SURG PATHOL, V35, P1578, DOI 10.1097/PAS.0b013e318227e7f4; Hes O, 2005, VIRCHOWS ARCH, V446, P383, DOI 10.1007/s00428-004-1187-x; Kuroda N, 2013, MED MOL MORPHOL, V46, P49, DOI 10.1007/s00795-012-0007-7; Lhermitte B, 2012, VIRCHOWS ARCH, V461, P13, DOI 10.1007/s00428-012-1255-6; Lin F, 2004, APPL IMMUNOHISTO M M, V12, P153; Padilha M, 2013, HISTOPATHOLOGY, V62, P941, DOI 10.1111/his.12106; Michal M, 1998, Ann Diagn Pathol, V2, P149, DOI 10.1016/S1092-9134(98)80001-4; Molinie V, 2006, HUM PATHOL, V37, P698, DOI 10.1016/j.humpath.2006.01.012; Monzon FA, 2009, ARCH PATHOL LAB MED, V133, P1917, DOI 10.1043/1543-2165-133.12.1917; Ohe C, 2012, MED MOL MORPHOL, V45, P98, DOI 10.1007/s00795-011-0546-3; Foix MP, 2016, VIRCHOWS ARCH, V469, P669, DOI 10.1007/s00428-016-2022-x; Peckova K, 2015, ANN DIAGN PATHOL, V19, P261, DOI 10.1016/j.anndiagpath.2015.05.001; Petersson F, 2010, VIRCHOWS ARCH, V456, P355, DOI 10.1007/s00428-010-0898-4; Ribalta T, 2000, HUM PATHOL, V31, P516, DOI 10.1053/hp.2000.6717; Russell AJ, 1999, BRIT J CANCER, V81, P684, DOI 10.1038/sj.bjc.6690748; Sandinha MT, 2004, BRIT J OPHTHALMOL, V88, P1527, DOI 10.1136/bjo.2004.044768; Siracusano S, 2012, BJU INT, V110, pE443, DOI 10.1111/j.1464-410X.2012.11121.x; Sperga M, 2013, VIRCHOWS ARCH, V463, P563, DOI 10.1007/s00428-013-1457-6; Tan MH, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-196; THOENES W, 1988, J PATHOL, V155, P277, DOI 10.1002/path.1711550402; THOENES W, 1985, VIRCHOWS ARCH B, V48, P207, DOI 10.1007/BF02890129; Truong LD, 2011, ARCH PATHOL LAB MED, V135, P92, DOI 10.1043/2010-0478-RAR.1; Vieira J, 2010, GENE CHROMOSOME CANC, V49, P935, DOI 10.1002/gcc.20805	36	0	0	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	AUG	2018	473	2					209	217		10.1007/s00428-018-2389-y			9	Pathology	Pathology	GO7VP	WOS:000440285100009	29931469				2019-10-28	
J	Eichhorn, P; Andraschke, U; Dross, F; Geppert, CI; Hartmann, A; Rau, TT				Eichhorn, Philip; Andraschke, Udo; Dross, Fritz; Geppert, Carol, I; Hartmann, Arndt; Rau, Tilman T.			Restoration of an academic historical gross pathology collection-refreshed impact on current medical teaching?	VIRCHOWS ARCHIV			English	Article						Macroscopy; Skill-oriented teaching; Historical collection; Survey; Autopsy	ANATOMICAL COLLECTION; AUTOPSY; EDUCATION; ATTITUDES; RELATIVES; FIXATION; REGISTRY	The declaration of Leiden pronounces the demand to conserve pathological-anatomical collections as cultural heritage. Likewise, the Institute of Pathology of the Friedrich-Alexander-University Erlangen-Nuremberg owns macroscopic pathological-anatomical specimens reaching back over 150 years. The purpose of this work is to examine the impact. meaning, and perception of such historical preparations during the current medical curriculum. Additionally, the experiences from the renovation process can be used as a template for other institutes. All preparations were documented, photographed, and catalogued in an electronic database. During a restoration period, a series of didactically suitable specimens were professionally restored. Hereby, the help of a special course of interested students was admitted. In a second step, the specimens were integrated into the regular teaching of students in macroscopic pathology. An evaluation was carried out on two student cohorts with and without historical specimens by means of a questionnaire with 23 items and two free text fields. In total, 1261 specimens were registered covering diseases from almost the complete human body with a strong representation of the cardiovascular, urinary, gastrointestinal, and central nervous systems. Hereby, exceptional rare and untreated cases with medical relevance could be found and stepwise implemented into the curriculum. The student evaluation positively addressed that the courses became livelier and interactive. Furthermore, a more comprehensive overview and a better understanding of the macroscopic pathology were appreciated. However, more self-study time with the specimen was demanded. The authenticity of historical specimens contrasts with the tendency to carry out virtual "online" didactic methods. The stereoscopic view on often untreated and, therefore, unbiased cases enhances a skill-oriented deeper understanding of diseases. In conclusion, historical specimens regain interest and even didactic value, especially in an era of declining autopsy rates.	[Eichhorn, Philip; Geppert, Carol, I; Hartmann, Arndt; Rau, Tilman T.] Friedrich Alexander Univ Erlangen Nuremberg, Inst Pathol, Krankenhausstr 8, D-91054 Erlangen, Germany; [Andraschke, Udo] Friedrich Alexander Univ Erlangen Nuremberg, Cent Curator Acad Collect, Schlosspl 4, D-91054 Erlangen, Germany; [Dross, Fritz] Friedrich Alexander Univ Erlangen Nuremberg, Inst Hist & Eth Med, Gluckstr 10, D-91054 Erlangen, Germany; [Rau, Tilman T.] Univ Bern, Inst Pathol, Murtenstr 31, CH-3008 Bern, Switzerland	Rau, TT (reprint author), Friedrich Alexander Univ Erlangen Nuremberg, Inst Pathol, Krankenhausstr 8, D-91054 Erlangen, Germany.; Rau, TT (reprint author), Univ Bern, Inst Pathol, Murtenstr 31, CH-3008 Bern, Switzerland.	Tilman.Rau@pathology.unibe.ch			Mercator Foundation; "fund for teaching expenses" of the Friedrich-Alexander-University Erlangen-Nuremberg; "Universitatsbund" of the Friedrich-Alexander-University Erlangen-Nuremberg	We want to thank Anthony Simpson for initial preparation assistance during the pilot phase of the project and Ute Meinel for perfecting, maintaining, and documenting the preparation protocols as well as students' teaching. Winfried Neuhuber as head of the Anatomical Institute I merits thanks for the interim housing of the historical specimens and space for the restoration processes. Navena Widulin and Thomas Schnalke from the Berlin Museum of Medical History provided excellent support and information for all restoration steps. The project was funded as one out of nine projects of the nationwide "SammLehr" initiative of the Mercator Foundation, which was opened to didactic academic collections of all kinds. Further funding was achieved by the local "fund for teaching expenses" and the "Universitatsbund" of the Friedrich-Alexander-University Erlangen-Nuremberg.	Bamber AR, 2015, ADV MED EDUC PRACT, V6, P159, DOI 10.2147/AMEP.S46669; Barbian L T, 2000, Ann Diagn Pathol, V4, P170, DOI 10.1016/S1092-9134(00)90041-8; Bieri U, 2015, VIRCHOWS ARCH, V466, P637, DOI 10.1007/s00428-015-1734-7; BOGERTS B, 1988, ARCH GEN PSYCHIAT, V45, P774; Burton JL, 2003, MED EDUC, V37, P1073, DOI 10.1046/j.1365-2923.2003.01710.x; Burton JL, 2007, LANCET, V369, P1471, DOI 10.1016/S0140-6736(07)60376-6; Chariot P, 2000, ARCH PATHOL LAB MED, V124, P739; Croy MJ, 1998, TECHNOL SOC, V20, P317, DOI 10.1016/S0160-791X(98)00016-5; Earle KM, 1981, INT ACAD PATHOLOGY U; Folberg R, 2002, HUM PATHOL, V33, P3, DOI 10.1053/hupa.2002.30226; Ford J, 2015, HUM PATHOL, V46, P637, DOI 10.1016/j.humpath.2015.01.016; Frommer M, 2011, MED EDUC, V45, P511, DOI 10.1111/j.1365-2923.2011.03965.x; Ghosh SK, 2017, ANAT SCI INT, V92, P305, DOI 10.1007/s12565-016-0373-7; Hamilton PW, 2012, APMIS, V120, P305, DOI 10.1111/j.1600-0463.2011.02869.x; Hartmann S, 2011, HISTOPATHOLOGY, V59, P1173, DOI 10.1111/j.1365-2559.2011.04069.x; Hayashi S, 2016, ANAT SCI INT, V91, P1, DOI 10.1007/s12565-015-0299-5; Huhns M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135297; Kaiserling C, 1922, VIRCHOWS ARCH A, V237, P467, DOI 10.1007/BF01944113; Kessler R, 1989, PRAPARATOR, V35, P161; Klopfleisch R, 2013, VET PATHOL, V50, P191, DOI 10.1177/0300985812441031; Knoeff H, 2012, LEIDEN DECLARATION H; Kovari E, 2011, ANN NY ACAD SCI, V1225, pE131, DOI 10.1111/j.1749-6632.2011.06008.x; Lugli A, 1999, LANCET, V354, P1391, DOI 10.1016/S0140-6736(05)76249-8; Marshall R, 2004, MED EDUC, V38, P302, DOI 10.1046/j.1365-2923.2004.01775.x; Mathieson W, 2016, AM J CLIN PATHOL, V146, P25, DOI 10.1093/ajcp/aqw023; Melato M., 2002, Pathologica (Genoa), V94, P130; Moch H, 2011, Pathologe, V32 Suppl 2, P282, DOI 10.1007/s00292-011-1521-4; Morcke AM, 2013, ADV HEALTH SCI EDUC, V18, P851, DOI 10.1007/s10459-012-9405-9; Morgagni GB, 1767, SEDIBUS CAUSIS MORBO; Morris MC, 2012, MED EDUC ONLINE, V17, DOI 10.3402/meo.v17i0.18398; Nesi Gabriella, 2007, Med Secoli, V19, P295; Oluwasola OA, 2009, ARCH PATHOL LAB MED, V133, P78, DOI 10.1043/1543-2165-133.1.78; Paluchowski P, 2016, POL J PATHOL, V67, P207, DOI [10.5114/PJP.2016.63771, 10.5114/pjp.2016.63771]; Panzer S, 2012, CLIN ANAT, V25, P299, DOI 10.1002/ca.21240; Patzak B, 2013, WIEN MED WOCHENSCHR, V163, P310, DOI 10.1007/s10354-013-0211-7; Ruhli FJ, 2003, AM J PHYS ANTHROPOL, V121, P15, DOI 10.1002/ajpa.10219; Tsitsikas DA, 2011, J CLIN PATHOL, V64, P412, DOI 10.1136/jcp.2010.086645; Turnbull A, 2015, J CLIN PATHOL, V68, P601, DOI 10.1136/jclinpath-2014-202700; Weber C, 2017, WISSENSCHAFTLICHE SA; Zenker FA, 1867, DTSCH ARCH KLINISCHE, P116; Zwijnenberg R, 2018, CULTURES COLLECTING	41	0	0	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	AUG	2018	473	2					219	228		10.1007/s00428-018-2369-2			10	Pathology	Pathology	GO7VP	WOS:000440285100010	29748715				2019-10-28	
J	Suzuki, Y; Ichihara, S; Kawasaki, T; Yanai, H; Kitagawa, S; Shimoyama, Y; Nakamura, S; Nakaguro, M				Suzuki, Yuka; Ichihara, Shu; Kawasaki, Tomonori; Yanai, Hiroyuki; Kitagawa, Satoshi; Shimoyama, Yoshie; Nakamura, Shigeo; Nakaguro, Masato			beta-catenin (CTNNB1) mutation and LEF1 expression in sinonasal glomangiopericytoma (sinonasal-type hemangiopericytoma)	VIRCHOWS ARCHIV			English	Article						Sinonasal glomangiopericytoma; beta-catenin; CTNNB1; LEF1	PERIVASCULAR MYOID DIFFERENTIATION; SOLITARY FIBROUS TUMOR; NUCLEAR EXPRESSION; MIMICS	Sinonasal glomangiopericytoma (SN-GPC) is an uncommon mesenchymal tumor with myoid differentiation. Recently, mutations in exon 3 of the gene coding for beta-catenin (CTNNB1) and its nuclear expression were discovered in SN-GPC. beta-catenin protein is a key regulatory molecule of the canonical Wnt signaling pathway. The expression of beta-catenin target proteins is not well characterized in SN-GPC. We examined three SN-GPCs by immunohistochemistry and CTNNB1 mutation analysis. All cases expressed nuclear beta-catenin. We identified CTNNB1 exon 3 mutations in two analyzable cases. Lymphoid enhancerbinding factor 1 (LEF1), a protein downstream from beta-catenin, was also expressed in all cases. Our results further characterized the activation of the Wnt signaling pathway caused by CTIVNB1 exon 3 mutation and suggest the utility of LEF 1 immunohistochemistry in the differential diagnosis of SN-GPC.	[Suzuki, Yuka; Shimoyama, Yoshie; Nakamura, Shigeo; Nakaguro, Masato] Nagoya Univ Hosp, Dept Pathol & Clin Labs, Showa Ku, 65 Tsururnai Cho, Nagoya, Aichi 4668560, Japan; [Ichihara, Shu; Kawasaki, Tomonori] Nagoya Med Ctr, Dept Pathol, Nagoya, Aichi, Japan; [Yanai, Hiroyuki] Okayama Univ Hosp, Dept Pathol, Okayama, Japan; [Kitagawa, Satoshi] Toyota Mem Hosp, Dept Pathol, Toyota, Japan	Nakaguro, M (reprint author), Nagoya Univ Hosp, Dept Pathol & Clin Labs, Showa Ku, 65 Tsururnai Cho, Nagoya, Aichi 4668560, Japan.	mnakaguro@med.nagoya-u.ac.jp	Ichihara, Shu/L-2371-2019; Nakamura, Shigeo/I-1571-2012	Ichihara, Shu/0000-0001-6596-5725; NAKAGURO, MASATO/0000-0001-6987-3043; Yanai, Hiroyuki/0000-0002-9989-5144	National Hospital Organization	This study was supported, in part, by a Grant-in-Aid for Clinical Research from the National Hospital Organization.	Agaimy A, 2014, HISTOPATHOLOGY, V65, P667, DOI 10.1111/his.12452; Bilodeau EA, 2015, HUM PATHOL, V46, P255, DOI 10.1016/j.humpath.2014.10.018; COMPAGNO J, 1976, AM J CLIN PATHOL, V66, P672; Doyle LA, 2014, MODERN PATHOL, V27, P390, DOI 10.1038/modpathol.2013.164; El-Naggar A, 2017, WHO CLASSIFICATION H; Granter SR, 1998, AM J SURG PATHOL, V22, P513, DOI 10.1097/00000478-199805000-00001; Haller F, 2015, AM J PATHOL, V185, P563, DOI 10.1016/j.ajpath.2014.10.019; Huss S, 2013, HISTOPATHOLOGY, V62, P294, DOI 10.1111/j.1365-2559.2012.04355.x; Jo VY, 2017, HEAD NECK PATHOL, V11, P119, DOI 10.1007/s12105-016-0737-2; Lasota J, 2015, MODERN PATHOL, V28, P715, DOI 10.1038/modpathol.2014.161; Pauli J, 2008, PATHOLOGY, V40, P396, DOI 10.1080/00313020802035857; Taketo MM, 2004, NAT GENET, V36, P320, DOI 10.1038/ng0404-320; Thompson LDR, 2003, AM J SURG PATHOL, V27, P737, DOI 10.1097/00000478-200306000-00004; Tse LLY, 2002, HISTOPATHOLOGY, V40, P510, DOI 10.1046/j.1365-2559.2002.01396.x; Zou YR, 2018, APPL IMMUNOHISTO M M, V26, P648, DOI 10.1097/PAI.0000000000000487	15	0	0	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	AUG	2018	473	2					235	239		10.1007/s00428-018-2370-9			5	Pathology	Pathology	GO7VP	WOS:000440285100012	29736797				2019-10-28	
J	Meier, M; Andersen, KJ; Knudsen, AR; Nyengaard, JR; Hamilton-Dutoit, S; Mortensen, FV				Meier, Michelle; Andersen, Kasper Jarlhelt; Knudsen, Anders Riegels; Nyengaard, Jens Randel; Hamilton-Dutoit, Stephen; Mortensen, Frank Viborg			Adaptive growth changes in the liver remnant are affected by the size of hepatectomy in rats	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY			English	Article						hepatic surgery; hepatocyte hyperplasia; hepatocyte hypertrophy; liver regeneration; posthepatectomy liver failure	FUNCTION TESTS; REGENERATION; MODEL; STEREOLOGY	In this study we investigated the dynamics of hepatocyte hyperplasia and hypertrophy in rats subjected to increasing sizes of partial hepatectomy (PH). A total of 104 rats were randomized according to the size of PH. On postoperative days (PODs) 1, 3 and 5, blood was drawn and the remnant liver removed for stereological analysis. Liver parameters and regeneration rate were significantly affected by size of PH. On POD 1, hepatocyte volumes had increased significantly in all PH groups. On POD 3, all groups showed hepatocyte volumes approximating baseline. On POD 5, hepatocyte volumes were significantly lower in PH (90) than in baseline, sham and PH (30) rats. Increasing hepatocyte proliferation was not observed following PH (30). Following PH (70), cell proliferation was significantly elevated on PODs 1 and 3, and following PH (90) on PODs 3 and 5. In conclusion, general hypertrophy of hepatocytes after different size of PH was followed by hepatocyte proliferation only in the liver remnant of PH (70) and PH (90).	[Meier, Michelle; Andersen, Kasper Jarlhelt; Knudsen, Anders Riegels; Mortensen, Frank Viborg] Aarhus Univ Hosp, Dept Surg Gastroenterol, Sect Upper Gastrointestinal & Hepatopancreticobil, Noerrebrogade 44,Bldg 1C, DK-8000 Aarhus, Denmark; [Nyengaard, Jens Randel] Aarhus Univ, Ctr Stochast Geometry & Adv Bioimaging, Ctr Mol Morphol, Sect Stereol & Microscopy,Dept Clin Med, Aarhus, Denmark; [Hamilton-Dutoit, Stephen] Aarhus Univ Hosp, Inst Pathol, Aarhus, Denmark	Andersen, KJ (reprint author), Aarhus Univ Hosp, Dept Surg Gastroenterol, Sect Upper Gastrointestinal & Hepatopancreticobil, Noerrebrogade 44,Bldg 1C, DK-8000 Aarhus, Denmark.	kasperjarlheltandersen@gmail.com		Meier, Michelle/0000-0002-8515-5401; Hamilton-Dutoit, Stephen/0000-0003-2158-3885; Andersen, Kasper Jarlhelt/0000-0002-5290-7515	Villum Foundation	Villum Foundation	Andersen KJ, 2013, INT J SURG, V11, P903, DOI 10.1016/j.ijsu.2013.07.009; Boyce RW, 2010, TOXICOL PATHOL, V38, P1011, DOI 10.1177/0192623310385140; Collier J, 2002, CLIN MED, V2, P406, DOI 10.7861/clinmedicine.2-5-406; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; GAUB J, 1984, HEPATOLOGY, V4, P902, DOI 10.1002/hep.1840040519; Higgins GM, 1931, ARCH PATHOL, V12, P186; Hoekstra LT, 2013, ANN SURG, V257, P27, DOI 10.1097/SLA.0b013e31825d5d47; Hosseini-Sharifabad M, 2007, J NEUROSCI METH, V162, P206, DOI 10.1016/j.jneumeth.2007.01.009; Hyder O, 2013, J AM COLL SURGEONS, V216, P1049, DOI 10.1016/j.jamcollsurg.2013.01.004; Inderbitzin D, 2006, MICROSURG, V26, P465, DOI 10.1002/micr.20271; Kim RD, 2001, J CELL BIOCHEM, V83, P56, DOI 10.1002/jcb.1205; Lintoiu-Ursut B, 2015, J Med Life, V8 Spec Issue, P12; Madrahimov N, 2006, ANN SURG, V244, P89, DOI 10.1097/01.sla.0000218093.12408.0f; Meier M, 2016, J SURG RES, V205, P76, DOI 10.1016/j.jss.2016.06.020; Michalopoulos GK, 2013, COMPR PHYSIOL, V3, P485, DOI 10.1002/cphy.c120014; Miyaoka Y, 2012, CURR BIOL, V22, P1166, DOI 10.1016/j.cub.2012.05.016; Muehlfeld C, 2010, CARDIOVASC PATHOL, V19, P65, DOI 10.1016/j.carpath.2008.10.015; Nyengaard JR, 1999, J AM SOC NEPHROL, V10, P1100; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; POULSEN HE, 1985, EUR J CLIN INVEST, V15, P285, DOI 10.1111/j.1365-2362.1985.tb00186.x; Rasmusson A, 2013, J MICROSC-OXFORD, V250, P88, DOI 10.1111/jmi.12022; SCHMIDT E, 1993, CLIN BIOCHEM, V26, P241, DOI 10.1016/0009-9120(93)90123-N; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9	23	1	1	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-9673	1365-2613		INT J EXP PATHOL	Int. J. Exp. Pathol.	AUG	2018	99	4					150	157		10.1111/iep.12282			8	Pathology	Pathology	GU8TE	WOS:000445614400001	30198172	Green Published			2019-10-28	
J	Hammadi, S; Chan, O; Abdellali, M; Medjerab, M; Agoun, H; Bellahreche, Z; Khalkhal, A; Dahmani, Y				Hammadi, Soumia; Chan, Owen; Abdellali, Mohamed; Medjerab, Maha; Agoun, Hadjer; Bellahreche, Zineb; Khalkhal, Ali; Dahmani, Yasmina			Hyperactivation of the hypothalamo-pituitary-adrenocortical axis in streptozotocin-diabetic gerbils (Gerbillus gerbillus)	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY			English	Article						adrenal gland; cortisol; Gerbillus gerbillus; HPA axis; streptozotocin; type 1 diabetes	ADRENAL-FUNCTION; ANIMAL-MODELS; RATS; RESPONSIVENESS; MELLITUS; CORTEX; CELLS	This study was designed to investigate the HPA-axis impairment in the streptozotocin (STZ)-diabetic gerbils (Gerbillus gerbillus). Twenty-six male gerbils (body weight 27g) were divided into 3 groups: vehicle control (n=10), 2days of diabetes (n=09) and 30days of diabetes (n=07). The latter 2 groups received an intraperitoneal injection of STZ (150mg/kg of body weight). At 2 and 30days of diabetes, streptozotocin-diabetic gerbils underwent a retro-orbital puncture for assessment of biochemical and hormonal parameters. Subsequently the animals were decapitated and the adrenal glands were removed, weighed and processed for light microscopy and stereology. Nondiabetic control gerbils that had been injected with citrate buffer were examined as a comparison. At 2days of diabetes, STZ gerbils exhibited symptoms that are characteristic of human diabetes type 1. The adrenal gland showed significant increase in weight, associated with a larger cortex layer, hypertrophy of the fasciculate cells and a significant decrease in the nucleocytoplasmic index. These changes were associated with higher plasma ACTH and cortisol concentrations compared to nondiabetic controls. At 30days postdiabetes, ACTH levels remained elevated, whereas cortisol levels decreased compared to the early stage of diabetes. Histological analysis revealed the existence of a band of connective tissue (collagen) that separates the cortical and medullary zones and is not present in humans or laboratory rodents, which represents a striking change seen throughout the disease. STZ-induced diabetes mellitus in Gerbillus gerbillus resulted in hyperactivation of the HPA axis in the early stages of diabetes mellitus which did not persist into the final stages of the disease, suggesting a possible reduction in adrenocortical sensitivity over time.	[Hammadi, Soumia; Medjerab, Maha; Agoun, Hadjer; Bellahreche, Zineb; Khalkhal, Ali; Dahmani, Yasmina] USTHB, FSB, Dept Biol & Physiol Organisms LBPO Nutr Metab, BP 32, Algiers 16111, Algeria; [Chan, Owen] Univ Utah, Sch Med, Dept Internal Med Metab & Diabet, Div Endocrinol, Salt Lake City, UT USA; [Abdellali, Mohamed] CHU Hussein Dey Ex Parnet, Serv Pathol & Anat, Algiers, Algeria	Hammadi, S (reprint author), USTHB, FSB, Dept Biol & Physiol Organisms LBPO Nutr Metab, BP 32, Algiers 16111, Algeria.	soumiahammadi@gmail.com			National Committee for Evaluation and Programming of University Research (C.N.E.P.R.U.) of the Algerian Government [F00220130075]	The authors would like to thank Professor Owen Chan for his review of the article and his advice. His help is greatly appreciated. The present study was approved by The National Committee for Evaluation and Programming of University Research (C.N.E.P.R.U.) of the Algerian Government (No. F00220130075).	ABDALLA MA, 1989, ACTA MORPHOL NEER SC, V26, P269; Almeida H, 2004, ANN NY ACAD SCI, V1019, P135, DOI 10.1196/annals.1297.024; Astort F, 2009, DIABETES-METAB RES, V25, P477, DOI 10.1002/dmrr.978; BROWN FM, 1990, J CLIN ENDOCR METAB, V71, P1491, DOI 10.1210/jcem-71-6-1491; CAMERON OG, 1984, ARCH GEN PSYCHIAT, V41, P1090; Chan O, 2003, Minerva Endocrinol, V28, P87; Chan O, 2002, ENDOCRINOLOGY, V143, P1761, DOI 10.1210/en.143.5.1761; Chan O, 2001, ENDOCRINOLOGY, V142, P4872, DOI 10.1210/en.142.11.4872; Cymeryng CB, 1999, ENDOCRINOLOGY, V140, P2962, DOI 10.1210/en.140.7.2962; Dallman MF, 1999, ENDOCRINOLOGY, V140, P4015, DOI 10.1210/en.140.9.4015; DENICOLA AF, 1977, HORM METAB RES, V9, P469, DOI 10.1055/s-0028-1093502; DENICOLA AF, 1976, HORM METAB RES, V8, P388, DOI 10.1055/s-0028-1093620; Elahi-Moghaddam Z, 2013, J DIABETES METAB DIS, V12, DOI 10.1186/2251-6581-12-9; Golden SH, 2007, J CLIN ENDOCR METAB, V92, P1358, DOI 10.1210/jc.2006-2674; Gylling H, 2004, DIABETES, V53, P2217, DOI 10.2337/diabetes.53.9.2217; Inouye K, 2002, DIABETES NUTR METAB, V15, P348; Kanter JE, 2012, P NATL ACAD SCI USA, V109, pE715, DOI 10.1073/pnas.1111600109; King AJF, 2012, BRIT J PHARMACOL, V166, P877, DOI 10.1111/j.1476-5381.2012.01911.x; Magarinos AM, 2000, P NATL ACAD SCI USA, V97, P11056, DOI 10.1073/pnas.97.20.11056; Mahar Y, 2012, PJMHS, V6, P843; Miller WL, 2005, CLIN PEDIAT ENDOCRIN, P293; Poulet S, 2004, THESIS, P4041; REBUFFAT P, 1988, VIRCHOWS ARCH B, V56, P13, DOI 10.1007/BF02889996; Rees DA, 2005, DIABETIC MED, V22, P359, DOI 10.1111/j.1464-5491.2005.01499.x; Repetto EM, 2010, ENDOCRINOLOGY, V151, P203, DOI 10.1210/en.2009-0592; Revsin Y, 2008, ENDOCRINOLOGY, V149, P3531, DOI 10.1210/en.2007-1340; Sachin A., 2009, GLOBAL J PHARM, V3, P81; Simunkova Katerina, 2010, Cas Lek Cesk, V149, P120; Tacke F, 2014, J HEPATOL, V60, P1090, DOI 10.1016/j.jhep.2013.12.025; Torres RC, 2013, J DIABETES METAB, V4, DOI 10.4172/2155-6156.S12-002; Unanue ER, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.MCHD-0048-2016; Wei Michael, 2003, Heart Lung Circ, V12, P44, DOI 10.1046/j.1444-2892.2003.00160.x; WEXLER BC, 1975, BRIT J EXP PATHOL, V56, P299; Yurii T, 2016, J ED HLTH SPORT, V6, P375	34	1	1	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-9673	1365-2613		INT J EXP PATHOL	Int. J. Exp. Pathol.	AUG	2018	99	4					172	179		10.1111/iep.12284			8	Pathology	Pathology	GU8TE	WOS:000445614400003	30256482	Green Published			2019-10-28	
J	Colin-Barenque, L; Bizarro-Nevares, P; Villalva, AG; Pedraza-Chaverri, J; Medina-Campos, ON; Jimenez-Martinez, R; Rodriguez-Rangel, DS; Resendiz, S; Fortoul, TI				Colin-Barenque, Laura; Bizarro-Nevares, Patricia; Gonzalez Villalva, Adriana; Pedraza-Chaverri, Jose; Noel Medina-Campos, Omar; Jimenez-Martinez, Ruben; Rodriguez-Rangel, Daniela S.; Resendiz, Stefanie; Fortoul, Teresa I.			Neuroprotective effect of carnosine in the olfactory bulb after vanadium inhalation in a mouse model	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY			English	Article						carnosine; granule cells; neuroprotection; olfactory bulb; oxidative stress; vanadium	CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; SYNAPTIC PLASTICITY; PARKINSONS-DISEASE; PRIMARY CULTURE; RAT; DYSFUNCTION; NEURONS; BRAIN	Carnosine (-alanyl-L-histidine) is synthesized in the olfactory system, has antioxidant activity as a scavenger of free radicals and has been reported to have neuroprotective action in diseases which have been attributed to oxidative damage. In neurodegenerative disorders, such as Parkinson's and Alzheimer's diseases, impairment of olfactory function has been described. Vanadium derivatives are environmental pollutants, and its toxicity has been associated with oxidative stress. Vanadium toxicity on the olfactory bulb was reported previously. This study investigates the neuroprotective effect of carnosine on the olfactory bulb in a mice model of vanadium inhalation. Male mice were divided into four groups: vanadium pentoxide (V2O5) [0.02 mol/L] inhalation for one hour twice a week; V2O5 inhalation plus 1 mg/kg of carnosine administered daily; carnosine only, and the control group that inhaled saline. The olfactory function was evaluated using the odorant test. Animals were sacrificed four weeks after exposure. The olfactory bulbs were dissected and processed using the rapid Golgi method; cytological and ultrastructural analysis was performed and malondialdehyde (MDA) concentrations were measured. The results showed evidence of olfactory dysfunction caused by vanadium exposure and also an increase in MDA levels, loss of dendritic spines and necrotic neuronal death in the granule cells. But, in contrast, vanadium-exposed mice treated with carnosine showed an increase in dendritic spines and a decrease in neuronal death and in MDA levels when compared with the group exposed to vanadium without carnosine. These results suggest that dendritic spine loss and ultrastructural alterations in the granule cells induced by vanadium are mediated by oxidative stress and that carnosine may modulate the neurotoxic vanadium action, improving the olfactory function.	[Colin-Barenque, Laura] UNAM FES Iztacala, Dept Neurociencias, Ave Barrios 1, Tlalnepantla 54090, Edo Mexico, Mexico; [Bizarro-Nevares, Patricia; Gonzalez Villalva, Adriana; Jimenez-Martinez, Ruben; Resendiz, Stefanie; Fortoul, Teresa I.] Univ Nacl Autonoma Mexico, Fac Med, Dept Biol Celular & Tisular, Mexico City, DF, Mexico; [Pedraza-Chaverri, Jose; Noel Medina-Campos, Omar; Rodriguez-Rangel, Daniela S.] Univ Nacl Autonoma Mexico, Fac Quim, Dept Biol, Mexico City, DF, Mexico	Colin-Barenque, L (reprint author), UNAM FES Iztacala, Dept Neurociencias, Ave Barrios 1, Tlalnepantla 54090, Edo Mexico, Mexico.	barenque@unam.mx			PAPIIT-DGAPA-UNAMPrograma de Apoyo a Proyectos de Investigacion e Innovacion Tecnologica (PAPIIT)Universidad Nacional Autonoma de Mexico [220414]	Authors thank Jesus Espinosa, Patricia Aley, Armando Zepeda Rodriguez and Francisco Pasos-Najera, for their technical assistance. Alejandra Nunez-Fortoul edited the English of the final version of the manuscript. PAPIIT-DGAPA-UNAM 220414 supported this study.	Afshin-Majd S, 2015, MOL NEUROBIOL, V51, P1064, DOI 10.1007/s12035-014-8771-0; Aureliano M, 2005, J INORG BIOCHEM, V99, P979, DOI 10.1016/j.jinorgbio.2005.02.024; Avila-Costa MR, 2005, NEUROSCI LETT, V381, P21, DOI 10.1016/j.neulet.2005.01.072; Avila-Costa MR, 2004, NEUROCHEM RES, V29, P1365, DOI 10.1023/B:NERE.0000026398.86113.7d; Babizhayev MA, 2011, CURR CLIN PHARMACOL, V6, P236, DOI 10.2174/157488411798375903; Bizarro-Nevares P, 2016, TOXICOL ENVIRON CHEM, V98, P266, DOI 10.1080/02772248.2015.1116072; Boldyrev A, 2008, REJUV RES, V11, P1; Boldyrev AA, 2013, PHYSIOL REV, V93, P1803, DOI 10.1152/physrev.00039.2012; Bonfanti L, 1999, PROG NEUROBIOL, V59, P333, DOI 10.1016/S0301-0082(99)00010-6; Budzen S, 2013, ADV CLIN EXP MED, V22, P739; Calderon-Garciduenas L, 2002, TOXICOL PATHOL, V30, P373, DOI 10.1080/01926230252929954; Campabadal A, 2017, PARKINSON REL DIS, V2017, P1; Cararo JH, 2015, AGING DIS, V6, P369, DOI 10.14336/AD.2015.0616; Cheng J, 2011, EUR J PHARMACOL, V650, P184, DOI 10.1016/j.ejphar.2010.09.033; Colin-Barenque L, 2008, J APPL TOXICOL, V28, P718, DOI 10.1002/jat.1326; Colin-Barenque L, 2015, TOXICOL PATHOL, V43, P282, DOI 10.1177/0192623314548668; Corona R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019380; Cuesta S, 2011, NEUROTOXICOL TERATOL, V33, P297, DOI 10.1016/j.ntt.2010.10.010; Dai LZ, 2016, J EXPO SCI ENV EPID, V26, P415, DOI 10.1038/jes.2015.83; De Marchis S, 2000, BIOCHEMISTRY-MOSCOW+, V65, P824; Dykstra MJ, 2003, BIOL ELECT MICROSCOP, P5; Dziembowska M, 2012, INT J BIOCHEM CELL B, V44, P709, DOI 10.1016/j.biocel.2012.01.023; Faddah LM, 2012, AFRI J PHARM PHARM, V6, P3305; Ferguson JN, 2000, NAT GENET, V25, P284, DOI 10.1038/77040; Fortoul TI, 2008, HISTOL HISTOPATHOL, V23, P1321, DOI 10.14670/HH-23.1321; Fortoul TI, 2002, ARCH ENVIRON HEALTH, V57, P446, DOI 10.1080/00039890209601436; Gallardo-Vera F, 2016, J IMMUNOTOXICOL, V13, P27, DOI 10.3109/1547691X.2014.996681; Garcia GB, 2005, DRUG CHEM TOXICOL, V28, P329, DOI 10.1081/DCT-200064496; Garcia GB, 2004, DRUG CHEM TOXICOL, V27, P281, DOI 10.1081/DCT-120037747; Gariballa SE, 2000, AGE AGEING, V29, P207, DOI 10.1093/ageing/29.3.207; Gerard-Monnier D, 1998, CHEM RES TOXICOL, V11, P1176, DOI 10.1021/tx9701790; Gruzewska K, 2014, J PHYSIOL PHARMACOL, V65, P603; Gutierrez-Castillo ME, 2006, ENVIRON MOL MUTAGEN, V47, P199, DOI 10.1002/em.20186; Haehner A, 2011, PARKINSONS DIS, V2011, P1, DOI 10.4061/2011/450939; Herculano B, 2013, J ALZHEIMERS DIS, V33, P983, DOI 10.3233/JAD-2012-121324; Heusinkveld HJ, 2016, NEUROTOXICOLOGY, V56, P94, DOI 10.1016/j.neuro.2016.07.007; Hipkiss AR, 2007, J ALZHEIMERS DIS, V11, P229; Hipkiss AR, 2014, NEUROBIOL AGING, V35, P1469, DOI 10.1016/j.neurobiolaging.2013.11.032; Hlushchenko I, 2016, CYTOSKELETON, V73, P435, DOI 10.1002/cm.21280; Hu YJ, 2005, PHARM RES-DORDR, V22, P1281, DOI 10.1007/s11095-005-5261-0; Imtiaz M, 2015, ENVIRON INT, V80, P79, DOI 10.1016/j.envint.2015.03.018; Kamal MA, 2009, AM J PHYSIOL-REG I, V296, pR986, DOI 10.1152/ajpregu.90744.2008; Kim NH, 2007, J BIOCHEM MOL BIOL, V40, P125; Kioumourtzoglou MA, 2015, EPIDEMIOLOGY, V26, P321, DOI 10.1097/EDE.0000000000000269; Kovacs T, 2001, NEUROREPORT, V12, P285, DOI 10.1097/00001756-200102120-00021; Kulkarni A, 2014, INHAL TOXICOL, V26, P772, DOI 10.3109/08958378.2014.960106; Li H, 2013, NEUROTOXICOLOGY, V36, P49, DOI 10.1016/j.neuro.2013.02.008; Lopachev AV, 2016, BIOCHEMISTRY-MOSCOW+, V81, P511, DOI 10.1134/S0006297916050084; Moreno T, 2010, SCI TOTAL ENVIRON, V408, P4569, DOI 10.1016/j.scitotenv.2010.06.016; Mukherjee B, 2004, TOXICOL LETT, V150, P135, DOI 10.1016/j.toxlet.2004.01.009; Nagy V, 2006, J NEUROSCI, V26, P1923, DOI 10.1523/JNEUROSCI.4359-05.2006; Ngwa HA, 2014, NEUROTOXICOLOGY, V43, P73, DOI 10.1016/j.neuro.2013.12.004; Ouyang L, 2016, BRAIN RES BULL, V124, P76, DOI 10.1016/j.brainresbull.2016.03.019; Prokopieva V. D., 2016, OXIDATIVE MED CELLUL, V2016, P1; Rodriguez-Lara V, 2016, TOXICOL IND HEALTH, V32, P367, DOI 10.1177/0748233713501364; Schoen P, 2003, CLIN CHEM, V49, P1930, DOI 10.1373/clinchem.2003.019398; Shen Y, 2010, ANAT REC, V293, P1017, DOI 10.1002/ar.21118; Stawarski M, 2014, FRONT NEUROANAT, V8, DOI 10.3389/fnana.2014.00068; Tanik N, 2016, NEUROSCI LETT, V620, P111, DOI 10.1016/j.neulet.2016.03.050; Turkcu UO, 2010, MOL CELL BIOCHEM, V339, P55, DOI 10.1007/s11010-009-0369-x; Valko M, 2006, CHEM-BIOL INTERACT, V160, P1, DOI 10.1016/j.cbi.2005.12.009; Valverde F., 1970, CONT RES METHODS NEU, P12; Wu CY, 2004, J NEUROCHEM, V90, P1477, DOI 10.1111/j.1471-4159.2004.02682.x; Zhang Z, 2001, ARCH BIOCHEM BIOPHYS, V392, P311, DOI 10.1006/abbi.2001.2464; Zhang ZY, 2015, CELL MOL NEUROBIOL, V35, P147, DOI 10.1007/s10571-014-0106-1; Zou YM, 2016, NEUROPSYCH DIS TREAT, V12, P869, DOI 10.2147/NDT.S104886; Zwolak I, 2014, TOXICOL MECH METHOD, V24, P1, DOI 10.3109/15376516.2013.843110	67	1	1	2	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-9673	1365-2613		INT J EXP PATHOL	Int. J. Exp. Pathol.	AUG	2018	99	4					180	188		10.1111/iep.12285			9	Pathology	Pathology	GU8TE	WOS:000445614400004	30198103	Green Published			2019-10-28	
J	Silva, APE; Soares, JRA; Mattos, EBD; Josetti, C; Guimaraes, IM; Campos, SMN; Teixeira, GAPB				Pereira e Silva, Airton; Soares, Joao R. A.; de Aquino Mattos, Erika Bertozzi; Josetti, Claudia; Guimaraes, Isabelle M.; Campos, Sylvia M. N.; Teixeira, Gerlinde A. P. B.			A histomorphometric classification system for normal and inflamed mouse duodenumQuali-quantitative approach	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY			English	Article						food allergy; gut inflammation; inflammation score; mouse	CELIAC-DISEASE; FOOD ALLERGY; ORAL TOLERANCE; SMALL-INTESTINE; MURINE MODEL; T-CELLS; MICE; DIAGNOSIS; HISTOPATHOLOGY; ANAPHYLAXIS	Gut-associated intestinal lymphoid tissue, the largest secondary lymphoid organ in the human body, constantly samples antigens from the gut lumen, presenting as a default response the activation of TCD4(+)FOXP3(+) regulatory T cells that secrete a profile of anti-inflammatory cytokines maintaining gut homeostasis denominated from an immunological perspective as mucosal tolerance. However, when antigens are sampled in an inflammatory setting, the immune response may either be protective, in the case of harmful pathogens, or cause further inflammatory reactions as in food allergy, inflammatory bowel diseases, coeliac disease or food protein-induced enterocolitis syndrome. Therefore, there is a need for accurate and consistent experimental models. However, a drawback in comparing these models is the lack of a classification system similar to that which is already used for humans. Thus, the aim of this work was to propose a classification system of the small intestinal histomorphology in experimental mice. To do this we used a mouse antigen-specific gut inflammation model developed by our research group. Duodenum sections stained with haematoxylin-eosin and Alcian blue were scanned using the APERIO scanning system and analysed with the ImageScope((R)) software. The evaluated parameters were villus area, villus height and width, enterocyte count, mononuclear intra-epithelial leucocyte and goblet cell counts, and architectural and cellular ratios. Food-sensitized animals challenged with a diet containing the corresponding food allergen presented, as for humans, time-dependent shortened and widened villi accompanied by leucocyte infiltrate and loss of goblet cells. With these data, we were able to establish a classification system for experimental intestinal inflammation in mice thus permitting better comparisons among and between experiments than has been possible previously.	[Pereira e Silva, Airton; Soares, Joao R. A.; de Aquino Mattos, Erika Bertozzi; Josetti, Claudia; Guimaraes, Isabelle M.; Campos, Sylvia M. N.; Teixeira, Gerlinde A. P. B.] Fed Fluminense Univ, Inst Biol, Dept Immunobiol, Gastrointestinal Immunol Grp, Niteroi, RJ, Brazil; [Pereira e Silva, Airton; de Aquino Mattos, Erika Bertozzi; Josetti, Claudia; Teixeira, Gerlinde A. P. B.] Fed Fluminense Univ, Antonio Pedro Hosp, Sch Med, Grad Program Pathol, Niteroi, RJ, Brazil; [Soares, Joao R. A.; Guimaraes, Isabelle M.; Teixeira, Gerlinde A. P. B.] Fed Fluminense Univ, Grad Program Sci & Biotechnol, Niteroi, RJ, Brazil; [Campos, Sylvia M. N.] VP Graduat Program, Dept Nutr, Sao Paulo, Brazil	Teixeira, GAPB (reprint author), Univ Fed Fluminense, Inst Biol, Dept Immunobiol, Barros Terra Ave, BR-24020510 Niteroi, RJ, Brazil.	gerlinde_teixeira@id.uff.br	de Aquino Mattos, Erika Bertozzi/J-6634-2014; Teixeira, Gerlinde/H-4944-2011	de Aquino Mattos, Erika Bertozzi/0000-0002-4407-1068; Teixeira, Gerlinde/0000-0001-7071-2378; Pereira e Silva, Airton/0000-0003-3955-9568	FAPERJ Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro-"Carlos Chagas Filho Foundation for Supporting of Research of the State of Rio de Janeiro" [E-26/110/409/2011]; CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico-"National Council for Scientific and Technological Development")National Council for Scientific and Technological Development (CNPq)	This work was supported by the grant provided by FAPERJ Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro-"Carlos Chagas Filho Foundation for Supporting of Research of the State of Rio de Janeiro" under Grant Number E-26/110/409/2011 and doctorate fellowship provided by CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico-"National Council for Scientific and Technological Development").	Almallouhi E, 2017, J PEDIATR GASTR NUTR, V65, P432, DOI 10.1097/MPG.0000000000001532; Atarashi K, 2013, NATURE, V500, P232, DOI 10.1038/nature12331; BANSEMIR AD, 1994, J PARASITOL, V80, P24, DOI 10.2307/3283340; Baptista M.L, 2006, PEDIATRIA, V28, P262; Bergstrom KSB, 2008, INFECT IMMUN, V76, P796, DOI 10.1128/IAI.00093-07; Bohnen C, 2013, ALLERGY, V68, P1021, DOI 10.1111/all.12192; Campos SMN, 2014, IMMUNOBIOLOGY, V219, P813, DOI 10.1016/j.imbio.2014.07.001; Chan JM, 2013, INFECT IMMUN, V81, P4649, DOI 10.1128/IAI.00655-13; Silva TSDE, 2010, REV ASSOC MED BRAS, V56, P122, DOI 10.1590/S0104-42302010000100027; Erben U, 2014, INT J CLIN EXP PATHO, V7, P4557; Feller L, 2013, OR SURG OR MED OR PA, V116, P576, DOI 10.1016/j.oooo.2013.07.013; Galvez J., 2014, INFLAMMATION, V2014, DOI 10.1155/2014/928461; Ganeshan K, 2009, J ALLERGY CLIN IMMUN, V123, P231, DOI 10.1016/j.jaci.2008.10.011; Gargala G, 2007, WORLD J GASTROENTERO, V13, P2333, DOI 10.3748/wjg.v13.i16.2333; Gersemann M, 2009, DIFFERENTIATION, V77, P84, DOI 10.1016/j.diff.2008.09.008; Grover Z, 2017, AUST FAM PHYSICIAN, V46, P565; Gujral N, 2012, WORLD J GASTROENTERO, V18, P6036, DOI 10.3748/wjg.v18.i42.6036; Hsieh KY, 2003, CLIN EXP ALLERGY, V33, P1595, DOI 10.1046/j.1365-2222.2003.01790.x; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kim Young S, 2010, Curr Gastroenterol Rep, V12, P319, DOI 10.1007/s11894-010-0131-2; Koon G, 2017, TRANSL PEDIATR, V6, P129, DOI 10.21037/tp.2017.03.10; Lebwohl B, 2018, LANCET, V391, P70, DOI 10.1016/S0140-6736(17)31796-8; Li XM, 1999, J ALLERGY CLIN IMMUN, V103, P206, DOI 10.1016/S0091-6749(99)70492-6; Liu TG, 2016, MOL IMMUNOL, V70, P104, DOI 10.1016/j.molimm.2015.11.011; Ludvigsson JF, 2009, JAMA-J AM MED ASSOC, V302, P1171, DOI 10.1001/jama.2009.1320; Marsh MN, 1995, INTESTINAL MANIFESTA, P14; McCauley HA, 2015, TRENDS MOL MED, V21, P492, DOI 10.1016/j.molmed.2015.06.003; Mills JR, 2016, CURR OPIN GASTROEN, V32, P80, DOI 10.1097/MOG.0000000000000245; Muraro A, 2014, ALLERGY, V69, P1008, DOI 10.1111/all.12429; Nobre S. Rito, 2007, J Port Gastrenterol., V14, P184; Nowak-Wegrzyn A, 2017, ANN NUTR METAB, V70, P7, DOI 10.1159/000457915; Nowak-Wegrzyn A, 2017, NAT REV GASTRO HEPAT, V14, P241, DOI 10.1038/nrgastro.2016.187; Oberhuber G, 1999, EUR J GASTROEN HEPAT, V11, P1185, DOI 10.1097/00042737-199910000-00019; Oberhuber G, 2000, BIOMED PHARMACOTHER, V54, P368, DOI 10.1016/S0753-3322(01)80003-2; Owen DR, 2018, ARCH PATHOL LAB MED, V142, P35, DOI 10.5858/arpa.2016-0608-RA; Pabst O, 2012, MUCOSAL IMMUNOL, V5, P232, DOI 10.1038/mi.2012.4; Parzanese Ilaria, 2017, World J Gastrointest Pathophysiol, V8, P27, DOI 10.4291/wjgp.v8.i2.27; Paschoal PO, 2009, IMMUNOBIOLOGY, V214, P269, DOI 10.1016/j.imbio.2008.09.007; Pereira e Silva A, 2016, AUST IMM, V1, P1; Silva APE, 2017, BIOMED REP, V7, P247, DOI 10.3892/br.2017.950; PERKKIO M, 1981, EUR J PEDIATR, V137, P63, DOI 10.1007/BF00441172; Reshma A, 2018, INDIAN J PEDIATR, V85, P60, DOI 10.1007/s12098-017-2436-8; Roy K, 1999, NAT MED, V5, P387; Rupa P, 2006, ALLERGY, V61, P836, DOI 10.1111/j.1398-9995.2006.01143.x; Russo M, 2001, AM J RESP CELL MOL, V24, P518, DOI 10.1165/ajrcmb.24.5.4320; Schaefer JS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056436; Srivastava Amitabh, 2015, Gastroenterol Hepatol Bed Bench, V8, P244; Stanisavljevic S, 2017, IMMUNOL LETT, V190, P282, DOI 10.1016/j.imlet.2017.08.017; Strid J, 2004, IMMUNOLOGY, V113, P293, DOI 10.1111/j.1365-2567.2004.01989.x; Suresh Kp, 2011, J Hum Reprod Sci, V4, P8, DOI 10.4103/0974-1208.82352; Tanoue T, 2016, NAT REV IMMUNOL, V16, P295, DOI 10.1038/nri.2016.36; Teixeira G, 2008, IMMUNOBIOLOGY, V213, P1, DOI 10.1016/j.imbio.2007.08.001; Treuting PM, 2003, COMP ANATOMY HISTOLO, P155; Veress B, 2004, SCAND J GASTROENTERO, V39, P138, DOI 10.1080/00365520310007675; Villanacci V, 2011, DIGEST LIVER DIS, V43, pS385, DOI 10.1016/S1590-8658(11)60594-X; Wells HG, 1921, J INFECT DIS, V29, P200; WRIGHT NA, 1989, CELL TISSUE KINET, V22, P425, DOI 10.1111/j.1365-2184.1989.tb00227.x; Yamaki K, 2012, ALLERGY, V67, P1259, DOI 10.1111/all.12000	58	0	0	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-9673	1365-2613		INT J EXP PATHOL	Int. J. Exp. Pathol.	AUG	2018	99	4					189	198		10.1111/iep.12286			10	Pathology	Pathology	GU8TE	WOS:000445614400005	30175413	Green Published			2019-10-28	
J	Zhang, P; Fan, CS; Du, J; Mo, XL; Zhao, QK				Zhang, Peng; Fan, Changsheng; Du, Jun; Mo, Xueli; Zhao, Qikang			Association of miR-1247-5p expression with clinicopathological parameters and prognosis in breast cancer	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY			English	Article						breast cancer; clinicopathological parameters; miR-1247-5p; prognosis	HEPATOCELLULAR-CARCINOMA; CIRCULATING MICRORNAS; PANCREATIC-CANCER; BIOMARKERS; MARKER; MIRNAS; GENES	Our study aimed to clarify the correlation between miR-1247-5p expression and clinicopathological parameters and survival of patients with breast cancer (BC). We evaluated the expression level of miR-1247-5p in 224 formalin-fixed, paraffin-embedded specimens (112 BC and matched cancer free tissues) by quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR). miR-1247-5p expression in BC tissues was found to be decreased compared with matched normal tissues (P<0.01). Additionally, low miR-1247-5p expression in BC tissues was significantly associated with the advanced TNM stage (P=0.007), lymph node metastasis (P=0.015), poorer pathological differentiation (P=0.005) and molecular subtype (P=0.027). The patients in the low miR-1247-5p group had a shorter disease-free survival and overall survival than those in the high miR-1247-5p group (P<0.01). Furthermore, the univariate and the multivariate analyses showed that miR-1247-5p expression was an independent predictor of overall survival (P<0.01). Our study showed that miR-1247-5p was related to the biological behaviour of breast tumour and prognosis of patients with BC. miR-1247-5p could be a novel tumour suppressor and act as a potential biomarker and therapeutic agent for breast carcinoma.	[Zhang, Peng; Fan, Changsheng; Du, Jun; Mo, Xueli; Zhao, Qikang] Peking Univ, Shougang Hosp, Dept Breast Dis, Beijing, Peoples R China	Zhang, P (reprint author), Peking Univ, Shougang Hosp, Dept Breast Dis, Beijing, Peoples R China.	qiaohao7618957@163.com			Natural Science Foundation of Beijing MunicipalityBeijing Natural Science Foundation [7132053]	Natural Science Foundation of Beijing Municipality, Grant/Award Number: 7132053.	Adhami M, 2018, BREAST CANCER-TOKYO, V25, P198, DOI 10.1007/s12282-017-0814-8; Agarwal S, 2015, BRIT J CANCER, V112, P61, DOI 10.1038/bjc.2014.573; Agostini A, 2017, ONCOTARGET, V8, P21554, DOI 10.18632/oncotarget.15795; Ahmad A, 2015, ONCOTARGET, V6, P12188, DOI 10.18632/oncotarget.3664; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Anwar SL, 2013, INT J CANCER, V133, P660, DOI 10.1002/ijc.28068; Aydogdu E, 2012, CARCINOGENESIS, V33, P1502, DOI 10.1093/carcin/bgs161; Basso D, 2017, ONCOTARGET, V8, P84928, DOI 10.18632/oncotarget.20863; Ben-Dayan MM, 2015, ARCH PATHOL LAB MED, V139, P1362, DOI 10.5858/arpa.2014-0624-OA; Berry DA, 2005, NEW ENGL J MED, V353, P1784, DOI 10.1056/NEJMoa050518; Cinegaglia NC, 2016, ONCOTARGET, V7, P28920, DOI 10.18632/oncotarget.8713; Dayem AA, 2016, NUTRIENTS, V8, DOI 10.3390/nu8090581; Di Leva G, 2014, ANNU REV PATHOL-MECH, V9, P287, DOI 10.1146/annurev-pathol-012513-104715; Dubey Ashutosh Kumar, 2015, Asian Pac J Cancer Prev, V16, P4237; He TL, 2014, EUR REV MED PHARMACO, V18, P108; Li WD, 2014, INT J CLIN EXP PATHO, V7, P3287; Mancikova V, 2015, MODERN PATHOL, V28, P748, DOI 10.1038/modpathol.2015.44; Motawi TK, 2016, CELL BIOCHEM FUNCT, V34, P142, DOI 10.1002/cbf.3171; Musilova K, 2015, LEUKEMIA, V29, P1004, DOI 10.1038/leu.2014.351; Nattinger AB, 2010, ANN INTERN MED, V152, P832, DOI [10.7326/0003-4819-152-12-201006150-00027, 10.7326/0003-4819-152-7-201004060-01004]; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Printz C, 2016, CANCER-AM CANCER SOC, V122, P339, DOI 10.1002/cncr.29881; Romano G, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112354; Scaravilli M, 2015, PROSTATE, V75, P798, DOI 10.1002/pros.22961; Shi S, 2014, CURR MOL MED, V14, P316, DOI 10.2174/1566524014666140228120014; Shukla Girish C, 2011, Mol Cell Pharmacol, V3, P83; Singletary SE, 2003, SURG CLIN N AM, V83, P803, DOI 10.1016/S0039-6109(03)00034-3; Sun ZP, 2017, ONCOTARGET, V8, P93839, DOI 10.18632/oncotarget.21288; Wang J, 2014, J CANCER, V5, P696, DOI 10.7150/jca.10094; Wang K, 2012, CARCINOGENESIS, V33, P2147, DOI 10.1093/carcin/bgs259; Xiong DD, 2017, ONCOL REP, V37, P3297, DOI 10.3892/or.2017.5600; Zhang J, 2016, INT J OPHTHALMOL-CHI, V9, P1, DOI 10.18240/ijo.2016.01.01; Zhao FY, 2015, INT J CLIN EXP PATHO, V8, P1451	33	1	1	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-9673	1365-2613		INT J EXP PATHOL	Int. J. Exp. Pathol.	AUG	2018	99	4					199	205		10.1111/iep.12287			7	Pathology	Pathology	GU8TE	WOS:000445614400006	30175411	Other Gold, Green Published			2019-10-28	
J	Graf, R; Guscetti, F; Welle, M; Meier, D; Pospischil, A				Graf, R.; Guscetti, F.; Welle, M.; Meier, D.; Pospischil, A.			Feline Injection Site Sarcomas: Data from Switzerland 2009-2014	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						cat; feline leukaemia virus; fibrosarcoma; vaccine	POSTVACCINAL SARCOMAS; CANCER REGISTRY; CATS; FIBROSARCOMA; VACCINATION	Feline injection site sarcomas (FISS) were first described in the early 1990s. Despite extensive research, the pathogenesis of these tumours has not been elucidated conclusively. Their appearance and the marked increase in their incidence has been mainly connected to the injection of vaccines, and it is assumed that a chronic inflammatory reaction at the injection site triggers subsequent malignant transformation. The role of alum-based adjuvants has been discussed, but is controversial. The present study of the Swiss Feline Cancer Registry (SFCR) with data from 2009 to 2014 revealed a marked decrease of the incidence of fibrosarcomas compared with the previous observation period. Notably, this drop occurred after a non-adjuvanted feline leukaemia virus vaccine was introduced in Switzerland in 2007. This observation, together with the previous findings of the SFCR, further supports the notion that alum-adjuvanted vaccines are involved in the genesis of FISS and that non-adjuvanted vaccines might be safer for cats. (C) 2018 Elsevier Ltd. All rights reserved.	[Graf, R.; Pospischil, A.] Univ Zurich, Coll Helveticum, Zurich, Switzerland; [Graf, R.; Pospischil, A.] Eidgenoss TH Zurich, Zurich, Switzerland; [Guscetti, F.; Pospischil, A.] Univ Zurich, Vetsuisse Fak, Inst Vet Pathol, Zurich, Switzerland; [Welle, M.] Univ Bern, Vetsuisse Fak, Inst Tierpathol, Bern, Switzerland; [Meier, D.] Zyto Histo Diagnost, Rorbas Freienstein, Switzerland	Guscetti, F (reprint author), Univ Zurich, Vetsuisse Fak, Inst Vet Pathol, Zurich, Switzerland.	gufo@vetpath.uzh.ch					Buracco P, 2002, VET J, V163, P105, DOI 10.1053/tvjl.2001.0617; Burton G, 1997, AUST VET J, V75, P102, DOI 10.1111/j.1751-0813.1997.tb14167.x; Daly MK, 2008, J FELINE MED SURG, V10, P202, DOI 10.1016/j.jfms.2007.10.011; Day MJ, 2007, VACCINE, V25, P4073, DOI 10.1016/j.vaccine.2007.02.049; De Man MMG, 2007, J FELINE MED SURG, V9, P432, DOI 10.1016/j.jfms.2007.05.002; Esplin DG, 1999, VET CANC SOC NEWSLET, V23, P8; European Pet Food Industry, 2016, FACTAND FIG; Graf R, 2016, J COMP PATHOL, V154, P195, DOI 10.1016/j.jcpa.2016.01.008; Graf R, 2015, J COMP PATHOL, V153, P266, DOI 10.1016/j.jcpa.2015.08.007; Hartmann K, 2015, J FELINE MED SURG, V17, P606, DOI 10.1177/1098612X15588451; HENDRICK MJ, 1991, J AM VET MED ASSOC, V199, P968; HENDRICK MJ, 1992, CANCER RES, V52, P5391; HENDRICK MJ, 1994, VET PATHOL, V31, P126, DOI 10.1177/030098589403100121; Kass PH, 2003, J AM VET MED ASSOC, V223, P1283, DOI 10.2460/javma.2003.223.1283; KASS PH, 1993, J AM VET MED ASSOC, V203, P396; Lester S, 1996, J AM ANIM HOSP ASSOC, V32, P91, DOI 10.5326/15473317-32-2-91; Macy DW, 1996, VET CLIN N AM-SMALL, V26, P103, DOI 10.1016/S0195-5616(96)50009-4; Srivastav A, 2012, JAVMA-J AM VET MED A, V241, P595, DOI 10.2460/javma.241.5.595; Swiss Association for Small Animal Medicine, 2008, IMPF SVK ASMPA; Wilcock B, 2012, CAN VET J, V53, P430; Woodward Kevin N, 2011, ISRN Vet Sci, V2011, P210982, DOI 10.5402/2011/210982	21	1	1	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	AUG	2018	163						1	5		10.1016/j.jcpa.2018.06.008			5	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GV3HE	WOS:000445984200001	30213367				2019-10-28	
J	Sakurai, M; Iwasa, R; Sakai, Y; Chambers, JK; Uchida, K; Morimoto, M				Sakurai, M.; Iwasa, R.; Sakai, Y.; Chambers, J. K.; Uchida, K.; Morimoto, M.			Expression of Stem Cell Factor in Feline Mast Cell Tumour	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						cat; kit; mast cell tumour; stem cell factor	C-KIT; SURVIVAL; ACTIVATION; MUTATIONS	Stem cell factor (SCF) is a ligand of the molecule Kit, which is expressed in mast cells and is important for mast cell proliferation, migration and survival. Mast cell tumours (MCTs) are associated with mutations of c-kit, a proto-oncogene encoding the Kit protein. In this study, we examined SCF expression in 23 samples of feline MCTs. SCF expression was detected in 10 cutaneous MCTs and a case of splenic mastocytosis. In the cutaneous MCTs, SCF-positive tumour cells were located at the margins. Kit was expressed in eight of the 10 cutaneous cases of SCF-cxpressing MCTs. In these cases, Kit-positive cells were located near to SCF-positive cells, and SCF/Kit double-positive tumour cells were found. Ki67-positive tumour cells were not found near to SCF-positive cells. These results suggest that SCF autocrine/paracrine mechanisms are involved in the expansion of cutaneous MCTs, but not in tumour proliferation. (C) 2018 Elsevier Ltd. All rights reserved.	[Sakurai, M.; Iwasa, R.; Sakai, Y.; Morimoto, M.] Yamaguchi Univ, Joint Fac Vet Med, Lab Vet Pathol, 1677-1 Yoshida, Yamaguchi, Japan; [Chambers, J. K.; Uchida, K.] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Med Sci,Lab Vet Pathol, Bunkyo Ku, Tokyo, Japan	Morimoto, M (reprint author), Yamaguchi Univ, Joint Fac Vet Med, Lab Vet Pathol, 1677-1 Yoshida, Yamaguchi, Japan.	morimasa@yamaguchi-u.ac.jp					Amagai Y, 2013, J LEUKOCYTE BIOL, V93, P245, DOI 10.1189/jlb.0512245; Amagai Y, 2014, RES VET SCI, V96, P124, DOI 10.1016/j.rvsc.2013.10.014; Baghestanian M, 2002, INT ARCH ALLERGY IMM, V129, P228, DOI 10.1159/000066773; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Dank G, 2002, AM J VET RES, V63, P1129, DOI 10.2460/ajvr.2002.63.1129; Ginn PE, 2007, JUBB KENNEDY PALNZER, V1, P771; Henry C, 2013, J FELINE MED SURG, V15, P41, DOI 10.1177/1098612X12470343; Isotani M, 2010, BRIT J HAEMATOL, V148, P144, DOI 10.1111/j.1365-2141.2009.07926.x; Lennartsson J, 2012, PHYSIOL REV, V92, P1619, DOI 10.1152/physrev.00046.2011; Lim KH, 2009, BLOOD, V113, P5727, DOI 10.1182/blood-2009-02-205237; Mallett CL, 2013, VET PATHOL, V50, P106, DOI 10.1177/0300985812441032; MEININGER CJ, 1992, BLOOD, V79, P958; Mekori YA, 2001, J CLIN IMMUNOL, V21, P171, DOI 10.1023/A:1011083031272; NILSSON G, 1994, J IMMUNOL, V153, P3717; Ohmori K, 2008, VET IMMUNOL IMMUNOP, V126, P43, DOI 10.1016/j.vetimm.2008.06.014; Okayama Y, 2006, IMMUNOL RES, V34, P97, DOI 10.1385/IR:34:2:97; Sabattini S, 2017, VET COMP ONCOL, V15, P1051, DOI 10.1111/vco.12246; Takeuchi Y, 2013, VET J, V196, P492, DOI 10.1016/j.tvjl.2012.11.018	18	0	0	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	AUG	2018	163						6	9		10.1016/j.jcpa.2018.06.005			4	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GV3HE	WOS:000445984200002	30213375				2019-10-28	
J	Setthawongsin, C; Tangkawattana, S; Rungsipipat, A; Techangamsuwan, S				Setthawongsin, C.; Tangkawattana, S.; Rungsipipat, A.; Techangamsuwan, S.			Computerized Cytomorphometric and Cytomorphological Analysis of Canine Transmissible Venereal Tumours	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						canine transmissible venereal tumour; chemotherapy; cytomorphology; cytomorphometry	VINCRISTINE SULFATE; NUCLEAR MORPHOMETRY; BREAST-CANCER; IN-VITRO; CELL; EXPRESSION; DOG; EVOLUTION; KI67	Canine transmissible venereal tumour (CTVT) has three cytomorphological types: plasmacytic, lymphocytic and mixed type. Cytomorphometry, a method of computerized image analysis, has been used recently in veterinary medicine. This study compared the nuclear and cellular morphometric parameters (i.e. radius, diameter, perimeter and area) in different types of CTVT with other canine round cell tumours including lymphoma, mast cell tumour (MCT) and histiocytic tumour (HCT). We also evaluated the relationship between clinical information and the different CTVT cytomorphologic types. CTVT cells from 44 dogs revealed that the measured parameters were significantly different between different round cell tumours and among the CTVT cytomorphological types. CTVT had the largest cells, followed by HCTs, MCTs and lymphomas. The mixed type of CTVT had the largest nuclear and cellular size, followed by the plasmacytic and lymphocytic types. Lymphocytic CTVTs had less aggressive biological behaviour than the other types. Mixed type CTVTs were more likely to show malignant behaviour including metastasis and resistance to chemotherapy; however, there was no significant correlation between cytomorphological type of CTVT and response to chemotherapy. (C) 2018 Elsevier Ltd. All rights reserved.	[Setthawongsin, C.; Rungsipipat, A.; Techangamsuwan, S.] Chulalongkorn Univ, Compan Anim Canc Res Unit, Dept Pathol, Fac Vet Sci, Bangkok, Thailand; [Tangkawattana, S.] Khon Kaen Univ, Fac Vet Med, Dept Vet Pathobiol, Khon Kaen, Thailand	Tangkawattana, S (reprint author), Khon Kaen Univ, Fac Vet Med, Dept Vet Pathobiol, Khon Kaen, Thailand.	somporn62@hotmail.com			Chulalongkorn UniversityChulalongkorn University	This research and C. Setthawongsin were supported by the Chulalongkorn University Graduate Scholarship to commemorate the 72nd Anniversary of the Birthday of His Majesty King Bhumibol Adulyadej and the Doctoral Degree Chulalongkorn University 100th Year Birthday Anniversary Scholarship.	Bassani-Silva Sandra, 2007, Revista Portuguesa de Ciencias Veterinarias, V102, P261; BELMONT AS, 1982, J CELL SCI, V58, P201; Chretien MF, 1998, HUM REPROD, V13, P2767, DOI 10.1093/humrep/13.10.2767; DUNCAN JR, 1979, VET PATHOL, V16, P673, DOI 10.1177/030098587901600605; Ferreira AJA, 2000, J SMALL ANIM PRACT, V41, P165, DOI 10.1111/j.1748-5827.2000.tb03187.x; Hantrakul S, 2014, J VET MED SCI, V76, P1549, DOI 10.1292/jvms.14-0180; Hsiao YW, 2002, VET IMMUNOL IMMUNOP, V87, P19, DOI 10.1016/S0165-2427(02)00026-0; Gaspar LFJ, 2010, TURK J VET ANIM SCI, V34, P447, DOI 10.3906/vet-0911-198; Kidwell MG, 2002, GENETICA, V115, P49, DOI 10.1023/A:1016072014259; Marcos R, 2006, VET CLIN PATH, V35, P106, DOI 10.1111/j.1939-165X.2006.tb00097.x; Melling N, 2016, J CLIN PATHOL, V69, P209, DOI 10.1136/jclinpath-2015-202985; Mozos E, 1996, VET PATHOL, V33, P257, DOI 10.1177/030098589603300301; Mueller RL, 2015, COLD SPRING HARBOR P, V7, P1; Murgia C, 2006, CELL, V126, P477, DOI 10.1016/j.cell.2006.05.051; Owen LN., 1980, TNM CLASSIFICATION T, P12; Paranzini CS, 2015, SEMIN-CIENC AGRAR, V36, P3795, DOI 10.5433/1679-0359.2015v36n6p3795; Park MS, 2006, J VET DIAGN INVEST, V18, P130, DOI 10.1177/104063870601800123; Prvulovic I, 2010, COLLEGIUM ANTROPOL, V34, P99; Rogers KS, 1998, J AM ANIM HOSP ASSOC, V34, P463, DOI 10.5326/15473317-34-6-463; Santos FGA, 2011, ARQ BRAS MED VET ZOO, V63, P1345, DOI 10.1590/S0102-09352011000600010; Setthawongsin C, 2016, J VET MED SCI, V78, P1167, DOI 10.1292/jvms.15-0710; Spugnini EP, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-58; Sudjaidee P, 2012, THAI J VET MED, V42, P117; Tan PH, 2005, MODERN PATHOL, V18, P374, DOI 10.1038/modpathol.3800254; Tan PH, 2001, MODERN PATHOL, V14, P937, DOI 10.1038/modpathol.3880415	25	0	0	0	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	AUG	2018	163						18	22		10.1016/j.jcpa.2018.07.003			5	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GV3HE	WOS:000445984200004	30213369				2019-10-28	
J	Herrero, A; Thompson, KD; Ashby, A; Rodger, HD; Dagleish, MP				Herrero, A.; Thompson, K. D.; Ashby, A.; Rodger, H. D.; Dagleish, M. P.			Complex Gill Disease: an Emerging Syndrome in Farmed Atlantic Salmon (Salmo salar L.)	JOURNAL OF COMPARATIVE PATHOLOGY			English	Review						Atlantic salmon; complex gill disease; pathology; salmon farming	INFLAMMATION; NORWAY	Gill disorders have become a significant problem during the marine phase of farming Atlantic salmon (Salmo salar L.). The term complex gill disease (CGD) includes a wide range of clinical gill disease presentations generally occurring from the end of summer to early winter on marine Atlantic salmon farms. The gross and histological lesions observed are the resultant culmination of exposure to a mixture of environmental insults, pathogenic organisms and farm management practices. None of the three principal agents purportedly associated with CGD (Desmozoon lepeophtherii, salmon gill poxvirus or Candidatus Branchiomonas cysticola) have been cultured successfully in-vitro, so individual in-vivo challenge studies to identify their pathogenesis have not been possible. Studies of cohabitation of single pathogen-infected fish with naive fish, and epidemiological investigations are required urgently to elucidate the roles of these pathogens and other factors in CGD. (C) 2018 Elsevier Ltd. All rights reserved.	[Herrero, A.; Thompson, K. D.; Dagleish, M. P.] Moredun Res Inst, Pentlands Sci Pk, Penicuik, Midlothian, Scotland; [Ashby, A.] Fish Vet Grp Ltd, 22 Carsegate Rd, Inverness, Scotland; [Rodger, H. D.] Fish Vet Grp Ireland, Unit 7b Oranmore Business Pk, Oranmore, Co Galway, Ireland	Dagleish, MP (reprint author), Moredun Res Inst, Pentlands Sci Pk, Penicuik, Midlothian, Scotland.	mark.dagleish@moredun.ac.uk	; Thompson, Kim/O-7707-2015	Rodger, Hamish/0000-0002-5336-8912; Thompson, Kim/0000-0003-3550-4842	Moredun Scientific; Fish Vet Group; Rural and Environment Science and Analytical Services division of the Scottish Government	AH was funded by Moredun Scientific and Fish Vet Group. MPD was funded by the Rural and Environment Science and Analytical Services division of the Scottish Government.	Freeman MA, 2009, PARASITE VECTOR, V2, DOI 10.1186/1756-3305-2-58; Gjessing MC, 2017, J FISH DIS, V40, P1253, DOI 10.1111/jfd.12608; Kvellestad A, 2005, DIS AQUAT ORGAN, V67, P47, DOI 10.3354/dao067047; Matthews CGG, 2013, J FISH DIS, V36, P861, DOI 10.1111/jfd.12084; Mitchell SO, 2011, J FISH DIS, V34, P411, DOI 10.1111/j.1365-2761.2011.01251.x; Mitchell SO, 2013, DIS AQUAT ORGAN, V103, P35, DOI 10.3354/dao02563; Nylund A, 2008, ARCH VIROL, V153, P1299, DOI 10.1007/s00705-008-0117-7; Nylund S, 2011, DIS AQUAT ORGAN, V94, P41, DOI 10.3354/dao02313; Nylund S, 2010, J EUKARYOT MICROBIOL, V57, P95, DOI 10.1111/j.1550-7408.2009.00451.x; Oldham T, 2016, AQUACULTURE, V457, P35, DOI 10.1016/j.aquaculture.2016.02.013; Rodger HD, 2011, REV FISH BIOL FISHER, V21, P423, DOI 10.1007/s11160-010-9182-6; Steinum T, 2010, DIS AQUAT ORGAN, V91, P201, DOI 10.3354/dao02266; Weli SC, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2303-5; Wiik-Nielsen J, 2017, J FISH DIS, V40, P1387, DOI 10.1111/jfd.12613	14	4	4	6	13	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	AUG	2018	163						23	28		10.1016/j.jcpa.2018.07.004			6	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GV3HE	WOS:000445984200005	30213370				2019-10-28	
J	Ramirez, GA; Altimira, J; Vilafranca, M				Ramirez, G. A.; Altimira, J.; Vilafranca, M.			Ganglioneuromatosis of the Gallbladder in a Dog with Cholecystitis and Cholestasis	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						cholecystitis; dog; gallbladder; ganglioneuromatosis	SMALL-INTESTINAL GANGLIONEUROMATOSIS; DIFFUSE GANGLIONEUROMATOSIS; COLONIC GANGLIONEUROMATOSIS	A 2-year-old entire female mixed-breed dog was presented with signs of cholestasis. Abdominal ultrasonography revealed a gallbladder with a thickened and hyperechoic wall and luminal calculi. Exploratory laparotomy with cholecystectomy was performed and histopathological examination of the specimens from the cholecystectomy demonstrated extensive proliferation of large, prominent nerves containing ganglion cells with no atypia mainly located in the gallbladder mucosa. The neural nature of these components was confirmed by immunohistochemical labelling with antibodies specific for synaptophysin, glial fibrillary acidic protein, S100 protein and neurofilaments. Based on these findings, the lesion was diagnosed as ganglioneuromatosis. Reports of ganglioneuromatosis in animals have so far been restricted to the intestine. This is the first case of ganglioneuromatosis affecting the gallbladder in an animal in which no intestinal involvement was apparent. (C) 2018 Elsevier Ltd. All rights reserved.	[Ramirez, G. A.] Univ Lleida, Sch Agr Food Sci & Vet Med, Dept Anim Sci, Lleida, Spain; [Altimira, J.; Vilafranca, M.] HISTOVET Vet Diagnost Serv, Avda Paisos Catalans 12D, Barcelona, Spain	Ramirez, GA (reprint author), Univ Lleida, Sch Agr Food Sci & Vet Med, Dept Anim Sci, Lleida, Spain.	gramirez@ca.udl.cat	RAMIREZ, GUSTAVO A./H-1532-2018	RAMIREZ, GUSTAVO A./0000-0002-8606-1378; Vilafranca, M/0000-0002-6850-2598			Bemelmans I, 2011, VET PATHOL, V48, P1012, DOI 10.1177/0300985810384411; Chambonniere ML, 2003, GASTROEN CLIN BIOL, V27, P219; CHETTY R, 1993, J CLIN PATHOL, V46, P1061, DOI 10.1136/jcp.46.11.1061; COLE DE, 1990, VET PATHOL, V27, P461, DOI 10.1177/030098589902700614; DESCHRYVERKECSKEMETI K, 1983, NEW ENGL J MED, V308, P635, DOI 10.1056/NEJM198303173081106; FAIRLEY RA, 1990, VET PATHOL, V27, P206, DOI 10.1177/030098589002700311; Hazell KLA, 2011, AUST VET J, V89, P15, DOI 10.1111/j.1751-0813.2010.00663.x; Higgins R, 2017, TUMORS DOMESTIC ANIM, P856; O'Donnell AM, 2011, PEDIATR SURG INT, V27, P491, DOI 10.1007/s00383-010-2828-6; Paris JK, 2013, J COMP PATHOL, V148, P323, DOI 10.1016/j.jcpa.2012.07.002; Porter BF, 2007, VET PATHOL, V44, P207, DOI 10.1354/vp.44-2-207; Sakuma T, 2011, INT J SURG PATHOL, V19, P524, DOI 10.1177/1066896908324129; Salvitti M, 2013, J PEDIATR UROL, V9, pE131, DOI 10.1016/j.jpurol.2013.01.006; Thway K, 2009, ANN DIAGN PATHOL, V13, P50, DOI 10.1016/j.anndiagpath.2007.06.001	14	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	AUG	2018	163						29	32		10.1016/j.jcpa.2018.07.002			4	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GV3HE	WOS:000445984200006	30213371				2019-10-28	
J	Beccati, F; Pepe, M; Antinori, L; Pascucci, L; Chiaradia, E; Mandara, MT				Beccati, F.; Pepe, M.; Antinori, L.; Pascucci, L.; Chiaradia, E.; Mandara, M. T.			Sympathetic Innervation and Adrenergic Receptors in Equine Deep Digital Flexor Tendinopathy: Preliminary Results	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						alpha-1 adrenergic receptor; equine deep digital flexor endinopathy; sympathetic innervation; tyrosine hydroxylase	LOCAL CATECHOLAMINE PRODUCTION; PALMAR FOOT PAIN; TENDON; HORSES	The aim of this study was to delineate the pattern of sympathetic innervation in the suprasesamoidean region of the deep digital flexor tendon (DDFT) in horses with tendinopathy by immunohistochemical labelling for tyrosine hydroxylase (TH) and alpha-1 adrenergic receptor (alpha 1-AR). Twelve forelimbs were obtained from 10 horses with DDFT tendinopathy and six feet obtained from six horses were used as healthy controls. Post-mortem radiographic, ultrasonographic and gross examinations were performed on the suprasesamoidean area of the DDFT to assess the presence of tendinopathy. Longitudinal sections were collected and processed. Lesions were classified as core lesions, dorsal border lesions and parasagittal oblique splits. Immunohistochemistry was performed and the degree of immunoreaction was classified as absent, mild or marked. Seven core lesions, four dorsal border lesions and one parasagittal oblique split were identified. There was no increased expression of sympathetic innervation in samples with a dorsal border lesion of the DDFT compared with healthy samples. In contrast, core lesions showed increased expression of alpha 1-AR and reduced expression of TH, which supports the hypothesis of a compensatory imbalance between the sympathetic mediator and the sympathetic receptors as a cause or effect of structural damage. In addition, adrenergic activation could stimulate cell proliferation and differentiation within these lesions. (C) 2018 Elsevier Ltd. All rights reserved.	[Beccati, F.; Pepe, M.; Pascucci, L.; Chiaradia, E.; Mandara, M. T.] Univ Perugia, Sport Horses Studies Ctr, Dept Vet Med, Via San Costanzo 4, Perugia, Italy; [Antinori, L.] Clin Vet Roma Sud, Via Pilade Mazza 24, Rome, Italy	Beccati, F (reprint author), Univ Perugia, Sport Horses Studies Ctr, Dept Vet Med, Via San Costanzo 4, Perugia, Italy.	francesca.beccati@unipg.it	Beccati, Francesca/X-7448-2019	Beccati, Francesca/0000-0002-3126-2738; Pascucci, Luisa/0000-0002-2562-1140			Ackermann PW, 2014, FRONT BIOSCI-LANDMRK, V19, P1251, DOI 10.2741/4280; Ackermann PW, 2013, INT J EXP PATHOL, V94, P271, DOI 10.1111/iep.12028; Beccati F, 2015, VET J, V205, P413, DOI 10.1016/j.tvjl.2015.06.004; Bjur D, 2008, HISTOL HISTOPATHOL, V23, P197, DOI 10.14670/HH-23.197; Blunden A, 2009, EQUINE VET J, V41, P25, DOI 10.2746/042516408X343028; Blunden A, 2006, EQUINE VET J, V38, P23, DOI 10.2746/042516406775374342; Bondi M, 2015, INT J ORTHOPAEDICS, V2, P289; Busoni V, 2005, VET RADIOL ULTRASOUN, V46, P279, DOI 10.1111/j.1740-8261.2005.00051.x; Butler J. A., 2008, CLIN RADIOLOGY HORSE, P1; Cillan-Garcia E, 2013, VET REC, V173, P70, DOI 10.1136/vr.101512; Coudry V, 2013, EQUINE VET EDUC, V25, P196, DOI 10.1111/j.2042-3292.2012.00382.x; Crisan MI, 2013, RES VET SCI, V95, P23, DOI 10.1016/j.rvsc.2013.03.006; Danielson P, 2007, MICROSC RES TECHNIQ, V70, P310, DOI 10.1002/jemt.20413; Denoix JM, 2009, EQUINE DISTAL LIMB A; Dyson S, 2007, EQUINE VET J, V39, P340, DOI 10.2746/042516407X185566; Maffulli N, 2004, J ROY SOC MED, V97, P472, DOI 10.1258/jrsm.97.10.472; Murray RC, 2006, VET RADIOL ULTRASOUN, V47, P17, DOI 10.1111/j.1740-8261.2005.00101.x; Murray RC, 2006, VET RADIOL ULTRASOUN, V47, P1, DOI 10.1111/j.1740-8261.2005.00100.x; Riley G, 2004, RHEUMATOLOGY, V43, P131, DOI 10.1093/rheumatology/keg448; Rio E, 2014, SPORTS MED, V44, P9, DOI 10.1007/s40279-013-0096-z; Schramme MC, 2011, EQUINE VET EDUC, V23, P403, DOI 10.1111/j.2042-3292.2011.00235.x; Scott A, 2009, FRONT BIOSCI, V14, P2203, DOI 10.2741/3372; Xu YH, 2008, CLIN ORTHOP RELAT R, V466, P1528, DOI 10.1007/s11999-008-0286-4	23	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	AUG	2018	163						33	37		10.1016/j.jcpa.2018.07.005			5	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GV3HE	WOS:000445984200007	30213372				2019-10-28	
J	Yang, C; Weisbrode, S; Yardley, J; Schroeder, E; Premanandan, C				Yang, C.; Weisbrode, S.; Yardley, J.; Schroeder, E.; Premanandan, C.			Metaphyeal and Diaphyseal Dysplasia of the Third Cervical Vertebra Secondary to Physeal Necrosis in a Quarter Horse Foal	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						bone dysplasia; horse; physeal necrosis; vertebra	ISCHEMIC NECROSIS; GROWTH-PLATE; EPIPHYSIS	Ischaemia-induced physeal injury has not been described previously in the horse. A 1-month-old Quarter horse foal was submitted for necropsy examination due to an acute onset of ataxia followed by a 4-week history of progressive decline. Focal narrowing of the spinal canal due to ventral compression by the rotation of the cranial aspect of the third cervical vertebra (C3) was observed. The metaphysis and diaphysis of C3 were markedly shortened and white-tan in colour, Microscopically, there was complete loss of the dorsal compact bone of C3 and replacement of 80% of the physis that runs parallel to the vertebral canal with fibrous tissue and thickened viable trabecular bone. Both cranial and caudal physes of C3 showed widespread bands of coagulative necrosis of the hypertrophic and calcifying zones. Marked bone marrow hypoplasia with slight fibrosis was observed in the metaphyses and diaphysis. There was no evidence of fracture or inflammation. The epiphyses were microscopically unremarkable. It was hypothesized that a regional transient incomplete and possibly multiphasic ischaemia involving the nutrient artery caused necrosis of the physes, resulting in dysplasia of the bone. Ischaemic injury to the physis should be considered in the pathogenesis of focal bone dysplasia in horses. (C) 2018 Published by Elsevier Ltd.	[Yang, C.; Weisbrode, S.; Yardley, J.; Schroeder, E.; Premanandan, C.] Ohio State Univ, Coll Vet Med, Columbus, OH 43210 USA	Premanandan, C (reprint author), Ohio State Univ, Coll Vet Med, Columbus, OH 43210 USA.	premanandan.1@osu.edu					Craig LE, 2015, JUBB KENNEDY PALMERS, V1, P17; FIRTH EC, 1983, RES VET SCI, V34, P231, DOI 10.1016/S0034-5288(18)32265-3; Firth EC, 1995, AUST VET J, V72, P452, DOI 10.1111/j.1751-0813.1995.tb03487.x; Kim HKW, 2002, J BONE JOINT SURG AM, V84A, P1329, DOI 10.2106/00004623-200208000-00007; Nyska M, 2005, J PEDIATR ORTHOPED, V25, P346, DOI 10.1097/01.bpo.0000153878.28185.2a; TRUETA J, 1960, J BONE JOINT SURG BR, V42, P571; Wirth T, 2002, CALCIFIED TISSUE INT, V70, P312, DOI 10.1007/s00223-001-2006-x; YOUNG MH, 1963, J PATHOL BACTERIOL, V85, P481, DOI 10.1002/path.1700850229	8	0	0	2	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	AUG	2018	163						38	41		10.1016/j.jcpa.2018.07.001			4	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GV3HE	WOS:000445984200008	30213373				2019-10-28	
J	Day, MJ				Day, M. J.			The Journal of Comparative Pathology Educational Trust and Petplan Charitable Trust Joint Research Award in Veterinary Pathology	JOURNAL OF COMPARATIVE PATHOLOGY			English	Editorial Material									[Day, M. J.] Murdoch Univ, Sch Vet & Life Sci, Murdoch, WA, Australia	Day, MJ (reprint author), Murdoch Univ, Sch Vet & Life Sci, Murdoch, WA, Australia.	profmjday@gmail.com						0	0	0	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	AUG	2018	163						42	43		10.1016/j.jcpa.2018.08.001			2	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GV3HE	WOS:000445984200009	30213374				2019-10-28	
J	Fraitag, S; Lamant, L				Fraitag, Sylvie; Lamant, Laurence			Dermatopathology histoseminar: Introduction	ANNALES DE PATHOLOGIE			French	Editorial Material									[Fraitag, Sylvie] Hop Necker Enfants Malad, AP HP, 149 Rue Sevres, F-75015 Paris, France; [Lamant, Laurence] Inst Univ Canc Toulouse, Oncopole, 1 Ave Irene Joliot Curie, F-31059 Toulouse 9, France	Fraitag, S (reprint author), Hop Necker Enfants Malad, AP HP, 149 Rue Sevres, F-75015 Paris, France.	sylvie.fraitag@aphp.fr					Emile JF, 2016, BLOOD, V127, P2672, DOI [10.1182/blood-2016-01-690636, 10.1182/blood-2016-01690636]; FAVARA BE, 1987, LANCET, V1, P208; Pileri SA, 2017, WHO CLASSIFICATION T	3	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	AUG	2018	38	4					207	209		10.1016/j.annpat.2018.05.003			3	Pathology	Pathology	GT8JC	WOS:000444782500001	29908855				2019-10-28	
J	Fraitag, S				Fraitag, Sylvie			Dermatopathology histoseminar. Case 1	ANNALES DE PATHOLOGIE			French	Editorial Material							CUTANEOUS MASTOCYTOSIS		[Fraitag, Sylvie] Hop Necker Enfants Malad, AP HP, 149 Rue Sevres, F-75015 Paris, France	Fraitag, S (reprint author), Hop Necker Enfants Malad, AP HP, 149 Rue Sevres, F-75015 Paris, France.	sylvie.fraitag@aphp.fr					Bodemer C, 2010, J INVEST DERMATOL, V130, P804, DOI 10.1038/jid.2009.281; Fraitag-Spinner S, 2007, ANN DERMATOL VENER, V134, P589, DOI 10.1016/S0151-9638(07)89281-7; Hartmann K, 2016, J ALLERGY CLIN IMMUN, V137, P35, DOI 10.1016/j.jaci.2015.08.034; Severino M, 2016, J AM ACAD DERMATOL, V74, P885, DOI 10.1016/j.jaad.2015.10.050	4	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	AUG	2018	38	4					215	218		10.1016/j.annpat.2018.05.010			4	Pathology	Pathology	GT8JC	WOS:000444782500002	29980307				2019-10-28	
J	Nohra, O; Fraitag, S				Nohra, Olivier; Fraitag, Sylvie			Dermatopathology histoseminar. Case 2	ANNALES DE PATHOLOGIE			French	Editorial Material							LANGERHANS CELL HISTIOCYTOSIS; HYPERPLASIA; SCABIES		[Nohra, Olivier] Cabinet Pathol, 273 Ave Carnot, F-17000 La Rochelle, France; [Fraitag, Sylvie] Hop Necker Enfants Malad, AP HP, 149 Rue Sevres, F-75015 Paris, France	Fraitag, S (reprint author), Hop Necker Enfants Malad, AP HP, 149 Rue Sevres, F-75015 Paris, France.	sylvie.fraitag@aphp.fr					Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bhattacharjee P, 2007, J CUTAN PATHOL, V34, P716, DOI 10.1111/j.1600-0560.2006.00723.x; Burch JM, 2004, PEDIATR DERMATOL, V21, P58, DOI 10.1111/j.0736-8046.2004.21113.x; Drut R, 2010, FETAL PEDIATR PATHOL, V29, P231, DOI 10.3109/15513811003789610; Grace SA, 2017, AM J DERMATOPATH, V39, P726, DOI 10.1097/DAD.0000000000000778; Hatter AD, 2015, AM J DERMATOPATH, V37, pe93, DOI 10.1097/DAD.0000000000000201; Kim SH, 2007, J CUTAN PATHOL, V34, P899, DOI 10.1111/j.1600-0560.2007.00751.x; Segura E, 2012, J EXP MED, V209, P653, DOI 10.1084/jem.20111457; Shanmugam V, 2017, AM J SURG PATHOL, V41, P1390, DOI 10.1097/PAS.0000000000000897; Valladeau J, 2000, IMMUNITY, V12, P71, DOI 10.1016/S1074-7613(00)80160-0	10	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	AUG	2018	38	4					219	222		10.1016/j.annpat.2018.05.011			4	Pathology	Pathology	GT8JC	WOS:000444782500003	30082023				2019-10-28	
J	Fraitag, S				Fraitag, Sylvie			Dermatopathology histoseminar. Case 3	ANNALES DE PATHOLOGIE			French	Editorial Material							HISTIOCYTOSES		[Fraitag, Sylvie] Hop Necker Enfants Malad, AP HP, 149 Rue Sevres, F-75015 Paris, France	Fraitag, S (reprint author), Hop Necker Enfants Malad, AP HP, 149 Rue Sevres, F-75015 Paris, France.	sylvie.fraitag@aphp.fr					Emile JF, 2016, BLOOD, V127, P2672, DOI [10.1182/blood-2016-01-690636, 10.1182/blood-2016-01690636]; Haroche J, 2012, BLOOD, V120, P2700, DOI 10.1182/blood-2012-05-430140; Morice A, 2017, J NEUROSURG PEDIAT, P1; Sandell RF, 2015, HUM PATHOL, V46, P1390, DOI 10.1016/j.humpath.2015.05.025; Shanmugam V, 2017, AM J SURG PATHOL, V41, P1390, DOI 10.1097/PAS.0000000000000897	5	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	AUG	2018	38	4					223	229		10.1016/j.annpat.2018.05.012			7	Pathology	Pathology	GT8JC	WOS:000444782500004	30082024				2019-10-28	
J	Frouin, E				Frouin, Eric			Dermatopathology histoseminar. Case 4	ANNALES DE PATHOLOGIE			French	Editorial Material							OROFACIAL GRANULOMATOSIS; CUTANEOUS SARCOIDOSIS; CROHNS-DISEASE; ROSACEA		[Frouin, Eric] CHU Poitiers, Serv Anat & Cytol Pathol, 2 Rue Mil, F-86021 Poitiers, France	Frouin, E (reprint author), CHU Poitiers, Serv Anat & Cytol Pathol, 2 Rue Mil, F-86021 Poitiers, France.	eric.frouin@chu-poitiers.fr					Ball NJ, 2004, J CUTAN PATHOL, V31, P160, DOI 10.1111/j.0303-6987.2004.00157.x; Bouaziz A, 2012, QJM-INT J MED, V105, P755, DOI 10.1093/qjmed/hcs042; Cribier B, 2013, J EUR ACAD DERMATOL, V27, P1336, DOI 10.1111/jdv.12121; Cribier B, 2008, ANN DERMATOL VENER, V58, P217; Fernandez-Flores A, 2009, BRATISL MED J, V110, P328; Ishak R, 2015, INT J DERMATOL, V54, P33, DOI 10.1111/ijd.12248; Lau YN, 2012, AM J DERMATOPATH, V34, P343, DOI 10.1097/DAD.0b013e31822d07bf; Lazzerini M, 2014, WORLD J GASTROENTERO, V20, P7497, DOI 10.3748/wjg.v20.i23.7497; Marcoval J, 2016, AM J DERMATOPATH, V38, P194, DOI 10.1097/DAD.0000000000000343; Miida H, 2010, J CUTAN PATHOL, V37, P504, DOI 10.1111/j.1600-0560.2009.01337.x; Munday WR, 2015, J CUTAN PATHOL, V42, P465, DOI 10.1111/cup.12484; Neri I, 2013, PEDIATR DERMATOL, V30, P109, DOI 10.1111/j.1525-1470.2011.01689.x; Skowron F, 2000, DERMATOLOGY, V201, P287, DOI 10.1159/000051539; Sung IY, 2015, J PERIODONTAL IMPLAN, V45, P247, DOI 10.5051/jpis.2015.45.6.247; Zbar AP, 2012, J CROHNS COLITIS, V6, P135, DOI 10.1016/j.crohns.2011.07.001	15	0	0	1	1	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	AUG	2018	38	4					230	235		10.1016/j.annpat.2018.05.006			6	Pathology	Pathology	GT8JC	WOS:000444782500005	29907341				2019-10-28	
J	Lamant, L				Lamant, Laurence			Dermatopathology histoseminar. Case 5	ANNALES DE PATHOLOGIE			French	Editorial Material							DENDRITIC CELL NEOPLASM; REVEALS		[Lamant, Laurence] Inst Univ Canc Toulouse Oncopole, Ave Hubert Curien, F-31100 Toulouse, France	Lamant, L (reprint author), Inst Univ Canc Toulouse Oncopole, Ave Hubert Curien, F-31100 Toulouse, France.	lamant.l@chu-toulouse.fr					Facchetti F, 2008, WHO CLASSIFICATION T; Facchetti F, 2016, MODERN PATHOL, V29, P98, DOI 10.1038/modpathol.2015.145; Julia F, 2014, AM J SURG PATHOL, V38, P673, DOI 10.1097/PAS.0000000000000156; Mathan TSM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00372; Menezes J, 2014, LEUKEMIA, V28, P823, DOI 10.1038/leu.2013.283; Petrella T, 2002, AM J SURG PATHOL, V26, P852, DOI 10.1097/00000478-200207000-00003; Sapienza MR, 2014, LEUKEMIA, V28, P1606, DOI 10.1038/leu.2014.64; Vitte F, 2012, AM J SURG PATHOL, V36, P1302, DOI 10.1097/PAS.0b013e31825dd4de	8	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	AUG	2018	38	4					236	240		10.1016/j.annpat.2018.05.009			5	Pathology	Pathology	GT8JC	WOS:000444782500006	29980305				2019-10-28	
J	Lamant, L				Lamant, Laurence			Dermatopathology histoseminar. Case 6	ANNALES DE PATHOLOGIE			French	Editorial Material							ROSAI-DORFMAN-DISEASE		[Lamant, Laurence] Inst Univ Canc Toulouse Oncopole, Ave Hubert Curien, F-31100 Toulouse, France	Lamant, L (reprint author), Inst Univ Canc Toulouse Oncopole, Ave Hubert Curien, F-31100 Toulouse, France.	lamant.l@chu-toulouse.fr					CHU P, 1992, J CUTAN PATHOL, V19, P201, DOI 10.1111/j.1600-0560.1992.tb01659.x; Emile JF, 2016, BLOOD, V127, P2672, DOI [10.1182/blood-2016-01-690636, 10.1182/blood-2016-01690636]; Gameiro A, 2016, AN BRAS DERMATOL, V91, P634, DOI 10.1590/abd1806-4841.20164477; Kong YY, 2007, AM J SURG PATHOL, V31, P341, DOI 10.1097/01.pas.0000213387.70783.b6; Martinez-Ciarpaglini C, 2017, HISTOPATHOLOGY, V70, P670, DOI 10.1111/his.13101; Menon MP, 2014, HISTOPATHOLOGY, V64, P455, DOI 10.1111/his.12274; Ortonne N, 2002, J CUTAN PATHOL, V29, P113, DOI 10.1034/j.1600-0560.2002.290209.x; Vuong V, 2013, ANN DERMATOL VENER, V140, P83, DOI 10.1016/j.annder.2012.06.036; Wang KH, 2006, BRIT J DERMATOL, V154, P277, DOI 10.1111/j.1365-2133.2005.06917.x	9	0	0	0	1	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	AUG	2018	38	4					241	244		10.1016/j.annpat.2018.05.008			4	Pathology	Pathology	GT8JC	WOS:000444782500007	29980306				2019-10-28	
J	Carlotti, A				Carlotti, Agnes			Dermatopathology histoseminar. Case 7	ANNALES DE PATHOLOGIE			French	Editorial Material							HISTOPATHOLOGY		[Carlotti, Agnes] Hop Cochin, AP HP, 27 Rue Faubourg St Jacques, F-75014 Paris, France	Carlotti, A (reprint author), Hop Cochin, AP HP, 27 Rue Faubourg St Jacques, F-75014 Paris, France.	agnes.carlotti@aphp.fr					Angelakis E, 2010, J INFECTION, V61, P266, DOI 10.1016/j.jinf.2010.06.007; Bartralot R, 2000, J CUTAN PATHOL, V27, P124, DOI 10.1034/j.1600-0560.2000.027003124.x; CASANOVA JL, 1995, LANCET, V346, P581, DOI 10.1016/S0140-6736(95)91421-8; Flynn JL, 2011, MUCOSAL IMMUNOL, V4, P271, DOI 10.1038/mi.2011.14; Fraitag S, 2016, HISTIOCYTOSES NONLAN, P511; Massone C, 2015, CLIN DERMATOL, V33, P38, DOI 10.1016/j.clindermatol.2014.10.003; Pinquier L, 2011, ANN DERMATOL VENER, V138, P777, DOI 10.1016/j.annder.2011.09.001	7	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	AUG	2018	38	4					245	248		10.1016/j.annpat.2018.05.007			4	Pathology	Pathology	GT8JC	WOS:000444782500008	30082025				2019-10-28	
J	Saal, C; Jeandel, R; Boukamel, S; Yver, M				Saal, Caroline; Jeandel, Roland; Boukamel, Samir; Yver, Matthieu			Fibrothecoma of the testis: A case report in an adult	ANNALES DE PATHOLOGIE			French	Article						Fibrothecomas in the testis; Sex cord stromal tumors	GONADAL STROMAL TUMOR	Fibrothecal tumors belong to sex cord/stromal tumors (SCSTS). They represent 1 to 4.7 % of the organics tumors of ovary (Chechia et al., 2008) but are extremely rare in the testis, with only a few cases described in the literature. We report a new case of a fibrothecoma in the testis in an adult. The extemporaneous diagnosis was made in the same time of the surgical intervention. The castration has been avoided. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Saal, Caroline; Jeandel, Roland; Yver, Matthieu] Ctr Hosp Marne La Vallee, Serv Pathol, 2-4 Cours Gondoire, F-77600 Jossigny, France; [Boukamel, Samir] Ctr Hosp Meaux, Serv Urol, 6-8 Rue St Fiacre, F-77104 Meaux, France	Saal, C (reprint author), Ctr Hosp Marne La Vallee, Serv Pathol, 2-4 Cours Gondoire, F-77600 Jossigny, France.	casaal89@hotmail.com					ALLEN PR, 1990, PATHOLOGY, V22, P227, DOI 10.3109/00313029009086667; Chechia A, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.03.053; Deveci MS, 2002, PATHOL INT, V52, P326, DOI 10.1046/j.1440-1827.2002.01345.x; Ditonno P, 2007, UROL ONCOL-SEMIN ORI, V25, P322, DOI 10.1016/j.urolonc.2006.08.019; Irving JA, 2006, AM J SURG PATHOL, V30, P929, DOI 10.1097/00000478-200608000-00001; Jones MA, 1997, AM J SURG PATHOL, V21, P296, DOI 10.1097/00000478-199703000-00005; Kao CS, 2014, AM J CLIN PATHOL, V142, P675, DOI 10.1309/AJCPGSCD1DGNZ0QO; Song Z, 2011, RARE TUMORS, V3, P117, DOI 10.4081/rt.2011.e37; Ueda M, 2010, J PEDIATR SURG, V45, pE1, DOI 10.1016/j.jpedsurg.2009.12.005; van der Horst Michiel P J, 2010, Ned Tijdschr Geneeskd, V154, pA190; YOUNG RH, 1987, SEMIN DIAGN PATHOL, V4, P342; Zhang M, 2013, AM J SURG PATHOL, V37, P1208, DOI 10.1097/PAS.0b013e318286c129	12	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	AUG	2018	38	4					249	252		10.1016/j.annpat.2018.04.001			4	Pathology	Pathology	GT8JC	WOS:000444782500009	29803360				2019-10-28	
J	Guilain, N; Grecourt, L; Smail, A; Toubeau, G; Chatelain, D				Guilain, Nelly; Grecourt, Lewis; Smail, Amar; Toubeau, Guillaume; Chatelain, Denis			Deficiency colitis	ANNALES DE PATHOLOGIE			French	Editorial Material									[Guilain, Nelly; Grecourt, Lewis; Toubeau, Guillaume; Chatelain, Denis] CHU Amiens Nord, Serv Anat & Cytol Pathol, Pl Victor Pauchet, F-80000 Amiens, France; [Smail, Amar] CHU Amiens Nord, Serv Med Interne, Pl Victor Pauchet, F-80000 Amiens, France	Guilain, N (reprint author), CHU Amiens Nord, Serv Anat & Cytol Pathol, Pl Victor Pauchet, F-80000 Amiens, France.	n.guilain@gmail.com					Chapel H, 2009, BRIT J HAEMATOL, V145, P709, DOI 10.1111/j.1365-2141.2009.07669.x; Daniels JA, 2007, AM J SURG PATHOL, V31, P1800, DOI 10.1097/PAS.0b013e3180cab60c; Pavic M, 2013, REV MED INTERNE, V34, P154, DOI 10.1016/j.revmed.2012.02.005; Sanchez LA, 2017, J CLIN IMMUNOL, V37, P592, DOI 10.1007/s10875-017-0415-5	4	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	AUG	2018	38	4					253	256		10.1016/j.annpat.2018.03.005			4	Pathology	Pathology	GT8JC	WOS:000444782500010	29680293				2019-10-28	
J	Setia, N; Alpert, L; van der Stoot, KWJ; Colussi, D; Stewart, KO; Misdraji, J; Khalili, H; Lauwers, GY				Setia, Namrata; Alpert, Lindsay; van der Stoot, Kimberley W. J.; Colussi, Dora; Stewart, Kathleen O.; Misdraji, Joseph; Khalili, Hamed; Lauwers, Gregory Y.			Lymphocytic colitis: pathologic predictors of response to therapy	HUMAN PATHOLOGY			English	Article						Lymphocytic colitis; Histology; Therapy; Response; Collagen table; Eosinophil clusters	INFLAMMATORY-BOWEL-DISEASE; MICROSCOPIC COLITIS; COLLAGENOUS COLITIS; PREVALENCE; PATTERNS; COHORT	Although the presence of intraepithelial lymphocytosis with surface epithelial damage is a unifying feature of lymphocytic colitis, there are nonclassical features that create morphologic heterogeneity between cases. Limited data on the significance of these secondary histologic features are available. Cases of lymphocytic colitis diagnosed between 2002 and 2013 were identified using the Research Patient Data Registry of a tertiary referral center. Diagnostic biopsy slides were reviewed and evaluated for histologic features of lymphocytic colitis. Clinical data including type of therapy and response to treatment were collected. chi(2) Test (or Fisher exact test) and logistic regression analysis were used where appropriate. Thirty-two cases of lymphocytic colitis with complete clinical data and slides available for review were identified. The mean age was 56.4 years, and the female-to-male ratio was 3:2. Eleven patients improved with minimal intervention (group 1), 14 patients responded to steroid therapy (group 2), and 7 patients responded to mesalamine, bismuth subsalicylate, and/or cholestyramine therapy (group 3). Histologic differences in the characteristics of the subepithelial collagen table (P=.018), the severity of lamina propria inflammation (P=.042), and the presence of eosinophil clusters (P=.016) were seen between groups 2 and 3. Patients in group 1 were more likely to have mild crypt architectural distortion in their biopsies than patients in groups 2 and 3. Lymphocytic colitis is a heterogeneous disease, and the evaluation of histologic factors may help identify various subtypes and predict therapy response. (C) 2018 Elsevier Inc. All rights reserved.	[Setia, Namrata; Alpert, Lindsay] Univ Chicago, Dept Anat Pathol, Chicago, IL 60637 USA; [van der Stoot, Kimberley W. J.] Univ Groningen, Univ Med Ctr Groningen, Dept Gastroenterol & Hepatol, NL-9700 RB Groningen, Netherlands; [van der Stoot, Kimberley W. J.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, NL-9700 RB Groningen, Netherlands; [Colussi, Dora] Univ Naples Federico II, Dept Gastroenterol, I-80138 Naples, Italy; [Colussi, Dora; Khalili, Hamed] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Colussi, Dora; Misdraji, Joseph; Khalili, Hamed] Harvard Med Sch, Boston, MA 02114 USA; [Stewart, Kathleen O.] Dartmouth Hitchcock Med Ctr, Dept Med, Lebanon, NH 03756 USA; [Misdraji, Joseph] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Lauwers, Gregory Y.] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Pathol, Tampa, FL 33612 USA; [Lauwers, Gregory Y.] Univ S Florida, Dept Oncol Sci, Tampa, FL 33612 USA	Setia, N (reprint author), Univ Chicago Med, Dept Anat Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA.	Namrata.Setia@uchospitals.edu		van der Sloot, Kimberley/0000-0002-0001-511X	Abbive; Samsung Bioepis; TakedaTakeda Pharmaceutical Company Ltd; Takeda PharmaceuticalsTakeda Pharmaceutical Company Ltd	N.S., L.A., K.W.J.S., D.C., K.O.S., J.M., and G.Y.L. have no disclosures. H.K. has received consulting fees from Abbive, Samsung Bioepis, and Takeda. H.K. has received funding from Takeda Pharmaceuticals to study microscopic colitis.	Ayata G, 2002, AM J SURG PATHOL, V26, P1414, DOI 10.1097/00000478-200211000-00003; Bonderup OK, 2015, SCAND J GASTROENTERO, V50, P393, DOI 10.3109/00365521.2014.940378; Carrasco A, 2016, J CROHNS COLITIS, V10, P1055, DOI 10.1093/ecco-jcc/jjw058; Colussi D, 2015, SCAND J GASTROENTERO, V50, P1382, DOI 10.3109/00365521.2015.1050692; Farrukh A, 2014, COLORECTAL DIS, V16, P957, DOI 10.1111/codi.12716; Fernandez-Banares F, 2005, EUR J GASTROEN HEPAT, V17, P1333, DOI 10.1097/00042737-200512000-00011; Fernandez-Banares F, 2016, J CROHNS COLITIS, V10, P805, DOI 10.1093/ecco-jcc/jjw037; Fine KD, 1998, GASTROENTEROLOGY, V114, P29, DOI 10.1016/S0016-5085(98)70629-8; GIARDIELLO FM, 1989, DIGEST DIS SCI, V34, P1730, DOI 10.1007/BF01540051; Goldstein NS, 1999, AM J SURG PATHOL, V23, P1075, DOI 10.1097/00000478-199909000-00010; Khor TS, 2012, J GASTROENTEROL, V47, P226, DOI 10.1007/s00535-012-0539-6; Koskela RM, 2008, EUR J GASTROEN HEPAT, V20, P276, DOI 10.1097/MEG.0b013e3282f2468d; LAZENBY AJ, 1989, HUM PATHOL, V20, P18, DOI 10.1016/0046-8177(89)90198-6; MEISEL JL, 1977, GASTROENTEROLOGY, V72, P1274; Mellander MR, 2016, SCAND J GASTROENTERO, V51, P556, DOI 10.3109/00365521.2015.1124283; Okamoto R, 2016, CLIN J GASTROENTEROL, V9, P169, DOI 10.1007/s12328-016-0656-5; Rasmussen J, 2016, J CROHNS COLITIS, V10, P262, DOI 10.1093/ecco-jcc/jjv200; Rasmussen MA, 2012, ALIMENT PHARM THER, V36, P79, DOI 10.1111/j.1365-2036.2012.05166.x; Rogler G, 2001, SCAND J GASTROENTERO, V36, P389, DOI 10.1080/003655201300051216; TOBLER A, 1992, BLOOD, V79, P45; Vigren L, 2012, SCAND J GASTROENTERO, V47, P1448, DOI 10.3109/00365521.2012.729085	21	1	1	1	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	AUG	2018	78						1	7		10.1016/j.humpath.2018.02.007			7	Pathology	Pathology	GR0GG	WOS:000442191800001	29452215				2019-10-28	
J	Lee, SJ; Kim, A; Kim, YK; Park, WY; Kim, HS; Jo, HJ; Oh, N; Song, GA; Park, DY				Lee, So Jeong; Kim, Ahrong; Kim, Young Keum; Park, Won Young; Kim, Hyun Sung; Jo, Hong-Jae; Oh, Nahmgun; Song, Geum Am; Park, Do Youn			The significance of tumor budding in T1 colorectal carcinoma: the most reliable predictor of lymph node metastasis especially in endoscopically resected T1 colorectal carcinoma	HUMAN PATHOLOGY			English	Article						Colorectal cancer; Lymph node metastasis; Risk factors; Endoscopic Mucosal Resection; Surgical Procedure	SUBMUCOSAL INVASION; RISK-FACTORS; CANCER; COLON; MANAGEMENT; DEPTH; CLASSIFICATION; INVOLVEMENT; GUIDELINES; POLYPS	Endoscopic resection is widely recognized as a first-line treatment for T1 colorectal cancers (CRC), although additional surgical intervention may be indicated based on the risk of lymph node (LN) metastasis. However, risk factors for LN metastasis in T1 CRC not fully established. We investigated the clinicopathological features of T1 CRC and evaluated their association with lymph node metastasis in 133 cases of T1 CRC, consisting of 87 cases with first-line endoscopic resection (EMR) followed by additional surgery and 46 cases with primary surgical resection. Among the total 133 cases, 16 cases (12.0%) showed LN metastasis; 13 cases (13/16, 81.25%) were included in endoscopic resection cohort. These were all of the non-pedunculated gross type and most of LN+ tumors invaded submucosa over 1000 mu m (surgical cohort versus endoscopic resection cohort; 3 versus 11). However, there was no statistical difference in the depth of submucosal invasion between the LN+ and LN in both surgical cohort (2799.42 mu m 401.56 versus 3000.00 mu m 721.69, P=.897) and endoscopic resection cohort (2066.55 mu m 142.96 versus 2305.77 mu m 345.62, P=.520). Conversely, presence of and a higher number of tumor budding foci were associated with an increase in the incidence of LN metastasis in both cohort (P<.0001). Positive resection margins as well as absence of adenoma component were also an independent predictive factor for lymph node metastasis in 87 cases with first-line endoscopic resection followed by additional surgery. We found that tumor budding was the most reliable LN metastasis predictor in T1 CRC in both surgically resected and endoscopic resection specimens.	[Lee, So Jeong; Kim, Ahrong; Kim, Young Keum; Park, Won Young; Park, Do Youn] Pusan Natl Univ Hosp, Dept Pathol, 1-10 Ami Dong, Busan 602739, South Korea; [Lee, So Jeong; Kim, Ahrong; Kim, Young Keum; Park, Won Young; Kim, Hyun Sung; Jo, Hong-Jae; Oh, Nahmgun; Song, Geum Am; Park, Do Youn] Pusan Natl Univ, Sch Med, 1-10 Ami Dong, Busan 602739, South Korea; [Lee, So Jeong; Kim, Ahrong; Kim, Young Keum; Park, Won Young; Kim, Hyun Sung; Jo, Hong-Jae; Oh, Nahmgun; Song, Geum Am; Park, Do Youn] Biomed Res Inst, Busan, South Korea; [Kim, Hyun Sung; Jo, Hong-Jae; Oh, Nahmgun] Pusan Natl Univ Hosp, Dept Surg, Busan, South Korea; [Song, Geum Am] Pusan Natl Univ Hosp, Dept Gastroenterol, Busan, South Korea	Park, DY (reprint author), Pusan Natl Univ Hosp, Dept Pathol, 1-10 Ami Dong, Busan 602739, South Korea.; Park, DY (reprint author), Pusan Natl Univ, Sch Med, 1-10 Ami Dong, Busan 602739, South Korea.	pdy220@pusan.ac.kr			National R&D Program for Cancer Control, Ministry for Health, Welfare, and Family Affairs, Republic of KoreaMinistry of Health & Welfare, Republic of Korea [0920050]	This study was supported by a grant (0920050) from the National R&D Program for Cancer Control, Ministry for Health, Welfare, and Family Affairs, Republic of Korea.	Asayama N, 2015, DIGESTION, V91, P64, DOI 10.1159/000368866; Bosch SL, 2013, ENDOSCOPY, V45, P827, DOI 10.1055/s-0033-1344238; COOPER HS, 1995, GASTROENTEROLOGY, V108, P1657, DOI 10.1016/0016-5085(95)90126-4; Edge SB, 2009, AM JOINT COMMITTEE C; Egashira Y, 2004, MODERN PATHOL, V17, P503, DOI 10.1038/modpathol.3800030; Graham RP, 2015, AM J SURG PATHOL, V39, P1340, DOI 10.1097/PAS.0000000000000504; HAGGITT RC, 1985, GASTROENTEROLOGY, V89, P326; Homma Y, 2010, J SURG ONCOL, V102, P230, DOI 10.1002/jso.21606; Kawachi H, 2015, MODERN PATHOL, V28, P872, DOI 10.1038/modpathol.2015.36; Kim JY, 2013, HUM PATHOL, V44, P2829, DOI 10.1016/j.humpath.2013.07.037; Kitajima K, 2004, J GASTROENTEROL, V39, P534, DOI 10.1007/s00535-004-1339-4; Kouyama Y, 2016, INT J COLORECTAL DIS, V31, P137, DOI 10.1007/s00384-015-2403-7; Kye BH, 2012, BMC SURG, V12, DOI 10.1186/1471-2482-12-16; KYZER S, 1992, CANCER, V70, P2044, DOI 10.1002/1097-0142(19921015)70:8<2044::AID-CNCR2820700805>3.0.CO;2-X; Labianca R, 2013, ANN ONCOL, V24, P64, DOI 10.1093/annonc/mdt354; Lee SH, 2011, J KOREAN SURG SOC, V80, P111, DOI 10.4174/jkss.2011.80.2.111; Maeda Y, 2016, SURG TODAY, V46, P303, DOI 10.1007/s00595-015-1150-2; Maguire A, 2014, WORLD J GASTROENTERO, V20, P9850, DOI 10.3748/wjg.v20.i29.9850; MINAMOTO T, 1993, AM J GASTROENTEROL, V88, P1035; Mitrovic B, 2012, MODERN PATHOL, V25, P1315, DOI 10.1038/modpathol.2012.94; Miyachi H, 2016, J GASTROEN HEPATOL, V31, P1126, DOI 10.1111/jgh.13257; Nakadoi K, 2014, SURG ENDOSC, V28, P1269, DOI 10.1007/s00464-013-3321-9; Nakadoi K, 2012, J GASTROEN HEPATOL, V27, P1057, DOI 10.1111/j.1440-1746.2011.07041.x; Nascimbeni R, 2002, DIS COLON RECTUM, V45, P200, DOI 10.1007/s10350-004-6147-7; Ogawa T, 2009, SCAND J GASTROENTERO, V44, P605, DOI 10.1080/00365520902718911; Ohtsuki K, 2008, ANTICANCER RES, V28, P1831; Saitoh Y, 2016, DIGEST ENDOSC, V28, P324, DOI 10.1111/den.12503; Satoh K, 2014, CANCER SCI, V105, P1487, DOI 10.1111/cas.12530; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Ueno H, 2004, GASTROENTEROLOGY, V127, P385, DOI 10.1053/S0016-5085(04)00717-6; Ueno H, 2002, HISTOPATHOLOGY, V40, P127, DOI 10.1046/j.1365-2559.2002.01324.x; van de Velde CJH, 2014, EUR J CANCER, V50, DOI 10.1016/j.ejca.2013.06.048; van de Velde CJH, 2013, EUR J CANCER, V49, P2784, DOI 10.1016/j.ejca.2013.04.032; Watanabe T, 2015, INT J CLIN ONCOL, V20, P207, DOI 10.1007/s10147-015-0801-z; Watanabe T, 2012, INT J CLIN ONCOL, V17, P1, DOI 10.1007/s10147-011-0315-2; Whitlow C, 1997, DIS COLON RECTUM, V40, P929, DOI 10.1007/BF02051200	36	4	4	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	AUG	2018	78						8	17		10.1016/j.humpath.2018.02.001			10	Pathology	Pathology	GR0GG	WOS:000442191800002	29447923				2019-10-28	
J	Park, JY; Lee, JH; Song, KB; Hwang, DW; Kim, KR; Kim, SC; Hong, SM				Park, Ji Y.; Lee, Jae Hoon; Song, Ki-Byung; Hwang, Dae Wook; Kim, Kyu-Rae; Kim, Song Cheol; Hong, Seung-Mo			Significance of microcystic, elongated, and fragmented glandular-like features in intraductal papillary mucinous neoplasm of the pancreas	HUMAN PATHOLOGY			English	Article						Intraductal papillary mucinous neoplasm; Pancreas; Microcystic; Elongated and fragmented (MELF); Adenocarcinoma; Prognosis	DUCTAL ADENOCARCINOMA; ENDOMETRIOID ADENOCARCINOMA; PRECURSOR LESIONS; SURGICAL OUTCOMES; RESECTION; CLASSIFICATION; EXPRESSION; CONSENSUS; MUC1; CARCINOGENESIS	Microcystic, elongated, and fragmented (MELF) glandular features are associated with epithelial-mesenchymal transition, invasion, and progression in endometrioid adenocarcinoma of the uterus. Similar histological features are also observed at the periphery of pancreatic intraductal papillary mucinous neoplasms (IPMNs). However, the clinicopathological significance of MELF-like features particularly whether they represent regenerative or truly neoplastic conditions in IPMNs remains unclear. We assessed a total of 152 surgically resected IPMNs. Fifty cases exhibited MELF-like features, including 26 cases of IPMNs with accompanying adenocarcinomas and 24 cases of IPMNs without accompanying adenocarcinomas. MELF-like features were more frequently observed in IPMN cases with accompanying adenocarcinomas, larger tumors, main-duct type, and non-gastric histologic subtype. A positive correlation between the presence of MELF-like features and high-grade dysplasia was observed in IPMNs without accompanying adenocarcinomas. Moreover, DPC4 loss and p53 overexpression in MELF-like glands were more commonly observed in IPMNs with high-grade dysplasia. IPMN patients with MELF-like features had worse overall and disease-specific survival by univariate analyses. Our observations suggest that MELF-like features in some IPMNs with high-grade dysplasia could be related to stromal invasion. Hence, when MELF-like features are observed in IPMNs, pathologists should carefully evaluate the results of microscopic examinations to identify the invasive components; and, immunohistochemical staining for DPC4 and p53 could help clarify its clinicopathological significance. (C) 2018 Elsevier Inc. All rights reserved.	[Park, Ji Y.] Kyungpook Natl Univ, Med Ctr, Sch Med, Dept Pathol, Daegu, South Korea; [Lee, Jae Hoon; Song, Ki-Byung; Hwang, Dae Wook; Kim, Song Cheol] Univ Ulsan, Asan Med Ctr, Hepatobiliary & Pancreat Surg, Coll Med, Seoul, South Korea; [Kim, Kyu-Rae; Hong, Seung-Mo] Univ Ulsan, Asan Med Ctr, Dept Pathol, Coll Med, 88,Olymp Ro 43 Gil, Seoul 05505, South Korea	Hong, SM (reprint author), Univ Ulsan, Asan Med Ctr, Dept Pathol, Coll Med, 88,Olymp Ro 43 Gil, Seoul 05505, South Korea.	shong28@amc.seoul.kr		Hong, Seung-Mo/0000-0002-8888-6007	National R&D Program for Cancer Control, the Ministry of Health Welfare, KoreaMinistry of Health & Welfare, Republic of Korea [1320200]	This work was supported by the National R&D Program for Cancer Control, the Ministry of Health & Welfare, Korea [1320200, SM Hong].	Adsay NV, 2004, AM J SURG PATHOL, V28, P839, DOI 10.1097/00000478-200407000-00001; Adsay NV, 2010, PATHOLOGY GENETICS T, V1, P304; Adsay V, 2016, ANN SURG, V263, P162, DOI 10.1097/SLA.0000000000001173; Basturk O, 2015, AM J SURG PATHOL, V39, P1730, DOI 10.1097/PAS.0000000000000533; Biankin AV, 2003, PATHOLOGY, V35, P14, DOI 10.1080/003130202201472; Chari ST, 2002, GASTROENTEROLOGY, V123, P1500, DOI 10.1053/gast.2002.36552; Crippa S, 2010, CLIN GASTROENTEROL H, V8, P213, DOI 10.1016/j.cgh.2009.10.001; Edge S. B., 2010, AJCCC CANC STAGING M, V7, P241, DOI DOI 10.1007/978-1-4614-2080-4; Furukawa T, 2005, VIRCHOWS ARCH, V447, P794, DOI 10.1007/s00428-005-0039-7; Hruban RH, 2004, AM J SURG PATHOL, V28, P977, DOI 10.1097/01.pas.0000126675.59108.80; Kitahashi T, 2015, PANCREAS, V44, P76, DOI 10.1097/MPA.0000000000000178; Koh YX, 2014, ANN SURG ONCOL, V21, P2782, DOI 10.1245/s10434-014-3639-0; LaFemina J, 2013, ANN SURG ONCOL, V20, P440, DOI 10.1245/s10434-012-2702-y; Matthaei H, 2012, ANN SURG, V255, P326, DOI 10.1097/SLA.0b013e3182378a18; Mohri D, 2012, J GASTROENTEROL, V47, P203, DOI 10.1007/s00535-011-0482-y; Murray SK, 2003, INT J GYNECOL PATHOL, V22, P324, DOI 10.1097/01.pgp.0000092161.33490.a9; Nara S, 2008, AM J SURG PATHOL, V32, P243, DOI 10.1097/PAS.0b013e3181484f1e; Niedergethmann M, 2008, WORLD J SURG, V32, P2253, DOI 10.1007/s00268-008-9692-8; Pavlakis K, 2011, HISTOPATHOLOGY, V58, P966, DOI 10.1111/j.1365-2559.2011.03802.x; Poultsides GA, 2010, ANN SURG, V251, P470, DOI 10.1097/SLA.0b013e3181cf8a19; Salvia R, 2004, ANN SURG, V239, P678, DOI 10.1097/01.sla.0000124386.54496.15; Schnelldorfer T, 2008, ARCH SURG-CHICAGO, V143, P639, DOI 10.1001/archsurg.143.7.639; Shi CJ, 2012, HUM PATHOL, V43, P1, DOI 10.1016/j.humpath.2011.04.003; Stewart CJR, 2011, HISTOPATHOLOGY, V59, P73, DOI 10.1111/j.1365-2559.2011.03893.x; Stewart CJR, 2009, HISTOPATHOLOGY, V55, P91, DOI 10.1111/j.1365-2559.2009.03327.x; Takahashi H, 2006, ANN SURG ONCOL, V13, P955, DOI 10.1245/ASO.2006.05.043; Tomishima K, 2017, PANCREAS, V46, P1127, DOI 10.1097/MPA.0000000000000902; Winter JM, 2013, ANN SURG, V258, P331, DOI 10.1097/SLA.0b013e31827fe9ce; Yokoyama S, 2016, ONCOTARGET, V7, P42553, DOI 10.18632/oncotarget.9924; Zhou R, 2016, ONCOGENE, V35, P5608, DOI 10.1038/onc.2015.516	30	1	1	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	AUG	2018	78						18	27		10.1016/j.humpath.2018.01.020			10	Pathology	Pathology	GR0GG	WOS:000442191800003	29410139				2019-10-28	
J	Mehrad, M; LaFramboise, WA; Lyons, MA; Bittar, HET; Yousem, SA				Mehrad, Mitra; LaFramboise, William A.; Lyons, Maureen A.; Bittar, Humberto E. Trejo; Yousem, Samuel A.			Whole-exome sequencing identifies unique mutations and copy number losses in calcifying fibrous tumor of the pleura: report of 3 cases and review of the literature	HUMAN PATHOLOGY			English	Review						Pleura; Calcifying fibrous tumor; Pseudotumor; Whole-exome sequencing; DNA	PSEUDOTUMOR	Calcifying fibrous tumor of the pleura (CFTP) is a rare mesenchymal tumor of unknown pathogenesis. The diagnosis often requires exclusion of other common entities. Our aim was to determine if genomic changes were associated with CFTP that could contribute to mechanisms underlying tumorigenesis. Three cases of CFTP with their corresponding uninvolved control lung tissue were identified. Two patients were male, and 1 was female (age range, 21-32 years). Tumors were multifocal in 2 cases and solitary in 1. Immunohistochemistry for STAT6, BCL-2, CD34, cytokeratin AE1/AE3, calretinin, desmin, 5100, ALK, and beta-catenin was used. All immunohistochemistries were negative in CFTPs. DNA was isolated from all 3 pairs of CFTPs and matching normal lungs for whole-exome sequencing. Damaging, tumor-specific, coding variants were identified in 3 genes including multiple heterozygotic, de novo mutations in the Zinc Finger Protein 717 (ZNF717), fascioscapulohumeral muscular dystrophy-1 (FRG1) and cell division cycle 27 (CDC27) genes. Whole-exome sequencing revealed statistically significant, focal, tumor-specific copy number losses among all CFTPs including a large (302 kb) loss at 6p22.2 comprising 32 genes of the histone cluster 1 family and the hemochromatosis (HFE) gene. This is the first study to evaluate the molecular pathogenesis of CFTP and to identify novel deleterious mutations in ZN717, FRG1, and CDC27 genes as well as significant copy number losses on 8 chromosomes with a large loss common to all samples on chromosome 6. These mutations deleteriously altered coding domains in a manner predicted to be damaging to protein function and may contribute to CFTP tumorigenesis. (C) 2018 Elsevier Inc. All rights reserved.	[Mehrad, Mitra] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA; [LaFramboise, William A.; Lyons, Maureen A.; Bittar, Humberto E. Trejo; Yousem, Samuel A.] UPMC, Dept Pathol, Pittsburgh, PA 15213 USA; [LaFramboise, William A.; Lyons, Maureen A.] Shadyside Hosp, UPMC Hillman Canc Ctr, Pittsburgh, PA 15232 USA	Mehrad, M (reprint author), Vanderbilt Univ, Sch Med, Pathol Microbiol & Immunol, 116 21St Ave South,C-3321A Med Ctr North, Nashville, TN 37232 USA.	mitra.mehrad@vanderbilt.edu			 [P30CA047904]	This project used the University of Pittsburgh Cancer Institute shared resource facility (Cancer Genomics Facility) supported in part by award P30CA047904 (Dr LaFramboise). No other funding from agencies in the public, commercial, or not-for-profit sectors was used in this study.	Agackiran Y, 2012, TUBERK TORAK, V60, P385, DOI 10.5578/tt.1503; Ammar A, 2003, ANN THORAC SURG, V76, P2081, DOI 10.1016/S0003-4975(03)00741-0; Bajpai J, 2011, J CANCER RES THER, V7, P500, DOI 10.4103/0973-1482.92022; Chen KTK, 2003, AM J CLIN PATHOL, V119, P811, DOI 10.1309/MXC6TWELUUH420W0; Chorti A, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003690; Cui J, 2015, INT J CANCER, V137, P86, DOI 10.1002/ijc.29352; Dissanayake SN, 2016, ANN THORAC SURG, V102, pE39, DOI 10.1016/j.athoracsur.2015.12.041; Doyle LA, 2014, MODERN PATHOL, V27, P390, DOI 10.1038/modpathol.2013.164; Farah RB, 2007, ANN DIAGN PATHOL, V11, P460, DOI 10.1016/j.anndiagpath.2006.06.004; Hainaut P, 1999, ACTA CLIN BELG, V54, P162, DOI 10.1080/17843286.1999.11754223; Hill KA, 2001, MODERN PATHOL, V14, P784, DOI 10.1038/modpathol.3880390; Isaka M, 2011, GEN THORAC CARDIOVAS, V59, P579, DOI 10.1007/s11748-010-0733-5; Ishida M, 2013, PATHOL INT, V63, P333, DOI 10.1111/pin.12062; Jang Ki Seok, 2004, Ann Thorac Surg, V78, pe87, DOI 10.1016/j.athoracsur.2004.03.100; Jeong Hwa Sook, 1997, Journal of Korean Medical Science, V12, P58; Jiang K, 2011, JPN J CLIN ONCOL, V41, P130, DOI 10.1093/jjco/hyq108; Kang WT, 2017, UROLOGY, V100, pE9, DOI 10.1016/j.urology.2016.09.022; Kawahara K, 2005, VIRCHOWS ARCH, V447, P1007, DOI 10.1007/s00428-005-0074-4; Kocova L, 1997, HISTOPATHOLOGY, V31, P182, DOI 10.1046/j.1365-2559.1997.5860817.x; Larson BK, 2015, ARCH PATHOL LAB MED, V139, P943, DOI 10.5858/arpa.2014-0032-RS; MacDonald JR, 2014, NUCLEIC ACIDS RES, V42, pD986, DOI 10.1093/nar/gkt958; Maeda A, 2002, ANTICANCER RES, V22, P1795; Mito K, 2005, VIRCHOWS ARCH, V446, P78, DOI 10.1007/s00428-004-1148-4; Mulholland PJ, 2006, CELL CYCLE, V5, P783, DOI 10.4161/cc.5.7.2631; Pinkard NB, 1996, AM J CLIN PATHOL, V105, P189; Shibata K, 2008, ANN THORAC SURG, V85, pE3, DOI 10.1016/j.athoracsur.2007.10.059; Suh JH, 2008, J THORAC ONCOL, V3, P1356, DOI 10.1097/JTO.0b013e318186a87a; Travis WD, 2015, WHO CLASSIFICATION T; Wu T, 2016, MOL CLIN ONCOL, V5, P252, DOI 10.3892/mco.2016.944; Yousem SA, 2001, HUM PATHOL, V32, P428, DOI 10.1053/hupa.2001.23523	30	1	1	1	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	AUG	2018	78						36	43		10.1016/j.humpath.2018.04.005			8	Pathology	Pathology	GR0GG	WOS:000442191800005	29689243				2019-10-28	
J	Li, L; Wang, YY; Mou, XZ; Ye, ZY; Zhao, ZS				Li, Li; Wang, Yuan-Yu; Mou, Xiao Zhou; Ye, Zai-Yuan; Zhao, Zhong-Sheng			Up-regulation of long noncoding RNA M26317 correlates with tumor progression and poor prognosis in gastric cancer	HUMAN PATHOLOGY			English	Article						Gastric cancer; lncRNA; Metastasis; Prognosis; M26317	GENE-EXPRESSION; PREDICTION	To investigate the expression and clinical significance of long noncoding RNA (lncRNA) in gastric cancer, we applied microarray analysis to obtain expression profiles of protein-coding genes and lncRNAs in tumor and paired adjacent nontumor tissues. We found that 41 lncRNAs were up-regulated and 31 lncRNAs were down-regulated more than 2-fold in gastric cancer versus noncancerous tissues (ratio >2.0, P<.01). We established a coexpression network of the differentially expressed lncRNAs and targeted coding genes that included 17 IncRNAs and 16 coding genes. Because the results of microarray analysis showed that IncRNA M26317 was up-regulated in gastric cancer tissues, we examined the expression level of M26317 in 103 gastric cancer tissues by reverse-transcription polymerase chain reaction and 436 gastric cancer tissues by in situ hybridization. Our data confirmed that M26317 was up-regulated in gastric cancer tissues. Moreover, expression of M26317 correlated with patient age, size of tumor, Lauren's classification, depth of invasion, lymph node and distant metastasis, TNM stage, and poor prognosis (P<.05), but was not associated with sex, location of tumor, and differentiation (P>.05). M26317 may have an important role in malignant transformation and metastasis of gastric cancer. (C) 2018 Elsevier Inc. All rights reserved.	[Li, Li; Mou, Xiao Zhou] Hangzhou Med Coll, Peoples Hosp, Zhejiang Prov Peoples Hosp, Clin Res Inst, Hangzhou 310014, Zhejiang, Peoples R China; [Wang, Yuan-Yu; Ye, Zai-Yuan] Hangzhou Med Coll, Peoples Hosp, Zhejiang Prov Peoples Hosp, Dept Gastrointestinal, 158 Shangtang Rd, Hangzhou 310014, Zhejiang, Peoples R China; [Wang, Yuan-Yu; Ye, Zai-Yuan] Hangzhou Med Coll, Peoples Hosp, Zhejiang Prov Peoples Hosp, Dept Pancreat Surg, 158 Shangtang Rd, Hangzhou 310014, Zhejiang, Peoples R China; [Wang, Yuan-Yu; Ye, Zai-Yuan] Key Lab Gastroenterol Zhejiang Prov, Hangzhou 310014, Zhejiang, Peoples R China; [Zhao, Zhong-Sheng] Zhejiang Prov Peoples Hosp, Dept Pathol, Hangzhou 310014, Zhejiang, Peoples R China	Wang, YY (reprint author), Hangzhou Med Coll, Peoples Hosp, Zhejiang Prov Peoples Hosp, Dept Gastrointestinal, 158 Shangtang Rd, Hangzhou 310014, Zhejiang, Peoples R China.; Wang, YY (reprint author), Hangzhou Med Coll, Peoples Hosp, Zhejiang Prov Peoples Hosp, Dept Pancreat Surg, 158 Shangtang Rd, Hangzhou 310014, Zhejiang, Peoples R China.	lywyy1979@126.com			Zhejiang Provincial Medical Science Research Foundation [2016140143, 2018247548]	This study was supported by Zhejiang Provincial Medical Science Research Foundation (2016140143 to Y. Y. W. and 2018247548 to L. L.).	Cheng DL, 2015, TUMOR BIOL, V36, P479, DOI 10.1007/s13277-015-3093-z; Cui ZL, 2016, ONCOTARGET, V7, P25791, DOI 10.18632/oncotarget.8268; Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Evans JR, 2016, J CLIN INVEST, V126, P2775, DOI 10.1172/JCI84421; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Guo XL, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gks967; Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040; Kaikkonen MU, 2011, CARDIOVASC RES, V90, P430, DOI 10.1093/cvr/cvr097; Li CY, 2016, INT J ONCOL, V48, P1965, DOI 10.3892/ijo.2016.3407; Li M, 2015, NAT STRUCT MOL BIOL, V22, P2, DOI 10.1038/nsmb.2946; Li TW, 2016, ONCOTARGET, V7, P8601, DOI 10.18632/oncotarget.6926; Liao Q, 2011, NUCLEIC ACIDS RES, V39, P3864, DOI 10.1093/nar/gkq1348; Love Michael I, 2014, Genome Biol, V15, P550; Mantione KJ, 2014, MED SCI MONIT BASIC, V20, P138, DOI 10.12659/MSMBR.892101; Orom UA, 2010, CELL, V143, P46, DOI 10.1016/j.cell.2010.09.001; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Sasako M, 2011, J CLIN ONCOL, V29, P4387, DOI 10.1200/JCO.2011.36.5908; Yuan J, 2016, ONCOTARGET, V7, P8131, DOI 10.18632/oncotarget.6993; Zhang H, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-37; Zhao ZS, 2010, CLIN CANCER RES, V16, P260, DOI 10.1158/1078-0432.CCR-09-1247	21	1	1	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	AUG	2018	78						44	53		10.1016/j.humpath.2018.04.008			10	Pathology	Pathology	GR0GG	WOS:000442191800006	29698700				2019-10-28	
J	Kadin, ME; Morgan, J; Xu, HY; Epstein, AL; Sieber, D; Hubbard, BA; Adams, WP; Bacchi, CE; Goes, JCS; Clemens, MW; Medeiros, LJ; Miranda, RN				Kadin, Marshall E.; Morgan, John; Xu, Haiying; Epstein, Alan L.; Sieber, David; Hubbard, Bradley A.; Adams, William P., Jr.; Bacchi, Carlos E.; Goes, Joao C. S.; Clemens, Mark W.; Medeiros, L. Jeffrey; Miranda, Roberto N.			IL-13 is produced by tumor cells in breast implant-associated anaplastic large cell lymphoma: implications for pathogenesis	HUMAN PATHOLOGY			English	Article						Breast implant-associated anaplastic large cell lymphoma; BIA-ALCL; Breast implants; IL-13; Lymphomagenesis	CANCER-RELATED INFLAMMATION; HODGKINS LYMPHOMA; IGE; INTERLEUKIN-13; EXPRESSION; CYTOKINES; SURVIVAL; SEROMA	More than 500 women worldwide have developed a CD30+ T-cell lymphoma around breast implants, strongly suggesting a cause-and-effect relationship, and designated as breast implant associated anaplastic large cell lymphoma (BIA-ALCL). The mechanism of lymphomagenesis is unknown. Recently, a bacterial biofilm containing gram-negative bacilli was discovered on the surface of breast implants associated with ALCL. We and others have described overexpression of the proto-oncogene JUNB and mutations of JAK1/2, TP53 and STAT3 in BIA-ALCL. Here we report that BIA-ALCL cell lines and anaplastic lymphoma cells in clinical specimens produce IL-13, the signature cytokine of allergic inflammation. Supporting the link of BIA-ALCL to allergic inflammation, lymphoma cells were often surrounded by eosinophils and mast cells, features typically absent in systemic ALCL. Because of the link of IL-13 to allergy, we looked for IgE and found it decorating the surface of mast cells and antigen-presenting follicular dendritic cells in capsules and lymph nodes infiltrated by anaplastic lymphoma cells, but not uninvolved capsules. Plasma cells within capsules and regional lymph nodes were identified as a possible source of IgE. Together, these findings suggest the hypothesis that an amplified immune response with features of a chronic allergic reaction in a susceptible patient underlies the pathogenesis of BIA-ALCL. (C) 2018 Elsevier Inc. All rights reserved.	[Kadin, Marshall E.; Morgan, John; Xu, Haiying] Roger Williams Med Ctr, Providence, RI 02908 USA; [Epstein, Alan L.] USC, Keck Sch Med, Los Angeles, CA 90033 USA; [Sieber, David] Sieber Plast Surg, San Francisco, CA 94904 USA; [Hubbard, Bradley A.] Dallas Plast Surg Inst, Dallas, TX 75231 USA; [Adams, William P., Jr.] UT Southwestern, Dept Plast Surg, Dallas, TX 75205 USA; [Bacchi, Carlos E.] Bacchi Pathol Lab, Sao Paulo 18602010, Brazil; [Goes, Joao C. S.] Inst Bras Controle Canc, Sao Paulo 04536010, Brazil; [Clemens, Mark W.] MD Anderson Canc Ctr, Plast Surg Div, Houston, TX 77030 USA; [Medeiros, L. Jeffrey; Miranda, Roberto N.] MD Anderson Canc Ctr, Hematopathol Div, Houston, TX 77030 USA	Kadin, ME (reprint author), Roger Williams Med Ctr, Dept Dermatol, 825 Chalkstone Ave, Providence, RI 02908 USA.	mkadin@me.com	Medeiros, L. Jeffrey/AAB-1018-2019		Aesthetic Surgery Education and Research Foundation (ASERF)	This study was supported by a grant from the Aesthetic Surgery Education and Research Foundation (ASERF).	Andorsky DJ, 2011, CLIN CANCER RES, V17, P4232, DOI 10.1158/1078-0432.CCR-10-2660; Burton OT, 2011, IMMUNOL REV, V242, P128, DOI 10.1111/j.1600-065X.2011.01024.x; Clemens MW, 2016, J CLIN ONCOL, V34, P160, DOI 10.1200/JCO.2015.63.3412; de Boer M, 2018, JAMA ONCOL, V4, P335, DOI 10.1001/jamaoncol.2017.4510; Ehrentraut S, 2016, ONCOTARGET, V7, P34201, DOI 10.18632/oncotarget.9077; Ehrentraut S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053767; Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755; Germano G, 2008, CYTOKINE, V43, P374, DOI 10.1016/j.cyto.2008.07.014; Gieseck RL, 2016, IMMUNITY, V45, P145, DOI 10.1016/j.immuni.2016.06.009; Hu H, 2016, PLAST RECONSTR SURG, V137, P1659, DOI 10.1097/PRS.0000000000002010; Kadin ME, 2016, AESTHET SURG J, V36, P773, DOI [10.1093/asj/sjw023, 10.1093/asj/sjw286]; Kadin ME, 2012, J INVEST DERMATOL, V132, P703, DOI 10.1038/jid.2011.351; KADIN ME, 1986, BLOOD, V68, P1042; Lamant L, 2010, HAEMATOL-HEMATOL J, V95, P449, DOI 10.3324/haematol.2009.015024; Laurent C, 2016, ANN ONCOL, V27, P306, DOI 10.1093/annonc/mdv575; Lechner MG, 2012, CLIN CANCER RES, V18, P4549, DOI 10.1158/1078-0432.CCR-12-0101; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; Miranda RN, 2014, J CLIN ONCOL, V32, P114, DOI 10.1200/JCO.2013.52.7911; Piccaluga PP, 2000, HAEMATOLOGICA, V85, P978; Platzer B, 2011, IMMUNOL LETT, V141, P36, DOI 10.1016/j.imlet.2011.08.004; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; Roden AC, 2008, MODERN PATHOL, V21, P455, DOI 10.1038/modpathol.3801024; Savan R, 2011, BLOOD, V117, P575, DOI 10.1182/blood-2010-05-285908; Skinnider BF, 2002, BLOOD, V99, P4283, DOI 10.1182/blood-2002-01-0099; Trieu Y, 2004, CANCER RES, V64, P3271, DOI 10.1158/0008-5472.CAN-03-3764; Trumper L, 1998, BRIT J HAEMATOL, V103, P1138; Vassallo J, 2006, AM J SURG PATHOL, V30, P223, DOI 10.1097/01.pas.0000179123.66748.c2; Vonderheid EC, 2017, CLIN DERMATOL, V2; Wynn TA, 2003, ANNU REV IMMUNOL, V21, P425, DOI 10.1146/annurev.immunol.21.120601.141142	30	10	10	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	AUG	2018	78						54	62		10.1016/j.humpath.2018.04.007			9	Pathology	Pathology	GR0GG	WOS:000442191800007	29689246				2019-10-28	
J	Augustin, J; Outh-Gauer, S; Mandavit, M; Gasne, C; Grard, O; Denize, T; Nervo, M; Mirghani, H; Laccourreye, O; Bonfils, P; Bruneval, P; Veyer, D; Pere, H; Tartour, E; Badoual, C				Augustin, Jeremy; Outh-Gauer, Sophie; Mandavit, Marion; Gasne, Cassandre; Grard, Ophelie; Denize, Thomas; Nervo, Marine; Mirghani, Haitham; Laccourreye, Ollivier; Bonfils, Pierre; Bruneval, Patrick; Veyer, David; Pere, Helene; Tartour, Eric; Badoual, Cecile			Evaluation of the efficacy of the 4 tests (p16 immunochemistry, polymerase chain reaction, DNA, and RNA in situ hybridization) to evaluate a human papillomavirus infection in head and neck cancers: a cohort of 348 French squamous cell carcinomas	HUMAN PATHOLOGY			English	Article						HPV; Oropharynx; p16; DNA PCR; RNAscope; In situ hybridization; Head and neck cancer	RISK HUMAN-PAPILLOMAVIRUS; OROPHARYNGEAL CANCER; HPV; ASSAY; METAANALYSIS; VALIDATION; SURVIVAL; TRIALS	It is now established that human papillomavirus (HPV) plays a role in the development of a subset of head and neck squamous cell carcinomas (SCCs), notably oropharyngeal (OP) SCCs. However, it is not clear which test one should use to detect HPV in OP and non-OP SCCs. In this study, using 348 head and neck SCCs (126 OP SCCs and 222 non-OP SCCs), we evaluated diagnostic performances of different HPV tests in OP and non-OP SCCs: polymerase chain reaction, p16 immunostaining, in situ hybridization targeting DNA (DNA-CISH) and RNA (RNA-CISH), combined p16 + DNA-CISH, and combined p16 + RNA-CISH. HPV DNA (polymerase chain reaction) was detected in 26% of all tumors (44% of OP SCCs and 17% of non-OP SCCs). For OP SCCs, RNA-CISH was the most sensitive stand-alone test (88%), but p16 + RNA-CISH was even more sensitive (95%). Specificities were the same for RNA-CISH and DNA-CISH (97%), but it was better for p16 + RNA-CISH (100%). For non-OP SCCs, all tests had sensitivities less than 50%, and RNA-CISH, DNA-CISH, and p16 + DNA-CISH had 100%, 97%, and 99% specificities, respectively. As a stand-alone test, RNA-CISH is the most performant assay to detect HPV in OP SCCs, and combined p16 + RNA-CISH test slightly improves its performances. However, RNA-CISH has the advantage of being one single test. Like p16 and DNA-CISH, RNA-CISH performances are poor in non-OP SCCs to detect HPV, and combining tests does not improve performances. (C) 2018 Elsevier Inc. All rights reserved.	[Augustin, Jeremy; Outh-Gauer, Sophie; Denize, Thomas; Bruneval, Patrick; Badoual, Cecile] Hop Europeen Georges Pompidou, Dept Pathol, F-75015 Paris, France; [Mandavit, Marion; Gasne, Cassandre; Grard, Ophelie; Nervo, Marine; Bruneval, Patrick; Veyer, David; Pere, Helene; Tartour, Eric; Badoual, Cecile] Univ Paris 05, Sorbonne Paris Cite, INSERM U970, F-75015 Paris, France; [Mandavit, Marion; Grard, Ophelie; Nervo, Marine; Badoual, Cecile] Equipe Labellisee Ligue Natl Canc, F-75013 Paris, France; [Gasne, Cassandre; Laccourreye, Ollivier; Bonfils, Pierre] Hop Europeen Georges Pompidou, Dept ENT Surg, F-75015 Paris, France; [Mirghani, Haitham] Inst Gustave Roussy, Dept ENT Surg, F-94800 Villejuif, France; [Veyer, David; Pere, Helene] Hop Europeen Georges Pompidou, Dept Microbiol, F-75015 Paris, France; [Tartour, Eric] Hop Europeen Georges Pompidou, Dept Immunol, F-75015 Paris, France	Badoual, C (reprint author), Hop Europeen Georges Pompidou, AP HP, Dept Pathol, 20 Rue Leblanc, F-75015 Paris, France.	jeremy.augustin@aphp.fr; sophieouthgauer@gmail.com; marion.mandavit@gmail.com; cassandre.gasne@gmail.com; ophelie.grard.14@gmail.com; denize.thomas@gmail.com; marine.nervo@gmail.com; Haitham.MIRGHANI@gustaveroussy.fr; ollivier.laccourreye@aphp.fr; pierre.bonfils@aphp.fr; patrick.bruneval@aphp.fr; david.veyer@aphp.fr; helene.pere@aphp.fr; eric.tartour@aphp.fr; cecile.badoual@aphp.fr					Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Bishop JA, 2012, AM J SURG PATHOL, V36, P1874, DOI 10.1097/PAS.0b013e318265fb2b; Braakhuis BJM, 2009, EUR J CANCER, V45, P2935, DOI 10.1016/j.ejca.2009.08.018; Castellsague X, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv403; Chan JKC, 2017, MODERN PATHOL, V30, pS68, DOI 10.1038/modpathol.2016.189; Chaturvedi AK, 2008, J CLIN ONCOL, V26, P612, DOI 10.1200/JCO.2007.14.1713; D'Souza G, 2007, NEW ENGL J MED, V356, P1944, DOI 10.1056/NEJMoa065497; D'Souza G, 2016, ORAL ONCOL, V62, P20, DOI 10.1016/j.oraloncology.2016.09.005; Dayyani F, 2010, HEAD NECK ONCOL, V2, DOI 10.1186/1758-3284-2-15; Dogan V, 2018, CLIN OTOLARYNGOL, V43, P13, DOI 10.1111/coa.12895; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Jordan RC, 2012, AM J SURG PATHOL, V36, P945, DOI 10.1097/PAS.0b013e318253a2d1; Kerr DA, 2015, AM J SURG PATHOL, V39, P1643, DOI 10.1097/PAS.0000000000000516; Khleif SN, 1996, P NATL ACAD SCI USA, V93, P4350, DOI 10.1073/pnas.93.9.4350; Leemans CR, 2018, NAT REV CANCER, V18, P269, DOI 10.1038/nrc.2018.11; Marur S, 2010, LANCET ONCOL, V11, P781, DOI 10.1016/S1470-2045(10)70017-6; Masterson L, 2014, EUR J CANCER, V50, P2636, DOI 10.1016/j.ejca.2014.07.001; Mendez-Pena JE, 2017, HUM PATHOL, V63, P184, DOI 10.1016/j.humpath.2017.02.021; Mirghani H, 2015, MODERN PATHOL, V28, P1518, DOI 10.1038/modpathol.2015.113; National Collaborating Centre for Cancer (UK), 2016, CANC UPP AER TRACT A; Prigge ES, 2017, INT J CANCER, V140, P1186, DOI 10.1002/ijc.30516; Qureishi A, 2017, EUR ARCH OTO-RHINO-L, V274, P2675, DOI 10.1007/s00405-017-4503-1; Schache AG, 2013, BRIT J CANCER, V108, P1332, DOI 10.1038/bjc.2013.63; Schlecht NF, 2011, MODERN PATHOL, V24, P1295, DOI 10.1038/modpathol.2011.91; Seethala RR, 2017, PATHOLOGISTS; Taberna M, 2017, ANN ONCOL, V28, P2386, DOI 10.1093/annonc/mdx304; Ukpo OC, 2011, AM J SURG PATHOL, V35, P1343, DOI 10.1097/PAS.0b013e318220e59d; Walline HM, 2013, JAMA OTOLARYNGOL, V139, P1320, DOI 10.1001/jamaoto.2013.5460	28	3	3	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	AUG	2018	78						63	71		10.1016/j.humpath.2018.04.006			9	Pathology	Pathology	GR0GG	WOS:000442191800008	29684499				2019-10-28	
J	Merino, MJ; Pinto, PA; Moreno, V; Gil, S; Schlom, J; Gulley, JL				Merino, Maria J.; Pinto, Peter A.; Moreno, Vanessa; Gil, Sara; Schlom, Jeffrey; Gulley, James L.			Morphological changes induced by intraprostatic PSA-based vaccine in prostate cancer biopsies (phase I clinical trial)	HUMAN PATHOLOGY			English	Article						Prostate adenocarcinoma; PSA-based vaccination; Inflammation; Eosinophils; Treatment effect	RADICAL PROSTATECTOMY; ANTIGEN; THERAPY; PROSTVAC; PROGRESSION; STATISTICS; GENERATION; GUIDELINES	Immunotherapy is a novel treatment for many tumors including prostate cancer. Little is known about the histological changes in prostate biopsies caused by the prostate-specific antigen (PSA) based vaccine. This study evaluated the histopathological effects in prostate biopsies of recombinant fowlpox (rF) virus based vaccine engineered to present the PSA and 3 costimulatory molecules (collectively labeled as PSA-TRICOM). This vaccine has shown that it can break tolerance of the PSA, and its administration directly into a tumor enables the affected tumor cells to act as antigen-presenting cells activating new T cells and broadening the immune response to recognize and kill tumor. We studied 10 patients with recurrent prostate cancer who had failed radiation therapy and/or androgen-deprivation therapy. Pre- and posttreatment biopsies were compared. Posttreatment biopsies induced 8 cases with residual adenocarcinoma despite evidences of treatment effect and inflammation, 2 cases did not show any residual tumor, and 1 one case did not have any inflammatory infiltrate or any evidence of treatment effect. The inflammatory infiltrate varied from mild to severe and was composed of mononuclear cells. Greater numbers of infiltrating CD8+ lymphocytes were identified around prostatic glands and within the epithelial lining. The most remarkable feature was the presence of increased eosinophils around the glands and stroma. Three cases showed areas of necrosis surrounded by lymphocytes and palisading epithelioid macrophages arranged in granuloma-like pattern with multinucleated giant cells. This description of these morphological changes induced by the PSA-TRICOM will help to interpret the results of future intratumoral vaccine therapy trials. (C) 2018 Published by Elsevier Inc.	[Merino, Maria J.; Moreno, Vanessa; Gil, Sara] NCI, Translat Surg Pathol, Lab Pathol, CCR,NIH, Bethesda, MD 20892 USA; [Pinto, Peter A.] NCI, Urol Oncol Branch, CCR, NIH, Bethesda, MD 20892 USA; [Schlom, Jeffrey; Gulley, James L.] NCI, Lab Tumor Immunol & Biol, CCR, NIH, Bethesda, MD 20892 USA	Merino, MJ (reprint author), 10 Ctr Dr,Room 3S235C, Bethesda, MD 20892 USA.	mjmerino@mail.nih.gov	Gulley, James L/Y-7576-2019	Gulley, James L/0000-0002-6569-2912	Intramural Research programs of the Center for Cancer Research - National Cancer Institute- National Institute of Health. Bethesda, Maryland	This work was supported by the Intramural Research programs of the Center for Cancer Research - National Cancer Institute- National Institute of Health. Bethesda, Maryland. MJM.	Arlen PM, 2006, CLIN CANCER RES, V12, P1260, DOI 10.1158/1078-0432.CCR-05-2059; Cha E, 2011, J CLIN ONCOL, V29, P3677, DOI 10.1200/JCO.2010.34.5025; Cookson MS, 2007, J UROLOGY, V177, P540, DOI 10.1016/j.juro.2006.10.097; Correale P, 1998, J IMMUNOL, V161, P3186; Correale P, 1997, JNCI-J NATL CANCER I, V89, P293, DOI 10.1093/jnci/89.4.293; Cox JD, 1997, INT J RADIAT ONCOL, V37, P1035; DiPaola RS, 2015, EUR UROL, V68, P365, DOI 10.1016/j.eururo.2014.12.010; Grosenbach DW, 2001, CANCER RES, V61, P4497; Guise Theresa A, 2007, Rev Urol, V9, P163; Gulley J, 2002, PROSTATE, V53, P109, DOI 10.1002/pros.10130; Gulley JL, 2014, CANCER IMMUNOL RES, V2, P133, DOI 10.1158/2326-6066.CIR-13-0108; Gulley JL, 2013, CANCER IMMUNOL IMMUN, V62, P1521, DOI 10.1007/s00262-013-1448-0; Higano CS, 2003, UROLOGY, V61, P32, DOI 10.1016/S0090-4295(02)02397-X; Kaufman HL, 2004, J CLIN ONCOL, V22, P2122, DOI 10.1200/JCO.2004.08.083; Klotz L, 2015, J CLIN ONCOL, V33, P272, DOI 10.1200/JCO.2014.55.1192; Kudo-Saito C, 2004, CLIN CANCER RES, V10, P1090, DOI 10.1158/1078-0432.CCR-03-0145; Madan RA, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.28611; Madan RA, 2009, EXPERT OPIN INV DRUG, V18, P1001, DOI 10.1517/13543780902997928; Mastrangelo MJ, 2002, CANCER GENE THER, V9, P1013, DOI 10.1038/sj.cgt.7700538; Pound CR, 1999, JAMA-J AM MED ASSOC, V281, P1591, DOI 10.1001/jama.281.17.1591; Sanda MG, 1999, UROLOGY, V53, P260, DOI 10.1016/S0090-4295(98)00539-1; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Slavin-Chiorini DC, 2004, CANCER GENE THER, V11, P665, DOI 10.1038/sj.cgt.7700741; Stamey TA, 2000, J UROLOGY, V163, P1155, DOI 10.1016/S0022-5347(05)67713-0; Terasawa H, 2002, CLIN CANCER RES, V8, P41	26	0	0	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	AUG	2018	78						72	78		10.1016/j.humpath.2018.04.013			7	Pathology	Pathology	GR0GG	WOS:000442191800009	29709495				2019-10-28	
J	Akazawa, Y; Saito, T; Hayashi, T; Yanai, Y; Tsuyama, S; Akaike, K; Suehara, Y; Takahashi, F; Takamochi, K; Ueyama, H; Murakami, T; Watanabe, S; Nagahara, A; Yao, T				Akazawa, Yoichi; Saito, Tsuyoshi; Hayashi, Takuo; Yanai, Yuka; Tsuyama, Sho; Akaike, Keisuke; Suehara, Yoshiyuki; Takahashi, Fumiyuki; Takamochi, Kazuya; Ueyama, Hiroya; Murakami, Takashi; Watanabe, Sumio; Nagahara, Akihito; Yao, Takashi			Next-generation sequencing analysis for gastric adenocarcinoma with enteroblastic differentiation: emphasis on the relationship with hepatoid adenocarcinoma	HUMAN PATHOLOGY			English	Article						Gastric adenocarcinoma with enteroblastic differentiation; Hepatoid adenocarcinoma; TP53; HER2; Next-generation sequencing	ALPHA-FETOPROTEIN; CLINICOPATHOLOGICAL FEATURES; PROGNOSTIC-FACTORS; CLEAR-CELL; CANCER; CARCINOMA; STOMACH; HISTOGENESIS; EXPRESSION; PHENOTYPE	Histologically tubulopapillary structures with glycogen-rich clear cytoplasm in gastric adenocarcinoma with enteroblastic differentiation (GAED) are well known, but a solid growth pattern can also be observed as a minor component. In contrast, hepatoid adenocarcinoma (HAC) of the stomach shows many overlapping features, including solid pattern and alpha-fetoprotein expression. In this study, we employed next-generation sequencing (NGS) to establish a molecular/clinicopathological concept of GAED and clarify whether these two tumors should be grouped together in one category. Among 2273 primary gastric cancers treated in our hospital between 2008 and 2017, we defined 51 cases as GAEDs showing tubulopapillary or solid patterns that express at least one of the following markers: alpha-fetoprotein, glypican-3, or spalt-like transcription factor 4. All cases previously diagnosed as HAC in our hospital had clear cytoplasm and were included as GAEDs by histological re-evaluation and immunohistochemical findings. We performed NGS for 24 histologically typical GAEDs and Sanger sequencing for the remaining cases. The most frequently mutated gene was TP53, and almost all cases with missense mutation showed p53 overexpression. An analysis of copy number variation revealed that ERBB2 amplification was the most frequent in GAED. Additionally, HER2 immunohistochemistry and fluorescence in situ hybridization confirmed that 22% of informative cases were HER2 positive. There was no correlation between molecular/clinicopathological parameters and a-fetoprotein expression or growth patterns in GAED. Our analysis showed that GAED frequently harbors TP53 mutations and ERBB2 amplification. As with conventional gastric adenocarcinoma, trastuzumab may be effective for GAED. Furthermore, HAC may be subcategorized as a solid-type GAED. (C) 2018 Elsevier Inc. All rights reserved.	[Akazawa, Yoichi; Saito, Tsuyoshi; Hayashi, Takuo; Yanai, Yuka; Tsuyama, Sho; Akaike, Keisuke; Yao, Takashi] Juntendo Univ, Grad Sch Med, Dept Human Pathol, Tokyo 1138421, Japan; [Ueyama, Hiroya; Murakami, Takashi; Watanabe, Sumio; Nagahara, Akihito] Juntendo Univ, Grad Sch Med, Dept Gastroenterol, Tokyo 1138421, Japan; [Saito, Tsuyoshi; Suehara, Yoshiyuki; Takahashi, Fumiyuki] Juntendo Univ, Intractable Dis Res Ctr, Grad Sch Med, Tokyo 1138421, Japan; [Akazawa, Yoichi; Akaike, Keisuke; Suehara, Yoshiyuki] Juntendo Univ, Grad Sch Med, Dept Orthopaed Surg, Tokyo 1138421, Japan; [Takahashi, Fumiyuki] Juntendo Univ, Grad Sch Med, Dept Resp Med, Tokyo 1138421, Japan; [Takamochi, Kazuya] Juntendo Univ, Grad Sch Med, Dept Gen Thorac Surg, Tokyo 1138421, Japan	Saito, T (reprint author), Juntendo Univ, Grad Sch Med, Dept Human Pathol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	tysaitou@juntendo.ac.jp			Ministry of Education, Science, Sports, and Culture, Tokyo, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [17K08704]; AMEDJapan Agency for Medical Research and Development (AMED) [JP17am0001009]	This work was financially supported in part by a Grant-in-Aid for General Scientific Research from the Ministry of Education, Science, Sports, and Culture (#17K08704 to T. Yao), Tokyo, Japan. This research was supported by AMED under Grant Number JP17am0001009.	Adachi Y, 2003, ONCOLOGY-BASEL, V65, P95, DOI 10.1159/000072332; Akiyama S, 2003, INT J CANCER, V106, P510, DOI 10.1002/ijc.11246; Bang YJ, 2010, LANCET, V376, P1302; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Bosman FT, 2010, WHO CLASSIFICATION T; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; CHANG YC, 1992, AM J GASTROENTEROL, V87, P321; CHANG YC, 1990, AM J GASTROENTEROL, V85, P1480; Cristescu R, 2015, NAT MED, V21, P449, DOI 10.1038/nm.3850; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Ghotli ZA, 2007, PATHOLOGY, V39, P466, DOI 10.1080/00313020701569972; Govender Dhirendra, 2004, Ann Diagn Pathol, V8, P69, DOI 10.1053/j.anndiagpath.2004.01.002; He L, 2016, ONCOTARGET, V7, P28448, DOI 10.18632/oncotarget.8571; Ikeda H, 2012, HUM PATHOL, V43, P1955, DOI 10.1016/j.humpath.2011.11.022; Kinjo T, 2012, AM J SURG PATHOL, V36, P56, DOI 10.1097/PAS.0b013e31823aafec; Kono K, 2002, DIGEST SURG, V19, P359, DOI 10.1159/000065838; Kumashiro Y, 2007, HUM PATHOL, V38, P857, DOI 10.1016/j.humpath.2006.10.020; Kwon SJ, 2011, J GASTRIC CANCER, V11, P78, DOI 10.5230/jgc.2011.11.2.78; Liu XW, 2010, J SURG ONCOL, V102, P249, DOI 10.1002/jso.21624; Matsumoto K, 2016, WORLD J GASTROENTERO, V22, P8203, DOI 10.3748/wjg.v22.i36.8203; MATSUNOU H, 1994, CANCER, V73, P534, DOI 10.1002/1097-0142(19940201)73:3<534::AID-CNCR2820730307>3.0.CO;2-X; Murakami T, 2016, GASTRIC CANCER, V19, P498, DOI 10.1007/s10120-015-0497-9; NAGAI E, 1993, CANCER, V72, P1827, DOI 10.1002/1097-0142(19930915)72:6<1827::AID-CNCR2820720606>3.0.CO;2-8; Shimakata T, 2016, HISTOPATHOLOGY, V69, P812, DOI 10.1111/his.13004; Tahara T, 2016, ONCOTARGET, V7, P42252, DOI 10.18632/oncotarget.9770; Ushiku T, 2010, AM J SURG PATHOL, V34, P533, DOI 10.1097/PAS.0b013e3181d1dcdd; Ushiku T, 2009, CANCER SCI, V100, P626, DOI 10.1111/j.1349-7006.2009.01108.x; Xu CY, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0382-x; Yamazawa S, 2017, AM J SURG PATHOL, V41, P989, DOI 10.1097/PAS.0000000000000869; Zhang L, 2014, ONCOGENE, V33, P5491, DOI 10.1038/onc.2013.495	30	6	6	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	AUG	2018	78						79	88		10.1016/j.humpath.2018.04.022			10	Pathology	Pathology	GR0GG	WOS:000442191800010	29751042				2019-10-28	
J	Zhang, HN; Jenkins, SM; Lee, CT; Harrington, SM; Liu, ZG; Dong, HD; Zhang, LZ				Zhang, Henan; Jenkins, Sarah M.; Lee, Chuang-Ta; Harrington, Susan M.; Liu, Zhuogang; Dong, Haidong; Zhang, Lizhi			Bim is an independent prognostic marker in intrahepatic cholangiocarcinoma	HUMAN PATHOLOGY			English	Article						Bim; Immunohistochemistry; Intrahepatic cholangiocarcinoma; Prognosis; Liver	KINASE INHIBITORS; BH3-ONLY PROTEINS; INDUCED APOPTOSIS; EXPRESSION; CELLS; RESISTANCE; PHOSPHORYLATION; IDENTIFICATION; CHEMOTHERAPY; DEGRADATION	Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver malignant tumor and has a poor prognosis. The prognostic factors associated with outcome remain poorly defined. In this study, we investigated the role of an important cell apoptosis initiator, Bcl-2 interacting mediator of cell death (Bim), by evaluating its expression and association with other clinicopathological features in ICCs. We analyzed 56 cases of ICC with clinical follow-up. The expression of Bim in ICC cells and other cellular components was evaluated by immunohistochemistry. Bim expression was considered up-regulated if Bim was detected in 10% or more of tumor cells. Of the 56 ICC samples, 19 (34%) had high Bim expression level, 15 (27%) were completely negative, and 22 (39%) were classified as low Bim expression (<10% positivity). Patients who had tumors with high Bim level had significantly longer overall survival than did those with low or no staining (median survival, 7.6 versus 2.6 years; hazard ratio, 0.40; P=.006). High Bim expression was also correlated with low Ki-67 index, and more importantly, none of the tumors with high Bim expression had lymph node metastases at the time of surgery. Our study demonstrates that Bim is an important and independent prognostic factor in ICC. Tumors with high Bim expression are associated with better prognosis through inhibiting tumor cell proliferation and metastatic ability. The development of new agents directly or indirectly targeting Bim may provide promising anticancer treatments. (C) 2018 Elsevier Inc. All rights reserved.	[Zhang, Henan; Liu, Zhuogang] China Med Univ, Shengjing Hosp, Dept Hematol, Huaxiang Rd 39, Shenyang 110000, Liaoning, Peoples R China; [Zhang, Henan] Mayo Clin, Div Hematol, Rochester, MN 55905 USA; [Jenkins, Sarah M.] Mayo Clin, Div Biomed Stat & Informat, Rochester, MN 55905 USA; [Lee, Chuang-Ta] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Pathol, Tainan 704, Taiwan; [Harrington, Susan M.; Dong, Haidong] Mayo Clin, Dept Immunol, 200 1st St SW, Rochester, MN 55905 USA; [Zhang, Lizhi] Mayo Clin, Dept Lab Med & Pathol, 200 1st St SW, Rochester, MN 55905 USA	Liu, ZG (reprint author), China Med Univ, Shengjing Hosp, Dept Hematol, Huaxiang Rd 39, Shenyang 110000, Liaoning, Peoples R China.; Dong, HD (reprint author), Mayo Clin, Dept Immunol, 200 1st St SW, Rochester, MN 55905 USA.; Zhang, LZ (reprint author), Mayo Clin, Dept Lab Med & Pathol, 200 1st St SW, Rochester, MN 55905 USA.	liuzg@sj-hospital.org; Dong.haidong@mayo.edu; Zhang.Lizhi@mayo.edu					Akiyama T, 2009, MOL CANCER THER, V8, P3173, DOI 10.1158/1535-7163.MCT-09-0685; Bavetsias V, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00278; Chen S, 2009, MOL CELL BIOL, V29, P6149, DOI 10.1128/MCB.01481-08; Chi HC, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.227; Dai DL, 2008, J INVEST DERMATOL, V128, P403, DOI 10.1038/sj.jid.5700989; Dai Y, 2008, CLIN CANCER RES, V14, P549, DOI 10.1158/1078-0432.CCR-07-1934; Dronca RS, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.86014; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Endo I, 2008, ANN SURG, V248, P84, DOI 10.1097/SLA.0b013e318176c4d3; Essafi A, 2005, ONCOGENE, V24, P2317, DOI 10.1038/sj.onc.1208421; Ewings KE, 2007, CELL CYCLE, V6, P2236, DOI 10.4161/cc.6.18.4728; Faber AC, 2011, CANCER DISCOV, V1, P352, DOI 10.1158/2159-8290.CD-11-0106; Gilley R, 2012, CELL SIGNAL, V24, P170, DOI 10.1016/j.cellsig.2011.08.018; Gong YX, 2007, PLOS MED, V4, P1655, DOI 10.1371/journal.pmed.0040294; Iwai Y, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0329-9; Kitada S, 2002, ONCOGENE, V21, P3459, DOI 10.1038/sj.onc.1205327; Knight ZA, 2007, CELL, V128, P425, DOI 10.1016/j.cell.2007.01.021; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Ley R, 2005, CELL DEATH DIFFER, V12, P1008, DOI 10.1038/sj.cdd.4401688; Liu JW, 2002, CANCER RES, V62, P2976; Menakongka A, 2010, WORLD J GASTROENTERO, V16, P713, DOI 10.3748/wjg.v16.i6.713; Merino D, 2015, ONCOGENE, V34, P3926, DOI 10.1038/onc.2014.313; Moustafa-Kamal M, 2013, CELL DEATH DIFFER, V20, P1393, DOI 10.1038/cdd.2013.93; Muthalagu N, 2014, CELL REP, V8, P1347, DOI 10.1016/j.celrep.2014.07.057; Pigneux A, 2007, CANCER BIOL THER, V6, P603, DOI 10.4161/cbt.6.4.4226; Sinicrope FA, 2008, CLIN CANCER RES, V14, P5810, DOI 10.1158/1078-0432.CCR-07-5202; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Tagawa H, 2005, ONCOGENE, V24, P1348, DOI 10.1038/sj.onc.1208300; Tan TT, 2005, CANCER CELL, V7, P227, DOI 10.1016/j.ccr.2005.02.008; Visco AG, 2008, INT UROGYNECOL J, V19, P607, DOI 10.1007/s00192-007-0498-2; Wang J, 2011, J BIOL CHEM, V286, P22384, DOI 10.1074/jbc.M111.239566; Washington K, 2013, PROTOCOL EXAMINATION; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Zantl N, 2007, ONCOGENE, V26, P7038, DOI 10.1038/sj.onc.1210510	35	1	1	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	AUG	2018	78						97	105		10.1016/j.humpath.2018.04.009			9	Pathology	Pathology	GR0GG	WOS:000442191800012	29698699				2019-10-28	
